<SEC-DOCUMENT>0001193125-25-172703.txt : 20250804
<SEC-HEADER>0001193125-25-172703.hdr.sgml : 20250804
<ACCEPTANCE-DATETIME>20250804171550
ACCESSION NUMBER:		0001193125-25-172703
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		102
FILED AS OF DATE:		20250804
DATE AS OF CHANGE:		20250804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289223
		FILM NUMBER:		251181531

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d942297ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sclx="http://www.scilexholding.com/20250801" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2025To03_31_2025" id="ixv-38807">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2025To03_31_2025" id="ixv-38808">0001820190</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden145656811" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">CA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden145656812" contextRef="P01_01_2025To03_31_2025">CA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20250801.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_11_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2023To04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-30</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_11_2024To06_11_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-06-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_16_2024To07_16_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-16</xbrli:startDate> <xbrli:endDate>2024-07-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_27_2023To06_27_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-27</xbrli:startDate> <xbrli:endDate>2023-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To07_01_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_13_2023To02_13_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-13</xbrli:startDate> <xbrli:endDate>2023-02-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_18_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:PublicWarrantsPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:Semnur2024StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ResearchMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PatentRightsAcquiredTechnologyAndAcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SemnurCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants5Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:GloperbaElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:GloperbaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CoveLaneMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:CoveLaneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_HudsonBayMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sclx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EpoladermMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EpoladermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ProbudurMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ProbudurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EnveltaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EnveltaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SeniorSubordinatedNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PurchasedRevenueLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants5Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-27</xbrli:startDate> <xbrli:endDate>2023-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_11_2024To06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:InitialClosingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-06-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:InitialClosingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-06-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondClosingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-06-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_18_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-17</xbrli:startDate> <xbrli:endDate>2024-09-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionsAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis_TrancheBNotesMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_08_2024_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-31</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-14</xbrli:startDate> <xbrli:endDate>2022-06-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-30</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2024To06_30_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-30</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-01</xbrli:startDate> <xbrli:endDate>2024-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-30</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionAxis">sclx:RemainingDrawableBalanceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-30</xbrli:startDate> <xbrli:endDate>2024-08-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-30</xbrli:startDate> <xbrli:endDate>2024-08-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_30_2024To08_30_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-30</xbrli:startDate> <xbrli:endDate>2024-08-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_30_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_11_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_11_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FourthInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FiveInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SixInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:DebtPayableAxis">sclx:MonthlyBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_20_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_20_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-23</xbrli:startDate> <xbrli:endDate>2024-09-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-23</xbrli:startDate> <xbrli:endDate>2024-09-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-21</xbrli:startDate> <xbrli:endDate>2024-12-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:InitialClosingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_11_2024_SecondClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SecondClosingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-11</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2024_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-08</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To12_31_2026_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To12_31_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-05</xbrli:startDate> <xbrli:endDate>2023-07-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-20</xbrli:startDate> <xbrli:endDate>2024-09-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-27</xbrli:startDate> <xbrli:endDate>2024-10-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-27</xbrli:startDate> <xbrli:endDate>2024-10-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-31</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-22</xbrli:startDate> <xbrli:endDate>2023-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-29</xbrli:startDate> <xbrli:endDate>2024-02-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-29</xbrli:startDate> <xbrli:endDate>2024-02-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-23</xbrli:startDate> <xbrli:endDate>2024-04-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-11</xbrli:startDate> <xbrli:endDate>2024-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-11</xbrli:startDate> <xbrli:endDate>2024-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-11</xbrli:startDate> <xbrli:endDate>2024-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-26</xbrli:startDate> <xbrli:endDate>2024-12-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_13_2023To02_13_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-13</xbrli:startDate> <xbrli:endDate>2023-02-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis_ThreeILpMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ThreeILpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_OramedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_BpyLimitedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:BpyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_NomisBayLtdMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:NomisBayLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-02</xbrli:startDate> <xbrli:endDate>2025-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2025To02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-22</xbrli:startDate> <xbrli:endDate>2025-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_22_2025To02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-22</xbrli:startDate> <xbrli:endDate>2025-02-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2025_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_GloperbaRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:GloperbaRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2025_ElyxybRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ElyxybRestOfWorldLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-28</xbrli:startDate> <xbrli:endDate>2025-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-28</xbrli:startDate> <xbrli:endDate>2025-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-21</xbrli:startDate> <xbrli:endDate>2025-01-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:PublicWarrantsPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:Semnur2024StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PatentRightsAcquiredTechnologyAndAcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SemnurCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:GloperbaElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ZTlidoRoyaltyMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RetainerSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PublicWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PurchasedRevenueLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_MinimumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_MaximumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_OramedMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TrancheBNoteMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2022To10_17_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-17</xbrli:startDate> <xbrli:endDate>2022-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_17_2025To04_17_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-04-17</xbrli:startDate> <xbrli:endDate>2025-04-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_17_2025To04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexBioJVMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-04-17</xbrli:startDate> <xbrli:endDate>2025-04-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexBioJVMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-04-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_03_2025To04_03_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-04-03</xbrli:startDate> <xbrli:endDate>2025-04-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Days"> <xbrli:measure>sclx:Days</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">As filed with the U.S.&#160;Securities and Exchange Commission on August&#160;4, 2025 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:right">Registration No.&#160;333-&#8195;&#8195;&#8195; </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549 </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2025To03_31_2025" id="ixv-44187">S-1</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;text-align:center"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT </div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center"><div style="font-style:italic;display:inline;">UNDER </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;text-align:center"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF&#160;1933 </div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2025To03_31_2025" id="ixv-44188">Scilex Holding Company</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as specified in its charter) </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellspacing="0" cellpadding="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:stateprovnameen" id="ixv-44189">Delaware</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2025To03_31_2025" id="ixv-44190">2836</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2025To03_31_2025" id="ixv-44191">92-1062542</ix:nonNumeric></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</div><div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Primary Standard Industrial</div><div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Classification Code Number)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</div><div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Scilex Holding Company </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2025To03_31_2025" id="ixv-44192">960 San Antonio Road</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2025To03_31_2025" id="ixv-44193">Palo Alto</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden145656812;display:inline;">CA</div>&#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2025To03_31_2025" id="ixv-44194">94303</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2025To03_31_2025" id="ixv-44195">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2025To03_31_2025" id="ixv-44196">516-4310</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Jaisim Shah </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Chief Executive Officer&#160;&amp; President </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-44197">960 San Antonio Road</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-44198">Palo Alto</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden145656811;display:inline;">CA</div>&#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-44199">94303</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-44200">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-44201">516-4310</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Jeffrey T. Hartlin, Esq. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Elizabeth A. Razzano, Esq. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Paul Hastings LLP </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">1117 S. California Avenue </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Palo Alto, CA&#160;94304 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(650) 320-1800 </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public:</div> As soon as practicable after this registration statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of&#160;1933, check the following box.&#8194;&#9746; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellspacing="0" cellpadding="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:18%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:55%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:22%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:entityfilercategoryen" id="ixv-44202">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:boolballotbox" id="ixv-44203">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:boolballotbox" id="ixv-44204">&#9746;</ix:nonNumeric></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:boolballotbox" id="ixv-44205">&#9746;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of&#160;1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div style="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt)"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p></div><div style="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt)"> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED AUGUST 4, 2025 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 1,390,443 Shares of Common </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">This prospectus relates to the resale, from time to time, of up to an aggregate of 1,390,443 shares (the &#8220;Resale Shares&#8221;) of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), of Scilex Holding Company (the &#8220;Company,&#8221; &#8220;Scilex,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) by Tumim Stone Capital, LLC (the &#8220;Selling Stockholder&#8221; or &#8220;Tumim&#8221;), or its permitted transferees or other successors-in-interest. The Resale Shares included in this prospectus consist of (i)&#160;shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Stockholder, from time to time after the date of this prospectus, pursuant to a common stock purchase agreement we entered into with the Selling Stockholder on July&#160;22, 2025 (the &#8220;Tumim Purchase Agreement&#8221;), in which the Selling Stockholder has committed to purchase from us, at our discretion, up to the lesser of: (A)&#160;$100,000,000 of Common Stock and (B)&#160;1,390,443 shares of Common Stock (which includes the Commitment Shares (as defined below) and represents the &#8220;Exchange Cap&#8221; (as defined in the Tumim Purchase Agreement), subject to terms and conditions specified in the Tumim Purchase Agreement (the &#8220;Tumim Equity Financing&#8221;). As consideration for the Selling Stockholder&#8217;s irrevocable commitment to purchase shares of our Common Stock at our election and in our discretion from time to time after the date of this prospectus, upon the terms and subject to the satisfaction of the conditions set forth in the Tumim Purchase Agreement, we have agreed to issue the Selling Stockholder 150,000 shares of Common Stock pursuant to the terms of the Tumim Purchase Agreement (the &#8220;Commitment Shares&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">The Selling Stockholder, or its permitted transferees or other successors-in-interest, may offer and sell the Resale Shares in a number of different ways and at varying prices, including through public or private transactions at prevailing market prices, at prices related to prevailing market prices, or at privately negotiated prices. We provide additional information about how the Selling Stockholder may sell the Resale Shares in the &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; section on page&#160;266 of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are not offering any shares of Common Stock for sale under this prospectus and will not receive proceeds from the sale of the Resale Shares by the Selling Stockholder, if any. We are registering the offer and resale of the Resale Shares to satisfy contractual obligations owed by us to the Selling Stockholder pursuant to the Tumim Purchase Agreement and documents ancillary thereto, including the Registration Rights Agreement we entered into with the Selling Stockholder on July&#160;22, 2025, in connection with the Tumim Equity Financing (the &#8220;Tumim Registration Rights Agreement&#8221;). Our registration of the Resale Shares does not mean that the Selling Stockholder will offer or sell any of the Resale Shares. If the 1,390,443 Resale Shares offered by the Selling Stockholder under this prospectus were issued and outstanding as of the date hereof, such Resale Shares would represent, as of the date hereof, approximately 16.7% of the total number of shares of our Common Stock outstanding as of July&#160;31, 2025, and approximately 24.7% of the total number of outstanding shares of our Common Stock held by non-affiliates as of July&#160;31, 2025. Any Resale Shares resold hereunder will have been issued by us and acquired by the Selling Stockholder prior to such resale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">The Selling Stockholder is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Selling Stockholder will pay or assume discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar expenses, if any, incurred for the sale of the Resale Shares. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting fees. No placement agent participated in this offering. See the section of this prospectus titled &#8220;Plan of Distribution&#8221; for additional information. We will bear all costs, expenses and fees in connection with the registration of the shares of our Common Stock hereunder. The Selling Stockholder will bear all commissions and discounts, if any, attributable to its sales of the Resale Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. On August 1, 2025, the last reported sales price per share of our Common Stock was $13.41. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">On April&#160;15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the &#8220;Reverse Stock Split&#8221;). Unless otherwise noted, the share and per share information in this prospectus reflects the effect of the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of&#160;2012 (the &#8220;JOBS Act&#8221;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings with the Securities and Exchange Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#8220;Where You Can Find More Information&#8221;, and any amendments or supplements carefully before you invest in any of our securities. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;</span><span style="font-weight:bold"><span style="font-style:italic"><a href="#tx942297_7">RISK FACTORS</a></span></span><span style="font-weight:bold">&#8221; BEGINNING ON PAGE 27 OF THIS PROSPECTUS. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#160;&#8195;&#8195;&#8195;&#8195;, 2025 </p></div> <p style="clear:both; font-size:1pt; height:0">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_3">CERTAIN DEFINED TERMS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_4">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_5">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_6">THE TUMIM EQUITY FINANCING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_7">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_8">MARKET AND INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_9">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_10">DETERMINATION OF OFFERING PRICE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_11">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_12">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_13">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_14">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_15">EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_17">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_18">SELLING STOCKHOLDER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_19">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_20">MATERIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_21">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_22">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_23">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_24">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx942297_25">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus supplement and any related free writing prospectus. Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the applicable document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">For Investors Outside the United States</span>: The Selling Stockholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States.<span style="font-weight:bold"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholder may, from time to time, sell the securities described in this prospectus. We will not receive any proceeds from the sale by such Selling Stockholder of the securities offered by it described in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement, any post-effective amendment or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Stockholder takes responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus entitled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221;<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the business combination (the &#8220;Business Combination&#8221;) pursuant to that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022 (as amended, restated or supplemented from time to time, including by Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022) (the &#8220;Merger Agreement&#8221;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#8220;Merger Sub&#8221;), and the pre-Business Combination Scilex Holding Company (&#8220;Legacy Scilex&#8221;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a domestication under Section&#160;388 of the Delaware General Corporation Law, as amended (the &#8220;DGCL&#8221;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Scilex,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#8220;Legacy Scilex&#8221; refer to the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221;<span style="font-style:italic"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>Certain statements contained in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;outlook,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus and our management&#8217;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks, uncertainties or other assumptions and other factors, many of which are outside the control of the Company and our directors, officers and affiliates, that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading &#8220;Risk Factors&#8221; in this prospectus. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements in this prospectus may include, but are not limited to, statements about: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our public securities&#8217; liquidity and trading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise financing in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our expected use of proceeds from future issuances of equity or convertible debt securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our future financial performance, including our revenue, costs of revenue and operating expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our future use of equity or debt financings to execute our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to use cash on hand to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract and retain qualified directors, officers, employees and key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to compete effectively in a highly competitive market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to protect and enhance our corporate reputation and brand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact from future regulatory, judicial and legislative changes in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain regulatory approval of any of our products and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to research, discover and develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to grow and manage growth profitably; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to execute our business plans and strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to prevent, respond to, and recover from a cybersecurity incident; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of any geopolitical conflicts or new or increased international tariffs, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of global economic and political developments, including the conflicts in Ukraine and Israel; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_3">CERTAIN DEFINED TERMS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">April 2024 RDO Common Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 428,572 shares of our Common Stock at an exercise price of $38.50 per share, issued to the investor named in and pursuant to the April 2024 RDO Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">April 2024 RDO Placement Agent Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 34,286 shares of our Common Stock at an exercise price of $43.75 per share, issued to the Placement Agents pursuant to the April 2024 RDO Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">April 2024 RDO Purchase Agreement</span>&#8221; means that certain securities purchase agreement, dated as of April&#160;23, 2024, entered into between us and the investor named therein. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">April 2024 RDO Warrants</span>&#8221; means the April 2024 RDO Common Warrants and the April 2024 RDO Placement Agent Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">A&amp;R Yorkville Purchase Agreement</span>&#8221; means the Amended and Restated Standby Equity Purchase Agreement, dated February&#160;8, 2023, between the Company and Yorkville, amending, restating and superseding the Standby Equity Purchase Agreement dated November&#160;17, 2022 between the Company and Yorkville. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">B. Riley</span>&#8221; means B. Riley Principal Capital II, LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">B. Riley Purchase Agreement</span>&#8221; means the Standby Equity Purchase Agreement, dated January&#160;8, 2023, between the Company and B. Riley. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Board</span>&#8221; means the board of directors of the Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Business Combination</span>&#8221; means the merger contemplated by the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Bylaws</span>&#8221; means the Bylaws of Scilex Holding Company, effective as of November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Incorporation</span>&#8221; means the Restated Certificate of Incorporation of Scilex Holding Company, filed with the Secretary of State of the State of Delaware on November&#160;10, 2022, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing</span>&#8221; means the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Code</span>&#8221; means the Internal Revenue Code of&#160;1986, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Commitment Letter</span>&#8221; means that certain Commitment Side Letter, dated as of June&#160;11, 2024, entered into between us and FSF. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Common Stock</span>&#8221; means the common stock, par value $0.0001&#160;per share, of Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Continental</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Convertible Debentures</span>&#8221; means certain convertible debentures in an aggregate amount of $20,000,000 issued to Yorkville pursuant to a securities purchase agreement dated March&#160;21, 2023 between the Company and Yorkville. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">December 2024 RDO Common Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 1,642,871 shares of our Common Stock, with an exercise price of $22.72 per share, issued to the investors named in and pursuant to the December 2024 RDO Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">December 2024 RDO Pre-Funded Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 68,604 shares of our Common Stock, with an exercise price of $0.0001 per share, issued to the investors named in and pursuant to the December 2024 RDO Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">December 2024 RDO Purchase Agreement</span>&#8221; means that certain securities purchase agreement, dated as of December&#160;11, 2024, entered into among us and the investors named therein. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">December 2024 RDO Warrants</span>&#8221; means the December 2024 RDO Pre-Funded Warrants, the December 2024 RDO Common Warrants and the StockBlock Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">December 2024 Warrants</span>&#8221; means the December 2024 RDO Common Warrants and the StockBlock Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Deposit Warrant</span>&#8221; means the warrant to purchase up to an aggregate of 3,250,000 shares of our Common Stock, with an exercise price of $1.20 per share, issued to FSF pursuant to the Commitment Letter. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">DGCL</span>&#8221; means the General Corporation Law of the State of Delaware, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Domestication</span>&#8221; means the change of our domicile pursuant to a transfer by way of continuation of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our de-registration in the Cayman Islands. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Effective Time</span>&#8221; means the time at which the Business Combination became effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Equity Incentive Plan</span>&#8221; means the Scilex Holding Company&#160;2022 Equity Incentive Plan, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">ESPP</span>&#8221; means the Scilex Holding Company&#160;2022 Employee Stock Purchase Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; means the Securities Exchange Act of&#160;1934, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Exchange Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 500,000 shares of our Common Stock, with an exercise price of $40.00 per share, issued pursuant to the Warrant Exchange Agreements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">February 2024 BDO Common Warrants</span>&#8221; means the February 2024 BDO Firm Warrants and the February 2024 BDO Optional Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">February 2024 BDO Firm Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 168,068 shares of our Common Stock, with an exercise price of $59.50 per share, issued to the Underwriters pursuant to the February 2024 BDO Underwriting Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">February 2024 BDO Optional Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 882,352 shares of our Common Stock, with an exercise price of $0.0092 per share, to which Underwriters had an option to purchase for a period of 30 days from the date of and pursuant to the February 2024 BDO Underwriting Agreement (which option expired unexercised). The number of shares subject to, and the exercise price of, the February 2024 BDO Optional Warrants is reflected on a pre-Reverse Stock Split basis as such warrants were never issued. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">February 2024 BDO Representative Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 13,446 shares of our Common Stock, with an exercise price of $74.38 per share, issued to StockBlock and Rodman&#160;&amp; Renshaw LLC, pursuant to the February 2024 BDO Underwriting Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">February 2024 BDO Underwriting Agreement</span>&#8221; means that certain underwriting agreement, dated as of February&#160;29, 2024, entered into among us, StockBlock and Rodman&#160;&amp; Renshaw LLC, as the representatives of the Underwriters. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Fee Warrant</span>&#8221; means the warrant to purchase up to an aggregate of 250,000 shares (on a pre-Reverse Stock Split basis) of our Common Stock, with an exercise price of $1.20 per share (on a pre-Reverse Stock Split basis), issued to IVI pursuant to a letter agreement, dated July&#160;16, 2024, entered into among us, FSF and IVI. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">FSF</span>&#8221; means FSF 33433 LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Inducement Plan</span>&#8221; means the Scilex Holding Company 2023 Inducement Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IPO</span>&#8221; refers to the initial public offering of&#160;13,800,000 Units (on a pre-Reverse Stock Split basis) of Vickers consummated on January&#160;11, 2021. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IRS</span>&#8221; means the United States Internal Revenue Service. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IVI</span>&#8221; means IVI 66766 LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex</span>&#8221; means the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Common Stock</span>&#8221; means the common stock of Legacy Scilex, par value $0.0001&#160;per share, prior to the Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Preferred Stock</span>&#8221; means the Series A Preferred Stock, par value $0.0001&#160;per share, of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to that certain Contribution and Satisfaction of Indebtedness Agreement, dated as of September&#160;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement</span>&#8221; means that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement Amendment</span>&#8221; means that Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022, by and among us, Merger Sub and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Sub</span>&#8221; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq</span>&#8221; means The Nasdaq Stock Market LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq Listing Rules</span>&#8221; means the rules and listing standards of Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">October 2024 Noteholder Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 214,284 shares of our Common Stock, with a current exercise price of $36.40 per share, issued to the Tranche B Noteholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">October 2024 Placement Agent Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 104,848 shares of Common Stock, with a current exercise price of $36.40 per share, issued to StockBlock and Rodman&#160;&amp; Renshaw LLC in connection with the Tranche B Securities Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">October 2024 Warrants</span>&#8221; means the October 2024 Noteholder Warrants and the October 2024 Placement Agent Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed</span>&#8221; means Oramed Pharmaceuticals Inc., a Delaware corporation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed Amendment</span>&#8221; means that certain amendment letter, dated as of January&#160;21, 2025, entered into between us and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed Note</span>&#8221; means that certain senior secured promissory note issued by us on September&#160;21, 2023 to Oramed due 18 months from the date of issuance in the principal amount of $101,875,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed RRA</span>&#8221;means that certain Registration Rights Agreement, dated as of September&#160;21, 2023, entered into between us and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Penny Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 13,000,000 shares of our Common Stock, each with an exercise price of $0.01 per share, issued to Oramed pursuant to the Scilex-Oramed SPA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Private Warrants</span>&#8221; means, on a pre-Reverse Stock Split basis, the&#160;6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan)&#160;Pte Ltd consummated on January&#160;11, 2021 (of which&#160;2,736,000 were forfeited pursuant to that certain Sponsor Support Agreement, dated March&#160;17, 2022, by and among the Sponsors, Pei Wei Woo, Suneel Kaji, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Steve Myint and Scilex, Inc. (f/k/a Scilex Holding Company) and&#160;3,104,000 were transferred to Sorrento pursuant to that certain Warrant Transfer Agreement, dated as of October&#160;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim Group LLC, in each case in connection with the Business Combination). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Public Warrants</span>&#8221; means the redeemable warrants that were included in the Units that, following the Business Combination and the Reverse Stock Split, entitle the holder of each whole warrant to purchase (1/35<sup style="font-size:75%; vertical-align:top">th</sup>)&#160;of a share of Common Stock at a price of $402.50&#160;per whole share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Reverse Stock Split</span>&#8221; means the reverse stock split of our Common Stock at a ratio of 1-for-35, which became effective on April&#160;15, 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Scilex-Oramed SPA</span>&#8221; means the Securities Purchase Agreement, dated as of September&#160;21, 2023, by and among us, Oramed and Acquiom Agency Services LLC, as the collateral agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SCLX JV</span>&#8221; means SCLX Stock Acquisition JV LLC, our indirect wholly owned subsidiary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SEC</span>&#8221; means the U.S.&#160;Securities and Exchange Commission. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; means the Securities Act of&#160;1933, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Series A Certificate of Designations</span>&#8221; means the Certificate of Designations of the Company, designating the series of preferred stock, par value $0.0001&#160;per share, of the Company as &#8220;Series A Preferred Stock&#8221;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Series A Preferred Stock</span>&#8221; means the preferred stock, par value $0.0001&#160;per share, of the Company, designated as Series A Preferred Stock pursuant to the Series A Certificate of Designations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento</span>&#8221; means Sorrento Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Group</span>&#8221; means Sorrento together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento SPA</span>&#8221; means that certain Stock Purchase Agreement, dated September&#160;21, 2023, between us and Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Trigger Event</span>&#8221; means the time that the Sorrento Group first ceases to beneficially own more than&#160;50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SPAC Warrants</span>&#8221; means the Private Warrants and the Public Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsors</span>&#8221; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan)&#160;Pte Ltd. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">StockBlock</span>&#8221; means StockBlock Securities LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">StockBlock Warrants</span>&#8221; means the warrants to purchase up to an aggregate of 131,472 shares of our Common Stock, with an exercise price of $25.81 per share, issued to StockBlock pursuant to the December 2024 RDO Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Stockholder Agreement</span>&#8221; means the Stockholder Agreement, dated as of September&#160;12, 2022, between Vickers and Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tranche B Investors</span>&#8221; means Nomis Bay Ltd., BPY Limited and 3i, LP. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tranche B Letter Agreement</span>&#8221; means that certain letter agreement, dated as of October&#160;2, 2025, entered into between us and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tranche B Noteholders</span>&#8221; means the Tranche B Investors and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tranche B Notes</span>&#8221; means those certain tranche B senior secured convertible notes issued by us on October&#160;8, 2024, to the Tranche B Noteholders, due on the second anniversary of the issuance date in the principal amount of $50.0 million. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tranche B Securities Purchase Agreement</span>&#8221; means that certain securities purchase agreement, dated as of October&#160;7, 2024, among us, the Tranche B Investors and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tumim Equity Financing</span>&#8221; means the equity line of credit transaction entered into via the Tumim Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tumim Purchase Agreement</span>&#8221; means the Common Stock Purchase Agreement, dated as of July&#160;22, 2025, between Scilex Holding Company and Tumim Stone Capital, LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Tumim Registration Rights Agreement</span>&#8221; means the Registration Rights Agreement, dated as of July&#160;22, 2025, between Scilex Holding Company and Tumim Stone Capital, LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Units</span>&#8221; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and one-half of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers</span>&#8221; means Vickers Vantage Corp. I, our predecessor company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Ordinary Shares</span>&#8221; means (i)&#160;the ordinary shares, par value $0.0001&#160;per share, of Vickers prior to the Domestication and (ii)&#160;the Common Stock following the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Warrant Exchange Agreements</span>&#8221; means each of the Warrant Exchange Agreements, dated July&#160;22, 2025, between us and each of the investors named therein. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Yorkville</span>&#8221; means YA II PN, Ltd., a Cayman Islands exempt limited partnership. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_4">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial products are: (i)&#160;ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain; (ii)&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup>, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii)&#160;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, which launched in June 2024. In addition, we have three product candidates: (i)&#160;SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which we have completed a Phase 3 study; (ii)&#160;SP-103 (lidocaine topical system) 5.4% (&#8220;SP-103&#8221;), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which we have completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;); and (iii)&#160;SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#8220;SP-104&#8221;), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed. We believe our currently approved products and future product candidates, if approved by the FDA, could uniquely address what we believe are the significant unmet needs of the targeted populations and become the preferred treatment option for their respective indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions. Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies. We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our first commercial product, ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8% in October 2018. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. ZTlido is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We license the rights to ZTlido from and rely exclusively on Oishi and Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;) pursuant to the Product Development Agreement (the &#8220;Product Development Agreement&#8221;) dated as of May&#160;11, 2011, by and among Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), Oishi and Itochu, and the Commercial Supply Agreement (the &#8220;Commercial Supply Agreement&#8221;), dated as of February&#160;16, 2017, by and among Scilex Pharma, Oishi and Itochu. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. In 2024, there were more than 206&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our second commercial product, ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> in April 2023.&#160;We acquired the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral solution) and the commercialization thereof in the United States and Canada from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. in February 2023.&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> is a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. In January 2025, we received approval from Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB for the acute treatment of migraine with or without aura in Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our third commercial product, GLOPERBA, in June 2024. We acquired certain rights to GLOPERBA and the exclusive license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;, pursuant to a License and Commercialization Agreement with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;), dated as of June&#160;14, 2022, which agreement was subsequently amended on January&#160;16, 2025 (such agreement, as so amended, the &#8220;Romeg License Agreement&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted us (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States, and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;. GLOPERBA is an FDA-approved, liquid, oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 9.2&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. Non-steroidal anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We commercialized GLOPERBA in June 2024 and believe we are well positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. In January 2025, we in-licensed the rights to commercialize GLOPERBA outside the U.S. For more information, please see the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired SP-102 (&#8220;SP-102&#8221; or &#8220;SEMDEXA&#8221;) from Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;) in March 2019 and are developing SP-102 to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by off-label epidural steroid injections (&#8220;ESI&#8221;), which are administered over 12&#160;million times annually in the United States. SEMDEXA&#8482; has been granted fast track designation by the FDA and, if approved, could become the only FDA-approved ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2022. We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute LBP associated with muscle spasms. SP-103 was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
toxicity or increased application site reactions with daily applications over one month treatment. SP-103 received FDA Fast Track status in LBP. We will continue to analyze the SP-103 Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown promising top-line efficacy and safety results. SP-103, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute pain. We are developing SP-104 as a novel delayed-release formulation of low-dose naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used off-label to treat fibromyalgia. There are no low-dose formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates completed and anticipated milestones for our current commercial products and novel product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g942297g78h35.jpg" alt="LOGO" style="width:6.30556in;height:2.32466in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>Our principal executive offices are located at&#160;960 San Antonio Road, Palo Alto, California&#160;94303, and our telephone number is (650)&#160;516-4310. For additional information about us, please see the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221;<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>See the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; in this prospectus for a discussion of some of the risks related to the execution of our business strategy.<span style="font-style:italic"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the Business Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&#160;prior to the Closing, Vickers effected the Domestication and (ii)&#160;at the Closing, and following the Domestication, the parties effected the Merger, with Legacy Scilex as the </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surviving company in the Merger, and, after giving effect to such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#8217;s shareholders at a meeting held on November&#160;9, 2022. In connection with the Business Combination, Vickers changed its name to &#8220;Scilex Holding Company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the time at which the Business Combination became effective (the &#8220;Effective Time&#8221;), (i)&#160;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive&#160;0.673498 shares of our Common Stock, (ii)&#160;each share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&#160;one share of Series A Preferred Stock (as defined below) and (b)&#160;one-tenth of one share of our Common Stock, and (iii)&#160;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the right to receive a comparable option to purchase shares of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>The rights of holders of our Common Stock and Warrants (as defined below) are governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement (the &#8220;Warrant Agreement&#8221;), dated January&#160;6, 2021, between Vickers and Continental Stock Transfer&#160;&amp; Trust Co. (&#8220;Continental&#8221;). See sections of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221; and &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>.&#8221;<span style="font-style:italic"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pending Merger of Semnur </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed by us, on August&#160;30, 2024, Semnur, our majority owned subsidiary, entered into an agreement and plan of merger (as amended by Amendment No.&#160;1 to the Agreement and Plan of Merger, dated April&#160;16, 2025 and Amendment No.&#160;2 to the Agreement and Plan of Merger, dated July&#160;22, 2025, the &#8220;Semnur Business Combination Agreement&#8221;) with Denali Capital Acquisition Corp., a Cayman Islands exempted company (&#8220;Denali&#8221;), and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#8220;Denali Merger Sub&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Denali Merger&#8221;), and (ii)&#160;prior to the closing of the Denali Merger, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the DGCL, and&#160;de-register&#160;in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Denali Domestication&#8221;). Upon the closing of the Denali Merger (the &#8220;Denali Merger Closing&#8221;), it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Common Shares.&#8221; Shares of Denali Series A preferred stock following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares.&#8221; Warrants to purchase New Semnur Common Shares following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Warrants.&#8221; The date on which the Denali Merger Closing actually occurs is hereinafter referred to as the &#8220;Semnur Business Combination Closing Date.&#8221; The Denali Merger and the other transactions contemplated by the Semnur Business Combination Agreement are hereinafter referred to as the &#8220;Semnur Business Combination.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Denali Domestication and at the effective time of the Denali Merger (the &#8220;Denali Merger Effective Time&#8221;): (i)&#160;each share of common stock of Semnur issued and outstanding immediately prior to the Denali </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Effective Time will be automatically converted into the right to receive, without interest, a number of New Semnur Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii)&#160;each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Denali Merger Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and&#160;(b)&#160;one-tenth&#160;of one New Semnur Common Share, and (iii)&#160;subject to Denali&#8217;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur common stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Denali Merger Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Business Combination is expected to close during the third quarter of 2025, following the receipt of the required approval by Denali&#8217;s shareholders (prior to the Denali Domestication) and the satisfaction or waiver of other customary closing conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, our Board approved the Reverse Stock Split of the Common Stock at a ratio of 1-for-35, which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share. Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. We also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Bio JV </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2025, we and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer&#8217;s disease. We contributed 5.0&#160;million shares of Semnur Common Stock owned by us to Scilex Bio, Inc. in exchange for a 60% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a 40% ownership interest in Scilex Bio, Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed Penny Warrant Repurchase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed and as described elsewhere in this prospectus, on September&#160;21, 2023, we issued Penny Warrants to purchase up to an aggregate of 6,500,000 shares of Common Stock to Oramed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, we entered into an Option Agreement for the Repurchase of Warrants with Oramed (the &#8220;Option Agreement&#8221;), pursuant to which, among other things, Oramed granted an option (the &#8220;Option&#8221;) to us to repurchase the Penny Warrants in two tranches (the &#8220;Penny Warrant Repurchase&#8221;) for an aggregate purchase price of $27,000,000 (the &#8220;Penny Warrant Repurchase Amount&#8221;), subject to the terms and conditions set forth </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therein. In consideration of the Option, we agreed to pay $1,500,000 (the &#8220;Option Payment Amount&#8221;) to Oramed in two equal installments occurring on or before August&#160;8, 2025 and December&#160;16, 2025, respectively. Provided that we have made the applicable option payment on or before such dates, we shall be entitled to purchase the Penny Warrants as follows: (i)&#160;on or before September&#160;30, 2025, we may repurchase 3,130,000 Penny Warrants for $13,000,000 and (ii)&#160;on or before December&#160;31, 2025, we may repurchase 3,370,000 Penny Warrants for $14,000,000. Additionally, if we effect the Penny Warrant Repurchase and pay the Option Payment Amount and Penny Warrant Repurchase Amount in full, in accordance with the terms of the Option Agreement, then the maturity date of the Oramed Note, shall be extended to March&#160;31, 2026 and any make-whole payment due thereunder upon prepayment shall be waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oramed shall have the right to terminate the Option Agreement if we (i)&#160;fail to make certain payments thereunder or (ii)&#160;have not exercised the Option by the applicable dates set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Option Agreement, we have agreed that, if the Option Agreement is terminated pursuant to the terms set forth therein, the Company will use commercially reasonable efforts to obtain the approval of our stockholders to permit the issuance of shares of Common Stock in excess of the Stockholder Approval Cap (as defined therein) upon exercise of any Penny Warrants retained by Oramed following such termination, subject to the terms and conditions set forth therein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Exchange Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, we entered into Warrant Exchange Agreements (each, a &#8220;Warrant Exchange Agreement&#8221; and collectively, the &#8220;Warrant Exchange Agreements&#8221;) with certain holders (the &#8220;Exchanging Warrant Holders&#8221;) of our existing Tranche B warrants to purchase shares of Common Stock (the &#8220;Existing Tranche B Warrants&#8221;). Pursuant to the Warrant Exchange Agreements, we and the Exchanging Warrant Holders, in reliance on Section&#160;3(a)(9) of the Securities Act, effected a voluntary securities exchange whereby the Exchanging Warrant Holders exchanged the Existing Tranche B Warrants, which were exercisable for an aggregate of 107,142 shares of Common Stock at an exercise price of $36.40 per share, originally issued pursuant to that certain Securities Purchase Agreement, dated October&#160;7, 2024, by and among us and the investors named therein, for warrants to purchase an aggregate of 500,000 shares of Common Stock (the &#8220;New Warrants&#8221;) at an exercise price of $40.00 per share. The New Warrants were immediately exercisable, but may only be exercised on a cash basis on or after the earlier of (i)&#160;the date that is 90 days following the Closing Date (as defined in the Warrant Exchange Agreement), and (ii)&#160;the initial date after the date of the Warrant Exchange Agreement that a registration statement is effective and available for the issuance of the shares of Common Stock underlying the New Warrants to the holders of the New Warrants (or the resale of shares of Common Stock underlying the New Warrants); provided, however, the New Warrants may only be exercised on a cashless basis if there is no registration statement to cover the issuance of the shares of Common Stock underlying the Warrants or the resale of such shares. The New Warrants have an expiration date of October&#160;8, 2029. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the JOBS Act. As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of&#160;2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S.&#160;generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Emerging Growth Company</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the initial public offering of 13,800,000 Units (on a pre-Reverse Stock Split basis) of Vickers consummated on January&#160;11, 2021 (the &#8220;IPO&#8221;), (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization, and we may be unable to generate sufficient revenue to support our operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The terms of the Oramed Note and the Tranche B Notes impose certain operating and financial covenants that restrict our operating and financial flexibility and any failure to comply with such covenants could result in an event of default that could adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to generate sufficient cash to service our indebtedness and other liquidity needs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Commercial Operations and Product Development </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We obtain, or historically have obtained, our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the intellectual property we in-license from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize SP-103 would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are party to the Romeg License Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg License Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Government Regulations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA and comparable non-U.S. regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. Moreover, gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any approved product candidate will be subject to ongoing and continued regulatory requirements, which may result in significant expense and limit our ability to commercialize such products. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Relationship with Sorrento </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Sorrento previously supported many of our important corporate functions. Accordingly, our historical consolidated financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we have and will continue to incur incremental costs as a stand-alone public company. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to this Offering </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">It is not possible to predict the actual number of shares we will sell under the Tumim Purchase Agreement to the Selling Stockholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the Tumim Purchase Agreement with the Selling Stockholder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The sale and issuance of our Common Stock to the Selling Stockholder will cause dilution to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Investors who buy shares of Common Stock at different times will likely pay different prices. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock to the Selling Stockholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Ownership of our Common Stock </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#8220;Vickers Vantage Corp. I&#8221; on February&#160;21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&#160;9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&#160;9, 2022, we changed our name to &#8220;Scilex Holding Company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at&#160;960 San Antonio Road, Palo Alto, California&#160;94303, and our telephone number is (650)&#160;516-4310. Our website address is www.scilexholding.com. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov</span>. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_5">THE OFFERING </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resale of Common Stock </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by the Selling Stockholder </p></td>
<td>Up to 1,390,443 shares of our Common Stock, consisting of (i)&#160;150,000 Commitment Shares and (ii)&#160;up to 1,240,443 shares of Common Stock we may elect, in our discretion, to issue and sell to the Selling Stockholder under the Tumim Purchase Agreement from time to time. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding before this Offering<sup style="font-size:75%; vertical-align:top">(1)</sup> . </p></td>
<td>6,955,697 shares of Common Stock </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding after the Offering </p></td>
<td>8,346,140 shares of Common Stock </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </p></td>
<td>The Selling Stockholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. However, we may receive up to $100,000,000 in aggregate gross proceeds under the Tumim Purchase Agreement from sales of Common Stock that we may elect to make to the Selling Stockholder pursuant to the Tumim Purchase Agreement, if any, from time to time in our discretion. We expect to use the net proceeds that we receive under the Tumim Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. See &#8220;Use of Proceeds.&#8221; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholder. See &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221; elsewhere in this prospectus. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </p></td>
<td>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>See &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 27 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. </td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The number of shares of Common Stock outstanding assumes that an aggregate of 6,955,697 shares are outstanding as of July&#160;31, 2025, and excludes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">18,657 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma&#160;2017 Plan&#8221;) with a weighted average exercise price of $27.03 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">431,287 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;2019 Stock Option Plan of Scilex, Inc. (the &#8220;2019 Stock Option Plan&#8221;) with a weighted average exercise price of $60.55 per share; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">560,121 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), with a weighted average exercise price of $203.07 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 507,063 shares of Common Stock available for future issuance under the Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 166,502 shares of Common Stock available for future issuance under the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to&#160;40,000 shares of Common Stock available for future issuance under the Scilex Holding Company&#160;2023 Inducement Plan (the &#8220;Inducement Plan&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 6,958,204 SPAC Warrants (as defined below on a pre-Reverse Stock Split basis), which are currently exercisable for an aggregate of up to 198,805 shares (on a post-Reverse Stock Split basis) of Common Stock, with an exercise price of $402.50 per whole share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">108,686 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $59.50&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">13,446 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $74.38&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">428,572 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $38.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">34,286 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $43.75&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">500,000 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $40.00 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">211,990 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with a current exercise price of $36.40 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">914,822 shares of Common Stock issuable upon conversion of the senior secured convertible notes, with a current conversion price of $36.40 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,642,871 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $22.72 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">131,472 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $25.81 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">3,250,000 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $1.20 per share; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,500,000 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $0.01 per share. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_6">THE TUMIM EQUITY FINANCING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, we entered into the Tumim Purchase Agreement with Tumim, pursuant to which we have the right, but not the obligation, to sell to Tumim, and Tumim is obligated to purchase up to the lesser of: (a)&#160;$100.0 million of our Common Stock (the &#8220;Total Commitment&#8221;), and (b)&#160;the Exchange Cap (as defined in the Tumim Purchase Agreement), at our sole direction from time to time over the term of the Tumim Purchase Agreement, subject to certain terms, conditions and limitations in the Tumim Purchase Agreement (the &#8220;Tumim Equity Financing&#8221;). In accordance with our obligations under the Tumim Registration Rights Agreement, we have filed the registration statement of which this prospectus forms a part with the SEC to register under the Securities Act the resale by Tumim of up to 1,390,443 shares of Common Stock, consisting of an aggregate amount of 150,000 Commitment Shares and up to 1,240,443 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to Tumim, from time to time under the Tumim Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the right to commence any sales of our Common Stock to Tumim under the Tumim Purchase Agreement until the date on which all of the conditions to Tumim&#8217;s purchase obligation set forth in the Tumim Purchase Agreement have been satisfied (such date, the &#8220;Commencement Date&#8221;), including that the registration statement of which this prospectus forms a part be declared effective by the SEC. From and after such date, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month immediately following&#160;the&#160;24-month&#160;anniversary&#160;of the date on which this registration statement has been declared effective by the SEC, to direct Tumim to purchase a number of shares of Common Stock not to exceed the applicable VWAP Purchase Maximum Amount as described further below under the heading &#8220;&#8212;<span style="font-style:italic">Purchase of Shares Under the Tumim Purchase Agreement</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Common Stock to Tumim. Actual sales of shares of our Common Stock to Tumim under the Tumim Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Tumim Purchase Agreement, we may not sell any shares of Common Stock thereunder and Tumim shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed 1,390,443 shares of Common Stock, which number of shares is equal to 19.99% of the aggregate amount of Common Stock issued and outstanding as of the date of the Tumim Purchase Agreement, unless: (i)&#160;we obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap, or (ii)&#160;the average price of all applicable sales of our Common Stock to Tumim under the Tumim Purchase Agreement equals or exceeds $8.09 (which is the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules)), such that such issuances and sales of our Common Stock to Tumim under the Tumim Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq Listing Rules. The Tumim Purchase Agreement also prohibits us from directing Tumim to purchase any shares of our Common Stock if those shares, when aggregated with all other shares of our Common Stock then beneficially owned by Tumim and its affiliates, would result in Tumim and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of our outstanding Common Stock (the &#8220;Beneficial Ownership Limitation&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds from sales, if any, under the Tumim Purchase Agreement will depend on the frequency and prices at which we sell shares of our Common Stock to Tumim. To the extent we sell shares under the Tumim Purchase Agreement, we currently plan to use any proceeds therefrom for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Tumim&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the Tumim Purchase Agreement, we will issue 150,000 Commitment Shares to Tumim at the time the registration statement of which this prospectus forms a part be declared effective by the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tumim Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purchase of Shares Under the Tumim Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the Commencement Date, we will have the right, but not the obligation, from time to time at our sole discretion until the first day of the month immediately following&#160;the&#160;24-month&#160;anniversary&#160;of the date on which this registration statement has been declared effective by the SEC, to direct Tumim to purchase amounts of our Common Stock under the Tumim Purchase Agreement, that we specify in irrevocable written notices to Tumim (each such notice, a &#8220;VWAP Purchase Notice&#8221; and the number of shares specified in such notice, the &#8220;VWAP Purchase Share Amount&#8221; and each such purchase, a &#8220;VWAP Purchase&#8221;) that we deliver to Tumim under the Tumim Purchase Agreement on any trading day. The VWAP Purchase Share Amount set forth in any VWAP Purchase Notice may not exceed that number of shares of Common Stock that is equal to the lowest of (such number, the &#8220;VWAP Purchase Maximum Amount&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">100% of the average daily trading volume in the Common Stock on the Trading Market (as defined in the Tumim Purchase Agreement) (or, in the event the Common Stock is then listed on an Eligible Market (as defined in the Tumim Purchase Agreement), 100% of the average daily trading volume in the Common Stock on such Eligible Market) for the five consecutive trading-day period ending on (and including) the trading day immediately preceding the applicable VWAP Purchase Exercise Date (as defined in the Tumim Purchase Agreement) for such VWAP Purchase; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the product (rounded up or down to the nearest whole number) obtained by multiplying (x)&#160;the daily trading volume in the Common Stock on the Trading Market (or an Eligible Market, as applicable) on the applicable VWAP Purchase Exercise Date for such VWAP Purchase by (y)&#160;0.40; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the quotient (rounded up or down to the nearest whole number) obtained by dividing (x)&#160;$3,000,000 by (y)&#160;the VWAP (as defined in the Tumim Purchase Agreement) on the Trading Market (or an Eligible Market, as applicable) on the trading day immediately preceding the applicable VWAP Purchase Exercise Date for such VWAP Purchase (in each case to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction during the applicable period). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumim is obligated to accept each VWAP Purchase Notice prepared and timely delivered on the VWAP Purchase Exercise Date by us in accordance with the terms of and subject to the satisfaction of the conditions contained in the Tumim Purchase Agreement; provided that, Tumim shall not be obligated to purchase any shares of Common Stock set forth in an otherwise valid VWAP Purchase Notice in excess of the VWAP Purchase Maximum Amount. We may deliver a VWAP Purchase Notice on a VWAP Purchase Exercise Date, provided that: (i)&#160;we may not deliver more than one VWAP Purchase Notice Tumim on any single trading day, (ii)&#160;we may not deliver a VWAP Purchase notice to Tumim on any trading day during the period until the termination of the applicable VWAP Purchase Valuation Period (as defined in the Tumim Purchase Agreement) for a prior VWAP Purchase Notice delivered by us to Tumim, (iii)&#160;all shares subject to all prior VWAP Purchase Notices (as applicable) previously delivered by us to Tumim have in fact been received by Tumim as DWAC Shares prior to our delivery of such VWAP Purchase Notice to Tumim. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of the shares of Common Stock that we may direct Tumim to purchase pursuant to a Purchase under the Tumim Purchase Agreement will be equal to 97% of the lowest daily dollar volume-weighted average price for the Common Stock during the Three-Day VWAP Purchase Valuation Period (as defined in the Tumim Purchase Agreement), or 96% of the lowest daily dollar volume-weighted average price for the Common Stock during the One-Day VWAP Purchase Valuation Period (as defined in the Tumim Purchase Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payment for, against simultaneous delivery of, shares in respect of each purchase and sale under the Tumim Purchase Agreement will be settled on the applicable purchase settlement date immediately following the applicable VWAP Purchase Valuation Period for such VWAP Purchase, as set forth in the Tumim Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conditions to Commencement and Delivery of VWAP Purchase Notices </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to deliver VWAP Purchase Notices to Tumim under the Tumim Purchase Agreement is subject to the satisfaction, both at the time of Commencement and at the time of delivery by us of any VWAP Purchase Notice to Tumim, of certain conditions, all of which are entirely outside of Tumim&#8217;s control, including, among other things, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accuracy in all material respects of certain of our representations and warranties included in the Tumim Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">us having performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Tumim Purchase Agreement and the Tumim Registration Rights Agreement to be performed, satisfied or complied with by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of the Registration Statement that includes this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the SEC shall not have issued any stop order suspending the effectiveness, prohibiting or suspending the use of the Registration Statement that includes this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there shall not have occurred any event and there shall not exist any condition or state of facts, which makes any statement of a material fact made in the Registration Statement that includes this prospectus untrue or which requires the making of any additions to or changes to the statements contained therein in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein not misleading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading in our Common Stock shall not have been suspended by the SEC or Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we shall have complied with all applicable federal, state and local governmental laws, rules, regulations and ordinances in connection with the execution, delivery and performance of the Tumim Purchase Agreement and the Tumim Registration Rights Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any statute, regulation, order, decree, writ, ruling or injunction by any court or governmental authority of competent jurisdiction which prohibits the consummation of or that would materially modify or delay any of the transactions contemplated by the Tumim Purchase Agreement or the Tumim Registration Rights Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any action, suit or proceeding before any arbitrator or any court or governmental authority seeking to restrain, prevent or change the transactions contemplated by the Tumim Purchase Agreement or the Tumim Registration Rights Agreement, or seeking material damages in connection with such transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of the Shares that may be issued pursuant to the Tumim Purchase Agreement shall have been approved for listing or quotation on Nasdaq (or if the Common Stock is not then listed on Nasdaq, on any Eligible Market (as defined in the Tumim Purchase Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no condition, occurrence, state of facts or event constituting a Material Adverse Effect (as defined in the Tumim Purchase Agreement) shall have occurred and be continuing; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no commencement of any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance by us of the Commitment Shares to Tumim; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the receipt by Tumim of the opinions, bring-down opinions and negative assurances from outside counsel to us in the forms mutually agreed to by us and Tumim prior to the date of the Tumim Purchase Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Short-Selling or Hedging by Tumim </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumim has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Prohibition on Variable Rate Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the period commencing on the date of the Tumim Purchase Agreement and expiring on the earlier of (i)&#160;the 24-month anniversary of the Effective Date and (ii)&#160;90 days following July&#160;22, 2025 (i.e., the date of the Tumim Purchase Agreement), we have agreed not to effect or enter into an agreement to effect any issuance by us of Common Stock or Common Stock Equivalents (as such terms are defined in the Tumim Purchase Agreement) (or a combination of units thereof) involving a Variable Rate Transaction (as such term is defined in the Tumim Purchase Agreement), subject to certain exceptions set forth therein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination of the Tumim Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the Tumim Purchase Agreement, the Tumim Purchase Agreement will terminate automatically on the earliest to occur of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the first day of the calendar month immediately following the 24-month anniversary of the date on which the initial registration statement or any subsequent registration statement is declared effective by the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the date on which Tumim shall have purchased shares of Common Stock under the Tumim Purchase Agreement for an aggregate gross purchase price equal to its Total Commitment under the Tumim Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the date on which the Common Stock shall have failed to be listed or quoted on Nasdaq or any other Eligible Market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the 30<sup style="font-size:75%; vertical-align:top">th</sup> full trading day next following the date on which, pursuant to or within the meaning of any bankruptcy law, the Company commences a voluntary case or any person or entity, whether natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority commences a proceeding against the Company, in each case that is not discharged or dismissed prior to such 30<sup style="font-size:75%; vertical-align:top">th</sup> trading day; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the date on which we commence a voluntary bankruptcy case or any third party commences a bankruptcy proceeding against us, a custodian is appointed for us in a bankruptcy proceeding for all or substantially all of its property, or we make a general assignment for the benefit of its creditors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to terminate the Tumim Purchase Agreement at any time after the Commencement Date, at no cost or penalty, upon prior five trading days written notice to Tumim. We and Tumim may also terminate the Tumim Purchase Agreement at any time by mutual written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumim also has the right to terminate the Tumim Purchase Agreement upon five trading days&#8217; prior written notice to us, but only upon the occurrence of certain events, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the occurrence of a Material Adverse Effect; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the occurrence of a Fundamental Transaction (as defined in the Tumim Purchase Agreement) involving us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to file with the SEC the Registration Statement that includes this prospectus or any additional registration statement we file with the SEC pursuant to the Tumim Registration Rights Agreement, within the time periods set forth in the Tumim Registration Rights Agreement or we are otherwise in breach or default in any material respect under any of the other provisions of the Tumim Registration Rights Agreement, and, if such failure, breach or default is capable of being cured, such failure, breach or default is not cured within ten trading days after notice of such failure, breach or default is delivered to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of the Registration Statement that includes this prospectus or any additional registration statement we file with the SEC pursuant to the Tumim Registration Rights Agreement lapses for any reason (including the issuance of a stop order by the SEC), or this prospectus or the prospectus included in any additional registration statement we file with the SEC pursuant to the Tumim Registration Rights Agreement otherwise becomes unavailable to Tumim for the resale of all of the shares of Common Stock included therein, and such lapse or unavailability continues for a period of 20 consecutive trading days or for more than an aggregate of 60 trading days in any 365-day period, other than due to acts of Tumim; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading in the Common Stock on Nasdaq (or if the Common Stock is then listed on an Eligible Market, trading in the Common Stock on such Eligible Market) has been suspended for a period of three consecutive trading days; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are in material breach or default of the Tumim Purchase Agreement, and, if such breach or default is capable of being cured, such breach or default is not cured within 10 trading days after notice of such breach or default is delivered to us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless notification thereof is required elsewhere in the Tumim Purchase Agreement, we are required to promptly (but in no event later than 24 hours) notify Tumim (and, if required under applicable law, including, without limitation, Regulation FD promulgated by the SEC, or under the applicable rules and regulations of the trading market, publicly disclose such information in accordance with Regulation FD and the applicable rules and regulations of the Trading Market) upon becoming aware of any of the events set forth above giving rise to a termination right by Tumim. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No termination of the Tumim Purchase Agreement by us or by Tumim will become effective prior to the first trading day immediately following the applicable settlement date related to any pending VWAP Purchase Notice that has not been fully settled in accordance with the terms and conditions of the Tumim Purchase Agreement, and will not affect any of our respective rights and obligations under the Tumim Purchase Agreement with respect to any pending VWAP Purchase, and both we and Tumim have agreed to complete our respective obligations with respect to any such pending VWAP Purchase under the Tumim Purchase Agreement. Furthermore, no termination of the Tumim Purchase Agreement will affect the Tumim Registration Rights Agreement, which will survive any termination of the Tumim Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effect of Performance of the Tumim Purchase Agreement on our Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Common Stock that may be issued or sold by us to Tumim under the Tumim Purchase Agreement that are being registered under the Securities Act for resale by Tumim in this offering are expected to be freely tradable. The shares being registered for resale in this offering may be issued and sold by us to Tumim from time to time at our discretion over a period of up to 24-months commencing on the Commencement Date. The resale by Tumim of a significant amount of Resale Shares registered hereby at any given time, or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales of our Common Stock, if any, to Tumim under the Tumim Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tumim all, some or none of the shares that may be available for us to sell to Tumim pursuant to the Tumim Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Tumim Purchase Agreement, we have the right, but not the obligation, to direct Tumim to purchase up to $100.0 million of our Common Stock, subject to certain limitations. The number of shares ultimately offered for resale under this prospectus is dependent upon the number of shares we direct Tumim to purchase under the Tumim Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of gross proceeds we would receive from Tumim from our sale of shares to Tumim under the Tumim Purchase Agreement at varying purchase prices: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Assumed Average Purchase</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Price Per Share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Registered&#160;Shares</span><br/><span style="font-weight:bold">to be Issued if</span><br/><span style="font-weight:bold">Full Purchase<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage of<br/>Outstanding&#160;Shares</span><br/><span style="font-weight:bold">After&#160;Giving&#160;Effect&#160;to</span><br/><span style="font-weight:bold">the Issuance to</span><br/><span style="font-weight:bold">Tumim<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Gross&#160;Proceeds&#160;from&#160;the&#160;Sale&#160;of<br/>Shares to Tumim Under the<br/>Purchase Agreement</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">33,333,333.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">82.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">100,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">25,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">77.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">100,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">14,285,714.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">66.78</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,998.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12,500,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">63.76</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">100,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.09<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12,360,939.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">63.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,996.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$9.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">11,111,111.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">60.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,999.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$10.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">58.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">100,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$11.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9,090,909.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">56.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,999.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$12.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8,333,333.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">53.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,996.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$13.41<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,457,121.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">51.21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,992.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$14.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,142,857.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">50.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">99,999,998.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Does not include the aggregate amount of 150,000 Commitment Shares that we issued to Tumim as consideration for its commitment to purchase shares of Common Stock under the Tumim Purchase Agreement. The number of shares of Common Stock offered by this prospectus may not cover all the shares we ultimately sell to Tumim under the Tumim Purchase Agreement, depending on the purchase price per share. We have included in this column only those shares being offered for resale by Tumim under this prospectus (excluding the 150,000 Commitment Shares), without regard for the Beneficial Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future stock performance. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The denominator is based on 6,955,697 shares outstanding as of July&#160;31, 2025 (which includes the aggregate amount of 150,000 Commitment Shares we issued to Tumim), adjusted to include the issuance of the number of shares set forth in the second column that we would have sold to Tumim, assuming the average purchase price in the first column. The numerator is based on the number of shares of Common Stock set forth in the second column. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the &#8220;Minimum Price&#8221; (as defined in the Tumim Purchase Agreement and determined in accordance with Nasdaq rules). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the closing price of the Common Stock on Nasdaq on August&#160;1, 2025, the trading day prior to the filing of the registration statement of which this prospectus forms a part. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tumim Registration Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Tumim Equity Financing, we entered into the Tumim Registration Rights Agreement. Under the Tumim Registration Rights Agreement, we agreed to file a resale Registration Statement covering the Resale Shares within 30 calendar days after the date of the Tumim Registration Rights Agreement, and to use commercially reasonable efforts to cause such resale Registration Statement to be declared effective by the SEC as soon as reasonably practicable after the filing thereof, but in any event no later than the forty-fifth </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
calendar day after the earlier of (1)&#160;the date on which this registration statement is filed and (2)&#160;August&#160;21, 2025 (the filing deadline being thirty calendar days from the closing date, July&#160;22, 2025) (the &#8220;Effectiveness Date&#8221;); provided, however, that in the event we are notified by the SEC that the resale Registration Statement will not be reviewed or is no longer subject to further review, the Effectiveness Date will be the third trading day following the date on which we are so notified if such date precedes the dates otherwise required above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_7">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization, and we may be unable to generate sufficient revenue to support our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent upon ZTlido sales to generate revenue, as ELYXYB and GLOPERBA are in the initial stages of commercialization. In February 2018, we obtained FDA regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN in adults, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in the United States in October 2018. In late February 2023, we acquired ELYXYB, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults, in the U.S. We launched ELYXYB in April of 2023. In June 2022, we acquired certain rights to GLOPERBA, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. We launched GLOPERBA in June 2024. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido, ELYXYB or GLOPERBA will gain market acceptance among physicians, health care payors, patients and the medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido, ELYXYB and GLOPERBA depends on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by physicians, major operators of clinics and patients of ZTlido, ELYXYB and GLOPERBA as a safe and effective treatment for the relief of neuropathic pain associated with PHN (ZTlido), acute migraine pain (ELYXYB), and prevention of gout flares (GLOPERBA); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability, cost and potential advantages of alternative treatments, including less expensive generic products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of other competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product labeling or any product inserts required by the FDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of adverse side effects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To successfully commercialize ZTlido, ELYXYB and GLOPERBA, we will need to expand our marketing efforts to develop new relationships and expand existing relationships. Physicians may decide not to prescribe ZTlido, ELYXYB or GLOPERBA for a variety of reasons, including changes in available offerings, adverse </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido, ELYXYB or GLOPERBA or the utilization of products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase, or may not develop for ELYXYB or GLOPERBA, as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we succeed in increasing market acceptance of ZTlido or developing market acceptance of ELYXYB and GLOPERBA, and maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido, ELYXYB and GLOPERBA will also depend on pricing and cost-effectiveness, including our ability to produce and market our products at a competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido, ELYXYB and GLOPERBA may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be successful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March 2019, our operations were conducted through Scilex Pharma, which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur, which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential non-opioid pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. Most of our revenue to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for most of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete ongoing clinical trials and obtain regulatory approvals for our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify new acquisition or in-licensing opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully identify new product candidates and advance those product candidates into pre-clinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">raise additional funds when needed and on terms acceptable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain experienced management and advisory teams; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">add operational, financial and management information systems and personnel, including personnel to support clinical, manufacturing and planned future commercialization efforts and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launch commercial sales of our product candidates, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $72.8 million and $114.3 million for the years ended December&#160;31, 2024 and 2023, respectively. For the three months ended March&#160;31, 2025 and 2024, we had net losses of $26.1 million and $24.4 million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, we had an accumulated deficit of $589.1 million and $563.1 million, respectively. For the foreseeable future, we expect to continue to incur significant expenses related to the commercialization of ZTlido, GLOPERBA and ELYXYB and the research and development of our product candidates, SEMDEXA, SP-103, and SP-104. We anticipate that our expenses will increase substantially due to any future trials related to SEMDEXA and SP-103 and initiation of the Phase 2 clinical trial for SP-104. Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq Listing Rules, or seek other sources of capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The terms of the Oramed Note and the Tranche B Notes impose certain operating and financial covenants that restrict our operating and financial flexibility and any failure to comply with such covenants could result in an event of default that could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023 (the &#8220;Oramed Closing Date&#8221;), we issued and sold to Oramed the Oramed Note pursuant to that certain securities purchase agreement we entered into with Oramed, dated as of September&#160;21, 2023 (the &#8220;Scilex-Oramed SPA&#8221;). Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x)&#160;four percent (4%)&#160;and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2)&#160;eight and one-half percent (8.5%), payable in-kind on a monthly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of $3,056,250 has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to cause all outstanding amounts under the Oramed Note to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus fifteen percent (15%)&#160;or (ii)&#160;the maximum rate permitted under applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any voluntary prepayments of the Oramed Note occurring prior to the one-year anniversary of the Oramed Closing Date are required to be paid together with a make-whole amount equal to 50% of the amount of additional interest that would accrue on the principal amount so prepaid under the Oramed Note from the date of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such prepayment through and including the maturity date. The make-whole amount was waived by Oramed for our voluntary prepayments in March 2024. If the Oramed Note is accelerated upon an event of default, we are required to repay the principal amount of the Oramed Note at a mandatory default rate of 125% of such principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring us and our subsidiaries to, following the earlier of (x)&#160;April&#160;1, 2024, and (y)&#160;the date on which the Acceptable Indebtedness (as defined in the Oramed Note) is repaid in full, use 70% of the net cash proceeds of any Cash Sweep Financing (as defined in the Oramed Note) or advance under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal amount of the Oramed Note (the &#8220;Mandatory Prepayment Sweep&#8221;). Following each of the April 2024 RDO, the receipt of the FSF Deposit and the ATM Sales Agreement (each as defined below), we made mandatory prepayments of $9,578,835, $7,000,000 and $1,760,796, respectively, to Oramed, which equals 70% of the net cash proceeds we received from each of the April 2024 RDO, the FSF Deposit and the sale of shares pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024 (the &#8220;Issuance Date&#8221;), we issued and sold in a registered offering to certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed (together with the Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;) senior secured convertible notes in the aggregate principal amount of $50,000,000 (the &#8220;Tranche B Notes&#8221;), which notes are convertible into shares of Common Stock, pursuant to the Tranche B Securities Purchase Agreement. In consideration for Tranche B Notes issued to Oramed, the outstanding principal balance of the Oramed Note was reduced by $22,500,000, and additional principal payments of an aggregate amount of $15,000,000 were made in November and December 2024. As of March&#160;31, 2025, the outstanding principal amount, as well as the accrued interest and fees, of the Oramed Note was $25,721,080, with the remaining amount due on March&#160;21, 2025, which maturity date was extended to December&#160;31, 2025 pursuant to an amendment letter we entered into with Oramed, dated as of January&#160;21, 2025. Additionally, if we effect the Penny Warrant Repurchase and have paid the Option Payment Amount and Warrant Repurchase Amount in full, in accordance with the terms of the Option Agreement, then the maturity date of the Oramed Note, shall be extended to March&#160;31, 2026 and any make-whole payment due thereunder upon prepayment shall be waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier converted or redeemed, the Tranche B Notes mature on the two-year anniversary of the Issuance Date, subject to extension at the option of the holder in certain circumstances as provided therein. The Tranche B Notes bear interest at a rate of 5.5%&#160;per annum, payable in arrears on the first trading day of each calendar quarter, beginning January&#160;2, 2025, payable, at our option, either in cash or in shares of Common Stock, subject to certain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Oramed Note and the Tranche B Notes contain affirmative and negative covenants binding on us and our subsidiaries which restrict, among other things, us and our subsidiaries from incurring indebtedness or liens, repaying certain indebtedness, or declaring or paying any cash dividends or distribution, selling or otherwise disposing of any assets, entering into transactions with affiliates, in each case as more fully set forth in, and subject to certain qualifications, exceptions, and &#8220;baskets&#8221; set forth in the Oramed Note and the Tranche B Notes. The Oramed Note also contains covenants requiring us to maintain a segregated bank account under specific terms and conditions, for purposes of receiving the Mandatory Prepayment Sweep, requiring SCLX Stock Acquisition JV LLC, our indirect wholly owned subsidiary (&#8220;SCLX JV&#8221;), to comply with the separateness representations and covenants in its organizational documents, and requiring our subsidiary, SCLX DRE Holdings LLC, to maintain its status as a passive holding company. The Tranche B Notes also require us to, at the request of the holder, not more frequently than once per fiscal year, hire an independent, reputable investment bank to investigate whether any breach of the Tranche B Notes has occurred if an event constituting an event of default has occurred and is continuing or any holder reasonably believes that an event constituting an event of default has occurred or is continuing. In addition, the Tranche B Notes prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our obligations under the Tranche B Notes under a written agreement approved by the required holders of the Tranche B Notes before the transaction is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completed. Upon consummation of specified fundamental transactions, the successor entity must confirm that upon conversion or redemption of the Tranche B Notes thereafter, shares of the successor entity will be issuable upon such conversion or redemption. The holders of the Tranche B Notes also have certain redemption rights upon a fundamental transaction constituting a change of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Oramed Note and the Tranche B Notes contain certain customary events of default, including, without limitation, a cross-default to other specified indebtedness or any other indebtedness involving an obligation of a certain amount, a failure in payment of principal, as well as any bankruptcy, insolvency or reorganization event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Oramed Note also contains additional events of default with respect to certain events relating to our obligations under the Oramed RRA and relating to (i)&#160;the Penny Warrants to purchase up to 13,000,000 shares of Common Stock, that we issued to Oramed pursuant to the Scilex-Oramed SPA (of which 6,500,000 of such warrants remain unexercised), and (ii)&#160;the shares of Common Stock underlying the Penny Warrants, in each case as more fully set forth in the Oramed Note. On July&#160;22, 2025 we entered into the Option Agreement with Oramed, pursuant to which we have the option to repurchase the remaining Penny Warrants for an aggregate warrant purchase price of $27 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, failure to comply with the covenants under the Oramed Note or Tranche B Notes could result in an event of default. The events of default under the Oramed Note include, among others, a change of control of our company and under the Tranche B Notes include, among others, any material adverse effect on our business, properties, assets, liabilities, operation, condition or prospects. Upon an event of default under the Oramed Note or the Tranche B Notes, subject to notice requirements in the case of certain events of default, all amounts outstanding under the Oramed Note may become immediately due and payable and the holders of the Tranche B Notes are entitled to certain conversion and redemption rights, respectively. We may not have sufficient funds or may be unable to arrange for additional financing to repay such indebtedness or to make any accelerated or redemption payments, and Oramed and/or the Tranche B Note holders could seek to enforce their security interests in the collateral securing such indebtedness or other remedies available to them under the Oramed Note or Tranche B Notes, respectively, or as provided by applicable law. Oramed could also seek to enforce the guaranty under the Subsidiary Guarantee entered into by us and each of our subsidiaries, dated as of September&#160;21, 2023, to carry out our payment obligations under the Oramed Note. Any failure by us to comply with the obligations under the Oramed Note or the Tranche B Notes could have a negative effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our outstanding indebtedness and any future indebtedness we may incur, combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our flexibility in planning for, or reacting to, changes in our business and the industry and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not have the ability to raise the funds necessary to settle the Oramed Note or the Tranche B Notes in cash upon a change of control or other event of default, and any future debt may contain limitations on our ability to pay cash upon conversion of the Tranche B Notes. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change of control transaction triggers an event of default under the Oramed Note, which will result in the full unpaid principal amount of the Oramed Note, together with interest and other amounts owing in respect thereof, to the date of acceleration becoming, at the election of the holder of the Oramed Note, immediately due and payable in cash at the Mandatory Default Amount (as defined in the Oramed Note). Similarly, a change of control transaction (including any fundamental transaction in which our successor is not a public company) triggers the redemption rights of the holders under the Tranche B Notes. If the Tranche B Notes are not retired in connection with such change of control transaction, each holder may require us to redeem in cash all, or any portion, of the Tranche B Notes at a 30% redemption premium to the greater of (i)&#160;the amounts then outstanding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Tranche B Notes to be redeemed; (ii)&#160;the equity value of our Common Stock underlying such Tranche B Notes; and (iii)&#160;the equity value of the change of control consideration payable to the holders of our Common Stock underlying such Tranche B Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span>In such events or in the event of any other redemption event or event of default under the Oramed Note or the Tranche B Notes, we may not have enough available cash or be able to obtain financing at the time we are required to pay cash with respect to the Oramed Note or the Tranche B Notes. In addition, our ability to pay cash upon default of the Oramed Note or the Tranche B Notes may be limited by law, regulatory authority, or any agreements governing our future indebtedness<span style="font-weight:bold"><span style="font-style:italic">. </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger (as amended, the &#8220;Semnur Acquisition Agreement&#8221;) we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary (&#8220;Sigma Merger Sub&#8221;), Fortis Advisors LLC, solely as representative (&#8220;Semnur Equityholders&#8217; Representative&#8221;) of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;), and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0 million in contingent cash consideration based on the achievement of certain milestones. A $40.0 million payment will be due upon obtaining the first approval of an NDA (as defined below) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0 million payment upon the achievement of $100.0 million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0 million payment upon the achievement of $250.0 million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of a Semnur product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of a Semnur product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido, GLOPERBA and ELYXYB, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, our cash and cash equivalents were approximately $5.8 million and we had an accumulated deficit of $589.1 million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs related to servicing of our debt; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of financing additional clinical, regulatory and commercial activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to generate sufficient cash to service our indebtedness and other liquidity needs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to make payments on and to refinance our indebtedness and to fund our other obligations, planned capital expenditures and other strategic investments will depend on our ability to generate cash in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. We may not generate sufficient cash flow from operations, and we cannot assure you that future borrowings will be available to us in an amount sufficient to enable us to pay our indebtedness or to fund our other liquidity needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not generate cash flow from operations sufficient to pay our debt service or other obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Our ability to refinance our debt and fund other obligations will depend on the condition of the capital markets and our financial condition at that time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. See Note 2 titled &#8220;Liquidity and Going Concern&#8221; of our consolidated financial statements included elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; of our unaudited condensed consolidated financial statements included elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. We have negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $589.1 million as of March&#160;31, 2025 and approximately $563.1 million as of December&#160;31, 2024.These conditions raise substantial doubt about our ability to continue as a going concern. Our unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and expenditures through additional debt and equity financing. We will need to seek additional financing to fund our current operations, including the commercialization of ZTlido, GLOPERBA and ELYXYB, as well as the development of our other material product candidates for the next 12 months. Our plans are substantially dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA among which ELYXYB and GLOPERBA are still in the early stages of commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido, ELYXYB and GLOPERBA and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have previously identified material weaknesses in our internal control over financial reporting. If we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to timely and accurately report our financial results and such material weaknesses may result in a material misstatement of our consolidated financial statements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements for the years ended December&#160;31, 2022 and 2021, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As more fully disclosed in Item&#8201;9A of our Annual Report on Form 10-K for the year ended December&#160;31, 2024, for the years ended December&#160;31, 2022 and 2021, the material weakness identified in our internal control over financial reporting related to ineffective control activities in the areas of revenue, business combination, debt and derivative liabilities caused by a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at our company to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our consolidated financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she served as Chief Financial Officer of the Company through September 2023. In May 2023, we appointed a Chief Accounting Officer, who became our Chief Financial Officer in September 2023. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have remediated the previously identified material weaknesses in our internal control over financial reporting, and we have not identified a material weakness in our internal control over financial reporting for the year ended December&#160;31, 2024. If we identify additional material weaknesses or deficiencies in internal controls in the future and we are unable to correct them in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, in the future, we identify material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&#160;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Commercial Operations and Product Development </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We obtain, or historically have obtained, our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a number of sole or single source suppliers and manufacturers, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the commercial supply of ZTlido, ELYXYB and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of SP-103; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of SP-104; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer for the clinical supply of SEMDEXA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement and the Commercial Supply Agreement, we license the rights to ZTlido from, and rely exclusively on, Oishi and Itochu for the manufacturing and supply of ZTlido and SP-103. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and SP-103 is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of March&#160;31, 2025, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of March&#160;31, 2025, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and SP-103 depend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our third-party manufacturers and suppliers of both GLOPERBA and ELYXYB are capable of providing sufficient quantities of these products to meet anticipated commercial demands; however, if third parties with whom we currently work are unable to meet our manufacturing and supply requirements, we will need to secure alternate manufacturers and suppliers or face potential delays or shortages. While we believe that there are other contract manufacturers and suppliers with the technical capabilities to manufacture and supply these products, we cannot be certain that identifying and establishing relationships with such sources would not result in significant delay or material additional costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have purchased our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SP-102, solely from Genzyme Corporation (&#8220;Genzyme&#8221;) pursuant to a supply agreement, which terminated as of May&#160;31, 2024. We anticipate that our current supply of sodium hyaluronate will be sufficient to satisfy our clinical and commercial supply requirements for sodium hyaluronate for at least 12 months following our expected commercial launch of SP-102 in 2027. Although we are currently in the process of identifying and certifying new suppliers, in each case to fulfill our future supply requirements for sodium hyaluronate, we may not be able find an alternative supplier of sodium hyaluronate on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under that certain Master Services Agreement (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), which we entered into on January&#160;27, 2017 through our wholly owned subsidiary, Semnur, with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&#160;if we (a)&#160;become insolvent, (b)&#160;cease to function as a going concern, (c)&#160;become convicted of or plead guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engage in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name; (3)&#160;if we fail to pay past due invoices upon 30 days&#8217; written notice, or (4)&#160;if we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer on commercially reasonable terms, or at all, may be difficult. On June&#160;6, 2023, Semnur entered into the Second Amendment to Lifecore Master Services Agreement with Lifecore, which extended the term of the agreement until December&#160;31, 2028. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under that certain master services agreement (the &#8220;Tulex Master Services Agreement&#8221;) and the statement of work with Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), we depend on Tulex to develop, test and manufacture clinical supplies of SP-104. Tulex has the right to terminate the Tulex Master Services Agreement under certain </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable statement of work) or (2)&#160;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&#160;without cause upon 30 days prior written notice to Tulex or (b)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under the current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA pre-approval inspection and inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the commercial supply of our commercial products, clinical supply of our product candidates and certain of the raw materials used in our product candidates are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability of ZTlido, the commercialization of GLOPERBA and ELYXYB, and the development of SEMDEXA, SP-103 and SP-104. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on a single third-party logistics distribution provider for ZTlido, ELYXYB and GLOPERBA. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#8220;Cardinal Health 105&#8221;) as our third-party logistics distribution provider for ZTlido, ELYXYB and GLOPERBA in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. If we are unable to maintain a favorable relationship with Cardinal Health 105, we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido, ELYXYB and GLOPERBA to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics provider, may negatively impact our sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of December&#160;31, 2024, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of December&#160;31, 2024, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;), to conduct GCP-compliant clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GCP-compliant clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future enter into collaborations, in-licensing arrangements, joint ventures, or strategic alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business, we may enter into collaborations, additional in-licensing arrangements (such as, for example, the Romeg License Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and generate additional revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with regulatory authorities on trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in identifying prospective clinical investigators or clinical trial sites that have necessary qualifications, interest and capacity to perform a requested protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining approval from one or more institutional review boards (&#8220;IRBs&#8221;); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable subjects to participate in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with GCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in subjects completing participation in a trial or returning for post-treatment follow-up; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites or subjects dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">key investigators departing their clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjects experiencing severe or unexpected drug-related adverse effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other sponsors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any changes to our manufacturing process that may be necessary or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials and/or not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and increased knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of SP-103, <span style="white-space:nowrap">SP-104</span> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be adversely affected by the effects of health pandemics or other health crises, which could cause significant disruptions in our operations and those of our CMOs, CROs and other third parties upon whom we rely. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health pandemics or other health crises, including COVID-19, have in the past and could again in the future result in a disruption of our businesses, delay our research and development programs and timelines, negatively impact our productivity and increase risks associated with cybersecurity. More specifically, these types of events may negatively impact personnel at third-party manufacturing facilities or the availability or cost of materials, which could disrupt our supply chain. Moreover, our clinical trials may be negatively affected. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources. Some patients may not be able or willing to comply with trial protocols if wide-spread health crisis impede patient movement or interrupt healthcare services. Our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure) may be hindered, which would adversely affect our trial operations. In addition, we rely on independent clinical investigators, CROs and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials, including the collection of data from our trials, and the effects of health pandemics or other health crises may affect their ability to devote sufficient time and resources to our programs. As a result, the expected timeline for data readouts, including incompleteness in data collection and analysis and other related activities, and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and adversely affect our business, financial condition, results of operations and prospects. In addition, the impact of such health pandemics or other health crises on the operations of the FDA or other regulatory authorities could negatively affect our planned trials and approval processes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical trials, the data may not be considered sufficient by regulatory authorities, those regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee is convened, including if such advisory committee recommends non-approval or restrictions </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, black box warnings or a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). The FDA may require labeling that includes warnings and precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are considered necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed or fail in obtaining marketing approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as we intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the products are administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to our reputation. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required follow-up periods. If patients are unwilling to participate in our clinical trials due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed. We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of patients to clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility and exclusion criteria for the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that enrolled patients will not complete a clinical trial; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to monitor patients adequately during and after treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential disruptions caused by COVID-19 (or other similar disruptions), including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate in relation to other available products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are common, but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective eligibility criteria in place to reduce the placebo effect and the impacts of COVID-19, and may experience similar issues with enrollment of our other planned clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the federal Food and Drug Omnibus Reform Act (the &#8220;FDORA&#8221;), sponsors are required to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug product. These plans are meant to encourage enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for diversity action plans. Unlike most guidance documents issued by the FDA, the diversity action plan guidance, when finalized, will have the force of law. In January 2025, in response to an executive order issued by President Trump on diversity, equity and inclusion programs, the FDA removed this draft guidance from its website. The implications of this action are not yet known. If we are not able to adhere to any new requirements, our ability to conduct clinical trials may be delayed or halted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or in-licensing product candidates and determining indications on which to focus in preclinical studies or clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, SP-103, face and will likely face competition from other prescription patches, generic topical lidocaine patches, and OTC lidocaine patches, including Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup>, generic lidocaine patches manufactured by Mylan N.V., Teva and Par Pharmaceutical, Inc., and various OTC patches. Additionally, SP-103, if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of chronic neck pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain non-steroid product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the off-label and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain non-opioid therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, SP-104, will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved, could decrease our ability to generate product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market acceptance and sales of ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs (such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require co-payments or co-insurance that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#8217; drug formularies for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. J-Codes are codes maintained by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific J-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our FDA-approved products, ZTlido, GLOPERBA and ELYXYB, we currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional in-licenses or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial was completed for SP-103 in 2023, and multiple Phase 1 trials were completed in the first half of 2022 for SP-104. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which reflect positive results with respect to primary and secondary endpoints, and we intend to use the results to support a NDA submission seeking approval for the treatment of sciatica. In November 2023, we had a Type C meeting with the FDA to discuss the requirements for filing a 505(b)(2) NDA for SEMDEXA. In the Type C meeting, the FDA indicated that it disagreed with us that the clinical data we had collected was sufficient to support the safety and efficacy of SEMDEXA. The FDA provided guidance regarding expectations for the additional confirmatory trial needed prior to a 505(b)(2) NDA filing and the circumstances under which one adequate and well-controlled trial would be sufficient for product registration. In February 2024, we had a Type D meeting with the FDA to preview a newly designed trial, in order to reduce the potential need for any other additional trials prior to a 505(b)(2) NDA filing. During the Type D meeting, the FDA provided further guidance with respect to efficacy requirements and expectations on the size of safety database needed to help best position us to be able to satisfy the requirements for a 505(b)(2) pathway approval. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent regulatory approval and, ultimately, the commercialization of that product for the proposed indication for use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the &#8220;top-line&#8221; data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive non-clinical studies, pre-clinical studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable non-U.S. regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable non-U.S. regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for clinical trials and approval may be different. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may suffer reputational harm due to failures of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA, ELYXYB and our product candidates. In the event that ZTlido, GLOPERBA or ELYXYB is identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido, GLOPERBA or ELYXYB or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido, GLOPERBA or ELYXYB. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA, ELYXYB and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA, ELYXYB and our product candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA, ELYXYB or our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate key executives to accomplish our business objectives, we may experience </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular, we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Stephen Ma, our Chief Financial Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido, GLOPERBA and ELYXYB. We do not carry &#8220;key person&#8221; insurance on any of our executive officers or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to qualified candidates than what we have to offer. In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued, generally prevent employers from entering into non-compete agreements with employees and require employers to rescind existing non-compete agreements, may lead to increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing &#8220;great resignation&#8221; occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to increase the size of our company and may not effectively manage our growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, we had 111 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including co-promotion activities. Future growth would impose significant added responsibilities on members of management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, recruiting, integrating, maintaining and motivating additional employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">improving our operational, financial and management controls, reporting systems and procedures. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no assurance that we will complete the Semnur Business Combination with respect to the sale of our majority owned subsidiary, Semnur, and/or our SP-102 product candidate, under the terms of the Semnur Business Combination Agreement or otherwise and the failure to complete the Semnur Business Combination could adversely affect our stock price and future business and financial results. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced, our Board authorized our management to explore ways in which to maximize the value of Semnur and SP-102 (SEMDEXA&#8482;), the product candidate held by Semnur, for us and our stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (as may be amended or restated from time to time in accordance with its terms, including by Amendment No.&#160;1 thereto, dated as of April&#160;16, 2025, and Amendment No.&#160;2 thereto, dated as of July&#160;22, 2025, the &#8220;Semnur Business Combination Agreement&#8221;) with Denali and Denali Merger Sub, in connection with the Semnur Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Semnur Business Combination is subject to the satisfaction or waiver of a number of closing conditions of the respective parties. The completion of the Semnur Business Combination is not assured and is subject to risks, including, among others, the risk that approval of the Semnur Business Combination by Denali&#8217;s shareholders is not obtained or that other closing conditions are not satisfied. There is also no assurance the Semnur Business Combination will actually maximize the value of Semnur and/or the SP-102 asset for us or our stockholders. In addition, we will remain liable for significant transaction costs, including legal, accounting and financial advisory fees. Furthermore, the market price of our Common Stock may reflect various market assumptions as to whether the Semnur Business Combination will occur. Consequently, the failure to complete the Semnur Business Combination could result in a significant change in the market price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry insurance for all categories of risk that our business may encounter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido, GLOPERBA and ELYXYB and clinical testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue from product sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates or products that we develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation of investigations by regulators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to defend the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area, California. Our facilities may be affected by natural or man-made disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or man-made disaster, we may be forced to curtail our operations and/or rely on third parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant out-of-pocket costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize than expected. If we are obligated to make any milestone payments in connection with an acquisition or licensing agreement, such obligations could impose substantial additional costs on us and divert resources from other aspects of our business. In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses or acquire intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business, financial condition and results of operations could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the new administration has substantially altered prior U.S. government international trade policy and has commenced activities to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. In addition, the new administration has initiated or is considering imposing tariffs on certain foreign goods. Related to this action, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain U.S. goods. It remains unclear what the new administration or foreign governments will or will not do with respect to tariffs or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
international trade agreements and policies. Although the new administration has not yet implemented tariffs on pharmaceuticals, there can be no assurance that it will not implement such tariffs in the future. A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, affect our suppliers, increase the cost of materials purchased to manufacture our products, impact our ability to sell our products outside the United States or to sell our products outside the United States at competitive prices and/or to affect the United States or global economy or certain sectors thereof and, thus, could adversely impact our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting business internationally involves a number of risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost and availability of shipping and other means of product transportation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in duties and tariffs, license obligations and other non-tariff barriers to trade; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the imposition of new trade restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor-reimbursement regimes or self-pay systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example, by failing to maintain accurate information and control over sales or distributors&#8217; activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The increasing use of social media platforms presents new risks and challenges. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of non-compliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business and operations would suffer in the event of a system failure. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented and maintain security measures, our computer systems and those of our CROs and other contractors and consultants are vulnerable to, and have experienced, computer viruses, unauthorized access, cybersecurity attacks, and other security incidents, including as perpetrated by hackers, or as the result of natural disasters, terrorism, war, or telecommunications or electrical failures. For example, there was a cyberattack on Change Healthcare in March 2024. We worked diligently with our co-pay savings card adjudicators to resolve the breakdown of processing of insurance claims by Change Healthcare, and restored the co-pay savings card processing for ZTlido and ELYXYB, which has been restored to normal operations. This incident did not have a material impact on the Company as a whole. A material system failure or security breach, if such an event were to occur, could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce such data. To the extent that any disruption or security breach were to result in the loss of or damage to our data or applications, or the unauthorized disclosure of confidential or proprietary information, including personal data, we could incur material legal liability or be the subject of legal claims, suffer damage to our reputation, lose or harm our intellectual property rights, and delay the continued research, development and commercial efforts of ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters or some other matter, that claim could have a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a security incident or privacy violation of the Company, those of our CROs and other contractors and consultants that leads to the unauthorized acquisition, interruption, modification, loss, theft, corruption, interference, or other unauthorized disclosure of, or prevents access to, personal data, including patient data or other protected health information, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability, and the ability of our CROs and other contractors and consultants, to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems and those of our CROs&#8217; and other contractors&#8217; and consultants may experience, and have experienced, interruptions, delays, or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are continually evolving and include, but are not limited to, malicious software, ransomware, attempts to gain unauthorized access to data under our custody or control, and other electronic security breaches that could lead, and have led to disruptions in systems, misappropriation of confidential or otherwise protected information, and corruption of data. If we, our CROs and other contractors and consultants are unable to prevent such cybersecurity attacks or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, we may suffer loss of reputation, we may be the subject of governmental investigations, legal claims, or litigation, or we may incur financial loss or other regulatory penalties, each of which may not be covered by our insurance and may be material to our Company as a whole. In addition, these breaches and other unauthorized access to our systems can be difficult to detect, and any delay in identifying any such event may lead to increased harm of the type described above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, as well as the continued hostilities between Russia and Ukraine and, more recently, Hamas&#8217; attack against Israel and the ensuing conflict. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Russia&#8217;s invasion of Ukraine and sanctions against Russia are causing disruptions to global economic conditions. The escalation in October 2023 of the conflict between Israel and Hamas also could cause disruptions to global economic conditions and affect the stability of the Middle East region. It is not possible to predict the broader consequences of these ongoing conflicts. It is also not possible to predict with certainty these ongoing conflicts and additional adverse effects on existing U.S. macroeconomic conditions and financial markets, all of which could impact the business, financial condition, and results of operations of the Company as well as our ability to raise capital. There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. In addition, the closure of any additional national or regional commercial banks could lead to further economic instability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to effectively monitor and respond to the rapid and evolving developments and expectations relating to corporate responsibility, corporate governance, sustainability and/or corporate involvement in social issues, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning factors such as corporate responsibility, corporate governance, sustainability and/or corporate involvement in social issues. Some investors and investor groups may use these factors&#8212;either in support or opposition&#8212; to guide their investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies or practices relating to these factors do not align with their expectations. Currently, a variety of third-party providers of corporate responsibility and sustainability ratings measure the performance of companies on these factors, and the results of these assessments are widely publicized. Certain investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and certain major institutional investors have publicly emphasized the importance of these factors to their investment decisions. Topics taken into account in such assessments include, among others, the risks faced by companies arising out of climate change, human rights, business ethics and compliance, and the role of companies&#8217; board of directors in overseeing various sustainability-related risks. Equally, certain investors, including institutional investors, actively reject the consideration of these matters when making their investment decisions. In light of certain investors&#8217; increased focus on these factors, if we are, for example, perceived as deviating from our peers in respect of practices and initiatives related to these factors, we may be exposed to shareholder activism and litigation (both in support of, or in opposition to, such practices and initiatives). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapidly evolving developments and changing expectations relating to such factors. As a result, the criteria by which our corporate responsibility and sustainability practices are assessed may change, which could cause us to undertake costly initiatives or actions to satisfy new demands. If we elect not to or are unable to adequately recognize and respond to such developments and changing (and sometimes conflicting) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental, societal, investor and/or consumer expectations relating to such factors, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may also face risk of consumer litigation or reputational damage in the event that our policies or practices do not meet the standards set by various constituencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable sustainability rating from third-party rating services. A low sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility and sustainability matters by investors and other stakeholders as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our risk management related to these factors may not maximize short-term financial results and may yield financial results that conflict with the market&#8217;s expectations. We may in the future make business decisions consistent with our risk management related to these factors that we believe, based on considered analysis, will create value and improve our financial performance over the long-term. These decisions, however, may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the intellectual property we in-license from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize SP-103 would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and SP-103 lidocaine tape products and the lidocaine in such products, including, among other things: (1)&#160;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications; (2)&#160;all know-how, work product, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not; (3)&#160;copyrightable works, copyrights and applications, registrations and renewals; (4)&#160;logos, trademarks, service marks, and all applications and registrations relating thereto; (5)&#160;other proprietary rights; (6)&#160;abbreviated new drug applications or other applications to market; and (7)&#160;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop SP-103 depends on the effectiveness and continuation of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and SP-103 as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and SP-103 is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of December&#160;31, 2024, Scilex&#8217;s net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of December&#160;31, 2024, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and SP-103, to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are party to the Romeg License Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg License Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022 (the &#8220;Original Signing Date&#8221;), we entered into the Romeg License Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025. Under the Romeg License Agreement, among other things, Romeg granted us (1)&#160;a license, with the right to sublicense, under the patents and know-how specified therein to (a)&#160;commercialize a pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b)&#160;develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2)&#160;an exclusive license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the know-how and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg Ex-U.S. Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg Ex-U.S. Territory and (b)&#160;to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg Ex-U.S. Territory. With respect to the foregoing clause (1), the license to know-how is exclusive for purposes of developing and commercializing Licensed Products in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, but is otherwise non-exclusive, and the license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Romeg U.S. Territory until July&#160;1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The Romeg U.S. Territory begins on the Original Signing Date and ends on the later of (i)&#160;expiration of the last-to-expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg U.S. Territory or (ii)&#160;the tenth anniversary of the Original Signing Date. With respect to the foregoing clause (3), the license to know-how patents (if any) is exclusive during the Romeg Ex-U.S. Territory Royalty Term, but is otherwise non-exclusive. The Romeg Ex-U.S. Territory Royalty Term begins on the date of the amendment agreement and ends on the tenth anniversary of such date. Our ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg License Agreement. If we lose the right to license the intellectual property rights granted by the Romeg License Agreement, our ability to develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg License Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg License Agreement under certain circumstances, including, among other things: (a)&#160;in the event we are in material breach of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Romeg License Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&#160;by written notice to us if sales of the Licensed Products do not commence or continue within specified periods agreed to by the parties; or (e)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg License Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#8217;s request to transfer all licensed intellectual property rights, including those relating to GLOPERBA and the Licensed Products, to Romeg or its designee, within thirty days after the termination of the Romeg License Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our financial or other obligations under the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense intellectual property rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA, ELYXYB and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States for GLOPERBA, in the United States and Canada for ELYXYB, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or in-licensing patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or in-license may fail to result in issued patents with claims that protect ZTlido, GLOPERBA, ELYXYB and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA, ELYXYB and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. Patent and Trademark Office (&#8220;PTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the non-compliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications may not result in any patents being issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any successful intellectual property challenge to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&#160;16, 2013. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or in-license with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA, ELYXYB and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates. Any such outcome could have a materially adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and in-licenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through acquisitions and licenses from third parties, related to ZTlido, SP-103 and GLOPERBA. Because our programs for ZTlido, GLOPERBA, ELYXYB, SP-103 and SP-104 may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or in-license proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA, ELYXYB and our product candidates. If ZTlido, GLOPERBA, ELYXYB or any of our product candidates, methods, processes and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">result in costly litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divert the time and attention of our technical personnel and management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cause development delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">some patent applications in the United States may be maintained in secrecy until the patents are issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States are typically not published until 18 months after the priority date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publications in the scientific literature often lag behind actual discoveries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our strategic partners&#8217; or licensees&#8217; rights to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement claims, which could severely harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on June&#160;22, 2022, we filed a complaint against Aveva and Apotex in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the market and for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is subject to change over time. In the United States, for small molecule drug products, such as ZTlido, GLOPERBA and ELYXYB, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#8220;ZTlido,&#8221; &#8220;SCILEX,&#8221; &#8220;ELYXYB,&#8221; and &#8220;RESPONSIBLE BY DESIGN,&#8221; and we have filed trademark applications for the marks &#8220;SEMNUR PHARMACEUTICALS,&#8221; &#8220;SCILEX BIO,&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also have trademark registrations for ZTlido in the UK and Greece and we have a pending trademark application for ZTlido in China. In China, we were involved in an ongoing dispute regarding third-party trademarks for ZTlido filed in the name of <span style="font-family:pmingliu; font-size:9pt">&#31206;&#30343;&#23798;&#24646;&#39423;&#21830;&#36031;&#26377;&#38480;&#20844;&#21496;</span><span style="font-family:Times New Roman; font-size:10pt"> (Qinhuangdao Hengjun Trading Co., Ltd.). The China National Intellectual Property Administration issued a decision in our favor in February 2025, which has now become final. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#8220;AIA&#8221;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <span style="font-style:italic">inter partes </span>review, post-grant review, or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. For example, recent decisions raise questions regarding the award of PTA for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in the future and whether patent expiration dates may be impacted. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system took effect June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA, ELYXYB and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. For example, on March&#160;12, 2021, we filed the Former Employee Action, as described under the section titled &#8220;<span style="font-style:italic">Legal Proceedings</span>&#8221; of this prospectus. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time-consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, know-how, patented inventions or other proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, know-how or other proprietary information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us from successfully commercializing ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Litigation relating to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims that ZTlido, GLOPERBA, ELYXYB or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as <span style="font-style:italic">inter partes </span>reviews, post-grant reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that the development and/or commercialization of ZTlido, GLOPERBA, ELYXYB or our product candidates may give rise to claims of infringement of the patent rights of others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions for products prior to commercial launch, third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA, ELYXYB or our product candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA, ELYXYB or our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA, ELYXYB or any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize ZTlido, GLOPERBA and ELYXYB, or develop and commercialize one or more of our product candidates. For example, Takeda filed the GLOPERBA Patent Litigation against us and Scilex Pharma on November&#160;6, 2023, alleging that our filing with the FDA of an application for approval of a proposed revision to the product label for our GLOPERBA product infringed the Colcrys Patents. Takeda sought an order that the effective date of any FDA approval of our labeling revision be no earlier than the expiration date of the Colcrys Patents, and such further and other relief as the court may deem appropriate. On March&#160;7, 2024, we entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Takeda to resolve the action and entered into a license agreement with Takeda pursuant to which Takeda granted a non-exclusive license to us and our affiliates of certain patents owned by Takeda. The Settlement Agreement was subject to review by the Federal Trade Commission and the U.S. Department of Justice, neither of which objected during the review period. After the expiration of the review period, the U.S. District Court for the District of Delaware entered a final consent judgment on May&#160;3, 2024. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8211; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido, GLOPERBA or ELYXYB, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or ELYXYB or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido, GLOPERBA or ELYXYB, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not obtain patent term extension and data exclusivity for any of our product candidates we are developing or may develop, our business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended; the extension cannot extend the total patent term beyond 14 years from approval; and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations, and prospects could be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido, GLOPERBA, ELYXYB and all of our product candidates throughout the world </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian patent applications. Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs, research institutions and/or investigators. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may be able to make products that are similar to ZTlido, GLOPERBA, ELYXYB or our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our pending patent applications may not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not develop additional proprietary technologies that are patentable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for PTA. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect ZTlido, GLOPERBA, ELYXYB and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. For example, recent decisions raise questions regarding the award of PTA for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will/will not be viewed in the future and whether patent expiration dates may be impacted. Similarly, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect on June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <span style="font-style:italic">inter partes </span>review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA, ELYXYB or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and comparable non-U.S. regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. Moreover, gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain marketing approval from the FDA or comparable non-U.S. regulatory authorities for a product candidate is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, following our March 2022 announcement of the final results from our Phase 3 CLEAR-1 trial for SEMDEXA, we believed that we had sufficient data to support the safety and efficacy of SEMDEXA, which would provide us with a pathway for a 505(b)(2) NDA submission. In November 2023, we had a Type C meeting with the FDA to discuss the requirements for filing a 505(b)(2) NDA for SEMDEXA. In the Type C meeting, the FDA indicated that it did not agree that the clinical data collected from the single Phase 3 CLEAR-1 trial was sufficient to support the safety and efficacy of SEMDEXA, given the risks associated with interventional procedures. The FDA requested that a confirmatory trial be conducted, noting the absence of any existing FDA-approved epidural steroid product for the treatment of sciatica. The FDA provided guidance regarding expectations for this additional trial needed prior to a 505(b)(2) NDA filing, including expectations for the size of the safety database and specific safety monitoring requirements. Specifically, the FDA requested that the confirmatory Phase 3 CLEAR-2 trial include a larger safety database to further validate the safety and efficacy of SEMDEXA. In February 2024, we had a Type D meeting with the FDA to preview the newly designed trial with the FDA, in order to reduce the potential need for any other additional confirmatory trials prior to a 505(b)(2) NDA filing. During the Type D meeting, the FDA provided further guidance with respect to the requirements needed to help best position us to be able to satisfy the requirements for a 505(b)(2) pathway approval. Our future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or comparable non-U.S. regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with the design or implementation of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to such authorities&#8217; satisfaction that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or ambiguous results from our clinical trials may not meet the level of statistical significance required for approval by the FDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA or comparable non-U.S. regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience submitting applications for marketing authorization to the FDA, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. With the change in presidential administrations in 2025, there is substantial uncertainty as to how, if at all, the new administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. The impending uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates. Furthermore, the U.S. Supreme Court&#8217;s June 2024 decision in Loper Bright Enterprises v. Raimondo, which overturned the long-standing Chevron doctrine that required courts to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes, could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which we rely. The Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations and other impacts to the agency rule-making process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval of a product candidate by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition, the clinical trials conducted in one country, and the data generated therefrom, may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&#160;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&#160;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, SP-103 and SP-104, we may seek FDA approval through the Section&#160;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;). Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&#160;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&#160;505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&#160;505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved product candidate will be subject to ongoing and continued regulatory requirements, which may result in significant expense and limit our ability to commercialize such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other requirements include submissions of safety and other post-marketing information and reports, registration and listing, product tracking and tracing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investigation or additional study obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">communications to prescribers or patients about specific information or issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning or untitled letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations may also alter the competitive landscape, potentially to our disadvantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed OTC and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#8217;s petition asking the FDA to clarify its requirements and take enforcement action against such products. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In addition, on March&#160;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law, which included statutory provisions reforming FDA&#8217;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#8220;GRASE&#8221;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by notice-and-comment rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. In 2023, the FDA has posted a final administrative order for external analgesic drug products for OTC human use. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products over-the-counter and compete with ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA ultimately denied our citizen&#8217;s petition in light of the new administrative order process under the CARES Act for considering OTC drug products. In February 2021, we filed a complaint against Sanofi and Hisamitsu, certain manufacturers of OTC lidocaine patches, to seek an award of damages and the entry of injunctive relief enjoining further dissemination of false and deceptive advertisement concerning claims about their lidocaine patches. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementation activities in the normal course, our business, financial condition and results of operations may be negatively affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, three decisions from the U.S. Supreme Court in June and July 2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact our business. The first decision overturned established precedent that required courts to defer to regulatory agencies&#8217; interpretations of ambiguous statutory language. The second decision overturned a regulatory agency&#8217;s ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies and impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, is unknown. We also cannot predict the extent to which FDA and other agency regulations, policies, and decisions may become subject to increasing legal challenges, delays and changes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A fast track product designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for the treatment of sciatica and SP-103 for the treatment of chronic neck pain. Even though SEMDEXA and SP-103 have received fast track designation, we may not experience a faster process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products and conduct other regulatory activities can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA temporarily postponed routine surveillance inspections of manufacturing facilities in 2020. Additionally, the new administration recently announced plans to reduce the number of federal employees by establishing voluntary termination programs, by position eliminations or by involuntary terminations. If a prolonged government shutdown occurs, if funding for the FDA or other federal agencies (including their workforce) is reduced or if future global health concerns prevent the FDA or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators are subject to federal, state and foreign data protection laws and regulations. In the United States, such laws may include, but are not limited to, U.S. state personal data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section&#160;5 of the FTC Act, each of which govern the collection, use, disclosure and protection of health-related and other personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as such terms are defined in HIPAA), we may have access to very sensitive data regarding patients who participate in, or whose tissue samples or other biospecimens are used in, our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens and litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to HIPAA and other privacy, data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a Covered Entity in a manner that is not authorized by HIPAA, and we may be subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, U.S. state laws and regulations relating to data privacy and security and consumer protection are constantly evolving. For example, the California Consumer Privacy Act and its implementing regulations (the &#8220;CCPA&#8221;), which went into effect on January&#160;1, 2020, created new individual privacy rights for California consumers and placed increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA has been amended by the California Privacy Rights Act (the &#8220;CPRA&#8221;), which largely took effect on January&#160;1, 2023. The CPRA also created a new state agency, the CPPA, vested with authority to implement and, along with the California Attorney General, enforce the CCPA. Further, Washington&#8217;s My Health My Data Act, taking effect July&#160;1, 2024, imposes requirements specific to consumer health data. Several other states have enacted or are considering similar state consumer privacy laws. The state privacy laws vary from each other in many ways, which may complicate compliance efforts. The effects on our business of the state privacy laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to so comply. Privacy laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal levels that could impose new obligations or limitations in areas affecting our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individuals about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including the EU&#8217;s and UK&#8217;s GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the EU, as well as fines for violations that can reach up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with international data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are or will be in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individual privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend against and could result in adverse publicity that could harm our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may be impacted by actions of the new U.S. administration, including executive orders, policies, new legislation and judicial decisions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the new U.S. administration is currently unknown. However, actions of the administration may cause us to change our business operations, with an unknown impact to our stakeholders, including patients, healthcare providers and employees. Failure to comply with new administration actions could expose us to litigation or other government actions. There can be no assurance that our compliance with new administration actions will provide sufficient mitigation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business involves the use of hazardous materials and we and third parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission or contracting, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations, FDA debarment, exclusion from government-funded healthcare programs or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance or advocacy and education programs. In addition, we may be subject to physician payment transparency laws and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs &#8212; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the statute in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of off-label uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS and Department of Veterans Affairs (&#8220;VA&#8221;), referred to as Government Program Statutory Price Reporting, where such reported prices are used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer&#8217;s ability to offer certain marketplace discounts. Additionally, if it is determined by the government, which could include a government agency such as CMS, Health Resources and Services Administration (&#8220;HRSA&#8221;), the VA, or by the Office of Inspector General or Department of Justice, that the Statutory Price Reporting was incorrect, causing the government to essentially pay more than they should through the reimbursement and/or discount, the manufacturer may be subject to significant False Claims Act investigations, civil monetary penalties and/or additional fines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our current and future research and development of our product candidates outside the United States, and any future sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted off-label uses of ZTlido, GLOPERBA, ELYXYB, or our product candidates, if approved, or if we are found to have improperly engaged in pre-approval promotion prior to the approval of such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as ZTlido, GLOPERBA, ELYXYB, and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. Physicians may use our products, and our product candidates if they receive marketing approval, for their patients in a manner that is inconsistent with the approved labels, if the physicians believe in their professional medical judgment they could be used in such manner. However, if we are found to have promoted any of our products for any off-label uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement or corporate mentorship, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA, ELYXYB, or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 included provisions that, effective January&#160;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the so-called &#8220;individual mandate.&#8221; It is unclear how healthcare reform measures enacted by Congress or implemented by the Trump administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2%&#160;per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the COVID-19 pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#8220;<span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects</span>.&#8221; While any proposed measures may require authorization through additional legislation to become effective, Congress and recent presidential administrations have each indicated an intent to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, or put pressure on our product pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido, GLOPERBA and/or ELYXYB may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&#160;1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact. In addition, potential policy changes by the new administration may introduce additional uncertainty for our business, including changes to the level of scrutiny applied by the HRSA to enforce non-compliance with the 340B program, new price restrictions on products we sell to Medicaid, Medicare or other government purchasers, or other regulatory changes impacting reimbursement or competitive dynamics in multisource markets. Any such policy shifts could significantly impact our business and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&#160;1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125% of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&#160;13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results of operations. In recent years, two U.S. Courts of Appeals for the Third Circuit and District of Columbia Circuits (the &#8220;Third Circuit&#8221; and &#8220;D.C. Circuit,&#8221; respectively) have ruled that, under Section&#160;340B, manufacturers are not required to provide the discounted drugs to an unlimited number of contract pharmacies, but can impose some contractual limitations on how products may be distributed. The Third Circuit also upheld the ADR rules. One other case is pending in the U.S. Court of Appeals for the Seventh Circuit. Various states have also enacted laws prohibiting manufacturers from placing conditions on covered entities&#8217; use of contract pharmacies. There is ongoing litigation over these state laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a manufacturer (i)&#160;is found to have knowingly submitted any false price or product information to the government, (ii)&#160;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&#160;fails to submit the required price data on a timely basis, or (iv)&#160;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#8217;s covered outpatient drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125% of the discount that was due. Furthermore, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), PL 117-169, seeks to limit manufacturers&#8217; price increases for drugs reimbursed by Medicare, to not more than the rate of inflation, at least where those increases would otherwise affect payments under Medicare. Under the provisions, beginning in October 2022, if a manufacturer increases the price of a drug reimbursed under Medicare by more than the rate of inflation (as measured by the consumer price index), the manufacturer must pay rebates to the federal government, equal to the amount by which the increase exceeds the rate of inflation in the relevant period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. The IRA also requires the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate prices for a limited number of single-source brand-name drugs or biologics without generic or biosimilar competitors that are covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). The number of drugs affected is limited to ten Part D drugs for 2026, another fifteen Part D drugs for 2027, another fifteen Part D and Part B drugs for 2028, and another twenty Part D and Part B drugs for 2029 and later years. On August&#160;29, 2023, HHS announced the list of the ten drugs for which negotiations will occur. Drugs that are less than 9 years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval or licensure date are excluded from the negotiation process. Small biotech drugs, defined as those which account for 1% or less of Part D or Part B spending and account for 80% or more of spending under each part on that manufacturer&#8217;s drugs, are also excluded until 2029. CMS has issued initial guidance on the implementation of the provisions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to foreign government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future conduct clinical trials for current or future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to conduct clinical trials internationally in the future. The acceptance of data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento previously supported many of our important corporate functions. Accordingly, our historical consolidated financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we have and will continue to incur incremental costs as a stand-alone public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed the process of replicating and replacing certain functions, systems and infrastructure previously provided by Sorrento (our former controlling stockholder) prior to and subsequent to the Business Combination. We currently have no shared services or other intercompany arrangements. We have made and continue to make investments and hire additional employees to operate without access to Sorrento&#8217;s operational and administrative infrastructure. These functions, systems and infrastructure are costly to implement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, Sorrento performed or supported many important corporate functions for us. Our consolidated financial statements for the fiscal years ended December&#160;31, 2023, 2022 and 2021 reflect charges for these services on an allocation basis. As a result, such consolidated financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento during such periods. We have incurred significant costs to replace the services and resources that are no longer provided by Sorrento. We are also incurring additional costs as a stand- alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. As we now operate separately from Sorrento, if we are not able to maintain adequate systems and business functions, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to this Offering </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">It is not possible to predict the actual number of shares we will sell under the Tumim Purchase Agreement to the Selling Stockholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the Tumim Purchase Agreement with the Selling Stockholder. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, we entered into the Tumim Purchase Agreement with the Selling Stockholder, pursuant to which the Selling Stockholder has committed to purchase up to $100,000,000 of Common Stock, subject to certain limitations and conditions set forth in the Tumim Purchase Agreement. The shares of our Common Stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that may be issued under the Tumim Purchase Agreement may be sold by us to the Selling Stockholder at our discretion from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of any sales of our shares of Common Stock to the Selling Stockholder under the Tumim Purchase Agreement. Sales of our Common Stock, if any, to the Selling Stockholder under the Tumim Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Stockholder all, some or none of the shares of our Common Stock that may be available for us to sell to the Selling Stockholder pursuant to the Tumim Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Stockholder for the shares of Common Stock that we may elect to sell to the Selling Stockholder under the Tumim Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock prior to each VWAP Purchase made pursuant to the Tumim Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales or additional sales, the number of shares of Common Stock that we will sell to the Selling Stockholder under the Tumim Purchase Agreement, the purchase price per share that the Selling Stockholder will pay for shares purchased from us under the Tumim Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Stockholder under the Tumim Purchase Agreement, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, although the Tumim Purchase Agreement provides that we may sell up to the lesser of (a)&#160;$100,000,000 of our Common Stock, and (b)&#160;the Exchange Cap, to the Selling Stockholder, only 1,390,443 shares of our Common Stock (including the aggregate amount of 150,000 Commitment Shares issued to the Selling Stockholder pursuant to the Tumim Purchase Agreement) are being registered for resale under the registration statement of which this prospectus forms a part. If we elect to sell to the Selling Stockholder all of the 1,390,443 shares of Common Stock being registered for resale under this prospectus, depending on the market price of our Common Stock prior to each VWAP Purchase made pursuant to the Tumim Purchase Agreement, the actual gross proceeds from the sale of all such shares may be substantially less than the $100,000,000 available to us under the Tumim Purchase Agreement, which could materially adversely affect our liquidity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Stockholder under the Tumim Purchase Agreement more than the 1,390,443 shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $100,000,000 under the Tumim Purchase Agreement, we must file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Stockholder of any such additional shares of our Common Stock we wish to sell from time to time under the Tumim Purchase Agreement, which the SEC must declare effective. Additionally, we would need to obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap under the Tumim Purchase Agreement in accordance with applicable Nasdaq Listing Rules, unless the average price of all applicable sales of our Common Stock to the Selling Stockholder under the Tumim Purchase Agreement equals or exceeds $8.09 (which is the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules)), such that such issuances and sales of our Common Stock to Tumim under the Tumim Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq Listing Rules. Any issuance and sale by us under the Tumim Purchase Agreement of shares of Common Stock in addition to the 1,390,443 shares of Common Stock being registered for resale by the Selling Stockholder under the registration statement of which this prospectus forms a part could cause additional dilution to our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Common Stock under the Tumim Purchase Agreement if such issuance would breach our obligations under the rules or regulations of Nasdaq. In addition, the Selling Stockholder will not be required to purchase any shares of our Common Stock if such sale or additional sale would result in the Selling Stockholder&#8217;s beneficial ownership exceeding 4.99% of the then outstanding voting power or number of Common Stock. Our inability to access a part or all of the amount available under the Tumim Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The sale and issuance of our Common Stock to the Selling Stockholder will cause dilution to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Stockholder under the Tumim Purchase Agreement will fluctuate based on the price of our Common Stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Common Stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Stockholder, the Selling Stockholder may resell all, some, or none of those shares at its discretion, subject to the terms of the Tumim Purchase Agreement. Therefore, sales to the Selling Stockholder by us could result in substantial dilution to the interests of other holders of our Common Stock. Additionally, the sale of a substantial number of shares of our Common Stock to the Selling Stockholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investors who buy shares of Common Stock at different times will likely pay different prices. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Tumim Purchase Agreement, we control the timing and amount of any sales of Common Stock to the Selling Stockholder. If and when we do elect to sell shares of our Common Stock to the Selling Stockholder pursuant to the Tumim Purchase Agreement, the Selling Stockholder may resell all, some, or none of such shares in its discretion and at different prices, subject to the terms of the Tumim Purchase Agreement. As a result, investors who purchase shares from the Selling Stockholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Stockholder in this offering as a result of future sales made by us to the Selling Stockholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Stockholder under the Tumim Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Stockholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock to the Selling Stockholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Common Stock to the Selling Stockholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Common Stock may fluctuate significantly, and investors in our Common Stock may lose all or a part of their investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. For example, from November&#160;11, 2022 (the first trading day following the closing of the Business Combination) to August&#160;1, 2025, our closing stock price </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ranged from $3.99 to $518.03. The market price of our Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our company and our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the risk factor below titled &#8220;<span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline</span>&#8221; for more factors affecting the trading price of our securities. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme volatility in the price of our Common Stock. Further, price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. Although we have had periods of high-volume daily trading in our Common Stock, generally our stock is thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. If an active trading market for our Common Stock does not continue, the price of our Common Stock may be more volatile and it may be more difficult and time consuming to complete a transaction in our Common Stock, which could have an adverse effect on the realized price of our Common Stock. In addition, an adverse development in the market price for our Common Stock could negatively affect our ability to issue new equity to fund our activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the status and cost of our marketing commitments for ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements regarding results of any clinical trials relating to our product candidates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA, ELYXYB or any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to ZTlido, GLOPERBA, ELYXYB or our product candidates, including but not limited to clinical trial requirements for approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning product development results or intellectual property rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future issuances of common stock or other securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated variations in quarterly operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates by the Company or by any securities analysts who might cover our stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuation of the market values of any of our potential strategic investments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with our contractual obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general political and economic conditions, including the wars in Ukraine and Israel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of natural or man-made catastrophic events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of public health crises, pandemics and epidemics; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control, such as the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the global equity markets in general have recently experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic, economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to our operating performance. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;, could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future and there is no assurance that we will complete the previously declared stock dividend. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid cash dividends on our Common Stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay cash dividends, a stockholder&#8217;s ability to receive a return on such stockholder&#8217;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Board declared a stock dividend (the &#8220;Dividend&#8221;) consisting of an aggregate of 5,000,000 shares (the &#8220;Dividend Stock&#8221;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share, to record holders of certain of our securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to such later date to be determined in the sole discretion of the Board) (such later record date as so determined by the Board, the &#8220;Record Date&#8221;). Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Certificate of Designation&#8221;) previously filed with the Secretary of State of the State of Delaware, designating the Dividend Stock, if the Dividend Stock is distributed, the holders of thereof may become entitled to a pro rata portion of the number of shares that represents the lesser of (a)&#160;10% of the shares of common stock, par value $0.00001 per share (the &#8220;Semnur Common Stock&#8221;), of Semnur (or such other securities into which or for which such stock may be exchanged or converted), held by us as of immediately prior to the Effective Date (as defined in the Semnur Business Combination Agreement) (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $200,000,000 divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is 10 trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) held by us as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). For purposes of the Certificate of Designation, (a)&#160;&#8220;Effective Time&#8221; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b)&#160;&#8220;Determination Date&#8221; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
converted) is listed for, and trading on, any national securities exchange, the date that is 15 trading days following the Registration Date, (c)&#160;&#8220;Registration Date&#8221; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Exchange Act and (ii)&#160;the time at which the Registration Statement is declared effective by the SEC and (d)&#160;&#8220;Registration Statement&#8221; means a registration statement, whether under the Exchange Act or the Securities Act, that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change such Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales, or the perception of future sales, of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our operating results may fluctuate significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variations in the level of expenses related to our development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the addition or termination of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any intellectual property infringement lawsuit in which we may become involved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments affecting ZTlido, GLOPERBA, ELYXYB or our product candidates, regulatory approvals of our product candidates, and the level of underlying demand for such products and purchasing patterns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect on pharmaceutical purchases and prices of the timing during which patients who purchase our product satisfy their deductibles under the reimbursement requirements of their health providers&#8217; plans. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2023, the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation and on March&#160;12, 2023, Signature Bank was closed by the New York State Department of Financial Services and the FDIC was named receiver. Although we do not maintain any bank accounts with Silicon Valley Bank or Signature Bank, we regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Any failure of a depository institution to return any of our deposits, or any other adverse conditions in the financial or credit markets </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affecting depository institutions, could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about the Company or our business. We may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading price for our capital stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities, whether upon conversion of the Tranche B Notes into Common Stock or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&#160;9, 2022, we are authorized to grant equity awards to our employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&#160;9, 2022, we are authorized to sell shares to our employees. Further, pursuant to the Inducement Plan, which was adopted on January&#160;17, 2023, we are authorized to grant equity awards to individuals as a material inducement to join the Company. A total of 703,670 shares of Common Stock (which number of shares accounts for the automatic annual increase on January&#160;1, 2025), 170,573 shares of Common Stock (which number of shares accounts for the annual increase on January&#160;1, 2025) and 40,000 shares of our Common Stock have been reserved for future issuance under the Equity Incentive Plan, the ESPP and the Inducement Plan, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&#160;1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Registration Rights Agreement, dated as of November&#160;10, 2022, by and among us, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (the &#8220;November 2022 Registration Rights Agreement&#8221;), which was entered into in connection with the Business Combination, certain stockholders of Vickers and Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of our other securities. We have filed a registration statement on Form S-1 (File No.&#160;333-268603) which was initially declared effective by the SEC on December&#160;27, 2022, in order to satisfy these obligations. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the November 2022 Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the market price of our securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido, GLOPERBA, ELYXYB or our product candidates, or grant licenses on terms unfavorable to us. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to maintain compliance with the continued listing standards of Nasdaq could result in a delisting of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;1, 2024, we received the Notice from Nasdaq notifying us that, because the closing bid price for our shares of Common Stock, has been below $1.00 per share for 30 consecutive business days, we did not comply with the Minimum Bid Price Requirement, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Under Nasdaq Listing Rules, we had 180 days, or until April&#160;30, 2025, to regain compliance with the Minimum Bid Price Requirement. Following the completion of the Reverse Stock Split, on April&#160;30, 2025, the Company received notification from Nasdaq that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2024, we received a second letter from Nasdaq advising us that we were not in compliance with Nasdaq&#8217;s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (&#8220;Listing Rule 5250(c)(1)&#8221;) as a result of our failure to file the Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2024 (the &#8220;Q3 Form 10-Q&#8221;) in a timely manner. Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic reports (the &#8220;Timely Reporting Requirement&#8221;) with the SEC. Under Nasdaq rules, we had 60 calendar days from receipt of such notice, or until January&#160;20, 2025, to submit a plan to regain compliance with the Listing Rule. We regained compliance with Listing Rule 5250(c)(1) by filing the Q3 Form 10-Q on January&#160;17, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, in the future, we are unable to maintain compliance with Nasdaq Listing Rules, Nasdaq could determine to delist our securities from trading on its exchange and if we are then unable to obtain listing on another national securities exchange, some or all of the following may occur, each of which could have a material adverse effect on our stockholders: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">causing our shares of Common Stock to be transferred to a more limited market than Nasdaq, which could affect the market price, trading volume, liquidity and resale price of such shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">causing an event of default under our existing debt instruments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reducing the number of investors, including institutional investors, willing to hold or acquire our Common Stock, which could negatively impact our ability to raise equity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreasing the amount of news and analyst coverage relating to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reducing the availability of information concerning the trading prices and volume of our Common Stock </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limiting our ability to issue additional securities, obtain additional financing or pursue strategic restructuring, refinancing or other transactions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impacting our reputation and, as a consequence, our business and operations. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may further decrease of total capitalization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;20, 2025, we held a special meeting at which our stockholders approved a reverse stock split at various ratios, after which our Board approved the Reverse Stock Split at a ratio of 1-for-35, which was effected on April&#160;15, 2025. The liquidity of our Common Stock may be adversely affected by the Reverse Stock Split as a result of the reduced number of shares outstanding following the Reverse Stock Split. The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization. If the per share market price of our Common Stock does not increase in proportion to the reverse stock split ratio, or following such increase does not maintain or exceed such price, then our value, as measured by our market capitalization, will be reduced. Additionally, any reduction in our market capitalization may be magnified as a result of the smaller number of total shares of Common Stock outstanding following a reverse stock split. In addition, the Reverse Stock Split may increase the number of stockholders who own odd lots of our Common Stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty affecting such sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of Common Stock for continued listing on the Nasdaq Capital Market. Although we have regained compliance with such requirement, there can be no assurance that we will maintain compliance with such requirement, or that we will not become deficient with respect to other Nasdaq listing requirements following, or as a result of, the Reverse Stock Split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and/or our directors and officers may be subject to litigation or other actions as a result of or relating to our internal investigation and our failure to timely file the Q3 Form 10-Q with the SEC and an unfavorable outcome with respect to such matters could harm our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, the audit committee of the Board (the &#8220;Audit Committee&#8221;) commenced an investigation with the assistance of independent counsel with respect to an evaluation of the following contracts: (i)&#160;the Commitment Side Letter (the &#8220;Commitment Letter&#8221;) entered into with FSF 33433 LLC (&#8220;FSF&#8221;) (a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part), (ii)&#160;a distribution agreement entered into with Endeavor Distribution LLC (&#8220;Endeavor&#8221;) in June 2024, and (iii)&#160;the Satisfaction Agreement entered into with FSF and Endeavor (a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part). The investigation relates to the accounting treatment of such contracts and related matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable laws or regulations, as interpreted and applied, or our reporting obligations with the SEC could have a material adverse effect on our reputation, the price of its securities and its business, financial condition and results of operations. We cannot predict the outcome of the above-referenced matters. Our management may be required to devote significant time and attention to these matters. An unfavorable outcome could have a material adverse impact on our financial position, results of operations or liquidity or the market for its securities, and could subject we and/or our directors and officers to litigation or other actions from third parties or regulatory bodies related to the above-referenced matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As a result of our failure to timely file the Q3 Form 10-Q, we are currently ineligible to file new short form registration statements on Form S-3, which may impair our ability to raise capital on terms favorable to us, in a timely manner or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Form S-3 permits eligible issuers to conduct registered offerings using a short form registration statement that allows the issuer to incorporate by reference its past and future filings and reports made under the Exchange Act. In addition, Form S-3 enables eligible issuers to conduct primary offerings &#8220;off the shelf&#8221; under Rule 415 of the Securities Act. The shelf registration process, combined with the ability to forward incorporate information, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allows issuers to avoid delays and interruptions in the offering process and to access the capital markets in a more expeditious and efficient manner than raising capital in a standard registered offering pursuant to a Registration Statement on Form S-1. The ability to register securities for resale may also be limited as a result of the loss of Form S-3 eligibility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of our failure to timely file the Q3 Form 10-Q, we are currently ineligible to file new short form registration statements on Form S-3, which may impair our ability to raise necessary capital to repay our debt obligations as they become due, pursue acquisition and development opportunities, and execute our business strategy. If we seek to access the capital markets through a registered offering during the period of time that we are unable to use a registration statement on Form S-3, we may experience delays in the offering process due to SEC review of a registration statement on Form S-1, experience downward pressure on our share price given that we will have to disclose the offering prior to formal commencement, and incur increased offering and transaction costs. If we are unable to raise capital through a registered offering, we would be required to conduct financing transactions on a private placement basis, subject to pricing, size and other limitations for equity raises under Nasdaq rules, or seek other sources of capital, which are not guaranteed. The foregoing limitations on our financing approaches could impair our ability to raise capital on terms favorable to us, in a timely manner or at all, which could have a material adverse effect on our results of operations, liquidity and financial position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming we continue to timely file our required Exchange Act reports, the earliest we would regain the ability to use Form S-3 is February&#160;1, 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short sellers have in the past and may attempt in the future to drive down the market price of our Common Stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller&#8217;s best interests for the price of the stock to decline, many short sellers (sometimes known as &#8220;disclosed shorts&#8221;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (&#8220;blogging&#8221;) have allowed many disclosed shorts to publicly attack a company&#8217;s credibility, strategy and veracity by means of so-called &#8220;research reports&#8221; that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including stockholder suits against the company that may be prompted by such allegations. We may in the future be the subject of stockholder suits that we believe were prompted by allegations made by short sellers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#8217;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a result of the Business Combination and may experience some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change net </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and JOBS Act of 2017 (&#8220;TCJA&#8221;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss (&#8220;NOL&#8221;) carryforwards. The TCJA, as modified by the CARES Act, limits a taxpayer&#8217;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December&#160;31, 2020. In addition, NOLs arising in tax years ending after December&#160;31, 2017 and before January&#160;1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&#160;31, 2020 may not be carried back. NOLs arising in tax years beginning after December&#160;31, 2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January&#160;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&#160;1, 2018 will continue to have a two-year carryback and 20-year carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Restated Certificate of Incorporation of the Company, filed with the Secretary of State of the State of Delaware on November&#160;10, 2022, as amended (the &#8220;Certificate of Incorporation&#8221;), the Bylaws of the Company, effective November&#160;10, 2022 (the &#8220;Bylaws&#8221;) and the DGCL, contain provisions that could make it more difficult for a third party to acquire the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for a classified board of directors with staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that special meetings may only be called by or at the direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that any alteration, amendment or repeal, in whole or in part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for nominations for elections to the Board and for proposing matters that can be acted upon by stockholders at stockholder meetings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We are governed by Section&#160;203 of the DGCL, except that the restrictions on business combinations of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For additional information regarding these and other provisions, see the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>.&#8221; In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL; <span style="font-style:italic">provided that</span>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. See the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221; for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235 billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by non-affiliates to equal or exceed $700 million as of the last business day of the second fiscal quarter of such year, and (2)&#160;the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for the Company to obtain directors&#8217; and officers&#8217; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have implemented an enterprise resource planning (&#8220;ERP&#8221;) system and will continue to invest in the system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&#160;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We have previously identified material weaknesses in our internal control over financial reporting. If we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to timely and accurately report our financial results and such material weaknesses may result in a material misstatement of our financial statements.&#8221; above for additional information regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comprehensive U.S. federal income tax reform could adversely affect the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA, which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a &#8220;worldwide&#8221; system of taxation to a modified territorial system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, then-President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&#160;16, 2022, former President Biden signed the IRA into law, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock buy-backs, and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many provisions of the TCJA expire at the end of 2025 or are modified beginning in 2026. The U.S. Congress and the current administration have indicated that they intend to pursue legislation in 2025 to make permanent the 2017 TCJA provisions but there is no guarantee that this initiative will be successful. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Warrants are exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;31, 2025, we have 6,958,204 outstanding SPAC Warrants (as defined below), which are currently exercisable for an aggregate of up to 198,805 shares of our Common Stock (on a post-Reverse Stock Split basis) in accordance with the terms of the Warrant Agreement, dated as of January&#160;6, 2021, between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and Vickers, governing those securities. The exercise price of these SPAC Warrants is $402.50 per whole share (on a post-Reverse Stock Split basis). &#8220;SPAC Warrants&#8221; means (i)&#160;the redeemable warrants that were included in the Units (each of which consisted of one Vickers ordinary share and one-half of one redeemable warrant) that, following the Business Combination and the Reverse Stock Split entitle the holder of each whole warrant to purchase (1/35<sup style="font-size:75%; vertical-align:top">th</sup>)&#160;of a share of Common Stock at a price of $402.50 per whole share (the &#8220;Public Warrants&#8221;), and (ii)&#160;the 6,840,000 warrants (which are currently exercisable for an aggregate of up to 195,429 shares of Common Stock, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on a post-Reverse Stock Split basis) sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&#160;11, 2021 (of which 2,736,000 (which are currently exercisable for an aggregate of up to 78,172 shares of Common Stock) were subsequently forfeited and 3,104,000 (which are currently exercisable for an aggregate of up to 88,686 shares of Common Stock, on a post-Reverse Stock Split basis) were transferred to Sorrento, in each case in connection with the Business Combination) (the &#8220;Private Warrants&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, (i)&#160;outstanding Penny Warrants to purchase an aggregate of 6,500,000 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $0.01 per share (though such Penny Warrants are subject to the Warrant Repurchase by us pursuant to the Option Agreement), (ii)&#160;outstanding February 2024 BDO Firm Warrants (as defined below) to purchase an aggregate of 108,686 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $59.50 per share; (iii)&#160;outstanding February 2024 BDO Representative Warrants (as defined below) to purchase an aggregate of 13,446 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $74.38 per share; (iv)&#160;outstanding Deposit Warrant (as defined below) to purchase an aggregate of 3,250,000 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $1.20 per share, (v)&#160;outstanding April 2024 RDO Common Warrants (as defined below) to purchase an aggregate of 428,572 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $38.50 per share and (vi)&#160;outstanding April 2024 RDO Placement Agent Warrants (as defined below) to purchase an aggregate of 34,286 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $43.75 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, we issued the October 2024 Noteholder Warrants (as defined below) to purchase an aggregate of 214,284 shares of Common Stock. On the same date, we also issued the October 2024 Placement Agent Warrants (as defined below) to purchase an aggregate of 104,848 shares of Common Stock, which became exercisable 180 days following the date of issuance. The current exercise price of both the October 2024 Noteholder Warrants and the October 2024 Placement Agent Warrants is $36.40 per share. As described elsewhere in this prospectus, on July&#160;22, 2025, we entered into the Warrant Exchange Agreements with the Tranche B Investors, pursuant to which October 2024 Noteholder Warrants to purchase up to 107,142 shares of Common Stock were surrendered in exchange for the Exchange Warrants. Oramed waived its right to participate in the exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;13, 2024, we issued the December 2024 RDO Pre-Funded Warrants (as defined below) to purchase an aggregate of 68,604 shares of Common Stock, which have been fully exercised as of the date of this prospectus. On the same date, we also issued the December 2024 RDO Common Warrants (as defined below) to purchase an aggregate of 1,642,871 shares of Common Stock and the StockBlock Warrants (as defined below) to purchase an aggregate of 131,472 shares of Common Stock, which will become exercisable 180 days following the date of issuance. The exercise price of both the December 2024 RDO Common Warrants and the StockBlock Warrants is $22.72 per share and $25.81 per share, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent the SPAC Warrants, the Penny Warrants, the February 2024 BDO Firm Warrants, the February 2024 BDO Representative Warrants, the Deposit Warrant, the Fee Warrant, the April 2024 RDO Common Warrants, the April 2024 RDO Placement Agent Warrants, the October 2024 Noteholder Warrants, the October 2024 Placement Agent Warrants, the December 2024 RDO Common Warrants, the StockBlock Warrants, and the Exchange Warrants (collectively, the &#8220;Warrants&#8221;) are exercised, additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. There is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless. See below risk factor, &#8220;<span style="font-style:italic">The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment</span>. <span style="font-style:italic">In addition, almost all of the other warrants to purchase shares of our Common Stock are out-of-the-money and may also expire worthless.</span>&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The SPAC Warrants may never be in the money, they may expire worthless and the terms of the SPAC Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment. In addition, almost all of the other warrants to purchase shares of our Common Stock are out-of-the-money and may also expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, the exercise price for our SPAC Warrants is $402.50 per whole share of Common Stock. On August 1, 2025, the closing price of our Common Stock on the Nasdaq Capital Market was $13.41. If the price of our shares of Common Stock remains below $402.50 per whole share, which is the exercise price of our SPAC Warrants, we believe our warrant holders will be unlikely to cash exercise their SPAC Warrants, resulting in little or no cash proceeds to us. There is no guarantee that our SPAC Warrants will be in the money prior to their expiration and, as such, our SPAC Warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SPAC Warrants were issued in registered form under the Warrant Agreement. The Warrant Agreement provides that the terms of the SPAC Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding SPAC Warrants to make any change that adversely affects the interests of the registered holders of SPAC Warrants. Accordingly, we may amend the terms of the SPAC Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment. Although our ability to amend the terms of the SPAC Warrants with the consent of majority of the then-outstanding SPAC Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the SPAC Warrants, convert the SPAC Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a SPAC Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as noted above, on August 1, 2025, the closing price of our Common Stock on the Nasdaq Capital Market was $13.41, making almost all of the Warrants out-of-the-money. If the price of our shares of Common Stock remains below the exercise prices of such other warrants, we believe the holders of such warrants will be unlikely to cash exercise such warrants, resulting in little or no cash proceeds to us. There is no guarantee that such out-of-the-money warrants will be in the money prior to their expiration and, as such, may expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem any unexpired SPAC Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the SPAC Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding SPAC Warrants (other than Private Warrants (as defined below) still held by the initial purchasers thereof) at any time after they become exercisable and prior to their expiration, at a price of $0.01 per SPAC Warrant, provided that the closing price of our Common Stock equals or exceeds $630.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any 30-trading-day period commencing after the SPAC Warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the SPAC Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding SPAC Warrants could force the holders thereof to: (i)&#160;exercise such SPAC Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii)&#160;sell such SPAC Warrants at the then-current market price when a holder might otherwise wish to hold such SPAC Warrants; or (iii)&#160;accept the nominal redemption price that, at the time the outstanding SPAC Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the SPAC Warrants (other than Private Warrants still held by the initial purchasers thereof) at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the SPAC Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their SPAC Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the SPAC Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_8">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.<span style="font-style:italic"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_9">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Common Stock offered by the Selling Stockholder pursuant to this prospectus will be sold by the Selling Stockholder for its own account. We may receive up to $100,000,000 aggregate gross proceeds from any sales we make to the Selling Stockholder pursuant to the Tumim Purchase Agreement. The net proceeds from sales, if any, under the Tumim Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Stockholder after the date of this prospectus. See the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; elsewhere in this prospectus for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the net proceeds that we receive under the Tumim Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the net proceeds as described above, we intend to invest the net proceeds pursuant to the Tumim Purchase Agreement in interest-bearing instruments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_10">DETERMINATION OF OFFERING PRICE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Stockholder under this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_11">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. Prior to the consummation of the Business Combination, Vickers&#8217;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#8220;VCKA,&#8221; &#8220;VCKAU&#8221; and &#8220;VCKAW,&#8221; respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock. As of July&#160;31, 2025, and taking into account the effect of the Reverse Stock Split, there were 123 holders of record of our Common Stock and one holder of record of our Public Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>Except as set forth below, we have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future, except as disclosed in the section titled &#8220;<span style="font-style:italic">Use of Proceeds</span>.&#8221;<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed on October&#160;27, 2024, our Board declared the Dividend consisting of the Dividend Stock of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share to record holders of certain of our securities. The last record date for the Dividend was May&#160;2, 2025, but on June&#160;23, 2025, the Board determined to defer such record date to a later day to be determined in the sole discretion of the Board (such date as may be set by the Board, the &#8220;Record Date&#8221;). Depending on the actual Record Date, the Company anticipates that the following Company securities will be entitled to participate in the Dividend, to the extent outstanding as of such Record Date: (i)&#160;our Common Stock (such record holders, the &#8220;Record Common Holders&#8221;), (ii)&#160;certain warrants to purchase Common Stock that have not been exercised prior to the Record Date (and which have the right to participate in the Dividend pursuant to the terms of their respective warrants, other than, for the avoidance of doubt any warrants to purchase Common Stock with an exercise price of $402.50 per whole share, and any other warrants that by their terms have not vested and are therefore not entitled to participate in the Dividend) (such warrants, the &#8220;Participating Warrants&#8221; and such record holders, the &#8220;Record Warrant Holders&#8221;), (iii)&#160;the Tranche B Notes issued by us in October 2024 (such notes, the &#8220;Participating Notes&#8221; and such record holders, the &#8220;Record Note Holders&#8221;), and (iv)&#160;our Series A Preferred Stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221; and such record holder, the &#8220;Record Preferred Holder&#8221; and together with the Record Common Holders, the Record Warrant Holders, and the Record Note Holders, the &#8220;Record Holders&#8221;). Subject to the Board&#8217;s right to change the Record Date and conditioned upon the effectiveness of the filing of our Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock designating shares of our Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Series 1 Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware (which condition has been satisfied), the Dividend (unless otherwise determined by the Board) shall be paid on such date to be determined by subsequent resolutions of the Board, which payment date shall be within 60 days following such Record Date (such date as determined by the Board, the &#8220;Payment Date&#8221;) and shall be apportioned on a pro rata basis among the Record Holders in accordance with each Record Holder&#8217;s ownership percentage of our Common Stock (assuming the full exercise of all Participating Warrants to purchase Common Stock held by the Record Warrant Holders, the conversion of all Participating Notes held by the Record Note Holders and deemed conversion of all outstanding Series A Preferred Stock held by the Record Preferred Holder) as of such Record Date as set forth in the records of our transfer agent (with respect to the Record Common Holders and Record Preferred Holder) and ours (with respect to the Record Warrant Holders and the Record Note Holders) as of such Record Date. As of the date of this prospectus, the Board has not yet set a new Record Date (or the related Payment Date) for the Dividend and retains the right to revoke the Dividend and continue to change the Record Date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_12">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018, in-licensed two commercial products in 2022 and 2023, and are developing our late-stage pipeline. Our commercial product, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We market ZTlido through a dedicated sales force of approximately 65 people, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), an FDA-approved prophylactic treatment for painful gout flares in adults, in the United States of America (&#8220;U.S.&#8221; or the &#8220;United States&#8221;). We launched GLOPERBA in June 2024 and believe we are well-positioned to market and distribute the product. In January 2025, we in-licensed the rights to commercialize GLOPERBA outside the U.S. In February 2023, we acquired the rights to patents, trademarks, regulatory approvals and other rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and its commercialization in the U.S. and Canada. In April 2023, we launched ELYXYB in the U.S. for the treatment of acute migraine, with or without aura, in adults. In January 2025, we received approval from Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB for the acute treatment of migraine with or without aura in Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, (i)&#160;SP-102 (&#8220;SEMDEXA&#8221;) (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain or sciatica with completed Phase 3 study, (ii)&#160;SP-103 (lidocaine topical system) 5.4% (&#8220;SP-103&#8221;), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain associated with muscle spasms and for which we have completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;), and (iii)&#160;SP-104 (4.5 mg, low dose naltrexone hydrochloride delayed-release capsules) (&#8220;SP-104&#8221;), a novel low-dose delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the first FDA-approved alternative to off-label epidural steroid injections, which are administered over 12&#160;million times annually in the United States. We have completed a pivotal Phase 3 study with final results received in March 2022, which results reflected achievement of primary and secondary endpoints. SP-103 has also been granted fast track designation by the FDA for LBP. We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute LBP </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with muscle spasms. SP-103 was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. We will continue to analyze the SP-103 Phase 2 trial data along with an investigator study of ZTlido in patients with neck pain completed in the second half of 2023, which also has shown promising top-line efficacy and safety results. SP-103, if approved, could become the first FDA-approved lidocaine topical product for the treatment of chronic neck pain associated with muscle spasms. SP-103 is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine three times higher than any lidocaine topical product that we are aware of, either approved or in development. We are examining SP-103 as a treatment for chronic neck pain associated with muscle spasms, a condition with high unmet need which we expect could affect over 20&#160;million patients in the United States as of 2023. On October&#160;20, 2024, we announced the successful end of a Phase 2 meeting with the FDA and leading to an agreed path forward to a new drug application (&#8220;NDA&#8221;) for our product candidate, SP-103. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our products. We obtain our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health 105, for ZTlido distribution in the United States. Cardinal Health 105 purchased and shipped ZTlido to customer wholesale distribution centers. Cardinal Health 105 also performed order management services on our behalf. On April&#160;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health 105 will continue to provide traditional third-party logistics functions for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. In June 2022, we in-licensed the exclusive right to commercialize GLOPERBA oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. In February 2023, we acquired rights to FDA-approved ELYXYB in the U.S. and Canada for the acute treatment of migraine. We intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of SP-103 and SP-104. Our ability to generate sufficient revenue to achieve profitability will depend on the successful commercialization of our products, ZTlido, GLOPERBA and ELYXYB, and the development of our product candidates. We had a net loss of $26.1 million and $24.4 million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025, we had an accumulated deficit of approximately $589.1 million. As of March&#160;31, 2025, we had cash and cash equivalents of approximately $5.8 million. Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; to our consolidated financial statements and our independent registered public accounting firm report included elsewhere in this prospectus for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido, GLOPERBA and ELYXYB and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, SP-103 and SP-104. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido, GLOPERBA and ELYXYB or delay, scale back or discontinue the development of one or more of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, our Board approved the Reverse Stock Split of the Common Stock at a ratio of 1-for-35, which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share. Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. We also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Reverse Stock Split, the Company&#8217;s outstanding Common Stock was reduced from approximately 243,312,885 shares to approximately 6,951,622 shares, based on the number of shares of Common Stock outstanding as of April&#160;14, 2025. All share and per share information in this prospectus has been retroactively adjusted to reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Instead, each fractional share remaining after completion of the reverse share split that was less than a whole share was rounded down and canceled in exchange for an amount in cash (without interest or deduction) equal to the fraction of one share to which such stockholder would otherwise be entitled multiplied by the closing price of the Common Stock on the Nasdaq Capital Market on the last trading day immediately preceding the effectiveness of the Reverse Stock Split. The Reverse Stock Split was applied to all of the Company&#8217;s outstanding Common Stock and therefore did not affect any shareholder&#8217;s ownership percentage of the shares, except for changes as a result of the elimination of fractional shares. The Reverse Stock Split did not alter the voting rights attached to the shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Bio JV </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2025, we and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer&#8217;s disease. We contributed 5.0&#160;million shares of Semnur Common Stock owned by us to Scilex Bio, Inc. in exchange for a 60% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a 40% ownership interest in Scilex Bio, Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed Penny Warrant Repurchase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed and as described elsewhere in this prospectus, on September&#160;21, 2023, we issued Penny Warrants to purchase up to an aggregate of 6,500,000 shares of Common Stock to Oramed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, we entered into the Option Agreement, pursuant to which, among other things, Oramed granted the Option to us for the Penny Warrant Repurchase for the Penny Warrant Repurchase Amount, subject to the terms and conditions set forth therein. In consideration of the Option, we agreed to pay the Option Payment Amount to Oramed in two equal installments occurring on or before August&#160;8, 2025 and December&#160;16, 2025, respectively. Provided that we have made the applicable option payment on or before such dates, we shall be entitled to purchase the Penny Warrants as follows: (i)&#160;on or before September&#160;30, 2025, we may repurchase 3,130,000 Penny Warrants for $13,000,000 and (ii)&#160;on or before December&#160;31, 2025, we may repurchase 3,370,000 Penny Warrants for $14,000,000. Additionally, if we effect the Penny Warrant Repurchase and have paid the Option Payment Amount and Penny Warrant Repurchase Amount in full, in accordance with the terms </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Option Agreement, then the maturity date of the Oramed Note, shall be extended to March&#160;31, 2026 and any make-whole payment due thereunder upon prepayment shall be waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oramed has the right to terminate the Option Agreement if we (i)&#160;fail to make certain payments thereunder or (ii)&#160;have not exercised the Option by the applicable dates set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Option Agreement, we have agreed that, if the Option Agreement is terminated pursuant to the terms set forth therein, we will use commercially reasonable efforts to obtain the approval of our stockholders to permit the issuance of shares of Common Stock in excess of the Stockholder Approval Cap (as defined therein) upon exercise of any Penny Warrants retained by Oramed following such termination, subject to the terms and conditions set forth therein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Exchange Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025 we entered into Warrant Exchange Agreements with the Exchanging Warrant Holders of our Existing Tranche B Warrants. Pursuant to the Warrant Exchange Agreements, we and the Exchanging Warrant Holders, in reliance on Section&#160;3(a)(9) of the Securities Act, effected a voluntary securities exchange whereby the Exchanging Warrant Holders exchanged the Existing Tranche B Warrants, which were exercisable for an aggregate of 107,142 shares of Common Stock at an exercise price of $36.40 per share, originally issued pursuant to that certain Securities Purchase Agreement, dated October&#160;7, 2024, by and among us and the investors named therein, for the New Warrants at an exercise price of $40.00 per share. The New Warrants were immediately exercisable, but may only be exercised on a cash basis on or after the earlier of (i)&#160;the date that is 90 days following the Closing Date (as defined in the Warrant Exchange Agreement), and (ii)&#160;the initial date after the date of the Warrant Exchange Agreement that a registration statement is effective and available for the issuance of the shares of Common Stock underlying the New Warrants to the holders of the New Warrants (or the resale of shares of Common Stock underlying the New Warrants); provided, however, the New Warrants may only be exercised on a cashless basis if there is no registration statement to cover the issuance of the shares of Common Stock underlying the Warrants or the resale of such shares. The New Warrants have an expiration date of October&#160;8, 2029. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sorrento Chapter 11 Filing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), together with its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al, Case Number 23-90085 (DRJ) (the &#8220;Chapter 11 Cases&#8221;). While we were previously majority-owned by Sorrento, we were not a debtor in Sorrento&#8217;s voluntary Chapter 11 filing. Pursuant to that certain Stock Purchase Agreement that we entered into with Sorrento on September&#160;21, 2023 (the &#8220;Sorrento SPA&#8221;), we repurchased shares of our Common Stock and Series A Preferred Stock from Sorrento. As a result, Sorrento no longer holds a majority of the voting power of our outstanding capital stock entitled to vote. As of March&#160;31, 2025, we had a $3.2 million receivable from Sorrento, which was fully reserved. We evaluate the collectability of this receivable on a quarterly basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists of product sales of ZTlido, ELYXYB and GLOPERBA in the United States. For product sales of ZTlido, ELYXYB and GLOPERBA, we record gross-to-net sales adjustments for government and commercial rebates, chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for our product. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Costs and Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists of the cost of purchasing ZTlido, ELYXYB and GLOPERBA from our manufacturing partners, inventory write-downs related to expiration dates for on-hand inventory, cost of shipments, and royalty payments to our manufacturers. We expect the cost of revenue to fluctuate with related net sales revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in research and development functions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to outside consultants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect to incur significant research and development expenses in connection with our clinical trials for SEMDEXA, SP-103 and SP-104. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selling, General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs, including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year-over-year in the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intangible Amortization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses and assembled workforce. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Legal Settlements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal settlements consist of gains on litigation settlements that were entered into during the first quarter of 2024. See Note 11 titled &#8220;<span style="font-style:italic">Commitments and Contingencies</span>&#8221; to our consolidated financial statements appearing elsewhere in this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other (Income) Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) Loss on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability includes the remeasurement of the warrant derivative liability. See Note 4 titled <span style="font-style:italic">&#8220;Fair Value Measurements&#8221;</span> to our consolidated financial statements appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Debt and Liability Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments includes the remeasurement of (i)&#160;the convertible debentures (the &#8220;Convertible Debentures&#8221;) issued to YA II, Ltd. (&#8220;Yorkville&#8221;) pursuant to that certain securities purchase agreement dated as of March&#160;21, 2023 and amended on October&#160;11, 2023, between Yorkville and us, (ii)&#160;senior secured promissory note to Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) issued in September 2023 in the principal amount of $101.9 million (the &#8220;Oramed Note&#8221;); (iii)&#160;senior secured convertibles notes issued in October 2024 in the principal amount of $50.0 million (the &#8220;Tranche B Notes&#8221;), (iv)&#160;the purchased revenue liability associated with the Purchase and Sale Agreement (the &#8220;ZTlido Royalty Purchase Agreement&#8221;) that the Company entered into in October 2024 with certain institutional investors (collectively, the &#8220;ZTlido Royalty Investors&#8221;) and Oramed, and (v)&#160;the purchased revenue liability associated with the ZTlido Purchase and Sale Agreement (the &#8220;Gloperba-Elyxyb Royalty Purchase Agreement&#8221;) that the Company entered into in February 2025 with certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed. See Note 4 titled <span style="font-style:italic">&#8220;Fair Value Measurements&#8221;</span> to our consolidated financial statements appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net for the three months ended March&#160;31, 2025 consists of interest on the balances due for government and commercial rebate programs and interest related to the deferred consideration for GLOPERBA license acquired from RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;) in 2022. Government rebate programs include state Medicaid drug rebate programs and commercial rebate programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates for access to and position on that provider&#8217;s patient drug formulary. Interest expense, net for the three months ended March&#160;31, 2024 consists of interest related to the loans in an aggregate principal amount of up to $30.0 million (the &#8220;Revolving Facility&#8221;) made available by eCapital Healthcare Corp. pursuant to a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) that Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;) entered into on June&#160;27, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) Loss on Foreign Currency Exchange </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) Loss on foreign currency exchange relates to foreign exchange (gain) loss on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and SP-103. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the three months ended March&#160;31, 2025 and 2024 and the years ended December&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months Ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Changes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">5,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">10,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(5,880</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">56,590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">46,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">9,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">16,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">15,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(3,105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">28,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">29,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,218</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">119,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">119,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(625</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(6,891</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(9,391</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(9,391</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total net operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">32,902</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">30,362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">139,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">152,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(12,188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(27,898</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(19,478</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(8,420</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(83,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(105,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other (income) expense, net:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(10,409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(10,866</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(17,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(17,890</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,407</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total other (income) expense, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,818</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,899</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(6,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(10,588</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(19,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(26,080</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(24,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(1,703</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">72,807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">41,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Three Months Ended March&#160;31, 2025 and 2024 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes net revenue by product for the three months ended March&#160;31, 2025 and 2024 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Three Months Ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">10,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(6,292</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">5,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">10,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(5,880</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the three months ended March&#160;31, 2025 and 2024 was $5.0 million and $10.9 million, respectively. The decrease of $5.9 million was primarily related to a $6.3 million decrease in net product sales of ZTlido, offset by an increase of $0.2 million in net product sales for each of ELYXYB and GLOPERBA, with GLOPERBA sales commencing in June 2024. The decrease in net sales of ZTlido was driven by a decrease in gross sales by approximately 55% due to a decrease in the sales volume, partially offset by a standard industry annual price increase effective January&#160;1, 2025. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Three Months Ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(837</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue - Royalties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,638</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue - Royalties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the three months ended March&#160;31, 2025 and 2024 was $1.4 million and $3.8 million, respectively. Cost of revenue for ZTlido decreased by $2.5 million, primarily driven by a decrease in gross product sales by approximately 55%. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the three months ended March&#160;31, 2025 and 2024 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:71%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Three Months Ended<br/>March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-102</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(740</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-102</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(714</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-103</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-103</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(104</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(139</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Three Months Ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(156</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">R&amp;D Discovery Project</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total R&amp;D Discovery Project</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the three months ended March&#160;31, 2025 and 2024 were $2.5 million and $3.1 million, respectively. The decrease was primarily attributed to reduced Chemistry, Manufacturing and Control development work related to SP-102. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the three months ended March&#160;31, 2025 and 2024 were $28.1 million and $29.3 million, respectively. The decrease of approximately $1.2 million was primarily due to a $1.8 million decrease in advisory and financing expenses, a $1.1 million decrease in personnel expense, primarily driven by a decrease in bonus accrual, a $1.2 million decrease in marketing expenses, a $0.5 million decrease in travel expenses, a $0.2 million decrease in insurance costs and a $1.1 million decrease in other expenses in the three months ended March&#160;31, 2025, partially offset by a $3.1 million increase in contracted services and a $1.6 million increase in legal fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the three months ended March&#160;31, 2025 and 2024 was $1.0 million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal Settlements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal settlements for the three months ended March&#160;31, 2025 and 2024 were nil and $6.9 million, respectively. The decrease was attributed to payments received from litigation settlements that were entered into during the first quarter of 2024. See Note 11 titled &#8220;<span style="font-style:italic">Commitments and Contingencies</span>&#8221; to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the three months ended March&#160;31, 2025 and 2024 was $(10.4) million and $0.5 million, respectively. The gain recognized during the three months ended March&#160;31, 2025 was attributed to the change in the fair value of the derivative warrant liability associated with the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the Deposit Warrant, the October </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below). The loss recognized during the three months ended March&#160;31, 2024 was attributed to the change in the fair value of the derivative warrant liability associated with the Private Warrants and the February 2024 BDO Firm Warrants.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Debt and Liability Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments for the three months ended March&#160;31, 2025 and 2024 was $6.1 million and $3.9 million, respectively. The loss recognized during the three months ended March&#160;31, 2025 was attributed to losses of $2.8 million for the Oramed Note, $0.8 million for the purchased revenue liability pursuant to the ZTlido Royalty Purchase Agreement and $2.5 million in change in fair value of the Tranche B Notes. The loss recognized during the three months ended March&#160;31, 2024 was primarily attributed to the Oramed Note. The Oramed Note was issued in September 2023 in the principal amount of $101.9 million, of which the principal amount of $25.7 million remained outstanding as of March&#160;31, 2025. The Tranche B Notes were issued in October 2024 in the principal amount of $50.0 million, of which the principal amount of $37.0 million remained outstanding as of March&#160;31, 2025.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net for the three months ended March&#160;31, 2025 and 2024 was $2.5 million and $0.5 million, respectively. Interest expense of $2.5 million for the three months ended March&#160;31, 2025 primarily consists of the interest on the balances due for government and commercial rebate programs. Interest expense of $0.5 million for the three months ended March&#160;31, 2024 consists of the interest related to the Revolving Facility. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Years Ended December&#160;31, 2024 and 2023 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes net revenue by product for the years ended December&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">52,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">46,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">5,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Net Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">56,590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">46,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">9,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2024 and 2023 was $56.6 million and $46.7 million, respectively. The increase of $9.9 million was comprised of $5.8 million, $3.8 million and $0.2 million increase in net product sales of ZTlido, ELYXYB and GLOPERBA, respectively, with GLOPERBA sales commencing in June 2024. The increase in net sales of ZTlido and ELYXYB was driven by an increase in gross sales by approximately 6% and 49%, respectively, as a result of an increase in the sales volume due to higher demand and a standard industry annual price increase, partially offset by an increase in rebates. The commercial launch of ELYXYB has been met with a strong response from the prescribing community since its commercial launch in April 2023 and continued to show growth during 2024, the first full year of commercialization. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes cost of revenue by product for the years ended December&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">6,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">6,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(382</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue - Royalties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9,854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(390</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ZTlido</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">16,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">15,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue - Royalties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">341</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Cost of Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">16,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">15,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2024 and 2023 was $16.7 million and $15.7 million, respectively. Cost of revenue for ZTlido increased by $0.5 million due to higher royalties primarily driven by an increase in gross product sales by approximately 6%, partially offset by a decrease due to favorable foreign currency exchange rate fluctuations affecting purchases from our foreign supplier, Itochu, and decrease in logistics costs due to the absence of air shipments in 2024 compared to 2023. Cost of revenue for ELYXYB increased by $0.5 million and was primarily due to the increase in gross product sales by approximately 49% with the sales commencing in April 2023. GLOPERBA sales commenced in June 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-102</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-102</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,547</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-103</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-103</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,874</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SP-104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(875</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Increase <br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(313</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(149</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SP-104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,337</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">813</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(195</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(529</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">9,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">12,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(3,105</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2024 and 2023 were $9.6 million and $12.7 million, respectively. The $3.1 million decrease was primarily attributed to reduced costs of SP-103 due to the completion of the Phase 2 clinical study and reduced development costs of SP-104. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2024 and 2023 were $119.0 million and $119.6 million, respectively. The decrease of approximately $0.6 million was primarily due to a $10.1 million decrease in legal fees, a $1.6 million decrease in insurance costs, a $0.4 million decrease in advisory and financing expenses and a $0.2 million decrease as a result of a $1.4 million decrease related to allowance for credit losses that was made in March 2023 for the receivable from Sorrento offset by a $1.2 million increase related to allowances for expected credit losses on accounts receivable, partially offset by a $5.5 million increase in rebate expense related to future shipments of the Additional Product (as defined below) under the Satisfaction Agreement, a $2.9 million increase in contracted services, a $1.7 million increase in personnel expense due to increase in headcount and a merit increase starting January 2024, a $0.5 million increase in travel expenses, a $0.1 million increase in marketing expenses and a $1.0 million increase in other expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for the years ended December&#160;31, 2024 and 2023 was $4.0 million and $4.1 million, respectively. The decrease of $0.1 million is related to the full amortization of the assembled workforce intangible asset (see Note 6 titled &#8220;<span style="font-style:italic">Goodwill and Intangible Assets</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal Settlements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal settlements for the years ended December&#160;31, 2024 and 2023 were $9.4 million and nil, respectively. The increase was attributed to litigation settlements that were entered into during the first quarter of 2024. See Note 11 titled &#8220;<span style="font-style:italic">Commitments and Contingencies</span>&#8221; to our consolidated financial statements appearing elsewhere in this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&#160;31, 2024 and 2023 was ($17.4) million and $0.5 million, respectively. The gain recognized during the year ended December&#160;31, 2024 was attributed to the change in the fair value of the derivative warrant liability associated with the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the Deposit Warrant, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants. The loss recognized during the year ended December&#160;31, 2023 was attributed to the change in the fair value of the derivative warrant liability associated with the Private Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Debt and Liability Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments for the years ended December&#160;31, 2024 and 2023 was $4.8 million and $7.2 million, respectively. The loss recognized during the year ended December&#160;31, 2024 was attributed to losses of $35.0 thousand for the Convertible Debentures, $3.6 million for the Oramed Note, $4.7 million for the FSF Deposit, $0.9 million for the purchased revenue liability pursuant to the ZTlido Royalty Purchase Agreement and a $2.6 million loss recognized upon issuance of the Tranche B Notes, partially offset by a gain of $6.6 million in change in fair value of the Tranche B Notes and $0.4 million gain on partial extinguishment of the Oramed Note pursuant to the Oramed Letter Agreement (as defined below). The loss recognized during the year ended December&#160;31, 2023 was attributed to losses of $4.4 million for the Convertible Debentures and $2.8 million for the Oramed Note. The Convertible Debentures were issued in March and April 2023 in an aggregate principal amount of $25.0 million, which were fully repaid during the first quarter of 2024. The Oramed Note was issued in September 2023 in the principal amount of $101.9 million, of which the principal amount of $25.0 million remained outstanding as of December&#160;31, 2024. The FSF Deposit was received in June 2024 in the principal amount of $10.0 million and was satisfied in November 2024 by the delivery of the Additional Product (as defined below) to Endeavor. The Tranche B Notes were issued in October 2024 in the principal amount of $50.0 million, of which the principal amount of $38.0 million remained outstanding as of December&#160;31, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net for the years ended December&#160;31, 2024 and 2023 was $2.0 million and $1.1 million, respectively. The increase was attributed to $0.8 million of interest related to the Revolving Facility and $0.1 million of interest related to deferred consideration for GLOPERBA license acquired from Romeg in 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, we had cash and cash equivalents of approximately $5.8 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the financing pursuant to the ATM Sales Agreement (as defined below). We also have indebtedness pursuant to the Oramed Note and Tranche B Notes as well as deferred consideration related to the GLOPERBA license acquired from Romeg in 2022. The following table summarizes the aggregate indebtedness of these issuances as of March&#160;31, 2025, December&#160;31, 2024, and December&#160;31, 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:57%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">March&#160;31,<br/>2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">December&#160;31,<br/>2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note (outstanding principal balance: $25.7 million, $25.0 million, and $100.9 million as of March&#160;31, 2025, December&#160;31, 2024 and 2023, respectively)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Debentures (outstanding principal balance: nil, nil, and $4.4 million as of March&#160;31, 2025, December&#160;31, 2024 and 2023, respectively)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes (outstanding principal balance: $37.0 million, $38.0 million, and $38.0 million as of March&#160;31, 2025, December&#160;31, 2024 and 2023, respectively)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased Revenue Liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revolving Credit Facility</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">49,522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">45,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">128,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Debt Financings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Oramed Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the fair value of the Oramed Note outstanding was $15.0 million pursuant to the Scilex-Oramed SPA (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221; to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Convertible Debentures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We fully repaid the Convertible Debentures in March 2024 (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tranche B Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the fair value of the Tranche B Notes outstanding was $24.5 million pursuant to the Tranche B Securities Purchase Agreement (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221; to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purchased Revenue Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the fair value of the purchased revenue liability was $7.3 million pursuant to the ZTlido Royalty Purchase Agreement and Gloperba-Elyxyb Royalty Purchase Agreement (see Note 7 titled </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;<span style="font-style:italic">Debt</span>&#8221; to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revolving Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We fully repaid the Revolving Facility in October 2024 (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Deferred Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, we have $2.8 million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license. Deferred consideration minimum royalty payments began in July 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido, ELYXYB and GLOPERBA Royalties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220; Product Development Agreement&#8221;) with Itochu and Oishi (together, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the three months ended March&#160;31, 2025 and 2024, Scilex Pharma made royalty payments in the amount of $0.9 million and $2.4 million, respectively. As of March&#160;31, 2025 and 2024, Scilex Pharma had ending balances of accrued royalty payables of $3.8 million and $4.0 million, respectively, which were recorded as accrued expenses under current liabilities on the unaudited condensed consolidated balance sheets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, we entered into an asset purchase agreement to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). We are obligated to make quarterly royalty payments on net sales of ELYXYB in the ELYXYB Territory that range from high single digits to low double digits on net sales based on the volume of sales. In April 2023, we launched ELYXYB in the U.S. During the three months ended March&#160;31, 2025 and 2024, we made royalty payments in the amount of $70.9thousand and $4.3 thousand, respectively. As of each of March&#160;31, 2025 and December&#160;31, 2024, we had ending balances of accrued royalty payables of $0.1 million, which were recorded as accrued expenses under current liabilities on the unaudited condensed consolidated balance sheets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, we entered into the Romeg License Agreement with Romeg, which agreement was subsequently amended in January 2025, to acquire certain rights to GLOPERBA and the exclusive license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;. As consideration for the license under the Romeg License Agreement, we are obligated to make royalty payments on net sales of GLOPERBA that range from low single digit to mid-single digit percentages based on annual net sales. During each of the three months ended March&#160;31, 2025 and 2024, we made royalty payments in the amount of $0.2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Contingent Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $280.0 million, $13.0 million and $23.0 million in aggregate contingent consideration obligations in connection with the SEMDEXA, GLOPERBA and SP-104 acquisitions, respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#8220;<span style="font-style:italic">Acquisitions</span>&#8221; to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Commitment Letter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, we entered into the Commitment Letter, pursuant to which FSF committed to provide us a loan in the aggregate amount of $100 million (the &#8220;Commitment Amount&#8221;). The Commitment Amount shall be payable as follows: (i)&#160;$85 million no later than the date that is 70 days following the date on which we receive the FSF Deposit (the &#8220;Outside Date&#8221; and the funding of the initial $85 million, the &#8220;Initial Closing&#8221;) and (ii)&#160;the remaining $15 million within 60 days following the Initial Closing. Pursuant to the Commitment Letter, FSF provided us the non-refundable FSF Deposit in immediately available funds in the aggregate principal amount of $10 million on June&#160;18, 2024 (the &#8220;Deposit Date&#8221;), which amount will be creditable towards the $85 million required to be funded by FSF at the Initial Closing. On the Deposit Date, we issued to FSF a warrant (the &#8220;Deposit Warrant&#8221;) to purchase up to an aggregate of 3,250,000 shares of Common Stock (subject to adjustment for certain stock dividends, stock splits, or similar transaction), with an exercise price of $1.20 per share. The terms of the Deposit Warrant were not subject to adjustment as a result of the Reverse Stock Split. Subject to certain ownership limitations, the Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Commitment Letter, we also entered into a letter agreement with FSF and FSF&#8217;s strategic consultant, IVI 66766 LLC (&#8220;IVI&#8221;), dated July&#160;16, 2024, pursuant to which we agreed to reimburse the actual, reasonable and documented consulting fees incurred by FSF in connection with the preparation, negotiation and execution of the Commitment Letter and the definitive documents with respect to the transactions contemplated thereby, which fees were satisfied in full by us issuing to IVI a warrant to purchase up to an aggregate of 250,000 shares (on a pre-Reverse Stock Split basis) of Common Stock (the &#8220;Fee Warrant&#8221;) on July&#160;16, 2024, with an exercise price of $1.20 per share (on a pre-Reverse Stock Split basis). In October 2024, the Fee Warrant was exercised by IVI. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock issuable upon exercise of the Deposit Warrant and the Fee Warrant were offered and sold by us in a private placement and were subsequently registered for resale on our registration statement on Form S-3 (the &#8220;Perigrove Form S-3 Registration Statement&#8221;) (which was initially filed with the SEC on July&#160;18, 2024, and was declared effective on July&#160;25, 2024 (File No.&#160;333-280882)). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, we entered into the Satisfaction Agreement with FSF and Endeavor, pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by our delivery of 28,000 cartons of ZTlido to Endeavor (the &#8220;Additional Product&#8221;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF nor we shall have any further liability or obligations thereunder. In consideration of Endeavor assuming our payment obligation in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to us for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2 million and (ii)&#160;the Additional Product. In November 2024, we delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tranche B Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;7, 2024, we entered into a securities purchase agreement (the &#8220;Tranche B Securities Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed (together with Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;), to refinance a portion of the Oramed Note and pay off certain other indebtedness. Pursuant to the Tranche B Securities Purchase Agreement, we agreed to issue and sell, in a registered offering directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the two-year anniversary of the issuance date and are convertible into shares of our Common Stock at a conversion price equal to $38.15 per share (which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and (ii)&#160;warrants (the &#8220;October 2024 Noteholder Warrants&#8221;) to purchase up to 214,284 shares of our Common Stock directly to the Tranche B Noteholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by us. We received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are immediately exercisable for cash at an exercise price equal to $38.15 per share of Common Stock (which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and conditions contained in the Tranche B Securities Purchase Agreement, we also agreed to reimburse the Tranche B Investors for all reasonable costs and expenses incurred by it or its affiliates in connection with the Tranche B Securities Purchase Agreement, the Tranche B Notes, the October 2024 Noteholder Warrants, the ZTlido Royalty Purchase Agreement and certain other transaction documents, and an aggregate amount of $950,000 non-accountable legal fees of outside counsel and special finance and collateral counsel, which shall be withheld by the Tranche B Investors from its purchase price at the closing of the transaction, less $20,000 previously paid by us. We shall also be responsible for the payment of a $2,000,000 fee to the placement agent in addition to the payment of any placement agent&#8217;s reasonable fees, financial advisory fees relating to or arising out of the transactions contemplated by the Tranche B Securities Purchase Agreement. In addition, in conjunction with and pursuant to the letter agreement we entered into with Oramed, dated as of October&#160;2, 2024 (the &#8220;Tranche B Letter Agreement&#8221;), we are also responsible for the payment of legal fees of outside counsel for Oramed relating to or arising out of the transactions contemplated hereby and the payment date extensions described under the Tranche B Letter Agreement. We shall also be responsible for the payment of any fees of the placement agent and the legal fees incurred thereby relating to or arising out of the transactions contemplated by the Tranche B Securities Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of the Tranche B Notes, we issued to StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC (the &#8220;October 2024 Placement Agents&#8221;) or their respective designees, (i)&#160;62,794 shares of Common Stock (the &#8220;October 2024 Placement Agent Shares&#8221;) and (ii)&#160;warrants to purchase up to 104,848 shares of Common Stock (the &#8220;October 2024 Placement Agent Warrants&#8221;). The October 2024 Placement Agent Shares were subject to a 120-day lock-up, which is now expired. In addition, during such 120-day period, the October 2024 Placement Agents (whether directly or indirectly through their respective affiliates) shall be prohibited from hedging, pledging or similar transactions and from short-selling our securities, subject to certain exceptions. The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the October 2024 Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2025, in connection with the formation of Scilex Bio, Inc. the Company entered into a Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note and Related Transaction Documents (collectively, the &#8220;Tranche B Consent and Waivers&#8221;) with each of the Tranche B Noteholders, pursuant to which certain definitions in the Tranche B Notes were modified to reflect, among other things, that Scilex Bio will not be deemed a subsidiary of Scilex under the terms of the Tranche B Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the Tranche B Consent and Waivers is not complete and is qualified in its entirety by reference to the full text of the Tranche B Consent and Waivers, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity Financings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Standby Equity Purchase Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with Yorkville. On February&#160;8, 2023, we entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. Pursuant to the A&amp;R Yorkville Purchase Agreement, we had the right, but not the obligation, to sell to Yorkville up to $500.0 million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto was declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Original Purchase Agreement was initially declared effective by the SEC on December&#160;9, 2022 and we were able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein. During the year ended December&#160;31, 2024, we sold 96,982 shares of Common Stock under the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of approximately $0.2 million. On, and effective as of, March&#160;25, 2024, we and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, we entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221;, together with the A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley, pursuant to which we had the right, but not the obligation, to sell to B. Riley up to $500.0 million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto was declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the B. Riley Purchase Agreement was initially declared effective by the SEC on January&#160;20, 2023 and we were able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein and the limitations set forth in the Convertible Debentures. During the year ended December&#160;31, 2024, we did not sell any shares of Common Stock under the B. Riley Purchase Agreement. On, and effective as of, February&#160;16, 2024, we and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">At-the-Market Sales Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, we entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, we were able to offer and sell (the &#8220;ATM Offering&#8221;) shares of Common Stock up to $170,000,000 (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the ATM Offering. We had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. The ATM Shares offered and sold in the ATM Offering were issued pursuant to our Shelf S-3 Registration Statement. The ATM Shares were offered by means of a prospectus forming a part of the Shelf S-3 Registration Statement. The Sales Agents were entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. We also agreed to reimburse the Sales Agents for certain expenses and have agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act of 1993, as amended (the &#8220;Securities Act&#8221;). During the three months ended March&#160;31, 2025, no sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 202 we sold 2,637 shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $0.1 million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">February 2024 Bought Deal Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, we entered into an underwriting agreement (the &#8220;February 2024 BDO Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC (&#8220;StockBlock&#8221;), as the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representatives (the &#8220;February 2024 BDO Representatives&#8221;) of the underwriters named in Schedule A (the &#8220;February 2024 BDO Underwriters&#8221;). Pursuant to the February 2024 BDO Underwriting Agreement, we sold, in an underwritten offering (the &#8220;February 2024 BDO&#8221;), 168,068 shares (the &#8220;February 2024 BDO Firm Shares&#8221;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 168,068 shares of Common Stock (the &#8220;February 2024 BDO Firm Warrants&#8221;). Each February 2024 BDO Firm Share was sold together with a February 2024 BDO Firm Warrant at a combined public offering price of $59.50. The combined price per Firm Share and accompanying February 2024 BDO Firm Warrant paid by the February BDO Underwriters was $54.74, which amount reflects the combined public offering price of $59.50, less underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the February 2024 BDO Common Warrants are exercisable immediately, will expire on the five-year anniversary of the date of issuance and have an exercise price of $59.50 per share. The exercise price of the February 2024 BDO Common Warrants is subject to certain adjustments, including (but not limited to) stock dividends, stock splits, combinations and reclassifications of the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the February 2024 BDO, pursuant to the February 2024 BDO Underwriting Agreement, we issued the February 2024 BDO Representatives warrants (the &#8220;February 2024 BDO Representative Warrants&#8221;, and together with the February 2024 BDO Common Warrants, the &#8220;February 2024 BDO Warrants&#8221;) to purchase up to an aggregate of 13,446 shares of Common Stock (which represents 8.0% of the aggregate number of February 2024 BDO Firm Shares sold in the February 2024 BDO). The February 2024 BDO Representative Warrants are immediately exercisable and have the same terms as the February 2024 BDO Common Warrants described above, except that the exercise price of the February 2024 BDO Representative Warrants is $74.38 per share, which represents 125% of the combined public offering price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant. We also agreed to pay certain expenses of the February 2024 BDO Representatives in connection with the February 2024 BDO, including their legal fees and out-of-pocket expenses up to $200,000 and up to $15,950 for clearing expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The February 2024 BDO Shares, the February 2024 BDO Warrants and the shares of Common Stock issuable upon exercise of the February 2024 BDO Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form S-3 (which was initially filed with the SEC on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File No.&#160;333-276245) (the &#8220;Shelf S-3 Registration Statement&#8221;)), a base prospectus dated January&#160;11, 2024 and a prospectus supplement dated February&#160;29, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">April 2024 Registered Direct Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, we entered into a securities purchase agreement (the &#8220;April 2024 RDO Purchase Agreement&#8221;) with the investor named therein, pursuant to which we sold and issued, in a registered direct offering (the &#8220;April 2024 RDO&#8221;): (i)&#160;an aggregate of 428,572 shares (the &#8220;April 2024 RDO Shares&#8221;) of Common Stock, and (ii)&#160;common warrants to purchase up to 428,572 shares of Common Stock (the &#8220;April 2024 RDO Common Warrants&#8221;). The offering price per share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $35.00, for aggregate gross proceeds to us of $15,000,000, before deducting the placement agent fees and other offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the six-month anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $38.50 per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC acted as exclusive placement agents (the &#8220;April 2024 RDO Placement Agents&#8221;) in connection with the April 2024 RDO. As compensation for such placement agent services, we paid the April 2024 RDO Placement Agents an aggregate cash fee equal to 8.0% of the gross </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds actually received by us from the April 2024 RDO. We also reimbursed the April 2024 RDO Placement Agents $100,000 for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and out-of-pocket expenses and $15,950 for clearing expenses. We also issued to the April 2024 RDO Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to 34,286 shares of Common Stock (the &#8220;April 2024 RDO Placement Agent Warrants&#8221;), representing up to 8.0% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $43.75 per share (which represents 125% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the six-month anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The April 2024 RDO Shares, the April 2024 RDO Warrants, and the shares of Common Stock issuable upon exercise of such warrants were offered and sold by us pursuant to the Shelf S-3 Registration Statement, a base prospectus dated January&#160;11, 2024 and a prospectus supplement dated April&#160;23, 2024. The April 2024 RDO closed on April&#160;25, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">December 2024 Registered Direct Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, we entered into a securities purchase agreement (the &#8220;December 2024 RDO Purchase Agreement&#8221;) with the investors named therein, pursuant to which we agreed to sell and issue, in a registered direct offering (the &#8220;December 2024 RDO&#8221;): (i)&#160;an aggregate of 753,009 shares of Common Stock, (ii)&#160;pre-funded warrants to purchase up to 68,604 shares of Common Stock (the &#8220;December 2024 RDO Pre-Funded Warrants&#8221;) and (iii)&#160;common warrants to purchase up to 1,642,871 shares of Common Stock (the &#8220;December 2024 RDO Common Warrants&#8221; and collectively with the December 2024 RDO Pre-Funded Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between us and StockBlock (the &#8220;StockBlock Warrants&#8221;), the &#8220;December 2024 RDO Warrants&#8221;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $20.65 and (b)&#160;per Pre-Funded Warrant and accompanying December 2024 RDO Common Warrants was $20.6499. We received approximately $17.0 million in gross proceeds from the December 2024 RDO, before deducting offering fees and expenses. We intend to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment to Common Stock Purchase Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, we entered into a warrant amendment (the &#8220;Warrant Amendment&#8221;) with one of the investors to exercise the outstanding amount of certain warrants that we issued to such investor in the February 2024 BDO on March&#160;5, 2024. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. The gross proceeds to us from such exercise was approximately $1.0 million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Liquidity Needs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs related to servicing of our debt; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA, ELYXYB and other product candidates not materialize at the anticipated rate contemplated in our business plan, we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise additional funds through various potential sources, such as equity and debt financings and license agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue generating products and the issuance of the Common Stock under the February 2024 BDO Underwriting Agreement, the April 2024 RDO Purchase Agreement, the Tranche B Securities Purchase Agreement and the December 2024 RDO Purchase Agreement, as of March&#160;31, 2025, we would receive up to an aggregate of approximately $74.4 million from the exercise of the private placement warrants we assumed from Vickers in November 2022 in connection with the Business Combination (the &#8220;Private Warrants&#8221;) and public warrants to purchase Common Stock (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220;SPAC Warrants&#8221;) (at an exercise price of $402.50 per whole share of Common Stock), assuming the exercise in full of all of the SPAC Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will depend on the market price of our Common Stock. If the price of our Common Stock remains below $402.50 per whole share, we believe warrant holders will be unlikely to cash exercise their SPAC Warrants, resulting in little or no cash proceeds to us. To the extent any of the February 2024 Firm Warrants, February 2024 BDO Representative Warrants, April 2024 RDO Common Warrants, October 2024 Placement Agent Warrants, warrant to purchase up to an aggregate of 3,250,000 shares of Common Stock pursuant to that certain Commitment Side Letter dated June&#160;11, 2024 (the &#8220;Deposit Warrant&#8221;), October 2024 Noteholder Warrants, October 2024 Placement Agent Warrants, December 2024 RDO Common Warrants and StockBlock Warrants is exercised, we will receive additional proceeds. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by issuing equity or convertible debt securities or as we have done pursuant to the Oramed Note and the Tranche B Notes, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, ELYXYB, or our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido, GLOPERBA or ELYXYB or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103 and SP-104 and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span>We anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is<span style="font-weight:bold"><span style="font-style:italic"> </span></span>substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. See Note 2 titled &#8220;<span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">Liquidity and Going Concern</span><span style="font-weight:bold"><span style="font-style:italic"></span></span>&#8221; to our unauduted condensed consolidated financial statements included elsewhere in this prospectus for additional information. Our existing cash and cash equivalents may be insufficient to enable us to fund our operating expenses, capital expenditure requirements, and to service our debt obligations (whether under the Oramed Note, the Tranche B Notes or otherwise) for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,<br/>2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three&#160;Months<br/>Ended<br/>March&#160;31<br/>2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three&#160;Months<br/>Ended<br/>March&#160;31,<br/>2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flow Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td colspan="13" style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash proceeds from operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">19,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(20,707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">6,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">6,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,675</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(395</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(18,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">25,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(3,084</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(1,457</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,528</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">(1,955</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2024, net cash proceeds from operating activities was approximately $19.3 million, attributable to non-cash reconciling items of $27.3 million related to allocated expense for financial instruments at fair value, stock-based compensation, change in fair value of debt and liability instruments, allowances for expected credit losses, depreciation and amortization, non-cash operating lease cost and gain on derivative liabilities, and changes in operating assets and liabilities that provided $64.8 million of cash, partially offset by our net loss of $72.8 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash used for operating activities was approximately $20.7 million, attributable to our net loss of $114.3 million, partially offset by other non-cash reconciling items of $27.9 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cash operating lease cost, and changes in operating assets and liabilities that provided $65.7 million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2025, net cash proceeds from operating activities were approximately $6.0 million, attributable to the changes in operating assets and liabilities that provided $27.2 million of cash and other non-cash reconciling items of $4.9 million related to stock-based compensation, change in fair value of debt and liability instruments, financing costs, depreciation and amortization, and non-cash operating lease cost and change on fair value of derivative liabilities, partially offset by our net loss of $26.1 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2024, net cash proceeds from operating activities were approximately $9.3 million, attributable the changes in operating assets and liabilities that provided $23.1 million of cash and other non-cash reconciling items of $10.6 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cash operating lease cost, partially offset by our net loss of $24.4 million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2024, net cash used for investing activities was approximately $2.7 million and was related to $0.6 million payments of deferred consideration for Romeg intangible asset acquisition under the Romeg License Agreement, $2.0 million purchase of the Class B ordinary shares of Denali and $0.1 million purchase of a convertible promissory note from Denali (see Note 5 titled &#8220;<span style="font-style:italic">Balance Sheet Components</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash used for investing activities was approximately $0.3 million, related to payments of deferred consideration for Romeg intangible asset acquisition and $30.0 thousand attributed to cash paid for property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2025, net cash used for investing activities was approximately $0.4 million and was related to the $0.2 million purchase of Gloperba Ex-U.S. rights-in-process research and development assets and $0.2 million related to payments of deferred consideration for the Romeg intangible asset acquisition under the Romeg License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2024, net cash used for investing activities was approximately $0.2 million, related to payments of deferred consideration for the Romeg intangible asset acquisition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2024, net cash used for financing activities was approximately $18.1 million and is primarily related to the repayment of an aggregate of $184.6 million of borrowings under the Revolving Facility, the Oramed Note, the Convertible Debentures and the Tranche B Notes, the payment of an aggregate of $4.4 million of transaction costs related to the February 2024 BDO, the April 2024 RDO and the December 2024 RDO, the payment of an aggregate of $4.2 million of transaction cost related to the Tranche B Notes and the ZTlido Royalty Purchase Agreement, a $1.4 million payment of deferred transaction costs related to the Semnur Business Combination, a $0.5 million payment of excise tax on stock repurchases, and a payment of $0.3 million cash in consideration of the repurchase of a certain portion of the SPAC Warrants, partially offset by $95.5 million in gross proceeds from the Revolving Facility, an aggregate of $42.0 million in gross proceeds from the issuance of shares under the February 2024 BDO, April 2024 RDO, December 2024 RDO and the exercise of the February 2024 BDO Firm Warrants, an aggregate of $25.0 million in gross proceeds from issuance of Tranche B Notes and ZTlido Royalty Purchase Agreement, $10.0 million in proceeds from receiving the FSF Deposit, an aggregate of $2.7 million in proceeds from the Standby Equity Purchase Agreements and the ATM Sales Agreement and an aggregate of $2.1 million in proceeds from the exercise of stock options and warrants and purchases under the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash provided by financing activities was approximately $23.6 million and is primarily related to $86.4 million in gross proceeds from the Revolving Facility between Scilex Pharma and eCapital Healthcare Corp., $35.5 million in proceeds from the Standby Equity Purchase Agreements, $24.0 million in proceeds from the Convertible Debentures and $1.1 million in proceeds from the exercise of stock options and warrants, partially offset by $89.6 million repayment of the borrowings under the Revolving Facility, Convertible Debentures, and Oramed Note, $20.0 million capital distribution to Sorrento, $10.0 million cash consideration paid for the securities purchased by the Company from Sorrento under the Sorrento SPA, $2.0 million payment of the transaction costs related to the Scilex-Oramed SPA and the Sorrento SPA and $1.8 million payment of the transaction costs related to the Business Combination and debt issuance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2025, net cash used for financing activities was approximately $3.1 million and was primarily related to a $1.6 million repayment of borrowings under the Tranche B Notes, a $0.8 million payment under the ZTlido Royalty Purchase Agreement, a $0.4 million payment of transaction costs in connection with the share repurchase, a $0.2 million payment of excise tax on the share repurchase and a $0.1 million payment of deferred transaction costs related to the Semnur Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2024, net cash used for financing activities was approximately $11.2 million and was primarily related to the $52.7 million repayment of borrowings under the Revolving Facility, Oramed Note, and Convertible Debentures and the $1.3 million payment of transaction costs related to the February 2024 BDO, partially offset by $32.6 million in gross proceeds from the Revolving Facility, $10.0 million in gross proceeds from the issuance of shares under the February 2024 BDO and $0.2 million in proceeds from the Standby Equity Purchase Agreements (see Note 2 titled &#8220;Liquidity and Going Concern&#8221; to our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#8217;s discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements which are prepared in accordance with the accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments and base them on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido, ELYXYB and GLOPERBA in the United States. We do not have significant costs associated with obtaining contracts with our customers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to receive from the customers in exchange for those products. In accordance with FASB ASC Topic 606 &#8220;<span style="font-style:italic">Revenue from Contracts with Customers</span>&#8221;<span style="font-style:italic">, </span>this process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our performance obligations with respect to sales of ZTlido, ELYXYB and GLOPERBA are satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer, because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rebates and Chargebacks </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. Both types of rebates vary over time.&#160;We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are recorded as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prompt Payment Discounts </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide our customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Service Fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Product Returns </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We currently estimate our product returns using historical trends and product return rates typically experienced in the industry and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Co-payment Assistance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance. We accrue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. Co-payment assistance is presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. The warrant liability associated with the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the Deposit Warrant, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrants is the expected volatility of the Common Stock. The expected volatility assumption is a blend of our own stock volatility and historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock-based compensation in accordance with FASB ASC Topic 718 &#8220;<span style="font-style:italic">Compensation &#8211; Stock Compensation</span>&#8221;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or non-employee&#8217;s vesting period. We account for forfeitures as incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Convertible Debentures, the Oramed Note, Tranche B Notes and Purchased Revenue Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We elected the fair value option to account for the Convertible Debentures in an aggregate principal amount of up to $25.0 million that were issued in March and April 2023, the Oramed Note in the principal amount of $101.9 million that was issued in September 2023, Tranche B Notes in the principal amount of $50.0 million that were issued in October 2024 and purchased revenue liability pursuant to the ZTlido Royalty Purchase Agreement. The Convertible Debentures, the Oramed Note, the Tranche B Notes and the purchased revenue liability are discussed in Note 7 titled &#8220;<span style="font-style:italic">Debt&#8221;</span> of the Notes to our consolidated financial statements included elsewhere in this prospectus. These instruments are measured at fair value on a recurring basis using Level 3 inputs. We employ the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures and Tranche B Notes, a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability, and a discounted cash flow model to measure the fair value of the Oramed Note, respectively, with any changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, except for changes due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 1 titled &#8220;<span style="font-style:italic">Nature of Operations and Basis of Presentation</span>&#8221; of the notes to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for a discussion of recent accounting pronouncements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;emerging growth company&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the JOBS Act, is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in GAAP or their interpretation, the adoption of new guidance or the application of existing guidance to changes in Scilex&#8217;s business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex qualifies and will remain as an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which Scilex has total annual gross revenue of at least $1.235 billion, or (c)&#160;in which Scilex is deemed to be a large accelerated filer, which means the market value of the common equity of Scilex that is held by non-affiliates equals or exceeds $700 million as of the last business day of its most recently completed second fiscal quarter; and (ii)&#160;the date on which Scilex has issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. Scilex qualifies and will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;Scilex has annual revenue of at least $100 million and a public float that equals or exceeds $700 million as of the last business day of its most recently completed second fiscal quarter or (ii)&#160;Scilex has a public float that equals or exceeds $250 million as of the last business day of its most recently completed second fiscal quarter. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_13">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial products are: (i)&#160;ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain; (ii)&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup>, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii)&#160;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, which launched in June 2024. In addition, we have three product candidates: (i)&#160;SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which we have completed a Phase 3 study; (ii)&#160;SP-103, a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which we have completed a Phase 2 trial in acute LBP; and (iii)&#160;SP-104, a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed. We believe our currently approved products and future product candidates, if approved by the FDA, could uniquely address what we believe are the significant unmet needs of the targeted populations and become the preferred treatment option for their respective indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions. Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies. We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our first commercial product, ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8% in October 2018. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. ZTlido is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi in Japan. We license the rights to ZTlido from and rely exclusively on Oishi and Itochu pursuant to the Product Development Agreement, and the Commercial Supply Agreement. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. In 2024, there were more than 206&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our second commercial product, ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> in April 2023.&#160;We acquired the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral solution) and the commercialization thereof in the United States and Canada from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. in February 2023.&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> is a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. In January 2025, we received approval from Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB for the acute treatment of migraine with or without aura in Canada. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our third commercial product, GLOPERBA, in June 2024. We acquired certain rights to GLOPERBA and the exclusive license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;, pursuant to the Romeg License Agreement we entered into with Romeg, dated as of June&#160;14, 2022, which agreement was subsequently amended on January&#160;16, 2025. GLOPERBA is an FDA-approved, liquid, oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 9.2&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. Non-steroidal anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We commercialized GLOPERBA in June 2024 and believe we are well positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. In January 2025, we in-licensed the rights to commercialize GLOPERBA outside the U.S. For more information, please see the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired SP-102 from Semnur in March 2019 and are developing SP-102 to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by off-label ESI, which are administered over 12&#160;million times annually in the United States. SEMDEXA&#8482; has been granted fast track designation by the FDA and, if approved, could become the only FDA-approved ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2022. We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute LBP associated with muscle spasms. SP-103 was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. SP-103 received FDA Fast Track status in LBP. We will continue to analyze the SP-103 Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown promising top-line efficacy and safety results. SP-103, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute pain. We are developing SP-104 as a novel delayed-release formulation of low-dose naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used off-label to treat fibromyalgia. There are no low-dose formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates completed and anticipated milestones for our current commercial products and novel product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g942297g78h35.jpg" alt="LOGO" style="width:6.30556in;height:2.32466in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel non-opioid and non-addictive treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the commercial potential of ZTlido</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold"></span>. We have assembled an integrated commercial organization using a dedicated sales force and sales management team, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of over 70 people, targeting over 10,000 primary care physicians, pain specialists, neurologists, rheumatologist, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing direct-to-patient marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial), United Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (&#8220;BCBS&#8221;), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Commercialize and successfully continue launch of ELYXYB</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold"> for migraine in the U.S. </span>We will utilize our current commercial infrastructure comprised of our sales, marketing and managed health care functions to promote ELYXYB for acute migraine to healthcare providers (&#8220;HCPs&#8221;) in the U.S. market. There is a good degree of overlap between the current Scilex sales force HCP targets and HCPs who prescribe medications for acute migraine, allowing for efficient dual promotion of ELYXYB and ZTlido. The principal elements of the ELYXYB strategy are the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Educate the market on the need for and value of a novel and differentiated option for the treatment of acute migraine, where a high degree of unmet medical need already exists. We will leverage our in-person sales field forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of ELYXYB features and benefits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Broaden access to ELYXYB. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy stakeholders to achieve uptake to key formularies. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold">Commercialize and successfully continue launch of GLOPERBA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold"> for gout in the U.S.</span> We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup> for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout, allowing for efficient dual promotion of GLOPERBA and ZTlido. The principal elements of the GLOPERBA strategy are as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow individualized, patient-by-patient therapy. Scilex will leverage its in-person sales forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of GLOPERBA&#8217;s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them identify and prescribe GLOPERBA to appropriate patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop and commercialize SEMDEXA<sup style="font-size:75%; vertical-align:top">TM</sup> as a novel epidural injection for the first approved treatment of sciatica.</span> We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used off-label. Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12&#160;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first FDA-approved epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Although such designation has been granted, it may not lead to a faster development or regulatory review process and such designation does not increase the likelihood that SEMDEXA will receive marketing approval. Due to the novelty of our formulation as well as the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full 6-month data analysis was completed in February 2022 and we have completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We have extensive clinical and pre-clinical data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of SP-102. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of SP-103 for the first approved topical treatment in patients with acute pain.</span> We are developing SP-103 as a triple-strength lidocaine topical system for the treatment of acute pain, to be used where we believe a high-dose strength and superior adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. SP-103 is designed to use ZTlido&#8217;s delivery and adhesion technology to deliver a dose of lidocaine that is three times higher than any other approved lidocaine topical products. We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute LBP associated with muscle spasms. SP-103 was safe and well tolerated. The increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. SP-103 received FDA Fast Track status in LBP. We will continue to analyze the SP-103 Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown promising top-line efficacy and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
safety results. SP-103, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute pain. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of SP-104 for the treatment of fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects.</span> We are developing SP-104 for fibromyalgia. Low-dose naltrexone hydrochloride delayed-release capsules are routinely used off-label to treat fibromyalgia and other chronic pain conditions such as complex regional pain. SP-104 addresses the shortcomings of using the high-dose commercial products and pharmacy-compounded products by delivering a low-dose of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. SP-104 has completed two Phase 1 studies to characterize the pharmacokinetics (&#8220;PK&#8221;) and safety of the product. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand our product portfolio by developing or acquiring non-opioid assets that leverage our novel delivery and adhesion technologies and our existing commercial infrastructure.</span> We are continuously evaluating opportunities to leverage our research and development experience to develop non-opioid therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to in-license or acquire non-opioid therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage our management team&#8217;s experience to further develop and commercialize its current and future product portfolio.</span> Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (&#8220;Teva&#8221;), Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Management Team </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in the pharmaceutical industry, as well as strong transactional and business development track records. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jaisim Shah has over 30 years of industry success in leading product development and commercializing innovative therapies and creating companies, with documented success in development and commercialization of some of today&#8217;s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive accomplishments at Scilex, Bristol-Myers Squibb, Roche, PDL Biopharma, Pfizer, and start-ups such as Elevation. Mr.&#160;Shah has served as our Chief Executive Officer and President and as a member of our board of directors since the closing of the business combination in November 2022. He has also served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharma since March 2019 and as a member of the board of directors of Scilex Pharmaceuticals, Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), since </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
November 2016. Mr.&#160;Shah has served as Chief Executive Officer and President of Semnur Pharmaceuticals since its inception in 2013. Mr.&#160;Shah served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, business strategy, mergers and acquisitions, and business development. He led the sale of Elevation to Sunovion Pharmaceuticals in 2012. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as Chief Business Officer and also held the position of senior vice president of marketing and medical affairs. During this time, he completed numerous licensing/partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka, and Biogen Idec. His leadership in marketing and portfolio management, including leading the commercial enterprise, helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000, Mr.&#160;Shah received the &#8220;Presidents Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. He has played a key role in the formulation of long-range plans and pre-launch and launch strategies for brands such as Abilify<sup style="font-size:75%; vertical-align:top">&#174;</sup>, Pegasys<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and Rituxan/MabThera<sup style="font-size:75%; vertical-align:top">&#174;</sup>, each of which have generated well over $1 billion in sales. Dr.&#160;Henry Ji is the holder of several issued and pending patents in the life science research field. Our Chief Financial Officer, Stephen Ma, has more than 15 years of finance and operational expertise across pharmaceuticals and venture-backed biotechnology companies. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel non-opioid and non-addictive treatments aiming to provide safe, effective and durable relief of multiple pain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver first-class pain management therapies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Product Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prescription Lidocaine Patch Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by the nerve injury and surrounding the affected area can persist for months and sometimes years. According to Evaluate Ltd., there were over 3.5&#160;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2024, there were more than 206&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of this number of prescriptions, there are only six main lidocaine patch manufacturers, which accounted for approximately 90% of the total prescriptions, according to Symphony </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system, ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for drug-to-drug interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various off-label treatments, including nonsteroidal anti-inflammatory drugs (&#8220;NSAIDS&#8221;) and opioids. These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the 12-month period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#8220;FAERS&#8221;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#8220;TDSs&#8221;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. There are also </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following figure depicts data derived from FAERS as of December&#160;31, 2023: </p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g14t04.jpg" alt="LOGO" style="width:6.30903in;height:2.41817in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver a sufficient amount of drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&#177; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#8217;s pliability can be compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &#177; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the 12-hour administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal marketing status. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#8220;Mylan&#8221;), while providing bioequivalent delivery of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Key Advantages of ZTlido vs. Lidoderm and Associated Generics </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g14k05.jpg" alt="LOGO" style="width:6.30555in;height:4.15876in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = Drug-in-adhesive </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Source: A Scilex-sponsored head-to-head comparative adhesion study (SCI-LIDO-ADH-003) </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products. ZTlido uses an advanced hot-melt technology, which uses premixing and hot-melt mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup> (a branded, prescription 5% lidocaine patch product) (&#8220;Lidoderm&#8221;) and Mylan&#8217;s generic lidocaine patch at 12 hours after application. In a head-to-head study of 44 subjects, ZTlido showed statistically significant adhesion at all-time points compared to Lidoderm. Further, ZTlido maintained greater than 90% mean adhesion over the labeled 12-hour administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#8217;s generic lidocaine patch. In this head-to-head study, ZTlido maintained greater than 90% mean adhesion throughout the labeled 12-hour administration period, while Mylan&#8217;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile without creating dermal sensitization and maintaining a benign irritation profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#8217;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol where adhesion could not be enhanced (i.e., no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#8217;s NDA approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g14p06.jpg" alt="LOGO" style="width:6.0001in;height:2.75333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from the patch to the skin. This was supported by a clinical study in which ZTlido achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the 12-hour administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to Lidoderm and Teva&#8217;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#8217;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of 30-minutes of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire 12-hour administration period. Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is supported by an adhesion or PK study showing that, while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no clinically meaningful change in PK. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (e.g., heating pad or blanket), the FDA-approved ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated sales force of approximately 65 people, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key formularies, including CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing efforts, have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-102 (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-102 (SEMDEXA) is a pivotal Phase 3, novel, injectable viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sciatica Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning LBP combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The estimated lifetime incidence of sciatica ranges from 13% to 40% of the U.S. population, and about one-third of these cases will develop symptoms lasting over a year. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with severe adverse events. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and non-invasive treatment options. Surgical intervention options include vertebroplasty, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&#160;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&#160;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants: and (iii)&#160;injectable pharmaceutical therapies such as off-label use of ESIs or nerve blocks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#8217;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being FDA-approved for the treatment of sciatica, currently-used ESIs also present various risks and challenges. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a non-particulate steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug product form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage: (1)&#160;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&#160;several particulate steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently off-label use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without the use of fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing SP-102 to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of sciatica. SP-102 is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a pre-filled syringe, so as to confer greater physician convenience. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications. Unlike currently-used steroids, SP-102 does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve tolerability and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe SP-102 may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, SP-102, which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe SP-102, if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, SP-102 could become the first FDA-approved ESI product for sciatica. We believe an FDA-approved therapy for the treatment of sciatica could potentially benefit from first-to-market advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. SP-102 benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Historically, we have purchased our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SP-102, from Genzyme pursuant to a supply agreement, which terminated as of May&#160;31, 2024. We anticipate that our current supply of sodium hyaluronate will be sufficient to satisfy our clinical and commercial supply requirements for sodium hyaluronate for at least 12 months following our expected commercial launch of SP-102 in 2027. We are currently in discussions with Sanofi, an affiliate of Genzyme, and are in the process of identifying and certifying new suppliers, in each case to fulfill our future supply requirements for sodium hyaluronate. Our complex manufacturing process, specialized equipment and know-how for sterile viscous product candidates are also key to our competitive edge. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed a pivotal Phase 3 Corticosteroid Lumbar Epidural Analgesia Radiculopathy (&#8220;CLEAR&#8221;) trial (NCT03372161), which was designed to evaluate the tolerability and clinical benefit of SP-102 in the proposed indication (i.e., treatment of LRP). The CLEAR clinical trial is a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial that enrolled 401 subjects with LRP at over 40 clinical sites across the United States, with a primary objective to evaluate the analgesic effect on average in the affected leg pain (as measured by the Numeric Pain Rating Scale (&#8220;NPRS&#8221;) in the affected leg) following a single epidural transforaminal (TF) injection of SP-102, compared to an intramuscular (i.e., the posterior multifidus muscle) injection of placebo over four weeks. After the primary Week Four analysis period, and if the subject continued to experience leg pain, a repeat injection of open-label SP-102 was made optional at the investigator&#8217;s discretion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-103 (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing SP-103 to be a triple-strength, non-aqueous lidocaine topical system for the treatment of acute pain. SP-103 leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength SP-103 is an investigational, non-aqueous lidocaine topical system undergoing clinical development in acute pain. If approved, we believe that SP-103 could become the lidocaine topical product for acute pain indications. This program builds on the learning from ZTlido because both products share the same superior adhesion and superior drug delivery formulation and manufacturing technology. We are developing SP-103 to deliver a dose of lidocaine that is at least three times higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture SP-103 to have a drug load of 108 mg lidocaine in a similar superior adhesion as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-103 has demonstrated delivery of three times the level of drug of ZTlido, and consequently delivers three times the level of drug of Lidoderm and associated generics by extrapolation. SP-103 has been granted fast track designation by the FDA in LBP. We believe SP-103, if successfully developed and approved, may be able to address the limitations of prescription lidocaine patches in treating acute pain by delivering a higher dose of lidocaine to the application site, but with systemic exposure of the drug remaining well below established safety thresholds. SP-103 has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver three times the level of the drug within a targeted area, with the convenience of a single topical system. This level of dosage for SP-103 is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a 24-hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute pain market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical non-opioid product targeting this segment of the pain population represents a commercially attractive strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Additional Markets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Neuropathic Pain Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neuropathic pain is triggered as a consequence of a disease or lesion to the somatosensory nervous system, altering its structure and function. It is maladaptive, meaning that the pain can be felt in the absence of a stimulus, and responses to innocuous and noxious stimuli are pathologically amplified. Neuropathic pain affects around 7-10% of the general population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common causes of the condition include postsurgical and post-traumatic nerve damage or nerve pressure, vascular malformations, alcoholism, metabolic diseases such as diabetes, cancer, viral infections, and neurological diseases such as multiple sclerosis. Chronic neuropathic pain may also be associated with an underlying condition such as diabetic neuropathy or cancer, and with treatments such as chemotherapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neuropathic pain often manifests as a burning sensation, with the affected regions becoming sensitive to even a slight touch. The symptoms of neuropathic pain include burning and sensations of electric shock, sleep disturbance, depression and anxiety, numbness, pins and needles, and difficulty in sensing temperatures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Neuropathic Pain: Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for drug-to-drug interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the 12-month period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. The safety of lidocaine patches is well supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FAERS. Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and TDSs conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. Since SP-103 uses the same technology as ZTlido, we anticipate that SP-103 will have similar superior adhesive properties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute&#160;&amp; Chronic LBP Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute and chronic LBP addresses a high unmet need and creates large market opportunities. LBP affects about 70% of people in resource-rich countries at some point in their lives. Acute and chronic LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate intensity pain and 15% have severe pain. Acute LBP has a high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5 billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute&#160;&amp; Chronic LBP: Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18&#8212;44, 45&#8212;64, and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group 65-74 years. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or possible osteoporosis), major or progressive motor or sensory deficit, new-onset bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-104 (4.5mg, low-dose naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing SP-104 for the treatment of fibromyalgia. Low-dose naltrexone hydrochloride delayed-release capsules are routinely used off-label to treat fibromyalgia and other chronic pain conditions such as complex regional pain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fibromyalgia Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&#160;million people in the United States and an estimated 3% to 6% of the world population. While it is most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12 billion to $14 billion each year and the condition accounts for a loss of 1% to 2% of the national overall productivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Complications of Fibromyalgia </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a non-exhaustive list of complications of fibromyalgia: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extreme allodynia with high levels of distress; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">opioid or alcohol dependence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marked functional impairment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severe depression and anxiety; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obesity and physical deconditioning; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">metabolic syndrome. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia are detailed in the chart below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15t02.jpg" alt="LOGO" style="width:5.70833in;height:4.44792in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new treatments with higher efficacy are needed to improve management of fibromyalgia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-104 has key clinical data supporting its use in fibromyalgia. There are investigational trials that support use and development of SP-104 for fibromyalgia. Currently there are no low-dose formulations (i.e., less than 5 mg) available. Physicians currently use the commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This approach can lead to errors in dosing and challenges with titration. The commercial products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SP-104 uses delayed burst release technology that bypasses the stomach and releases the drug in the gut (upper intestine). When taking SP-104 at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#8217;s potential to elicit compensatory response. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to developing SP-104 for fibromyalgia. Phase 1 studies are designed to characterize the PK and safety profile of SP-104. If successful, we believe SP-104 can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercialization and Market Access </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales&#160;&amp; Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our three current marketed products, ZTlido, ELYXYB and GLOPERBA, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product, ELYXYB in the migraine market, and GLOPERBA in the grout market. Our dedicated sales force of over 70 people has broad experience in pain management and is exclusively focused on promoting ZTlido, ELYXYB and GLOPERBA. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients and migraine patients. We believe these same call points provide treatment for the sciatica, acute LBP, and acute pain patients that could benefit from SEMDEXA and SP-103, if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2024, ZTlido had gained approximately 9.2% market share of the lidocaine patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the year ended December 31, 2024 grew by approximately 2.4% over the year ended December 31, 2023, according to Symphony Healthcare&#8217;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We are also </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of SP-102, SP-103 and SP-104, if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other non-opioid pain management therapeutics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market Access </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#8217; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&#160;million of the over 300&#160;million lives, with the remaining 25&#160;million to be considered in the future. Currently, ZTlido is covered for over 200&#160;million lives in the United States and coverage continues to improve. As of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Formulary Coverage - Over 90% of Lives Covered or In Negotiation </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15y04.jpg" alt="LOGO" style="width:6.07379in;height:2.93792in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying out-of-pocket. With the co-pay assistance program, qualifying patients do not have to pay any co-payment for their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clinical Development Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstrated bioequivalence to Lidoderm in study SCI-LIDO-PK-002A; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <span style="white-space:nowrap">12-hour</span> administration period in study SCI-LIDO-ADH-001; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed superior adhesion to Lidoderm and Mylan&#8217;s generic lidocaine patch in studies SCI-LIDO-AHD-002 and SCI-LIDO-ADH-003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was not meaningfully impacted by heat or exercise in study SCI-LIDO-HEX-001; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was able to be used under showering and bathing conditions in study SCI-LIDO-ADH-004; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">did not show clinically meaningful dermal irritation in study SCI-LIDO-DERM-001. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Study Details </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Bioequivalence Study </span>- SCI-LIDO-PK-002A </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose PK study between ZTlido and Lidoderm designed as a two-way cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#8217;s analgesic effects for ZTlido&#8217;s approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mean Lidocaine Plasma Concentration Time Profiles - Semilog Scale </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15y06.jpg" alt="LOGO" style="width:5.07323in;height:3.40333in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Adhesion Study</span> - SCI-LIDO-ADH-001 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the 12-hour administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the 12-hour administration period, over 90% of the subjects (49 out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Maintained Greater Than 90% Adhesion Over the 12-Hour Time Period </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15r06.jpg" alt="LOGO" style="width:5.47512in;height:2.92667in"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the product label. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Head-to-Head Adhesion Study versus Lidoderm </span>- SCI-LIDO-ADH-002 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a 12-hour administration period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the 12-hour administration period, while Lidoderm fell below 90% mean adhesion within three hours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15k07.jpg" alt="LOGO" style="width:4.75047in;height:3.18in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Head-to-Head Adhesion Study versus Mylan&#8217;s Generic</span> - SCI-LIDO-ADH-003 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, two-period, single-application adhesion performance study in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a 12-hour administration period. The purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a non-aqueous formulation. We selected Mylan&#8217;s generic lidocaine patch as a comparator because it has similar product characteristics, including a non-aqueous polymer drug-in-adhesive system allowing for a thinner patch and a lower drug load as compared to Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance compared to Mylan&#8217;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the 12-hour administration period, while the generic product had a mean adhesion score of only 80% immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Superior Adhesion Compared to Mylan&#8217;s Generic Lidocaine Patch </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15e08.jpg" alt="LOGO" style="width:5.16519in;height:4.28167in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PK and Adhesion Study under Exercise and Heat Conditions </span>- SCI-LIDO-HEX-001 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal conditions, respectively. The three treatment periods were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following the application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following the application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment period, topical systems were applied to the mid-lower back and worn for 12 hours. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the subjects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g15h09.jpg" alt="LOGO" style="width:4.6461in;height:3.5075in"/>
 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dermal Sensitization and Irritation Study</span> - SCI-LIDO-DERM-001 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a 7-point scale where a score of 0 indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Photoallergy and Phototoxicity Studies</span> - SCI-LIDO-PHOT0-001 and SCI-LIDO-PHOTO-002 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a 6-week randomized study, SCI-LIDO-PHOTO-001, to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we observed that ZTlido was not photoallergic. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a 4-day, randomized study, SCI-LIDO-PHOTO-002, to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Studies for ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Water Stress Study (Shower and Swimming)</span> - SCI-LIDO-ADH-004 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (PK) of ZTlido when it is exposed to two separate water stress conditions of (1)&#160;showering (10 minutes) and (2)&#160;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the 12-hour administration period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investigator-Sponsored Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-102 (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed a Phase 3 pivotal study of SP-102. The CLEAR study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of SP-102 to placebo. We announced final results from this study in March 2022. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SP-102 has been evaluated in a number of preclinical studies and clinical trials as a potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Repeat injections of SP-102 showed continued pain reduction with no unexpected adverse events based on preliminary results from the SP-102-03 study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SP-102 showed an extended local activity with epidural administration in the ES-1504 study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SP-102 showed an extended residence time and tolerability in the 1014-1512 and the 1014-2847, preclinical studies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The introduction of SP-102 into blood vessels did not result in neurological complications in the UPD003-IS21 preclinical toxicology study. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SP-102 (SEMDEXA) Study Details Phase 3 Pivotal Clinical Trial - CLEAR </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study included an open-label extension where subjects were followed for up to 24 weeks after treatment to evaluate the safety of administering SP-102 in a larger patient population. After week 4, subjects who met certain pain criteria received open-label SP-102 to investigate the safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of SP-102. The schematic of this Phase 3 trial is demonstrated in the flowchart below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic effect of SP-102 on average leg pain, measured using the NPRS following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a four-week period. The secondary objectives of this study include (i)&#160;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&#160;characterization of the change of the subject&#8217;s radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&#160;evaluation of the safety of a single and repeat SP-102 injection. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Schematic of CLEAR - SP-102 (SEMDEXA) Phase 3 Pivotal Trial </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g16k01.jpg" alt="LOGO" style="width:6.30554in;height:2.76505in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A full 6-month data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and secondary endpoints. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and majority of secondary endpoints, are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For the intent-to-treat (&#8220;ITT&#8221;) population, the primary endpoint of change in average daily NPRS pain in the affected leg over four weeks following the initial injection of SP-102 demonstrated least square (&#8220;LS&#8221;) mean treatment difference (standard error (&#8220;SE&#8221;)) of -0.52 (0.163) units [95% confidence interval (&#8220;CI&#8221;): -0.84,&#8212;0.20] compared to placebo (P=0.002). The change from baseline to Week Four in the mean daily average NPRS pain score (standard deviation (&#8220;SD&#8221;)) in the affected leg was -1.81 (1.896)&#160;for SP-102 versus -1.29 (1.814)&#160;in the placebo group. The calculated standardized effect size (Cohen&#8217;s D calculated as the group mean difference divided by the pooled standard deviation) associated with the ITT population is 0.28. A statistically significant difference in the mean daily average NPRS pain change between SP-102 and placebo was observed at Week One with a mean change from baseline of -1.49 (1.519)&#160;for SP-102 and -1.02 (1.472)&#160;for placebo (P=0.002), which was maintained through Week Four. These highly significant differences between SP-102 and placebo were also observed following sensitivity analyses for fixed effects. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Likewise for the ITT population, most of the secondary endpoints at four weeks also demonstrated statistically significant results. For the key secondary endpoint of mean change in Oswestry Disability Index (&#8220;ODI&#8221;) from baseline, the LS mean treatment difference (SE) </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
for SP-102 was -3.38 (1.388)&#160;units [95% CI: -6.11, -0.65] compared to placebo (P=0.015). SP-102 treatment resulted in a -8.88 point reduction from baseline, which exceeds the minimal clinically important difference of -8 established in a reported pain study. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional secondary endpoints with statistically significant results for the ITT population include worst pain in affected leg at Week Four (P=0.004) and over four weeks (P=0.001), current pain in the affected leg (P=0.009), average pain in lower back (P=0.035), Brief Pain Inventory-Short Form (&#8220;BPI-SF&#8221;) for pain severity (P=0.003) and pain interference (P=0.049), Patient Global Impression of Change (&#8220;PGIC&#8221;) (P&lt;0.001) and Clinical Global Impression of Change (&#8220;CGIC&#8221;) (P&lt;0.001), with the proportion of patients achieving a response at 30% (P=0.002). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The time to repeat injection (50th quantile [95% CI]) for the ITT population was 84 (71, 100) days for SP-102 versus 58 (50, 69) days for placebo (P=0.001). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional analyses were performed with the modified ITT population (&#8220;mITT&#8221;), the population with fluoroscopically confirmed needle placement. The primary endpoint group mean difference, associated standardized effect size (Cohen&#8217;s D), and statistical significance were improved for the mITT population (i.e., -1.08 (0.171), Cohen&#8217;s D = 0.68, P&lt;0.001), which were initially observed at week one and improved through Week Four. Similarly, the mITT population was observed to have improved with mostly highly statistically significant outcomes for SP-102 over placebo for the secondary efficacy endpoints. In contrast to the ITT population, the mITT population was observed to have statistically significant PainDETECT (a tool to detect neuropathic pain components) for SP-102 over placebo (P=0.037) as well as number of subjects experiencing a 50% reduction in pain in the affected leg (P&lt;0.001). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For the mITT population, the time to repeat injection (50th quantile [95% CI]) was 99 (78, 129) days for SP-102 versus 57 (49, 67) days for placebo. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There were no serious adverse events (&#8220;SAEs&#8221;) related to SP-102 or its administration procedure. There were no adverse events (&#8220;AEs&#8221;) leading to death, and no AEs of special interest (&#8220;AESIs&#8221;) (i.e., paraplegia, hematoma, or infection at the injection site). There were four (1.4%)&#160;subjects experiencing SAEs and one (0.3%) subject experiencing an AE leading to early withdrawal after receiving SP-102. Two (1.0%)&#160;subjects experienced an SAE, with one (0.5%) subject experiencing an AE leading to early withdrawal and one patient death following placebo. The fatal SAE was considered unrelated to the placebo or study procedure, as were the SAEs leading to early withdrawal. In general, a slightly higher proportion of subjects in the SP-102 group had treatment emergent AEs (&#8220;TEAEs&#8221;) than in the placebo group, (60 [29.7%] subjects vs 42 [21.1%] subjects with any TEAE). The most common TEAEs by system organ class (SOC) were nervous system disorders: 20 (9.9%)&#160;in the SP-102 group, 16 (8.0%)&#160;in the placebo group, and 20 (7.0%)&#160;in the SP-102 repeat injection group. The most common TEAEs by preferred term (&#8220;PT&#8221;) were headache, reported in 13 (6.4%)&#160;subjects in the SP-102 group, 11 (5.5%)&#160;subjects in the placebo group, and 10 (3.5%)&#160;subjects the SP-102 repeat injection group. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Overall, headaches were more commonly reported in subjects exposed to SP-102 than in subjects not exposed to SP-102 through 12 weeks (6.5% vs 2.1%). Headaches were generally mild, transient, and associated with the epidural injection. Pain at the site of injection was only reported for subjects receiving SP-102 following the initial injection (2.0%)&#160;and repeat injection (0.7%). Otherwise, TEAEs occurring &#8805;2% of subjects were low and balanced between SP-102 and placebo. TEAEs occurring with an incidence &#8805;2% remained low following the repeat injection. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There were no meaningful differences observed in physical examinations, vital signs, or laboratory parameters between treatment groups. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data from the primary endpoint analyses is graphically presented below. Summary tables are also provided for primary and secondary endpoints. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mean Change From Baseline in NPRS Average Pain Score (Standard Error) in the Affected Leg (ITT Population) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SP-102 vs Placebo Weeks 1,2,3,4: p = 0.002, 0.005, 0.003, 0.003. Overall treatment Effect (Mean SP-102 vs Placebo difference): Diff = -0.52, SE= 0.163, p = 0.002. Error Bars: 95% Confidence Limits. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Primary and Secondary Outcomes: NPRS Average Leg Pain In Affected Leg, ODI Total Score, Mean Daily NPRS (worst, current, and lower back), PainDetect, BPI-SF (Change from Baseline to Four Weeks; ITT Population) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Endpoint</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">SP-102 N=202<br/>Mean&#160;Change&#160;from<br/>Baseline<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">Placebo N=199<br/>Mean&#160;Change&#160;from<br/>Baseline</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">LSM&#160;(SE)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">95%&#160;CI</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap">P-value</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NPRS Average Pain Score in the Affected Leg (primary endpoint)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.81(1.896)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.29&#160;(1.814)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.55<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.187</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.92,&#160;-0.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ODI total score (key secondary endpoint)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-8.88&#160;(14.684)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-5.48&#160;(13.083)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-3.38<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(1.388</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-6.11, -0.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Worst pain in affected leg at Week Four<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.88&#160;(2.014)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.33&#160;(1.946)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.57<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.198</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.96, -0.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Worst pain in affected leg over Four Weeks<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.56<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.173</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.90, -0.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current pain in affected leg<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.8 (2.28)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.2&#160;(2.41)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.6<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.23</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.1, -0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average pain in lower back<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.7 (2.54)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.2 (2.48)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.5<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.23</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.9, 0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PainDETECT<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-2.7 (6.47)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-2.5 (6.07)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.3<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.62</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.5, 0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brief Pain Inventory &#8211; Short Form score (pain severity)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.56 (1.952)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.98 (1.928)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.59<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.200</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><span style="white-space:nowrap">-0.98,&#160;-0.20</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brief Pain Inventory &#8211; Short Form score (pain interference)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-1.16 (2.413)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.71 (2.095)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="vertical-align:bottom;text-align:right">-0.44<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(0.221</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">-0.87, 0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Baseline NPRS score is the mean of at least five days and no more than seven days of scores from the screening visit until treatment randomization. For the current pain, baseline is the last score prior to treatment. Baseline ODI is defined as the last ODI assessment score prior to the first dose on Day 1. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The analysis uses a REML-based MMRM with fixed effects for treatment (SP-102 or placebo), week, site, Pain Catastrophizing Scale group (&lt;30 or &#8805;30), baseline score, and treatment-by-week interaction. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The analysis uses an ANCOVA model with fixed effects for treatment (SP-102 or placebo), site, Pain Catastrophizing Scale group (&lt;30 or &#8805;30), and baseline score. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ANCOVA: analysis of covariance; ANOVA: analysis of variance; BPI-SF: Brief Pain Inventory &#8211; Short Form; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CI: confidence interval; ITT: intent-to-treat (randomized population); LSM: least-squares mean; MMRM: mixed model for repeated measures; NPRS: numeric pain rating scale; REML: restricted maximum likelihood; SE: standard error </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC) &#8211; ITT Population </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">SP-102</span><br/><span style="font-weight:bold">N=202</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Placebo</span><br/><span style="font-weight:bold">N=199</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGIC Responders (number of patients who responded with &#8220;very much improved&#8221; or &#8220;much improved&#8221;<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">71&#160;(35.1%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">39&#160;(19.6%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chi-Square</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P&lt;0.001</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logistic regression (odds ratio [95% CI])<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">2.25 (1.42, 3.54)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P&lt;0.001</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CGIC Responders (number of patients assessed as &#8220;very much improved&#8221; or &#8220;much improved&#8221;<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">76&#160;(37.6%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">39&#160;(19.6%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chi-Square</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P&lt;0.001</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logistic regression (odds ratio [95% CI])<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">2.49&#160;(1.58, 3.91)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P&lt;0.001</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><span style="font-weight:bold"></span><sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt;text-align:left"><span style="font-weight:bold"></span>7-point scale rating patient&#8217;s overall improvement. Patient change is rated from &#8220;very much improved&#8221;, &#8220;much improved&#8221;, &#8220;minimally improved&#8221;, &#8220;no change&#8221;, &#8220;minimally worse&#8221;, &#8220;much worse&#8221; or &#8220;very much worse&#8221;. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Logistic regression models with treatment (SP-102 or placebo), site, and Pain Catastrophizing Scale group (&lt;30 or &#8805;30) as factors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CI: confidence interval; ITT: intent-to-treat (randomized population) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Time to Repeat Injection &#8211; ITT Population </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">SP-102</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">N=202</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Placebo</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">N=199</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of patients with Repeat Injection of SP-102 (patients who received open-label SP-102 between 4 and 20 weeks after initial injection)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">134&#160;(66.3%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">152&#160;(76.4%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of censored patients<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">68&#160;(33.7%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">47 (23.6%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chi-Square</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P=0.026</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time (days) to Repeat Injection </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:73%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">N</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">134&#160;(66.3%)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">152&#160;(76.4%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean (SD)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">67.0 (33.31)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">57.8 (31.69)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">57.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">43.0</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Min, Max</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">27, 143</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">26, 148</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25th quantile (95% CI)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">45 (43, 57)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">36 (34, 40)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50th quantile (95% CI)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">84 (71, 100)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">58 (50, 69)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75th quantile (95% CI)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">143&#160;(141,&#160;143)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">126&#160;(87,&#160;146)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comparison to Placebo<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">0.68 (0.54, 0.86)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Hazard ratio [95% CI]):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">P=0.001</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Censored patients are the following: (1)&#160;patients who do not receive a repeat injection of SP-102 and (2)&#160;patients who discontinued the study prior to Week 20 without receiving a repeat injection. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Quartiles are estimated using Kaplan-Meier estimation. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and Pain Catastrophizing Scale (&lt;30 or &#8805;30). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CI: confidence interval; ITT: intent-to-treat (randomized population); SD: standard deviation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg)<sup style="font-size:75%; vertical-align:top">(1)</sup> &#8211; ITT Population </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">SP-102</span><br/><span style="font-weight:bold">N=202</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Placebo</span><br/><span style="font-weight:bold">N=199</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30% reduction</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">88&#160;(43.6%)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">57&#160;(28.6%)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chi-Square</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">P=0.002</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logistic&#160;regression<sup style="font-size:75%; vertical-align:top">(2)</sup> (odds&#160;ratio&#160;[95%&#160;CI])</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">1.96&#160;(1.28,&#160;2.98)&#8199;&#8199;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">P=0.002</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% reduction</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">58&#160;(28.7%)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">41&#160;(20.6%)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chi-Square</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">P=0.060</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logistic regression<sup style="font-size:75%; vertical-align:top">(2)</sup> (odds ratio [95% CI])</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">1.58&#160;(0.99, 2.52)</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="5">P=0.055</td>
<td style="vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Patients that discontinued or have missing scores at Week Four were considered non-responders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">(2)</sup></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Logistic regression models with treatment (SP-102 or placebo), site, and Pain Catastrophizing Scale group (&lt;30 or &#8805;30), and baseline averaged daily pain score as factors were used to compare the treatment groups at each week. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CI: confidence interval; ITT: intent-to-treat (randomized population) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 2 Repeat Dose Study</span>&#8212;SP-102-03 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-arm, pharmacodynamics (&#8220;PD&#8221;) and tolerability study of repeat epidural injections of SP-102 in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat SP-102 epidural injections four to eight weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the 28-day observation period for both treatments. Based on a preliminary review of the results, SP-102 injections were generally well tolerated and there were no new unexpected adverse events observed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g942297g16h05.jpg" alt="LOGO" style="width:5.51119in;height:2.5725in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 Trial of SP-102 (SEMDEXA) Compared to Reference Listed Drug</span>&#8212;ES-1504 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-arm, two-period, fixed sequential-dose study to evaluate the PK, PD and tolerability of SP-102 when administered by epidural injection. SP-102 was compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received SP-102 followed by the intravenous dexamethasone sodium phosphate injection (Reference Listed Drug (&#8220;RLD&#8221;)) administered one month later. A RLD is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between SP-102 and the RLD. The Tmax observed with the administration of SP-102 was four hours, compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and tolerability profiles of both products were similar, and SP-102 did not prolong cortisol suppression time. SP-102 also maintained analgesic effects throughout a one-month observation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as SP-102 or injected intravenously, with a mean AUCinf of 0.916 &#181;g*h/mL (observed with SP-102) compared to 0.943 &#181;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a 16- fold increase in the time to maximum serum concentration (&#8220;Tmax&#8221;) following epidural injection of SP-102. The median Tmax was 4.00 hours for SP-102 compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the one-month observation period following a single epidural injection of SP-102. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural injection of SP-102 did not exceed the exposure following intravenous injection of the RLD. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as the tolerability profile, were similar between the two treatments. SP-102 injections were generally well tolerated and did not result in new unexpected side effects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Toxicology Studies</span>&#8212;Study Nos. 1014-1512 and 1014-2847 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two non-rodent animal species to assess SP-102 administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended residence time of the viscous gel formulation of SP-102 at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with administration of dexamethasone sodium phosphate. Based on these studies, we selected the 10mg Dexamethasone in 2mL volume dose for our further clinical studies. This selection was endorsed by the FDA during our pre-IND meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical Toxicology Study</span>&#8212;UPD003-IS21 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates. A 2 mL (10 mg of dexamethasone) injection of SP-102 was injected over one to two minutes into the vertebral artery of large animal species. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre- and post-dose angiography showed no remarkable changes and all animals survived for approximately 24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hydrodynamic Study</span>&#8212;SP-PC002 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of SP-102 in non-rodent animal species, which showed that epidural administration of SP-102 demonstrated an increased local residence half-life and a decreased flow from the injection site. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intravascular Injection Study</span>&#8212;SEM-005 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of SP-102 into the vertebral artery of non-rodent animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of SP-102 following a 24-hour survival period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-103 (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-103 is an investigational, non-aqueous lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, SP-103 will build on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of SP-103 for the treatment of acute LBP. A Phase 1 study was completed that demonstrated bioequivalent PK between the administration of a single SP-103 and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of SP-103 (i.e., one, two or three patches) over a 12-hour administration period. Adhesion performance was assessed and found to be comparable between SP-103 and ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute LBP associated with muscle spasms. SP-103 was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. SP-103 received FDA Fast Track status in LBP. We will continue to analyze the SP-103 Phase 2 trial data along with an investigator study at Johns Hopkins University completed in the second half of 2023, investigating ZTlido in patients with chronic non-radicular neck pain, which also has shown promising top-line efficacy and safety results. While the phase 2 trial in acute LBP had demonstrated an effect in a subpopulation of patients who had acute LBP associated with more severe muscle spasms, the investigator-initiated randomized, crossover, placebo-controlled trial showed substantial reduction of average daily pain in general population of patients with chronic non-radicular neck pain following the application of ZTlido. We therefore plan to prioritize further potential development of SP-103 for the treatment of acute pain. SP-103, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute pain. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-104 (4.5mg, low-dose naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been completed for SP-104 at investigative sites in New Zealand: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SP-104-01 is a food effect and bridging PK study comparing SP-104 to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment, randomized study to characterize the PK and safety and tolerability of SP-104 under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The study also serves as a &#8220;pharmaceutical bridge&#8221; between SP-104 and the commercial RLD (Naltrexone HCI tablets, USP 50 mg) to support the eventual Section&#160;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for SP-104 will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#8217;s findings of safety for the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficacy of SP-104 in the treatment of fibromyalgia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SP-104-02 is a Phase 1 study of SP-104 conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, two-period, two-treatment crossover study to evaluate the safety of SP-104, compared to immediate release naltrexone capsules. The </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
primary purpose of the study is to test the hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over trial in healthy volunteers comparing SP-104 (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#8220;compared drug&#8221;), there were no serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of SP-104, there were 21 (40%)&#160;patients experiencing at least one TEAE, 14 (27%)&#160;patients experiencing at least one treatment-related TEAE, 12 (23%)&#160;patients experiencing at least one treatment-related TEAE within 72 hours after first administration of SP-104. Notable AEs of special interest were nausea and headache within 72 hours after first administration of SP-104. SP-104 administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of SP-140 when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of SP-104 (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea (SP-104: n=0; the compared drug: n=3) and headache (SP-104: n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#8220;adequate and well-controlled&#8221; study to establish the efficacy of SP-104 in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of SP-104 or an additional Phase 3 study may be required. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Medical Affairs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes in-house medical expertise, health economics and third-party payor support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. The Medical Affairs team also develops lifecycle planning and works with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing and Supply Chain </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our Quality System, Standard Operating Procedures and contract manufacturing organizations (&#8220;CMOs&#8221;) comply with cGMP and regulatory requirements. We selected our CMOs for specific </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competencies having met our development, manufacturing, quality and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi in Japan. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and hot-melt mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business&#8212;Material Agreements&#8212;Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business&#8212;Material Agreements&#8212;Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding the manufacturing and supply chain of ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation (&#8220;McKesson&#8221;), Cardinal Health 110, LLC (&#8220;Cardinal Health 110&#8221;) and AmerisourceBergen Corporation (&#8220;AmerisourceBergen&#8221;). Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2020 and 2021 and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies from the second quarter of 2022. In April 2022, we discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-102 (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-102 is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a pre-filled glass syringe with a 2 mL deliverable volume. SP-102 also contains sodium hyaluronate, which is a novel, biocompatible, viscosity- enhancing excipient and is listed in the European Pharmacopeia. Historically, we have purchased our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SP-102, from Genzyme pursuant to a supply agreement, which terminated as of May&#160;31, 2024. We anticipate that our current supply of sodium hyaluronate will be sufficient to satisfy our clinical and commercial supply requirements for sodium hyaluronate for at least 12 months following our expected commercial launch of SP-102 in 2027. We are currently in discussions with Sanofi, an affiliate of Genzyme, and are in the process of identifying and certifying new suppliers, in each case to fulfill our future supply requirements for sodium hyaluronate. SP-102 is manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of SP-102. In March 2022, we announced final results of the Phase 3 clinical trial, satisfying the primary and key secondary endpoints. The manufacturing process is proprietary and includes trade secrets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of SP-102, if approved. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Lifecore Master Services Agreement</span>&#8221; for additional information regarding the manufacturing of our SP-102 product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-103 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-103 contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi, using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the SP-103 manufacturing protocols in a supplemental new drug application. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SP-104 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing SP-104, a novel low-dose, naltrexone hydrochloride delayed release formulation for treating fibromyalgia. SP-104 is 4.5 mg, low-dose naltrexone hydrochloride delayed release capsule product in clinical development, for which Phase 1 studies were completed in the second quarter of 2022. It is manufactured by a contract manufacturer, Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), located in Cranbury, NJ. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily available capital, and established research and development organizations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, SP-103, if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm, generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc., and over-the-counter lidocaine patches. Additionally, SP-103, if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of chronic neck pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ELYXYB for treatment of acute migraine pain. ELYXYB faces competition from other NSAID products, triptans and newly launched CGRP inhibitors. NSAIDs and triptans are well established for the treatment of migraine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched GLOPERBA, our liquid colchicine formulation, in June 2024. GLOPERBA will face competition from generic colchicine formulations, uric acid lowering products like alopurinol, and other products that are used for the prophylaxis treatment of gout. GLOPERBA is the only liquid colchicine product approved by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SP-102, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica. While there are currently no FDA-approved ESIs indicated for the treatment of sciatica, we are aware of certain non-steroid product candidates in development. SP-102, if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the off-label and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our product candidate SP-104, while there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain non-opioid therapeutics currently in a late-stage Phase 3 pipeline containing two 505(b)(2) development programs. Therefore, we believe that SP-104 will likely face direct competition from these candidates. </p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido, GLOPERBA, ELYXYB, SP-102, SP-103 and SP-104 are likely to be their clinical benefit, durability, tolerability, price, intellectual property protection, and the availability of reimbursement from government and other third-party payors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with the Developers. Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and SP-103 (the &#8220;Products&#8221;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&#160;source and provide the active pharmaceutical ingredient for the Products for manufacturing, (2)&#160;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&#160;conduct product development activities necessary to support the filing of applications for regulatory approvals for the Products and (4)&#160;conduct manufacturing scale-up activities and preclinical studies for the Products. We are responsible for, among other things, (a)&#160;conducting all pivotal human clinical trials for the Products, (b)&#160;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and (c)&#160;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the active pharmaceutical ingredient, any associated method of use, method of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable, worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#8217; development obligations under the Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters after the commercial launch equals a negative amount (a &#8220;Net Loss&#8221;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with U.S. GAAP. Under the Product Development Agreement, if our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&#160;2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive one-year renewal periods unless we or the Developers terminate it upon six months&#8217; written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;our total net profits of the Products are equal to or less than five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to re-file. The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&#160;any failure by either of us to comply with all applicable laws, or (3)&#160;our respective negligence or willful misconduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to this prospectus. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;16, 2017, Scilex Pharma entered into the Commercial Supply Agreement with Itochu and Oishi. Pursuant to the Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a 12-month rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the years ended December&#160;31, 2024 and 2023, we purchased inventory in the amount of $5.0 million and $8.2 million, respectively, under the Itochu and Oishi Commercial Supply Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement. Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&#160;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving written notice specifying the nature of the breach, or (2)&#160;in the event of any of the parties&#8217; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product Development Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its amendments in the forms filed as exhibits to this prospectus. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">ELYXYB</span></span><sup style="font-size:75%; vertical-align:top">&#174;</sup> <span style="font-weight:bold"><span style="font-style:italic">License and Commercialization Agreement </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;ELYXYB Sellers&#8221;) the rights to certain patents, trademarks, regulatory approvals, data, contracts and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral solution) and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, we assumed various rights and obligations under that certain asset purchase agreement, dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited (&#8220;DRL&#8221;), a company incorporated under the laws of India, including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. Additionally, under the DRL APA, the ELYXYB Sellers granted us an irrevocable, royalty-free, exclusive license to know-how related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the ELYXYB Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by us include obligations to pay royalties for sales of ELYXYB in the ELYXYB Territory for all indications and additional amounts if certain net sales and regulatory milestones are achieved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Romeg License and Commercialization Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022 (the &#8220;Original Signing Date&#8221;), we entered into the Romeg License Agreement with Romeg, which agreement was subsequently amended on January&#160;16, 2025. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg License Agreement, among other things, Romeg granted us (1)&#160;a license, with the right to sublicense, under the patents and know-how specified therein to (a)&#160;commercialize a pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b)&#160;develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2)&#160;an exclusive license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the know-how and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg Ex-U.S. Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg Ex-U.S. Territory and (b)&#160;to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg Ex-U.S. Territory. With respect to the foregoing clause (1), the license to know-how is exclusive for purposes of developing and commercializing Licensed Products in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, but is otherwise non-exclusive, and the license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Romeg U.S. Territory until July&#160;1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the Romeg U.S. Territory Royalty Term for such purposes. The Romeg U.S. Territory Royalty Term begins on the Original Signing Date and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg U.S. Territory or (ii)&#160;the tenth anniversary of the Original Signing Date. With respect to the foregoing clause (3), the license to know-how patents (if any) is exclusive during the Romeg Ex-U.S. Territory Royalty Term, but is otherwise non-exclusive. The &#8220;Romeg Ex-U.S. Territory Royalty Term&#8221; begins on the date of the amendment agreement and ends on the tenth anniversary of such date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, we agreed to pay Romeg (1)&#160;an up-front payment of $2.0 million, (2)&#160;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0 million, (3)&#160;certain royalties in the mid-single digit percentage, based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $150,000, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties in the low-single digit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg Ex-U.S. Territory during the Romeg Ex-U.S. Territory Royalty Term and (b)&#160;a one-time, non-refundable, non-creditable payment of $700,000. Pursuant to the amendment agreement, we also transferred to Romeg 779,371 shares of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg License Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg License Agreement (1)&#160;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&#160;at any time, without cause, upon written notice to Romeg, which termination will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0 million shall be paid to Romeg depending on when during the 10-year period following the date of the agreement any such termination notice set forth in the immediately preceding clause (2)&#160;has been provided. Romeg may terminate the Romeg License Agreement (a)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (b)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&#160;by written notice to us if sales of the Licensed Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg License Agreement (1)&#160;in the event the other party materially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was provided or (2)&#160;in the event the other party (a)&#160;files in any court or agency a petition in bankruptcy or insolvency, (b)&#160;is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&#160;makes an assignment of substantially all of its assets for the benefit of its creditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg License Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg License Agreement (including the amendment thereto) in the forms filed as exhibits to this prospectus. You should read the form of the agreements for a complete understanding of all of their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lifecore Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2017, through our majority owned subsidiary, Semnur, we entered into that certain Master Services Agreement (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#8220;Lifecore Statement of Work&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&#160;27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1)&#160;project management support, (2)&#160;development services, (3)&#160;clinical trial materials, and (4)&#160;stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#8217;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SP-102, without additional right, title or interest in our intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expires on December&#160;31, 2028, unless terminated earlier in accordance with the terms of such agreement, or unless renewed further by the parties. Either party may terminate the Lifecore Master Services Agreement (1)&#160;if the other party is in material breach of the agreement and fails to cure such breach within 30 days of written notice, subject to certain exceptions; or (2)&#160;immediately upon written notice to the other party if the other party (a)&#160;becomes insolvent, (b)&#160;ceases to function as a going concern, (c)&#160;is convicted of or pleads guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engages in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name. In addition, Lifecore may terminate the agreement if (i)&#160;we fail to pay past due invoices upon 30 days&#8217; written notice, or (ii)&#160;we reject or fail to respond to a major change or minor change proposed by Lifecore that does not change SEMDEXA&#8217;s written and approved acceptance criteria. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendments thereto in the forms filed as exhibits to the registration statement of which this prospectus is a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Semnur Acquisition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex acquired Semnur pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub, the Semnur Equityholders&#8217; Representative, and for limited purposes, Sorrento. Pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub merged with and into Semnur (the &#8220;Semnur Acquisition&#8221;), with Semnur surviving as Legacy Scilex&#8217;s wholly owned subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Acquisition Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay former holders of Semnur&#8217;s capital stock (the &#8220;Semnur Equityholders&#8221;) up to $280.0 million in aggregate contingent cash consideration based on the achievement of certain milestones (which amount is expected to be charged back to Semnur through an intercompany arrangement), comprised of a $40.0 million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&#160;a $20.0 million payment upon the achievement of $100.0 million in cumulative net sales of a Semnur product, (ii)&#160;a $20.0 million payment upon the achievement of $250.0 million in cumulative net sales of a Semnur product, (iii)&#160;a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of a Semnur product, and (iv)&#160;a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Acquisition Agreement also provided that following the consummation of Legacy Scilex&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to Legacy Scilex of at least $40.0 million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&#160;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Acquisition Agreement, and (ii)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Acquisition Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received $55.0 million of shares of Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share, in each case on a pre-Reverse Stock Split basis) (the &#8220;the Stock Consideration&#8221;) were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Acquisition, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the 60-day period commencing the date that was the 18-month anniversary of the closing of the Semnur Acquisition (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $55.0 million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the 30-day trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) as of the consummation of the Share Exchange and (b)&#160;$5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#8217; Representative on September&#160;28, 2020, on October&#160;9, 2020, Sorrento paid $55.0 million in cash to the Semnur Equityholders in lieu of issuing $55.0 million of shares of Sorrento&#8217;s common stock at the Exchange Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Acquisition Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus is a part. You should read the Semnur Acquisition Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Semnur-Denali Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into the Semnur Business Combination Agreement with Denali and Denali Merger Sub. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Denali Merger&#8221;), and (ii)&#160;prior to the closing of the Denali Merger, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the DGCL, and de-register in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Denali Domestication&#8221;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Common Shares&#8221;. Shares of Denali Series A preferred stock following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares&#8221;. Warrants to purchase New Semnur Common Shares following the Denali Domestication are hereinafter referred to as &#8220;New Semnur Warrants&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution and delivery of the Semnur Business Combination Agreement, Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the &#8220;Denali Sponsor&#8221;), and the Company entered into a Sponsor Interest Purchase Agreement (the &#8220;SIPA&#8221;) dated August&#160;30, 2024 (the &#8220;Signing Date&#8221;). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class B ordinary shares, par value $0.0001 per share (the &#8220;Purchased Interests&#8221;), of Denali that are currently held by the Denali Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i)&#160;$2,000,000 (the &#8220;Cash Consideration&#8221;) and (ii)&#160;8,571 shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Denali Sponsor contingent upon and following the occurrence of the Denali Merger Effective Time. The Purchased Interests will convert automatically, on a one-for-one basis, into one New Semnur Common Share at the effective time of the Denali Domestication pursuant to the terms of the Semnur Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Aardvark Asset Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone (DBR-LDN) asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &#8220;SP-104 Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of SP-104 for Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to SP-104 and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the SP-104 Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &#8220;SP-104 Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the SP-104 Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a)&#160;2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i)&#160;$3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii)&#160;$20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus, none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the SP-104 Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tien-Li Lee, M.D., a former member of our board of directors (the &#8220;Board&#8221;), is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus is a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tulex Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the SP-104 Acquisition, Legacy Scilex acquired the Tulex Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of SP-104 for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master services agreement (the &#8220;Tulex Master Services Agreement&#8221;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&#160;15, 2022 and will remain in effect until five years after the effective date, unless terminated early by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&#160;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&#160;in the event of the other party&#8217;s insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex Statement of Work (1)&#160;without cause upon 30 days prior written notice to Tulex or (2)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&#160;such party&#8217;s breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&#160;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master Services Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an exhibit to the registration statement of which this prospectus is a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our drug products, product candidates, and related technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements, drug products, and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our novel adhesion and delivery technology, platforms and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, the patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of December&#160;31, 2024 contains approximately 27 issued and unexpired U.S. patents and nine pending U.S. patent applications. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand, South Africa, Taiwan, and certain countries within the European Patent Convention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and SP-103, our patents and patent applications cover compositions and methods of treatment. We license eight issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640, 11,278,623, 11,786,455, and 11,793,766, all of which expire in 2031. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, 10,383,821, and 11,672,759, which relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No.&#160;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ELYXYB, our patents and patent applications relate to liquid oral celecoxib formulations and associated methods of use. The issued patents include U.S. Pat. Nos. 9,572,819, 9,795,620, 9,949,990, 10,376,527, 10,799,517, 10,722,456, and 12,168,000. U.S. Pat. No.&#160;12,168,000 expires in 2041. The remaining patents related to ELYXYB expire in 2036. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our product candidate SEMDEXA, our patents and patent applications that we own include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to SP-104, our pending U.S. patent application covers oral delayed burst formulations of low-dose naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements regarding the expiration of our owned and licensed patents are calculated as 20 years after the earliest nonprovisional priority date and do not account for any patent term adjustment (&#8220;PTA&#8221;), regulatory extension, or terminal disclaimers not already in force as of December&#160;31, 2024; these calculations also assume that all annuity and/or maintenance fees are paid timely. We believe that we have certain know-how and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks, Trade Secrets and Other Proprietary Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for the marks &#8220;SCILEX,&#8221; &#8220;ZTlido,&#8221; &#8220;ELYXYB,&#8221; and &#8220;RESPONSIBLE BY DESIGN.&#8221; We also own pending trademark applications for &#8220;SEMNUR PHARMACEUTICALS,&#8221; &#8220;SCILEX BIO,&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also license the GLOPERBA trademark as discussed in relation to the Romeg License Agreement described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how, we rely on trade secret protection and confidentiality agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#8217;s relationship with us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Historically, we have purchased our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SP-102, from Genzyme pursuant to a supply agreement, which terminated as of May&#160;31, 2024. We anticipate that our current supply of sodium hyaluronate will be sufficient to satisfy our clinical and commercial supply requirements for sodium hyaluronate for at least 12 months following our expected commercial launch of SP-102 in 2027. We are currently in discussions with Sanofi, an affiliate of Genzyme, and are in the process of identifying and certifying new suppliers, in each case to fulfill our future supply requirements for sodium hyaluronate. Our complex manufacturing process, specialized equipment and know-how for sterile viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable tolerability profiles and clinical benefit to SEMDEXA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation and Product Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are marketing and developing. SP-102, SP-103, SP-104 and any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Drug Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as imposition of a clinical hold, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, inspection scrutiny, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, or reimbursements, restitution, disgorgement of profits or other civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#8220;GLPs&#8221;) or other applicable regulations: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of FDA&#8217;s drug substance (Part 210), drug product (Part 211), combination of product and device (Part 820) and all Module 3, Chemistry, Manufacturing and Control (&#8220;CMC&#8221;), and the cGMP requirements for NDA filing; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an institutional review board (&#8220;IRB&#8221;) covering each clinical site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials according to the laws and regulations pertaining to the conduct of human clinical trials, collectively referred to as Good Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug for its intended use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an NDA or other marketing application (collectively, an &#8220;NDA&#8221;), for a proposed new drug, including its specific formulation and labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug substance, drug product, packaging components and device are produced to assess compliance with the FDA&#8217;s cGMP requirements to assure that the facilities, manufacturing, methods and controls are adequate to preserve the drug product&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA prior to any commercial marketing, sale, distribution or shipment of the drug. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, non-compliance, or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected and other safety related findings. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#8217;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to and signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 1</span></span>. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 2</span></span>. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 3</span></span>. The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse reactions), findings from other studies that suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to study subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, the end of Phase 3 and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials or manufacturing process validation and testing and their pre-NDA meeting that they believe will support approval of the new drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as validate a process for commercial manufacturing the product in accordance with cGMP requirements. The commercial manufacturing process must be capable of consistently and continuously producing quality batches of the drug candidate and, among other things, the manufacturer must develop appropriate methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review and Approval Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are required to be submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-use submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for direct-to-consumer advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#8217;s approved labeling, which is known as &#8220;off-label use,&#8221; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hatch-Waxman Amendments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product, but some of the data are not owned by or licensed to the applicant. Section&#160;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application (&#8220;ANDA&#8221;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be substituted by pharmacists under prescriptions written for the branded reference drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&#160;no patent information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV Certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. Thus, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s or patent owner&#8217;s decision to initiate patent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for non-protected characteristics and labeling. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-Party Payor Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order for the company&#8217;s products to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. See the discussion below under &#8220;<span style="font-style:italic">U.S. Healthcare Reform&#8221;</span>, and regarding the Inflation Reduction Act for further information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#8220;EEA&#8221;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some countries in the EEA operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2020 (the &#8220;ACA&#8221;) was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (1)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for follow-on biologic products, (2)&#160;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4)&#160;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5)&#160;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, (6)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (7)&#160;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9)&#160;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The TCJA included a provision that repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;), among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50% to 70% the point-of-sale discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. On June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, former President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&#160;16, 2022, former President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Trump administration or other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2%&#160;per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the COVID-19 pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On May&#160;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#8217;s prescription drug benefit. Similarly, since 2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&#160;16, 2022, former President Biden signed into law the Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses at $2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part B or Part D. The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#8220;remuneration&#8221; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of off-label uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the U.S. federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (&#8220;HIPAA&#8221;) impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security law and regulation promulgated by both the U.S. federal government and the U.S. states in which we conduct our business. For example, under HIPAA, the U.S. Department of Health and Human Services imposes upon </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;covered entities&#8221; (broadly, healthcare providers, health plans and healthcare clearinghouses) and their respective &#8220;business associates&#8221; (individuals or entities that create, receive, maintain or transmit protected health information on behalf of a covered entity) the HIPAA Privacy and Security Rules which include privacy obligations; requirements to implement appropriate administrative, physical and technical safeguards to ensure the confidentiality, integrity, and security of electronic protected health information; and breach response notification obligations. Although we are neither a covered entity nor business associate, and therefore not subject to the HIPAA Privacy and Security Rules, we must monitor developments with these requirements for changing obligations that may apply to us. The Federal Trade Commission (the &#8220;FTC&#8221;) also requires companies to take appropriate steps to keep consumers&#8217; personal information secure and to make accurate statements regarding how they secure personal information under their custody or control, such as in a privacy notice. The FTC also expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of personal information it holds, the size and complexity of its business, and the cost of available tools to improve data security and reduce vulnerabilities. Individually identifiable health information, which we process, is considered sensitive data that merits stronger safeguards. Violations of the foregoing FTC requirements may constitute unfair or deceptive acts or practices under Section&#160;5(a) of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;). While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to bring enforcement actions based on the FTC&#8217;s interpretation of public privacy statements. Further, events that we cannot fully control, such as data breaches, may also result in civil penalties, FTC enforcement or enforcement by U.S. state attorneys general or other regulators. Various U.S. states have implemented privacy laws and regulations that regulate the use and disclosure of health information and other personal information. For example, the CCPA, established a privacy framework for covered businesses by, among other items, expanding the definition of personal information, establishing new data privacy rights for consumers who are California residents, imposing rules on the collection of personal information from minors, and creating a statutory damages framework for violations of the CCPA, including for failure to implement reasonable security procedures and practices to prevent data breaches. Penalties for violations of the CCPA include civil penalties and may result in related legal claims. The CPRA, most provisions of which became operative on January&#160;1, 2023, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency. Several other states have implemented similar consumer privacy laws that took effect in the past year or will take effect in the near future. Further, Washington&#8217;s My Health My Data Act, taking effect July&#160;1, 2024, imposes requirements specific to consumer health data. The foregoing U.S. state privacy laws impose many similar obligations as the CCPA on our processing of personal information. Other U.S. states are considering similar privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, complexity, and potential inconsistency surrounding the implementation and interpretation of the CCPA and other enacted or forthcoming U.S. state privacy laws exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of non-compliance with such laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local, state, provincial, and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. Such laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to remediate issues caused by such breaches. Compliance with these laws is challenging, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&#160;1, 2022, these reporting obligations are extended to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act. If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health (&#8220;NIH&#8221;) at www.ClinicalTrials.gov. We are subject to various environmental, health and safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of non-compliance, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Marketing Exclusivity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hatch-Waxman Exclusivity</span>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&#160;505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Exclusivity</span>. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This six-month exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe/Rest of World Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#8220;CTA&#8221;) must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#8220;Clinical Trials Directive&#8221;) and the related national implementing provisions of the relevant individual EEA country&#8217;s requirements, the clinical trial described in that CTA may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#8220;Clinical Trials Regulation&#8221;) was adopted. The Clinical Trials Regulation entered into force on January&#160;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the prior Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&#160;31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of three years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&#160;31, 2023 can continue to be conducted under the Clinical Trials Directive until January&#160;31, 2025. An </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a country-by-country basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#8220;EMA&#8221;). If the EMA issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#8220;centralized&#8221; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#8220;centralized&#8221; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a &#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#8220;decentralized&#8221; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January&#160;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in the EEA could be negatively affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited by, data privacy and security regulations in the EEA, Switzerland, or the United Kingdom (&#8220;UK&#8221;), where the legislative and regulatory landscape continues to evolve. There has been increased regulator attention to privacy and data security issues that could potentially affect our business, including through legislation such as the EEA General Data Protection Regulation (&#8220;EEA GDPR&#8221;) and UK General Data Protection Regulation (&#8220;UK GDPR,&#8221; and together, the &#8220;GDPR&#8221;), which each imposes strict obligations on the processing of personal data, including the transfer of personal data from the EEA, Switzerland, or UK to third countries that the European Commission has determined does not ensure an adequate level of protection, such as the United States. If we violate the GDPR, we may face significant penalties of up to EUR 10,000,000 or 2% of our total worldwide annual turnover, or for more serious violations, up to EUR 20,000,000 or 4% of our total worldwide annual turnover. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR and other EEA and UK data privacy and security regulations generally restrict the transfer of personal data from the EEA, United Kingdom and Switzerland, to the United States and certain other third countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards on which companies may rely to import or export personal data from had been the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the EU-U.S. Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#8220;CJEU&#8221;) in a case known as &#8220;<span style="font-style:italic">Schrems II</span>.&#8221; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#8220;FDPIC&#8221;) announced that the Swiss-U.S. Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to third countries that are deemed as not providing adequate protection, including the United States. While the FDPIC does not have authority to invalidate the Swiss-U.S. Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the Swiss-U.S. Privacy Shield as a compliance mechanism for Swiss-U.S. data transfers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CJEU&#8217;s decision in <span style="font-style:italic">Schrems II</span> also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in <span style="font-style:italic">Schrems II</span>, it made clear that reliance on the Standard Contractual Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in <span style="font-style:italic">Schrems II</span> and subsequent draft guidance from the European Data Protection Board (the &#8220;EDPB&#8221;) would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a lawful &#8220;transfer mechanism.&#8221; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that any combination of such measures may not be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8220;in the clear&#8221; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8220;necessary and proportionate in a democratic society&#8221; - which may, following the CJEU&#8217;s conclusions in <span style="font-style:italic">Schrems II</span> on relevant powers of United States public authorities and commentary in draft EDPB guidance, include the United States in certain circumstances (<span style="font-style:italic">e.g</span>., where Section&#160;702 of the U.S. Foreign Intelligence Surveillance Act applies). Further, the UK Information Commissioner&#8217;s Office has provided for separate international data transfer mechanisms for restricted transfers of data from the UK: an international data transfer agreement (the UK equivalent of the EU Standard Contractual Clauses) (&#8220;IDTA&#8221;) and an international data transfer addendum (which amends the EU Standard Contractual Clauses for purposes of international data transfers from the UK to countries without an essentially equivalent data protection framework) (the &#8220;Addendum&#8221;). Both the IDTA and the Addendum came into force in March 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to implement a valid solution to transfer personal data from the EEA to the United States or other countries that have not been deemed to provide an essentially equivalent level of data protection, we may face increased exposure to regulatory action, substantial fines, or injunction orders to stop processing personal data from EEA, Swiss, or UK residents. Any inability to import personal data to the United States may also restrict our clinical trials activities in the EU; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to EU data privacy and security laws; and require us to increase our data processing capabilities in the EU and the UK at a significant expense. Additionally, other countries outside of the EU have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in the EEA, Switzerland, and the UK will likely also arise in other jurisdictions that adopt laws similar to the GDPR or regulatory frameworks of equivalent complexity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions or criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had approximately 115 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our workforce, 11 employees were primarily engaged in research and development, 85 were primarily engaged in sales and marketing and 19 were primarily engaged in general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. We focus on identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve our human capital management strategies and find ways to foster engagement and growth within our company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#8217; lives. The success of our business is fundamentally connected to the well-being, health and safety of our employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Former Employee Action </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, and together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its 95-page opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, we and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, we and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax would be obligated to make the following payments to us to settle the Former Employee Action: (i)&#160;$3.5 million by two business days after the Effective Date (as defined therein), which payment has been made; (ii)&#160;$2.5 million by July&#160;1, 2024, which payment has been made on July&#160;8, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a)&#160;6% of annual Net Sales (as defined therein) of Epoladerm; (b)&#160;6% of annual Net Sales of Probudur and (c)&#160;6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). We and Virpax provided mutual releases of all claims that existed as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect our claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. The court has requested additional oral argument on the topic of remedies against Mr.&#160;Mack, which argument occurred on November&#160;15, 2024. The parties are awaiting a final judgment from the court. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Patent Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic 30-month stay preventing them from selling a generic version of ZTlido during that time which was extinguished by the U.S. District Court for the Southern District of Florida decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#8217;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#8217;s product does not infringe our ZTlido Patents. We are appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and we filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. Briefing is underway in that appeal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Corporate History </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&#160;18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#8220;Contribution&#8221;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5 million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into the Semnur Acquisition Agreement with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#8217;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes. Pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub, Inc. merged with and into Semnur, with Semnur surviving the Semnur Acquisition as Legacy Scilex&#8217;s wholly owned subsidiary. As a result of the Contribution and the Semnur Acquisition, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Acquisition, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the Business Combination with Vickers and Legacy Scilex. In connection with the Business Combination, Vickers changed its name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Website Access to SEC Filings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including Scilex. We maintain an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Internet website at www.scilexholding.com. The information contained on our website or that can be accessed through our website does not constitute a part of this report. We make available, free of charge through our Internet website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file or furnish this information to the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_14">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of July&#160;31, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:63%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Officers</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Executive Chairperson and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer, Senior Vice President and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Non-employee&#160;Directors</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(1)(2)(3)(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annu Navani<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Director</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Audit Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Compensation Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Nominating and Corporate Governance Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Commercialization and Transaction Committee. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jaisim Shah</span></span><span style="font-style:italic">.</span> Mr.&#160;Shah has served as our Chief Executive Officer and President and a member of our Board since November&#160;10, 2022. Prior to that, he served as Legacy Scilex&#8217;s President, Chief Executive Officer and a board member from March 2019 to November 2022. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Legacy Scilex in March 2019. Mr.&#160;Shah has served on the board of directors of Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), since November 2016. Prior to his time at Semnur, Mr.&#160;Shah was a consultant to several businesses, including Sorrento, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&#160;Shah led a successful sale of Elevation Pharmaceuticals, Inc. to Sunovion Pharmaceuticals Inc. in September 2012. Prior to his time at Elevation Pharmaceuticals, Inc., Mr.&#160;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to his time at Zelos Therapeutics, Inc., Mr.&#160;Shah was the Senior Vice President and Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&#160;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic transactions with pharmaceutical and biotech companies. Prior to his time at PDL BioPharma, Inc., Mr.&#160;Shah was at Bristol-Myers Squibb Company, most recently as Vice President of Global Marketing where he received the &#8220;President&#8217;s Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. Previously, Mr.&#160;Shah was at F.&#160;Hoffman-La&#160;Roche AG in international marketing and was global business leader for corporate alliances with Genentech, Inc. and IDEC Corporation. Mr.&#160;Shah previously served as a director of Celularity Inc. (Nasdaq: CELU) from June 2017 to July 2021. He served as a director of Sorrento from September 2013 until November 2023. Mr.&#160;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&#160;Shah&#8217;s extensive operational, executive and business development experience qualifies him to serve on our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Henry Ji, Ph.D</span></span>. Dr.&#160;Ji has served as the Executive Chairperson and a member of our Board since September&#160;22, 2023 and previously served as our Executive Chairperson and a member of our Board from November 2022 to August 2023. Prior to that, he served as Legacy Scilex&#8217;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&#160;Ji has served on the board of directors of Scilex Pharma since November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. Dr.&#160;Ji has served as Semnur&#8217;s Treasurer and Secretary and a board member since its inception in 2013. He currently serves as the Chief Executive Officer of Vivasor Holding Company and Vivasor, Inc. He&#160;co-founded&#160;and has served as a director of Sorrento since January 2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&#160;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr.&#160;Ji served as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix Corporation, Dr.&#160;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr.&#160;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr.&#160;Ji&#160;co-founded&#160;Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr.&#160;Ji previously served as a director of Celularity Inc. (Nasdaq: CELU) from June 2017 to July 2021. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Dr.&#160;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&#160;Ji has demonstrated significant leadership skills as President and Chief Executive Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on our Board. We believe that Dr.&#160;Ji&#8217;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Stephen Ma.</span></span> Mr.&#160;Ma has served as our Chief Financial Officer and Senior Vice President since September&#160;22, 2023 and as our Corporate Secretary since March&#160;6, 2024. Mr.&#160;Ma previously served as our Chief Accounting Officer from May 2023 until his appointment as our Chief Financial Officer and as our Vice President of Finance from January 2022 to April 2023. Mr.&#160;Ma has more than 15 years of finance and operational expertise across pharmaceuticals and venture backed biotechnology companies. He most recently served as Director of Finance and Operations for Anwita Biosciences, Inc., a clinical stage company, from August 2019 to January 2022. Prior to that, from May 2016 to August 2019, he served as the Senior Director of Finance and Controller of Semnur. Prior to that, he served as Controller for Globavir and part of the management team that worked on its initial public offering process. He also served as the Controller for Ardelyx, which went public in 2014. Prior to that, Mr.&#160;Ma served in various finance positions at PDL BioPharma, Inc. and Hyperion Therapeutics, Inc. Mr.&#160;Ma began his career with more than 10 years in high technology companies and has a wealth of experience in finance, strategic planning, commercial launching, debt financing, public offerings and M&amp;A transactions. Mr.&#160;Ma holds a B.S. in Finance and M.A. in Economics from San Jose State University.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Non-Employee Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jay Chun, M.D., Ph.D.</span></span> Dr.&#160;Chun has served as a member of our Board since September&#160;22, 2023. Dr.&#160;Chun served as the Chief of Neurosurgery at Overlook Medical Center at Atlantic Health System from June 2015 to June 2023, and as Director of the Atlantic Health Spine Center at Overlook Medical Center from September 2022 to May 2024. Dr.&#160;Chun has served as a member of our Scientific Advisory Board since August 2021 and previously served as a member of Celularity, Inc.&#8217;s (Nasdaq: CELU) Scientific Advisory Board from September 2020 to January 2023. Dr.&#160;Chun completed his M.D. and Ph.D. at Columbia University College of Physicians<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Surgeons. His neurosurgical residency was completed at the University of California at San Francisco, followed by specialization in the discipline of complex and minimally invasive spine surgery at Emory University in Atlanta, Georgia. Dr.&#160;Chun is board certified and specializes in complex and minimally invasive spine surgery as well as artificial discs. While a member of the Columbia University faculty from June 1995 to June 1997, Dr.&#160;Chun worked in the field of biotechnology. He has received many honors including Medical Research Fellowships from NIH, working with the late Nobel Laureate Marshall Nirenberg. He received his Ph.D. with Richard Axel, a recipient of the 2004 Nobel Prize. In honor of his stem cell research, he received the NIH Individual National Research Service Award. We believe that Mr.&#160;Chun&#8217;s experience as a member of our Scientific Advisory Board, extensive scientific background and business experience qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dorman Followwill</span></span>. Mr.&#160;Followwill has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento from October 2017 to April 2024 and as its lead independent director from August 2020 to April 2024. From 2016 to September 2020, Mr.&#160;Followwill was Senior Partner of Transformational Health at Frost&#160;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries. Prior to that time, he served in various roles at Frost&#160;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost&#160;&amp; Sullivan to help found the Consulting practice in January 1988. Mr.&#160;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&#160;Followwill&#8217;s extensive knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Annu Navani, M.D</span></span><span style="font-style:italic">.</span> Dr.&#160;Navani has served as a member of our Board since July&#160;21, 2024. Dr.&#160;Navani founded and has served as the Chief Executive Officer of Comprehensive Spine and Sports Center from 2013 until 2022 as a leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care. She has also been serving as the Chief Medical Officer at Boomerang Healthcare since May 2022. Over the last decade, she has scaled a solo practice to a large multispecialty group practice with more than twenty service lines that operate via multiple state-of-the-art centers in Northern and Southern California. Since 2003, Dr.&#160;Navani has served as a Clinical Professor in the Division of Pain Medicine at Stanford University School of Medicine. She has also served as an Advisor to Le Reve Regenerative Wellness, the center for cutting edge restorative and regenerative solutions for clinical applications and research, since 2013. Dr.&#160;Navani completed her Anesthesiology residency at the Medical College of Wisconsin, Milwaukee and Fellowship in Pain Medicine at the University of California, Davis. She is board certified in Anesthesiology and Pain Medicine by American Board of Anesthesiology, in Interventional Pain by American Board of Interventional Pain Physicians and in Regenerative Medicine by American Board of Regenerative Medicine. We believe that Dr.&#160;Navani&#8217;s scientific background and business experience in various roles in the life sciences industry qualify her to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Yue Alexander Wu, Ph.D.</span></span> Dr.&#160;Wu has served as a member of our Board since September&#160;22, 2023. Dr.&#160;Wu is&#160;the co-founder&#160;and Chief Executive Officer of Cothera Bioscience, Inc., a translation medicine and precision therapeutics company developing cancer therapeutics for previously undruggable targets. He was previously President, Chief Executive Officer and Chief Strategy Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he&#160;co-founded&#160;in 2006, until 2017. From 2004 to 2006, Dr.&#160;Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr.&#160;Wu was a venture capitalist with Burrill&#160;&amp; Company where he was head of Asian Activities. Dr.&#160;Wu has served as a director of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) since June 2013 and Sorrento from August 2016 to April 2024. Dr.&#160;Wu received his Ph.D. in Molecular Cell Biology and his M.B.A. from University of California at Berkeley. He<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">
</span></span>earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China. We believe that Dr.&#160;Wu&#8217;s scientific background and business experience in various roles in the life sciences industry qualify him to serve on our Board.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>On February&#160;13, 2023, Sorrento (our former controlling stockholder), together with its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court, jointly administered under the caption&#160;<span style="font-style:italic">In re Sorrento Therapeutics, Inc., et al.</span>&#160;(Case Number: 23-90085&#160;(DRJ)). While we were majority-owned by Sorrento when the voluntary proceedings were commenced, we were not (and are not) a debtor in Sorrento&#8217;s voluntary Chapter 11 filing. As of September&#160;21, 2023, Sorrento no longer held a majority of the voting power of our outstanding capital stock entitled to vote.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the Chapter 11 filing, Dr.&#160;Ji was and continues to serve as Chairman of the board of directors, President and Chief Executive Officer of Sorrento; Mr.&#160;Shah was serving as a director of Sorrento and served as a director until November 2023; Dr.&#160;Wu was serving as a director of Sorrento and served as a director until April 2024; and Mr.&#160;Followwill was serving as a director of Sorrento and served as a director until April 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Board Composition</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>Our business and affairs are managed under the direction of our Board, which currently consists of six members. Dr.&#160;Ji serves as Executive Chairperson of our Board. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <span style="font-style:italic">ad hoc </span>basis as required.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our Certificate of Incorporation and our Bylaws, our Board is divided into three classes with staggered three-year terms, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;I director is Dorman Followwill, and his term will expire at our annual meeting of stockholders to be held in&#160;2026; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;II directors are Jay Chun, M.D., Ph.D., Yue Alexander Wu, Ph.D., and Annu Navani, M.D. and their term will expire at our annual meeting of stockholders to be held in&#160;2027; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;III directors are Henry Ji, Ph.D. and Jaisim Shah, and their term will expire at our annual meeting of stockholders to be held in&#160;2028. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our Board. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of one-third of the directors. No decrease in the number of directors constituting our Board will shorten the term of any incumbent director. Our directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and our Certificate of Incorporation, and subject to the rights of the holders of any series of our preferred stock, any vacancy on our Board shall be filled only by our Board and not by our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders. Any director elected in accordance with the preceding sentence shall hold office until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#8217;s earlier death, resignation, retirement, removal or disqualification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#8217;s criteria for &#8220;independence.&#8221; Our Board has determined that each of the directors on our Board, other than Dr.&#160;Ji and Mr.&#160;Shah (as a result of their positions as our Executive Chairperson and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules, and our Board consists of a majority of &#8220;independent directors&#8221; as defined under the rules of the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of our Audit Committee, as discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into its corporate strategy and day-to-day business operations. Management discusses strategic and operational (including cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks we face. Throughout the year, senior management reviews these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#8217;s risk oversight process builds upon management&#8217;s risk assessment and mitigation processes, which include reviews of long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of our Board. Our Board is chaired by Dr.&#160;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#8217;s performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically review its leadership structure and may make such changes in the future as it deems appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#8217;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge, experience, skills and expertise that are likely to enhance our ability, as well as the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as: personal and professional integrity, ethics and values, experience in corporate management, such as serving as an officer or former officer of a publicly held company, and experience as a board member or executive officer of another publicly held company. In addition, our Board may consider </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Committees of our Board</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standing committees of our Board are as follows: the Audit Committee, a compensation committee (the &#8220;Compensation Committee&#8221;) and a nominating and corporate governance committee (the &#8220;Nominating and Corporate Governance Committee&#8221;). Our Board has adopted a charter for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. In addition, our Board has established a commercialization and transaction committee (the &#8220;C&amp;T Committee&#8221;). Copies of the charters for the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee are available on the investor relations portion of our website at <span style="font-style:italic">www.scilexholding.com</span>. The composition and responsibilities of each of the committees of our Board are as set forth below. The reference to our website address does not constitute incorporation by reference of the information contained at or available or accessible through our website, and you should not consider it to be a part of this prospectus. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. Our Board may establish other committees as it deems necessary or appropriate from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee consists of Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D., with Dorman Followwill serving as the chairperson of the committee. Each of the members of the Audit Committee satisfies the independence requirements under the applicable Nasdaq Listing Rules and SEC rules. Each member of the Audit Committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the Audit Committee are included in a written charter. The Audit Committee assists our Board in fulfilling our Board&#8217;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this purpose, the Audit Committee performs several functions. The Audit Committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between us, or persons in financial oversight roles with us, and such independent registered public accounting firm or their affiliates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving engagements of the independent registered public accounting firm, prior to commencement of the engagement, and the scope of and plans for the audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management and the independent registered public accounting firm any fraud that includes management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the results of management&#8217;s efforts to monitor compliance with our programs and policies designed to ensure compliance with laws and rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our programs, policies, and procedures related to our information technology systems, including information asset security and data protection; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm&#8217;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the Audit Committee by the independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#8217;s review of our quarterly financial information prior to public disclosure and our disclosures in our periodic reports filed with the SEC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dorman Followwill qualifies as an audit committee financial expert within the meaning of SEC regulations and each of Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D. meets the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management periodically meet separately with the Audit Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee reviews, discusses and assesses its own performance and composition at least annually. The Audit Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Audit Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee consists of Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D., with Yue Alexander Wu, Ph.D. serving as the chairperson of the committee. Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D. each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the Compensation Committee is a non-employee director as defined in Rule 16b-3 promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The Compensation Committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing our compensation policies, plans and programs, and in reviewing and determining the compensation to be paid to our executive officers and non-employee directors. The responsibilities of the Compensation Committee are included in its written charter. The Compensation Committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding) our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of employment agreements, severance agreements, change-of-control protections and other compensatory arrangements for our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducting periodic reviews of the base compensation levels of all of our employees generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the type and amount of compensation to be paid or awarded to non-employee directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, the responsibilities of the Compensation Committee will also include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive compensation to be included in our annual meeting proxy statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form&#160;10-K, registration statements and our annual meeting proxy statements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as appropriate. The Compensation Committee reviews, discusses and assesses its own performance and composition at least annually. The Compensation Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee Processes and Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agenda for each meeting is usually developed by the chairperson of our Compensation Committee, in consultation with the Chief Executive Officer. Our Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by our Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer and the Executive Chairperson may not participate in, or be present during, any deliberations or determinations of our Compensation Committee regarding their compensation or individual performance objectives. The charter of our Compensation Committee grants our Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, our Compensation Committee has the authority to obtain, at the expense of the Company, advice and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that our Compensation Committee considers necessary or appropriate in the performance of its duties. Our Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising our Compensation Committee. In particular, our Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under the charter, our Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to our Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Compensation Committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee consists of Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D., with Jay Chun, M.D., Ph.D. serving as the chairperson of the committee. Dorman Followwill, Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D. each satisfy the independence requirements under the Nasdaq Listing Rules. The responsibilities of the Nominating and Corporate Governance Committee are included in its written charter. The Nominating and Corporate Governance Committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing all aspects of our nominating and corporate governance functions. The responsibilities of the Nominating and Corporate Governance Committee include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations to our Board regarding corporate governance issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria approved by our Board); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the minimum qualifications for service on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating incumbent directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">instituting and overseeing director orientation and director continuing education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as a focal point for communication between candidates, non-committee directors and our management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making other recommendations to our Board regarding matters relating to the directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing succession plans for our Chief Executive Officer and our other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and overseeing matters of corporate responsibility and sustainability, including potential long- and short-term trends and impacts to our business of environmental, social, and governance issues, and our public reporting on these topics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering any recommendations for nominees and proposals submitted by stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee periodically reviews, discusses and assesses the performance of our Board and the committees of our Board. In fulfilling this responsibility, the Nominating and Corporate Governance Committee seeks input from senior management, our Board and others. In assessing our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board, the Nominating and Corporate Governance Committee evaluates the overall composition of our Board, our Board&#8217;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The Nominating and Corporate Governance Committee reviews, discusses and assesses its own performance and composition at least annually. The Nominating and Corporate Governance Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Nominating and Corporate Governance Committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Commercialization and Transaction Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our C&amp;T Committee consists of Jaisim Shah, Jay Chun, M.D., Ph.D., Henry Ji, Ph.D. and Annu Navani, M.D., with Jaisim Shah serving as the chairperson of the committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the C&amp;T Committee are included in a written charter. The C&amp;T Committee (a)&#160;assists the Board in its oversight of the Company&#8217;s (i)&#160;commercial strategy and operations, including product launch preparation and execution, (ii)&#160;medical affairs activities, and (iii)&#160;research and development (&#8220;R&amp;D&#8221;) portfolio management and (b)&#160;evaluates certain potential strategic transactions, chooses strategic transactions which it believes are in the best interest of the stockholders and takes action to oversee the Company&#8217;s negotiation of the terms and conditions of any such transaction and recommend any such transaction to the Board, and in each case performs such other functions as may be deemed necessary or convenient in carrying out the foregoing. The C&amp;T Committee&#8217;s responsibilities include, among others, the following commercialization matters: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing strategic, directional and operational oversight and guidance to the Company regarding its commercial activities and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the alignment of the Company&#8217;s commercial and R&amp;D programs and progress with the Company&#8217;s strategic goals and objectives, taking into account the results of the Company&#8217;s pre-clinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing periodic reviews of the Company&#8217;s product development pipeline, intellectual property portfolio and commercial strategies, including a review and analysis of the progress and results of the Company&#8217;s pre-clinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing key commercial and medical launch strategies prior to regulatory approval of new products or indications as well as the R&amp;D elements of the Company&#8217;s long-range plan and lifecycle management plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing management on the scientific and R&amp;D aspects of business development opportunities, including licensing opportunities (both in-licensing and out-licensing), and M&amp;A opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing, approving, modify, monitoring and directing the process and procedures related to the review and evaluation of certain potential strategic transactions and determining whether to proceed with any such process, procedures, review or evaluation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining on behalf of the Board and the Company whether a possible strategic transaction is advisable and is fair to, and in the best interests of, the Company and its stockholders (or any subset of the stockholders of the Company that the C&amp;T Committee determines to be appropriate), (ii)&#160;rejecting or approving a possible strategic transaction, or recommending such rejection or approval to the Board, (iii)&#160;approving or recommending to the Board the consummation of a possible strategic transaction, and (iv)&#160;reviewing, evaluating and monitoring proceedings and activities of the Company related to certain potential strategic transactions. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the C&amp;T Committee may form, and delegate authority to, subcommittees as appropriate. The C&amp;T Committee reviews, discusses and assesses its own performance at least annually. The C&amp;T Committee also periodically reviews the charter of the C&amp;T Committee and the compliance procedures in place to implement such charter and recommend necessary clarifications or changes to such charter to the Board for approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has adopted a written code of business conduct and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of business conduct and ethics is posted on our website at <span style="font-style:italic">www.scilexholding.com</span>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our Compensation Committee is currently, or has been at any time in the past year, one of our officers or employees. Other than Dr.&#160;Ji and Mr.&#160;Shah, none of our executive officers currently serves, or has served during the last completed fiscal year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or Compensation Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clawback Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, our Board adopted a clawback policy (the &#8220;Clawback Policy&#8221;) that complies with the SEC rules and Nasdaq Listing Rules. Our Clawback Policy provides for our recovery of erroneously awarded incentive-based compensation from our current and former executive officers (as defined in Rule 10D-1 promulgated under the Exchange Act and Nasdaq Listing Rule 5608) who were employed by the Company during the applicable recovery period. Under the policy, if the Company is required to prepare an accounting restatement of its financial statements due to its material noncompliance with any financial reporting requirement under the securities laws, the Company shall promptly demand in writing and recoup the amount of any incentive-based compensation received by the applicable executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare such accounting restatement. The amount to be recouped is that which exceeds the amount of incentive-based compensation that otherwise would have been received by the applicable executive had such compensation been determined based on the restated amounts in the accounting restatement. Incentive-based compensation includes any compensation that is granted, earned or vested based wholly or in part upon the attainment of one or more measures derived from our financial statements. Our Compensation Committee administers our Clawback Policy and has the authority to determine the amount of recoverable compensation and manner of recovery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Limitation of Liability and Indemnification of Directors and Officers</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the case of our directors, unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director or officer derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of our directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;), and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer, employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We also maintain directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_15">EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#8217;s named executive officers in 2024. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or the Compensation Committee, with input from our Executive Chairperson and Chief Executive Officer, historically determined the compensation for Scilex&#8217;s named executive officers. Our named executive officers for the year ended December&#160;31, 2024, were Jaisim Shah, our Chief Executive Officer and President, Henry Ji, our Executive Chairperson, and Stephen Ma, our Chief Financial Officer and Senior Vice President. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to our named executive officers for the fiscal years ended December&#160;31, 2024 and December&#160;31, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:28%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Name and<br/>Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Salary</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Bonus<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock<br/>Awards<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Awards ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Non-Equity<br/>Incentive</span><br/><span style="font-weight:bold">Plan<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Non-</span><br/><span style="font-weight:bold">Qualified<br/>Deferred<br/>Compensation<br/>Earnings</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">16,574</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,266,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer, President and Director</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">917,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,402,460&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">54,023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,373,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">11,651</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,261,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Executive Chairperson</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">821,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">33,034,32&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">63,965</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#8194;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">33,919,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">600,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">13,821</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">613,821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer, Senior Vice President and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">470,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,427,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,900,705</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (a) matching contributions made to the named executive officer under the Company&#8217;s 401(k) plan and (b) life insurance premiums paid by the Company for his benefit. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (a) matching contributions made to Mr. Shah under the Company&#8217;s 401(k) plan, (b) accrued unused paid time off and (c) life insurance premiums paid by the Company for his benefit. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents compensation expense allocated by Sorrento to (and paid by) the Company for services provided by Dr. Ji (on behalf of Sorrento) to the Company in January 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr. Ma was appointed as our Chief Financial Officer, Senior Vice President and Secretary on September&#160;22, 2023. Represents compensation paid or accrued as our Chief Accounting Officer (from May 2023 until his appointment as our Chief Financial Officer, Senior Vice President and Secretary in September 2023) and as our Chief Financial Officer. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with Mr.&#160;Shah. The material terms of the offer letter are described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Offer Letter and Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&#160;Shah (the &#8220;Shah Offer Letter&#8221;), dated April&#160;19, 2019, pursuant to which Mr.&#160;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&#160;Shah&#8217;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November&#160;11, 2022 (but became effective as of March&#160;17, 2022). On September&#160;22, 2023, our Compensation Committee approved an increase in Mr.&#160;Shah&#8217;s annual base salary to $1,250,000 and a bonus target of 150% of his base salary, effective as of October&#160;16, 2023. Mr.&#160;Shah&#8217;s employment with Scilex is at-will, and either Scilex or Mr.&#160;Shah may terminate the terms and conditions of the employment relationship at any time, with or without cause and with or without notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;6, 2019, Scilex issued to Mr.&#160;Shah an option to purchase 232,195 shares of Common Stock, with an exercise price equal to $60.55 per share. On December&#160;21, 2020, Scilex issued to Mr.&#160;Shah an option to purchase 46,471 shares of Common Stock, with an exercise price equal to $60.55 per share. The shares subject to the forgoing options are now fully vested. The foregoing number of shares and exercise prices for Mr.&#160;Shah&#8217;s options reflect the application of the Exchange Ratio (as defined below) in the Business Combination. On January&#160;17, 2023, Scilex issued to Mr.&#160;Shah an option to purchase 48,571 shares of Common Stock, with an exercise price of $282.80 per share, and on October&#160;4, 2023, Scilex issued to Mr.&#160;Shah an option to purchase 5,714 shares of Common Stock, with an exercise price of $49.35 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Mr.&#160;Shah providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Mr.&#160;Shah is a party). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ji Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not entered into an offer letter or employment agreement in connection with Dr.&#160;Ji&#8217;s service as our Executive Chairperson. On November&#160;11, 2022, our Compensation Committee approved Dr.&#160;Ji&#8217;s annual base salary of $792,000 and bonus of $554,400, effective as of March&#160;17, 2022. On September&#160;22, 2023, our Compensation Committee approved an increase in Dr.&#160;Ji&#8217;s annual base salary to $1,250,000 and a bonus target of 150% of his base salary, effective as of October&#160;16, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, Scilex issued to Dr.&#160;Ji, in connection with his service as a director, an option to purchase 58,048 shares of Common Stock, with an exercise price equal to $60.55 per share. The shares subject to such option are now fully vested. The foregoing number of shares and exercise price for Dr.&#160;Ji&#8217;s option reflects the application of the Exchange Ratio in the Business Combination. On January&#160;17, 2023, Scilex issued to Dr.&#160;Ji an option to purchase 257,142 shares of Common Stock, with an exercise price of $282.80 per share, and on October&#160;4, 2023, Scilex issued to Dr.&#160;Ji an option to purchase 5,714 shares of Common Stock, with an exercise price of $49.35 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Dr.&#160;Ji providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Dr.&#160;Ji is a party). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ma Compensation </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not entered into an offer letter or employment agreement in connection with Mr.&#160;Ma&#8217;s service as our Chief Financial Officer, Senior Vice President and Secretary. On September&#160;22, 2023, our Compensation Committee approved Mr.&#160;Ma&#8217;s annual base salary of $600,000 and a bonus target of 60% of his base salary, effective as of October&#160;16, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, Scilex issued to Mr.&#160;Ma an option to purchase 10,000 shares of Common Stock, with an exercise price of $282.80 per share, and on October&#160;4, 2023, Scilex issued to Mr.&#160;Ma an option to purchase 4,285 shares of Common Stock, with an exercise price of $49.35 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Mr.&#160;Ma providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Mr.&#160;Ma is a party). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our Compensation Committee to review and advise on our compensation practices, our Compensation Committee did not make any change to the base salaries or bonus targets for our named executive officers in 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Severance and Change in Control Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;22, 2023, our Compensation Committee approved the material terms of, and authorized us to enter into, severance and change in control arrangements with our Executive Chairperson, Chief Executive Officer, Chief Financial Officer and each other executive of the Company holding a senior vice president position or above (each, a &#8220;Participating Executive&#8221;), with such arrangements to be set forth in severance and change in control agreements (each a &#8220;Severance Agreement&#8221;). The named executive officers executed their respective Severance Agreements on November&#160;8, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Severance Agreements generally provide for, among other things, the following benefits in the event of (i)&#160;the executive&#8217;s termination without cause or resignation for good reason and (ii)&#160;a change in control of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination without a change in control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Participating Executive (including each of our named executive officers) is terminated without cause or resigns for good reason, in either case, prior to a change in control, and subject to an irrevocably effective general release of claims in our favor, such executive shall be entitled to receive (i)&#160;one year&#8217;s base salary, paid on a monthly basis, (ii)&#160;12 months of benefits and (iii)&#160;with respect to any Company stock options held by such executive that have vested as of the date of such termination or resignation, such stock options shall be exercisable for a period of 24 months following such date of termination or resignation (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Payments upon a change in control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a change in control of the Company, Dr.&#160;Ji, our Executive Chairperson, and Mr.&#160;Shah, our Chief Executive Officer, each shall be entitled to received (i)&#160;a lump sum payment equal to three times such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to three times such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 36 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a change in control of the Company, Mr.&#160;Ma, our Chief Financial Officer, Senior Vice President and Secretary, shall be entitled to receive (i)&#160;a lump sum payment equal to two times such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to two times such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 24 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any other Participating Executive, upon a change in control, such executive shall be entitled to receive (i)&#160;a lump sum payment equal to such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 12 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Perquisites, Health, Welfare and Retirement Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pension Benefits and Nonqualified Deferred Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. We made matching contributions to the 401(k) plan totaling $0.6 million and $0.5 million for each of the years ended December&#160;31, 2024 and 2023, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Shah, Dr.&#160;Ji and Mr.&#160;Ma participate in our tax-qualified Section&#160;401(k) plan and we provide a 4% matching contribution up to an annual compensation limit ($345,000 in 2024). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not provide any other pension plan for our employees, and none of our named executive officers participated in a nonqualified deferred compensation plan during the year ended December&#160;31, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at Fiscal Year-End 2024 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of our named executive officers as of December&#160;31, 2024. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger Agreement and the 2019 Stock Option Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="22"><span style="font-weight:bold">Option Awards<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Vesting<br/>Commencement<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Exercise<br/>Price Per<br/>Share ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6/6/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">232,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">60.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6/6/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">46,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">60.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">23,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">25,297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">282.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">49.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="22"><span style="font-weight:bold">Option Awards<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Vesting<br/>Commencement<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Exercise<br/>Price Per<br/>Share ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9/20/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">58,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">60.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9/20/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">123,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">133,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">282.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">49.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6/13/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">60.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6/13/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">60.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">282.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">49.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">On November&#160;10, 2022, the Company consummated the previously announced Business Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub, and Legacy Scilex. Pursuant to the terms of the Merger Agreement, on November&#160;10, 2022, (i) Merger Sub merged with and into Legacy Scilex, with Legacy Scilex as the surviving company in the Business Combination, and, after giving effect to such Business Combination, Legacy Scilex became a wholly owned subsidiary of Vickers and changed its name to &#8220;Scilex, Inc.&#8221;, and (ii) Vickers changed its name to &#8220;Scilex Holding Company&#8221;. Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on November&#160;10, 2022, outstanding equity awards under the Scilex Pharma 2017 Plan and 2019 Stock Option Plan were adjusted as follows: (i) each option to purchase Legacy Scilex common stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#8220;Option&#8221;) except that (x) such Option relates to that whole number of shares of our Common Stock (rounded down to the nearest whole share) equal to the number of Legacy Scilex common stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1 (the &#8220;Exchange Ratio&#8221;), and (y) the exercise price per share for each such share of our Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share numbers outstanding and exercise prices as of December&#160;31, 2024, in each case after giving effect to the Exchange Ratio. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Options granted in 2019 and 2020 were granted under the 2019 Stock Option Plan, and options granted in 2023 were granted under the Equity Incentive Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Options have fully vested. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested as to 1/4th of the shares subject to the option on the one-year anniversary of the vesting commencement date and 1/48th of the original number of shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary commencing on the vesting commencement date, subject to full acceleration in the event of a Corporate Transaction (as defined in the Equity Incentive Plan) in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding awards or substitute similar awards for such outstanding awards. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity Award Timing Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Item&#8201;402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (&#8220;MNPI&#8221;). We generally grant equity awards annually, and any such equity awards granted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are recommended by the Compensation Committee and approved by our Board on or before the grant date. We do not grant equity awards in anticipation of the release of material non-public information and do not time, and do not plan to time, the release of material non-public information in coordination with grants of equity awards in a manner that intentionally affects the value of executive compensation. Additionally, our Insider Trading Policy prohibits directors, officers and employees from trading in our common stock while in possession of or on the basis of MNPI about us. We have not timed, and do not plan to time, the disclosure of MNPI for the purpose of affecting the value of executive compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December&#160;31, 2024, no options were granted to our named executive officers within four business days prior to, or one business day following, the filing or furnishing of a periodic or current report by us that disclosed MNPI. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity-Based Incentive Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, our Board adopted the Scilex Pharma 2017 Plan. In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2019 Stock Option Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, our Board adopted the 2019 Stock Option Plan, which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2022 Equity Incentive Plan </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, our Board adopted the Equity Incentive Plan. The total number of shares of Common Stock for which incentive stock options (&#8220;ISOs&#8221;) may be granted under the Equity Incentive Plan is not to exceed 579,332 shares, which was increased from 417,791 as a result of the automatic annual increase on January&#160;1, 2023 pursuant to the Equity Incentive Plan provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, our stockholders approved the amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by 285,714 shares from 579,332 shares to 865,046 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 865,046 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January&#160;1, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, options to purchase 1,027,977 shares of Common Stock were outstanding under all equity incentive plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose of the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of ISOs within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it became effective will not exceed (i)&#160;417,791 shares of our Common Stock, plus (ii)&#160;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the&#160;2019 Stock Option Plan, that, following the effective date of the Equity Incentive Plan, (a)&#160;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&#160;are not issued because the award or any portion thereof is settled in cash, (c)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&#160;are withheld or reacquired to satisfy the exercise, strike or purchase price or (e)&#160;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will automatically increase on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (1)&#160;4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year, (2)&#160;208,895 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (3)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Equity Incentive Plan was adopted, the authorized number of shares of our Common Stock referenced in the preceding clause&#160;(i) was increased each year in accordance with the terms thereof and as of January&#160;1, 2025, and the current number of authorized shares of Common Stock is 1,275,299 based on the foregoing provisions. Similarly, as of January&#160;1, 2025, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan is 1,275,299 shares, which amount will increase on each January&#160;1st ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i)&#160;4% of the total number of shares of Common Stock outstanding on December&#160;31 of the preceding year, (ii)&#160;208,895 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (iii)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, our stockholders approved an amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by&#160;285,714 shares to&#160;865,046 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of incentive stock options to&#160;865,046 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of incentive stock options to January&#160;1, 2024. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of Common Stock that are issued upon settlement of the stock appreciation right </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, administers the Equity Incentive Plan. Our Board, or a duly authorized committee of our Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by applicable law, the terms of such awards; and (ii)&#160;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board, will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&#160;our Board will not, without stockholder approval, (a)&#160;reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&#160;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our Common Stock, cancel and re-grant or exchange such option or stock appreciation right for a new award with a lower (or no)&#160;purchase price or for cash, and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the day-to-day operations of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except the exercise price of a stock option generally will not be less than&#160;100% (or&#160;110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than&#160;10% of our total combined voting power or that of any of our parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be determined by our Board. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of&#160;18&#160;months following the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of Common Stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of Common Stock issued upon the exercise of a stock option will be determined by our Board and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration acceptable to our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitations on ISOs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than&#160;10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least&#160;110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five years from the date of grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our Board. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of Common Stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in the restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of Common Stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of&#160;18&#160;months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Performance Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Non-Employee Director Compensation Limit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service as a non-employee director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees paid by us to such non-employee director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a non-employee director is first appointed or elected to our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our Board will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity Incentive Plan; (ii)&#160;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at&#160;100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as our Board determines (or, if our Board does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by our Board, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clawback/Recovery </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the time during which an award grant under the Equity Incentive Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend, suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments will also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Federal Income Tax Consequences Associated with the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general summary under current law of the material federal income tax consequences to participants in the Equity Incentive Plan. This summary deals with the general tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of income taxation that may be relevant in light of a holder&#8217;s personal investment circumstances. This summarized tax information is not tax advice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nonstatutory Stock Options</span>. For federal income tax purposes, if an optionee is granted an NSO under the Equity Incentive Plan, the optionee will not have taxable income on the grant of the option, nor will we be entitled to any deduction. Generally, upon exercise of NSOs, the optionee will recognize ordinary income, and we will be entitled to a deduction, in an amount equal to the excess of the fair market value of a share of our Common Stock over the option exercise price on the date each such option is exercised. The optionee&#8217;s basis for the stock for purposes of determining gain or loss on subsequent disposition of such shares generally will be the fair market value of our Common Stock on the date the optionee exercises such option. Any subsequent gain or loss will be generally taxable as capital gains or losses.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Incentive Stock Options</span>. There is no taxable income to an optionee when an optionee is granted an ISO or when that option is exercised. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an &#8220;item of adjustment&#8221; for the optionee for purposes of the alternative minimum tax. Gain realized by the optionee on the sale of an ISO is taxable at capital gains rates, and no tax<span style="font-style:italic"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">
</span>deduction is available to us, unless the optionee disposes of the shares within (a)&#160;two years after the date of grant of the option or (b)&#160;within one year of the date the shares were transferred to the optionee. If the shares acquired upon exercise of the ISO are sold or otherwise disposed of before the end of the two-year and one-year periods specified above, the excess of the fair market value of a share of our Common Stock over the option exercise price on the date of the option&#8217;s exercise will be taxed at ordinary income rates (or, if less, the gain on the sale), and we will be entitled to a deduction to the extent the optionee must recognize ordinary income. If such a sale or disposition takes place in the year in which the optionee exercises the option, the income the optionee recognizes upon sale or disposition of the shares will not be considered an item of adjustment for alternative minimum tax purposes.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An ISO exercised more than three months after an optionee terminates employment, for reasons other than death or disability, will be taxed as an NSO, and the optionee will recognize ordinary income on the exercise. We will be entitled to a tax deduction equal to the ordinary income, if any, realized by the optionee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock.</span> An individual to whom restricted stock is issued generally will not recognize taxable income upon such issuance, and we generally will not then be entitled to a deduction, unless an election is made by the participant under Section&#160;83(b) of the Code (&#8220;Section&#160;83(b)&#8221;). However, when restrictions on shares of restricted stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the individual generally will recognize ordinary income, and we generally will be entitled to a deduction for an amount equal to the excess of the fair market value of the shares at the date such restrictions lapse over the purchase price. If a timely election is made under Section&#160;83(b) with respect to restricted stock, the participant generally will recognize ordinary income on the date of the issuance equal to the excess, if any, of the fair market value of the shares at that date over the purchase price of such shares, and we will be entitled to a deduction for the same amount.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights</span>. A participant will not be taxed upon the grant of a stock appreciation right. Upon the exercise of the stock appreciation right, the participant will recognize ordinary income equal to the amount of cash or the fair market value of the stock received upon exercise. At the time of exercise, we will be eligible for a tax deduction as a compensation expense equal to the amount that the participant recognizes as ordinary income.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Performance Awards and Other Stock Awards</span>. The participant will have ordinary income upon receipt of stock or cash payable under performance awards, dividend equivalents, restricted stock units and stock payments. We will be eligible for a tax deduction as a compensation expense equal to the amount of ordinary income recognized by the participant.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Section&#160;162(m) of the Code</span>. Section&#160;162(m) of the Code generally limits to $1.0&#160;million the amount of compensation that we may deduct in any calendar year for certain current and former executive officers. For grants under the Equity Incentive Plan, we will not be able to take a deduction for any compensation in excess of $1.0&#160;million that is paid to a covered officer.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Requirements of Section&#160;409A of the Code</span>. Certain awards under the Equity Incentive Plan may be considered &#8220;nonqualified deferred compensation&#8221; for purposes of Section&#160;409A of the Code (&#8220;Section&#160;409A&#8221;), which imposes certain requirements on compensation that is deemed under Section&#160;409A to involve nonqualified deferred compensation. Among other things, the requirements relate to the timing of elections to defer, the timing of distributions and prohibitions on the acceleration of distributions. Failure to comply with these requirements (or an exception from such requirements) may result in the immediate taxation of all amounts deferred under the nonqualified deferred compensation plan for the taxable year and all preceding taxable years, by or for any participant with respect to whom the failure relates, the imposition of an additional&#160;20% income tax on the participant for the amounts required to be included in gross income and the possible imposition of penalty interest on the unpaid tax. Generally, Section&#160;409A does not apply to incentive awards that are paid at the time the award vests. Likewise, Section&#160;409A typically does not apply to restricted stock. Section&#160;409A may, however, apply to incentive awards the payment of which is delayed beyond the calendar year in which the<span style="font-style:italic"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">
</span>award vests. Treasury regulations generally provide that the type of awards provided under the Equity Incentive Plan will not be considered nonqualified deferred compensation. However, to the extent that Section&#160;409A applies to an award issued under the Equity Incentive Plan, the Equity Incentive Plan and all such awards will, to the extent practicable, be construed in accordance with Section&#160;409A. Under the Equity Incentive Plan, the administrator has the discretion to grant or to unilaterally modify any award issued under the Equity Incentive Plan in a manner that conforms with the requirements of Section&#160;409A with respect to deferred compensation or voids any participant election to the extent it would violate Section&#160;409A. The administrator also has sole discretion to interpret the requirements of the Code, including Section&#160;409A, for purposes of the Equity Incentive Plan and all awards issued under the Equity Incentive Plan.<span style="font-style:italic"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2022 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&#160;9, 2022, our stockholders approved the ESPP. The ESPP became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. As of the date of this prospectus, we have not commenced any offerings under the ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S.&#160;employees to purchase our Common Stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code (the &#8220;423 Component&#8221;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&#160;423 of the Code. We intend (but make no undertaking or representation to maintain) the&#160;423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&#160;423(b) of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the &#8220;Non-423 Component&#8221;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S.&#160;while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the&#160;423 Component. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share Reserve </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed&#160;41,779 shares of our Common Stock. On January&#160;1, 2023, the maximum number of shares of our Common Stock that may be issued under the ESPP was increased to&#160;82,164 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common Stock that will be reserved for issuance will automatically increase on January&#160;1 of each year for a period of up to ten years, commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i)&#160;1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding calendar year; (ii)&#160;52,223 shares of our Common Stock; and (iii)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year, provided however, that our Board may act prior to January&#160;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses&#160;(i) to (iii)&#160;above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common Stock under the&#160;423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the Non-423 Component. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased under such purchase right will again become available for issuance under the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board. All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the&#160;423 Component or the Non-423 Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and revoke rules and regulations for the ESPP&#8217;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the&#160;423 Component; and to adopt such rules, procedures and sub-plans as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offerings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the&#160;423 Component, will comply with the requirements of Section&#160;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed&#160;27&#160;months beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&#160;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&#160;a purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock on the first day of that offering, then (i)&#160;that offering will terminate immediately as of that first trading day, and (ii)&#160;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or related corporations as designated by our Board) on the first day of an offering if such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the&#160;423 Component: (i)&#160;being customarily employed by us, or any of our related corporations or affiliates, for more than&#160;20 hours per week and more than five months per calendar year; or (ii)&#160;such other criteria as our Board may determine consistent with Section&#160;423 of the Code with respect to the&#160;423 Component. Our Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related corporation) determined in accordance with the rules of Section&#160;424(d) of the Code. As specified by Section&#160;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#8217;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which, when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&#160;423(b)(4)(D) of the Code, or a subset of such highly compensated employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the Non-423 Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation of such eligible employee is not advisable or practical for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase Rights; Purchase Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed&#160;15% of such employee&#8217;s earnings (as defined by our Board) during the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase up to&#160;285 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&#160;a maximum number of shares of our Common Stock that may be purchased by any participant on any purchase date during an offering, (ii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#8217;s accumulated contributions, will be made in as nearly a uniform manner as will be practicable and equitable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock acquired pursuant to purchase rights will not be less than the lesser of (i)&#160;85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii)&#160;85% of the fair market value of a share of our Common Stock on the date of purchase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Participation; Withdrawal; Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by our Board. Each participant&#8217;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire transfer prior to a purchase date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#8217;s purchase right in that offering will immediately terminate and we will distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#8217;s purchase right in that offering shall then terminate. A participant&#8217;s withdrawal from that offering will have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the participant either (i)&#160;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&#160;is otherwise no longer eligible to participate. We will distribute the individual&#8217;s accumulated but unused contributions as soon as practicable to such individual. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the&#160;423 Component to an offering under the Non-423 Component, the exercise of the participant&#8217;s purchase right will be qualified under the&#160;423 Component only to the extent such exercise complies with Section&#160;423 of the Code. If a participant transfers from an offering under the Non-423 Component to an Offering under the&#160;423 Component, the exercise of the purchase right will remain non-qualified under the Non-423 Component. Our Board may establish different and additional rules governing transfers between separate offerings within the&#160;423 Component and between offerings under the&#160;423 Component and offerings under the Non-423 Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase of Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase date, each participant&#8217;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ESPP and the applicable offering, at the purchase price specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#8217;s account after the purchase of shares on the final purchase date of an offering, then such remaining amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be exercised to any extent unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material compliance with all applicable U.S.&#160;federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except that the purchase date will in no event be more than&#160;27&#160;months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the payment of interest is otherwise required by applicable law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#8217;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our transfer agent). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the ESPP; (ii)&#160;the class(es) and maximum number of securities by which the share reserve is to increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of securities that are subject to purchase limits under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then (i)&#160;the participants&#8217; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&#160;our Board, in its discretion, may terminate outstanding offerings, cancel the outstanding purchase rights and refund the participants&#8217; accumulated contributions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ESPP, a &#8220;corporate transaction&#8221; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&#160;a sale or other disposition of all or substantially all, as determined by our Board, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#8217;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to fulfill any withholding obligation for taxes arising out of or in relation to a participant&#8217;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by (i)&#160;withholding from the participant&#8217;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&#160;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP, either through a voluntary sale or a mandatory sale arranged by us; or (iii)&#160;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment, Suspension or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&#160;with the consent of the person to whom such purchase rights were granted, (ii)&#160;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations&#160;(including, without limitation, the provisions of Section&#160;423 of the Code), or (iii)&#160;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2023 Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the Compensation Committee of our Board adopted the Inducement Plan and it became effective on the date of its adoption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purpose of the Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Inducement Plan is to advance our interests by providing a material inducement for individuals to join us as employees and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Awards and Eligibility </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inducement Plan provides for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of awards. We intend to grant awards pursuant to the Inducement Plan only to persons to whom we may issue shares of our Common Stock without stockholder approval under Section&#160;5635 of the Nasdaq Listing Rules. The Inducement Plan provides that awards may be granted to a natural person to whom we or one of our subsidiaries makes an offer of employment, provided that (i)&#160;such person was not previously an employee or us or one of our affiliates, or the person is returning to employment with us or one of our subsidiaries following a bona-fide period of non-employment; and (ii)&#160;the grant of an award under the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inducement Plan is a material inducement to the person&#8217;s decision to enter into employment with us or one of our subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An aggregate of&#160;40,000 shares of our Common Stock have been reserved for issuance pursuant to awards granted under the Inducement Plan, subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Inducement Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Inducement Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Inducement Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Inducement Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Inducement Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will delegate administration of the Inducement Plan to a duly authorized committee of our Board (the &#8220;Committee&#8221;) and to the extent required by applicable law, including the Nasdaq Listing Rules, each member of such Committee will be an &#8220;independent director&#8221;, as defined in Section&#160;5605(a)(2) of the Nasdaq Listing Rules. Under the Inducement Plan, the Committee will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; and the fair market value applicable to an award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, (i)&#160;the Committee will not, without stockholder approval, reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the day-to-day operations of the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by the Committee and each option will be an NSO. The Committee will determine the exercise price for stock options, within the terms and conditions of the Inducement Plan, except the exercise price of a stock option will generally not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. Options granted under the Inducement Plan will vest at the rate specified in the stock option agreement as will be determined by the Committee. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of&#160;18&#160;months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the Committee and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option; or (v)&#160;other legal consideration acceptable to the Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Committee provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of the Committee or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Inducement Plan, each restricted stock unit award will have such terms and conditions as determined by the Committee. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. The Committee may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the Committee and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by the Committee and set forth in the restricted stock unit award agreement. At the time of grant, the Committee may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by the Committee. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to the Committee and permissible under applicable law. The Committee will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by the Committee and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by the Committee and denominated in shares of Common Stock equivalents. The terms of separate stock appreciation rights need not be identical. The Committee will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Inducement Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the Committee. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by the Committee and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will determine the term of stock appreciation rights granted under the Inducement Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of&#160;18&#160;months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. The Committee will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, the Committee will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Inducement Plan; and (ii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the Committee at the time of grant, any awards outstanding under the Inducement Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at&#160;100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as the Committee determines (or, if the Committee does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, the Committee may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by the Committee, equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Inducement Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by the Committee, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Inducement Plan or the form of award agreement, awards granted under the Inducement Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clawback/Recovery </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Inducement Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an award agreement as the Committee determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may accelerate the time at which an award granted under the Inducement Plan may first be exercised or the time during which an award grant under the Inducement Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. The Committee will have the authority to amend, suspend, or terminate the Inducement Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No awards may be granted under the Inducement Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Emerging Growth Company Status </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform&#160;Act of&#160;2010, which is part of the Dodd-Frank Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the total compensation that was earned by or paid to each of our non-employee directors during the year ended December&#160;31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold">Name</span><sup style="font-size:75%; vertical-align:top"></sup><span style="font-size:5pt"><sup style="font-size:75%; vertical-align:top">(1)<span style="font-weight:bold"></span></sup><span style="font-weight:bold"></span></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Fees Earned<br/>or Paid in<br/>Cash ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Awards<br/>($)</span><sup style="font-size:75%; vertical-align:top"></sup><span style="font-size:5pt"><sup style="font-size:75%; vertical-align:top">(2)<span style="font-weight:bold"></span></sup><span style="font-weight:bold"></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Non-Employee Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">73,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">42,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">115,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">170,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">131,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">301,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">127,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">42,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">170,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annu Navani, M.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">239,225</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">239,225</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Non-Employee Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">120,000&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">88,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">208,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr. Ji, our Executive Chairperson, and Mr. Shah, our Chief Executive Officer and President, are not included in this table, as each of them was our employee and therefore receives no compensation for his </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
service as a director. Dr. Ji&#8217;s and Mr. Shah&#8217;s compensation as named executive officers are included in the section titled &#8220;Executive and Director Compensation &#8212; Summary Compensation Table&#8221; above. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December 31, 2024, each of our current non-employee directors held options to purchase the following number of shares of our Common Stock: Dr. Chun: 2,857; Mr. Followwill: 5,685; Dr. Wu: 2,857; and Dr. Navani: 7,142. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr. Navani was appointed to our Board on July 21, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr. Lemus resigned from our Board effective November 27, 2024. As of December 31, 2024, Lemus held options to purchase 71 shares of our Common Stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Employee Director Compensation </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Non-Employee Director Compensation Policy for the compensation of our non-employee directors, during&#160;2024, each of our non-employee directors received annual retainers, subject to proration, for service on our Board and its committees as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:88%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Annual Cash Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">82,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercialization and Transaction Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercialization and Transaction Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">Number</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our non-employee directors are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, pro-rated for any partial months of service. The equity compensation paid to our non-employee directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#8217;s attendance at Board and committee meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee directors receive no additional compensation for their service as a director. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&#160;1, 2023 and any currently proposed transactions to which the Company was or is to be a participant in which the amount involved exceeded or will exceed $120,000 or one percent of the average of the Company&#8217;s total assets as of December&#160;31, 2024 for the last two completed fiscal years, and in which any of the Company&#8217;s directors, executive officers or, to the Company&#8217;s knowledge, beneficial owners of more than 5% of the Company&#8217;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the sections of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries) (the &#8220;Sorrento Group&#8221;) beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento had the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&#160;we were required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties previously agreed that our Board will continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also had the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provided that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&#160;amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations of Series A Preferred Stock, filed with the Secretary of State of the State of Delaware on November&#160;10, 2022 (the &#8220;Series A Certificate of Designations&#8221;)) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&#160;take any action that would have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&#160;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&#160;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our subsidiaries; (v)&#160;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts) or (B)&#160;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of $10,000,000 (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts); (vi)&#160;consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture or corporate reorganization by the Company or any of our subsidiaries; (vii)&#160;declare or pay any dividend or distribution on our Common Stock, other Junior Security (as defined below) or Parity Security (as defined below); or (viii)&#160;purchase, redeem or otherwise acquire for consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&#160;a reclassification of any Junior Security for or into other Junior Securities, (B)&#160;a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&#160;a reclassification of any Parity Security into a Junior Security, (D)&#160;the exchange or conversion of any Junior Security for or into another Junior Security, (E)&#160;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&#160;the exchange or conversion of any Parity Security for or into any Junior Security or (G)&#160;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock ranks (i)&#160;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or winding-up of the Company (&#8220;Junior Securities&#8221;); and (ii)&#160;on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or winding-up of the Company (&#8220;Parity Securities&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court on September&#160;12, 2023, the Bankruptcy Court entered a final order approving, among other things, the termination of the Stockholder Agreement, upon the closing of the Equity Repurchase Transaction (as defined below). Accordingly, the Stockholder Agreement terminated on September&#160;21, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intercompany Dividend </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;4, 2023, Scilex Pharma distributed $20,000,000 to Legacy Scilex (via a dividend) and Legacy Scilex distributed $20,000,000 to Scilex (via a dividend). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Junior&#160;Debtor-in-Possession&#160;Financing with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our former controlling stockholder, Sorrento, together with its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter&#160;11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the Bankruptcy Court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court on March&#160;29, 2023, the Bankruptcy Court entered a final order approving a&#160;non-amortizing&#160;super-priority senior secured term loan facility in an aggregate principal amount not to exceed $75,000,000 in term loan commitments (the &#8220;Senior DIP Facility&#8221;), provided to the Debtors by JMB Capital Partners Lending, LLC (the &#8220;Senior DIP Lender&#8221;), on a final basis. The Debtors then negotiated definitive financing documentation, including a Senior Secured, Super-Priority&#160;Debtor-in-Possession&#160;Loan and Security Agreement and other documents evidencing the Senior DIP Facility. At the time of the entry of the Interim DIP Order (as defined below), the Debtors&#8217; liquidity was projected to last only until July&#160;7, 2023. The Senior DIP Facility matured on July&#160;31, 2023 and was not repaid on such date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2023, the Debtors filed the Debtors&#8217;&#160;<span style="font-style:italic">Emergency Motion for Entry of Interim and Final Orders (I)&#160;Authorizing the Debtors to (A)&#160;Obtain Junior Secured Superpriority Postpetition Financing and (B)&#160;Use Cash Collateral, (II)&#160;Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (III)&#160;Modifying the Automatic Stay, (IV)&#160;Scheduling a Final Hearing, and (V)&#160;Granting Related Relief</span>&#160;(the &#8220;DIP Motion&#8221;), seeking the Bankruptcy Court&#8217;s approval of the Junior DIP Facility (as defined below) and certain related relief. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Terms of the Junior DIP Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;5, 2023, the Company and the Debtors executed that certain&#160;Debtor-in-Possession&#160;Term Loan Facility Summary of Terms and Conditions (the &#8220;Junior DIP Term Sheet&#8221;), pursuant to which the Company (or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its designees or its assignees) agreed to provide the Debtors with a&#160;non-amortizing&#160;super-priority junior secured term loan facility in an aggregate principal amount not to exceed the sum of (i)&#160;$20,000,000 (the &#8220;Base Amount&#8221;), plus (ii)&#160;the amount of the commitment fee and the funding fee, each equal to 1% of the Base Amount, plus (iii)&#160;the amount of the DIP Lender Holdback (as defined in the Interim DIP Order) (the &#8220;Junior DIP Facility&#8221;), subject to the terms and conditions set forth in the Junior DIP Term Sheet. The Junior DIP Term Sheet granted to the Company a right of first refusal to provide any&#160;debtor-in-possession&#160;financing during the course of the Chapter&#160;11 Cases to the Debtors occurring after the date of the Interim DIP Order until the Chapter&#160;11 Cases were concluded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interest rate under the Junior DIP Facility was 12.00%&#160;per annum payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Term Sheet). Upon the occurrence and during the continuance of an event of default as defined in the Junior DIP Term Sheet, the interest rate on outstanding DIP Loans (as defined in the Junior DIP Term Sheet) would increase by 2.00%&#160;per annum (payable in kind). The commitment fee and the funding fee described above became payable upon the funding of the DIP Loans (as defined in the Junior DIP Term Sheet), in each case as set forth in the Junior DIP Term Sheet. Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Term Sheet) in whole or in part, the Debtors were to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP Facility on the date of the Draw (as defined below). The Junior DIP Facility terms state that it was required to be paid in full in cash under any Chapter&#160;11 plan of reorganization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interest rate return on the Senior DIP Lender was 14.0% on an annual basis. Based on the terms of the Junior DIP Facility and the Senior DIP Facility including the fees associated therewith, respectively, we believe that the annualized returns to the Senior DIP Lender exceeded the returns to the Junior DIP Lender as a result of the differences in the following between the Senior DIP Facility and the Junior DIP Facility, respectively:&#160;(i)&#160;non-default&#160;annualized interest rate of 14.0% as compared to 12.0%; (ii)&#160;maturity term of five months as compared to three months; (iii)&#160;a commitment fee of 2.5% as compared to 1.0%; (iv)&#160;a funding fee of 2.5% as compared to 1.0%; and (v)&#160;an exit fee of 7.0% as compared to 2.0%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Junior DIP Facility was set to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii)&#160;the effective date of any Chapter&#160;11 plan of reorganization with respect to the Debtors; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of the Debtors pursuant to section 363 of the Bankruptcy Code; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments in accordance with the DIP Documents (each as defined in the Junior DIP Term Sheet); and (v)&#160;dismissal of the Chapter&#160;11 Cases or conversion of the Chapter&#160;11 Cases into cases under Chapter&#160;7 of the Bankruptcy Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Junior DIP Facility afforded us certain valuable protections. First, the Junior DIP Facility was secured by liens on and security interests in substantially all assets of Sorrento, other than certain excluded assets as described more fully in the Interim DIP Order, including (i)&#160;a first-priority security interest in and continuing lien on all proceeds of the DIP Facility in the DIP Accounts, and the Junior DIP Lender Holdback (each as defined in the Interim DIP Order) and (ii)&#160;subject to certain terms and exclusions, a second-priority security interest in and continuing lien on substantially all other assets, in each case, whether then owned or existing or thereafter acquired, created or arising and wherever located other than certain excluded assets as described in the Interim DIP Order. The Junior DIP Facility was also granted super priority administrative expense priority ahead of certain other administrative expenses in Chapter&#160;11 and ahead of&#160;pre-petition&#160;unsecured claims, which means it had to be paid in full, in cash in order for the Debtors to emerge from bankruptcy under a Chapter&#160;11 Plan, unless otherwise agreed to by us. This priority status gave us a voice in Sorrento&#8217;s plan to emerge from Chapter&#160;11. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of that certain intercreditor and subordination agreement, dated as of September&#160;21, 2023, entered into by and among the Senior DIP Lender and the Company (the &#8220;Intercreditor and Subordination Agreement&#8221;), the Debtors&#8217; obligations to the Company under the Junior DIP Facility were subordinated to the obligations of the Debtors to Senior DIP Lender on the terms and conditions set forth therein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;5, 2023, at a hearing before the Bankruptcy Court, the Bankruptcy Court entered an interim order (the &#8220;Interim DIP Order&#8221;) approving the Junior DIP Facility among the Debtors (as borrowers) and the Company (as lender) on an interim basis. Upon entry of the Interim DIP Order and satisfaction of all applicable conditions precedent, as set forth in the Junior DIP Term Sheet, the Debtors were authorized to make a single draw under the Junior DIP Facility (the &#8220;Draw&#8221;) to be funded by the Company as the lender under the Junior DIP Facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bankruptcy Court entered the final order approving on the Junior DIP Facility on July&#160;27, 2023. Other definitive financing documentation was then negotiated, including a Junior Secured, Super Priority&#160;Debtor-in-Possession&#160;Loan and Security Agreement, which was entered into on July&#160;28, 2023 between the Company and the Debtors (the &#8220;Junior DIP Loan Agreement&#8221;), which agreement memorialized the terms of the Junior DIP Term Sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court on August&#160;7, 2023, the Bankruptcy Court on August&#160;7, 2023, entered a final order (the &#8220;Replacement DIP Order&#8221;) approving a&#160;non-amortizing&#160;super-priority&#160;debtor-in-possession&#160;term loan facility in an aggregate principal amount of $100,000,000 (the &#8220;Replacement DIP Facility&#8221;) provided to the Debtors by Oramed on a final basis. The Replacement DIP Facility was to be used to, among other things, refinance the existing Senior DIP Facility. The Replacement DIP Facility included certain milestones for the sale of the Company&#8217;s equity interests owned by the Debtors. The lender under the Replacement DIP Facility was permitted to use the loan to credit bid for the collateral securing the Replacement DIP Facility (including the equity interests of the Company), subject to the terms therein. The Replacement DIP Order provided that the liens securing the Junior DIP Facility were junior to the liens securing the Replacement DIP Facility and the Company was not permitted to exercise certain remedies until the payment in full of the Replacement DIP Facility (all as set forth in the Replacement DIP Order). Though junior to the Replacement DIP Facility, the Company would still have been treated as a secured creditor with priority over other claimants in the Chapter 11 Cases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We funded the Junior DIP Facility with cash on hand, including from a portion of the net proceeds from the eCapital Credit Agreement that were distributed to us by our wholly owned subsidiary, Scilex Pharma. As noted below, the Junior DIP Facility was terminated on September&#160;21, 2023, pursuant to the&#160;Pay-Off&#160;Letter (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the Junior DIP Facility is not complete and is qualified in its entirety by reference to the Junior DIP Term Sheet, the Junior DIP Loan Agreement and the Intercreditor and Subordination Agreement, each of which are filed as an exhibit to the Current Report on Form 8-K, filed with the SEC on July&#160;7, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Purchase Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Oramed Closing Date, we entered into, and consummated the transactions contemplated by, the Scilex-Oramed SPA. Pursuant to the Scilex-Oramed SPA, among other things, on September&#160;21, 2023, we (i)&#160;issued to Oramed (A)&#160;the Oramed Note due 18 months from the date of issuance in the principal amount of $101,875,000, (B)&#160;the Penny Warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock, with an exercise price of $0.01 per share and certain restrictions on exercisability, and (ii)&#160;caused the Transferred Warrants to purchase up to an aggregate of 114,286 shares of Common Stock, with an exercise price of $402.50 per whole share, that we acquired from Sorrento pursuant to the Sorrento SPA to be transferred to Oramed. Pursuant to the terms and conditions contained in the Scilex-Oramed SPA, we also agreed to reimburse Oramed for up to $2,910,000 for its legal and other advisor costs, fees and expenses incurred by Oramed in connection with the Sorrento SPA, the Senior DIP Facility, the Scilex-Oramed SPA and certain other transaction documents, $1,910,000 of which was paid on the Oramed Closing Date, and $1,000,000 of which was included in the initial principal amount of the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, in connection with the Scilex-Oramed SPA, we and Sorrento entered into and consummated the Equity Repurchase Transaction contemplated by the Sorrento SPA, pursuant to which, among </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other things, we purchased from Sorrento (i)&#160;1,716,245 shares of Common Stock, (ii)&#160;29,057,097 shares of Series A Preferred Stock, and (iii)&#160;warrants exercisable for 128,304 shares of Common Stock, each with an exercise price of $402.50 per whole share ((i) through (iii)&#160;collectively, the &#8220;Purchased Securities&#8221;). The aggregate consideration for the Purchased Securities was (i)&#160;$100,000,000 (the &#8220;DIP Amount&#8221;), which such amount is satisfied by the Company&#8217;s assumption of the Debtors&#8217; outstanding obligations under the Senior DIP Facility (the &#8220;Oramed DIP Assumption&#8221;), (ii)&#160;a credit bid, on&#160;a&#160;dollar-for-dollar&#160;basis,&#160;pursuant to Section&#160;363(k) of the Bankruptcy Code, in respect of any and all amounts of principal and accrued but unpaid interest outstanding, and any other obligations of the Debtors, in each case, under the Junior DIP Facility as of September&#160;21, 2023 (the &#8220;Credit Bid Amount&#8221;), (iii)&#160;$10,000,000 in cash (the &#8220;Cash Payment&#8221;) and (iv)&#160;the assumption and assignment of certain obligations of Sorrento for legal fees and expenses in the approximate amount of $12.25&#160;million (the &#8220;Legal Fee Assumption&#8221; and, together with the DIP Amount, the Credit Bid Amount and the Cash Payment, the &#8220;Purchase Price&#8221;). Following the sale of the Purchased Securities, Sorrento retained 54,777 shares of Common Stock in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento who may be entitled to receive shares of Common Stock pursuant to the terms of the applicable warrants as a result of the previously declared and announced dividend of shares of Common Stock by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the Scilex-Oramed SPA is not complete and is qualified in its entirety by reference to the full text of the Scilex-Oramed SPA, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed DIP Assumption and Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Oramed DIP Assumption, on September&#160;21, 2023, we entered into an assignment, assumption and release agreement (the &#8220;DIP Assignment Agreement&#8221;) with the Debtors. Pursuant to the DIP Assignment Agreement, the Debtors assigned and transferred to us all of their rights, title and interest and duties, liabilities and obligations under that certain Senior Secured,&#160;Super-Priority&#160;Debtor-In-Possession&#160;Loan&#160;and Security Agreement entered into by the Debtors and Oramed on August&#160;9, 2023, to provide the Senior DIP Facility. On September&#160;21, 2023, the Debtors&#8217; aggregate outstanding obligation under the Senior DIP Facility was $101,875,000, comprised of $100,000,000 of principal, $875,000 accrued and unpaid interest and $1,000,000 in fees and expenses payable under the Senior DIP Facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the DIP Assignment Agreement is not complete and is qualified in its entirety by reference to the full text of the DIP Assignment Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Credit Bid&#160;Pay-Off&#160;Letter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Sorrento SPA, in connection with acquiring the Purchased Securities, we made a credit bid, on&#160;a&#160;dollar-for-dollar&#160;basis,&#160;pursuant to Section&#160;363(k) of the Bankruptcy Code, in respect of the obligations of the Debtors under the Junior DIP Loan Agreement, accrued and outstanding as of September&#160;21, 2023 for the Credit Bid Amount. As noted above, the Credit Bid Amount is part of the Purchase Price for the Purchased Securities. On September&#160;21, 2023, we entered into a letter agreement (the&#160;&#8220;Pay-Off&#160;Letter&#8221;)&#160;with the Debtors, pursuant to which, upon Closing (as defined in the Sorrento SPA), the Junior DIP Loan Agreement, that certain Intellectual Property Security Agreement, dated as of July&#160;28, 2023, by the Debtors in our favor, any other Loan Document (as defined in the Junior DIP Loan Agreement) and any other notes, security agreements, mortgages, pledge agreements, guarantees or other agreements, documents, certificates or instruments related thereto automatically terminated, and all obligations thereunder were paid and discharged in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the Pay-Off&#160;Letter is not complete and is qualified in its entirety by reference to the full text of the Pay-Off&#160;Letter, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal Fee Assumption Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Legal Fee Assumption in accordance with the Sorrento SPA, we and Sorrento entered into a letter agreement on September&#160;21, 2023, pursuant to which, among other things, we agreed to assume all of Sorrento&#8217;s obligations for certain legal fees and expenses in the aggregate amount of approximately $12.25&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subsidiary Guarantee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, in connection with the Scilex-Oramed SPA, we and each of our subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a subsidiary guarantee (the &#8220;Subsidiary Guarantee&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and the Agent, as the collateral agent for the holder of the Oramed Note, pursuant to which, the Guarantors have agreed to guarantee and act as surety for payment of the Oramed Note and any additional notes issued by us after the closing date of the transactions contemplated by the Scilex-Oramed SPA in full or partial substitution of the Oramed Note (the &#8220;Additional Notes&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the refinancing disclosed above under &#8220;<span style="font-style:italic">Tranche B Securities Purchase Agreement</span>&#8221;, our Company, the Guarantors, Oramed and the Agent agreed to amend the Subsidiary Guarantee by entering into the Subsidiary Guarantee Amendment (the &#8220;Subsidiary Guarantee Amendment&#8221;), dated October&#160;8, 2024, to reflect the refinancing arrangement as set out below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the Subsidiary Guarantee and the Subsidiary Guarantee Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Subsidiary Guarantee and the Subsidiary Guarantee Amendment, a copy of each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed Letter Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Company and Oramed entered into a Letter Agreement (the &#8220;Oramed Letter Agreement&#8221;), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the &#8220;Specified September Payment&#8221;) on September&#160;23, 2024, which payment was applied as follows: (i)&#160;$1,700,000 of such payment to the amortization payment due under the Oramed Note on the March&#160;21, 2025 and (y)&#160;$300,000 of such payment to purchase warrants (the &#8220;Purchased Warrants&#8221;) to purchase an aggregate of 114,285 (on a post-Reverse Stock Split basis) shares of Common Stock with an exercise price of $402.50 per share (on a post-Reverse Stock Split basis). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Oramed Letter Agreement, the parties agreed that, notwithstanding the definition of the &#8220;Exercise Eligibility Date&#8221; in the CS-5 Warrant, Oramed may immediately exercise the CS-5 Warrant with respect to up to 1,062,500 (subject to adjustment as provided therein) shares of Common Stock subject to such warrant at any time after September&#160;20, 2024. The parties further agreed, upon receipt of the Specified September Payment, (i)&#160;that notwithstanding the minimum Liquidity (as defined therein) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined therein) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $0, and (ii)&#160;to extend the due date of the $20,000,000 amortization payment from September&#160;23, 2024 to September&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;2, 2024, the Company and Oramed entered into a Consent and Side Letter (the &#8220;Consent and Side Letter&#8221;), pursuant to which Oramed agreed to extend the due date of the September&#160;23, 2024 payment to October&#160;7, 2024. Oramed has agreed to further extend such due date to October&#160;8, 2024 to allow additional time to close the Company&#8217;s convertible debt financing that was announced earlier the same day. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above descriptions of the Oramed Letter Agreement and the Consent and Side Letter are not complete and are qualified in their entirety by reference to the full text of the Oramed Letter Agreement and the Consent and Side Letter, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amended and Restated Security Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, we and the Guarantors entered into a security agreement (the &#8220;Security Agreement&#8221;) with the Holder and the Agent, pursuant to which we and the Guarantors granted to the Agent (on behalf of and for the benefit of the holder of the Oramed Note and any Additional Notes) a security interest in all or substantially all of the property of our Company and each Guarantor, respectively, to secure the prompt payment, performance and discharge in full of all of our Company&#8217;s obligations under the Oramed Note and Additional Notes and the Guarantors&#8217; obligations under the Subsidiary Guarantee, subject to certain customary limitations. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, in each case as more fully set forth in the Security Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the refinancing, we, the Guarantors, Oramed and the Agent agreed to amend and restate the Security Agreement by entering into the Amended and Restated Security Agreement (the &#8220;Amended and Restated Security Agreement&#8221;), dated October&#160;8, 2024, to grant to the Agent (on behalf of and for the benefit of the holder of the Oramed Note, any Additional Notes and the Notes) a security interest in all or substantially all of the property of our Company and each Guarantor, respectively, to secure the prompt payment, performance and discharge in full of all of our Company&#8217;s obligations under the Notes in addition to the obligations under the Oramed Note, the Additional Notes and the Guarantors&#8217; obligations under the Subsidiary Guarantee, which had previously been secured under the Security Agreement, subject to certain customary limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Security Agreement, Semnur will be excluded as a Guarantor after the consummation of the business combination contemplated by that certain agreement and plan of merger between Semnur, Denali Capital Acquisition Corp. and Denali Merger Sub Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Amended and Restated Security Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Security Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ABL Subordination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Scilex Pharma entered into a subordination agreement (the &#8220;ABL Subordination Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;ABL Lender&#8221;) and the Agent. Pursuant to the ABL Subordination Agreement, the parties agreed that ABL Lender&#8217;s rights and interests under that the eCapital Credit Agreement previously entered into between Scilex Pharma and ABL Lender will be secured by first priority liens on certain collateral (the &#8220;ABL Priority Collateral&#8221;) and the Agent&#8217;s rights and interests under the Subsidiary Guarantee shall be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. Among other customary interlender terms, the ABL Subordination Agreement requires that the Facility Cap (as defined in the eCapital Credit Agreement) shall not exceed $30,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the ABL Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the ABL Subordination Agreement were terminated, canceled and are of no further force and effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the ABL Subordination Agreement is not complete and is qualified in its entirety by reference to the full text of the ABL Subordination Agreement, a copy of which is filed as an exhibit to our Current Report on Form&#160;8-K&#160;filed on September&#160;26, 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tranche B Securities Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;7, 2024, we entered into the Tranche B Securities Purchase Agreement with the Tranche B Noteholders, to refinance a portion of the Oramed Note and pay off certain other indebtedness of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Securities Purchase Agreement, we agreed to issue and sell, in a registered offering by the Company directly to the Buyers, (i)&#160;the Tranche B Notes in the aggregate principal amount of $50,000,000, which Tranche B Notes are convertible into shares of Common Stock and (ii)&#160;the October 2024 Noteholder Warrants to purchase up to 214,284 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Tranche B Securities Purchase Agreement, we agreed that so long as any Tranche B Notes remain outstanding, we and each of our subsidiaries will not effect or enter into an agreement to effect any issuance of shares of Common Stock or Common Stock equivalents involving a variable rate transaction; provided that the foregoing restriction will not apply to our prior&#160;at-the-market&#160;offering program, which has been terminated as of March&#160;5, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and conditions contained in the Tranche B Securities Purchase Agreement, we also agreed to reimburse the Investors for all reasonable costs and expenses incurred by it or its affiliates in connection with the Tranche B Securities Purchase Agreement, the Tranche B Notes, the October 2024 Noteholder Warrants, the ZTlido Royalty Purchase Agreement (as defined below) and certain other transaction documents, and an aggregate amount of $950,000&#160;non-accountable&#160;legal fees of outside counsel and special finance and collateral counsel, which shall be withheld by the Investors from its purchase price at the closing of the transaction, less $20,000 previously paid by us. We were also responsible for the payment of a $2,000,000 fee to the placement agent in addition to the payment of any placement agent&#8217;s reasonable fees, financial advisory fees relating to or arising out of the transactions contemplated by the Tranche B Securities Purchase Agreement. In addition, in conjunction with and pursuant to the Tranche B Letter Agreement, we were also responsible for the payment of legal fees of outside counsel for Oramed relating to or arising out of the transactions contemplated by the Tranche B Securities Purchase Agreement and the payment date extensions described under the Tranche B Letter Agreement. We were also responsible for the payment of any fees of the Agent and the legal fees incurred thereby relating to or arising out of the transactions contemplated by the Tranche B Securities Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Tranche B Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Tranche B Securities Purchase Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment to Scilex-Oramed SPA </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Tranche B Securities Purchase Agreement, on October&#160;8, 2024, we entered into Amendment No.&#160;1 to Securities Purchase Agreement (the &#8220;Amendment No.&#160;1 to Scilex-Oramed SPA&#8221;) with Oramed and the Agent. The Amendment No.&#160;1 to Scilex-Oramed SPA was entered into to account for the issuance of the Tranche B Notes and the execution of certain related documents including the ZTlido Subordination Agreement (as defined below) and an agreement among the holders of the Tranche B Notes addressing the allocation of various rights and obligations as among the holders of the Tranche B Notes and the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Amendment No.&#160;1 to Scilex-Oramed SPA does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment No.&#160;1 to Scilex-Oramed SPA, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Senior Convertible Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate principal balance of the Tranche B Notes is $50,000,000. The aggregate purchase price for the Tranche B Notes and the related warrants (described below) is $45,000,000. The Tranche B Notes have an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
original issue discount of 10.0%. We received in exchange for the issuance of the Tranche B Notes to the Investors an aggregate amount in cash equal to $22,500,000, excluding fees and expenses (as noted above) from the Investors. We received from Oramed in consideration for the Note issued to Oramed an exchange and reduction of the principal balance under Oramed Note of an equivalent amount. The Tranche B Notes bear interest at a rate of 5.5%&#160;per annum, payable in arrears on the first trading day of each calendar quarter, beginning January&#160;2, 2025, payable, at our option, either in cash or in shares of Common Stock, subject to certain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier converted or redeemed, the Tranche B Notes mature on the&#160;two-year&#160;anniversary of the issuance date (the &#8220;Maturity Date&#8221;), subject to extension at the option of the holder in certain circumstances as provided in the Note. All amounts due under the Note are convertible at any time, in whole or in part, and subject to certain beneficial ownership limitations, at the option of the holder into shares of Common Stock at a current conversion price equal to $36.40 per share, subject to adjustment as described in the Tranche B Notes. The Tranche B Notes are our senior secured obligation (alongside and in certain circumstances described herein subordinate to, the Oramed Note) and rank senior to the right to payment of the holders of our unsecured debt, except as described herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after issuance, all amounts due under the Tranche B Notes are convertible, in whole or in part, at the holder&#8217;s option, into Common Stock at the current conversion price of $36.40 per share (the &#8220;Conversion Price&#8221;), which is subject to (i)&#160;proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions; and (ii)&#160;full-ratchet adjustment (down to the Conversion Price Floor (as defined below)) in connection with a subsequent offering at a per share price less than the fixed conversion price then in effect. The Conversion Price cannot be lower than $36.40 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events, the &#8220;Conversion Price Floor&#8221;) unless shareholder approval is obtained to allow the Tranche B Notes to convert at a price lower than the Conversion Price Floor in accordance with the Nasdaq listing rules. We are under no obligation to seek or obtain such shareholder approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes held by an individual holder of the Tranche B Notes may not be converted into shares of Common Stock to the extent such conversion would result in holder (together with certain related parties of holder) would beneficially own in excess of 4.99% (the &#8220;Maximum Percentage&#8221;) of shares of the Common Stock outstanding immediately after giving effect to such conversion. The Maximum Percentage with respect to a holder and certain related parties may be raised or lowered to any other percentage not in excess of 9.99%, at the option of the holder, except that any increase will only be effective upon 61 days&#8217; prior notice to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right (assuming no failure of certain specific conditions relating to our equity) to redeem in cash all, but not less than all, the amount then outstanding under the Tranche B Notes at a 35% redemption premium to the greater of (i)&#160;the amount then outstanding under the Tranche B Notes to be redeemed, and (ii)&#160;the equity value of Common Stock underlying such Tranche B Notes. We have a mandatory obligation to redeem the Tranche B Notes upon an event of default bankruptcy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes are subject to redemption by our Company at the election of a holder in certain circumstances as more fully described therein, including, among other events, a change of control of our Company, a subsequent placement of certain securities of our Company, and asset sales by our Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes contain affirmative and negative covenants binding on our Company and our subsidiaries which restrict, among other things, our Company and our subsidiaries from incurring indebtedness or liens, redeeming securities, repaying certain indebtedness or declaring or paying any cash dividend or distribution, selling or disposing of any assets or rights of our Company and our subsidiaries, entering into or being a party to any transactions with any affiliates, incurring or guaranteeing any indebtedness or permitting the acceleration of any indebtedness, in each case as more fully set forth in, and subject to certain qualifications, exceptions, and &#8220;baskets&#8221; set forth in the Oramed Note. In addition, at the request of the holder, not more frequently than once per fiscal year, we will hire an independent, reputable investment bank to investigate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether any breach of the Tranche B Notes has occurred if an event constituting an event of default has occurred and is continuing or any holder reasonably believes that an event constituting an event of default has occurred or is continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes contain certain customary events of default, including, without limitation, a cross-default to other specified indebtedness or any other indebtedness involving an obligation of $5,000,000 or more. The interest rate of the Tranche B Notes automatically increases to 15.0%&#160;per annum (the &#8220;Default Rate&#8221;) upon the occurrence and continuance of an event of default. We are also required to pay a late charge of 15.0% on any amount of principal or other amounts that are not paid when due (solely to the extent such amounts are not then accruing interest at the Default Rate). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes prohibit our Company from entering into specified fundamental transactions unless the successor entity assumes all of our obligations under the Tranche B Notes under a written agreement approved by the required holders of the Tranche B Notes before the transaction is completed. Upon consummation of specified fundamental transactions, the successor entity must confirm that upon conversion or redemption of the Tranche B Notes thereafter, shares of the successor entity will be issuable upon such conversion or redemption. As noted above, the holders of the Tranche B Notes have certain redemption rights upon a fundamental transaction constituting a change of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any amortization, certain redemptions or other repayment of the Tranche B Notes, we will also pay an amount equal to the amount of additional interest that would accrue under such Tranche B Notes at the interest rate then in effect assuming that the amount so converted, redeemed, amortized or otherwise repaid on such date of determination instead remained outstanding through and including the Maturity Date of such Tranche B Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Tranche B Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Tranche B Notes, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">October 2024 Noteholder Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are exercisable immediately from the date of issuance and expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are exercisable for cash at a current exercise price equal to $36.40 per share of Common Stock (the &#8220;Exercise Price&#8221;). The Exercise Price is subject to adjustment for any stock split, stock dividend, stock combination, recapitalization or similar event. The Exercise Price is also subject to full-ratchet adjustment (down to the Exercise Price Floor (as defined below)) in connection with a subsequent offering at a per share price less than the exercise price then in effect. The Exercise Price cannot be lower than the Exercise Price Floor, unless shareholder approval is obtained to allow the October 2024 Noteholder Warrants to be exercised at a price lower than the Exercise Price Floor in accordance with the Nasdaq listing rules. We are under no obligation to seek or obtain such shareholder approval. If at the time of exercise of the October 2024 Noteholder Warrants, there is no effective registration statement registering the shares of Common Stock underlying the October 2024 Noteholder Warrants, such warrants may be exercised on a cashless basis pursuant to their terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder shall not have the right to exercise any portion of an October 2024 Noteholder Warrant to the extent that, after giving effect to such conversion, the holder (together with certain related parties) would beneficially own in excess of the Maximum Percentage of shares of Common Stock outstanding immediately after giving effect to such conversion. The Maximum Percentage may be raised or lowered to any other percentage not in excess of 9.99%, at the option of the holder, except that any increase will only be effective upon 61 days&#8217; prior notice to us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants prohibit our Company from entering into specified fundamental transactions unless the successor entity (subject to certain exceptions) assumes all of our Company&#8217;s obligations under the October 2024 Noteholder Warrants under a written agreement before the transaction is completed. Upon specified corporate events, an October 2024 Noteholder Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the October 2024 Noteholder Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified changes of control, holders of October 2024 Noteholder Warrants will have the right to force our Company to repurchase such holder&#8217;s October 2024 Noteholder Warrant for a purchase price in cash equal to the Black Scholes value, as calculated under the October 2024 Noteholder Warrants, of the then unexercised portion of the October 2024 Noteholder Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the October 2024 Noteholder Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the October 2024 Noteholder Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Royalty Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, but as a distinct and separate matter, on October&#160;8, 2024, we and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Investors and Oramed (together, the &#8220;ZTlido RPA Purchasers&#8221;). Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido RPA Purchasers the right to receive 8% of all aggregate net sales worldwide (the &#8220;Purchased Receivables&#8221;) with respect to ZTlido (lidocaine topical system) 1.8%,&#160;SP-103&#160;(lidocaine topical system) 5.4%, and any related, improved, successor, replacement or varying dosage forms of the foregoing (the &#8220;ZTlido Covered Products&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In full consideration for the sale, transfer, conveyance and granting of the Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the Purchased Receivables was $5,000,000 (net of expenses of the ZTlido RPA Purchasers). The ZTlido RPA Purchasers paid to Scilex Pharma an aggregate amount equal to $2,500,000 minus the expenses of the ZTlido RPA Purchasers, and Oramed paid to Scilex Pharma an amount equal to $2,500,000 minus Oramed&#8217;s expenses (collectively, the amount so paid by the ZTlido RPA Purchasers, the &#8220;RPA Closing Payment&#8221;). Oramed&#8217;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the RPA Closing Payment, which amount extinguished and reduced $2,500,000 of the outstanding balance under the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ZTlido Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the Purchased Receivables to which each ZTlido RPA Purchaser is entitled hereunder during the period commencing on the date of the closing of the transactions contemplated thereby and expiring on the tenth anniversary of such closing date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We subsequently amended the ZTlido Royalty Purchase Agreement on February&#160;28, 2025, pursuant to the ZTlido Royalty Amendment with the Scilex Pharma and the ZTlido RPA Purchasers. Pursuant to the ZTlido Royalty Amendment, we and Scilex Pharma may assign our respective rights or delegate our respective obligations under the ZTlido Royalty Purchase Agreement without the prior written consent of the ZTlido RPA Purchasers if we receive a commitment, contingent upon an asset purchase of ZTlido Covered Products (as defined in the ZTlido Royalty Purchase Agreement), that would allow us to pay in full all obligations owed under the Debt Instruments (as defined therein), provided that such purchaser of ZTlido Covered Products agrees to assume all of the obligations of our company and Scilex Pharma under the ZTlido Royalty Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the ZTlido Royalty Purchase Agreement and the ZTlido Royalty Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the ZTlido Royalty </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase Agreement and the ZTlido Royalty Amendment, a copy of each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Royalty Security Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the ZTlido Royalty Purchase Agreement, Scilex Pharma entered into a Security Agreement with the collateral agent (as identified therein) for the benefit of the ZTlido RPA Purchasers, dated as of October&#160;8, 2024 (the &#8220;ZTlido Royalty Security Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ZTlido Royalty Security Agreement, our Company&#8217;s and Scilex Pharma&#8217;s due performance and payment under the ZTlido Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and the regulatory approvals, in each case related to the ZTlido Covered Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the ZTlido Royalty Security Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ZTlido Royalty Security Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Subordination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the ZTlido Royalty Purchase Agreement and ZTlido Royalty Security Agreement, Scilex Pharma entered into that certain ZTlido Subordination Agreement, dated as of October&#160;8, 2024 (the &#8220;ZTlido Subordination Agreement&#8221;), by and among Scilex Pharma, the ZTlido RPA Purchasers and the Note Agent. The parties agreed that all obligations, liabilities and indebtedness under the ZTlido Royalty Purchase Agreement will be secured by first priority liens on the collaterals under the ZTlido Royalty Security Agreement (the &#8220;Royalty Collateral&#8221;), and all obligations under the Amended and Restated Security Agreement (as defined therein) will be secured by the Royalty Collateral and second priority liens on the collaterals under the ZTlido Royalty Security Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the ZTlido Subordination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ZTlido Subordination Agreement, a copy of which is filed as an exhibit the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed Note Consent and Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the refinancing, we entered into a Consent and Amendment for the Oramed Note (the &#8220;Consent and Amendment&#8221;), dated as of October&#160;8, 2024 with Oramed. Pursuant to the Consent and Amendment, we and Oramed consent to (i)&#160;our Company&#8217;s (and, to the extent applicable, our subsidiaries&#8217;) entry into and performance of the Tranche B Securities Purchase Agreement, the issuance of the Tranche B Notes and the October 2024 Noteholder Warrants and performance of the terms thereof, the entry into and performance of the ZTlido Royalty Purchase Agreement and other related amendment documents and the consummation of the refinancing, (ii)&#160;modifications to certain defined terms under the Oramed Note, and (iii)&#160;the payment of all transaction fees and expenses related to the refinancing transactions. Oramed further agreed that the proceeds of the refinancing transactions utilized to repay the Oramed Note shall not constitute a voluntary prepayment, and no Make-Whole Amount (as defined in the Oramed Note) or other premium shall be payable with respect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Consent and Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Consent and Amendment, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Deferral and Consent under Tranche B Senior Secured Convertible Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Notes, commencing on January&#160;2, 2025 (the &#8220;First Amortization Payment Date&#8221;), we are required to make the First Amortization Payment to redeem in cash such portion of the principal amount of the Notes equal to the Holder Pro Rata Amount (as defined in the Notes) of each Tranche B Noteholder of $6,250,000 per fiscal quarter at a redemption price equal to 100% of such Amortization Amount (as defined in the Notes). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2025, we entered into the Tranche B Consents pursuant to which the Tranche B Noteholders agreed to defer our obligation to make the First Amortization Payment until January&#160;31, 2025. In consideration of such deferral, and to limit the Tranche B Noteholders&#8217; right to exercise certain secured creditor remedies (including recourse against the assets of SCLX JV as a grantor under the Security Agreement (as defined in the Tranche B Consents)), SCLX JV delivered to the Tranche B Noteholders (or their designee) by deposit/withdrawal at custodian with the Depository Trust Company an aggregate of 142,855 shares of Common Stock (as defined in, and contemplated pursuant to, the Term Sheet) held by SCLX JV, of which 71,428 shares were delivered to Oramed, 20,571 shares were delivered to BPY Limited, 36,571 shares were delivered to Nomis Bay Ltd, and 14,285 shares were delivered to 3i, LP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the Tranche B Consents, effective as of the latest of (i)&#160;the time of execution and delivery of the Tranche B Consents, (ii)&#160;the time of the delivery of the Scilex shares and (iii)&#160;the time of grant of the Royalty and Exclusive Rights (each as defined in, and contemplated pursuant to, the Term Sheet), the Tranche B Noteholders agreed to further defer our obligation to make the First Amortization Payment until October&#160;8, 2026, provided that, as contemplated in the Term Sheet, we pay an aggregate of $1.1 million in respect of a portion of the First Amortization Payment and related make-whole interest (which amount has been paid). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the Tranche B Consents do not purport to be complete and are qualified in their entirety by reference to the full text of the Tranche B Consents, a copy of each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment to the Oramed Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;21, 2025, we entered into the Oramed Amendment, pursuant to which, among other things, Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV, with a fair value of $1.4 million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Oramed Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Oramed Amendment, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Rest of World License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Lido Effective Date, Scilex Pharma entered into the Lido License Agreement with the Licensee with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, between Scilex Pharma, Oishi and Itochu, as amended, which include the Lido Product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
non-transferable right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido Products outside of the United States and in the Lido Licensee Territory. The Licensee granted to Scilex Pharma a non-exclusive, non-transferable, right and license under the Licensee Non-Blocking Patents (as defined therein) (i)&#160;in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (each as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field (each as defined therein). Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for SP-103 and all existing Lido Products in each country or jurisdiction in the Licensor Territory (as defined therein). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the Lido Effective Date, Scilex Pharma is required to (i)&#160;facilitate an introduction between Oishi, Itochu, and the Licensee, and (ii)&#160;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with the Licensee for the manufacturing or supply of the Lido Product in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lido License Term commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Lido License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lido License Agreement, a copy of which is filed an as exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Parent Guarantee for Lido License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025, in connection with Lido License Agreement, we entered into the Parent Guarantee with the Licensee, pursuant to which we agreed to guarantee the due and proper performance of Scilex Pharma&#8217;s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee. Pursuant to the terms of the Parent Guarantee, we shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Parent Guarantee does not purport to be complete and is qualified in its entirety by reference to the full text of the Parent Guarantee, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gloperba-Elyxyb Royalty Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As contemplated by the Term Sheet in respect of the Royalty and Exclusive Rights described therein, on February&#160;28, 2025 (the &#8220;Closing Date&#8221;), we entered into the Gloperba-Elyxyb Royalty Purchase Agreement with Scilex Pharma and the Gloperba-Elyxyb RPA Purchasers. Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma sold to the Gloperba-Elyxyb RPA Purchasers the Gloperba-Elyxyb Purchased Receivables with respect to the Gloperba-Elyxyb Covered Products. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Further Deferral and representing the &#8220;grant of the Royalty and Exclusive Rights&#8221; (as defined in the Term Sheet), during the period commencing on the Closing Date and expiring on the tenth anniversary of the Closing Date (the &#8220;Payment Term&#8221;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#8217;s account such Gloperba-Elyxyb RPA Purchaser&#8217;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Gloperba and Elyxyb Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter (commencing with the calendar quarter beginning January&#160;1, 2025) promptly, but in any event no later than 60 calendar days after the end of each calendar quarter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Payment Term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gloperba-Elyxyb Royalty Security Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Gloperba-Elyxyb Royalty Purchase Agreement, we entered into the Gloperba-Elyxyb Royalty Security Agreement with Scilex Pharma and the collateral agent (as identified therein) for the benefit of the Gloperba-Elyxyb RPA Purchasers, dated as of February&#160;28, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma&#8217;s due performance and payment under the Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered Products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gloperba-Elyxyb Subordination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, we entered into the Gloperba-Elyxyb Subordination Agreement, by and among us, Scilex Pharma, the Gloperba-Elyxyb RPA Purchasers and the Note Agent. Pursuant to the Gloperba and Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by the Gloperba-Elyxyb Royalty Collateral and the Note Agent&#8217;s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a second priority lien. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the Gloperba-Elyxyb Royalty Purchase Agreement, the Gloperba-Elyxyb Royalty Security Agreement and the Gloperba-Elyxyb Subordination Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, a copy of each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gloperba Rest of World License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Effective Date, we entered into the Gloperba License Agreement with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of us, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Romeg License Agreement, as amended by that certain First Amendment to License and Commercialization Agreement, dated January&#160;16, 2025, by and between Romeg and us, as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by us ((i) and (ii)&#160;collectively, the &#8220;Gloperba Product&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Gloperba License Agreement, we granted to the Licensee during the Gloperba License Term a worldwide, exclusive, non-transferable (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by us to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to us a non-exclusive, non-transferable (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee Non-Blocking Patents (as defined therein) (i)&#160;in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit the Gloperba Product for commercialization of the Gloperba Products in the United States in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture the Gloperba Product for commercialization in the United States in the Field (as defined therein). Each of the Licensee and we will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#8217;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to us an amount required for us to receive its share of the Net Revenue on a quarterly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the Effective Date, we are required to (i)&#160;facilitate an introduction between the Licensee and the Gloperba CMO as of the Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, we agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Gloperba License Term commences on the Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Gloperba License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Gloperba License Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consent, Waiver and Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2025, in connection with the formation of Scilex Bio, Inc. the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed (the &#8220;Oramed Consent and Waiver&#8221;), pursuant to which certain definitions in the Oramed Note were modified to reflect, among other things, that Scilex Bio will not be deemed a subsidiary of Scilex under the terms of the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above descriptions of the Oramed Consent and Waiver is not complete and is qualified in its entirety by reference to the full text of the Oramed Consent and Waiver, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed Penny Warrant Repurchase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed and as described elsewhere in this prospectus, on September&#160;21, 2023, the Company issued Penny Warrants to purchase up to an aggregate of 6,500,000 shares of Common Stock to Oramed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025, the Company entered into the Option Agreement with Oramed, pursuant to which, among other things, Oramed granted the Option to the Company to repurchase the Penny Warrants in two tranches for an aggregate purchase price of $27,000,000, subject to the terms and conditions set forth therein. In consideration of the Option, the Company agreed to pay $1,500,000 to Oramed in two equal installments occurring on or before August&#160;8, 2025 and December&#160;16, 2025, respectively. Provided that the Company has made the applicable option payment on or before such dates, the Company shall be entitled to purchase the Penny Warrants as follows: (i)&#160;on or before September&#160;30, 2025, it may repurchase 3,130,000 Penny Warrants for $13,000,000 and (ii)&#160;on or before December&#160;31, 2025, it may repurchase 3,370,000 Penny Warrants for $14,000,000. Additionally, if the Company effects the Penny Warrant Repurchase and has paid the Option Payment Amount and Penny </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant Repurchase Amount in full, in accordance with the terms of the Option Agreement, then the maturity date of the Oramed Note shall be extended to March&#160;31, 2026 and any make-whole payment due thereunder upon prepayment shall be waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oramed shall have the right to terminate the Option Agreement if the Company (i)&#160;fails to make certain payments thereunder or (ii)&#160;has not exercised the Option by the applicable dates set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Option Agreement, the Company has agreed that, if the Option Agreement is terminated pursuant to the terms set forth therein, the Company will use commercially reasonable efforts to obtain the approval of its stockholders to permit the issuance of shares of Common Stock in excess of the Stockholder Approval Cap (as defined therein) upon exercise of any Penny Warrants retained by Oramed following such termination, subject to the terms and conditions set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Option Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Option Agreement, a copy of which is filed an as exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officer and Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the sections titled &#8220;Executive and Director Compensation&#8221; for information regarding the compensation of our executive officers and non-employee directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with our named executive officers, other than Dr.&#160;Ji and Mr.&#160;Ma, that, among other things, provide for certain compensatory benefits. In addition, we have also entered into severance and change of control agreements with our named executive officers which provide for severance payments upon certain terminations of employment as well as in connection with a change of control of the Company. For descriptions of such agreements, see the section titled &#8220;Executive and Director Compensation.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section titled &#8220;Board of Directors and Corporate Governance &#8212; Limitation of Liability and Indemnification of Directors and Officers&#8221; for information regarding our arrangements to provide indemnification to our officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Person Transaction Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit Committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks, costs and benefits to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of other sources for comparable services or products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board, determines in the good faith exercise of our discretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_17">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of July&#160;31, 2025 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or &#8220;group&#8221; known to be the beneficial owner of more than 5% of our outstanding Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our named executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently exercisable or exercisable within 60 days of July&#160;31, 2025 are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is based on 6,955,697 shares of such common stock outstanding as of July&#160;31, 2025. Voting power is based on 6,955,697 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of July&#160;31, 2025, with the Series A Preferred Stock entitled to an aggregate of 922,447 votes as a result of adjustments to the deemed conversion price of such preferred stock in accordance with the terms of the Series A Certificate of Designations. Shares of Series A Preferred Stock are held solely by SCLX JV. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Series A Preferred Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Address of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares of<br/>Common<br/>Stock<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">% of<br/>Total<br/>Common<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares of<br/>Series A<br/>Preferred<br/>Stock<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">% of<br/>Total<br/>Series A<br/>Preferred<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">% of<br/>Total<br/>Vote</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Directors and Named Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">320,863</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.41</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">251,493</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">12,680</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8,636</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8,287</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annu Navani, M.D.<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,934</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,681</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All Directors and Executive Officers as a Group (7 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">621,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8.24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">5% Beneficial Owners</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,472,281</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(9)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">30.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Pharmaceuticals Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">732,717</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(10)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">9.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the business address of each of the following individuals is 960 San Antonio Road, Palo Alto, CA 94303. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 312,430 shares subject to options exercisable within 60 days of July 31, 2025, 3,980 shares held directly and an aggregate of 4,453 shares held by family trusts for the benefit of Mr.&#160;Shah, his spouse and his children. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 232,041 shares subject to options exercisable within 60 days of July&#160;31, 2025, 9,147 shares held directly, an aggregate of 1,794 shares held through an entity owned by Dr.&#160;Ji, 161 shares held by Dr.&#160;Ji&#8217;s spouse and an aggregate of 8,350 shares held by family trusts for the benefit of Dr.&#160;Ji, his spouse and his children. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 12,028 shares subject to options exercisable within 60 days of July 31, 2025 and 652 shares held directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 5,422 shares subject to options exercisable within 60 days of July 31, 2025 and 3,214 shares held directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 8,222 shares subject to options exercisable within 60 days of July 31, 2025 and 65 shares held directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 1,934 shares subject to options exercisable within 60 days of July 31, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 16,967 shares subject to options exercisable within 60 days of July 31, 2025 and 714 shares held directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (a) 1,458,263 shares of Common Stock held directly and (b) 14,018 shares underlying the Private Warrants held by SCLX JV, all of which are currently exercisable, in each case, transferred to SCLX JV in connection with the Equity Repurchase Transaction. Does not include any shares of Series A Preferred Stock. SCLX JV holds 490,617 Private Warrants. In connection with the Reverse Stock Split, the SPAC Warrants (which include the Private Warrants) were adjusted in accordance with their terms such that the number of SPAC Warrants outstanding was unchanged, but each SPAC Warrant now entitles the holder to purchase 1/35th of a share of Common Stock at an exercise price of $402.50 per whole share (provided that in no event shall the holder of any such warrants be entitled, upon the exercise of such warrants, to receive a fractional interest in a share of Common Stock upon such exercise and the Company shall, upon such exercise, round up to the nearest whole number of shares of Common Stock to be issued to such holder). Accordingly, the Private Warrants held by SCLX JV are currently exercisable for 14,018 shares of Common Stock. The voting and dispositive power of the equity securities of the Company (including the Series A Preferred Stock) held by SCLX JV are subject to the control of an independent manager, Xiao Xu, until such time as the Oramed Note and any Additional Notes are paid in full. The business address of SCLX Stock Acquisition JV LLC is 960 San Antonio Road, Palo Alto, CA 94303. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 350,000 shares of Common Stock held directly and 382,717 shares underlying certain warrants to purchase Common Stock, with an exercise price of $0.01 per share, held by Oramed exercisable within 60 days of July 31, 2025. Such warrants held by Oramed are subject to a 9.99% beneficial ownership limitation and the number of shares of Common Stock set forth in the table above give effect to such limitation. The foregoing ownership information for Oramed is based on information supplied by Oramed in a statement on Schedule 13G/A filed with the SEC on May 8, 2025 that reports its sole voting power and sole dispositive power. The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue of the Americas, Third Floor, New York, NY 10036. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_18">SELLING STOCKHOLDER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale from time to time by the Selling Stockholder of any or all of the shares of common stock that have been and may be issued by us to the Selling Stockholder under the Tumim Purchase Agreement. For additional information regarding the issuance of our common stock covered by this prospectus, see the section titled &#8220;<span style="font-style:italic">The Tumim Equity Financing</span>&#8221; above. We are registering the Shares included in this prospectus pursuant to the provisions of the Tumim Registration Rights Agreement we entered into with Tumim on July&#160;22, 2025, in order to permit the Selling Stockholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions with 3i, LP, an affiliate of Tumim, described in &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>,&#8221; the transactions contemplated by the Tumim Purchase Agreement and the Tumim Registration Rights Agreement, Tumim has not had any material relationship with us within the past three years. As used in this prospectus, the term &#8220;Selling Stockholder&#8221; means Tumim Stone Capital, LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Stockholder and the shares of common stock that may be resold by the Selling Stockholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Stockholder, and reflects holdings as of July&#160;31, 2025. The number of shares in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221; represents all of the shares of common stock being offered for resale by the Selling Stockholder under this prospectus. The Selling Stockholder may sell some, all, or none of its shares being offered for resale in this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know how long the Selling Stockholder will hold the shares before selling them, and, except as set forth in the section titled &#8220;Plan of Distribution&#8221; in this prospectus, we are not currently aware of any existing agreements, arrangements or understandings between the Selling Stockholder and any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common stock being offered for resale by this prospectus by the Selling Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the Selling Stockholder has sole or shared voting and investment power. The percentage of shares of common stock beneficially owned by the Selling Stockholder prior to the offering shown in the table below is based on an aggregate of 6,955,697 shares of our common stock outstanding on July&#160;31, 2025. Because the purchase price of the shares of common stock issuable under the Purchase Agreement is determined on each VWAP Purchase Date, with respect to a VWAP Purchase, the number of shares that may actually be sold by the Company under the Purchase Agreement may be fewer than the number of shares being offered for resale by this prospectus. The fourth column assumes the sale of all of the shares offered for resale by the Selling Stockholder pursuant to this prospectus. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of Shares of<br/>Common Stock<br/>Owned Prior to this<br/>Offering(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Maximum&#160;Number<br/>of Shares of<br/>Common Stock to<br/>be<br/>Offered&#160;Pursuant&#160;to<br/>this Prospectus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Maximum Number of<br/>Shares of Common<br/>Stock Owned After<br/>this Offering</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Selling Stockholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percent<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number<sup style="font-size:75%; vertical-align:top">(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percent<sup style="font-size:75%; vertical-align:top">(5)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tumim Stone Capital, LLC<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">299,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,390,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1.79</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Tumim may be required to purchase under the Tumim Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Tumim Purchase Agreement, the satisfaction of which are entirely outside of Tumim&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the VWAP Purchases of common stock are subject to certain agreed upon maximum </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
amount limitations set forth in the Tumim Purchase Agreement. Also, the Tumim Purchase Agreement prohibits us from issuing and selling any shares of our common stock to Tumim to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Tumim, would cause Tumim&#8217;s beneficial ownership of our common stock to exceed 4.99%. The Tumim Purchase Agreement also prohibits us from issuing or selling shares of our common stock under the Tumim Purchase Agreement in excess of a 19.99% exchange cap unless we obtain stockholder approval to do so, or unless sales of common stock are made at a price equal to or greater than $8.09 per share, such that the exchange cap limitation would not apply under applicable Nasdaq rules. Neither the beneficial ownership limitation nor the exchange cap (to the extent applicable under Nasdaq rules) may be amended or waived under the Tumim Purchase Agreement. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 150,00 Commitment Shares that Tumim has the right to receive within 60 days of July&#160;31, 2025 (assuming that the registration statement of which this prospectus forms a part has been declared effective during that time) and 149,140 shares of our common stock underlying certain warrants held by an affiliate of Tumim exercisable within 60 days of July&#160;31, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Applicable percentage ownership is based on 6,955,697 shares of our common stock outstanding as of July&#160;31, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the sale of all shares being offered pursuant to this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of Tumim is 2 Wooster Street, 2nd Floor, New York, New York 10013. Tumim&#8217;s principal business is that of a private investor. Maier Joshua Tarlow is the manager of 3i Management, LLC, the general partner of 3i, LP, which is the sole member of Tumim, and has sole voting control and investment discretion over securities beneficially owned directly by Tumim and indirectly by 3i Management, LLC and 3i, LP. 3i Management, LLC is also the manager of Tumim. We have been advised that none of Mr.&#160;Tarlow, 3i Management, LLC, 3i, LP, or Tumim is a member of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr.&#160;Tarlow as to beneficial ownership of the securities beneficially owned directly by Tumim and indirectly by 3i Management, LLC and 3i, LP. 3i, LP is a holder of Tranche B Notes in the aggregate principal amount of $1,346,848 and the holder of 149,140 warrants to purchase shares of our common stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_19">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock offered by this prospectus are being offered by the Selling Stockholder. The shares may be sold or distributed from time to time by the Selling Stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the shares of our Common Stock offered by this prospectus could be effected in one or more of the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokers&#8217; transactions;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">transactions involving cross or block trades;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through brokers, dealers, or underwriters who may act solely as agents;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;at the market&#8221; into an existing market for the Common Stock;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; or</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any combination of the foregoing.</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumim is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. Tumim has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock that it has acquired and may in the future acquire from us pursuant to the Tumim Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act. Tumim has informed us that each such broker-dealer will receive commissions from Tumim that will not exceed customary brokerage commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters or agents participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Stockholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Stockholder may be less than or in excess of customary commissions. Neither we nor the Selling Stockholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Stockholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the Selling Stockholder, any compensation paid by the Selling Stockholder to any such brokers, dealers, underwriters or agents, and any other required information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Stockholder, and have agreed to reimburse Tumim for the fees and disbursements of its counsel incurred in connection therewith, in an amount not to exceed $10,000. As consideration for its irrevocable commitment to purchase our Common Stock under the Tumim Purchase Agreement, we have issued to Tumim 150,000 shares of our Common Stock as the Commitment Shares (as defined in the Tumim Purchase Agreement). We also have agreed to reimburse Tumim for the fees and disbursements of its counsel, payable upon execution of the Tumim Purchase Agreement, in an amount not to exceed $60,000 (inclusive of the $10,000 referenced above, all of which has been paid as of the date hereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify Tumim and certain other persons against certain liabilities in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Tumim has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Tumim specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed elsewhere in this prospectus, although all shares of common stock being offered in this offering are being offered directly by the selling stockholder, we are obligated to pay certain fees to StockBlock in connection with the Tumim Equity Financing pursuant to certain contractual obligations between us and StockBlock. Accordingly, pursuant to such contractual obligations, we will pay StockBlock a fee in cash equal to (a)&#160;2.0% on the aggregate gross proceeds up to and including $10,000,000; (b)&#160;3.0% on the aggregate gross proceeds in excess of the first $10,000,000 referred to in the preceding (a)&#160;and equal to or less than $25,000,000; and (c)&#160;5.0% on the aggregate gross proceeds in excess of the first $35,000,000 referred to in the preceding (a)&#160;and (b), from the Tumim Equity Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses for the offering will be approximately $500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumim has represented to us that at no time prior to the date of the Tumim Purchase Agreement has Tumim or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Common Stock or any hedging transaction, which establishes a net short position with respect to our Common Stock. Tumim has agreed that during the term of the Tumim Purchase Agreement, neither Tumim, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;SCLX.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_20">MATERIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S.&#160;federal income tax considerations generally applicable to the purchase, ownership and disposition of our Common Stock. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S.&#160;federal income tax consequences relating to the purchase, ownership and disposition of our Common Stock. In addition, this discussion does not address all aspects of U.S.&#160;federal income tax consequences to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S.&#160;federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S.&#160;federal&#160;3.8% Medicare tax imposed on certain net investment income or any aspects of U.S.&#160;federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S.&#160;state and local, or non-U.S.&#160;tax laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S.&#160;federal income tax consequences to a holder of the purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S.&#160;federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our Common Stock as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S.&#160;federal income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the U.S.&#160;tax laws, such as, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, or insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities who elect to apply a mark-to-market method of accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subchapter&#160;S corporations, partnerships or other pass-through entities or investors or beneficial owners in such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">grantor trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S.&#160;persons whose &#8220;functional currency&#8221; is not the U.S.&#160;dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporations that accumulate earnings to avoid U.S. federal income tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">accrual method taxpayers that file applicable financial statements as described in Section&#160;451(b) of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or through a tax-qualified retirement plan or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding Common Stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our Common Stock as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; &#8220;constructive sale&#8221; or other integrated investment or risk reduction transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;qualified foreign pension funds&#8221; (within the meaning of Section&#160;897(l)(2) of the Code and entities whose interests are held by qualified foreign pension funds; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to which there are one or more United States shareholders within the meaning of Treasury Regulation&#160;Section&#160;1.367(b)-3(b)(1)(ii). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As used in this discussion, the term &#8220;U.S.&#160;Holder&#8221; means a beneficial owner of our Common Stock that is, for U.S.&#160;federal income tax purposes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S.&#160;federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (i)&#160;if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S.&#160;person for U.S.&#160;federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;Non-U.S.&#160;Holder&#8221; means a beneficial owner of our Common Stock, that is neither a U.S.&#160;Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S.&#160;federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S.&#160;federal income tax purposes, holds our Common Stock, the U.S.&#160;federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors with regard to the U.S.&#160;federal income tax consequences of the ownership and disposition of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or non-U.S. taxation, or any U.S. federal taxes (such as gift and estate taxes) other than income taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S.&#160;FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S.&#160;FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&#160;FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S.&#160;Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Taxation of Distributions</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S.&#160;Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S.&#160;federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S.&#160;federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S.&#160;Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;<span style="font-style:italic">U.S.&#160;Holders &#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S.&#160;Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S.&#160;Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. Non-corporate U.S.&#160;Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4) of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the applicable holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S.&#160;Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption that is treated as a sale or exchange under Section&#160;302 of the Code. In the case of a redemption, such redemption generally will be treated as a sale or exchange of the Common Stock (rather than as a corporate distribution) if the redemption (i)&#160;is &#8220;substantially disproportionate&#8221; with respect to the U.S. Holder, (ii)&#160;results in a &#8220;complete termination&#8221; of the U.S. Holder&#8217;s interest or (iii)&#160;is &#8220;not essentially equivalent to a dividend&#8221; with respect to the U.S. Holder. The redemption of our Common Stock will not be &#8220;essentially equivalent to a dividend&#8221; if a U.S. Holder&#8217;s redemption results in a &#8220;meaningful reduction&#8221; of the U.S. Holder&#8217;s proportionate interest in us. Whether the redemption will result in a meaningful reduction in a U.S. Holder&#8217;s proportionate interest will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority stockholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a &#8220;meaningful reduction.&#8221; A U.S. Holder should consult with its own tax advisors as to the tax consequences of a redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such gain or loss recognized on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption as described above, will be capital gain or loss, and will be long-term capital gain or loss if the U.S.&#160;Holder&#8217;s holding period for the Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S.&#160;Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S.&#160;Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S.&#160;Holder&#8217;s acquisition cost for such Common Stock, less any prior distributions treated as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by non-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate U.S.&#160;Holders are generally eligible for reduced rates of tax. If the U.S.&#160;Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S.&#160;Holder on the sale or exchange of our Common Stock will generally be treated as U.S.&#160;source gain or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Non-U.S.&#160;Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Taxation of Distributions</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>In general, any distributions (including constructive distributions) we make to a Non-U.S.&#160;Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S.&#160;federal income tax principles), will constitute dividends for U.S.&#160;federal income tax purposes under the same rules as described above under &#8220;<span style="font-style:italic">U.S. Holders &#8212; Taxation of Distributions</span>&#8221; and &#8220;<span style="font-style:italic">U.S. Holders &#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; and, provided such dividends are not effectively connected with the Non-U.S.&#160;Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of&#160;30%, unless such Non-U.S.&#160;Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form&#160;W-8BEN or W-8BEN-E, as applicable). Special certification and other requirements apply to certain Non-U.S.&#160;Holders that are pass-through entities rather than corporations or individuals. In the case of any constructive dividend, it is possible that this tax would be withheld from any amount owed to a Non-U.S.&#160;Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S.&#160;Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the Non-U.S.&#160;Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#8220;<span style="font-style:italic">Non-U.S.&#160;Holders &#8212; Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding corporation&#8221; (subject to the third bullet below in &#8220;<span style="font-style:italic">Non-U.S.&#160;Holders &#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below), we will withhold&#160;15% of any distribution that exceeds our current and accumulated earnings and profits.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a Non-U.S.&#160;Holder that are effectively connected with such Non-U.S.&#160;Holder&#8217;s conduct of a trade or business within the United States (or if a tax treaty applies are attributable to a U.S.&#160;permanent establishment or fixed base maintained by the Non-U.S.&#160;Holder) will generally not be subject to U.S.&#160;withholding tax, provided such Non-U.S.&#160;Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form&#160;W-8ECI). Instead, such dividends generally will be subject to U.S.&#160;federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S.&#160;Holders. If the Non-U.S.&#160;Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of&#160;30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>A Non-U.S.&#160;Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption that is treated as a sale or exchange under Section&#160;302 of the Code (determined under the same rules as described above under &#8220;<span style="font-style:italic">U.S. Holders &#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock.</span>&#8221;<span style="font-style:italic"> </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Non-U.S.&#160;Holder generally will not be subject to U.S.&#160;federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the Non-U.S.&#160;Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S.&#160;permanent establishment or fixed base maintained by the Non-U.S.&#160;Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Non-U.S.&#160;Holder is an individual who is present in the United States for&#160;183&#160;days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S.&#160;federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S.&#160;Holder held our Common Stock and, in the case where shares of our Common Stock are regularly traded on an established securities market, the Non-U.S.&#160;Holder has owned, directly or constructively, more than&#160;5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S.&#160;Holder&#8217;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S.&#160;federal income tax rates as if the Non-U.S.&#160;Holder were a U.S.&#160;resident. Any gains described in the first bullet point above of a Non-U.S.&#160;Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a&#160;30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat&#160;30% U.S.&#160;federal income tax. Non-U.S.&#160;Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a Non-U.S.&#160;Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax at generally applicable U.S.&#160;federal income tax rates. In addition, a buyer of our Common Stock from such holder may (to the extent the publicly traded exemption to such withholding does not apply) be required to withhold U.S.&#160;income tax at a rate of&#160;15% of the amount realized upon such disposition. Non-U.S.&#160;Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Account Tax Compliance Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections&#160;1471 to&#160;1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) a&#160;30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S.&#160;persons and by certain non-U.S.&#160;entities that are wholly or partially owned by U.S.&#160;persons and to withhold on certain payments, or (b)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S.&#160;authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our Common Stock is held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that is a non-financial non-U.S.&#160;entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of&#160;30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S.&#160;Department of Treasury. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">272 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding.</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of Common Stock. Backup withholding may also apply if the holder fails to provide certification of exempt status or a correct U.S. taxpayer identification number and otherwise comply with the applicable backup withholding requirements (including claims to a reduced rate of withholding under a treaty). Generally, a holder will not be subject to backup withholding if it provides a properly completed and executed IRS Form W-9 certifying no withholding is required or appropriate IRS Form W-8, as applicable. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a Non-U.S.&#160;Holder will be allowed as a credit against such holder&#8217;s U.S.&#160;federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">273 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_21">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws, the Series A Certificate of Designations, the Series 1 Certificate of Designation, and the provisions of applicable law. Copies of the Certificate of Incorporation and the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i)&#160;740,000,000 shares of Common Stock and (ii)&#160;45,000,000 shares of Preferred Stock, of which (A)&#160;29,057,097 shares have been designated as Series A Preferred Stock and (B)&#160;5,000,000 shares have been designated as Series 1 Mandatory Exchangeable Preferred Stock. As of July&#160;31, 2025, there are 6,955,697 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock issued and outstanding and no shares of Series 1 Mandatory Exchangeable Preferred Stock issued and outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of the Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by the Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is present, is decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by a plurality of the votes cast. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Right to Receive Liquidation Distributions </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Preemptive or Similar Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">274 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fully Paid and Non-Assessable </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding shares of our Common Stock are fully paid and&#160;non-assessable.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to&#160;45,000,000 shares of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders. The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our outstanding stock entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Series A Certificate of Designations, which designated 29,057,097 shares of our preferred stock as &#8220;Series A Preferred Stock&#8221;, all of which are issued and outstanding as of March&#160;31, 2025. We filed the Series 1 Certificate of Designation, which designated 5,000,000 shares of our preferred stock as Series 1 Mandatory Exchangeable Preferred Stock, none of which are issued or outstanding as of March&#160;31, 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series A Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Number and Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, 29,057,097 shares of the Series A Preferred Stock are held by SCLX JV, which shares were repurchased from Sorrento pursuant to the terms of the Sorrento SPA and represent all of the shares of Series A Preferred Stock that were previously owned by Sorrento. The shares of Series A Preferred Stock have all of the rights, preferences and privileges set forth in the Series A Certificate of Designations for such series of preferred stock as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rank </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock shall rank (i)&#160;senior to all Junior Securities; and (ii)&#160;on parity with all Parity Securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">275 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i)&#160;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&#160;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or winding-up of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conversion and Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Series A Certificate of Designations will be determined based on an as-converted-to-Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth in the Series A Certificate of Designation (a &#8220;Deemed Conversion&#8221;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&#160;stated value by (ii)&#160;$10.00 (subject to anti-dilution adjustments). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting and Other Preferred Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Series A Certificate of Designations, the holders of shares of Series A Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock (a)&#160;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms of the Series A Certificate of Designations; (b)&#160;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or winding-up of the Company, or increase the authorized amount of any such other class or series; or (c)&#160;amend the Certificate of Incorporation or the Series A Certificate of Designations in any manner that adversely affects the holders of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the November 2022 Registration Rights Agreement, certain of our stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering the resale of all such registrable securities. We have filed a registration statement on Form&#160;S-1 (File No.&#160;333-268603) which was initially declared effective by the SEC&#160;on December&#160;27, 2022, in order to satisfy these obligations. The registration of these securities will enable the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">276 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public sale of such securities, subject to certain contractual restrictions imposed by the November 2022 Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of Common Stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Matters in our Governing Documents and Under Delaware Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized but Unissued Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Impact of the Equity Repurchase Transaction on Provisions Related to a Sorrento Trigger Event </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation related to the number of authorized directors, filling vacancies on the Board, removal of directors, stockholder actions by written consent, calling of special meetings of our stockholders, our election to not be governed by Section&#160;203 of the DGCL and amendments to our Certificate of Incorporation and our Bylaws lapse upon or are triggered at the time Sorrento first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors (the &#8220;Sorrento Trigger Event&#8221;). Upon the closing of the equity repurchase transaction pursuant to the Sorrento SPA in which we purchased from Sorrento (i)&#160;1,716,245 shares of Common Stock, (ii)&#160;29,057,097 shares of Series A Preferred Stock, and (iii)&#160;warrants exercisable for 128,304 shares of Common Stock, each with an exercise price of $402.50 per whole share (the &#8220;Equity Repurchase Transaction&#8221;), a Sorrento Trigger Event occurred. The disclosures below related to the foregoing provisions are based on the occurrence of such event. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that our Board is divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class III directors shall expire at our 2025 annual meeting of stockholders (with three-year terms subsequently)), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Directors; Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be removed only for cause and only by the affirmative vote of the holders of at </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">277 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
least&#160;66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes in our management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware Anti-Takeover Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we are governed by Section&#160;203 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially owned by them. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board, our Board or the Chief Executive Officer, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Nominations and Stockholder Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">278 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#8217;s notice must be delivered to our secretary at our principal executive offices not earlier than the close of business on the&#160;120th day nor later than the close of business on the&#160;90th day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however, that, if the date of the annual meeting is advanced more than&#160;30&#160;days prior to or delayed by more than&#160;60&#160;days after the anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the&#160;120th day prior to such annual meeting and not later than the close of business on the later of the&#160;90th day prior to such annual meeting and the&#160;10th day following the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specify requirements as to the form and content of a stockholder&#8217;s notice. The Bylaws allow any previously scheduled meeting of our stockholders to be postponed, adjourned or canceled by resolution of our Board. In addition, the Bylaws allow the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Action by Written Consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;228 of the DGCL and the terms of the Certificate of Incorporation, any action required or permitted to be taken by our stockholders must be effected by a duly called annual or special meeting of such stockholders, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Certificate of Incorporation or Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the affirmative vote of the holders of at least&#160;66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article&#160;V (Board of Directors), Article&#160;VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article&#160;VII (Limitation of Liability), Article&#160;VIII (Corporate Opportunities and Competition), Article&#160;IX (Exclusive Forum), Article&#160;X (Section&#160;203 of the DGCL) and Article&#160;XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the provisions set forth in any of such Articles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that our Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. The affirmative vote of the holders of at least&#160;66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">279 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusive Forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">280 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any Covered Person and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of&#160;1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">281 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&#160;otherwise investing in or providing services to any person that is engaged in the same or similar business activities as we or our affiliates are or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section&#160;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#8217;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">SPAC Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;31, 2025, there are 6,958,204 SPAC Warrants outstanding, which are currently exercisable for an aggregate of up to 198,805 shares of Common Stock. The &#8220;SPAC Warrants&#8221; include (i)&#160;5,555,249 Public Warrants and (ii)&#160;1,402,955 Private Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase 1/35th of a share of our Common Stock at a price of $402.50 per whole share, subject to adjustment as described in the Warrant Agreement. Pursuant to the Warrant Agreement, a Public Warrant holder may exercise its Public Warrants only for a whole number of shares of Common Stock. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least 20 days&#8217; prior written notice to registered holders of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five years from the consummation of the Business Combination (i.e., November&#160;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">282 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Warrants), in whole and not in part, at a price of $0.01 per warrant: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at any time while the warrants are exercisable, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption to each warrantholder, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Common Stock equals or exceeds $630.00 per share (as adjusted for share&#160;sub-divisions,&#160;share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available throughout the&#160;30-day&#160;redemption. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon surrender of such warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&#160;the fair market value. The &#8220;fair market value&#8221; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#8220;cashless basis&#8221; will depend on a variety of factors, including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under the Warrant Agreement. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Warrants) in order to make any change that adversely affects the interests of the registered holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances, including in the event of (i)&#160;a stock dividend or split up, (ii)&#160;a consolidation, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">283 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination, reverse stock split or reclassification of the Common Stock, (iii)&#160;extraordinary dividend or (iv)&#160;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span><span style="font-weight:bold"><span style="font-style:italic">Private Warrants</span></span><span style="font-style:italic"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Warrants are identical to the Public Warrants except that such Private Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the SPAC Warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the specimen warrant certificate and the Warrant Agreement that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">284 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Penny Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the transactions contemplated by the Scilex-Oramed SPA, we issued the Penny Warrants, having an exercise price of $0.01 per share, subject to adjustment as provided therein, to Oramed. As of March&#160;31, 2025, of the 13,000,000 Penny Warrants initially issued to Oramed, warrants to purchase 6,500,000 shares of Common Stock have been exercised and warrants to purchase 6,500,000 shares of Common Stock remain outstanding, are currently exercisable and will expire on the date that is the fifth anniversary of the issuance date. The remaining Penny Warrants are subject to repurchase by us pursuant to the Option Agreement described elsewhere in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants issued to Oramed pursuant to the Scilex-Oramed SPA is $0.01 per share, subject to adjustment as provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event we combine (by combination, reverse stock split or otherwise) our Common Stock into a smaller number of shares. Accordingly, there was no adjustment made in connection with the Reverse Stock Split. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to us, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the Penny Warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the form of Penny Warrants that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">February 2024 BDO Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, we entered into the February 2024 BDO Underwriting Agreement, pursuant to which we sold, in an underwritten offering, (i)&#160;the February 2024 BDO Firm Warrants to purchase up to 108,686 shares of Common Stock, issued to certain investors, with an exercise price of $59.50 per share and (ii)&#160;the February 2024 BDO Representative Warrants to purchase up to 13,446 shares of Common Stock, issued to StockBlock and Rodman&#160;&amp; Renshaw LLC, as the representatives of the underwriters named therein, with an exercise price of $74.38 per share. As of March&#160;31, 2025, there were 122,132&#160;February 2024 BDO Warrants that remain outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the February 2024 BDO Firm Warrants are exercisable immediately from the date of issuance and expire on the five-year anniversary of the date of issuance. The exercise price of the February 2024 BDO Firm Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder (together with its affiliates) may not exercise any portion of the February 2024 BDO Firm Warrants to the extent that the holder would own more than 4.99% of the Common Stock outstanding immediately after exercise (the &#8220;February 2024 BDO Beneficial Ownership Limitation&#8221;). However, upon at least 61 days&#8217; prior notice from the holder to the Company, a holder may increase or decrease the February 2024 BDO Beneficial Ownership Limitation in accordance with the terms of the February 2024 BDO Firm Warrants, provided that it does not exceed 9.99%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The February 2024 BDO Representative Warrants are exercisable immediately from the date of issuance and have the same terms as the February 2024 BDO Firm Warrants described above, except that the exercise price of the February 2024 BDO Representative Warrants is $74.38 per share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">285 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the terms and conditions of the February 2024 BDO Warrants do not purport to be complete and are qualified in their entirety by reference to the copies of the forms of February 2024 BDO Warrants that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">April 2024 RDO Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, we entered into the April 2024 RDO Purchase Agreement, pursuant to which we sold, in a registered direct offering, (i)&#160;the April 2024 RDO Common Warrants to purchase up to 428,572 shares of Common Stock, issued to the investor, with an exercise price of $38.50 per share and (ii)&#160;the April 2024 RDO Placement Agent Warrants to purchase up to 34,286 shares of Common Stock, issued to the Placement Agents, as the exclusive placement agents in connection with the offering, with an exercise price of $43.75 per share. As of March&#160;31, 2025, all of the April 2024 RDO Warrants remain outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the six-month anniversary from the date of issuance and expire on the five-year anniversary of the date of issuance. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder (together with its affiliates) may not exercise any portion of the April 2024 RDO Common Warrants to the extent that the holder would own more than 4.99% (or, at the purchaser&#8217;s option upon issuance, 9.99%) of the Common Stock outstanding immediately after exercise (the &#8220;April 2024 RDO Beneficial Ownership Limitation&#8221;). However, upon at least 61 days&#8217; prior notice from the holder to the Company, a holder may increase or decrease the April 2024 RDO Beneficial Ownership Limitation in accordance with the terms of the April 2024 RDO Common Warrant, provided that it does not exceed 9.99%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The April 2024 RDO Placement Agent Warrants are exercisable on the six-month anniversary of the date of issuance, expire five years from the commencement of sales in the offering and are substantially in the form of the April 2024 RDO Common Warrants described above, except that the exercise price of the April 2024 RDO Placement Agent Warrants is $43.75 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the terms and conditions of the April 2024 RDO Warrants do not purport to be complete and are qualified in their entirety by reference to the copies of the forms of April 2024 RDO Warrants that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Deposit Warrant </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Commitment Letter, we issued to FSF the Deposit Warrant to purchase up to an aggregate of 3,250,000 shares of Common Stock. As of March&#160;31, 2025, the full amount of the Deposit Warrant remains outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Deposit Warrant is exercisable immediately from the date of issuance and expires on the fifth anniversary of such date. The exercise price of the Deposit Warrant is $1.20 per share, subject to adjustment as provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Deposit Warrant are subject to adjustment in the event of any stock dividend, stock split, recapitalization or similar transaction, as described in the Deposit Warrant; provided that there shall not be any adjustment to the exercise price of the Deposit Warrant in the event we combine (by combination, reverse stock split or otherwise) the Common Stock into a smaller number of shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the Deposit Warrant does not purport to be complete and is qualified in its entirety by reference to the copy of the form of Deposit Warrant that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">286 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">October 2024 Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;7, 2024, we entered into the Tranche B Securities Purchase Agreement with the Tranche B Noteholders, pursuant to which we sold, in a registered offering, (i)&#160;the October 2024 Noteholder Warrants to purchase up to 214,284 shares of Common Stock, issued to the Tranche B Noteholders, with a current exercise price of $36.40 per share and (ii)&#160;the October 2024 Placement Agent Warrants to purchase up to 104,848 shares of Common Stock, issued to the Placement Agents, with a current exercise price of $36.40 per share (together, the &#8220;October 2024 Warrants&#8221;). As of March&#160;31, 2025, there were 319,132&#160;October 2024 Warrants that remain outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are exercisable immediately from the date of issuance and expire five years from the issuance date. The exercise price of the October 2024 Noteholder Warrants is subject to adjustment for any stock split, stock dividend, stock combination, recapitalization or similar event, and is also subject to full-ratchet adjustment (down to the Exercise Price Floor) in connection with a subsequent offering at a per share price less than the exercise price then in effect. The exercise price cannot be lower than $1.04 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events, the &#8220;Exercise Price Floor&#8221;), unless shareholder approval is obtained to allow the October 2024 Noteholder Warrants to be exercised at a price lower than the Exercise Price Floor in accordance with Nasdaq listing rules. We are under no obligation to seek or obtain such shareholder approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder shall not have the right to exercise any portion of a October 2024 Noteholder Warrant to the extent that, after giving effect to such exercise, the holder (together with certain related parties) would beneficially own in excess of 4.99% (the &#8220;October 2024 Beneficial Ownership Limitation&#8221;) of shares of Common Stock outstanding immediately after giving effect to such exercise. The October 2024 Beneficial Ownership Limitation may be raised or lowered to any other percentage not in excess of 9.99%, at the option of the holder, except that any increase will only be effective upon 61 days&#8217; prior notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2024 Placement Agent Warrants have the same terms as the October 2024 Noteholder Warrants described above, except that the Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the terms and conditions of the October 2024 Warrants do not purport to be complete and are qualified in their entirety by reference to the copies of the forms of October 2024 Warrants that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A portion of the October 2024 Warrants (also referred to elsewhere in this prospectus as the &#8220;Tranche B Warrants&#8221;) were exchanged for the Exchange Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tranche B Notes </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Securities Purchase Agreement, we issued to the Tranche B Noteholders the Tranche B Notes in the aggregate principal amount of $50,000,000, which notes are convertible into shares of Common Stock. As of March&#160;31, 2025, we had Tranche B Notes in the aggregate principal amount of $36,994,298 that remain outstanding, which notes are convertible as of such date into 1,114,770 shares of Common Stock at the Conversion Price (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate principal balance of the Tranche B Notes is $50,000,000. The aggregate purchase price for the Tranche B Notes and the related warrants (described above) is $45,000,000. The Tranche B Notes have an original issue discount of 10.0%. We received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash equal to $22,500,000, excluding fees and expenses. We received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of an equivalent amount. The Tranche B Notes bear interest at a rate of 5.5%&#160;per annum, payable in arrears on the first trading day of each calendar quarter, beginning January&#160;2, 2025, payable, at our option, either in cash or in shares of Common Stock, subject to certain conditions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">287 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier converted or redeemed, the Tranche B Notes will mature on the&#160;two-year&#160;anniversary of the issuance date, subject to extension at the option of the holder in certain circumstances as provided in the Tranche B Notes. All amounts due under the Tranche B Notes are convertible at any time, in whole or in part, and subject to certain beneficial ownership limitations, at the option of the holder into shares of our Common Stock at the Conversion Price, subject to adjustment as described in the Tranche B Notes. The Tranche B Notes are our senior secured obligation (alongside and in certain circumstances described herein subordinate to, the Oramed Note) and rank senior to the right to payment of the holders of our unsecured debt, except as described herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after issuance, all amounts due under the Tranche B Notes are convertible, in whole or in part, at the holder&#8217;s option, into Common Stock at the Conversion Price, which is subject to (i)&#160;proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions; and (ii)&#160;full-ratchet adjustment (down to the Conversion Price Floor) in connection with a subsequent offering at a per share price less than the fixed conversion price then in effect. The Conversion Price cannot be lower than the Conversion Price Floor unless shareholder approval is obtained to allow the Tranche B Notes to convert at a price lower than the Conversion Floor Price in accordance with Nasdaq listing rules. We are under no obligation to seek or obtain such shareholder approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes held by an individual holder may not be converted into shares of Common Stock to the extent such conversion would result in holder (together with certain related parties of holder) would beneficially own in excess of the Maximum Percentage of shares of the Common Stock outstanding immediately after giving effect to such conversion. The Maximum Percentage with respect to a holder and certain related parties may be raised or lowered to any other percentage not in excess of 9.99%, at the option of the holder, except that any increase will only be effective upon 61 days&#8217; prior notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right (assuming no failure of certain specific conditions relating to our equity) to redeem in cash all, but not less than all, the amount then outstanding under the Tranche B Notes at a 35% redemption premium to the greater of (i)&#160;the amount then outstanding under the Tranche B Notes to be redeemed, and (ii)&#160;the equity value of Common Stock underlying such Tranche B Notes. We have a mandatory obligation to redeem the Tranche B Notes upon an event of default bankruptcy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes are subject to redemption by us at the election of a holder in certain circumstances as more fully described therein, including, among other events, a change of control of the Company, a subsequent placement of certain securities of the Company, and asset sales by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes contain affirmative and negative covenants binding on the Company and its subsidiaries which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, redeeming securities, repaying certain indebtedness or declaring or paying any cash dividend or distribution, selling or disposing of any assets or rights of the Company and its subsidiaries, entering into or being a party to any transactions with any affiliates, incurring or guaranteeing any indebtedness or permitting the acceleration of any indebtedness, in each case as more fully set forth in, and subject to certain qualifications, exceptions, and &#8220;baskets&#8221; set forth in the Oramed Note. In addition, at the request of the holder, not more frequently than once per fiscal year, we shall hire an independent, reputable investment bank to investigate whether any breach of the Tranche B Notes has occurred if an event constituting an event of default has occurred and is continuing or any holder reasonably believes that an event constituting an event of default has occurred or is continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes contain certain customary events of default, including, without limitation a cross-default to other specified indebtedness or any other indebtedness involving an obligation of $5,000,000 or more. The interest rate of the Tranche B Notes will automatically increase to the Default Rate upon the occurrence and continuance of an event of default. We are also required to pay a late charge of 15.0% on any amount of principal or other amounts that are not paid when due (solely to the extent such amounts are not then accruing interest at the Default Rate). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">288 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tranche B Notes prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our obligations under the Tranche B Notes under a written agreement approved by the required holders of the Tranche B Notes before the transaction is completed. Upon consummation of specified fundamental transactions, the successor entity must confirm that upon conversion or redemption of the Tranche B Notes thereafter, shares of the successor entity will be issuable upon such conversion or redemption. As noted above, the holders of the Tranche B Notes have certain redemption rights upon a fundamental transaction constituting a change of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any amortization, certain redemptions or other repayment of the Tranche B Notes, we shall also pay an amount equal to the amount of additional interest that would accrue under such Tranche B Notes at the interest rate then in effect assuming that the amount so converted, redeemed, amortized or otherwise repaid on such date of determination instead remained outstanding through and including the maturity date of such Tranche B Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the terms and conditions of the Tranche B Notes do not purport to be complete and are qualified in their entirety by reference to the copies of the forms of Tranche B Notes that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exchange Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;22, 2025 we entered into Warrant Exchange Agreements with the Exchange Warrant Holders pursuant to which each of the Exchange Warrant Holders surrenders its October 2024 Noteholder Warrants in exchange for the Exchange Warrants. An aggregate of 500,000 shares of Common Stock may be issued upon exercise of the Exchange Warrants, with a current exercise price of $40.00 per share. The Exchange Warrants expire on the fifth anniversary of the issuance date of the October 2024 Noteholder Warrants. The exercise price of the Exchange Warrants is subject to adjustment for any stock split, stock dividend, stock combination, recapitalization or similar event, and is also subject to full-ratchet adjustment (down to the exercise price floor) in connection with a subsequent offering at a per share price less than the exercise price then in effect. The exercise price floor is $36.40, and may be adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events, unless shareholder approval is obtained to allow the Exchange Warrants to be exercised at a price that is lower than $36.40 in accordance with Nasdaq Listing Rules. The Company is under no obligation to seek or obtain such shareholder approval. The Exchange Warrants also provide for a voluntary adjustment to the exercise price, subject to certain conditions set forth therein, including compliance with Nasdaq rules and having obtained the prior written consent of the Required Holders (as defined in the Tranche B Securities Purchase Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Warrants have the same terms as the October 2024 Noteholder Warrants described above, except that the exercise price is $40.00 per share and the exercise price floor is $36.40 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the Exchange Warrants do not purport to be complete and are qualified in their entirety by reference to the copy of the form of Exchange Warrant that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December 2024 Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, we entered into the December 2024 RDO Purchase Agreement, pursuant to which we sold, in a registered direct offering, (i)&#160;an aggregate of 753,009 shares of Common Stock, (ii)&#160;the December 2024 RDO Pre-Funded Warrants to purchase up to 68,604 shares of Common Stock, with an exercise price of $22.72 per share, (iii)&#160;the December 2024 RDO Common Warrants to purchase up to 1,642,871 shares of Common Stock, issued to the investors, with an exercise price of $22.72 per share, and (iv)&#160;the StockBlock Warrants to purchase up to 131,472 shares of Common Stock, issued to StockBlock, with an exercise price of $25.81 per share (together with the December 2024 RDO Common Warrants, the &#8220;December 2024 Warrants&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">289 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, there were 1,774,343&#160;December 2024 Warrants that remain outstanding. All of the December 2024 RDO Pre-Funded Warrants have been exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December 2024 RDO Common Warrants, subject to certain ownership limitations, become exercisable on the six month anniversary of the date of issuance and one half of the December 2024 RDO Common Warrants have a term that expires five years from the date of issuance and the remaining&#160;one-half&#160;of such December 2024 RDO Common Warrants have a term that expires two and&#160;one-half&#160;years from the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The StockBlock Warrants are exercisable on the six-month anniversary of the date of issuance and one half of the StockBlock Warrants have a term that expires five years from the commencement of sales in the offering and the remaining&#160;one-half&#160;of such StockBlock Warrants have a term that expires on the date that is two and&#160;one-half&#160;years from the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the December 2024 Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. A holder (together with its affiliates) may not exercise any portion of the December 2024 Warrants to the extent that the holder would own more than 4.99% (or, at the holder&#8217;s option upon issuance, 9.99%) of the outstanding shares of Common Stock immediately after exercise (the &#8220;December 2024 RDO Beneficial Ownership Limitation&#8221;). However, upon at least 61 days&#8217; prior notice from the holder to the Company, a holder may increase or decrease the December 2024 RDO Beneficial Ownership Limitation in accordance with the terms of the December 2024 RDO Warrant, provided that it does not exceed 9.99%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the terms and conditions of the December 2024 Warrants do not purport to be complete and are qualified in their entirety by reference to the copies of the forms of December 2024 Warrants that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#8217;s address is&#160;1 State Street, 30th Floor, New York, New York 10004. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW&#8221;, respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">290 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_22">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_23">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company as of December&#160;31, 2024 and December&#160;31, 2023, and for each of the two years in the period ended December&#160;31, 2024, appearing in this prospectus, have been audited by BPM LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note&#160;2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_24">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span>We have filed a registration statement on Form&#160;S-1, including exhibits, under the Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement of which this prospectus is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those documents&#8217; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov</span>.<span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">291 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden145657738" contextRef="PAsOn12_31_2024">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden145657739" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden145657740" contextRef="PAsOn03_31_2025">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden145657741" contextRef="PAsOn12_31_2024">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="hidden145659148" contextRef="PAsOn03_31_2025">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="hidden145659460" contextRef="PAsOn12_31_2024">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20250801.xsd"/></ix:references></ix:header></div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx942297_25"><div style="display:inline;"></div>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Audited Consolidated Financial Statements as of December&#160;31, 2024 and 2023 and for each of the two years in the period ended December&#160;31, 2024 </div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 96%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_1">Report of Independent Registered Public Accounting Firm (PCAOB ID: 207)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_2">Consolidated Balance Sheets as of December&#160;31, 2024 and 2023</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_3">Consolidated Statements of Operations and Comprehensive Loss for the Years ended December&#160;31, 2024 and 2023</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_4">Consolidated Statements of Stockholders&#8217; Equity / (Deficit) for the Years ended December&#160;31, 2024 and 2023</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_5">Consolidated Statements of Cash Flows for the Years ended December&#160;31, 2024 and 2023</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_6">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">F-8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unaudited Interim Consolidated Financial Statements as of March&#160;31, 2025 and for the Three Months Ended March&#160;31, 2025 and 2024. </div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_10">Financial Statements (Unaudited) </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_11">Condensed Consolidated Balance Sheets as of December&#160;31 2024 and March&#160;31, 2025 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_12">Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2024 and 2025</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_13">Condensed Consolidated Statements of Stockholders&#8217; Deficit</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-60</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_14">Condensed Consolidated Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2025</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-61</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin942297_15">Notes to Unaudited Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-62</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin942297_1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the Board of Directors and stockholders of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Scilex Holding Company </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial <div style="display:inline;">Statements</div> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of Scilex Holding Company and Subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity/(deficit), and cash flows for each of the two years in the period ended December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024 and 2023, and the results of their operations and cash flows for each of the two years in the period ended December&#160;31, 2024, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These consolidated financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ BPM LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Walnut Creek, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;31, 2025 (August&#160;4, 2025 as to the last paragraph of Note&#160;14, Subsequent Events) </div><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-weight:bolder;display:inline;"><a href="#toc"><br/></a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SCILEX HOLDING COMPANY </div></div></div><div id="fin942297_2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except for par value and share amounts) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 77%;">&#160;</td>
<td style="width: 5%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 5%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ASSETS</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44216">3,272</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44217">3,921</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivable, net</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44218">26,442</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44219">34,597</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Inventory</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44220">2,436</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44221">4,214</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44222">9,397</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44223">4,049</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44224">41,547</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44225">46,781</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44226">708</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44227">722</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> asset</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44228">2,225</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44229">2,943</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangibles, net</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44230">32,453</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44231">36,485</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Investments" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44232">2,420</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Investments" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44233">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44234">13,481</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44235">13,481</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other long-term assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44236">119</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44237">897</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44238">92,953</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44239">101,309</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44240">52,620</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44241">40,954</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued payroll</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44242">1,505</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44243">2,681</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued rebates and fees</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44244">162,517</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44245">89,658</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44246">2,841</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44247">7,408</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current portion of deferred consideration</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44248">447</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44249">491</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Debt, current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44250">34,876</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44251">108,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchased revenue liability, current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44252">4,115</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44253">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current portion of operating lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44254">714</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44255">759</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44256">259,635</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44257">250,380</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Long-term portion of deferred consideration</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44258">2,448</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44259">2,895</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Debt, net of issuance costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44260">845</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44261">17,038</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchased revenue liability, net of current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44262">2,685</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44263">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Derivative liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44264">18,303</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44265">1,518</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liabilities, net of current portion</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44266">1,523</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44267">2,237</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other long-term liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44268">155</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44269">179</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44270">285,594</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44271">274,247</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (See Note 11)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-44272"></ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-44273"></ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; deficit:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44274"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44275">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44276"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44277">45,000,000</ix:nonFraction></ix:nonFraction> shares authorized</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series A, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44278"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44279"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44280"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44281">29,057,097</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of each of December&#160;31, 2024 and December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44282">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44283">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series 1, <ix:nonFraction name="sclx:PreferredStockDividendShares" contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44284">5,000,000</ix:nonFraction> shares declared as a stock dividend, not yet distributed as of December&#160;31, 2024; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-44285"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-44286"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-44287">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding as of December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44288">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44289">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44290"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44291">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44292"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44293">740,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="sclx:CommonStocksSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44294">6,951,622</ix:nonFraction> shares issued and <ix:nonFraction name="sclx:CommonStocksSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44295">5,493,359</ix:nonFraction> shares outstanding as of December&#160;31, 2024; <ix:nonFraction name="sclx:CommonStocksSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44296">4,573,693</ix:nonFraction> shares issued and <ix:nonFraction name="sclx:CommonStocksSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44297">2,857,448</ix:nonFraction>&#160;shares outstanding as of December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44298">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44299">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AdditionalPaidsInCapitals" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44300">454,614</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AdditionalPaidsInCapitals" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44301">407,828</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated other comprehensive income</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44302">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44303">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44304">563,052</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44305">490,245</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury stock, at cost; <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44306"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44307">1,716,245</ix:nonFraction></ix:nonFraction> shares as of each of December&#160;31, 2024 and December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44308">90,522</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44309">90,522</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; deficit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44310">192,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44311">172,938</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44312">92,953</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44313">101,309</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See accompanying notes to audited consolidated financial statements </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-3 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SCILEX HOLDING COMPANY </div></div></div> <div id="fin942297_3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except for net loss per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 81%;">&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net revenue</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44314">56,590</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44315">46,743</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating costs and expenses:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cost of revenue</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44316">16,689</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44317">15,681</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44318">9,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44319">12,746</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Selling, general and administrative</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44320">119,016</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44321">119,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible amortization</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44322">4,031</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44323">4,106</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Legal settlements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44324">9,391</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44325">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total net operating costs and expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44326">139,986</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44327">152,174</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44328">83,396</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44329">105,431</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other (income) expense, net:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Gain) loss on derivative liability</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44330">17,378</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44331">512</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of debt and liability instruments</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44332">4,782</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44333">7,189</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest expense, net</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44334">1,963</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44335">1,068</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on foreign currency exchange</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44336">45</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44337">118</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other (income) expense, net</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44338">10,588</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44339">8,887</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss before income taxes</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44340">72,808</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44341">114,318</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax (benefit) expense</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44342">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44343">13</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44344"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44345"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44346">72,807</ix:nonFraction></ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44347"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44348"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44349">114,331</ix:nonFraction></ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share attributable to common stockholders &#8212; basic</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-44350">7.24</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-44351">44.86</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share attributable to common stockholders &#8212; diluted</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-44352">8.05</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-44353">44.86</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average number of shares during the period &#8212; basic</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44354">10,061</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44355">3,722</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average number of shares during the period &#8212; diluted</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44356">10,145</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44357">3,722</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44358"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44359"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44360">72,807</ix:nonFraction></ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44361"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44362"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44363">114,331</ix:nonFraction></ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other comprehensive income:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in fair value attributable to instrument-specific credit risk</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44364">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44365">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44366">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44367">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44368">66,490</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44369">114,331</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See accompanying notes to audited consolidated financial statements </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">SCILEX HOLDING COMPANY </div></div></div> <div id="fin942297_4" style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY / (DEFICIT) </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 43%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Preferred Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div><br/> Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated<br/> Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Comprehensive<br/> Income</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Treasury Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Equity<br/> (Deficit)</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance, December&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44370">29,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44371">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44372">4,038</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44373">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44374">412,149</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44375">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44376">375,914</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:fixed-zero" id="ixv-44377">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44378">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44379">36,239</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under the Standby Equity Purchase Agreements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44380">379</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44381">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44382">34,258</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44383">34,258</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Disbursement of funds to Sorrento</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:DisbursementOfFundsToSorrentoAmount" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44384">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:DisbursementOfFundsToSorrentoAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44385">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Repurchase of Treasury Stock, Preferred Stock, and warrants</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44386">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44387">53,196</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" contextRef="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44388">1,716</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44389">90,522</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44390">143,721</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Penny Warrants</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfPennyWarrants" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44391">10,401</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfPennyWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44392">10,401</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock in connection with Settlement Agreement</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44393">14</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44394">750</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44395">750</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Convertible Debentures into common stock</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44396">18</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44397">7,735</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44398">7,735</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Retainer shares issued</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssued" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44399">114</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44400">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44401">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock upon warrants exercise</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44402">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44403">521</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44404">521</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options exercised</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44405">10</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44406">614</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44407">614</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44408">14,596</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44409">14,596</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44410">114,331</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44411">114,331</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance, December&#160;31, 2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44412">29,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44413">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44414">4,574</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44415">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44416">407,828</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44417">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44418">490,245</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44419">1,716</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44420">90,522</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44421">172,938</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under the Standby Equity Purchase Agreements and under the ATM Sales Agreement</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44422">81</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44423">2,671</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44424">2,671</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under the February 2024 BDO</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingShare" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44425">168</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingValue" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44426">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44427">3,769</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44428">3,769</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under the April 2024 RDO</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedDuringPeriodSharesRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44429">429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44430">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44431">5,919</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44432">5,919</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">April 2024 RDO Placement Agent Warrants and February 2024 BDO Representative Warrants</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44433">956</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44434">956</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Retainer shares issued</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssued" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44435">286</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44436">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44437">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Fee Warrant issued in connection with the Commitment Letter</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44438">310</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44439">310</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Repurchase of warrants</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:RepurchaseOfWarrants" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44440">298</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:RepurchaseOfWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44441">298</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock issuable under the SIPA</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44442">345</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44443">345</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Placement Agent Shares and October 2024 Placement Agent Warrants</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44444">63</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44445">3,792</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44446">3,792</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Tranche B Notes into common stock</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStockShares" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44447">263</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStock" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44448">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStock" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44449">9,256</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44450">9,256</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under December 2024 RDO</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderDecemberRegisteredDirectOfferingShares" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44451">753</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44452">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44453">328</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:SharesIssuedUnderDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44454">328</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">StockBlock Warrants issued in connection with the December 2024 RDO</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44455">1,265</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44456">1,265</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock dividend declared, not yet distributed</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:StockDividendDeclaredNotYetDistributedShares" contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44457">5,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:StockDividendDeclaredNotYetDistributed" contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44458">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="sclx:StockDividendDeclaredNotYetDistributed" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44459">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock upon warrants exercise</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseShares" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44460">321</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44461">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44462">2,311</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44463">2,311</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issued under ESPP</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44464">10</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44465">246</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44466">246</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options exercised</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44467">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44468">227</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44469">227</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44470">15,690</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44471">15,690</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Other comprehensive income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44472">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44473">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44474">72,807</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44475">72,807</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance, December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44476">34,057</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44477">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-44478">6,952</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44479">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44480">454,614</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44481">6,317</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44482">563,052</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44483">1,716</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44484">90,522</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44485">192,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See accompanying notes to audited consolidated financial statements </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-5 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SCILEX HOLDING COMPANY </div></div></div><div id="fin942297_5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 81%;">&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44486">72,807</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44487">114,331</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash proceeds from (used for) operating activities:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation and amortization</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44488">4,046</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44489">4,146</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization of debt issuance costs and debt discount</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44490">316</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44491">65</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> operating lease cost</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44492">718</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44493">507</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44494">15,689</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44495">14,596</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of shares under Settlement Agreement</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44496">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44497">750</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Gain) loss on derivative liability</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44498">17,378</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44499">512</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Allocated expense for financial instruments at fair value</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44500">17,297</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44501">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of debt and liability instruments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44502">4,782</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44503">7,189</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Allowances for expected credit losses</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AllowancesForCreditLosses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44504">1,186</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:AllowancesForCreditLosses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44505">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44506">661</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44507">57</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in operating assets and liabilities:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivables, net</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44508">6,267</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44509">13,361</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Inventory</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44510">1,462</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44511">2,838</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44512">479</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44513">441</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other long-term assets</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44514">30</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44515">855</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44516">7,419</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44517">19,880</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued payroll</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44518">1,176</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44519">1,327</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44520">8,167</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44521">2,310</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued rebates and fees</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44522">72,859</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44523">58,765</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liability</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44524">758</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44525">711</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other long-term liabilities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44526">24</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44527">16</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash proceeds from (used for) operating activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44528">19,349</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44529">20,707</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investing activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Acquisition consideration paid in cash for Romeg intangible asset acquisition</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44530">600</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44531">300</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of equity securities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:PurchaseOfEquitySecurities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44532">2,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchaseOfEquitySecurities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44533">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of convertible promissory note from Denali</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:PurchaseOfConvertiblePromissoryNote" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44534">75</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PurchaseOfConvertiblePromissoryNote" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44535">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of property and equipment</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44536">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44537">30</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used for investing activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44538">2,675</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44539">330</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financing activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44540">2,671</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44541">35,458</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of Convertible Debentures</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44542">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44543">24,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of Revolving Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44544">95,438</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44545">86,354</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of FSF Deposit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfFsfDeposit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44546">10,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfFsfDeposit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44547">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of Tranche B Notes and purchased revenue liability</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44548">25,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44549">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Repayment of Revolving Facility</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44550">112,791</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44551">69,001</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Repayment of Oramed Note</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44552">64,200</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44553">5,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash consideration paid in connection with warrant repurchase</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44554">300</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44555">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Transaction costs paid related to the Business Combination</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44556">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44557">1,372</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Repayment of Convertible Debentures</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44558">4,375</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44559">15,625</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Repayment of Tranche B Notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:RepaymentOfDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44560">3,283</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:RepaymentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44561">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-6 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 83%;">&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 2%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Payments of debt issuance costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44562">4,172</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44563">380</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Disbursement of funds to Sorrento</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:DisbursementOfFunds" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44564">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:DisbursementOfFunds" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44565">20,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash consideration paid in connection with share repurchase</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44566">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44567">10,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Transaction costs paid in connection with share repurchase</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44568">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44569">1,987</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Excise tax paid in connection with share repurchase</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:ExciseTaxPaidInConnectionWithShareRepurchase" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44570">450</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ExciseTaxPaidInConnectionWithShareRepurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44571">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of shares under direct offerings</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44572">41,967</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44573">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Payments of direct offering issuance costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44574">4,370</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44575">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Payments of deferred transaction costs related to Semnur Business Combination</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44576">1,379</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44577">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from stock options and warrants exercised and ESPP</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44578">2,113</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44579">1,135</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash (used for) proceeds from financing activities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44580">18,131</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44581">23,582</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44582">1,457</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44583">2,545</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44584">4,729</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44585">2,184</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44586">3,272</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44587">4,729</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Supplemental disclosure:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash paid for interest</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOperatingPaidInCash" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44588">1,561</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOperatingPaidInCash" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44589">1,426</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> investing and financing activities</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44590">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44591">1,869</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance costs related to direct offerings included in accrued expenses and account payables</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44592">1,845</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44593">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fee Warrants issued and exercised in connection with the Commitment Letter</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44594">610</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44595">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Settlement of FSF Deposit</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:SettlementOfFSFDeposit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44596">13,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:SettlementOfFSFDeposit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44597">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred transaction costs related to Semnur Business Combination included in accrued expenses and account payable</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44598">4,602</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44599">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Oramed Note into Tranche B Notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfOramedNoteIntoTrancheBNotes" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44600">25,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfOramedNoteIntoTrancheBNotes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44601">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Tranche B Notes into common stock</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44602">9,256</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfTrancheBNotesIntoCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44603">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Debt issuance costs included in accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:DebtIssuanceCostsIncludedInAccruedExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44604">3,063</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:DebtIssuanceCostsIncludedInAccruedExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44605">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Placement Agent Shares and October 2024 Placement Agent Warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44606">3,792</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44607">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">StockBlock Warrants issued in connection with the December 2024 RDO</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44608">1,265</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44609">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Convertible Debentures into common stock</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44610">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44611">7,735</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease liabilities with lease modification</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44612">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44613">2,523</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Oramed Note issuance at fair value</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:OramedNoteIssuanceAtFairValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44614">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:OramedNoteIssuanceAtFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44615">106,252</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> consideration in connection with share repurchase</div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44616">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44617">26,154</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Excise tax in connection with share repurchase included in accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44618">860</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44619">1,310</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See accompanying notes to audited consolidated financial statements </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-7 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">SCILEX HOLDING COMPANY </div></div></div> <div id="fin942297_6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657357" id="ixv-24090"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">1. Nature of Operations and Basis of Presentation </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12-hour</div> administration period. In June 2022, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;) in the third quarter of 2023, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. Since inception, the Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and the commercialization of ZTlido. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Chapter 11 Filing </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, and Sorrento&#8217;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#8220;Scintilla&#8221; and together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Debtors&#8217; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">23-90085</div> (DRJ) (the &#8220;Chapter 11 Cases&#8221;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. Pursuant to that certain Stock Purchase Agreement that the Company entered into with Sorrento on September&#160;21, 2023 (the &#8220;Sorrento SPA&#8221;), the Company repurchased shares of its Common Stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-44620">0.0001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), and Series A Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-44621">0.0001</ix:nonFraction> per share (the &#8220;Series A Preferred Stock&#8221;), from Sorrento. As a result, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. As of December&#160;31, 2024, the Company had a $<ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44622">3.2</ix:nonFraction>&#160;million receivable from Sorrento, which was fully reserved. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657357" continuedAt="TextSelectionAppend_145657357_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_1" continuedAt="TextSelectionAppend_145657357_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_2" continuedAt="TextSelectionAppend_145657357_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_3" continuedAt="TextSelectionAppend_145657357_4"><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24139"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24146"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the consolidated statements of operations and comprehensive loss. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the consolidated statements of operations and comprehensive loss and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the consolidated balance sheets. Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24153"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24159"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the years ended December&#160;31, 2024 and 2023, each of which individually generated <ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-44624"><ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-44625">10</ix:nonFraction></ix:nonFraction>% or more of the Company&#8217;s total revenue. These customers accounted for <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44626">86</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44627">85</ix:nonFraction>% of the Company&#8217;s revenue for the years ended December&#160;31, 2024 and 2023, respectively, individually ranging from <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44628">23</ix:nonFraction>% to <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44629">34</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44630">22</ix:nonFraction>% to <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44631">32</ix:nonFraction>%, respectively. As of December&#160;31, 2024 and 2023, three customers represented <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44632">95</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44633">91</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44634">30</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44635">33</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44636">24</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44637">36</ix:nonFraction>% for respective periods. Additionally, during the years ended December&#160;31, 2024 and 2023, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). In November 2023 and February 2024, respectively, the Company started purchasing ELYXYB and GLOPERBA inventories from its sole suppliers, Contract Pharmaceuticals Ltd Canada (CPL) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers and limits its credit exposure by setting credit limits. During the years ended December&#160;31, 2024 and 2023, the Company had allowances for expected credit losses of $<ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44638">1.2</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-44639">nil</ix:nonFraction>, respectively. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657357_4" continuedAt="TextSelectionAppend_145657357_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_5" continuedAt="TextSelectionAppend_145657357_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_6" continuedAt="TextSelectionAppend_145657357_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_7" continuedAt="TextSelectionAppend_145657357_8"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24184"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, FSF Deposit and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 1</div></div> - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 2</div></div> - Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 3</div></div> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24204"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consisted of deposits placed in a segregated bank account as required under the terms of the eCapital Credit Agreement (as defined below), which is discussed further in Note 7. Restricted cash was recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. There is no restricted cash as of December&#160;31, 2024, because Scilex Pharma paid off the outstanding amount of all obligations and indebtedness under the eCapital Credit Agreement in October 2024, which agreement was terminated thereafter. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents were immaterial as of December&#160;31, 2024 and 2023. </div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24212"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44641">3,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44642">3,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44643">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44644">808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44645">3,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44646">4,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657357_8" continuedAt="TextSelectionAppend_145657357_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_9" continuedAt="TextSelectionAppend_145657357_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_10" continuedAt="TextSelectionAppend_145657357_11"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_11" continuedAt="TextSelectionAppend_145657357_12"><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24317"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of December&#160;31, 2024, the Company recorded $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44648">1.2</ix:nonFraction>&#160;million of allowances for credit losses on its accounts receivable. As of December&#160;31, 2023, the Company did <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-44649">no</ix:nonFraction>t deem any allowances for expected credit losses on its accounts receivable necessary. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24323"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2024 and 2023, the Company&#8217;s inventory was primarily comprised of finished goods. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24333"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657402" id="ixv-24339"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations and comprehensive loss unless there is an alternative future use. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div></ix:nonNumeric></ix:continuation> </div> </div> <ix:continuation id="TextSelection_145657402" continuedAt="TextSelectionAppend_145657402_1"><ix:continuation id="TextSelectionAppend_145657357_12" continuedAt="TextSelectionAppend_145657357_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_13" continuedAt="TextSelectionAppend_145657357_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_14" continuedAt="TextSelectionAppend_145657357_15"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_15" continuedAt="TextSelectionAppend_145657357_16"><ix:continuation id="TextSelectionAppend_145657402_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></ix:continuation><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24370"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ContingentLiabilityReserveEstimatePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24377"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statements of operations and comprehensive loss. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging</div></div>, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div></ix:nonNumeric><ix:nonNumeric name="sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657405" id="ixv-24384"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contracts on an Entity&#8217;s Own Equity,</div></div> the Company determines how to account for warrants either assumed in connection with the Business Combination or issued under various financing arrangements. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. The Company records them in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. Warrants accounted for as liabilities are recorded at their estimated fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_145657405" continuedAt="TextSelectionAppend_145657405_1"><ix:continuation id="TextSelectionAppend_145657357_16" continuedAt="TextSelectionAppend_145657357_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_17" continuedAt="TextSelectionAppend_145657357_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_18" continuedAt="TextSelectionAppend_145657357_19"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_19" continuedAt="TextSelectionAppend_145657357_20"><ix:continuation id="TextSelectionAppend_145657405_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized in the consolidated statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </div></ix:continuation><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24412"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div></ix:nonNumeric><ix:nonNumeric name="sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24417"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Debentures, the Oramed Note, FSF Deposit and Tranche B Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures, the FSF Deposit, the Tranche B Notes (each as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below) that were issued in March and April 2023, June 2024, October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. The weighted-average interest rates for the short-term loans, including these financial instruments, were <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44652">6.67</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44653">13.55</ix:nonFraction>% for the years ended December&#160;31, 2024 and 2023, respectively. </div></ix:nonNumeric><ix:nonNumeric name="sclx:PurchasedRevenueLiabilityPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24426"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Purchased Revenue Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchased revenue liability is associated with the Purchase and Sale Agreement (the &#8220;ZTlido Royalty Purchase Agreement&#8221;) that the Company entered into in October 2024 (Note 7). The Company elected the fair value option to account for the purchased revenue liability (as described in Note 4 &#8220;Fair Value Measurements&#8221; below). The Company recorded the ZTlido Royalty Purchase Agreement at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the purchased revenue liability were expensed as incurred. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24431"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24436"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Research and Development</div></div>. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_145657357_20" continuedAt="TextSelectionAppend_145657357_21"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_145657357_21" continuedAt="TextSelectionAppend_145657357_22"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></div></div></ix:continuation></div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657357_22" continuedAt="TextSelectionAppend_145657357_23"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24463"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2024 and 2023, the Company maintained a full valuation allowance against its deferred tax assets. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24474"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657414" id="ixv-24482"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido, ELYXYB and GLOPERBA. The Company&#8217;s performance obligation with respect to sales of ZTlido, ELYXYB and GLOPERBA is satisfied at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">point-in-time,</div></div> when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2024 and 2023 were not material. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns, special marketing programs and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:nonNumeric></ix:continuation> </div> </div> <ix:continuation id="TextSelection_145657414" continuedAt="TextSelectionAppend_145657414_1"><ix:continuation id="TextSelectionAppend_145657357_23" continuedAt="TextSelectionAppend_145657357_24"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_24" continuedAt="TextSelectionAppend_145657357_25"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_25" continuedAt="TextSelectionAppend_145657357_26"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657357_26" continuedAt="TextSelectionAppend_145657357_27"><ix:continuation id="TextSelectionAppend_145657414_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Payment</div> Assistance </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-payment</div> assistance is presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> </ix:continuation><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657415" id="ixv-24535"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, <div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#160;&#8211; Stock<div style="display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation</div></div><div style="font-size: 10pt;display:inline;">, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee&#8217;s</div><div style="font-size: 10pt;display:inline;"> vesting period. The Company accounts for forfeitures as incurred.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:nonNumeric></ix:continuation> </div> </div> <ix:continuation id="TextSelection_145657415" continuedAt="TextSelectionAppend_145657415_1"><ix:continuation id="TextSelectionAppend_145657357_27" continuedAt="TextSelectionAppend_145657357_28"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_28" continuedAt="TextSelectionAppend_145657357_29"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_29" continuedAt="TextSelectionAppend_145657357_30"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents<br/></a></div></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657357_30" continuedAt="TextSelectionAppend_145657357_31"><ix:continuation id="TextSelectionAppend_145657415_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. </div> </ix:continuation><ix:nonNumeric name="sclx:TreasuryStockPolicyTextblock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24574"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24580"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method required for participating securities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants, which consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share to the extent all vesting conditions or exercise contingencies are removed except for the passage of time. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657419" id="ixv-24592"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Improvements to Reportable Segment Disclosures</div></div> (Topic 280), which requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted this ASU retrospectively on December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44657">5</ix:nonFraction>% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div>, which will require additional expense disclosures for all public entities. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:nonNumeric></ix:continuation> </div> </div> <ix:continuation id="TextSelection_145657419" continuedAt="TextSelectionAppend_145657419_1"><ix:continuation id="TextSelectionAppend_145657357_31" continuedAt="TextSelectionAppend_145657357_32"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657357_32" continuedAt="TextSelectionAppend_145657357_33"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657357_33" continuedAt="TextSelectionAppend_145657357_34"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657357_34"><ix:continuation id="TextSelectionAppend_145657419_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8212;Debt with Conversion and Other Options</div></div>, which clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> </ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657359" id="ixv-24635"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">2. Liquidity and Going Concern </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44659">500.0</ix:nonFraction>&#160;million of shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-44660">0.0001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#8217;s and B. Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44661">7,142</ix:nonFraction> commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B. Riley (the &#8220;B. Riley Commitment Shares&#8221;). On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of up to $<ix:nonFraction name="sclx:Convertibledebentureprincipalamount" contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44662">25.0</ix:nonFraction>&#160;million (the &#8220;Convertible Debentures&#8221;) for net cash proceeds of $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2024_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44663">24.0</ix:nonFraction>&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender made available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $<ix:nonFraction name="sclx:PrincipalLaonAmount" contextRef="P06_27_2023To06_27_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44664">30.0</ix:nonFraction>&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657359" continuedAt="TextSelectionAppend_145657359_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657359_1" continuedAt="TextSelectionAppend_145657359_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657359_2" continuedAt="TextSelectionAppend_145657359_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657359_3" continuedAt="TextSelectionAppend_145657359_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">ATM Offering</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#8221;) shares of Common Stock up to $</div><ix:nonFraction name="sclx:CommonStockIssuableValue" contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44666">170.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the </div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">ATM Offering</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. As of December&#160;31, 2024, the Company sold </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44667">78,975</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $</div><ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44668">2.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. As of December&#160;31, 2023, </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-44669">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> sales of Common Stock had been made under the ATM Sales Agreement.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#8220;Commitment Letter&#8221;) with FSF 33433 LLC (&#8220;FSF Lender&#8221;), pursuant to which FSF Lender committed to provide the Company a loan (the &#8220;FSF Loan&#8221;) in the aggregate amount of $<ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44670">100.0</ix:nonFraction>&#160;million (the &#8220;Commitment Amount&#8221;). The Commitment Amount shall be payable as follows: (i) $<ix:nonFraction name="sclx:CommitmentAmountPayable" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44671">85.0</ix:nonFraction>&#160;million no later than the date that is <ix:nonNumeric name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="P06_11_2024To06_11_2024" format="ixt-sec:durday" id="ixv-44672">70</ix:nonNumeric> days following the date on which the Company receives the FSF Deposit (as defined below) (the &#8220;Outside Date&#8221; and the funding of the initial $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44673">85.0</ix:nonFraction>&#160;million, the &#8220;Initial Closing&#8221;) and (ii)&#160;the remaining $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44674">15.0</ix:nonFraction>&#160;million within <ix:nonNumeric name="sclx:CompanyReceivesTheDepositPeriod" contextRef="P06_11_2024To06_11_2024" format="ixt-sec:durday" id="ixv-44675">60</ix:nonNumeric> days following the Initial Closing (the funding of the second $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44676">15.0</ix:nonFraction>&#160;million, the &#8220;Second Closing&#8221;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> deposit in immediately available funds in the aggregate principal amount of $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44677">10.0</ix:nonFraction>&#160;million (the &#8220;FSF Deposit&#8221; and the date on which such funds are fully received, the &#8220;Deposit Date&#8221;), which amount will be creditable towards the $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44678">85.0</ix:nonFraction>&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_18_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44679">3,250,000</ix:nonFraction> shares of the Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) (the &#8220;Deposit Warrant&#8221;), with an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfTheWarrants" contextRef="PAsOn06_18_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44680">1.20</ix:nonFraction> per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#8220;Satisfaction Agreement&#8221;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#8220;Endeavor&#8221;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#8220;Additional Product&#8221;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44681">13.2</ix:nonFraction>&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $<ix:nonFraction name="us-gaap:LossContingencyAccrualProductLiabilityGross" contextRef="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44682">20,000,000</ix:nonFraction>. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#8220;Tranche B Securities Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) (together with the Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44683">50.0</ix:nonFraction>&#160;million (the &#8220;Tranche B Notes&#8221;) which notes will mature on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis_TrancheBNotesMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44684">38.15</ix:nonFraction> per share (which was </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657359_4" continuedAt="TextSelectionAppend_145657359_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657359_5" continuedAt="TextSelectionAppend_145657359_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657359_6" continuedAt="TextSelectionAppend_145657359_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657359_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">automatically reduced to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44686">36.40</ix:nonFraction> per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes). The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44687">22,500,000</ix:nonFraction>, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $<ix:nonFraction name="sclx:ReductionOfThePrincipalBalance" contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44688">22,500,000</ix:nonFraction>. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company&#8217;s negative working capital was $<ix:nonFraction name="sclx:WorkingCapital" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44689">218.1</ix:nonFraction>&#160;million, including cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44690">3.3</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2024, the Company had operating losses of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-44691">83.4</ix:nonFraction>&#160;million and cash flows from operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44692">19.3</ix:nonFraction>&#160;million. The Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-44693">563.1</ix:nonFraction>&#160;million as of December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the Tranche B Notes or otherwise) for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA is still in the early stages of commercialization. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. </div> </ix:continuation><ix:nonNumeric name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657361" id="ixv-24698"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">3. Acquisitions and License Agreements </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Acquisition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $<ix:nonFraction name="sclx:AmountDueForNewDrugApplication" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44694">3.0</ix:nonFraction>&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44695">20.0</ix:nonFraction>&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2024 and December&#160;31, 2023, the contingent consideration associated with the Development Milestone Payment was $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44696"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44697">0.2</ix:nonFraction></ix:nonFraction>&#160;million, recorded in the other long-term liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA License Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022 (the &#8220;Original Signing Date&#8221;), the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) (&#8220;Romeg&#8221;) for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensing</div> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#8220;Romeg License Agreement&#8221;). Under the Romeg License Agreement, </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657361" continuedAt="TextSelectionAppend_145657361_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657361_1" continuedAt="TextSelectionAppend_145657361_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657361_2" continuedAt="TextSelectionAppend_145657361_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents<br/></a></div></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657361_3" continuedAt="TextSelectionAppend_145657361_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> specified therein to (a)&#160;commercialize a pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2)&#160;an exclusive license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory and (b)&#160;to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44699">2.0</ix:nonFraction>&#160;million, (2)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44700">13.0</ix:nonFraction>&#160;million, (3)&#160;certain royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44701">150,000</ix:nonFraction>, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-single</div> digit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory during the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory Royalty Term and (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> payment of $<ix:nonFraction name="sclx:Non-RefundableNon-CreditablePayment" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44702">700,000</ix:nonFraction>. Pursuant to the amendment agreement, we also transferred to Romeg <ix:nonFraction name="sclx:TransferOfCommonStockShares" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44703">22,267</ix:nonFraction>&#160;shares of our Common Stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44704">5.7</ix:nonFraction>&#160;million, which is comprised of the upfront license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44705">2.0</ix:nonFraction>&#160;million and deferred consideration of $<ix:nonFraction name="sclx:Deferredconsiderationliabilities" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44706">3.7</ix:nonFraction>&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44707">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44708">0.3</ix:nonFraction>&#160;million, respectively. <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44709"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44710">No</ix:nonFraction></ix:nonFraction> contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2024 or December&#160;31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ELYXYB Acquisition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $<ix:nonFraction name="sclx:AccruedRoyaltyPayables" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44711">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="sclx:AccruedRoyaltyPayables" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44712">5.0</ix:nonFraction>&#160;thousand, respectively, which was recorded as accrued expenses under current liabilities on </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657361_4" continuedAt="TextSelectionAppend_145657361_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657361_5" continuedAt="TextSelectionAppend_145657361_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657361_6" continuedAt="TextSelectionAppend_145657361_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657361_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the consolidated balance sheets. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44714">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44715">26.0</ix:nonFraction>&#160;thousand, respectively. As of December&#160;31, 2024, <ix:nonFraction name="sclx:PaymentToAcquireLicense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44716">no</ix:nonFraction> sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. </div> </ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657365" id="ixv-24778"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">4. Fair Value Measurements </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-24781"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:46%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44717">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44718">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44719">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44720">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44721">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44722">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44723">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44724">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased Revenue Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44725">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44726">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44727">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44728">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657738;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44729">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44730">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44731">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44732">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44733">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44734">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44735">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44736">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44737">60,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44738">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44739">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44740">60,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 46%;"/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Unobservable<br/>Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44741">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44742">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44743">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44744">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44745">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44746">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44747">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44748">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657739;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44749">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44750">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44751">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44752">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44753">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44754">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44755">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44756">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44757">110,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44758">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44759">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44760">110,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The Oramed Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44761">101.9</ix:nonFraction>&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of such note recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2024 and 2023 was determined to be $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44762">12.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44763">104.1</ix:nonFraction>&#160;million, respectively, by applying a discount rate of <ix:nonFraction name="sclx:SecuredNoteDiscountRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44764">128.82</ix:nonFraction>% and <ix:nonFraction name="sclx:SecuredNoteDiscountRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44765">13.05</ix:nonFraction>%, respectively. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44766">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44767">2.8</ix:nonFraction>&#160;million in change in fair value of the Oramed Note, respectively. For the years ended December&#160;31, 2024 and 2023, the change in fair value due to instrument-specific credit risk recorded as a component of other comprehensive income was $<ix:nonFraction name="sclx:ChangeInFairValueDueToCreditRisk" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44768">6.3</ix:nonFraction>&#160;million and <ix:nonFraction name="sclx:ChangeInFairValueDueToCreditRisk" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-44769">nil</ix:nonFraction>, respectively. During the year ended December&#160;31, 2024 the Company reclassified $<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44770">5.0</ix:nonFraction>&#160;million from accumulated other comprehensive income to the consolidated statement of operations. This reclassification was related to the principal payments and partial conversion of the Oramed Note balance into the Tranche B Notes (see Note 7). </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657365" continuedAt="TextSelectionAppend_145657365_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657365_1" continuedAt="TextSelectionAppend_145657365_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657365_2" continuedAt="TextSelectionAppend_145657365_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657365_3" continuedAt="TextSelectionAppend_145657365_4"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">FSF Deposit </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2024, the Company received the FSF Deposit in the aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P06_30_2024To06_30_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44772">10.0</ix:nonFraction>&#160;million from FSF Lender (see Note 2 and Note 7). The Company elected the fair value option to account for the FSF Deposit with any changes in the fair value of the deposit recorded in the consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2024To12_31_2024_SeniorSubordinatedNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44773">4.7</ix:nonFraction>&#160;million in change in fair value of the FSF Deposit in the consolidated statement of operations. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. Upon the satisfaction of the FSF Deposit, the Deposit Warrant became a freestanding instrument under ASC 480 and was included in derivative liabilities on the Company&#8217;s consolidated balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44774">50.0</ix:nonFraction>&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Tranche B Notes are measured at fair value on a recurring basis using the Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of December&#160;31, 2024, was determined to be $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44775">23.6</ix:nonFraction>&#160;million. For the year ended December&#160;31, 2024, the Company recorded a gain of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44776">6.6</ix:nonFraction>&#160;million in change in fair value of the Tranche B Notes in the consolidated statement of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Purchased Revenue Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In October 2024, the Company entered into the ZTlido Royalty Purchase Agreement with certain institutional investors (collectively, the &#8220;ZTlido Royalty Investors&#8221;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The fair value as of December&#160;31, 2024, was determined to be $<ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44777">6.8</ix:nonFraction>&#160;million. For the year ended December&#160;31, 2024, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2024To12_31_2024_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44778">0.9</ix:nonFraction>&#160;million in change in fair value of the purchased revenue liability in the consolidated statement of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Debentures </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P04_30_2023To04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44779">25.0</ix:nonFraction>&#160;million (see Note 7). The Convertible Debentures were measured at fair value on a recurring basis using Level&#160;3 inputs. The Company used the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations and comprehensive loss. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44780">35.0</ix:nonFraction>&#160;thousand and a loss of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44781">4.4</ix:nonFraction>&#160;million in change in fair value of the Convertible Debentures, respectively. The Company fully repaid the Convertible Debentures in March 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company recorded a gain of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To12_31_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44782">17.4</ix:nonFraction>&#160;million for the year ended December&#160;31, 2024, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">as defined below). The Company recorded a loss of $</div><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-44783">0.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million for the year ended December&#160;31, 2023, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination (&#8220;Private Warrants&#8221;)</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-22</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657365_4" continuedAt="TextSelectionAppend_145657365_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;text-indent: 0px;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657365_5" continuedAt="TextSelectionAppend_145657365_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;text-indent: 0px;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657365_6" continuedAt="TextSelectionAppend_145657365_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657365_7" continuedAt="TextSelectionAppend_145657365_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">As </div>of December&#160;31, 2024, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44785">1,000,000</ix:nonFraction> Private Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44786">28,572</ix:nonFraction> shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44787">3,803,447</ix:nonFraction> February 2024 BDO Firm Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44788">108,686</ix:nonFraction> shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44789">15,000,000</ix:nonFraction>&#160;April 2024 RDO Common Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44790">428,572</ix:nonFraction> shares of Common Stock, </div></div> <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44791">3,250,000</ix:nonFraction> Deposit Warrant,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to </div></div> <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44792">3,250,000</ix:nonFraction>&#160;<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">shares of Common Stock, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44793">7,500,000</ix:nonFraction> </div></div>October 2024 Noteholder Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44794">214,284</ix:nonFraction> shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44795">57,512,958</ix:nonFraction>&#160;December 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44796">1,642,871</ix:nonFraction> shares of Common Stock</div></div>. As of December&#160;31, 2024, the fair value of derivative warrant liabilities related to these warrants was $<ix:nonFraction name="sclx:DerivativeWarrantLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44797">18.3</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-25346"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table includes a summary of the derivative liabilities measured at fair value during the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 89%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44798">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44799">512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ForfeitureOfPrivateWarrants" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44800">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44801">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IssuanceOfFirmWarrants" contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44802">34,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44803">1,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellation of Private Warrants as part of Oramed Letter Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44804">445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant amendment and exercise as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44805">428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44806">984</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44807">17,378</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44808">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#8217;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </div></div></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_145657365_8" continuedAt="TextSelectionAppend_145657365_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657365_9" continuedAt="TextSelectionAppend_145657365_10"><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div></ix:continuation> </div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657365_10" continuedAt="TextSelectionAppend_145657365_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657429" id="ixv-25504">
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">February<br/>2024&#160;BDO<br/>Firm<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">April&#160;2024<br/>RDO<br/>Common<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Deposit<br/>Warrant</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">October<br/>2024<br/>Noteholder<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(2.5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 44%;"/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 3%;"/>
<td/>
<td/>
<td/></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44809">402.50</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44810">59.50</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44811">38.50</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44812">1.20</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44813">36.40</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44814">22.72</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44815">22.72</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44816">2.86</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44817">4.18</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44818">4.32</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44819">4.47</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44820">4.77</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44821">4.95</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44822">2.45</ix:nonNumeric></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44823">109.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44824">81.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44825">80.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44826">73.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44827">77.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44828">76.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44829">95.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44830">4.22</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44831">4.29</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44832">4.30</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44833">4.30</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44834">4.32</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44835">4.33</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44836">4.21</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44837">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44838">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44839">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44840">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44841">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44842">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44843">0.0</ix:nonFraction></td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-23</ix:exclude></div></div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_145657429" continuedAt="TextSelectionAppend_145657429_1"><ix:continuation id="TextSelectionAppend_145657365_11" continuedAt="TextSelectionAppend_145657365_12"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657429_1" continuedAt="TextSelectionAppend_145657429_2"><ix:continuation id="TextSelectionAppend_145657365_12" continuedAt="TextSelectionAppend_145657365_13"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657365_13" continuedAt="TextSelectionAppend_145657365_14"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657365_14"><ix:continuation id="TextSelectionAppend_145657429_2"><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 19%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:19%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44845">402.50</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-44846">3.86</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44847">76.0</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44848">3.90</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44849">0.0</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contingent Consideration Related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Acquisition </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> the Company will transfer $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44850">3.0</ix:nonFraction>&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and a discount rate of <ix:nonFraction name="us-gaap:ProductLiabilityContingencyAccrualDiscountRate" contextRef="PAsOn12_31_2024" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-44851">10.0</ix:nonFraction>%. As of December&#160;31, 2024 and 2023, the fair value of contingent consideration related to the Development Milestone Payment was $<ix:nonFraction name="sclx:FairValueOfContingentConsideration" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44852"><ix:nonFraction name="sclx:FairValueOfContingentConsideration" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44853">0.2</ix:nonFraction></ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&#160;31, 2024 and 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657366" id="ixv-25950"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">5. Balance Sheet Components </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Investments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Promissory Note </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#8220;Denali&#8221;) issued a convertible promissory note (the &#8220;Convertible Promissory Note&#8221;) in the total principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44854">180,000</ix:nonFraction> to the Company. The Convertible Promissory Note was issued with an initial principal balance of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44855">15,063.74</ix:nonFraction>, with the remaining<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44856">164,936.26</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> drawable at Denali&#8217;s request and upon the consent of the Company prior to the maturity of the Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#8217;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44857">164,936.26</ix:nonFraction> principal amount available under the Convertible Promissory Note are expected to fund future </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-month</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44858">10.00</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> per ordinary share (the &#8220;Conversion Shares&#8221;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC in connection with Denali&#8217;s initial public offering (the &#8220;IPO&#8221;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. </div><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44859">No</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of December&#160;31, 2024, the balance of the Convertible Promissory Note was $</div><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44860">75.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;thousand as a result of additional draws after the initial amount.</div></div> </ix:nonNumeric></div></div> </div></div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_145657366" continuedAt="TextSelectionAppend_145657366_1"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (the &#8220;Semnur Business Combination Agreement&#8221;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#8220;Denali Merger Sub&#8221;).</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-24</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657366_1" continuedAt="TextSelectionAppend_145657366_2"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657366_2" continuedAt="TextSelectionAppend_145657366_3"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657366_3" continuedAt="TextSelectionAppend_145657366_4"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657366_4" continuedAt="TextSelectionAppend_145657366_5"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Semnur Business Combination&#8221;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-register</div> in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Domestication&#8221;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#8220;New Semnur Common Shares&#8221;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares&#8221;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#8220;New Semnur Warrants&#8221;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#8220;Effective Time&#8221;): (i) each share of common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="5" scale="0" format="ixt:num-dot-decimal" id="ixv-44862">0.00001</ix:nonFraction> per share (the &#8220;Semnur Common Stock&#8221;), of Semnur, issued and outstanding immediately prior to the Effective Time, will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;one-tenth</div> of one New Semnur Common Share, and (iii)&#160;subject to Denali&#8217;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. <br/></div></ix:continuation></div></div> </div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657366_5" continuedAt="TextSelectionAppend_145657366_6"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business<div style="display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Combination, these costs will be classified in stockholders&#8217; deficit as a reduction of additional </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024 and 2023, deferred offering costs related to the Semnur Business Combination totaled $</div><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44863">6.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million and </div><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2023_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44864">nil</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">, respectively, and were included in prepaid expenses and other current assets in the Company&#8217;s consolidated balance sheet.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution and delivery of the Semnur Business Combination Agreement, Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), and the Company entered into a Sponsor Interest Purchase Agreement (the &#8220;SIPA&#8221;) dated August&#160;30, 2024 (the &#8220;Signing Date&#8221;). Pursuant to the SIPA, the Company agreed to purchase <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44865">500,000</ix:nonFraction> Class&#160;B ordinary shares, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-44866">0.0001</ix:nonFraction> per share (the &#8220;Purchased Interests&#8221;), of Denali that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44867">2,000,000</ix:nonFraction> (the &#8220;Cash Consideration&#8221;) and (ii) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44868">8,571</ix:nonFraction> shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#8217;s own stock and meets the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div>. The Purchased Interests will convert automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-for-one</div></div> basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price which consists of the $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44869">2,000,000</ix:nonFraction> paid by the Company to the Sponsor and the value of the <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn08_30_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-44870">8,571</ix:nonFraction> shares of the Common Stock at the closing price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44871">40.25</ix:nonFraction> per share on the Signing Date for a total of $<ix:nonFraction name="us-gaap:CapitalUnitsNetAmount" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44872">2.3</ix:nonFraction>&#160;million. <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-25</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657366_6" continuedAt="TextSelectionAppend_145657366_7"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657366_7" continuedAt="TextSelectionAppend_145657366_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657366_8" continuedAt="TextSelectionAppend_145657366_9"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657366_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company </div></div> elected to subsequently measure the investment at cost less any impairment. As of December&#160;31, 2024, the Company&#8217;s investment in the Purchased Interests had a balance of $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2024To12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44874">2.3</ix:nonFraction>&#160;million. <ix:nonFraction name="sclx:ImpairmentLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44875">No</ix:nonFraction> impairment loss was recognized during the year ended December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-26051"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44876">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44877">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44878">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44879">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44880">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44881">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44882">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44883">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44884">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44885">780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44886">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44887">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44888">708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44889">722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44890">14.0</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44891">40.0</ix:nonFraction>&#160;thousand for the years ended December&#160;31, 2024 and 2023, <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">respectively. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div></div></div> <div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><ix:nonNumeric name="sclx:AccruedExpensesTextblock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-26208"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44892">667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44893">2,029</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44894">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44895">1,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44896">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44897">1,546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44898">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44899">1,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued litigation expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44900">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44901">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44902">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44903">280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44904">2,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44905">7,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657368" id="ixv-26341"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">6. Goodwill and Intangible Assets </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, the Company had recorded goodwill of $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44906"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44907">13.5</ix:nonFraction></ix:nonFraction>&#160;million. <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44908"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-44909">No</ix:nonFraction></ix:nonFraction> goodwill impairment was recognized for the years ended December&#160;31, 2024 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, ranging from <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-44910">6.8</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-44911">13.0</ix:nonNumeric> years. <ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657438" id="ixv-44912">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2024 and 2023 is as follows (in thousands): </ix:nonNumeric></div> <ix:continuation id="TextSelection_145657438"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Intangibles,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44913">32,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44914">17,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44915">14,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44916">21,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44917">9,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44918">12,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44919">5,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44920">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44921">4,796</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44922">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44923">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44924">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44925">60,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44926">28,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44927">32,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-26</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_145657368" continuedAt="TextSelectionAppend_145657368_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657368_1" continuedAt="TextSelectionAppend_145657368_2"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657368_2" continuedAt="TextSelectionAppend_145657368_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">As of December&#160;31, 2024, the weighted average remaining life for identifiable intangible assets was <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-44929">8.5</ix:nonNumeric> years. Aggregate amortization expense was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44930">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44931">4.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Patent rights, acquired technology and acquired licenses are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2024_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen" id="ixv-44932">15-year</ix:nonNumeric></div> period. Assembled workforce is amortized over a <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:durwordsen" id="ixv-44933">five-year</ix:nonNumeric> period. </div></ix:continuation></div></div> </div></div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657368_3"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-26532"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Estimated future amortization expense related to intangible assets as of December&#160;31, 2024 is as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44934">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44935">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44936">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44937">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44938">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44939">12,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44940">32,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657372" id="ixv-26615"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">7. Debt </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Debentures </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44941">25.0</ix:nonFraction>&#160;million. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-26623">The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to <ix:nonFraction name="sclx:ConvertibleDebenturesIssuedPercent" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-44942">96</ix:nonFraction>% of the applicable principal amount in three tranches as follows: (i) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44943">10.0</ix:nonFraction>&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44944">7.5</ix:nonFraction>&#160;million upon the filing of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44945">7.5</ix:nonFraction>&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.</ix:nonNumeric> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bore interest at an annual rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-44946">7.00</ix:nonFraction>% and were initially set to mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-44947">December 21, 2023</ix:nonNumeric>. On October&#160;11, 2023, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44948"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44949">70.00</ix:nonFraction></ix:nonFraction> per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44950"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44951">17.50</ix:nonFraction></ix:nonFraction> per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-44952">March 15, 2024</ix:nonNumeric>. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest, may be converted into shares of Common Stock, at a conversion price of $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44953">280.00</ix:nonFraction> per share at the option of the holder of the Convertible Debentures. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentPaymentTerms" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-44954">The Company had the option to repay either (i)&#160;in cash, with premium equal to&#160;<ix:nonFraction name="sclx:DebtInstrumentPrincipalAmountPercentage" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44955">5</ix:nonFraction>% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.</ix:nonNumeric> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentRedemptionDescription" contextRef="P01_01_2024To12_31_2024" id="ixv-44956">The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion</ix:nonNumeric> </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-27</ix:exclude> </div></div></div> <div style="background: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657372" continuedAt="TextSelectionAppend_145657372_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_1" continuedAt="TextSelectionAppend_145657372_2"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657372_2" continuedAt="TextSelectionAppend_145657372_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Price<div style="display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the Convertible Debentures and recorded the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Pursuant to the Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44958">15.0</ix:nonFraction>&#160;million in April 2023 for $<ix:nonFraction name="sclx:NetCashProceeds" contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44959">14.4</ix:nonFraction>&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $<ix:nonFraction name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44960">5.0</ix:nonFraction>&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44961">18,069</ix:nonFraction> shares of Common Stock at a conversion price of $<ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-44962">280.00</ix:nonFraction> per share and reducing the outstanding Convertible Debentures fair value balance by $<ix:nonFraction name="sclx:DebtInstrumentOutstandingPrincipal" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44963">7.7</ix:nonFraction>&#160;million. The Company repaid $<ix:nonFraction name="us-gaap:DebtInstrumentRepaidPrincipal" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44964">4.4</ix:nonFraction>&#160;million of the Convertible Debentures during the year ended December&#160;31, 2024. Interest expense related to the Convertible Debentures and included in the changes in fair value was $<ix:nonFraction name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-44965">35.0</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44966">0.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div> <ix:nonNumeric name="us-gaap:ConvertibleDebtTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-26660"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-44967">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfConvertibleDebenture" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44968">4,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebentures" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-44969">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-44970">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revolving Facility </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:FinancingReceivableRevolvingConvertedToTermLoan" contextRef="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44971">30.0</ix:nonFraction>&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $<ix:nonFraction name="sclx:DebtInstrumentOutstandingPrincipal" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-44972">250,000</ix:nonFraction>&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds <ix:nonFraction name="sclx:ExistingFacilityCapMaximum" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44973">95</ix:nonFraction>% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and <ix:nonFraction name="sclx:ExistingFacilityCapMinimum" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44974">85</ix:nonFraction>% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the eCapital Credit Agreement, interest would accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus <ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44975">1.5</ix:nonFraction>%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provided for an early termination fee of <ix:nonFraction name="sclx:TerminationFees" contextRef="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44976">0.5</ix:nonFraction>% of the Facility Cap if Scilex Pharma voluntarily prepaid and terminated in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#8217;s collections and eCapital Credit Agreement funding accounts, which permitted the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement would be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement was earlier terminated. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eCapital Credit Agreement contained a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44977">1.0</ix:nonFraction>&#160;million at all times. Scilex Pharma&#8217;s obligations under the eCapital Credit Agreement <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">were </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-28</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657372_3" continuedAt="TextSelectionAppend_145657372_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657372_4" continuedAt="TextSelectionAppend_145657372_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_5" continuedAt="TextSelectionAppend_145657372_6"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657372_6" continuedAt="TextSelectionAppend_145657372_7"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">secured by a continuing security interest in Scilex Pharma&#8217;s accounts receivable, arising from customers in the ordinary course of business. The eCapital Credit Agreement contained customary events of default and also provided that an event of default included a change of control of Scilex Pharma and the failure by the Company to issue at least $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44979">75.0</ix:nonFraction>&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. <br/></div></ix:continuation> </div> </div> </div> </div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657372_7" continuedAt="TextSelectionAppend_145657372_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#8220;Subordination Agreement&#8221;) with the Lender and Acquiom Agency Services LLC (the &#8220;Agent&#8221;). Pursuant to the Subordination Agreement, the </div></div><div style="font-size: 10pt;display:inline;">rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consisted of all of the Company&#8217;s properties identified in the description of collateral in the </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">UCC-1</div><div style="font-size: 10pt;display:inline;"> Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#8217;s rights and interests under the Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by the Company and each of its subsidiaries with Oramed and the Agent (the &#8220;Subsidiary Guarantee&#8221;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also included other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $</div><ix:nonFraction name="us-gaap:FinancingReceivableRevolvingConvertedToTermLoan" contextRef="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44980">30.0</ix:nonFraction><div style="font-size: 10pt;display:inline;">&#160;million.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement were terminated, canceled and are of no further force and effect. As of December&#160;31, 2024 and 2023, the outstanding balance under the Revolving Facility for Scilex Pharma was nil and $<ix:nonFraction name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44981">17.0</ix:nonFraction>&#160;million, respectively, which was classified as a long-term liability in the consolidated balance sheet. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The Oramed Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44982">101.9</ix:nonFraction>&#160;million, matures on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-44983">March 21, 2025</ix:nonNumeric>. It is payable in six principal installments, with the first installment of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44984">5.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-44985">December 21, 2023</ix:nonNumeric>, the second installment in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44986">15.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-44987">March 21, 2024</ix:nonNumeric>, the next three installments each in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44988">20.0</ix:nonFraction>&#160;million payable on each of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-44989">June 21, 2024</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-44990">September 21, 2024</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-44991">December 21, 2024</ix:nonNumeric> and the last installment in the entire remaining principal balance of the Oramed Note payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-44992">March 21, 2025</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" id="ixv-26772">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44993">4</ix:nonFraction>% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-44994">8.5</ix:nonFraction>%, payable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-kind</div> on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $<ix:nonFraction name="sclx:DebtRepaymentExitFee" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-44995">3.1</ix:nonFraction>&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than <ix:nonFraction name="sclx:DebtInstrumentOwnedPercentage" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44996">50</ix:nonFraction>% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus <ix:nonFraction name="sclx:DebtInstrumentDefaultInterestRate" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44997">15</ix:nonFraction>% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to <ix:nonFraction name="sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44998">50</ix:nonFraction>% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of <ix:nonFraction name="sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-44999">125</ix:nonFraction>% of the principal amount (together with <ix:nonFraction name="sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45000">100</ix:nonFraction>% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of <ix:nonFraction name="sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45001">70</ix:nonFraction>% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the sale of shares of Common Stock pursuant to the ATM Sales Agreement, the Company made a mandatory</ix:nonNumeric></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-29</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657372_8" continuedAt="TextSelectionAppend_145657372_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657372_9" continuedAt="TextSelectionAppend_145657372_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_10" continuedAt="TextSelectionAppend_145657372_11"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657372_11" continuedAt="TextSelectionAppend_145657372_12"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;display:inline;">prepayment of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45003">9,578,835</ix:nonFraction><div style="font-size: 10pt;display:inline;">, $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45004">7,000,000</ix:nonFraction><div style="font-size: 10pt;display:inline;"> and $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45005">1,760,796</ix:nonFraction><div style="font-size: 10pt;display:inline;">, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from the April 2024 RDO, the FSF Deposit and sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note.</div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Company and Oramed entered into a letter agreement (the &#8220;Oramed Letter Agreement&#8221;), pursuant to which the Company agreed to pay to Oramed $<ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_20_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45006">2,000,000</ix:nonFraction> (the &#8220;Specified September Payment&#8221;) on September&#160;23, 2024, which payment was applied as follows: (i) $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45007">1,700,000</ix:nonFraction> was applied to the amortization payment due under the Oramed Note on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45008">March 21, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and (y) $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45009">300,000</ix:nonFraction> to purchase an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45010">4,000,000</ix:nonFraction> SPAC Warrants (as defined below<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45011">114,286</ix:nonFraction> shares of Common Stock</div></div>) owned by Oramed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined therein) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined therein) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45012">0</ix:nonFraction>, and (ii)&#160;to extend the due date of the $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45013">20,000,000</ix:nonFraction> amortization payment from <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45014">September 23, 2024</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45015">September 30, 2024</ix:nonNumeric>. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed (&#8220;Oramed Consent and Amendment&#8221;) under which: (i)&#160;the Company made a payment of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45016">12,500,000</ix:nonFraction> to Oramed in lieu of&#160;the payment due on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45017">September 23, 2024</ix:nonNumeric>, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45018">15,000,000</ix:nonFraction> payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45019">March 21, 2025</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-45020">December 31, 2025</ix:nonNumeric>. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the Oramed Note was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45021">12.2</ix:nonFraction>&#160;million, which is classified as debt, current in the consolidated balance sheet.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-30</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657372_12" continuedAt="TextSelectionAppend_145657372_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657372_13" continuedAt="TextSelectionAppend_145657372_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_14" continuedAt="TextSelectionAppend_145657372_15"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657372_15" continuedAt="TextSelectionAppend_145657372_16"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div> <ix:nonNumeric name="sclx:ScheduleOfTheOramedNoteTableTextBlock" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" escape="true" id="ixv-26829"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45023">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfConvertibleDebenture" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45024">64,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion into Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45025">25,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; recorded in the consolidated statements of operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebentures" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45026">3,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; due to instrument-specific credit risk recorded as a component of other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45027">6,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45028">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation></div> </div> </div> </div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_16" continuedAt="TextSelectionAppend_145657372_17"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Commitment Letter</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into the Commitment Letter with FSF Lender, pursuant to which FSF Lender committed to provide the Company the FSF Loan in the aggregate amount of $<ix:nonFraction name="sclx:LoanAmount" contextRef="PAsOn06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45029">100.0</ix:nonFraction>&#160;million. The Commitment Amount should be payable as follows: (i) $<ix:nonFraction name="sclx:CommitmentAmount" contextRef="PAsOn06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45030">85.0</ix:nonFraction>&#160;million no later than the Outside Date, which is <ix:nonNumeric name="sclx:CompanyReceivesTheFsfDepositPeriod" contextRef="P06_11_2024To06_11_2024" format="ixt-sec:durday" id="ixv-45031">70</ix:nonNumeric> days following the date on which the Company received the FSF Deposit and (ii)&#160;the remaining $<ix:nonFraction name="sclx:CompanyReceivesTheFsfDepositAmount" contextRef="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45032">15.0</ix:nonFraction>&#160;million within 60 days following the Initial Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Commitment Letter, FSF Lender provided the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> FSF Deposit in immediately available funds in the aggregate principal amount of $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45033">10.0</ix:nonFraction>&#160;million on the Deposit Date, which amount would be creditable towards the $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45034">85.0</ix:nonFraction>&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender the Deposit Warrant to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_11_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45035">3,250,000</ix:nonFraction> shares of Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction), with an exercise price of $<ix:nonFraction name="sclx:DepositWarrantExercisePrice" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45036">1.20</ix:nonFraction> per share. The Deposit Warrant was immediately exercisable and would expire five years from the date of issuance. If the Initial Closing did not occur on or prior to the Outside Date, the FSF Deposit should automatically convert into an unsecured loan on the first day after the Outside Date. Within five days after such automatic conversion occurs, the Company should issue a promissory note (the &#8220;Unsecured Promissory Note&#8221;) to FSF Lender to evidence such unsecured loan, which note should be unsecured, had a maturity date of five years after the date of the Unsecured Promissory Note and was prepayable without premium or penalty. The Unsecured Promissory Note should bear interest, payable quarterly in arrears, in an amount equal to the Unsecured Applicable Interest Amount (as defined<div style="display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px;display:inline;">in the Commitment Letter) for such period based on the actual number of days elapsed while principal is outstanding.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It was contemplated by the Commitment Letter that the Company and FSF Lender would enter into definitive documents with respect to the FSF Loan on terms to be mutually agreed in good faith. If such definitive documents were entered into on or before the Outside Date, the Company agreed to issue to FSF Lender (i)&#160;at the Initial Closing, a warrant to purchase up to an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45037">24,375,000</ix:nonFraction> shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#8220;Initial Closing Warrant&#8221;), and (ii)&#160;at the Second Closing, a warrant to purchase up to an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn06_11_2024_SecondClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45038">4,875,000</ix:nonFraction> shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#8220;Second Closing Warrant&#8221;), each to have an exercise price of $<ix:nonFraction name="sclx:DepositWarrantExercisePrice" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45039">1.20</ix:nonFraction> per share (with such exercise price and underlying shares presented on a pre-Reverse Stock Split basis); however, neither the Initial Closing Warrant nor Second Closing Warrant were ever issued. The Initial Closing Warrant and the Second Closing Warrant would expire five years from the date of issuance. To evidence the FSF Loan, the Company agreed to issue to FSF Lender a Senior Secured Promissory Note (the &#8220;Secured Promissory Note&#8221;), which shall have a maturity date of </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-31</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_17" continuedAt="TextSelectionAppend_145657372_18"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657372_18" continuedAt="TextSelectionAppend_145657372_19"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_19" continuedAt="TextSelectionAppend_145657372_20"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_20" continuedAt="TextSelectionAppend_145657372_21"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">five years after the date of issuance. The Secured Promissory Note shall bear interest, payable quarterly in arrears, in an amount equal to the Secured Applicable Interest Amount (as defined in the Commitment Letter) for such period, based on the actual number of days elapsed, while principal is outstanding, subject to certain conditions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the FSF Deposit would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Commitment Letter, the Company also entered into an agreement with FSF Lender and the FSF Lender&#8217;s strategic consultant, IVI 66766 LLC (&#8220;IVI&#8221;), dated July&#160;16, 2024, pursuant to which the Company agreed to reimburse the actual, reasonable and documented consulting fees incurred by FSF Lender in connection with the preparation, negotiation and execution of the Commitment Letter and the definitive documents with respect to the transactions contemplated thereby, which fees were satisfied in full by the Company issuing to IVI a warrant to purchase up to an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45041"><ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45042">7,142</ix:nonFraction></ix:nonFraction> shares of Common Stock (the &#8220;Fee Warrant&#8221;) on July&#160;16, 2024, with an exercise price of $<ix:nonFraction name="sclx:DepositWarrantExercisePrice" contextRef="P07_16_2024To07_16_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45043">42.00</ix:nonFraction> per share. Subject to certain ownership limitations, the Fee Warrant is immediately exercisable and will expire five years from the date of issuance. The <div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;">Company accounted for the Fee Warrant as an equity classified instrument and recognized the Fee Warrant in additional </div><div style="font-size: 10pt; text-align: left; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div><div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;"> capital in the Company&#8217;s consolidated balance sheets. The fair value of the Fee Warrant as of the date of issuance was $</div><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45044">0.3</ix:nonFraction><div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. In October 2024, the Fee Warrant was exercised by IVI.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into the Satisfaction Agreement with FSF Lender and Endeavor, pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor, which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2024To12_31_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45045">13.2</ix:nonFraction>&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $<ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45046">20,000,000</ix:nonFraction>. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div><ix:nonNumeric name="sclx:SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-26947"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of June&#160;11, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Deposits" contextRef="PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45047">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeposits" contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45048">4,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45049">1,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfDeposit" contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45050">13,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Deposits" contextRef="PAsOn12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45051">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-32</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657372_21" continuedAt="TextSelectionAppend_145657372_22"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_145657372_22" continuedAt="TextSelectionAppend_145657372_23"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_23" continuedAt="TextSelectionAppend_145657372_24"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_24" continuedAt="TextSelectionAppend_145657372_25"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $<div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45053">38.15</ix:nonFraction></div> per share (which was automatically reduced to $<div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45054">36.40</ix:nonFraction></div> per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and (ii)&#160;warrants (the &#8220;October 2024 Noteholder Warrants&#8221;) to purchase up to <div style="display:inline;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45055">214,284</ix:nonFraction></div> shares of Common Stock directly to the Tranche B Noteholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45056">22,500,000</ix:nonFraction>, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of $<ix:nonFraction name="sclx:ReductionOfThePrincipalBalance" contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45057">22,500,000</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are immediately exercisable for cash at an exercise price equal to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45058">38.15</ix:nonFraction> per share of Common Stock (which was automatically reduced to $<ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="P10_08_2024To10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45059">36.40</ix:nonFraction> per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such warrants) and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45060">107,142</ix:nonFraction> shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45061">107,142</ix:nonFraction> shares of Common Stock. </div></ix:continuation></div></div> </div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_25" continuedAt="TextSelectionAppend_145657372_26"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#8220;StockBlock&#8221;) and its affiliate, Rodman&#160;&amp; Renshaw LLC (collectively, the &#8220;Placement Agents&#8221;) or their respective designees, (i) </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45062">62,794</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;Placement Agent Shares&#8221;) and (ii)&#160;warrants to purchase up to </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_31_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45063">104,848</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;October 2024 Placement Agent Warrants&#8221;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement (as defined below) for $<ix:nonFraction name="us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45064">5.0</ix:nonFraction>&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $<ix:nonFraction name="sclx:ProceedsReceivedFromPurchaseAgreement" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45065">50.0</ix:nonFraction>&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45066">2.6</ix:nonFraction>&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statement of operations during the year ended December&#160;31, 2024. </div><ix:nonNumeric name="sclx:ScheduleOfTrancheBNotesTableTextBlock" contextRef="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" escape="true" id="ixv-27059"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn10_08_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45067">42,740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Tranche B notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45068">9,255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfTrancheBNotes" contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45069">3,283</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ChangeInFairValueOfTrancheBNotes" contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45070">6,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45071">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate principal repayments for the Company&#8217;s outstanding debt will be $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2025To12_31_2025_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45072">47.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2026To12_31_2026_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45073">19.5</ix:nonFraction>&#160;million in 2025 and 2026, respectively.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-33</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657372_26" continuedAt="TextSelectionAppend_145657372_27"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_145657372_27" continuedAt="TextSelectionAppend_145657372_28"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657372_28" continuedAt="TextSelectionAppend_145657372_29"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_29" continuedAt="TextSelectionAppend_145657372_30"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Royalty Purchase Agreement</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive <ix:nonFraction name="srt:FederalFundsPurchasedAverageRatePaid" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45075">8</ix:nonFraction>% of all aggregate net sales worldwide (the &#8220;ZTlido Purchased Receivables&#8221;) with respect to ZTlido, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $<ix:nonFraction name="us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45076">5.0</ix:nonFraction>&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $<ix:nonFraction name="sclx:PaidToRoyaltyInvestors" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45077">2.5</ix:nonFraction>&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $<ix:nonFraction name="us-gaap:PaymentsToAcquireReceivables" contextRef="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45078">2.5</ix:nonFraction>&#160;million minus Oramed&#8217;s expenses (collectively, the amount so paid by the ZTlido Royalty Purchasers, the &#8220;ZTlido RPA Closing Payment&#8221;). Oramed&#8217;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45079">2.5</ix:nonFraction>&#160;million of the outstanding balance under the Oramed Note.&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;">The Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. </div></ix:continuation></div></div> </div><ix:continuation id="TextSelectionAppend_145657372_30" continuedAt="TextSelectionAppend_145657372_31"><div></div></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_145657372_31" continuedAt="TextSelectionAppend_145657372_32"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657372_32"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45080">6.8</ix:nonFraction>&#160;million, recorded as a purchased revenue liability on the consolidated balance sheet. The Company incurred $<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45081">0.2</ix:nonFraction>&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. </div><ix:nonNumeric name="sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-27168"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity during the year ended December&#160;31, 2024 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn10_08_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45082">5,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfPurchasedRevenueLiability" contextRef="P10_08_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45083">900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45084">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145658314" id="ixv-27223"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">8. Junior DIP Facility and Sorrento Stock Purchase Agreement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Junior DIP Facility </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, the Company entered into an agreement to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45085">20.0</ix:nonFraction>&#160;million (the &#8220;Junior DIP Loan Agreement&#8221;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45086">12.0</ix:nonFraction>% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45087">2.00</ix:nonFraction>% of the aggregate principal amount of the Junior DIP<div style="display:inline;">&#160;</div>Facility.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#160;</div>The Junior DIP </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-34</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_145658314" continuedAt="TextSelectionAppend_145658314_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658314_1" continuedAt="TextSelectionAppend_145658314_2"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658314_2" continuedAt="TextSelectionAppend_145658314_3"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" id="ixv-45089">Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Sorrento&#8217;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into the Sorrento SPA, pursuant to which the Company purchased from Sorrento (i) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45090">1,716,245</ix:nonFraction> shares of Common Stock, (ii) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45091">29,057,097</ix:nonFraction> shares of Series A Preferred Stock and (iii) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45092">1,386,617</ix:nonFraction> Public Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45093">39,617</ix:nonFraction> shares of Common Stock</div></div> and <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45094">3,104,000</ix:nonFraction> Private Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45095">88,685</ix:nonFraction> shares of Common Stock</div></div> (collectively, the &#8220;Purchased Securities&#8221;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. <br/></div></ix:continuation></div></div> </div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658314_3" continuedAt="TextSelectionAppend_145658314_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;display:inline;">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of </div><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45096">4,500,000</ix:nonFraction><div style="font-size: 10pt;display:inline;"> shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45097">0.01</ix:nonFraction><div style="font-size: 10pt;display:inline;"> per share and restrictions on exercisability, and warrants to purchase up to an aggregate of </div><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45098">8,500,000</ix:nonFraction><div style="font-size: 10pt;display:inline;"> shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45099">0.01</ix:nonFraction><div style="font-size: 10pt;display:inline;"> per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed </div><ix:nonFraction name="sclx:TransferOfWarrants" contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45100">4,000,000</ix:nonFraction><div style="font-size: 10pt;display:inline;"> SPAC Warrants, which </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_21_2023_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45101">114,286</ix:nonFraction> shares of Common Stock, which </div></div><div style="font-size: 10pt;display:inline;">were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $</div><ix:nonFraction name="sclx:CashPayment" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45102">10.0</ix:nonFraction><div style="font-size: 10pt;display:inline;">&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $</div><ix:nonFraction name="us-gaap:LegalFees" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45103">12.3</ix:nonFraction><div style="font-size: 10pt;display:inline;">&#160;million.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Series A Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary (&#8220;SCLX JV&#8221;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-35</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145658314_4" continuedAt="TextSelectionAppend_145658314_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145658314_5" continuedAt="TextSelectionAppend_145658314_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658314_6" continuedAt="TextSelectionAppend_145658314_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658314_7" continuedAt="TextSelectionAppend_145658314_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $<ix:nonFraction name="sclx:FairValueOfSharesRepurchased" contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45105">52.6</ix:nonFraction>&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45106">March 14, 2025</ix:nonNumeric>, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company issued four Subsequent Penny Warrants, each for <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45107"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45108"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45109"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45110">2,125,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45111">March 19, 2024</ix:nonNumeric> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-2</div> Warrant&#8221;), <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45112">June 17, 2024</ix:nonNumeric> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-3</div> Warrant&#8221;), <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45113">September 15, 2024</ix:nonNumeric> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-4</div> Warrant&#8221;) or <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45114">December 14, 2024</ix:nonNumeric> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-5</div> Warrant&#8221;) (each, the &#8220;Subsequent Penny Warrant Vesting Date&#8221;) and (ii)&#160;the earliest of (A)&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45115">March 14, 2025</ix:nonNumeric>, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a letter agreement the Company entered into with Oramed, dated as of <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P08_30_2024To08_30_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45116">August 30, 2024</ix:nonNumeric>, the parties agreed that: (i)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CS-4</div> Warrant shall fully vest on August&#160;30, 2024 and (ii)&#160;Oramed may immediately exercise the Oramed Warrants with respect to up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45117">5,437,500</ix:nonFraction> shares of Common Stock. Pursuant to the Oramed Letter Agreement the Company entered into with Oramed, dated as of September&#160;20, 2024, the parties agreed that Oramed may immediately exercise the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CS-5</div> Warrant with respect to up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45118">1,062,500</ix:nonFraction> shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45119">0.01</ix:nonFraction> per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of <ix:nonFraction name="sclx:NumberOfShareOutstanding" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45120">9.9</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $<ix:nonFraction name="sclx:FairValueOfWarrants" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45121">10.4</ix:nonFraction>&#160;million.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-36</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145658314_8" continuedAt="TextSelectionAppend_145658314_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_145658314_9" continuedAt="TextSelectionAppend_145658314_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658314_10" continuedAt="TextSelectionAppend_145658314_11"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658314_11"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">During the year ended December&#160;31, 2024, there were <ix:nonFraction name="sclx:PennyWarrantsExercised" contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45123">6,500,000</ix:nonFraction> Penny Warrants exercised by Oramed for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45124">0.1</ix:nonFraction>&#160;million. As of December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45125">6,500,000</ix:nonFraction> Penny Warrants outstanding that were fully vested and such warrants became exercisable on <ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-45126">March 14, 2025</ix:nonNumeric>. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45127">1.3</ix:nonFraction>&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the consolidated balance sheet. During the year ended December&#160;31, 2024, the Company made a total of $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45128">0.5</ix:nonFraction>&#160;million payments for the excise tax. As of December&#160;31, 2024, the remaining balance of the excise tax liability recorded as accrued expenses was $<ix:nonFraction name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" contextRef="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45129">0.8</ix:nonFraction>&#160;million. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657375" id="ixv-27357"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">9. Stockholders&#8217; Deficit </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SPAC Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2024_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45130">402.50</ix:nonFraction> per share (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220;SPAC Warrants&#8221;). <br/></div> </ix:nonNumeric></div></div> </div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_145657375" continuedAt="TextSelectionAppend_145657375_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">If the reported last sale price of the Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45131">630.00</ix:nonFraction> per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45132">0.01</ix:nonFraction> per warrant upon not less than 30 days&#8217; prior written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45133">4,000,000</ix:nonFraction> of the SPAC Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2024To03_31_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45134">114,286</ix:nonFraction> shares of Common Stock,</div></div> held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45135"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45136">5,467,692</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45137"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45138">6,854,309</ix:nonFraction></ix:nonFraction>&#160;Public Warrants outstanding, <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45139">156,220</ix:nonFraction> shares of Common Stock and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45140">195,838</ix:nonFraction> shares of Common Stock, </div></div>respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45141">1,000,000</ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45142">3,613,383</ix:nonFraction>&#160;Private Warrants outstanding, <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2024_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45143">28,572</ix:nonFraction> shares of Common Stock and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45144">103,240</ix:nonFraction> shares of Common Stock, respectively.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-37</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_1" continuedAt="TextSelectionAppend_145657375_2"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_2" continuedAt="TextSelectionAppend_145657375_3"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_3" continuedAt="TextSelectionAppend_145657375_4"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_4" continuedAt="TextSelectionAppend_145657375_5"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45146"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45147">45,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock (the &#8220;Preferred Stock&#8221;) of which there are two series in total. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45148"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45149">29,057,097</ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series 1 Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On October&#160;27, 2024, the Board declared a stock dividend (the &#8220;Dividend&#8221;) consisting of an aggregate of <ix:nonFraction name="us-gaap:PreferredStockDividendsShares" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45150">5,000,000</ix:nonFraction> shares (the &#8220;Dividend Stock&#8221;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockDividendsPerShareDeclared" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-45151">0.0001</ix:nonFraction> per share (the &#8220;Series 1 Preferred Stock&#8221;), of the Company to record holders of certain of the Company&#8217;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;">such later date to be determined in the sole discretion of the Board). </div> Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Certificate of Designation&#8221;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into <div style="letter-spacing: 0px; top: 0px;display:inline;"></div>account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $<ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45152">200,000,000</ix:nonFraction> divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45153">10</ix:nonFraction>&#160;trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Certificate of Designation, (a) &#8220;Effective Time&#8221; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#8220;Determination Date&#8221; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45154">15</ix:nonFraction>&#160;trading days following the Registration Date, (c) &#8220;Registration Date&#8221; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and (ii)&#160;the time at which the Registration Statement is declared effective by the Securities and Exchange Commission and (d) &#8220;Registration Statement&#8221; means a registration statement, whether under the Exchange Act, or the Securities Act, that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025).</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-38</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_5" continuedAt="TextSelectionAppend_145657375_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_6" continuedAt="TextSelectionAppend_145657375_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_7" continuedAt="TextSelectionAppend_145657375_8"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_8" continuedAt="TextSelectionAppend_145657375_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of December&#160;31, 2024 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, there were <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45156"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45157">1,716,245</ix:nonFraction></ix:nonFraction> shares of Treasury Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">A&amp;R Yorkville Purchase Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the Company had the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45158">500.0</ix:nonFraction>&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> anniversary of the date on which the Company&#8217;s registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-1</div> registering such shares was declared effective by the SEC. Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elected to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to <ix:nonFraction name="sclx:PurchaseOfStockPercentage" contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45159">98</ix:nonFraction>% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#8220;VWAP&#8221; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#8220;AQR&#8221; function. Pursuant to the terms of the Original Purchase<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-268607)</div> (as it may be amended or supplemented from time to time, the &#8220;Yorkville Registration Statement&#8221;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. </div></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_9" continuedAt="TextSelectionAppend_145657375_10"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville </div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45160">7,142</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock. During the year ended December&#160;31, 2024, the Company sold </div><ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45161">2,770</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of $</div><ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45162">0.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. During the year ended December&#160;31, 2023, the Company sold </div><ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45163">330,059</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of $</div><ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45164">32.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">B. Riley Purchase Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Pursuant to the B. Riley Purchase Agreement, the Company had the right, but not the obligation, to sell to B. Riley up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45165">500.0</ix:nonFraction>&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth therein, from time to time at the Company&#8217;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-269205)</div> (as it may be amended or supplemented from time to time, the &#8220;B. Riley Registration Statement&#8221;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023.</div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_10" continuedAt="TextSelectionAppend_145657375_11"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-39 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_11" continuedAt="TextSelectionAppend_145657375_12"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_12" continuedAt="TextSelectionAppend_145657375_13"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_13" continuedAt="TextSelectionAppend_145657375_14"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_14" continuedAt="TextSelectionAppend_145657375_15"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;display:inline;">The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to </div><ix:nonFraction name="sclx:PurchaseOfStockPercentage" contextRef="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45166">98</ix:nonFraction><div style="font-size: 10pt;display:inline;">% of the VWAP (as defined in such agreement) during the pricing period prescribed therein.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45167">7,142</ix:nonFraction> shares of Common Stock. During the year ended December&#160;31, 2024, the Company did not sell any shares of Common Stock pursuant to the B. Riley Purchase Agreement. During the year ended December&#160;31, 2023, the Company sold an aggregate of <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45168">40,415</ix:nonFraction> shares of Common Stock for aggregate net proceeds of $<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45169">3.2</ix:nonFraction>&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Issued under Settlement Agreement with Hudson Bay Parties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In August 2023, the Company, along with Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221;), Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), and HBC Investments LLC (&#8220;HBC&#8221; and collectively, the &#8220;Hudson Bay Parties&#8221;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45170">118.6</ix:nonFraction>&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-45171">8.65</ix:nonFraction>&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024_CoveLaneMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45172">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024_HudsonBayMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45173">0.5</ix:nonFraction>&#160;million, respectively. This resulted in the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_25_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45174">13,562</ix:nonFraction> shares of Common Stock on September&#160;25, 2023.&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">At-the-Market</div></div> Sales Agreement</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ATM </div></div>Offering&#8221;) shares of Common Stock up to $<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45175">170,000,000</ix:nonFraction> (the &#8220;ATM Shares&#8221;), through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers at any time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The ATM Shares offered and sold in the <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ATM </div></div>Offering were issued pursuant to the Company&#8217;s shelf registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-3&#160;(which</div> was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-276245))</div> (the &#8220;Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement&#8221;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Sales Agents were entitled to a commission equal to <ix:nonFraction name="sclx:ProceedSOfSaleOfCommonSharesPercentage" contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45176">3.0</ix:nonFraction>% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024, the Company sold <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45177">78,975</ix:nonFraction> shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45178">2.7</ix:nonFraction>&#160;million. As of December&#160;31, 2023, <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-45179">no</ix:nonFraction> sales of Common Stock had been made under the ATM Sales Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">February 2024 Bought Deal Offering Underwriting Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;February 2024 BDO Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#8220;February 2024 BDO&#8221;), <ix:nonFraction name="sclx:CommonStockSold" contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45180"><ix:nonFraction name="sclx:CommonStockSold" contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45181">168,068</ix:nonFraction></ix:nonFraction>&#160;shares of Common Stock (the &#8220;February 2024 BDO Firm Shares&#8221;) and accompanying common warrants to purchase up to an aggregate of</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-40</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_15" continuedAt="TextSelectionAppend_145657375_16"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_16" continuedAt="TextSelectionAppend_145657375_17"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_17" continuedAt="TextSelectionAppend_145657375_18"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><br/></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_18" continuedAt="TextSelectionAppend_145657375_19"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45183"><ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45184"><ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45185">168,068</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;February 2024 BDO Firm Warrants&#8221;). The securities in the February 2024 BDO were offered and sold by us pursuant to the Shelf </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> Registration Statement,&#160;a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The February 2024 BDO closed on March&#160;5, 2024, and the combined price per Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $<ix:nonFraction name="sclx:CombinedPricePaidOfWarrant" contextRef="PAsOn02_29_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45186"><ix:nonFraction name="sclx:CombinedPricePaidOfWarrant" contextRef="PAsOn02_29_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45187">54.74</ix:nonFraction></ix:nonFraction>, which amount reflects the combined public offering price of $<ix:nonFraction name="sclx:PublicOfferingPrice" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45188"><ix:nonFraction name="sclx:PublicOfferingPrice" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45189">59.50</ix:nonFraction></ix:nonFraction>, less underwriting discounts and commissions. Pursuant to the February 2024 BDO Underwriting Agreement, the Company also granted the underwriters a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> option to purchase up to <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn02_29_2024_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45190">25,211</ix:nonFraction> additional shares of Common Stock and/or common warrants to purchase up to <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45191">25,211</ix:nonFraction> shares of Common Stock (the &#8220;February 2024 BDO Optional Warrants&#8221;, and together with the February 2024 BDO Firm Warrants, the &#8220;Common Warrants&#8221;). The underwriters did not exercise this option and it expired on March&#160;30, 2024. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45192">59.50</ix:nonFraction> per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#8220;February 2024 BDO Representative Warrants&#8221;) to the underwriters, allowing them to purchase up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45193">13,446</ix:nonFraction> shares of Common Stock, with these warrants being immediately exercisable at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45194">74.38</ix:nonFraction> per share, representing <ix:nonFraction name="sclx:PublicOfferingPriceCombined" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45195">125</ix:nonFraction>% of the combined public offering price per Firm Share and accompanying February 2024 BDO Firm Warrant. <br/></div></ix:continuation></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_19" continuedAt="TextSelectionAppend_145657375_20"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note 4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in </div> capital in the Company&#8217;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling,</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45196">0.3</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a warrant amendment (the &#8220;Warrant Amendment&#8221;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45197">50,421</ix:nonFraction> shares of Common Stock in cash at an amended exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45198">20.65</ix:nonFraction> per share. During the year ended December&#160;31, 2024, there were <ix:nonFraction name="sclx:NumberOfWarrantsExercised" contextRef="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45199">59,398</ix:nonFraction> February 2024 BDO Firm Warrants exercised for total net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45200">1.6</ix:nonFraction>&#160;million, including the amended February 2024 BDO Firm Warrants. As of December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45201">3,803,447</ix:nonFraction> February 2024 BDO Firm Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:NumberOfWarrantsExercised1" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45202">108,686</ix:nonFraction> shares of Common Stock outstanding</div></div> and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45203">470,588</ix:nonFraction> February 2024 BDO Representative Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45204">13,446</ix:nonFraction> shares of Common Stock</div></div> outstanding. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">April 2024 Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#8220;April 2024 RDO Purchase Agreement&#8221;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;April 2024 RDO&#8221;): (i) an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45205">428,572</ix:nonFraction> shares of Common Stock (the &#8220;RDO Shares&#8221;), and (ii)&#160;common warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45206">428,572</ix:nonFraction> shares of Common Stock (the &#8220;April 2024 RDO Common Warrants&#8221;). The offering price per RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45207">35.00</ix:nonFraction>, for aggregate gross proceeds to the Company of $<ix:nonFraction name="sclx:AggregateGrossProceedsFromOffering" contextRef="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45208">15,000,000</ix:nonFraction>, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45209">38.50</ix:nonFraction> per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC, acted as exclusive placement agents (the &#8220;Placement Agents&#8221;) in connection with the April 2024 RDO. As compensation for such placement agent services, the</div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_20" continuedAt="TextSelectionAppend_145657375_21"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-41 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_21" continuedAt="TextSelectionAppend_145657375_22"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_22" continuedAt="TextSelectionAppend_145657375_23"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_23" continuedAt="TextSelectionAppend_145657375_24"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_24" continuedAt="TextSelectionAppend_145657375_25"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">Company paid the Placement Agents an aggregate cash fee equal to <ix:nonFraction name="sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45210">8.0</ix:nonFraction>% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the Placement Agents $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45211">100,000</ix:nonFraction> for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses and $<ix:nonFraction name="sclx:ClearingExpenses" contextRef="P04_23_2024To04_23_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45212">15,950</ix:nonFraction> for clearing expenses. The Company has also agreed to issue to the Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45213">34,286</ix:nonFraction> shares of Common Stock (the &#8220;April 2024 RDO Placement Agent Warrants&#8221;), representing up to <ix:nonFraction name="sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45214">8.0</ix:nonFraction>% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45215">43.75</ix:nonFraction> per share (which represents <ix:nonFraction name="sclx:PercentOfCombinedOfferingExercisePricePerShare" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45216">125</ix:nonFraction>% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note 4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of April 2024 RDO Placement Agent Warrants as of the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn04_23_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45217">0.6</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45218">15,000,000</ix:nonFraction> April 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45219">428,572</ix:nonFraction> shares of Common Stock outstanding,</div></div> and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45220">1,200,000</ix:nonFraction> April 2024 RDO Placement Agent Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45221">34,286</ix:nonFraction> shares of Common Stock</div></div> outstanding. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">December 2024 Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#8220;December 2024 RDO Purchase Agreement&#8221;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;December 2024 RDO&#8221;): (i) an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45222">753,009</ix:nonFraction> shares of Common Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> warrants to purchase up to <ix:nonFraction name="sclx:PreFundedWarrantsToPurchase" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45223">68,604</ix:nonFraction>&#160;shares of Common Stock (the &#8220;December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) and (iii)&#160;common warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45224">1,642,871</ix:nonFraction> shares of Common Stock (the &#8220;December 2024 RDO Common Warrants&#8221; and together with the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#8220;StockBlock Warrants&#8221;), the &#8220;December 2024 RDO Warrants&#8221;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45225">20.65</ix:nonFraction> and (b)&#160;per December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant and accompanying December 2024 RDO Common Warrants was $<ix:nonFraction name="sclx:PreFundedWarrantPerShare" contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-45226">20.6499</ix:nonFraction>. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45227">17.0</ix:nonFraction>&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of StockBlock Warrants as of the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45228">1.3</ix:nonFraction>&#160;million. On December&#160;26, 2024, the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants were exercised by the holder for total net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45229">0.2</ix:nonFraction>&#160;million.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-42</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_25" continuedAt="TextSelectionAppend_145657375_26"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657375_26" continuedAt="TextSelectionAppend_145657375_27"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657375_27" continuedAt="TextSelectionAppend_145657375_28"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657375_28"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As of December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45231">57,512,958</ix:nonFraction> December 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45232">1,642,871</ix:nonFraction> shares of Common Stock outstanding,</div></div> and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45233">4,601,036</ix:nonFraction>&#160;StockBlock Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45234">131,472</ix:nonFraction> shares of Common Stock</div></div> outstanding. </div></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657379" id="ixv-27658"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">10. Stock Incentive and E<div style="display:inline;">mploye</div>e Benefit Plan </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). As of December&#160;31, 2024, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45235">575,220</ix:nonFraction> shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2024 pursuant to the Equity Incentive Plan. <br/></div></ix:nonNumeric></div></div></div></div></div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelection_145657379" continuedAt="TextSelectionAppend_145657379_1"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2023 Inducement Plan</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn01_17_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45236">40,000</ix:nonFraction> shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the years ended December&#160;31, 2024 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45237">1,027,977</ix:nonFraction> shares of Common Stock were outstanding under all equity incentive plans.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-43</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657379_1" continuedAt="TextSelectionAppend_145657379_2"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657379_2" continuedAt="TextSelectionAppend_145657379_3"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657379_3" continuedAt="TextSelectionAppend_145657379_4"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657379_4" continuedAt="TextSelectionAppend_145657379_5"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-27710"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes stock option activity during the year ended December&#160;31, 2024 (shares in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 55%;">&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45239">946</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45240">153.15</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-45241">7.5</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45242">7,459</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45243">129</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45244">33.21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45245">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45246">51.67</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited/Cancelled</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45247">43</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45248">160.56</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45249">1,028</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45250">138.23</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-45251">6.43</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45252">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45253">1,028</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45254">138.23</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-45255">6.43</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45256">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45257">727</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45258">113.01</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" format="ixt-sec:duryear" id="ixv-45259">5.5</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45260">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024 and 2023 was $</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45261">23.49</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> and $</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45262">113.00</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> per share, respectively. The total intrinsic values of options exercised during the years ended December&#160;31, 2024 and 2023 were $</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45263">47.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;thousand and $</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45264">1.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million, respectively. The maximum term of options granted under each of the equity incentive plans is ten years.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45265">15.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45266">14.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> stock option grants as of December&#160;31, 2024 were $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45267">27.8</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric name="sclx:WeightedAveragePeriodOverGrant" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-45268">2.3</ix:nonNumeric> years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45269">85</ix:nonFraction>% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2024, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45270">127,902</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">, which was increased from </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45271">82,164</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares as a result of automatic annual increase on January&#160;1, 2024.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45272">242.8</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45273">21.0</ix:nonFraction>&#160;thousand for the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45274"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45275">9,551</ix:nonFraction></ix:nonFraction> and nil shares of Common Stock issued under the ESPP during the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-44</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657379_5" continuedAt="TextSelectionAppend_145657379_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657379_6" continuedAt="TextSelectionAppend_145657379_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657379_7" continuedAt="TextSelectionAppend_145657379_8"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657379_8" continuedAt="TextSelectionAppend_145657379_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP:</div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-28154"> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 71%;"/>
<td style="vertical-align: bottom; width: 4%;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45277">0.00</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45278">72.00</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45279">119.08</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45280">3.79</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;-<div style="display:inline;">&#160;</div></div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45281">4.71</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear" id="ixv-45282">3.0</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear" id="ixv-45283">6.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45284">0.00</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45285">129.30</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45286">5.39</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear" id="ixv-45287">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Semnur 2024 Stock Option Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (&#8220;Semnur 2024 Plan&#8221;). Under the Semnur 2024 Plan, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45288">40,000,000</ix:nonFraction> shares of Semnur Common Stock were reserved for future issuance and nonstatutory stock options (&#8220;NSOs&#8221;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of December&#160;31, 2024, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45289">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45290">0.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div></ix:continuation> </div> </div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657379_9"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Retainer Shares </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;2023 SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_13_2023To02_13_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45291">114,286</ix:nonFraction> shares of Common Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#8220;2024 SIA&#8221;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P07_01_2023To07_01_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45292">285,714</ix:nonFraction> shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#8220;Retainer Shares&#8221;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of December&#160;31, 2024, it was <ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45293">no</ix:nonFraction>t probable that any of the Retainer Shares would be applied against any <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">outstanding legal fees. </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-45 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657380" id="ixv-28285"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">11. Commitments and Contingencies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi Koseido Co., Ltd. (&#8220;Oishi,&#8221; and together with Itochu, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45294">25</ix:nonFraction>% and <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45295">35</ix:nonFraction>% to the Developers based on net profits. For each of the years ended December&#160;31, 2024 and 2023, Scilex Pharma made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45296"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To12_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45297">8.3</ix:nonFraction></ix:nonFraction>&#160;million. As of December&#160;31, 2024 and 2023, Scilex Pharma had ending balances of accrued royalty payables of $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45298">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45299">2.4</ix:nonFraction>&#160;million, respectively. Total royalty expense recorded within cost of revenue was $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45300">9.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45301">8.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until <ix:nonNumeric name="sclx:AgreementMaturityDate" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-45302">October 2, 2028</ix:nonNumeric>, the date that is ten years from the date of the first commercial sale of ZTlido. <ix:nonNumeric name="sclx:MaturityRenewalDescription" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-28295">The Product Development Agreement will renew automatically for subsequent successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon six months&#8217; written notice.</ix:nonNumeric> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div></div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, the Company filed an action (the &#8220;OTC Action&#8221;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">respective </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-46</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_145657380" continuedAt="TextSelectionAppend_145657380_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657380_1" continuedAt="TextSelectionAppend_145657380_2"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657380_2" continuedAt="TextSelectionAppend_145657380_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">OTC lidocaine</div></div> patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#8217;s claims, but which motions the court largely rejected. Discovery proceeded. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolved the OTC Action. The terms of those agreements are confidential. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Action </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, and together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">95-page</div> opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax would be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2024To12_31_2024_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45304">3.5</ix:nonFraction>&#160;million (the &#8220;Initial Payment&#8221;) by two business days after the Effective Date (as defined therein), which payment has been made; (ii) $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2024To12_31_2024_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45305">2.5</ix:nonFraction>&#160;million by July&#160;1, 2024, which payment has been made on July&#160;8, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2024To12_31_2024_EpoladermMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45306">6</ix:nonFraction>% of annual Net Sales (as defined therein) of Epoladerm; (b) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2024To12_31_2024_ProbudurMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45307">6</ix:nonFraction>% of annual Net Sales of Probudur and (c) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2024To12_31_2024_EnveltaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45308">6</ix:nonFraction>% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provided mutual releases of all claims that existed as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. The court has requested additional oral argument on the topic of remedies against Mr.&#160;Mack, which argument occurred on November&#160;15, 2024. The parties are awaiting a final judgment from the court. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-month</div> stay preventing them from selling a generic version of ZTlido during that time which was extinguished by the U.S. District Court for the Southern District of Florida decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-47</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657380_3" continuedAt="TextSelectionAppend_145657380_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657380_4" continuedAt="TextSelectionAppend_145657380_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657380_5" continuedAt="TextSelectionAppend_145657380_6"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657380_6" continuedAt="TextSelectionAppend_145657380_7"><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div></ix:continuation> </div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657380_7" continuedAt="TextSelectionAppend_145657380_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#8217;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#8217;s product does not infringe the Company&#8217;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA Patent Litigation </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#8220;GLOPERBA Patent Litigation&#8221;) alleging that the Company&#8217;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#8217;s colchicine product, Colcrys<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"> </div>(the &#8220;Colcrys Patents&#8221;). Takeda sought an order that the effective date of any FDA approval of the Company&#8217;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The Company had previously accrued $<ix:nonFraction name="sclx:DueFromRelatedParty" contextRef="PAsOn12_31_2024_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45310">0.5</ix:nonFraction>&#160;million with respect to the GLOPERBA Patent Litigation. On March&#160;7, 2024, the Company entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Takeda to resolve the action and entered into a license agreement with Takeda pursuant to which Takeda granted a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to the Company and its affiliates of certain patents owned by Takeda. The terms of those agreements are confidential. The Settlement Agreement was subject to review by the Federal Trade Commission and the U.S. Department of Justice, neither of which objected during the review period. After the expiration of the review period, the U.S. District Court for the District of Delaware entered a final consent judgment on May&#160;3, 2024. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2024, the Company&#8217;s leases have remaining lease terms of approximately <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-45311">2.8</ix:nonNumeric> years. The terms of the Company&#8217;s leases, ranging from <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-45312">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-45313">5</ix:nonNumeric> years, include extension options that were not reasonably certain to be exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2024, the Company has <ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45314">no</ix:nonFraction> <div style="-sec-ix-hidden:hidden145659460;display:inline;">finance leases</div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">In April 2023, the Company modified the lease term</div></div> for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45315"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45316">2.5</ix:nonFraction></ix:nonFraction>&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45317">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45318">1.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">presented. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-48</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657380_8" continuedAt="TextSelectionAppend_145657380_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657380_9" continuedAt="TextSelectionAppend_145657380_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657380_10" continuedAt="TextSelectionAppend_145657380_11"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657380_11"><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-28419"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 69%;"/>
<td style="vertical-align: bottom; width: 10%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 9%;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45320">1,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45321">1,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2024" format="ixt-sec:duryear" id="ixv-45322">2.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-45323">3.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45324">11.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45325">11.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-28498"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:86%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45326">916</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45327">944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45328">724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45329">2,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45330">347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45331">2,237</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45332">714</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:LeaseLiabilityNetOfCurrentPortion" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45333">1,523</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657371" id="ixv-28605"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">12. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total loss before income taxes for the years ended December&#160;31, 2024 and 2023 did not include a foreign component. </div> </ix:nonNumeric></div> </div> </div> </div> </div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_145657371" continuedAt="TextSelectionAppend_145657371_1"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-28614"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision (benefit) expense were as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax (benefit) expense:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45334">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45335">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45336">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45337">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current income tax (benefit) expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45338">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45339">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax benefit:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45340">16,279</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45341">16,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45342">2,803</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45343">11,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax benefit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45344">19,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45345">27,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45346">2,155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45347">1,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45348">16,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45349">29,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax (benefit) expense from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45350">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45351">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">tax purposes. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-49</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657371_1" continuedAt="TextSelectionAppend_145657371_2"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657371_2" continuedAt="TextSelectionAppend_145657371_3"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657371_3" continuedAt="TextSelectionAppend_145657371_4"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657371_4" continuedAt="TextSelectionAppend_145657371_5"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-28847"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45353">85,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45354">71,434</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsDebtRelatedInterest" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45355">16,228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsDebtRelatedInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45356">16,898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45357">5,228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45358">4,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45359">4,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45360">3,960</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45361">1,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45362">525</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45363">1,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45364">1,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased revenue liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsPurchasedRevenueLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45365">1,754</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsPurchasedRevenueLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45366">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45367">577</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45368">774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45369">303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45370">159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45371">116,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45372">100,270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45373">113,703</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45374">96,776</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45375">2,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45376">3,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45377">2,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45378">2,734</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45379">574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45380">760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45381">2,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45382">3,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45383">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45384">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-29164"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 70%;"/>
<td style="vertical-align: bottom; width: 6%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 6%;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45385">15,290</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45386">24,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45387">18,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45388">29,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45389">2,772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45390">3,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45391">485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45392">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">true-up</div> and carryback</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45393">1,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45394">5,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45395">2,705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45396">5,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45397">4,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45398">1,752</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45399">2,155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45400">1,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45401">346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45402">655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"/>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45403">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45404">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"/>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45405">113.7</ix:nonFraction>&#160;million against its deferred tax assets as of December&#160;31, 2024. Realization of the deferred tax assets will be primarily dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45406">336.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45407">248.2</ix:nonFraction>&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in <ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-45408">2033</ix:nonNumeric> for <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">both federal </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-50</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657371_5" continuedAt="TextSelectionAppend_145657371_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657371_6" continuedAt="TextSelectionAppend_145657371_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657371_7" continuedAt="TextSelectionAppend_145657371_8"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657371_8" continuedAt="TextSelectionAppend_145657371_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">and state. As </div></div> of December&#160;31, 2024, the Company had a total of $<ix:nonFraction name="sclx:IndefiniteOperatingLossCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45410">313.5</ix:nonFraction>&#160;million of federal net operating losses that have an indefinite life and will not expire, and had federal research and development income tax credits of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45411">3.7</ix:nonFraction>&#160;million which will begin to expire in <ix:nonNumeric name="sclx:IncomeTaxCreditsExpirationYear" contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-45412">2034</ix:nonNumeric>. As of December&#160;31, 2024, the Company had California research and development income tax credits of $<ix:nonFraction name="sclx:TaxCreditCarryforwardNotSubjectToExpireAmount" contextRef="PAsOn12_31_2024_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45413">2.2</ix:nonFraction>&#160;million that have an indefinite life and will not expire. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2024 and 2023, there was no impact of such limitations on the Company&#8217;s income tax provision. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#8217;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2024. </div> <ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-29367"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the beginning of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45414">1,071</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45415">408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45416">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45417">536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to current year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45418">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45419">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the end of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45420">1,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45421">1,071</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, the Company had $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45422">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45423">1.1</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">million in total unrecognized tax benefits, respectively, which have been reflected as a reduction in deferred tax assets. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. </div></div></div></ix:continuation> </div> </div> </div> </div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657371_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense</div></div>. <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45424"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45425">No</ix:nonFraction></ix:nonFraction> interest or penalties have been recognized as of and for the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that <ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45426">no</ix:nonFraction> material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>December<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>31,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2024. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-51 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657382" id="ixv-29539"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">13. Net Loss Per Share </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-29542"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2024 and 2023 (in thousands except per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45427">72,807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45428">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45429">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45430">52,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45431">72,807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45432">166,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reversal of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">mark-to-market</div></div> adjustment for liability classified warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45433">8,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45434">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45435">81,702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45436">166,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageNumberOfSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45437">3,561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageNumberOfSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45438">3,722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45439">6,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45440">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45441">10,061</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45442">3,722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45443">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45444">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45445">10,145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45446">3,722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45447">7.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45448">44.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45449">8.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45450">44.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Series A Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the Series A preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. Shares of the Dividend Stock, as declared by the Board of Directors of the Company on October&#160;27, 2024 and not yet distributed as of December&#160;31, 2024, are also excluded from the computation of net loss per share because the associated Series 1 Preferred Stock is not considered to be a participating security. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45451">8,500,000</ix:nonFraction> shares of Common Stock were not vested as of the closing date of September&#160;21, 2023 and the vesting was based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). The Subsequent Penny Warrants became vested during the year ended December&#160;31, 2024, and therefore are included in the computation for basic and diluted net income per share as of December&#160;31, 2024, since all other exercise contingencies were removed except for the passage of <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">time. </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-52 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_145657382" continuedAt="TextSelectionAppend_145657382_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657382_1" continuedAt="TextSelectionAppend_145657382_2"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657382_2"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-29834"> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45452">1,027,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45453">946,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45454">156,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45455">195,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45456">108,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45457">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45458">34,286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45459">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45460">399,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45461">114,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45462">28,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45463">103,240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45464">13,446</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45465">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to the ESPP</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45466">2,204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45467">851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45468">8,571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45469">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45470">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45471">15,626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45472">104,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45473">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45474">1,642,871</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45475">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45476">131,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45477">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45478">1,158,617</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-45479">&#8212;</ix:nonFraction>&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45480">4,817,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45481">1,376,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_145657384" id="ixv-30061"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">14. Subsequent Events </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferral and Consent under Tranche B Senior Secured Convertible Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025 (the &#8220;First Amortization Payment Date&#8221;), the Company is required to redeem in cash (the &#8220;First Amortization Payment&#8221;) such portion of the principal amount of the Tranche B Notes equal to each Tranche B Noteholder&#8217;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45482">6,250,000</ix:nonFraction> per fiscal quarter at a redemption price equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45483">100</ix:nonFraction>% of such Amortization Amount (as defined in the Tranche B Notes). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#8220;Nomis Bay Consent&#8221;), (ii) Oramed (the &#8220;Oramed Consent&#8221;) and (iii) 3i, LP (the &#8220;3i Consent&#8221; and, together with the Nomis Bay Consent and the Oramed Consent, the &#8220;Tranche B Consents&#8221;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#8217;s obligation to make the First Amortization Payment until January&#160;31, 2025. In consideration of such deferral, and to limit the Tranche B Noteholders&#8217; right to exercise certain secured creditor remedies (including recourse against the assets of SCLX JV as a grantor under the Security Agreement (as defined in the Tranche B Consents)), SCLX JV delivered to the Tranche B Noteholders (or their designee) by deposit/withdrawal at custodian with the Depository Trust Company an aggregate of <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45484">142,855</ix:nonFraction> Scilex <div style="letter-spacing: 0px; top: 0px;display:inline;">s</div>hares held by SCLX JV, of which <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_OramedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45485">71,428</ix:nonFraction> shares were delivered to Oramed, <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_BpyLimitedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45486">20,571</ix:nonFraction> shares were delivered to BPY Limited, <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_NomisBayLtdMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45487">36,571</ix:nonFraction> shares were delivered to Nomis Bay Ltd, and <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis_ThreeILpMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45488">14,285</ix:nonFraction> shares were delivered to 3i, LP. <br/></div> </ix:nonNumeric></div></div> </div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelection_145657384" continuedAt="TextSelectionAppend_145657384_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">In addition, pursuant to the Tranche B Consents</div></div>, effective as of the latest of (i)&#160;the time of execution and delivery of the Tranche B Consents, (ii)&#160;the time of the delivery of the Scilex <div style="letter-spacing: 0px; top: 0px;display:inline;">s</div>hares and (iii)&#160;the time of grant of the Royalty and Exclusive Rights (each as defined in, and contemplated pursuant to, the Term Sheet that is an exhibit to the Tranche B Consents (the &#8220;Term Sheet&#8221;)), the Tranche B Noteholders agreed to further defer the Company&#8217;s obligation to make the First Amortization Payment until October&#160;8, 2026, provided that, as contemplated in the Term Sheet, the Company pays an aggregate of $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45489">1.1</ix:nonFraction>&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(which amount has been paid). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Sheet provides that the Company and the Tranche B Noteholders would enter into an agreement pursuant to which the Tranche B Noteholders shall collectively receive a 10 year, assignable, freely transferable, </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-53</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657384_1" continuedAt="TextSelectionAppend_145657384_2"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657384_2" continuedAt="TextSelectionAppend_145657384_3"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_3" continuedAt="TextSelectionAppend_145657384_4"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657384_4" continuedAt="TextSelectionAppend_145657384_5"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4% royalty on the worldwide Net Sales (as defined therein) of GLOPERBA and ELYXYB, excluding sales of ELYXYB in Canada. Please see section below titled &#8220;Gloperba and Elyxyb Royalty Purchase Agreement&#8221; for a description of such royalty agreement entered into by us. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Senior Secured Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;21, 2025, the Company entered into an amendment letter with Oramed (the &#8220;Oramed Amendment&#8221;), pursuant to which, among other things, Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of <ix:nonFraction name="sclx:SharesDelivered" contextRef="PAsOn01_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45491">92,857</ix:nonFraction> shares of Common Stock held by SCLX JV. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Rest of World License Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025 (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Effective Date</div></div></div></div>&#8221;), Scilex Pharma entered into a License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Agreement</div></div></div></div>&#8221;) with RoyaltyVest Ltd. (the &#8220;Licensee&#8221;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, between Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) <ix:nonFraction name="sclx:PercentageOfLidocaineTopicalSystem" contextRef="P02_22_2025To02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45492">1.8</ix:nonFraction>%, including the composition of matter with the NDC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">69557-111-30</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;SP-103</div> (collectively, the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Product</div></div></div></div>&#8221;). The Lido License Agreement supersedes and replaces the that certain Rest of World License Term Sheet parties entered into on October&#160;8, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido Products outside of the United States and certain territories stated in the Lido License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Licensee Territory</div></div></div></div>&#8221;). The Licensee granted to Scilex Pharma a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable,</div> right and license under the Licensee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (each as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field (each as defined therein). Each of the Licensee and Scilex Pharma will receive <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45493">50</ix:nonFraction>% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $<ix:nonFraction name="sclx:AggregatePaymentOfCompany" contextRef="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45494">200,000</ix:nonFraction>, <div style="letter-spacing: 0px; top: 0px;display:inline;">or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and all existing Lido Products in each country or jurisdiction in the Licensor Territory (as defined therein). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Promptly after the Lido Effective Date, Scilex Pharma is required to (i)&#160;facilitate an introduction between Oishi, Itochu, and the Licensee, and (ii)&#160;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with the Licensee for the manufacturing or supply of the Lido Product in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-54</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657384_5" continuedAt="TextSelectionAppend_145657384_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657384_6" continuedAt="TextSelectionAppend_145657384_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_7" continuedAt="TextSelectionAppend_145657384_8"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_145657384_8" continuedAt="TextSelectionAppend_145657384_9"><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_145657384_9" continuedAt="TextSelectionAppend_145657384_10"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Term</div></div></div></div>&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Parent Guarantee for Lido License Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">On February&#160;22, 2025, in connection with Lido License Agreement, the Company entered into that certain Parent Guarantee for Lidocaine License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Parent Guarantee</div></div></div></div>&#8221;) with the Licensee, pursuant to which the Company agreed to guarantee the due and proper performance of Scilex Pharma&#8217;s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee. Pursuant to the terms of the Parent Guarantee, the Company shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gloperba-Elyxyb Royalty Purchase Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">As contemplated by the Term Sheet in respect of the Royalty and Exclusive Rights described therein, on February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Closing Date&#8221;), the Company entered into a Purchase and Sale Agreement (the &#8220;Gloperba-Elyxyb Royalty Purchase Agreement&#8221;) with Scilex Pharma, certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#8220;Gloperba-Elyxyb RPA Purchasers&#8221;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma sold to the Gloperba-Elyxyb RPA Purchasers the right to receive</div></div>&#160;<ix:nonFraction name="us-gaap:RetailLandSalesReceivablesStatedInterestRate" contextRef="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45496">4</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#160;</div></div><div style="display:inline;">of all aggregate net sales worldwide (the &#8220;Gloperba-Elyxyb Purchased Receivables&#8221;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#8220;Gloperba-Elyxyb Covered Products&#8221;).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In consideration of the Further Deferral and representing the &#8220;grant of the Royalty and Exclusive Rights&#8221; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#8220;Gloperba-Elyxyb Payment Term&#8221;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#8217;s account such Gloperba-Elyxyb RPA Purchaser&#8217;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter (commencing with the calendar quarter beginning January&#160;1, 2025) promptly, but in any event no later than</div></div>&#160;<ix:nonFraction name="sclx:NoOfCalendarDays" contextRef="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45497">60</ix:nonFraction> calendar days after the end of each calendar quarter. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Payment Term. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Royalty Security Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the terms of the Gloperba-Elyxyb Royalty Purchase Agreement, the Company entered into a Security Agreement with Scilex Pharma and the collateral agent (as identified therein) for the benefit of the Gloperba-Elyxyb RPA Purchasers, dated as of February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Royalty Security Agreement&#8221;). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma&#8217;s due performance and payment under the Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered Products. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-55</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_145657384_10" continuedAt="TextSelectionAppend_145657384_11"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_145657384_11" continuedAt="TextSelectionAppend_145657384_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_12" continuedAt="TextSelectionAppend_145657384_13"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_145657384_13" continuedAt="TextSelectionAppend_145657384_14"><div> <div style="line-height:normal;display: inline;"> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> </div> </div></ix:continuation> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657384_14" continuedAt="TextSelectionAppend_145657384_15"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subordination Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, the Company entered into that certain Subordination Agreement, dated as of February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Subordination Agreement&#8221;), by and among the Company, Scilex Pharma the Gloperba-Elyxyb RPA Purchasers and the Note Agent (each as defined in the Subordination Agreement). Pursuant to the Gloperba-Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by first priority liens on the collateral under the Gloperba-Elyxyb Royalty Security Agreement (the &#8220;Gloperba-Elyxyb Royalty Collateral&#8221;) and the Note Agent&#8217;s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a second priority lien. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Amendment No.&#160;1 to ZTlido Royalty Purchase Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;28, 2025, the Company and Scilex Pharma entered into an Amendment No.&#160;1 to Purchase and Sale Agreement (the &#8220;ZTlido Royalty Amendment&#8221;) with the purchasers (the &#8220;ZTlido Royalty Purchasers&#8221;) under that certain Purchase and Sale Agreement, dated as of October&#160;8, 2024 (the &#8220;ZTlido Royalty Purchase Agreement&#8221;). Pursuant to the Royalty Amendment, the Company and Scilex Pharma may assign their respective rights or delegate their respective obligations under the ZTlido Royalty Purchase Agreement without the prior written consent of the Purchasers if the Company receives a commitment, contingent upon an asset purchase of Covered Products (as defined in the ZTlido Royalty Purchase Agreement), that would allow the Company to pay in full all obligations owed under the Debt Instruments (as defined therein), provided that such purchaser of Covered Products agrees to assume all of the obligations of the Company and Scilex Pharma under the ZTlido Royalty Purchase Agreement. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gloperba Rest of World License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;28, 2025 (the &#8220;Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Gloperba License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;collectively, the &#8220;Gloperba Product&#8221;). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Gloperba Product for commercialization of Gloperba Products in the United States in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Gloperba Product for commercialization in the United States in the Field (as defined therein). Each of the Licensee and the Company will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#8217;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-56</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_15" continuedAt="TextSelectionAppend_145657384_16"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657384_16" continuedAt="TextSelectionAppend_145657384_17"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_17" continuedAt="TextSelectionAppend_145657384_18"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657384_18" continuedAt="TextSelectionAppend_145657384_19"><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc"></a></div></div></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657384_19"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Promptly after the Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#8217;s contract manufacturer of the Gloperba Product (the &#8220;Gloperba CMO&#8221;) as of the Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The term of the Gloperba License Agreement commences on the Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Gloperba License Term&#8221;). </div></div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Reverse Stock Split </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share. Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant, which were not affected by the Reverse Stock Split. </div></ix:continuation><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-57 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> </div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin942297_10" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY</div><div id="fin942297_11" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDENSED CONSOLIDATED BALANCE SHEETS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(In thousands, except for par value and share amounts)</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Unaudited) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">March&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45500">5,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45501">3,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45502">10,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45503">26,442</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45504">3,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45505">2,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45506">9,268</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45507">9,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45508">28,704</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45509">41,547</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45510">707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45511">708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45512">2,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45513">2,225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45514">31,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45515">32,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Investments" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45516">2,465</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Investments" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45517">2,420</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45518">13,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45519">13,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45520">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45521">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45522">78,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45523">92,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45524">57,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45525">52,620</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45526">1,654</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45527">1,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued rebates and fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45528">168,429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45529">162,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45530">3,482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45531">2,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45532">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45533">447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45534">39,442</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45535">34,876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased revenue liability, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45536">4,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45537">4,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45538">740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45539">714</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45540">275,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45541">259,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45542">2,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45543">2,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45544">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45545">845</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased revenue liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45546">2,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45547">2,685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45548">7,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45549">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45550">1,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45551">1,523</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45552">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45553">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45554">290,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45555">285,594</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Commitments and contingencies (See Note 11)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Stockholders&#8217; deficit:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45556"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45557">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45558"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45559">45,000,000</ix:nonFraction></ix:nonFraction> shares authorized</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45560"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45561"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45562"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45563">29,057,097</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of each of March&#160;31, 2025 and December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45564">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45565">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series 1, <ix:nonFraction name="sclx:PreferredStockDividendShares" contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45566"><ix:nonFraction name="sclx:PreferredStockDividendShares" contextRef="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45567">5,000,000</ix:nonFraction></ix:nonFraction> shares declared as a stock dividend, not yet distributed as of each of March&#160;31, 2025 and December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45568">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45569">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45570"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45571">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45572"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45573">740,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45574">6,951,622</ix:nonFraction> shares issued and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45575">5,493,359</ix:nonFraction> shares outstanding as of March&#160;31, 2025; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45576">6,951,622</ix:nonFraction> shares issued and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45577">5,235,377</ix:nonFraction> shares outstanding as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45578">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45579">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AdditionalPaidsInCapitals" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45580">448,244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AdditionalPaidsInCapitals" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45581">454,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45582">6,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45583">6,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45584">589,132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45585">563,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Treasury stock, at cost; <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45586">1,458,263</ix:nonFraction> and <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45587">1,716,245</ix:nonFraction> shares as of March&#160;31, 2025 and December&#160;31, 2024, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45588">76,915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45589">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45590">211,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45591">192,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total liabilities and stockholders&#8217; deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45592">78,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45593">92,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-58 </div></div></div></div><div></div></div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY</div><div id="fin942297_12" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(In thousands, except for net loss per share amounts) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Unaudited) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:82%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Net revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45594">5,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45595">10,884</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Net operating costs and expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45596">1,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45597">3,840</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45598">2,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45599">3,108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45600">28,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45601">29,278</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45602">1,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45603">1,027</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal settlements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45604">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45605">6,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total net operating costs and expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45606">32,902</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45607">30,362</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45608">27,898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45609">19,478</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Other (income) expense, net:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Gain) loss on derivative liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45610">10,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45611">457</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of debt and liability instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45612">6,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45613">3,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45614">2,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45615">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Gain) loss on foreign currency exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45616">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45617">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Total other (income) expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45618">1,818</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45619">4,899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45620">26,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45621">24,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders - basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45622"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45623">2.26</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45624"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-45625">8.33</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares during the period - basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45626"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45627">11,565</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45628"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45629">2,926</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-59 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY</div><div id="fin942297_13" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(In thousands) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Unaudited) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Common Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Additional</div><br/> <div style="font-weight:bold;display:inline;"><div style="white-space:nowrap;display:inline;">Paid-in</div><br/> Capital</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other</div><br/> <div style="font-weight:bold;display:inline;">Comprehensive<br/> Income</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated</div><br/> <div style="font-weight:bold;display:inline;">Deficit</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Treasury Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div><br/> <div style="font-weight:bold;display:inline;">Deficit</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance, December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45630">34,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45631">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45632">6,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45633">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45634">454,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45635">6,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45636">563,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45637">1,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45638">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45639">192,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45640">5,353</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45641">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45642">7,535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45643">2,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury Stock paid for Gloperba <div style="white-space:nowrap;display:inline;">Ex-U.S.</div> License</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:TreasuryStockPaidForGloperbaEx-USLicense" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45644">808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45645">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockPaidForGloperbaEx-USLicense" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45646">1,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockPaidForGloperbaEx-USLicense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45647">366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury Stock transferred to Oramed for the Oramed Note maturity extension</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45648">3,523</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45649">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45650">4,898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45651">1,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45652">3,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45653">3,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45654">26,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45655">26,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance, March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45656">34,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45657">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45658">6,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45659">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45660">448,244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45661">6,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45662">589,132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45663">1,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45664">76,915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45665">211,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Common Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Additional</div><br/> <div style="font-weight:bold;display:inline;"><div style="white-space:nowrap;display:inline;">Paid-in</div><br/> Capital</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated</div><br/> <div style="font-weight:bold;display:inline;">Deficit</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Treasury Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div><br/> <div style="font-weight:bold;display:inline;">Deficit</div></td>
<td rowspan="2" style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance, December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45666">29,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45667">4,574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45668">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45669">407,828</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45670">490,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45671">1,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45672">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45673">172,938</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45674">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45675">156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45676">156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued under Bought Deal Offering</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingShare" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45677">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingValue" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45678">3,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:SharesIssuedUnderBoughtDealOfferingValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45679">3,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock options exercised</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45680">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45681">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45682">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45683">3,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45684">3,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45685">24,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45686">24,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance, March&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45687">29,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45688">4,748</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45689">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45690">415,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45691">514,622</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45692">1,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45693">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45694">189,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-60 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY</div><div id="fin942297_14" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(In thousands) </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Unaudited) </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:82%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45695">26,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45696">24,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash proceeds from operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45697">1,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45698">1,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt issuance costs and debt discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45699">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45700">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">Non-cash</div> operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45701">176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45702">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45703">3,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45704">3,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45705">10,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45706">457</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs and allocated expense for financial instruments at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45707">4,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45708">1,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="white-space:nowrap;display:inline;">In-process</div> research and development expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45709">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45710">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45711">6,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45712">3,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45713">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45714">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivables, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45715">15,823</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45716">4,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45717">584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45718">726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45719">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45720">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45721">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45722">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45723">5,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45724">1,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45725">149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45726">1,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45727">841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45728">1,120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued rebates and fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45729">5,912</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45730">14,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:OperatingLeaseLiability1" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45731">170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:OperatingLeaseLiability1" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45732">197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45733">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45734">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net cash proceeds from operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45735">6,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45736">9,391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition consideration paid in cash for Romeg intangible asset acquisition</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45737">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45738">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for <div style="white-space:nowrap;display:inline;">in-process</div> research and development, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45739">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45740">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of convertible promissory note from Denali</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:PurchaseOfConvertiblePromissoryNote" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45741">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchaseOfConvertiblePromissoryNote" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45742">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net cash used for investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45743">395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45744">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45745">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45746">156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Revolving Facility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45747">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45748">32,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Revolving Facility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45749">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45750">33,313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45751">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45752">15,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45753">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45754">4,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Tranche B Notes principal and interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfDebt" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45755">1,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:RepaymentOfDebt" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45756">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments on purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredRevenueRefundPayments1" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45757">797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredRevenueRefundPayments1" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45758">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs paid in connection with share repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45759">396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45760">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares under direct offerings</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45761">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45762">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of direct offering issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45763">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45764">1,277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excise tax paid in connection with share repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ExciseTaxPaidInConnectionWithShareRepurchase" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45765">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ExciseTaxPaidInConnectionWithShareRepurchase" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45766">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of deferred transaction costs related to Semnur Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45767">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45768">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock options exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45769">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45770">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net cash used for financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45771">3,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45772">11,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net change in cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45773">2,528</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45774">1,955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash, cash equivalents and restricted cash at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45775">3,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45776">4,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash, cash equivalents and restricted cash at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45777">5,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45778">2,774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="white-space:nowrap;display:inline;">Non-cash</div> investing and financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs related to February 2024 BDO included in accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45779">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45780">1,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-61 </div></div></div></div><div></div></div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY</div><div id="fin942297_15" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Unaudited) </div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657358" id="ixv-33027"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. Nature of Operations and Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC (&#8220;SCLX JV&#8221;). The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12-hour</div> administration period. In June 2022, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. In January 2025, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the rights to commercialize GLOPERBA outside the U.S. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;) in the third quarter of 2023, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. The Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and the commercialization of ZTlido, ELYXYB and GLOPERBA. </div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657389" id="ixv-33053"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, include all adjustments of a normal recurring nature necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2024 as filed with the SEC on March&#160;31, 2025 (the &#8220;Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K&#8221;).</div> The interim </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-62</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657389" continuedAt="TextSelectionAppend_145657389_1"><ix:continuation id="TextSelection_145657358" continuedAt="TextSelectionAppend_145657358_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_1" continuedAt="TextSelectionAppend_145657358_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_2" continuedAt="TextSelectionAppend_145657358_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657358_3" continuedAt="TextSelectionAppend_145657358_4"><ix:continuation id="TextSelectionAppend_145657389_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025 or for any future <div style="letter-spacing: 0px; top: 0px;display:inline;">periods.</div> </div></ix:continuation><ix:nonNumeric name="sclx:ReverseStockSplitPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33081"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, <ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P04_03_2025To04_03_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="ixv-33086">the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">1-for-35</div></div> (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-Reverse</div> Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.</ix:nonNumeric>&#160;Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33090"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single, reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the unaudited condensed consolidated statements of operations. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the unaudited condensed consolidated statements of operations and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the unaudited condensed consolidated balance sheets. Accordingly, the unaudited condensed consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33096"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657394" id="ixv-33101"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the three months ended March&#160;31, 2025 and 2024, each of which individually generated <ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-45782">10</ix:nonFraction>% or more of the Company&#8217;s total revenue. These customers accounted for <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45783">99</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45784">85</ix:nonFraction>% of the Company&#8217;s revenue for the three months ended March&#160;31, 2025 and 2024, respectively, and individually ranging from <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45785">14</ix:nonFraction>% to <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45786">47</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45787">24</ix:nonFraction>% to <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45788">31</ix:nonFraction>%, respectively. As of March&#160;31, 2025 and 2024, these customers represented <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45789">89</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45790">94</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivable, individually ranging </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-63</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_145657394" continuedAt="TextSelectionAppend_145657394_1"><ix:continuation id="TextSelectionAppend_145657358_4" continuedAt="TextSelectionAppend_145657358_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_5" continuedAt="TextSelectionAppend_145657358_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_6" continuedAt="TextSelectionAppend_145657358_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657358_7" continuedAt="TextSelectionAppend_145657358_8"><ix:continuation id="TextSelectionAppend_145657394_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">between <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45792">18</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45793">37</ix:nonFraction>%, and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45794">25</ix:nonFraction>% and <ix:nonFraction name="sclx:ConcentrationRiskThresholdPercentage" contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45795">36</ix:nonFraction>% for respective periods. Additionally, during the three months ended March&#160;31, 2025 and 2024, the Company purchased ZTlido, ELYXYB and GLOPERBA inventories from its sole suppliers, Itochu, Contract Pharmaceuticals Ltd. Canada (&#8220;CPL&#8221;) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the three months ended March&#160;31, 2025 and <div style="display:inline;">2024.</div> </div></ix:continuation><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33128"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2025, as compared to the significant accounting policies described in Note 1 of the Notes to Consolidated Financial Statements in the Company&#8217;s audited consolidated financial statements included in the Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33133"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the condensed consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 1 - </div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 2 - </div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 3 - </div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33143"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Cash equivalents were immaterial as of March&#160;31, 2025 and December&#160;31, 2024. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657399" id="ixv-33147"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as selling, general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-64</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_145657399" continuedAt="TextSelectionAppend_145657399_1"><ix:continuation id="TextSelectionAppend_145657358_8" continuedAt="TextSelectionAppend_145657358_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_9" continuedAt="TextSelectionAppend_145657358_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657358_10" continuedAt="TextSelectionAppend_145657358_11"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657358_11"><ix:continuation id="TextSelectionAppend_145657399_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company reviews reserves and makes adjustments based on historical experience, current economic conditions and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for credit losses on accounts receivable were $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45797">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45798">1.2</ix:nonFraction>&#160;million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for prompt payment discounts were $<ix:nonFraction name="sclx:AllowancesForPromptPaymentDiscounts" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45799">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="sclx:AllowancesForPromptPaymentDiscounts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45800">0.6</ix:nonFraction>&#160;million,<div style="display:inline;"> respectively.</div> </div></ix:continuation><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33170"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note and Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Tranche B Notes (as defined in Note 2 &#8220;<div style="font-style:italic;display:inline;">Liquidity and Going Concern</div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style:italic;display:inline;">Fair Value Measurements</div>&#8221; below) that were issued in October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of&#160;changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. As of March&#160;31, 2025 and December&#160;31, 2024, the weighted-average interest rates for the short-term loans, including these financial instruments, were <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn03_31_2025_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45801">8.35</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45802">6.67</ix:nonFraction>%, respectively. </div></ix:nonNumeric><ix:nonNumeric name="sclx:TreasuryStockPolicyTextblock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33176"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Treasury Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33180"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space:nowrap;display:inline;">2024-03,</div> <div style="font-style:italic;display:inline;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</div>, which will require additional expense disclosures for all public entities. The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space:nowrap;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space:nowrap;display:inline;">2024-04,</div> <div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options</div>, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space:nowrap;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space:nowrap;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657360" id="ixv-33192"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Liquidity and Going Concern </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-65</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657360" continuedAt="TextSelectionAppend_145657360_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_1" continuedAt="TextSelectionAppend_145657360_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_2" continuedAt="TextSelectionAppend_145657360_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657360_3" continuedAt="TextSelectionAppend_145657360_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45804">500.0</ix:nonFraction>&#160;million of shares of Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#8217;s and B.&#160;Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45805">7,142</ix:nonFraction> commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B.&#160;Riley (the &#8220;B. Riley Commitment Shares&#8221;). On, and effective as of, February&#160;16, 2024, the Company and B.&#160;Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of $<ix:nonFraction name="sclx:Convertibledebentureprincipalamount" contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45806">25.0</ix:nonFraction>&#160;million (the &#8220;Convertible Debentures&#8221;)&#160;for net cash proceeds of $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn03_31_2025_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45807">24.0</ix:nonFraction>&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender made available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $<ix:nonFraction name="sclx:PrincipalLaonAmount" contextRef="P06_27_2023To06_27_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45808">30.0</ix:nonFraction>&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B.&#160;Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;ATM Offering&#8221;) shares of Common Stock up to $<ix:nonFraction name="sclx:CommonStockIssuableValue" contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45809">170.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the ATM Offering. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. During the three months ended March&#160;31, 2025, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-45810">no</ix:nonFraction> sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45811">2,637</ix:nonFraction>&#160;shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2024To03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45812">0.1</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#8220;Commitment Letter&#8221;) with FSF 33433 LLC (&#8220;FSF Lender&#8221;), pursuant to which FSF Lender committed to provide the Company a loan (the &#8220;FSF Loan&#8221;) in the aggregate amount of $<ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45813">100.0</ix:nonFraction>&#160;million (the &#8220;Commitment Amount&#8221;). The Commitment Amount shall be payable as follows: (i) $<ix:nonFraction name="sclx:CommitmentAmountPayable" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45814">85.0</ix:nonFraction>&#160;million no later than the date that is <ix:nonNumeric name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="P06_11_2024To06_11_2024" format="ixt-sec:durday" id="ixv-45815">70</ix:nonNumeric> days following the date on which the Company receives the FSF Deposit (as defined below) (the &#8220;Outside Date&#8221; and the funding of the initial $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45816">85.0</ix:nonFraction>&#160;million, the &#8220;Initial Closing&#8221;) and (ii)&#160;the remaining $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45817">15.0</ix:nonFraction>&#160;million within <ix:nonNumeric name="sclx:CompanyReceivesTheDepositPeriod" contextRef="P06_11_2024To06_11_2024" format="ixt-sec:durday" id="ixv-45818">60</ix:nonNumeric> days following the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-66</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657360_4" continuedAt="TextSelectionAppend_145657360_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_5" continuedAt="TextSelectionAppend_145657360_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_6" continuedAt="TextSelectionAppend_145657360_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657360_7" continuedAt="TextSelectionAppend_145657360_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial Closing (the funding of the second $<ix:nonFraction name="sclx:CompanyReceivesTheDepositAmount" contextRef="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45820">15.0</ix:nonFraction>&#160;million, the &#8220;Second Closing&#8221;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a <div style="white-space:nowrap;display:inline;">non-refundable</div> deposit in immediately available funds in the aggregate principal amount of $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45821">10.0</ix:nonFraction>&#160;million (the &#8220;FSF Deposit&#8221; and the date on which such funds are fully received, the &#8220;Deposit Date&#8221;), which amount was creditable towards the $<ix:nonFraction name="sclx:NonRefundableDepositAmount" contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45822">85.0</ix:nonFraction>&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_18_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-45823">3,250,000</ix:nonFraction> shares of the Common Stock (subject to adjustment for any stock dividend, stock split or similar transaction, provided that there shall not be any adjustment to the exercise price of the warrant in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares) (the &#8220;Deposit Warrant&#8221;), with an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfTheWarrants" contextRef="PAsOn06_18_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45824">1.20</ix:nonFraction> per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#8220;Satisfaction Agreement&#8221;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#8220;Endeavor&#8221;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#8220;Additional Product&#8221;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor would not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45825">13.2</ix:nonFraction>&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company was to fail to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $<ix:nonFraction name="us-gaap:LossContingencyAccrualProductLiabilityGross" contextRef="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45826">20,000,000</ix:nonFraction>. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#8220;Tranche B Securities Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;, and together with the Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45827">50.0</ix:nonFraction>&#160;million (the &#8220;Tranche B Notes&#8221;), which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45828">36.40</ix:nonFraction> per share. In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45829">22,500,000</ix:nonFraction> in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $<ix:nonFraction name="sclx:ReductionOfThePrincipalBalance" contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45830">22,500,000</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the Company&#8217;s negative working capital was $<ix:nonFraction name="sclx:WorkingCapital" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45831">247.0</ix:nonFraction>&#160;million, including cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45832">5.8</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2025, the Company had operating losses of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-45833">27.9</ix:nonFraction>&#160;million and cash flows received from operating activities of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45834">6.0</ix:nonFraction>&#160;million. The Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-45835">589.1</ix:nonFraction>&#160;million as of March&#160;31, 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the FSF Deposit or otherwise) for at least twelve months from the issuance of these unaudited condensed consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA and ELYXYB are still in the early stages of commercialization.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-67</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657360_8" continuedAt="TextSelectionAppend_145657360_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_9" continuedAt="TextSelectionAppend_145657360_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657360_10" continuedAt="TextSelectionAppend_145657360_11"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657360_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are<div style="letter-spacing: 0px; top: 0px;display:inline;"> issued.</div> </div></ix:continuation><ix:nonNumeric name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657362" id="ixv-33261"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Acquisitions and License Agreements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space:nowrap;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $<ix:nonFraction name="sclx:AmountDueForNewDrugApplication" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45837">3.0</ix:nonFraction>&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45838">20.0</ix:nonFraction>&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of each of March 31, 2025 and December&#160;31, 2024, the contingent consideration associated with the Development Milestone Payment was $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45839">0.2</ix:nonFraction>&#160;million, recorded in the other long-term liabilities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022, the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;) for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensing</div> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#8220;Romeg License Agreement&#8221;). Under the Romeg License Agreement, among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> specified therein, to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; and (2)&#160;an exclusive license, with a right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory and (b)&#160;use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45840">2.0</ix:nonFraction>&#160;million, (2)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45841">13.0</ix:nonFraction>&#160;million, (3)&#160;certain royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Royalty Term, with a quarterly minimum royalty of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45842">150,000</ix:nonFraction>, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-single</div> digit </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-68</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657362" continuedAt="TextSelectionAppend_145657362_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_1" continuedAt="TextSelectionAppend_145657362_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_2" continuedAt="TextSelectionAppend_145657362_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657362_3" continuedAt="TextSelectionAppend_145657362_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory during the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory Royalty Term and (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> payment of $<ix:nonFraction name="sclx:Non-RefundableNon-CreditablePayment" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45844">700,000</ix:nonFraction>. Pursuant to the amendment agreement, we also transferred to Romeg <ix:nonFraction name="sclx:TransferOfCommonStockShares" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45845">22,267</ix:nonFraction> shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45846">5.7</ix:nonFraction>&#160;million, which is comprised of the upfront license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45847">2.0</ix:nonFraction>&#160;million and deferred consideration of $<ix:nonFraction name="sclx:Deferredconsiderationliabilities" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45848">3.7</ix:nonFraction>&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. For each of the three months ended March&#160;31, 2025 and 2024, the Company made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To03_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45849"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2025To03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45850">0.2</ix:nonFraction></ix:nonFraction>&#160;million. <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45851">No</ix:nonFraction> contingent consideration was recognized as a liability or included in the fair value of the assets as of March&#160;31, 2025 or December&#160;31, 2024.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ELYXYB Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and patents of DRL related to ELYXYB that is necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company had ending balances of accrued royalty payables of $<ix:nonFraction name="sclx:AccruedRoyaltyPayables" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45852"><ix:nonFraction name="sclx:AccruedRoyaltyPayables" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45853">0.1</ix:nonFraction></ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2025, the Company made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45854">0.1</ix:nonFraction>&#160;million. The Company did <ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45855">no</ix:nonFraction>t make any royalty payments during the three months ended March&#160;31, 2024. As of March&#160;31, 2025, <ix:nonFraction name="sclx:PaymentToAcquireLicense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-45856">no</ix:nonFraction> sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Rest of World License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025 (the &#8220;Lido Effective Date&#8221;), Scilex Pharma entered into a License Agreement (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Agreement</div></div>&#8221;) with RoyaltyVest Ltd. (the &#8220;Licensee&#8221;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, among Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) <ix:nonFraction name="sclx:PercentageOfLidocaineTopicalSystem" contextRef="P02_22_2025To02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45857">1.8</ix:nonFraction>%, including the composition of matter with the NDC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">69557-111-30</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;SP-103</div> (collectively, the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Product</div></div>&#8221;). The Lido License Agreement supersedes and replaces that certain Rest of World License Term Sheet the parties entered into on October&#160;8, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-69</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657362_4" continuedAt="TextSelectionAppend_145657362_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_5" continuedAt="TextSelectionAppend_145657362_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_6" continuedAt="TextSelectionAppend_145657362_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657362_7" continuedAt="TextSelectionAppend_145657362_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Products outside of the United States and certain territories stated in the Lido License Agreement (the &#8220;<div style="font-style:italic;display:inline;">Lido Licensee Territory</div>&#8221;). The Licensee granted to Scilex Pharma a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable,</div> right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field. Each of the Licensee and Scilex Pharma will receive <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="PAsOn02_22_2025_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45859">50</ix:nonFraction>% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $<ix:nonFraction name="sclx:AggregatePaymentOfCompany" contextRef="PAsOn02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45860">200,000</ix:nonFraction>, or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for <div style="white-space:nowrap;display:inline;">SP-103</div> and all existing Lido Products in each country or jurisdiction in the Licensor Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Lido License Term&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Gloperba Rest of World License Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Gloperba Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Gloperba License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#8220;Gloperba Product&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit the Gloperba Product for commercialization of the Gloperba Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture the Gloperba Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="PAsOn02_28_2025_GloperbaRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45861">50</ix:nonFraction>% of the Net Revenue (as defined therein) generated based on Licensee&#8217;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Gloperba Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#8217;s contract manufacturer of the Gloperba Product (the &#8220;Gloperba CMO&#8221;) as of the Gloperba Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-70</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657362_8" continuedAt="TextSelectionAppend_145657362_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_9" continuedAt="TextSelectionAppend_145657362_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657362_10" continuedAt="TextSelectionAppend_145657362_11"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657362_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Gloperba License Agreement commences on the Gloperba Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Gloperba License Term&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Elyxyb Rest of World License Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Elyxyb Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Elyxyb License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Elyxyb that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Elyxyb APA, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#8220;Elyxyb Product&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Elyxyb License Agreement, the Company granted to the Licensee during the Elyxyb License Term (as defined below) a worldwide, exclusive, <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Elyxyb License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Elyxyb Products, in all cases solely for commercialization of the Elyxyb Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Elyxyb License Agreement), right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Elyxyb Product for commercialization of Elyxyb Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture Elyxyb Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="PAsOn02_28_2025_ElyxybRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-45863">50</ix:nonFraction>% of the Canadian Net Revenue (as defined therein) generated based on the Licensee&#8217;s sale of the Elyxyb Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Canadian Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Elyxyb License Agreement, the Licensee shall obtain and maintain regulatory approval for the Elyxyb Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Elyxyb Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and CPL as of the Elyxyb Effective Date, and (ii)&#160;use reasonable efforts to cause CPL to accept a direct engagement with the Licensee for the manufacturing or supply of the Elyxyb Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Elyxyb Product in the entire world other than the United States during the Elyxyb License Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Elyxyb License Agreement commences on the Elyxyb Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Elyxyb License Term&#8221;). </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-71 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657364" id="ixv-33401"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Fair Value Measurements </div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33403"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45864">14,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;<ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45865">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;<ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45866">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45867">14,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45868">24,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45869">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45870">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45871">24,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45872">7,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45873">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45874">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45875">7,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657740;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45876">7,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45877">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45878">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45879">7,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45880">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45881">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45882">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45883">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45884">54,791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45885">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45886">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45887">54,791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45888">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;<ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45889">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;<ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45890">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45891">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45892">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45893">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45894">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45895">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45896">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45897">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657741;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45898">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45899">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45900">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45901">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45902">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45903">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45904">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45905">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45906">60,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45907">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-45908">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45909">60,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_01_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45910">101.9</ix:nonFraction>&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of March&#160;31, 2025 and December&#160;31, 2024 was determined to be $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45911">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45912">12.2</ix:nonFraction>&#160;million, respectively, by applying a discount rate of <ix:nonFraction name="sclx:SecuredNoteDiscountRate" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45913">129.07</ix:nonFraction>% and <ix:nonFraction name="sclx:SecuredNoteDiscountRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45914">128.82</ix:nonFraction>%, respectively. For the three months ended March&#160;31, 2025 and 2024, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45915">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2024To03_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45916">3.8</ix:nonFraction>&#160;million in change in fair value of the Oramed Note in the unaudited condensed consolidated statements of operations, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45917">50.0</ix:nonFraction>&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-72</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657364" continuedAt="TextSelectionAppend_145657364_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657364_1" continuedAt="TextSelectionAppend_145657364_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657364_2" continuedAt="TextSelectionAppend_145657364_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657364_3" continuedAt="TextSelectionAppend_145657364_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranche B Notes are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45919">24.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45920">23.6</ix:nonFraction>&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45921">2.5</ix:nonFraction>&#160;million in change in fair value of the Tranche B Notes in the unaudited condensed consolidated statement of operations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Purchased Revenue Liability </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into a Purchase and Sale Agreement (&#8220;ZTlido Royalty Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;ZTlido Royalty Investors&#8221;) and Oramed (see Note 7). In February 2025, the Company also entered into a Purchase and Sale Agreement (&#8220;Gloperba-Elyxyb Royalty Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability for both agreements with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The aggregate fair value of both agreements as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $<ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45922">7.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45923">6.8</ix:nonFraction>&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2025To03_31_2025_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45924">0.8</ix:nonFraction>&#160;million in change in fair value of the purchased revenue liability in the unaudited condensed consolidated statement of operations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2025To03_31_2025_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-45925">10.4</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, Deposit Warrant, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each as defined below). The Company recorded a loss of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To03_31_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45926">0.5</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2024, attributed to warrant liability consisting of the Private Warrants and the February 2024 BDO Firm Warrants. The Company assumed the private placement warrants from Vickers in November 2022 in connection with the Business Combination (the &#8220;Private Warrants&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45927">1,000,000</ix:nonFraction>&#160;Private Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45928">28,572</ix:nonFraction>&#160;shares of Common Stock, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45929">3,803,447</ix:nonFraction>&#160;February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45930">108,686</ix:nonFraction>&#160;shares of Common Stock, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45931">15,000,000</ix:nonFraction> April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45932">428,572</ix:nonFraction> shares of Common Stock, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45933">3,250,000</ix:nonFraction> Deposit Warrant, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45934">3,250,000</ix:nonFraction> shares of Common Stock, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45935">7,500,000</ix:nonFraction>&#160;October 2024 Noteholder Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45936">214,284</ix:nonFraction>&#160;shares of Common Stock, and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45937">57,512,958</ix:nonFraction>&#160;December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-45938">1,642,871</ix:nonFraction> shares of Common Stock. As of March&#160;31, 2025, the fair value of derivative warrant liabilities related to these warrants was $<ix:nonFraction name="sclx:DerivativeWarrantLiabilities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-45939">7.9</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33916"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45940">18,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-45941">10,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-45942">7,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-73</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657364_4" continuedAt="TextSelectionAppend_145657364_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657364_5" continuedAt="TextSelectionAppend_145657364_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657364_6" continuedAt="TextSelectionAppend_145657364_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657364_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be a Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#8217;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (as defined below), described in Note 9 of the Notes to Consolidated Financial Statements in the Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div></div><ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-33988"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of March&#160;31, 2025 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45944">402.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45945">59.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45946">38.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45947">1.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45948">36.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45949">22.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45950">22.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:duryear" id="ixv-45951">2.61</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45952">3.93</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45953">4.07</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45954">4.22</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45955">4.52</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-45956">4.70</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-45957">2.20</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45958">109.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45959">85.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45960">83.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45961">76.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45962">80.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45963">79.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45964">98.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45965">3.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45966">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45967">3.89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45968">3.89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45969">3.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45970">3.91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-45971">3.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45972">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45973">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45974">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45975">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45976">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45977">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45978">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45979">402.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45980">59.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45981">38.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45982">1.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45983">36.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45984">22.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-45985">22.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-45986">2.86</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45987">4.18</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45988">4.32</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45989">4.47</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:duryear" id="ixv-45990">4.77</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-45991">4.95</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-45992">2.45</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45993">109.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45994">81.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45995">80.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45996">73.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45997">77.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45998">76.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-45999">95.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46000">4.22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46001">4.29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46002">4.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46003">4.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46004">4.32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46005">4.33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-46006">4.21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46007">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46008">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46009">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46010">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46011">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46012">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46013">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Contingent Consideration Related to <div style="white-space:nowrap;display:inline;">SP-104</div> Acquisition </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space:nowrap;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space:nowrap;display:inline;">SP-104,</div> the Company will transfer $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46014">3.0</ix:nonFraction>&#160;million in cash or shares of Common Stock to Aardvark, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space:nowrap;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space:nowrap;display:inline;">SP-104,</div> and a discount rate of <ix:nonFraction name="us-gaap:ProductLiabilityContingencyAccrualDiscountRate" contextRef="PAsOn03_31_2025" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-46015">9.6</ix:nonFraction>%. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of contingent consideration related to the Development Milestone Payment was $<ix:nonFraction name="sclx:FairValueOfContingentConsideration" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46016">0.2</ix:nonFraction>&#160;million. </div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657367" id="ixv-34458"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. Balance Sheet Components </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Convertible Promissory Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#8220;Denali&#8221;) issued a convertible promissory note (the &#8220;Convertible Promissory Note&#8221;) in the total principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46017">180,000</ix:nonFraction> to the Company. The Convertible Promissory Note was issued with an initial principal balance of $<div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46018">15,063.74</ix:nonFraction></div>, with the remaining $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46019">164,936.26</ix:nonFraction> drawable at Denali&#8217;s request and upon the consent of the Company prior to the maturity of the </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-74 </div></ix:exclude></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_145657367" continuedAt="TextSelectionAppend_145657367_1"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_145657367_1" continuedAt="TextSelectionAppend_145657367_2"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657367_2" continuedAt="TextSelectionAppend_145657367_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#8217;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46020">164,936.26</ix:nonFraction> principal amount available under the Convertible Promissory Note are expected to fund future <div style="white-space:nowrap;display:inline;">one-month</div> extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46021">10.00</ix:nonFraction> per ordinary share (the &#8220;Conversion Shares&#8221;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), in connection with Denali&#8217;s initial public offering (the &#8220;IPO&#8221;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. <ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-46022">No</ix:nonFraction> interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of March&#160;31, 2025 and December&#160;31, 2024, the balance of the Convertible Promissory Note was $<ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="PAsOn03_31_2025_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46023">120.5</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46024">75.3</ix:nonFraction>&#160;thousand, respectively, as a result of additional draws after the initial amount. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (as may be amended or restated from time to time in accordance with its terms, including by Amendment No.&#160;1 and Amendment No.&#160;2 thereto, dated as of April&#160;16, 2025 (&#8220;Amendment No.1&#8221;) and July&#160;22, 2025, respectively, the &#8220;Semnur Business Combination Agreement&#8221;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#8220;Denali Merger Sub&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Semnur Business Combination&#8221;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and <div style="white-space:nowrap;display:inline;">de-register</div> in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Domestication&#8221;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#8220;New Semnur Common Shares&#8221;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares&#8221;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#8220;New Semnur Warrants&#8221;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#8220;Effective Time&#8221;): (i) each share of common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2025_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="5" scale="0" format="ixt:num-dot-decimal" id="ixv-46025">0.00001</ix:nonFraction> per share, of Semnur (the &#8220;Semnur Common Stock&#8221;), issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and <div style="white-space:nowrap;display:inline;">(b)&#160;one-tenth</div> of one New Semnur Common Share, and (iii)&#160;subject to Denali&#8217;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. Pursuant to Amendment No.&#160;1, among other things, the parties agreed to (i)&#160;modify certain covenants of the parties to address the potential delisting of the Denali ordinary shares and warrants from the Nasdaq Capital </div></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_3" continuedAt="TextSelectionAppend_145657367_4"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-75 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657367_4" continuedAt="TextSelectionAppend_145657367_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_5" continuedAt="TextSelectionAppend_145657367_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_6" continuedAt="TextSelectionAppend_145657367_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657367_7" continuedAt="TextSelectionAppend_145657367_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market, (ii)&#160;extend the Outside Date (as defined in Amendment No.&#160;1) to September&#160;30, 2025, and (iii)&#160;require Denali to amend its organizational documents to extend the period of time within which Denali can complete a business combination to December&#160;11, 2025, or such other date that is mutually agreed to by Semnur and Denali. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business Combination, these costs will be classified in stockholders&#8217; deficit as a reduction of additional <div style="white-space:nowrap;display:inline;">paid-in</div> capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations. As of March&#160;31, 2025 and December&#160;31, 2024, deferred offering costs related to the Semnur Business Combination totaled $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46026">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46027">6.0</ix:nonFraction>&#160;million, respectively, and were included in prepaid expenses and other current assets in the Company&#8217;s unaudited condensed consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution and delivery of the Semnur Business Combination Agreement, the Sponsor and the Company entered into a Sponsor Interest Purchase Agreement (the &#8220;SIPA&#8221;) dated August&#160;30, 2024 (the &#8220;Signing Date&#8221;). Pursuant to the SIPA, the Company agreed to purchase <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46028">500,000</ix:nonFraction> Class&#160;B ordinary shares, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-46029">0.0001</ix:nonFraction> per share, of Denali (the &#8220;Purchased Interests&#8221;) that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46030">2,000,000</ix:nonFraction> (the &#8220;Cash Consideration&#8221;) and (ii) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46031">8,571</ix:nonFraction> shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#8217;s own stock and meets the conditions to be classified in equity under FASB ASC 815, <div style="font-style:italic;display:inline;">Derivatives and Hedging</div>. The Purchased Interests will convert automatically, on a <div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">one-for-one</div></div> basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price, which consists of the $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46032">2,000,000</ix:nonFraction> paid by the Company to the Sponsor and the value of the <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46033">8,571</ix:nonFraction> shares of the Common Stock at the closing price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46034">40</ix:nonFraction> per share on the Signing Date for a total of $<ix:nonFraction name="us-gaap:CapitalUnitsNetAmount" contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46035">2.3</ix:nonFraction>&#160;million. The Company elected to subsequently measure the investment at cost less any impairment. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company&#8217;s investment in the Purchased Interests had a balance of $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2025To03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46036">2.3</ix:nonFraction>&#160;million. <ix:nonFraction name="sclx:ImpairmentLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-46037">No</ix:nonFraction> impairment loss was recognized during the three months ended March&#160;31, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Property and equipment, net </div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-34521"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2025_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46038">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46039">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2025_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46040">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46041">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2025_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46042">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46043">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2025_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46044">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46045">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46046">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46047">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46048">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46049">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46050">707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46051">708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46052">1.0</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46053">4.0</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </div></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_8" continuedAt="TextSelectionAppend_145657367_9"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-76 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657367_9" continuedAt="TextSelectionAppend_145657367_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_10" continuedAt="TextSelectionAppend_145657367_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657367_11" continuedAt="TextSelectionAppend_145657367_12"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657367_12"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div><ix:nonNumeric name="sclx:AccruedExpensesTextblock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-34688"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46054">2,153</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46055">667</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46056">337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46057">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46058">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46059">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46060">663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46061">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46062">147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46063">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46064">3,482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46065">2,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657369" id="ixv-34808"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Goodwill and Intangible Assets </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, the Company had recorded goodwill of $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46066"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46067">13.5</ix:nonFraction></ix:nonFraction>&#160;million. <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-46068"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-46069">No</ix:nonFraction></ix:nonFraction> goodwill impairment was recognized for the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, with remaining useful lives ranging from <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-46070">6.58</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-46071">12.75</ix:nonNumeric> years. <ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657437" id="ixv-46072">A summary of the Company&#8217;s identifiable intangible assets as of March&#160;31, 2025 and December&#160;31, 2024 is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_145657437"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46073">32,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46074">18,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46075">14,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46076">21,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46077">9,509</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46078">12,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46079">5,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46080">1,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46081">4,704</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46082">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46083">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46084">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46085">60,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46086">29,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46087">31,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46088">32,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46089">17,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46090">14,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46091">21,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46092">9,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46093">12,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46094">5,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46095">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46096">4,796</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46097">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46098">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46099">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46100">60,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46101">28,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46102">32,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the weighted average remaining life for identifiable intangible assets was <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:duryear" id="ixv-46103">8.3</ix:nonNumeric> years. Aggregate amortization expense was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46104">1.0</ix:nonFraction>&#160;million for each of the three months ended March&#160;31, 2025 and 2024. Patent rights, acquired technology and acquired licenses are amortized over a <div style="white-space:nowrap;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn03_31_2025_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-46105">15</ix:nonNumeric>-year</div> period. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-77 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657369" continuedAt="TextSelectionAppend_145657369_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657369_1" continuedAt="TextSelectionAppend_145657369_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657369_2" continuedAt="TextSelectionAppend_145657369_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657369_3"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-35141"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of March&#160;31, 2025 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46106">3,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46107">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46108">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46109">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46110">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46111">12,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46112">31,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657373" id="ixv-35222"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">7. Debt </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46113">101.9</ix:nonFraction>&#160;million, was to mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46114"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46115">March 21, 2025</ix:nonNumeric></ix:nonNumeric>. It is payable in six principal installments, with the first installment of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46116">5.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46117"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46118">December 21, 2023</ix:nonNumeric></ix:nonNumeric>, the second installment in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46119">15.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-46120"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-46121">March 21, 2024</ix:nonNumeric></ix:nonNumeric>, the next three installments each in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46122">20.0</ix:nonFraction>&#160;million payable on each of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46123"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46124">June 21, 2024</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46125"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46126">September 21, 2024</ix:nonNumeric></ix:nonNumeric> and <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-46127"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-46128">December 21, 2024</ix:nonNumeric></ix:nonNumeric> and the last installment in the entire remaining principal balance of the Oramed Note payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46129"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46130">March 21, 2025</ix:nonNumeric></ix:nonNumeric>. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P01_01_2025To03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" id="ixv-35227">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable <div style="white-space:nowrap;display:inline;">in-kind</div> on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space:nowrap;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).</ix:nonNumeric> Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the ATM Sales Agreement, the Company made a mandatory prepayment of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46131">9,578,835</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46132">7,000,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2025To03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46133">1,760,796</ix:nonFraction>, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from each of the April 2024 RDO, the FSF Deposit and the sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-78 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657373" continuedAt="TextSelectionAppend_145657373_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_1" continuedAt="TextSelectionAppend_145657373_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_2" continuedAt="TextSelectionAppend_145657373_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657373_3" continuedAt="TextSelectionAppend_145657373_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025, the fair value of the Oramed Note was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46134">15.0</ix:nonFraction>&#160;million, which is classified as a current liability in the unaudited condensed consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Company and Oramed entered into a Letter Agreement (the &#8220;Oramed Letter Agreement&#8221;), pursuant to which the Company agreed to pay to Oramed $<ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_20_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46135">2,000,000</ix:nonFraction> (the &#8220;Specified September Payment&#8221;) on September&#160;23, 2024, which payment was applied as follows: (i) $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46136">1,700,000</ix:nonFraction> was applied to the amortization payment due under the Oramed Note on the <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46137">March 21, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and (y) $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46138">300,000</ix:nonFraction> to purchase an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn03_31_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46139">4,000,000</ix:nonFraction>&#160;SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock) owned by Oramed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined in the Oramed Note) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined in the Oramed Note) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_01_2025To03_31_2025_MinimumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46140">0</ix:nonFraction>, and (ii)&#160;to extend the due date of the $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_01_2025To03_31_2025_MaximumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46141">20,000,000</ix:nonFraction> amortization payment from <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46142">September 23, 2024</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46143">September 30, 2024</ix:nonNumeric>. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed under which: (i)&#160;the Company made a payment of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46144">12,500,000</ix:nonFraction> to Oramed in lieu of the payment due on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-46145">September 23, 2024</ix:nonNumeric>, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46146">15,000,000</ix:nonFraction> payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of <ix:nonFraction name="sclx:SharesDelivered" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46147">92,857</ix:nonFraction> shares of Common Stock held by SCLX JV, with a fair value of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_OramedMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46148">1.4</ix:nonFraction>&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the Oramed Note was $<ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46149">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46150">12.2</ix:nonFraction>&#160;million, respectively, which is classified as debt, current in the consolidated balance sheets. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-79</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657373_4" continuedAt="TextSelectionAppend_145657373_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_5" continuedAt="TextSelectionAppend_145657373_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_6" continuedAt="TextSelectionAppend_145657373_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657373_7" continuedAt="TextSelectionAppend_145657373_8"><ix:nonNumeric name="sclx:ScheduleOfTheOramedNoteTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-35270"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46152">12,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Oramed Note - recorded in the consolidated statements of operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebentures" contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46153">2,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46154">14,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46155">36.40</ix:nonFraction> per share and (ii)&#160;warrants (the &#8220;October 2024 Noteholder Warrants&#8221;) to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46156">214,284</ix:nonFraction> shares of Common Stock directly to the Tranche B Noteholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46157">22,500,000</ix:nonFraction> in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note of $<ix:nonFraction name="sclx:ReductionOfThePrincipalBalance" contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46158">22,500,000</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are immediately exercisable for cash at a current exercise price equal to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46159">36.40</ix:nonFraction> per share and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46160">107,142</ix:nonFraction> shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46161">107,142</ix:nonFraction> shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#8220;StockBlock&#8221;) and its affiliate, Rodman&#160;&amp; Renshaw LLC (together, the &#8220;October 2024 Placement Agents&#8221;) or their respective designees, (i) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_08_2024_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46162">62,794</ix:nonFraction> shares of Common Stock (the &#8220;October 2024 Placement Agent Shares&#8221;) and (ii)&#160;warrants to purchase up to <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn10_31_2024_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46163">104,848</ix:nonFraction> shares of Common Stock (the &#8220;October 2024 Placement Agent Warrants&#8221;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the October 2024 Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement for $<ix:nonFraction name="us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46164">5.0</ix:nonFraction>&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables (as defined below) in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $<ix:nonFraction name="sclx:ProceedsReceivedFromPurchaseAgreement" contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46165">50.0</ix:nonFraction>&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46166">2.6</ix:nonFraction>&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statements of operations during the year ended December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025, the Company was required to redeem in cash (the &#8220;First Amortization Payment&#8221;) such portion of the principal amount of the Tranche B Notes equal to each </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-80</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657373_8" continuedAt="TextSelectionAppend_145657373_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_9" continuedAt="TextSelectionAppend_145657373_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_10" continuedAt="TextSelectionAppend_145657373_11"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657373_11" continuedAt="TextSelectionAppend_145657373_12"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranche B Noteholder&#8217;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46168">6,250,000</ix:nonFraction> per fiscal quarter at a redemption price equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46169">100</ix:nonFraction>% of such Amortization Amount (as defined in the Tranche B Notes). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#8220;Nomis Bay Consent&#8221;), (ii) Oramed (the &#8220;Oramed Consent&#8221;) and (iii) 3i, LP (the &#8220;3i Consent&#8221; and, collectively with the Nomis Bay Consent and the Oramed Consent, the &#8220;Tranche B Consents&#8221;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#8217;s obligation to make the First Amortization Payment until January&#160;31, 2025 and then further to October&#160;8, 2026. In consideration of such deferral, (i)&#160;SCLX JV delivered to the Tranche B Noteholders an aggregate of <ix:nonFraction name="sclx:TotalNumberOfSharesGranted" contextRef="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46170">142,855</ix:nonFraction> shares of Common Stock held by SCLX JV, with a fair value of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TrancheBNoteMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46171">2.2</ix:nonFraction>&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations, (ii)&#160;the Company paid an aggregate of $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="P01_02_2025To01_02_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46172">1.1</ix:nonFraction>&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest, and (iii)&#160;the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement (as described below). </div><ix:nonNumeric name="sclx:ScheduleOfTheTrancheBNoteTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-35352"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche&#160;B Notes (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46173">23,560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Tranche B Notes principal and interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfTrancheBNotes" contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46174">1,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfTrancheBNotes" contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46175">2,516</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:TrancheBNote" contextRef="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46176">24,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate principal repayments for the Company&#8217;s outstanding debt will be $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2025To12_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46177">46.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2026To12_31_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46178">19.3</ix:nonFraction>&#160;million in 2025 and 2026, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">ZTlido Royalty Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive <ix:nonFraction name="srt:FederalFundsPurchasedAverageRatePaid" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46179">8</ix:nonFraction>% of all aggregate net sales worldwide (the &#8220;ZTlido Purchased Receivables&#8221;) with respect to ZTlido, <div style="white-space:nowrap;display:inline;">SP-103</div> and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $<ix:nonFraction name="us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46180">5.0</ix:nonFraction>&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $<ix:nonFraction name="sclx:PaidToRoyaltyInvestors" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46181">2.5</ix:nonFraction>&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $<ix:nonFraction name="us-gaap:PaymentsToAcquireReceivables" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46182">2.5</ix:nonFraction>&#160;million minus Oramed&#8217;s expenses (the amount so paid by the ZTlido Royalty Purchasers, collectively, the &#8220;ZTlido RPA Closing Payment&#8221;). Oramed&#8217;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46183">2.5</ix:nonFraction>&#160;million of the outstanding balance under the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ZTlido Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. </div></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_12" continuedAt="TextSelectionAppend_145657373_13"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-81 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657373_13" continuedAt="TextSelectionAppend_145657373_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_14" continuedAt="TextSelectionAppend_145657373_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657373_15" continuedAt="TextSelectionAppend_145657373_16"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657373_16"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2025To03_31_2025_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46184">6.8</ix:nonFraction>&#160;million, recorded as a purchased revenue liability on the consolidated balance sheets. The Company incurred $<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46185">0.2</ix:nonFraction>&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. </div><ix:nonNumeric name="sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-35438"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn12_31_2024_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46186">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="sclx:RepaymentOfPurchasedRevenueLiability" contextRef="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46187">797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:ChangeInFairValueOfPurchasedRevenueLiability" contextRef="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46188">797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:PurchasedRevenueLiability" contextRef="PAsOn03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46189">6,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Gloperba-Elyxyb Royalty Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Closing Date&#8221;), the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement with certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#8220;Gloperba-Elyxyb RPA Purchasers&#8221;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma transferred to the Gloperba-Elyxyb RPA Purchasers the right to receive <ix:nonFraction name="us-gaap:RetailLandSalesReceivablesStatedInterestRate" contextRef="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46190">4</ix:nonFraction>% of all aggregate net sales worldwide (the &#8220;Gloperba-Elyxyb Purchased Receivables&#8221;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#8220;Gloperba-Elyxyb Covered Products&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the Further Deferral and representing the &#8220;grant of the Royalty and Exclusive Rights&#8221; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#8220;Gloperba-Elyxyb Payment Term&#8221;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#8217;s account, such Gloperba-Elyxyb RPA Purchaser&#8217;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter no later than <ix:nonFraction name="sclx:NoOfCalendarDays" contextRef="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46191">60</ix:nonFraction> calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Gloperba-Elyxyb Payment Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the Gloperba-Elyxyb Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of February&#160;28, 2025 and&#160;March&#160;31, 2025, the fair value of the ZTlido Royalty Purchase Agreement was $<ix:nonFraction name="sclx:PurchasedRevenueLiabilityCurrent" contextRef="PAsOn03_31_2025_ZTlidoRoyaltyMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46192">0.5</ix:nonFraction>&#160;million, recorded as a purchased revenue liability on the unaudited condensed consolidated balance sheet.</div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145658315" id="ixv-35505"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">8. Sorrento Stock Purchase Agreement </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into that certain Stock Purchase Agreement (the &#8220;Sorrento SPA&#8221;) with Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, pursuant to which the </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-82 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145658315" continuedAt="TextSelectionAppend_145658315_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658315_1" continuedAt="TextSelectionAppend_145658315_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658315_2" continuedAt="TextSelectionAppend_145658315_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658315_3" continuedAt="TextSelectionAppend_145658315_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company purchased from Sorrento (i) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46193">1,716,245</ix:nonFraction> shares of Common Stock, (ii) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46194">29,057,097</ix:nonFraction> shares of Series A Preferred Stock, par value $<ix:nonFraction name="sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-46195">0.0001</ix:nonFraction> per share (the &#8220;Series A Preferred Stock&#8221;), and (iii) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46196">1,386,617</ix:nonFraction> Public Warrants (as defined below), which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46197">39,617</ix:nonFraction> shares of Common Stock and <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46198">3,104,000</ix:nonFraction> Private Warrants (collectively, the &#8220;Purchased Securities&#8221;), which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn03_31_2025_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46199">88,685</ix:nonFraction> shares of Common Stock. As a result, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46200">4,500,000</ix:nonFraction> shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46201">0.01</ix:nonFraction> per share and restrictions on exercisability, and warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46202">8,500,000</ix:nonFraction> shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46203">0.01</ix:nonFraction> per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed <ix:nonFraction name="sclx:TransferOfWarrants" contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46204">4,000,000</ix:nonFraction> SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46205">114,286</ix:nonFraction> shares of Common Stock), which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the agreement that the Company entered into in July 2023, to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_21_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46206">20.0</ix:nonFraction>&#160;million, a $<ix:nonFraction name="sclx:CashPayment" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46207">10.0</ix:nonFraction>&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46208">12.3</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants (as defined below) based on their relative fair values as of September&#160;21, 2023. Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;SCLX JV, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary, which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 2). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $<ix:nonFraction name="sclx:FairValueOfSharesRepurchased" contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46209">52.6</ix:nonFraction>&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div></ix:continuation><ix:continuation id="TextSelectionAppend_145658315_4" continuedAt="TextSelectionAppend_145658315_5"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-83 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145658315_5" continuedAt="TextSelectionAppend_145658315_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658315_6" continuedAt="TextSelectionAppend_145658315_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145658315_7" continuedAt="TextSelectionAppend_145658315_8"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145658315_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46210">0.01</ix:nonFraction> per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of <ix:nonFraction name="sclx:NumberOfShareOutstanding" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46211">9.9</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares of Common Stock for the Company to settle the exercise of the warrants in shares of Common Stock. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $<ix:nonFraction name="sclx:FairValueOfWarrants" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46212">10.4</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46213"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46214">6,500,000</ix:nonFraction></ix:nonFraction> Penny Warrants outstanding that were fully vested and such warrants became exercisable on <ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2025To03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-46215">March 14, 2025</ix:nonNumeric>. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46216">1.3</ix:nonFraction>&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the unaudited condensed consolidated balance sheets. During the three months ended March&#160;31, 2025, the Company made a total of $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46217">0.2</ix:nonFraction>&#160;million payments for the excise tax. As of March&#160;31, 2025, the remaining balance of the excise tax liability recorded as accrued expenses was $<ix:nonFraction name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" contextRef="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46218">0.6</ix:nonFraction>&#160;million. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657376" id="ixv-35574"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">9. Stockholders&#8217; Deficit </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SPAC Warrants</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2025_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46219">402.50</ix:nonFraction> per whole share (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220;SPAC Warrants&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46220">630.00</ix:nonFraction> per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46221">0.01</ix:nonFraction> per warrant upon not less than 30 days&#8217; prior written notice.</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-84</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657376" continuedAt="TextSelectionAppend_145657376_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_1" continuedAt="TextSelectionAppend_145657376_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_2" continuedAt="TextSelectionAppend_145657376_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657376_3" continuedAt="TextSelectionAppend_145657376_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space:nowrap;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46223">4,000,000</ix:nonFraction> of the SPAC Warrants (which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2025To03_31_2025_SpacWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46224">114,286</ix:nonFraction> shares of Common Stock) held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46225">5,467,692</ix:nonFraction> Public Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46226">156,220</ix:nonFraction> shares of Common Stock are outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46227">1,000,000</ix:nonFraction>&#160;Private Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46228">28,572</ix:nonFraction> shares of Common Stock are outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46229">45,000,000</ix:nonFraction> shares of preferred stock (the &#8220;Preferred Stock&#8221;) of which there are two series in total. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46230">29,057,097</ix:nonFraction> shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Series 1 Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;27, 2024, the Board declared a stock dividend (the &#8220;Dividend&#8221;) consisting of an aggregate of <ix:nonFraction name="us-gaap:PreferredStockDividendsShares" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46231">5,000,000</ix:nonFraction> shares (the &#8220;Dividend Stock&#8221;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockDividendsPerShareDeclared" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-46232">0.0001</ix:nonFraction> per share, of the Company (the &#8220;Series 1 Preferred Stock&#8221;) to record holders of certain of the Company&#8217;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to such later date to be determined in the sole discretion of the Board) (such later record date as so determined by the Board, the &#8220;Record Date&#8221;). Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Certificate of Designation&#8221;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $<ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46233">200,000,000</ix:nonFraction> divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46234">10</ix:nonFraction> trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-85</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_145657376_4" continuedAt="TextSelectionAppend_145657376_5"><div></div></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_145657376_5" continuedAt="TextSelectionAppend_145657376_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_6" continuedAt="TextSelectionAppend_145657376_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_7" continuedAt="TextSelectionAppend_145657376_8"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657376_8" continuedAt="TextSelectionAppend_145657376_9"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Certificate of Designation, (a) &#8220;Effective Time&#8221; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#8220;Determination Date&#8221; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Days" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46236">15</ix:nonFraction> trading days following the Registration Date, (c) &#8220;Registration Date&#8221; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and (ii)&#160;the time at which the Registration Statement is declared effective by the SEC and (d) &#8220;Registration Statement&#8221; means a registration statement, whether under the Exchange Act, or the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of March&#160;31, 2025 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Treasury Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn03_31_2025_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46237">1,458,263</ix:nonFraction> and <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46238">1,716,245</ix:nonFraction> shares of Treasury Stock, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;"><div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">At-the-Market</div></div> Sales Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into the ATM Sales Agreement with the Sales Agents, which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell the ATM Shares through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM Shares offered and sold in the ATM Offering were issued pursuant to the Company&#8217;s shelf registration statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (which was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File <div style="white-space:nowrap;display:inline;">No.&#160;333-276245))</div> (the &#8220;Shelf <div style="white-space:nowrap;display:inline;">S-3</div> Registration Statement&#8221;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf <div style="white-space:nowrap;display:inline;">S-3</div> Registration Statement. The Sales Agents were entitled to a commission equal to <ix:nonFraction name="sclx:ProceedSOfSaleOfCommonSharesPercentage" contextRef="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46239">3.0</ix:nonFraction>% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2025, <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-46240">no</ix:nonFraction> sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46241">2,637</ix:nonFraction> shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46242">0.1</ix:nonFraction>&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-86</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657376_9" continuedAt="TextSelectionAppend_145657376_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_10" continuedAt="TextSelectionAppend_145657376_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_11" continuedAt="TextSelectionAppend_145657376_12"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657376_12" continuedAt="TextSelectionAppend_145657376_13"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">February 2024 Bought Deal Offering Underwriting Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;February 2024 BDO Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#8220;February 2024 BDO&#8221;), <ix:nonFraction name="sclx:CommonStockSold" contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46244">168,068</ix:nonFraction> shares of Common Stock (the &#8220;February 2024 BDO Firm Shares&#8221;) and accompanying common warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46245">168,068</ix:nonFraction> shares of Common Stock (the &#8220;February 2024 BDO Firm Warrants&#8221;). The securities in the February 2024 BDO were offered and sold by the Company pursuant to the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement, a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The February 2024 BDO closed on March&#160;5, 2024, and the combined price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $<ix:nonFraction name="sclx:CombinedPricePaidOfWarrant" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46246">54.74</ix:nonFraction>, which amount reflects the combined public offering price of $<ix:nonFraction name="sclx:PublicOfferingPrice" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46247">59.50</ix:nonFraction>, less underwriting discounts and commissions. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46248">59.50</ix:nonFraction> per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#8220;February 2024 BDO Representative Warrants&#8221;) to the underwriters, allowing them to purchase up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46249">13,446</ix:nonFraction> shares of Common Stock, with these warrants being immediately exercisable at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46250">74.38</ix:nonFraction>&#160;per share, representing <ix:nonFraction name="sclx:PublicOfferingPriceCombined" contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46251">125</ix:nonFraction>% of the combined public offering price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note&#160;4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46252">0.3</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a warrant amendment (the &#8220;Warrant Amendment&#8221;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46253">50,421</ix:nonFraction> shares of Common Stock in cash at an amended exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46254">20.65</ix:nonFraction> per share. During each of the three months ended March&#160;31, 2025 and 2024, there were <ix:nonFraction name="sclx:NumberOfWarrantsExercised" contextRef="P07_01_2024To09_30_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-46255">no</ix:nonFraction> February 2024 BDO Firm Warrants exercised. As of each of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="sclx:NumberOfWarrantsExercised1" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46256">3,803,447</ix:nonFraction> February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="sclx:NumberOfWarrantsExercised1" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46257">108,686</ix:nonFraction> shares of Common Stock outstanding and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46258">470,588</ix:nonFraction> February 2024 BDO Representative Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46259">13,446</ix:nonFraction> shares of our Common Stock outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">April 2024 Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#8220;April 2024 RDO Purchase Agreement&#8221;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;April 2024 RDO&#8221;): (i) an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46260">428,572</ix:nonFraction> shares of Common Stock (the &#8220;April 2024 RDO Shares&#8221;), and (ii)&#160;common warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46261">428,572</ix:nonFraction> shares of Common Stock (the &#8220;April 2024 RDO Common Warrants&#8221;). The offering price per April 2024 RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46262">35.00</ix:nonFraction>, for aggregate gross proceeds to the Company of $<ix:nonFraction name="sclx:AggregateGrossProceedsFromOffering" contextRef="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46263">15,000,000</ix:nonFraction>, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46264">38.50</ix:nonFraction> per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-87</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657376_13" continuedAt="TextSelectionAppend_145657376_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_14" continuedAt="TextSelectionAppend_145657376_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_15" continuedAt="TextSelectionAppend_145657376_16"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657376_16" continuedAt="TextSelectionAppend_145657376_17"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC, acted as exclusive placement agents (the &#8220;April 2024 RDO Placement Agents&#8221;) in connection with the April 2024 RDO. As compensation for such placement agent services, the Company paid the April 2024 RDO Placement Agents an aggregate cash fee equal to <ix:nonFraction name="sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46266">8.0</ix:nonFraction>% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the April 2024 RDO Placement Agents $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46267">100,000</ix:nonFraction> for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses and $<ix:nonFraction name="sclx:ClearingExpenses" contextRef="P04_23_2024To04_23_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46268">15,950</ix:nonFraction> for clearing expenses. The Company has also agreed to issue to the April 2024 RDO Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46269">34,286</ix:nonFraction>&#160;shares of Common Stock (the &#8220;April 2024 RDO Placement Agent Warrants&#8221;), representing up to <ix:nonFraction name="sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46270">8.0</ix:nonFraction>% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46271">43.75</ix:nonFraction> per share (which represents <ix:nonFraction name="sclx:PercentOfCombinedOfferingExercisePricePerShare" contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46272">125</ix:nonFraction>% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note&#160;4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of the April 2024 RDO Placement Agent Warrants as the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46273">0.6</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46274">15,000,000</ix:nonFraction>&#160;April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46275">428,572</ix:nonFraction> shares of Common Stock outstanding and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46276">1,200,000</ix:nonFraction>&#160;April 2024 RDO Placement Agent Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46277">34,286</ix:nonFraction> shares of our Common Stock outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">December 2024 Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#8220;December 2024 RDO Purchase Agreement&#8221;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;December 2024 RDO&#8221;): (i) an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46278">753,009</ix:nonFraction> shares of Common Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> warrants to purchase up to <ix:nonFraction name="sclx:PreFundedWarrantsToPurchase" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46279">68,604</ix:nonFraction> shares of Common Stock (the &#8220;December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) and (iii)&#160;common warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46280">1,642,871</ix:nonFraction> shares of Common Stock (the &#8220;December 2024 RDO Common Warrants&#8221; and collectively with the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#8220;StockBlock Warrants&#8221;), the &#8220;December 2024 RDO Warrants&#8221;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46281">20.65</ix:nonFraction> and (b)&#160;per December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant and accompanying December 2024 RDO Common Warrants was $<ix:nonFraction name="sclx:PreFundedWarrantPerShare" contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-46282">20.6499</ix:nonFraction>. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46283">17.0</ix:nonFraction>&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-88</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657376_17" continuedAt="TextSelectionAppend_145657376_18"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_18" continuedAt="TextSelectionAppend_145657376_19"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657376_19" continuedAt="TextSelectionAppend_145657376_20"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657376_20"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of StockBlock Warrants as of the date of issuance was $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46285">1.3</ix:nonFraction>&#160;million. On December&#160;26, 2024, the December 2024 RDO <div style="white-space:nowrap;display:inline;">Pre-Funded</div> Warrants were exercised by the holder for total net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46286">0.2</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46287"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46288">57,512,958</ix:nonFraction></ix:nonFraction> December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46289"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46290">1,642,871</ix:nonFraction></ix:nonFraction> shares of Common Stock outstanding and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46291"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46292">4,601,036</ix:nonFraction></ix:nonFraction> StockBlock Warrants, which are currently exercisable for an aggregate of up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46293"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46294">131,472</ix:nonFraction></ix:nonFraction> shares of Common Stock outstanding. </div></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657378" id="ixv-35739"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">10. Stock Incentive and Employee Benefit Plan </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). As of March&#160;31, 2025, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46295">703,670</ix:nonFraction> shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2025 pursuant to the Equity Incentive Plan. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2023 Inducement Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space:nowrap;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-46296">40,000</ix:nonFraction> shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46297">1,022,353</ix:nonFraction> shares of Common Stock were outstanding under all equity incentive plans. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-89</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657378" continuedAt="TextSelectionAppend_145657378_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657378_1" continuedAt="TextSelectionAppend_145657378_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657378_2" continuedAt="TextSelectionAppend_145657378_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657378_3" continuedAt="TextSelectionAppend_145657378_4"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-35770"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the three months ended March&#160;31, 2025 (in thousands, except for per share amounts and contractual life): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:57%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46299">1,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46300">138.23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-46301">6.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46302">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46303">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46304">149.37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46305">1,022</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46306">138.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:duryear" id="ixv-46307">6.1</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46308">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46309">1,022</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46310">138.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:duryear" id="ixv-46311">6.1</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46312">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46313">756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-46314">116.98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2025To03_31_2025" format="ixt-sec:duryear" id="ixv-46315">5.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46316">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. No stock options were granted during the three months ended March&#160;31, 2025. No options were exercised during the three months ended March&#160;31, 2025. The maximum term of options granted under each of the equity incentive plans is ten years. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46317">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46318">3.6</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space:nowrap;display:inline;">non-employee</div> stock option grants as of March&#160;31, 2025 were $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46319">24.5</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric name="sclx:WeightedAveragePeriodOverGrant" contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-46320">2.1</ix:nonNumeric> years. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="P10_17_2022To10_17_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46321">85</ix:nonFraction>% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of March&#160;31, 2025, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46322">170,573</ix:nonFraction>, which was increased from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46323">127,902</ix:nonFraction> shares as a result of automatic annual increase on January&#160;1, 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46324">50.2</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-46325">58.0</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, there were no shares of Common Stock issued under the ESPP. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options granted to employees and nonemployees and shares issued under ESPP using the Black-Scholes option pricing method. The Black-Scholes option pricing method requires the use of subjective assumptions. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Semnur 2024 Stock Option Plan</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (the &#8220;Semnur 2024 Plan&#8221;). Under the Semnur 2024 Plan, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2025_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46326">40,000,000</ix:nonFraction> shares of Semnur Common Stock were reserved </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-90</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657378_4" continuedAt="TextSelectionAppend_145657378_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657378_5" continuedAt="TextSelectionAppend_145657378_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657378_6" continuedAt="TextSelectionAppend_145657378_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657378_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">for future issuance and Nonstatutory Stock Options (&#8220;NSOs&#8221;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of March&#160;31, 2025, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46328"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46329">0.2</ix:nonFraction></ix:nonFraction>&#160;million for each of the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Retainer Shares</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;2023 SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_13_2023To02_13_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46330">114,286</ix:nonFraction> shares of Common&#160;Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#8220;2024 SIA&#8221;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P07_01_2024To07_01_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46331">285,714</ix:nonFraction> shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#8220;Retainer Shares&#8221;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of March&#160;31, 2025, it was <ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" xsi:nil="true" id="ixv-46332"></ix:nonFraction>not probable that any of the Retainer Shares would be applied against any outstanding legal fees. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657381" id="ixv-36014"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">11. Commitments and Contingencies </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi (together, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space:nowrap;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46333">25</ix:nonFraction>% and <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46334">35</ix:nonFraction>% to the Developers based on net profits. Scilex Pharma made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2025To03_31_2025_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46335">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To03_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46336">2.4</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, Scilex Pharma had ending balances of accrued royalty payables of $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46337">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46338">4.0</ix:nonFraction>&#160;million, respectively. Total royalty expense recorded within cost of revenue was $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46339">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2024To03_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46340">2.3</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-91</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657381" continuedAt="TextSelectionAppend_145657381_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657381_1" continuedAt="TextSelectionAppend_145657381_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657381_2" continuedAt="TextSelectionAppend_145657381_3"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657381_3" continuedAt="TextSelectionAppend_145657381_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until <ix:nonNumeric name="sclx:AgreementMaturityDate" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-46342">October 2, 2028</ix:nonNumeric>, the date that is ten years from the date of the first commercial sale of ZTlido. <ix:nonNumeric name="sclx:MaturityRenewalDescription" contextRef="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-36037">The Product Development Agreement will renew automatically for subsequent successive <div style="white-space:nowrap;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon <div style="white-space:nowrap;display:inline;">six-months&#8217;</div> written notice.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the Developers to provide commercial supply of ZTlido and <div style="white-space:nowrap;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following lawsuit, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the&#160;procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic <div style="white-space:nowrap;display:inline;">30-month</div> stay preventing them from selling a generic version of ZTlido during that time, which was extinguished by the U.S. District Court decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#8217;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#8217;s product does not infringe the Company&#8217;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. Briefing is underway in that appeal. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Operating Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space:nowrap;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of March&#160;31, 2025, the Company&#8217;s leases have remaining lease terms of approximately <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-46343">2.5</ix:nonNumeric> years. The terms of the Company&#8217;s leases, ranging from <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-46344">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-46345">5</ix:nonNumeric> years, include extension options that are not reasonably certain to be </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-92</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_145657381_4" continuedAt="TextSelectionAppend_145657381_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657381_5" continuedAt="TextSelectionAppend_145657381_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657381_6" continuedAt="TextSelectionAppend_145657381_7"><ix:exclude><div style="font-size:10pt;font-weight:bold; margin-top: 1.67em; margin-bottom: 1.67em;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657381_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets or lease liabilities, and are immaterial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of March&#160;31, 2025, the Company has <ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" xsi:nil="true" id="ixv-46347"></ix:nonFraction>no&#160;<div style="-sec-ix-hidden:hidden145659148;display:inline;">finance leases</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46348"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-46349">0.3</ix:nonFraction></ix:nonFraction>&#160;million for each of the three months ended March&#160;31, 2025 and 2024, and was primarily comprised of operating lease costs. The lease expense included variable lease costs and sublease income, which were immaterial for the periods presented. </div><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-36078"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:79%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46350">227</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46351">277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2025" format="ixt-sec:duryear" id="ixv-46352">2.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2024" format="ixt-sec:duryear" id="ixv-46353">3.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46354">11.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-46355">11.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-36156"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46356">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46357">944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46358">724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46359">2,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46360">290</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46361">2,067</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46362">740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:LeaseLiabilityNetOfCurrentPortion" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46363">1,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-93 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657383" id="ixv-36270"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">12. Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" continuedAt="TextSelection_145657467" id="ixv-46364">The following table sets forth the reconciliation of basic and diluted loss per share for the three months ended March&#160;31, 2025 and 2023 (in thousands except per share data): </ix:nonNumeric></div><ix:continuation id="TextSelection_145657467"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46365">26,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-46366">24,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageNumberOfSharesOutstanding" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46367">5,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageNumberOfSharesOutstanding" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46368">2,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-46369">6,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46370">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46371">11,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46372">2,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46373">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-46374">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46375">11,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46376">2,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-46377"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-46378">2.26</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-46379"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-46380">8.33</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_21_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46381">8,500,000</ix:nonFraction> shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-94</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_145657383" continuedAt="TextSelectionAppend_145657383_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657383_1" continuedAt="TextSelectionAppend_145657383_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_145657383_2" continuedAt="TextSelectionAppend_145657383_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_145657383_3"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-36457"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:68%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">March&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46383">1,022,353</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46384">1,027,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_RetainerSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46385">399,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46386">399,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46387">1,114,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46388">1,158,617</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_PublicWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46389">156,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46390">156,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_PrivateWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46391">28,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46392">28,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46393">9,557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46394">2,204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46395">8,571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46396">8,571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46397">108,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46398">108,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46399">13,446</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46400">13,446</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46401">428,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-46402">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46403">34,286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46404">34,286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposit Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46405">3,250,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-46406">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Noteholder Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46407">214,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-46408">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46409">104,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46410">104,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46411">1,642,871</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46412">1,642,871</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46413">131,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46414">131,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46415">8,668,507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-46416">4,817,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2025To03_31_2025" escape="true" id="ixv-36700"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">13. Subsequent Events </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Bio JV </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2025, the Company and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">MAO-B</div> Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer&#8217;s disease. The Company contributed <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-46417">5.0</ix:nonFraction>&#160;million shares of Semnur Common Stock owned by the Company to Scilex Bio, Inc. in exchange for a <ix:nonFraction name="sclx:OwnershipInterestRate" contextRef="P04_17_2025To04_17_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46418">60</ix:nonFraction>% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a <ix:nonFraction name="sclx:OwnershipInterestRate" contextRef="P04_17_2025To04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-46419">40</ix:nonFraction>% ownership interest in Scilex Bio, Inc. In connection with the formation of Scilex Bio, Inc. and the related transactions, on April&#160;16, 2025, the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed, and the Company entered into a Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note with each of the Tranche B Noteholders. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-95 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN THE PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by Scilex Holding Company (the &#8220;Registrant&#8221;) in connection with the sale of the Common Stock being registered. The security holders will not bear any portion of such expenses. All amounts shown are estimates except for the registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 2,354.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">425,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing, transfer agent fees and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">502,354.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant&#8217;s restated certificate of incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;) contains provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant&#8217;s directors and officers will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director or officer, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any director, unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director or officer derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant&#8217;s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant&#8217;s bylaws (the &#8220;Bylaws&#8221;) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information as to all of the Registrant&#8217;s securities sold in the last three years (on a pre-Reverse Stock Split basis) which were not registered under the U.S.&#160;Securities Act of&#160;1933, as amended (the &#8220;Securities Act&#8221;). Capitalized terms used and not defined in this Item&#160;15 have the meaning given to them in the prospectus which forms a part of this registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On October&#160;17, 2022, the Registrant issued an aggregate of&#160;533,057 shares of common stock, par value $0.0001 per share, of the Registrant (the &#8220;Common Stock&#8221;) to the Sponsors pursuant to the Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;), dated as of October&#160;17, 2022, between the Sponsors and the Registrant, in exchange for the Sponsors&#8217; contribution to the Registrant of approximately $5.3&#160;million of indebtedness described in the Debt Contribution Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On November&#160;17, 2022, the Registrant issued&#160;250,000 shares of Common Stock to YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;), in consideration for Yorkville&#8217;s irrevocable commitment to purchase shares of Common Stock pursuant to the standby equity purchase agreement the Registrant entered into with Yorkville on November&#160;17, 2022 (the &#8220;Original Purchase Agreement&#8221;), as amended and restated on February&#160;8, 2023 (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2023, the Registrant issued&#160;250,000 shares of Common Stock to B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#8220;B. Riley&#8221;), in consideration for B. Riley&#8217;s irrevocable commitment to purchase shares of Common Stock pursuant to the standby equity purchase agreement the Registrant entered into with B. Riley on January&#160;8, 2023 (the &#8220;B. Riley Purchase Agreement&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On February&#160;13, 2023, the Registrant issued&#160;4,000,000 shares of Common Stock (the &#8220;Retainer Shares&#8221;) to Paul Hastings LLP, pursuant to a stock issuance agreement dated as of such date, as a retainer for legal services to be provided by Paul Hastings LLP to the Registrant and its affiliates following such date, and as payment for prior services provided to the Registrant, to be held by Paul Hastings LLP until such time as the Retainer Shares are applied against the outstanding legal fees or returned to the Registrant, in each case in accordance with the terms of such agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Between February&#160;15, 2023 and December&#160;28, 2023, the Registrant has sold 1,414,554 shares of Common Stock pursuant to advances under the B. Riley Purchase Agreement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Between February&#160;16, 2023 and February&#160;12, 2024, the Registrant sold 11,649,056 shares of Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On March&#160;21, 2023, the Registrant entered into a securities purchase agreement with Yorkville, pursuant to which the Registrant sold and issued to Yorkville convertible debentures in the following aggregate principal amounts on the specified dates: (i)&#160;$10,000,000, on March&#160;21, 2023, (ii)&#160;$7,500,000, on April&#160;11, 2023, and (iii)&#160;$7,500,000, on April&#160;20, 2023, each of which is convertible into shares of the Registrant&#8217;s Common Stock. In April&#160;2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the convertible debentures, resulting in the issuance of&#160;632,431 shares of the Registrant&#8217;s Common Stock at a conversion price of $8.00&#160;per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On September&#160;15, 2023, the Registrant entered into a settlement agreement with Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), HBC Investments LLC (&#8220;HBC&#8221;)&#160;and Hudson Bay Capital Management LP, pursuant to which the Registrant issued, on September&#160;25, 2023, an aggregate of&#160;474,683 shares of Common Stock, consisting of&#160;161,392 shares of Common Stock to Cove Lane and&#160;313,291 shares of Common Stock to HBC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On September&#160;21, 2023, the Registrant entered into the Securities Purchase Agreement, dated as of such date, with Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;), pursuant to which, among other things, the Registrant issued to Oramed (i)&#160;a senior secured promissory note due&#160;18&#160;months from the date of issuance in the principal amount of $101,875,000 (ii)&#160;a warrant to purchase up to an aggregate of&#160;4,500,000 shares of Common Stock, with an exercise price of $0.01&#160;per share and restrictions on exercisability, and (iii)&#160;warrants to purchase up to an aggregate of&#160;8,500,000 shares of Common Stock, each with an exercise price of $0.01&#160;per share and each with restrictions on exercisability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On June&#160;18, 2024, the Registrant issued a warrant to purchase up to an aggregate of 3,250,000 shares of Common Stock (the &#8220;Deposit Warrant&#8221;) pursuant to the Commitment Letter that the Registrant entered into with FSF 33433 LLC, a Delaware limited liability company, on June&#160;11, 2024. The exercise price of the Deposit Warrant is $1.20 per share. The Registrant will receive up to $3.9 million from the exercise of the Deposit Warrant, assuming the exercise in full of the Deposit Warrant for cash. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;1, 2024, the Registrant issued 10,000,000 shares of Common Stock to a law firm, pursuant to a stock issuance agreement dated as of such date, as a retainer for legal services to be provided by such law firm to the Registrant and its subsidiaries following such date, and as payment for prior services provided to the Registrant, to be held by such law firm until such time as such shares are applied against the outstanding legal fees or returned to us, in each case in accordance with the terms of such agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;16, 2024, the Registrant issued a warrant to purchase up to an aggregate of 250,000 shares of Common Stock (the &#8220;Fee Warrant&#8221;) pursuant to the Tranche B Letter Agreement that the Registrant entered into with IVI 66766 LLC, a Delaware limited liability company, dated July&#160;16, 2024. The exercise price of the Fee Warrant is $1.20 per share. The Registrant received $0.3 million from the exercise of the Fee Warrant, when it was exercised in full in October 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Upon effectiveness of this registration statement, the Registrant is obligated to issue 150,000 shares of Common Stock to Tumim Stone Capital, LLC, a Delaware limited liability company (&#8220;Tumim&#8221;), in consideration for Tumim&#8217;s irrevocable commitment to purchase shares of Common Stock pursuant to the common stock purchase agreement the Registrant entered into with Tumim on July&#160;22, 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;22, 2025, the Registrant entered into Warrant Exchange Agreements (each, a &#8220;Warrant Exchange Agreement&#8221; and collectively, the &#8220;Warrant Exchange Agreements&#8221;) with certain holders (the &#8220;Exchanging Warrant Holders&#8221;) of its existing Tranche B warrants to purchase shares of Common </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Stock (the &#8220;Existing Tranche B Warrants&#8221;). Pursuant to the Warrant Exchange Agreements, the Registrant and the Exchanging Warrant Holders, in reliance on Section&#160;3(a)(9) of the Securities Act, effected a voluntary securities exchange whereby the Exchanging Warrant Holders exchanged the Existing Tranche B Warrants, which were exercisable for an aggregate of 107,142 shares of Common Stock at an exercise price of $36.40 per share, originally issued pursuant to that certain Securities Purchase Agreement, dated October&#160;7, 2024, by and among us and the investors named therein, for warrants to purchase an aggregate of 500,000 shares of Common Stock at an exercise price of $40.00 per share. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act in reliance on the exemption afforded by Section&#160;3(a)(9) thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;16. Exhibits and Financial Statements Schedules. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>a) <span style="font-weight:bold">Exhibits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibits are filed as part of this registration statement: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d1.htm">Agreement and Plan of Merger, dated as of March 18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No. 1 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d2.htm">Amendment No. 1 to Agreement and Plan of Merger, dated as of August 7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.2 of Amendment No. 1 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on October June 27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.3#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d3.htm">Bill of Sale and Assignment and Assumption Agreement, dated May 12, 2022, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 of Amendment No. 1 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.4&#x5E;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d4.htm">Asset Purchase Agreement, dated April 23, 2021, between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc., as assumed by Scilex Holding Company on May 12, 2022, pursuant to the Bill of Sale and Assignment and Assumption Agreement, dated as of such date, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.4 of Amendment No. 1 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm">Agreement and Plan of Merger, dated as of March 17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on March 21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm">Amendment No. 1 to Agreement and Plan of Merger, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 14, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.7#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex21.htm">Agreement and Plan of Merger, dated as of August 30, 2024, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 3, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.8#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017025056022/sclx-ex2_1.htm">Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on April 21, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162969/d21770dex21.htm">Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on July 23, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525080856/d943368dex31.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Scilex Holding Company, filed with the Secretary of State of the State of Delaware on April 14, 2025 (incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on April 15, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017024117557/sclx-ex3_1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on October 28, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm">Warrant Agreement, dated as of January 6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.1 of Vickers&#8217;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on January 11, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390020042745/fs12020ex4-3_vickers1.htm">Specimen Warrant Certificate of Scilex Holding Company (f/k/a Vickers Vantage Corp. I) (incorporated by reference to Exhibit 4.3 of Vickers&#8217;s Form S-1 (File No. 333-251352), filed with the SEC on December 15, 2020). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex41.htm">Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc. on September 21, 2023 (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 26, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex42.htm">Form of Scilex Holding Company Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 26, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex41.htm">Form of Common Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on March 5, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex42.htm">Form of Representative Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on March 5, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524114000/d820664dex41.htm">Form of Common Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on April 25, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524114000/d820664dex42.htm">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on April 25, 2024). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524181039/d699096dex48.htm">Warrant to Purchase Common Stock, issued to FSF 33433 LLC on June 18, 2024 (incorporated by reference to Exhibit 4.8 of our Registration Statement on Form S-3 (File No. 333-280882), filed with the SEC on July 18, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex41.htm">Form of Tranche B Senior Secured Convertible Note issued by Scilex Holding Company. (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex42.htm">Form of Warrant to Purchase Common Stock issued by Scilex Holding Company. (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex43.htm">Form of Placement Agent Warrant issued by Scilex Holding Company (incorporated by reference to Exhibit 4.3 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524278311/d836578dex41.htm">Form of Pre-Funded Warrant issued by Scilex Holding Company (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on December 13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524278311/d836578dex42.htm">Form of Common Warrant issued by Scilex Holding Company (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on December 13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.15</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524278311/d836578dex43.htm">Form of StockBlock Warrant issued by Scilex Holding Company (incorporated by reference to Exhibit 4.3 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on December 13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524278311/d836578dex44.htm">Amendment No. 1 to Common Stock Purchase Warrant, dated December 11, 2024, between Scilex Holding Company and the investor named therein (incorporated by reference to Exhibit 4.4 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on December 13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex106.htm">Form of Warrant to Purchase Common Stock issued by Scilex Holding Company (incorporated by reference to Exhibit 10.6 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on July 23, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297dex51.htm">Opinion of Paul Hastings LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No. 1 of Vickers&#8217;s Form S-4 (File No. <span style="white-space:nowrap">333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523137199/d327950dex101.htm">Scilex Holding Company 2022 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on May&#160;5, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:90%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex101.htm">Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex102.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex103.htm">Form of Restricted Stock Unit Award Grant Notice and Award Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm">Offer Letter, dated as of April&#160;19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm">Office Lease, dated as of August&#160;8, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm">First Amendment to Office Lease, dated as of September&#160;15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523177931/d378841dex1039.htm">Amended and Restated Industrial Lease, dated as of April&#160;12, 2023, by and between Scilex Pharmaceuticals, Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.39 of Amendment No.&#160;4 of Scilex&#8217;s Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-271401),</span> filed with the SEC on June&#160;29, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm">Commercial Supply Agreement, dated as of February&#160;16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm">First Addendum to Commercial Supply Agreement, dated as of August&#160;31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm">Second Addendum to Commercial Supply Agreement, dated as of May&#160;9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm">Third Addendum to Commercial Supply Agreement, dated as of August&#160;30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm">Exclusive Distribution Agreement, dated as of August 6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No. 4 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm">Amendment to Exclusive Distribution Agreement, dated as of May 24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.27 of Amendment No. 4 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm">Second Amendment to Exclusive Distribution Agreement, dated as of September&#160;19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm">Third Amendment to Exclusive Distribution Agreement, dated as of October&#160;1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.25&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm">Product Development Agreement, dated as of May&#160;11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm">First Amendment to Product Development Agreement, dated as of April&#160;2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.27&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm">Second Amendment to Product Development Agreement, dated as of February 20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No. 2 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.28&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm">Third Amendment to Product Development Agreement, dated as of August 29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No. 2 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm">Fourth Amendment to Product Development Agreement, dated as of December 13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No. 2 of Vickers&#8217;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm">Fifth Amendment to Product Development Agreement, dated as of April&#160;30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.&#160;2 of <span style="white-space:nowrap"><span style="white-space:nowrap">Vickers&#8217;s&#160;Form&#160;S-4&#160;(File&#160;No.&#160;333-264941),&#160;filed</span></span> with the SEC on July&#160;21, 2022).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.31#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm">Master Services Agreement - <span style="white-space:nowrap">SP-102,</span> dated as of January&#160;27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.32</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm">Amendment No.&#160;1 to Master Services Agreement, dated as of April&#160;26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.33&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017025047800/sclx-ex10_33.htm">Second Amendment to Master Services Agreement, dated as of June&#160;6, 2023, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.33 of our Annual Report on Form <span style="white-space:nowrap">10-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;31, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.34</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm">Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.35#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm">Master Services Agreement, dated as of November&#160;23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May&#160;12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.43 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.36#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm">License and Commercialization Agreement, dated as of June&#160;14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.37#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017025047800/sclx-ex10_37.htm">First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.37 of our Annual Report on Form <span style="white-space:nowrap">10-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;31, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.38</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm">Amended and Restated Registration Rights Agreement, dated as of November&#160;10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.39</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex102.htm">Registration Rights Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.40#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex101.htm">Securities Purchase Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.41#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex102.htm">Amendment No.&#160;1 to Securities Purchase Agreement, dated October&#160;8, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.42#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex103.htm">Subsidiary Guarantee, dated September&#160;21, 2023, made by certain of the Company&#8217;s subsidiaries in favor of the holders of that certain Senior Secured Promissory Note dated as of the date thereof due March&#160;21, 2025 in the original aggregate principal amount of $101,875,000 (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex107.htm">Subsidiary Guarantee Amendment, dated October&#160;8, 2024, made by certain of the Company&#8217;s subsidiaries in favor of the holders of that certain Oramed Note (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.44</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex108.htm">Amended and Restated Security Agreement, dated October&#160;8, 2024, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.45#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex106.htm">Stock Purchase Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.6 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex107.htm">Assignment, Assumption and Release Agreement, dated September&#160;21, 2023, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.47#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex108.htm">Letter Agreement, dated September&#160;21, 2023, by and among Scilex Holding Company, Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.48#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex109.htm">Letter Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.9 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.49#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex11.htm">Underwriting Agreement, dated February&#160;29, 2024, among Scilex Holding Company, Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC. (incorporated by reference to Exhibit 1.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;5, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.50*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_12.htm">Severance and Change of Control Agreement, dated as of November&#160;8, 2023, by and between Jaisim Shah and Scilex Holding Company (incorporated by reference to Exhibit 10.12 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.51*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_13.htm">Severance and Change of Control Agreement, dated as of November&#160;9, 2023, by and between Henry Ji and Scilex Holding Company (incorporated by reference to Exhibit 10.13 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.52*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_14.htm">Severance and Change of Control Agreement, dated as of November&#160;8, 2023, by and between Stephen Ma and Scilex Holding Company (incorporated by reference to Exhibit 10.14 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017024058630/sclx-ex10_2.htm">Settlement Agreement, dated February&#160;29, 2024, by and between Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Virpax Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on May&#160;13, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524114000/d820664dex101.htm">Form of Securities Purchase Agreement, dated April&#160;23, 2024, by and between Scilex Holding Company and the purchaser party thereto. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on April&#160;25, 2024).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.55</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524159926/d55926dex101.htm">Commitment Side Letter, dated June&#160;11, 2024, by and between Scilex Holding Company and FSF 33433 LLC. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on June&#160;12, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.56&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex101.htm">Sponsor Support Agreement, dated as of August&#160;30, 2024, by and among Denali Capital Acquisition Corp. and each of the Persons set forth on Schedule I attached thereto. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;3, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.57#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex102.htm">Company Stockholder Support Agreement, dated as of August&#160;30, 2024, by and among Scilex Holding Company, Semnur Pharmaceuticals, Inc. and Denali Capital Acquisition Corp. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;3, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.58#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex103.htm">Sponsor Interest Purchase Agreement, dated as of August&#160;30, 2024, by and between Denali Capital Global Investments LLC and Scilex Holding Company. (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;3, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.59#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex104.htm">Contribution and Satisfaction of Indebtedness Agreement, dated as of August&#160;30, 2024 by and between Scilex Holding Company and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;3, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex105.htm">Stockholder Agreement, dated as of August&#160;30, 2024, by and between Denali Capital Acquisition Corp. and Scilex Holding Company (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.001-39852),</span> filed with the SEC on September&#160;3, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524211651/d852041dex106.htm">Letter Agreement, dated August&#160;30, 2024, by and between Oramed Pharmaceuticals, Inc. and Scilex Holding Company (incorporated by reference to Exhibit&#160;10.6 of our Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;3, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017024107615/sclx-ex10_1.htm">Satisfaction Agreement, dated as of September&#160;17, 2024, by and among Endeavor Distribution LLC, FSF 33433 LLC and Scilex Holding Company. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;18, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.63</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017024108658/sclx-ex10_1.htm">Letter Agreement, dated as of September&#160;20, 2024, by and between Oramed Pharmaceuticals Inc. and Scilex Holding Company. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;23, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.64</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524233897/d900238dex101.htm">Consent and Side Letter, dated October&#160;2, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 of our Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;7, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.65#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex101.htm">Securities Purchase Agreement, dated October&#160;7, 2024, by and between Scilex Holding Company and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.66#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex103.htm">Purchase and Sale Agreement, dated October&#160;8, 2024, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.67#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex104.htm">Security Agreement, dated October&#160;8, 2024, by and among Scilex Pharmaceuticals Inc., and the purchasers signatory thereto (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.68</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex105.htm">Subordination Agreement, dated October&#160;8, 2024, by and among Scilex Pharmaceuticals Inc., Acquiom Agency Services LLC and other signatories thereto (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on October&#160;8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.69</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524234244/d853982dex106.htm">Consent and Amendment, dated as of October<span style="text-decoration:underline"></span>&#160;8, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.6 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on October<span style="text-decoration:underline"></span>&#160;8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.70</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524273896/d905678dex101.htm">Consent under Securities Purchase Agreement and Senior Secured Promissory Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on December 10. 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.71</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524273896/d905678dex102.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Nomis Bay Ltd, BPY Limited, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on December&#160;10, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.72</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524273896/d905678dex103.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on December&#160;10, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.73</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524273896/d905678dex104.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated December&#160;9, 2024, by and among Scilex Holding Company, 3i, LP, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on December&#160;10, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.74</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524278311/d836578dex101.htm">Form of Securities Purchase Agreement, dated December&#160;11, 2024, by and between the Company and the purchasers party thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on December&#160;13, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.75</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525000984/d894156dex101.htm">Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January<span style="text-decoration:underline"></span>&#160;2, 2025, by and among Scilex Holding Company, Nomis Bay Ltd, BPY Limited, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on January<span style="text-decoration:underline"></span>&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525000984/d894156dex102.htm">Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January<span style="text-decoration:underline"></span>&#160;2, 2025, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on January<span style="text-decoration:underline"></span>&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.77</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525000984/d894156dex103.htm">Deferral and Consent under Tranche B Senior Secured Convertible Note, dated January<span style="text-decoration:underline"></span>&#160;2, 2025, by and among Scilex Holding Company, 3i, LP, SCLX Stock Acquisition JV LLC and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on January<span style="text-decoration:underline"></span>&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.78</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525009911/d849453dex101.htm">Amendment to Senior Secured Note, dated January&#160;21, 2025, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc. and SCLX Stock Acquisition JV LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;22, 2025).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.79</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/d859484dex101.htm">License Agreement (ZTlido), dated February&#160;22, 2025, by and between Scilex Pharmaceuticals Inc. and Royaltyvest Ltd. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on February&#160;27, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.80</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/d859484dex102.htm">Parent Guarantee for Lidocaine License Agreement, dated February&#160;22, 2025, by and between Scilex Holding Company and Royaltyvest Ltd. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on February&#160;27, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.81</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577dex101.htm">Purchase and Sale Agreement, dated February&#160;28, 2025, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.82</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577dex102.htm">Security Agreement, dated February&#160;28, 2025, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.83</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577dex103.htm">Subordination Agreement, dated February&#160;28, 2025, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc., Acquiom Agency Services LLC and other signatories thereto (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.84</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577dex105.htm">License Agreement (Gloperba), dated February&#160;28, 2025, by and between Scilex Holding Company, Scilex Pharmaceuticals Inc. and RoyaltyVest Ltd. (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.85</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577dex104.htm">Amendment No.&#160;1 to Purchase and Sale Agreement, dated February&#160;28, 2025, by and among Scilex Holding Company, Scilex Pharmaceuticals Inc., Oramed Pharmaceuticals Inc. and the other signatories thereto (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;3, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.86#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525115054/d866836dex1075.htm">Consent under Securities Purchase Agreement and Senior Secured Promissory Note, dated April<span style="text-decoration:underline"></span>&#160;16, 2025, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.75 of our Post-Effective Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Form <span style="white-space:nowrap">S-3</span> on Form <span style="white-space:nowrap">S-1</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-276245</span> and <span style="white-space:nowrap">333-280882),</span> filed with the SEC on May<span style="text-decoration:underline"></span>&#160;7, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.87#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525115054/d866836dex1076.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated April<span style="text-decoration:underline"></span>&#160;16, 2025, by and among Scilex Holding Company, Nomis Bay Ltd, BPY Limited and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.76 of our Post-Effective Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Form <span style="white-space:nowrap">S-3</span> on Form <span style="white-space:nowrap">S-1</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-276245</span> and <span style="white-space:nowrap">333-280882),</span> filed with the SEC on May<span style="text-decoration:underline"></span>&#160;7, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.88#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525115054/d866836dex1077.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated April<span style="text-decoration:underline"></span>&#160;16, 2025, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.77 of our Post-Effective Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Form <span style="white-space:nowrap">S-3</span> on Form <span style="white-space:nowrap">S-1</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-276245</span> and <span style="white-space:nowrap">333-280882),</span> filed with the SEC on May<span style="text-decoration:underline"></span>&#160;7, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.89#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525115054/d866836dex1078.htm">Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note, dated April<span style="text-decoration:underline"></span>&#160;16, 2025, by and among Scilex Holding Company, 3i, LP and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.78 of our Post-Effective Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Form <span style="white-space:nowrap">S-3</span> on Form <span style="white-space:nowrap">S-1</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-276245</span> and <span style="white-space:nowrap">333-280882),</span> filed with the SEC on May<span style="text-decoration:underline"></span>&#160;7, 2025).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:87%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.90</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017025068621/sclx-ex10_1.htm">Scilex Holding Company Amended and Restated <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on May<span style="text-decoration:underline"></span>&#160;12, 2025.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.91#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex101.htm">Common Stock Purchase Agreement, dated July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and Tumim Stone Capital, LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.92#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex102.htm">Registration Rights Agreement, dated July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and Tumim Stone Capital, LLC (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.93#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex103.htm">Warrant Exchange Agreement, dated as of July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and Nomis Bay Ltd. (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.94#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex104.htm">Warrant Exchange Agreement, dated as of July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and BPY Limited (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.95#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex105.htm">Warrant Exchange Agreement, dated as of July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and 3i, LP (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.96&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162dex107.htm">Option Agreement for the Repurchase of Warrants, dated July<span style="text-decoration:underline"></span>&#160;22, 2025, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;23, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297dex211.htm">List of Subsidiaries of the Registrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297dex231.htm">Consent of BPM LLP, independent registered public accounting firm. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2<sup style="font-size:75%; vertical-align:top">+</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297dex51.htm">Consent of Paul Hastings LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297ds1.htm#sig">Power of Attorney (included on the signature page hereto). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942297dexfilingfees.htm">Filing Fee Table </a></td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">+</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#x5E;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K</span> because such information is both (i)&#160;not material and (ii)&#160;information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">#</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Item&#160;17. Undertakings.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of&#160;1933, as amended (the &#8220;Securities Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement&#160;(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)&#160;pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a&#160;20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however</span>, that: Paragraphs&#160;(1)(i), (1)(ii)&#160;and (1)(iii)&#160;of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iv)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, State of California, on the 4th&#160;day of August&#160;2025. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Scilex Holding Company</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name: Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title: Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints each of Jaisim Shah and Stephen Ma, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement&#160;(and any additional registration statement related hereto permitted by Rule&#160;462(b) promulgated under the Securities Act of&#160;1933, as amended (and all further amendments, including post-effective amendments thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Ma</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Financial and Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry Ji, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Executive Chairperson and Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dorman Followwill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yue Alexander Wu, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay Chun, M.D., Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Annu Navani, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Annu Navani, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">August&#160;4, 2025</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-17 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d942297dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g942297g0802021745893.jpg" ALT="LOGO" STYLE="width:1.94514in;height:0.583333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">August&nbsp;4, 2025&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">960 San Antonio Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Palo Alto, CA 94303 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Re:</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We have acted as counsel to
Scilex Holding Company, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the preparation and filing on the date hereof with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) of a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), including a related prospectus filed
with the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), relating to the registration of the offer and sale from time to time, in each case, by the selling securityholder named in the Registration Statement (the
&#147;<B><I>Selling Securityholder</I></B>&#148;) of (i) 150,000 shares (the &#147;<B><I>Commitment Shares</I></B>&#148;) of common stock, par value $0.0001 per share, of the Company (the &#147;<B><I>Common Stock</I></B>&#148;) to be issued to the
Selling Securityholder by the Company as consideration for the Selling Securityholder&#146;s commitment to purchase shares of Common Stock pursuant to that certain Common Stock Purchase Agreement, dated as of July&nbsp;22, 2025, between the Company
and the Selling Securityholder (the &#147;<B><I>Purchase Agreement</I></B>&#148;), and (ii)&nbsp;up to 1,240,443 shares of Common Stock (the &#147;<B><I>VWAP Purchase Shares</I></B>&#148; and, together with the Commitment Shares, the
&#147;<B><I>Shares</I></B>&#148;) that may be issued and sold to the Selling Stockholder from time to time by the Company pursuant to the Purchase Agreement. This opinion letter is being furnished in accordance with the requirements of Item 601 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As such counsel and for purposes of our opinion set forth below, we have
examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and other instruments of the Company and corporate records furnished to us by the Company, and have
reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Restated Certificate of Incorporation of the Company, as amended, certified by the Secretary of State of the State
of Delaware as of August&nbsp;1, 2025 (the &#147;<B><I>Charter</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(iv)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Bylaws of the Company as presently in effect, certified by an officer of the Company as of August&nbsp;4, 2025;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(v)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Purchase Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g942297g0802021746162.jpg" ALT="LOGO" STYLE="width:4.77847in;height:0.328472in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g942297snap1.jpg" ALT="LOGO" STYLE="width:1.36319in;height:0.497917in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">August 4, 2025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Page 2 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(vi)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a certificate, dated as of August&nbsp;1, 2025, from the Secretary of State of the State of Delaware certifying as to
the existence and good standing of the Company in the State of Delaware (the &#147;<B><I>Good Standing Certificate</I></B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">(vii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">resolutions adopted by the board of directors of the Company on July&nbsp;16, 2025, certified by an officer of the
Company, relating to, among other things, the approval of the Purchase Agreement, the filing of the Registration Statement and the registration, sale and issuance of the Shares (the &#147;<B><I>Resolutions</I></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth in
this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In such examination and in rendering the opinion expressed below, we have assumed, without independent investigation or
verification: (i)&nbsp;the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii)&nbsp;the authenticity and completeness of all agreements, instruments, corporate
records, certificates and other documents submitted to us as originals; (iii)&nbsp;that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or
other copies conform to originals thereof, and that such originals are authentic and complete; (iv)&nbsp;the legal capacity, competency and authority of all persons executing all agreements, instruments, corporate records, certificates and other
documents submitted to us; (v)&nbsp;the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted
to us have been amended or terminated orally or in writing except as has been disclosed to us in writing; (vii)&nbsp;that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the
Company and other persons on which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (viii)&nbsp;that there has not been any change in the good standing status of the Company from that reported
in the Good Standing Certificate; (ix)&nbsp;that each of the officers and directors of the Company has properly exercised his or her fiduciary duties; (x)&nbsp;the Shares will not be issued or transferred in violation of any restriction contained in
the Charter and that upon the issuance of any of the Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Charter;
and (xi)&nbsp;that prior to the issuance of any of the Shares, the Board of Directors of the Company (or the duly authorized persons thereof) will determine the price and certain other terms of issuance of such Shares in accordance with the
Resolutions (the &#147;<B><I>Board Proceedings</I></B>&#148;). As to all questions of fact material to this opinion letter, and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation
or verification) upon representations and certificates or comparable documents of officers and representatives of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Based upon the
foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that<I> </I>upon completion of all of the Board Proceedings, the Shares will be duly authorized
for issuance and, when and if issued and delivered by the Company in accordance with the Resolutions, and the Board Proceedings against payment therefor in accordance with the Purchase Agreement, the Shares will be validly issued, fully paid and
nonassessable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g942297snap1.jpg" ALT="LOGO" STYLE="width:1.36319in;height:0.497917in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">August 4, 2025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Page 3 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Without limiting any of the other limitations, exceptions, assumptions and qualifications stated
elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the General Corporation Law of the State of Delaware, as in effect on the date of this opinion letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly
stated herein from any matter addressed in this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This opinion letter is rendered solely in connection with the filing of the
Registration Statement. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters
set forth herein, even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We hereby consent
to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement, and to the reference to our firm under the heading &#147;Legal Matters&#148; in the Registration Statement. In giving such consent, we do not hereby admit that we are
within the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules or regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">/s/ Paul Hastings LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d942297dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of Scilex Holding Company </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>State or Jurisdiction of Incorporation or Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scilex, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scilex Pharmaceuticals Inc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Semnur Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SCLX Stock Acquisition JV LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SCLX DRE Holdings LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scilex Bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d942297dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>EXHIBIT 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> and the related preliminary prospectus
of Scilex Holding Company (the &#147;Registration Statement&#148;) of our report (which report includes an explanatory paragraph relating to Scilex Holding Company&#146;s ability to continue as a going concern as described in Note 2 to the
consolidated financial statements) dated March&nbsp;31, 2025 (August&nbsp;4, 2005 as to the last paragraph of Note&nbsp;14, Subsequent Events), relating to the consolidated financial statements of Scilex Holding Company as of and for the years ended
December&nbsp;31, 2024 and 2023, which appears in such Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in the Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">/s/ BPM LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Walnut Creek, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">August 4, 2025 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d942297dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-331">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-332">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-333">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-334">0001820190</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-335">Scilex Holding Co</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-08-04</xbrli:startDate> <xbrli:endDate>2025-08-04</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-08-04</xbrli:startDate> <xbrli:endDate>2025-08-04</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-363">S-1</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-364">Scilex Holding Co</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-365">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-366">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-367">Common Stock, par value $0.0001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457aFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-368">457(a)</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">1,390,443</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">11.06</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-371">15,378,299.58</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-372">0.0001531</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-373">2,354.42</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fees Previously Paid </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">15,378,299.58</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">2,354.42</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-376">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-377">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-378">2,354.42</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-379"> Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), the shares being registered hereunder include such indeterminate number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. The amount registered includes 150,000 shares of common stock, par value $0.0001 per share (the "Common Stock") of Scilex Holding Company, a Delaware corporation (the "Company"), to be issued by the Company to the selling securityholder named herein (the "Selling Securityholder") and 1,240,443 shares of Common Stock that are available to be issued and sold by the Company to the Selling Securityholder from time to time at the Company's election pursuant to the common stock purchase agreement, dated as of July 22, 2025, between the Company and the Selling Securityholder, subject to satisfaction of the conditions set forth therein. The proposed maximum offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on July 25, 2025 (such date being within five business days of the date that this registration statement was filed with the U.S. Securities and Exchange Commission). </ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sclx-20250801.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 05-August-2025 [01:43:38] {AM}-->
<schema targetNamespace="http://www.scilexholding.com/20250801" elementFormDefault="qualified" xmlns:sclx="http://www.scilexholding.com/20250801" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.scilexholding.com/role/CoverPage" id="CoverPage">
        <link:definition>1001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" id="CondensedConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity / (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation" id="NatureOfOperationsAndBasisOfPresentation">
        <link:definition>1007 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
        <link:definition>1008 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements" id="AcquisitionsAndLicenseAgreements">
        <link:definition>1009 - Disclosure - Acquisitions and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/BalanceSheetComponents" id="BalanceSheetComponents">
        <link:definition>1011 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
        <link:definition>1012 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/Debt" id="Debt">
        <link:definition>1013 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement" id="SorrentoStockPurchaseAgreement">
        <link:definition>1014 - Disclosure - Sorrento Stock Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>1015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan" id="StockIncentiveAndEmployeeBenefitPlan">
        <link:definition>1016 - Disclosure - Stock Incentive and Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>1018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>1019 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>1020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies" id="NatureOfOperationsAndBasisOfPresentationPolicies">
        <link:definition>1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables" id="NatureOfOperationsAndBasisOfPresentationTables">
        <link:definition>1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>1023 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables">
        <link:definition>1024 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
        <link:definition>1025 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtTables" id="DebtTables">
        <link:definition>1026 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables" id="StockIncentiveAndEmployeeBenefitPlansTables">
        <link:definition>1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>1028 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>1029 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>1030 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" id="NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" id="NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails">
        <link:definition>1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" id="LiquidityAndGoingConcernAdditionalInformationDetails">
        <link:definition>1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails" id="AcquisitionsAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>1034 - Disclosure - Acquisitions and License Agreements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" id="FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis">
        <link:definition>1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" id="FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue">
        <link:definition>1037 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" id="FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities">
        <link:definition>1038 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" id="BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails">
        <link:definition>1039 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails" id="BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails">
        <link:definition>1040 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses - Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails" id="BalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>1041 - Disclosure - Balance Sheet Components (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" id="GoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>1042 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
        <link:definition>1043 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
        <link:definition>1044 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtAdditionalInformationDetails" id="DebtAdditionalInformationDetails">
        <link:definition>1045 - Disclosure - Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails" id="DebtSummaryOfOutstandingConvertibleDebentureDetails">
        <link:definition>1046 - Disclosure - Debt - Summary of Outstanding Convertible Debenture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails" id="DebtScheduleOfFsfDepositDetails">
        <link:definition>1047 - Disclosure - Debt - Schedule of FSF Deposit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails" id="DebtScheduleOfTheTrancheBNoteDetails">
        <link:definition>1048 - Disclosure - Debt - Schedule of the Tranche B Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails" id="DebtScheduleOfRevenueLiabilityActivityDetails">
        <link:definition>1049 - Disclosure - Debt - Schedule of revenue liability activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails" id="DebtScheduleOfTheOramedNoteDetails">
        <link:definition>1050 - Disclosure - Debt - Schedule of the Oramed Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" id="JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails">
        <link:definition>1051 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails" id="ShareholdersEquityAdditionalInformationDetails">
        <link:definition>1052 - Disclosure - Shareholders' Equity (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" id="StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails">
        <link:definition>1053 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" id="StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails">
        <link:definition>1054 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" id="StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>1055 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" id="CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails">
        <link:definition>1056 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" id="CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>1057 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>1058 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" id="IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
        <link:definition>1059 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" id="IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
        <link:definition>1060 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>1061 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>1062 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
        <link:definition>1063 - Disclosure - Income Taxes (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" id="NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails">
        <link:definition>1064 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" id="NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
        <link:definition>1065 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails" id="NetLossPerShareAdditionalInformationDetails">
        <link:definition>1066 - Disclosure - Net Loss Per Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails" id="SorrentoStockPurchaseAgreementAdditionalInformationDetails">
        <link:definition>1067 - Disclosure - Sorrento Stock Purchase Agreement (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
        <link:definition>1068 - Disclosure - Subsequent Events (Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk" >
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CoverPage" roleURI="http://www.scilexholding.com/role/CoverPage"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NatureOfOperationsAndBasisOfPresentation" roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#LiquidityAndGoingConcern" roleURI="http://www.scilexholding.com/role/LiquidityAndGoingConcern"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#AcquisitionsAndLicenseAgreements" roleURI="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurements" roleURI="http://www.scilexholding.com/role/FairValueMeasurements"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#BalanceSheetComponents" roleURI="http://www.scilexholding.com/role/BalanceSheetComponents"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssets"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#Debt" roleURI="http://www.scilexholding.com/role/Debt"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#SorrentoStockPurchaseAgreement" roleURI="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockholdersEquity" roleURI="http://www.scilexholding.com/role/StockholdersEquity"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockIncentiveAndEmployeeBenefitPlan" roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CommitmentsAndContingencies" roleURI="http://www.scilexholding.com/role/CommitmentsAndContingencies"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxes" roleURI="http://www.scilexholding.com/role/IncomeTaxes"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NetLossPerShare" roleURI="http://www.scilexholding.com/role/NetLossPerShare"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#SubsequentEvents" roleURI="http://www.scilexholding.com/role/SubsequentEvents"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NatureOfOperationsAndBasisOfPresentationPolicies" roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NatureOfOperationsAndBasisOfPresentationTables" roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurementsTables" roleURI="http://www.scilexholding.com/role/FairValueMeasurementsTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#BalanceSheetComponentsTables" roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtTables" roleURI="http://www.scilexholding.com/role/DebtTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesTables" roleURI="http://www.scilexholding.com/role/IncomeTaxesTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NetLossPerShareTables" roleURI="http://www.scilexholding.com/role/NetLossPerShareTables"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" roleURI="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#LiquidityAndGoingConcernAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#AcquisitionsAndLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" roleURI="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails" roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#BalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#GoodwillAndIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/DebtAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtSummaryOfOutstandingConvertibleDebentureDetails" roleURI="http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtScheduleOfFsfDepositDetails" roleURI="http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtScheduleOfTheTrancheBNoteDetails" roleURI="http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtScheduleOfRevenueLiabilityActivityDetails" roleURI="http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#DebtScheduleOfTheOramedNoteDetails" roleURI="http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#ShareholdersEquityAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" roleURI="http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#NetLossPerShareAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#SorrentoStockPurchaseAgreementAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="sclx-20250801.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"  />
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CoverPage" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1721" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_1721" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1723" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1721" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1724" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1723" xlink:to="loc_dei_AddressTypeDomain_1724" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1725" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1724" xlink:to="loc_dei_BusinessContactMember_1725" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1722" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1721" xlink:to="loc_dei_DocumentInformationLineItems_1722" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1730" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_DocumentType_1730" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1731" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_AmendmentFlag_1731" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_112" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityCentralIndexKey_112" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_113" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityTaxIdentificationNumber_113" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_114" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityRegistrantName_114" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_115" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityIncorporationStateCountryCode_115" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_116" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressAddressLine1_116" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_118" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressCityOrTown_118" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_119" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressStateOrProvince_119" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_121" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressPostalZipCode_121" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_122" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_CityAreaCode_122" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_123" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_LocalPhoneNumber_123" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_131" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityFilerCategory_131" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_132" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntitySmallBusiness_132" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_133" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityEmergingGrowthCompany_133" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_134" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityExTransitionPeriod_134" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1732" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityPrimarySicNumber_1732" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_147" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_155" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_147" xlink:to="loc_us-gaap_StatementTable_155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_154" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_154" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_169" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_154" xlink:to="loc_us-gaap_ClassOfStockDomain_169" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_150" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_169" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_150" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_159" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_169" xlink:to="loc_sclx_SeriesOnePreferredStockMember_159" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_163" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_155" xlink:to="loc_us-gaap_StatementLineItems_163" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_148" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_AssetsAbstract_148" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_156" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsCurrentAbstract_156" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_149" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_158" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_158" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_166" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_InventoryNet_166" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_173" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_173" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_164" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsCurrent_164" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_171" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_171" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_181" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments_185" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Investments_185" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_189" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Goodwill_189" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_192" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_192" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_194" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Assets_194" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_152" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_152" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_151" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccountsPayableCurrent_151" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_160" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccruedSalariesCurrent_160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_167" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_167" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses_174" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_AccruedExpenses_174" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_sclx_CurrentPortionOfDeferredConsideration_178" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_CurrentPortionOfDeferredConsideration_178" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_182" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_DebtCurrent_182" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityCurrent_186" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_PurchasedRevenueLiabilityCurrent_186" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_190" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_190" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_161" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_LiabilitiesCurrent_161" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_sclx_LongTermPortionOfDeferredConsideration_168" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_sclx_LongTermPortionOfDeferredConsideration_168" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_175" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_175" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityNoncurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityNoncurrent_179" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_sclx_PurchasedRevenueLiabilityNoncurrent_179" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_183" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_183" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_187" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_187" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_191" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_191" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_193" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_Liabilities_193" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_195" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_CommitmentsAndContingencies_195" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_165" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_StockholdersEquityAbstract_165" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_153" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_PreferredStockValue_153" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_162" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_CommonStockValue_162" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdditionalPaidsInCapitals" xlink:label="loc_sclx_AdditionalPaidsInCapitals_170" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_sclx_AdditionalPaidsInCapitals_170" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_176" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_176" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_180" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_180" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_184" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_TreasuryStockValue_184" use="optional" order="46" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_188" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_StockholdersEquity_188" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_172" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_172" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_197" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_201" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_197" xlink:to="loc_us-gaap_StatementTable_201" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_200" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementClassOfStockAxis_200" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_200" xlink:to="loc_us-gaap_ClassOfStockDomain_206" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_199" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_206" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_199" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_203" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_206" xlink:to="loc_sclx_SeriesOnePreferredStockMember_203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_204" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementLineItems_204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_198" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_198" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_202" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_202" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_205" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesIssued_205" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_207" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_207" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreferredStockDividendShares" xlink:label="loc_sclx_PreferredStockDividendShares_208" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_PreferredStockDividendShares_208" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesIssued" xlink:label="loc_sclx_CommonStocksSharesIssued_3152" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_CommonStocksSharesIssued_3152" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesOutstanding" xlink:label="loc_sclx_CommonStocksSharesOutstanding_3151" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_CommonStocksSharesOutstanding_3151" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_213" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_TreasuryStockCommonShares_213" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_215" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_217" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_Revenues_217" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_223" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_OperatingExpensesAbstract_223" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_218" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_CostOfRevenue_218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_224" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_229" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_229" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_232" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_232" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_235" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_238" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_238" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_241" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_223" xlink:to="loc_us-gaap_OperatingIncomeLoss_241" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_220" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_220" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_225" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_225" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating_230" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_InterestExpenseNonoperating_230" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_233" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_233" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_236" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_236" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_239" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_239" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_242" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_228" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_242" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_231" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_NetIncomeLoss_231" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_234" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_EarningsPerShareAbstract_234" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_221" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_234" xlink:to="loc_us-gaap_EarningsPerShareBasic_221" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_226" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_234" xlink:to="loc_us-gaap_EarningsPerShareDiluted_226" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_237" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_237" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_222" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_237" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_222" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_227" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_237" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_227" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_240" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_240" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_219" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_240" xlink:to="loc_us-gaap_NetIncomeLoss_219" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_243" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_243" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_216" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_243" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_216" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_244" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_244" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_245" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_215" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_245" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_247" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_251" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_247" xlink:to="loc_us-gaap_StatementTable_251" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_252" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_251" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_252" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_249" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_252" xlink:to="loc_us-gaap_EquityComponentDomain_249" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_250" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_PreferredStockMember_250" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_254" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_CommonStockMember_254" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_257" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_259" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_261" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_RetainedEarningsMember_261" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryShareMember" xlink:label="loc_sclx_TreasuryShareMember_263" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_sclx_TreasuryShareMember_263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember_2785" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_TreasuryStockPreferredMember_2785" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_251" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1967" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" xlink:to="loc_us-gaap_RelatedPartyDomain_1967" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_255" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_251" xlink:to="loc_us-gaap_StatementLineItems_255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_248" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_SharesOutstanding_248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_253" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_253" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaap_TreasuryStockPreferredShares_2494" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_TreasuryStockPreferredShares_2494" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_256" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_256" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_258" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_258" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount_260" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_DisbursementOfFundsToSorrentoAmount_260" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_262" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_262" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_264" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_264" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants_265" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfPennyWarrants_265" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_266" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_266" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_267" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_267" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_268" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_268" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_269" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_269" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued_270" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RetainerSharesIssued_270" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue_271" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RetainerSharesIssuedValue_271" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_272" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_272" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_273" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_273" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_274" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_274" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_275" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_275" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xlink:label="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation_276" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation_276" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_277" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_ProfitLoss_277" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue_278" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue_278" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement_279" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement_279" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingShare" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare_280" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare_280" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingValue" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue_281" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue_281" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering_282" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering_282" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering_283" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering_283" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xlink:label="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering_284" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering_284" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xlink:label="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter_285" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter_285" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepurchaseOfWarrants" xlink:label="loc_sclx_RepurchaseOfWarrants_286" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RepurchaseOfWarrants_286" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xlink:label="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement_287" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement_287" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares_288" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares_288" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_289" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_289" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares_290" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares_290" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStock" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_291" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_291" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares_292" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares_292" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering_293" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering_293" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xlink:label="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_294" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_294" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributedShares" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributedShares_295" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockDividendDeclaredNotYetDistributedShares_295" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributed" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributed_296" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockDividendDeclaredNotYetDistributed_296" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_297" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_297" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_298" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_298" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_299" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_299" use="optional" order="56" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xlink:label="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral_2977" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral_2977" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares_2981" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares_2981" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockPaidForGloperbaEx-USLicense" xlink:label="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense_2989" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense_2989" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xlink:label="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares_2992" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares_2992" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xlink:label="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension_2999" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension_2999" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares_3002" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares_3002" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3073" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_ShareBasedCompensation_3073" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_300" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_300" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_301" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_SharesOutstanding_301" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaap_TreasuryStockPreferredShares_3081" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_TreasuryStockPreferredShares_3081" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_303" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_307" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_307" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_306" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_307" xlink:to="loc_us-gaap_NetIncomeLoss_306" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_307" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_310" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_310" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_317" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_317" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_sclx_NonCashOperatingLeaseCost_323" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_sclx_NonCashOperatingLeaseCost_323" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_329" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_ShareBasedCompensation_329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_335" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_335" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_340" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_340" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xlink:label="loc_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue_2721" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue_2721" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2809" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2809" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_345" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_345" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_350" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_350" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForCreditLosses" xlink:label="loc_sclx_AllowancesForCreditLosses_354" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_sclx_AllowancesForCreditLosses_354" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_358" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_358" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_305" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_313" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_313" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_320" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_320" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_326" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_326" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_332" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_332" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_sclx_IncreaseDecreaseInAccruedPayroll_338" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_sclx_IncreaseDecreaseInAccruedPayroll_338" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_343" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_343" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees_348" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees_348" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_353" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_353" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLeaseLiability1" xlink:label="loc_sclx_OperatingLeaseLiability1_2873" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_sclx_OperatingLeaseLiability1_2873" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_sclx_OtherLongTermLiabilities_357" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_362" xlink:to="loc_sclx_OtherLongTermLiabilities_357" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_361" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_307" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_361" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_308" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_308" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2292" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2292" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfEquitySecurities" xlink:label="loc_sclx_PurchaseOfEquitySecurities_316" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_sclx_PurchaseOfEquitySecurities_316" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfConvertiblePromissoryNote" xlink:label="loc_sclx_PurchaseOfConvertiblePromissoryNote_322" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_sclx_PurchaseOfConvertiblePromissoryNote_322" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_328" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_328" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_334" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_315" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_334" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xlink:label="loc_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement_311" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement_311" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_318" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_318" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility_324" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility_324" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfFsfDeposit" xlink:label="loc_sclx_ProceedsFromIssuanceOfFsfDeposit_330" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_ProceedsFromIssuanceOfFsfDeposit_330" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_336" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_336" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_sclx_RepaymentOfRevolvingFacility_341" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_RepaymentOfRevolvingFacility_341" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_346" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_RepaymentsOfDebt_346" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_351" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_351" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_355" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_355" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_359" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_359" use="optional" order="46" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDebt" xlink:label="loc_sclx_RepaymentOfDebt_363" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_RepaymentOfDebt_363" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRefundPayments1" xlink:label="loc_us-gaap_DeferredRevenueRefundPayments1_2810" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_DeferredRevenueRefundPayments1_2810" use="optional" order="48" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase_371" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase_371" use="optional" order="49" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_375" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_375" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_365" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_365" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_376" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_376" use="optional" order="52" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_ExciseTaxPaidInConnectionWithShareRepurchase_373" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_ExciseTaxPaidInConnectionWithShareRepurchase_373" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xlink:label="loc_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger_377" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger_377" use="optional" order="54" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_378" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_378" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFunds" xlink:label="loc_sclx_DisbursementOfFunds_367" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_sclx_DisbursementOfFunds_367" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_369" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_369" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_379" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_321" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_379" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_327" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_327" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_333" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_333" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_339" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_339" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_344" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_344" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperatingPaidInCash" xlink:label="loc_us-gaap_InterestIncomeOperatingPaidInCash_309" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_344" xlink:to="loc_us-gaap_InterestIncomeOperatingPaidInCash_309" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_303" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_304" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_us-gaap_StockIssued1_304" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xlink:label="loc_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses_312" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses_312" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xlink:label="loc_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter_319" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter_319" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SettlementOfFSFDeposit" xlink:label="loc_sclx_SettlementOfFSFDeposit_325" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_SettlementOfFSFDeposit_325" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xlink:label="loc_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable_331" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable_331" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfOramedNoteIntoTrancheBNotes" xlink:label="loc_sclx_ConversionOfOramedNoteIntoTrancheBNotes_337" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_ConversionOfOramedNoteIntoTrancheBNotes_337" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStock" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_342" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_342" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xlink:label="loc_sclx_DebtIssuanceCostsIncludedInAccruedExpenses_347" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_DebtIssuanceCostsIncludedInAccruedExpenses_347" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_360" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_360" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xlink:label="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_364" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_364" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_366" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_366" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:label="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification_368" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification_368" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedNoteIssuanceAtFairValue" xlink:label="loc_sclx_OramedNoteIssuanceAtFairValue_370" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_OramedNoteIssuanceAtFairValue_370" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:label="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase_372" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase_372" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:label="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses_374" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_349" xlink:to="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses_374" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_401" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_402" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_401" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/LiquidityAndGoingConcern" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_404" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_405" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_404" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_407" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_408" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_407" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurements" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_410" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_411" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_410" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponents" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_413" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_414" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_413" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_416" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_417" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_416" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_417" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/Debt" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_434" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_435" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_434" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1786" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1787" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1786" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1787" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockholdersEquity" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_440" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_441" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_440" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_443" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_444" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_443" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingencies" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_449" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_450" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_449" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_450" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxes" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_428" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_429" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_428" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_429" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerShare" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_455" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_456" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_455" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_456" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SubsequentEvents" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_458" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_459" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_458" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_461" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_464" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_464" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_484" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_484" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_465" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_UseOfEstimates_465" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_466" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_466" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_467" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_467" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_468" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_468" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_469" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_469" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_470" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_470" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_471" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_471" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_472" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_472" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_474" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_474" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_473" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_473" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_475" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_475" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_476" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_DebtPolicyTextBlock_476" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:label="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock_462" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock_462" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityPolicyTextBlock" xlink:label="loc_sclx_PurchasedRevenueLiabilityPolicyTextBlock_463" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_sclx_PurchasedRevenueLiabilityPolicyTextBlock_463" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_478" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_478" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_479" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_479" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_480" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_480" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_481" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_481" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_482" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_482" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_483" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_483" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockPolicyTextblock" xlink:label="loc_sclx_TreasuryStockPolicyTextblock_477" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_sclx_TreasuryStockPolicyTextblock_477" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_485" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_485" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_486" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_486" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReverseStockSplitPolicyTextBlock" xlink:label="loc_sclx_ReverseStockSplitPolicyTextBlock_2405" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_sclx_ReverseStockSplitPolicyTextBlock_2405" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2757" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2757" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2841" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2841" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_488" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_489" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_488" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_495" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_496" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_495" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_496" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_498" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_495" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_498" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_499" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_495" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_499" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_501" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_502" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_502" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpensesTextblock" xlink:label="loc_sclx_AccruedExpensesTextblock_503" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_501" xlink:to="loc_sclx_AccruedExpensesTextblock_503" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_505" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_506" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_505" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_507" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_505" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_507" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_509" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_513" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_509" xlink:to="loc_us-gaap_DebtInstrumentTable_513" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_512" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_513" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_512" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_514" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_512" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_510" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_514" xlink:to="loc_us-gaap_SeniorNotesMember_510" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_515" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_514" xlink:to="loc_sclx_TrancheBNotesMember_515" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_517" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_513" xlink:to="loc_us-gaap_DebtInstrumentLineItems_517" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_511" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_511" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_516" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_516" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xlink:label="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit_518" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit_518" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTrancheBNotesTableTextBlock" xlink:label="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock_519" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock_519" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xlink:label="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock_520" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock_520" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock_2341" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock_2341" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_522" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_523" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_522" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_524" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_522" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_526" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_528" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_526" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_528" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_529" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_531" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_532" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_532" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_533" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_533" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_534" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_534" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_535" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_531" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_535" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerShareTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_537" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_538" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_537" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_539" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_537" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_539" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_544" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_544" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_558" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_558" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_552" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_558" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_552" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_553" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_552" xlink:to="loc_us-gaap_ConvertibleDebtMember_553" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_562" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_562" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_555" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_562" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_555" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_546" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_555" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_546" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_559" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" xlink:to="loc_us-gaap_SalesRevenueNetMember_559" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_563" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" xlink:to="loc_us-gaap_AccountsReceivableMember_563" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_567" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_567" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_554" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" xlink:to="loc_sclx_SorrentoMember_554" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_569" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_srt_RangeAxis_569" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_551" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_569" xlink:to="loc_srt_RangeMember_551" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_549" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_551" xlink:to="loc_srt_MinimumMember_549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_560" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_551" xlink:to="loc_srt_MaximumMember_560" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_571" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_srt_MajorCustomersAxis_571" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_547" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_571" xlink:to="loc_srt_NameOfMajorCustomerDomain_547" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember_548" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_547" xlink:to="loc_sclx_ThreeCustomersMember_548" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2345" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2345" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2079" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2345" xlink:to="loc_us-gaap_EquityComponentDomain_2079" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_2526" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_TransactionTypeAxis_2526" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_2080" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_2526" xlink:to="loc_us-gaap_TransactionDomain_2080" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2737" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2737" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2737" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2882" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2882" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2087" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2087" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2076" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2087" xlink:to="loc_us-gaap_SubsequentEventMember_2076" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_550" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_550" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_561" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_561" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_564" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_ReceivablesNetCurrent_564" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_566" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_566" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConcentrationRiskThresholdPercentage" xlink:label="loc_sclx_ConcentrationRiskThresholdPercentage_568" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_ConcentrationRiskThresholdPercentage_568" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_570" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_570" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_572" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_572" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors_574" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_PercentageOfNetRevenueSoleDistributors_574" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForPromptPaymentDiscounts" xlink:label="loc_sclx_AllowancesForPromptPaymentDiscounts_2696" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_AllowancesForPromptPaymentDiscounts_2696" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2797" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2797" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_577" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1726" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_577" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1726" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_579" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_579" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_580" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_580" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_581" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_581" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_583" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_604" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_583" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_604" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_594" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_DebtInstrumentAxis_594" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_611" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_594" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InitialClosingMember" xlink:label="loc_sclx_InitialClosingMember_607" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_611" xlink:to="loc_sclx_InitialClosingMember_607" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondClosingMember" xlink:label="loc_sclx_SecondClosingMember_613" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_611" xlink:to="loc_sclx_SecondClosingMember_613" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_609" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_dei_LegalEntityAxis_609" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_617" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_609" xlink:to="loc_dei_EntityDomain_617" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_588" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_617" xlink:to="loc_sclx_OramedMember_588" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionsAxis" xlink:label="loc_sclx_LongTermDebtTransactionsAxis_615" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_sclx_LongTermDebtTransactionsAxis_615" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_603" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LongTermDebtTransactionsAxis_615" xlink:to="loc_sclx_LongTermDebtTransactionDomain_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_598" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LongTermDebtTransactionDomain_603" xlink:to="loc_sclx_PrincipalBalanceMember_598" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_620" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_620" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_602" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_602" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeniorSecuredConvertibleNotesMember" xlink:label="loc_sclx_SeniorSecuredConvertibleNotesMember_584" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_602" xlink:to="loc_sclx_SeniorSecuredConvertibleNotesMember_584" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_623" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_623" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_589" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_589" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_591" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_589" xlink:to="loc_us-gaap_CommonStockMember_591" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_601" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" xlink:to="loc_us-gaap_RelatedPartyDomain_601" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_628" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_srt_RangeAxis_628" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_597" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_628" xlink:to="loc_srt_RangeMember_597" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_592" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_597" xlink:to="loc_srt_MaximumMember_592" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_630" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_TypeOfArrangementAxis_630" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_630" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SatisfactionAgreementMember" xlink:label="loc_sclx_SatisfactionAgreementMember_612" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_SatisfactionAgreementMember_612" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_621" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_621" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InvestorAgreementMember" xlink:label="loc_sclx_InvestorAgreementMember_624" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_InvestorAgreementMember_624" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_632" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_sclx_PurchaseAgreementAxis_632" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_600" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_632" xlink:to="loc_sclx_PurchaseAgreementDomain_600" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_586" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_600" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_586" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_606" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_600" xlink:to="loc_sclx_AtmSalesAgreementMember_606" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_634" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_StatementClassOfStockAxis_634" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_616" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_634" xlink:to="loc_us-gaap_ClassOfStockDomain_616" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_2393" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_616" xlink:to="loc_sclx_DepositWarrantsMember_2393" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_587" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_587" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3156" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_VestingAxis_3156" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3157" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_3156" xlink:to="loc_us-gaap_VestingDomain_3157" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_3158" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3157" xlink:to="loc_sclx_TrancheBNotesMember_3158" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_638" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_sclx_LiquidityAndGoingConcernLineItems_638" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_593" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_593" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_608" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_WorkingCapital_608" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_619" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_OperatingIncomeLoss_619" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_622" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_622" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_625" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_625" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_627" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_627" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount_629" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_Convertibledebentureprincipalamount_629" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount_631" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_PrincipalLaonAmount_631" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_633" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_ConvertibleDebt_633" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_635" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_635" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmountPayable" xlink:label="loc_sclx_CommitmentAmountPayable_637" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CommitmentAmountPayable_637" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_639" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_639" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheDepositAmount_640" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CompanyReceivesTheDepositAmount_640" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheDepositPeriod_641" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CompanyReceivesTheDepositPeriod_641" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonRefundableDepositAmount" xlink:label="loc_sclx_NonRefundableDepositAmount_642" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_NonRefundableDepositAmount_642" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_643" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_643" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityGross" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityGross_644" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityGross_644" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_645" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_645" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_646" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CommonStockSharesIssued_646" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfTheWarrants" xlink:label="loc_sclx_ExercisePriceOfTheWarrants_647" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ExercisePriceOfTheWarrants_647" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_648" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_648" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue_649" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CommonStockIssuableValue_649" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReductionOfThePrincipalBalance" xlink:label="loc_sclx_ReductionOfThePrincipalBalance_650" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ReductionOfThePrincipalBalance_650" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_652" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_652" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_653" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_653" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_654" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_654" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1728" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1728" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_688" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_688" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_698" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_698" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_698" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember_690" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" xlink:to="loc_sclx_LicenseAgreementMember_690" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_701" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_dei_LegalEntityAxis_701" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_704" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_701" xlink:to="loc_dei_EntityDomain_704" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_691" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_704" xlink:to="loc_sclx_RomegLicenseAgreementMember_691" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2432" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_704" xlink:to="loc_sclx_ScilexPharmaMember_2432" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_703" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_703" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_695" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_703" xlink:to="loc_us-gaap_SegmentDomain_695" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_692" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" xlink:to="loc_us-gaap_PatentsMember_692" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_708" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_708" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_693" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_699" xlink:to="loc_sclx_SorrentoMember_693" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2652" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2652" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2652" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1782" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1782" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember_2435" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember_2435" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ElyxybRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember_2451" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember_2451" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_710" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_710" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_694" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_694" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee_700" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Upfrontlicensefee_700" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales_702" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PaymentUponTheAchievementOfNetSales_702" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_705" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_PaymentsForRoyalties_705" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Non-RefundableNon-CreditablePayment" xlink:label="loc_sclx_Non-RefundableNon-CreditablePayment_707" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Non-RefundableNon-CreditablePayment_707" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfCommonStockShares" xlink:label="loc_sclx_TransferOfCommonStockShares_709" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_TransferOfCommonStockShares_709" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_711" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_711" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities_712" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Deferredconsiderationliabilities_712" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_713" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_RoyaltyExpense_713" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_714" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_714" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense_715" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PaymentToAcquireLicense_715" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables_716" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AccruedRoyaltyPayables_716" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication_717" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AmountDueForNewDrugApplication_717" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfLidocaineTopicalSystem" xlink:label="loc_sclx_PercentageOfLidocaineTopicalSystem_2960" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PercentageOfLidocaineTopicalSystem_2960" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2961" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2961" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregatePaymentOfCompany" xlink:label="loc_sclx_AggregatePaymentOfCompany_2979" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AggregatePaymentOfCompany_2979" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_757" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_757" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_758" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_TypeOfArrangementAxis_758" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_758" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_769" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_769" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_769" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_761" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_us-gaap_PrivatePlacementMember_761" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantsMember" xlink:label="loc_sclx_February2024BDOFirmWarrantsMember_771" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_February2024BDOFirmWarrantsMember_771" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_775" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_775" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_780" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_DepositWarrantsMember_780" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_784" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_784" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_787" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_787" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_773" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_773" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_767" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_773" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_767" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_759" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_us-gaap_SeniorNotesMember_759" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_770" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_TrancheBNotesMember_770" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityMember" xlink:label="loc_sclx_PurchasedRevenueLiabilityMember_774" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_PurchasedRevenueLiabilityMember_774" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_779" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_779" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember_2620" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember_2620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_778" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_778" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_765" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_778" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_765" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_766" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_765" xlink:to="loc_us-gaap_ConvertibleDebtMember_766" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_783" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_AwardTypeAxis_783" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_781" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_sclx_WarrantsMember_781" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2377" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2377" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1994" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2377" xlink:to="loc_us-gaap_EquityComponentDomain_1994" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1973" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1994" xlink:to="loc_us-gaap_CommonStockMember_1973" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_768" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DebtInstrumentFairValue_768" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate_772" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_SecuredNoteDiscountRate_772" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_777" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_777" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DerivativeWarrantLiabilities" xlink:label="loc_sclx_DerivativeWarrantLiabilities_785" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_DerivativeWarrantLiabilities_785" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_788" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_788" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_789" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_789" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_790" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_PurchasedRevenueLiability_790" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_791" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_791" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueDueToCreditRisk" xlink:label="loc_sclx_ChangeInFairValueDueToCreditRisk_792" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_ChangeInFairValueDueToCreditRisk_792" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_793" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_793" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_794" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_794" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration_795" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_FairValueOfContingentConsideration_795" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_797" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_797" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_802" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_802" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_807" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_810" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_810" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2426" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2426" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1803" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1803" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_806" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" xlink:to="loc_us-gaap_LiabilitiesAbstract_806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_804" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_SeniorNotes_804" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_809" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_809" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote_812" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_sclx_TrancheBNote_812" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_813" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_sclx_PurchasedRevenueLiability_813" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_814" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_814" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_815" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_DerivativeLiabilities_815" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_816" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_816" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_817" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_817" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_828" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_828" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_834" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_834" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_837" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xlink:to="loc_sclx_PurchaseAgreementAxis_837" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_833" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_837" xlink:to="loc_sclx_PurchaseAgreementDomain_833" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_830" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_833" xlink:to="loc_sclx_OramedLetterAgreementMember_830" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_831" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_DerivativeLiabilities_831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_836" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_836" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants_838" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ForfeitureOfPrivateWarrants_838" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfFirmWarrants" xlink:label="loc_sclx_IssuanceOfFirmWarrants_840" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_IssuanceOfFirmWarrants_840" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:label="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_841" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_841" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xlink:label="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering_842" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering_842" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_843" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_843" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_846" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_DerivativeLiabilities_846" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_848" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_848" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_853" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_853" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantsMember" xlink:label="loc_sclx_February2024BDOFirmWarrantsMember_851" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_February2024BDOFirmWarrantsMember_851" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_857" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_857" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_861" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DepositWarrantsMember_861" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_864" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_864" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsFiveYearMember_866" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DecemberCommonWarrantsFiveYearMember_866" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember_868" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember_868" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_858" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_858" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_850" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_858" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_850" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberRDOCommonWarrantsMember" xlink:label="loc_sclx_DecemberRDOCommonWarrantsMember_859" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_850" xlink:to="loc_sclx_DecemberRDOCommonWarrantsMember_859" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3148" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_srt_RestatementAxis_3148" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3149" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3148" xlink:to="loc_srt_RestatementDomain_3149" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3150" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3149" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3150" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_856" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_856" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_863" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_863" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_865" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_865" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_867" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_867" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_877" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_877" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_881" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_ConstructionInProgressMember_881" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_885" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_885" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_887" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_ComputerEquipmentMember_887" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_888" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_888" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_878" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_878" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_886" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_886" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_891" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_891" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_892" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_892" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_sclx_AccruedResearchAndDevelopmentCosts_893" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_sclx_AccruedResearchAndDevelopmentCosts_893" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_894" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_894" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_895" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_895" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_896" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_896" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses_897" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_890" xlink:to="loc_sclx_AccruedExpenses_897" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_899" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_911" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_srt_RangeAxis_911" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_908" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_911" xlink:to="loc_srt_RangeMember_908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_907" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_908" xlink:to="loc_srt_MaximumMember_907" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_918" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_918" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_914" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_918" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_914" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertiblePromissoryNoteMember" xlink:label="loc_sclx_ConvertiblePromissoryNoteMember_900" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_914" xlink:to="loc_sclx_ConvertiblePromissoryNoteMember_900" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionAxis" xlink:label="loc_sclx_LongTermDebtTransactionAxis_920" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_sclx_LongTermDebtTransactionAxis_920" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_905" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LongTermDebtTransactionAxis_920" xlink:to="loc_sclx_LongTermDebtTransactionDomain_905" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_909" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LongTermDebtTransactionDomain_905" xlink:to="loc_sclx_PrincipalBalanceMember_909" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RemainingDrawableBalanceMember" xlink:label="loc_sclx_RemainingDrawableBalanceMember_917" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LongTermDebtTransactionDomain_905" xlink:to="loc_sclx_RemainingDrawableBalanceMember_917" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_922" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_922" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_903" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_922" xlink:to="loc_us-gaap_EquityComponentDomain_903" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903" xlink:to="loc_us-gaap_CommonStockMember_906" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurCommonStockMember" xlink:label="loc_sclx_SemnurCommonStockMember_916" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903" xlink:to="loc_sclx_SemnurCommonStockMember_916" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_924" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_sclx_PurchaseAgreementAxis_924" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_912" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_924" xlink:to="loc_sclx_PurchaseAgreementDomain_912" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember_902" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_912" xlink:to="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember_902" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_926" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_926" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_926" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_901" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" xlink:to="loc_us-gaap_CashMember_901" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3153" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_srt_RestatementAxis_3153" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3154" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3153" xlink:to="loc_srt_RestatementDomain_3154" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3155" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3154" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3155" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_904" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_904" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_915" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_915" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_919" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_919" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_921" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_921" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_923" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_923" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_925" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_925" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_927" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DeferredOfferingCosts_927" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_929" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_929" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_930" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CommonStockSharesIssued_930" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_931" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_931" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsNetAmount" xlink:label="loc_us-gaap_CapitalUnitsNetAmount_932" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CapitalUnitsNetAmount_932" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ImpairmentLoss" xlink:label="loc_sclx_ImpairmentLoss_933" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_sclx_ImpairmentLoss_933" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_934" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_Depreciation_934" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_936" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_936" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_950" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" xlink:to="loc_sclx_AssembledWorkforceMember_950" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_954" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_srt_RangeAxis_954" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_939" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_954" xlink:to="loc_srt_RangeMember_939" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_937" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_939" xlink:to="loc_srt_MaximumMember_937" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_948" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_939" xlink:to="loc_srt_MinimumMember_948" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xlink:label="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember_942" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" xlink:to="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember_942" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_938" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_Goodwill_938" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_949" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_949" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_952" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_952" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_955" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_955" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_957" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_957" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_959" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_959" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_961" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_961" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember_964" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_PatentRightsMember_964" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember_968" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AcquiredTechnologyMember_968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember_971" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AcquiredLicensesMember_971" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_972" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AssembledWorkforceMember_972" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_962" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_967" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_967" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_974" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_974" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_975" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_975" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_977" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_977" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_978" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_978" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_979" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_979" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive_980" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive_980" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_981" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_981" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_982" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_982" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2141" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_976" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2141" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_984" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1008" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_984" xlink:to="loc_us-gaap_DebtInstrumentTable_1008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1002" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_CreditFacilityAxis_1002" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1011" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1002" xlink:to="loc_us-gaap_CreditFacilityDomain_1011" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1004" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1011" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1004" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeniorSecuredConvertibleNotesMember" xlink:label="loc_sclx_SeniorSecuredConvertibleNotesMember_1021" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1011" xlink:to="loc_sclx_SeniorSecuredConvertibleNotesMember_1021" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1006" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" xlink:to="loc_us-gaap_RelatedPartyDomain_1006" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InitialClosingMember" xlink:label="loc_sclx_InitialClosingMember_1001" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1006" xlink:to="loc_sclx_InitialClosingMember_1001" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondClosingMember" xlink:label="loc_sclx_SecondClosingMember_1019" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1006" xlink:to="loc_sclx_SecondClosingMember_1019" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1029" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_dei_LegalEntityAxis_1029" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1030" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1029" xlink:to="loc_dei_EntityDomain_1030" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_991" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_OramedMember_991" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1016" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_RodmanRenshawLlcMember_1016" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1027" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_ScilexPharmaMember_1027" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRoyaltyMember" xlink:label="loc_sclx_ZTlidoRoyaltyMember_2547" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_ZTlidoRoyaltyMember_2547" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1036" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_sclx_PurchaseAgreementAxis_1036" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1005" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_1036" xlink:to="loc_sclx_PurchaseAgreementDomain_1005" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_988" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_988" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_1025" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_AtmSalesAgreementMember_1025" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_1033" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_OramedLetterAgreementMember_1033" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1040" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_VestingAxis_1040" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_990" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1040" xlink:to="loc_us-gaap_VestingDomain_990" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1007" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1007" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1022" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1022" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1031" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1031" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNoteMember" xlink:label="loc_sclx_TrancheBNoteMember_1037" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_sclx_TrancheBNoteMember_1037" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1043" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1043" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_992" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043" xlink:to="loc_us-gaap_EquityComponentDomain_992" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_995" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_992" xlink:to="loc_us-gaap_CommonStockMember_995" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1045" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1045" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1045" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_986" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_986" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SatisfactionAgreementMember" xlink:label="loc_sclx_SatisfactionAgreementMember_1013" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_SatisfactionAgreementMember_1013" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InvestorAgreementMember" xlink:label="loc_sclx_InvestorAgreementMember_1024" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_InvestorAgreementMember_1024" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_RoyaltyPurchaseAgreementMember_1032" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_RoyaltyPurchaseAgreementMember_1032" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_2471" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_2471" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1047" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1047" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1010" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1047" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1010" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_985" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_us-gaap_SeniorNotesMember_985" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_1012" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_sclx_PrincipalBalanceMember_1012" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:label="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_2640" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_2640" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1049" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_DebtInstrumentAxis_1049" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1023" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1049" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1023" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember_994" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FristInstallmentMember_994" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember_1017" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_SecondInstallmentMember_1017" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember_1028" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_ThirdInstallmentMember_1028" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember_1035" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FourthInstallmentMember_1035" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember_1039" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FiveInstallmentMember_1039" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember_1042" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_SixInstallmentMember_1042" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1051" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_srt_RangeAxis_1051" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1000" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1051" xlink:to="loc_srt_RangeMember_1000" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_996" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1000" xlink:to="loc_srt_MaximumMember_996" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1018" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1000" xlink:to="loc_srt_MinimumMember_1018" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_987" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_987" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OctoberCommonWarrantsMember" xlink:label="loc_sclx_OctoberCommonWarrantsMember_1009" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_987" xlink:to="loc_sclx_OctoberCommonWarrantsMember_1009" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1055" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1055" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_993" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_993" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1003" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_993" xlink:to="loc_us-gaap_SubsequentEventMember_1003" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis_1057" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_sclx_DebtPayableAxis_1057" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_997" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DebtPayableAxis_1057" xlink:to="loc_sclx_DebtPayableDomain_997" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember_998" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DebtPayableDomain_997" xlink:to="loc_sclx_MonthlyBasisMember_998" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3144" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_srt_RestatementAxis_3144" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3145" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3144" xlink:to="loc_srt_RestatementDomain_3145" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3146" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3145" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3146" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1059" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1059" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_989" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_989" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LoanAmount" xlink:label="loc_sclx_LoanAmount_1015" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_LoanAmount_1015" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonRefundableDepositAmount" xlink:label="loc_sclx_NonRefundableDepositAmount_1026" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NonRefundableDepositAmount_1026" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantExercisePrice" xlink:label="loc_sclx_DepositWarrantExercisePrice_1034" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DepositWarrantExercisePrice_1034" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1038" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1038" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmount" xlink:label="loc_sclx_CommitmentAmount_1041" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CommitmentAmount_1041" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositAmount_1044" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CompanyReceivesTheFsfDepositAmount_1044" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositPeriod_1046" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CompanyReceivesTheFsfDepositPeriod_1046" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_1048" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_1048" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_1050" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_1050" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1052" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1052" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1054" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1054" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1056" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1056" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1058" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1058" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReductionOfThePrincipalBalance" xlink:label="loc_sclx_ReductionOfThePrincipalBalance_1060" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ReductionOfThePrincipalBalance_1060" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsReceivedFromPurchaseAgreement" xlink:label="loc_sclx_ProceedsReceivedFromPurchaseAgreement_1061" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ProceedsReceivedFromPurchaseAgreement_1061" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1062" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1062" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_1063" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_1063" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_1064" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_1064" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_1065" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentDescription_1065" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds_1066" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NetCashProceeds_1066" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_1067" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LongTermNotesPayable_1067" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees_1068" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_TerminationFees_1068" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1069" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1069" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1070" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1070" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1071" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1071" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1072" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1072" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_FederalFundsPurchasedAverageRatePaid" xlink:label="loc_srt_FederalFundsPurchasedAverageRatePaid_1073" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_srt_FederalFundsPurchasedAverageRatePaid_1073" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1074" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RepaymentsOfDebt_1074" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1075" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1075" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1076" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1076" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee_1077" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentExitFee_1077" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_1078" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_1078" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_1079" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_1079" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum_1080" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ExistingFacilityCapMaximum_1080" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum_1081" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ExistingFacilityCapMinimum_1081" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal_1082" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentOutstandingPrincipal_1082" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_1083" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_1083" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1084" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1084" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1086" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1086" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1087" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1087" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage_1089" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentPrincipalAmountPercentage_1089" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_1090" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_1090" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1091" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1091" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent_1092" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ConvertibleDebenturesIssuedPercent_1092" use="optional" order="111" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1093" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_Cash_1093" use="optional" order="112" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1094" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1094" use="optional" order="113" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" use="optional" order="114" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_1096" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_1096" use="optional" order="115" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1098" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CommonStockSharesIssued_1098" use="optional" order="116" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_1099" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_1099" use="optional" order="117" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1100" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1100" use="optional" order="118" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage_1101" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentOwnedPercentage_1101" use="optional" order="119" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate_1102" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentDefaultInterestRate_1102" use="optional" order="120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_1103" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_1103" use="optional" order="121" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_1104" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_1104" use="optional" order="122" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_1105" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_1105" use="optional" order="123" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_1106" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_1106" use="optional" order="124" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaidToRoyaltyInvestors" xlink:label="loc_sclx_PaidToRoyaltyInvestors_1108" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PaidToRoyaltyInvestors_1108" use="optional" order="125" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaap_PaymentsToAcquireReceivables_1109" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsToAcquireReceivables_1109" use="optional" order="126" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1110" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1110" use="optional" order="127" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1111" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1111" use="optional" order="128" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1112" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1112" use="optional" order="129" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2550" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2550" use="optional" order="130" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:label="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_2706" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_2706" use="optional" order="131" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NoOfCalendarDays" xlink:label="loc_sclx_NoOfCalendarDays_2727" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NoOfCalendarDays_2727" use="optional" order="132" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:label="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice_2878" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice_2878" use="optional" order="133" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TotalNumberOfSharesGranted" xlink:label="loc_sclx_TotalNumberOfSharesGranted_2951" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_TotalNumberOfSharesGranted_2951" use="optional" order="134" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityCurrent_2968" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PurchasedRevenueLiabilityCurrent_2968" use="optional" order="135" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_2997" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtCurrent_2997" use="optional" order="136" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesDelivered" xlink:label="loc_sclx_SharesDelivered_3014" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_SharesDelivered_3014" use="optional" order="137" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3034" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3034" use="optional" order="138" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_3087" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_3087" use="optional" order="139" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1114" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1118" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1114" xlink:to="loc_us-gaap_DebtInstrumentTable_1118" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1117" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1118" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1117" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1119" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1117" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1119" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1116" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1119" xlink:to="loc_us-gaap_SeniorNotesMember_1116" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1121" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1119" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1121" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1118" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1115" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_ConvertibleDebt_1115" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture_1120" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_sclx_RepaymentOfConvertibleDebenture_1120" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1123" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1123" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1124" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1124" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_1125" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_1125" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1126" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_ConvertibleDebt_1126" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1128" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1128" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1131" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1133" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1133" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FSFLoanMember" xlink:label="loc_sclx_FSFLoanMember_3143" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1133" xlink:to="loc_sclx_FSFLoanMember_3143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaap_Deposits_1129" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_Deposits_1129" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInDeposits_1134" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_IncreaseDecreaseInDeposits_1134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:label="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_1136" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_1136" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDeposit" xlink:label="loc_sclx_RepaymentOfDeposit_1137" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_sclx_RepaymentOfDeposit_1137" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaap_Deposits_1138" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_Deposits_1138" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1140" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1140" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1143" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1143" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1145" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_1142" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1145" xlink:to="loc_sclx_TrancheBNotesMember_1142" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote_1141" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_TrancheBNote_1141" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1146" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfTrancheBNotes" xlink:label="loc_sclx_RepaymentOfTrancheBNotes_1148" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_RepaymentOfTrancheBNotes_1148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfTrancheBNotes" xlink:label="loc_sclx_ChangeInFairValueOfTrancheBNotes_1149" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_ChangeInFairValueOfTrancheBNotes_1149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote_1150" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_TrancheBNote_1150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1152" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1152" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1154" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1154" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1156" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1154" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRoyaltyMember" xlink:label="loc_sclx_ZTlidoRoyaltyMember_2107" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1156" xlink:to="loc_sclx_ZTlidoRoyaltyMember_2107" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_1153" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_PurchasedRevenueLiability_1153" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfPurchasedRevenueLiability" xlink:label="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability_1157" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability_1157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_1159" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_PurchasedRevenueLiability_1159" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfPurchasedRevenueLiability" xlink:label="loc_sclx_RepaymentOfPurchasedRevenueLiability_2335" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_RepaymentOfPurchasedRevenueLiability_2335" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1740" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1741" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1740" xlink:to="loc_us-gaap_DebtInstrumentTable_1741" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1744" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1741" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1744" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1742" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1744" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1742" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1745" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1742" xlink:to="loc_us-gaap_SeniorNotesMember_1745" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1741" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1746" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1741" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1747" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_us-gaap_ConvertibleDebt_1747" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1805" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1818" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_us-gaap_ConvertibleDebt_1818" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1161" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1161" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1173" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1173" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_1172" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" xlink:to="loc_sclx_SorrentoMember_1172" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1183" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_srt_RangeAxis_1183" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1171" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1183" xlink:to="loc_srt_RangeMember_1171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1169" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1171" xlink:to="loc_srt_MaximumMember_1169" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1187" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1187" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1176" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1187" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1176" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_1163" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1176" xlink:to="loc_sclx_JuniorDipFacilityMember_1163" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1179" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1176" xlink:to="loc_us-gaap_SeniorNotesMember_1179" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1191" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1191" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1191" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_1164" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" xlink:to="loc_sclx_StockPurchaseAgreementMember_1164" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1175" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_ClosingPennyWarrantMember_1175" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_1184" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_1184" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_1188" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_PennyWarrantsMember_1188" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member_1195" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants2Member_1195" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member_1198" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants3Member_1198" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member_1201" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants4Member_1201" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants5Member" xlink:label="loc_sclx_SubsequentPennyWarrants5Member_1204" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants5Member_1204" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1197" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_AwardDateAxis_1197" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1166" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_1197" xlink:to="loc_us-gaap_AwardDateDomain_1166" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1200" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1200" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1167" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1200" xlink:to="loc_us-gaap_EquityComponentDomain_1167" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1168" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_us-gaap_CommonStockMember_1168" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1180" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_us-gaap_PreferredStockMember_1180" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1186" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_sclx_PrivateWarrantsMember_1186" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1190" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_sclx_PublicWarrantsMember_1190" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3162" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_srt_RestatementAxis_3162" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3163" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3162" xlink:to="loc_srt_RestatementDomain_3163" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_3171" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_sclx_PurchaseAgreementAxis_3171" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_3172" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_3171" xlink:to="loc_sclx_PurchaseAgreementDomain_3172" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_3173" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_3172" xlink:to="loc_sclx_OramedLetterAgreementMember_3173" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1203" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_StatementLineItems_1203" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1162" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1162" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1178" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1178" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1185" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1185" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_1189" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentDescription_1189" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1193" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1193" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1199" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1199" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1202" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1202" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_1205" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_NumberOfShareOutstanding_1205" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_1206" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_TransferOfWarrants_1206" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1207" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_LegalFees_1207" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_1208" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_CashPayment_1208" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_1209" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_FairValueOfSharesRepurchased_1209" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_1210" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_FairValueOfWarrants_1210" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1211" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1211" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate_1212" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_WarrantVestingDate_1212" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1213" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1213" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1214" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1214" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1215" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1215" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsExercised" xlink:label="loc_sclx_PennyWarrantsExercised_1216" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_PennyWarrantsExercised_1216" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1217" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1217" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1218" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1218" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1220" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable_1241" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1220" xlink:to="loc_sclx_ShareholdersEquityDetailsTable_1241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1243" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1229" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1243" xlink:to="loc_us-gaap_EquityComponentDomain_1229" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1231" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1231" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SpacWarrantsMember" xlink:label="loc_sclx_SpacWarrantsMember_1253" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_SpacWarrantsMember_1253" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_3175" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_PublicWarrantsMember_3175" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_3176" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_PrivateWarrantsMember_3176" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1244" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_ClosingPennyWarrantMember_1244" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonWarrantsMember" xlink:label="loc_sclx_CommonWarrantsMember_1256" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_CommonWarrantsMember_1256" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentWarrantsMember" xlink:label="loc_sclx_PlacementAgentWarrantsMember_1267" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_PlacementAgentWarrantsMember_1267" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1266" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1266" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1245" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1266" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1245" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1222" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1245" xlink:to="loc_us-gaap_SeniorNotesMember_1222" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1274" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_AwardTypeAxis_1274" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_1272" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="loc_sclx_WarrantsMember_1272" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsPurchaseCommonStockMember" xlink:label="loc_sclx_PublicWarrantsPurchaseCommonStockMember_1276" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="loc_sclx_PublicWarrantsPurchaseCommonStockMember_1276" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepresentativeWarrantsOutstandingMember" xlink:label="loc_sclx_RepresentativeWarrantsOutstandingMember_1226" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_RepresentativeWarrantsOutstandingMember_1226" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantsMember" xlink:label="loc_sclx_FirmWarrantsMember_1250" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_FirmWarrantsMember_1250" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RegisteredDirectOfferingMember" xlink:label="loc_sclx_RegisteredDirectOfferingMember_1259" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_RegisteredDirectOfferingMember_1259" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1279" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1279" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1235" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1279" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1235" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1238" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1235" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1238" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_1246" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_1246" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1283" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1283" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember_1223" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" xlink:to="loc_sclx_WarrantTransferAgreementMember_1223" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1285" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_sclx_PurchaseAgreementAxis_1285" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1242" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_1285" xlink:to="loc_sclx_PurchaseAgreementDomain_1242" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_1227" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_1227" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember_1260" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_BRileyPurchaseAgreementMember_1260" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember_1270" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_AtTheMarketSalesAgreementMember_1270" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1287" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_dei_LegalEntityAxis_1287" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1264" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1287" xlink:to="loc_dei_EntityDomain_1264" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember_1252" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_HudsonBayMember_1252" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1261" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_RodmanRenshawLlcMember_1261" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember_1271" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_CoveLaneMember_1271" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1289" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_TitleOfIndividualAxis_1289" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1289" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1291" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1291" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1263" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1291" xlink:to="loc_us-gaap_ClassOfStockDomain_1263" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1234" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1234" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1254" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_CommonStockMember_1254" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1262" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_PreferredStockMember_1262" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_1273" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_SeriesOnePreferredStockMember_1273" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_3177" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_3177" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsMember" xlink:label="loc_sclx_StockBlockWarrantsMember_3178" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_StockBlockWarrantsMember_3178" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1293" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1293" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1293" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1295" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_RangeAxis_1295" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1236" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1295" xlink:to="loc_srt_RangeMember_1236" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1232" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1236" xlink:to="loc_srt_MaximumMember_1232" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3140" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_RestatementAxis_3140" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3141" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3140" xlink:to="loc_srt_RestatementDomain_3141" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3142" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3141" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3142" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems_1297" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_sclx_ShareholdersEquityDetailsLineItems_1297" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1221" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockSharesIssued_1221" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1248" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SharePrice_1248" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1257" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1257" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1268" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1268" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1275" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1275" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1278" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1278" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1280" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1280" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage_1282" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PurchaseOfStockPercentage_1282" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1284" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CommonStockSold_1284" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_1286" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_1286" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1288" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1288" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_1290" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PaymentsOfDividends_1290" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1292" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockValue_1292" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1294" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1294" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1296" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1296" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1298" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1298" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1299" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1299" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1300" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1300" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1301" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1301" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares_1302" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockDividendsShares_1302" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_1303" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_1303" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_1304" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_1304" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1305" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1305" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1306" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1306" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1307" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1307" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1308" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PublicOfferingPrice_1308" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1309" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1309" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant_1310" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ExercisePriceOfCommonWarrant_1310" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined_1312" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PublicOfferingPriceCombined_1312" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1313" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1313" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1314" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1314" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantsToPurchase" xlink:label="loc_sclx_PreFundedWarrantsToPurchase_1315" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PreFundedWarrantsToPurchase_1315" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1316" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1316" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantPerShare" xlink:label="loc_sclx_PreFundedWarrantPerShare_1317" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PreFundedWarrantPerShare_1317" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1318" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1318" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xlink:label="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents_1319" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents_1319" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1320" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_LegalFees_1320" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClearingExpenses" xlink:label="loc_sclx_ClearingExpenses_1321" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ClearingExpenses_1321" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xlink:label="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering_1322" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering_1322" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfCombinedOfferingExercisePricePerShare" xlink:label="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare_1323" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare_1323" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregateGrossProceedsFromOffering" xlink:label="loc_sclx_AggregateGrossProceedsFromOffering_1324" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_AggregateGrossProceedsFromOffering_1324" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised" xlink:label="loc_sclx_NumberOfWarrantsExercised_1325" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_NumberOfWarrantsExercised_1325" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised1" xlink:label="loc_sclx_NumberOfWarrantsExercised1_2885" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_NumberOfWarrantsExercised1_2885" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3174" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3174" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/label" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1348" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3165" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1348" xlink:to="loc_us-gaap_StatementTable_3165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3166" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3165" xlink:to="loc_srt_RestatementAxis_3166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3167" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3166" xlink:to="loc_srt_RestatementDomain_3167" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3168" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3167" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3168" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3169" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3165" xlink:to="loc_us-gaap_StatementLineItems_3169" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1349" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1349" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1350" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1350" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1351" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1351" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1352" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1352" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1353" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1353" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1354" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1354" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1355" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1355" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1356" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1356" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1357" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1357" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1358" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1358" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1359" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1359" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1360" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1360" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1361" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1361" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1362" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1362" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1363" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1363" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1364" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1364" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1365" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1365" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1366" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1366" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1367" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1367" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1368" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1368" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1370" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1370" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1376" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1376" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1372" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1376" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1372" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember_1379" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1372" xlink:to="loc_sclx_BlackScholesOptionPricingMethodMember_1379" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1383" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1383" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1383" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1375" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" xlink:to="loc_us-gaap_StockOptionMember_1375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember_1382" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" xlink:to="loc_sclx_EmployeeStockPurchasePlanMember_1382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1385" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_srt_RangeAxis_1385" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1374" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1385" xlink:to="loc_srt_RangeMember_1374" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1373" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1374" xlink:to="loc_srt_MinimumMember_1373" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1381" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1374" xlink:to="loc_srt_MaximumMember_1381" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1380" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1380" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1384" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1384" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1386" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1386" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1388" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1388" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1389" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1389" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1393" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1393" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1405" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_PlanNameAxis_1405" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1397" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1397" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1413" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Semnur2024StockOptionPlanMember" xlink:label="loc_sclx_Semnur2024StockOptionPlanMember_1419" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_Semnur2024StockOptionPlanMember_1419" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1424" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1424" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1428" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1428" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1412" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_srt_RangeAxis_1412" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1401" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1412" xlink:to="loc_srt_RangeMember_1401" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1398" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1401" xlink:to="loc_srt_MaximumMember_1398" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1418" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1418" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1418" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1423" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1423" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1423" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1404" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" xlink:to="loc_us-gaap_RelatedPartyDomain_1404" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1431" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_AwardTypeAxis_1431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1433" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1433" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1416" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1433" xlink:to="loc_us-gaap_ClassOfStockDomain_1416" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3159" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_srt_RestatementAxis_3159" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3160" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_3159" xlink:to="loc_srt_RestatementDomain_3160" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3161" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3160" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3161" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1395" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1395" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1409" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1409" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1414" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1414" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1420" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1420" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1425" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1425" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1429" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1429" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1432" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensation_1432" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1434" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1434" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1436" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1436" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1437" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1437" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1438" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1438" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1439" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1439" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant_1442" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_sclx_WeightedAveragePeriodOverGrant_1442" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1449" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1451" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1449" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1451" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1450" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1451" xlink:to="loc_us-gaap_OperatingLeasePayments_1450" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1453" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1451" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1453" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1454" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1451" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1454" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2044" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2044" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1457" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1457" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1458" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1458" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1459" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1459" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1461" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1461" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1462" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1462" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1463" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_OperatingLeaseLiability_1463" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1464" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1464" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="loc_sclx_LeaseLiabilityNetOfCurrentPortion_1465" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_sclx_LeaseLiabilityNetOfCurrentPortion_1465" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1467" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable_1481" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1467" xlink:to="loc_sclx_CommitmentsAndContingenciesTable_1481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1480" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1480" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1480" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_1469" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_1469" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember_1484" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" xlink:to="loc_sclx_NonCancelableLeaseAgreementsMember_1484" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1487" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1487" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1491" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1491" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1475" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1491" xlink:to="loc_us-gaap_SegmentDomain_1475" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1482" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_ScilexPharmaMember_1482" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember_1488" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_EpoladermMember_1488" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember_1492" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_ProbudurMember_1492" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember_1496" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_EnveltaMember_1496" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1479" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" xlink:to="loc_us-gaap_RelatedPartyDomain_1479" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember_1474" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_DevelopersMember_1474" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember_1486" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_GloperbaMember_1486" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember_1490" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_FormerEmployeeMember_1490" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember_1494" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_FormerEmployeeOneMember_1494" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1498" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_srt_RangeAxis_1498" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1473" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1498" xlink:to="loc_srt_RangeMember_1473" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1471" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1473" xlink:to="loc_srt_MinimumMember_1471" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1485" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1473" xlink:to="loc_srt_MaximumMember_1485" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1478" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" xlink:to="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1478" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems_1503" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_sclx_CommitmentsAndContingenciesLineItems_1503" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1468" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1468" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1483" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LitigationSettlementExpense_1483" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1489" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1489" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1493" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_RoyaltyExpense_1493" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1497" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1497" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate_1500" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_AgreementMaturityDate_1500" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription_1502" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_MaturityRenewalDescription_1502" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty_1505" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_DueFromRelatedParty_1505" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1506" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1506" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1507" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1507" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1508" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_FinanceLeaseLiability_1508" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1509" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1509" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1510" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseExpense_1510" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1511" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1511" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1512" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1512" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1515" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1516" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1517" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1518" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1519" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1518" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1519" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1520" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1520" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1521" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1521" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1522" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1522" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1523" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1523" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1524" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1514" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1524" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1527" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_sclx_DeferredTaxAssetsDebtRelatedInterest_1528" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_sclx_DeferredTaxAssetsDebtRelatedInterest_1528" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1529" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1529" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1530" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1531" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1531" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves_1532" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves_1532" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsPurchasedRevenueLiability" xlink:label="loc_sclx_DeferredTaxAssetsPurchasedRevenueLiability_1533" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_sclx_DeferredTaxAssetsPurchasedRevenueLiability_1533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_1534" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_1534" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1535" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1535" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1536" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1536" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1537" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1537" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1538" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1538" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1540" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1540" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1541" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1541" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1542" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1542" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1543" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1526" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1543" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1546" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1546" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xlink:label="loc_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate_1547" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate_1547" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1548" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1548" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_1549" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_1549" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1550" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1550" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1551" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1551" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount_1552" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount_1552" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount_1553" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount_1553" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1554" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1554" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1555" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1545" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1555" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1557" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1558" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1557" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1558" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1559" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1557" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1560" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1557" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1561" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1557" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1561" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1563" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1567" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1563" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1567" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1566" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1566" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1569" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1566" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1570" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1569" xlink:to="loc_us-gaap_DomesticCountryMember_1570" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1573" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1569" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1573" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1572" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1572" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1572" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1564" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" xlink:to="loc_us-gaap_ResearchMember_1564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_1575" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xlink:to="loc_sclx_IncomeTaxDisclosureLineItems_1575" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1565" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1565" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1571" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1571" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards_1574" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_IndefiniteOperatingLossCarryforwards_1574" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_1576" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_1576" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1577" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1577" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1578" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1578" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear_1579" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_IncomeTaxCreditsExpirationYear_1579" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1580" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1580" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1581" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1581" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1582" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1582" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1584" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1585" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_NetIncomeLoss_1585" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="loc_us-gaap_PreferredStockRedemptionPremium_1586" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_PreferredStockRedemptionPremium_1586" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1587" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1587" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1588" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1588" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1589" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1589" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAverageNumberOfSharesOutstanding" xlink:label="loc_sclx_WeightedAverageNumberOfSharesOutstanding_1590" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_sclx_WeightedAverageNumberOfSharesOutstanding_1590" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xlink:label="loc_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration_1591" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration_1591" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1592" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1592" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="loc_sclx_EffectOfDilutiveSecurities_1593" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_sclx_EffectOfDilutiveSecurities_1593" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1594" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1594" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1595" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_EarningsPerShareBasic_1595" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1596" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1584" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1596" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1598" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1602" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1598" xlink:to="loc_us-gaap_StatementTable_1602" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1601" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1602" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1601" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1607" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1601" xlink:to="loc_us-gaap_ClassOfStockDomain_1607" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember_1600" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_StockOptionsMember_1600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember_1610" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_RetainerSharesMember_1610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderTrancheBNotesMember" xlink:label="loc_sclx_SharesIssuableUnderTrancheBNotesMember_1624" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuableUnderTrancheBNotesMember_1624" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1603" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_PublicWarrantsMember_1603" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1613" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_PrivateWarrantsMember_1613" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember_1616" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuablePursuantToEsppMember_1616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember_1617" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember_1617" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantMember" xlink:label="loc_sclx_February2024BDOFirmWarrantMember_1606" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_February2024BDOFirmWarrantMember_1606" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDORepresentativeWarrantsMember" xlink:label="loc_sclx_February2024BDORepresentativeWarrantsMember_1614" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_February2024BDORepresentativeWarrantsMember_1614" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_2881" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_2881" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOPlacementAgentWarrantsMember" xlink:label="loc_sclx_April2024RDOPlacementAgentWarrantsMember_1609" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_April2024RDOPlacementAgentWarrantsMember_1609" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_2923" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_DepositWarrantsMember_2923" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_2943" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_2943" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024PlacementAgentWarrantsMember" xlink:label="loc_sclx_October2024PlacementAgentWarrantsMember_1620" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_October2024PlacementAgentWarrantsMember_1620" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_1622" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_1622" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsMember" xlink:label="loc_sclx_StockBlockWarrantsMember_1623" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_StockBlockWarrantsMember_1623" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember_1618" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_ConvertibleDebenturesMember_1618" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1604" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1602" xlink:to="loc_srt_RestatementAxis_1604" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1605" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1604" xlink:to="loc_srt_RestatementDomain_1605" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3138" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1605" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3138" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1608" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1602" xlink:to="loc_us-gaap_StatementLineItems_1608" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1599" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1608" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1599" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1627" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1632" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1627" xlink:to="loc_us-gaap_StatementTable_1632" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1631" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1632" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1631" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1629" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1631" xlink:to="loc_us-gaap_EquityComponentDomain_1629" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1630" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1629" xlink:to="loc_us-gaap_WarrantMember_1630" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1633" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1632" xlink:to="loc_us-gaap_StatementLineItems_1633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1628" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1633" xlink:to="loc_us-gaap_CommonStockSharesIssued_1628" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1766" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1766" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1773" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1773" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_1782" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" xlink:to="loc_sclx_SorrentoMember_1782" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1791" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_srt_RangeAxis_1791" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1774" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1791" xlink:to="loc_srt_RangeMember_1774" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1809" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1809" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1775" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1809" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1775" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_1781" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="loc_sclx_JuniorDipFacilityMember_1781" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1789" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="loc_us-gaap_SeniorNotesMember_1789" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1812" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1812" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_1770" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" xlink:to="loc_sclx_StockPurchaseAgreementMember_1770" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1768" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_ClosingPennyWarrantMember_1768" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_1795" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_1795" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_1807" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_PennyWarrantsMember_1807" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1824" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_AwardDateAxis_1824" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1778" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_1824" xlink:to="loc_us-gaap_AwardDateDomain_1778" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1827" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1827" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1779" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1827" xlink:to="loc_us-gaap_EquityComponentDomain_1779" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1769" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_us-gaap_CommonStockMember_1769" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1792" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_us-gaap_PreferredStockMember_1792" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1808" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_sclx_PrivateWarrantsMember_1808" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1814" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_sclx_PublicWarrantsMember_1814" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1830" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_StatementLineItems_1830" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1780" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1780" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1832" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1832" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1833" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1833" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_1834" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_1834" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1835" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1835" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1836" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1836" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_1837" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_NumberOfShareOutstanding_1837" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_1838" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_FairValueOfWarrants_1838" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_1839" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_TransferOfWarrants_1839" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1840" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_LegalFees_1840" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_1841" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_CashPayment_1841" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_1842" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_FairValueOfSharesRepurchased_1842" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1843" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1843" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1846" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1846" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1851" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1851" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1635" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1654" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1635" xlink:to="loc_us-gaap_SubsequentEventTable_1654" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1652" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1652" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1642" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1652" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1642" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1647" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1642" xlink:to="loc_us-gaap_SubsequentEventMember_1647" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1662" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1662" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1641" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1662" xlink:to="loc_us-gaap_EquityComponentDomain_1641" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1659" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1641" xlink:to="loc_us-gaap_CommonStockMember_1659" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1667" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1648" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1667" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1648" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1670" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1670" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1653" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1670" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1653" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:label="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_1636" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1653" xlink:to="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_1636" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1673" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1673" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1673" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1637" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" xlink:to="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1637" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_1656" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" xlink:to="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_1656" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1676" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_VestingAxis_1676" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1639" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1676" xlink:to="loc_us-gaap_VestingDomain_1639" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1679" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_srt_StatementScenarioAxis_1679" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1650" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1679" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1650" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1655" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1650" xlink:to="loc_srt_ScenarioForecastMember_1655" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1682" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_dei_LegalEntityAxis_1682" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1666" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1682" xlink:to="loc_dei_EntityDomain_1666" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeILpMember" xlink:label="loc_sclx_ThreeILpMember_1658" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ThreeILpMember_1658" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1665" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ScilexPharmaMember_1665" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_1669" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_OramedMember_1669" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BpyLimitedMember" xlink:label="loc_sclx_BpyLimitedMember_1672" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_BpyLimitedMember_1672" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NomisBayLtdMember" xlink:label="loc_sclx_NomisBayLtdMember_1675" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_NomisBayLtdMember_1675" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1681" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_RodmanRenshawLlcMember_1681" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexBioJVMember" xlink:label="loc_sclx_ScilexBioJVMember_2049" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ScilexBioJVMember_2049" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1685" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_srt_RangeAxis_1685" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1646" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1685" xlink:to="loc_srt_RangeMember_1646" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1644" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1646" xlink:to="loc_srt_MaximumMember_1644" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1660" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1646" xlink:to="loc_srt_MinimumMember_1660" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1687" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_SubsequentEventLineItems_1687" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1638" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1638" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1657" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1657" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TotalNumberOfSharesGranted" xlink:label="loc_sclx_TotalNumberOfSharesGranted_1664" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_TotalNumberOfSharesGranted_1664" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1668" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1668" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfLidocaineTopicalSystem" xlink:label="loc_sclx_PercentageOfLidocaineTopicalSystem_1677" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PercentageOfLidocaineTopicalSystem_1677" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_1680" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_1680" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:label="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_1683" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_1683" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NoOfCalendarDays" xlink:label="loc_sclx_NoOfCalendarDays_1686" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_NoOfCalendarDays_1686" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1688" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1688" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesDelivered" xlink:label="loc_sclx_SharesDelivered_1692" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_SharesDelivered_1692" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregatePaymentOfCompany" xlink:label="loc_sclx_AggregatePaymentOfCompany_1693" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_AggregatePaymentOfCompany_1693" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1695" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1695" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1698" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_CommonStockSold_1698" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1699" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1699" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1706" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PublicOfferingPrice_1706" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1717" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1717" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OwnershipInterestRate" xlink:label="loc_sclx_OwnershipInterestRate_2050" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_OwnershipInterestRate_2050" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2355" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_CommonStockSharesIssued_2355" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"  />
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CoverPage" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1722" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1721" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_DocumentInformationTable_1721" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1723" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1721" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1723" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1724" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1723" xlink:to="loc_dei_AddressTypeDomain_1724" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1724_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1723" xlink:to="loc_dei_AddressTypeDomain_1724_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1725" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1724" xlink:to="loc_dei_BusinessContactMember_1725" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1730" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_DocumentType_1730" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1731" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_AmendmentFlag_1731" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_112" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityCentralIndexKey_112" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_113" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityTaxIdentificationNumber_113" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_114" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityRegistrantName_114" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_115" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityIncorporationStateCountryCode_115" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_116" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressAddressLine1_116" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_118" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressCityOrTown_118" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_119" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressStateOrProvince_119" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_121" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityAddressPostalZipCode_121" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_122" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_CityAreaCode_122" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_123" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_LocalPhoneNumber_123" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_131" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityFilerCategory_131" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_132" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntitySmallBusiness_132" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_133" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityEmergingGrowthCompany_133" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_134" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityExTransitionPeriod_134" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1732" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1722" xlink:to="loc_dei_EntityPrimarySicNumber_1732" use="optional" order="22" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_163" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_155" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_StatementTable_155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_154" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_154" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_169" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_154" xlink:to="loc_us-gaap_ClassOfStockDomain_169" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_169_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_154" xlink:to="loc_us-gaap_ClassOfStockDomain_169_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_150" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_169" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_150" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_159" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_169" xlink:to="loc_sclx_SeriesOnePreferredStockMember_159" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_148" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_AssetsAbstract_148" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_156" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsCurrentAbstract_156" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_149" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_149" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_158" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_158" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_166" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_InventoryNet_166" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_173" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_156" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_173" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_164" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsCurrent_164" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_171" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_171" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_181" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_181" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments_185" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Investments_185" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_189" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Goodwill_189" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_192" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_192" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_194" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Assets_194" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_152" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_152" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_151" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccountsPayableCurrent_151" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_160" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccruedSalariesCurrent_160" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_167" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_167" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses_174" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_AccruedExpenses_174" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_sclx_CurrentPortionOfDeferredConsideration_178" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_CurrentPortionOfDeferredConsideration_178" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_182" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_DebtCurrent_182" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityCurrent_186" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_sclx_PurchasedRevenueLiabilityCurrent_186" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_190" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_190" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_161" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_LiabilitiesCurrent_161" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_sclx_LongTermPortionOfDeferredConsideration_168" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_sclx_LongTermPortionOfDeferredConsideration_168" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_175" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_175" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityNoncurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityNoncurrent_179" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_sclx_PurchasedRevenueLiabilityNoncurrent_179" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_183" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_183" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_187" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_187" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_191" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_191" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_193" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_Liabilities_193" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_195" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_157" xlink:to="loc_us-gaap_CommitmentsAndContingencies_195" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_165" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_StockholdersEquityAbstract_165" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_153" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_PreferredStockValue_153" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_162" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_CommonStockValue_162" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdditionalPaidsInCapitals" xlink:label="loc_sclx_AdditionalPaidsInCapitals_170" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_sclx_AdditionalPaidsInCapitals_170" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_176" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_176" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_180" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_180" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_184" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_TreasuryStockValue_184" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_188" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_165" xlink:to="loc_us-gaap_StockholdersEquity_188" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_172" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_172" use="optional" order="48" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_204" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_201" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_StatementTable_201" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_200" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementClassOfStockAxis_200" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_200" xlink:to="loc_us-gaap_ClassOfStockDomain_206" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_206_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_200" xlink:to="loc_us-gaap_ClassOfStockDomain_206_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_199" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_206" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_199" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_203" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_206" xlink:to="loc_sclx_SeriesOnePreferredStockMember_203" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_198" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_198" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_202" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_202" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_205" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesIssued_205" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_207" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_207" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreferredStockDividendShares" xlink:label="loc_sclx_PreferredStockDividendShares_208" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_PreferredStockDividendShares_208" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesIssued" xlink:label="loc_sclx_CommonStocksSharesIssued_3152" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_CommonStocksSharesIssued_3152" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesOutstanding" xlink:label="loc_sclx_CommonStocksSharesOutstanding_3151" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_sclx_CommonStocksSharesOutstanding_3151" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_213" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_TreasuryStockCommonShares_213" use="optional" order="18" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_255" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_251" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StatementTable_251" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_252" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_251" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_252" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_249" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_252" xlink:to="loc_us-gaap_EquityComponentDomain_249" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_249_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_252" xlink:to="loc_us-gaap_EquityComponentDomain_249_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_250" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_PreferredStockMember_250" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_254" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_CommonStockMember_254" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_257" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_257" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_259" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_259" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_261" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_RetainedEarningsMember_261" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryShareMember" xlink:label="loc_sclx_TreasuryShareMember_263" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_sclx_TreasuryShareMember_263" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember_2785" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_249" xlink:to="loc_us-gaap_TreasuryStockPreferredMember_2785" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_251" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1967" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" xlink:to="loc_us-gaap_RelatedPartyDomain_1967" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1967_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2379" xlink:to="loc_us-gaap_RelatedPartyDomain_1967_default" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_248" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_SharesOutstanding_248" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_253" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_253" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaap_TreasuryStockPreferredShares_2494" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_TreasuryStockPreferredShares_2494" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_256" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_256" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_258" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_258" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount_260" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_DisbursementOfFundsToSorrentoAmount_260" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_262" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_262" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_264" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_264" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants_265" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfPennyWarrants_265" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_266" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_266" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_267" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_267" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_268" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_268" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_269" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_269" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued_270" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RetainerSharesIssued_270" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue_271" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RetainerSharesIssuedValue_271" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_272" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_272" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_273" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_273" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_274" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_274" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_275" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_275" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xlink:label="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation_276" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation_276" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_277" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_ProfitLoss_277" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue_278" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue_278" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement_279" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement_279" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingShare" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare_280" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare_280" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingValue" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue_281" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue_281" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering_282" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering_282" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering_283" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering_283" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xlink:label="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering_284" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering_284" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xlink:label="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter_285" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter_285" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepurchaseOfWarrants" xlink:label="loc_sclx_RepurchaseOfWarrants_286" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_RepurchaseOfWarrants_286" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xlink:label="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement_287" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement_287" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares_288" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares_288" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_289" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants_289" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares_290" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares_290" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStock" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_291" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock_291" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares_292" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares_292" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering_293" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering_293" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xlink:label="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_294" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering_294" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributedShares" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributedShares_295" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockDividendDeclaredNotYetDistributedShares_295" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributed" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributed_296" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_StockDividendDeclaredNotYetDistributed_296" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_297" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_297" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_298" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_298" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_299" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_299" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xlink:label="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral_2977" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral_2977" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares_2981" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares_2981" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockPaidForGloperbaEx-USLicense" xlink:label="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense_2989" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense_2989" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xlink:label="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares_2992" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares_2992" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xlink:label="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension_2999" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension_2999" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares_3002" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares_3002" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3073" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255" xlink:to="loc_us-gaap_ShareBasedCompensation_3073" use="optional" order="64" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_517" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_513" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentTable_513" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_512" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_513" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_512" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_514" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_512" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_514" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_514_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_512" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_514_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_510" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_514" xlink:to="loc_us-gaap_SeniorNotesMember_510" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_515" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_514" xlink:to="loc_sclx_TrancheBNotesMember_515" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_511" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_511" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_516" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_516" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xlink:label="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit_518" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit_518" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTrancheBNotesTableTextBlock" xlink:label="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock_519" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock_519" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xlink:label="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock_520" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock_520" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock_2341" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock_2341" use="optional" order="12" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_558" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_558" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_552" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_558" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_552" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_552_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_558" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_552_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_553" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_552" xlink:to="loc_us-gaap_ConvertibleDebtMember_553" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_562" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_562" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_555" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_562" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_555" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_555_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_562" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_555_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_546" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_555" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_546" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_565" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_559" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" xlink:to="loc_us-gaap_SalesRevenueNetMember_559" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_563" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_545" xlink:to="loc_us-gaap_AccountsReceivableMember_563" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_567" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_567" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_554" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557" xlink:to="loc_sclx_SorrentoMember_554" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_569" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_srt_RangeAxis_569" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_551" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_569" xlink:to="loc_srt_RangeMember_551" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_551_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_569" xlink:to="loc_srt_RangeMember_551_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_549" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_551" xlink:to="loc_srt_MinimumMember_549" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_560" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_551" xlink:to="loc_srt_MaximumMember_560" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_571" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_srt_MajorCustomersAxis_571" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_547" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_571" xlink:to="loc_srt_NameOfMajorCustomerDomain_547" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_547_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_571" xlink:to="loc_srt_NameOfMajorCustomerDomain_547_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember_548" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_547" xlink:to="loc_sclx_ThreeCustomersMember_548" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2077" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2078_default" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2345" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2345" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2079" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2345" xlink:to="loc_us-gaap_EquityComponentDomain_2079" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2079_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2345" xlink:to="loc_us-gaap_EquityComponentDomain_2079_default" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_2526" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_TransactionTypeAxis_2526" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_2080" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_2526" xlink:to="loc_us-gaap_TransactionDomain_2080" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_2080_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_2526" xlink:to="loc_us-gaap_TransactionDomain_2080_default" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2737" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2737" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2737" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2737" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2083_default" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2882" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_556" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2882" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2087" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2087" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2087_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2882" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2087_default" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2076" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2087" xlink:to="loc_us-gaap_SubsequentEventMember_2076" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_550" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_550" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_561" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_561" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_564" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_ReceivablesNetCurrent_564" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_566" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_566" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConcentrationRiskThresholdPercentage" xlink:label="loc_sclx_ConcentrationRiskThresholdPercentage_568" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_ConcentrationRiskThresholdPercentage_568" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_570" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_570" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_572" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_572" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors_574" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_PercentageOfNetRevenueSoleDistributors_574" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForPromptPaymentDiscounts" xlink:label="loc_sclx_AllowancesForPromptPaymentDiscounts_2696" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_sclx_AllowancesForPromptPaymentDiscounts_2696" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2797" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_573" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2797" use="optional" order="54" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1726" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1726" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_579" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_579" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_580" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_580" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_581" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1727" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_581" use="optional" order="4" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_638" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_604" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_604" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_594" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_DebtInstrumentAxis_594" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_611" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_594" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_611" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_611_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_594" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_611_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InitialClosingMember" xlink:label="loc_sclx_InitialClosingMember_607" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_611" xlink:to="loc_sclx_InitialClosingMember_607" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondClosingMember" xlink:label="loc_sclx_SecondClosingMember_613" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_611" xlink:to="loc_sclx_SecondClosingMember_613" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_609" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_dei_LegalEntityAxis_609" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_617" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_609" xlink:to="loc_dei_EntityDomain_617" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_617_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_609" xlink:to="loc_dei_EntityDomain_617_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_588" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_617" xlink:to="loc_sclx_OramedMember_588" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionsAxis" xlink:label="loc_sclx_LongTermDebtTransactionsAxis_615" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_sclx_LongTermDebtTransactionsAxis_615" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_603" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_LongTermDebtTransactionsAxis_615" xlink:to="loc_sclx_LongTermDebtTransactionDomain_603" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_603_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_LongTermDebtTransactionsAxis_615" xlink:to="loc_sclx_LongTermDebtTransactionDomain_603_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_598" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LongTermDebtTransactionDomain_603" xlink:to="loc_sclx_PrincipalBalanceMember_598" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_620" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_620" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_602" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_602" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_602_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_602_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeniorSecuredConvertibleNotesMember" xlink:label="loc_sclx_SeniorSecuredConvertibleNotesMember_584" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_602" xlink:to="loc_sclx_SeniorSecuredConvertibleNotesMember_584" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_623" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_623" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_589" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_589" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_589_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_623" xlink:to="loc_us-gaap_EquityComponentDomain_589_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_591" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_589" xlink:to="loc_us-gaap_CommonStockMember_591" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_601" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" xlink:to="loc_us-gaap_RelatedPartyDomain_601" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_601_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_626" xlink:to="loc_us-gaap_RelatedPartyDomain_601_default" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_628" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_srt_RangeAxis_628" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_597" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_628" xlink:to="loc_srt_RangeMember_597" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_597_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_628" xlink:to="loc_srt_RangeMember_597_default" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_592" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_597" xlink:to="loc_srt_MaximumMember_592" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_630" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_TypeOfArrangementAxis_630" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_630" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_630" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595_default" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SatisfactionAgreementMember" xlink:label="loc_sclx_SatisfactionAgreementMember_612" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_SatisfactionAgreementMember_612" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_621" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_621" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InvestorAgreementMember" xlink:label="loc_sclx_InvestorAgreementMember_624" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_595" xlink:to="loc_sclx_InvestorAgreementMember_624" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_632" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_sclx_PurchaseAgreementAxis_632" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_600" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_632" xlink:to="loc_sclx_PurchaseAgreementDomain_600" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_600_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_632" xlink:to="loc_sclx_PurchaseAgreementDomain_600_default" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_586" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_600" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_586" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_606" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_600" xlink:to="loc_sclx_AtmSalesAgreementMember_606" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_634" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_StatementClassOfStockAxis_634" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_616" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_634" xlink:to="loc_us-gaap_ClassOfStockDomain_616" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_616_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_634" xlink:to="loc_us-gaap_ClassOfStockDomain_616_default" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_2393" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_616" xlink:to="loc_sclx_DepositWarrantsMember_2393" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596_default" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_587" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_596" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_587" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3156" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_604" xlink:to="loc_us-gaap_VestingAxis_3156" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3157" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_3156" xlink:to="loc_us-gaap_VestingDomain_3157" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3157_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_3156" xlink:to="loc_us-gaap_VestingDomain_3157_default" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_3158" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3157" xlink:to="loc_sclx_TrancheBNotesMember_3158" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_593" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_593" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_608" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_WorkingCapital_608" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_619" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_OperatingIncomeLoss_619" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_622" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_622" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_625" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_625" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_627" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_627" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount_629" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_Convertibledebentureprincipalamount_629" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount_631" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_PrincipalLaonAmount_631" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_633" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_ConvertibleDebt_633" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_635" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_635" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmountPayable" xlink:label="loc_sclx_CommitmentAmountPayable_637" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CommitmentAmountPayable_637" use="optional" order="64" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_639" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_639" use="optional" order="65" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheDepositAmount_640" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CompanyReceivesTheDepositAmount_640" use="optional" order="66" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheDepositPeriod_641" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CompanyReceivesTheDepositPeriod_641" use="optional" order="67" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonRefundableDepositAmount" xlink:label="loc_sclx_NonRefundableDepositAmount_642" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_NonRefundableDepositAmount_642" use="optional" order="68" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_643" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_643" use="optional" order="69" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityGross" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityGross_644" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityGross_644" use="optional" order="70" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_645" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_645" use="optional" order="71" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_646" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CommonStockSharesIssued_646" use="optional" order="72" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfTheWarrants" xlink:label="loc_sclx_ExercisePriceOfTheWarrants_647" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ExercisePriceOfTheWarrants_647" use="optional" order="73" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_648" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_648" use="optional" order="74" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue_649" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_CommonStockIssuableValue_649" use="optional" order="75" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReductionOfThePrincipalBalance" xlink:label="loc_sclx_ReductionOfThePrincipalBalance_650" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_ReductionOfThePrincipalBalance_650" use="optional" order="76" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_652" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_652" use="optional" order="77" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_653" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_653" use="optional" order="78" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_654" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_654" use="optional" order="79" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1728" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_638" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1728" use="optional" order="80" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_710" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_698" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_698" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_698" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_698" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember_690" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_696" xlink:to="loc_sclx_LicenseAgreementMember_690" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_701" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_dei_LegalEntityAxis_701" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_704" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_701" xlink:to="loc_dei_EntityDomain_704" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_704_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_701" xlink:to="loc_dei_EntityDomain_704_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_691" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_704" xlink:to="loc_sclx_RomegLicenseAgreementMember_691" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2432" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_704" xlink:to="loc_sclx_ScilexPharmaMember_2432" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_703" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_703" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_695" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_703" xlink:to="loc_us-gaap_SegmentDomain_695" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_695_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_703" xlink:to="loc_us-gaap_SegmentDomain_695_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689_default" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_692" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_689" xlink:to="loc_us-gaap_PatentsMember_692" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_708" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_708" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699_default" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_693" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_699" xlink:to="loc_sclx_SorrentoMember_693" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2652" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_697" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2652" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2652" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2652" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793_default" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1782" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1782" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember_2435" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember_2435" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ElyxybRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember_2451" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1793" xlink:to="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember_2451" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_694" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_694" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee_700" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Upfrontlicensefee_700" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales_702" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PaymentUponTheAchievementOfNetSales_702" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_705" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_PaymentsForRoyalties_705" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Non-RefundableNon-CreditablePayment" xlink:label="loc_sclx_Non-RefundableNon-CreditablePayment_707" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Non-RefundableNon-CreditablePayment_707" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfCommonStockShares" xlink:label="loc_sclx_TransferOfCommonStockShares_709" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_TransferOfCommonStockShares_709" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_711" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_711" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities_712" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_Deferredconsiderationliabilities_712" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_713" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_RoyaltyExpense_713" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_714" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_714" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense_715" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PaymentToAcquireLicense_715" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables_716" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AccruedRoyaltyPayables_716" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication_717" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AmountDueForNewDrugApplication_717" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfLidocaineTopicalSystem" xlink:label="loc_sclx_PercentageOfLidocaineTopicalSystem_2960" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_PercentageOfLidocaineTopicalSystem_2960" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2961" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_2961" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregatePaymentOfCompany" xlink:label="loc_sclx_AggregatePaymentOfCompany_2979" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_710" xlink:to="loc_sclx_AggregatePaymentOfCompany_2979" use="optional" order="43" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_758" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_TypeOfArrangementAxis_758" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_758" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_758" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_762_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_769" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_769" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_769" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_769" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764_default" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_761" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_us-gaap_PrivatePlacementMember_761" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantsMember" xlink:label="loc_sclx_February2024BDOFirmWarrantsMember_771" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_February2024BDOFirmWarrantsMember_771" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_775" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_775" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_780" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_DepositWarrantsMember_780" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_784" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_784" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_787" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_764" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_787" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_773" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_773" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_767" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_773" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_767" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_767_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_773" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_767_default" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_759" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_us-gaap_SeniorNotesMember_759" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_770" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_TrancheBNotesMember_770" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityMember" xlink:label="loc_sclx_PurchasedRevenueLiabilityMember_774" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_PurchasedRevenueLiabilityMember_774" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_779" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_779" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember_2620" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_767" xlink:to="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember_2620" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_778" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_778" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_765" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_778" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_765" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_765_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_778" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_765_default" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_766" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_765" xlink:to="loc_us-gaap_ConvertibleDebtMember_766" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_783" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_AwardTypeAxis_783" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_783" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776_default" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_781" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_776" xlink:to="loc_sclx_WarrantsMember_781" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2377" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_763" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2377" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1994" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2377" xlink:to="loc_us-gaap_EquityComponentDomain_1994" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1994_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2377" xlink:to="loc_us-gaap_EquityComponentDomain_1994_default" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1973" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1994" xlink:to="loc_us-gaap_CommonStockMember_1973" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_768" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DebtInstrumentFairValue_768" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate_772" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_SecuredNoteDiscountRate_772" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_777" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_777" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DerivativeWarrantLiabilities" xlink:label="loc_sclx_DerivativeWarrantLiabilities_785" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_DerivativeWarrantLiabilities_785" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_788" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_788" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_789" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_789" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_790" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_PurchasedRevenueLiability_790" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_791" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_791" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueDueToCreditRisk" xlink:label="loc_sclx_ChangeInFairValueDueToCreditRisk_792" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_ChangeInFairValueDueToCreditRisk_792" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_793" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_793" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_794" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_794" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration_795" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_786" xlink:to="loc_sclx_FairValueOfContingentConsideration_795" use="optional" order="46" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_799" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_802" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_802" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_807" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_807" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_810" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_798" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_810" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2426" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2426" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1803" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1803" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1803_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1803_default" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_806" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_805" xlink:to="loc_us-gaap_LiabilitiesAbstract_806" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_804" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_SeniorNotes_804" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_809" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_809" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote_812" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_sclx_TrancheBNote_812" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_813" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_sclx_PurchasedRevenueLiability_813" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_814" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_814" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_815" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_DerivativeLiabilities_815" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_816" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_816" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_817" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_817" use="optional" order="19" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_835" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_834" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_829" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_834" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_837" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_832" xlink:to="loc_sclx_PurchaseAgreementAxis_837" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_833" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_837" xlink:to="loc_sclx_PurchaseAgreementDomain_833" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_833_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_837" xlink:to="loc_sclx_PurchaseAgreementDomain_833_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_830" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_833" xlink:to="loc_sclx_OramedLetterAgreementMember_830" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_831" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_DerivativeLiabilities_831" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_836" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_836" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants_838" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ForfeitureOfPrivateWarrants_838" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfFirmWarrants" xlink:label="loc_sclx_IssuanceOfFirmWarrants_840" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_IssuanceOfFirmWarrants_840" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:label="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_841" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_841" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xlink:label="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering_842" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering_842" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_843" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_839" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_843" use="optional" order="16" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_853" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_853" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantsMember" xlink:label="loc_sclx_February2024BDOFirmWarrantsMember_851" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_February2024BDOFirmWarrantsMember_851" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_857" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_857" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_861" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DepositWarrantsMember_861" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_864" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_864" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsFiveYearMember_866" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DecemberCommonWarrantsFiveYearMember_866" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember_868" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_852" xlink:to="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember_868" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_858" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_858" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_850" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_858" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_850" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_850_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_858" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_850_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberRDOCommonWarrantsMember" xlink:label="loc_sclx_DecemberRDOCommonWarrantsMember_859" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_850" xlink:to="loc_sclx_DecemberRDOCommonWarrantsMember_859" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3148" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_854" xlink:to="loc_srt_RestatementAxis_3148" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3149" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3148" xlink:to="loc_srt_RestatementDomain_3149" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3149_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3148" xlink:to="loc_srt_RestatementDomain_3149_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3150" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3149" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3150" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_856" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_856" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_860" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_863" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_863" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_865" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_865" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_867" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_867" use="optional" order="23" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_880" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_881" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_ConstructionInProgressMember_881" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_885" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_885" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_887" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_ComputerEquipmentMember_887" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_888" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_879" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_888" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_878" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_878" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_886" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_884" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_886" use="optional" order="11" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_911" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_srt_RangeAxis_911" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_908" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_911" xlink:to="loc_srt_RangeMember_908" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_908_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_911" xlink:to="loc_srt_RangeMember_908_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_907" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_908" xlink:to="loc_srt_MaximumMember_907" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_918" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_918" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_914" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_918" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_914" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_914_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_918" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_914_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertiblePromissoryNoteMember" xlink:label="loc_sclx_ConvertiblePromissoryNoteMember_900" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_914" xlink:to="loc_sclx_ConvertiblePromissoryNoteMember_900" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionAxis" xlink:label="loc_sclx_LongTermDebtTransactionAxis_920" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_sclx_LongTermDebtTransactionAxis_920" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_905" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_LongTermDebtTransactionAxis_920" xlink:to="loc_sclx_LongTermDebtTransactionDomain_905" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain_905_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_LongTermDebtTransactionAxis_920" xlink:to="loc_sclx_LongTermDebtTransactionDomain_905_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_909" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LongTermDebtTransactionDomain_905" xlink:to="loc_sclx_PrincipalBalanceMember_909" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RemainingDrawableBalanceMember" xlink:label="loc_sclx_RemainingDrawableBalanceMember_917" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LongTermDebtTransactionDomain_905" xlink:to="loc_sclx_RemainingDrawableBalanceMember_917" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_922" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_922" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_903" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_922" xlink:to="loc_us-gaap_EquityComponentDomain_903" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_903_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_922" xlink:to="loc_us-gaap_EquityComponentDomain_903_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903" xlink:to="loc_us-gaap_CommonStockMember_906" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurCommonStockMember" xlink:label="loc_sclx_SemnurCommonStockMember_916" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903" xlink:to="loc_sclx_SemnurCommonStockMember_916" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_924" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_sclx_PurchaseAgreementAxis_924" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_912" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_924" xlink:to="loc_sclx_PurchaseAgreementDomain_912" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_912_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_924" xlink:to="loc_sclx_PurchaseAgreementDomain_912_default" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember_902" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_912" xlink:to="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember_902" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_926" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_926" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_926" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_926" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_901" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_910" xlink:to="loc_us-gaap_CashMember_901" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3153" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_913" xlink:to="loc_srt_RestatementAxis_3153" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3154" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3153" xlink:to="loc_srt_RestatementDomain_3154" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3154_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3153" xlink:to="loc_srt_RestatementDomain_3154_default" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3155" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3154" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3155" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_904" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_904" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_915" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_915" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_919" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_919" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_921" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_921" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_923" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_923" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_925" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_925" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_927" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_DeferredOfferingCosts_927" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_929" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_929" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_930" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CommonStockSharesIssued_930" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_931" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_931" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsNetAmount" xlink:label="loc_us-gaap_CapitalUnitsNetAmount_932" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_CapitalUnitsNetAmount_932" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ImpairmentLoss" xlink:label="loc_sclx_ImpairmentLoss_933" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_sclx_ImpairmentLoss_933" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_934" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="loc_us-gaap_Depreciation_934" use="optional" order="44" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_947" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_950" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_940" xlink:to="loc_sclx_AssembledWorkforceMember_950" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_946_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_954" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_srt_RangeAxis_954" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_939" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_954" xlink:to="loc_srt_RangeMember_939" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_939_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_954" xlink:to="loc_srt_RangeMember_939_default" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_937" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_939" xlink:to="loc_srt_MaximumMember_937" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_948" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_939" xlink:to="loc_srt_MinimumMember_948" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_945" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941_default" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xlink:label="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember_942" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_941" xlink:to="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember_942" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_938" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_Goodwill_938" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_949" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_949" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_952" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_952" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_955" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_955" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_957" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_957" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_959" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_958" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_959" use="optional" order="23" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_965" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_966" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember_964" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_PatentRightsMember_964" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember_968" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AcquiredTechnologyMember_968" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember_971" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AcquiredLicensesMember_971" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_972" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_963" xlink:to="loc_sclx_AssembledWorkforceMember_972" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_962" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_962" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_967" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_967" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_969" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_970" use="optional" order="11" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1059" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1008" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentTable_1008" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1002" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_CreditFacilityAxis_1002" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1011" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1002" xlink:to="loc_us-gaap_CreditFacilityDomain_1011" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1011_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1002" xlink:to="loc_us-gaap_CreditFacilityDomain_1011_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1004" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1011" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1004" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeniorSecuredConvertibleNotesMember" xlink:label="loc_sclx_SeniorSecuredConvertibleNotesMember_1021" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1011" xlink:to="loc_sclx_SeniorSecuredConvertibleNotesMember_1021" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1006" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" xlink:to="loc_us-gaap_RelatedPartyDomain_1006" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1006_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1020" xlink:to="loc_us-gaap_RelatedPartyDomain_1006_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InitialClosingMember" xlink:label="loc_sclx_InitialClosingMember_1001" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1006" xlink:to="loc_sclx_InitialClosingMember_1001" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondClosingMember" xlink:label="loc_sclx_SecondClosingMember_1019" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1006" xlink:to="loc_sclx_SecondClosingMember_1019" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1029" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_dei_LegalEntityAxis_1029" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1030" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1029" xlink:to="loc_dei_EntityDomain_1030" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1030_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1029" xlink:to="loc_dei_EntityDomain_1030_default" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_991" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_OramedMember_991" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1016" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_RodmanRenshawLlcMember_1016" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1027" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_ScilexPharmaMember_1027" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRoyaltyMember" xlink:label="loc_sclx_ZTlidoRoyaltyMember_2547" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1030" xlink:to="loc_sclx_ZTlidoRoyaltyMember_2547" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1036" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_sclx_PurchaseAgreementAxis_1036" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1005" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_1036" xlink:to="loc_sclx_PurchaseAgreementDomain_1005" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1005_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_1036" xlink:to="loc_sclx_PurchaseAgreementDomain_1005_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_988" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_988" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_1025" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_AtmSalesAgreementMember_1025" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_1033" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1005" xlink:to="loc_sclx_OramedLetterAgreementMember_1033" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1040" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_VestingAxis_1040" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_990" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1040" xlink:to="loc_us-gaap_VestingDomain_990" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_990_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1040" xlink:to="loc_us-gaap_VestingDomain_990_default" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1007" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1007" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1022" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1022" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1031" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1031" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNoteMember" xlink:label="loc_sclx_TrancheBNoteMember_1037" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_990" xlink:to="loc_sclx_TrancheBNoteMember_1037" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1043" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1043" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_992" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043" xlink:to="loc_us-gaap_EquityComponentDomain_992" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_992_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043" xlink:to="loc_us-gaap_EquityComponentDomain_992_default" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_995" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_992" xlink:to="loc_us-gaap_CommonStockMember_995" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1045" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1045" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1045" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1045" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999_default" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_986" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_986" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SatisfactionAgreementMember" xlink:label="loc_sclx_SatisfactionAgreementMember_1013" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_SatisfactionAgreementMember_1013" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InvestorAgreementMember" xlink:label="loc_sclx_InvestorAgreementMember_1024" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_InvestorAgreementMember_1024" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_RoyaltyPurchaseAgreementMember_1032" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_RoyaltyPurchaseAgreementMember_1032" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_2471" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_999" xlink:to="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_2471" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1047" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1047" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1010" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1047" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1010" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1010_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1047" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1010_default" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_985" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_us-gaap_SeniorNotesMember_985" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember_1012" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_sclx_PrincipalBalanceMember_1012" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:label="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_2640" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1010" xlink:to="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_2640" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1049" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_DebtInstrumentAxis_1049" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1023" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1049" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1023" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1023_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1049" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1023_default" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember_994" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FristInstallmentMember_994" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember_1017" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_SecondInstallmentMember_1017" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember_1028" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_ThirdInstallmentMember_1028" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember_1035" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FourthInstallmentMember_1035" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember_1039" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_FiveInstallmentMember_1039" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember_1042" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1023" xlink:to="loc_sclx_SixInstallmentMember_1042" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1051" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_srt_RangeAxis_1051" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1000" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1051" xlink:to="loc_srt_RangeMember_1000" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1000_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1051" xlink:to="loc_srt_RangeMember_1000_default" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_996" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1000" xlink:to="loc_srt_MaximumMember_996" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1018" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1000" xlink:to="loc_srt_MinimumMember_1018" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" use="optional" order="64" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_987" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_987" use="optional" order="65" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_987_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_987_default" use="optional" order="66" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OctoberCommonWarrantsMember" xlink:label="loc_sclx_OctoberCommonWarrantsMember_1009" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_987" xlink:to="loc_sclx_OctoberCommonWarrantsMember_1009" use="optional" order="67" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1055" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1055" use="optional" order="68" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_993" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_993" use="optional" order="69" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_993_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_993_default" use="optional" order="70" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1003" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_993" xlink:to="loc_us-gaap_SubsequentEventMember_1003" use="optional" order="71" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis_1057" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_sclx_DebtPayableAxis_1057" use="optional" order="72" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_997" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_DebtPayableAxis_1057" xlink:to="loc_sclx_DebtPayableDomain_997" use="optional" order="73" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_997_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_DebtPayableAxis_1057" xlink:to="loc_sclx_DebtPayableDomain_997_default" use="optional" order="74" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember_998" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DebtPayableDomain_997" xlink:to="loc_sclx_MonthlyBasisMember_998" use="optional" order="75" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3144" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1008" xlink:to="loc_srt_RestatementAxis_3144" use="optional" order="76" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3145" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3144" xlink:to="loc_srt_RestatementDomain_3145" use="optional" order="77" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3145_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3144" xlink:to="loc_srt_RestatementDomain_3145_default" use="optional" order="78" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3146" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3145" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3146" use="optional" order="79" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_989" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_989" use="optional" order="80" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LoanAmount" xlink:label="loc_sclx_LoanAmount_1015" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_LoanAmount_1015" use="optional" order="81" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonRefundableDepositAmount" xlink:label="loc_sclx_NonRefundableDepositAmount_1026" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NonRefundableDepositAmount_1026" use="optional" order="82" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantExercisePrice" xlink:label="loc_sclx_DepositWarrantExercisePrice_1034" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DepositWarrantExercisePrice_1034" use="optional" order="83" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1038" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1038" use="optional" order="84" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmount" xlink:label="loc_sclx_CommitmentAmount_1041" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CommitmentAmount_1041" use="optional" order="85" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositAmount_1044" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CompanyReceivesTheFsfDepositAmount_1044" use="optional" order="86" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositPeriod_1046" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_CompanyReceivesTheFsfDepositPeriod_1046" use="optional" order="87" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_1048" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_1048" use="optional" order="88" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_1050" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_1050" use="optional" order="89" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1052" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1052" use="optional" order="90" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1054" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1054" use="optional" order="91" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1056" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1056" use="optional" order="92" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1058" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_1058" use="optional" order="93" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReductionOfThePrincipalBalance" xlink:label="loc_sclx_ReductionOfThePrincipalBalance_1060" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ReductionOfThePrincipalBalance_1060" use="optional" order="94" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsReceivedFromPurchaseAgreement" xlink:label="loc_sclx_ProceedsReceivedFromPurchaseAgreement_1061" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ProceedsReceivedFromPurchaseAgreement_1061" use="optional" order="95" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1062" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1062" use="optional" order="96" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_1063" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_1063" use="optional" order="97" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_1064" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_1064" use="optional" order="98" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_1065" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentDescription_1065" use="optional" order="99" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds_1066" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NetCashProceeds_1066" use="optional" order="100" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_1067" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LongTermNotesPayable_1067" use="optional" order="101" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees_1068" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_TerminationFees_1068" use="optional" order="102" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1069" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1069" use="optional" order="103" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1070" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1070" use="optional" order="104" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1071" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1071" use="optional" order="105" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1072" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1072" use="optional" order="106" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_FederalFundsPurchasedAverageRatePaid" xlink:label="loc_srt_FederalFundsPurchasedAverageRatePaid_1073" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_srt_FederalFundsPurchasedAverageRatePaid_1073" use="optional" order="107" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1074" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RepaymentsOfDebt_1074" use="optional" order="108" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1075" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1075" use="optional" order="109" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1076" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1076" use="optional" order="110" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee_1077" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentExitFee_1077" use="optional" order="111" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_1078" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_1078" use="optional" order="112" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_1079" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_1079" use="optional" order="113" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum_1080" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ExistingFacilityCapMaximum_1080" use="optional" order="114" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum_1081" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ExistingFacilityCapMinimum_1081" use="optional" order="115" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal_1082" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentOutstandingPrincipal_1082" use="optional" order="116" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_1083" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_1083" use="optional" order="117" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1084" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_1084" use="optional" order="118" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1086" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1086" use="optional" order="119" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1087" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1087" use="optional" order="120" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage_1089" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentPrincipalAmountPercentage_1089" use="optional" order="121" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_1090" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_1090" use="optional" order="122" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1091" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1091" use="optional" order="123" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent_1092" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_ConvertibleDebenturesIssuedPercent_1092" use="optional" order="124" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1093" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_Cash_1093" use="optional" order="125" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1094" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1094" use="optional" order="126" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" use="optional" order="127" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_1096" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_1096" use="optional" order="128" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1098" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_CommonStockSharesIssued_1098" use="optional" order="129" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_1099" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_1099" use="optional" order="130" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1100" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1100" use="optional" order="131" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage_1101" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentOwnedPercentage_1101" use="optional" order="132" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate_1102" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentDefaultInterestRate_1102" use="optional" order="133" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_1103" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_1103" use="optional" order="134" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_1104" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_1104" use="optional" order="135" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_1105" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_1105" use="optional" order="136" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_1106" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_1106" use="optional" order="137" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaidToRoyaltyInvestors" xlink:label="loc_sclx_PaidToRoyaltyInvestors_1108" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PaidToRoyaltyInvestors_1108" use="optional" order="138" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaap_PaymentsToAcquireReceivables_1109" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsToAcquireReceivables_1109" use="optional" order="139" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1110" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1110" use="optional" order="140" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1111" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1111" use="optional" order="141" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1112" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1112" use="optional" order="142" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2550" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2550" use="optional" order="143" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:label="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_2706" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_2706" use="optional" order="144" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NoOfCalendarDays" xlink:label="loc_sclx_NoOfCalendarDays_2727" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_NoOfCalendarDays_2727" use="optional" order="145" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:label="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice_2878" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice_2878" use="optional" order="146" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TotalNumberOfSharesGranted" xlink:label="loc_sclx_TotalNumberOfSharesGranted_2951" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_TotalNumberOfSharesGranted_2951" use="optional" order="147" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityCurrent_2968" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_PurchasedRevenueLiabilityCurrent_2968" use="optional" order="148" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_2997" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_DebtCurrent_2997" use="optional" order="149" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesDelivered" xlink:label="loc_sclx_SharesDelivered_3014" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_sclx_SharesDelivered_3014" use="optional" order="150" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3034" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1059" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3034" use="optional" order="151" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1118" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_DebtInstrumentTable_1118" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1117" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1118" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1117" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1119" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1117" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1119" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1119_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1117" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1119_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1116" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1119" xlink:to="loc_us-gaap_SeniorNotesMember_1116" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1121" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1119" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1121" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1115" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_ConvertibleDebt_1115" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture_1120" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_sclx_RepaymentOfConvertibleDebenture_1120" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1123" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1123" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1124" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1124" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_1125" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1122" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_1125" use="optional" order="11" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1131" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1132" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1131" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1133" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1133" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1133_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1133_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FSFLoanMember" xlink:label="loc_sclx_FSFLoanMember_3143" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1133" xlink:to="loc_sclx_FSFLoanMember_3143" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaap_Deposits_1129" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_Deposits_1129" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInDeposits_1134" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_us-gaap_IncreaseDecreaseInDeposits_1134" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:label="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_1136" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit_1136" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDeposit" xlink:label="loc_sclx_RepaymentOfDeposit_1137" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1135" xlink:to="loc_sclx_RepaymentOfDeposit_1137" use="optional" order="9" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1143" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1144" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1143" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1145" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1145" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1145_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1145_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember_1142" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1145" xlink:to="loc_sclx_TrancheBNotesMember_1142" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote_1141" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_TrancheBNote_1141" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1146" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1146" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfTrancheBNotes" xlink:label="loc_sclx_RepaymentOfTrancheBNotes_1148" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_RepaymentOfTrancheBNotes_1148" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfTrancheBNotes" xlink:label="loc_sclx_ChangeInFairValueOfTrancheBNotes_1149" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1147" xlink:to="loc_sclx_ChangeInFairValueOfTrancheBNotes_1149" use="optional" order="9" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1154" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_1155" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1154" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1156" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1154" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1156" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1156_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1154" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1156_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRoyaltyMember" xlink:label="loc_sclx_ZTlidoRoyaltyMember_2107" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1156" xlink:to="loc_sclx_ZTlidoRoyaltyMember_2107" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability_1153" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_PurchasedRevenueLiability_1153" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfPurchasedRevenueLiability" xlink:label="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability_1157" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability_1157" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfPurchasedRevenueLiability" xlink:label="loc_sclx_RepaymentOfPurchasedRevenueLiability_2335" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1158" xlink:to="loc_sclx_RepaymentOfPurchasedRevenueLiability_2335" use="optional" order="8" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1741" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_us-gaap_DebtInstrumentTable_1741" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1744" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1741" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1744" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1742" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1744" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1742" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1742_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1744" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1742_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1745" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1742" xlink:to="loc_us-gaap_SeniorNotesMember_1745" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1741" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1746" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1746" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1746_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1801" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1746_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_1747" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_us-gaap_ConvertibleDebt_1747" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1805" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_1802" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_1805" use="optional" order="10" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1203" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1173" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1173" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1173" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1173" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_1172" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1177" xlink:to="loc_sclx_SorrentoMember_1172" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1183" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_srt_RangeAxis_1183" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1171" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1183" xlink:to="loc_srt_RangeMember_1171" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1171_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1183" xlink:to="loc_srt_RangeMember_1171_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1169" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1171" xlink:to="loc_srt_MaximumMember_1169" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1187" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1187" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1176" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1187" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1176" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1176_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1187" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1176_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_1163" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1176" xlink:to="loc_sclx_JuniorDipFacilityMember_1163" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1179" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1176" xlink:to="loc_us-gaap_SeniorNotesMember_1179" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1191" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1191" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1191" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1191" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_1164" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1170" xlink:to="loc_sclx_StockPurchaseAgreementMember_1164" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1165_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1194" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1165_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1175" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_ClosingPennyWarrantMember_1175" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_1184" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_1184" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_1188" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_PennyWarrantsMember_1188" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member_1195" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants2Member_1195" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member_1198" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants3Member_1198" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member_1201" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants4Member_1201" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants5Member" xlink:label="loc_sclx_SubsequentPennyWarrants5Member_1204" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1165" xlink:to="loc_sclx_SubsequentPennyWarrants5Member_1204" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1197" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_AwardDateAxis_1197" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1166" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_1197" xlink:to="loc_us-gaap_AwardDateDomain_1166" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1166_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_1197" xlink:to="loc_us-gaap_AwardDateDomain_1166_default" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1200" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1200" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1167" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1200" xlink:to="loc_us-gaap_EquityComponentDomain_1167" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1167_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1200" xlink:to="loc_us-gaap_EquityComponentDomain_1167_default" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1168" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_us-gaap_CommonStockMember_1168" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1180" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_us-gaap_PreferredStockMember_1180" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1186" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_sclx_PrivateWarrantsMember_1186" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1190" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1167" xlink:to="loc_sclx_PublicWarrantsMember_1190" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3162" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_srt_RestatementAxis_3162" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3163" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3162" xlink:to="loc_srt_RestatementDomain_3163" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3163_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3162" xlink:to="loc_srt_RestatementDomain_3163_default" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_3171" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1174" xlink:to="loc_sclx_PurchaseAgreementAxis_3171" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_3172" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_3171" xlink:to="loc_sclx_PurchaseAgreementDomain_3172" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_3172_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_3171" xlink:to="loc_sclx_PurchaseAgreementDomain_3172_default" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember_3173" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_3172" xlink:to="loc_sclx_OramedLetterAgreementMember_3173" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1162" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1162" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1178" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1178" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1185" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1185" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_1189" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DebtInstrumentDescription_1189" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1193" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1193" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1199" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1199" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1202" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1202" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_1205" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_NumberOfShareOutstanding_1205" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_1206" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_TransferOfWarrants_1206" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1207" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_LegalFees_1207" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_1208" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_CashPayment_1208" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_1209" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_FairValueOfSharesRepurchased_1209" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_1210" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_FairValueOfWarrants_1210" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1211" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1211" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate_1212" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_WarrantVestingDate_1212" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1213" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1213" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1214" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1214" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1215" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1215" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsExercised" xlink:label="loc_sclx_PennyWarrantsExercised_1216" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_sclx_PennyWarrantsExercised_1216" use="optional" order="64" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1217" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1217" use="optional" order="65" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1218" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1218" use="optional" order="66" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems_1297" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable_1241" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ShareholdersEquityDetailsTable_1241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1243" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1243" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1229" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1243" xlink:to="loc_us-gaap_EquityComponentDomain_1229" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1229_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1243" xlink:to="loc_us-gaap_EquityComponentDomain_1229_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1231" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1231" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SpacWarrantsMember" xlink:label="loc_sclx_SpacWarrantsMember_1253" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_SpacWarrantsMember_1253" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_3175" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_PublicWarrantsMember_3175" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_3176" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1229" xlink:to="loc_sclx_PrivateWarrantsMember_3176" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1225_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1255" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1225_default" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1244" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_ClosingPennyWarrantMember_1244" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonWarrantsMember" xlink:label="loc_sclx_CommonWarrantsMember_1256" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_CommonWarrantsMember_1256" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentWarrantsMember" xlink:label="loc_sclx_PlacementAgentWarrantsMember_1267" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1225" xlink:to="loc_sclx_PlacementAgentWarrantsMember_1267" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1266" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1266" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1245" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1266" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1245" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1245_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1266" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1245_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1222" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1245" xlink:to="loc_us-gaap_SeniorNotesMember_1222" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1274" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_AwardTypeAxis_1274" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_1272" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="loc_sclx_WarrantsMember_1272" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsPurchaseCommonStockMember" xlink:label="loc_sclx_PublicWarrantsPurchaseCommonStockMember_1276" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="loc_sclx_PublicWarrantsPurchaseCommonStockMember_1276" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepresentativeWarrantsOutstandingMember" xlink:label="loc_sclx_RepresentativeWarrantsOutstandingMember_1226" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_RepresentativeWarrantsOutstandingMember_1226" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantsMember" xlink:label="loc_sclx_FirmWarrantsMember_1250" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_FirmWarrantsMember_1250" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RegisteredDirectOfferingMember" xlink:label="loc_sclx_RegisteredDirectOfferingMember_1259" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1240" xlink:to="loc_sclx_RegisteredDirectOfferingMember_1259" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1279" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1279" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1235" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1279" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1235" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1235_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1279" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1235_default" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1238" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1235" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1238" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_1281" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237_default" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_1246" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_1237" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_1246" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1283" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1283" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233_default" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember_1223" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1233" xlink:to="loc_sclx_WarrantTransferAgreementMember_1223" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1285" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_sclx_PurchaseAgreementAxis_1285" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1242" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_1285" xlink:to="loc_sclx_PurchaseAgreementDomain_1242" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1242_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_1285" xlink:to="loc_sclx_PurchaseAgreementDomain_1242_default" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_1227" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_1227" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember_1260" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_BRileyPurchaseAgreementMember_1260" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember_1270" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1242" xlink:to="loc_sclx_AtTheMarketSalesAgreementMember_1270" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1287" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_dei_LegalEntityAxis_1287" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1264" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1287" xlink:to="loc_dei_EntityDomain_1264" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1264_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1287" xlink:to="loc_dei_EntityDomain_1264_default" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember_1252" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_HudsonBayMember_1252" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1261" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_RodmanRenshawLlcMember_1261" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember_1271" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1264" xlink:to="loc_sclx_CoveLaneMember_1271" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1289" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_TitleOfIndividualAxis_1289" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1289" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1289" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1224_default" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1291" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1291" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1263" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1291" xlink:to="loc_us-gaap_ClassOfStockDomain_1263" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1263_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1291" xlink:to="loc_us-gaap_ClassOfStockDomain_1263_default" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1234" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1234" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1254" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_CommonStockMember_1254" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1262" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_us-gaap_PreferredStockMember_1262" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember_1273" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_SeriesOnePreferredStockMember_1273" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_3177" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_3177" use="optional" order="64" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsMember" xlink:label="loc_sclx_StockBlockWarrantsMember_3178" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1263" xlink:to="loc_sclx_StockBlockWarrantsMember_3178" use="optional" order="65" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1293" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1293" use="optional" order="66" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1293" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230" use="optional" order="67" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1293" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230_default" use="optional" order="68" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1295" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_RangeAxis_1295" use="optional" order="69" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1236" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1295" xlink:to="loc_srt_RangeMember_1236" use="optional" order="70" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1236_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1295" xlink:to="loc_srt_RangeMember_1236_default" use="optional" order="71" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1232" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1236" xlink:to="loc_srt_MaximumMember_1232" use="optional" order="72" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3140" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1241" xlink:to="loc_srt_RestatementAxis_3140" use="optional" order="73" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3141" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3140" xlink:to="loc_srt_RestatementDomain_3141" use="optional" order="74" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3141_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3140" xlink:to="loc_srt_RestatementDomain_3141_default" use="optional" order="75" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3142" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3141" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3142" use="optional" order="76" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1221" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockSharesIssued_1221" use="optional" order="77" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1248" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SharePrice_1248" use="optional" order="78" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1257" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1257" use="optional" order="79" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1268" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1268" use="optional" order="80" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1275" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1275" use="optional" order="81" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1278" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1278" use="optional" order="82" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1280" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1280" use="optional" order="83" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage_1282" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PurchaseOfStockPercentage_1282" use="optional" order="84" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1284" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CommonStockSold_1284" use="optional" order="85" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_1286" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_1286" use="optional" order="86" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1288" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1288" use="optional" order="87" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_1290" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PaymentsOfDividends_1290" use="optional" order="88" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1292" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockValue_1292" use="optional" order="89" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1294" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1294" use="optional" order="90" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1296" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1296" use="optional" order="91" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1298" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1298" use="optional" order="92" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1299" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_1299" use="optional" order="93" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1300" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1300" use="optional" order="94" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1301" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1301" use="optional" order="95" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares_1302" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockDividendsShares_1302" use="optional" order="96" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_1303" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_1303" use="optional" order="97" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_1304" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_1304" use="optional" order="98" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1305" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1305" use="optional" order="99" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1306" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1306" use="optional" order="100" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1307" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1307" use="optional" order="101" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1308" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PublicOfferingPrice_1308" use="optional" order="102" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1309" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1309" use="optional" order="103" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant_1310" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ExercisePriceOfCommonWarrant_1310" use="optional" order="104" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311" use="optional" order="105" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined_1312" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PublicOfferingPriceCombined_1312" use="optional" order="106" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1313" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1313" use="optional" order="107" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1314" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1314" use="optional" order="108" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantsToPurchase" xlink:label="loc_sclx_PreFundedWarrantsToPurchase_1315" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PreFundedWarrantsToPurchase_1315" use="optional" order="109" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1316" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1316" use="optional" order="110" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantPerShare" xlink:label="loc_sclx_PreFundedWarrantPerShare_1317" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PreFundedWarrantPerShare_1317" use="optional" order="111" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1318" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1318" use="optional" order="112" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xlink:label="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents_1319" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents_1319" use="optional" order="113" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1320" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_LegalFees_1320" use="optional" order="114" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClearingExpenses" xlink:label="loc_sclx_ClearingExpenses_1321" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_ClearingExpenses_1321" use="optional" order="115" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xlink:label="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering_1322" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering_1322" use="optional" order="116" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfCombinedOfferingExercisePricePerShare" xlink:label="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare_1323" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare_1323" use="optional" order="117" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregateGrossProceedsFromOffering" xlink:label="loc_sclx_AggregateGrossProceedsFromOffering_1324" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_AggregateGrossProceedsFromOffering_1324" use="optional" order="118" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised" xlink:label="loc_sclx_NumberOfWarrantsExercised_1325" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_NumberOfWarrantsExercised_1325" use="optional" order="119" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised1" xlink:label="loc_sclx_NumberOfWarrantsExercised1_2885" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_sclx_NumberOfWarrantsExercised1_2885" use="optional" order="120" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3174" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3174" use="optional" order="121" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3169" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1349" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1349" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1350" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1350" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1351" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1351" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1352" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1352" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1354" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1354" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1355" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1355" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1356" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1356" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1357" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1357" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1358" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1358" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1359" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1359" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1361" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1361" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1362" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1362" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1363" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1363" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1364" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1364" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1365" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1365" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1366" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1366" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1367" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1367" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1368" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1368" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3165" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3169" xlink:to="loc_us-gaap_StatementTable_3165" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3166" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3165" xlink:to="loc_srt_RestatementAxis_3166" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3167" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3166" xlink:to="loc_srt_RestatementDomain_3167" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3167_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3166" xlink:to="loc_srt_RestatementDomain_3167_default" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3168" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3167" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3168" use="optional" order="23" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1376" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1376" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1372" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1376" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1372" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1372_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1376" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1372_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember_1379" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1372" xlink:to="loc_sclx_BlackScholesOptionPricingMethodMember_1379" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1383" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1383" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1383" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1383" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1375" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" xlink:to="loc_us-gaap_StockOptionMember_1375" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember_1382" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1377" xlink:to="loc_sclx_EmployeeStockPurchasePlanMember_1382" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1385" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1378" xlink:to="loc_srt_RangeAxis_1385" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1374" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1385" xlink:to="loc_srt_RangeMember_1374" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1374_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1385" xlink:to="loc_srt_RangeMember_1374_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1373" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1374" xlink:to="loc_srt_MinimumMember_1373" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1381" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1374" xlink:to="loc_srt_MaximumMember_1381" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1380" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1380" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1384" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1384" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1386" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1386" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1388" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1388" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1389" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1387" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1389" use="optional" order="20" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1405" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_PlanNameAxis_1405" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1397" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1397" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1397_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1405" xlink:to="loc_us-gaap_PlanNameDomain_1397_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1413" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1413" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Semnur2024StockOptionPlanMember" xlink:label="loc_sclx_Semnur2024StockOptionPlanMember_1419" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_Semnur2024StockOptionPlanMember_1419" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1424" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1424" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1428" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1397" xlink:to="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1428" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1412" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_srt_RangeAxis_1412" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1401" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1412" xlink:to="loc_srt_RangeMember_1401" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1401_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1412" xlink:to="loc_srt_RangeMember_1401_default" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1398" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1401" xlink:to="loc_srt_MaximumMember_1398" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1418" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1418" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1418" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1418" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403_default" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1423" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1423" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1423" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1423" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1399_default" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1404" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" xlink:to="loc_us-gaap_RelatedPartyDomain_1404" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1404_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1427" xlink:to="loc_us-gaap_RelatedPartyDomain_1404_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1431" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_AwardTypeAxis_1431" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1417_default" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1433" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1433" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1416" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1433" xlink:to="loc_us-gaap_ClassOfStockDomain_1416" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1416_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1433" xlink:to="loc_us-gaap_ClassOfStockDomain_1416_default" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_3159" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1406" xlink:to="loc_srt_RestatementAxis_3159" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3160" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_3159" xlink:to="loc_srt_RestatementDomain_3160" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_3160_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_3159" xlink:to="loc_srt_RestatementDomain_3160_default" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3161" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3160" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3161" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1395" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1395" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1409" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1409" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1414" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1414" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1420" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1420" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1425" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1425" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1429" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1429" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1432" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensation_1432" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1434" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1434" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1436" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1436" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1437" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1437" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1438" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1438" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1439" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1439" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant_1442" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_sclx_WeightedAveragePeriodOverGrant_1442" use="optional" order="44" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems_1503" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable_1481" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_CommitmentsAndContingenciesTable_1481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1480" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1480" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1480" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1480" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_1469" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_1469" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember_1484" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1472" xlink:to="loc_sclx_NonCancelableLeaseAgreementsMember_1484" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1487" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1487" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1487" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1487" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1470_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1491" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1491" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1475" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1491" xlink:to="loc_us-gaap_SegmentDomain_1475" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1475_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1491" xlink:to="loc_us-gaap_SegmentDomain_1475_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1482" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_ScilexPharmaMember_1482" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember_1488" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_EpoladermMember_1488" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember_1492" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_ProbudurMember_1492" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember_1496" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1475" xlink:to="loc_sclx_EnveltaMember_1496" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1479" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" xlink:to="loc_us-gaap_RelatedPartyDomain_1479" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1479_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1495" xlink:to="loc_us-gaap_RelatedPartyDomain_1479_default" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember_1474" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_DevelopersMember_1474" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember_1486" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_GloperbaMember_1486" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember_1490" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_FormerEmployeeMember_1490" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember_1494" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1479" xlink:to="loc_sclx_FormerEmployeeOneMember_1494" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1498" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_srt_RangeAxis_1498" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1473" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1498" xlink:to="loc_srt_RangeMember_1473" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1473_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1498" xlink:to="loc_srt_RangeMember_1473_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1471" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1473" xlink:to="loc_srt_MinimumMember_1471" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1485" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1473" xlink:to="loc_srt_MaximumMember_1485" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476_default" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1478" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476" xlink:to="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1478" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1468" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1468" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1483" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LitigationSettlementExpense_1483" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1489" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1489" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1493" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_RoyaltyExpense_1493" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1497" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1497" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate_1500" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_AgreementMaturityDate_1500" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription_1502" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_MaturityRenewalDescription_1502" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty_1505" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_sclx_DueFromRelatedParty_1505" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1506" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1506" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1507" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1507" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1508" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_FinanceLeaseLiability_1508" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1509" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1509" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1510" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseExpense_1510" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1511" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1511" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1512" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1503" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1512" use="optional" order="47" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_1575" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1567" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1566" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1566" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1569" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1566" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1569" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1569_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1566" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1569_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1570" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1569" xlink:to="loc_us-gaap_DomesticCountryMember_1570" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1573" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1569" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1573" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1572" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1567" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1572" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1572" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1572" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1564" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1568" xlink:to="loc_us-gaap_ResearchMember_1564" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1565" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1565" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1571" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1571" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards_1574" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_IndefiniteOperatingLossCarryforwards_1574" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_1576" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_1576" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1577" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1577" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1578" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1578" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear_1579" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_sclx_IncomeTaxCreditsExpirationYear_1579" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1580" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1580" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1581" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1581" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1582" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1575" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1582" use="optional" order="20" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1608" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1602" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1608" xlink:to="loc_us-gaap_StatementTable_1602" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1601" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1602" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1601" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1607" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1601" xlink:to="loc_us-gaap_ClassOfStockDomain_1607" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1607_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1601" xlink:to="loc_us-gaap_ClassOfStockDomain_1607_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember_1600" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_StockOptionsMember_1600" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember_1610" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_RetainerSharesMember_1610" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderTrancheBNotesMember" xlink:label="loc_sclx_SharesIssuableUnderTrancheBNotesMember_1624" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuableUnderTrancheBNotesMember_1624" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1603" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_PublicWarrantsMember_1603" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1613" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_PrivateWarrantsMember_1613" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember_1616" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuablePursuantToEsppMember_1616" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember_1617" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember_1617" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantMember" xlink:label="loc_sclx_February2024BDOFirmWarrantMember_1606" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_February2024BDOFirmWarrantMember_1606" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDORepresentativeWarrantsMember" xlink:label="loc_sclx_February2024BDORepresentativeWarrantsMember_1614" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_February2024BDORepresentativeWarrantsMember_1614" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember_2881" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_April2024RDOCommonWarrantsMember_2881" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOPlacementAgentWarrantsMember" xlink:label="loc_sclx_April2024RDOPlacementAgentWarrantsMember_1609" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_April2024RDOPlacementAgentWarrantsMember_1609" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember_2923" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_DepositWarrantsMember_2923" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember_2943" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_October2024NoteholderWarrantsMember_2943" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024PlacementAgentWarrantsMember" xlink:label="loc_sclx_October2024PlacementAgentWarrantsMember_1620" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_October2024PlacementAgentWarrantsMember_1620" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember_1622" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_December2024RDOCommonWarrantsMember_1622" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsMember" xlink:label="loc_sclx_StockBlockWarrantsMember_1623" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_StockBlockWarrantsMember_1623" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember_1618" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1607" xlink:to="loc_sclx_ConvertibleDebenturesMember_1618" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1604" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1602" xlink:to="loc_srt_RestatementAxis_1604" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1605" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1604" xlink:to="loc_srt_RestatementDomain_1605" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1605_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1604" xlink:to="loc_srt_RestatementDomain_1605_default" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3138" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1605" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3138" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1599" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1608" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1599" use="optional" order="26" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1633" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1632" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1633" xlink:to="loc_us-gaap_StatementTable_1632" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1631" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1632" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1631" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1629" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1631" xlink:to="loc_us-gaap_EquityComponentDomain_1629" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1629_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1631" xlink:to="loc_us-gaap_EquityComponentDomain_1629_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1630" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1629" xlink:to="loc_us-gaap_WarrantMember_1630" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1628" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1633" xlink:to="loc_us-gaap_CommonStockSharesIssued_1628" use="optional" order="6" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1830" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1773" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1773" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1773" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_1782" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1772" xlink:to="loc_sclx_SorrentoMember_1782" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1791" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_srt_RangeAxis_1791" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1774" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1791" xlink:to="loc_srt_RangeMember_1774" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1774_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1791" xlink:to="loc_srt_RangeMember_1774_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1809" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1809" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1775" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1809" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1775" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1775_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1809" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1775_default" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_1781" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="loc_sclx_JuniorDipFacilityMember_1781" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1789" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="loc_us-gaap_SeniorNotesMember_1789" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1812" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1812" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1812" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776_default" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_1770" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1776" xlink:to="loc_sclx_StockPurchaseAgreementMember_1770" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1777_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1821" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1777_default" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_1768" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_ClosingPennyWarrantMember_1768" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_1795" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_1795" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_1807" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1777" xlink:to="loc_sclx_PennyWarrantsMember_1807" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_1824" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_AwardDateAxis_1824" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1778" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_1824" xlink:to="loc_us-gaap_AwardDateDomain_1778" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_1778_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_1824" xlink:to="loc_us-gaap_AwardDateDomain_1778_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1827" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1827" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1779" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1827" xlink:to="loc_us-gaap_EquityComponentDomain_1779" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1779_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1827" xlink:to="loc_us-gaap_EquityComponentDomain_1779_default" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1769" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_us-gaap_CommonStockMember_1769" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1792" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_us-gaap_PreferredStockMember_1792" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1808" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_sclx_PrivateWarrantsMember_1808" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1814" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1779" xlink:to="loc_sclx_PublicWarrantsMember_1814" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1780" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1780" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1832" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_1832" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1833" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1833" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_1834" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_1834" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_1835" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_1835" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1836" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1836" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_1837" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_NumberOfShareOutstanding_1837" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_1838" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_FairValueOfWarrants_1838" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_1839" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_TransferOfWarrants_1839" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1840" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_LegalFees_1840" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_1841" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_CashPayment_1841" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_1842" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_sclx_FairValueOfSharesRepurchased_1842" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1843" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1843" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1846" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1846" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1851" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1830" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1851" use="optional" order="48" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1687" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1654" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_SubsequentEventTable_1654" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1652" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1652" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1642" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1652" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1642" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1642_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1652" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1642_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1647" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1642" xlink:to="loc_us-gaap_SubsequentEventMember_1647" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1662" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1662" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1641" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1662" xlink:to="loc_us-gaap_EquityComponentDomain_1641" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1641_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1662" xlink:to="loc_us-gaap_EquityComponentDomain_1641_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1659" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1641" xlink:to="loc_us-gaap_CommonStockMember_1659" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1667" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1667" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1648" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1667" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1648" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1648_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1667" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1648_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1670" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1670" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1653" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1670" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1653" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1653_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1670" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1653_default" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:label="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_1636" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1653" xlink:to="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember_1636" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1673" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1673" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1673" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1673" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645_default" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1637" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" xlink:to="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember_1637" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_1656" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1645" xlink:to="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember_1656" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1676" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_us-gaap_VestingAxis_1676" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1639" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1676" xlink:to="loc_us-gaap_VestingDomain_1639" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1639_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1676" xlink:to="loc_us-gaap_VestingDomain_1639_default" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1679" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_srt_StatementScenarioAxis_1679" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1650" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1679" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1650" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1650_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1679" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1650_default" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1655" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1650" xlink:to="loc_srt_ScenarioForecastMember_1655" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1682" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_dei_LegalEntityAxis_1682" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1666" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1682" xlink:to="loc_dei_EntityDomain_1666" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1666_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1682" xlink:to="loc_dei_EntityDomain_1666_default" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeILpMember" xlink:label="loc_sclx_ThreeILpMember_1658" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ThreeILpMember_1658" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1665" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ScilexPharmaMember_1665" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember_1669" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_OramedMember_1669" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BpyLimitedMember" xlink:label="loc_sclx_BpyLimitedMember_1672" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_BpyLimitedMember_1672" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NomisBayLtdMember" xlink:label="loc_sclx_NomisBayLtdMember_1675" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_NomisBayLtdMember_1675" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1681" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_RodmanRenshawLlcMember_1681" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexBioJVMember" xlink:label="loc_sclx_ScilexBioJVMember_2049" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1666" xlink:to="loc_sclx_ScilexBioJVMember_2049" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1685" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1654" xlink:to="loc_srt_RangeAxis_1685" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1646" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1685" xlink:to="loc_srt_RangeMember_1646" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1646_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1685" xlink:to="loc_srt_RangeMember_1646_default" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1644" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1646" xlink:to="loc_srt_MaximumMember_1644" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1660" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1646" xlink:to="loc_srt_MinimumMember_1660" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1638" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1638" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1657" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1657" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TotalNumberOfSharesGranted" xlink:label="loc_sclx_TotalNumberOfSharesGranted_1664" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_TotalNumberOfSharesGranted_1664" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1668" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1668" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfLidocaineTopicalSystem" xlink:label="loc_sclx_PercentageOfLidocaineTopicalSystem_1677" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PercentageOfLidocaineTopicalSystem_1677" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_1680" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_1680" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:label="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_1683" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate_1683" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NoOfCalendarDays" xlink:label="loc_sclx_NoOfCalendarDays_1686" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_NoOfCalendarDays_1686" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1688" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1688" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesDelivered" xlink:label="loc_sclx_SharesDelivered_1692" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_SharesDelivered_1692" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregatePaymentOfCompany" xlink:label="loc_sclx_AggregatePaymentOfCompany_1693" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_AggregatePaymentOfCompany_1693" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1695" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1695" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1698" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_CommonStockSold_1698" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1699" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1699" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1706" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_PublicOfferingPrice_1706" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1717" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1717" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OwnershipInterestRate" xlink:label="loc_sclx_OwnershipInterestRate_2050" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_sclx_OwnershipInterestRate_2050" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2355" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1687" xlink:to="loc_us-gaap_CommonStockSharesIssued_2355" use="optional" order="61" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0" />
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails" >
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_SCLX_AccruedExpenses" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_SCLX_AccruedResearchAndDevelopmentCosts" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_SCLX_AccruedResearchAndDevelopmentCosts" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" use="optional" order="6" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="4" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_SCLX_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" use="optional" order="2" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfEquitySecurities" xlink:label="loc_SCLX_PurchaseOfEquitySecurities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_PurchaseOfEquitySecurities" use="optional" order="3" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfConvertiblePromissoryNote" xlink:label="loc_SCLX_PurchaseOfConvertiblePromissoryNote" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_PurchaseOfConvertiblePromissoryNote" use="optional" order="4" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="5" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" use="optional" order="6" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="8" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="9" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="11" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="12" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" use="optional" order="13" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_SCLX_NonCashOperatingLeaseCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_NonCashOperatingLeaseCost" use="optional" order="14" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="15" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="16" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="17" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" use="optional" order="18" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_SCLX_IncreaseDecreaseInAccruedPayroll" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseDecreaseInAccruedPayroll" use="optional" order="19" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="20" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="21" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" use="optional" order="22" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_SCLX_IncreaseDecreaseInAccruedRebatesAndFees" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseDecreaseInAccruedRebatesAndFees" use="optional" order="23" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" use="optional" order="24" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="25" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForCreditLosses" xlink:label="loc_SCLX_AllowancesForCreditLosses" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_AllowancesForCreditLosses" use="optional" order="26" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_SCLX_OtherLongTermLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_OtherLongTermLiabilities" use="optional" order="27" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="28" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xlink:label="loc_SCLX_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" use="optional" order="29" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="30" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLeaseLiability1" xlink:label="loc_SCLX_OperatingLeaseLiability1" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_OperatingLeaseLiability1" use="optional" order="31" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="32" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xlink:label="loc_SCLX_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" use="optional" order="33" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="34" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_SCLX_ProceedsFromIssuanceOfRevolvingFacility" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromIssuanceOfRevolvingFacility" use="optional" order="35" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfFsfDeposit" xlink:label="loc_SCLX_ProceedsFromIssuanceOfFsfDeposit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromIssuanceOfFsfDeposit" use="optional" order="36" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt" use="optional" order="37" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_SCLX_RepaymentOfRevolvingFacility" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfRevolvingFacility" use="optional" order="38" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfDebt" use="optional" order="39" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants" use="optional" order="40" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_SCLX_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" use="optional" order="41" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="42" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDebt" xlink:label="loc_SCLX_RepaymentOfDebt" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfDebt" use="optional" order="43" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="44" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFunds" xlink:label="loc_SCLX_DisbursementOfFunds" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_DisbursementOfFunds" use="optional" order="45" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" use="optional" order="46" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_SCLX_TransactionCostsPaidInConnectionWithShareRepurchase" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_TransactionCostsPaidInConnectionWithShareRepurchase" use="optional" order="47" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xlink:label="loc_SCLX_ExciseTaxPaidInConnectionWithShareRepurchase" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ExciseTaxPaidInConnectionWithShareRepurchase" use="optional" order="48" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="49" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="50" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xlink:label="loc_SCLX_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" use="optional" order="51" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="52" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRefundPayments1" xlink:label="loc_us-gaap_DeferredRevenueRefundPayments1" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_DeferredRevenueRefundPayments1" use="optional" order="53" weight="-1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" use="optional" order="5" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpenseNonoperating" use="optional" order="6" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="8" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="9" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="11" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="12" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="13" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_PaymentsForLegalSettlements" use="optional" order="14" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="15" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" use="optional" order="16" weight="-1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdditionalPaidsInCapitals" xlink:label="loc_SCLX_AdditionalPaidsInCapitals" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_SCLX_AdditionalPaidsInCapitals" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" use="optional" order="8" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="9" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="11" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="12" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_SCLX_AccruedExpenses" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_AccruedExpenses" use="optional" order="14" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_SCLX_CurrentPortionOfDeferredConsideration" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_CurrentPortionOfDeferredConsideration" use="optional" order="15" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtCurrent" use="optional" order="16" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_SCLX_PurchasedRevenueLiabilityCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_PurchasedRevenueLiabilityCurrent" use="optional" order="17" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="18" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_SCLX_LongTermPortionOfDeferredConsideration" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_LongTermPortionOfDeferredConsideration" use="optional" order="19" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent" use="optional" order="20" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityNoncurrent" xlink:label="loc_SCLX_PurchasedRevenueLiabilityNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_PurchasedRevenueLiabilityNoncurrent" use="optional" order="21" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="22" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="23" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="24" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="25" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="26" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="27" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="28" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="29" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="30" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="31" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="32" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Investments" use="optional" order="33" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="34" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" use="optional" order="35" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_SCLX_DeferredTaxAssetsDebtRelatedInterest" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsDebtRelatedInterest" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_SCLX_DeferredTaxAssetsAccruedExpenseAndReserves" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsAccruedExpenseAndReserves" use="optional" order="8" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsPurchasedRevenueLiability" xlink:label="loc_SCLX_DeferredTaxAssetsPurchasedRevenueLiability" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsPurchasedRevenueLiability" use="optional" order="9" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="11" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="12" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="13" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="14" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="15" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xlink:label="loc_SCLX_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_SCLX_IncomeTaxReconciliationAcquisitionRelatedCharges" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_IncomeTaxReconciliationAcquisitionRelatedCharges" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" use="optional" order="8" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="9" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents" use="optional" order="2" weight="1" />
        </link:calculationLink>
        <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeriesOnePreferredStockMember" xlink:label="loc_sclx_SeriesOnePreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SeriesOnePreferredStockMember" xml:lang="en-US">Series One Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SeriesOnePreferredStockMember" xml:lang="en-US">Series One Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SeriesOnePreferredStockMember" xml:lang="en-US">Series 1 Preferred Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SeriesOnePreferredStockMember" xlink:to="lab_sclx_SeriesOnePreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SeriesOnePreferredStockMember" xml:lang="en-US">Series One Preferred Stock [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Additional ROU assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangibles, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaap_Investments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Investments" xml:lang="en-US">Investments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Investments" xml:lang="en-US">Investments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xml:lang="en-US">Other long-term assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued rebates and fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedExpenses" xlink:to="lab_sclx_AccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_sclx_CurrentPortionOfDeferredConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CurrentPortionOfDeferredConsideration" xlink:to="lab_sclx_CurrentPortionOfDeferredConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, current</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityCurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasedRevenueLiabilityCurrent" xml:lang="en-US">Purchased Revenue Liability Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasedRevenueLiabilityCurrent" xml:lang="en-US">Purchased revenue liability, current</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasedRevenueLiabilityCurrent" xlink:to="lab_sclx_PurchasedRevenueLiabilityCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasedRevenueLiabilityCurrent" xml:lang="en-US">Purchased Revenue Liability Current</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less current portion of lease liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_sclx_LongTermPortionOfDeferredConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongTermPortionOfDeferredConsideration" xlink:to="lab_sclx_LongTermPortionOfDeferredConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Other Long-Term Debt, Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Debt, net of issuance costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityNoncurrent" xlink:label="loc_sclx_PurchasedRevenueLiabilityNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasedRevenueLiabilityNoncurrent" xml:lang="en-US">Purchased Revenue Liability Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasedRevenueLiabilityNoncurrent" xml:lang="en-US">Purchased revenue liability, net of current portion</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasedRevenueLiabilityNoncurrent" xlink:to="lab_sclx_PurchasedRevenueLiabilityNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasedRevenueLiabilityNoncurrent" xml:lang="en-US">Purchased Revenue Liability Noncurrent</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Corresponding lease liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (See Note 11)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdditionalPaidsInCapitals" xlink:label="loc_sclx_AdditionalPaidsInCapitals" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdditionalPaidsInCapitals" xml:lang="en-US">Additional Paids In Capitals</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdditionalPaidsInCapitals" xml:lang="en-US">Additional paid-in capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdditionalPaidsInCapitals" xlink:to="lab_sclx_AdditionalPaidsInCapitals" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdditionalPaidsInCapitals" xml:lang="en-US">Additional paid in capitals.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, par value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preference shares issue</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreferredStockDividendShares" xlink:label="loc_sclx_PreferredStockDividendShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PreferredStockDividendShares" xml:lang="en-US">Preferred Stock Dividend Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PreferredStockDividendShares" xml:lang="en-US">Preferred stock dividend shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PreferredStockDividendShares" xlink:to="lab_sclx_PreferredStockDividendShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PreferredStockDividendShares" xml:lang="en-US">Preferred Stock Dividend Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury stock share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock Common Shares Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesOutstanding" xlink:label="loc_sclx_CommonStocksSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStocksSharesOutstanding" xml:lang="en-US">Common Stocks Shares Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStocksSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStocksSharesOutstanding" xlink:to="lab_sclx_CommonStocksSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStocksSharesOutstanding" xml:lang="en-US">Common stocks shares outstanding.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStocksSharesIssued" xlink:label="loc_sclx_CommonStocksSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStocksSharesIssued" xml:lang="en-US">Common Stocks Shares Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStocksSharesIssued" xml:lang="en-US">Common stock, shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStocksSharesIssued" xlink:to="lab_sclx_CommonStocksSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStocksSharesIssued" xml:lang="en-US">Common stocks shares issued.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Net revenue</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Net operating costs and expenses:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Intangible amortization</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xml:lang="en-US">Payments for Legal Settlements</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xml:lang="en-US">Legal settlements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Total net operating costs and expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (income) expense, net:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">(Gain) loss on derivative liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">(Gain) loss on derivative liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change In Fair Value Of Debt And Liability Instruments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change in fair value of debt and liability instruments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:to="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change In Fair Value Of Debt And Liability Instruments</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest expense, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">(Gain) loss on foreign currency exchange</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (income) expense, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share attributable to common stockholders - basic and diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic (Loss) income Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share attributable to common stockholders - basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Loss per share, Basic</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share attributable to common stockholders - diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Loss per share, Diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average number of shares during the period - basic and diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares during the period-basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares - basic</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares during the period -diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares, diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Comprehensive loss:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xml:lang="en-US">Changes in fair value attributable to instrument-specific credit risk</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive income</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryShareMember" xlink:label="loc_sclx_TreasuryShareMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryShareMember" xml:lang="en-US">Treasury Share [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryShareMember" xml:lang="en-US">Treasury Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryShareMember" xlink:to="lab_sclx_TreasuryShareMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockPreferredMember" xml:lang="en-US">Treasury Stock, Preferred [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockPreferredMember" xml:lang="en-US">Treasury Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockPreferredMember" xlink:to="lab_us-gaap_TreasuryStockPreferredMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under the Standby Equity Purchase Agreements (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:to="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">value issued under Standby Equity Purchase Agreements</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under the Standby Equity Purchase Agreements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:to="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">value issued under Standby Equity Purchase Agreements</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DisbursementOfFundsToSorrentoAmount" xlink:to="lab_sclx_DisbursementOfFundsToSorrentoAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:to="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Repurchase of Treasury Stock, Preferred Stock, and warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:to="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of Penny Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of penny warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfPennyWarrants" xlink:to="lab_sclx_IssuanceOfPennyWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of Penny Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock in connection with Settlement Agreement, (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock issued for services, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock in connection with Settlement Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of Convertible Debentures into common stock, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of Convertible Debentures into common stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesIssued" xlink:to="lab_sclx_RetainerSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer Shares Issued Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesIssuedValue" xlink:to="lab_sclx_RetainerSharesIssuedValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer shares issued value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of common stock upon warrants exercise, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:to="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of common stock upon warrants exercise</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:to="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Value</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock options exercised (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options Outstanding, Exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock options exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xlink:label="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xml:lang="en-US">Adjustment of Additional Paid in Capital of Share based Compensation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xml:lang="en-US">Stock-based compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xlink:to="lab_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" xml:lang="en-US">Adjustment of additional paid in capital of share based compensation.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xlink:to="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xlink:to="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingShare" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingShare" xml:lang="en-US">Shares issued under Bought Deal Offering, Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingShare" xml:lang="en-US">Shares issued under Bought Deal Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderBoughtDealOfferingShare" xlink:to="lab_sclx_SharesIssuedUnderBoughtDealOfferingShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingShare" xml:lang="en-US">Shares issued under Bought Deal Offering, Share</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderBoughtDealOfferingValue" xlink:label="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingValue" xml:lang="en-US">Shares issued under Bought Deal Offering, value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingValue" xml:lang="en-US">Shares issued under Bought Deal Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderBoughtDealOfferingValue" xlink:to="lab_sclx_SharesIssuedUnderBoughtDealOfferingValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderBoughtDealOfferingValue" xml:lang="en-US">Shares issued under Bought Deal Offering, value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xml:lang="en-US">Shares Issued During Period, Shares, Registered Direct Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xml:lang="en-US">Shares issued under Registered Direct Offering, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:to="lab_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" xml:lang="en-US">Shares Issued During Period Registered Direct Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xml:lang="en-US">Shares Issued During Period, Values, Registered Direct Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xml:lang="en-US">Shares issued under Registered Direct Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xlink:to="lab_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" xml:lang="en-US">Shares Issued During Period, Values, Registered Direct Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xlink:label="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xml:lang="en-US">Value Issued Under Placement Agent Warrants Issued In Connection With Registered Direct Offering And Representative Warrants Issued In Connection With Bought Deal Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xml:lang="en-US">Placement Agent Warrants issued in connection with Registered Direct Offering and Representative Warrants issued in connection with Bought Deal Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xlink:to="lab_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" xml:lang="en-US">Value Issued Under Placement Agent Warrants Issued In Connection With Registered Direct Offering And Representative Warrants Issued In Connection With Bought Deal Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xlink:label="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xml:lang="en-US">Fee Warrant issued in connection with the Commitment Letter</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xml:lang="en-US">Fee Warrant issued in connection with the Commitment Letter</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xlink:to="lab_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" xml:lang="en-US">Fee Warrant issued in connection with the Commitment Letter</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepurchaseOfWarrants" xlink:label="loc_sclx_RepurchaseOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepurchaseOfWarrants" xml:lang="en-US">Repurchase Of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepurchaseOfWarrants" xml:lang="en-US">Repurchase of warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepurchaseOfWarrants" xlink:to="lab_sclx_RepurchaseOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepurchaseOfWarrants" xml:lang="en-US">Repurchase of warrants.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xlink:label="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xml:lang="en-US">Common stock issuable under Sponsor Interest Purchase Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xml:lang="en-US">Common stock issuable under Sponsor Interest Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xlink:to="lab_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" xml:lang="en-US">Common stock issuable under Sponsor Interest Purchase Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xml:lang="en-US">Placement Agent Shares and October Placement Agent Warrants, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xml:lang="en-US">Placement Agent Shares and October 2024 Placement Agent Warrants, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xlink:to="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" xml:lang="en-US">Placement Agent Shares and October Placement Agent Warrants, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xlink:label="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xml:lang="en-US">Placement Agent Shares and October Placement Agent Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xml:lang="en-US">Placement Agent Shares and October 2024 Placement Agent Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xlink:to="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" xml:lang="en-US">Placement Agent Shares and October Placement Agent Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xml:lang="en-US">Conversion of Tranche B Notes into Common Stock, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xml:lang="en-US">Conversion of Tranche B Notes into common stock, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xlink:to="lab_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStockShares" xml:lang="en-US">Conversion of Tranche B Notes into Common Stock, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfTrancheBNotesIntoCommonStock" xlink:label="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStock" xml:lang="en-US">Conversion of Tranche B Notes into Common Stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStock" xml:lang="en-US">Conversion of Tranche B Notes into common stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfTrancheBNotesIntoCommonStock" xlink:to="lab_sclx_ConversionOfTrancheBNotesIntoCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfTrancheBNotesIntoCommonStock" xml:lang="en-US">Conversion of Tranche B Notes into Common Stock</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xml:lang="en-US">Shares issued under December Registered Direct Offering, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xml:lang="en-US">Shares issued under December 2024 RDO, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xlink:to="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" xml:lang="en-US">Shares issued under December Registered Direct Offering, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xlink:label="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xml:lang="en-US">Shares issued under December Registered Direct Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xml:lang="en-US">Shares issued under December 2024 RDO, Value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xlink:to="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" xml:lang="en-US">Shares issued under December Registered Direct Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xlink:label="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xml:lang="en-US">StockBlock Warrants issued in connection with December Registered Direct Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xml:lang="en-US">StockBlock Warrants issued in connection with the December 2024 RDO</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xlink:to="lab_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" xml:lang="en-US">StockBlock Warrants issued in connection with December Registered Direct Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributedShares" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributedShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributedShares" xml:lang="en-US">Stock dividend declared, not yet distributed, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributedShares" xml:lang="en-US">Stock dividend declared, not yet distributed, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockDividendDeclaredNotYetDistributedShares" xlink:to="lab_sclx_StockDividendDeclaredNotYetDistributedShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributedShares" xml:lang="en-US">Stock dividend declared, not yet distributed, Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockDividendDeclaredNotYetDistributed" xlink:label="loc_sclx_StockDividendDeclaredNotYetDistributed" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributed" xml:lang="en-US">Stock dividend declared, not yet distributed</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributed" xml:lang="en-US">Stock dividend declared, not yet distributed</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockDividendDeclaredNotYetDistributed" xlink:to="lab_sclx_StockDividendDeclaredNotYetDistributed" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockDividendDeclaredNotYetDistributed" xml:lang="en-US">Stock dividend declared, not yet distributed</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Shares issued under ESPP, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Shares issued under ESPP</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaap_TreasuryStockPreferredShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockPreferredShares" xml:lang="en-US">Treasury Stock, Preferred, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TreasuryStockPreferredShares" xml:lang="en-US">Balance (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TreasuryStockPreferredShares" xml:lang="en-US">Balance, ( In shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockPreferredShares" xlink:to="lab_us-gaap_TreasuryStockPreferredShares" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xlink:label="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xml:lang="en-US">Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xml:lang="en-US">Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xlink:to="lab_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" xml:lang="en-US">Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xml:lang="en-US">Number of Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xml:lang="en-US">Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xlink:to="lab_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" xml:lang="en-US">Number of Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockPaidForGloperbaEx-USLicense" xlink:label="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryStockPaidForGloperbaEx-USLicense" xml:lang="en-US">Treasury Stock paid for Gloperba Ex-U.S. License</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryStockPaidForGloperbaEx-USLicense" xml:lang="en-US">Treasury Stock paid for Gloperba Ex-U.S. License</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryStockPaidForGloperbaEx-USLicense" xlink:to="lab_sclx_TreasuryStockPaidForGloperbaEx-USLicense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TreasuryStockPaidForGloperbaEx-USLicense" xml:lang="en-US">Treasury Stock paid for Gloperba Ex-U.S. License</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xlink:label="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xml:lang="en-US">Number of Treasury Stock Paid For Gloperba Ex-US License Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xml:lang="en-US">Treasury Stock paid for Gloperba Ex-U.S. License, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xlink:to="lab_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" xml:lang="en-US">Number of Treasury Stock Paid For Gloperba Ex-US License Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xlink:label="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xml:lang="en-US">Treasury Stock transferred to Oramed for the Oramed Note maturity extension</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xml:lang="en-US">Treasury Stock transferred to Oramed for the Oramed Note maturity extension</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xlink:to="lab_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" xml:lang="en-US">Treasury Stock transferred to Oramed for the Oramed Note maturity extension</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xlink:label="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xml:lang="en-US">Number of Treasury Stock transferred to Oramed for the Oramed Note maturity extension Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xml:lang="en-US">Treasury Stock transferred to Oramed for the Oramed Note maturity extension, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xlink:to="lab_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" xml:lang="en-US">Number of Treasury Stock transferred to Oramed for the Oramed Note maturity extension Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash proceeds from operating activities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_sclx_NonCashOperatingLeaseCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non Cash Operating Lease Cost</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non-cash operating lease cost</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashOperatingLeaseCost" xlink:to="lab_sclx_NonCashOperatingLeaseCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non cash operating lease cost.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xml:lang="en-US">Issuance of shares under Settlement Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US">Deferred Debt Issuance Cost, Writeoff</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US">Allocated expense for financial instruments at fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForCreditLosses" xlink:label="loc_sclx_AllowancesForCreditLosses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AllowancesForCreditLosses" xml:lang="en-US">Allowances for Credit Losses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AllowancesForCreditLosses" xml:lang="en-US">Allowances for expected credit losses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AllowancesForCreditLosses" xlink:to="lab_sclx_AllowancesForCreditLosses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AllowancesForCreditLosses" xml:lang="en-US">Allowances for Credit Losses</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivables, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Prepaid expenses and other</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_sclx_IncreaseDecreaseInAccruedPayroll" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Increase Decrease In Accrued payroll</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Accrued Payroll</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseDecreaseInAccruedPayroll" xlink:to="lab_sclx_IncreaseDecreaseInAccruedPayroll" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Increase Decrease In Accrued payroll</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Increase (Decrease) in Accrued Rebates and Fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Accrued rebates and fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:to="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Increase (Decrease) in Accrued Rebates and Fees</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_sclx_OtherLongTermLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherLongTermLiabilities" xlink:to="lab_sclx_OtherLongTermLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLeaseLiability1" xlink:label="loc_sclx_OperatingLeaseLiability1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingLeaseLiability1" xml:lang="en-US">Operating Lease Liability 1</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_OperatingLeaseLiability1" xml:lang="en-US">Operating lease liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingLeaseLiability1" xlink:to="lab_sclx_OperatingLeaseLiability1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingLeaseLiability1" xml:lang="en-US">Operating Lease Liability 1</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xlink:label="loc_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xml:lang="en-US">Financing Costs and Allocated Expense for Financial Instruments at Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xml:lang="en-US">Financing costs and allocated expense for financial instruments at fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xlink:to="lab_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" xml:lang="en-US">Financing Costs and Allocated Expense for Financial Instruments at Fair Value</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">In-process research and development expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash proceeds from operating activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition consideration paid in cash for Romeg intangible asset acquisition</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:to="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfEquitySecurities" xlink:label="loc_sclx_PurchaseOfEquitySecurities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfEquitySecurities" xml:lang="en-US">Purchase Of Equity Securities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_PurchaseOfEquitySecurities" xml:lang="en-US">Purchase of equity securities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfEquitySecurities" xlink:to="lab_sclx_PurchaseOfEquitySecurities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfEquitySecurities" xml:lang="en-US">Purchase of equity securities</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfConvertiblePromissoryNote" xlink:label="loc_sclx_PurchaseOfConvertiblePromissoryNote" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfConvertiblePromissoryNote" xml:lang="en-US">Purchase of convertible promissory note</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_PurchaseOfConvertiblePromissoryNote" xml:lang="en-US">Purchase of convertible promissory note from Denali</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfConvertiblePromissoryNote" xlink:to="lab_sclx_PurchaseOfConvertiblePromissoryNote" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfConvertiblePromissoryNote" xml:lang="en-US">Purchase of convertible promissory note</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, plant, and equipment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used for investing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xml:lang="en-US">Cash paid for in-process research and development, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xlink:label="loc_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xml:lang="en-US">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xml:lang="en-US">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xlink:to="lab_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" xml:lang="en-US">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from Issuance of Revolving Facility</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from issuance of Revolving Facility</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:to="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from Issuance of Revolving Facility</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromIssuanceOfFsfDeposit" xlink:label="loc_sclx_ProceedsFromIssuanceOfFsfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromIssuanceOfFsfDeposit" xml:lang="en-US">Proceeds from issuance of FSF Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromIssuanceOfFsfDeposit" xml:lang="en-US">Proceeds from issuance of FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromIssuanceOfFsfDeposit" xlink:to="lab_sclx_ProceedsFromIssuanceOfFsfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromIssuanceOfFsfDeposit" xml:lang="en-US">Proceeds from issuance of FSF Deposit</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from issuance of Tranche B Notes and purchased revenue liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_sclx_RepaymentOfRevolvingFacility" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfRevolvingFacility" xlink:to="lab_sclx_RepaymentOfRevolvingFacility" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayment of Oramed Note</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayment of debt prinnciple installment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Cash consideration paid in connection with warrant repurchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Repurchase of warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Repurchase of warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the recapitalization transaction</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the Business Combination</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:to="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the recapitalization transaction</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayment of Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDebt" xlink:label="loc_sclx_RepaymentOfDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfDebt" xml:lang="en-US">Repayment Of Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_RepaymentOfDebt" xml:lang="en-US">Repayment of Tranche B Notes principal and interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfDebt" xlink:to="lab_sclx_RepaymentOfDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfDebt" xml:lang="en-US">Repayment Of Debt</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of debt issuance costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of debt issuance costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DisbursementOfFunds" xlink:label="loc_sclx_DisbursementOfFunds" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement Of Funds</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement of funds to Sorrento</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DisbursementOfFunds" xlink:to="lab_sclx_DisbursementOfFunds" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement Of Funds</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xml:lang="en-US">Accelerated Share Repurchases, Adjustment to Recorded Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xml:lang="en-US">Cash consideration paid in connection with share repurchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xml:lang="en-US">Cash Consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:to="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xml:lang="en-US">Excise Tax Paid In Connection With Share Repurchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xml:lang="en-US">Excise tax paid in connection with share repurchase</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xlink:to="lab_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExciseTaxPaidInConnectionWithShareRepurchase" xml:lang="en-US">Excise Tax Paid In Connection With Share Repurchase</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of shares under direct offerings</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of direct offering issuance costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xlink:label="loc_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xml:lang="en-US">Payments of Deferred Transaction Costs Related to Semnur Merger</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xml:lang="en-US">Payments of deferred transaction costs related to Semnur Business Combination</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xlink:to="lab_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" xml:lang="en-US">Payments of Deferred Transaction Costs Related to Semnur Merger</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from stock options exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used for financing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRefundPayments1" xlink:label="loc_us-gaap_DeferredRevenueRefundPayments1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueRefundPayments1" xml:lang="en-US">Deferred Revenue, Refund Payments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredRevenueRefundPayments1" xml:lang="en-US">Payments on purchased revenue liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRefundPayments1" xlink:to="lab_us-gaap_DeferredRevenueRefundPayments1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperatingPaidInCash" xlink:label="loc_us-gaap_InterestIncomeOperatingPaidInCash" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOperatingPaidInCash" xml:lang="en-US">Interest Income, Operating, Paid in Cash</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOperatingPaidInCash" xml:lang="en-US">Cash paid for interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperatingPaidInCash" xlink:to="lab_us-gaap_InterestIncomeOperatingPaidInCash" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash investing and financing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xlink:label="loc_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xml:lang="en-US">Issuance costs related to Bought Deal Offering included in accrued expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xml:lang="en-US">Issuance costs related to direct offerings included in accrued expenses and account payables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xlink:to="lab_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" xml:lang="en-US">Issuance costs related to Bought Deal Offering included in accrued expenses</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xlink:label="loc_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xml:lang="en-US">Fee Warrants Issued and Exercised in Connection with the FSF Commitment Letter</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xml:lang="en-US">Fee Warrants issued and exercised in connection with the Commitment Letter</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xlink:to="lab_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" xml:lang="en-US">Fee Warrants Issued and Exercised in Connection with the FSF Commitment Letter</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SettlementOfFSFDeposit" xlink:label="loc_sclx_SettlementOfFSFDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SettlementOfFSFDeposit" xml:lang="en-US">Settlement of FSF Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SettlementOfFSFDeposit" xml:lang="en-US">Settlement of FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SettlementOfFSFDeposit" xlink:to="lab_sclx_SettlementOfFSFDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SettlementOfFSFDeposit" xml:lang="en-US">Settlement of FSF Deposit</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xlink:label="loc_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xml:lang="en-US">Deferred Transaction Costs Related to Semnur Merger Included in Accrued Expenses And Account Payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xml:lang="en-US">Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xlink:to="lab_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" xml:lang="en-US">Deferred Transaction Costs Related to Semnur Merger Included in Accrued Expenses And Account Payable</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfOramedNoteIntoTrancheBNotes" xlink:label="loc_sclx_ConversionOfOramedNoteIntoTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfOramedNoteIntoTrancheBNotes" xml:lang="en-US">Conversion of Oramed Note into Tranche B Notes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfOramedNoteIntoTrancheBNotes" xml:lang="en-US">Conversion of Oramed Note into Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfOramedNoteIntoTrancheBNotes" xlink:to="lab_sclx_ConversionOfOramedNoteIntoTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfOramedNoteIntoTrancheBNotes" xml:lang="en-US">Conversion of Oramed Note into Tranche B Notes</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xlink:label="loc_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xml:lang="en-US">Debt Issuance Costs Included in Accrued Expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xml:lang="en-US">Debt issuance costs included in accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xlink:to="lab_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtIssuanceCostsIncludedInAccruedExpenses" xml:lang="en-US">Debt Issuance Costs Included in Accrued Expenses</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into Common Stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into common stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into Common Stock</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:label="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:to="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedNoteIssuanceAtFairValue" xlink:label="loc_sclx_OramedNoteIssuanceAtFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OramedNoteIssuanceAtFairValue" xlink:to="lab_sclx_OramedNoteIssuanceAtFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:label="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:to="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:label="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:to="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Nature of Operations and Basis of Presentation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Liquidity and Going Concern</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xml:lang="en-US">Disclosure Text Block [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xml:lang="en-US">Acquisitions and License Agreements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Balance Sheet Components</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Sorrento Stock Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Stock Incentive and Employee Benefit Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:label="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:to="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityPolicyTextBlock" xlink:label="loc_sclx_PurchasedRevenueLiabilityPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasedRevenueLiabilityPolicyTextBlock" xml:lang="en-US">Purchased Revenue Liability [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasedRevenueLiabilityPolicyTextBlock" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasedRevenueLiabilityPolicyTextBlock" xlink:to="lab_sclx_PurchasedRevenueLiabilityPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasedRevenueLiabilityPolicyTextBlock" xml:lang="en-US">Purchased Revenue Liability [Policy Text Block]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Customer and Supplier Concentration Risk</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable, Net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Acquisitions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xml:lang="en-US">Contingent Consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Other Long-Lived Assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Public Warrant And Private Placement Warrants [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:to="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Public Warrant And Private Placement Warrants [Policy Text Block]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">The Oramed Note and Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TreasuryStockPolicyTextblock" xlink:label="loc_sclx_TreasuryStockPolicyTextblock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock Policy TextBlock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryStockPolicyTextblock" xlink:to="lab_sclx_TreasuryStockPolicyTextblock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock Policy TextBlock</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss per Share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReverseStockSplitPolicyTextBlock" xlink:label="loc_sclx_ReverseStockSplitPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReverseStockSplitPolicyTextBlock" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ReverseStockSplitPolicyTextBlock" xml:lang="en-US">Reverse Stock Split</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReverseStockSplitPolicyTextBlock" xlink:to="lab_sclx_ReverseStockSplitPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReverseStockSplitPolicyTextBlock" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Significant Accounting Policies</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value assets measured on a recurring basis</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Fair Value, Concentration of Risk [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Schedule of quantitative information regarding Level 3 fair value measurements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and equipment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedExpensesTextblock" xlink:label="loc_sclx_AccruedExpensesTextblock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Accrued expenses Textblock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedExpensesTextblock" xlink:to="lab_sclx_AccruedExpensesTextblock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Accrued expenses Textblock</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Summary of identifiable intangible assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Estimated future amortization expense related to intangible assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Oramed Note</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Oramed Note [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNotesMember" xlink:label="loc_sclx_TrancheBNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheBNotesMember" xml:lang="en-US">Tranche B Notes [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheBNotesMember" xml:lang="en-US">Tranche BNotes Member</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheBNotesMember" xlink:to="lab_sclx_TrancheBNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TrancheBNotesMember" xml:lang="en-US">Tranche B Notes [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Schdule of Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of The Oramed Note Table Text Block</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of the Oramed Note</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:to="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of The Oramed Note Table Text Block</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xlink:label="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xml:lang="en-US">Summary Of The Changes In The Balance And The Estimated Fair Value Of The FSF Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xml:lang="en-US">Schedule of FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xlink:to="lab_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" xml:lang="en-US">Summary of the Changes in the Balance and the Estimated Fair Value of the FSF Deposit</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTrancheBNotesTableTextBlock" xlink:label="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfTrancheBNotesTableTextBlock" xml:lang="en-US">Schedule Of Tranche B Notes [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfTrancheBNotesTableTextBlock" xml:lang="en-US">Schedule of Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfTrancheBNotesTableTextBlock" xlink:to="lab_sclx_ScheduleOfTrancheBNotesTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfTrancheBNotesTableTextBlock" xml:lang="en-US">Schedule Of Tranche B Notes [Table Text Block]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xlink:label="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xml:lang="en-US">Schedule of Revenue Liability Activity [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xml:lang="en-US">Schedule of revenue liability activity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xlink:to="lab_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" xml:lang="en-US">Schedule of Revenue Liability Activity [Table Text Block]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xml:lang="en-US">Schedule of The Tranche B Note [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xml:lang="en-US">Schedule of the Tranche B Note</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xlink:to="lab_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfTheTrancheBNoteTableTextBlock" xml:lang="en-US">Tavular disclosure of The Tranche B Note Table Text Block</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Stock Options Outstanding Activity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Stock Options Valuation Assumption Used</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Leases Supplemental Quantitative Information</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Lease Maturities of Lease Liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Benefit for Income Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of the reconciliation of basic and diluted loss per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Description of Organization and Business Operations (Details) [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Descriptionof Organizationand Business Operations Details Table</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SorrentoMember" xlink:to="lab_sclx_SorrentoMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThreeCustomersMember" xlink:to="lab_sclx_ThreeCustomersMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Description of Organization and Business Operations (Details) [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Descriptionof Organizationand Business Operations Details Line Items</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables, Net, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConcentrationRiskThresholdPercentage" xlink:label="loc_sclx_ConcentrationRiskThresholdPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConcentrationRiskThresholdPercentage" xml:lang="en-US">Concentration Risk Threshold Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConcentrationRiskThresholdPercentage" xml:lang="en-US">Concentration risk, percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConcentrationRiskThresholdPercentage" xlink:to="lab_sclx_ConcentrationRiskThresholdPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConcentrationRiskThresholdPercentage" xml:lang="en-US">Concentration risk threshold percentage.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xml:lang="en-US">Provision for Other Credit Losses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xml:lang="en-US">Expected Credit Losses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForOtherCreditLosses" xlink:to="lab_us-gaap_ProvisionForOtherCreditLosses" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Allowances for expected credit losses accounts receivable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributors</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributor</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfNetRevenueSoleDistributors" xlink:to="lab_sclx_PercentageOfNetRevenueSoleDistributors" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributors</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income taxes paid</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AllowancesForPromptPaymentDiscounts" xlink:label="loc_sclx_AllowancesForPromptPaymentDiscounts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AllowancesForPromptPaymentDiscounts" xml:lang="en-US">Allowances for Prompt Payment Discounts</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AllowancesForPromptPaymentDiscounts" xml:lang="en-US">Allowances for prompt payment discounts</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AllowancesForPromptPaymentDiscounts" xlink:to="lab_sclx_AllowancesForPromptPaymentDiscounts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AllowancesForPromptPaymentDiscounts" xml:lang="en-US">Allowances for Prompt Payment Discounts</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Description of Stockholders' Equity, Reverse Stock Split</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and Going Concern [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTable" xlink:to="lab_sclx_LiquidityAndGoingConcernTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and Going Concern [Table]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InitialClosingMember" xlink:label="loc_sclx_InitialClosingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InitialClosingMember" xml:lang="en-US">Initial Closing [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_InitialClosingMember" xml:lang="en-US">Initial Closing [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InitialClosingMember" xlink:to="lab_sclx_InitialClosingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_InitialClosingMember" xml:lang="en-US">Initial Closing [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondClosingMember" xlink:label="loc_sclx_SecondClosingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecondClosingMember" xml:lang="en-US">Second Closing [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecondClosingMember" xlink:to="lab_sclx_SecondClosingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecondClosingMember" xml:lang="en-US">Second Closing [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedMember" xlink:label="loc_sclx_OramedMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OramedMember" xml:lang="en-US">Oramed [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OramedMember" xml:lang="en-US">Oramed [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OramedMember" xlink:to="lab_sclx_OramedMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OramedMember" xml:lang="en-US">Oramed [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionsAxis" xlink:label="loc_sclx_LongTermDebtTransactionsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongTermDebtTransactionsAxis" xml:lang="en-US">Long Term Debt Transactions [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongTermDebtTransactionsAxis" xlink:to="lab_sclx_LongTermDebtTransactionsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongTermDebtTransactionsAxis" xml:lang="en-US">Long Term Debt Transactions [Axis]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionDomain" xlink:label="loc_sclx_LongTermDebtTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongTermDebtTransactionDomain" xml:lang="en-US">Long-Term Debt, Transaction [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongTermDebtTransactionDomain" xlink:to="lab_sclx_LongTermDebtTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongTermDebtTransactionDomain" xml:lang="en-US">Long-Term Debt, Transaction [Domain]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalBalanceMember" xlink:label="loc_sclx_PrincipalBalanceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrincipalBalanceMember" xml:lang="en-US">Principal Balance [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrincipalBalanceMember" xml:lang="en-US">Principal Balance [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrincipalBalanceMember" xlink:to="lab_sclx_PrincipalBalanceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrincipalBalanceMember" xml:lang="en-US">Principal Balance [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SeniorSecuredConvertibleNotesMember" xlink:label="loc_sclx_SeniorSecuredConvertibleNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SeniorSecuredConvertibleNotesMember" xml:lang="en-US">Senior Secured Convertible Notes [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SeniorSecuredConvertibleNotesMember" xml:lang="en-US">Senior Secured Convertible Notes [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SeniorSecuredConvertibleNotesMember" xlink:to="lab_sclx_SeniorSecuredConvertibleNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SeniorSecuredConvertibleNotesMember" xml:lang="en-US">Senior Secured Convertible Notes [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SatisfactionAgreementMember" xlink:label="loc_sclx_SatisfactionAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SatisfactionAgreementMember" xml:lang="en-US">Satisfaction Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SatisfactionAgreementMember" xml:lang="en-US">Satisfaction Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SatisfactionAgreementMember" xlink:to="lab_sclx_SatisfactionAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SatisfactionAgreementMember" xml:lang="en-US">Satisfaction Agreement Member</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecuritiesPurchaseAgreementMember" xlink:to="lab_sclx_SecuritiesPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_InvestorAgreementMember" xlink:label="loc_sclx_InvestorAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvestorAgreementMember" xml:lang="en-US">Investor Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_InvestorAgreementMember" xml:lang="en-US">Investor Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvestorAgreementMember" xlink:to="lab_sclx_InvestorAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_InvestorAgreementMember" xml:lang="en-US">Investor Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseAgreementAxis" xml:lang="en-US">Purchase Agreement [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseAgreementAxis" xlink:to="lab_sclx_PurchaseAgreementAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseAgreementAxis" xml:lang="en-US">Purchase Agreement Axis</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseAgreementDomain" xml:lang="en-US">Purchase Agreement [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseAgreementDomain" xlink:to="lab_sclx_PurchaseAgreementDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseAgreementDomain" xml:lang="en-US">Purchase Agreement Domain</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A R Yorkville Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A&amp;R Yorkville Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ARYorkvillePurchaseAgreementMember" xlink:to="lab_sclx_ARYorkvillePurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A R Yorkville Purchase Agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AtmSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AtmSalesAgreementMember" xlink:to="lab_sclx_AtmSalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AtmSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantsMember" xlink:label="loc_sclx_DepositWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositWarrantsMember" xml:lang="en-US">Deposit Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositWarrantsMember" xml:lang="en-US">Deposit Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_DepositWarrantsMember" xml:lang="en-US">Deposit Warrant [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositWarrantsMember" xlink:to="lab_sclx_DepositWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositWarrantsMember" xml:lang="en-US">Deposit Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xml:lang="en-US">Equity Unit Purchase Agreements [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xml:lang="en-US">Equity Purchase Agreement with Yorkville and B. Riley [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:to="lab_us-gaap_EquityUnitPurchaseAgreementsMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and Going Concern [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems" xlink:to="lab_sclx_LiquidityAndGoingConcernLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and Going Concern [Line Items]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Negative working capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapital" xlink:to="lab_sclx_WorkingCapital" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt principal amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Initial principal amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">ConvertibleDebentureprincipalAmount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">Convertible Debenture principal Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Convertibledebentureprincipalamount" xlink:to="lab_sclx_Convertibledebentureprincipalamount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">ConvertibleDebentureprincipalAmount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal laon amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal loan amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrincipalLaonAmount" xlink:to="lab_sclx_PrincipalLaonAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal laon amount</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debenture</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible debentures, beginning period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible debentures, ending period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Long Term Commitment Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmountPayable" xlink:label="loc_sclx_CommitmentAmountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentAmountPayable" xml:lang="en-US">Commitment Amount Payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommitmentAmountPayable" xml:lang="en-US">Commitment Amount Payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentAmountPayable" xlink:to="lab_sclx_CommitmentAmountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentAmountPayable" xml:lang="en-US">Commitment Amount Payable</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xml:lang="en-US">Long term Purchase Period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompanyReceivesTheDepositAmount" xml:lang="en-US">Company Receives The Deposit Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CompanyReceivesTheDepositAmount" xml:lang="en-US">Company receives the Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompanyReceivesTheDepositAmount" xlink:to="lab_sclx_CompanyReceivesTheDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompanyReceivesTheDepositAmount" xml:lang="en-US">Company Receives The Deposit Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheDepositPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompanyReceivesTheDepositPeriod" xml:lang="en-US">Company Receives The Deposit Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CompanyReceivesTheDepositPeriod" xml:lang="en-US">Company Receives The Deposit Period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompanyReceivesTheDepositPeriod" xlink:to="lab_sclx_CompanyReceivesTheDepositPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompanyReceivesTheDepositPeriod" xml:lang="en-US">Company Receives The Deposit Period</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonRefundableDepositAmount" xlink:label="loc_sclx_NonRefundableDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonRefundableDepositAmount" xml:lang="en-US">Non-Refundable Deposit Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonRefundableDepositAmount" xml:lang="en-US">Non-Refundable Deposit Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonRefundableDepositAmount" xlink:to="lab_sclx_NonRefundableDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonRefundableDepositAmount" xml:lang="en-US">Non-Refundable Deposit Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Agreement amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityGross" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityGross" xml:lang="en-US">Loss Contingency Accrual, Product Liability, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityGross" xml:lang="en-US">Liquidated damages</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProductLiabilityGross" xlink:to="lab_us-gaap_LossContingencyAccrualProductLiabilityGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt Instrument Repurchased Face Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfTheWarrants" xlink:label="loc_sclx_ExercisePriceOfTheWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExercisePriceOfTheWarrants" xml:lang="en-US">Exercise Price Of The Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExercisePriceOfTheWarrants" xml:lang="en-US">Deposit Warrant Exercise Price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExercisePriceOfTheWarrants" xlink:to="lab_sclx_ExercisePriceOfTheWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExercisePriceOfTheWarrants" xml:lang="en-US">Exercise Price Of The Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromSaleOfCommonStock" xlink:to="lab_sclx_ProceedsFromSaleOfCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common Stock Issuable Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common Stock Issuable Value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockIssuableValue" xlink:to="lab_sclx_CommonStockIssuableValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common Stock Issuable Value</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReductionOfThePrincipalBalance" xlink:label="loc_sclx_ReductionOfThePrincipalBalance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReductionOfThePrincipalBalance" xml:lang="en-US">Reduction of the Principal Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ReductionOfThePrincipalBalance" xml:lang="en-US">Reduction of the principal balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReductionOfThePrincipalBalance" xlink:to="lab_sclx_ReductionOfThePrincipalBalance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReductionOfThePrincipalBalance" xml:lang="en-US">Reduction of the Principal Balance</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Common stock at a conversion price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt conversion price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to Sell Maximum Number of Common Stock Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to sell maximum number of common stock shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:to="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to Sell Maximum Number of Common Stock Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Decrease</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xml:lang="en-US">Decrease in common stock at a conversion price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LicenseAgreementMember" xlink:to="lab_sclx_LicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RomegLicenseAgreementMember" xlink:to="lab_sclx_RomegLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaMember" xlink:to="lab_sclx_ScilexPharmaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Development milestones payment was recognized under other long-term liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">UpFrontLicenseFee</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">Up-front license fee</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Upfrontlicensefee" xlink:to="lab_sclx_Upfrontlicensefee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">UpFrontLicenseFee</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentUponTheAchievementOfNetSales" xml:lang="en-US">Payment upon the achievement of net sales</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentUponTheAchievementOfNetSales" xlink:to="lab_sclx_PaymentUponTheAchievementOfNetSales" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentUponTheAchievementOfNetSales" xml:lang="en-US">Payment Upon The Achievement of Net Sales</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments for Royalties</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments for royalties</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Non-RefundableNon-CreditablePayment" xlink:label="loc_sclx_Non-RefundableNon-CreditablePayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Non-RefundableNon-CreditablePayment" xml:lang="en-US">Non-Refundable, Non-Creditable Payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Non-RefundableNon-CreditablePayment" xml:lang="en-US">Non-Refundable, Non-Creditable Payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Non-RefundableNon-CreditablePayment" xlink:to="lab_sclx_Non-RefundableNon-CreditablePayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Non-RefundableNon-CreditablePayment" xml:lang="en-US">Non-Refundable, Non-Creditable Payment</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfCommonStockShares" xlink:label="loc_sclx_TransferOfCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransferOfCommonStockShares" xml:lang="en-US">Transfer of Common Stock Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransferOfCommonStockShares" xml:lang="en-US">Transfer of Common Stock Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransferOfCommonStockShares" xlink:to="lab_sclx_TransferOfCommonStockShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransferOfCommonStockShares" xml:lang="en-US">Transfer of Common Stock Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible asset</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">DeferredConsiderationLiabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">Deferred consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Deferredconsiderationliabilities" xlink:to="lab_sclx_Deferredconsiderationliabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">DeferredConsiderationLiabilities</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration, liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to Acquire License</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to acquire license</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToAcquireLicense" xlink:to="lab_sclx_PaymentToAcquireLicense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to Acquire License</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedRoyaltyPayables" xlink:to="lab_sclx_AccruedRoyaltyPayables" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmountDueForNewDrugApplication" xml:lang="en-US">Amount due for New Drug Application</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmountDueForNewDrugApplication" xlink:to="lab_sclx_AmountDueForNewDrugApplication" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmountDueForNewDrugApplication" xml:lang="en-US">Amount due for New Drug Application</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfLidocaineTopicalSystem" xlink:label="loc_sclx_PercentageOfLidocaineTopicalSystem" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfLidocaineTopicalSystem" xml:lang="en-US">Percentage of Lidocaine Topical System</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfLidocaineTopicalSystem" xml:lang="en-US">Percentage of Lidocaine Topical System</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfLidocaineTopicalSystem" xlink:to="lab_sclx_PercentageOfLidocaineTopicalSystem" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfLidocaineTopicalSystem" xml:lang="en-US">Percentage of Lidocaine Topical System</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US">Percentage of net revenue</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregatePaymentOfCompany" xlink:label="loc_sclx_AggregatePaymentOfCompany" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregatePaymentOfCompany" xml:lang="en-US">Aggregate Payment Of Company</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregatePaymentOfCompany" xml:lang="en-US">Aggregate Payment Of Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregatePaymentOfCompany" xlink:to="lab_sclx_AggregatePaymentOfCompany" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregatePaymentOfCompany" xml:lang="en-US">Aggregate Payment Of Company</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ZTlidoRestOfWorldLicenseAgreementMember" xml:lang="en-US">ZTlido Rest of World License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ZTlidoRestOfWorldLicenseAgreementMember" xml:lang="en-US">Tlido Rest Of World License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_ZTlidoRestOfWorldLicenseAgreementMember" xml:lang="en-US">ZTlido Rest of World License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ZTlidoRestOfWorldLicenseAgreementMember" xlink:to="lab_sclx_ZTlidoRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ZTlidoRestOfWorldLicenseAgreementMember" xml:lang="en-US">ZTlido Rest of World License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GloperbaRestOfWorldLicenseAgreementMember" xml:lang="en-US">Gloperba Rest of World License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GloperbaRestOfWorldLicenseAgreementMember" xml:lang="en-US">Gloperba Rest of World License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GloperbaRestOfWorldLicenseAgreementMember" xlink:to="lab_sclx_GloperbaRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GloperbaRestOfWorldLicenseAgreementMember" xml:lang="en-US">Gloperba Rest of World License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ElyxybRestOfWorldLicenseAgreementMember" xlink:label="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ElyxybRestOfWorldLicenseAgreementMember" xml:lang="en-US">Elyxyb Rest Of World License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ElyxybRestOfWorldLicenseAgreementMember" xml:lang="en-US">Elyxyb Rest of World License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ElyxybRestOfWorldLicenseAgreementMember" xlink:to="lab_sclx_ElyxybRestOfWorldLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ElyxybRestOfWorldLicenseAgreementMember" xml:lang="en-US">Elyxyb Rest Of World License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantsMember" xlink:label="loc_sclx_February2024BDOFirmWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_February2024BDOFirmWarrantsMember" xml:lang="en-US">February2024BDOFirmWarrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_February2024BDOFirmWarrantsMember" xml:lang="en-US">February 2024 BDO Firm Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_February2024BDOFirmWarrantsMember" xlink:to="lab_sclx_February2024BDOFirmWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_February2024BDOFirmWarrantsMember" xml:lang="en-US">February2024BDOFirmWarrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOCommonWarrantsMember" xlink:label="loc_sclx_April2024RDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_April2024RDOCommonWarrantsMember" xml:lang="en-US">April 2024 RDO Common Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_April2024RDOCommonWarrantsMember" xml:lang="en-US">April 2024 RDO Common Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_April2024RDOCommonWarrantsMember" xlink:to="lab_sclx_April2024RDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_April2024RDOCommonWarrantsMember" xml:lang="en-US">April 2024 RDO Common Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024NoteholderWarrantsMember" xlink:label="loc_sclx_October2024NoteholderWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_October2024NoteholderWarrantsMember" xml:lang="en-US">October 2024 Noteholder Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_October2024NoteholderWarrantsMember" xml:lang="en-US">October 2024 Noteholder Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_October2024NoteholderWarrantsMember" xlink:to="lab_sclx_October2024NoteholderWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_October2024NoteholderWarrantsMember" xml:lang="en-US">October 2024 Noteholder Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_December2024RDOCommonWarrantsMember" xlink:label="loc_sclx_December2024RDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_December2024RDOCommonWarrantsMember" xml:lang="en-US">December 2024 RDO Common Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_December2024RDOCommonWarrantsMember" xml:lang="en-US">December 2024 RDO Common Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_sclx_December2024RDOCommonWarrantsMember" xml:lang="en-US">December 2024 RDO Common Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_December2024RDOCommonWarrantsMember" xml:lang="en-US">December 2024 RDO Common Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_December2024RDOCommonWarrantsMember" xlink:to="lab_sclx_December2024RDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_December2024RDOCommonWarrantsMember" xml:lang="en-US">December 2024 RDO Common Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiabilityMember" xlink:label="loc_sclx_PurchasedRevenueLiabilityMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasedRevenueLiabilityMember" xml:lang="en-US">Purchased Revenue Liability [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasedRevenueLiabilityMember" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasedRevenueLiabilityMember" xlink:to="lab_sclx_PurchasedRevenueLiabilityMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasedRevenueLiabilityMember" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember" xml:lang="en-US">Senior Subordinated Notes [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember" xml:lang="en-US">FSF Deposit Member</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorSubordinatedNotesMember" xlink:to="lab_us-gaap_SeniorSubordinatedNotesMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba Elyxyb Royalty Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba Elyxyb Royalty Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xlink:to="lab_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba Elyxyb Royalty Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsMember" xlink:to="lab_sclx_WarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Estimated fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Secured Note Discount Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Note discount rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecuredNoteDiscountRate" xlink:to="lab_sclx_SecuredNoteDiscountRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Secured Note Discount Rate</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Debt Instrument, Issued, Principal</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Principle amount of issued debt</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="lab_us-gaap_DebtInstrumentIssuedPrincipal" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DerivativeWarrantLiabilities" xlink:label="loc_sclx_DerivativeWarrantLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DerivativeWarrantLiabilities" xml:lang="en-US">Derivative Warrant Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DerivativeWarrantLiabilities" xml:lang="en-US">Derivative warrant liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DerivativeWarrantLiabilities" xlink:to="lab_sclx_DerivativeWarrantLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DerivativeWarrantLiabilities" xml:lang="en-US">Derivative Warrant Liabilities</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change In Fair Value Of Convertible Debentures Include Interest Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change in fair value of debt and liability instruments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:to="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change In Fair Value Of Convertible Debentures Include Interest Expense</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchasedRevenueLiability" xlink:label="loc_sclx_PurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasedRevenueLiability" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasedRevenueLiability" xml:lang="en-US">Purchased revenue liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_sclx_PurchasedRevenueLiability" xml:lang="en-US">Ending Balance as of December 31, 2024</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_sclx_PurchasedRevenueLiability" xml:lang="en-US">Ending Balance as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasedRevenueLiability" xlink:to="lab_sclx_PurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasedRevenueLiability" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueDueToCreditRisk" xlink:label="loc_sclx_ChangeInFairValueDueToCreditRisk" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueDueToCreditRisk" xml:lang="en-US">Change In Fair Value Due To Credit Risk</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueDueToCreditRisk" xml:lang="en-US">Change in fair value due to credit risk</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueDueToCreditRisk" xlink:to="lab_sclx_ChangeInFairValueDueToCreditRisk" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueDueToCreditRisk" xml:lang="en-US">Change In Fair Value Due To Credit Risk</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Common stock upon conversation of cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xml:lang="en-US">Product Liability Contingency, Accrual, Discount Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xml:lang="en-US">Discount rate of FDA</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:to="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Fair value of contingent consideration</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Development Milestone Payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfContingentConsideration" xlink:to="lab_sclx_FairValueOfContingentConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Fair value of contingent consideration.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior Notes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Oramed Note</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible debenture</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNote" xlink:label="loc_sclx_TrancheBNote" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheBNote" xml:lang="en-US">Tranche B Note</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheBNote" xml:lang="en-US">Tranche B Notes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_sclx_TrancheBNote" xml:lang="en-US">Ending Balance as of December 31, 2024</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_sclx_TrancheBNote" xml:lang="en-US">Ending Balance as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheBNote" xlink:to="lab_sclx_TrancheBNote" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TrancheBNote" xml:lang="en-US">Tranche B Note</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value, beginning</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value, ending</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities measured at fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OramedLetterAgreementMember" xlink:label="loc_sclx_OramedLetterAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OramedLetterAgreementMember" xml:lang="en-US">Oramed Letter Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OramedLetterAgreementMember" xml:lang="en-US">Oramed Letter Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OramedLetterAgreementMember" xlink:to="lab_sclx_OramedLetterAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OramedLetterAgreementMember" xml:lang="en-US">Oramed Letter Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">ChangeInValuationInputsOrOtherAssumptions</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in fair value measurement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:to="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ForfeitureOfPrivateWarrants" xlink:to="lab_sclx_ForfeitureOfPrivateWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssuanceOfFirmWarrants" xlink:label="loc_sclx_IssuanceOfFirmWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfFirmWarrants" xml:lang="en-US">Issuance Of Firm Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfFirmWarrants" xml:lang="en-US">Issuance of February 2024 BDO Firm Warrants as part of the February 2024 BDO, April 2024 RDO Common Warrants as part of the April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of the December 2024 RDO, and December 2024 RDO Pre-Funded Warrants as part of the December 2024 RDO</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfFirmWarrants" xlink:to="lab_sclx_IssuanceOfFirmWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfFirmWarrants" xml:lang="en-US">Issuance Of Firm Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:label="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xml:lang="en-US">Reclass of Deposit Warrant Liability upon satisfaction of the FSF Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xml:lang="en-US">Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xml:lang="en-US">Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xlink:to="lab_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" xml:lang="en-US">Reclass of Deposit Warrant Liability Upon Satisfaction Of The FSF Deposit</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xlink:label="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xml:lang="en-US">Firm warrant amendment and exercise as part of the December Registered Direct Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xml:lang="en-US">Warrant amendment and exercise as part of the December 2024 RDO</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xlink:to="lab_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" xml:lang="en-US">Firm warrant amendment and exercise as part of the December Registered Direct Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Settlement of December 2024 RDO Pre-Funded Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value of the Fee Warrant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xml:lang="en-US">Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xml:lang="en-US">Schedule Of Derivative Component Of The Obligation Is Initially Valued And Classified As A Derivative Liability Abstract</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsFiveYearMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DecemberCommonWarrantsFiveYearMember" xml:lang="en-US">December Common Warrants Five Year [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DecemberCommonWarrantsFiveYearMember" xml:lang="en-US">December Common Warrants Five Year [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DecemberCommonWarrantsFiveYearMember" xlink:to="lab_sclx_DecemberCommonWarrantsFiveYearMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DecemberCommonWarrantsFiveYearMember" xml:lang="en-US">December Common Warrants Five Year</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xlink:label="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xml:lang="en-US">December Common Warrants Two Point Five Year [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xml:lang="en-US">December Common Warrants Two Point Five Year [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xlink:to="lab_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DecemberCommonWarrantsTwoPointFiveYearMember" xml:lang="en-US">December Common Warrants Two Point Five Year</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DecemberRDOCommonWarrantsMember" xlink:label="loc_sclx_DecemberRDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DecemberRDOCommonWarrantsMember" xml:lang="en-US">December RDO Common Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DecemberRDOCommonWarrantsMember" xml:lang="en-US">December RDO Common Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DecemberRDOCommonWarrantsMember" xlink:to="lab_sclx_DecemberRDOCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DecemberRDOCommonWarrantsMember" xml:lang="en-US">December RDO Common Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term, in years</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term of options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock -price volatility</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in progress [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers and equipment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional service fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued sales and marketing costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_sclx_AccruedResearchAndDevelopmentCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedResearchAndDevelopmentCosts" xlink:to="lab_sclx_AccruedResearchAndDevelopmentCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xml:lang="en-US">Taxes Payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xml:lang="en-US">Accrued tax payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure" xml:lang="en-US">Accrued litigation expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xml:lang="en-US">Accrued others</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertiblePromissoryNoteMember" xlink:label="loc_sclx_ConvertiblePromissoryNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertiblePromissoryNoteMember" xlink:to="lab_sclx_ConvertiblePromissoryNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LongTermDebtTransactionAxis" xlink:label="loc_sclx_LongTermDebtTransactionAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongTermDebtTransactionAxis" xml:lang="en-US">Long-Term Debt, Transaction [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongTermDebtTransactionAxis" xlink:to="lab_sclx_LongTermDebtTransactionAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongTermDebtTransactionAxis" xml:lang="en-US">Long-Term Debt, Transaction [Axis]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RemainingDrawableBalanceMember" xlink:label="loc_sclx_RemainingDrawableBalanceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RemainingDrawableBalanceMember" xml:lang="en-US">Remaining Drawable Balance [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RemainingDrawableBalanceMember" xml:lang="en-US">Remaining Drawable Balance [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RemainingDrawableBalanceMember" xlink:to="lab_sclx_RemainingDrawableBalanceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RemainingDrawableBalanceMember" xml:lang="en-US">Remaining Drawable Balance [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurCommonStockMember" xlink:label="loc_sclx_SemnurCommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SemnurCommonStockMember" xml:lang="en-US">Semnur Common Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SemnurCommonStockMember" xml:lang="en-US">Semnur Common Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SemnurCommonStockMember" xlink:to="lab_sclx_SemnurCommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SemnurCommonStockMember" xml:lang="en-US">Semnur Common Stock [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xlink:to="lab_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashMember" xml:lang="en-US">Cash [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashMember" xml:lang="en-US">Cash [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Debt accrued interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:to="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred offering costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Price per share (in Dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalUnitsNetAmount" xlink:label="loc_us-gaap_CapitalUnitsNetAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitsNetAmount" xml:lang="en-US">Capital Units, Net Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalUnitsNetAmount" xml:lang="en-US">Net Amount of shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsNetAmount" xlink:to="lab_us-gaap_CapitalUnitsNetAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ImpairmentLoss" xlink:label="loc_sclx_ImpairmentLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ImpairmentLoss" xml:lang="en-US">Impairment Loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ImpairmentLoss" xml:lang="en-US">Impairment Loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ImpairmentLoss" xlink:to="lab_sclx_ImpairmentLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ImpairmentLoss" xml:lang="en-US">Impairment Loss</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssembledWorkforceMember" xlink:to="lab_sclx_AssembledWorkforceMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xlink:label="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xml:lang="en-US">Patent Rights, Acquired Technology and Acquired Licenses [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xml:lang="en-US">Patent Rights Acquired Technology And Acquired Licenses [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xlink:to="lab_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" xml:lang="en-US">Patent Rights, Acquired Technology and Acquired Licenses [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US">Goodwill impairment charges</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite Lived Intangible Asset Useful Life</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Weighted average remaining life for identifiable intangible assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property Plant And Equipment Useful Life</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PatentRightsMember" xlink:to="lab_sclx_PatentRightsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredTechnologyMember" xlink:to="lab_sclx_AcquiredTechnologyMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredLicensesMember" xlink:to="lab_sclx_AcquiredLicensesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangibles, net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xml:lang="en-US">As of March 31,2023</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2026</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2027</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2028</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2029</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Five</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">2029</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:to="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Five</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Four</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xml:lang="en-US">Thereafter</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Four</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">2025 (remainder of 2025)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RodmanRenshawLlcMember" xlink:to="lab_sclx_RodmanRenshawLlcMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ZTlidoRoyaltyMember" xlink:label="loc_sclx_ZTlidoRoyaltyMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ZTlidoRoyaltyMember" xml:lang="en-US">ZTlido Royalty [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ZTlidoRoyaltyMember" xlink:to="lab_sclx_ZTlidoRoyaltyMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ZTlidoRoyaltyMember" xml:lang="en-US">ZTlido Royalty [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Tranche One</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Tranche Two</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Tranche Three</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TrancheBNoteMember" xlink:label="loc_sclx_TrancheBNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheBNoteMember" xml:lang="en-US">Tranche B Note [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheBNoteMember" xlink:to="lab_sclx_TrancheBNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TrancheBNoteMember" xml:lang="en-US">Tranche B Note [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_RoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RoyaltyPurchaseAgreementMember" xml:lang="en-US">Royalty Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RoyaltyPurchaseAgreementMember" xlink:to="lab_sclx_RoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RoyaltyPurchaseAgreementMember" xml:lang="en-US">Royalty Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:label="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba-Elyxyb Royalty Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba-Elyxyb Royalty Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xlink:to="lab_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" xml:lang="en-US">Gloperba-Elyxyb Royalty Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:label="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xml:lang="en-US">Deferral and Consent under Tranche B Senior Secured Convertible Note [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xml:lang="en-US">Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xlink:to="lab_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" xml:lang="en-US">Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">Frist Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">First installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FristInstallmentMember" xlink:to="lab_sclx_FristInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">Frist Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecondInstallmentMember" xlink:to="lab_sclx_SecondInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThirdInstallmentMember" xlink:to="lab_sclx_ThirdInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FourthInstallmentMember" xlink:to="lab_sclx_FourthInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiveInstallmentMember" xlink:to="lab_sclx_FiveInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SixInstallmentMember" xlink:to="lab_sclx_SixInstallmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OctoberCommonWarrantsMember" xlink:label="loc_sclx_OctoberCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OctoberCommonWarrantsMember" xml:lang="en-US">October Common Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OctoberCommonWarrantsMember" xlink:to="lab_sclx_OctoberCommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OctoberCommonWarrantsMember" xml:lang="en-US">October Common Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtPayableAxis" xml:lang="en-US">Debt Payable [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtPayableAxis" xlink:to="lab_sclx_DebtPayableAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtPayableAxis" xml:lang="en-US">Debt Payable [Axis]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtPayableDomain" xml:lang="en-US">Debt Payable [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtPayableDomain" xlink:to="lab_sclx_DebtPayableDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtPayableDomain" xml:lang="en-US">Debt Payable [Domain]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MonthlyBasisMember" xlink:to="lab_sclx_MonthlyBasisMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LoanAmount" xlink:label="loc_sclx_LoanAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LoanAmount" xml:lang="en-US">Loan Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LoanAmount" xml:lang="en-US">Loan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LoanAmount" xlink:to="lab_sclx_LoanAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LoanAmount" xml:lang="en-US">Loan Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DepositWarrantExercisePrice" xlink:label="loc_sclx_DepositWarrantExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositWarrantExercisePrice" xml:lang="en-US">Deposit Warrant Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositWarrantExercisePrice" xml:lang="en-US">Warrant Exercise Price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositWarrantExercisePrice" xlink:to="lab_sclx_DepositWarrantExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositWarrantExercisePrice" xml:lang="en-US">Deposit Warrant Exercise Price</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentAmount" xlink:label="loc_sclx_CommitmentAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentAmount" xml:lang="en-US">Commitment Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommitmentAmount" xml:lang="en-US">Commitment Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentAmount" xlink:to="lab_sclx_CommitmentAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentAmount" xml:lang="en-US">Commitment Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositAmount" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositAmount" xml:lang="en-US">Company receives the FSF Deposit Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositAmount" xml:lang="en-US">Company receives the FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompanyReceivesTheFsfDepositAmount" xlink:to="lab_sclx_CompanyReceivesTheFsfDepositAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositAmount" xml:lang="en-US">Company receives the FSF Deposit Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CompanyReceivesTheFsfDepositPeriod" xlink:label="loc_sclx_CompanyReceivesTheFsfDepositPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositPeriod" xml:lang="en-US">Company Receives The FSF Deposit Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositPeriod" xml:lang="en-US">Company Receives The FSF Deposit Period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompanyReceivesTheFsfDepositPeriod" xlink:to="lab_sclx_CompanyReceivesTheFsfDepositPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompanyReceivesTheFsfDepositPeriod" xml:lang="en-US">Company Receives The FSF Deposit Period</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xml:lang="en-US">Date of Maturity Start</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants execiseable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Aggregate purchase of private placement warrants (in Shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedsReceivedFromPurchaseAgreement" xlink:label="loc_sclx_ProceedsReceivedFromPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsReceivedFromPurchaseAgreement" xml:lang="en-US">Proceeds Received from Purchase Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsReceivedFromPurchaseAgreement" xml:lang="en-US">Proceeds received from purchase agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsReceivedFromPurchaseAgreement" xlink:to="lab_sclx_ProceedsReceivedFromPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsReceivedFromPurchaseAgreement" xml:lang="en-US">Proceeds Received from Purchase Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercised price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price per share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per share, warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xml:lang="en-US">Warrant, Exercise Price, Decrease</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xml:lang="en-US">Warrant, exercise price, decrease</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xml:lang="en-US">Maturity Date End</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt Instrument, Description</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt instrument, description</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescription" xlink:to="lab_us-gaap_DebtInstrumentDescription" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">net cash proceeds</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">Net cash proceeds</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetCashProceeds" xlink:to="lab_sclx_NetCashProceeds" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">net cash proceeds</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Payment to Oramed</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">termination fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">Termination fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TerminationFees" xlink:to="lab_sclx_TerminationFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">termination fees</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Purchase Of Common Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Warrant Purchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Common Warrants Purchase</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfCommonWarrants" xlink:to="lab_sclx_PurchaseOfCommonWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Purchase Of Common Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xml:lang="en-US">Endeavor for Liquidated Damages</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xml:lang="en-US">Cost, Amortization</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xml:lang="en-US">Amortization payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_FederalFundsPurchasedAverageRatePaid" xlink:label="loc_srt_FederalFundsPurchasedAverageRatePaid" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_FederalFundsPurchasedAverageRatePaid" xml:lang="en-US">Federal Funds Purchased, Average Rate Paid</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_FederalFundsPurchasedAverageRatePaid" xml:lang="en-US">Federal funds purchased, average rate paid</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_FederalFundsPurchasedAverageRatePaid" xlink:to="lab_srt_FederalFundsPurchasedAverageRatePaid" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentExitFee" xlink:to="lab_sclx_DebtRepaymentExitFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xml:lang="en-US">Debt Instrument, Repaid, Principal</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xml:lang="en-US">Convertible Debentures Repaid</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="lab_us-gaap_DebtInstrumentRepaidPrincipal" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" xml:lang="en-US">Common Stock at a conversion price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Existing Facility Cap Maximum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Facility cap maximum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExistingFacilityCapMaximum" xlink:to="lab_sclx_ExistingFacilityCapMaximum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Existing Facility Cap Maximum</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Existing Facility Cap Minimum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Facility cap minimum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExistingFacilityCapMinimum" xlink:to="lab_sclx_ExistingFacilityCapMinimum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Existing facility cap minimum</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Debt Instrument Outstanding Principal</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Outstanding debt instrument</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentOutstandingPrincipal" xlink:to="lab_sclx_DebtInstrumentOutstandingPrincipal" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Debt instrument outstanding principal</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Servicing Liability at Fair Value, Other Changes in Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Change in fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Loss in changes in fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt instrument, interest rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt maturity date</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity Date</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPrincipalAmountPercentage" xlink:to="lab_sclx_DebtInstrumentPrincipalAmountPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt payment terms</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesIssuedPercent" xlink:to="lab_sclx_ConvertibleDebenturesIssuedPercent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash on hand</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Redemption Premium</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument, Redemption, Description</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument Redemption</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xml:lang="en-US">Loan, Held-in-Portfolio, Principal Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xml:lang="en-US">Outstanding principal amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xml:lang="en-US">Financing Receivable, Revolving, Converted to Term Loan</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xml:lang="en-US">Accounts receivable revolving loan facility in an aggregate amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:to="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line Of Credit Facility Interest Rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt Instrument, Owned, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt instrument, owned, percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentOwnedPercentage" xlink:to="lab_sclx_DebtInstrumentOwnedPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt Instrument, Owned, Percentage</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt instrument, default interest rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentDefaultInterestRate" xlink:to="lab_sclx_DebtInstrumentDefaultInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt Instrument, Percentage of Interest Accrued on Principal Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt instrument, percentage of interest accrued on principal amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:to="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt Instrument, Percentage of Interest Accrued on Principal Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt repayment, percentage of mandatory default rate of principal amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:to="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt repayment, percentage of mandatory default rate of accrued and unpaid interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:to="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of Usage of Cash Proceeds from Cash Sweep Financing</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of usage of cash proceeds from cash sweep financing</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:to="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of Usage of Cash Proceeds from Cash Sweep Financing</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PaidToRoyaltyInvestors" xlink:label="loc_sclx_PaidToRoyaltyInvestors" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaidToRoyaltyInvestors" xml:lang="en-US">Paid to Royalty Investors</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaidToRoyaltyInvestors" xml:lang="en-US">Paid to royalty investors</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaidToRoyaltyInvestors" xlink:to="lab_sclx_PaidToRoyaltyInvestors" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaidToRoyaltyInvestors" xml:lang="en-US">Paid to Royalty Investors</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaap_PaymentsToAcquireReceivables" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireReceivables" xml:lang="en-US">Payments to Acquire Receivables</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireReceivables" xml:lang="en-US">Amount paid for purchased receivables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireReceivables" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Amount extinguished and reduced</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Purchased Revenue Liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:label="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetailLandSalesReceivablesStatedInterestRate" xml:lang="en-US">Retail Land Sales Receivables, Stated Interest Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetailLandSalesReceivablesStatedInterestRate" xml:lang="en-US">Percentage of aggregate net sales</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetailLandSalesReceivablesStatedInterestRate" xlink:to="lab_us-gaap_RetailLandSalesReceivablesStatedInterestRate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NoOfCalendarDays" xlink:label="loc_sclx_NoOfCalendarDays" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NoOfCalendarDays" xml:lang="en-US">No of Calendar Days</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NoOfCalendarDays" xml:lang="en-US">No of Calendar Days</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_NoOfCalendarDays" xml:lang="en-US">No of calendar days</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NoOfCalendarDays" xlink:to="lab_sclx_NoOfCalendarDays" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NoOfCalendarDays" xml:lang="en-US">No of Calendar Days</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:label="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xml:lang="en-US">Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xml:lang="en-US">Purchase price for the purchased receivables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" xlink:to="lab_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TotalNumberOfSharesGranted" xlink:label="loc_sclx_TotalNumberOfSharesGranted" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TotalNumberOfSharesGranted" xml:lang="en-US">Total Number Of Shares Granted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TotalNumberOfSharesGranted" xml:lang="en-US">Total number of shares granted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_TotalNumberOfSharesGranted" xml:lang="en-US">Total Number of Shares Granted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TotalNumberOfSharesGranted" xlink:to="lab_sclx_TotalNumberOfSharesGranted" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TotalNumberOfSharesGranted" xml:lang="en-US">Total Number of Shares Granted</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesDelivered" xlink:label="loc_sclx_SharesDelivered" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesDelivered" xml:lang="en-US">Shares Delivered</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesDelivered" xml:lang="en-US">Shares Delivered</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SharesDelivered" xml:lang="en-US">Shares delivered</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesDelivered" xlink:to="lab_sclx_SharesDelivered" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesDelivered" xml:lang="en-US">Shares Delivered</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xml:lang="en-US">Convertible Debentures [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debenture</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfConvertibleDebenture" xlink:to="lab_sclx_RepaymentOfConvertibleDebenture" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debenture</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Conversion of Tranche B notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible Debentures</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible debentures</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Oramed Note - recorded in the consolidated statements of operations</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConvertibleDebentures" xlink:to="lab_sclx_ChangeInFairValueOfConvertibleDebentures" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible Debentures</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xml:lang="en-US">Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xml:lang="en-US">Change in fair value due to instrument specific credit risk recorded as a component of other comprehensive income</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FSFLoanMember" xlink:label="loc_sclx_FSFLoanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FSFLoanMember" xml:lang="en-US">FSF Loan [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FSFLoanMember" xlink:to="lab_sclx_FSFLoanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FSFLoanMember" xml:lang="en-US">F S F Loan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaap_Deposits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Deposits" xml:lang="en-US">Deposits</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Deposits" xml:lang="en-US">Beginning Balance as of January 1, 2024</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Deposits" xml:lang="en-US">Ending Balance as of September 30, 2024</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Deposits" xlink:to="lab_us-gaap_Deposits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInDeposits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeposits" xml:lang="en-US">Increase (Decrease) in Deposits</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeposits" xml:lang="en-US">Change in fair value of FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeposits" xlink:to="lab_us-gaap_IncreaseDecreaseInDeposits" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfDeposit" xlink:label="loc_sclx_RepaymentOfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfDeposit" xml:lang="en-US">Repayment of Deposit</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaymentOfDeposit" xml:lang="en-US">Repayment of FSF Deposit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfDeposit" xlink:to="lab_sclx_RepaymentOfDeposit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfDeposit" xml:lang="en-US">Repayment of Deposit</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfTrancheBNotes" xlink:label="loc_sclx_RepaymentOfTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfTrancheBNotes" xml:lang="en-US">Repayment of Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfTrancheBNotes" xlink:to="lab_sclx_RepaymentOfTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfTrancheBNotes" xml:lang="en-US">Repayment of Tranche B Notes</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfTrancheBNotes" xlink:label="loc_sclx_ChangeInFairValueOfTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfTrancheBNotes" xml:lang="en-US">Change in Fair Value of Tranche B Notes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfTrancheBNotes" xml:lang="en-US">Change in fair value of Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfTrancheBNotes" xlink:to="lab_sclx_ChangeInFairValueOfTrancheBNotes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfTrancheBNotes" xml:lang="en-US">Change in Fair Value of Tranche B Notes</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ChangeInFairValueOfPurchasedRevenueLiability" xlink:label="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfPurchasedRevenueLiability" xml:lang="en-US">Change in Fair Value of Purchased Revenue Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfPurchasedRevenueLiability" xml:lang="en-US">Change in fair value of purchased revenue liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfPurchasedRevenueLiability" xlink:to="lab_sclx_ChangeInFairValueOfPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfPurchasedRevenueLiability" xml:lang="en-US">Change in Fair Value of Purchased Revenue Liability</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepaymentOfPurchasedRevenueLiability" xlink:label="loc_sclx_RepaymentOfPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfPurchasedRevenueLiability" xml:lang="en-US">Repayment of purchased revenue liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaymentOfPurchasedRevenueLiability" xml:lang="en-US">Repayment of purchased revenue liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfPurchasedRevenueLiability" xlink:to="lab_sclx_RepaymentOfPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfPurchasedRevenueLiability" xml:lang="en-US">Repayment of purchased revenue liability</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_JuniorDipFacilityMember" xlink:to="lab_sclx_JuniorDipFacilityMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Sorrento Stock Purchase Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Sorrento Stock Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockPurchaseAgreementMember" xlink:to="lab_sclx_StockPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClosingPennyWarrantMember" xml:lang="en-US">Closing Penny Warrant [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ClosingPennyWarrantMember" xml:lang="en-US">Closing Penny Warrant [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClosingPennyWarrantMember" xlink:to="lab_sclx_ClosingPennyWarrantMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClosingPennyWarrantMember" xml:lang="en-US">Closing Penny Warrant [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrantsMember" xml:lang="en-US">Subsequent Penny Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubsequentPennyWarrantsMember" xml:lang="en-US">Subsequent Penny Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrantsMember" xlink:to="lab_sclx_SubsequentPennyWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrantsMember" xml:lang="en-US">Subsequent Penny Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PennyWarrantsMember" xml:lang="en-US">Penny Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PennyWarrantsMember" xml:lang="en-US">Penny Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PennyWarrantsMember" xlink:to="lab_sclx_PennyWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PennyWarrantsMember" xml:lang="en-US">Penny Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants2Member" xml:lang="en-US">Subsequent Penny Warrants 2 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubsequentPennyWarrants2Member" xml:lang="en-US">Subsequent Penny Warrants 2 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants2Member" xlink:to="lab_sclx_SubsequentPennyWarrants2Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants2Member" xml:lang="en-US">Subsequent Penny Warrants 2 [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants3Member" xml:lang="en-US">Subsequent Penny Warrants 3 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubsequentPennyWarrants3Member" xml:lang="en-US">Subsequent Penny Warrants 3 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants3Member" xlink:to="lab_sclx_SubsequentPennyWarrants3Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants3Member" xml:lang="en-US">Subsequent Penny Warrants 3 [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants4Member" xml:lang="en-US">Subsequent Penny Warrants 4 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubsequentPennyWarrants4Member" xml:lang="en-US">Subsequent Penny Warrants 4 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants4Member" xlink:to="lab_sclx_SubsequentPennyWarrants4Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants4Member" xml:lang="en-US">Subsequent Penny Warrants 4 [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SubsequentPennyWarrants5Member" xlink:label="loc_sclx_SubsequentPennyWarrants5Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants5Member" xml:lang="en-US">Subsequent Penny Warrants 5 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubsequentPennyWarrants5Member" xml:lang="en-US">Subsequent Penny Warrants 5 [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants5Member" xlink:to="lab_sclx_SubsequentPennyWarrants5Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants5Member" xml:lang="en-US">Subsequent Penny Warrants 5 [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivateWarrantsMember" xlink:to="lab_sclx_PrivateWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantsMember" xlink:to="lab_sclx_PublicWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Exit fee</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of Warrants to Purchase Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssueOfWarrantsToPurchaseShares" xlink:to="lab_sclx_IssueOfWarrantsToPurchaseShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of Warrants to Purchase Shares</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfShareOutstanding" xlink:to="lab_sclx_NumberOfShareOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransferOfWarrants" xlink:to="lab_sclx_TransferOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal fees and expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CashPayment" xlink:to="lab_sclx_CashPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair value of Shares Repurchased</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair Value of stock repurchased</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfSharesRepurchased" xlink:to="lab_sclx_FairValueOfSharesRepurchased" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair value of Shares Repurchased</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfWarrants" xlink:to="lab_sclx_FairValueOfWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Warrants exercisable date</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant Vesting Date</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant vesting date</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantVestingDate" xlink:to="lab_sclx_WarrantVestingDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant Vesting Date</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Excise tax liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xml:lang="en-US">Accrued Liabilities for Commissions, Expense and Taxes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xml:lang="en-US">Accured expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xml:lang="en-US">Accrued Liabilities for Commissions, Expense and Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:to="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PennyWarrantsExercised" xlink:label="loc_sclx_PennyWarrantsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PennyWarrantsExercised" xml:lang="en-US">Penny Warrants exercised</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PennyWarrantsExercised" xml:lang="en-US">Penny Warrants exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PennyWarrantsExercised" xlink:to="lab_sclx_PennyWarrantsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PennyWarrantsExercised" xml:lang="en-US">Penny Warrants exercised</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from warrant exercises</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareholdersEquityDetailsTable" xml:lang="en-US">Shareholders' Equity (Details) [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareholdersEquityDetailsTable" xlink:to="lab_sclx_ShareholdersEquityDetailsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareholdersEquityDetailsTable" xml:lang="en-US">Shareholders Equity Details Table</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SpacWarrantsMember" xlink:label="loc_sclx_SpacWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SpacWarrantsMember" xml:lang="en-US">SPAC Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SpacWarrantsMember" xml:lang="en-US">SPAC Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SpacWarrantsMember" xlink:to="lab_sclx_SpacWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SpacWarrantsMember" xml:lang="en-US">SPAC Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonWarrantsMember" xlink:label="loc_sclx_CommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonWarrantsMember" xml:lang="en-US">Common Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonWarrantsMember" xml:lang="en-US">Common Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonWarrantsMember" xlink:to="lab_sclx_CommonWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonWarrantsMember" xml:lang="en-US">Common Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PlacementAgentWarrantsMember" xlink:label="loc_sclx_PlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PlacementAgentWarrantsMember" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PlacementAgentWarrantsMember" xml:lang="en-US">Placement Agent Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PlacementAgentWarrantsMember" xlink:to="lab_sclx_PlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PlacementAgentWarrantsMember" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicWarrantsPurchaseCommonStockMember" xlink:label="loc_sclx_PublicWarrantsPurchaseCommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantsPurchaseCommonStockMember" xml:lang="en-US">Public Warrants Purchase Common Stock[Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantsPurchaseCommonStockMember" xml:lang="en-US">Public Warrants Purchase Common Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantsPurchaseCommonStockMember" xlink:to="lab_sclx_PublicWarrantsPurchaseCommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicWarrantsPurchaseCommonStockMember" xml:lang="en-US">Public Warrants Purchase Common Stock[Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RepresentativeWarrantsOutstandingMember" xlink:label="loc_sclx_RepresentativeWarrantsOutstandingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepresentativeWarrantsOutstandingMember" xml:lang="en-US">Representative Warrants Outstanding[Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepresentativeWarrantsOutstandingMember" xml:lang="en-US">Representative Warrants Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepresentativeWarrantsOutstandingMember" xlink:to="lab_sclx_RepresentativeWarrantsOutstandingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepresentativeWarrantsOutstandingMember" xml:lang="en-US">Representative Warrants Outstanding[Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FirmWarrantsMember" xlink:label="loc_sclx_FirmWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FirmWarrantsMember" xml:lang="en-US">Firm Warrants[Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FirmWarrantsMember" xml:lang="en-US">Firm Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FirmWarrantsMember" xlink:to="lab_sclx_FirmWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FirmWarrantsMember" xml:lang="en-US">Firm Warrants[Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RegisteredDirectOfferingMember" xlink:label="loc_sclx_RegisteredDirectOfferingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered Direct Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RegisteredDirectOfferingMember" xlink:to="lab_sclx_RegisteredDirectOfferingMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RegisteredDirectOfferingMember" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantTransferAgreementMember" xlink:to="lab_sclx_WarrantTransferAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B Riley Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B. Riley Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BRileyPurchaseAgreementMember" xlink:to="lab_sclx_BRileyPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B Riley Purchase Agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market Sales Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market Sales Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AtTheMarketSalesAgreementMember" xlink:to="lab_sclx_AtTheMarketSalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market Sales Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_HudsonBayMember" xlink:to="lab_sclx_HudsonBayMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoveLaneMember" xlink:to="lab_sclx_CoveLaneMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title and Position [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title and Position [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockBlockWarrantsMember" xlink:label="loc_sclx_StockBlockWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockBlockWarrantsMember" xml:lang="en-US">StockBlock Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_StockBlockWarrantsMember" xml:lang="en-US">StockBlock Warrants [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockBlockWarrantsMember" xlink:to="lab_sclx_StockBlockWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockBlockWarrantsMember" xml:lang="en-US">StockBlock Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareholdersEquityDetailsLineItems" xml:lang="en-US">Shareholders' Equity (Details) [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems" xlink:to="lab_sclx_ShareholdersEquityDetailsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareholdersEquityDetailsLineItems" xml:lang="en-US">Shareholders Equity Details Line Items</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfStockPercentage" xlink:to="lab_sclx_PurchaseOfStockPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockSold" xlink:to="lab_sclx_CommonStockSold" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payments of Dividends</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payment made to Investor</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number sale of common stock shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceed's of sale of common shares percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceed's of sale of common shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:to="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceed s of sale of common shares percentage</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="loc_us-gaap_PreferredStockDividendsShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsShares" xml:lang="en-US">Preferred Stock Dividends, Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendsShares" xml:lang="en-US">Preferred Stock Dividends, Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsShares" xlink:to="lab_us-gaap_PreferredStockDividendsShares" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareDeclared" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareDeclared" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_PreferredStockDividendsPerShareDeclared" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Trading Days</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CombinedPricePaidOfWarrant" xlink:to="lab_sclx_CombinedPricePaidOfWarrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPrice" xlink:to="lab_sclx_PublicOfferingPrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise Price Of Common Warrant</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise price of warrant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExercisePriceOfCommonWarrant" xlink:to="lab_sclx_ExercisePriceOfCommonWarrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise Price Of Common Warrant</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock shares reserved for future issuance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Public Offering Price Combined</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Public Offering Price Combined</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPriceCombined" xlink:to="lab_sclx_PublicOfferingPriceCombined" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Public Offering Price Combined</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantsToPurchase" xlink:label="loc_sclx_PreFundedWarrantsToPurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PreFundedWarrantsToPurchase" xml:lang="en-US">Pre Funded Warrants to Purchase</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PreFundedWarrantsToPurchase" xml:lang="en-US">Pre-funded warrants to purchase</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PreFundedWarrantsToPurchase" xlink:to="lab_sclx_PreFundedWarrantsToPurchase" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PreFundedWarrantsToPurchase" xml:lang="en-US">Pre Funded Warrants to Purchase</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PreFundedWarrantPerShare" xlink:label="loc_sclx_PreFundedWarrantPerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PreFundedWarrantPerShare" xml:lang="en-US">Pre Funded Warrant Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PreFundedWarrantPerShare" xml:lang="en-US">Pre funded warrant per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PreFundedWarrantPerShare" xlink:to="lab_sclx_PreFundedWarrantPerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PreFundedWarrantPerShare" xml:lang="en-US">Pre Funded Warrant Per Share</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xlink:label="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xml:lang="en-US">Cash Fee Percentage of Gross Proceeds Paid to Placement Agents</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xml:lang="en-US">Cash fee percentage of gross proceeds paid to placement agents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xlink:to="lab_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" xml:lang="en-US">Cash Fee Percentage of Gross Proceeds Paid to Placement Agents</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ClearingExpenses" xlink:label="loc_sclx_ClearingExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClearingExpenses" xml:lang="en-US">Clearing Expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ClearingExpenses" xml:lang="en-US">Clearing expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClearingExpenses" xlink:to="lab_sclx_ClearingExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClearingExpenses" xml:lang="en-US">Clearing Expenses</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xlink:label="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xml:lang="en-US">Percent of Total Number of Shares Issued to Agents in the Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xml:lang="en-US">Percent of total number of shares issued to agents in the Offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xlink:to="lab_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" xml:lang="en-US">Percent of Total Number of Shares issued to Agents in the Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_PercentOfCombinedOfferingExercisePricePerShare" xlink:label="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentOfCombinedOfferingExercisePricePerShare" xml:lang="en-US">Percent of Combined Offering Exercise Price Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentOfCombinedOfferingExercisePricePerShare" xml:lang="en-US">Percent of combined offering exercise price per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentOfCombinedOfferingExercisePricePerShare" xlink:to="lab_sclx_PercentOfCombinedOfferingExercisePricePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentOfCombinedOfferingExercisePricePerShare" xml:lang="en-US">Percent of Combined Offering Exercise Price Per Share</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AggregateGrossProceedsFromOffering" xlink:label="loc_sclx_AggregateGrossProceedsFromOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregateGrossProceedsFromOffering" xml:lang="en-US">Aggregate Gross Proceeds From Offering</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregateGrossProceedsFromOffering" xml:lang="en-US">Gross proceeds from offering</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregateGrossProceedsFromOffering" xlink:to="lab_sclx_AggregateGrossProceedsFromOffering" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregateGrossProceedsFromOffering" xml:lang="en-US">Aggregate Gross Proceeds From Offering</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised" xlink:label="loc_sclx_NumberOfWarrantsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfWarrantsExercised" xlink:to="lab_sclx_NumberOfWarrantsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NumberOfWarrantsExercised1" xlink:label="loc_sclx_NumberOfWarrantsExercised1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfWarrantsExercised1" xml:lang="en-US">Number Of Warrants Exercised 1</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfWarrantsExercised1" xml:lang="en-US">Number Of Warrants Exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfWarrantsExercised1" xlink:to="lab_sclx_NumberOfWarrantsExercised1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfWarrantsExercised1" xml:lang="en-US">Number Of Warrants Exercised 1</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding, Beginning Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding, Ending Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of option outstanding to purchase common stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options Outstanding, Granted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options Outstanding, Forfeited/Cancelled</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Vested and expected to vest as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options Outstanding, Exercisable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price,Vested and expected to vest as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding, Weighted-average Remaining Contractual Life, (in Years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Life, in year,Vested and expected to vest as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Exercisable, Weighted-average Remaining Contractual Life, (in Years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value ,Vested and expected to vest as of March 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BlackScholesOptionPricingMethodMember" xml:lang="en-US">Black-Scholes Option Pricing Method [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BlackScholesOptionPricingMethodMember" xlink:to="lab_sclx_BlackScholesOptionPricingMethodMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BlackScholesOptionPricingMethodMember" xml:lang="en-US">Black-Scholes Option Pricing Method</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Stock Option [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EmployeeStockPurchasePlanMember" xlink:to="lab_sclx_EmployeeStockPurchasePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">2022 Equity Incentive Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_Semnur2024StockOptionPlanMember" xlink:label="loc_sclx_Semnur2024StockOptionPlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Semnur2024StockOptionPlanMember" xml:lang="en-US">Semnur 2024 Stock Option Plan [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Semnur2024StockOptionPlanMember" xml:lang="en-US">Semnur 2024 Stock Option Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Semnur2024StockOptionPlanMember" xlink:to="lab_sclx_Semnur2024StockOptionPlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Semnur2024StockOptionPlanMember" xml:lang="en-US">Semnur 2024 Stock Option Plan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">Two Thousand Twenty Three Inducement Plan [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">2023 Inducement Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:to="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">Two Thousand Twenty Three Inducement Plan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand Twenty Two Employee Stock Purchase Plan [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">2022 Employee Stock Purchase Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:to="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand Twenty Two Employee Stock Purchase Plan [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Purchase price of the common stock percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of shares available for grant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Options granted weighted-average grant date fair value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of option exercise</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized compensation cost related to unvested stock option grants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Employee benefit plan contributions by employer</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued legal fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WeightedAveragePeriodOverGrant" xml:lang="en-US">Weighted average period over grant</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WeightedAveragePeriodOverGrant" xml:lang="en-US">Weighted average period over grant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WeightedAveragePeriodOverGrant" xlink:to="lab_sclx_WeightedAveragePeriodOverGrant" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WeightedAveragePeriodOverGrant" xml:lang="en-US">Weighted average period over grant</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows from operating leases (in thousands)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term in years - operating leases</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate - operating leases</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2026</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2027</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2027</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="loc_sclx_LeaseLiabilityNetOfCurrentPortion" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LeaseLiabilityNetOfCurrentPortion" xlink:to="lab_sclx_LeaseLiabilityNetOfCurrentPortion" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2025 (Remainder of 2025)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsAndContingenciesTable" xlink:to="lab_sclx_CommitmentsAndContingenciesTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProductDevelopmentAgreementMember" xlink:to="lab_sclx_ProductDevelopmentAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCancelableLeaseAgreementsMember" xml:lang="en-US">Non-cancelable Lease Agreements [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCancelableLeaseAgreementsMember" xml:lang="en-US">Non-cancelable Lease Agreements [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCancelableLeaseAgreementsMember" xlink:to="lab_sclx_NonCancelableLeaseAgreementsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCancelableLeaseAgreementsMember" xml:lang="en-US">Non-cancelable Lease Agreements [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EpoladermMember" xml:lang="en-US">Epoladerm [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EpoladermMember" xlink:to="lab_sclx_EpoladermMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EpoladermMember" xml:lang="en-US">Epoladerm Member</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProbudurMember" xml:lang="en-US">Probudur [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProbudurMember" xlink:to="lab_sclx_ProbudurMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProbudurMember" xml:lang="en-US">Probudur Member</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EnveltaMember" xml:lang="en-US">Envelta [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EnveltaMember" xlink:to="lab_sclx_EnveltaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EnveltaMember" xml:lang="en-US">Envelta Member</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DevelopersMember" xml:lang="en-US">Developers [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DevelopersMember" xml:lang="en-US">Developers [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DevelopersMember" xlink:to="lab_sclx_DevelopersMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DevelopersMember" xml:lang="en-US">Developers [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GloperbaMember" xml:lang="en-US">GLOPERBA [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GloperbaMember" xlink:to="lab_sclx_GloperbaMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GloperbaMember" xml:lang="en-US">GLOPERBA [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormerEmployeeMember" xml:lang="en-US">Former Employee [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormerEmployeeMember" xlink:to="lab_sclx_FormerEmployeeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormerEmployeeMember" xml:lang="en-US">Former Employee [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormerEmployeeOneMember" xml:lang="en-US">Former Employee One[Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormerEmployeeOneMember" xlink:to="lab_sclx_FormerEmployeeOneMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormerEmployeeOneMember" xml:lang="en-US">Former Employee One[Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ResearchAndDevelopmentFacilitiesMember" xml:lang="en-US">Research and Development Facilities [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ResearchAndDevelopmentFacilitiesMember" xml:lang="en-US">Research and Development Facilities [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ResearchAndDevelopmentFacilitiesMember" xlink:to="lab_sclx_ResearchAndDevelopmentFacilitiesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ResearchAndDevelopmentFacilitiesMember" xml:lang="en-US">Research and Development Facilities [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems" xlink:to="lab_sclx_CommitmentsAndContingenciesLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty Payment Percentage Related To Future Years</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty payment percentage related to future years</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:to="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty Payment Percentage Related To Future Years</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Fee Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Agreement settlement payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Royalty Payment Percentage On Net Sale</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Percentage on net sale</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RoyaltyPaymentPercentageOnNetSale" xlink:to="lab_sclx_RoyaltyPaymentPercentageOnNetSale" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Royalty Payment Percentage On Net Sale</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US">Accrued royalty payables</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement Maturity Date</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement maturity date</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementMaturityDate" xlink:to="lab_sclx_AgreementMaturityDate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement Maturity Date</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Maturity Renewal Description</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Agreement maturity renewal description</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaturityRenewalDescription" xlink:to="lab_sclx_MaturityRenewalDescription" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Maturity Renewal Description</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DueFromRelatedParty" xml:lang="en-US">Due From Related Party</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DueFromRelatedParty" xml:lang="en-US">Due From Related Party</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DueFromRelatedParty" xlink:to="lab_sclx_DueFromRelatedParty" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DueFromRelatedParty" xml:lang="en-US">Due From Related Party</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease, remaining lease term</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Operating lease, lease term</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance lease liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Lease Expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred income tax benefit:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Changes in tax rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Changes in valuation allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_sclx_DeferredTaxAssetsDebtRelatedInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Deferred Tax Assets, Debt Related Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Debt related interest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:to="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Deferred tax assets, debt related interest.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized research and development</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock based compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Deferred Tax Assets, Accrued Expense and Reserves</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Accrued expense and reserves</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:to="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Deferred tax assets, accrued expense and reserves.</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsPurchasedRevenueLiability" xlink:label="loc_sclx_DeferredTaxAssetsPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsPurchasedRevenueLiability" xml:lang="en-US">Deferred Tax Assets Purchased Revenue Liability</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsPurchasedRevenueLiability" xml:lang="en-US">Purchased revenue liability</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsPurchasedRevenueLiability" xlink:to="lab_sclx_DeferredTaxAssetsPurchasedRevenueLiability" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsPurchasedRevenueLiability" xml:lang="en-US">Deferred Tax Assets Purchased Revenue Liability</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less valuation allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Intangible assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Operating lease right-of-use assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at federal statutory rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xlink:label="loc_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income Tax Reconciliation Valuation Allowance At Federal Statutory Income Tax Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Valuation allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xlink:to="lab_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax reconciliation valuation allowance at federal statutory income tax rate.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Income Tax Reconciliation Acquisition Related Charges</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Acquisition related charges</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:to="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Income tax reconciliation acquisition related charges.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Prior year true-up and carryback</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State, net of federal tax benefit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Change in fair value of Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Change in tax rates</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Beginning Balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Ending Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increase related to prior year tax positions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increase related to current year tax positions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research and Development Income Tax Credits [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems" xlink:to="lab_sclx_IncomeTaxDisclosureLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite Operating Loss Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite net federal operating loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndefiniteOperatingLossCarryforwards" xlink:to="lab_sclx_IndefiniteOperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite Operating Loss Carryforwards</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards, expiration year</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_sclx_OperatingLossCarryforwardsExpirationYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development income tax credits</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax Credit Carryforward, Not Subject to Expire, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax credit, not subject to expire</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:to="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax Credit Carryforward, Not Subject to Expire, Amount</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income Tax Credits Expiration Year</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income tax credits, expiration year</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxCreditsExpirationYear" xlink:to="lab_sclx_IncomeTaxCreditsExpirationYear" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income Tax Credits Expiration Year</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income tax expense, interest and penalties</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liabilities for uncertain tax positions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="loc_us-gaap_PreferredStockRedemptionPremium" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPremium" xml:lang="en-US">Preferred Stock Redemption Premium</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPremium" xml:lang="en-US">Premium on redemption of Series A Preferred Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPremium" xlink:to="lab_us-gaap_PreferredStockRedemptionPremium" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss for basic and diluted loss per share available to common stockholders</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Reversal of mark-to-market adjustment for liability classified warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss for diluted loss per share available to common stockholders</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAverageNumberOfSharesOutstanding" xlink:label="loc_sclx_WeightedAverageNumberOfSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WeightedAverageNumberOfSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WeightedAverageNumberOfSharesOutstanding" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WeightedAverageNumberOfSharesOutstanding" xlink:to="lab_sclx_WeightedAverageNumberOfSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WeightedAverageNumberOfSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xlink:label="loc_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xml:lang="en-US">Weighted Average Common Stock Warrants Exercisable, Nominal Consideration</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xml:lang="en-US">Weighted average common stock warrants exercisable for nominal consideration</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xlink:to="lab_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" xml:lang="en-US">Weighted average common stock warrants exercisable for nominal consideration</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="loc_sclx_EffectOfDilutiveSecurities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of dilutive securities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectOfDilutiveSecurities" xlink:to="lab_sclx_EffectOfDilutiveSecurities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockOptionsMember" xlink:to="lab_sclx_StockOptionsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDOFirmWarrantMember" xlink:label="loc_sclx_February2024BDOFirmWarrantMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_February2024BDOFirmWarrantMember" xml:lang="en-US">February 2024 BDO Firm Warrant</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_February2024BDOFirmWarrantMember" xlink:to="lab_sclx_February2024BDOFirmWarrantMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_February2024BDOFirmWarrantMember" xml:lang="en-US">February 2024 BDO Firm Warrant [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_April2024RDOPlacementAgentWarrantsMember" xlink:label="loc_sclx_April2024RDOPlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_April2024RDOPlacementAgentWarrantsMember" xml:lang="en-US">April 2024 RDO Placement Agent Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_April2024RDOPlacementAgentWarrantsMember" xml:lang="en-US">April 2024 RDO Placement Agent Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_April2024RDOPlacementAgentWarrantsMember" xlink:to="lab_sclx_April2024RDOPlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_April2024RDOPlacementAgentWarrantsMember" xml:lang="en-US">April 2024 RDO Placement Agent Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesMember" xlink:to="lab_sclx_RetainerSharesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_February2024BDORepresentativeWarrantsMember" xlink:label="loc_sclx_February2024BDORepresentativeWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_February2024BDORepresentativeWarrantsMember" xml:lang="en-US">February 2024 BDO Representative Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_February2024BDORepresentativeWarrantsMember" xlink:to="lab_sclx_February2024BDORepresentativeWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_February2024BDORepresentativeWarrantsMember" xml:lang="en-US">February 2024 BDO Representative Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares Issuable pursuant to ESPP [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares issuable pursuant to ESPP</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuablePursuantToEsppMember" xlink:to="lab_sclx_SharesIssuablePursuantToEsppMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares Issuable pursuant to ESPP [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xlink:label="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Shares Issuable Under Sponsor Interest Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Shares issuable under the SIPA</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xlink:to="lab_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" xml:lang="en-US">Shares Issuable Under Sponsor Interest Purchase Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesMember" xlink:to="lab_sclx_ConvertibleDebenturesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_October2024PlacementAgentWarrantsMember" xlink:label="loc_sclx_October2024PlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_October2024PlacementAgentWarrantsMember" xml:lang="en-US">October 2024 Placement Agent Warrants [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_October2024PlacementAgentWarrantsMember" xml:lang="en-US">October 2024 Placement Agent Warrants</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_October2024PlacementAgentWarrantsMember" xlink:to="lab_sclx_October2024PlacementAgentWarrantsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_October2024PlacementAgentWarrantsMember" xml:lang="en-US">October 2024 Placement Agent Warrants [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesIssuableUnderTrancheBNotesMember" xlink:label="loc_sclx_SharesIssuableUnderTrancheBNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuableUnderTrancheBNotesMember" xml:lang="en-US">Shares issuable under Tranche B Notes [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuableUnderTrancheBNotesMember" xml:lang="en-US">Shares issuable under Tranche B Notes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuableUnderTrancheBNotesMember" xlink:to="lab_sclx_SharesIssuableUnderTrancheBNotesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuableUnderTrancheBNotesMember" xml:lang="en-US">Shares issuable under Tranche B Notes [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:to="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ThreeILpMember" xlink:label="loc_sclx_ThreeILpMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThreeILpMember" xml:lang="en-US">Three i LP [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThreeILpMember" xml:lang="en-US">Three i LP [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThreeILpMember" xlink:to="lab_sclx_ThreeILpMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThreeILpMember" xml:lang="en-US">Three i LP [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_BpyLimitedMember" xlink:label="loc_sclx_BpyLimitedMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BpyLimitedMember" xml:lang="en-US">BPY Limited [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BpyLimitedMember" xml:lang="en-US">BPY Limited [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BpyLimitedMember" xlink:to="lab_sclx_BpyLimitedMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BpyLimitedMember" xml:lang="en-US">BPY Limited [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_NomisBayLtdMember" xlink:label="loc_sclx_NomisBayLtdMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NomisBayLtdMember" xml:lang="en-US">Nomis Bay Ltd [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NomisBayLtdMember" xml:lang="en-US">Nomis Bay Ltd [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NomisBayLtdMember" xlink:to="lab_sclx_NomisBayLtdMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NomisBayLtdMember" xml:lang="en-US">Nomis Bay Ltd [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_ScilexBioJVMember" xlink:label="loc_sclx_ScilexBioJVMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexBioJVMember" xml:lang="en-US">Scilex Bio JV [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexBioJVMember" xml:lang="en-US">Scilex Bio JV</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexBioJVMember" xlink:to="lab_sclx_ScilexBioJVMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexBioJVMember" xml:lang="en-US">Scilex Bio JV [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
          <link:loc xlink:type="locator" xlink:href="sclx-20250801.xsd#sclx_OwnershipInterestRate" xlink:label="loc_sclx_OwnershipInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OwnershipInterestRate" xml:lang="en-US">Ownership Interest Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OwnershipInterestRate" xml:lang="en-US">Ownership Interest Rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OwnershipInterestRate" xlink:to="lab_sclx_OwnershipInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OwnershipInterestRate" xml:lang="en-US">Ownership Interest Rate</link:label>
        </link:labelLink>
      </link:linkbase>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <element name="SeriesOnePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SeriesOnePreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CurrentPortionOfDeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CurrentPortionOfDeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PurchasedRevenueLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchasedRevenueLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="LongTermPortionOfDeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongTermPortionOfDeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PurchasedRevenueLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchasedRevenueLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="AdditionalPaidsInCapitals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AdditionalPaidsInCapitals" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PreferredStockDividendShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PreferredStockDividendShares" substitutionGroup="xbrli:item" />
  <element name="CommonStocksSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommonStocksSharesOutstanding" substitutionGroup="xbrli:item" />
  <element name="CommonStocksSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommonStocksSharesIssued" substitutionGroup="xbrli:item" />
  <element name="ChangeInFairValueOfDebtAndLiabilityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="TreasuryShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryShareMember" substitutionGroup="xbrli:item" />
  <element name="SharesIssuedUnderStandbyEquityPurchaseAgreements" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" substitutionGroup="xbrli:item" />
  <element name="ValueIssuedUnderStandbyEquityPurchaseAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DisbursementOfFundsToSorrentoAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DisbursementOfFundsToSorrentoAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" substitutionGroup="xbrli:item" />
  <element name="StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IssuanceOfPennyWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfPennyWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ConversionOfConvertibleDebenturesIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" substitutionGroup="xbrli:item" />
  <element name="ConversionOfConvertibleDebenturesIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RetainerSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesIssued" substitutionGroup="xbrli:item" />
  <element name="RetainerSharesIssuedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesIssuedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IssuanceOfCommonStockUponWarrantsExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" substitutionGroup="xbrli:item" />
  <element name="IssuanceOfCommonStockUponWarrantsExerciseValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement" substitutionGroup="xbrli:item" />
  <element name="SharesIssuedUnderBoughtDealOfferingShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderBoughtDealOfferingShare" substitutionGroup="xbrli:item" />
  <element name="SharesIssuedUnderBoughtDealOfferingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderBoughtDealOfferingValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SharesIssuedDuringPeriodSharesRegisteredDirectOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering" substitutionGroup="xbrli:item" />
  <element name="SharesIssuedDuringPeriodValuesRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="FeeWarrantIssuedInConnectionWithTheCommitmentLetter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RepurchaseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepurchaseOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CommonStockIssuableUnderSponsorInterestPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares" substitutionGroup="xbrli:item" />
  <element name="PlacementAgentSharesAndOctoberPlacementAgentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ConversionOfTrancheBNotesIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfTrancheBNotesIntoCommonStockShares" substitutionGroup="xbrli:item" />
  <element name="ConversionOfTrancheBNotesIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfTrancheBNotesIntoCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SharesIssuedUnderDecemberRegisteredDirectOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares" substitutionGroup="xbrli:item" />
  <element name="SharesIssuedUnderDecemberRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderDecemberRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="StockDividendDeclaredNotYetDistributedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockDividendDeclaredNotYetDistributedShares" substitutionGroup="xbrli:item" />
  <element name="StockDividendDeclaredNotYetDistributed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockDividendDeclaredNotYetDistributed" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares" substitutionGroup="xbrli:item" />
  <element name="TreasuryStockPaidForGloperbaEx-USLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryStockPaidForGloperbaEx-USLicense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares" substitutionGroup="xbrli:item" />
  <element name="TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares" substitutionGroup="xbrli:item" />
  <element name="NonCashOperatingLeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashOperatingLeaseCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AllowancesForCreditLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AllowancesForCreditLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncreaseDecreaseInAccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseDecreaseInAccruedPayroll" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncreaseDecreaseInAccruedRebatesAndFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseDecreaseInAccruedRebatesAndFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="OtherLongTermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherLongTermLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="OperatingLeaseLiability1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingLeaseLiability1" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PurchaseOfEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseOfEquitySecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PurchaseOfConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseOfConvertiblePromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ProceedsFromIssuanceOfRevolvingFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromIssuanceOfRevolvingFacility" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ProceedsFromIssuanceOfFsfDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromIssuanceOfFsfDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RepaymentOfRevolvingFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfRevolvingFacility" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="TransactionCostsPaidRelatedToTheRecapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RepaymentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DisbursementOfFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DisbursementOfFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="TransactionCostsPaidInConnectionWithShareRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsPaidInConnectionWithShareRepurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ExciseTaxPaidInConnectionWithShareRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExciseTaxPaidInConnectionWithShareRepurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SettlementOfFSFDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SettlementOfFSFDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ConversionOfOramedNoteIntoTrancheBNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfOramedNoteIntoTrancheBNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DebtIssuanceCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtIssuanceCostsIncludedInAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ConversionOfConvertibleDebenturesIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="OramedNoteIssuanceAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OramedNoteIssuanceAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="OtherNonCashConsiderationInConnectionWithShareRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="PurchasedRevenueLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PurchasedRevenueLiabilityPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="TreasuryStockPolicyTextblock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryStockPolicyTextblock" substitutionGroup="xbrli:item" />
  <element name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ReverseStockSplitPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="AccruedExpensesTextblock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AccruedExpensesTextblock" substitutionGroup="xbrli:item" />
  <element name="TrancheBNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheBNotesMember" substitutionGroup="xbrli:item" />
  <element name="ScheduleOfTheOramedNoteTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfTheOramedNoteTableTextBlock" substitutionGroup="xbrli:item" />
  <element name="SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit" substitutionGroup="xbrli:item" />
  <element name="ScheduleOfTrancheBNotesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfTrancheBNotesTableTextBlock" substitutionGroup="xbrli:item" />
  <element name="ScheduleOfRevenueLiabilityActivityTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock" substitutionGroup="xbrli:item" />
  <element name="ScheduleOfTheTrancheBNoteTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfTheTrancheBNoteTableTextBlock" substitutionGroup="xbrli:item" />
  <element name="DescriptionofOrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="SorrentoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SorrentoMember" substitutionGroup="xbrli:item" />
  <element name="ThreeCustomersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ThreeCustomersMember" substitutionGroup="xbrli:item" />
  <element name="DescriptionofOrganizationandBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" substitutionGroup="xbrli:item" />
  <element name="ConcentrationRiskThresholdPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConcentrationRiskThresholdPercentage" substitutionGroup="xbrli:item" />
  <element name="PercentageOfNetRevenueSoleDistributors" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfNetRevenueSoleDistributors" substitutionGroup="xbrli:item" />
  <element name="AllowancesForPromptPaymentDiscounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AllowancesForPromptPaymentDiscounts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="LiquidityAndGoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="InitialClosingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InitialClosingMember" substitutionGroup="xbrli:item" />
  <element name="SecondClosingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SecondClosingMember" substitutionGroup="xbrli:item" />
  <element name="OramedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_OramedMember" substitutionGroup="xbrli:item" />
  <element name="LongTermDebtTransactionsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LongTermDebtTransactionsAxis" substitutionGroup="xbrldt:dimensionItem" />
  <element name="LongTermDebtTransactionDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LongTermDebtTransactionDomain" substitutionGroup="xbrli:item" />
  <element name="PrincipalBalanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrincipalBalanceMember" substitutionGroup="xbrli:item" />
  <element name="SeniorSecuredConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SeniorSecuredConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="SatisfactionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SatisfactionAgreementMember" substitutionGroup="xbrli:item" />
  <element name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SecuritiesPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="InvestorAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InvestorAgreementMember" substitutionGroup="xbrli:item" />
  <element name="PurchaseAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseAgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
  <element name="PurchaseAgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseAgreementDomain" substitutionGroup="xbrli:item" />
  <element name="ARYorkvillePurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ARYorkvillePurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AtmSalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AtmSalesAgreementMember" substitutionGroup="xbrli:item" />
  <element name="DepositWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DepositWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernLineItems" substitutionGroup="xbrli:item" />
  <element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="Convertibledebentureprincipalamount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Convertibledebentureprincipalamount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PrincipalLaonAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PrincipalLaonAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CommitmentAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentAmountPayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="CompanyReceivesTheDepositAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CompanyReceivesTheDepositAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CompanyReceivesTheDepositPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CompanyReceivesTheDepositPeriod" substitutionGroup="xbrli:item" />
  <element name="NonRefundableDepositAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonRefundableDepositAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ExercisePriceOfTheWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ExercisePriceOfTheWarrants" substitutionGroup="xbrli:item" />
  <element name="ProceedsFromSaleOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromSaleOfCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="CommonStockIssuableValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommonStockIssuableValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ReductionOfThePrincipalBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ReductionOfThePrincipalBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RightToSellMaximumNumberOfCommonStockShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RightToSellMaximumNumberOfCommonStockShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="RomegLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RomegLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ScilexPharmaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaMember" substitutionGroup="xbrli:item" />
  <element name="Upfrontlicensefee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Upfrontlicensefee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentUponTheAchievementOfNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentUponTheAchievementOfNetSales" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="Non-RefundableNon-CreditablePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Non-RefundableNon-CreditablePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="TransferOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TransferOfCommonStockShares" substitutionGroup="xbrli:item" />
  <element name="Deferredconsiderationliabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Deferredconsiderationliabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PaymentToAcquireLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToAcquireLicense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="AccruedRoyaltyPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AccruedRoyaltyPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AmountDueForNewDrugApplication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AmountDueForNewDrugApplication" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="PercentageOfLidocaineTopicalSystem" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfLidocaineTopicalSystem" substitutionGroup="xbrli:item" />
  <element name="AggregatePaymentOfCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AggregatePaymentOfCompany" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ZTlidoRestOfWorldLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ZTlidoRestOfWorldLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="GloperbaRestOfWorldLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_GloperbaRestOfWorldLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ElyxybRestOfWorldLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ElyxybRestOfWorldLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="February2024BDOFirmWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_February2024BDOFirmWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="April2024RDOCommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_April2024RDOCommonWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="October2024NoteholderWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_October2024NoteholderWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="December2024RDOCommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_December2024RDOCommonWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="PurchasedRevenueLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchasedRevenueLiabilityMember" substitutionGroup="xbrli:item" />
  <element name="GloperbaElyxybRoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsMember" substitutionGroup="xbrli:item" />
  <element name="SecuredNoteDiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SecuredNoteDiscountRate" substitutionGroup="xbrli:item" />
  <element name="DerivativeWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DerivativeWarrantLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PurchasedRevenueLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchasedRevenueLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ChangeInFairValueDueToCreditRisk" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueDueToCreditRisk" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="FairValueOfContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FairValueOfContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="TrancheBNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TrancheBNote" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="OramedLetterAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_OramedLetterAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChangeInValuationInputsOrOtherAssumptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInValuationInputsOrOtherAssumptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ForfeitureOfPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ForfeitureOfPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IssuanceOfFirmWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfFirmWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" substitutionGroup="xbrli:item" />
  <element name="DecemberCommonWarrantsFiveYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DecemberCommonWarrantsFiveYearMember" substitutionGroup="xbrli:item" />
  <element name="DecemberCommonWarrantsTwoPointFiveYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DecemberCommonWarrantsTwoPointFiveYearMember" substitutionGroup="xbrli:item" />
  <element name="DecemberRDOCommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DecemberRDOCommonWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConvertiblePromissoryNoteMember" substitutionGroup="xbrli:item" />
  <element name="LongTermDebtTransactionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LongTermDebtTransactionAxis" substitutionGroup="xbrldt:dimensionItem" />
  <element name="RemainingDrawableBalanceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RemainingDrawableBalanceMember" substitutionGroup="xbrli:item" />
  <element name="SemnurCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SemnurCommonStockMember" substitutionGroup="xbrli:item" />
  <element name="SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="SharesPurchasedUnderStockPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesPurchasedUnderStockPurchaseAgreement" substitutionGroup="xbrli:item" />
  <element name="ImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ImpairmentLoss" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AssembledWorkforceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AssembledWorkforceMember" substitutionGroup="xbrli:item" />
  <element name="PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember" substitutionGroup="xbrli:item" />
  <element name="PatentRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PatentRightsMember" substitutionGroup="xbrli:item" />
  <element name="AcquiredTechnologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredTechnologyMember" substitutionGroup="xbrli:item" />
  <element name="AcquiredLicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredLicensesMember" substitutionGroup="xbrli:item" />
  <element name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RodmanRenshawLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RodmanRenshawLlcMember" substitutionGroup="xbrli:item" />
  <element name="ZTlidoRoyaltyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ZTlidoRoyaltyMember" substitutionGroup="xbrli:item" />
  <element name="TrancheBNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheBNoteMember" substitutionGroup="xbrli:item" />
  <element name="RoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RoyaltyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="Gloperba-ElyxybRoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element name="FristInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FristInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="SecondInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SecondInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="ThirdInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ThirdInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="FourthInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FourthInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="FiveInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FiveInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="SixInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SixInstallmentMember" substitutionGroup="xbrli:item" />
  <element name="OctoberCommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_OctoberCommonWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="DebtPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtPayableAxis" substitutionGroup="xbrldt:dimensionItem" />
  <element name="DebtPayableDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtPayableDomain" substitutionGroup="xbrli:item" />
  <element name="MonthlyBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MonthlyBasisMember" substitutionGroup="xbrli:item" />
  <element name="LoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LoanAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DepositWarrantExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DepositWarrantExercisePrice" substitutionGroup="xbrli:item" />
  <element name="CommitmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommitmentAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CompanyReceivesTheFsfDepositAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CompanyReceivesTheFsfDepositAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CompanyReceivesTheFsfDepositPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CompanyReceivesTheFsfDepositPeriod" substitutionGroup="xbrli:item" />
  <element name="ProceedsReceivedFromPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsReceivedFromPurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="NetCashProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NetCashProceeds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="TerminationFees" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TerminationFees" substitutionGroup="xbrli:item" />
  <element name="PurchaseOfCommonWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchaseOfCommonWarrants" substitutionGroup="xbrli:item" />
  <element name="DebtRepaymentExitFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentExitFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ExistingFacilityCapMaximum" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExistingFacilityCapMaximum" substitutionGroup="xbrli:item" />
  <element name="ExistingFacilityCapMinimum" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExistingFacilityCapMinimum" substitutionGroup="xbrli:item" />
  <element name="DebtInstrumentOutstandingPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentOutstandingPrincipal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DebtInstrumentPrincipalAmountPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentPrincipalAmountPercentage" substitutionGroup="xbrli:item" />
  <element name="ConvertibleDebenturesIssuedPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesIssuedPercent" substitutionGroup="xbrli:item" />
  <element name="DebtInstrumentOwnedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentOwnedPercentage" substitutionGroup="xbrli:item" />
  <element name="DebtInstrumentDefaultInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentDefaultInterestRate" substitutionGroup="xbrli:item" />
  <element name="DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" substitutionGroup="xbrli:item" />
  <element name="DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" substitutionGroup="xbrli:item" />
  <element name="DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" substitutionGroup="xbrli:item" />
  <element name="PercentageOfUsageOfCashProceedsFromCashSweepFinancing" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" substitutionGroup="xbrli:item" />
  <element name="PaidToRoyaltyInvestors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaidToRoyaltyInvestors" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="NoOfCalendarDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NoOfCalendarDays" substitutionGroup="xbrli:item" />
  <element name="TotalNumberOfSharesGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TotalNumberOfSharesGranted" substitutionGroup="xbrli:item" />
  <element name="SharesDelivered" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesDelivered" substitutionGroup="xbrli:item" />
  <element name="RepaymentOfConvertibleDebenture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfConvertibleDebenture" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ChangeInFairValueOfConvertibleDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConvertibleDebentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="FSFLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FSFLoanMember" substitutionGroup="xbrli:item" />
  <element name="RepaymentOfDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfDeposit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RepaymentOfTrancheBNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfTrancheBNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ChangeInFairValueOfTrancheBNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfTrancheBNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ChangeInFairValueOfPurchasedRevenueLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfPurchasedRevenueLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="RepaymentOfPurchasedRevenueLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfPurchasedRevenueLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="JuniorDipFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_JuniorDipFacilityMember" substitutionGroup="xbrli:item" />
  <element name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StockPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ClosingPennyWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClosingPennyWarrantMember" substitutionGroup="xbrli:item" />
  <element name="SubsequentPennyWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="PennyWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PennyWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="SubsequentPennyWarrants2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants2Member" substitutionGroup="xbrli:item" />
  <element name="SubsequentPennyWarrants3Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants3Member" substitutionGroup="xbrli:item" />
  <element name="SubsequentPennyWarrants4Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants4Member" substitutionGroup="xbrli:item" />
  <element name="SubsequentPennyWarrants5Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants5Member" substitutionGroup="xbrli:item" />
  <element name="PrivateWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivateWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="IssueOfWarrantsToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_IssueOfWarrantsToPurchaseShares" substitutionGroup="xbrli:item" />
  <element name="NumberOfShareOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfShareOutstanding" substitutionGroup="xbrli:item" />
  <element name="TransferOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TransferOfWarrants" substitutionGroup="xbrli:item" />
  <element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CashPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="FairValueOfSharesRepurchased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FairValueOfSharesRepurchased" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="FairValueOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="WarrantVestingDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantVestingDate" substitutionGroup="xbrli:item" />
  <element name="PennyWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PennyWarrantsExercised" substitutionGroup="xbrli:item" />
  <element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ShareholdersEquityDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="SpacWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SpacWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="CommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommonWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="PlacementAgentWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PlacementAgentWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="PublicWarrantsPurchaseCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantsPurchaseCommonStockMember" substitutionGroup="xbrli:item" />
  <element name="RepresentativeWarrantsOutstandingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RepresentativeWarrantsOutstandingMember" substitutionGroup="xbrli:item" />
  <element name="FirmWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FirmWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RegisteredDirectOfferingMember" substitutionGroup="xbrli:item" />
  <element name="WarrantTransferAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantTransferAgreementMember" substitutionGroup="xbrli:item" />
  <element name="BRileyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_BRileyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AtTheMarketSalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AtTheMarketSalesAgreementMember" substitutionGroup="xbrli:item" />
  <element name="HudsonBayMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_HudsonBayMember" substitutionGroup="xbrli:item" />
  <element name="CoveLaneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CoveLaneMember" substitutionGroup="xbrli:item" />
  <element name="StockBlockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StockBlockWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ShareholdersEquityDetailsLineItems" substitutionGroup="xbrli:item" />
  <element name="PurchaseOfStockPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchaseOfStockPercentage" substitutionGroup="xbrli:item" />
  <element name="CommonStockSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockSold" substitutionGroup="xbrli:item" />
  <element name="ProceedSOfSaleOfCommonSharesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedSOfSaleOfCommonSharesPercentage" substitutionGroup="xbrli:item" />
  <element name="CombinedPricePaidOfWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CombinedPricePaidOfWarrant" substitutionGroup="xbrli:item" />
  <element name="PublicOfferingPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPrice" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceOfCommonWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ExercisePriceOfCommonWarrant" substitutionGroup="xbrli:item" />
  <element name="PublicOfferingPriceCombined" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPriceCombined" substitutionGroup="xbrli:item" />
  <element name="PreFundedWarrantsToPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PreFundedWarrantsToPurchase" substitutionGroup="xbrli:item" />
  <element name="PreFundedWarrantPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PreFundedWarrantPerShare" substitutionGroup="xbrli:item" />
  <element name="CashFeePercentageOfGrossProceedsPaidToPlacementAgents" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents" substitutionGroup="xbrli:item" />
  <element name="ClearingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ClearingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering" substitutionGroup="xbrli:item" />
  <element name="PercentOfCombinedOfferingExercisePricePerShare" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentOfCombinedOfferingExercisePricePerShare" substitutionGroup="xbrli:item" />
  <element name="AggregateGrossProceedsFromOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AggregateGrossProceedsFromOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfWarrantsExercised" substitutionGroup="xbrli:item" />
  <element name="NumberOfWarrantsExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfWarrantsExercised1" substitutionGroup="xbrli:item" />
  <element name="BlackScholesOptionPricingMethodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_BlackScholesOptionPricingMethodMember" substitutionGroup="xbrli:item" />
  <element name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
  <element name="Semnur2024StockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_Semnur2024StockOptionPlanMember" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyThreeInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyThreeInducementPlanMember" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
  <element name="WeightedAveragePeriodOverGrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WeightedAveragePeriodOverGrant" substitutionGroup="xbrli:item" />
  <element name="LeaseLiabilityNetOfCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LeaseLiabilityNetOfCurrentPortion" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="ProductDevelopmentAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProductDevelopmentAgreementMember" substitutionGroup="xbrli:item" />
  <element name="NonCancelableLeaseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NonCancelableLeaseAgreementsMember" substitutionGroup="xbrli:item" />
  <element name="EpoladermMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EpoladermMember" substitutionGroup="xbrli:item" />
  <element name="ProbudurMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProbudurMember" substitutionGroup="xbrli:item" />
  <element name="EnveltaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EnveltaMember" substitutionGroup="xbrli:item" />
  <element name="DevelopersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DevelopersMember" substitutionGroup="xbrli:item" />
  <element name="GloperbaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_GloperbaMember" substitutionGroup="xbrli:item" />
  <element name="FormerEmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FormerEmployeeMember" substitutionGroup="xbrli:item" />
  <element name="FormerEmployeeOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FormerEmployeeOneMember" substitutionGroup="xbrli:item" />
  <element name="ResearchAndDevelopmentFacilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ResearchAndDevelopmentFacilitiesMember" substitutionGroup="xbrli:item" />
  <element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsAndContingenciesLineItems" substitutionGroup="xbrli:item" />
  <element name="RoyaltyPaymentPercentageRelatedToFutureYears" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" substitutionGroup="xbrli:item" />
  <element name="RoyaltyPaymentPercentageOnNetSale" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RoyaltyPaymentPercentageOnNetSale" substitutionGroup="xbrli:item" />
  <element name="AgreementMaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementMaturityDate" substitutionGroup="xbrli:item" />
  <element name="MaturityRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaturityRenewalDescription" substitutionGroup="xbrli:item" />
  <element name="DueFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DueFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DeferredTaxAssetsDebtRelatedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsDebtRelatedInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DeferredTaxAssetsAccruedExpenseAndReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DeferredTaxAssetsPurchasedRevenueLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsPurchasedRevenueLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncomeTaxReconciliationAcquisitionRelatedCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
  <element name="IndefiniteOperatingLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_IndefiniteOperatingLossCarryforwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
  <element name="TaxCreditCarryforwardNotSubjectToExpireAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncomeTaxCreditsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxCreditsExpirationYear" substitutionGroup="xbrli:item" />
  <element name="WeightedAverageNumberOfSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WeightedAverageNumberOfSharesOutstanding" substitutionGroup="xbrli:item" />
  <element name="WeightedAverageCommonStockWarrantsExercisableNominalConsideration" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration" substitutionGroup="xbrli:item" />
  <element name="EffectOfDilutiveSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectOfDilutiveSecurities" substitutionGroup="xbrli:item" />
  <element name="StockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StockOptionsMember" substitutionGroup="xbrli:item" />
  <element name="February2024BDOFirmWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_February2024BDOFirmWarrantMember" substitutionGroup="xbrli:item" />
  <element name="April2024RDOPlacementAgentWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_April2024RDOPlacementAgentWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="RetainerSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesMember" substitutionGroup="xbrli:item" />
  <element name="February2024BDORepresentativeWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_February2024BDORepresentativeWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="SharesIssuablePursuantToEsppMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuablePursuantToEsppMember" substitutionGroup="xbrli:item" />
  <element name="SharesIssuableUnderSponsorInterestPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ConvertibleDebenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesMember" substitutionGroup="xbrli:item" />
  <element name="October2024PlacementAgentWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_October2024PlacementAgentWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="SharesIssuableUnderTrancheBNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuableUnderTrancheBNotesMember" substitutionGroup="xbrli:item" />
  <element name="SharesPurchasedAtParValueUnderStockPurchaseAgreement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" substitutionGroup="xbrli:item" />
  <element name="ThreeILpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ThreeILpMember" substitutionGroup="xbrli:item" />
  <element name="BpyLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_BpyLimitedMember" substitutionGroup="xbrli:item" />
  <element name="NomisBayLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NomisBayLtdMember" substitutionGroup="xbrli:item" />
  <element name="ScilexBioJVMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexBioJVMember" substitutionGroup="xbrli:item" />
  <element name="OwnershipInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OwnershipInterestRate" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g942297g0802021745893.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g0802021745893.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +@# 2(  A$! Q$!_\0
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/$DRLYQGA0.AZT444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g942297g0802021746162.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g0802021746162.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? <0# 2(  A$! Q$!_\0
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M0*#V&3G\30!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5CB\NUUR]A:6'[.D<9C5P1@GJ<UL
M4TQHQRR*3C&2* *6IZBVG1QLMM-.7<+B-2<9J*:6Y_MO3]LS+;RI)NA*8.0!
M@DUI\48&0<<CI0!S>HW]V^J3"*4I:P0+*A5\>8<\X]?2HI]1O8HY;E)_-\TN
ML:(^?+ [E<=A72F" [<PQG9]W*CY?I3A%$)#((T#MU8*,G\: ,BQN?)NI(C>
M/-$85?<YR5<YX_+G%4'O7M[AP^I2_99(0ZS##9.[G 'W?05TJ00QC"1(HSNP
M% Y]:3[-;X8>1%A_O?(.?K0!SD4MV\XAN+R:"W*/)&^X;N.S'VZX]ZO-=7=Q
MX7DF2?R;Q;<NS;,D';GI[UJ_9K?8$\B+8#D+L&,T\(@SA0-W7CK0!R^IWM^L
MRM#.P2*WC=_F"X)/)Q_%D=J9/J%W'9QW<5U*UQ+(ZR0D<1KW..VVNI>&*1E9
MXD9E^Z2H)'TI1#$)#((T#L,%MHR?QH R]-ED&I3VXN7N(1"DFYSDJQSD9^@!
M_&KL<CG4IXRQV*BD#TZU/'%'"NV*-$!.<*N*=QG- &+JNLW&GW8MX[=)&=1(
MA+$?(#^\)^@_F*JR>)+E0C1VJ,LX\V#)(W1 _,?J%P<>XKI"JDY(!(&.12;$
MX^5>!@<=!0!S;^);A=K+;QLLX\ZW.3\T(/S,?<+@_P# A5Q]<_XDOV]%C&]T
M\L.2 8VD"JQ_ YK8V)Q\J\# XZ"HYK6WGC\N6)67Y>,>AR/UH P9]=NHGN+<
M>4TL&YMX!VN H;\.N#3+CQ)(VE32(BI*TAB3!Y&8RX:NB^S6^U5\F/:IRHV#
M /M2B"$-N$4>[&,[1G'I0!S5KK%];6275TZ/ TKQY8'< $9LG_OG'XTX:]>F
M:2V"1&4%&![[64GA>Y&/UKIMJXQM&!VQ47V6V\O9Y$6S^[L&* .:?7[Q#+<@
MI+"2C0QJ"N ;=G.?8L*N2ZM?P7T=E(L.^;8PF&=L88/P?Q3 ^M;GEQYSL7.,
M=.W^2:CNK2*[BV.67D$,AP>/Y_C0!@Q>(KAS'(RP"$2>6[(2V?WK1Y]0/E!!
M]ZNW>J2"\>*WEMTCCA$Q>4G#Y9E('TV\_45?M["UMHHXXX5Q'G:6&2"3DG)]
M34I@A.S,49V'*_*/E/J* .?F\074-K]J$,3B3S0D )W1E QRWM\N#Z$BICJF
MH0W,BR)"T<-W%;MMSEA)MP?;!?\ 2MH0Q"1G$:!V&&8*,GZT_"^@Y.>E "T4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g942297g14k05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g14k05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[2:$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )F<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%C-"4G*"D\$D8G.RTA<E-#5#4U1C@^$F1'2BH_ V9,+Q1;/3X@A5A)3#_\0
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M?/YL9J5RUO939VO![NJX@<_GA^"V*;2%%462:VR-E[B5P<0)-]B#S^A;?@>
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MVCS8ZF9[GSGC,?MLQR)_%=0C&&IP87&:K'Y/FQY>3>*I$1>A\P1$0$1$!$1
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M2?<MP=R6C=H45?4VZ:GHHFR"2)[79(!WY<RM8>W'F_JQG97_ *HIR=_4D_\
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MSAC[E8ZGBGAK:5L\YE>8_:^E9O1-J-)-AK'< C< 2X'](*QUA;[E47&GDIH
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MGAK.+.#X;I<:B Z8J\,=GC;_ 'F^:Z_&/+>3+*:;3H69E-;'2/(:T0M=D[
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M<1O\5;W^HMS+P8Z>GD96\ (D)VQX<_Y+.HZ3DR^.]L]9-7?*0G;)#%'*S #
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M&\\_%7;1E3@>]/E4G'%NV(CE[*H-/SY[^:NR.G((!A-U?C%D:3+<'/Q54-,
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M-BYVSB+),+>^QPC\HZ@'GZ([^^Q>WEP_B^#X7-EER.A=I5%6S6^HFI*KN2V
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MN T;)*JWW!TX]>F9ZF/<>?P45L DT722N!XS.0=_-RQ<M5<>WT")XG-+A(S
MZ\0V7FVMIGO<P3Q%S?!X7"*[4_R?IRO#I&-B+<N)83X+4K1JBTMJ&5-+5<55
M*1Q@QOQSZ;+ICVS\NGU6TYZ;JM8K3M>^X4)ED+2>,MV&%E4LTU*(B**(B("(
MB""5#B!N7 #S*JZ*RN,4,].6S%W#D<EFTCU]-I0[A-3#Q<L=X,KU$C".(/:6
MGJ"N ZZHK!9Z[TF">85I=)(QKLD%X/N\5DX-7FC[/;;4][&)WSN8[,9(QQ2?
M@%-]+)VV#M'GEXVR4E>Q@;%NQK]R>)<UU'<+K0T5IJ6W"8,FJ&M(:X\O/X*]
MN>EWPQ^G]T\3</>,^<&#GR^E8S6XG.F;!&6CC-2 X?%8XK_),NGT1:*^&>$G
MOV<7$0 7C/)7[ZB&( R2L:#R)< N$55MFL=WAJ&1\,;&9)<X.W.1T6/U;J^E
MDAHX+O4-C@RY@+(W9QL#R!Z+OGTSB^B(ZJGD_-SQ/_9>"J6UE,7%O?Q9SC'&
M%\TZ4U)0P:E91V"H$M+W;G R1NSG&_,!;':J"E-U9)<R^.228.BX3SWWY9\E
ME=_3L.H8A6THC@K8(7AX=ES^F"LF)(XV O>Q@ W+CA<)[0:9E'$9Z?/=F1K0
M7'/Z)_!936=\J:VNM]H<8RVLBX>$-P3OT/3DIEEIJ1V)E73/)#)XG8\'@JEU
M=2@;U$.?#C&2N 5U!4:5C951Q\ G=W1+W!VW/I[EABU];KNV4M&.\;)"[/0Y
M >>ON5Q[8MT^F8JN"4XBFC<1S#7 X5PN%V.%^G[X'1-X9*F=K)>,\7Z73'O*
M[E&<MRM6:)=JD1%&D$9/DL3?+1'<HV->V-P:[(XAGHLNBS9L<TK.SNIFEQ%4
MTK(",.9AV"?A[EL-#I:.BM;J:-L#9'P]VYS6[$XQG[5M)V]R8R-E9-(Y >R>
MJ[S+*JB:[QX7?@O6F[+:N&*H:VKI!W@WPUV_/R761Q8W&ZGG]"EBN/QZ&JK!
M_23-"_B^;Q$TYWW\/)<^H/2Q//'$V:-SI#AW"5]/21MD'K9QY+'&Q49?Q?.9
M_:5QZ33F.F++=+A2EDM6> QG ?G'/"R^FNS8VAG=2/HWQ%Y>6L:<'( \/)=&
MI:=E.P,CS@#&Y7K@ *V;)U-.:5?9Y4NK734-32TX+^(@ C(S[EN&F[74VVE$
M=1.V5P<3EN>JS1'@I:,#"LOTFEA>Z%U?034['-:9(W,R[EN,+G]+V;U$5TDJ
M#44N"SAP&NST\O)=0/+94X//JL?'O;3EU-V8N@:]L4E&UKCD@-._V+.V^@_)
M2 22M$P<WNL0CZ>ON6Z@ ;>*\IH&SMX9,\(W&"K>TDTY;24T6H]:VVX"E[MD
M,;H2)6[^R\__ *2Z!=[)#7V]E,Z.(\#"UO$-AMA7M'114FT/%PYR<E76 ,^:
MJN80]G5QII^.FKZ:.(#9K0X?R7I=NSFHN-5;9YZBED-(_C!>"3S:=MOZJZ4W
M#=NJEH#?I2=(QMAM[[=0Q0.>TA@=[/+<D_S630C.RC)R,<DVJ41$!$1 1$0%
M!'ALI130T#6VAZC450'"HIP.Z;'\X">3B?YK"4_9?<(F,C-?2=RS + '8(\.
M2ZUA1NDZ+=M/L&BJ6U-#F0TK:@$XD8W!P>BUJM[-*NLKC4.JZ4\$A>WB#LC)
MSX+JAPX8*D@X ')+V.4U'9E73CUJVE+/U2'?@M^DM3G6R:E+V$R-#<]%F-PW
M9!A!S.A[.:BGO=56MJ*4-EY !V>8\O)=)IVEK"'')RJM_H50530B(BB(B M0
MU)^?/[96WK4=2CY[]\H,"-RO0<E2.2J!RB(4A,*,H)*@(@\D$IU0(@*0H"("
M*$R@E"B( 1 B!E3E0>2! ZIT1.B&A0>:*4$*44C.$$*<J,(4!%.5"""JAR5*
MG* H4@H4$@#A\U2BE 7HW:,[]5YX7HP>H46/,GR6J=H'^IW_ -HU;8>:U/M
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MXT6(9 #\YZ&&GW9X$KFUU?6Q-ALU93<+R \1.]7)Y\NB[>BAI\[ZOLMZEHQ
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MJD$* IP@" G525 0$1$ *>%1C90"<(&5(0!"@(B(&%"D<T(00I'(HHZ()"*
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M0)'G?EG<^07A5:#TY52NEEMC'2//$YQED&?_ '+$FJWO;E%NN5(_M1MTT4\
MIQ$X&1KAP@]V_JMUNG9VZ\5<5?%J.Y0L>\SAD3O5PXAV.?)9^G[/M+T\[9X+
M4QLC>3N]D]WZWFMFIXXJ>&.&)O#'&T,:/ #8+K\NG.8]L?IVT&T44=.ZKFJ2
MTD\<O,Y.5E#D$#&0>JD$%#GHLM(=ZHV&5IO:!>ZBTT,[(:42QF'C=(<CAWQC
M[%N8Y>MS5C=+31W2!\-? )HGMX7-+B,CZ"L7';4KYKNE/Z5-%<65+Y)*F3B=
M"#D1K:KZ^6CO\=6YCIJ9L0#I'^QDY&"?@NHQ:%TY%@-MC T>R.]?M_[E=UNF
M;/6TSJ>6B:^-Q!(+W#E]*U.IHVXQK6Z4EQ?IAL'H[7QO]<1$$Y)9S^"NM9PO
MII'U0B);EK<D;<O%>/:'I=D%XMGR''%3-@J'][Q/<<@.;C&<^!73;+9Z&]69
MD=WIQ4.+R3EQ;R.W(A/:Y5R62Y1SWJQ.S&T1D!Q!Y<N:Q.KK)+7ZKKJ]]340
M44H8(YV^PXAC1@'D>1^!7>!H+3+7B3Y+9Q-W![V3_$KNHTG9*JACII*%KJ9C
MN)K#(\8._GYE73$<5I]#6]M#,;5?Y;A(#MW9#CGPV/@LII"OAT_-7TMQ$0/<
M]TUU2>$N=]/5=6MFD;):<_)] V%A/$0)'G?EU*HK]%:>N,W?5=M;))Q<?$9'
MC?Z'*58Y9IBR5%;71U;8IHXVES"QC/5)QS]^ZMH:QMMJ+Y%,UC7/+V,$FQ<0
M7;!=PH+31T$1CHX!&TGBQQ$[_25BZS15AK9G35-N8^5SB\N[QX]8G).Q1BX[
MKD_9_64[[PP5SX:4<#MGD#[U>W-]OH;I3.ME?#5/?(261O'/.PV71HM"Z<CE
M[WY,9WN,<7>OY?64Q:$TW'4,GBMC&RL=Q!W>OV/C[23VUI>:5J):BTTQFB,9
M+2=_VBLR7._55%-!'30MCA;PL;L!G*]521YN)X1@;KG';;41#1]SIR8^]<V$
M@9W_ #K?P72\+#WO3=KO0>VYTC9V. :X%[FY .1R(ZK&>.V\;IP:&ZV_\GZ.
M'OJ5LK*5K'-XAG/ !@^:IJJ^D_($4['P&I[W/"".+'%X+KP[,=)$[6:/;_G2
M_P")>H[.M*X[LVEG\:3_ !+>$U&<NZY!'(VHI(YX@US:>,%Q;N!@9W\.276[
M1R62F;&V)SQ)D@')'M+M5+HG3]/3S006YK(91B1O>/\ 6'+Q7B>S[3/#@6IG
M".0[V3_$IE-LR.<:EO\ 2RS0!LU/CN@#AXVW*QNJ"VJLEI?$UL@X^++=]EUB
M;L]TO*09+4PX&/SLG^)7;='V(TT=/\GM[F(88WO'[?:ICCI;W7(-6W*CD#GQ
MNIL\+1EI'BMFI=*,U;8K6:>_5=(:>!KG-I7Y]IHV._3"VZ3L^TS.TB:U,<T_
M\V3_ !+,6BS4%GC[JV4X@CPUI <3L.7,E:33$Z,TL_3T+&/N=76EO%O.=SD^
M]5=H#W-TQ<BP9/H[^7N6R!V92/):UV@9&E[GP['T=_W+')=1Z/&G^Y' ;%4S
MNNTS7->UHBSG)\6KZ094.ALYF:SC>QC<-\>2^:[(^3Y4FXG9^;_F%],4+&RT
M+(W#(<T9'T+S\/=KZWY.3''#3CNJ+C^4%UN%%5S"W"F)>US7X+SC'"<K7]/4
MM1'I6J@B$SY'3Y#0#D^ST^A=OET5I^IJYJBHMS7U$F[W]X\9/Q5Q1Z5L](,4
M]$U@SGVW'?Z2O1KI\3;E-/>J3Y&JJ6I;2Q31TYC]8@.+N$@_3E7NCJ45.BVA
M@X_GW; 9ZK)=H6DK1#3.EM]$R*IE$KG/,CSEV-CN3U5'9'25$-#'1UCF/9Q2
M.X6\ON6\+UIBSO;GUHN'H5)?J>6&,.E):WCV/Z0V7M/'-<M,TE/2M>Z9K^,L
MB!+@/6Z?2%VB;06G)9'/-L87.)+CWLFY/[RO:#2-DH3Q4M V,XX=I'G;Z2L?
M'MO;YZT[I"WU)<:O4DL,P?AD+GCU]O E9JNT_)9FP3T\U171%X #AEH'//V+
MK\79_IIE0V<6M@E8<M=WLFW_ +EE'V"U2P"G?2 QL& WC=^*WO3.MN.ZIK(M
M1S.I+;%"]\K&ALE-ZS@6GB.,>05E=[9-:Z:S.E9*2PMX^\;C'"&YRNQVK1EA
MM=0R>@M[89&$EI$CSC(P>9\%>W+3ULN3 RMI6RM&=B]PY\^14R[7'IPFHND%
M1J5T_'"R$LQW@=MR\5O5^;:YZ"FFJ*^GADC@S&"YN7;96R'L]TN!PBTLX?#O
M9/\ $KRJT;8:R-C*FWM>V-O P=X\8'AL59TE[K3M"7&;TV2.EB](A$)X9&DD
M.]8>"ZBS=HR-UB;18+;9F@6VE;  TMV>X[$YZD]5EQR5J2"(BC0B(@(B("(B
M B(@(B('5>4V3"_;?"]5!Y'/)2]P<0U-Q4&HZVIJ(<1OF(!D& >O-6@$U[[1
M*"Z6^D+J5D1C+Z=O$P$,?U'7<+L-WTU:KNT>G4C9?6XMWN&_T%3:-.VNS1B.
MVTC8&!Q=@/<[<['F2F$TE<7U)>ZBZ3U-NJX?0VTCWQ->"07[EN^?<LGV<T]/
M!'!1U%4! .,]\\CGSPNEUNB[#63OGGM['RR/,CW&1XR2<D\UZ4VD;'3M#8*!
MK6CIWC_Q5]CFFI30T-9&ZWU\4\N2X1,>/7<#L,#Q6F:HM-?=8#65+*ND;*\<
MFD $#&,GW+O$FB-/NJ8IS;6=ZQW$UW>OV.<^*OJG3]KJJ9M)/2!\+3Q!O&X;
M[^?FLZ6.)Z$TC:HKS15;-1NFJ(906PES3Q''+FN]T+."!OK$[+!6S1%@MU0R
M>EMS(YF.XVN$CS@_25LC&AC>%HP NEO3,B41.BQMI3(X-;DD >:LZ:YTT\KH
MXIX7N:[A(:\$@K&ZTKY:"S.FA>6.[QHR #X^*XQI35T]/=J^:>:5T;*GB< Q
MN2,E9^79I]"G8DC?*#U0N257:5F9QIYJIL>V 8F+:J+6,$UGJ:EQJ"8\;\#<
M]//S6_:;;>X^JXXZ;>:YWJW7UQL-XBIA:F/A=")#(]SA@DN&/L'Q6*KNT8TU
M6.*:I[E[PUK1$S98;M3N;*UCZB/CPV)C/6 !]L_BLQ8[#IVZ.NUJIJMT;6.E
MB;(6M.0,A9$DXR!OX+BFC=<^A4=OI))*C#FQQ -C:1X+.:E[0VVJZ&#O*D ,
M!PV-IY^\JVZ3;J0(QYJ#EQP=AXKF-GU^)ZVGCDDJ7"5[0!W;>I]ZR&I=<Q4$
MKXHW5#7 MY1M/,9ZE79&^R.(C=@9/0+G=^UU<;7=):9MK:^)LO=B1Q<,CQ5K
MIWM"947"&EK)*F225^&_-M QCKNK37$L<U0V1@/K5 ._N7/?9EU'4Z"H](@+
MR #G& O<#A).<Y7-;SK6*T!U%$ZH94N >US6-+1D^9\BK:R]H@DJFQ54M2_B
M<UHQ&SGGWKI3'TZH#MOLH&#DYY+GFJ==QV^HDBB?4,(#3M&T\_>5JM-VHR&X
M04SJBJ+IY QOS3,;G&_Q691VX;A1G??9<BK^T:6BKI8))ZG+,>S$PC<968KM
M;&.\4%*))QW[0<=VW',K2;='"*TMDIJ*.*;.>-N=U=HL$1$41$0$1$!$1 1$
M0$1$!$1 1$0$1$%).Q\5SWM9JH8K?2"3N^+O3LX_U5T,_:L3>=.VN]-:VYTC
M9PUW$,O<W?Z"%BSM97 [=<*&+1M="Z6F$[I<M!<.+&6\O@5GRU]ST];O0W.E
M]&@#GMB];]$<\>Y=#_R:Z4+"WY(9@_\ .D_Q+,6S2]GMD#X:&B;%&]@8X![C
MD#IN?-725QR&]0SZ5%!)3TT=7WO'P;<>,^'/"L:VF]%M\KZK,7'$YT;9!@/&
M.F?H78OR$TX*KT@VQG>8X>+O7\OK*YN.DK+<8XHZVA;*R-O P=X\8;X;'W+?
MUIG3C0NMN'9[;HC+2-J!.XN9Q#B XG]/@MFM%D;J2U3-@NU13'9G]'=Y ^*V
MUW9MI0L$;[0PQ#<#OI.?UEG+/8+=9V%ENIFPM)XB ]QWQCJ5G&:,IMA-&:2D
ML!+GW2LK.)G!B<\M\YYK<#MT5+1@GP4YSR6K5QZ,^2P>KZ^2V6A]7!%WSPYK
M> \MRLYX_:K>MHH*ZF,%3&'QD@\))'+W+-FUE?.=PE%XKVSOJ3$Z"0NX&NSD
MDYP?@O>NIZB.W,J&"66)S^$;$MZ_@NS1Z"TU&Y[V6M@<\Y<>]DW/UE>'3%F=
M1MI!1-]':[B#.-VQW\\]5G6HONN6:AO=!7T>(/0^^;'PAL;@22K*[12QZ9M4
M[*0O+GC/J\A@KWUWIBEM];3-LD$=,YS"<E[COGGOE;WI&T1U^G:&FNC&SF.(
M$^L0,\NF/%7"=,9?X<TU%>HJJ]TTD;(# V+A=,TY#3EVV?I'Q7EKJTR76T69
MT=1.R+VB^/<-:6C?W+K_ .0&F@PL^2V=T=R.]DW_ /<L@_3-G=11TIHFFG8S
MNVLXW;-QC'/P3*+CTX5I#1%J=7Q3,U5)-/APX.-I)&/>O:RPRZ5O%2:^%SH:
MF<&.2J;P@M:XY+<\]G#[%V2WZ%TW;IFS45L;%(W(!$KSS][E=WC2]GN[8&W*
MB;.(01'E[APYQGD1X!5;W'(ZFC=?[[/-0,)9(T.::=O$-@ <8\UC+0\V"Y10
MU,89QR<?SPX3CE_)=RLVG+79RWY/I&P\(+1A[CL3D\RK:YZ-L=RJ&35= V25
MHP'&1XQOGH54QFG'-.U],=:WNHFEA9'*!PDN&.8Y+/ZEDH+?/WUOK(9Y6,!;
M&QP]8Y(Z>2WEG9_IICW/CM;!(?:/>R;_ /N7N_1&GWS![[<PN QGO'_BI)HO
M9HFMJ*VU0.GIC$.Y86G?ULA;)Y<UXT=)#1T\<%,P,BC:&M;DG '+FO<YQLM;
M)-(._(KC7;U/"+?W7%&Z4549+<C('=N796XW^U8&^:1LE\>Z2ZT#:ASB'$F1
M[=P,#D1T7/*;;QNG$KO=K?+3TS(IJ4N$(!X7#(*L]6UU-/I*U00&%TL<I+N
M@NQAW-=E;V::1!R;,S/3YZ3_ !+U_P G.EG-X'6EA8.0[Z3_ !+>%TQEVY1>
MY34V:HJXV!_ 6LRW<>T.OTJQJ+FQ\-A9PQ\4<C>+?=NXYKN4>C;&RADI/0&>
MCR.XG,[Q^YV\_(*V/9_IGB8[Y*9EIR/G9/\ $I5OIH6O[O3S:*FI62PND,S'
M8#P3S\%Y5U1'6:?C,? _N:;UN'?'JCGX<ET>IT-IRI88YK8UP/3O7C_])>U+
MI*R0T\T$= UL4C>!S>\?N-QCFK.C&Z<<JJVC&AZ6,NIQ,)R2W(XL9<MDT/%%
M?K)<:2*N-.^1P8'0N]8;<PMSET!IN1G ^UL,0.0.]DY_65_8]+6>R%QM=$V#
M+@XX>YV_TDJ8=;3/NM8T]V?RVROEG??;E.'-X>"0G W!\?)="8WA&,Y4H#E5
M8(B("(B M2U(?GOWRMM6HZE'S_[[D1@CS58Y+S)W5;3L@E2%2IZ) *!.: [H
M!"-Y)E!R0,*"%(ZJ2@I"G.R!$ %% "()'-,("A03A0@*C*"0B H@(G)0"B*E
M&$3JBH50V4!$$!2$4<D%6%3U4@ICJB04#JB(HB*0@A2,CD-D"G!QG.R+%3CD
M#R7F^G95DL>3@[[*<\(.=U:5ES9;XC*Z,NP0-CCFKC[<>2R3MML5AIC$W=_(
M=!^"OK?:H*1Y?&79+<;X\5JD>N*<1CYE^P'^T"RFG]4Q72L?!'$]I;&7[N!Z
M@?S77+'+3S\?)Q6ZC&=J[3\DU;BWU1 W)_?7*+W$*[3EMCILO='ASPW]$8*^
MC*ZWT=RA?%6T[)HGCA<UXR".:Q[=*6../@CM=,UN.' ;T7GQCW?3YQLEDT]6
M%IJ;M-'4$D!C7#EC]E;#-BR5EL.<T7&TB67?YMI;ZVWENNPPZ"TU \2,LU&'
MCD0U7U7I:RUD,4=3;:>2.-O"UKF\AX?8M[9TP=EO&G:^1M11W*&29P(X6<L#
M;P7))+U;&:JC=)5Q!K*K<GH.-=TH=(V*@(-#;*:#&<<#>6>:LY.S_2SYN\?8
MZ)TA/$7%F^<\USL[:^M.61:GL<.J*^8W& ,<P '?')OEY+!:%O\ :8[O%+4U
MD+,2.YYQCA*[<_LZTH]Y>;%1<1YG@*B+LYTE$[BCL-"UWB&%;,?XN,T5VH)]
M7:@DAJF%DA]0MY%932=\I+*T0WF6&F=Q.<1(#G!&WW+J\6@],4\CI(++1LD?
M[3@W<JNMT1IVN?Q55HI97XQES>BS(9=N/:1:YESU=<Y064$LIJ(IOT7QYD=Q
M#RP05[6NZ4=QOCO0ZEDN8_T/+"[/!IFT0T3Z1E! *9\?=.C#=BS&,>["MJ'1
M6G:"7O*&T4L#\8XF-Z*Y3:2:<FTU>*:Q37!EYDBIA/-Q1]Z#ZS1G<?8K>RQS
M7+M!NMSH(S+;9Z<"*=GLN($8./I:?@NPW#1>G[@0:RU4LSF@AI<WDO&IL-!:
M+9%':J2*F#7<($8Z')(^*SC_ !6N&5L=@KJN(7:YFE]7'JD#;??<'JNG=G45
MACHI:>TUXJR(.'?!.,\^07,Z>IL[)V_*.G'U;NA+>0\%O>EJ&*@AENUOIO1J
M>HBXF4[6X+ -\?8M2=)?;7=66NNM6HX3!2O,0@!+G>)+AT77-'41AML$SVEK
MY88W$'QQG^:U*PS/U?5,JJB)\<8S$8YADG SG[5TNDA$%-%$W :Q@:,>0PM3
MJ)[KV')$11H1$0$1$!$1 1$0$1$!$1 1$0$/)$0>4[>*(^.%P'M:M=;-J"-U
M/3/D9Z,P9'CQ.7T _D<\EJNH!;S4 U4,3Y. 8+B,XR5QYL98^A^/YLN+/>+F
MG9!;:N"NJC4P/C!,.,]=RNZQ##5JED?0-D=Z+#&P^KDM(63J[]!12F.09(&?
M; 4XM8]'G\F7+G\LF9;U506%IK[!42L:S#<D#VQNO>MO$%*W+\'?'M +N^<R
M$SFQL,CSAK>96)&H[0:E\ KX>_:<.9OD%4TUZIKBPQ\( <>'!<#E<POD3*;4
MU5)" W,^_#X94GMK73M+=QMR4K7V:DIVRB)S,$[[O"N*B_T\+&.<W/&,CUPJ
MRRYVW'-.BP4.I::1W#PX/F\*8]14\H>0 .#;'&-U)5O3.CELHPL/2WR">5S&
MX! S[84UU]@I'@. =MG9X5)VR[>94K%07F":(2- W&<<05O!J.FF'JL_]X1/
M3-N8T[\+3]"EH '(!>$%4V:$O:,#ASS6,FU!3PU!A> 7 9]L+-NE9L=<J#XA
M81NHZ9V?5&W]<+UI+Y!43NC;@$-S[853;+<ALI'+=8BNOD-(.)["=L^T O..
M_03TDDL8QPL+\<8*FU9D<L%2#C8_0N3V?M"=5ZAIXW=\("UV6F08)P?^RWV#
M4-/*TG V&<<86HFV1K[E1V]A?65#(6C R[S5Q%(R5@?&X.:0"".H6N5UQME>
M3%6TL<H."0]P5Y)>*:A$,88 UXPT!P& $B[9GGLI&_)8*74E+&,\(/39X69B
M?WF[=AX(CT1$11$1 1$0$1$!$4$'Q0-@5K>NX'RZ;N38VESG0/  ]RV/F%97
M+N_191. Z/A/$#R(6<IN.G%=92OG.RVBO%RE)I9.'N^>WB%]'6]O!2,#MO5&
M?@M8B^2^_<(H(6NQT<%M+GB*E<_FUH&RY<<^+V>9RY<F.,J:FLIZ*/O*F5L;
M#R<Y8AFL]/&01?*U/WAW#=_P6B7:Y5FHM2U5JIIY((J20.<''+7-.!@8]ZQ/
M:5:Z*RUP?24\<3A"T@L&.;B%VEV^??;M<$T53$V2%S9(W@.#AU!Y%>K6M;[(
M ]P6F:/U'3OM-#"6$.$$322\;GA 6;J+_3TU087@$XSGC 51FE!\UC9;M%%W
M9)!X]QZP5-1>H(:=LK@""<8XAY_@HLFWA#JNR3U<=+!<8'SR'#6#.25FF.#F
M!P.QZK@]PDI:;7%E=1Q-B;N7!IYG==6H-14_<MB</68W<\85TN4^+8SOMT3I
MMT6-;=H31/J< ,:<%I</'_NK.'4E,^;N^'F['MCQ4VC/-.1NI5C57&*F@,KB
M"T$#'$%B_P JJ7C#>'&^/S@W51L17G-*R*%\DK@UC1DGP6+=?Z=L+9<##CCV
MPJ(;Q2W&GDCX 6N/"6EP.5*L1!JJRRU,M+#<8'SP_G&#.6^]7E-=Z&JF$=-4
MQR//(!<HDI:>#5MU=3PMC+W@$CJLGJ"">Q7AE12S]U"R,9:S;<Y"F-W&<KJZ
M=2!\.JJ6(T[6FLMM.]Y+G&)CB2<Y)"RZTLNQ$1%$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0875C2^TD-;Q'C;LN&=Z);?J.EB#342%[&, W+O6&%]$SPQSQ\$K
M0YN<X*PK-)V..9\K+93-D>[C<X-W)\5RN/;4O3YDM%GMS)3%?:R:BG#27,R-
MCG;H>FZWLV*EHK)4R6>HFJFX#CQ$$9VVV Z+K%9H?3E;(Z:>T4CYG8XGN;N<
M#'X*^@L-K@A=3QT,+8G\V@;%=(YV;<[TCJ&RFVP4%VK8*>IIV>LS'K!V>1V/
MBM=[3;M;/2NZIJN-[#"PD^?&5ULZ)TX:A\QL](9G^T_AW*HJ]#:;JCQ5-GI)
M'8QES>B+)IQ*MO\ :646G0:R$&$M+^>V.'FFJ=2V:LJW.CKX'>JT;979SV=Z
M4>UHDL5$X-]G+#LJ7=FVD#SL%#Q>/ 5G79IRV^7^TR36..FK87N(#3C.0?56
M.-6Z@U/4UT@;Z"^,1ME?[)=ANWV%=G_(#3!DB?\ (M'QQ'+#P>S[O@KJ?1]C
MGA$,UMIGQ \0:6[96TD<COM=37[4UI?9Y&5,4;2R1T7Z)W.%.J;M24%/!!-4
M1ME9*&.:[.0<%=;M^D;%;W<=#:Z:!P.<L;C=>=PT;I^OD,E;::6=Y=Q9<WKX
MK$PTN7;A\\WH/:!0W9V#;8(B))W^RTEKQ@_2X?%9;4=SI;_/;A:98ZA\<W%(
M(OT<D877Y](6*>G?!-;*9\3N;2W8[Y7C3:-L-N;))0VNEADQG+&[[<EK+TF,
MTY!JAL/I,E-=9#318:7/ZCP\5>Z I-*TUPB,=Y<^<SQEC'$'+L[#V?%>FN33
MQ7J:2NM[JR$-8"S',XV4:9I+57U,530V441IY&..6[N.<@_8F'18VWM'LXK+
M4:BD:Z0OF;[.,8 (_DL'V84<U;,*FKC+'0U'",<L8"R%_P!12CCMS*>HQ$X.
MXARY9_FMTTK:H:&C?P1L:7OX]AC? 5GLTSC!PM :-E6@& B+!$1%$1$!$1 1
M$0$1$!$1 1$0$1$!$1 3&>:+&7*\0T! E;G?'M )L9-%K[-2TQ/#@9/7C"RS
M:R-U,R8.;PN;Q>T%-BZ\EC[G>K=:^'Y0JXX.($CBSOCFK!^IJ5L_=\&3C.0\
M+"]H<5)5V*>H?$Q\C:25['<RT\.59$VV^VW"EN5(RIH9V3P/SPO;R.#@_:%=
M Y7,NS&]1T&B+?WS2[>09X@/]HXK=H[Y3OIWRM  ;_7"BLOR182;45/#!'(Y
MNSCCVPC=14SAL![^,(1F3YH/!81^HZ8%K2T')P#QA7CKG"RD-0<<(/#CB"1&
M14#[5@J?4M-.]S0S!!Q[85;M0T[*AT1 R!GVPKH9DM:=^$$^Y1C ]4#*L[=<
M(ZX.,8X0TXYY2XW**A:'2 ;NX?: 3TJ](P<CFI'FL&=24S>8!\^,*J74--&(
MB6@B0[>N-E!FT6-GNT45,9\<30<8#@K.FU+33/+>#A((&[QNF^R,\4PN5ZPU
MU)07:IIX3,UK"W'"\8W:#_-;?0ZIIY61AS<.<!S>%5TV">:.%H,C@T>)7E0U
M]-7Q&6CF;-&#PES?'P6&J]0T;CP2Q!P!ZO"]*2MM]NI'^AP,CA#N(ACAC.P_
M!2^DC/HL''J*F<"<#Q]L*\MUQCK8PZ,8SGKE6)MD$4#DI11$1 1$0$1$!$1
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M4M4^.)H:6F)Q#AMM[:3J-:[<WTK:Z:IO$T=X,D40B)RP[\61CD#TROI"B@9
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M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"
M%K6IM%6?4?#\IPR/X7\8X92W?&.BV3<;<U5T4T-=T]I2U:;@[NVQ2,CXS)AT
MA=N1CK[EL#<%H(Y*2-CME2WDJ .=PJ?9SE3C=2@P6I=+VS4U*(+K%))$)!(
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M]1G>9F/<5N"8086T6Z2ED<2]I]7&P\U5>[<^L>',>UI#0-QYK,(B::B+!/\
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M@5M@.3Y*0,(-2_)^?&\S"/#!5]:+7)2GUY&N/%G8%9],;Y0:S762:>LFD$K
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M]RJ')4JH<E$0.:D)T14$RI5*"5*@*1R00H4HB0;U4JE2.2*C*GFH4A!!'FI
M3=-T H$0H&44*<IH$*!.>R00I"83" HPJL( @#DH\4!3*!T0)A!S* 4Z)A$(
M@G9&J<!$#"]&CYL^]>:]6?FS[U%CR<M2[0M[*_\ M&+;7+4^T#_4S_[1J[\/
M]G@\WK"N8'JM][&O_P 2U'_HW?WV+1'=5O?8S_\ B6H_](_^^Q>_EG\7Y_PN
M^5] TY]0^]>J\J<>J?>O5?+OM^NQ]"(BBB(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("=$0\D'C4#YIV_0KYU[8Q_P")8B=_Z*S^\]?1
M-1O$['@5\[=LFVHH\_\ "L_O.7E\G^K[?X2_[W:Z[&A_G"KQMZT/WN7T# /F
M\97S]V-9^4*D_P!:'[ROH*#!;D)XW]>V?S&OV]/3H@W"@;94/D:QN3R7IV^,
MGKG.R$^2MXJR%[PQI=D^2]G2-:,G*J*\[*!UZ+QBJ(WGA&<GR4RS,C X\_0A
M'J-MN:E>,4S)6!T>=_%2Z5K'-8[/$[D@]40;!$40\D4/(#23R0!L$XMLX7AZ
M5$26[Y&W)/28S(6$GBY\DB/<'*E0TY&RE%@A.$1 14/D$;27]/!5-/$T$<CN
M@E$WSY(@(B'D@#WHJ<G?P5+)0_V5-CT4 YV0^:I>]K&\;LX5%:9V5O'612.X
M6EV<XY+WSN<I!*(B B*!U00-RM7[0?\ \,7,#_AW_<MI ]9:MVA-/Y,7,CGZ
M._[EC/T[^-_>/GNR#%WGR,GNOYM7U#:3_1(_V1]R^7;'Q?+$^<9[K^;5]16H
M?T*/]D?<O/P;W7U/REGPPTO44'8!2,$;+UOABIY'GGR56< ^2MS4Q&;N_6XL
M9Y)M7NTYSMA2O)\S&-)=G '@O."LAE>6L+LXSN$%R>?-%;2U<3'!CLY=RV7L
MQ_$P%O+S4@J!R>2E4-D:YX SE5C.ZJ"<D4'FBI)V4<6_)4EW"3GDO*.ICD:X
MLS@'!V0>_),YVY+Q94,D<6LSD<\A>HWW"(J"(B*(F509&\9;OD(*T1$!$1 /
M)$4.<&C)02BI9(U_LJHD! RHSNJ7O:P<1SA>4=3',?FR<^84E1[YWY*52UW0
MJ1MLJ1*(B*(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("C.YV4J,@902HST7B^IC8<.)^"]6O#F\0Y8RI
M+T*AR\5 .>B\9*N*,D.)R/)5F4</%^B$V*QS.Z9VSA6\=3"^1P;Q<0Y[+W+N
M$9=R"J*AR0*&D.&1U4HHA.R*,X&Z@;#D@*\IIXXB.//T!4FJC#0XYP>6R0>X
M.VZE><<K)6%S<X!PJ\9 PJB40G 4<OI14].2)U\E1%*V4$LY XW05HB("8WR
MB! 49\E/N7D^9@>6'.0@]>2A-N'R4'EZJEHGBWQA2O"6JCB>&.)XB,\E5'()
M!EOO5B/4%0!C.2G,;*441$0$1$!$1 1$0%J&IOS_ .^5MZU'4WY[]\H,%U7H
M#LO/JJQR"B!.R#F@&5*H*%!4XV0!U3BWY*%5C9!2IZ* ,Y4\D$ *<(3X* @=
M5/)$YH"93HB*)E H02$QA A/1$% V*84H!.4"A2B)RH10BIQLHPI4H *@<RA
M1 RB@<U)Y((ZH GN4H 5;-XS[U0>2](\!A]Z58\G<UJG:#_J9_\ :,6V.P2M
M4[0!_F=^/]XQ=>'V\/G7_;KF)!.5OG8X"-25!/\ PCO[[%H8#B2 1GHM^[&P
M_P#*6H#R#_1'<OVV+Z'+/XOSO@S_ '7?J;V#[UZKRIAZA]Z]2OEWV_78^C(S
MA% P3GJI4:.J*,X&ZGD,H"(#D(@)T4.('--QS02#E%&P^E3U0$0(@(B("9"*
MG(!Y;J;%6?BH!SE"-\CFH9G?*HJ10#OCJI0$SNBC;/F@$@<R%*I+6G.VX4#)
M]R"M$4!V7$=0@E.JI!+O93/Q4%2*!L-U.501!YH@(>11#RV0>;QEF%SK6FEZ
M"Y7)L]3<HX'")K. L!VR=^?FNB39$9P=\+A':O?+A27Z.&GG#&FF8[' T[\3
MO$>2X\UFNWT?QV&>>>L+JMWT;INAM<\LE+<8Z@N+"0U@&,$^:VBLO7HE48#$
MWA !XR["Y1V2WJMK:VK953<8:8@/4:.9.>076KA;J6>(S21Y>2!GB(6>*S71
MY^&>&7^Y=U=4UTI)< 5$/$<;<87/.U*^OBA=!"XMX*AOK-D(SZI_%*FO@IZR
M-E*U[)"X@$C(SGWJRU7IVMO5KCF@D@$[Y0YSI'$9 !'0>Y;RKYT8-^GJG1U?
M#5NNU56QQCOB),M&^1@[E9&_:KENMLHX*8%KW. <8Y22 1A:Y?*^^U-2RBNM
M9%,)6 >HQH'#D[9#1U"JME ^EFIR\LX"YH !/BM\??M*R,-OK=%7:.IGK:JL
MIX07.=,2QOK MP=SU(7CVC7BHKJ:URQRR4[962.!9(<$$-*VOM>,8M58W!QP
M1_WPKBFT52WW2]D?+#&YS:.,M+I7MQQ,;X>Y,NJ8-?[)[K)21T\=34/EC D^
M<DD.^Y\5ME*ZHU#=X:F,RQ14DP!#"7!PSG?X+7VV*&S2_)D+&MJF#BX@\N;@
M[]?P5E6:LFL=3%!9I)(&2'Y\&-KN)P.,C.?/P5F4O1K7;M<#2R(-))QU*HJJ
MN"EC=)/*R-C1DEQP %KVB[Y-=K=#).]SY',<XDM Y.QT5YJFE](M=3RX>[P<
MGS3*_$QNUQ!?[5.XMCN%*YPY@2 KTN-=304[C4U$<+1C)<['5?/-PNLEIO4\
M=,YS"V3A.&AVWTK<;M=ZG45S;04TA#)& XE: ,C)YC)Z)[BWIK^LV]QJ6EEM
M]XDJ6UE6YSF1O.(P7C V/F?@KRK[RW:YE=/<91%W &'O(&2!YK%7NRU=LO%K
M-0^%PDJ/5X"3R<WR\UEM749J]5RM]7/=-.Y(Z+-NJGMV"R7>AJ:6%L%7#*\,
M:#PO!.<*YJ[Q;Z1Q;55D$3@<$/>!YKB]@FKK-71COF")SP2&@$X'O"US6FM'
MR:MKZ65\KHXPQP'=MY\#>OTE;EVF]/I""X4L\3I(:B)[&G!+7 @+P-[MHD=$
M:ZF[UO-G>#(7%=&ZKJJJAGAAE<"Z3'K1M\ O5SJB*ZNGJ'M<9G@>J$O37MU&
M]NH:\%K[M'3.+0,!PZ'.>:R=$^"AHHC)5-='W8Q(XX! '-<HUR*JBG[Z"1C8
M6QMR,9.2XCJ/<O2_:DJHK39*;O7<=7&(F^HW&2UHW^*S;I9'46WZV/DX(Z^F
M=)C/")!E>DMZM\('?5E.PGV0Z0#*XA>+;>K-;#=&5-.'!PCRW<[^1;A6U\N=
M=6NM_HTP:X-]?C:-R<>2U.V=N[17VV2'A;7TQ<!D@2!9#BR%\\54=WMEMBN3
MZF'AE=W?J@$]>A&/T5] 02=[$"/:P-REA*UG6U_^3Z6..!K99'2=V6A^"-BK
M'2%.ZBI6UUQK'Q-C>X%LQP,$8&Y/B5JFLZB>34$T)>.%E3RP%T&Y4,518:B,
M,]0D;$G]8+,]+]LE#?K7.>"&OII'#8AL@."M+[5=30VZSU$4<T?>-?'REX3N
M5SFHNIM>I!34Q<P.J^[=AH.</QU]ZR7:I;'UECJ*UY8>)\;=R0=CCDI_:ENH
MQ%/'+:JFEN,-VFJXRYM3(WC(:S!SPDY.RZ[HO5U-=J6-KY(6.X'./SO%^EA<
MZN&FIJ72;W9AR^B+VX<3^A[EK5JFK+#8:6JAE:V20F,EH#MLD\B/);WJZ9UN
M;?1D6HK3+((X[C2.D)P&B49*]);U;H=I:VG8>7K2 +Y>I-80,KXI8!.V1KN9
M8WG\5L.HKM7U5LMM333!KYWY<7,&_P!B3NJ^AZ:OI:EP$$\4A_JNRKD=5IFB
MK770QB:HEA=PO</5/E[EN8!X1D[XW5LT1)Y+$:@I&55LJ8)9!''+&YKGD9X0
M>JRV,A:[KFIEIM-W&2)W"]D#R#@'?"QEZ=>*6Y332:+1ULAK)'QW>)[BW!:(
MQMR\UU&F:&1-8#M@#*^<+-J&YR7.4&I&.[_W;?$>2^A!+)\E\;' 2\#<$CW+
MCQV;Z>[S<,YCC\ZN9JZE@);-41,(V]9V%C:K4$<4XC@;',",Y#UI=VN;FW%[
M;@72-XP &-'/[%M5HM]!4P&H; [U7%N[CX>_S7??3YF^V!U_K1ELM\#&,C,E
M2U[,=[PEIP/+S6FZ(MQOUR;73WJ6FE+7,]'XB[8=>87CK6VRW:_4],"S@CJW
ML8'$C +P.@\E%915NC+@91+$UC6@8C]<^M^T%,;M<IILW:16S]Q24D;I(XW1
MOC=.UQ'"-AQ'[U9=GNG86SBJ&HY)Y'PN!A)SP^L-_:\OM6\2V6AOUJC?/#QO
M[D;N>YN[AY%<_MH-CUG7T5/ZD4,7"UH];&>$\SOU6M,XUIFI*VLK+G3S2U51
M2&)I C[P^ON=^:ZIH^_.IK%2MF/'F -#WR>T5.H^SZBJ)HJH01]W&SU@9GY.
M_189E.RD+J<C^CP#$;0<XQYK,JMPTE3U,SHZRH=*SA<YI8[.#M_W6X!W+.WA
MYKB=/KNNI*YDC)Y!:F@]Y$(F%Y=@C;Z<=5UVS58N-JI*K<B:%DK>(8(XF@[X
M6OI)>WM672BHB?2ZJ&'&,\;P.:II;K0U8/HM7!-T/ \'!6IZZHA-!,^8!V2S
MJ0N;:'U,^FFN#'.DQ'. ,,;L 2L3+?3=FIMV+4570F$13W&*E>UX)R\ \CMS
M7'=#QSS,J(&W">1LE01Q\9.-AYK*EE=JF_50;+&8. 2-;(.$C #>@\RK#LTH
MY:5\D<[F%QJ21PGI@+IC.NS#5>.G*I]LUO?(JJXR&-I#6]Y(0.?3==UH[G1U
M3..FJ8969QECP1E?/E;:JFMUS?A"^(!K\^L3Y>2SMDNU;8H#'439;Q%Y$;0>
M8QU \%F7I,IJNQ3WNVT[^"HKJ:-Y. '2 '*]OE*C[COA4PF/..+B&%\UW76
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MJZCOE5>;?2$^D5E/$/Z[P%(O-O[LO-93A@&>+C&,>*^==3:ND?=33U;Y'L+
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M&_VKKG#MMS\5B[Q9:>XPD.BB,@:0USAR)ZK%G>QSO7UMK[W0":QT[ZQSYFN
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MJ:R5Q</1H(B9'D';<].:UZ?4M#4W";AG:6N=ZI$;AG[%]'U=@M%6S%3:Z"4
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MUCM]_<NZQ^RL11:8LE',^2EL]MA<\8)CI6-/V!9D;)M9-"(BC0B(@(B("(B
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MKO\ !GA./%>V"1NO.F]@^]>J^7?;]=CZ1PXY<TP1R^E2B*8WRH P=E*("(B
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M$=#XJ6YQOS1$!1C')2B"&CAV')241  P,!1C!V4H@(B( ^Q$1 1$0$1$!$1
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M&N#,'/(>15U>;C-&(.$,W!YCW(TV;(\0F1XA:,;M4</*/X?]U)N]1MM'\/\
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MCB<O>N@KYYG>C&/AV]I:Y1B>UW6%LY;\Y*''AWZKTXXS3YW)G9EMT7C:WVB
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M$>1Z@\0OHZVN,E*QSN?"/N7/CS^73V>7P?JQQO\ E;MM-/C\U%_#"&T4[O\
M9Q#]P+(C.^>2D8QLNSYSP@IV0L+6AN",;#"MYK9#*_B<R//FP%7Z(K&&S4_Z
MD7\,*GY&ISMW<7\,+*H@M8:*.*%\8:S#N>&JV=:*<N+C'$<^,8631$TQGR/3
MY_-Q?PPJFVFG:01'%M_4"R*(KS;"P1<'"WA\,;*P?:("_/=Q;G/L!9-$&--H
MIQN(HOX84"STX.0R+^&%DT06WHD1A;$6,PWEZJM!9J<?[.+^&%E$1-,8VST^
M3\W%_#"]([7!&_B:R,;=&!7Z(KPFIV31<#@W&.'<95F+/3Y]B(_],+)H@Q;;
M/3X.8XOX853;/ UP(9%L<_FPLDB"UJ:.*I!XV,)QC=N5:FST_P#NXOX8641!
MC!9Z<#'!%_#"]J6W14[N)C6 Y!V9A7J(+>JI(ZAN'M:=\[MRK46>G /S<7\,
M+)(@QGR/3_[N+^&%Z4ULAIYFR,9'EO@P!7Z(+&HMT,Q+G,C)))W8"O$6>GX?
MS<6?[,+*(@Q@L]/@_-Q?PPKFFH8H0 &,P!T;A72(:8TVF!Y),<7TL"CY'I_]
MW%_#"R:(,8VSTX=O'$?^F%<TM%%3<8C8P<>QX6X5TB)ICY;5!(XDQQD^)8%Y
MBS4X.>"+^&%E$0TQIL]/_NXOX85Y#3LBC+6M;@^ PO9$5CY[7#,\O<R/).=V
M JDVBG/^SB_AA9)$&,-FI_\ =Q?PPKF&BBBI^Z#&<.<[-V5TB#&&T4Y<28XC
MD_[L(;-3](XA_P!,+)H@QK+3 UP<&19']0*XEHXI(FL+&8']572(,8VS4X.>
M"(_],*'6>GSM'%O_ ,L+*(@Q]-;(:>8/8R,$#HP!7,].R=A:]K3MC<97NB#%
M_(U/^I$?^F%4+138_-1?PPLDB)ICXK5!&21'%OX,"]:BAAJ"2^./.,;M!5VB
M#&?(U/G\W%_#"&S4_P#NXOX8631%6E'0QTI/=M8,D'U6X4U=%'4DE[6$YSNW
M*ND08PV>GY\$7\,(VST_,QQ?PPLFB"SIJ"& Y;'']# %1/;(9GDN9'SSNP%7
MZ(,:VT4X;CNXOX84?(]/^I%_#"R:(:6]+3,I8PUC6[>#<+PFM<,I!<R/;Q8%
M?H@QGR/!^I%_#"D6>G#2.[B_AA9)$32UIJ**$/#6,PX8V;A6\EH@>[)CB^H%
MDD0TQGR/3_[N+^&$-GI\?FXOX8631#3S;$T1EF!@^2LI;3!(\N+8\GQ8%D41
M6,^1H/U(OX806>G'^SBS_9A9-$%L*.+T?NN!G#G/LJU^1J?B)X(N>?S8631!
MC?D>GR?FXOX8545K@C>'B*($># L@B"TGH8IV!KHV8!SNW*MQ9Z<[]U%_#"R
M:(,9\C4^?8B_AA>]+;X::0/8R,$>#<*\1!X5-+'4 ![&'&>;<JS-GI\Y[N+^
M&%DT08SY&I\?FXOX87K36V&!Q+61Y(QLP!7R(+.HM\,[LN9'RQNS*\/DBGW^
M;B_AA9-$&+;9Z<'/=1>[NPKNDHXZ4/[MC!Q8SPMPKE$32QJK?%4$N<QF2>K,
MKR^1Z?\ W<7\,+)HAIBS9Z?GW<7\,*XIZ&*!N&L9C.=FX5XB&F/DM<$CG.+(
MR3ONP+S;9Z?_ '<7\,+*(AIB_D> _H1_PPKZF@;3P-C8!@> PO9$5CY+7!*2
M3''GS8%2+/3_ .[B_AA9)$-,8+-3C_9Q?PPKEE%$R+@#&8QCV5=(B:8WY)I^
M9CB)_LPH^1J??YN+^&%DT0TQ@LU..3(OX85U4T<<[>%S68QC=N5<HBL8+/3C
M_9Q?PPH-GI_]W%_#"RB(,?!;(8G<361@^3 %D$1 1$0%J.I?SW[Y6W+4=2_G
MOWR@P95I<89)H2(R\$-/LA717JP'A/N1FQA;/331,'>]Z3@^T#XK"W6R3558
MR8&<<!/LL)ZK= <;IEH&,'==)FX9<4R:Y#:'34,4,ID]7?+F9\5CY;+-+220
MDSX<?U"MSR&M'#L4 X3LG[+*S?'EFFH4=FF@@[L&;9N/8(5E%I^=D!8'5 WS
M^;*WSF2IRT-W!RM?MK/^FD:G8;++1"L#^]/?X]IA'C\>:HJK&14ND:QY) &T
M:W!QXN#'1"6\9#AE9_95GBSVP<5 1"X-8YFW1N%:/M<CYG8=*/,-*V4$DX'+
MJJL-!( ]93]EVW^B::;+99C<(7YF+0-SP' YJ]KK-WD$7#Q<3=\AFZV-I' 3
M^CU"#ED<CR5_94_1--7H[0^642SF3B&1Z[/Q5I<;%++/&YAFPQY(PP^*W-K<
M\N2G+>6"K.2I_IL6AR:?GDG=([TC?_EE;C1,<R$-<3L -U=<6#Y*@*7/;7'P
MS&I 4M)(.Q0>2J.6M(SLN5>B;>:J:% 0%6!U1!S4[((4852A$!NG).2#=%!N
MF$.R((PI 1,H"(HY(@ JV[-*IRO1N.Z.>>5*U%!ZK4]?@?([]_\ :-6UE:GV
M@D"S/P/]HS^:[\/MX?.L_77,CN<^"WOL9.=45(QC^AN_OL6A/) .#LM[[&'#
M\IJ@]?0W?WV+W<O]7Y[P;_NOH.F]@^]>J\J;V#[UZKYE]OUN/H1$4:$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$/)$0>4X!B=TV*^=
M.V)W_B:(D;>BL_O/7T54 F-WN*^=>V9I&I8FC_A6?WGKR^3/XOM_A+)S=KKL
M: %QJR#C+H?O<OH*G]CFOGWL8WKZS/Z)A^]R[D^YPTIX9&R$_P!4#\4\::B?
MF++R],HBMJ6KCJ 3&'#&.85SS"]3XHF5!QC*M'W&)DA86R9!QR'XJ"\11GKT
M4J@BA[@QN3R5K3UT<SW, ?GBX=P%!=9\ I0;(J"+RFG;"/6#C[E%-4-J&<3
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M4V*6H#V..SF@CE[UR?2E";?J=X94SRB2N#B'NY>OR6%[.=9551>XJ9AJ&4_
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M'T^*]#Y2H9WRIZ(.2("@9SY* 2W)<<IQCAR@J10#E2@(B("(B B(@(B("(B
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MS5L&7L[UF <'S_FNJX&,=%3RY-5G4TECC5HT=J*[5\7Y44#*6!V1(ZGF9D
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M875$]QIK:9+3#%-4\;1PR';'7J%RK3.J]9U^I?1JFVVYM,RJ$;W,]H-XB/\
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MH"(B M1U)^?_ 'W+;EJ&I/SY_;*@P0YKTQL%1U5?0(@B!250SLJ0,%2U#S0
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M9K=0SN)GI*9Y_KQ-/\E+V3IPC0^IZ>34S<N=PU%4'>QT)/XKO='(R:%LD.>
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MG -S,,GW*;GK2CHGNCXJ=SVN (,P!Y+TOER[;<=@522<#"UVGU32OMTU4Y\
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M9A&U]+("T.XN_ \54[7%%'2F?CIR"SC/SXP-LJ;&XCSYH#G*TRV:ZH[A3B2
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M2@U!!,^8/K,B+$9.?:Y^',+"T<E"X"JI^\[Z08.>6/\ Z OK,V2U$_ZLH?\
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MO&< 8RN=]IFK;/6T$5/!70/<R<./#G..$^7FIM9'4+;<8KC Z:G#PQIX2'@
M_P#W=7K3D97/M$W.BMMGJ)*NI9&QLO$2[.PX0LM#KW3\TKXV72F);SQQ?@JR
MVHCX*  3[EK$NN;!%4B":YT['D<6#G./@O3\L[*(WO-P@X ,YWY?!/0V54';
MW+5H->Z<F=P1W:F=)SX1Q<O@M-/:%056HZ>-]13L:R<L:07>L,\U-E].N-(/
M)2>>ZU2?7=@I8@9[G3L?G!!S^"RMIO\ ;;IDT%7'/AW#ZN>>,K7Q^TVR501W
M;O<OG3MBVU/$!_PK/[SU]%3Y[MV!G(*^?.V&AJ)=0Q]W$YS?1F;C]IR\GDS<
M?<_#9S#EW578^>*MK0[<9B^]RR7:-34L6HY*@QN[SNV-R"?#WJS['J">&NJC
M+&YHS#C/O*Z5K;1$&K*)T514ST_$YIS& 3ZOO7/@POVOY;DF6?\ &N=7**D%
MZT_W,;FO<X;DGGEOFL[<-+BKJ9*A[8SQG]=P/)/\BE!WL#S=:[YO'Z+5<U_8
MY;ZJF;$;O7-:'<0(:WS_ !7MLZ?!QFFE7&],;I.Y147>,<>7$T$9V6KVFT7:
MY-IY::>G:\\+W%^V1GW+NUK[.J.ALE5;165#XYW\9D<UN1L!_):W+V)T'IQJ
M676NR7\6 UN.:8S35[876-76TL$U#<)6OA<UKG-8T;^MMO@'F%;WFUVJGH+#
M/!3O;+/$'O)>3EV&'//S*ZG>-$4MQLT]O?53-9*6DO#1D8<#_):._L%MCY>\
M^6KAGBXL<+=MUF_V/IOW9\0=.TX'/B?_ 'BMHX@,#J5K6C-*0:9H(J:GJ9IV
MQEQ!D !/$<]%LA+N6-O%=*F,TK'+=%#1@84J-"(B L9?*J"GI2:EKW-XALW_
M /6LF1E8Z]6QETI.X?(Y@X@[+>>RQ5C@FNWT57))+;HWQNCX^(R>.>FY6<MM
M-#6=EMF;6M[P"=YV)&_'+X+*5'8I;YWU)==:X=^XN.&MVR2KF3L@H38*:U"Y
MUO=0/+P_A;DY+C_^DKKHK3=$V"VOTK<WR4Y+Q*,'C=X-\U[:-LEO^6+X1 <Q
MTY<WUW;'XK;-)]D5%IT.;#<JR8.?Q^NUOACHKRG[+Z2GO=9<F5]47U)'$SA;
M@>[X)G/\)'#F_*%VN<<39H_6;CUACED] MQI['616*Y&X/AD:RE<8^ G;#3Y
M#R6\:F[)J"^US9Y;C5P$1AF(VMZ$G^:MI>QRAFHS3.NE:&"/NPX-;DC&,IA/
M\I6%[$;12U=NB-1'Q^M)^D1]R[?"P,8&-&&@8"T'L][-J31LS'TE?4U/"'#$
MH:/:]RZ"%TM3$1%!"RTE$3.VZD#HH'LIGPW5)+O!*.4]L38ZBXVV-P)S&]OA
MU"U*:STM'9Z>H@BX9WNX7.XB<C?H?<%O_:#V7TFL:VDJ*FX5=,8&N;B(-(.3
MGJM8E_\ Z?[4^%L9OMQ#0<YX6?@L2#2M>5];4W^@IF2MX9( ""T?K.\E<6&S
MW:C>9^_I^ZD P!N<9]RZ?5=E-%-;)J0U]5B1O#Q\+<A8ZT=C-%;2\QW.NDXV
M\)#FMV6L8-.U_)15MOEJ*".1F QOSG//%OU/BK>IH*>JL5H[]G$6P#](C]%J
MWA_8G;B_/RM7$?LM63H^RFA@I)H!<:LA[.#):W;8A-=EO2[[);=2TNFX701E
MKN.09XB>JRW:!ANF;C_Z=_W+QT+HR'25&R"EJIZD-+MY0![1ST5UKMLCM,W)
ML;.)SJ=^WT*\O<=/%ZSEKY\L3S\L3\.Q[K^;5]+4LS*>W-DD!(:UIV]P7SA8
MJ"K;>)W.@< 8L?:U?1T$/^;.$DY+1_)>7@QU:^O^2RF6.&O_ 'ICZ+5UNJ[E
M44$<=2)H,<1<T<._AOYK86'B&W-<4HF\':+>@20 YO\ ^BNEW/5MHL\O!<:Z
M&#U0[U\\B<#[EZI>GQ,IJZ9*\W>GM$ EJFR.:0X_-@'D,GF0K>P:AH[W$):1
MDS021\XT#E[B5A;S?;3>]/7(T==%+P4LCAP9ZL..?N6@=FFH[?9:=GIM5%$
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MKN9*1SW\43SL<-R/MPMJD[&Z;TN>9CK@3*3GYZ+']U>EH['J2WEI8^X%[22
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MRC[AA?GTB4YQ^\O32\^I*6TU$%S="(W2DD-#3ZN!X>Y6EJN-V9>K@RW.CXG
MM/$T<L^:UEWZ:QG7;8]"ZJKZ(Q4MSJ*RMD+W.,DL[CMP[#?/@L=--?M2W.\2
M6^_7"@BHIGN[ML\F' N=@#!&,</VK/Z1TE5S,9/=(FF4/<,MD'+&W)85UMO]
MCNEU;0-A9!53.'K%KB6ASL<^6SEG'_MCM=Z<U%<J9K*"JJJVIG;EQE=,XD]>
MNZ\[=!?I*N62?4=="QTO$UDD\@VSR&7+(:<L=:9V5]:QO&06DAP]PV7GJ&DN
M%574K:4,)&6C) WSLI?;6F)N]1?+?7S2?E!731$AK6-J'X&W/VO)>5YK+Y1Z
MNM4(U!7NAD8'.8VH>&G=W,<7DKS4&G+X+7 Z*.+TDR>OEXQC!_[+"76V7VKO
ME%70MB,5.P-<2YHP<GI]*5O'6C5-PU#0UC)8[_<C%/+PMC942 -^U;#JBMN]
MAHI'37FLD<WA/Y][3N<=2M<NMLU!<98 &PN;'('>TT+?M=:;FOMHF>8P^?U&
MCU^$8#LJW^K$_LYE%?[[37&CJ!?[C4PU$K7F%M4\AC<@\)W\\?0OH;3UP-PM
M[:AT;V$DCA<<G8KAUBTFZEK0V:(!S9& 8DSN"NYV.G=3T#68PX$]<]5J>F;[
M94<E'4H-@J7GU<A9K<<R[0[9=)*=TU#JF6@X(@.!D[FEQXN>S@M9T'<+Q+/=
M:&HOM95/IZ8XE=4/=D^(R5=:RMMZJ[E31R-B-,Z/#_6 /,_]EBM+V6YVFY72
M6)D;6S0\#<N!RL?2UBK0-4U$@B_*BZ.<XG?TB4]/VET'25]K*&EN0N-54U;X
M(AZTLI)RT.R=\XSA:58J34=%4L<1"' D\VGHLK8*"\U<MW95"(ME!!P0.?%E
M;Q].=WM-=/>-7UY?;+U6V^!S1AC9GEH+>?(@+W[*V31W*JCJI7SO;4,;QO).
MX)R=U8T]LO\ 8:ON[:V%E,!D<3FN.3SYJ[T!0WRDO+I*X1".2H8X\):=LG/W
MK.,[;R].V1[#GE>B\X2'1A>FZW4GI976K%'2ND<"=CUQT7%)?ES54GIU%?JZ
MAI<=V:?OGEI(WSL0.H^"[5=Z1M92/C(R<'&^-\%<6I:#4%C(I*<0LI_;():X
MY/G] 7*R[::M:Z&ZQ5UX%/>*B&6&4]Y(Q[FF4@NW.#Y'XK/OJ[\_1XD%_N#9
M^\QWOI#^+'%RSG*M[19[[Z7=Y*IL6*F3B9AS=\EWXA5U%IOYM_H#&P]V#Q</
M$WQSS767IC)>^EWR:P5D[+Y7A\$!/$)WYR&DYSG96=FI=47FS4\D>I[G YV7
M&0SRG."1C/$O*CI=00VJX4@$(;,PL(RW?8CFMATI37FCL5+3R"(-8'8&0>;B
M5S[VW],=8*B^SZ5NADO]>Z=DA:V5U0\N;L.1SD+'V=NIZR::,:ENCNZ;G/?R
MG/\ [EX6VFU'26^LI!W($SR[&6G/+K]"O]/1ZBH9*@M[D%[.$^R5TR<L=LU'
M?KG%I2H!K:V6H[T$2]\[B R-LYRM$N,VJ)JD24^K;FP2/)$3:J7+,G9N Y99
MKKU1VF2.H,09QY.,'P2W6\![:QS?7RV5QSUY\EG#VW73NRJDNT=FBDN]QJJN
M7B>":ASW..^WM%9;7_\ ^&;D0,XIW_<FB+H*^WL<'<62[]''(JYUC22U5AKH
M*4 RRPN:T$XW*O+ZNG3Q;K./G.S.S>)]L?-\OJKZ?M6]'&2,>J.?N7 ;;I&\
M0W:=\T40!CQM(/)=VFDDI+(^0D!S&-\_!>7@QU;M];\GG,L,)/\ WIE!CWA3
MLN=Z>UJZMU%7VU\V33@>KW6,9(Z_2NAMY97K?&J41$$%.0\2IPK:MK8:*+O9
MR0PGAV&=_P#Z$%QPCR4@;87C#,V7<'*]1S*)#/12B(H>7) B#/5 1$0 $1%(
M"(BH(B("($.>B@!$14$1$#DB@<_)2@*D>SN=U5@*,9Y\U!(Y*!N-PI')%03F
M-D3&!L@(B("(B <=5 W6'U-7RV^VF>%P:_C#<D9YK!:-U5)>:BIBDEXS%(V/
M\WP\\_@I+!NR84#P4J@B'/11L3YH(!W.0JE:RUT,<HC<X\1=P\NJN6D'DD1*
M(B*@?%2F B B(@(B(")C9$!$1 1$0$1!YH"81$!%#5.$01$11$3J@(H!WPIZ
MJ0 G5$Y*@B(@(J1G!6H:XU#/9(XG,D# Z0M]CBZ94@W#Z5("UK1E^^7:!U09
M./$ICSP</( _S6RA4.B(@0,;J&]<J<]%9BY4YG;$'.XW' '"@O$ZH"",CD@.
M4#"(B B(@(AY)OCS0$*(@CD$RIPH(SA!/).B(@!$0) 3&R(-T#"8"(@(B((
MV4\D0=5 PH.W3FI0'*H(A&42 B(@(B("(B M1U)^?_?*VY:CJ7\]^^Y!@B/-
M5@;!4]%4.01$%%*A Z*5'12>10 @1O5$! H1!(V3FH4A!/10%*I0$0*43TA2
M-D&^R(HF-N:84=4$A$1!"G.$4#=!/,(G1!YH V0HB" IQYJ,(@D\D')0-E(/
M-0$!3*85#/DJV[MY;>*I \56T^H1T38IR/$;*RN%TCML9GDX,9#<.?P\U=N
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M@/4X9[_@M<UM44]1'-:2UQK96M<TGV< YY^X'HL5I2\4UE;54E0).\FX8F\
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MX"X)V?24SM24396.=+Z1@'IR]Z^B:0 1-#>6%ULC.WL-T0#"++3"ZM -I=D
MCC;L?I7$K-JNIT]<;C)26>2N8)RYY8\M#<$\\-*[3K*=D%H<Z3);QMY?2N*6
MNY6YM/J .BEXG/=T_:\UQMN^FIJQU'36OH;K;(:FIIXJ*9X=Q0OJ 2W#B.H'
M/&>75:[)VORMKVPQV#CILD/J!5'A9SY^IC[>JT6US"J>64.6$-)];PS]*UVQ
MVO4%2ZH@]*@,4DI!:<#/_M77'_MR^W?ZG6]5\BTU=;;+)7OER3%#(7<(WWR&
MGP6"L_:I5UE?'25^FY+?(_)'>SD' !.<%@\"%@'WFJTAIR@BEF+)'YA)B:'#
M.YZA:Y!45L^JZ2KKI1)"R,M<  #R=CD/$J+],OJ'7%S_ "G@92V6JGC-9C,<
MKB,<0\&KL^FZ^HKZ 355')2/XB.!Y.??N N,&IAI[W0/<'<,M2WAQ^T%W*WR
M-FAXH\AN3S6YZ3M>Y0*,@*5&Q,HB4><LHBC+W8 'B<+FVH^U06RMDIJ"U-N+
MHI71R]U4[QAIQEP#3CJM_O#7.M\P80';<_>%\MUUMO@U??\ T.IA8R6KE#@<
M;M,COZJYRW;6H[-%VH35%K])I;&9ZDNP*:.H+G$9Y[,S]BL[=VO.JX*POL@B
MJ8,AD!JLND=OZH'!G.1A8#1]NELM/'6W+@>QI<T]V<G?8>"P-1#2-N4MSH8S
M'3T\IGJ 2>)P!XC@9YX!\%TOIETN'M%NTEMCJW:3JV!Y(P9';;D<^#R6.9VM
M7.6-\D&D*F2)AP][9W$-/F>[5[9M1V^ZZ5I&TK9P2YSO7;C8.</%:UIV\T$%
MCN<#V2\4DAY#;D/-9PMOMG*Z;]:-?TE=01RS,IZ>I+.*2G=4CBC/@=@?L6M3
M=KE:V4.ATQ++1 >O5-J#W;#X$\&/#KU6B4ELJY[K755,Z-M/*,M!.^/@LA9K
MK;8]$5U#4QRNEDFXA@;8RSS\DMNVL>XZ=%K^GDMD=4R&%TSXN\,(J 2#C/#R
M^CDL?9>T2Y7$CBTQ41 YW[UQY?N+5-$VJ&6.LEJXP^$L:ZG <06C?G]GBKR&
M[2V^Z]Q'(YL(9GA#0=S[U-U&8':=5MND='+IZ5CI).[:73D$[XR!P;J7]J$\
M>H:FUS6)T8AC#^]=4$9R&G&.#^MX]%JMZJ!3ZFL5149+72]YZHWQQ K#WN[T
MTO:#<GD2&$Q,P,;YX6>:L])WMO,G:S4,J6P#3SC*_P!AOI!R[W#@5Q6=J;Z6
MECDELW#,XX,+JG#@?#V%H-%6457J^U>H\D9 SMT/FK/M.HZ\5C);=)'&UTXQ
MQ;]/,%.]M_3IVE>TZ2[W*&BN5F^2Y92[ FJ/6X0TG."T;'!"Z-!*)HVO;@M<
M,@@Y!7SWI*R7JLU!2UMTG@FECXV!P.,-X3M@ #F2N^6EAAMU,Q^.)K #A=+)
MISQMM7G5$19;%&/-2G1!;U=5%2Q&29[&#H7.QE<UN7:G6P2 V[34MPI0WUZB
M&<EC'9]DD,(SRZ]0MLUS3U,]L:*9[6D/)/%X<)7+-%W:WT6G:NAK8Y722S\8
MX1MC#?/R*Y[NVNF\TO:.RIM[IHJ&-]1'%WDM.VHRZ,XSPN]7(WVY+%VSM6JK
MB&M@TY(^<YQ$RH+G8'EP+1=.,[NYZFGBVAD#W-'7ARXA97LGEI9-0TSN!W><
M$F_T'S763ISMKMMLJY:NE9+-3NIWN:UQ8[F"1RY#DKP<EY-(PWP.,+U2K$#9
M:#VJ</H--F-KCWIZ?U5OW7=<Z[6:J*GHZ;O0XYE(V']58:CGW9]KZLLEN,3K
M#++!WSGNG,I:UN6@8/J'P\>JZV=:4K+-3UT@@:^:'O1$Z< YQGASC^2XG;KA
M1MT57-<R3O#+L<>;?-7EY+ZS3=K]!/ YE.22_P#9&/%2VHW2W]KTE15\$]B]
M'I\$]^ZJ]7/A[&/M6>O>M[A14D-1;M.U%Q;)$93W+W$-VR!D,/-<-TO:;W7T
MS8:FH@DBR3C(&X]P70J_457:J*EM\$[F2R1=R,,:1Q !HW(Y*LRLUIWM1GNM
M>^CJ[&Z@JF1F1\4E02]NXQD%@.X(*TBTZTNLNL*2-MEJWL,KAM(XCK_56-TN
M^J':/<IKG()974F"YH&_YO'(#H%F]-3-BU=0\>=Y21CW%=)K36W<;14R55N@
MFF@=!(\9,;N;=_<KQO)>%$X/I8WMZA7 &.2B01$44)PO*>>.!G%*]K&YQESL
M!5OQU6&U-$^:W-;&0#W@._N*QE;/1&@5_:_)%4M916+TR#<231566Q^_#"K]
M_:95&WPU%-8)*A\F[HV3DE@\=F+AUBH+ZYU33T]3"V*23#FG&_\ [5TZR1FR
M6N)UTP_CC[OYO?UN?DK/2,LWM<EDIGFFL7?UF?4IF5)+Y/' #,\LGET5=?VI
M7>BI:::?1]6SOAR?*YN-O[-<[I'066Z07.9I#( <EFYW!;L#[UN^J+Y2W6PV
MJ2$2X:P2.XF@;%H\U=_2Q[M[7:UK.^J-+RPTO(SOJ"& ^&3'A;/7:^HZ:UQU
M+13OJ)83)%3^D@.D=PY#&[9))('+JN6WNYVZMT%)1P1RBI,H<"X8& [/BL;>
M+764TVFZJH?&:>)S9"&G?A' 3T\%K6HSC=UT*C[5ZU\Y%?IF6BI\;32SD-)\
M-V ?_J6Q:AUU':X.*FIHZR<Q<;(63X<\^ P"N<:DN5#<=/1PTS)!-WH<2X8&
M!GS6R1V>G[F.HK8@^IC:#&\./JCW<EC;<7M%VCW.I@#_ ,EJEK\9+.]<2/\
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MS.-G$?R7S9IW2NH;Q45PBOT=/$9N%S'M.X)*[IV;Z?K+';H:>KK8ZK@C<W+
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M3E_>-;@.<>$DC.XRL[:=;N6H;;;LMJJIL;QC8L<>?N"NJ"XTM>PNI9A(!C)
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M;"0W)!._T>Y8RAU=8ZN3NX*]KWDX [MXW^D*-6&E- &U4D,;>\&\A &<'Q7
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MCB(:[<C)&=^2M9QMKK=+J>TU;G"GK&OP,^PX;?2%9BKL]5<X7MJW&JQAC0"
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M/Z[M[A#3&WBECPU@+@3PCZ%UCID)G;DO+K7;ZOUIRBZZ1U17:ECKY!1F%L?
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M$UH#._DR=QZW,++2V?657:JFGK#0F22(QCA( W:1X+I**ZZT.*2]G>H9;1%
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MC&]5M6'XYA3@XV6B7?M"HZ&H?%'+3O+<>UQ=5>6_6U#5V^IJ(IX'=RW+L!V
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MNV\G'BW6;339-3ZLH-/1\=;%4O\ 4X_FFM.V<=2%<:;U!2WZF9/2,F:R2,2
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M<C#RSRPT>*L[MV3V*YUAJ:BIN37%H;ZDC -O>Q5,+IQV>:>&GNC:%YAC'$"
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MUSXY]MYWI;=I%+.[6='1TLPBADI XMZ9XI-_L"R.D](5\-/75$M= ^)\0=P
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MI]O<-X7-=D9.^Y5GJ!HIWL@;M V4-:T<@%U[4V@K7J"J@J*R:L9)"TM:(GM
M.3G?+2J:C0%KJ+5!0235HAA]DA[>+J-_5\USPFFL[\G--:VRAMM,^IM-.RFJ
M(V-+7M))!+L'["NKZ&DFDTQ:GSR%[G4<1)/4\(6O6'LFL5HKHJJEJ;DY\9)
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M;)JQINLE)3O_ #<O=N!9YX69N=L;6SEQ!.0.N%!ZVVT6VB:30T=/"TX([M@
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M.N%12R=[#&_JYH/Q5P%ZM/D1YAC6[C'P0L8=RQI/N51PT%8VX7$0Q2]WQ![
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MD;G).P"JTE:[C:]8UTC)813&FX&M!R0<L/4>16>*:K'(ZK5F2*VO[L.?(UH
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M%QQEX_K+N]AMLMOM@II:V6J>'EW>OSG?IS*Y3<+1<Q=;?51RP!YJ!)(2>?K
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MC.Z"I05*IZH0504*0@%4JHJE!/1 B@()SA0G5$$@84]%&40 40(@A2U $.R
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M(!CGNI"J(+0>8!4<#/U6_!5(BHX&CDT?!0&-!V:WX*I$$$ C<!2 !R "(@$
M\P"HX6Y]D?!2B""QIYM'P3@;^JWX*401PM_5'P3@:.31\%*(*>!GZK?@I#0.
M0 ^A2B B(@(B("(B B(@(B("(B M1U*/GOWBMN6H:E_/_OE!@\JL<E1C=5@;
M(@BE0.J"0=E"8V4(B<*GJJAR1%0I1,[( ZHHRGTH*@BC"<D$*0$4()Y%1E!S
M3Z$#&0JL;* 5(.4%*!25'1!4H10@J"@E1@J0$#W( >B-"'R0"H&R94CW(&5&
M5*((QE %/,( ?%  7K'^;/O7EA>D8]0[J#S<-UJ?:%_J9X'^\8MLSDN"U/M
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M42U'%)S'$W ^Q;$-T4L6=-1CT';6N#Q45F1_6;_A5+=!V[BD/I%9ZQW]9O\
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M$IQ'+&[IZKP41<(K=U=2L>YKZB%KAS!> J?E&C_XJ#^($5=(K7Y0H^M53_Q
MO>*:.5O%'(QP\6G*"M%;OK:9CB))X6GS> J?E&D_XJ#^($%T$5J;A2 X]*@_
MB!>L4\4@)CE8\ 9/"X'"(]<[X09SNK7Y0I,9]*@S_:!2+A1X_P!+I_X@15RA
MRK87"C)QZ5!_$"J-3"T<3IHPWGDN"(]T&>JM?E&D/*J@_B!!<:,_^:@_B!!=
M(K7Y0H^E5 3_ &@7H^JA8PN=+& .I< @]D'FK47&C_XJ#^($^4*,[>ETX/\
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M X^ D""Z3ILO&6IAB.)98V#&?6< O/Y1H]_Z53_Q @NAG&Z*U%QI#SJH!_U
MJXZNFE.(JB)YY8:\%![HO&6J@B)$DT37#F'/ 7F+C1_\5!_$"(ND5J+C1G_S
M5/\ Q JXZRFED#(JB%[CR#7@DHKW0YQLO&:JAAQWLL;,[>LX!4?*%'_Q=/\
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M@$&B.X@=SLMATV<\>?ZG\UF!:HB-R[X!7--2,@!X23G'-!KNJ/S\@Z>K]RP
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M=I)0[ X6]?)4)&[G? (+5"/TG? (-'BSQMSXA9^\?Z)(!RV^]9KY+ASGB=\
MO>:D9*TM<2 4'/AUPJ3MN>:WP6J$?I.^ 4&U0G])WP"#5;.3Z5%CEWC<_%7&
MHB34/QRXA]RV6&W11.#@3L<\@JZBACG<2XD9\$'/@2?94YP-UO/R5" <.=\
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M&.9_>%TI<P 8QG!']5=C%3QVX3L&0]A(X3Y=%QJ&L=K/5ENK+>2RBC'<2,G
M:XN'$[;&=O6'5=@AC%':61/&6PQG9N_(*VW3,G;B\NM[K#K*FM/HU2>\C+_S
MS\^RX^SCR54FN;I!6S024U2"Z0L9Q3.!.^-AA:M==44$7:=179\=0:>* M<
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M0^.DKOFWEGJR//\ )=/LE&R&QTTI:.^=D.()W]8KC=BU5%965,%5WSN.8O\
MFV-.W+J1X)A?\E;YHW5]372U-'51OBEIXQGCF)=G/4'DM=OFK+A:*P.>^H<
MP'@=.YH.20O+3M%73W*X7JEEB93UK>-@=[8'F,8^U:G>[LRYT,CZ\/EJMFAX
M :.$'EM]*F2MHU[J"X5MFL<U.*AO>Q.<X1R./,-YXYJ^T1?ZRV:8C=/'-M(X
M?./<WF?-8Z4MJ-.6HQ AM/3 G/APCE\%[4O%=M%L]"(9(9SO)ML"?>F#&?\
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M<9+H2&\(=GGX+98Y6Q1!DDH]&'LESO4SY=/%;1JZJ?)74=#&[#:C,3@0,')
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M$YHEXA@G."/#'FLSK*Z.H*6".(N:Z63NSAH/,>:5F-(I@RDB-+%.U]*\\;I
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M-=/I1M7 6\8?ZHZX*\_E*DR1WNXY^J?P7$NSR_7FOMS:&M?7=_)*X^D2D^J
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MGO!E_:^@*<9:?>O8+RI_9/O7JOEWV_7X^A$110;(B( "(B 1E$1 1$0$ZHB
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MTLB#>^#0!GEG9</M6M:J6XRQO;*0(\[U!/AY+N]$_CIV.QS:#]BX\4G>GO\
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MY#JO"X53*6 /&=W8V^E<RCUK2M8T&6'E^H]933UZIK]7R4K96DMC,GJ-(.Q
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M&!^*HR"94-Y96,O%YI[2QKZADC@XG 8!T]Y4VK*(L39;U#=XFRT[)6-=D 2
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MDK&AX9+&96,#3\V",@9\EKY:Z33;]-UEKIPRF%4?2!Q'@(/+X+:7R\,#G@C
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MPXH PR DO:X[#/@5TBUZRH:RU0U3ZJ'+R1ZK'8V)'\ES.R_)3;9??3(*5T_
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MD#VL_P T^,TLY;O3<&2!_K-.054<!6M#$88&!SBX@8W5US!)YKE>GIQMTA%
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MJ809&N=WV0>';/FNGL #<!6U-0T],/Z-!%!MC,; W(\-E=#9""(B*(B("(B
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M_*^@*8>J?>O5>5-[!]Z]5\J^WZ_'T(B(HB(@ 81$0$ QR1$!$1 P$PB("(B
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M.^.1PK$:?9GD[ZR*\?RBQOW3_K*]MUV])/L.'K8W*\OR?B/,/^LKJAM;:8C
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M<TG>EIYXQE8674'!(YO=/YX]I9QM.!3=UOC.>:Q,MAC>\NP[<Y]I!;_E#O\
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MUE>6Z[^E2AO=N'K ;N\5XC3\8Z.^LKJ@M+*60. =S!W=GDBO2YUWHP/J$GB
MV/DL5^4/_*?]99FX4+:EISG.0>>%C3I]G0.^LB/ ZBV_-/\ K*ZMUY-56QQ<
M#P'9YN\BJ/R>BQR?G]I7-%:&TU4R4!WJYYN\B@\KC>?19"WNW.]8C9RM!J'?
M\T_'[2R%=:&53RYP=[1(P["M?R?9GD['[2#Q_*')_-O^LLC;[H*D#+'#()W/
MFK7\GX\\G8_:5]1VV.F P'8 QN<H,;-?^!_#W;_K*D:@V_-O^LKF2PQ2.SAW
MUE1\@,QL'?60CP.H<#B[I^/#B61M-T],;.>!PX #N<^*M?R?81@AV/VE?VVV
MLHVRAH/K@#<Y\45CJN^]U(6]V\_O+R&HL_[)_P!97=39&2R%Q#OK+R&GX_!W
MUE$>)U"1_LY/K+-T-7W].^0M(X3R)6+^0&>#OK++4E*(('Q[X)\51BJV^=Q.
M]G=N.#C9R\#J'?\ -/\ K*\JK+'/,]Y#MSGVEX_(#,\G8_:0>(U#G_9/^LLE
M27+O:'OBQWM8YJS_ "?CZ!WUE?T]O$5'W.#CBSS16+?J+#G#NG[''M*G\H\#
M\T_ZRN'6",EQ =D_UE3^3T>-P[/[2"F*_P#$\-[I^_\ 65_4W+NJ6.3@=ZWF
MK6.Q,:\.P[(_K*]FMS9:=D9!PWS1&)_* G_9O^LGY0_\M_UE[_(#.@=]9/R?
MCVV=]9"*[;>O2JL1=VX9!.[LJ_N59Z+'Q<)/JEVQ5K0V=E+4B5@=L"-W95[7
M4@J8^%V?9(V**P;=1^,3_K*1J+(/S3_K+U_)Z/.X=C]I2-/QCH[ZR(IIK[WK
MR.[>,?UE=W.Z^BR</ X^J#L?-><%C9$XD!V_]97%?:V53^(AV<8V.$&,&H>?
MS3_K*!J+_E/^LK@6!F^SOK*!I^,='?6075GN?II>.!PP0-SE+K<_0W$<#G8(
M&QQTRO2UVUM&7\(/K$'<Y2Y6UM827 [D'8XZ816*_*$C_9/^LI_*'(_-/^LO
M;\GV'F'?64?D^SH'8_:07%MNWI3P.!PW(W.>B\JZ]=Q,YO=O.'$;.5S06IM*
M\$ [$G=V>BHJ[.R>5SR';DGVD18'4).PC?\ 60:CQL8G_67N-/LSG#OK)^3T
M1YA^?VD&2M5;Z9"UW"1G/,YZK'UEZ]'>&F-YS_663MU&VDA:QN=L\SGJK"JL
MS9W!S@[;P<@LAJ/<CNG_ %E/Y0[_ )I_UEZ-T_'DG#OK*H:?CZAWUD%U;[GZ
M0R1W X<+>+<JQGO_  .([M_UEDJ*VMIV2- .'-X>:M);%&]Q.'?606WY0[?F
MG_64?E"0/S;_ *R]SI^/H'?64?D^S')WUD&99/FF=(0=AE86IOO=RN8(W[']
M99P0 4[H]\$8YK$5%BCDD<_#LD_K(+7\H<-/S;\_M(W47(&)YS_67N-/1<)R
M'Y_:4MT_&-\.V_K(+MMQ_H'?<#O:QC*QIU#ZQ'=/V./:65%O9Z'W)!]K/-6)
ML$9<2 [<_K(/#\H"?]F_ZR]*._=],UAC?N<;N51L#,[!WUEZ4UC9#,UX#MCG
MVE!ZUUU[B)K@QVYQL58?E"1_LW_663J[8V=@&#L<\U9?(#,\G?65'B-0YSB-
M^W]97=JNYK*T1<#AD$[NRO(6",<@[?GZRN;;:6TE4)0#D C=V45[7.O]%:/4
M<<@\CCDL5^4.#^:>?WEF;A0LJFC.=@>1PL8+!&>COK(CQ_*'_E/^LKJW7GTF
M5S.[<,#.[LKS%@9@[.^LKB@M#:61SF@Y(QN[**HN-W]'> (W>SG9WFK3\H=O
MS3_K+(5UI;4/!P<8Q[2M?D!F.3OK(CP&HL#>%_UED[-<#7"<\+F\&.9SSS^"
MLVZ?B(W#_K+(6J@%")@T'U\<SGEG\4(M;C=O1)'MX'.P0-CCHK+\HCC\T_ZR
MR=?:F53G.>'9)!V=A67Y/L\'?617@=0D#/=O^LLA;KKZ1$7&-WM8W*MCI]AV
MP[ZROZ*V,IXRT XSGFD1855\[J5S1&_8D>TO$:BP,F)Y_>5Y4V1DLCG8=N2?
M:7DVP1G9P=C]I!X'4./]D_?^LLY:ZGTJ@CF(/K9V)SU(6)^0(SG9VW]99BW4
MPI:-D(SAN>N>N45B*N^]U)@1/V_K+P_*+_E/^LKVILL<K\X=O_67A^3T?@[Z
MR#Q.H3_NG_661@N?%3=YW;MVYYJU-@9X.^LK^&VM93]W@[-QS4&*?J L?@QO
M/[R?E'_RG_67N^PL>[)#OK*/R>C\'?65@\#J+_E/^LLK<+CZ+%Q<#CZN=CA6
M/Y/L\'?661K:!M5'PN!Y8V.$1AQJ+(SW3_K*/RBP?S3_ *RN/R?9RP['[2@Z
M>B+MP_ZR"NW7KTF8MX'#ES=YK/+"4-E92S%S0[F.;LK-HHB(@+4=2_GOWRMN
M6HZE_/\ [Y08'JJQR48W570(B%.<C&$"((\E(4!/>@E1E2$.,HAA2J5(32F4
M3"(('O3*(!S03S484H@@*<HB!]*!0I&Z",HU%(\D$DX!5+1LIPI04J0B@HIA
M2-D!SR4X1$9\E"J&RA !\D"*41'4H$ZH@9\E6T9:3G'DJ%Z,_-GWJ5J/)PYY
MW6J:_ %E>W _.-_FML/-:GV@_P"IG_VC%WX?;P^;_P =<R.!T6]]C+0-3U+@
M>=&_^^Q:)SR%O?8T"W4U2/\ \F[^^Q>_DG\7YWP?^5] 4^[#XYYKV V7C3^S
M]*]E\N^WZ['T@>"GH@WW11H V48\U*('+F44$ \T:X'D@G'FB(@)UYH@'CS0
M$QMS3*=?)  0CS1$!$1 "(B!A$1 1$0 B(@(B<QL@(.?-02 F=@4$A"B("@9
M!\5*("@<CO\ 2IY<U3@-'DH1YS[QN'D=U\[=KYQJ:(N./Z*SG^T]?1,P)C=P
M^"X!VO6V6HU'$6<&?16#<_UG+S^1+9T^S^'SF'+NJNQO'RA5EH'M0[CWN7?H
M/8\?-<*[';?405]9WA9PYAY'S<NZQ>JW 3Q^L4_+93+EZ>AYJ3R4*0O2^.(G
M+W*"=MD#&RD*"=\=5* H QG=3G?"IR<H*B$1% 1$5!$1 (0#?FB(&$1$!$Q@
M;)T01^DI4-^U-B4$\NJ*-B<*3L"@*#SSGZ%(W"C&VR02$ZJ,@8\U* G5$0 B
M(@84';IS4J"@@C; .ZU;M!'_ (7N0S_Y=_W+:=@_S6MZ\@?+IFY-;C+J=X&?
M<L9S<=N#KDE?/-A#1=ILD'YK^;5]/VH?T2,<P6C?Z%\V6.T5(NLSB8\=WX^8
M\E])6SB91L!QLT?<N'#-6OI_DLIEACJKT#!.ZD*AAYYYJIIR%ZGQDHB("(B
MB(@(B("(B @1$!$1!&/-2B("(B",;'=2-AXHB HQOS4H@(B(&$ QURB("(B
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M]H'^IG_VC5M><DK5>T ?YE>[_F-_FN_#[>'S?^.N8.Y%;YV,$#4M1OOZ&_\
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M!ZPST/3*Y_H:]7V2]7:FNUP%0V&H;&P-8T #B<#R \ I!U)[FC<G"CO&C8N
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M(GPQ\LHP!UR5Z:GKZF@>0V*,Q<8#7.Z[9\51J"\-J:J"&W:>JJ21X+1*R+'
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M]6=EZ;G'ML.0Y*IN2-]BK6WU4=931SQ.;B1O$ ' X5V!@;G*)!$1%$1$!$1
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M]"U$:U@;=1134<L;>#B[U[@&^Y;3!*V:,/8X$$ ['*L[-O8HH!]7?=2BB(B
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MPJ+9#,,<3L[#E[1'\ER?M(N-=:M24$%+3QR1RQ\3B_F#Q$>(77Z*F%+2LIV
M#@SNT8&Y)_FN+=JE35/U+;ZN*VUDT4$/K,9&3Q>L?)8SMWTWCU&/N=VKK;2P
M5AIX@:AW#ZV2/HP5D#=[I07RG>^DA'"W.^_B.A6LZ@OE3=;=1T\6GKC$87\1
M)B)S]BO+Q=JVMJVR1V:X,PP-_-N\3Y+M-:8D= UC>JV&QVJH9!"141N=)G.&
MC Y;^97,(+T:RM[BW".=W#D#!'OYX6RZKKYG6#3_ 'K)F!D?KQ/R"[9N6X5O
M8-76.DJ 1HI[) #\Z(6CZ,\*QA[7/TZ_I*.5EIA=.WA>8HSCSX5SN_U%1<.T
MVZ4'=-[N.!D@+>?L,\3YKINGZZ.X6]LD,!@:Z-I:P_H@C8?0N<ZTH)K3JFLO
M(EVF#(<,!#O8;U_=3/VSAZ9/M"%31TD,E)$).& $\1ZY]ZU%L=XGM=/5&B9P
MR<B'#'7S\EMO:%<(I+ 9(I&N+:<9#7@DG(6B6O5-546^&AAMM>\0#/>-!+7;
M]-O-9P[7+I?5?:2V?3U4]QI0X/  #'^+5@K/K6E%?'PRPF2ID:UPX';$GI\5
ME[GV>2VW3U4'-CJ7<3789"<G+FA>&G*BUT7!3U.B7S5$(:WOS2C=P_2!+5I<
M5Q<KY7,UFVGHZ>&4=QQ9.<\CYKJ^CJ2II8I))XN S!CN8/C^*Y#<*J9^MFUL
M-DK&1"#@X1$>>#Y+NUK)DH:=Q:6$QM.#S&RUCZ3+VR Y;HH;RYY4J*(B("(B
M B(@+4-2?G_WRMO6HZE_/?OE!@NBJ')0I"(E%(4Y""D;IA3C<H2D1!3"93H@
MD=5'5 B*GGR493HHP@D*1LH"DH*2I')0B!@J4"(0Z(H4A!"D'9$" @!4)E!5
ME%2IP@(H!4A  \4PI3HB(0(B*D(>2I4H 56/5*H7JP9C*+%+^'U<9\UC[O=H
M[5"Z>1V&@AN2TGG[E>NYK5.T'>SO_M&+IQX[NGE\GDN&.VP1]IEKX '5&X '
MYAZSFE]:T-[K7TU--QO;&9".Z<W8$#K[U\[ X/+(\5OO8[OJ>IP-O1';_OL7
MJSX9C-Q\KQ_.SY,_C7T"W#AE20"O* DL/3=:SJK5\FGS'FV23M?+W0=WG /?
M[)7@OO3[T[C:V-#&X"C R3U5E9JX7.F])#>['$6\/%Q<O-7XWSLJJ,G'FI P
MH)PWEDJ1OU4(@MR5(  /@I"=%12YO$ A:3N>:D;(4WI- &R'89"Q=^N\5HHW
MSR%CG-8][6&0-+RT9P%J%K[3(:RM,-10,I6<)/&^I&,^&[0I+OTOIT(-YXY'
MFH[IOFO*CJX:N%LD$D;P0">!X=C/N5QE5!$3**(H&W52$! <\E&/6SGZ%/(H
M&=T*=52!@$9R4@GW*DL&<CFJAN/!2H*.#(W4AO"W#54BHCASS0C;"E$%('#R
MY)P#.>JJ1-"DMXAARGA& /!2B"DM3A52*:%.#UY)C8JI#R533S)]5:IJ*IMC
M:D-JY96R< P&@\LGR6TSG$;L>!7SWVQ553'J*/N9YF#T5GJM>1^DY<.;+XXO
MI?CN#]W)K;KMAJ+8Z1PHI9'.]7BX@?HZ+:F9X?57 ^QRJGDKZH332OWA]IY/
M5R[W&[$>0,J<&7RB>?P?ISUM4 &E2  XE0][6,+I'-:T#)+C@!><-1!*X]U/
M%)MG#7 KN^>]B,C"I+1@#H%/,'?"CIC.<)Z$C8J?%8755[DL=IJ*V*A?6&+A
MQ&QQ!=EP'/!\<K'Z=U5\N4L\K*,Q20L:YT0EXCD@GA.PP=L).Z7IM',^2D;+
M&6NYSUCFMEH9:<'.[L[?8%D^BJ1!;D[\D:#PGB1O,^M]"MZZI=2TLLPB+^ 9
MX0<946/?@!R%SO7.EKM<*WTJU0,DD$;6#CD:!S.>9\"MHM.IJ6NJ9H)##!)&
M!EKI@3GPQLL^I%ETY38--ZH:]T=TI*=D/JM!9(TGAZ]?!=(M- RVTC:>#BX
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M KK--$V*/A8 !G.RJ'JM ')5*D$1$41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZNH[%3M>'",;?URKJ:VQ20MCX=F_UBD---]+G)_/2C]\J#53_P#$2_7*V?Y
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M5(+75TMPG+*:21CY>9'3)W^U;C:HW1TS>\9P'?;'FK?CIGCF>^UIJ&XFBIG
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MN5(*S(T]4_JQ_657Y/5/A']9$83/DI!V69_)ZJ/(1_63\G:OPC^LBL+E5L<
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M^PC_ ,*I?V@ZF_0N#<]?F(_\*LX*Q_\ H8?X?1XD:1L1GPRI,@'4?%<1[/\
M6M\NFHX:6NK1)&YCR6]RQO(;;@+=M<WJMM="9*2;NW=P]^>!IW VYA9O'WIW
MQ\F98_)NIF;Y?%2)FGJ/BOG+_*'J@N+A<6\'3YB/_"JF]H6I3N+@W^!'_A6O
MT5QOY#"73Z+[UOB/BG?#/3XK@]AUWJ"JJ'LJ*X.  _V+!U]RV#7NJ;O:JPQT
M54(V=TUV.[8[<N(ZCR4_56O];CK;JYG;XCXH)F^(^*^=!VAZD)=BX#^!'_A0
M=H>I@,_*+?X$?^%7]-8__0P?1@E!SR^*GO!C<@?2N5]F>I[K>#5?*=2)BQ[
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M'Q=VWVL$YQA2\-ACYV&3IG?-\1\4[YOB/BOGB;M!U(U_"RX-'_0C_P *\O\
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MRXAH>_AX0X#U <Y__4LT&'&ZGA4^34XL9-::,_0U.XD=[C_HA0W0=.#O-_\
M"%O?"%1P.\0K^RL?Z;"=Z8:RV*.VQAL;^+#2WV .N59W?3,-P=Q2/X3P\/YL
M'KE;0T$<U#FY69G72\6-FFBMT-3[_/?_ !!&Z&IFMQWV?^B%O(9C/+"&,= %
MK]E8_P!-A_A@M.Z?BLXG,4G'WP;GU W&,_BO*]:;AN<SGR2<.<?[,'DMC#<
MIP;+/R;_ %S6M-$.AJ?B_/\ _P 03\A:;.>__P#A"WKNQX*.[]RU\ZY_Z?#_
M  QM);&04[XFNV<<D\*PEQTA!55#Y72X+CG\T"MP#0!L%3P9RLS*NEXL;.VB
M'0E,X_G\?]$*INA:?D9L^?<A;OW9\E5P;#&%K]E<_P#38?X8NSVMMMM\=+&>
M)K"3GAQS)/)8:OTA#5/+G2]2?S8/-;;PGQ"GA69E8Z7BQRFK&B'0E.1^>_\
MA"]Z31,$$[)!+NTY_- +<C&>(D8PJFM/4K7[*Q/'PEWICG6YOH;( =FC&>%:
MS+H>G>[)FX3_ &06\ *DLR=\*3.QK+AQR]M&&AJ;_?<O^4%4W0M,YOK3\/\
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M(_A) 'L \CE88Z$I\Y[_ /\ A"WHL!Z;JGNW9YC"DSL,N#"^XT@:%I\_G?\
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MFAT=3TU7%.R;+F'..Z 6Y!@!Y*ED6#DX3]E2>/A/4:]=-.17"%D<C^$-/%[
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66L(ZA5K%NW7CPF'I3P^:)@HLNC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g942297g14p06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g14p06.jpg
M_]C_X  02D9)1@ ! 0$ 90!E  #_[1DH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &0L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                    _^$_K6AT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A
M9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@.2XQ+6,P
M,#(@-SDN9C,U-&5F8RP@,C R,R\Q,2\P.2TQ,CHT,#HR-R @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @
M(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!H;W1O<VAO<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @
M(" @(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF
M9B\Q+C O(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O
M8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(U+3 X+3 Q5#$Q.C,X.C Y*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U
M+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R-2TP."TP,50Q,CHQ-SHU."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C4M,#@M,#%4,3(Z,3<Z
M-3@K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,"XP("A7:6YD;W=S*3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E
M9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@14Q/0R!296=I<W1R
M871I;VX@4W1A=&5M96YT(&]N($9O<FT@4RTQ(%\W+C,Q+C(U7S$X,S<U-S@Y
M-2XR.5\\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(S-3DP.3,\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z
M9F]R;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T
M;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C8Q,SEB83=B+3AB.3@M96,T8BUA8V,X+34S8S(Q,69E9&-D83PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^
M861O8F4Z9&]C:60Z<&AO=&]S:&]P.CDT9#EB968Y+65B.#$M83 T."UA,C@R
M+68P,60Y,C(Q8C@P,SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C8W-S$X860V+3$S9#8M
M-C$T8BTX8V%C+3=C-C=C-S9F.3AA83PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-C<W,3AA9#8M,3-D-BTV,31B+3AC86,M-V,V
M-V,W-F8Y.&%A/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(U+3 X+3 Q5#$R.C$W.C4X*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @,C4N-" H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD
M97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-C$S.6)A
M-V(M.&(Y."UE8S1B+6%C8S@M-3-C,C$Q9F5D8V1A/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 X+3 Q
M5#$R.C$W.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C4N-" H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HV-S<Q.&%D-BTQ,V0V+38Q-&(M.&-A
M8RTW8S8W8S<V9CDX86$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-C<W,3AA9#8M,3-D-BTV,31B
M+3AC86,M-V,V-V,W-F8Y.&%A/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-C<W,3AA
M9#8M,3-D-BTV,31B+3AC86,M-V,V-V,W-F8Y.&%A/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @
M(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^
M"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C$P,3,S,3<O,3 P,# \+W1I
M9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C$P
M,3,S,3<O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F
M.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @
M(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*
M(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C8P.#PO97AI9CI0:7AE
M;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXR
M-SD\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
M !$( SH'" ,!(@ "$0$#$0'_Q  <  $  04! 0              ! $"!08'
M PC_Q !A$  " 0,!! 0)!0H*!@<' @<  0(#!!$%!A(A,1-!49$'%"(R4F%Q
M<M$5(S.!P18T-4*2H;'"TN$X4U168G2"A9.R%R1#1&-S""4F=8.B\!@H-E6C
ML_%&E-/RXN-EA*3_Q  : 0$! 0$! 0$              0(#! 4&_\0 *A$!
M  (" @(" @,  P$  P    $" Q$$(1(Q$T$4404B,B-"85(5,_#_V@ , P$
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MN^,Q_P TC'>$!/[HKS>[8?Y$3QB)2<UIKMM&K[3W]C>PS<5>BW,N*2YY9O\
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M_)!/)3+*F74                             "V4,O)< **."H
M                                                #60 **."H
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MF+MFAG'$N+8Y[>"+D\GF?2@  4
M
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M5?E3?"/]!G?+"6_;PGQQ*,6D^K@3/K?3IP=Q74I  /.^@
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M?LGW@3@0)NO%-[LN\]K.I*>\I9REV@20  (3^^E[WVDTA/[ZC[WV@30
M
M
M                A:EYU#WB:0M1\ZA[P$NEYA<6TO,+@   @R_"T?<^).(,
MOPM#W/B3@
M
M                              "RO]%(CV/GU"16^BD>%EY]0"4  !"?
MWTO>)I#?WU'W@)@!Y5:]*DGTM6G3]Z20'J#SI5:=9;U*K"<5S<9)ETYQ@LSE
M&*[6\ 7 B+4;*<]R-[;.?/=56.?TDKF\I\ *C)&JW]G2DXU;JWA+.,2J)//>
M>E"M2K1S2JPFGZ,DP/7(&..0WA  >4JT8YRTDNO)90NZ%59I5J<_=FF74IY0
MD M4TRXB@*9]14
M
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MU!:GE91<N*(V)Y 7    N0
M
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M-/D
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M/:7[R[2-1.U04WEVC>054#*             !D
M
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M17$JGE<!I-JH !0
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M%
M                                  %E;Z*1'LO/J$BM]%(CV7GU )8
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M07]L]J>T>F23_P!>H?E$\):C-6?MGMY#>1AX:[I\O-NZ+_M'I'5[//"XI/\
MM$\9:^2O[93*&40/E"VSCIX=YZPNZ+7DU(OZQXRL7C]I8/*%2$EG?1558XYH
MFI:\H>@+%5AZ2'20])$T;A>"SI(KDTQTD7UHNC<+P44ECF6MD-KPGG):GCK*
MY"JYXX"XEK:;:S@2DHK(-KL@Q>HZI3LI1WG#RDWQ>"197T;JA"I!Q:DL\'DU
MXS[8B\;TF IE2Y,M3:YHRVO!126 WPX 5   9
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M]04CWE3+H <N;*97:!4!/( -X*)IE0 R@              HGEL"H
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MK Y=X;_H]!_KGV(WW9O\&+WF:%X;_HM!_KGV(WW9O\&1]Y@90    GGD
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M2\B.>9+TS5*-Y3<Z6_C/6L=1KPG6W.,U9GQVR@+8R3BGVE=Y&77:H
M            9     "F4!4!/*R@  ;">0+*WT4B/9>?4)%;Z*1'LO/J 2P
M (<OOJ/O$PA2^^H^\!-           /DP *+EQ.13:?_ $C.'_RW]4Z[GFL'
M%=4=7_VAGXNY1E\G+S?= [6N2!H,?EUU)?/WJ6]P\F1?0^7%.JIU[UKJ;C+@
M!O:]8.?V=77;?5JCKSOJUON84=V6,\#U^5-7\?I0\7OMQKB]V6.OU ;V63IJ
M2XFC5K_6%=1W:=]N;W)1EC&?86W.J:Q&HU&WO\9ZHR^!F8BWM8;!JFAT+VE)
M8<<I+R8KM-#U396XM*M2K;JO+#<DLI)\38;O:+4*%=4XZ7?SBXYWHQ>.OU'E
M=:[?3Z-2T>^FI+CY+X?F/+DXT3Z>G%R)KU+ Z5KEYI=1T[BE%;JW?+;?7[3=
MM(VCMKMI=+3WGG@DS2]?C<5:-.K3T6Z<ZDN.*4FUPZ^!K%[#7-*S4MK#49XQ
M]'2GU_4>:(R8I>J8QYH=]A4C-;R9>GE<#B.C^$2]LEB^L+ZIQSNSFUPQZT;/
M1\)D)4%.&E7$Y..>CC43?LY'KQ\F)ZEX[\>U?3I -(TO;BXOZ"J/9Z_HYSPD
MGU?V2_2]N)WUE4KST:[MW&>YN5'Q?+CR]?YCT1:)].$UF/;= :;;[;.M.O#Y
M*N8]$\9<O.Y\N'J/2CMC*<Y0>E7.8K//]QI&W T^EMM&594ZNG5J65G,YX^P
MDQVNMW.,.ASO/^,0&SC/#@:Q]UM!5YT^ASC'^T7 K4VLMH2<%27MZ1 ;,6M*
M7/D8/[I["+BJE:A!M?C5HHI/:G3:<HIW-MY3Q'Y^/$#.J$4WCAZBY&OW&U6G
M6]%5JMQ;QA)[N95XI9]OU'N]I-,I+-S?6E&'-RJ5XQ2[V$9D&*6T.C;JD]6T
M]1:RGXS#&.\2VCT914OE;3]Q\I>,PP_SA64SPX%4\K@8RCK^D58;U/5+"4,X
MS&X@U^DNIZWI<XRE#4+*48\VJ\6E[>(&10,?#6M-GEQU"S:7'*KQ^)2&MZ94
M>*>HV<W_ $:\7]H&1"ZR#3UC3JC\B_M)>RM%_:7O4K+/"\MG_P"+'XA$O"*-
M9(JU*Q<W!7ELY+CCI8Y_25>HV2J*#O+92:X1Z6.?T@2=T)),\8W=O+.[7I/V
M317QFAUU::?KDBCT<1N(\G=4$_*KTH^IS1?&K"?FU(OV,FS2N['CQ&%CAQ+E
MCL&%[!LTINIEKA'M+\>LIA=JR-FGG*C'&?L,/K>DPO;65*47EXY)9YF;X^ME
M90WEZ^TU6TPQ?'%XU+YMVIV/O+.]FZ5&K)5)3:RX]IE]B-AJ]:4:]Y3K4XN.
M5YK6=X[7>:3;W4HNM1IS:]*.3VM;&E;TU"E",(I822P=_GG6GSH_CJQ?: M*
MHRCATXK^RCQJ:!;U'EPPUV11GMU)>LN43CYR]_P5_34J^Q]K6E)MS6>R,?@8
M^IX/K.7'I:R]D8_ WS=XOB4<7C@R_)+$\:GZ<TK^#F@XMPJ5V_9'X&/N/!TE
M%[DKC+3]$ZTH87,IN)]7(ORRQ/#HXG6\'5TEB'C??$@U=@M3IRW81O'U^?'X
MG>W3BUYJ+7;P;RXQ[BQE8GA5^GS[/8_5Z+S&-V\=LU\2R.E:];M[MM7ECMJ?
MO/H"5A1EG,(/ZCREI=L^=&F_[)KY88_#F/4N#4[C:*WJ?>$FL=<_WGM':+7[
M=YE81[>,W\3MDM$LY/+MJ3_LGA5V;T^HGFTH?7 L9*I^+D^I<EI[;:M"*52R
MHQQ_2E\252\(-:G#YVG0B_;(Z+5V0TZ:^\[?_#(=7872Y\[*U_PAYU9^#+#6
M+;PC4OQYVZ_*,C2\(EF\9K6ZY=4B3<>#VPDOFK>VA[*)C:_@X@\]'*C'GC%%
M_$?UE8KGJS%OMUI]1<;F@OJD3Z&U^G3J;OC5+ND:74\'-RL]'=QBO51?Q(-7
MP?:O36]3U*>?51E\1JJ_)ECVZ?3VDTY_[U3[F>\-:L:G&-S!_4SCU3937Z$9
M.-W=3:[*,CP\0VDMTE'Y1ECLI3^ ^*)7\F\>X=,VHVLM=-M7NUJ3J*:6[+>Y
M/)R.IMC=U=0A<J,,4VUA2EA\_68W:6IJ<+F?RC&Z4/)^EBTLXX<S .33\F6%
MUKM/1CPQ,/D\KFWFSO>QFV-+4*<*56=*-11@FEO<V= IUXN*XH^5="O+NVNM
M^TE6;WHMJGGJ9O<]K=8ITDE2U!O/4W\#CDPQOI[N)SIFNK0[ETT,><BJJPQY
MR.#4=L]:SY5#4L>MOX$B6WNHTTHSH7N>7&;^!R^%[(YL?IW%58>DBO20](X6
MMO[]/C1O'_;_ '$VCX1*\8YJ6]S]=3]Q/A7\VOZ=GZ2'I%JJ0R\2.,OPF<6G
M3JK_ ,9? NI>$R*EQI5'_P",O@/B/S*_IV;I(]H<XXYG)(^$VBEQH3_QU\"[
M_2=0_D\_\=? ?%+7Y=76%-=3*J2;YG+:7A/M4O*H/ZZ\?@7_ .E"TZJ#_P >
M)/BE?RJ?MU#>0WD<QAX4;.3P[?'K=Q$F0\(UC*.6H+AUW$1\<K^33]NA93ZR
MB:SS.??Z1+#MI_\ [B)[V^W^GU)8<Z4?6[B(^.3\FG[;UO+M&^C3/NYTW^.M
M_P#]Q$NAMOILG]\6Z]MQ$?'*_DT_;<E+M+=[K9K5+:_2I+C?6:]MS#XC[K=*
M;^_[/_\ <0^)/CE?R*?MLKEP?8>-6ZA1AF4DEZS!0VJTN::5_9K_ /V(<?SF
M@^$/;F-'-OI]5RE&K'RZ-9/*W7V&Z8IF=.67ETI7>V]O:W3E>0HJZI-R6>4O
M7\#/VEW"XIQG2DI1DD\KUGR=2U:\E659W%7>CPSO<?\ UQ.E^#W;6?C$+:\N
M)X;IP725DEP3[3I?CS$;>/C_ ,C%[>,NX)Y0(NGW,+JC&I3DI1:RFGE$H\LQ
MI]>L[C80M1\ZA[Q-(>H^=1]X*E4O,+BVEYA<   $&7X6C[GQ)Q!E^%H^Y\2<
M              <N\-[^:T'^N?8C8;+5ZME0Z.%.$DGGCDU[PW_1:#_7/L1N
MN@V5M7T]3K483EO/C) 8:AM?<2J.,J%%++6>)*H;42G.2<*7YS-2T33WG=M*
M"?;NEE/0[.$F_%Z/'^B!AEM7)ZA.WW*/DQWNO/4'M9):A3M]RCB4<YXYZ_@9
ME:%8JYE6\6H[S6,[G$H]"L7<1J^+4=Y+">YQ Q[VGIPFE-TEO/UB>U%&,L;U
M+&?63*^S]K4FI=%16'GS"R6SEJWQIT>?H 1JVU-&G/"G2?>7K:>VCCI*E**?
MJ9[5-G+2<][HJ/Y!;<;-VU6&%"BN&/, 5-IK&$(2=>GB;PGA\2LMI;*/&5>F
MH]N&>%79:A.C1A\TNC>?,YEU79BA.&[BES] #VAM+8N$I.XIJ*Z\,]H[1Z5T
M3J2O*:C%9D\/A^8@_<M1Z"=/YKRNO</&>R,)494U4I)2BXOR ,K;[0Z7<04Z
M-Y3E!\FD_@6T-I-(KTI5*5]3E!/#:3Y]QCK'92%K2C34Z6(I\H8Z\GG8['PM
M:$J724G&4M[A#V? #,4=H-*K.2I7D).+P^#X?F/1:SI\FTKJ#:Y\&:[2V1E;
MSK2A7@U4DY)1@^!Z4-F:RJ3DZZXKT&!G'KFG=5U#/L?P+H:Q85)*$;F#D^2P
MS75LI6SO>,Q]FXP]F;FG6A4A<XW>R# V=:C:[SCTT<KGP8>I6:>.GCGV,U1Z
M!J/3U)*\J)2?H,LEL[J._GQVI^0P-NEJ%HGAUH\?4R^-W;R7DU$_J-3KZ#?N
MM&2NYX2]!D.[T/6NEI.A?W$(J7%1A+B@-Z\8HI9=18*NO2B\.:R:/?Z-K=2S
MIQHZA<0J*:;:A++7$]=2TG6)TI=#?7"GPPU"7:!NL:L)>;),O-#GI>NQMXJ&
MH7*J;O-1EG)Y_)VT:MH+Y4O-_CE[LL@= !H-OIVT6YNSU2[SVN,BRWL-HZ=O
M<=)J5Y.>?)\F6?J Z"#0+:.OTH356XO:C:X9C+@76;UWIFZM:]<<<G&0&^@T
M&WEKO2K>K7KCGENR*VU?6X7%3I7?2AO\$XRY9 WT&B+4M7^4*L.@ONC26'NR
MQU>HI4U+5UJ]*$:%\Z+AEXC+&>/J WQ-/D4QQ9H]74=6A5CNT+YQZ\1E\"VI
MM%J5!J+TW4*CSC*C+X ;UN\<E<<#1M2VBU*VM)5:>F:A5DFEN0C+/Z"Z[VCU
M"E34HZ7?R>ZGA)_ (W;=0<4S2*FU5_:VU*L]'OZ[J+.XD\Q]O 4]M[OQ:-66
MSNH[S>-QIY7K\T'3=]U%JAS-,AMO=NTG5>S>HJ47C<:>7R_HEM';B[J0J2>S
MFHTU!9\I/C_Y1LU#<YTTUQ-+VPV2I:M2G+RU4:BL04>IDNTVPE7I.4M*N8-)
MO$GQ_0>%';-U[-UWI-SPEN[C?']!JMYK+EEPUR1J6F[,>#V5*_J5+A5TH54X
MYW>*RSJEAIM.WMH4XQX1BER1KM#:W>;<='N8<>/K_,3;;:RG-S4[2=/=7XTT
MOL-VR3+GAXU,?J&==G3GQ<5W(LE84F_HH/\ LHPE':ZWJ7KH1I?BY^D1>]K:
M"KQI.@\RZ^D1S\I=_"&2JZ51GSI07]E$2>S]O.;EN<_Z*([VNM85E3J*$-Z6
M[F55+K)$]IM/@VG<V_\ C1+YRQ.*L^X8ZIL;:R33E-9_HQ^! J[ 6;WL5:W'
M^C'X&PU=I+"G+$KFWSC/&M$\ZFTVG04<W-MY7+Y^)J,DL3QJ3]-4N/!W;8\F
MK7SGLC\#&W?@[<J>*;N,^K=.A1VBT>-&-2XU*QI1GP727$%Q^MGK/7M&IKYS
M5-/@_P"E<07VEC++G/$I+E%QX.[G&*3NVFN.'$@U-@]2IY45>87+RXG9?EO1
M-UR6JZ=NKF_&887YRWY9T6<=Y:EI\D^M7$&OTFHRL_A5_;B-39'6:,O)A=M]
MCJ+XAZ?KU&<90MJTHKGFI^\[?3N]'KQWX7MA47+,:L7]IXPJZ%5IR<+K3I03
MPY*K!I/O'RPS/#GZEQ6-SM'0E)JPDXKK<^SZR12VEV@MEEZ=!]7&;^)U_<T"
MHFHW&FRQSQ4B_M/)Z;H-=8@]/GCCPE%_:6,E6?Q<D>I<MI;<:K"/SEG1C_:E
M\2;2\(5Q"*WZ5!<L\9</SF\U- T"L]V$-.;?9NO[2+4V7V?DW#_JU2?#'DYS
MWEB]4^'-^VOV_A'IN,5.5O''O&0AX1[-^=6MTNW$B^>Q.C5*DH4I:?O+G&,4
MVOSD*X\'UK*?D5;6,<<NC_>/ZR:S59RAMSI]3=S<T</U2(NO[;6=&RGT%>C.
M4H22\[L,%4V GA]%?T8=F*;^)A-?V*O;>U<W=NJH1D\*F^I%K6NV,N3+6DM*
MUW6*^HWDZLY-)I<%)XX(R^Q>TE72KV&])2BY-^6WZ+1K%>#I2<:D6I+M6"1I
M=M5O+NG"WISE)Y6(1<GR;ZCUS6OB^)7+EB^WTIHFT5K=6%*I*M34G2A)I9X9
M1D(ZQ:2Y5X/ZF<7M-&UZWM(RI3O8Q<$U!4I<L<CR5OM*IO=^4DO^5/X'CG'6
M9Z?=IR[Q6-P[>M9LY/A7AGV,]8W]NUPJQ?><,=MM-&>5'4UP_BI_ OJU]J*,
M4XTM6GA?BTI_ GQ0W^9;].X?*-!-J56*[RZ%[1F\*HGWG!9ZAM2TGXGK+?\
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M]RRO]#(CV7GU"17^BD1['SZ@$L  "%+[ZC[WVDTA/[ZC[WV@30
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M?0[&UHUZMMJ3A5GN)1IP;SQ_I^HD7GA-T>UBY5+?4&ECS:</VS>'!/F'%-8
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M,H   6>L       !YZ@       'GJ  #CD  LYX@     XY]0 #!3''CR*@
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M[C2T'^N?8C?=F_P8O>8&4
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MFO)FF>BJQ?)H]D7K/V\DUG[AZ MWRJ>3<3#*H *
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MB"H *!"U'SJ'O$TA:CYU#W@)=+S"XMI>87   !!E^%H^Y\2<09?A:/N?$G
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MO+>9POPC[6:GJM;1J5WIU.A"%VFG&3>>1W/9EYTN+QCRV(73*@ J
M
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MIU9T;5N7;!FC;/:13T/P_*SH*"HK3W+=@L++B=RCR.0U/X1W]V_JA77D N2
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M
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M\^'8522Y 64J<:5-0BL)&O[3[)V>T"E&[N+FFFHKYII<GGK3-C*-9$QOV>F
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M@
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M-.0S_A'/_NW]40.OKD@%R0
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M687(%$RN2[07(%.&"#6U"G3NZ5'>69+L9)M$+%9GTG@LC-22:+RQW"  *
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M6_MX\F"V-.#]11,J>CVX"Y<0 4
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MPCO[M_5.OKD<@E_"._NW]4#KZY(!<D
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MPKPDLJ2?9AGNKEK/V\,TM'N'JGD%JDL!//,W$Q+*[/$%,]A4H#/J
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MVJ GD&D
M           ,\.)J^VVMVNG:7<1K7-&E.=&INJ511;:75WFT-)KB:UM-LI9Z
M]&*NJ-.INJ26]*2QO<^7L,6C:PYSLWLO;[22G>4]8Z.56&^XPBIXXXY[QIWA
M!T6ALAKKN:>HJK6A2BN2IO$LKGEG>-E]E[30:>Y;T:<([FYY,I/KSUF,VNV
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M_JG7UR.03_A'?W;^J!U]<@%R0
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MTHRSC&\^PVRA<1JTXRBTTUP]9]#%GK>'S\F&V.>WN"D7E<2IW<@
M                                                    "6  */#^
MHI'B\ER!!1KKZT57( H<.8QE<1@ .H+GZ@" N  **+.7V!)+D5  IA-E0!1+
MRFPN?'F5  (                    +*WT4CPL_.F>];Z*1X67GU )0  $)
M_?2]XFD)_?4?>^T":           ?)@/DP*+D<AEQ_Z1W]V_JG7H^:<AE_"-
M_NW]4D#KZY +D@4
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M4?>)A#U#SJ/O 2J7F%Q;2\PN   "#+\+1]PG$&7X7C[GQ)P       7%!O"
M +U    .7>&_Z+0?ZY]B-]V;_!D?>9H7AO\ HM!_KGP-]V;_  8O>8&4
M      %LHIIY63#ZMH=O?4VITJ><IYDF9HHUDYWQ5O';=+S6>I<@U;9R[TNK
MTMGE)+>^;@^W!D=G-J*EK.%OJ#JM[T()S:BH\>/,Z/7MX5J<HR64_6:/M/LI
M3JRG7MH14O+E)RF^?4?/OBMCG=7OQYJY8\;MPL=2M[J"E2K4YY3>(S3ZR=GC
MPY'%*%[?:#<3ITZD([JW>$5+GQZSHNA;36^H\(]+O.3BLP2Y+/:=</)W_6SC
MFXLU[JV=YRBIYTJBG!-9Y(].9[:S$O',: .H&@
M
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ML+R@
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M>_'EK;T^??':D]KQQR,KM0.S
M
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MV/\ _&_JA775E/F7%(K"*@
M
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MH1;:7:(-*U:<:L'"HLQ?4:)=^##0+F\KW%33Z<IU:DJDGT]59;>>TWU>H!7
M/"=L+I.@U=&KV%G"E*I>)2:JU)92P^MG:]FDEI:W5A;[-"\.'&CH"ZE>?8C?
M=FEC2UCTF!E                  !9*$9<)+.37->V:H7^]+HZ>\WG+G)=7
MJ-FP,<#E?%6\:ETIDM2=PXI>6-]L[=*4*U-.,<^1Y7/AUHVK9C:_QF:I7#K2
MFY**>Y%+D;GJ%E"[HRIS<DGCS6CG&T.R,[=NK:0JS23;WZD>>?J/GVI;#/\
M5[Z9*9HU;VZ7;UXU8*?%IK*)"S)Y_%.0:+K=QI%54:\:4(K$.*<GP?J9T72-
M;M[ZFG3J1;>>4)+E[3T8>3%NI>?+QIKW#. MZ18SDMA5C-M0>7'F>R+1+R:>
M@"8*
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MM_5.O+D<AG_"/?\ W;^J!UY<@%R
M
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M3^L^UBSUO#X>3%:DS$KWG**A/(.WMS  4
M
M 65OHI$>R\^H2*WT4CPLO/J 2@  ,=72Z9J7)MF1(#DU=XE%8<NOVDT-)U_3
M;VKJ-:>GPA+>DL[\ERP;#LWI4+#3'1KJ2EON7"6>PG:CIG3RE.G.<6WG$>!@
MI:;J/28CXPXX]/\ >(26?M?%;2HX4G/,Y9X\>)DX-2BFNLQ&EZ7*BXU*TZCD
MN.)//49A+"PC4D  (H,<0  ZF ^0"/(Y#4_A'?W;^J=>7(Y#-_\ O&_W;^J0
M=>7) +D@4
M
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MY9-AM[JG66833/;3/6[QWPWI[A)!3*P$SK$[<E1E 8*
M
M      LK_0R/"R\Z9[7'T,CQLO.F!*   AO'C'%9\K@3"&_OA9](DCWK5%3I
MN3:BEQXO!JU?;*-.7S>FUZL<>="65^@V#5:?26DO4F_S,Y7INJW%K;.@Y+.\
MY>;D5['4-$U'Y1H2J]'*EAKR9/U&2-<V-K3N+.M*;3>^NKU&QHU*0  B@  !
M\F ^3 I'S3D4OX1S_P"[?U3KT>1R&I_"._NW]4#KRY +D@
M
M                                                  A:CYU#WB:0
MM1\ZA[P$NEYA<6TO,+@   @3_"T?<^(UB4HV=5P3;4'R%3+U2*7/<(]]*]\7
MK[DJ>$GC))(:K.G2J*I4JSIQJI;R4GQS\3/;(5ZU:RATBJ+C+SO::AJ&G7U>
M[E6;I9WE+GV&Z;*2N/$8*X<6\RY>TU'I)]L\ @10       '+O#?]%H/]<^Q
M&^[-_@R/O,T+PWOYK0?ZY]B-]V;_  8O>8(90
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M:K:[A5BG'.&D^1[*9ZV>2^&U/:6"D99Y%6\'>)VX@*>PJ4
M
M   'G<?0R/&RYS^H]Z_T4B/9>?4 E@  09??<?>^TG/D0*GDW$7S\K))1Z:B
MYJWEN)/@^?L.<4]-T^K0=2\KUJ=SG"A'ECMY/])T2I=YWXRHY45GB_W&DW>H
MVTZ_2*RI0IXQS6/T"OM6P;(*HK>I%Q71QFE%];6.#-D,1L[<T;BU;HTX4TL)
MJ+7'@9<U*0  B@  #J Z@"Y'(:G\([^[?U3KRY'(:G\([^[?U0.O+D@%R
M
M
M "%J/G4/>)I"U+SJ'O 2Z7F%Q;2\PN   "!+\,0]SXEVKU:E*RK2I13:@WQ+
M9/\ ZWA[GQ*ZQ-4[*LY)-;CX,S8ASVZU:^JW%2ET-'%/CPS\3;]D+FO<6,'6
MA"+S+S?;[33U6IU;^Z>["&['>Y\S;=C+BG7L(.FHI9EYKSUFX])/ML@ (H
M     #EWAO\ HM!_KGV(WW9O\&+WF:'X;_HM!_KGV(WS9O\ !D?>8&4
M                              HUDJ +)033SUF*U'1J5VGO.IS3X-?
MS!3FNPYVQ5MTW7):OIS+6-C)+,[>->32ZYP[3#6TM0T6MY5""BI+C-YX1]C.
MQN$91:E%?6C&ZAI%M=4Y)T*.6FLNFGS/%?B>/=7LQ\O?5FK:1MG2:4+J=&$E
M'JA/M-NLM3MKB/S=12XX\UHTG5MC&YRG;UNC;:X0H>KU,UU5=6T>HM[QZI!>
M4WY<5QX'.N;)CZETG#CR]U=FA)23P7K/6<ZT3;%2G&%=;G%)N=?EWHW"QUBV
MNDMRM1?#/"JF>S'R*V>3)Q[4948+824N*DG[&7'HB8EYP %
M                                                           %
ME;Z*1'LO/J$BM]%(CV7GU )8  $%X=TD_2)RX$+@[I8YJ0'GJD>CH3E2X2DF
ML\^HY(E?UUXC"K!5I>4I27DX]N/4=BOZL:=O-R>.#_0<RM;CIKE1>,-=2)7V
M2VS853IVE2G5>9J:3:Y9P;6C7-C[BE5M[A4VWNU-U\.O!L:[4;LD  ,J   '
MR8#Y,"D>1R*3_P#>._NW]4Z['S3D4_X1S_[M_5 Z\N0"Y
M
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M*/3%HGT\\QKVJ &5 !(
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M7ER
M
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MMASUR>G'-AMB]O<%%Z^94]+@ %..>8%0
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MI4;6[E2?)J?#E[37MB*-Y;>'",=1A4A7\1EE5'EXW> 5WY<@%U
M
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MI:"Z5O1@_'.<8)-\CHVS3SI:X8\I@90
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MSIVV:S&-?HH/@GF3-DL]I+.LDW<4EPZFSTTY5;/+?BWJV,$2WNZ-;C"JI=7
MDJ:?6>B+Q+SS68]K@43XLJ;0
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M2@N>2Y\BB7#!7J(JD5PP<BFE_P"T;CJ^3?U3KRY'(:G\([^[?U0.O+D N2
M
M
M  "%J/G4?>)I"U'SJ'O 2Z7F%Q;2\PN   "#+\+1]SXDX@R_"T?<)P#   %E
M2E"HL3BI+UEX LI4:=)8IP45ZBVO;TJZQ6IQFN7$]0!XT;6C0^BIQA[#VP
M  '+O#@DZ6@_US[$;[LU^#(^\S0O#?\ 1:#_ %WX&^[-_@Q>\P,H
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M .H!\@"Y'(:G\([^[?U3KT>1R&I_".?_ ';^J!UY<D N0
M
M                                                 0M1\ZA[Q-(6
MH^=1]X"72\PN+:7F%P   09?A:/N?$G$&7X6C[GQ)P             !R[PW
M_1Z#_7/L1ONS?X,7O,T+PW_1Z#_7/L1ONS?X,C[S!#*         MF\(\>E6
M?/7>6(VDSI(!X=/'TEWE57CVKO&I3RA[ \.G7I+O(=YJ]I:2@KFYHTG+*COU
M$LX'C*3>(]LF"#;7U*X@JE&K"I!\G&64SWZ>+64UWC4K%XE[@\(UDN<EWEW3
MQ[5WC1Y0]060FGPRLF.URM7IVTXV^_ON/"4&\KB9F=-1VR@.?7:U6G1E6J:C
M>4DTY1BVUGU+B>VQ=WJ=Y<1G=U;KH7&7&I)N.?K+'9/3>P8:XU:%5]#0E'?D
MN$H3RU_ZP8/2M2N_E>O2JUJLX],HI2F\);S W4&.J4:[O)U8UZFXTDJ:SA$J
M]WO%Y=')QEPXKGS$D=O<&DZ1J5XM7J4*]6M.,J^ZMZ;X++-UCR J"G$J
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M;^J=>7(Y#4_A'?W;^J!UY<@%R0
M
M                              0M1\ZA[Q-(6H^=0]X"72\PN+:7F%P
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M0Y??4?> F           'R ?( N1R&:_]X[^[?U3KRY'(9_PC_[M_5$#KRY
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MM:+75;4+ZK<V\5Y4(K&<\%U=IT2PN8W5M"I'KBGWHC20
M
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M7F-"DO9!"=O1GY]&G+VQ3/4 64Z-.FOFZ<(>[%(O
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MS&G!/U)%XCUHUV  *
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MX"Y%.:X\#W/$MK_12(]CY]0D5_HI$>Q\^H!+   A/[Z7O$TA/[Z7O?:!-
M        =0'4 7(Y!+^$=_=OZIU]<CD$_P"$<_\ NW]4#KZY +D@
M
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M1OJ,Y[D-[+[4%2P1ZUW2I+R][ZD74+F%99AGZP/8
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M!4//443;RL8#DHK,FDNU@$UC*? JB';:G87$U3H7EK4F^4(58MOZDR8@
M
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M(1\Y4..>\RNSVBUK&;Z2K4J<%YT&NOVFX],Z;5'&?67%%VXPRIE8  %
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M6<ZV(IQL]6KV<<[L*+EQXOC)/[3HJ]99(G8 "*
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M(-I++ J,+.3"7&N4Z%YT,I8\O<7DOM,Q3G&I'>AQ0%X"]8   "F>#$>LJ
M
M  +*WT4B/9>?4)%?Z*1'L?/J 2P  (;^^H^\3"&_OJ/O 3 ^0 !  !CCD8X
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MD(&B:!LU<V>I5;BI4N,SI[OE1]:]?J-[00030  H
M                                                         $/4
M?.H^\3"'J'.C[P$JEYA<6TO,+@   @R_"T?<^).(,OPM'W/B3@
M   #EWAO^BT'^N? WW9O\&+WF:%X;_HM!_KGV(WW9O\ !B]Y@90
M            ,/M+"$M)NG.$9/<ZUZS,&$VJK0IZ3<J<XIN'6\=9)6&EZ5>Z
M92C=TZTK6-3H]U1DEG/$D[(2K4[Q5:5.4J6[)87(\-F=)TV_NJ\Z\*-2;2>=
M[KS[3;KVG;:#IV_0MLXEC$&^LN])K;&0VON83W;JPC1]<IOEW&,VHVEK_P"H
MNC1X5'+C&;]1@+ZM5OXRN5<QC"'D.F\-OC^\DZE34K;1V^*23D_R1 VO1]HN
MATFE.[48-N2S.?-Y>$4M=KIU:\:5S:4Z47Q;E/\ <:WKL=W1;>=&#J0Z=<(<
M?2-HMJ.B7M-U(JVA-/=2=7C^DDC6-9O5;ZQ:UZ%.,W*JYX7#K3-HV>VE\;KS
MH5J4*<H)?CY?%FKZGXI'6+2#=-P55I/>X)91?9U+>EM!7Z*I347*"34EA\C<
M>F?MT^I+=ADT6I4>IZS1IN3W%-P:SE<V;M4\NEY,L\>HT/2%XMKL%4:\JLWQ
MX=IS^VOIY;;:32A2MU0A'I(;_&,$GG"P3O!Y?25&%A7DXU81G-J4N/G=GUE^
MTMU0G?6\'5IX=3#6\O4:]K-6MHNHU-0L=Z4))4TJ:SS7'CQ["I"1MW<RU"O%
M4^-%4U&3B\I/>9F](O9:7HD)T;6-3=H1DWRY1,'J]*%MH-U*M./C#2E'+P\9
M75WFR;-0I7VA]%*<).5O"+X\LQ+!*_2]J97D>-O",MUMI3SUD:6LO6=+JJI;
MPA!R46\[W)IFL:LJ^D:Q<4;:%3<CB*W(\.*3-LK6=MI>@7&5"+4T^+QS:762
M8VJ!LK=5+:WU"5&ETCC-82>,\R7#:ZXA<NE<V,:4<I*4IOC^8P.C:Q2L[2_>
M[ON4LK$D8?5*U>ZN*-S&Z2IU*B:I<&XFD;YKFUCTQMNWIRI)+RY3PLLLH;6N
M=>G"K;TX1GQRY_N-9VZE0J:)4BI0=3>CREQYE^H2LXTZ,J4Z6\J:Y37,DK/I
ML^O6D+JTI7M*26$ZKW5ZL\R5L??*[TZ'E)R\I^=GK(/C,/N:IQ4XMSMVN#7H
MEO@]MIT;&,I/@U)<OZ168[;AU@=8(T
M                                       +*_T4B/8^?4)%;Z*1X67G
MU )0  $)_?2]XFD)_?2]X":           ?(!\@"Y'()+_WC?[M_5.OKD<@E
M_"._NW]4#KZY(!<@
M
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M8I4I[B4GU9-QTBS\2M(TFO*3?)YZR4J<$W)1CE^HN7/+"0KU@ *
M
M+*WT4CPL_.F>]?Z*1X67G3 E   0G]]1][[2:0G]]+W@)H          !\F
M^3 I'S3D,OX1O]V_JG7H\CD,_P"$<_\ NW]4@Z^N2 7) H
M
M                       =00 I.<81<IRC&*ZV\(J8?:BE>5]'N*>G5:=.
MYDH[DI\EY2SU/JR29TL1M[5M>TBC*4:VJV%.46TU*X@FL?6+77]'NZKIVFK:
M?7J);SA3N82:7;A,^<K31]:O=K;^AK%S;5Z/CFYNQ\GR7-J2X1749"G9?<YM
M]?TK%*E1C0C&,4W+&5!OGZQ6?*">G=9;6[.0ENRV@TB+['>TU^L6?=ALT\XV
MBT=O^NTOVCY_O]3\&5&HY76A:K*ICBXSE_\ Q2-2U3P5REY&@:NG)]=27_\
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MR/O,$,H                        'P0              !3J*H  UPX<
M  *<BH HEQYE0  P !19;SR]14
M                                     LK_ $4CQL_.F>U?Z&1X67G3
M E   0G]]1]XFD-_?4?> F           'R8#Y,"BY'(9O\ ]XY_]V_JG7X\
MCD$^'_2/_NW]4@Z^N2 7(%
M
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M+WF:%X;_ */0?ZY]B-]V;_!B]Y@AE
M
M                 &4 !CK_ %S2]/\ O[4+:WXX^<J*/$MTS7])U2:CIVI6
MMU)YPJ552Y<^0&3!3*[40YZK84ZW0SO*$:N]N[CFLY[ )H*1DI+,6FO45
M      LK_12/"S\Z9[U_HI'A9^=,"4  !"?WTO>)I"?WU'W@)H        '4
M,I "F>94/D 7(Y#/^$?Q_P#EOZIUY<CD,_X1W]V_J@=>7(!<@
M
M                                                     AZCYU'W
MB80]1\ZC[P$JEYA<6TO,+@   @S_  M'W/B3B#+\+1]SXDX       9XX,)K
M>OVNF)JI4Q/=4DG!OKQU 9L<<OL-<TC:BVOJNXJB;<DEB#7,V*,E*.8\@$7E
M<"H '+O#?]'H/]=^Q&^[-_@Q>\S0O#?]%H/]<^Q&^[-_@Q>\P0R@
M
M                                   !Y5JU.BMZI*,5RXO!ZF@^%*RT
MN[T^DM4JUH15=-='V[K]3,VG2Q&VW0U>T?*I%?VE\2E2]IW%.4+>O3C-\$W)
M'SD]"V5:>_=7J]G_ /*979?1=EJ6K6TJ5S>N:FMW/_\ *:CMF>G4=4V.>KU*
ML]0G;W%-MRBFY+#^HYG5A<;#[=NG95%"RA;YZ&BMY[TES\H[9;2MK+1(5*,I
M.DJ3W7)9X+)SS1M+EM!M@M8PW:2HNEOQDH\4NQ\3'KTUOIO6K:NK'9]W<M_>
M=*$^&,\<?$X9I^T=[JFW%52JU.BC?1W5**7!S]1T/:W6K.K?VNGUJK4'!P>(
M//!]OU'.8:A86VU5.-&K-Q5Y%/>B^2G[#5>Y9^GT982?B\6WGG^DEF,T2ZI7
M-E"=&68/.'C'69,U*5]  (T     +*WT4B/9>?4)%?Z*1'LO/J 2P  (3^^H
M^]]I-(4OOJ/O 30     \Z]6%"E*<Y)17-L]#6]MKR5MI==0DT]R+X/^D2>B
M'A?;5*E7E"A&E4C&34GE\$971-8I:C36[*'28;<8OL>#5ME]-IWEE>U;B$9R
MG24HN2Y-J1C]&N)Z?M9<VD)-4X45A+EQW7]I8](Z>N0;X,MB^)5X28%8\4<@
MJ-?^T?CK^3?U3K<6LRQ-<N6>1R*#C_[1>[-J4_DWS_[(5V"+317)9F*:Q*/>
M5WH^DN\"[(RBW>CZ2[QO1[5W@790R6[T/2CWC>AZ4>\"X%N]'TH]Y7?CZ2[P
M*@IO1])=XWX^DN\"H*;\?27>-^/I+O J,HIO1])=Y3>CVQ[P+LKM&2W,.V/>
M5WH]J[P*@IOQ])=XWH^DN\"H*;T?27>-Z/I+O J,E-Z/I+O*;T?27>!<$T^1
M3>CZ2[RV#BEC>CW@7Y&44WH]J[RF]#TH]X%V4"W>AZ4>\KO1])=X%04WX^DN
M\;T?27>!4%-^/I+O&_'TEW@5&2F_'TEWE-Z/I+O NR,EN]'TEWC>CZ2[P+LK
MM&5VEN8=L>\;T.V/>!7*[2N46YAVQ[QO0]*/>!=E#*+=Z'I1[QO0]*/>!<VE
MS!:Y0:XN/>5WH^DN\"N4"W>AZ4>\.4>U=X%P31;O0]*/>-Z*3XKO NR,HMWH
M]J[QO0])=X%V4,HMWH=L>\;T.V/>!=E#*[2W>AVQ[QO0[8]X%V1E%N]'TEWC
M>CVKO NR4RNTIO1])=XS#MCW@797:,HMWH=L>\;T.V/>!=E=HRBW,.V/>-Z'
MI1[P+L@MWH^E'O*[T?27>!4%-^/I+O&]'TEW@5!3>CZ2[RF]'TEW@7 MWH^E
M'O*[T?27>!4%-^/I+O&_'TEW@5!3?CZ2[QO1])=X%1DIO1])=XWH]L>\"N04
MWH^DN\;T?27>!4%-^/I+O&]'TEW@5!3?CZ2[QO1])=X%04WX^DN\;\?27>!4
M%-^/I+O&_'TEW@5!3?CZ2[QOQ])=X%04WX^DN\;T?27> WDEG/ JFGCUEDG%
M4WPRNQ%5Q46N"QR N!1<WQR5 $/4?.H^\3"%J/G4/> ETO,+BVGPB7   !!E
M^%X^X3B#+\+Q]PG     *,"DWNK)RO2&M:VCM:E23=..]!KFN"D^OVG4JW&'
MUG+?!^E2U:E3J+RI5)M9X?B,S7V3Z3]J+>.G:A82H<([S;PL<FNPW/9ZNZ^E
MT)/DTWG/K9JNWJ4KJRC%KCOK\Z-BV2BXZ-;1?5%_YF;AEG(\BF5QX\CSN8SG
M1DJ4MR?4SE&HZ!MO.^NY6^U-6G1E5DX04'Y,<O"[B-)7APDE2T!M\'>_8C?=
MFY+Y,CQ_&9\]>$S1MJK>AI/RGM!4NE*XQ33BUN2[3:-&T';>5DG2VIJQCO/A
MN/X =QRNT97:<=^Y_;O^=E7\A_ ?<]MW_.RK^0_@!V/*[2F5VG''L_MW_.RK
M^0_@5^Y_;O/_ ,65?R'\ .Q;R[1E=IQW[GMN_P"=E7\A_ I]SVW?\[*OY#^
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MQ2\3J=%+>3>\^/+"]1L/W.[=N*_[6U?R'\ .QO@4RNTX[+9_;O\ G95?]A_
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M\[*OY#^ ^Y_;O^=E7\A_ #L>5VC*[3CGW/;=_P [*OY#^!5;/;=_SLJ_D/X
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M>&L\P.;>""SG;76TCEN^7=I\'ZY'2$N+]92$%%O$5'V+F7 $L<$
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MGE'L'C#(,7H6CVVD6L*%M2I0C!-+HX**XO)E,<?44BUC@5*
M             ?JY@1[^TA>V5>VK*,H58N#4EE8?J(FBZ/;Z5#=MX4H)1W<0
MAN]>3)_I*976P*@)Y                          Q>K:1;ZK2E&YITYY6
M[Y<-[AG)E/4BC?'&2#PT^VA965&VI**A2@H145A)+U$@I'@WE\RI0
M                  &0,)+9ZUEM';ZPZ='QJC3=.,^C6^DU)<)?VF9K//U#
M@^)1XXKM N7$%(K"QU%0!#U#G1]XF$/4?.H>\!*I>87%M+S"X   (,OPO'W"
M<09?A:/N?$G            !3/E8ZB+J5VK*RKUY9:IQSA<R"4NL9X9.>U-=
MUW4:]9Z5=TJ-*GY;56G'.[V<GQ,KLGM#6OZL;>]DYUVI2WE%)87L+"3TVX!
M*                        #ZS$ZU>UZ%&4+:6[6<4XR<4TN)IU_J^T6FU
MJ56YO:$[>K+>484UE17->;SPR1['1P8G9W4GJ>FTKA[V]/>SE)<I-=1EBZ(
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M/+P<CN=1^4M;KQU&BK2.XI8K2SQ222XI'7:3AN+<<6O45%Z>0$ H
M              H^'$\KRKT-!S[&NO!!BM=UNE80W8SCTDHO"E%OBC6J-SK.
MHU^DMK:A.E)J2><</KD:_JKNM9UB,*+K;L*LH/<;DN+)-KJ-UL]=NC7IUG3R
MJ<93DX)]9:DNH6G2*EBJDI9Y(]\$:RK*XH[\6N>.#R2>?)B4@  4
M             0]2O(6-OTDY)+>2XIO]!H4M3UF[Z2M;6]O.E!X;Y?ID9SPE
M2K1T'YA5-[IH\89SR9Y;&5;6OH]RG*CG?2?%/J1(-*[,[03KUIVUYT<*E/=C
MB,7SS@W%<3ET)*GM-75!)IW"3W/>.G4<[JSDTS"\ $:
M  8ZP'R Q6T%[4L[*I.DHM[DGY2[$:9LSM'>WVT%U;584%"%+>6[%I\X^OUF
M_:E3A.QKJ<(S\B7G+/4<VT&$:>W&I1A&,4J"Y+'H"#73HFKW7B]G4:QTG#":
M]9I6J7>M1B[FC;6[H4\R<F^2ZN&\;Y=VT:\&IXXXYK)!UJE1I:-7CN4TNBQR
M2R!C=DM:EJ%/HZVXJL(9DHQ:QQ-H6>LT'8RSG'5+JK%R5.4%A)<.?4;\BH$+
M4?.H>\32%J/G4/>(J72\PN+:7F%P   09?A:/N?$G$&7X7C[A.
M  :CM_44+24/2I/])MN/*SGZC5]N;:5:PJ3C!O<IOBHYZR"-L=1BM+4FWY5$
MUNGBW\(6(/*\7Z_8;%L;=0AITJ=3=71T>M^TUZP@[[;[I:2<J3MVMZ*WEG':
M6GMFWIU"G+YB+Z\(]8\8H\J4=V$8OL1ZHLK  "*
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M)%=@:-2G:+>4MUTXXRN',Z,-O2PO45*+GSR5(U
M$/5E)Z==;JX]%/\ 0R8658JI3G"6,23CQ(0YEL/<QI[22A7>[45&64E["=MY
M*'C%*5-MSZ/@G[Q77MF';W\[VA>2M\I0\BGN]7:GZC#VMM<:EK-M%U*M:FE*
M,I/,TN#9:I+H6S6]\DVF\EQH4_\ *99<N!&L:/B]E;TTO-IQB^&.2)2Y%D@
M!%                  !0/D5#Y$'-=J&EK]@UU7$O\ ,C>-+BJFGTF\X>?T
MLTC:;<^7K+RUO.O+$?[2X&\Z.LZ?23\GGP^MEKZ27O:6].TH;D'+=SGB<\JV
MWC.TUO.EEQA6>\\XQQ-RUG45!.A;XG5X-1A+CCV'EHVGT;7>JW$H=).2FM^*
M37>()9BT@J=O"/8CVQE<2V$HSCY.&NK!=%87/((6U_H9'A9>=,]ZWT4CQL_.
MF%20  (;^^H^\3"%+[ZC[P$T          "DEF+*@DCF^U]&5IK4;K&54KP7
M!>I? V3:"_I?(<JK\I=(EA-9)VO:1#4K91:;G%[T<2QQP\&JT-F-4K1Z"]IT
M_%N?DS6<BO4#V\'MK./C527!.LI)8ZL&]$/3[&%G2C"FGR6<O/43#4SM(@ !
M%                      \ZJA*+4\8ZTST6<,UG7J&NU*W_5L+=T\O.^UR
MZOM(-9\)>GVT+;QBTA"%>5:$6XO+QNOX(WC074\2ETS<I;W7V81KEMLU>WLW
M/6(04FLOHYI<5P7YC=H148X1815<@ %       IE<?4!4%,K&2N0    !/(
M   "F\LX J1-3INI:2BGUK])+*26]'!)(<QV>FK37JD*O^TN>#Y=;/7PC0A6
M\7Z)Q<O&$VT\]1F=?V8J5J\:]A#-6.]+RI\,Y(NF[+WM6OO:I"*BN*Z.:YY+
M7T3[;+LY3G2T]JJ]Z6^_L,LDER+*4=R.%R+UGK"0  *
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M[9#57<3EINI4K:C)\88?&/9R,UL[L[#2DIU.CG765OQSR9G\%4L"!1+M*@
M                       8/6[#5;F$OD[4%;RW4D\9XY^!A;?9G6*]6+U3
M4Z=U3BT]UQ?+KZNLW5+"X%>HD")IUC1L;>-*C3C%1SYOK>26%R!0
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MK*WT4CQL_.F>U;Z*1X6?G5 )0  $-_?4?>)A"DO]:C[P$T
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M-0JJ%)XEE-/B-$MEV=U-:G9NJMWSG'@\\C*FF[#2P]VEPH^5P7+/ W+K+)
M"*
M 0M1\ZA[Q-(6H^=0]X"72\PN+:7F%P   09?A>/N$X@R_"T?<^).
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MLR1 T:BJ%I&"AN)-\,8)X(  %
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M(]EY]0\I4JTDTX/O/>SI.EO.2:RNL"2
M                                          @  H         =8
M
M     &  SQP$6?[7ZB\
M
H                                          %%S8%0 !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g942297g14t04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g14t04.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X5?V:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @
M(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL
M;'5S=')A=&]R+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(U+3 X+3 Q5#$S.C0U.C4X*S U
M.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TP."TP,50Q
M,SHT-3HU."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C4M,#@M,#%4,3,Z-#4Z-3@K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FAE:6=H=#XQ,# \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!6D%%04%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.5%7=')B
M9E9O=C-39EE8.6ME1TLF(WA!.W%N,5<Q+S-Y;B]!:BMM2W4K<3)V*RM5+S1%
M9C!X5C,Q5S$O,WEN+T%J*VU+<U=(;C=Y;TY4=610;6=K:6MT<%AG3"MK:S-+
M4DI6:#0F(WA!.W)(03 P=TQ-,W=C:TA,=&PO=T-8;%9U4"M::EI(9"M/:38U
M."]E4UE91VQ2>F--0GE71TLR:S5S=%(X635);SE-.&A2>65*-TA!3E F(WA!
M.TY*,450>"M0=%9M.#=E4T9926)L3U)#;FE,955N:35:47AP2'-T54Y4,$AF
M<4U(9U0W:RM01'95-"]/96=$4G1,,5,T=$=I:C%75# F(WA!.S1O>$=#,%DU
M1E1*2GE#55)A0W)$>$9+-&9"3FMD>6I/3T5(=E5B;CAW+TIT=F5F5C)J;&5-
M9F)U:W1M35%O2FEX1S-.,5@V=3%74E,F(WA!.W9V,6]2<#5%351Q64$Q*T]V
M-FM1;FYR>4I*9$YA4EA34S-+>D,S355D=DLW96]34E%"67I55D@R:'1G.$-D
M6%1,.'A#-G1:1C4X.&PF(WA!.TY!6EI8.4%G2&MJ,C=S45%13TY9,61#.4-'
M-&AI,417;4IW5%@X>$)7=79/2&Q+,70W3S9L+S-J=E9L84LT14152&]/<U1+
M>49F5C4F(WA!.T8U06](1$%-36I9-VQ/94E!4%%R;#@T9517;4U1;$A.9E0U
M5G1P9T%:5D1O<%EX,$1&5#EN<4\K4&=Y4TTP5SE-.#(K5'15=2]Q;6XF(WA!
M.WIR8S-00T]1>'@R.'!)4UAJ>%DO=3EH.%DU12]:+V%P:DQ$2TES:%E:-%-.
M07),:GIH-5=T=%)V3$<T5F\U3$EX<3AG9TUI=3AH5F4F(WA!.T51:41U>DLP
M:6AV:#)*1TEW>4E"2%9">GA"25!29&1E82],8T9R2&1P16)I,FUS<#E2:6MI
M:E@T;V)F:'I&2$M-1U!Q0V=)*V1-4F@F(WA!.VM46&Y3;DY%0R]+,49V4&YK
M6E9:;6XT.$-1=RMQ>FLW8RM21DEJ5E8Y1C9S3FAX3RM(=THY>41Q260O,V]7
M+R]!1$DX:C(X36=G;%<F(WA!.S9V1E5L3$I96D9K2D0X0W!$4B]#4G530TLP
M,W!42E(P,'HW:TA644A89$8V:#4P.'(V9G%K;6TS8U125%)E:U=D;S%#8TI6
M-6,Y>4<F(WA!.W!'2V,Y<6EO,GE-8TUI3$1+5V%)3D935#AX9GDV65)K86A$
M*RM6;FI":&M"25-O3WAJ<4-E3W=/-3=6=R]L.&YC>$=Q>#DV;S-N8GDF(WA!
M.W1(85$S:S!-:TYR3DYC=T-74T-H53)G675Z>"\S9T(T8D1J>3A134AG4W5M
M6&IX<2MM+S))-C(Q,U%B<5=W4S)J.55A9S V478V6$0F(WA!.VDQ="]E3$ES
M9U(Q24EP5&IK5&I)=2MJ25I!87)Q;%$O34QY84AH4C%D1VQK;&EE='5323)I
M1&UJ<V]:4U@Y4#1647-X<4YS;BM8:W<F(WA!.R]-=U)B96102DE&5&-,<VI3
M34)B>6MQ135C;%E#3W%U4%1B-$0X5W@R>5!G5#=K*U!$=E$Y<"M92&ME-6LT
M2DI13DES8U5H=#-+4'DF(WA!.T521%965S1,5V1&<DIX,WE2,#AW9V%M0B](
M=2]7=FPX."M4+T%.169P5S!+,W1P.5E7,%EX<DA%5FQ95DA),TIG5E9P*S!4
M5$%-17(F(WA!.V\W3"M9:'<X43-(-#<P4$HK66YL04,Q4T].:F182G0R3G$P
M1'$X8U9Y>6HQ1UE)>45+2"]!1U=.5'1H+TQY4BM::G0S-V9A:5EV4% F(WA!
M.VLR5SEG=%DR2BMS06-*=G$W:4U->E)Q:71647DX+U=1<7A8:5%2.%<T=V5"
M2W)4*UEH9$UK*W$R=BLK52]W0T)(.4UP8C-F5F)8+V8F(WA!.TMF.$%!:BMM
M2W4K<3)V.$%V;% K0D@Y3595-W$Q='9Q,'8W<%!S3BMY4$1&5E,Q+S-L:"\Q
M1B]535968U9D:7)S5E,O.4%A4C9F<"LF(WA!.V@X2#%O,SE/5"\W,&PK6F9R
M+TUA,#9E,E0T>BMH:G=$.4M73BM89FLY9T%B13=B06EE-$)#-U5J<4I+*VU/
M26]N,E(T6E!X-3DW6"LF(WA!.UAH,V9J.&1(3"M86&LT4TY*.5%*9&U$3510
M3V9S:VYJ47E5-%99,50W2C=J2'@U.38O;#1D,S-Q.&YK:GET3&)25W,Q9W,Y
M=F)X4U$F(WA!.S(X8WI34VE.2FTU4#9F3FTT3EAO=RM)9$%134AJ4W4W4V-%
M0TM)56PO3"]Y:W)-=W-M2F--<')08T5"6%=21U916D-&0D4X;7<X83DF(WA!
M.V-F2&XS;R],=S=V>"M#<VLO3')Y8DM#2DY/1%9F,4MM5V%T87-A03@V:%-8
M66QF<VMN<&@X969E<# X1#!8+S1!.'!62BMO-TAC<C8F(WA!.S O2&Q59D9X
M-3 U9D-">38P,C994$AN,W X0TAC<C-8:WIY,617:U9P4%HX-V5$,6925#%*
M4G@Y95%3>45%3415=6]A=&1U,4U!>7DF(WA!.T)U,&Y$16EI14EF>3,X;&QU
M43 O:7=2541*4&-+445#<4M&6D)1,%)A:V)N=FMV>D4K.6@K6&@S27949DHS
M;#-42FA.65=Z5SAI<6DF(WA!.T%P3D]0:&HT9TQ4;E-H-$1K4#)Q9D9827EY
M>5!.;DA$1U!*2V9-,FPK4CE"=&AR5B]P>D9L=6QK931H3&5S,'-K;VQ$4W1Z
M47E+<VDF(WA!.VAU3$5G53)'5UDU5&ME149Q>7=X=TA%4C%3;CE0+VQ:93)-
M1G!D3$QB,CEH.5IT-U=.+W))-5%X9TY..&-$4'IJ64I8:3=B,#9:4&<F(WA!
M.WEG,D]V=5E(2FE);SE,-S%Q-FXK57!I=4IR:4]3,5,S85-Y:SE:8G144UE4
M<5)X0EEJ;4HU<4)Q34%A,$9":#1C=E0Y2&MG>7<Q6CDF(WA!.S-8>B]!1FQ-
M.4$X=6533F1T<FY5;TY-94U3>C-%3&QP3&A#-5-6;$UO0EIA33-::'5V,F$W
M57E%.&LT;7)B365/16=30C-P-V9E5"\F(WA!.T%#-69Z1V$X<WA02WI)>D\W
M>45K>'AM2F$O1B])>$(X92M64GEY2$ET<W-55'I#15 U9"M4;5968E0K4593
M=GA45'-46&PX5$5V5FTF(WA!.U@Q1S1S,C8Q,DEY6&IZ-S)0-65(8W)Y95-F
M3%5L;$A:4U=J4U<X5'EY;W)Z5',S3V5V<7-83#@R3&-J,4]$>'!89' X1TY6
M4W),-54F(WA!.S!/4DEL.4M73#!*6G T;FAU3&E&,6MU5TQ415!&26IF150P
M<E1!37-K;D9(.%=G,R],>GEE.&YQ3EE(;%9N,FYN035V>7$O15-5-2\F(WA!
M.T=A3C%(8F]-;#0X*SEI9%!$=2LY=50X=F9+16Q/9&A59U5R-C Y4V%S,TUN
M;E5Y5F1V,V@K3&9R:C0X*SEF>3A/-SAF:G$S0BM8,VPF(WA!.T,S1$-'=S0X
M=78W-F,O=%)V,V8K84)0=3EZ9T]E6C9Q345","](-$-,<R]+;6=79'1&8E<Q
M<G=H:&Y3-VI5>5--4DY';U)'-4UX63@F(WA!.U9!54%M;$YQ641L:U1:6E)X
M4D%O2TYZ-4DX<UA..4YF5%=F2S9U1T1Y>4-76F%S1U)U45980W%A=W!59V(P
M=VI.24-R46--4V)R9C@F(WA!.V9Q5U%E42]+:T%(<#)21D].0UIP;5 W=&\S
M459,;EI40DA19&=+9$YS5&YN,V]'0T$V9FHX0E X<6)N67$W1E9+-B\S;&TO
M,4<O56,F(WA!.U9D82\W>7<O-FDO<4=+<75+=7A6,DMS3W1F>DIS,C%(5V)'
M.7-N=$I.2#5->3AW-6QJ16EX<7E':7AJ-&Y&950O1#AQ:T=L55HO>E<F(WA!
M.S!Q,G-$<4YX65A1<VYC:3)-9G!34T]I3$589&LU9TM"2D]Q8DU46'=X<%A3
M+VTY-5AJ;FQG359Y6&EK35IO24%#4G-P*TM58U999VHF(WA!.VLQ05 R<6)6
M859$6%@U>BM8;U!S,E8V,T=1<$IZ4D592T9,8VQ4;7IK=%-G0D%O86-U3E)6
M<%9:9GIF,$(W*TLQ:G1,;VE6459D:$4F(WA!.VA,3DMS459585-P25ET>7)1
M:FHS>'!68E4O>E@X=F%D<54Y:$YA,W)3449H-G%*1C948TI403%(85)14#-G
M2S%A;E0U5F%61%AN-7@F(WA!.V%$1W)M,G1,:68P*U)D,S12;T(V5'EX;6]:
M,BM0,'E/4$AK3BM10C),4V]U,2].4'DO8U<Y.4],83=J5%1O6DIR:T]K6$E'
M3U)9+U0F(WA!.T%74G%S>&-C9C)4-#%"06%60V8X<FLX=E9K:TYL94<R5TE3
M4GE+:4TW>4$P94PP=S%62T1E<FMF9%%S,'$V-"]/4'EZ07%S,7)E<VHF(WA!
M.WA*36I,2$534355530K<GI"5791,5AS859X<%=V32]N;GE:3S$Y<$]R5U8S
M8W@V9DI'6E9736A7;#E.<&=Q,&1'4$99,G)79S)Y55HF(WA!.T=*<TU:4D5H
M4EET2G)8-59Q:V)X*U@W,#(U:31Z3UI':4-)8F-L531T8T1K-5=4:5!M,4-D
M.',X969E,69L-&1Y8S8Q<5 U87AA=&8F(WA!.U=T-7!T>3$P,#!,6#!Q4T9%
M370R:G8X044S<F]0:%8S1&5Z14-O<FM2;6U/<51H9V5I3C!V.'AF2C%H0SA.
M;%HS5G-K>$XT65=-9$8F(WA!.SE:5$TW04=:*T$W.$8X87%P05EI16E4>F))
M>$$U2V-8-3)E6%-Q4U,R5C1K3&A+4TEG9C1M85)725=Q='=(<&).4W!R.6M9
M2UI),C4F(WA!.R].6%-,4WET-VTV<W)P1W95;6QT23!#4V=X=WE02'ED-#):
M5BMW1TY+:6A&0V-A5E%T9GIA<UHY0W8X059M,"M73DQ,,$=61$EJ:5,F(WA!
M.T\T8FIY1$IY;WEC2D-Y,"]:.&1G,'$K>B].=E):9VYQ,F,X4FUO8EE+,$0X
M,4Y&2E W>&50>#AW2R]Y,"LR46U.2W!F.')N.'1L;%HF(WA!.TQ3.&5";UAN
M3$Q'<&-+:W)25C1C=G-K<%=O3F9%57)2<%58<4@U<V57-T<R:'5*;TQT;&UT
M27(W9W-C9DY9-6U+24=5>4$Q*T4Q+UHF(WA!.S9B-VER4W%D=BMA*VQ44S(X
M9C%+6D1*3VM5-5HT9C-35%9%8VQ/9DEI<E(X=&A4;'-35DEX<%5B<5@U:39:
M<"MP3EE3,E8S3DUL07DF(WA!.S(V2DTT9C!&=4-P5E@S*T-29# U9"MW<FI3
M<5DO35<R;&DQ4U,S,#8T-6%D87<S2W=49U<X<WI45BM"56-B8U!H-4=V9EE(
M87)3;V$F(WA!.S(O36UA-6TO8S99<E=Y4TUS<VXQ9SAX1T=I5E=64%,T;&DP
M-G)W-6HT<6IS84Y+>FI!<G-69&EQ;&1F-WEZ9C9J9G%/2W5T9CDU668F(WA!
M.SE29C%$1E981EA9<3=&5DU7='-'6FA%9UIW5F,X4E5G:W-19D5%<U1I<31X
M4FM52T-G-D-G.&$O<GA65$9J6FEA4V-14BMT2V]34U0F(WA!.VE/5$M#5T%*
M-VER131Q=DU%2C9X<65V541V<V-68DU-4DY3:3%'-$Y"5W1A+W)X5E1M<W)/
M8V\P,$-31TIU8UI:465,8B]%2SDO:4\F(WA!.TMR>D)!97-A-VUP,DA89F8X
M5&EQ:$9P=6U*9%A&-49B4DQC,U%#,U4V;W9/45(W04]A8C!X5E@Y0T=H2'!R
M4G1M1D)U2U4S*VI&6$TF(WA!.VM.4GE686LW5D$V9SAV,6EU2W1M3TUK:W%+
M;G)S3CEQ9G%X5F]W46YR1W V9&@R,D=+=45C3$5U1E5K;F1Q0W16<78T9$U6
M9#9%2"LF(WA!.RLQ*S1D:'@O5G1I<EAP5S9L9F=116XT9&=.-D@K0D]+<G93
M:6]"=U=I:6EI9S)".$U68TE99W9%26]8<%-G<%0O331Q=%=+,TEQ<4HF(WA!
M.U%B8D%D5F%V-$YV.#A68D5%049"1V]!0D%(161$,4@T-'%P+U4W2EIN;#E'
M35-Z.%9D*TDU3G<S544Y-E4R>%95.4-(9CDR=2MX,D@F(WA!.U1&5VMT-V1*
M2&Q33E9K;$EA4G=!1UIG;U5%;G8X24%X5GAI=#-L.5%O<E-O0VY/9TQ!3GA*
M5W97:#1Q9G5X5GHR,74T55!%:D)716DF(WA!.V=Q1%)W95%B-3AT+VYI<6]7
M049384-O2#!N65EQ-T9867%P6$Q!,C T0G%1:D$K>#0Q>%8Q<B]V3$0O<4PK
M;UEQ<31Q-T9867$W1E<F(WA!.TI1*U4Y6G-O-V5',CAX>FEK4'!%5&=0>FPT
M='IK6#1L-C%',CE/=&$W-%968DAY,35K9U=Z:G5.9&$T5S%+5G%R<5I&4C%9
M:#939D8F(WA!.U5!<G98.65+;V1F2U!M2DQY,FUF>DY-66]/6D5:56IN2DME
M9GAF2'A90GHX24E.1BM(1E<T4$LS;3)):' O33AK=$%!95515W4V;G,F(WA!
M.W=P5&HY4&9B1E549657+TU-:TUA5S)V4WA44F\V3DE6<GE6=E8T1FAY*S!V
M<4E/6"M46$955'!M:BM9;TY63C%E-GEB<3 O94%787@F(WA!.T)&;S-(:'53
M>#(T;B]/=4)71S9P*UA(;6$K,5,K=DQE.'0P9W5,;6%33D=K;$1"5VM99T5#
M36I.;$16=T510T1Y9$)M-TUZ4VY+46LF(WA!.TM*4%4O<5$S+TMQ+TYV.$%Y
M,U<S+TDR8B]Q;FMV>G50=5 R3F8X:S4O=T-C4&UF,4Q7+TLW>EER241F5S%8
M3D(K.6TV,$HO,S,W62\F(WA!.VYC9F-F<U@K4V,O.#1F32]Q6&8X<7(X,B]W
M1$QD8F8X:EIV*W%E4#4S2#-(-T8O:VY0.$%Z:#AZ*W S+T%#<79Z8B]Y,U<S
M+T%#3FTF(WA!.R]W0W%E4#4S2#-(-T8O:VY0+T](>E V;'%F;&0U<V134F97
M,4%34#<R8G%P25 X075V,G@O3S0K-"]9=CAK-2\U=RM:+U5U+S566#4F(WA!
M.W0O-6)R8B]K8DXO,51X+T\T*S0O678X04I/9BMC4&UF,4Q7+TLW>EER241F
M5S%83D(K.6TV,$HO,S,W62]N8V9C9G-8*U-C+S@T9DTF(WA!.R]Q6&8X<7(X
M,B\X04QD8F8X:EIV*W%E4#4S2#-(-T8O:VY0+T%$:#AZ*W S+TMQ+TYV.$%Y
M,U<S+TDR8B]Q;FHK9'@Y>"MX9C5*>B\F(WA!.T%--&9-+W%7<"M6,VUX,4I&
M.6)50DDO=EIU<6MG+S=R.7-F>G50=5 R3"]*3V8X06Y$-6XY4S<O04I66#5T
M+S5B<F(O04I'>F8Y53@F(WA!.V9Z=5!U4#),+TI/9BMC4&UF,4Q7+TLW>EER
M241F5S%83D(K.6TV,$HO=T(Y*S)0-3-(,T@W1B]K;E X07IH.'HK<&0O>7%V
M>F(O>3,F(WA!.U<S+TDR8B]Q;FHK9'@Y>"MX9C5*>B]Z:#AZ*W S+TMQ+TYV
M+T%#,U<S+TDR8B]Q;FHK9'@Y>"MX9C5*>B]W031F32]Q5W(K5C-M>&TF(WA!
M.V-#*W1Q;V%(.3=.,6]$+W9V,W@O3S0K-"]9=CAK-2\U=RM:+U5U+S566#5T
M+W=#5S8R+S5'>F8Y53AF>G50=5 R3"]*3V8X06Y$-6XF(WA!.SE39390-4DQ
M>7@P1%9D4'5B-5DU-SAW<D)C5S=Y355O,41U4D=25W9B35A5-6]Z26]/>C!'
M;&YI0D5Z9&\R,SAJ-FEB1G)/.3%U-74F(WA!.TLS16LO=T):5G!%;4-Y44Y%
M159V56%N1C)6>#$V6FI7-T).=DME:F%P;RMK0W@Q3%4S,6%:2DAA3S=L6&I*
M-F)';U)J53AI1%AF07$F(WA!.U!K+W5B>C9F*U1A-'%V=&Y145%)5T%D;S%+
M<EAC9T%6;TU65G$T<31S0E%%,$HV67$V;W)3=2]7;4MR9E5J-6U0:U!507%5
M<4LP.&$F(WA!.UEQ;&5T*U<Y3S%M4TIR='!!.79(2VM":F-O56%89V951E R
M:S1!<EAB,C99<6QB+T%*9C):=5I*-#E2=DDR8U-,1W%U=D=*6E-/4W@F(WA!
M.T%R.$AW-V)98E9E;FM/>E,R34EV<FMS8FM84FUB,#-C:U)X>#!Q>4AF:D50
M:2LP3C9(1S%54#A!;%A6;$EK<3-'<#-L>5I%-%9L9$<F(WA!.S0W=61H>&].
M,T].<7%Z95)R865W=&]P3E-U:$Y"13!4,U-0>%HK66PU13$U9G142&%V86U.
M<6I.33AQ2EDV<6123V\S;'DU.5-K33 F(WA!.V=-445N2#EL46\R-%E&651Q
M=C5B,SDY<3$Y94IQ1G!';'AC>E-+:G-W64)P1TY$45IS.&5S06E"4C504#5U
M>7!3;DM81DAC:V]8+VPF(WA!.U97<&8Y6$MY+W=#1&(O;6Y*9FY2,T9Q+VME
M6#@V2S%V>70Q1E-O+U-6;652;U!I8G=*+VPY<V9Z;S=I=CAJ>2]N4EAF.'%Q
M,4PO<34F(WA!.U=8+T)T+WI4:BMD2&-6+VME6#@V3'8X06Q65W!F.5A+>2\T
M3G8K86-F>F\W:78X04DX=C4P5G%F;&)Q3$-O,4MZ1S5'-TXR3E U9F(F(WA!
M.T@X-D\T<B]).'8U,%8S+TMQ=%,O-G56;"]W04<S+TY/4#4P9'A8*U(U9GIO
M=&HX<#E88FIW=G)6=WIC459,:U9!3&9Y*S)0-3908U4F(WA!.VIS85HO:4-P
M+W=!<6<Q>B]!2F)B8B]K<"]W03 T4'HX931P+VM79C@T3R\U5D)R;B],8F)F
M.&Q0*V%C9GHX931R+TES+W=#8T9Q9FPF(WA!.TAR8G%33'DR,DI8+T%(6BMY
M4U U9F)(."](=4LO=T%I>B]N0F0O>7%$6% K5S(R+S5+9C@P-"]N-#EX6"M2
M6B]Z9W1B.&\Y8E9K0G8F(WA!.TQB-'IX2#DU-$4O>2LR4#4K4&-6+VM79C@T
M3'8K5E%A-2]Y,C(S+TI4+VUN2#@O2'5++WE,4#A!;D(S+T%#<4184#A!;'1T
M=BM3;B\F(WA!.T%$5&HK9FHS1F8U1FXO3T,Q9GEJ,71M8T,X='9G4$4O,VYG
M1"],-S0O;C0Y>%@K4EHO>F=Y2'EP-4(Q5%(P,4I:3#%%93ET;6=H;G0F(WA!
M.RM83TIZ5VMG-4)D,7)58C5J86Y51$E"461H;TY$3$%34U%B4DYT-4XQ3S(P
M*V$R;#%M9'A03%I/6E9E55-Q8F0T*UE6>DE30DEQ;&$F(WA!.V1/+VE->%A:
M<&XU4#AV-G)O5VUY5U=O879,<D9*3U9V4&-+0DEK9D)2=UIQ;FQ29V%6-UE&
M5#-&54Y*+V,S;C O=T1*=&-64W4X.',F(WA!.S)U<'DR=#-.2S9'3T)9:6E"
M3C$S4#)I0WDQ-45':#-W<6PP2#5F2W-6-V)81W)89'AB6%5C56-F26=3>&5K
M-GE65CEX,5%5;V]P.%(F(WA!.S9N1S%7,VXU6F%69'5R>3,Y-E=I<C9(-S!(
M,'E9;&EQ=%9.3FLW9DQP:F%Q,#,U93)-,7<X-V%J96\W<7EL;S51:DAK>&%P
M64QY2D(F(WA!.U!C-#)Q24AK:E1H=V-83C!,:%)!:'505E!*:W0Q0VA7-T=T
M3U)05W101$<Q5W8U1C Y<#1:5G5R;4U10W%*1WER.&9P4GA&>65.5'0F(WA!
M.T)',RMS2S0R<5@R+S5B4C(X8GA0<E8V.$(U1FY:+S-O0E5I9VPW0W).,C9'
M;FI6=%58+V=/>&MG:E=05DPY559L94YO<"M047-D=4DF(WA!.S,U8VA5+S5)
M4&IJ87)J-4,P-'1#-C-L>6HR.7,Q<79";%931UHR<7EH9'HK.4DX2UDR<4%B
M.'-.3&MT<E-%87)F1S)T5VI:13E60W(F(WA!.VU,:48U,%=H*WAV.'IJ87 S
M;R]L83(P>E5*8BM/.'5:,VU6,#E/851L1W%U>70X2S!&2T9F=DQ(=F=69RMR
M9FPY.60Q82MU+S!V85$F(WA!.RMV8WI396LU;WDX<$=.1'9M>G@V=6]G8THU
M4% U=7DK2V-P8UDS2E%N+TMS=BLQ,UIF.$%"9C(U3#@U+U),5B]*4#A!5&DW
M+T%*5FTF(WA!.WAD15A78DYM:V)I041896A0:C=9+VY0-DI4+TI(.4]+2R\U
M52]Q5F%F<$=#=FAX8DDO;G@S32\U16PO3T,Q9GEJ=C)*0S9N8G-2<U$F(WA!
M.T%X-D5J.6%N2#@K3S5F-45L+T]$;R]Y:#%*,4I';U%I:%IF<W8K>5-0-%DO
M;G@S3"]):W8U=UAF.'%E,5 O<3119CA!079J*V9(8W8F(WA!.SAI4R]N0FM7
M;"M49%$P,WEX8V%/;#)N,7$W;FME2S18,4963U5)6&9G>5 K>#0U:6%J34UK
M<F1P;V1+8TU$16TY-U=84&M8>D)C5T$F(WA!.W1$-6EN:4)L=5I';50Q4%5!
M=45+<6]*:R]93S1R-&XU-5)B;7-I.'0V6G%/;6%21%IA:'%$-G!C=VQX.61K
M54Q)-D9Y534P-G-&;T,F(WA!.V4K0E5D8F8S6B\Q-5 K2FY&5EA&5DMB*SAG
M+S%Z+WA"<U968U9D:7%L1"]E5"\V-"]W0TE,:7%R:7%L8R]W0C)0.650+VE9
M>%96>%8F(WA!.S)+;V%4*S5V4' O-4YR:7%P82\W>7<O-FDO<4=+<75+=7A6
M,DMU>%8R2V]F54Q32RMS8FUX:UEQ;'I%.$QL86-G<VEL4U)8=E)S5EDF(WA!
M.W1E9FPQ1DQ$271R<71Z87IY>4=34FPT*VU3=T$T96MV04)".%)#<5)U9#8T
M8E9&,UAK3WAU3E%L=FUV-S%*2C)I85=.2E%Q3C9+>$DF(WA!.T%10C!):$(K
M6DIX=%5*6B]L>F\Q<7IW46%H8RMM1'HK<',V3D=L4U=Q<UA':3=T*W9X>'15
M,C!8>7)B-E1D<F-26'0S8T57+S%94E@F(WA!.T5P:UAI2D]986@O855544AW
M.3A#<TPQ5'E(<$8U<6PY9%,K67)E,FMN=5IN94)L47-H85)J>$Y:5C9F3$YL
M1%9315%/13AV>#!D0FTF(WA!.S=.:$MC:C1G1FLO:FUH:"M7*VE%,$AM:3)*
M4%%C22\K<3)3+T]3+VU(.&9"<B]K<4@K<40X9C5Y4'1F>7-H<V12=%IJ<D-U
M,$5Q4W0F(WA!.T=947 T<%8V;CDV84$X2U9Y=5=U<T56.7)K62MX=4=1;'@X
M:C-F=%IJ9F57.4YV.5=H,55U>3-L=45%8G!W3D1&-F]7=%9B;UIM>E@F(WA!
M.W4W4W)4+WDS,'5X,2LS,3)+-W56=F]0559L:DMX47E2>4Y),T(T:U5*4E1,
M='0R1T<Q6E)B9C-:+W="950O:5IW2W$T<7!49C-K2"LF(WA!.W5F.$%I1%EQ
M<31Q-T962S(O=7HO04LX;B]%>FEQ<FEQ;$XO95%F-C4O=T-)3FEQ<FER<U95
M;V8W>68X03%X+WA"8U968U95<FXK-T@F(WA!.RMV2"]!351'2W%U2W5X5D13
M9C-.-3E0+T%#8EA&5VAD5SER<#94,TUI>%%O:6-N63!!<E%$-WEA67$S1G%E
M;7I/<V-6,41)-U9+<7(F(WA!.W%344LQ;T%D+W-N1E=H<75M37%-3'5%:5%O
M<UI%:2]%,'!O9T<O5G4S:FEQ,E!79$IL04UD-4-W6B]356@Q,V,Y1D<O53EV
M2$96-V$F(WA!.W!P:4UQ3F1W<7I6-&=Y2T-E4%=M+V%U2W)H<49G535I-6E+
M8DAK2%=L0U-O,W(T<5(Y1TMS83$O42],<SDW3'%&>G%S=&Q.37E7-W0F(WA!
M.T9-<6=04F5#,&]A3E).=FXX<TMR3&IY8F]6,7%"=7AQ,7=S<E1V9$UK8SAD
M1$Y)1VDU1&)A9TA#9R]L<#0T<6A,<GEN-6-E6F]7.'<F(WA!.S-C53AV2V,O
M-E5+;4]C=49!-59(13@K,UAF>$]+;W4W.',V03DU9%AK;7-Y=W1E0TY:0VQW
M<4Y6659T,"M0<C$T4#=T5#59<6IF3#,F(WA!.VPO4V1.=6ML=&1193AN1412
M=#9S:5-S>75Y4'IQ0EAO1DAY<&ER1G)Z>4IO3W V,61S3F9I4SEU8FU::EIR
M-F)32WAK66QE4%!L568F(WA!.TQ.:$A5>FI%96Y90C!75',W1E!)9C-N<4I/
M,GEO=C545T5-<74R<T5&6$%O63%(>&9A0R]B-C!Y2C$U-VUC97AO9S-X2#5-
M;S%Z>70F(WA!.W R<E!/-W568E5)571*6D5%8F9U-'A+,W=L;&)D:31Q9CAK
M56]26$U",U,S>70U23 S>3%C,S!U;C-&>3AD*W=K;'0U<$]C87EC;5DF(WA!
M.W-G;T]03&Q1+TQ&5U$T<7!7,SDR9CEE5"]I6GA65GA64VTO=DE0.$%84#A!
M>$)S5E9C5F1I<6QB9C-:+S$U4"M*;D966$962V(K.&<F(WA!.R]W0F,O=T1%
M1WA65GA6,DMQ55 Y-5 X038T+S1G=4MQ=4MQ5GHO9&HO6&HO04]*:D966$98
M67%H<% W;3@K;B]!2DYR:7%N4' Y<G$F(WA!.T]K:7EU;$QW5%)O2%5%:71+
M34]N=4U64W5,>40U5VEM33!D;W=L2W-N4#%P:5%(<GEO4SEA;798<FAT5E=(
M>58U8F=L:FQG=%!484\F(WA!.UE82SA88T0Q1DE+-U8V07%+3#!W5W%L+V=(
M>7@V<GEM,V-T3"]E07EY55EC=5<T-64U=S)Q:&-F;#4U44YR8U)Z=T],5U%+
M6C%A95$F(WA!.TE&:D%P,6)904M++TQ',557.' O;#1956M):$514E5J8UA$
M531G16=!."LT;#,K67A61G)O;FLK,%-70G!56#8O26YQ0U,T4$M35TTF(WA!
M.TUI,'$S,G9G879Y4&AI<41U4$M0:T)4-CAX4E5E54)Q6$QH0S=/,'EQ=U8V
M9G1%,#A-5E94-6$X:EA';D%&-#5.3VE73T5J-G=414<F(WA!.U(R:E%N-'%C
M*U1-;%0W:D961B],4#5D4&%V8G4X3'=H;%IW8FQI87-#2U9$,2M0-'-65%13
M4$PS;&EW=F\U=$Y61G4T-$1#06MP66TF(WA!.TI3<6YK=DDQ;WE!5E!F07%3
M85(U5C!2+TYL>'%L=G%F<E@P1GI03E!:<GA0074W<5$Q3GA3=5IK.#AV1$53
M3G%D5FDP94QX:D]-<FLF(WA!.T-346U6>C5/,$\U=7)N-CE+2F\W=30K=5-7
M<$532V8S6FE12&E!,4%73&-Q,4QD.'A(87$S;&9Y<F%E5TY.:#!U>G5B:31T
M:&-02D8F(WA!.SE:9C%'44Y'86]P;TM,549Q94I/0E4O>%8R2W%6="]D;B]8
M:R]W0TIN1E981E9+8BLX9R\Q>B]X0G-65F-69&EQ;&)F,UHO,350.$$F(WA!
M.VE:>%96>%93;2]V25 Y8R\X46)&5EA&6%EQ<%$O=T(U4"]R:B]I0S1Q<31Q
M<%A0.3)0.$%8:B\T;4U65F-69&EQ1VLO=6)Z-F8K5&$F(WA!.S1Q<5=V*SAS
M4"MO=C9H:7%R:7)S5F1I<6IE5VQV95=S=')C3'IG;55P2VQ33U-N<7!P5%EJ
M631Q>&DT+TPS>5A%9CA!4U9:67!H3D,F(WA!.W-5:S=):%=B-&I'=39K0D95
M.$%$<TLK,41A<DQJ>68K6#%X4$,P>&I:*TI71F9R3%4T24,Q0E(K:6E59E)4
M1E553D,X:VQ'=&QE3#0F(WA!.U=J85928T=T64]:6&PX6&(Q5R]Z06]Q:#0O
M3&8U9F%F8C-7;C%H:6DQ1DEP2C!E-&(T,$0X;VE'3%9!-61+2&9&5C%Z-5DX
M:5!Q140F(WA!.U-S:3-34D=30E)/=TA$:7=:=T]82&]R8BMX.3A64BMK-DPU
M571D5FMM,#<P:G%006U13$U88U)L;5=V2&MA04=Q.4\R0E5&-64P>E$F(WA!
M.TQF5CEC=F)E.3EA95-356%J0S552D9Y;&1J53!(.' V;DUN3$]2:D5%8F1(
M0C R2$A(2D]55%I*,SAT,&TQ<GDQ*UA&,W Q=' R;S8F(WA!.W9(1W-6;EHR
M.6I-3&E+2U9)27=7:65.;$,O,W%R=C)P,'!M3S5Z3TQE,4YP8E=&<5I8;DU!
M5TEZ>6YL22]#27)Z8SDR86Q49U9&-'$F(WA!.S=&5DLR+W5Z+W)Y9CA43TMQ
M=4MQ53,Y-4(O<FXO:419<7$T<3=&5DLR+W5Z+W)Y9CA43TMQ=4MQ53,Y-4(O
M<FXO:419<7$T<3=&5DLF(WA!.T@K.&XO=T)C9CA16$966$962S4O=7@O<G@O
M.$%%>&EQ<FER<U91,&XY>F5F5"]Y8EA&5E,Q+S-L:"\Q1B]535968U9D:7)S
M5F1I<5<F(WA!.S8U-60P=E<T4D9F>',T5EA73FQ9<55,,'%Y,#(U9D0S2#1%
M-'%L;R],>GEU6%=34T-35U9'-5)Y3DLT6F5L04]*555&3G$T8E9P9GDF(WA!
M.S8X<&DP5S K<4UB9%-715IL;#9S4U1V>7(S>'156$XU3S!#6C1N93-A<TU1
M9VEP23E&44U7;TXO131,5E(O=T@U5RMQ2F%I>G!&2$4F(WA!.UE)>4AF:TDR
M36I&959A-W1->%!J,S9$1S%6=$@X;F58.4AU4')&:&)'2V)I5D1&,V%I:VLP
M05EK9%=/2W%M:F57-U!3-WI5<GE&-4@F(WA!.VPQ4U5Z5'$U57%$>F1G14%6
M5"]U>G983&-M57E!0C9/3F@P<V-C<%-&*W,R9G@X54)E9FQX-4]V3&-W6%9G
M2C1V4FIT,41U-T95:&\F(WA!.T4T:W1514%!5C8P>7$S2E0R0WII=#1,5S-G
M2$=#,4-P1W!*66A%46]O<6%K+U1I<4EX5C)+<DEK2TM193=-,R]!051%+W=!
M8U98-'$F(WA!.W-D0WI2:V9S3GE0+T%!2D@X8U98-'$W1E9K4T9&25!D;6(O
M9VU*+VII<2]&5FIO5V%-:CEH=5(O-$5J*T]+<CA69&EQ>$5+=$E4*S(F(WA!
M.S-)9CA#0B]$1E8K2W)*54QQ04]Z2S,O07-$+T1&5BM+=7A646Y1<D)D12]T
M:&U(+T%!04@X3595;W96.4I05#EB,"M)-&8S4%-M,U@F(WA!.T96+RMK9CA!
M1C,O2DA&6&8V4B]X9"]Y4GA6,RMK9CA!1C,O2DA&6&8V4B]X9"]Y4GA6,RMK
M9CA!1C,O2DA&6&8V4B]X9"]Y4GA6,RLF(WA!.VMF.$%&,R]*2$989C92+WAD
M+WE2>%8S*VMF.$%&,R]*2$989C92+WAD+WE2>%8S*VMF.$%&,R]*2$989C92
M+WAD+WE2>%8S*VMF.$$F(WA!.T8S+TI(1EAF-E(O>&0O>5)X5C,K:V8X048S
M+TI(1EAF-E(O>&0O>5)X5C,K:V8X048S+TI(1EAF-E(O>&0O>5)X5C,K:V8X
M048S+THF(WA!.TA&6&8V4B]X9"]Y4GA6,RMK9CA!1C,O2DA&6&8V4B]X9"]Y
M4GA6,RMK9CA!1C,O2DA&6&8V4B]X9"]Y4GA6,RMK9CA!1C,O2DA&6&8F(WA!
M.S92+WAD+WE2>%8S*VMF.$%&,R]*2$989C92+WAD+WE2>%8S*VMF.$%&,R]*
M2$989C92+WAD+WE2>%9:3#9V<% V;G)E;GA04"LU-E4F(WA!.S,V67$O=T0O
M,E$]/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N
M86EL<SX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R
M>2 Q-RXP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,31T,#0\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q-'0P-"YA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C8Q-30S,B8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,#$M075G+3(P,C4@,3,Z-#4Z-3,F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,#$M075G+3(P,C4@,#0Z,34Z-3,F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[XH"B(#$P(&AA:7)L:6YE(')U;&5S(&-H86YG960@=&\@,"XR
M-2XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @
M(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @(" @07)I86PM0F]L
M9$U4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^<G(S-3DP.3,\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @
M(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @
M(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G
M.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R
M<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,3(N,# P
M,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW.3(N,# P,# P
M/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T
M1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @
M(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;"U)=&%L
M:6--5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^271A;&EC/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@
M5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/F%R:6%L:2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# S
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I7U]?7U\N<&9B.R!A
M<FE?7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$YA;64^07)I86PM0F]L9$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&
M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD
M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L8F0N='1F/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @
M(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @/&EL;'5S=')A=&]R.D-R
M96%T;W)3=6)4;V]L/D%D;V)E($EL;'5S=')A=&]R/"]I;&QU<W1R871O<CI#
M<F5A=&]R4W5B5&]O;#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#IA.#=A-C%C82UA-3$W+3EC-#8M8F(X,"TU-S)B9#EF93DW83(\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM
M<"YI:60Z83@W838Q8V$M834Q-RTY8S0V+6)B.# M-3<R8F0Y9F4Y-V$R/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z.#(V,V4Q-#<M,68Q9"TY8S1B+3AA,F8M,V$U.39B
M.&8Q,&)D/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#
M;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HR931A,SAF."TY830Y+6(R-&0M.# Y,BTW8C$P9F5D-3DR-#8\
M+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N
M=$E$/GAM<"YD:60Z,F4T83,X9C@M.6$T.2UB,C1D+3@P.3(M-V(Q,&9E9#4Y
M,C0V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.#(V,V4Q-#<M,68Q9"TY8S1B+3AA
M,F8M,V$U.39B.&8Q,&)D/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E
M9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C@R-C-E,30W+3%F,60M.6,T8BTX83)F+3-A-3DV
M8CAF,3!B9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-2TP."TP,50Q,SHP.3HP,"LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@,C<N." H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.F$X-V$V,6-A+6$U,3<M.6,T-BUB8C@P+34W,F)D.69E.3=A,CPO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R-2TP."TP,50Q,SHT-3HU."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@,C4N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
M !$( M4'90,!(@ "$0$#$0'_Q  <  $  P # 0$             !08' @0(
M P'_Q !;$  ! P("! <+" 8(! 4$  <  0(#! 4&$0<2(3$3%4%159/1%!<B
M-E1A<72!D;(6,C62H;&SXC,T4E-RPB,W0G."@Z+!"&)UTB0E0^'P1%:4P_%D
MHR9&E:3_Q  : 0$  P$! 0               0(#! 4&_\0 -!$!  ("  0%
M P($!P$! 0    $" Q$$$A12$Q4A,5%!D:$S<04R@? B(S1AL<'10N$D_]H
M# ,!  (1 Q$ /P#T-AVR6N:PVZ26W4CY'T\;G.="U55=5-J["1X@M'1E%U+>
MP88\7;9ZM'\*$D!&\06CHRBZEO8.(+1T91=2WL)( 1O$%HZ,HNI;V#B"T=&4
M74M["2 $;Q!:.C*+J6]@X@M'1E%U+>PD@!&\06CHRBZEO8.(+1T91=2WL)(
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MGEJY9Y [.EOY]K]$O\H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
M
M
M
M
M
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MZ4:BY>T[%AQ-9[]K):JZ.=[4S6/:UZ)SZJY+D8<EM;UZ.CQ*3/+OU3  *K@
M                                   #.M+?S[7Z)?Y0-+?S[7Z)?Y06
MA"YX8\7;9ZM'\*$D1N&/%VV>K1_"A)%4@
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MI9=;/^%3S_HJ\?K1_$_\-Q;#DM?%;F5SXJX\U.7^_5Z3 !YSU'G?3)X^5O\
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M^A21-BM8U$UE3F7:B>TA_P#A_P#U*]?WD7W..G_Q ,?W597KGJ*R5$].;?\
MV*6F;\1RV]H_\:5B,?#3>OO/_JOZ.,"+BIE15UE0^"BB?P><:(KY'99KEGNR
MS3WG:QMHTJ[1-3.L3:JXP3*K5:D>L^-4Y\DRR7GV%XT&R,?@V1C53695/1R>
ME&J72\7>@L\$<UTJHZ:*1_!M<_<KLE7+[%*WXC)7+,1]EL?"XK88F?NAM'*W
MEN&XH,0P2154+E8QTCD5SV;,E7)=_)MYCSU=G2,Q'6.@5R2MJWJQ6[T=KKEE
M[3U#;KG0W.)TENK*>J8W8Y89$?EZ<MQYH1$=CC)=J+<<EZTMPL[M:9A7C*ZK
M2(G;3:#1!2RT"/NEQJUN,B:SW1ZNHUR\^:*KO3FF9E\+ZG#&*_Z.3_Q%!5*Q
M7-V([5=DOL5/O/4IY@QUX[7GUQ_Q$\+DMDF8LCB\-,45FD:EZ?1<T14W*#C'
M^C;Z$.1YSU                                     !G6EOY]K]$O\
M*!I;^?:_1+_*"T(7/#'B[;/5H_A0DB-PQXNVSU:/X4)(JD
M                       4/39MP0_+RB/_ '*;H#14OUSS3_Z9/B0VX&]<
MW+CG'KW<UN'YLL9=^P #!TJGI6\0+O\ PQ_B-,WT#(J8IKLT_P#HW?&PW0&U
M,W+CFFO=SWP<V6,F_8,1TIX$K(;I47>T0/J*6H<LDT<:9NB>N]<N5%W^;:;<
M"N++.*VX7S8:YJ\LO/5JTGXAMMO;1JM//P::C))XU5[43DS14S]IU+%A^]XZ
MO;JJH658Y'YSUDC<FM3F3D5<MB(GV'H>:WT<\G"34E/))^T^-%7WY'8:U&M1
MK41$38B(='517<TKJ9<T<':VHR7W$(]EFHV6'B=L>5%P'<^KRZN67O\ /SGG
MB]6>\8'Q R5NO&Z)^M3U36^#(GW;MZ*>F#C+%'-&K)6->Q=[7)FB^PRPYYQS
M._6):Y^'C+$:])AA4F.L4XM@XFM]+"V2=-21].QR.5J[%S555&ISJ56R4CZ'
M&]!22*CGP7&.)SF[E5LJ)FGN/3E-304S%;30Q0M7>D;$:GV'U-8XJ*[BM?1E
M/!VMJ;6W*$QK:'WW"]PM\2IPTK$6//8FLU4<B>]$0\]6*ZW3!M^=-'#P54Q%
MBEAG:J(YJ\BIOY$7,]0'PJ:.FJLNZ:>&;+=PC$=E[S/#G\.)K,;B6F?A_$M%
MZSJ88;>;[B7'5IJG=S1TMHI(W3S.8U4:]6HJHBN7>OF3TJ?F@I%3&,^:?_1O
M^-AO+&-8Q&L:C6IL1$3)$/TM/$QR32*ZB58X2>>+S;<PS_2U@^;$-%#6VUNO
M7TJ*W@^65F_)/.B[4]*F6X:QG?,(MFH8F,6+6574]5&O@.Y<MJ*GH/21\*FC
MI:I46IIH9E3=PD:.R]Y&/B.6O)>-PG+PW-?Q*3J7FZHEOV/K\U_!+45"HC$2
M-NK'"WT\B;>4]!89LD5CP]2VN)VLD3,GOR^<Y=KE]ZJ2<,,<#$9#&R-B?V6-
M1$^PYE<N?Q(BL1J(6P</X4S:9W,O*[V5^%L1M5\:Q5M%-K-1[=BY+L7SHIN6
MBW%-=BBBN$UQ;"U\,K6M2)BM;DJ>=5YE+A4TE-59=TT\,VKNX1B.R]Y](HV1
M,1D3&L8FYK4R1"V7B(R5U,>JN'AIPVW%O3X<CS5I*NZWS%];+&JN@A7N>'+]
MENS-/2N:^T]*@IARQBG>MM.(PSFKR[T@L$69+'A>@HG,1)6QZ\NS^V[:[[5R
M]A.:J<R'Z#*TS:=RUK6*Q$0\]Z8K+Q9BV2HB9E!7-X=,DV([<Y/?M_Q&E:/*
MR+%6C_N&N57.CC=13<^67@K]54V\Z*7H&]L_-2*S'K'U84X;DR3>)])^CS-=
M;7><#8@9*FO%)"_6@J6M\"1/NVIO0L4F-L4XR@XFM]+"UTZ:DKZ=CD56KOS5
M55&MYS=)HHYHU9-&R1B[VO3-%]AQIZ:"F9J4T,<+/V8VHU/L+SQ46C=J[EE'
M!S69BMM5EYFPS3/I,=6VF>J.=#<(XU5-RJDB)G]ALVF;Q%J?[V/XB\ K?B.>
M\6U[+X^%Y*6IOW8OH 14N5WS3_TH_B4T#2AXAW?^[;\;2T I?+S9.?33'@Y,
M7A[81H)14Q=59I_]&_XV%FTPX-J;JZ.\6J)9JB-G!SPL3-SVIN<B<JINR]',
M:B"UN(F<GB1"E>%B,7A6G;SUAC2-=\.6_BY]/%4Q19I&V9%1T?FV<GF4ZMLB
MQ%C;$[ZJG?-'+*Y.%J(\V1PM39O3F3<F]3T/44-)4OUJBE@E=SR1HY?M/M'&
MR)B,C8UC$W-:F2(:=36-S6OK+/I+3JMK[B%=Q5AV:YX26UT=7,RIB8W@IG2+
MF]S4R\-=ZY[<_3F8E8[U?,!7BH2:E<U\B(V:"H1<GY;E1??DJ;-IZ1/G/!%.
MS4GB9*S]E[4<GVF>+/R1-;1N):Y>'YYBU9U,,"Q9I&N&)K8ZULH88(IE;KHQ
M5>]V2YHB>U$Y"ZZ&L)U=GBJ;I<XW0SU+$CBB<F3FLSS57)R9JB;/,:)3T-)3
M.UJ:E@A=SQQHW[CL$WSQR<E(U"N/AIB_B9+;E@&FU%7&RY)_]-'_ +FN:.VH
MN!K.UR9HM.B*B^TL8*WS<U(IKV7QX.3);)OW>>L=8(N.&[I)66V*62W:_"13
M19JL.W-$=EM3+D4^C=*V(TH.Y]:D675U>Z%B\/T[]7/V'H$ZJVZB67A5HZ;A
M-^OP3<_?D:1Q,3$1DKO3&>$FLS..VML&P+@JX8GNC:ZZ,E9;E?PLLTN:.G7/
M-4;GOSY5-;TEM1N KLUB(C4A1$1.1-9"T SOGF]HM/T;8^&KCI-8]Y^K!M!*
M*F,*G-/_ *)_QL-BQEXHWSU&?\-Q+@C)EY[\^DX</AX^3;SMH<1?E[0[%^9+
M\"GHD 9LOBVYM:.'P^#7EWL//6F=%^753L7]%'\)Z%!&'+X5N;6S/A\:O+O2
MD8=M;KQHKHJ".=]/++2IJ2L545KD7--W)FFWS9F1T=7?\ XA=-/ YDZHK'MF
M159,W/D7EW9YHIZ3.$L4<S%9,QLC%WM<F:%Z<1R[B8W$J9.&YHK,3J88/B/2
MC<+U:9[=%004[:AO!R.1RO<J+O1.;[2?T,X1K*.K?>KE"^!%C6.GC>F3ESWN
M5.1,MB<^9J<%OHZ=^O!24\3_ -ID36K]B'9)MGCEFE(UM%.&GGB^2VYABVE[
M"ET2Y2W6B[HJJ"7PI(VJKEA=EMV?LKO\VTZ5FTM7.@MT5+544%6^)J,;*YRM
M<J)NUN=?<;L=6:W44S]>:CII'_M.B:J_<37B(FL5O7>D6X:T7F^.VMO.W 7K
M2#B:2HCIDX256M>]C52*%J)EM7T>U3T'36J&"P1VEJJL#*9*;/E5NKJYG>CC
M9$Q&1L:QB;D:F2(<BF7-.341&HAIAX>,6YF=S+R[54MUP;B-BR,=#5TLFM$]
M6^"]$Y4YT5/O+G\L,48XB6SVVCA@9,FI431-=DC5WYN55U4^U=QM=13PU+-2
MHACE9^S(U')]I^P0Q01HR"-D;$_LL:B)[D-+<5%O6:^K&O!S29B+?X9>:M'D
M:QX\M+5VZM1EG[S9])^%7XFLC4I-7N^E<KX45<M=%^<W/DSR3VH7$%,G$3:\
M7B-::8N%BE)QS.XEYPPQBN\X'J*BC=3?T;G9R4U2U6Y.W9IRHOWG&\7R^XYO
M=/W/ ]98TU88:9%1&(J[55?=FJ\QZ+J:6GJFHE3!%,B;DD8COO.5/3PT[-2G
MACB;S,:C4^PTZJN^;E]671VUR3?_  HK!]JGLU@IJ2LJI*JJ1-:61[U=X2\B
M*O(FXR32GB&\T&-*RGH;G64].UD:MCCE<UJ9L15V(;H#''EY;3:8VZ,N'GI%
M*SK2,PO+)/AJTS3O=)+)21/>]RYJY58BJJ^<DP#*9W.VT1J-,+TX7A:W$$-M
MB55BHF9OR_>.VK[DU?>I=]#-F2W83;52LRGKG\*N:;=1-C4^]?\ $7T&UL^\
M<8XC3GIP^LLY9G;\U4YD,<T\674J*&\0L\%Z=SS9)RIFK5]V:>Q#9 4Q9)QV
MYH:9L49:3667:"KRL]JJ[1,[PZ5W"Q(O[#EVHGH=\1F$R+\N7[%^DE_%/4 -
MJ\1%;6M$>["W"S:E:S;V_P!@\Q8_1?EM>=B_K3_O/3H,\&;PIF=;:<1@\:(C
M>G"#]#'_  H<P#%T(7&%BCQ%A^IMSW(Q[T1T;U_LO3:B^CD7S*IYWJ*6^8.O
M"/<V>AJXU5&2M^:]/,NYR'J(XR1LE8K)6->U=Z.3-%.C#GG''+,;AS9^&C+/
M-$ZEYUJM)>)ZFE= M<R-')DKXXFM=[^3V'[@'!5?B*Y0SU,,D5L:]'RS2(J<
M(F?S6\ZKS\AZ 9:Z!C]=E#2M=SI"U%^X[9I/%1$:QUTRC@YFT3DML1$1,DV(
M>7\*(ORXM.Q?I"+\1#U #+#F\.)C7NVSX/%FL[UH/+]W1?ES6[%^DG_BJ>H
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M#-X4S.MK<1@\:(C>G&/]&WT(<@#%T
M      #.M+?S[7Z)?Y0-+?S[7Z)?Y06A"YX8\7;9ZM'\*$D1N&/%VV>K1_"A
M)%4@
M
M                         #\>]L;%=(Y&M3>JKDB'P[NI/*H.L3M&C;L
M_&N:]J.8J.:J9HJ+FBGY+(R)FM*]K&\[ER0#D#K]W4GE4'6)VG8145$5%S11
MHV      !QD>R-BOD<UC$WN<N2(!R!\H:F"9RMAFCD5$S5&N13Z@
M
M
M                        9UI;^?:_1+_*!I;^?:_1+_*"T(7/#'B[;/5H
M_A0DB-PQXNVSU:/X4)(JD
M
M                                          5C2;XB7C^Z3XD/-!Z7
MTF^(EX_ND^)#!,,6[C&GOK&MS?#;W3M\VI)&J_9F>EP<ZQS/^[RN.KS9(B/C
M_P!;;H?N/=^":5CG9R4CW4[O8N:?8J$%IZN/!6BW6]KO"GE65R?\K$R^]WV$
M5H#N.I77.VN=LEC;.Q/.U<E^)/<0FF6O6OQM)3QKK-I8V0(B?M+X2_%E["E<
M6N(G[KWR[X6/LH9ZTM7T71_W+/A0\SXUH$M>(JBA:B?^'CAC7SJD3<U]^9Z0
MCK(;=AR.LJ7:L$%*DCU\R-S)XR>:M9CZHX&.2UXGZ?\ ZD@>?*[&&*<67=:>
MT2U,*/5>"IJ1VHK6\[G)DOI55R]!U[JN.,,MCJ+A572GC<[5:]U3PC%7F7)R
MIR<IE'"3[3:-MIXV/>*S,?+T6"CZ*L6U&)K;4QW!&]VTBM1SVIDDC79Y+ER+
ML7,J6F#$5WM6*8J>VW&HIH5I6/5D;LDS5S]OV(95P6F_A_5K;B*UQQD^C92H
MZ6OZOKMZ(OQ6&35N*<4XCB@BM;KDL5+"QLBTB/5SW(GA/>K=NU<RTS+=)-"=
MRGO53//-*]BLX?:YC$E8B(JKMWHJ[><UC!..U9F?K#&>)C+6U:Q])1>@3QFN
M'J:_&TW(PO00]L>(KD^1R-8VB57.<N2(B/;M4_,<Z1;A<KPE-ANIF@I(G:C'
M1;'SNW9\^7,G_P 2^;%;+EF(4X?/7#@B;-U!5< 6N\4=N[HQ%<*FIK9T1>!D
M?FV%.;SNY_=Z:5I+TC55-<)K38)$BX%=2:I1$5RNY6MYLMRKOS^WGKAF]N6O
MJZKYXI3GO&FO@\]+38_IZ+C5TMX2!$X17+4*JHG.K-;/+V%WT7:0)[S5):;T
MK75BM589T3+A,DS5JINSRVYI_P#QO?AIK7FB=Z9X^+BUHK:)C:VX\Q!)AK#L
MMP@@;-*CVQM:]<D15Y5Y_04W0_?[E?[U>:BZ5+YG)''J,W,8F;MC4W(0FFEU
M[XUG:O=?$>4>6Q>"U\N?=GF4O"S\0,EJ/DTE;PF2<+W*U57+;EGE[3?'@B<,
M^VY<^7B+1GCWU'T>H@=##RU"V&VK7:_=:TT7#<)\[7U4UL_/GF=\X)C4Z>E$
M[C8 "$@
M
M                         SK2W\^U^B7^4#2W\^U^B7^4%H0N>&/%VV>K
M1_"A)$;ACQ=MGJT?PH215(
M
M                                           K&DWQ$O']TGQ(99H.
MA948DN,,J9QR4#V.3G17L134])OB)>/[I/B0S#0-XV5GJ3OC8=N']"SS\_\
MJ:?W\H+!U4N&-($"53M1D%0^FF5=B9+FQ57S(NWV'+"S'8ETD4\LB*J3UCJE
MZ+^RBJ_+[,C[Z7[?W!C>K<B9,JFMJ&^U,E^U%)W0);N%O%QN#D\&GA2)J_\
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MM_!\+?5Q5]!3UE,JN@GC;*Q53)<E3-#[G"]&)V
M
M                                                           ,
MZTM_/M?HE_E TM_/M?HE_E!:$+GACQ=MGJT?PH21&X8\7;9ZM'\*$D52
M
M
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M8LBYN5$YSM@&<SOU:1&HU   D
M
M                                           &=:6_GVOT2_R@:6_G
MVOT2_P H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
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M4=PI7:E12R_.8O\ NFQ>1-QU,6XRDM=W@LMEMS[I>9FZ_!([5;&WG<OL\WI
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MI^&15JF:VQR_LYI&OO4U*;$R6K"K;OB6FXNDVHZF1_".ULU1K479FJHF?_\
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MJL=5Z/[>CUS= KX<_,CER^Q4+L
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MF?"=U-19%7:KE])\ZVFQ5B#&F'+C6X=6W1T,[>$D;.U^;%<BKGZ$S]YV;5I
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MKYL166G:VLJ/Z*H>Y%21%V>"Y,\N1NXM!0M$&&JVP6:KEN<:05-=*DO<Z?\
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MI;^?:_1+_*!I;^?:_1+_ "@M"%SPQXNVSU:/X4)(C<,>+ML]6C^%"2*I
M                                 !414R5$5/.   1,DR0
M         9UHWLUQBQ9BB\W:DEIG54NK!PB;58KE7[D8:*
M                 433'0W.Z86BH+122U,DU0U9$C3<Q$5=OMU2]@#JVJD;
M06RCHX_F4\+(D]#41/\ 8[0            "@8[H\3TF(J"^8=6:LI(6(R>W
MI,K6NR5=NKGDN:+YU140OX RJ]7O&&*;?+:*'"\]L;4MX.:HJ7JB-8N_+-$Y
M/3LY"^X1L<6',/4ELA=K\"WPWY9:[U7-R^]?=D3
M
M                                   "EZ7:2XW#!TE#::66IFJ)F->R
M--J,1=;/WM3WEDP[0\66&W4.62T].R)?2C41?M)                  "@X
M(M=78L<8GI74TR6VL<VK@GU%X/-57-J+NS\+=_RE^            0M%99$O
M\]WN%2E1/J+!3,:S59!$JYY;US<N29KYB:          ^55,E-32S.9)(D;5
M=J1,5[G9<B(FU5*7@RR5=;>ZG%6(8715\Z<'24KTVTL.Y,^9RI]Z\Y>0
M                                    !G6EOY]K]$O\H&EOY]K]$O\
M*"T(7/#'B[;/5H_A0DB-PQXNVSU:/X4)(JD
M
M
M
M
M                                              !G6EOY]K]$O\H&
MEOY]K]$O\H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
M
M
M
M
M                                                       &=:6_
MGVOT2_R@:6_GVOT2_P H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
M
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M:/EV =?NVE\I@ZQ!W;2^4P=8@U)S1\NP#K]VTOE,'6(.[:7RF#K$&I.:/EV
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M0DB-PQXNVSU:/X4)(JD
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MN6"*2IKZB6IJ'22(LDKE<Y41ZHFU2R37BV05/<\UQHXZC/+@GSM1WN5<S.\
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M"?Q]XW7+^-/A0@#W</Z=?V?&\7^O?]Y_Y  :.<
M
M
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MB7^4#2W\^U^B7^4%H0N>&/%VV>K1_"A)$;ACQ=MGJT?PH215(
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M9E)$YR2-S545%:B\_MY"<P7?+KB:[W:N1KXL.:O!T398D:Z1VS-^>_+8OO\
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M%OP9:*"JIFNUJRKEH\F1MS3YNY<]^_>N1IY\X((J=FI!$R)G[+&HU/L/H
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MX&7]V_ZJC9J7 '/@9?W;_JJ.!E_=O^JHV:EP!SX&7]V_ZJC@9?W;_JJ-FI<
M<^!E_=O^JHX&7]V_ZJC9J7 '/@9?W;_JJ.!E_=O^JHV:EP!SX&7]V_ZJC@9?
MW;_JJ-FI< <^!E_=O^JHX&7]V_ZJC9J7 '/@9?W;_JJ.!E_=O^JHV:EP!SX&
M7]V_ZJC@I,\N#?GZ!LU+@#GP,O[M_P!51P,O[M_U5&S4N .? R_NW_54<#+^
M[?\ 54;-2X Y\#+^[?\ 54<#+^[?]51LU+@#GP,O[M_U5' R_NW_ %5&S4N
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MX&7]V_ZJC9J7 '/@9?W;_JJ.!E_=O^JHV:EP!SX&7]V_ZJC@9?W;_JJ-FI<
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M5$/])DF2*]JJU51/.J*I8B.PY:*>PV.BM=%K=STL21M5V]V6]5\ZKFOM)$
M    $7#XSU?J</QR$H1</C/5^IP_'(!*     ,ZTM_/M?HE_E TM_/M?HE_E
M!:$+GACQ=MGJT?PH21&X8\7;9ZM'\*$D52
M
M                    ",LGZ>[>N+^&PDR,LGZ>[>N+^&PDP
M          ",Q']'Q^M4_P",PDR,Q']'Q^M4_P",PDP
M     1D/C/5^IP_'*29&0^,]7ZG#\<H$F                     '"?]!)
M_"OW',X3_H)/X5^X#I8<^@+;ZM'\*$@1^'/H"V^K1_"A(
M       $7B']6I?7(/Q&DH1>(?U:E]<@_$:2@                      (
MRW_3=V_ROA),C+?]-W;_ "OA DP                       1>%_H*D]"_
M$I*$7A?Z"I/0OQ*2@                     !&8B_4(O6J?\9A)D9B+]0B
M]:I_QF$F                      "+A\9ZOU.'XY"4(N'QGJ_4X?CD E
M   &=:6_GVOT2_R@:6_GVOT2_P H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DB
MJ0                                                   #,,2WK%
M%1I&DL&'[C3TL?<[96\-"UR)LS7;JJH&G@SB6WZ2X&.ECO-IJ5:F?!<$C=?S
M?,3[T)K1QBQ^*+94=V0)3W&CDX*HC;GEGR*F>[<NSS 6T     !!8ZN%3:L)
M7.NH7I'4P1:S'*U'9+FG(NP^N#JZ>Y86M5;6/1]1/3LDD<B(F;E3;L0"8
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M@=JRPT\DC%RSR<C55/N [H*IHOO%;?<'TU?<Y4EJGOD:YR-1N:(Y438FPM8
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M6X>7U?7.[1T$]QYU7L_+T,#SSQK</+ZOKG=HXUN'E]7USNT=!/<>=5[/R]#
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M>-UR_C3X4( ]W#^G7]GQO%_KW_>?^0 &CG
M
M
M         +7HP\;8/[M_PE4+7HP\;8/[M_PF6?\ 3M^SHX/]>G[PV< 'AOLF
M6:;*B>Y5N&<)4\[H(KQ59U3V+DO L5,T^U5_PH+I!HSN-JEPQ3U=C@F5BQ0O
M9JZT<F62.23E=GY]NY2!TZVQUQTA8*IGS2005KEI72,7)41SVHY$7G5K\O:7
M;$>C7"U1A:JH8+/14KHX'+%41QHV1CD1<G*_>OGS5<P.553U&"]$E=!5W!:Z
M>@H)61U"LU%78J,3+-=V;4W\AG& I-&=MPA:(<3NM,MWEC669TD*RN36<JM1
MRM143)JHF2EAT=U%'BG0JRCQ?7<!1)(M(ZHDG2)7-8Y',36=LY$3V%XM6!<+
MT5ECM]/9Z&:E5F2OEB;(Z39\Y7*F:JO/[@.]A6WV*BMW"X8@HHJ*I5)->D1-
M23DSS3>3)CNA5CK-C;&F&J61[[51S)) URY\&JJJ9>[)%_A-B S#2=%BJ^UK
MK);HX[=A]7P-J+BJYR2*][4U6)YE5/=O3<=7_AH;J8#KFIN;<I4_T1FBXC^C
MXO6J?\9AGG_#7XC7#_J<OP1@?:HU%_XA(.,M752S_P#@>$W:^OMU?/EK^P^6
M :BFHM(FD:IIWQQ66%T,DCV_HVR(Q5D7FSSULR]XHPI9<40Q1WRA94\$JK&_
M65CV9[\G-5%3T%$QA:J*'BG1WA:G;117%_=%>L6><=,U?"5RKM57*B(BKS9<
MH$GHLIIKS673&MQC<V>ZNX*B8_?%2,7)J>;65,U]"+RFAF7)<,0W_%5VL.#[
MC2V.UV"..!7NI4F66147)N2_-:FJJ;.;ESV6+1?B>JQ-8:A]SBCCN=#5/HJI
M(_FN>S+PD3DS1??F!;P               "+A\9ZOU.'XY"4(N'QGJ_4X?CD
M E     &=:6_GVOT2_R@:6_GVOT2_P H+0A<\,>+ML]6C^%"2(W#'B[;/5H_
MA0DBJ0                                                  #J<6
MT/&/&'<D'=VKJ=T<&G":O-K;\CM@ <98V2Q/CE:U\;T5KFN3-%1=Z*<@!UZ"
MBI;?3-IJ"GBIJ=N:MCB8C6IFN:[$.%SME#=*?@+E20546>:-E8CD1>=,]QVP
M!%VC#]HL[G.M=NI:5[DR5\<:(Y4YL]YWZJGAJZ=\%5%'-"],G1R-1S7)YT4^
MH A:/"EAHFS)36BBC29JLD_HD76:N]-O)YB5IZ:"FIF4]/#'%3L;J-C8U$:U
MO,B<Q]0!"T^$[!3UR5D%GH65*+K(]L*;%YT3<BDC14%)0\-W%30T_#/623@F
M(W7<N]RY;U\YV0!$77#-ENTZ37*UTE1-^\?&FLOI7>I(45'34-,RGHH(J>!G
MS8XFHUJ>Q#[@",;8+2VZ<9-MM*VOS5W#I&B/S78JY\_G), #A-%'/$^*>-DD
M3TR<Q[45%3SHI MP5AIL_#)8Z#7SS_1)E[MQ80! 5F$+-4WBDNG<B05U,Y'-
MD@7@];+<CD38J$E=K3;[O D-SHX*J-%S1)6([57S<QW0!$0X:LD-%W''::)*
M77218^!:J*Y-SEV;5\YWKC;Z2Y4SJ>X4T-3 NU62L1R9\^WE.R (FUX:LMK5
MZV^UTD#GHK7.;&F:HN],]^7F/LVR6MEM=;FVZD2@<NLZG2)O!JN>>>KEEO1%
M)  =*KM5OJZ&.BJJ*FFI(\M2&2-',;DF29(NQ,D/M64=-6TCZ6LIXIZ=Z9.B
MD:CFK[%/N *Q>+A:,!69LL-MDCI))M58Z*)%\-47:J9I^SEGZ"'T96ZHJKC>
M<4W&E=33W.3*")Z9.9"F[/TY)Z=7/E+^ !QEC9-$^*5C7QO:K7-<F:.1=Z*<
M@!UZ"AI;=3-IZ"GAIJ=JJJ1Q,1K4SW[$(FJP=AVJJ5J)[+0OF5<U=P2)FO.J
M<I/ #A3PQ4\+(:>-D43$R:QC4:UJ<R(A"UF$,/5E2M14V:ADF<N;G+$B:R\Z
M\_M)T ?.FIX:6!D--%'#"Q,FLC:C6M3S(A$U>%+#65JU=5:**6I5=97NB3-R
M\Z\_M)H =6"W45/62U<%)!'52M1CY61HCG-1$1$5>9,D]Q\KM9K;>(VLNE#3
MU36_-X5B.5OH7>AWP!'6BQVNS-<EKH*:EUOG+$Q$5WI7>I(@   !AF/O&ZY?
MQI\*$ ;G;[705E9=I*NBIIY$JU;K21-<N6HS9FJ'=X@M'1=#U#>P]#'QE:UB
MNO9X>;^$WR9+7BT>LO/X/0'$%HZ+H>H;V#B"T=%T/4-["_75^&7DU^Z'G\'H
M#B"T=%T/4-[!Q!:.BZ'J&]@ZZOP>37[H>?P>@.(+1T70]0WL'$%HZ+H>H;V#
MKJ_!Y-?NAY_!Z X@M'1=#U#>P<06CHNAZAO8.NK\'DU^Z'G\'H#B"T=%T/4-
M[!Q!:.BZ'J&]@ZZOP>37[H>?P>@.(+1T70]0WL'$%HZ+H>H;V#KJ_!Y-?NAY
M_!Z X@M'1=#U#>P<06CHNAZAO8.NK\'DU^Z'G\'H#B"T=%T/4-[!Q!:.BZ'J
M&]@ZZOP>37[H>?P;??K):XJ&-T=MHV.6I@;FV%J;%E:BINY4)'B"T=%T/4-[
M!UU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J
M&]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!UU?@\FOW0
M\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&]@X@M'1=#
MU#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!UU?@\FOW0\_@] <06CH
MNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&]@X@M'1=#U#>P==7X/)
MK]T//X/0'$%HZ+H>H;V$=%9+6N(JF);;1\&E+$Y&\"W)%5\F:Y9>9/<.NK\'
MDU^Z&( ] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&]@X@M
M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!UU?@\FOW0\_@] <
M06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&]@X@M'1=#U#>P==
M7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!UU?@\FOW0\_@] <06CHNAZAO8
M.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&]@X@M'1=#U#>P==7X/)K]T//X
M/0'$%HZ+H>H;V'":PVA(9%2UT**C5_\ 0;V#KJ_!Y-?NA@0-QL-DM4MCM\DE
MMHWO=3QN<YT+5555J;5V'?X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B
M"T=%T/4-[!UU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T
M!Q!:.BZ'J&]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!
MUU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ'J&
M]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4-[!UU?@\FOW0\
M_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#;K[9+7%3TRQVZC8JU4+55
ML+4S17HBIN)+B"T=%T/4-[!UU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'
M75^#R:_=#S^#T!Q!:.BZ'J&]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;
MV#B"T=%T/4-[!UU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S
M^#T!Q!:.BZ'J&]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V#B"T=%T/4
M-[!UU?@\FOW0\_@] <06CHNAZAO8.(+1T70]0WL'75^#R:_=#S^#T!Q!:.BZ
M'J&]@X@M'1=#U#>P==7X/)K]T//X/0'$%HZ+H>H;V$=0V2UNN]S8ZVT:L9P6
MJU86Y)FW;EL'75^#R:_=#$ >@.(+1T70]0WL'$%HZ+H>H;V#KJ_!Y-?NAY_!
MZ X@M'1=#U#>P<06CHNAZAO8.NK\'DU^Z'G\'H#B"T=%T/4-[!Q!:.BZ'J&]
M@ZZOP>37[H>?P>@.(+1T70]0WL'$%HZ+H>H;V#KJ_!Y-?NAY_!Z X@M'1=#U
M#>P<06CHNAZAO8.NK\'DU^Z'G\'H#B"T=%T/4-[!Q!:.BZ'J&]@ZZOP>37[H
M>?P>@.(+1T70]0WL'$%HZ+H>H;V#KJ_!Y-?NAY_!Z X@M'1=#U#>P<06CHNA
MZAO8.NK\'DU^Z'G\'H#B"T=%T/4-[!Q!:.BZ'J&]@ZZOP>37[H>?P;=ARR6N
M6S4SY;=1O>J+FYT+55?"7S$EQ!:.BZ'J&]@ZZOP>37[H>?P>@.(+1T70]0WL
M'$%HZ+H>H;V#KJ_!Y-?NAY_!Z X@M'1=#U#>P<06CHNAZAO8.NK\'DU^Z'G\
M'H#B"T=%T/4-[!Q!:.BZ'J&]@ZZOP>37[H>?RUZ,/&V#^[?\)JO$%HZ+H>H;
MV'UI;3;Z29):6AI8943)'QQ-:OO1"F3C*WK-=>[7!_";XLE;S:/27= !Y[W%
M2TDX.9C"SPQ15"TERI)4GHZE/_3>G/YEV>Y%Y"IU]+I2O%K?9*N.R4<<S>!G
MN4<BJYS%V*K6\BJGF3V&L@"E3:.[;)HX3"+7O; V/P:C+PDESUN$R_BY.;85
MRVP:4K+:X[-3062M9"S@8;A)*J*UB;$5S<TS5$\WO-8 %.T:8,^25OJWUE5W
M;>+A+P];4\CW;=B>9,U]*JOH.QA*#%45YOCL2U5--;GS9VYD2-1S(]9VQV34
M7/5U-ZKN+2 (O$?ZA%ZU3_C,*SH<PM<,)89JJ"[<#P\E;).W@GZR:JM8B;<D
MV^"I9\1?J$7K5/\ C,),#\<NJU5R5<DSR3>I2='ECN$=PO.(\10<!>+G-JMA
M5R.6GIV;&,S3-.3-<M^SE+N ,QGM>),)8TOMUP[9X[U07K4D?%W2V%\$K45,
MUUM[5S5=G/R9;9[1=AFKPU8:A+H^-]SKZI];4\&N;6O?EX*+RY9>_,N
M             $7#XSU?J</QR$H1</C/5^IP_'(!*     ,ZTM_/M?HE_E T
MM_/M?HE_E!:$+GACQ=MGJT?PH21&X8\7;9ZM'\*$D52
M
M                             ",LGZ>[>N+^&PDR,LGZ>[>N+^&PDP
M                   ",Q']'Q^M4_XS"3(S$?T?'ZU3_C,),
M           $9#XSU?J</QRDF1D/C/5^IP_'*!)@
M!PG_ $$G\*_<<SA/^@D_A7[@.EASZ MOJT?PH2!'X<^@+;ZM'\*$@
M               1>(?U:E]<@_$:2A%XA_5J7UR#\1I*
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MY=F6:HNQ/<!J(*/HSQ!<[E+>;5?G1R7&U3)$Z9B(B2(JN3/)/.U=N2;%0O
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MEB2)G.N6]5\ZKM7SJ!WP       1>(?U:E]<@_$:2A%XA_5J7UR#\1I*
M                   C+?\ 3=V_ROA),C+?]-W;_*^$"3
M         !%X7^@J3T+\2DH1>%_H*D]"_$I*                      $9
MB+]0B]:I_P 9A)D9B+]0B]:I_P 9A)@                      BX?&>K]
M3A^.0E"+A\9ZOU.'XY )0    !G6EOY]K]$O\H&EOY]K]$O\H+0A<\,>+ML]
M6C^%"2(W#'B[;/5H_A0DBJ0S'20YK-(^"7/<C6I*JJJKDB>$TTXKV*<'VC$\
MM/)=XI9'0(K6:DBMR1=^[T 2\MRH88W22UM,QC4S5SI6HB?:9G:ZAN,M+C;G
M0YR6JSP<&DV7@R/76RR]KE7T-)N/1/A1CT<M'.]$Y'5#\E]REPM5LHK31MI+
M;314U.W:C(TRV\Z\Z^=0*%1?UZU__3$_D&G1>#L%HF<B\'%<8W/7F35>7..P
M4$>(Y;XUC^,)(> <[775U=G)[$.S=[91WBWRT5R@;/32IDYCOL5%WHOG C\7
MW*DI<(7*KEGC2!]*]&.UDR>KFJC43GSS0RZFH9J[_A^U:=JN?#(Z96IO5K9E
MS]R9K["\6S1EAR@J4F2&HJ-3/@V3RJ]D:KRHG/Z<R2DI(L'X.J([)0OJXZ1K
MI&TSI%57HKLW;<EY%5=P'VPK>J"OPK15\53$D#(&\*JN1$B5&[4=S9%-T25\
M-SQ7C2MI5S@FJ(W,7G;G)DOMWD721:,;A3,NU2D%)*YJ22T?#/35?RMU$W[>
M9,E)O0W2.>[$%Y93+345QJLZ6-6ZO]&U799)S>%E[% T@S+"_P#7=BGU1OW1
M&FD11X=M])B&LO4#'I7U;$CE<KU5%1-7<G)\U *=@[^MO&/\$7W-/W2Q]/8)
M_P"I)\3"Y4%@H*&]U]VIV/2LK41)G*]51<MV2<FX7JP4%YJ;?/7,>Z2AEX:!
M6O5N3LT7;S[D S/'5LIYM+- EVJJJBHJZE1D51!+P:H],TU=947ER^LAWL58
M+P]8K--67>]X@=2IDU8^ZVN615_LHU6[30,06*W8@H>Y+M3-GBSS;GFCFKSH
MJ;4*Y0Z,L/4M5%/+'55G!+G''53*]C?9_LH$+CJGI:70LV*WI4)2(R!8NZ,N
M$U5D14ULN7:2>.OZGI_4X/O86R_V:COMJEMUQ8YU+(K5<UKE:NQ45-J>=#\N
M-DHKC8G6BJ8]:)T;8U:CE1=5N66WV(!GF.*2:JT)VQ8&J[@*>EF>B?LHU$5?
M9GG[#L6# UFNUEI:^DO]]6"6-'>#6IDQ<MJ+X.S+<:)1T-/26V&@C8BTL420
MM8_PLV(F62Y[]A3ZG1=AR6:1\3*RFBD7-\$%0K8W>S:!#8.M=CJ*/%L6&*BY
MU51) ^EDGJW-<R1RHY$5CD3;Z>94)70G6PSX'IZ-KD2IHY)(YHUV.:JO<Y,T
M]"_8I;[+::&R4#**UT[*>F9M1K>5>=57:J^=2 O6CVQ76X25SHZBEJI/TDE)
M*L>OZ4W =R@Q335^+:VQ4L+Y'4D2/EJ&JBL:NSP?3M^Q>8J^@MS>(KNS--=M
MQDS;RIX+>Q2YX;P[;,.4;J:TTR1->NL]RJKG/7G55WD918$L=#B1+Y20RPUF
MNY^39%U,W(J*NK[5V 0.A7]7Q)_U.3[BNW>Z/P%>\74,>;(KC E70HG)(]=5
M<O0JN7T,0U3#]@H+"VK;;F/8E5,L\FL]79N7?OW'QO\ A:U7ZMH:NY4ZR34;
MM:)4<J)O1<EYTS3<! 6_#4MOT35%IA8O=LM#(Y[4WNE<U55/Y?8531KA*U8A
MPQ!.EXO$-5&KF3T\%4C6QNS7+)NKL14R7WFRE/N^CJPW*ODK4CJ*.IE7.1U)
M*L>NO+FF[W 0.%[/ARATAK3T%=>*Z[T<+E>^:5LD345,E:KLL\TUMW.OI-.(
M;#.&;5AJF?#::9(N$7.21RJY[_2J_=N)D#,9FH[3Q&CD14[@W*G_ "J:7P,7
M[MGU4(M<.V]<2)?58_C%(N!1VNNKJ[MQ+@9OIMC?':K-<48Y\%#7,DE1$W-Y
M_>F7M+]%<*26W)7LJ8EHECX7AM9-75WYYGUJZ:&LII:>JB9-!*U6OC>F:.3F
M5"E+HLPVLBY,K4IU=K+3)4NX//T;_M K> \ZNR:0KO&U4I*Y\[H55,LT1LB_
MSH6K0U_5U:O3+^*\L[+51QVAUL@@9#0K$Z'@H_!1&JBHN7O7:<;#:*2Q6J&W
M6]KF4T.MJ(YRN7:JJNWTJH'?,LQO/'8]+6'+S6KP=!) ZG=*NYKO#3:O^-J^
M\U,Z%[L]!>Z%U'=:9E13N7/5=O1>=%3:B^= .R^KIF4O=+ZB%M-JZW"J]-3+
MGSW9&::,)$N^.\67RGS6BD>D,4F6Q^WD]C47VH=]-$.&$FUU;6JS//@UG\'[
ML_M+O:K;1VFACH[;3QT]-'\UC$^U>=?.H%"P)_6?C7^*/_<_=*7C9@3U]?BB
M+E;;!06Z\7"YTK'I5URHLSE>JHN6[).07FP4%WK;;5UK'NFM\O"P*UZHB.S1
M=J<OS4 I6*;E=;QI!APM07-]II6P<-)-$G])*N6>35]'-S+O*WI3PQ;;#AI9
MJF[7*ONDLC6PI5U.ORYN5&\V7+YT--Q1@ZT8DEAFN$4C:J%,F5$+U9(U-^6?
M+[3H0Z.</,I*F&:GFJ7SM1CYZB57R(B*BID[^SM3D JNDJICI,+X)JI=L4-1
M3R.]",15^XTNONU%1V66Z2SQK1,BX5)$<BM<F6S+GSY/29[I<H8*2T84H6-5
MU-%710HV1=;-J)EDN>_832:,,-]U)(L-2Z!':Z4JSNX%%]&_[0*98:.:ET#W
MB29JM2J<Z9B+^SK,:GPJ:-H[N%-78)M$M/(Q6Q4S(I,E^8YC41R+S;CK:3HV
M0Z.KO%"QK(V0-:UK4R1J(Y,D1" PYH\L5VPS:*R9E3#)/1PNG;3S*QLJZB;7
M)V ?NCER7/'^+KS2KK4+GMIXY$^:]4WJG/\ -S_Q(<] GB;4^O2?"POEHM='
M9Z".BMM.RGIH_FL;]ZKO5?.IUL-6"@PY0/H[6Q[('2+*J/>KEUE1$7:OH0"C
M8<F9:=,6(:6N<D;[C&R2F<_8C]RY)]OU5)#397P08)J*)SD6JK9(XX8DVN<J
M/1RJB>SWJA9,387M6)(8V76FX1T?Z.5CE:]GH5/NW$;8]']BM->RN9%/5U;/
MF2U<JR*ST)N]H'1Q;AR2OT71V]S<ZZBI(I(\M_"1L3-$\ZHCD]I6+'='8^Q5
MAE'YNI[52)5U7,L^>7WHU?1F;"0F&\+6K#CZQ]I@6)U4Y'29N5V[/)$SW)M4
M#/\ 2W0PNQMAJIN4\]-;96NIWU$+]1T;LUVZV2Y?.3V(I(7O MBM5GJ*^X7Z
M_)21QJYW_C4773F3P=JKN1/.7Z\VJBO-!)17.G944S]['<B\Z+O1?.A4X-%N
M'(YHW2,K*B&-<V035"NC;[/_ ' I^++=21Z);34V%E:^VT]:E5JU:)PFHJO1
M57+9EFJ9>936X;M0RVAMT;4Q]P+'PO#*[P4;ERG8?2P/I%I7PQK3*S@UB5J:
MNKEEJY;LLBG1Z+\-QU7")#4K!KZ_<JSN6'/^'?\ :!'Z#)FU%@O$T:9,DN<K
MVIS(K&*:.16'K!08?IZB"V1NCBGF=.]%=GX2HB+ES)L382H&9:+?'C'?KB?'
M(?71KX^8\]:9\4A<;/AVWVBXW*MHF/;47!_"3JYZJBKFJ[$Y/G*<K38*"U7*
MY5U&Q[:BX/22=7/54545=R<GSE IFD7^L' WK#_O8?.ED9:--]P6N<D;+G1M
M2F>[8CG(C$U<_P# [[.<N]UL%!=+G;KA5L>ZIH'*^!4>J(BKEO3EW(<,2X;M
MF)*1L%VITE1BYQO:NJ]B^94 I^GBOIX,')1R/;W343LX-F>W)JYJN7-R>T^>
ME_Z.PM_U"+[B6CT8X<2FFBGBJ:E\N2+--.KI$1%S1$7D0G[YAZWWN*CCKV/<
MVDE;-%JO5N3DW9\X%*Q)(RU:9K%7UKDCI*FD=3LE=L:U_A[,_P#$WZQ<L7XC
MI<,6:2X5B+)DYK&1-<B.D55W)[,U]AV+_8[??Z!:.[4S9X<\TSV*U>=%3:BE
M?M>C?#]!7152QU-7)"N<254RR-CYLDW>_,"#Q)>[M>\86K#M!6RV2&HI6U,L
MB(G#*JHJZB+SIEEL7?GS$)I/PM;;%A::HK+Q<Z^YR.8RG2KJ=9%7617*C?X<
M_>AI6*,(VG$JPON4+TJ(=D<\+U9(U-^6?:1U/HYP]'3U$<U/-5R3LX-T]3,K
MY$;_ ,J_V?8!7-(&W0I0*F[N>D7[&DAI->V31%,YCD<U8J945.5-=A;9</6Z
M;#C;'41.EMS8FPHQ[E54:WYNW?FF2>XB:+1_8Z2PUMGC94.H:M[9)6NE7/-J
MHJ9+R;D I^/<Z.VZ/[O*U5HZ&2%9E1,]5%2-<_\ 0IJ4UPI(;<ZODJ(DHFQ\
M*LVLFKJY9YYG"6UT<UI2V5$#9J)(DBX.3:BM1,D^[>5)FBS#;94S96OIT=K)
M3.J7<&B^C?\ :!4\'QR/T7XTN"L5D-:ZHDB14WMU=_OS3V%]T7>(%E_N?YE)
MNHM-'/9I+5P+8Z%\2P+%'X*(Q4RR3+<<K/;:>T6RGH*)KFTT#=5B.7-43//>
M!1-'7]86.O[^/[WFCD5:K!06NZ7&X4C'MJ;@Y'SJKU5%5,\LDY-ZDJ   &&8
M^\;KE_&GPH0!/X^\;KE_&GPH0![N'].O[/C>+_7O^\_\@ -'.
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M-<O9YP-A       !%XA_5J7UR#\1I*$7B']6I?7(/Q&DH
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MQL<;$U6M:F2(G,B'(
M!4F88M5XN5UJ:^G=),E3J(J2.;L1C.9?.?7Y!X?\C?US^TE;)^GNWKB_AL),
MTC+>(U%I83PV&T[FD;_95_D'A_R-_7/[1\@\/^1OZY_:6@$^-D[I1TF#LC[0
MJ_R#P_Y&_KG]H^0>'_(W]<_M+0!XV3NDZ3!V1]H5?Y!X?\C?US^T?(/#_D;^
MN?VEH \;)W2=)@[(^T*O\@\/^1OZY_:/D'A_R-_7/[2T >-D[I.DP=D?:%7^
M0>'_ "-_7/[1\@\/^1OZY_:6@#QLG=)TF#LC[0J_R#P_Y&_KG]H^0>'_ "-_
M7/[2T >-D[I.DP=D?:%7^0>'_(W]<_M'R#P_Y&_KG]I: /&R=TG28.R/M"K_
M "#P_P"1OZY_:/D'A_R-_7/[2T >-D[I.DP=D?:%)O."['34;)(:5[7+/"Q5
MX5R['2-:O+S*IWOD'A_R-_7/[25Q']'Q^M4_XS"3'C9.Z3I,'9'VA5_D'A_R
M-_7/[1\@\/\ D;^N?VEH \;)W2=)@[(^T*O\@\/^1OZY_:/D'A_R-_7/[2T
M>-D[I.DP=D?:%7^0>'_(W]<_M'R#P_Y&_KG]I: /&R=TG28.R/M"K_(/#_D;
M^N?VCY!X?\C?US^TM 'C9.Z3I,'9'VA5_D'A_P C?US^T?(/#_D;^N?VEH \
M;)W2=)@[(^T*O\@\/^1OZY_:/D'A_P C?US^TM 'C9.Z3I,'9'VA5_D'A_R-
M_7/[1\@\/^1OZY_:6@#QLG=)TF#LC[0J_P @\/\ D;^N?VCY!X?\C?US^TM
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M                       B\0_JU+ZY!^(TE"+Q#^K4OKD'XC24
M              !&6_Z;NW^5\))D9;_IN[?Y7P@28
M    (O"_T%2>A?B4E"+PO]!4GH7XE)0                      C,1?J$7
MK5/^,PDR,Q%^H1>M4_XS"3                      !%P^,]7ZG#\<A*$7
M#XSU?J</QR 2@    #.M+?S[7Z)?Y0-+?S[7Z)?Y06A"YX8\7;9ZM'\*$D1N
M&/%VV>K1_"A)%4@
M                   !3<1Z1;+A^[RVVNCK75,:-<[@HD<F2IFG*G.!<@9_
M!I;PS)*UDKJVG15RUY8-B>Y54O-#5T]?215-%-'/3R)K,D8N:.0#[@
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M $$G\*_<<SA/^@D_A7[@.EASZ MOJT?PH2!'X<^@+;ZM'\*$@
M           1>(?U:E]<@_$:2A%XA_5J7UR#\1I*
M   C+?\ 3=V_ROA),C+?]-W;_*^$"3                       !%X7^@J
M3T+\2DH1>%_H*D]"_$I*                      $9B+]0B]:I_P 9A)D9
MB+]0B]:I_P 9A)@                      BX?&>K]3A^.0E"+A\9ZOU.'
MXY )0    !G6EOY]K]$O\H&EOY]K]$O\H+0A<\,>+ML]6C^%"2(W#'B[;/5H
M_A0DBJ0
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M4]\LV#J&I<M!'*EQN3FZK(&M1=9K%_:V*F?NYTM^AIRNT96!SE556%<U5?\
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MN0?B-)0                      $9;_IN[?Y7PDF1EO^F[M_E?"!)@
M                   B\+_05)Z%^)24(O"_T%2>A?B4E
M       ",Q%^H1>M4_XS"3(S$7ZA%ZU3_C,),                      $
M7#XSU?J</QR$H1</C/5^IP_'(!*     ,ZTM_/M?HE_E TM_/M?HE_E!:$+G
MACQ=MGJT?PH21&X8\7;9ZM'\*$D52
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MB5#D5JJK47;DFK]QJ01$1,D3)  (R'QGJ_4X?CE),C(?&>K]3A^.4"3
M                #A/^@D_A7[CF<)_T$G\*_<!TL.?0%M]6C^%"0(_#GT!;
M?5H_A0D                      "+Q#^K4OKD'XC24(O$/ZM2^N0?B-)0
M                     $9;_IN[?Y7PDF1EO^F[M_E?"!)@
M           B\+_05)Z%^)24(O"_T%2>A?B4E                      "
M,Q%^H1>M4_XS"3(S$7ZA%ZU3_C,),                      $7#XSU?J<
M/QR$H1</C/5^IP_'(!*     ,ZTM_/M?HE_E TM_/M?HE_E!:$+GACQ=MGJT
M?PH21&X8\7;9ZM'\*$D52
M
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MI*                      $9B+]0B]:I_QF$F1F(OU"+UJG_&828
M                (N'QGJ_4X?CD)0BX?&>K]3A^.0"4     9UI;^?:_1+_
M "@:6_GVOT2_R@M"%SPQXNVSU:/X4)(C<,>+ML]6C^%"2*I
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ME5-7?YP-"!GV#ZVJQ5CB[7QE3.VPV_.WT439%2.>1/TDJIN=OR1?/YC00
M           1D/C/5^IP_'*29&0^,]7ZG#\<H$F
M'"?]!)_"OW',X3_H)/X5^X#I8<^@+;ZM'\*$@1^'/H"V^K1_"A(
M             $7B']6I?7(/Q&DH1>(?U:E]<@_$:2@
M     (RW_3=V_P KX23(RW_3=V_ROA DP                       1>%_
MH*D]"_$I*$7A?Z"I/0OQ*2@                     !&8B_4(O6J?\9A)D
M9B+]0B]:I_QF$F                      "+A\9ZOU.'XY"4(N'QGJ_4X?
MCD E     &=:6_GVOT2_R@:6_GVOT2_R@M"%SPQXNVSU:/X4)(C<,>+ML]6C
M^%"2*I
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MN0?B-)0                      $9;_IN[?Y7PDF1EO^F[M_E?"!)@
M                   B\+_05)Z%^)24(O"_T%2>A?B4E
M       ",Q%^H1>M4_XS"3(S$7ZA%ZU3_C,),                      $
M7#XSU?J</QR$H1</C/5^IP_'(!*     ,ZTM_/M?HE_E TM_/M?HE_E!:$+G
MACQ=MGJT?PH21&X8\7;9ZM'\*$D52
M
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M C[G9+5=9(WW.VT58^/YCIX&R*WT9IL.^QK6-1K$1K43)$1,D1#]
M       (R'QGJ_4X?CE),C(?&>K]3A^.4"3                     #A/^
M@D_A7[CF<)_T$G\*_<!TL.?0%M]6C^%"0(_#GT!;?5H_A0D
M         "+Q#^K4OKD'XC24(O$/ZM2^N0?B-)0
M $9;_IN[?Y7PDF1EO^F[M_E?"!)@                       B\+_05)Z%
M^)24(O"_T%2>A?B4E                      ",Q%^H1>M4_XS"3(S$7ZA
M%ZU3_C,),                      $7#XSU?J</QR$H1</C/5^IP_'(!*
M    ,ZTM_/M?HE_E TM_/M?HE_E!:$+GACQ=MGJT?PH21&X8\7;9ZM'\*$D5
M2      (>XXGL=MG6"NNU%!,FQ8W3)K)Z4Y#OV^OI+C!P]OJH*F'=KPO1Z>]
M .R#K25])%6Q4<E5 RKE36CA=(B/>FW:C=Z[E]QV0 .M)7TD=='1254#:R1N
MLR!TB(]R;=J-WJFQ?<IV0    '4CN=!+7OH8ZVF?6L3-T#96K(WTMSS [8
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M                       $7A?Z"I/0OQ*2A%X7^@J3T+\2DH
M            1F(OU"+UJG_&829&8B_4(O6J?\9A)@
M    BX?&>K]3A^.0E"+A\9ZOU.'XY )0    !G6EOY]K]$O\H&EOY]K]$O\
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MBI&-;3Q1-:U$38NS:OMW^TSW T;;9I'QC:Z-$;0ZC9TC;\UKER7)$Y/GJGL
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MOI:1C6PL@9\U/G*J9JJ^=5VE&P9&VV:7,46VB1&44D#:A8V[&M?X"[$Y/GN
M[]7I6P[3TL<R=V2N>]S>"9$FNU&[W+FN2)[2;OF,[19;91UM=)*BUC$?!3M9
MG*]%1%^;R;TWE1T#4,"6:[5BQM6>2L=$KE3;JM:U43T9N4^E!&RXZ<KCW6U'
M);J)O<S7)\W-&;4^N[W@0VD[&=NOV#ZBBCAK*.N26.1*>LAX-SFYKM3>BFI/
MN5':,/0UMQG9!310L5SW>A-B<Z^9"GZ=:&"HP2^JD8WAZ69BQORVIK+JJGHV
MY^PA=+$TTC\%T#*9:R&5Z2.I4?JI.YJ,1&Y\FQ53V@6&/2E955CY:2ZP43UR
M;624W]$OGS1<_L+7<KW14%BEN\DBRT+(TEUX?"UFKEDJ<^\IE9B#$=9;Y:*?
M1_(ZFEC6-T?=S,M7++++4(6CH+K:]"E[HKU3R4\L*N2)CU15X-5:O(O.K@+3
M%I,L4]XH[=3)5SRU*QM1\<2*UCGY9-5<]^W;EGD?>\Z0;5;KG+;X(*^XU<.R
M5E%#PG!KS*N:;?0??1I0P4F!K,V&)B<) V9RY;5<[PE5?/M*A%28IP->+M-:
M[3'>;775"U"K&O\ 2HJJJY;-O+S*@%XPKBRUXF;,ENDD;40?I:>9FI(STIV$
M^9]@C$-@O6**N9MLGMF))(M69D^:*]J99HFW+9DF]$78:"   &&8^\;KE_&G
MPH0!/X^\;KE_&GPH0![N'].O[/C>+_7O^\_\@ -'.'H^#]!'_"GW'G ]'P?H
M(_X4^X\_C_\ Y>Y_!?>_]/\ MS !YSWF428HQ7C'$MTMV"9:*W6RV2<#-7U$
M?".DDS5%1J*BIEL7DW;<]J(?2VXJQ/AC&-ML&.'4=;371=2DN%,S477S1-5S
M=B;U1-W*FU31J>CMMG@J9::GHZ"%RK-.^-C8FJN6USE3+D3>IDC*E^D_29;:
MRW1N3#.'9%D2J<F23S9HN3?:UOL3/E1 -H*7C:''4ERA7!]3:8J'@421*Q%5
MRR:RYY9-79EJ_:70 89C'$&DS"5L;6W:Y6#5?(D4<44:NDD<O(U-5,^<N%XQ
M3>\,:*&WF^PPNQ K$;P2-R:DCW9-143F:J9ISHJ%?L2=\+2W6W2?^DL>'%X&
MD8NUKY\_G^?:BK[&%\TDX9=BW"%;:HI6PU#]62%[MR/:N:9^9=WM I]1=,68
M,N6'9\17J&[T%VJ64E1%W,V)::1^Y6.;O1-N_FW;=EETG7^LM5LI+=8G(E^N
MTZ4M'L1=3]N147D:GWH5R:SXLQ=<K!'BFV4EJMUHG;5SRLJ4E6JD8FS51/FM
MWYY\BGYA^ZT5RQ#>,?WRI93V2ASM]K?+\W51<GRHG*KEV)EMWIR :A11204<
M$4T[JB6-C6OF>B(LBHFURHFS;OV'V*_A?&5AQ0^9EDN+*B6),WQ*US'HG/JN
M1%5/.6 ",Q']'Q^M4_XS"3(S$?T?'ZU3_C,),                      $
M9#XSU?J</QRDF1D/C/5^IP_'*!)@                    !PG_ $$G\*_<
M<SA/^@D_A7[@.EASZ MOJT?PH2!'X<^@+;ZM'\*$@
M   1>(?U:E]<@_$:2A%XA_5J7UR#\1I*                       C+?\
M3=V_ROA),C+?]-W;_*^$"3                       !%X7^@J3T+\2DH1
M>%_H*D]"_$I*                      $9B+]0B]:I_P 9A)D9B+]0B]:I
M_P 9A)@                      BX?&>K]3A^.0E"+A\9ZOU.'XY )0
M !G6EOY]K]$O\H&EOY]K]$O\H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
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M/8GNY<U0OP R+&EJQIC*B@66TPT%/3S->RC[H:Y\CMN;U=FB9(FS+?M-=3<
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MQ[]9SWJG-K.55R\Q/@1F(_H^/UJG_&829&8C^CX_6J?\9A)@
M          C(?&>K]3A^.4DR,A\9ZOU.'XY0),                     .
M$_Z"3^%?N.9PG_02?PK]P'2PY] 6WU:/X4) C\.?0%M]6C^%"0
M            (O$/ZM2^N0?B-)0B\0_JU+ZY!^(TE
M    1EO^F[M_E?"29&6_Z;NW^5\($F                       "+PO]!4
MGH7XE)0B\+_05)Z%^)24                      (S$7ZA%ZU3_C,),C,1
M?J$7K5/^,PDP                      1</C/5^IP_'(2A%P^,]7ZG#\<@
M$H     SK2W\^U^B7^4#2W\^U^B7^4%H0N>&/%VV>K1_"A)$;ACQ=MGJT?PH
M215(
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M/Q&DH                      ",M_TW=O\KX23(RW_ $W=O\KX0),
M                  $7A?Z"I/0OQ*2A%X7^@J3T+\2DH
M       1F(OU"+UJG_&829&8B_4(O6J?\9A)@                      B
MX?&>K]3A^.0E"+A\9ZOU.'XY )0    !G6EOY]K]$O\ *!I;^?:_1+_*"T(7
M/#'B[;/5H_A0DB-PQXNVSU:/X4)(JD
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M)24                      (S$7ZA%ZU3_ (S"3(S$7ZA%ZU3_ (S"3
M                   !%P^,]7ZG#\<A*$7#XSU?J</QR 2@    #.M+?S[7
MZ)?Y0-+?S[7Z)?Y06A"YX8\7;9ZM'\*$D1N&/%VV>K1_"A)%4@
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ML/@HNLB;\D5=J\YK@   1F(_H^/UJG_&829&8C^CX_6J?\9A)@
M            C(?&>K]3A^.4DR,A\9ZOU.'XY0),
M .$_Z"3^%?N.9PG_ $$G\*_<!TL.?0%M]6C^%"0(_#GT!;?5H_A0D
M               "+Q#^K4OKD'XC24(O$/ZM2^N0?B-)0
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MSHJQ3,6-Z(N6:*F2[4])]0!%X:L-OPW:H[;9X%@HV.<YK%>KUS5<UVJJJ2@
M$)=L-4=UO]JNM;).]]M5SH(-9."UW)EKJF6:N3DV[#MW^S4-_M-1;;K D]).
MF3VJN2\Z*B\BHNW,D !3\-Z/;58[K'<EJKE<JR"/@J>2X5'#=SLYF)DF6S87
M     (S$?T?'ZU3_ (S"3(S$?T?'ZU3_ (S"3                      !
M&0^,]7ZG#\<I)D9#XSU?J</QR@28                     <)_T$G\*_<<
MSA/^@D_A7[@.EASZ MOJT?PH2!'X<^@+;ZM'\*$@
M  1>(?U:E]<@_$:2A%XA_5J7UR#\1I*                       C+?]-W
M;_*^$DR,M_TW=O\ *^$"3                       !%X7^@J3T+\2DH1>
M%_H*D]"_$I*                      $9B+]0B]:I_QF$F1F(OU"+UJG_&
M828                      (N'QGJ_4X?CD)0BX?&>K]3A^.0"4     9U
MI;^?:_1+_*!I;^?:_1+_ "@M"%SPQXNVSU:/X4)(C<,>+ML]6C^%"2*I
M
M                                          !&63]/=O7%_#829$6B
M:*.INR22,:O=:[%<B?\ IL)+NF#]_%]="=(W#Z@^7=,'[^+ZZ'U((F)  $@
M              (S$?T?'ZU3_C,),C,1_1\?K5/^,PDP
M      1D/C/5^IP_'*29&0^,]7ZG#\<H$F                     '"?\
M02?PK]QS.$_Z"3^%?N Z6'/H"V^K1_"A($?ASZ MOJT?PH2
M         !%XA_5J7UR#\1I*$7B']6I?7(/Q&DH
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M>E*Z6R"IL5_L=QH9ZRVS(QT4$[7.=$O)DB[MBI_B4NN,ZJ*NT=W:JIG:\,]
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MM9V?V\X&C@(J*B*BYHO*    C,1_1\?K5/\ C,),C,1_1\?K5/\ C,),
M                  $9#XSU?J</QRDF1D/C/5^IP_'*!)@
M       !PG_02?PK]QS.$_Z"3^%?N Z6'/H"V^K1_"A($?ASZ MOJT?PH2
M                    !%XA_5J7UR#\1I*$7B']6I?7(/Q&DH
M            ",M_TW=O\KX23(RW_3=V_P KX0),
M   $7A?Z"I/0OQ*2A%X7^@J3T+\2DH                      1F(OU"+U
MJG_&829&8B_4(O6J?\9A)@                      BX?&>K]3A^.0E"+A
M\9ZOU.'XY )0    !G6EOY]K]$O\H&EOY]K]$O\ *"T(7/#'B[;/5H_A0DB-
MPQXNVSU:/X4)(JD
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MLE;;J6V5$J+(ZFIH]1K,UV9IR+EEF=Z__05R]6D^%3O!R(YJHY$5%V*B\H%
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MOA DP                       1>%_H*D]"_$I*$7A?Z"I/0OQ*2@
M                !&8B_4(O6J?\9A)D9B+]0B]:I_QF$F
M        "+A\9ZOU.'XY"4(N'QGJ_4X?CD E     &=:6_GVOT2_R@:6_GVO
MT2_R@M"%SPQXNVSU:/X4)(C<,>+ML]6C^%"2*I
M
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M_P H+0A<\,>+ML]6C^%"2(W#'B[;/5H_A0DBJ0
M
M
M
M
M                                                 &=:6_GVOT2_
MR@:6_GVOT2_R@M"%SPQXNVSU:/X4)(C<,>+ML]6C^%"2*I
M
M
M
M
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M^4=\EW1;>O\ R@#0=\EW1;>O_*.^2[HMO7_E &@[Y+NBV]?^4=\EW1;>O_*
M-!WR7=%MZ_\ *.^2[HMO7_E &@[Y+NBV]?\ E'?)=T6WK_R@#0=\EW1;>O\
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M )1WR7=%MZ_\H T'?)=T6WK_ ,H[Y+NBV]?^4 :#ODNZ+;U_Y1WR7=%MZ_\
M* -!WR7=%MZ_\H[Y+NBV]?\ E &@[Y+NBV]?^4=\EW1;>O\ R@#0=\EW1;>O
M_*.^2[HMO7_E &@[Y+NBV]?^4=\EW1;>O_* -"N8OQ*M_=2JM*D' HY-DFMG
(GEYDY@ !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g942297g15e08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15e08.jpg
M_]C_X  02D9)1@ ! 0$ =0!U  #_[1=84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %SL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8G)S@K'2)&.#H:/"-4-TLO!$192B)O$EA+/_Q  : 0$!  ,! 0
M     0(#! 4&_\0 *A$!  (! P0" @(" P$       $" P01,1(3(4$442(R
M!6$5(T)2<23_V@ , P$  A$#$0 _ /U2,5;J9X(-FFY>F9UC3W@GZFJ-&'J\
M8.CU>, DZFJ-T>KQ@Z/5XP"3J:HT8>KQ@Z/5XP"3J:HW1ZO&#H]7C ).IJC=
M'J\8.CU>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&DZ/5XP"3J:HW1ZO&#H]7C ).I
MJC='J\8.CU>, DZFJ-T>OQI.CU>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&#H]7C
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MJ-T>KQ@Z/5XP"3J:HT8>KQ@Z/5XP"3J:HW1ZO&",/5XP"3J:HW1ZO&#H]7C
M).IJC='J\8.CU>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&DC#U>, DZFJ-T>KQ@Z/
M5XP"3J:HW1ZO&#H]7C ).IJC='J\8.CU>-().IJC='J\8.CU>, DZFJ-T>KQ
M@Z/5XP"3J:HW1ZO&#H]7C2"3J:HW1ZO&#H]7C ).IJC='J\8.CU^-().IJC=
M'J\8.CU>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&#H]7C ).IJC='J\8.CU>, DZF
MJ-T>K3K@C#U>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&#H]7C ).IJC='J\8.CU>,
M DZFJ-T>KQ@Z/5XP"3J:HW1ZO&#H]7C2"3J:HW1ZO&#H]7C ).IJC='JTZX.
MCU>, DZFJ-T>KQ@Z/5XP"3J:HW1ZO&#H]7C ).IJC1AZO&DZ/5XP"3J:HW1Z
MO&#H]7C ).IJC='J\8.CU>-().IJC='J\8.CU>, DZFJ-T>KQI.CU>, DZFJ
M-T>K3KI.CU^-().IJC='K\:3H]7C ).IJC='J\8.CU>, DZFJ-T>KQ@Z/5XP
M"3J:HW1ZO&DZ/5XP"3J:HW1ZO&#H]7C ).IJC='J\8.CU>, DZFJ-T>KQ@Z/
M5XP"3J:HW1ZO&#H]7C ).IJC='J\:3H]7C ).IJC='J\8.CU>, DZFJ-T>KQ
M@Z/5XP"3J:HW1ZO&#H]7C ).IJC='J\:3H]7C ).IJC='J\8>:[%<4S,33N!
M+$; U3/.1,Z\G1)!BOL5<$; S.D\$FOL5<$; ]_ $H          &.$@R,=^
MNN[P-?$&1B==-Q$[M9W SJ1O(W^^&-=^D R$2 &H\1,ZSOT!ZUWLO,1O_P#F
M]Z
M
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M$L@:B@2QN\09".KQ8C<#(
M
M                                                      #S<[%7
M!Z>;G8JX CX+MWN,)2+@NW>XPE Q7V*N"-@>_@DU]BK@C8+OX E
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MBM>5%5W=JL%NNTV](_WTS_W/$;8YO@_Y;FM8\9JG_N7K7A*:NYXZ!:F-]/\
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M34         .\
M
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M6/?U/32Y-GN&S.Q%S#W;<S/\V*Z9F-VO=Q;>F=8\4F)@K>+1O#V$=0C,
M
M                                                          >;
MG8JX/3S<[%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L#W\$FOL5<$; ]_ $H
M              !6'IK_ "C8W].X?[UGJP]-?Y3L;^G</]X+.H[++%'99
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M,QVC9=X?0>*:J=.T]15'BFQNR,1W[R-160
M
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MNW>XPE(N"[=[C"4#%?8JX(V"[^"37V*N"-@>_@"4
MJ_TU_E.QOZ=P_P!ZT%7^FO\ *=C?T[A_O!9]OLPRQ1V89
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MFYV*N#T\W.Q5P!'P7;O<82D7!=N]QA*!BOL5<$; ]_!)K[%7!&P/?P!*
M                5?Z:YCI.QL:3K].X?[UH*P]-?Y1L;^G</]X+.M]F&7RK
MNTV;%5RN8BFFF:IF=W4T%W;'++5VNBJ]:B:9TG\;2#I!S/KIE?\ 36?FTGKI
ME?\ 36?FT@Z8<SZZ97_36?FTGKIE?]-:^;2#IAS/KIE?]-9^;2>NF5_TUKYM
M(.F',^NF5_TUGYM)ZZ97_36?FT@Z8<SZZ97_ $UGYM)ZZ97_ $UGYM(.F',^
MNF5_T]GYM)ZZ97_3V?FT@Z8<SZZ97_36?FTGKIE?]-9^;2#IAS/KIE?]/9^;
M2>NF5_TUKYM(.F',^NF5_P!-9^;2^EK;#*:Z=:L9AZ)\)O4@Z(:'ULRC\^PO
MSJ3ULRC\]PWSJ0;X:'ULRC\^POSJ3ULRC\^PWSJ0;X:'ULRC\^PWSJ3ULRC\
M^POSJ0;X:'ULRC\^PWSJ3ULRC\^PWSJ0;X:'ULRC\^POSJ3ULRC\^PWSJ0;X
M:'ULRC\^PWSJ3ULRC\^POSJ0;X:'ULRC\^PWSJ3UKRC\^POSJ0;X:'ULRC\^
MPWSJ3ULRC\^PWSJ0;X:'ULRC\^POSJ3ULRC\^POSJ0;X:'ULRC\^POSJ3ULR
MC\^PWSJ0;X:'ULRC\^PWSJ3ULRC\^POSJ0;X:'ULRC\^PWSJ6/6W*/SW#?.I
M!OQI+>U.3U3'*S#"4Z^-ZGS?;UCR;[5P7SJ?,&U&J]8\F^U<%\ZGS/6/)?M7
M!?.I\P;4:KUCR;[5P7SJ?,]8\E^U<%\ZGS!M1JO6/)OM7!?.I\SUCR;[5P7S
MJ?,&U&J]8\F^U<%\ZGS/6/)OM7!?.I\P;4:KUCR7[5P7SJ?,]8\F^U<%\ZGS
M!M1JO6/)OM7!?.I\SUCR;[5P7SJ?,&U&J]8\F^U<%\ZGS/6/)?M7!?.I\P;4
M:KUCR;[5P7SJ?,]8\F^U<%\ZGS!M1JO6/)OM7!?.I\SUCR;[5P7SJ?,&U&J]
M8\F^U<%\ZGS/6/)OM7!?.I\P;4:KUCR;[5P7SJ?,]8\F^U<%\ZGS!M1JO6/)
M?M7!?.I\V8VBR:9TC-,%,_WU/F#:#7_366?:&%^;!]-99]H87YL V U_TUEG
MVAA?FP?366?:&%^; -@-?]-Y9]H87YL'TWEGVAA?FP#8#7_3>6?:&%^;!]-Y
M9]H87YL V$]2-?L1<MU1W3&CX?366:_^(87YL>9]-97]H87YL$3LDQNU6"R"
M+&9XC$S,3SE5,QU[M'06[<4T[]^B'&<Y9K/_ /D,+I_>QYLQG65Q_P#<,+\V
M%FV["F.*\)\1&FXWH'TUEGVAA?FP1G>6?G^%^;"-B?/6=?4@?3>6?:&%^;!]
M-99]H87YL GQ$Z;V-WA*#]-99]H87YL'TWEGVAA?FP;ILGQ3!R80/IO+/M#"
M_-@^FLL^T,+\V#<V3^3#SR*4+Z:RO[0POS8/IK*_M#"_-CS#9,FBEGFXT0OI
MK*_M#"_-@^FLK^T,+\V%W-DV+=.AS=,Q.Y"^F\L^T,+\V'TIS3 51K3C,/,>
MZY";FS[\S2<S#Y?26"_.['[<,?26"_.['[<+N=,/K-BGP.8CN?+Z2P7YW8_;
M@^DL%^=V/VX-TZ8>ZL/3/6QS%'A+S])8+\[L?MPQ])8+6?\ :K'[<$6DZ8>I
MP]NJ)UIGXO$8*S/\R=>,LQF6"W_[78_;AF,QP7YW8_;A>J4Z*O'0+._6F?C+
MQ]&8>=?JS^U+[?26"_.['[<'TC@?SJQ^W!U2G:K]/C.68?V)_:E\ZLGPE4[Z
M)_:E*^D<%^=V/VX/I' _G5C]N#JD[5?I%C)<+W43^U+Y7MG\'=CZUN?VI3_I
M'!=V+L?MP?26"_.['[<'7*=FGTU$[+X'^CG]NIBO9; 5T:3;G3^W4W'TC@OS
MNQ^W!])8+\[L?MPO7,)V*?3G*MBLKJF9FS5\RIY]2<LTTBS5\RITOTC@?SJQ
M^W!](X+7\KL?MP=R4^/3Z<A5Z/\ *JYUFQ5\RIC\'F4SUV*OF5NP^DL%K^56
M/VX/I+!?G=C]N#N2GQJ?3A[WHTR:Y,ZX>KYM?F^7X+\D_-ZOFU^;O8S+!?G5
MG]N#Z1P7YW8_;A>Y)\:GTK^YZ+LGF/JV)B??=K\VHS_T<V[."JJP<1%=,Q$;
MZI[UKSF."_.K'[</G7CL#5&_%V/VX6N68:[Z.EH?FBU?N82Y58NTU4U1,]<:
M&'PE_-\739L6ZZHW3,Q3,]^G=Q6UM1LAE>8W)OX.</%R=(G2J:IZYU[_ 'MW
MLKL[EN2VYFB+,7IUB:XJGJF8G3?/N=<ZK\=H>=7^/MU[3PY&QZ,?Q%-%5RW,
MT[XWU=;Q>]%UVJ?JW[,3_B6U3?P\=5VW^T=(L1U7:/VG)WI>C&CILJ*/1;B(
M_P#J;&O^+R>;OHQS+3\3C<-3QIJG[EO](L:?RUO7^T=(L?TUO]I>[*?"QJ;_
M  9YSII](X3]BKR)]'&<VJ?R_"SPHJ\ER=(L3'\K;_:8F_8T_EK?[1W93X5%
M)^HV=1_]59G_ (=7D]^I.>VXF8Q=B?\ A3Y+HYZQINNV_P!ICGK$_P#FT1_B
M.[*?"JHV[LUGUNN8F[35PLSY%K(,^IKB:;D1IUZV9\EX\[8UWW;?[1SEC7^5
MMS_B7NI\*/M2&(PFT5F=(FJK3PP\^3XQ&T.NDV[O_P"//DO7G,/_ $EO]ICG
M,/W7*/B=U?A_VI*O'[28>CZMN]5IX8;]R-].;2S&_"XK7_TO[EZ37A]?Y2W\
M37#1_P"9;_:.X?$G[4E9VFVFHITZ+BO_ ,7]SW&UNTD1^3XG7_TO[ETST:8T
MFY;_ &GRYC!SKK7:_:(R0?&MZE3UK;+::G_R,1_^+'D]3MUM'3.E5J__ /C1
MY+>Z-@9_G6OVGPN9;EM=4S5%F9_M3YG763L98XE5%&WN?\N.59OS'_IX\DB?
M2%FE$?7L8C7^YIC[EFQE65^S9_:GS?&YD.37=><M69_QSYG75.SF^U<QZ1LR
M_H[NG]U2EVO23?IIUN8?$:_V*8=O.S.0_F]CYE7F\W-E]GZZ=*L-8G_B5>:]
M5#LY_P#LXG\)]SKYJ[^S2^V']*5N/Y7#7YX13#J?4O9G?_L>'^95YL4[$[-U
MZQ1@;$S[KE7F=5/I.UJ/^SGOPIX:=8Z)B/\ ]?-FWZ5,+%6E6%Q$Q_A\V]JV
M R69G3 VXCC7YO/X/\D_,+7[5?FN^-.G4_;5?A6P$=>#Q/QI\V8]*N G=T/$
M1QFGS2[_ *.LJKGZF%M4_KJ\WRCT;Y=_.L6I_:\T_P!:_P#T_;ZQZ2\!._F;
MD<:J?-[_  DY?K,<W7^W3YH>(]&V KHB+=FU3.O];S1OP8X;PM?"KS-L9OJ&
M]P^WN7W:==>3QN4^;[1MSE_]+1\RCS<W7Z,</-,Q3S,?JJ\T2?193K.EVS'^
M&KS-J+OG=G8VSR^],_C[5.F[ZUVCS28VIRZ/_K,/\VCS<'^"N-=>>L_LU>;X
M7/1=7%6Z[:F/[%7F=-#KS1RL6C:G+ZO_ *S#?-H\WV]8<N^T,)\ZCS5E^#"Y
M$[J[?[%3X7?1EB*>S73/"W4G17T1FRQS"U/6'+N['X2?^-3YOGBMH,#:PMV[
M&*L5111-6D7:=^D<551Z-<9$ZTUQ'_#J>L3L'F5K"W8IN35]2=T6I\%BE6-M
M1DVX:_:S:W$YQCKN'LS/1HKF(CDTSNG3OC@UV3[0XS(,535:F9MU3RIB*(GJ
MXM5-JYE6-N8?$4545Q5R=:HTZN+QB[M5^8MV:9KKJW?5WZNV,=.EY<Y;S;J]
MOT1LQGUK-,#;NTW*>7R:9JCE1KK,:]SHJ*HJIU57Z/-FL=A,'%VJ[S<78IKY
M,T3'72M"S3R+=%,[](C67G9(B)\/>T]K6K^3Z@-;H'FYV*N#T\W.Q5P!'P7;
MO<82D7!=N]QA*!BOL5<$; ]_!)K[%7!%P/?P!+                    5A
MZ;(_'[&_IW#_ 'K/5AZ;-]_8W3[=P_W@LF[9IOX:NU7&L5TS3.OO<S>V'RZ[
M=KN54V]:IUG\7^]U=OL0R#D/4/+?9M_+_>>H>6^S;^7/FZ\!R$;!Y=KU6_E_
MO/4++O"W\O\ >Z\!R'J'ENG9M_+_ 'GJ'EOLV_ESYNO <AZAY;[-OY?[SU#R
MWV;?R_WNO <AZAY;[-OY<^9ZAY;[-OY?[W7@.0]0LM]FW\O]YZAY;[-OY<^;
MKP'(>H66^%OY?[SU"RWPM_+_ 'NO <AZA9;X6_E_O/4/+?"W\O\ >Z\!R'J%
MEOA;^7^]'N^CS UU\JF[11&G5S7\3MP'#QZ.\'_3T_)_B/P=X/\ IZ?D_P 3
MN '#_@[P?]/3\G^(_!W@_P"GI^3_ !.X </^#O!_G%/R?XF/P=X/\XI^3_$[
MD!PWX.\)^<4_)_B/P=X2/_/I^3_$[D!PWX.\'^<4_)_B/P=X3^GI^3_$[D!P
M_P"#O!_T]/R?XF/P=X3^GI^3_$[D!PWX.\'_ $]/R?XF?P=X/^GI^3_$[@!P
MWX.\'_3T_)_B/P=X/^GI^3_$[D!P_P"#O!_T]/R?XF(]'>#_ *>GY/\ $[D!
MP_X.\'_3T_)_B/P=X/3^7I^3_$[@!PWX.\'_ $]/R?XC\'>#_IZ?D_Q.Y!'#
MQZ.\'I_+T_)_B/P>8/3^6I^5_$[@%<'<]'&&KCZN+BG_ (/\3X_@TL_:'_0_
MB6$ K[\&EK[1_P"A_$?@TL_:'_0_B6" K[\&MG[0_P"A_$?@UL_:'_0_B6"
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MO!9U'9AEBWV(9
M
M                                                   !CDLQ  :
M   /-SL5<'IYN=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@>_@"4
M                    J_TV?E&QOZ=P_P!ZT%7^FO\ *=COT[A_O!9]OL0R
MQ;[$,@
M
M                                                  /-SL5<'IYN
M=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@N_@"4
M       J_P!-?Y3L;^G</]ZT%8>FN/\ :=C?T[A_O!9U'9AEBCLL@
M
M
M                                     /-SL5<'IYN=BK@"/@NW>XPE
M(N"[=[C"4#%?8JX(V![^"37V*N"-@>_@"4                    K#TU_E
M&QOZ=P_WK/5AZ:_RG8W].X?[P6=1V66*.S#(
M
M
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MJO\ 37^4;&_IW#_>"S[?9AEYM]B'J
M
M
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M73<'%J],<[1$<J9F(UUJGN==$Q\71@RQEKO#FRXYQVFLL@-S6
M
M
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M*N53K#W,>2+QX>)>DTG:7H.X;& $
M
M
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MJS5,T]6^)AOPZB+>)<V;3S3S'";&]EBF=>IF9T=;G B=0
M
M
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M[U,56ZHF)][[N^MHM&\.&8F/$@"H
M
M
M  /-SL5<'IYN=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@>_@"4
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M,]6KI;==-75,.['EK?AQ9,5J3M+V VM9
M
M
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MPZB+>):,NGFGF.&U&*9B8ZV=[JB=W, *
M
M
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M,1,;DG67?6T6C>'#-9KXED!D@
M
M                                                   \W.Q5P>GF
MYV*N (^"[=[C"4BX+MWN,)0,5]BK@C8'OX)-?8JX(V![^ )0
M       "L/39^4;&_IW#_>L]6'IK_*-C?T[A_O!9U'9AEBCLPR
M  #Y7+=-RFJ*NJ8<=M/LK3C.7>P\1%S2J=:JYZ]VG<[:88JC6GW-&3!7)'EM
MQY;8Y\*DRO,,7L]C.;Q-,\S3/)F::->K6.N=%A9+G>&S"U17;KTG2-U6D3U:
M^+QM!D=C-,+51<IWS&Z=9C3?$]W!7&,R[,-G\;-RQK5:IF9CDVYG=OB-\PXO
MRP3_ $[=J:B/[7%%43&L/4>]Q^S6U5K&1S>(GF[D=]<TT]40ZVW<IKIUIJB8
M]TN[%FB\.')BMCG:7L-1N:P
M
M                                              !YN=BK@]/-SL5<
M 1\%V[W&$I%P7;O<82@8K[%7!&P7?P2:^Q5P1L#W\ 2@
M   %7^FO\HV-_3N'^]:"K_39^4;&_IW#_>"SZ.S#+%OL0R
M!*)CL);Q-JJBY3%43I_FESU,,;5BWB5K,UG>%8;2[*7;%?/8&-)TT^K1,]\L
M[.;47\+5%G,><UC7MS%/!9=VU1<^K73$PY':'96QB(JN8:F+=S=OIHU\?>\_
M)@MCGJH[\>HKDCINZ7!8VSBJ.5:N4UQ[JM4RG?'BJ+!YEF60W^;Q--WF_"J>
M3USKX+ R+:'"YG:IYN[;B[IK5;BO68WZ-V'4;^+-.;3S7S7AOABFJ*HUCJ9=
M<3$N4@!0
M
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M8G28ZXU[TV)=]+Q;AQ6K-9VD 9L0
M
M                                             !YN=BK@]/-SL5<
M1\%V[W&$I%P7;O<82@8K[%7!&P/?P2:^Q5P1L#W\ 2@
M  %8>FO\HV-_3N'^]9ZK_39^4;&_IW#_ '@L^CLLL4=F&0
M  &)Z_>R :_%AD!XKHBN-)C=+E=J-EK68VJJ[4U4WJ=9ITF(B9F8Z]SK28UA
MIR8JWALQY+4G>%.6<3CMF\7R+O-U6J9GKF:IW;O&%@Y!G]K,[<<C7E1NGZNG
M=Q3LVRNUCK%=%<=<:=>G?JK7.,BQF37YO87D\GKZYJZYF/!PS%\,^.'=6:9X
M\^)6Y3,50]. V9VKINZ6<3-45QK_ #8B.[WNYM7J:XUIF)X.W%GK>''EPSCG
MR^PQ&DD1I,M[2R
M
M                              \W.Q5P>GFYV*N (^"[=[C"4BX+MWN,
M)0,5]BK@C8'OX)-?8JX(V![^ )0            03,1U@#X3C,/35R:K]JFK
MPFN'UBY1R9JY4<CKY6NX'H1J<=A9N<B,19Y>NFG+C64B)B8B8WQ/>#(1O %7
M^FS\HV-_3N'^]:"L/39'^T;&;X_\>P_W@LZCLPRQ1NC1D
M       "8U1\18HN4335$S$^](-_BQM6+1M*Q,Q/A7>T>Q\S75>P-5-,[MU4
MU3XM7DFU.)RNOFL?;N31/5$41&^9]ZU:Z.5'O<UM#LQ8S"CE1;IYV.^9J\)<
M.3!-)ZJ.[%J(M'3D;;*\SL8ZS3<M51];7=K&O7HV43K"G;?TELUC*=(N\Q%4
M1/)M[M.N=\P[W9W:3#8^U3%5RFFY.D<FJN->N>YGAU/_ !LUY=-M^5.'2CS1
M735&M,Q/!ZUW.R)W<@ H!
M
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M%VRP6?YKLEAL-51RJ,ZP]>Z9GOT[XCQ07O1V89>+7\G'B]QU*
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M'>-C$
M
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MNK%J(NX\F"V/E)XC$3K#,=3I:0
M
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M,3YAQ3$P]:[S7>Q/NG>RH!&\
M
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M0 4        5?Z;/RG8W].X?[UH*O]-?Y3L;^G</]X+/H[$,L4=ED
M                         "?>Q,:QHR AXW VL79JMWJ>5$Q,=<QUQ[E>
M;1;*7,#=JQ>6:T54S-6E-%5?#KU6>^5RU3=B8KB)I\)<V73Q;S'+?ASSC_\
M%;[.;68C"5TX7,HJUB8IY5?)HTTC@Z;,MJ+&%PG.TUT553$3$1<I[Y:[:S9J
MQ?IKO6J:+5<1,\J*->_BK/&7;T7:K5R[573;F:-_NEYN747T_P",O3PZ;'J?
MRA>649C;S'#1>MU4Z]6ZJ)[HG[VRTWZJCV"SNK"XNG#7JYYN9JJUFK2.S'DM
M>W<BO?$_J=^EU$9:\O/U6GG#?;T^H=VYB-W>['*R'?U@
M
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M>K#TU_E&QOZ>P_W@LZCLPRQ1V60
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M[4
M
M/-SL5<'IYN=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@N_@"4
M Q7.E,S/<RQ5V9!P^TF<9K<QLX;*+=BK33MZQUQQCO:FO";;1'*KP^$BCKW7
MI_U)FT^*Q>!S6JO"Q;_F]N)GN1JMI\WF/K4X72?"B?-(276;)=+C"3&8:1B(
MBGE13.L1.]T#1;*8J]B\+-R_%,5S$3]6-/%O61!'?J B@       "L/37^4;
M&_IW#_>L]6'IK_*-C?T[A_O!9U'9AEBCLL@
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MC6)ETX]16[FOI[43R/>\TUQ,;GKK=$3$M  H
M
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MZSU8>FO\IV-_3N'^\%G4=F&6*.RR
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MXJF(W3<IUZM73CU-;>)<^337JWQ#Y6[E-<?5JC3B^FKHBT2YIB8Y9#O-&0
M
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M-,]\/M3.KLBT3&\.68F.60B==14 CK
M
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MQU=F83J:M9=E;UMPY)K->7H"&;$
M
M       >;G8JX/3S<[%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L#W\$FOL5<$; ]
M_ $H    D?.[>MVXF*KE%,Z=4U1 -)M)DMC,Z)BNNY373O\ JU1$=7!R-C8Z
MU%VW7B;M[FJ*HJB*;D>/!,SNU5F>9S9KO6>1')G?5I[BK8S"Z533=L<K^^GR
M2(V\DNOR2W8P^$IL8;E\BW$1];K[VR:39? TX##56::J*HIB(B::M8[V[92D
M "*        *O]-?Y1L;^G</]ZT%8>FO\IV-_3N'^\%G4=F&6*.S#(
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M[5Y?0!M8
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M
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M6U=HF/=5JZL>HK=RWPVIRE3.]EC=++=#4 *
M
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MC8W].X?[UGJP]-?Y3L;^G</]X+.H[,,L4=F&0
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M.IF8\&^)B6AD!0
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M5AZ:_P IV-_3N'^]9TQKP5AZ:H_VC8R>[Z=P^G_,%GT=EEBCLL@
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M1,,\&HKEX89L%L/+[C':IDB=.OJ=+0R,1OZF0
M                                                         'FY
MV*N#T\W.Q5P!'P7;O<82D7!=N]QA*!BOL5<$; ]_!)K[%7!&P/?P!*
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MM\G?RO)^A9B)ZU7>FNF.D;&^/T[A_O!9]OL0]1&CS;[$/0
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MFR5]-X/A:Q5NY&M-=,Q[IA]8KB>IOB\2TS$P]#S%>L]4O2[H!$ZDRH!&\
M
M          >;G8JX/3S<[%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L#W\$FOL5<$
M; ]_ $H           !BJ(JB8F-89 0+>48*WBZL338IB[.GUM9[NKO]R7>L
MT7;<T7*>53,:3#Z -1;V<RJWB)OTX2F+LSRN5RJNOXMK;HBBFFFG=33&D1X0
M]   "L/37^4;&_I[#_>L]6'IL_*-C?T[A_O!9U'9AEBWV(9
M
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M49( *
M             #S<[%7!Z>;G8JX CX+MWN,)2+@NW>XPE Q7V*N"-@>_@DU]
MBK@C8'OX E                    *P]-?Y1L;^G</]ZSU8>FO\HV-_3N'^
M\%G4=F&6*.RR
M                               :0       ,33$OE<P]NN)BJBF>,/L
M,9I$\K$S'#2XW9[ 8BF>5A,/RI_G3:B9<OF&P=,U37A[W)_JTVHC[UA3U,3$
M>#1;34LW4U%Z^U2W<DSS+YY6'OXKD^%-SD_?[GUPVTV9Y=I3B[-VYIUS7?\
MU^]:%=BBY&E=%,Q[XAK\5DF#Q-,\K#VN/-T^3GG2VKYK+HKJJV_:'.9;MQAK
ML1&)TM5?VIGOX.AP.>83%_R5Z*IW=T^32X_8S"W8FJU$T3I/8IIC[G/8O9K,
M\#K7@J\3,1_OHI^](OFIS#+MX,GZRLVU=IJWQ5J^T;U1V\YSG*ZN3B*:IB/;
MNS5_E+=8#;NB9BG$U6Z)X5RVUU<<6:K:2W-?*P89:' [1X'%4QR+\:SX451]
MS<T7::M\5:PZ*9JV<UL=J\P^HQK'BRV1+  4
M                                      'FYV*N#T\W.Q5P!'P7;O<8
M2D7!=N]QA*!BOL5<$; ]_!)K[%7!&P/?P!*                    5AZ:_
MRC8S]/8?[UGJP]-G\OL;^G</]X+.H[++%OLPR
M
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MC?XZ.FF>MG-;#:O,)H^47*:N_7@^G'J;HM$\-4Q,,Q(Q$L]:@$1H
M                                               /-SL5<'IYN=BK
M@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@>_@"4
M    K#TV?E&QOZ=P_P!ZSU7^FS\HV-_3N'^\%GV^Q#+%OL0R
M
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M)W]>L-\7B>&B:S'+T!,LD CJ  ._K #4@
M                 !YN=BK@]/-SL5< 1\%V[W&$I%P7;O<82@8K[%7!&P7?
MP2:^Q5P1L%W\ 2@                   %8>FS\HV-_3N'^]9ZL/37^4;&_
MIW#_ '@LZCLPRQ1V89
M
M   CCJ3HQ^ID'BNB*MVB)B,MP]^F8N6XG7BFS$^+,=3"<=;<LHO,<.3Q^QN
MQ'*JBS3%4^Z9^]S^+V,Q&%Y5>#OU1I.ZFFS,Z;^*S)>9IUUUASVTM9X=%-7>
MO*IHQ&>Y95-,4XFNFGOYO3W>#9X/;BY9GDXNU,3_ %KD1]SOKN#LWHF+EJB=
M?&-6HQ^RV7XFW,=&P]-7M<U$M,X,E/UEMC/BO^\/& VKP6)I^M>LVY\)NPW=
MC&V+U$3;NT5Q/?35JK[&[#7K4<K"XBJ9]FFW$?\ <U5>#V@RS?%S%<BGNBO2
M/'Q2,^2GBT'8QY/UG9;D5Q/5,/43&G6JS![88W!\FC%X>Y.G755>_<Z7+=L<
M!B(CG+M%NO2-W*F?N;J:NL\M5M+>./+KMWB:;IT0,)F>&Q$1-JY35KU::ID7
M(\71&2L^8<]J6KS#WOUZ]S,.>S_:&SEEO?,55:QNY4QU_J;#)\RMYA8YRU,:
M:S&D3JQC-6;=,,IQ6BO5,-B$3$]1JW-8!J
M               \W.Q5P>GFYV*N (^"[=[C"4BX+MWN,)0,5]BK@C8'JG@D
MU]BK@C8+OX E                    *P]-?Y3L;^G</]ZSU8>FO\IV-_3N
M'^\%G4=F&6*.RR
M
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M:_RG8W].X?[UGJP]-?Y3L;^G</\ >"SJ.S#+%'99
M
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M;NQ7&L5TS'%[U\);HF)X:MI9@(%#?J
M\W.Q5P>GFYV*N (^"[=[C"4BX+MWN,)0,5]BK@C8'OX)-?8JX(V![^ )0
M                "L/37^4;&_IW#_>L]6'IK_*-C?T[A_O!9U'9AEBCLL@
M
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M+MWN,)2+@NW>XPE Q7V*N"-@>_@DU]BK@C8'OX E
M*P]-?Y3L;^G</]ZSU8>FO\HV-_3N'^\%G4=EEBCLPR
M
M                                                     Q,:]^C(
M#Q-%,]<0C7\MPU^-+MFBKC"8:,)QUMS"Q:8X<OF.R&78BB8MV+5FK7M4VXUZ
MG-8_8S$86.5@\1=KF-\131$?>LN:=>\Y$:;][1;2UGCPWTU-Z\^51\]M%E>D
MSTJJW3W35I"?@=N<7:JIHQ>%Y,1NFJJ[/DL>]A+-V)BY:HJC^M3$M1C=FL'B
M>5/-6J9GPM4M$X+T_66^,^._[1LCY=M9@,3%,57[5-4QU<J9[N#<X?,+%Z-;
M==-43X.)S#8FJ)JJPMRNF=?YO)I[^+37,KSS+*YJM57[E-/=-^(]WBD9\E/%
MH7L8K_I*VJ:Z9[.DO43JJK![6XS!S-.*M[^O?<F729;MK@[^Z[7%$^ZFJ?N;
M::NL^):KZ2]>'90-;@LWPN*I_%7.5/\ 9F/N3XN15&[K=5<E;<2YK4M7F'L>
M8F?!G7Q9;L60[MQ"@                \W.Q5P>GFYV*N (^"[=[C"4BX+M
MWN,)0,5]BK@C8'OX)-?8JX(N![^ )8                   "L/39^4;&_I
MW#_>L]6'IK_*-C?T[A_O!9U'9AEBCLPR
M
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M^4;&_IW#_>"SK?8AEBCLPR
M
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M6$P=NY,3=KJMU1NW:Z=?Q?7)<#7FN=W<SOTS%$\FNB)C6-:=(W3^II]J*?\
M^8X7E]72*=(G_"0-QB]FK4;-S?M4TTXOFHF+D1.NN[>E; 9I5?P]_"7JYJN8
M:N+.^8W\F/W-YBM(R&=.J+<;O@XCT>\KZ>S337D],KU_YLJ^6,K+[NIEXJB9
MZJN3+.^(GO17K6/%5_IKF.D;&_6C7Z=P^[XIF?[7[58',9L9?L3B<;8BF*N>
MIO\ )C7OC3DRKW;G:3:+.,ZV3M9ULG?RFQ3G.&JHOW+W+BJK73DZ<F.Z9G]0
MK]"6YUHAZ>;>ZG?&DE/:J^MK[O 'H
M
M                                                        #33J
M  8F-89$V'QNX>BN-*HB8:W%Y!@\3$\NQ1,_K;@86Q5MS#.N2U>)<%C]B;5=
M<S8BBGA3,_>T-_9[.,OJY6&NW*H_J6__ )X+;TA\IM45=>DN6VDCTZ::RT<J
MLL9_FV JB,3:Q,Q'7,Q$>_P;W+=M[%<Q1?CDU=7UJX\738O)L)B8F+EFB=?&
M'.9MLA@.:N7;?(P\T4S5-44>$<6FU,N+SNVQDPY.88VDVFP\Y9<IL5TUUUTS
M$<FN)T?#87.Z+FMJ[7$7)FF(B:HUG=+@LPCFL379HN\Y;HG2*^IC*L;7@,=;
MNQ,Z4U:]>FK@C6VC)Y>C\"O:\+\HJY41+UJUF1XZC&8*U<BJ)GD4ZZ3KOT;/
MK>_CO%XW?/WK-9V &QB/-SL5<'IYN=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V"
M[^"37V*N"-@>_@"4           #Y8J_1AK4W+M6E,*NVCVXPMS&Q;BY',T\
MFK7ZVD_JT6E?LTW[<T5QK3+35[*Y575K7A;-4^^U1/W)L.2P&W>!N18PF7TV
M^777%$11%5/7/#QE]MI\#?N1@<QBW]:W55<KG6.[3OZ^YU6&V8RO#W:;EK"V
M8JIF)B8M4QI,?J;2YAK5RS-JNW351I,:33$JD.(QFTEB[LY5AK5?^U3:BGDQ
MRHG7=WZ)NP>5UX7"W,1>ITKQ%47=9TF=\>/ZV[IR' 4W(KBS1XZ<BG3_ ";.
MU;HM44T44Q333&D1$:+$[&QOUCZL:>+-,:1O9$5CE1XJP]-DQTC8R.5,:9]A
MYT^*T-(\%7^FN(Z3L;N_^^X?[P6=3OIB6:8WS]6(^\H[,,@
M
M
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MV66*.S#(
M
M                                              ,:,[]-P)L,1O9!
M0  >;G8JX/3S<[%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L#W\$FOL5<$; ]_ $H
M                   !6'IK_*-C?T[A_O6>J_TU_E.QOZ=P_P!X+/H[,,L4
M=F&4 !0
M
M                                                 >;G8JX/3S<[
M%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L%W\$FOL5<$; ]_ $H
M     !5_IK_*=C?T[A_O6@J_TU_E.QWZ=P_W@L^CLPRQ1V89
M
M
M                                 >;G8JX/3S<[%7 $?!=N]QA*1<%V
M[W&$H&*^Q5P1L%W\$FOL5<$; ]_ $H                   !5_IJ_*MCOT
M[A_O6@J_TU?E.QOZ=P_W@L^WV(98H[,,@
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MZ=P_W@LZCLPRQ1V89
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MW=4Z?<[.O^3JX CX+MWN,)2+@NW>XPE(K%?8JX(V![^"37V*N"-@>_@"4
M                 K#TU_E.QOZ=P_WK/5AZ:_RG8W].X?[P6=1V898H[+(
M
M                   #'7W2RQW> //)IZ^J7N.O1C2)C22(TGK$V9 %  -=
M^FA.Z/$ (W@ ,:Z^YD!C73WLQO- &)U9"4 !0  [V)B)W3&YF 'B;5'?#S%J
MWX1\7TZ^N&-(\&';B?2]4L133'5#T1U]3+*(B$WW(@8C7>S"C&^.LUWZ:2R
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ML;^G</\ >M!5_IK_ "G8[].X?[P6?1V898H[,,@
M
M
M                       /-S^3JX/3S<[%7 $?!=N]QA*1<%V[W&$H&*^Q
M5P1L%W\$FOL5<$;!=_ $H                   !5_IK_*=C?T[A_O6@K#T
MU_E&QOZ=P_W@LZCLPRQ1V60
M
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M[UGJP]-?Y3L;^G</]X+.H[++%'99
M
M
M!BJ=^G<IKT^8JU1@Z+?)KJNS13,13O\ YZYNY4&T.77<_P#23EE%^Q<JPUNQ
M=HJFJF8IW<J8WPPM'E8X:'/\KYG8ZWC<1,<[^+IB(F8^K,1W.S]&-F,LV6N5
M7Z*ZZ>=KW4;YZH\>#1>F2,1%BW@\/A[URW%JUV*)JC=5+O\ 8*:_HN8NV;MN
M>75VZ=/!G7VPGTK6YZ1=GZ;M45;/[2S,=\6*=/\ W$>DG9^8W[/;2Z_W%/\
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M%7!&:/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@>_@"4
M   ,:[V0  %8>FO\HV-_3V'^]9ZK_37^4[&_IW#_ '@L^CLLL4=F&0
M
M
M                          $:G!8:F_S\6:8NQKI5W[TF8- 0L7EF#QLZ
MXK#T7*M--:O!)M6:+-')MTQ3'7I#WIO9(  'QQ>%LXNS5:Q-NFY;F-)IGO:K
MU5R29F9RVQ.ONENS3KW@B8'+L)@:)IPEBBU3/=2E54Q5&D[X\&8 1,-@,/AJ
MIFS:IHF>^$J(WL@#S<[%7!Z>;G8JX CX+MWN,)2+@NW>XPE Q7V*N"-@>_@D
MU]BK@C8'OX E              QKOF&OS?-+.66*KEVK?R9F(F)G73@V$SI$
MSWJVVQQ5S$[1X3":_B^>Y-41KU3R4W&YP^V,SB*.D6+=O#5S]6Y$S,S'CI\'
M5X6_1B;%N[:G6BNF*HG33=.]RFTF6V?5"[S=$4W+=F(IJB(B>N._1X]'&.KO
MY=<LW*M9L33;CK[J5CRD^':0$=0**O\ 37^4[&_IW#_>M!5_IK_*=C?T[A_O
M!9]'9AEBCLPR
M
M                                                         \W.
MQ5P>GFYV*N (^"[=[C"4BX+MWN,)0,5]BK@C8+OX)-?8JX(V![^ )0
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MZV(C1EB)W;]P,C&N_<S'?OU
M&)ZI[_<1IIX S(=S$=>H,C%.NF_K9
M    !C7W[P9&/#4U[HG>#(Q$,@
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MJFJ9[M.#L:>_15E^J<+Z0;L4?5BN_9B=-W=2M*U.MNF?<R]&ST B@
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M&VM<5;56YP\Z5<FWKR=V[5G$,96W$^_<R^5N)Y.]]:>K>BP "@
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MYV*N#T\W.Q5P!'P7;O<82D7!=N]QA*!BOL5<$; ]_!)K[%7!&P/?P!*
M             ) ')^D#"U7LOMU41KI=B>O^K4;#XFFK9NW.NDTT7)F([HY4
MNGQ%BF_:FBOJGP<?7LOC,/>NTX&JB;%RGD3SE>^(GKTTCK8P2T^%M?2&W%^Y
M1]:FU>LU3/P\>"S*8B(TCJAI=G,BMY5:F>555>KB.5K,3&Z9T[F[9H (H
M                             3U #$3K#Y5<U>UIFFFO3=,54ZO=ZW%V
MW51,S$3X.'N;*YC9S&O$X.Y35K555$7+DZ;]?"/>@T^V& L8?:6U<R_6B_S&
MO(IB*8WU5:^"T;<3%,1+G,JV;BWC:,=C:JIQ5,31%--431I/ZM>^72Q[V7I
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M/?P2:^Q5P1L#W\ 2@
M
M
M                        'FYV*N#T\W.Q5P!'P7;O<82D7!=N]QA*!BOL
M5<$; ]_!)K[%7!&P/?P!*
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MOZ_!TV48ZG'X*F]3$:]F8B==^D+")W5!'5O 4
M                                                 >;G8JX/3S<[
M%7 $?!=N]QA*1<%V[W&$H&*^Q5P1L#W\$FOL5<$; ]_ $H
M
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M37<JK[N^(4=-$LPQ$:0S"+
M                                   \W.Q5P>GFYV*N (^"[=[C"4BX
M+MWN,)0,5]BK@BX'OX)5?8JX(V![^ )0
M
M #$QN9 -(\(8TB-[(#$4QKKIUFD>$,Z;P&.3'A!I'A#.@@Q-,:[B(T[HT9%&
M(GX(F9X&C'8:NU7K$S3,1,:=<QHF&B#39%E=S+N<HF>5;G33E5:]6OFV\4Q$
MSH]"C')CP9TCJ &--(W1!.D3O9 8TB.Z#DQOW0R1&@,1'7!IIW0SH YNO(KF
M,S*,1C*IBW3K3%--6Z8WZ:Q+HK=--%$4TQI$;GH B=8W!
M                                                           \
MW.Q5P>GFYV*N (^"[=[C"4BX+MWN,)0,5]BK@C8'OX)-?8JX(V![^ )0
M
M
M
M   #S<[%7!Z>;G8JX CX+MWN,)2+@NW>XPE Q7V*N"-@>_@DU]BK@C8+OX E
M
M
M
M        /-SL5<'IYN=BK@"/@NW>XPE(N"[=[C"4#%?8JX(V![^"37V*N"-@
M>_@"4
M
M
M             \W/Y.K@]/-SL5< 1\%V[W&$I%P7;O<82@8K[%7!&P/?P2:^
MQ5P1L#W\ 2@
M
M
M                  'FYV*N#T\W/Y.K@"/@NW>XPE(N"[=[C"4#%?8JX(V!
M[^"37V*N"-@>_@"4
M
M
M                        \W.Q5P>GFYV*N (^"[=[C"4BX+MWN,)0,5]B
MK@C8'OX)-?8JX(V![^ )0
M
M
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MM'(G?_R>.AV_:K^+'0[?M5_$&,#OJO3W3,)3Q:M4VHF*==_B]@
M
M
M
%    _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g942297g15h09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15h09.jpg
M_]C_X  02D9)1@ ! 0$ @@""  #_[1F 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &6,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@$' 5R P$B  (1 0,1 ?_$ !P
M 0 !!0$!               $ 0,%!@<""/_$ %(0  (! P$$!0@&" 4!!0@!
M!0 ! @,$$04&$B$Q%$%1<9$'$R(R4F%RL6.!E*'!T147,S0U0E3A%B,D8I+P
M0U."LM(E57-TDZ+"\41D&$6#XO_$ !H! 0$  P$!               ! @,$
M!0;_Q  G$0$  @(" @(" P # 0       0(#$00Q$B$%01,B%#)1%4)A4O_:
M  P# 0 "$0,1 #\ ^J3SO1SS645GZDL=A!H475E5;J36)8Y@3=^/:AOQ]I%C
MHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^($C?CVHIOQ]I%CHGTL_$=$^
MEGX@2-^/:BF_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M
M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHG
MTL_$=$^EGX@2-^/:BF_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EG
MX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAO
MQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S
M\1T3Z6?B!?WX]J&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7
M]^/:AOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2*[\>U
M$?HGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T
M3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/:AOQ]I%CHGTL_$=$^EGX@7]^/
MM(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CH
MGTL_$=$^EGX@7]^/M(KOQ[41^B?2S\1T3Z6?B!?WX^TBN_'M1'Z)]+/Q'1/I
M9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(
M;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGT
ML_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2*[\>U$?HGTL_$=$^EGX
M@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?CVH;\?:18Z)]+/Q'1/I9^(%_?C[2&_'
MVD6.B?2S\1T3Z6?B!?WX^TAOQ[46.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$
M=$^EGX@7]^/:AOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?
MC[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\>U%C
MHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z
M6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2
M&_'M18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX]J&_'VD6.B?2
MS\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(
M%_?C[2&_'VD6.B?2S\1T3Z6?B!(WX]J*;\?:18Z)]+/Q'1/I9^(%_?C[2*[\
M>U$?HGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\
M1T3Z6?B!(WX]J*;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?
MWX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD
M6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1
M/I9^(%_?C[2&_'M18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^
MTAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B
M?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+/Q'1/I9
M^(%_?CVH;\?:18Z)]+/Q'1/I9^($C?CVHIOQ]I%CHGTL_$=$^EGX@7]^/:BN
M_'M1'Z)]+/Q'1/I9^($C?CVHIOQ]I%CHGTL_$=$^EGX@7]^/M(;\?:18Z)]+
M/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?WX^TAOQ]I%CHGTL_$=$^EGX@
M7]^/M(;\?:18Z)]+/Q'1/I9^(%_?C[2*[\>U$?HGTL_$=$^EGX@7]^/M(;\?
M:18Z)]+/Q'1/I9^(%_?C[2&_'VD6.B?2S\1T3Z6?B!?4XMX4D>B!6HNE4I8J
M3>7VDZ'J1[@*@ "D_4EW$:QYUOB),_4EW$:QYUOB E
M
M
M
M                            "+>^O1[V2:?J1[D1;[UZ/>R53]2/<@*@
M "D_4EW$>QYUOB)$O5EW$>RYUOB D@
M
M
M
M               "+?>M2[V2:?[./<B+?>O1[V2J?[./<@*@ "DO5EW$>RYU
MOB)$_4EW$>QYUOB D@
M
M
M
M   "+?>O1[V2:?J1[D1;[UZ/>R53]2/<@*@ "D_4EW$>QYUOB)$_4EW$:QYU
MOB E
M
M
M                                                  "+>^O1[V2:
M?J1[D1;[UJ7>R53_ &<>Y 5  %)^I+N(UCSK?$29^I+N(UCSK?$!*
M       .L
M
M
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MW)2:XOW(S8(  GEOW!0#(
M
M
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M;9YMJ3?7!?(N%JVQT:EGV5\BZ
M
M
M                                           1;WUZ/>R33]2/<B-?
M>O1[V2:?J1[D!4  4GZDNXC6/.M\1)GZDNXC6/.M\0$H
M       !G.?*EQU[9OOK_*)T8YSY4?X]LWWU_E$(Z%:_NU+X%\BX6[7]VI?
MOD7 H
M
M
M                      BWOKT>]DFGZD>Y$:]]>CWLDT_4CW("H  I/U)=
MQ&L>=;XB3/U)=Q&L>=;X@)0                       &#G7E2_CNS??7^
M43HISGRI?Q[9KOK_ "B!T*U_=J7P+Y%PMVO[M2^!?(N
M                                #S4FJ=.<WRBFV>BU>?NE?X)?)@8M
M;0VS_P"SJ?=^96GK]O.2BH3SGW?F:CCW%R@O\ZFU[2^9M\&6F_T:BJTXS2:3
M[3V6+#]TIY["^:F(
M
M                                     BWOKT>]DFGZD>Y$:]]>CWLD
MT_4CW("H  I/U)=Q&L>=;XB3+U9=Q'LN=;X@)(
M !SKRI?Q[9KOK_*!T4YSY4OX]LUWU_E$#H5K^[4O@7R+A;M?W:E\"^1<
M                                             %NYBY6U:*YN#2\&
M7 ^3 Y[5MZE">[46&^\I:P<J\,>TOF3]=J[U_4BEZLF0;>3C5@T\8DF;XZ9_
M3?+).-K33YX+Q&TZIYRT@_<233/;  !
M
M                                                  $6]]>CWLDT
M_4CW(BWWKTN]DJG^SCW("H  I/U)=Q'L>=;XB1/U)=Q&L>=;X@)0
M     "S=5Z=M2E5K2W8)9(&G:[9:A6E2M:T9R3PTDU[^M 94%,I)ODDLY,+J
M>TNG6$]RM7BI\5AJ7Y"!FP0Z-]0J6<KB,UYM+.</LR8JAM9IM:Z5O&O'SF<8
MQ+\@-A!Y@U**:><GH <Y\J7\>V:[Z_RB=&;2YG.?*C)?I[9OOK_*('0K7]VI
M? OD7"U;9Z-1QQ]&/R+H
M         \U7BE-]B9Z+-Y+=M:S_ -C^3$#2+N7G+^KQ]:1<U&U=NXOCQ2+-
MJO.WD,];-@V@H9MJ<EU8^3-N]>E7MFJV_:;G9C\3,FJ;,U]RO*#?!M?)FUKB
M86C4H  Q
M
M                           1+[UJ7>R53_9Q[D1;[UZ7>R53_9Q[D!4
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MO2JO]EN\DO>^TBNTVO[M1^!?(NEJU_=:.>'H+Y%T
M                             8[7*GF[%OM>/N9D>LP>U-7%I&"?'?3^
MYEKV0PNAT]_4*7N?X,VO4J/G;245U)_)FN[,4W*YW_9:SX,VR:S"2[5@RM/M
M6BVTNC:A'/#=?'P-WMY*=&,EUI&DZQ3=*_J=_P"!MFC555L8-/EP^X6ZV)P'
M:#!               ^H-@ "F7GD!4%,E0  Z^8  )Y  #JX@    ;P,@
M "  )]O,IGCVKY 5 ^\     ;P   Z^8  )I\@         "          !Y
M      N"X@    *+/%/Q J BF<<V!4%,KM&?>!4#**974!4   "BSV@5!3GE
M)E0    !//(    &>(  =12/+GD"H   9   -]BR  '7@           (M]Z
M]'O9)I^I'N1%OO6I=[)5/]G'N0%0 !2?J2[B/8\ZWQ$B?J2[B/8\ZWQ 20
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MHG1CG7E1Q^G=F\K/&O\ *('0+9XMJ/P1^1=+=K^[4O@7R+@
M                                    UC:JI_FJ'<_N9LW::;KU3SMX
MWW+YF=.UADMDJ>*=:3Z]W\383%[/4]RRB\>LE^)DTL9,9[1JVU%!QKJIU2R_
MD2ME:[=)TGU9E\B7K]#SUMGV5^*,%H-?HU\W+DTX8^M<3./=5AN0 -:
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MRI?Q[9OOK_*('0;7]VI? OD7"W:_NU+X%\BX
M                        !23Q%LT.^EYR]DO]V/O-VOI;EK4?9CYFC1].
M_A[ZB^9G3_5ANVEPW+&BNM1)1XI0W*:CV'MF"+5U3\Y0G#M-'JYI7O9NSS]Y
MOII>T%'S-ZVNM)_,SI*PVZSJJO;PFN362\8G9NNJMDH9]1+\3+&,QJ4  0
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M"^1<+=K^[4O@7R+@
M    $#69[MC4]^/FC5-*I^<OUUX>]]YL.TD]VT:SS7XHQ.S$-Z_FW[#^:-E?
M4+#;P :T#7=JZ&:<:JY[RC]S-B(>JT%7LY1?\OI?<RQ/LA@=EJ^Y7E2?*6/N
M3-J-#TNHZ-]%Y[?DS>J<MZG%^Y%M"R]  Q0
M
M                                                  !%O?7H][),
M/4CW$6^]>CWLE4_V<>Y 5  %)^I+N(UCSK?$29^I+N(UCSK?$!*     "W5H
MTJO[2G"7?%,N#* UO4="LW/>C7J4JKY+SBBO=U$.%MJ6GR<Z4Z=6DNV3E[B%
MM?#4+W5:=#3I2A*&[)M)/M761Y7NIZ38U:5_4E-O'%I+K]Q*]$]MNTC5J5Y!
M*<HJIGDN"^9ET\HYEH*E^BG?1J8G3E*6,=G$WS0;OIFG4JCYN*;9>TZ],B
MH        <Y\J/\ 'MF^^O\ *!T9G.?*C_'MF^^O\HA'0K7]VI? OD7"W:_N
MU+X%\BX%                                               ,#7=I
MZB:4/=^*/.RU/UI]337WHB;1U-Z\:3Y&8V<I*%FNW+9LZA?IEP :T#S..:<H
M]J9Z @:'>P=OJ%5-847P\#<-*JJK:II\N'W(U_:>AN5X5.J3;?W$W9>OO0G3
M;Y9?R-EO<*SX -:
M
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MH/S%]V>E^)G7W&EAO:XH%JUGOT(RR73!
M
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MYRJO_/J*2X*/9%=IVLYSY4OX]LWWU_E$@Z%:_NU'X%\BX6[7]VI? OD7 H
M                                           $'6);EE-KL?R9.,/M
M'5W+1Q[<_)EKV0U[1UYS4J;?++^3-X@L17<:=LS3W[M/L?X,W)<C*_:@ ,$
M !22RL=1INLTO,7:DN_[V;F:[M31S&$XKK2^9E2?9"=H%PJMKC/%?FS*&K[+
M5L3G!OAE8^\V@EH]J  B
M
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M4O@7R+A;M?W:E\"^1<
M    !KFU=3"A%=;7R9L9J.TU3>N8Q[OQ,J1[6$C96EB4I^_\&;,8;9FGBTWN
M[\3,BW9( #%   #'ZW152S?#BG^#,@6[F&_1G'W,1V-*T>JZ%_374WQ\&;O3
MDIP378:)>P=M=M]:?X&Y:7556RIR]R7W&=E2P 8(
M
M                                                     (E]ZU+O
M9*I_LX]R(M]Z]+O9*I_LX]R J  *3]27<1K'G6^,DS]27<1['G6^("2
M%']Q4$D<[VQO:&G:Y2K5*/G5Z'"5/>7-LM/;+3VL/3J?'_\ I69W:^ZTNT<*
ME[1\_6RMV"FXO.'@UZSUNPJU?\_1ZU.@_P":59X)3HLV_92ZIW5GOTH;BR^&
M[N]9GC'Z-3M86R=DDH9?)M_,R!DD  "@       !SGRI?QW9OOK_ "B=&.=>
M5+^.[-]]?Y1 Z#:_NU+X%\BX6[7]VI? OD7
M                      WA&D:M+SE^OJ7WFZU7B#9HDI.K?QZWO+YF=%AM
MNB0\W91]Z,@1[".[:4U[B083V@     #FF !J.TM#<N=]<GG\#);+U]^U<&^
M*;?R*[34-^@II<D_FC%;,U_-7LHR?HN+\<HS[A6X+D #!
M
M                                                          !%
MO?7H][)-/U(]R(U]ZU'O9)I_LX]R J  *3]27<1K'G6^(DS]27<1K'G6^("4
M     %&LHJ8J^UFC:WM*VJ84JBDTW+'(@PFITJ,M?4M1IPG2W([J<4UG/O)&
MJW6C6EC*3H4&DEPC2B^LC[9WVFJ"M]1A!N2X;U1QYIFDVM'9ZWN?/>;I2P^"
M\[+LQVBJ2Z+L=4E5M'/BH9EA?6C83#;-7M*\LTZ$-V&7UY,R920  B@
M  !SKRI?QW9KOK_*!T4YSY4G_P"WMFN^O\H@="M?W:E\"^1<+=K^[4O@7R+@
M                                             !&U&IYJTJ2]R^9I
MNFQ\Y?+XE\S9MHY[NGU%GFOQ1@= I[]XI=C7S1G7I8;A1CNTHKL1[ ,$
M    1=3I*M9U8];7XFET9.WO>'5+'WF_-933-(UB@Z-]+WO.?K9G3_%ANE&?
MG*<9+K/9 T2LJMA36<RBN/BR>82@
M
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M_FB/LM3WJDI=B_%'G:NHI5J*3X+>S]Q,V6IN-&4L<\KY&?\ U9?3.@ P8@
M     !K>U-#THUDN'"/S-D,?KE%UK%QBLM2S]S+6=20QFRU9)U(-\\8^\V,T
MC0ZZHWJ>>'5X,W:#WH1?:LEM"RJ #%
M
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MFOP^J)%= MM[H]'EZB^1>+%NET>B]UM[D?D7P
M                     'FH]VG.78FP-,U^>_?U8]49-&QZ!#<LO?O,U6]E
MYR_K2[9-FZ:?3\W;I?69V]0J0 #!         \5H[]*4>U,]CJ T"M!VM\XK
MAN/\#=M.J^=M82[$E]QJ^T5'S=VZGMM_@9C9JOYRVE'/)_@C.WN-K+,@ P0
M
M
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M1SGRHK&O;-X[:_RB=&.<^5+^.[-]]?Y1 Z%:_NU+X%\BX6[7]VI? OD7
M                                        %B^EN6E=Y_DE\F7S&Z]4
M\W92_P!V5]S+ U2UBZMPL\6V;W36(1[C3= I^<O8+JS^#-T7!8,KK( #!
M        8':FAO4(S2Y9_ @;-7'FZLH9YY_ V+5**KVDXX_ZR:=9S\Q>O/##
MQ]YLB=QI8;X@6[>>_1C+M+AK0
M
M                                   $2^]>CWLE4_V<>Y$6^]>CWLE4
M_4CW("H  I/U)=Q&L>=;XB3/U)=Q'L>=;X@)(     .66 0:'MC>ZQ5U&%GH
M^Y&3W6WYQP?'*YY,/+2-N4GBY>/_ )R7YF2VYH:G^DJ573XU$UN^DJ6\NOW&
M)5;:C*QY_CU]&7'[A7HLWG9&%W&RW;^;G5R^+EO=:ZS/HP.R72E8XO%)5,OU
MH[O69XJ0  *        '.?*C_'MF^^O\HG1F<Y\J/#7MF^^O\HA'0K7]VI?
MOD7"W:_NU+X%\BX%                                           ,
M#M54Q;0A_O7R9GC5=JYYK[G9A_<S*O:P;+4]ZO*?LM?)FU& V2ABC6ECGN_B
M9\6[)  8H          "DUO1:9HVJTE0ONQ9SP[V;M7DXTI-&AWE:56YJ.?4
MVEXF=%AN.B5O.V,'EO\ _;)YH5O>UZ,%&G/"7N3-IV<KU+BPG.K+>EYQK.,=
M2%JZ]DPR@ ,$
M
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MYY)&Y-[JR:'J#=6^?ODD9T6&T[.PW+"$L>O%,RA%TN'F["A'LBD2C&>T  0
M         !:NN%"9H%?A6J?&_F=#E%2BT^3,5/0K2<Y2<7E_[F95G2PTW>YM
M<C;MDN.F3_\ BOY(Q&M:6K2:G23W./;[B]LW?JW;H3PH-N7%]? SM[A9EM8"
M>5D)8Y&IB
M
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MY1 Z%:_NU+X%\BX6[7]VI? OD7
M        ZP +%[+<M9R75CYFD0?G-0II]=1?,V_6Y[MA47;CYHU71X>=OU[F
MG]YG7I8;O2CN045R7 ]=87(&"              4XY*@"Q=V\;FC*$TGE&DW
M]&5I>2C'AQRL/JRS?3%:[8JYH[\5F:QV\N)E6=+"NA7W2J&)OTXKCXLRAHVF
MW$[2[3GE)/LP;E:5XUZ2E%I\.T6C2+X ,0
M
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M$5W&U_=J7P+Y%PLVK_TU'X%\B\
M         &$VFJ;M%1[5^*,9LM3WKVI)KAN?BB_M3-.<8YY+\2[LK2>XZBY-
M-?>C./ZK]-B !@@                &DUA@=> -4V@L71FZL%B+[,>XKL]?
M;DG3J2>'Q7/W&QWE!5[>4)=9I5_;SLKGD\9SR]_]C9$[C2M\3365R!B=!OE<
MVZC)K>CU?6S+&N8T@
M
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M]LWUO-?Y1.CI=O,YUY4>&O;-=]?Y1 W^WST>CA+U(_(O%JVST:E\"^1="@
M                                      Y('FH\4Y/L3 U#:2>]>XZN
M)F]FX;EBE[V:WK4G.]F^>&S;M(AN6<$9STL])@ ,$
M,5K=C&XH[T5Z:_N94I)9C@1.AHMA<U+&XYXXK>63=;.LJ]O"<7G*6>_!KFT-
MBZ=3SU-<'W\,)%O0=2="3HS?HMM]7/@9S&XVO;;0$\K@#!
M
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MRB!T&U_=J7P+Y%PMVO[M2^!?(N
M       "S<RW;:J_]K^1>(>K24+*J\_RR^3$=C3YKSM_)/CEOY&[6:W;>*]Q
MIVEQ\[J,/K^3-UIK$$C.RR]  P0   $>ZO*-M!SKU84XKG*<DDBEI>T+J&]0
MK4ZL<XS"2:^XNI8^4;TD@($9             "S=4(UZ,H22>5CD:1J%O*TO
M91QCFUCLR_R-\Z^XQVLZ>KRGE>LDOQ,JSI8>-#OND4(QF_37?VLRIH5C7G:7
MBE).+SQ37(W:RN(W%",XM/@L\?<+1HF%\ &*
M
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M[4O@7R+A;M?W:E\"^1<
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MNUF8,)C2  (
M
M        "+>^O1[V28>I'N1&O?7H][)-/U(]R J  *3]27<1K'G6^(DS]27<
M1['G6^("2     %./85*8 U;:_7-,L*7F[Z-.I-KU9PD^I]B-(H;3:#1K>=A
M:VN\NKS<E^!GML+ZSTW7*5:ZA*:]#@I+MSUEJ6V>A-<;6K_SA^9*)9M^S.IP
MU.S52E%167P6>HS)@ME;BA=6F_;Q<8MOFUVF=7 RD@ !%        #G/E2_C
MVS??7^43HQSKRH_QW9OOK_*('0;7]VI? OD7"W:_NU+X%\BX
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M:F6LX_%FP&J8TQ  0
M
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M9QZ)SGRHY6N[-O*YU_E$#H=K^[4O@7R+A:MOW:C\$?D70
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M1/CPEX+\SU0U]U*D8X?'W(OC*Z;&"D7F*?:BI$
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MJ>33,:8O0 (
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M^O\ *)T8YSY4OX[LWWU_E$#H-M^[4?@7R+I;M?W:E\"^1<
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MQN&UT*D:M/?@\IGLU#3-4E;3W)MN#ZC:Z%:%:FIP><HUS&F6EP $0
M
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M "B!T*U_=J7P+Y%PMVO[M2^!?(N
M      \UGNTIR[(MGHL7TMVSKO\ V2^3 T>[?G+^M+VIMF\64/-T%$T:VBZM
MXHO^9OEW&_QX11G;I95*2>$RI#O[A6]M5JS:2A%R?<DS&(VQM.HVYAY9]<=K
M8]#IR>_7B^3:QB47V&J>2;1^G:C*[FENTDI/*SRE%]IA=M[]ZUM%<-2WJ,:D
MO-X['_\ HZ=LO:1V>V;E%_MZKDOJ:X=G8;>3ECCX=R\7!CGE\K?U#(;0WGG*
M\J-)^A#@D9;9/3?-1\_4BLR37WIFN:/0J:C?)2Y-O+^I_D=(M**I48Q74CYW
MB8YSY9R6?69[?BI&.J[%=AZ /;B-/..9XG34DTUE,]@36)C4D>FI[0:#&:=:
MWQ&76DN?+WFM65U6T^Y:4GPYK/O_ +'3JD-Y&OZ]HD;FGOTN$U_?W'C\KAS6
M?/&[\'(]>-TG1=6IWM/&]B2YKC[_ '&9BTUP.6?ZC3;I8X3B^M/'_7$W/0-;
MIW4%"IZ-1+CG"75[S/B<V9_2_;'/QM?M7IL*!123Y%3U8G?3B ,A%   %UEN
MI34D7 $UMH.VVQ5OJ]M4J4(0A<<TU%9;X+K?N.*7$+_9G4YTTY0FF\-27%9Q
MU9[#ZFE',6C3]MME+76;1N:<9QXY3QV^[WG5BS?4O*YG"\OWQ]M?V&V_H7E!
MTK^HX5XXY[TLY;[%W'0-+U>UOZ4I6U3?49;LO1:X_6CY9U6UJZ3>SMU)YACB
ML\<K/XF3V7VJOM"NHU*+C*+>91FF^>,]?N-M\$6CRJX^/\G:D^&1]2IIMX94
MY]H_E$T^YM(5*N:3EG*FXK'%_P"XS=OM=I=995[;1^*M#\SDG%:'LTY6.T>I
M;,##TM?L)OT;RV?=5C^9*IZC0GZM6G)/EB2?XF/C+;&6L_:<"/"YA)>M'Q+B
MJQ?6C'4LO*%PQ.K:1TZO"IYQPW8XQNYZ^\RD9I]:*3J*/-HL;A=M>_PV_P#O
MG_Q_N9#2=+Z!O/SF<^[!>6IVGG?->?I><]G?6?#)[K7U&E%RG4C%?[I)&7[2
MGY(UVE/EQY%N5:$4^/!&F[1;?:;I<)-5%</#PJ,XRZOB.8Z]Y3M1OJDZ5C2A
M"@WPWZ?I<_=(SKAF7'FY^/']NS:SM)8Z91E*ZJ[F.K=D^KW(YMM%Y4HQE*GI
M]-SP_64Y1Z_?$YM2HZKJ]51C3N*F7S49-=AN.@>2^]O=VK?5:<*;6=U.49+*
M]\3HC%2GN7G6Y6?D3JD::U?[6:KJTU"5>KZ7HJ+GGGP[#(Z'L7J^L3A4JTW"
ME/CYS?A+J[-X[%L_L-IFCP2H0J3><YJ-2Z^XV>C:4Z:2C%12[$86SQ']6S'\
M=:_O++0-"\FMC:2WKC<KR_W4TNOO,K'8#3(W].YA0I+=4LQ\WSS]9ND8J*PB
MN#3.6T_;T:\/%7Z1*%E3IPW5%)+W%SHM/V5X%\&ORET12L?2/T2GV+P*]%I^
MRO O@;D\(1U:4^Q> =K3]E>!( W)X0C]%I^RO .TIM<EX$@#RD\(:+M%L'9Z
MI>PK[L(N.,K<SG#;[?><]VZV$KV+E<V,5*@LMI;L=WBDNOWG>\(C7MK"X@XU
M(YBS;3-:KBS\''DB?7M\Y;';8W.BWT*-><Y4=[#3D\++7'@GV'>M"UBUUFQC
M4@]^+2?%/AQ?:O<<MV^\GRH4YWNF*;QZT7EOE)O"4>XTK9O:2^V8O\J$G#^>
M$XMO@GC"RNTZ+5C)&X>=AS9.'?QOT[SK.D^:_P Z@DXOFDL=K(NFZE4M9I-M
MPZUDE[([36FOV'G*<HJ6=V4)..<X67C+[2]JND)MUJ#RGEM<_P #FGUZE[N/
M+&2-PSEG<PN::G!\.1(-*M;FI8U$UGGQ3-IT^_IW=-.+6]V91A,:9Z3  8@
M
M          "+?>O1[V2:?J1[D1;[UZ7>R53_ &<>Y 5  %)^I+N(UCSK?$29
M^I+N(UCSK?$!*     "S.A3E5524%OQX1?>7C7M4U.YHZO;V].G)TY*>\]S/
M+EQ(0@;0N>FZHK^<<TG&,>+Y8XF*U;;6A<VLK:S<9UI8X)M<4\]:[$9';/6*
M]I4A2C;.K&6/^RWN:9J4;ZK&JZBT][SX\+<M4EO^QE*XIV&;A--N7/':;$C
M[)W56ZLMZM#=>7PW<=9GBR0  B@       !SGRI?Q[9KOK_*)T8YUY4OX[LW
MWU_E$#H-K^[4O@7R+A;M?W:E\"^1<
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M7433MU]6/R,7<^3K3ZDFX4TOK_L7\E)^F,\7DUZLTVV\K=SQ=2UBO_\ 8_\
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M/V&MTIT\5M[>7N7YFN:_XW:9H&/CJ]M)I+>RWCJ_,R$6I+*Y&.M(
M
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M3C+AA%TIXA-0P<M$IO4(W4<+#3QN]GUF9I045@N?4"S;;&M(KT  C,
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MZO2NHI2]"?OPOQ,DFFLII]QJUI%0
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MDL/KR9C3-;EO1C7Y=;Q_<QFO^+ILHR6Z-:%:&]!K!<YK@8H
M                                                (M]ZU'O9)I_L
MX]R(U]Z]+O9)I_LX]R J  *3]27<1K'G6^(DS]27<1K'G6^("4     %&NK'
M/K*OD47+!)&K[6:_I.E[JOHQJU>:B]Y=3[$S4;S;79^[A%5=/IS45A)U)?\
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M_P!N[-]]?Y1"NA6O[M2^!?(N%JU_=J/P+Y%T
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MA)IT(&(V7J2J6$W.3D_.<V\]2,N8S&D  0
M                           $2^]>CWLE4_4CW(C7OKT>]DFGZD>Y 5
M%)^I+N(UCSK?$29^I+N(UCSK?$!*      "F"2.<;9+3J.NTJFH[LH/<6ZVU
MU^XM.]V02QT2B_?YZH9O:>UT^]U&G3NH5)26Z_12-=U:CH=I<QH4Z5>I-YRE
M",L"G26[;MLG*VE:9LTO-9?)OM]YGC";+0MX6*5MO)9?"6#-F4D  (H
M   <Y\J7\=V;[Z_RB=&.=>5+^/;-=]?Y1 Z!:_NU'X%\BZ6[7]VI? OD7
M                       !&O+VE:13K9PWC@!)0;23;Y(QGZ;M,9WI?=^9
M U/6XNG*-#/%8Y>[O+$2NDG4]8C04H4TG+MS[^XUFG&K>UTI-RD\8X'NWMJU
M[6RLO/%YR;;IVFTK2"]%.?:\,S]5.EC2=+C;TXRF\SZ^'N[S+8[ @83.T.0
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M7!1/)4P0
M 1+[UZ/>R53]2/<B-?>O2[V2:?J1[D!4  4GZDNXC6/.M\1)EZLNXCV7.M\0
M$D     ':!R0&E;44KNUOY75K:2N5."@DIJ.Z^+SQ,5I&E5HJXU+4+5NM.2E
M"DY+*SP?%&8VQVCK:?55O9VT*U3";WX.7-/L9J-?:O6[FUJ4U9VT8K";5.::
MX]Y*$N@;)TZD;9SJ1<&\K=YXXHV!&N[%UZ]?3E*YC34LOU,]J[38C*4@ !%
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MQY\%@Y,EXO:9AZO PVQ8_:\O<$%U@Q=X
M !  "C[BH&A1Q3+%6UIU,[T4\D@&NV.MNX6+3'3 W>SMK6RXTXJ7U_F8*]V5
MJ1;=*IO+/".[R^\WO!1Q3YHY,G QW^G13E9*_;F%?3;ZU]:C**7'.469WE?S
M3I.;6.XZ?6MZ<TU**>>U&K;0:&G3J3H+$F\\._N/,Y'!OCB9I+LP\J+SJ[3X
MRDN.]Q[21;PKW<O-PS.74BD;.M*HH*$L]S-MV6TF5!NI52R^7AW'#QN/ER6U
M+JS9J4KN$;2]F)-[]RTTGZK7]S9[+3J%M!*G!1QWDR,4EC!ZY'TF'ATQ^]/'
MR9[7[>5#'+@>D =D1IH                     !Y"[L  4<4R#J&G4;NG*
M,XIM]9/&,FK)BK>-3#*MIK.X<ZUO1Y:>G4C+T6\<N_W^XP:ECF_K.FZW9=+M
M)0ZUQ^YG.JUG7I5-V4&W[DSYKF\6V.WZ/9XF>+U_=*T?4:EI73<VX&\:9J]"
MYIQ]-;_6N/O]QI=MHMW.GOI0Q[\_D6*UK>4)-/>CCKAE&?&SYL,>X8YL6/+/
MJ73H5(M93/?!G-+35+VSX)[R^DWG^)FK/:G&%<P>?]D?S9Z>/Y&L^K.*_#M'
MN&Y(\RC%\6LF+M-:MZZ6);N>W"_$GPN*<O5FG]9W4STMU+FMCM7N&-UG0[74
MZ;C<T(S7O;]_O]YQO;?8%:<I7-G4BJ*S)P4.2276Y'>U)8(UU94;B+C5A"<7
MS4DF=>+-KJ7!R>'7+'7M\GRKW%!.FJC4,\L(S6RFU5YH5Y3<)R=OG$J::65G
M//#-W\I>Q4U4=YIL([J23ACK<GU*)S6MIEQ:4%7KTIK>]3T7C*[>!WQ>F2NG
MS=\6;C9-OHO3:M':'1Z%U#"G.$7VX]%/'5VF,J6]:QKXE%Q::PS4/)MMO3H6
ML;"^@H3@\1=..%A1BESESX,ZS4IT-0H-IIRP\-8[CBO7PE]-P^1&6G?M#TC5
MMY*%PVNI-]W<9Y--91I&H6M6UJ-<<9X-=YE-$UC_ +*X[D_K][-<U^X=<PV,
M'B$E..8O,7Q/9@@
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MIC?N'<W %JWKPKTU*$D\I,NF"
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MTUF<HQ[W@YQY3Z\)Z]LXH3BVG6Y/W1".C6O[M2^!?(N%JU_=J/P+Y%T*
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M/1ZV+'&.NH:+6\IW( #:Q
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MF_);UT( 'H.8
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MZ?JU*Y6)M1EX&N:Z-,F"BDFLIIKW%3%
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M3C#CG/7P.@T::A!1BDDCR^%AG+?\EWI<G)%*_CJ]Q6$5"![<1KT\T !0
M
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M>HV&_+UDWRSU,SYE*0  B@       !SGRI+.O;-=]?Y1.C'.O*E_'MFN^O\
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M<?'N>Y932;16MK"'6DD9%<BB22*GMXL<8ZZAYMK3:=R  VL0
M
M                                  #&:GIL+RE)-8>'VF3*+L9JR8HR
M5U+*EII.X<PU73:MC6EB,FLO#Q[R7'5(W&G2M;RFYQDFLYW>?<;KJ5E2N*4E
M4A%OMPCFMQZ%1Q74?/<BM^%?RI+U<7CRJ^-V>V9IV%&E5HJ"C&4][#F^PQ^U
M'D[M+]2JVLMR;^*6>&.TQ]*K4IO-.33[\&Y:+K<)6\87+S)>YOK.[@_+S/J\
MN#F?$TF-1#A&M;*ZEI%>;C1JRC%M*?F\+&<&2V4V\O\ 2JT:5U_FP<EU1CCC
MW'=JM'3M1IM5:=*:?MQ3]_6:%M3Y-K2XA.KIL73J1BVE#<BFTN')'T./EX\L
M>WS>7X_+QY\L;9-G=M+'4J4<UJ5.ICC%S3?+N-FJTZ%W3RVGGD\GS-J&FZMH
M%Y)/SL&F\.G)X[.HV+9ORCW]E.-.]FIP367-SD\9^(LX8GW66>'Y":3XY8=6
MU'2JE*4I4TZD6\X2]Y#LKVO:3PO16>*:1,T#:VPU>C!PJ1WFEE36.K/6S*W&
MFVUU!RII*?;%)&J=QZEZV/-7)&XEXMM=ING_ )J2?OES+OZ<M_\ ;_R-8U*V
ME:5O-R?=Q(N> BD3TVZ;Y8WU.[WO-XX>_)+-6V7KPIRG&<DFVODS:(R4EF+R
M:YC4I*H (@                             B7WK4N]DJG^SCW(C7WK4N
M]DFG^SCW("H  I/U)=Q'L>=;XB1/U)=Q&L>=;X@)0     1*^H4+>ZI4*TU&
M=1-K+["6:?Y0-#OM4H4JNF5I4:])-)QJ;CXM=:)(IM79U+N#K:7=TZ5=+#]'
M>RL/AQ]YILK#:"]B[2\O5"VY2WJ,4GCBN*6>:1"M=,U=U/-5]3O83SCA7E@R
M\-C=:N*>:>KW?'E_J66(TEIVWO9.UH6E@J5NT\-MM-_B9Y&O['V=:RLO-W$W
M.:;XMYZS8"R0  B@       !SGRI?QW9KOK_ "B=&.<^5+^.[-=]?Y1 Z%:_
MNU+X%\BX6[7]VI? OD7                 !1E3Q6J*G2G-_P JR!AMI;Q4
MZ'F8OTY8?WF(T"S=>Z4VO16&_$C:C<2NKR3>7B32[LLVK0[16]G%OUWG/B;.
MH7ID()1@HI<(\"-?W,;:E4G4DHP@FVWU+!)DTHY9S;RI;1NPL*EM2;\Y4C*$
MN+6,Q_N3'3RES\C+&*DVES;RD:U+6]:G".94J4I4X\O22F\-8-]\DFS$K&ET
MVO#$YIQP\Y6)=_N.<[%:3/7M<A&;;BW)MOCU9ZSZ(KU:.DV3DH1C%9PHQQ[^
MHW<C+7#3V\O@8)Y&2<MF16(QPS4-JM5]&5"C+*Y2QCDT6+G:BK*<O-Q6[GAS
M_,P]"G4U"\A%O+G))Y?U'S'*YT9?TH^NP<2:?O=-V;TN5Y756HLTX_D="IQ2
M7N(6E6,;.UA""65%)M+KP9 [^%QOQ5W+DY&;\E@ '>YP
M
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M9A-?\;&[ Q%CK5*NL2RI=QE83C)9BS'1IZ !
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M?7^43HQSGRI?Q[9KOK_* '0K7]VI? OD7"W:_NU+X%\BX
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MTGSY=IXO"X=YOY6>KR>36*S6&6IK"/07 'U%8U&GB  ,@
M
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M9*MH.TVSU2MM!JNI;TJKW;NJY)82]_O^XBNXVO[M2^!?(N%JUST>EV;B^1=
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ML21\]@PVY.3\E^GTV7)7!3PKVNT*2I4HQ@L)+!=QCDBJ![M:Q6-/-F=@ ,D
M
M
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M)?>O1[V2J?[./<B+?>O1[V2J?[./<@*@ "D_4EW$>QYUOB)$_4EW$:QYUOB
ME                Q&OZ0]4MU252,%G/%>YK\3#0V3KTZ2IPNJ:C'@O09N
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MGV%*TXF*(CM)TBPC9VT8+L7R,B,+& >YBQQCKXP\^UIM.Y  ;&(
M
M
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M+6
M
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M+"2X(D'%Q^/X?M/;W,F2;>OH0 .MJ
M
M
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M'/)'IM]"Y55R?F)*3QO+K4>H[C%>CQYG)FK%K;>M\?7QQBS@J 1W
M
M
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MM2[V2:?[./<B->^O1[V2:?J1[D!4  4GZDNXCV/.M\1(EZLNXCV7.M\8$D
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MNX#E/Z@MAOZ2]^UR'Z@MAOZ2]^UR.K #E/Z@MAOZ2]^UR'Z@MAOZ2]^UR.K
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M6 '*?U!;#?TE[]KD/U!;#?TE[]KD=6 '*?U!;#?TE[]KD/U!;#?TE[]KD=6
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M^UR.H6EI0LZ3IVM&%*#>\XP6%GM^XO <I_4%L-_27OVN0_4%L-_27OVN1U8
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MF/D2TJCHU/4[*TA.%O35/<4VV^+FWQ?O9T\C6EA:V;J.TH4Z+GC><%C..1)
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M &<>Y 5  %)^I+N(UCSK?$29>K+N(]ESK?$!)
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M>CWLDT_4CW("H  I+U9=Q'LN=;XR1/U)=Q&L>=;X@)0
M            &LK  &.J:-95*OG)4O2Y\&3J,(TX;L$HQ7)(]I8
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M^WOHI7$7)+WX_P"N1, $'3]+M;!MVT'%O@^/_783@ (='3K:E6=6$,3[28
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MOB),_4EW$:QYUOB E
M
M     6KFM&A2=27) 70:9/;JE%3DK5.G%9<O./\ ])2WV[I7$'.E:*4$\-^<
M:Q_]H[&Z PUKJ535=/5:QBU)YX*7OQUX,C8JLJ*Z1G?PN;3 D #( %,]O J
M SS[2DI*$7*7!("H-6EM%4KW$W:4M^C".\WOXSV\&B'';NCTOHJMDZRRFM]\
MU_X0-U!@=:VA_1=NJU2W4H<6WO\ ))9["SL[M3#6JJC0H)4W_-OOLSR:0&R
M)Y     "F>I@5"+-W*<;:HZ2S)1>...HP>C:[YVZE:74-RJGNKTM[.$\\E[A
M V(%$^TJ
M                                  1;WUZ/>R33]2/<B+?>M2[V2J?[
M./<@*@ "D_4EW$:QYUOB),_4EW$>RYUOB D@
M
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M@IKCDR8(  %
M                                 !$OO7I=[)5/]G'N1&O?7H][)-/U
M(]R J  *2]67<1[+G6^(D2]67<1[+G6^,"2
M
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M5O!QH04(]B"O=..[%17)'H
M                                                 BWWK4N]DFG^
MSCW(C7OK4N]DFG^SCW("H  I+U9=Q'LN=;XR1+U9=Q'LN=;XP)(
M
M
M
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)EU<$    '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g942297g15k07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15k07.jpg
M_]C_X  02D9)1@ ! 0$ ?P!_  #_[17V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %=D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MXYWV N[]'.IZS?HYT=:UP>.=]AP>.=]@+N_1SJ>LWZ.='6M<'CG?8<'CG3U
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M =( "W77$3QRJIJCSFR;J@!0
M
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MBKS@JU-7FKT
M
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MU1H  "(
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M 4  "-?*\U!Z  !Q@!&OE>3.G*#T4=\IU5Z^<-P(
M            ->.0 U  (G7D
M    !&Q7SJ4E&Q7SJ4D  %-SZ.KHE9P?)7TKUSZ.OHE9P?)7T@D
M           Q&U_Z,9G^XJ^YA^YG^9[G\G]++[7_ *,9G^XJ^YB.YG^9[G\G
M](0V\   %.D3KO0HKM15$Q,<4KGEY'K,UB>2)V8?&9#@L7$]]LQ,^?>J[6OX
MW8;"W)F;-$43_-/XMWX^/B>N-M-2W,.]-1>G$N5W=F\SRZY->!N5?)XXW;6O
MWEK.\[R^O3%4WJJ8\]%-/X.HUVXF)XH0\3E>&Q%,Q=LVZM?/3$N$Z:U?I+O7
M51;[PU+ ;<VJIBF_3N?M5QY^AG\%M'@L3II?M:SY-^&.S#8[!7Z9[U;HMSYZ
M+=,>1K>.V.Q^&F9RZY=KF.2-^FG\7/JS8^?+?3@R<>'3+.(MW8UHKB8]4KD3
M'&Y#P[/,GKCA4W(B/)-_7[I]3+9=MY5$Q3BZ*8B.6=:I=::O_IROI)YI.[I,
M3ZS2-6O9;M3EV,B(MWOEZ<<;E78S=K$T5Q&[/%T/33-6_$O/;%>O,+X\UA[K
M#KNY@1.O(>4 ->,          !YY9/5/&]><?2"QB+%-ZU5173K3,:3#G&U&
MP^'Q.:6:L-9W:;LU3<F-Z=?-Y73^E15:HJF)FF-8Y.)JMYJXY,-<G+$;.Y-A
M\JP--BQ;BBGEJXYXZM(CRSZF5[U3S5R*8AZDVF6ZTBL;0M19I\RGO-,?Y=5\
M-Y7IA8[U3S5JO!6;DSO6_ME+AZ=4G1$L5<R/!US.]:B=?]4]J)<V5RNN9WL)
M$_SU=K/Z/?(O7+/9I^-5G8G)9I_Y&/>5]J/5L)D\S.[A*8_GK[6Y$1'F6+RS
M."D^FA5]SO*ZJ)BFQ3'\U?\ <B7.YEE]5,Q%NF/;_N=(B-!>[9GXN/\ '+KG
M<NPNGR=R/X5?W(ESN7411,T7*=?V*NUUS1YIZH6,LLSI,;C-WN:7:+<S;N1-
M7JMU=JW=V!S.W.]:Q$Q_T7:-SU0;ODW87NRQ\.KBO@MM#8G6UBJ_X8>"K+MK
M+'RJ,3>_VU/8[1WJ)GCB-%,X>B>*:*9_@=T^)'J7%XO;8V9X[N(JC_Z>GL5?
MEG:RQ7&MG%5QIY+-,?\ :['.#M5<MNCV8459?8GELVY_EA>Y#/QK>I<AHVKV
MDL3I=PF*]W3'_:O4[>9O9XKN#Q'\8IC_ +74[F3X6N=:L/:GIHA'N;.Y?<^=
MA+'NZ3KJ=C+'$N<6>Z/C*9F+^$O1TS3'X)%KNF4Q,Q=LU1TUT]C=J]E,LKG6
MK!8:?^E2CU[%Y17,ZX#"Z_N*.Q>JC/;S_K6\/W3,+5KOQ$3Z[D=B7:[I6 T^
M551'_5CL3KVP64U5:QA;%'[-FA N]S?+JIG2*8CU6J3>DFV>/:7;[H>754Z]
M]M^]CL2[.W&6W*=9Q-F/^I#7:^YCA=9W<1<ICS112BU=RZ./<S#$QZHW8-J+
MUYX;M:VORVN)F,98]Y"31M)EE4?\]A]?VX<XGN:XRC6+>,Q.GGWJ8_%#KV S
MJB9FW?Q,^;_&IC\3HJD9LT<U=;ISW 5::8JS/\\+L9GAJHUIOV^/_4XS.Q^U
M5NF>]S?JF.3_ (FF/^Y1.1;;6J>.U>TCB_YRG^X[=?T^3DCFKMU&*M3QQ=IG
M^*[%VGEWHF'"YM[96J=:HOQ$<?\ S<?W+56;;4X>-;MS$133R_\ %:_BG:C]
M6-9/NKO-=ZFFF9F8XO6T;;+;6QE5%=NQ<IF_QQI%<:Z\7DF/6Y]=VNSNFW5%
M=5S3337O\]K3LTQN(Q^*JNXFJJ:IG7CJF?\ WR-XL,3+SZK73%?\?#>LC[HV
M-HS*NK&W9JL53,Q$[D::SQ<>CL>4YKA\PP\7,/=HKIG7YM6OET?*D<L]+<MC
M-JL9E-4T4S5=MZ<E=<Z?.U=,N"(CP\^CU]M]KOHF*H\E40JWH\\./7>ZA?M5
M;LX2S[52GQJW_)A+.G[53S=J7U?ET_78MZGSP]WJ?/#D=GNHQ73,UV;<3_.K
M\:-OZNW_ /GV':LL:K'^NLZTQY8-?6Y/'=1M^6W;T_G[$RWW3L#-%.]<IB=(
MUC=K[#M6/EX_UTS7UO(F>ES6.Z;E_P!;'L5]BJCNFY=O<=V(C]BOL.U8^5C_
M %TB)5>1H%/=)R68_P";F)_=7.Q[XR<EX]<7/NKG8G;LOR<?ZWV-?.]:%1W2
M<CF>/&3'_2N=B1'='V>TX\=/N;G]J=NWXU&HQ_K=1I?C'V=\N/J]S<_M7+?=
M#V?N3I1CIF?W-SL.W;\7OX_UN U;PXR7TN?=5]AX<9+Z7/NJ^PZ+?B]_'^MI
M&MV-L,IOSI;Q4S_TZX_!?\)LN](GV*NPZ+?AWJ?K.C!>$V7>D3[%78OV<\P=
M[Z.],_RU=AT6_#O4_66&._*F'^L__&3\JX?ZS_\ &4Z)7NT_61$.C&VZXUIJ
MUCHE7PFGSG3*]<)(C<*I\YPFGSITRO7"2(\8FGSG":?.;2=4) L<)I\LD8FG
MSFTG5"^+,8BE5WZGSFTKU0N"WWVGSK&)Q5%JU7755I33&LSQD1,I-HA<OWZ+
M-,S55$1'K6\-CL/BHF;-VBY'GIG5QS;[;>]<Q-W"8"[71%%<TS51553/%+!;
M(;:XC+<9$8J]<JLU<4Q575,1K5&LZ.\8)FN[Y]OY"E;]+Z)Y:?DO8XH8K),U
MP^8X.W?P]R:J*Z8JB=)C[V3IKB9<)C9[ZWBT;PK'F_3YWF_3YT:W5#S>CSF]
M'G#=Z/-Z/.;U/G#=Z/-Z/.]U@4'F]!O1YP>A$P\U@'H\WH\YO0#T>;T><WH\
MX/1YK!O1YP>CS6#>@'H:P\WH\X/0U@U    U@     >53I'K8G'9]@<#=IMX
MF]-%=6D1&Y5/+T0L1,LS:*\LN+-B_3=IB:9UB5V*H398F)>CR*HUTU>B@ (V
M*^=2DHV*^=2DA  "FY]'5T2LX/DKZ5ZY]'7T2LX/DKZ02
M     8?;#]&,T_<5?<P_<S_,]?\ )_2S&V'Z,9I^XJ^YA^YG^9Z_Y/Z0;@
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M?C-(MXB-^?)%-78[TU5+.%]->G,,\+=%VFJ.757$Q+O%HEQVV>@-(
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M]HJ#X<Y9_P";[$=JJG;?+)Y:YICUQ$?BF>!^0_J^CVZ^U;N[$;.W?GY91/\
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MF([F?YGK_D_I9C:_]&,S_<5?<P_<S_,]?\G](-O                  T
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M5-41515N3$Z>2FGM;#$TS'*]./)%Z[O-DI-+3654>LU>1IY'L3ZV]V B=04
M                                             (CE
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MS5\VY3/15"NFNB>2J.MN+UGVQ-9A<%,3'G51,+N@$R\U4>A
M                                              !/$*;E=-NB:JIB
M(CCF9:[C=LLJPN(FQ7<WZHG29HKHF(^TW&R:FL<?J1L#C+&,L1>P]RBNW,1Q
MQ5$Z<6NG$Q.8;5Y9@,1%F[=BJJ=..FNG2/M!G]1"P^8X7$8.,3;NT3:F(F9B
MJ.+7D\K$87;+*L3CIPMJ]3%<>6:Z-)X]-(X^4&R"S-ZF*.^5U4Q;\E4SQ1TK
M>7XZUCJ*ZK,ZQ17-$\<<L='2"4$<8!KQZ##4[1Y=5C^!TXBWW^(B=-^GR_QU
M\K,4U1,:QY0>FL*+UR+5NJNJ?DQ&K1,N[H^"QV>XG+;=B_%=BJF)JFFG2=Z-
M><F_H_MOPTS(MN\)FVTE_*+-B_3<LU7*9KJIIW=:9TY8J_!N,>6(5(G=5J/*
M?+J\UF>@54/(G2./E8O.LSN9?;BJUA[M^9F(TMT;W+J#*B/@[TWK$5S351,Z
M\54:2OZ\4^H'HIB?++V?).H/0  @        !&Q7SJ4E&Q7SJ4D  %-SZ.OH
ME9P?)7TKUSZ.OHE9P?)7T@D            #6]L\YNY7@Z:</IWRY731K,3Q
M1.L>28XV(IRK%T95.9_E7,9O[LUS;G$S-O6)TY/BD3N-[&O[-9K=Q.6UU8K3
M?M3%&L:\?%R\<L-A+N,VGNW+M.*OX;#TT[U'![LVYFJ.+2>7B4;R-4R#,L18
MS"K+\5<FYNU31%=<S55.[$\<SKZFUQR   P^V'Z,9G^XJ^YB.YI^9Z_Y/Z67
MVPC79C,_W%7W,1W-(TR:O^3^D&W@                               $
M ")B<!A\1QWK453Z]4?\C8*.6Q3]O:R8YSBK,[S#47M'$L=3E&#IG7O-/VIM
MJW1;HW:(B(7#1:XZUX@FTVYE3'%R0J\D@WLR\\G(\W50FT"G=B5-5FBKEC5<
M$FD2N\H5S+\-7\ZW3/6B7LBP5R)UL4\?3VLQI'F&)PUGTU&2T>VK7]D<#<F9
M[U3$]$]K&XC8>Q.LV]*9_8GM;WH:.<Z6DNM=3DCVYG=V(Q-&O><3-/1:^*)<
MV>SFQ]'B;E41YK4=KJTTQ/DA3-JB>6F.IRG1QZ=(UEO;DVYM%AOF47[FGFIB
M%RG/<[PTZWK5[3US$?@ZG.'MS_X='5"/7EN$NQI7A[4]-$=C'Q+QQ+?RZS]J
MN>6MM\1:G_&MU>O6N.QD,/M[:F=*[4=/??@VJYD&6UQ,58/#S_TJ>Q O[(9;
M=F?\&*.+_)33'_:G:S5]KW<%N:H^&VSP5SY]5%'37\&0L[2Y=<CCQ-OK^#"7
M]@L#5,S;O8JF?573'_:@7MA+E$SP?$7]/)O78[#KS53HP6XG9O%K-<+=^CO4
M3T2E47:*Z=8JB7,+FR^>V)F;.)F*?W\ZHUW#Y_@IX\7>G3R=_JE8U5Z\P?%I
M;BSK<5QYWNL.16]H<[PL_*F*OVIKG\4FUMQF]$_XEC#;O[%>O]3<:R/<,3H[
M>IW=5B8'.L-M],<6)MTQ/^FW5_<REC;K 5S$3WV)G_R_BZ1JZ3[8G2Y(]-Q&
M!PVTF$Q&FY55&OGC3\60M9C9N<E<.D9Z3[<YPWCF$X6:<115R50KBN)CBETB
M\2Y[3"L>;T:<I$\36Z/0>3Q1(/1Y'&\JG=CEXC?85"S:OT7*YBFK68XE[EA(
MF)X68F.0>1_%ZJ                                        -9[H.,
MO8+9^[<P\S%4S-,S'FW*NQH/<_R?*,^R*YB,91:NXNNC6JN9G6F=ZJ(GBGS1
M#K.9X*SC\)78Q-$56ZM8G6(GR3'EZ7(]KMD<IV4PV(S+ YUGMBN:9JIPUG$T
MQ:F:8CBW*:8XN/S^5SXE?3&]S_:;$8"G.<'-R:[5G'WK=''$:4Q$1$<GJ9/8
MG(,/M#L_BL=F=N+M^Y153175$ZTS$S&O%,:L/L7LIB+6RV/Q]<U57,3C)O4U
M55:SNU4TSQ\6K:>Y5F%JUL9B.^3I59IN5S$_M2U'#/MJV0YEF$8+:C)[%5<\
M&Q5-FS$:?-IJ\D=$>=K677,+5>PEO#333F=.,B;FDZU33O>;IT;WW*,-.-VO
MVDQ5VW359KQ]=5,3'%,3%7DENFT&4Y'E=J;^'RS!48RY.[173AZ(G>F)F)UB
M->6(68VF$K.\2@YAF>*Q>%PF2X::N_WMZF]7&DS;T^5&L>OI;CD>76\NP5-N
MB(BJ=*JIY-:M(B9^QR_:V[BMG-C,7F]&DYG?HIF*IF9BB8KB.*8TF.*?.UO*
MLUS7([^&QDYOF&,C$44W*K6)Q-=RFF:_)$:QI$:<1$[SLL^(W?0O(A9MBXP>
M"N7IGYNGE]>B]8N3=L[TSIKYF@]T[,<9<POY-RBNW.-NTQ-,7*IB/DU1,ZS$
M^:)9O^-5\N2YG1C<OVBP6=555TVKM^U:F)B/),3/'_#S/HK9W&1CLHPV)IGB
MKIUY=?++B&UV1=T&_D,TX_+MFK>&PTU7XJL37%>L4SYY\VK<.X[GMS%[(3AL
M17'"\+%-%41,Z:S,SQ:RW'UV9GG=G-J=M\+@+M6#P^$C,+LTZS13=W9CCF)\
MD\FGVN3[%8C#X[NE8Z:<)&'IKNV=ZWO[VGR?.V'N;UV,?M!F%69TQ<NTUWJ:
M>^1%7R8F-.7^+%95.&PG=>QM-,4VZ:K]G2*(B(^9#-8\P6G_ !F(2<IQV%R3
MNGX[O5JF9JKQ$][BK37Y<\?E=%V6V[L9YB*L/=PT82_3&]5;JN[TQ&NGFCSM
M&R2QAL3W5,957;MW-)Q/SZ8G_-*Q@J*;.UV9<'F+>[AJ9C<XI\GF6)\RD1XA
MO^>;>VL!BKN'R_!?E&Y:JFBNFW>W9IF)TT^;*[D6WN7YEA;URN*,->MQ5,VI
MN;T\41Y='&MC=F<-M3M7GD8_.L[P=V,97$1A<5%N)XJIGEIGS-_P'<JRK)L-
MB9PF;YS?OW**XCA&*HJC68]5$>9(^N[4\[,U9[H47*[U5>633AZ-)HO3?XJX
M\L_-2<Z[H.591;PW?KEJ;V(MT7HMS<TG2K7U>IR^]F&>;$W[=C-<#E.*R6N=
M(KKIJO7MV..?+$:ZU>9([J-> S'*<KS'"V+=%5RS8W?\.*=*9WITCS1QF_C=
M(B=]G7<=M-A<'D_Y0O33%-6]%-,UZ;TQY-=/4U6CNH6Z,1$8W*9PV$JUF,17
MB-:9CR3IN^7BZVH[8XBY;L9);NUU<$G%Z54TS.DQI.NL<C8ML<!EF([GUNY1
M:MQ5WFSNU4T4Q5'RJ?4L$,]G7=)R7*YP\3?LW:KU5-$1WS=Y?X(-_NF6;.-P
MMJ]E^F&OS,4XB;_%I'ETW?6Y->R^*L+E=S&445SPZBF)KB)G3^+;NZIAL-AM
MC,NN8>W1;N=ZNS%5-,1,?*HY)@B?([;AKU-^Q1<HTW:Z8JCHF%QA=DJYKR#!
M3-4U?X5'',Z_Y89I2  4       !&Q7SJ4E&Q7SJ4D(  4W/HZNB5G!\E?2O
M7/HZ^B5G!<E?2"0           # [7Y=;Q^5U4UU4T335%5,U3.FL:Z0T;"Y
MOC<);IR['V[D87YL79IB*=)XYX_XMD[H&)Q%BWAYMU54X?OMO?F*M/+.O%T+
M^,HRS&;.57=VW5$6ZIBN;?'R]"5%./KMX?9:F[@:Z9WN]S,Q.O+"GN;TTQD-
MNJF=8JFN-(\GREC9G#5XG*<58K^79[Y$VXJX_DQ'%Q>13L%BJ,OP4X+%SN7;
M=-54QI,\LZ^3B6$0LTNU6]ML-31$Q&]=U]?%+HEG7O5.OFAHF#P_Y3VMG$1Q
MVK5RY&O3$^=OE$:4Q'FC05ZQ6TM['6,LFO*Z*J\1OQ&E-.].G'KQ,J Y5M-F
M>U%60XZ+N%OTT3:JBO6Q$<6G0V'N4U5U[/Q-V)BYNV]Z)CR[K.;81$[,9I^X
MJ^YA^YE&F3U_R?T@W
M           #5Y/'Y'I,:PFPIW8TT4][B8TF%>[ZWL1ZTFL&\H]>&HKCY4:_
MQ1+^3X6_&E=$S_-+)C,XJSS#<9+1Q+7;FR>75:_X,^W5VL=BMA\'7KWJF*9]
M==3<S1SG38Y].D:G)'MSF[L'QSNUT:>;6I$JV,QEB=;-=$?RS+J&[#R:(GR.
M<Z2OIN-7;VY=^3,]PFO>JXF/5:U_ C';26)^5;N51'FLQV.GS9HGEICJ43A;
M,\MNB?Y88G26]2Z1JX]U<YM[49G8G_'PF(XO_+IA(M[=54SI>L7J>F*8;M>R
MK"7-=ZQ:GIHA"N[-Y?<UF<+8G_I4L]G+'$KWL5N88.SMWA)G2O6.F:60PVUV
M NZ?XM-/35"B_L;@+D3I9MT>N+=+&W=@K,US-O%7:(\U-,0F^>J[:>S9+6T&
M7U\?"K7F^=#%[4;1V<-@JN#W::JJHG3=F)\S6\9L9B\/3579Q-^J*>/YT1^+
M4,TF_9Q%=F_<KJW)T^55J\NHUF3'7:T/3I='BRVWK+,[-9Y<L9S<NW*M:;DU
M3Q1'EEV##WHNT153,:2^>;5=5%>]3\F?4W'+-LL7A+<4U6XN>NJN?.YZ+7[>
M+.VM_CYGS2'6X\KUH."V_L51IBHIM]$53^#-X/:[*\55%-O$3-4^3O=78^O7
M54L^/;39*<PV,1K.-LW:8FBK6.B5VF[3+M&2L^W*:S',+@\BK6.-['&UNR#R
M-?,3.BCT>15$O=0                                1<SL7L1A*[>'N
M4V[DQ,;U4:QR2T;"]SV;V8V\5G-ZUB9MU15'>YJHZ>3^#H8FPCTX6W&'IP^[
M/>Z:8B(UY(CB<]S+N;W+F,KJP&)L6<-<B*;E%6],S3Y>-TIYIQSQ\IL,-LSD
M6'R/ TX?#Q&]--._,53,3,1IY5.-R&WB\RIQ5V:9BG=TC68GB9N(TA[HJ1&S
M#;2Y#A\\R2]EU^-;5R(CYTQ_FB?)T-*R+N81@\?W_'W[-^W3$TT4T35$Q'DA
MT[02(V\K/F-EGO6EFJW1Q3IQ3+F^([G>87=J*\XX?AM[OERJW3NSK$5:\7)I
MY73IAY$<>NIMYW/Z8K/LNNYEE=W#6;E-%5RFJB9JCBTF)C\7/]F^YCC<BS:<
M9AL?A8BNK>N1I5,S.[,1R]+JQ,:P1&TGK9S;-^YM.)Q\8W W[-G$;D4555[T
MZ\<S/%_%#L=R6Q&:UYA>N6JL5O15%<55Q&L1IR<CJHJ;.59=W,,7@L\O9C1C
M</O5S7I&E6L15*K ]S/&8?/XS*<=AJIF:-^(BK68IF)T^QU,B-!7,L[[F,W\
MWC,LJOV<-B)FJNN;DU5:U5>73D\LLW@MD*Z<'-.,NV[F(XXWZ=8C33S-R-$V
M\;)MYW<XQ/<_Q6,Q-%&)Q=BK+M?E68BJ*II\VJWM;W-*LYHPMG"XBS9PV'M4
M6J:*]Z9^3,Z<?1,.EZ!$;>%W:/5L-&)V>C+LPNV[M5&]-%5,U4Q$S,\?$Q."
M[FV(MUTVL5B\/<P5,:1:IBJ)TCDX^ITXT4<UVI[FU>;XG#58;$6;5NQ537$5
M[TSK&J-M!W-,=G&7X3"WL?AMRQ353QTU1RZ>;H=3(CCE(@8;9;*KV3Y;1A;U
MVBYN\F['DTB/P9F.(T%(          1L5\ZE)1L5\ZE)"  %-SZ.KHE9P?)7
MTKUSZ.KHE9P?)7T@D            CXS"VL5:FW?IWJ)\C"6]D,KHO=\BF]O
M:ZS'?9TZFQFA L8?#6[%F+=JG2BF(B/X,?F6S^!S&NFO$T5[T3$ZT5S3]S+G
MD!%P& L8&W%O#TZ4QI''.LI1H   Q&U_Z,9G^XJ^YA^YG^9Z_P"3^EE]L/T8
MS/\ <5?<Q'<S_,]?\G](-O
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MVF)MUQ,+]-RFKDEUB\3PY368Y5!K V@
M                                "-B_G4I*-BOG4I(0  IN?1U=$K.#
MY*^E>N?1U=$K.#Y*^D$@                   &'VP_1C,_W%7W,1W,_P S
MU_R?TLOMA^C&9_N*ON8CN:?F>O\ D_I!MX
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M+ZO)Y5BSBK5V/D7*:NA>WHU=HO$\.<Q,<J@B=1=T %
M                                $;%?.I24;%?.I20  4W/HZNB5G!\
ME?2O7/HZNB5G!\E?2"0                   ##[8?HQF?[BK[F([F?YGK_
M )/Z67VO_1C,_P!Q5]S$=S3\SU_R?T@V\
M
M#2/, #R:8GR+==BW5\ZBF>F%T3:%B9CA"O9;A;L:5X>U5TT1+&8K9G+KT3_P
MF'B9\L6:=?N; 1Y7*V"DMUS7KQ+1,9L)AZYFJS>N6Y\U$4PQ5_8[,K&LX6]?
MJZ;L1^+I\]!NQ/*XSHZSP[5U=X<CKPNT. GY5V_$1_\ R?BN6MK<RP<Z7([Y
M/^NY5/XNJS:IGEB)A'OY=8NTS%5N-)XI<_BWK]9=?EUMXM#1L'M]$Q$8JBBW
M/ETWI9S![99=?TB+TZ_L5=B5?V7R^]KK9GVI8;%[#X>J9G#Z4SZZJDVST(^/
M9M&'S*QB*8JMUS,3ZI2[=VFN.*7-,3LAC+$S-BY\J/-O3^"/N9]@(THWJHCS
M69G\"-3DK]H/C4M]9=7UT>N5V=JLVPU7_$6+\Q^YT9+";<1K$8BW<IG_ %13
M#I765GTYSH[QPZ#,O8:SAMJ\#=TUNT1TUT]K*8?.,)=^;B+6O[RGM=JYZ3Q+
MC;!>O,,EH>=9HQ-JOYM=,]$PN;T3R2ZQ>)<YK,*B.3C8S.<SM9;AIN7*HCCC
MBUB/+ZV,V:VCM9MK$3I7&L\<QYXCR.<YJQ;I;KAM->ILP1)+LY@
M                              (V*^=2DHV*Y:4D  %-SZ.OHE9P?)7T
MKUSZ.OHE9P?)7T@D                    Q&U_Z,9G^XJ^YA^YI^9Z_P"3
M^EE]K_T8S/\ <5?<Q'<T_,]?\G](-O
M
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MA5#<2R]#R"@                               "-B_G4I*-BOG4I(0
MIN?1U]$K.#Y*^E>N?1U=$K.#Y*^D$@                   &'VP_1C,_W%
M7W,1W,_S/7_)_2R^V'Z,9G^XJ^YB.YG^9Z_Y/Z0;>
M
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MC8KYU*2$  *;GT=71*S@^2OI7KGT=?1*S@N2OI!(       B=>0
M   &(VO_ $8S/]Q5]S#]S/\ ,]?\G]++[8?HQF?[BK[F([F?YGK_ )/Z0;>
M
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M]S$=S2-,GK]>Y_2#;@
M
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M_P#@XC6-//NML[DTW)V<HF]KWS<M[VL:<>[&H0W8
M
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MQ5]S$=S/\SU_R?TLOM?^C&9_N*ON8CN9_F>O^3^D&W@
M
M
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MJ:8FFY$^3ECM(17D^46LOHB(F*[GEKW=)Y9];*Q&BU9KBY1%=/)*['($  H
M      #$;7_HQF?[BK[F'[FGYGK_ )/Z67VP_1C,_P!Q5]S$=S/\SU_R?T@V
M\
M
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MEE]L/T8S/]Q5]S$=S/\ ,]?\G](-O
M
M
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M/\SU_P G](-O
M
M                                           !&Q?SJ4E&Q7SJ4D
M%-SZ.OHE9P7)7TKUSZ.KHE9P?)7T@D    ,!A,@HPV8XG%=\KUNVYHTFOBY=
M?-ZF?6<7KP:YNQK.[/W)(T;&[(V<;C[]<XJJ)JF-=+VFG%T,;X+8.;T6Z<75
M-=,\G?\ S3T*\US.C+XQF[=BK&U:;E'),3'+ZN25G#Y;1@\!P_%WXC%W+D3&
MM.GR:HB?/IRZK5)=-PEOO5FBB..*>U?1<MKJKP=NJN-)G7[Y2@@ %
M 8?;#]&,S_<5?<Q'<S_,]?\ )_2R^V'Z,9G^XJ^YB.YI^9Z_Y/Z0;>
M
M
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M++[7_HQF?[BK[F([F?YGN?R?T@V\
M
M                                                           $
M;%?.I24;%?.I20  4W/HZ^B5G!\E?2O7/HZNB5G!\E?2"0    IN5Q11555.
ME-,:RJ:+G6V%6&Q-["<&Q-?R=-:+43R_Q3<1]IMK<OHQ-RQ."M8FJB=-:XF/
M-ZF+P>V>%L3$83*L/:KF>6FJ8_!:R[:2<'B[MW\GXNK>TY;$3Y_6GW=LZ;M,
M458#$41-4<=6'B/Q:K&QRZ+@KDW</35/+/+UKVG'KJBY=5%>&HF(F.GI2TE(
MX !0       &'VO_ $8S/]Q5]S$=S/\ ,]S^3^EF-K_T8S/]Q5]S#]S/\SU_
MR?T@V\
M
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M&U^+PT[-9G'?[,_X%6D17''Q,=W,N/)JYC32=R8T_9!N
M
M
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M6?[E-KO&S\6X_P M-NGJI9O;"/\ X9S33E[Q5]S$=S+\SW-?]'](0W
M
M
M                          $;%?.I24;%?.I20  4W/HZNB5G!_Y^E>N?
M1U=$K.#Y*^D$@   !353O4Z<7'RJA!@<XV<P^/IJTUBJ>76J8C_WQ,%B<NS7
M++$6[$4W+>]$_(IJJGS>;U-[>54Q5&E4:PL"Q@:JJL-1OQ,5<>L3&GE2'D1$
M<CT(  (]8 &@ &@   ,1M?Q;,9G^XJ^YA^YI^9Z_Y/Z68VO_ $8S/]Q5]S#]
MS3\SU_R?T@V\
M
M                                           $;%?.I24;%?.I20
M4W/HZNB5G!\E?2O7?HJ^B5C!<E?2"2        <@           P^U_Z,9G^
MXJ^YB.YG^9Z_Y/Z67VP_1C,_W%7W,1W-/S/7_)_2#;P
M
M
M              1L5\ZE)1L5\ZE)  !3<^CKZ)6<'R5]*]<^CKZ)6<'R5]()
M                    ,/MA^C&9_N*ON8CN9_F>O^3^EE]L/T8S/]Q5]S$=
MS/\ ,]?\G](-O
M
M                                            !&Q7SJ4E&Q7SJ4D(
M  4W/HZNB5G!\E?2O7/HZNB5G!\E?2"0                   ##[8?HQF?
M[BK[F([F?YGK_D_I9C:_]&,S_<5?<P_<S_,]?\G](-O
M
M
M              !&Q7SJ4E&Q7SJ4D(  4W/HZNB5G!\E?2O7?HZ^B5G!<E?2
M"0                   #$;7_HQF?[BK[F'[F?YGK_D_I9C:_\ 1C-/W%7W
M,/W,_P SU_R?T@V\
M
M                                               $;%?.I24;%?.I
M20  4W/HZNB5G!\E?2O7/HZNB5G!\E?2"0                   ##[8?HQ
MF?[BK[F([F?YGK_D_I9?;#]&,S_<5?<Q'<S_ #/7_)_2#;P
M
M
M                  1L7RTI*-B^6E)  !3<^CJZ)6<'R5]*]<^CJZ)6<'R5
M]()             @9IF' K?R*(N7I^;1KIKKZVNXG:K'X*[3&8Y3%BU,\5R
M;T3T\40@W&/*(>78^WC<'1B+6DTU4Q5Q>N-6#Q6TURJ_5;RS"QB]R(JJ^7NZ
M1Y^.%&T##Y+G5.83-%RB+5^GBJHUUTG3CCD9@  &'VP_1C,_W%7W,/W,_P S
MW/Y/Z68VP_1C,_W%7W,1W,_S/7_)_2#;P
M
M
M    1L5\ZE)1L7\ZE)"  %-SZ.OHE9P?)7TKUSZ.OHE9P?)7T@D
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M;8R''WJ*:-ZW:JJCCKXN+]IL/<HLQA]GJ;,<E%-NF/X4@W4
M
M
M                  $;%?.I24;%?.I20  4W/HZNB5G!\E?2O7/HZ^B5G!\
ME?2"0           #5]LL!F^86N\Y75-NB8C6JF[N3KQZ_@TJUL=M?:M[MO-
M,71'^G%S'XNNB1X&M[(9/BLOP-=&9WJ[]ZO2:IN5;_'IQ\?2BWLDS' 8NNK*
M-)LUQ%.YO[D4^>8B&W"ILP&1Y+5A;U6)Q<[V(KG>G72=)F)UTG^+/@*  Q&U
MVO@OFGGX/7]S$=S2-,FJX^9_2R^U_P"C&9_N*ON8?N9_F>O^3^D&W@
M
M
M                         C8KEI24;%?.I20  4W/HZ^B5G!<E?2O7/HZ
MNB5G!_Y^D$@                   &'VP_1C,_W%7W,1W-/S/7_ "?TLQM?
M^C&:?N*ON8?N:?F>O^3^D&W@
M
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M<S_,]?\ )_2R^V'Z,9G^XJ^YB.YG^9Z_Y/Z0;>
M
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M7W,1W,_S/7_)_2#;P
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M'VP_1C,_W%7W,1W,_P SU_R?TLOMA^C&9_N*ON8CN9_F>O\ D_I!MX
M
M
M                         (V*^=2DHV*^=2DA  "FY]'7T2LX+DKZ5ZY]
M'5T2LX/DKZ02                    8?;#]&,S_<5?<Q'<S_,]?\G]+,;7
M_HQF?[BK[F'[F?YGK_D_I!MX
M
M                                         #S7C(TB-.1!S;-,#E&%
MG$9GC+.%P],3,UW:MV(CI_C"3.PGD<;"8+:G),;@ZL5@\UPE[#TU;LW*+D33
M$Z:Z:_Q7,HVBRC.*JHRK,<-BIHTWN]5Q5IKR?<J,N,%FVUV0Y/?BSFF;8/"W
M9B9BF[=BF>*=$#QB[(\OA#EOOX2)W5MCRJ=(XVNY=MMLYF.)HP^!SK W[]>N
M[11>B9G2)F>+HB6<OWJ+5J;E=<4TQ&N]/)HL^!YB\7:PF'N7K\Z441K*-E&<
MX3-:;M6$FN8MU[D[T:<;BO=EVGQF:9=BL+E544X&W1,55Q3%<78F*>2=.+28
MEOG<>RRK ;(X.NJ)WK]JU=F9C3EMTI7R6\-]WO-IHQ>+V@P6%S*U@;E54XBY
M$S3$1K'%RL3MEM+1E>%KP^%FFYC;D31333,:T533\F=/+QZ.2=SK#8S/>Z/B
ML;F%4S7AK]RBKY&FDS;J\R5MO.Q/B-WT-%6M,3'E>J+=/R8B?(K:(1L7\ZE)
M1L9RT_P20  4W/HZNB5G!\E?2O7/HZNB5G!\E?2"0                //\
MWE>@  P^U_Z,9G^XJ^YB.YG^9Z_Y/Z67VP_1C,_W%7W,1W-/S/7_ "?T@V\
M
M
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MX_W'Q/&9DOU./]Q\0;P-&\9F2Z?0X_W'Q([IN3>6SC_<?$&\C1O&;DOU./\
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M?:J[64 8OP?RST2GVJNT\'\L]$I]JKM90!B_!_+/1*?:J[3P?RST2GVJNUE
M&+\'\L]$I]JKM/!_+/1*?:J[64 8OP?RST2GVJNT\'\L]$I]JKM90!B_!_+/
M1*?:J[3P?RST2GVJNUE &+\'\L]$I]JKM/!_+/1*?:J[64 8OP?RST2GVJNT
M\'\L]$I]JKM90!B_!_+/1*?:J[3P?RST2GVJNUE &+\'\L]$I]JKM/!_+/1*
M?:J[64 8OP?RST2GVJNT\'\L]$I]JKM90!B_!_+/1*?:J[3P?RST2GVJNUE
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MD1&LSH#&_D#+/1*?:J[3P?RST2GVJNUE &+\'\L]$I]JKM/!_+/1*?:J[64
M8OP?RST2GVJNT\'\L]$I]JKM90!B_!_+/1*?:J[3P?RST2GVJNUE &+\'\L]
M$I]JKM/!_+/1*?:J[64 8OP?RST2GVJNT\'\L]$I]JKM90!B_!_+/1*?:J[3
MP?RST2GVJNUE &+\'\L]$I]JKM/!_+/1*?:J[64 8OP?RST2GVJNT\'\L]$I
M]JKM90!B_!_+/1*?:J[3P?RST2GVJNUE &+\'\L]$I]JKM/!_+/1*?:J[64
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M*XKXHB>.-?/T@B;$<>S&#X]8^7_74SB+EN"MY?@;>%LS\BC72=-.69G\4H
M  $;%?.I24;%_.I20@ !3<^CJZ)6<'R5]*]<^CJZ)6<'R5]()
M        &H MW[]NQ1OW:MVGSZ3*WAL;A\3,Q8N;TQQ?-F/O!(")UY
M                            /(B8C,L)AZXHO7=VJ?)NS/X EBFBY373
M%5,ZQ/'"H                                   8K-L[PN6Z1>N1%<\
MD335^$*LGS:WF5$U6]-(C7BU\^GE!DP
M    !;OWK=BC?NU;M/GTU6<+F.%Q54TX>[OS$:_-F/O@$H-8
M                     !8OXNQ8^EKW?X3*]35353$Q/%(/18Q.+L86(F_7
MNQ/JF?N4X;'X;$_07-[^68^\$D   $;%?.I24;%?.I20  4W/HZNB5G!\E?2
MO7/HZ^B5G!\E?2"0                  \F8XY\SU1<X[=?\4D:9FF+G-<^
MC+Z:IW*9IFJ:>+BF(1\\P\[/7K6*M5U]ZIIG?WJM>.>+U>='V8U\+\5WWY^Y
M1R_P3>ZM/_P_=TG2=*?ZX7B&8\RW/"7:;^'HN43Q3$+S%;.3/Y+LS/F96!8
M!0                             %K$Q55:JBCYT\C YED]B[A+M6-O3;
MKGCB8KBGR^N&QSR3IRM.VNR3-<?;N5X;,ZXHCDL19B>68XM=4#N?W,55:Q=&
M(BKO=%^NFB9B>.(BG3E;BTK8#-[F(HO8'$6IMWK-57'-6LU1&[&NFGG;JTD
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M-7GB8\WK6J2W;*<5&+P%F]3,?*IB93&+V;L]XRC#4;N[.Y$,HLD "*
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M^NVJ;MNJBN-8F-%&'PMJQ]'3I_%(#"V:;%BBW3$1%,1R0NQ][WH%(
M                         0LXQLY?@;F(BG>W(F9C37DB9_!@,!MGA,53
M--5JY%SBXN]SI][:KE,5T335QQ/$C4Y=AHJFJ*)UG_5*#7=D,MN6\;BL;=II
MIWZJXIBGS3,3JVUY33%,:1Y.)ZJ0 "@
M&C#;3913FN!JM\45Q$[L\6L:Z=C,@-&PEW-<%A^ [ENJBG2FFN:YUTB-&=V;
MR?\ )]N:Z])N51I,\7G9P$V @%                              #SAR
MST U[/,YR^U5-C%8:+]<3INUVHJIXI8G+LHC,<=%^K"X>S9ITJBFBB(XXF/)
MHV^O!V:[G?*J9FKSZRD1$1&D$"FW1%NBFFF(B(C14
M            #R9TU]4/2 <U[IV9V;E-O#4TW)N4;T?-XN6EMNS686L1E=&Y
MO_)CCUC3DB&2O9?8NUU57*)F:IUY97;&&M6:9IMTZ1TD>(V)<_VPVTX'B:<-
MA[=R:8UWIW9UXXB?)/K0,O[H-$[F'L8/=KJTWJN]S$S/EF9U=*N9=AKE<U54
M3-4_ZI>4Y;A::HF*)UC_ %21X28599<JNX2BNOYTS/+TI1$:1I *  C8KYU*
M2C8KYU*2$  *;GT=71*S@^2OI7KGT=71*S@^2OI!(
M                                     (\H
M     $  /./CY-36=9Y >CR)TXIY?*]     B8F#7J'GX ]'GJ>_>@!QZ>L4
M       @CD
M                  !&Q7SJ4E&Q7SJ4D(  4W/HZNB5G!\E?2O7/HZ^B5G!
M<E?2"0
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M*+DQ&_373Q^7BB5_8W%3B\FLU53,S&]Q^?Y51 SP H
M                                               "-BOG4I*-BOG4
MI(  *;GT=71*S@^2OI7KGT=?1*S@^2OI!(
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MB\XQ^]B8FBQ1R1%6L3I/FGI;;9MT6;<6[=,4T1R1$:0"L 4
M                                                    !&Q7SJ4E
M&Q7SJ4D  %-SZ.KHE9P?)7TKUSZ.KHE9P?)7T@D
M
M           1ZWDP]@ B(CDC0        F  B(CS
M                                                  C8KYU*2C8K
MYU*2$  *;GT=?1*S@^2OI7KGT=71*S@^2OI!(
M
M
M                              !&Q7SJ4E&Q7SJ4D(  4W/HZNB5G!\E
M?2O7/HZ^B5G!\E?2"0
M
M
M           "-BOG4I*-BOG4I(  *;GT=71*S@^2OI7KGT=?1*S@N2OI!(
M
M
M                                                   !&Q7SJ4E&
MQ7SJ4D  %-SZ.OHE9P7)7TKUSZ.KHE9P?)7T@D
M
M
M                                C8KYU*2C8KYU*2$  *;GT=?1*S@^
M2OI7KGT=71*S@^2OI!(
M
M
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MX52<*I!($?A5)PJD$@1^%4^;[2,53Y@W2!'X53ZCA5/J$W2!'X53ZCA5(;I
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.J >113')3'4]   '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g942297g15r06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15r06.jpg
M_]C_X  02D9)1@ ! 0$ ;P!O  #_[1KH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &LL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M !H! 0$! 0$! 0             ! @,$!0;_Q  J$0$  @ %! ,  @,! 0$
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M06A>$7J-I_H\9],G_NOGX\OT>[P*F('6_P#_ ,DZ%UDA9"9"T!NJ;LWX=)3
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M?0HDL/\ :5>O\\S[W();1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$#"(B B(@(B("(B B(@(B("(B!A,#J1$# Z
M@J;(Z@JH@ILCJ'U*FPWJ'U+TB)D\[#?BCZDYMOQ1]2](F9D^9A:?T1]2\>#L
M^*WZ@ONBN<ITPMS31GBQI^@+R**']5'ZH5TB=4G1"T=0PNXPQG_2%\_%M/\
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MLAXSE!>(K:IKZ2FQX14Q19W#;<!E>H*RFGC+X)XY& 9):X$ (/NAQTJR;=:
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MCY]#3O<3'>:R/?\ H@C_ )6Z4]PHZK=3U,,IX>:X%>9+C112<W)50L?G&"X
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M7J:LC@BH[W00Q0OVV-<PG'_R]:S#>36OJM.TM'=ZVDJ:VG+GLE;M-:'Y=LG
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M(B*(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M/^%(Q(! )WE1MR=4SZNYU]Q:#S$LXFC<#N<UVT0<<>!"D&XPOFHIHXBX/<W
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MZU]/XWI^6_RD_P#Z2^3][LNZUZ!7E^YYRO07I?'5RJ$[D5>C<@9W)G"(JO\
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M^1-]LSO71CZ>)@W@#.[@@@9LX#03T[DW4KVG#<Y#0FH#PHF^V9WJHT)J#./
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M11-!<3S9=N''@"L59-6:<O<LD=KK!,^,M#AS#VX)SCBT=13=2=IP^4(^0FH
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M^%LKK=<V.?0R"5K7;)][+=_'I':K'RI.TX?* FZ#O[>-$SVS.]?.30=_:"?
MF^V9WKH\4["/@CZ@O%0R""%TDX#6-XG9RFZD[3A\N<?(34!('@;<G]LSO7HZ
M$O\ C\R;N_;,[UT)03T%<V1U(\/$;MEWF$8/TA73:5ASEH^H)NI3M.'RYO&A
M-0#_ *)OMF=Z#0=_SGP-OMF=ZZ1\$C^*/J">"1_%'U!-S)VFCFTZ#O\ M ^!
MMQ_&9WJOD)?\C%&W'3[\SO72/@D?Q1]05?!8_BCZ@FYD[33ES;Y"7_)_H;?;
M,[UZ;H:_]-&WVS.]=(>"Q_%'U!/!8_BCZ@FYD[3AN</(:_?(V^V9WJ@T/?\
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M^2R74K*U_FD'[C?N5ZO);V^WAQE6!$19;$1$!$1 1$0$1$!$1 1$0$1$!$1
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MG '8HG%8[5FHFTPGD;#LN81&2!EN3P*D75$CH[1(X;G;3>GM4>\DL;'U<TI
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MS2RT3ZZZ2"J;*3'2N87,F?@88=V,'</I6@VFHK(-;4X;;8*"F=50AA@PT/\
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MRM,5*Z6EDC;3AWG.;$6[]W1CT+2N5/3<(T]+X%/)1[X_,IP& ^=QW?\ YN6
MCMKZK1-4X5]5$YLS6Y8XCXJSFUE$QFD"KY0M+4<;Y*BZ[#6'!]XE/3CH:LG9
MK[:-0P.-LJ_"8R<$\VYN_&?T@%#O)WINFJ;56MK975'])(VIFA_0WK66Y%R8
MKE70!YYL5DH'H#%K+PYPOKV^HT=JFGJ6R2.MS]N68R.\UI.T -D<=Y'0I/MU
M0VLHH*ECO,EC;(,=HS_RH^Y=86C1-QJ0<21LC#3T[Y6]/TK:- /=)I:VDN)/
M@L/$_P" )7TMO;91P3"#@BBF$PB(&$1$!$13,,)A$5!,(B!@)A$04PF%5$ #
M"81$#"81$#"81$#"81$S%,)LA51!39"KA$0,)A$3,,)A$0,)A$0,)A$0,)@(
MB9AA,(B9AA,(F],PPF$1 PF$1 PF$1 PF$1,PPF$1!\J@>85!U?_ &CTG^8F
M^]RG&H_)E0=</[1:7^/-][EVPI>'Y?TFJV?FL/[C?N5XK.U_FD'[C?N5XN=O
M;UX?\8$1%EL1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$ =2(B#3]?6V2LHG&. 2_!&R0,<3UJ/:B_U=/0245+11
MF<N#@P.QD?\ X%(/*#>JBV6]PIJ832>:0W:QQ)4:,BU+*_G6Z9!)X.VVY68:
MGTWSDQM5934TDU>V2-[IG.#'$$8+1VK?R3T!:;H&2O=3N;<(Y(G\X?-<_:W;
M(6YX727.KSQ!R,+1=9\GWE+6153;[7T+HFEH$!ZSGK6]XW\51N=^1A<\FG-]
MAY/JF'7,4;KS<)(V3R-,CG;]P=OXK8J)IT-<KA'5DN95SND;)+Q< 2,[L]:F
M9M#2,F,S*2 39)VQ& [/7G"^=9:;?7$.KJ"DJ'#@9H6O(]&0K"Y^,FD<GE#4
M3UM=<I:810SS">%PQ[XUVT0>OI"WNXP&KHY:=LCHN<;L\XSBWM"^E-!%31B*
M")D4;0&M:QH: !P  7U(6I9B$65_)/45E543C65\B$CBX,9(<-ST#SEKG)K8
MG6'75WIG7*JN!%7$SG*@Y.XNW\>G*G;=@X&_J42V YY2;UYH;BN9P]+E%2VO
MG-\ ^A?0KYS?DSZ%824!7/\ M=DQ\O@^]JGJ GFV* [JX1\K4[GG %="?YM4
MV0W6F#&@R-R/2N^)$Y0^=\6]:WOG/VRI.\A8>]6:.Z1[)>8W YVVM&>&%<MN
ME.03SC?YH+I38_*-W>E<8K,/;-Z3]L=8M/,M@\Z9]0[&-J0#/'*SDGFL5GXT
MI2,B5O\ -4?<Z8M(,C?YJY3+,6I$>)0_RHEPU*SS1^5BW_Z5)]QK[?;[0R:Z
M\R:?G-D<ZS:&U@GA@[\ J*N4NH9+J-CHW!S>=BW_ .E2JV>VUE$V*KCIZB(.
MV@V5@<,]>".U=;UGIAX_CXE=2WE@(.4W2\$>Q'7TT3?BLC>!_)JNZ+E*L57+
MS<-="XXSN:_N5X;3I,C/B6S'_P#@X_PKU#;],PNS#:;4P_&;2,!_\5QBLO=.
M+7EL[7%S<X6E:QK=3P28L=F\+;AN\3!F_)ST^A;)XSIL8$S1]:]>-:;ASK?Y
MJ325C%KRT[2^DZN:7PN^B7G02WFYL2#&-W2>DE9K6&FH[U;'0,W/\T#9:,X!
MSTK+BZ4Y.>='HWKT+G3@9VV@?2KTR1BUY0S)I[5]9&^TSVVHBM[SM&83M.,<
M/-VNG 4M:7L\5GM[88P"XX<X[(!!V0#P]"N1=Z8Y'.-S]*KXSIAQD:/K2*S"
M3BUG[8>_VJJNUQAADYQE"YA$C@01D$D;L[]^%?7JR15FGY;?&T#:B$>TUHR<
M8[E=>-*?]8TCZ54W.GQCG&C/3O3IE8Q:\H/\BM3-NE11-MLQMLDI9S_.-^ "
M<'9RIITM;3:K-1TI'G,A8QV0!O QT+[>-:;@)&GZU476GZ9&]G%.F35KRU+E
M+&H)J5L5CMSJO+9 X-E#.K'$CM3DSIKW2TCQ>;4*-[FQC)>'$G?G@?0ML\:4
MW2]G\U0W:F. )6[O2IT2:U>41\JVG=2W:]0S6>SND9!,Y[98Y&M+O@X.\CJ6
M7LMFU!=-)U%LOEN?3/%*^*-YD:]Q<X.'7QX*1C<Z?!]\;_-!=*? R]H^M6*S
MDDXM>4)4NF=96VEK+-34-6^@DB-.R?PAH\UP.2&[71DKZZ/Y-;U8C657/USY
MW1;HW2 !Q&\#(=TJ:#=:8G'.-R/2J.NE,,YE;_-.F?9J5Y012V/7%+JFNN<>
MG9)!4!C<F=G0!_BST*M1I[6U;J:2KJ+!(R&1T>??V$8 :#^EV*=V72FV=TC?
MYIXTICOYQN/I2*RLXM9^T37C2>H**L-RLUNDDJ7D-=$Q[6 - Z\]8"V"QU&K
M:R&07:TR4AV'$ 5 =EV=PX]2WD72GQ^5:?K3QE3@;WM]*168@U:^\T'^3NLV
M:LDKQ8Y71/C:S:,[<<6_XNQ25J[2S]2V%D51%S=0V828 :X[@X#>?2MF\:4_
M$RMP=W2GC2G^")&Y^E.F9C(U:^\T2V ZZLS/!&6.:>(9=MOJAG)[-I;;J[1\
MM_TN*&9\KIN?;)M$!SL 'K]*VTW*FS\-F55MRI^<_*MSCAO3IG(C%KG[0?%I
MW6]?1FV5E#60TY=SOA'A(<[(Z,;2VCD>T%7Z9C=)75%6SWQYYE[ALG( SN/8
MI%\:TP;ND;GZ5[\:4Q/Y1O\ -7IF$U:S]O=WI?"J%T7')!47Z!E?:;^:2H8&
M->^23)]&.CT*33=J79R9&X^E:=J2UTU54"LH:CF9FL# V)NSG><G/TJ12<UG
M%KE[8SE T?7U%4RY6&&22I9&&M9$6LVLN.3G(Z"OKI.;5\[FTUXM$E)$#L\Y
MX0'' ;N/'I(6YVNX-BI6LFEVG#&]Q)/!7GC*GR//:!UI%9A-6L_;2;Y1:@IH
MWS45'+7.;P@?* UV_&_)Z!O^A8G1.EKN+E)<KE;W6V5LKG-AC<TB3:!WG![5
M)9NE/^L:?K7GQK39SSS<#HWIT2NK7E&5]MVJ&25D,-I?<(YY'.9SLS3@;6X#
M)X*ZM&@)Y-/US*T215-6UCS%AIYH\2T;^ X*0VW.FSGG&N[=^Y>Q<Z<YQ(W^
M:36<LEC&K'VA^U6W6FG:V:EM]HGJZ-TFR)'5 ;AK<@8&UTA9C6%#JFX:?YNG
MM4DM1)"0^/GAYKCC=O/I4D>,Z?&=MH^M!=:8?WC=_I3IE(Q:\H+H;1KFFL53
M0MTX\BHB$;CX0W+< _XNU9GDZL>JJ)]3!=;3)3P2<VT/,S78 VLG /:%+7C6
MFR0V5I^M4%UI7;0$K?-X\4Z9R-6L?:*Z/2VH+;JRY5=)1S/IZF9I#^<:W(!.
M_CVK!:GTYK.MU=0UD-HGEIZ2L;,'<^W! +3TN[%.7C2FQ^5;_-/&=.<D2-[>
M*164U*S]H=U3I?4M?4VVX1VN2>=DXE?"Z1I#<$=)/3A?)^E-35-YH*^2TR0E
ME0R1\;9&[+ ".WL4S^-*?=Y[>P;T-TI_UC>WBKTS$YKJURRS1=REVC5%UIZ:
M.WVF2;9ER=F5HW8[2L:VS:Q;I*FMHL<G.1<YNY]N=Y<?C=JF072FW'G6D'TJ
MANM,UQS*W/5O4Z9-6O*.^2BUZAM5*R"\6Q]*&L<,ND:[)+\XW$]"^/*=IP7"
M^,GI97LF,T6VV, >:&XX_4MWU!>7LH\T#>=ER=S7$'@5K-ABJ*RH\,O,DD$C
MA^2>[; ((Q_()%9A)Q:\MUT]1-H;<R$#@3T8XE9"<.$+]C+G8. K*.YTP^"]
MN$%U@VB!(T_6EJS)&+2/M!%78-<>6<MZ9I^5X?3B'!G;CH_Q9Z%YO]BUW<[L
M:CR<D8W8#?-J&='^I3P;K3-9DRMQ]*KXVIL_E6_S4BDK.+6?M&>HM)7BJ'C"
MAI)(Z[='L1.:T[._?G*\6ZVZLOC^:OULFHX-_G<^).'#=E2@+M3!N>=;L]>]
M5\:4P..<;_-:RE-2O+W;:)E#3\U'N&<G QOQ_P"RUCE,IKM7V26GLU&ZID=L
M'#7AN\.W\2.A;&+I3\3(W^:KXUI1OYQ@^M9FLRL8E8^T,:1MVM[+;*F+R;<]
M[YS( Z=N\$ ?&[%7DIL6K[#?Y'W&R214<]1+.^1TS2&ES" , ]>%,IN]*-_/
M-Q]*&[4I'Y1N/I5BLP:M>4)ZYM6M[QJ6"LBL4K:>!CHP]E0W!&78/PNT+9KC
M9;_?]%5%)<+:^GJF,CBB8)&N+P"TDYSV%2+XTIBT@R-<#T'*"ZT^-TC<#HWI
M%9-6O+5N3RU7:@IXXKE!+ R(-8T%X(< W&=Q6Q:CM++M;:BG/FN>, @ GCE?
M<76F&??FGZ]RJVZ4X/Y1N_TI-9DU:\HC99M8V.KJ*>UV^IJJ.60^>:@-#6@G
M9P-KJ6VZ4T]6T,%5755.XU\VS+S3R#Y^_(SGM6X>-*;?[XW^:\^-:9I YUN3
MPXITR:M>4*ZMLNM:[4U/6TM@D=%3SO>PB=H!!(Q^EV+:=0^5U5H^"AI["7SS
M4SHY@)P#&2!V[^E2%XVICG$K=WI5/&]+G'/-_FD5F(R-6N?M%7)5;]7V.NDB
MN=EDBII71-=(^=IPT$Y. 3UJ8:B+GH7-VBPD$;E9&ZTQ.Z5O\UZ;=*?!]\:?
MK2:S*1BUS]HMOFD;Y'J[PZVT\\T3JACW.#VMW#&_CZ5B=9Z?UA6W.EEI+/-4
M-BG#R>?;P&.MW8IH%TI\$\XW^:"[4O1(S/3Q4Z)RR75KGGF@^_6G75QHZ.G;
MIR0-@DV\BH;O]/G+)#1=\N&GZ3PNW/I:Z NDV6N:27 G SGT*7A=:8D@2M]&
M]5%TIR3[XW^:N4FK7E%^F)-;T;FT-79)6TK-PF=4@G>[)W;71DJ4K7$^*F:V
M5[B_?G:.>E>/&5,1\-A[57QE3 ?#:KE.2:E>6+UK15]9;XFVWG>=;,'GFW[)
M(#3N._AG"C:^6;5%ZJ?!:C3C8Z;9#_"1(PNR/T>/:I<-VI@-\K?YJGC>FZ9&
MCZUGHEK6KR@G7&D-67&O#(+-+44W-M\XRLQD$]!<LE2V'5]MF;46^T2A[6[/
M-,F:P'/$[G*9?&E,3^4:?K5!=:4;N=:/K5K68AF<6L_:,M6QZSO%F?3-L+Q(
M2WX-0W.XYZUKM%:-=1V.>B?IZ4;<H?GPAN>C_%V*<#=:<\)&Y^E!=J8G\JW'
MTJ=$M1C5]9H.T]:=<VN@J86Z?D)DEV\FH:.@?XNQ7O)?8M76;48DN5EDBI)9
MI)7R.F:=G+#C<#UX4QFZTV?RK0/I7QN%VA%'(Z.0;0QC&1TK64LQB5Y:#RP3
MF[4/B&F)=45D32&M._+7[1X[OT2M\TE1F@L%MA<2'QTT37 ]88 M3L]HA\>L
MN5?5.FF8YYCCF;M9:X'@3P&];E%<Z7!#7L#6[CCH2*S$)JUF?;*HL;XVIOUK
M?YIXVIOUK?YJ=,M:M>6218WQM3?K6_S3QM3?K6_S3IDU:\LDBQOC:F_6M_FG
MC:F_6M_FG3)JUY9)%C?&U/\ K6_S3QM3?K6_S3IDU:\LCOZDR>I8[QM3?K6_
MS3QM3?K6_P TZ935KRR.3U)D]2QOC:F_6M_FJ^-:;]:W^:=,FK7ED<GJ0$]2
MQWC6F_6M_FGC:F_6M_FG3)JUY9)%C?&U-^M;_-/&U-^M;_-.F5U:\LCD]29/
M4L<+M3?K6_S5/&U-^M;_ #3IDU:\LED]2JL9XVIOUK?YJOC:F_6M_FG3)JUY
M9)%C?&U/^M;_ #3QM3?K6_S3IDU:\LEO3Z%C?&U/^M;_ #3QM3_K6_S3IDU:
M\LCDIE8[QM3?K6_S5/&M-^M;_-.F35KRR657Z%C/&U-^M;_-5\;4V/RK?YIT
MR:M>6218WQM3?K6_S3QM3?K6_P TZ9-6O+)(L;XVIOUK?YIXVIOUK?YITRFK
M7ED2<)M=BQOC:F_6M_FGC6F_6M_FG3)JUY9+:[%4<%C/&M-^M;_-5\;4WZUO
M\TZ975KRR2+&^-J;]:W^:IXVI_UK?YITR:M>62R>I,GJ6.\;4WZUO\T\;4WZ
MUO\ -.F4U:\LCD]29/4L=XVIOUK?YIXVI_UK?YITR:M>61R>I,GJ6.\;4WZU
MO\T\;4WZUO\ -.F35KRR.3U)D]2QOC:F_6M_FJ^-J;]:W^:=,FK7EDMZ+&^-
MJ;]:W^:>-J;]:W^:=,KJUY9)-_4L;XVIOUK?YIXVIOUK?YITR:M>6218WQM3
M?K6_S5?&M/@^^M_FG3)JUY7E0/,.]0=</[1J3?\ ]1-][E,$USIRP@2C^:AN
MJD;+RB4A8=KW^7_[EUPXF'C^5>)RR3=;/S2']QOW*\5G:_S2#/Q&_<KQ<K>W
MMP_XP(B++8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B(&1G'2M?U;55M-0E]#'(^3+=S'[*V# SGI6O:PCJ9* BD
M$A?ENYA[2L6]-5]H<N-5JF[-<9K=5[(.SDS%W J]I[KJN*/9-LK T=//E8BK
M;JFE#@?&#1G/Y0C_ )5[+;=7"E,O_J>SN_3/>K5)27R?U%5/$YU9&^.3G",.
M=G]$+=@H^Y,9IS3O96;?.\Z[X9R?@A2"%TLQ41$66A$1 1$0,<5$EA_M*O7^
M>;][E+?0HDL7]I5Z_P \W[W(B6^@KYR_DCZ%[Z"O,GY)WH5@GTYIU\9AKVY^
M#%XFY]NR6'!!P,87P#]3 -_I%Q]//N[UG;M$V3E8G9(T.:^NA;@C/2U31#8J
M L;FDIS_ +07LG$BL0^%7XML7$M,3]N?FR:F /\ 2KCP_7N[UXYW4W357(9_
M;N[UT1XBM^T?Z'3^R"LJRBL],=F:GI&G/3&%C6AVGX-HC^2!-K4W157+V[N]
M5YS4Y'YS<O;N[U/U-;+7.W;AI:5[3P(C"^QL=!@GP.G'^T$UH38VF/Y.9ZXW
M#PC%=).9<C?(\DYZ.E9)C]2!GO51<,=0G=WK9>4BD@@U$UL4,;6F6(8:T#]%
M25-145%;V2^ P2$OV<%@'7V=BZWQ8RAYL+X=IO,9H1VM3-&!4W%QZN?=WHUV
MI\_G%QV>OGW=ZG&C%EF&7T]'&_XNP#_PLL+';W-\VDIR/X07+6AZNWWY<\;>
MI1PJKB?]]W>G_P#<YW^%7('^.[O70XL-O P*.G/;S06OZGJK;9&;K92RNW'!
M ;QSV=B:\+L+_I#(?JC;WU%R Z^?=WH'ZG!QX7<SV<^[O6]R:UHHP3-8*1@Z
MR\?A6[VF*V5U":LT-*QH=L_ !' 'J[4UH38W_2#B[4H&ZIN/IY]W>O0DU-D#
MPFXD=?/N[U(%=JR@IZPP0V.DG;ORX. WY/\ A[%M\#+6;8:RIHJ6!@QG+!@9
MQTX[4UH-A?\ 2#><U.'9=4W( ='/NW_S02ZG+7?TFY;7Z(Y]V_\ FI&IM762
M>["D?;Z%L>7#G<@\,]&SV+>HK5;7T[)Q24VPYH<'<V.!36@V%_T@!K]3 9\)
MN))XCGW;OYH)-39.:FX^W=WJ<J&*UU=5/!%1TI,;]@D,';V=BRC;%0$'-'3^
MR":T$? O/_3G@2:F!WU5Q/IG=WH7ZEWXJ+CG^.[O70K[%;F,+G4E, -_Y(+Q
M%9K9+G8IJ8XZH@D8\&PORY]Y[4V,&IN(_P!]W>J&34_F[-3<CC]N[O70_B&@
M/&CI_9!/$%O&<4E/[()K0;"_+GCG-39R*FY9Z??W=ZJ'ZF=DFJN/HY]W>NAO
M$- -_@=/[()XBM_11TX_V@FO!L+_ *<[\YJ;'YS<6_[[N]>Q)J;9PVIN)'\=
MW>N@Y+-;8VDR4E, .DQA>(+5:YF@PTM*X=D836@V%_TY^#]3@>=57(#^.[O5
M3)J<C\[N6.OGW;_YJ?ZRV6NE@,D]+3-:/C1A:/6ZKL\%888[71/CR//R!Q_T
MI&-!L+_I'3I-3; )J;CQX<^[O597:G<\[%3<@[J$[N]3A9X;/=*7G8:>D(WG
M 8#P/H6MZ@U':;95F.GM]'4.W9P0W<?H5UHA-C?+^2,F2:EV?SJXN_WW=Z\<
MYJ?F-KPJY;><?EW9^]39IV2S7FFYR"DHP<GS6L!X?0L'J+4=DM5?X(R@H9W;
M(?T#CGHPIK1Z78W_ $C1[]2>$;ZBX!N/U[N]?%[]3\14W+/5S[N]3GI]MHO5
M(:FGI:1[ XLRU@/#'9VJE9%:H)Q$*6E=(1M8V #CZE=6(-C?](-VM3XV?";D
M>SGW=Z;>IOE-Q]N[O70[+%;SAW@E/P_5!5\0V\;O!*<_[04UH6/@7Y<\B34V
M0?"KEZ.?=WISFIVQNS57+C^O=WJ?ZNV6RDIW334=*UC< DQCK6MZ>O%BOE7)
M30TM#MMD='AH!SLC/4D8\3X-A>/^D2"34X'YS<C_ +[N]5+M2![<U-QW\1S[
MN]=!LLM!\CI_9A5-CM_%U'3^R":T0FPO/_3GELFI@V3%3<COW>_N[T$FI\#^
MDW(9_;N[U+5SONGJ"[16]U/0<[(7#> #D9Z,=BI5WO3\%130\S0E\P) P.Y(
MQXDGX-H]V1.)M3$$>%7'/\=W>@DU/TU%QQ_'=WJ?:2U6ZHI8YV45-LR,#P1&
M.D97W%CH,9\#ISV<T%=:"/@6_3GKG=2Y);4W'V[N]!)J;CX1<1GC[^[?_-=#
M"PV_&? Z<?[05#8:#.ZDI_9!36@V%^7/1EU,<XJ;CN_;N[T$VI6\:JXC/[=W
M>NAA8;?T4=/[((;!;SQHZ?=^R":\&PORYXYW4V3_ $FY=GO[N]5YS4Q;^=7+
M/3[^[O70HL-O/_14_L@OC6VJUT=-)--2TK6M:7;XP. RFO$&PO/V@'G-3;+<
M5-RX_KW=Z.?J4G)J;CG^.[O4MVFZV*Y7*2DIZ>B<YFS\$ \<=G:MJ%AH"3FC
MI_9!6<:"/@7Y<\A^I7$@U-Q'^^[O1TFIL8-1<<_QW=ZGZOMMIHH#)-34K0.D
MQ@9W95E9H[7=07145+C!.0P'@<=2D8T$_ O^D'F34QW"IN+2-^Z=W>J"74VT
M2*FX^W=WKH9MCH.FAIQ_M!#8+>.%'3^R":T$?X^_Z<\%^I3N\*N)'5S[N]4V
M]39_.+B#_'=WKH@V"WCA14_L@J^(*#Y)3^R":T+L+\N=Q-J5PQX1<0.KGW=Z
MJ9=3'?X5<L_QW=ZZ&-AM^-U%3^R">(;?G\SI_9!-:$V%^7/7.ZE(P*JX^W=W
MKQSFIAN=4W'';.[O71#;#;\?F=./]H(;!;^FCIS_ +036@V%^7.^WJ7'YS<3
M_ON[U42:F(QX1<?;N[UT-X@MX_Z.G]D%7Q#;_D=/[()K0NPORYX$FI@?.J;B
M!_'=WJH?J;.ZIN)'\=W>NA38*#?_ $.G/^T$\14 'YI3C_:":T2FPORY[+M2
M[QX3<=_[=W>J%^IMG=57(D?MW=ZZ$=9K>T;3J.FV1Q/-A:O)>+ V\"WLIZ%T
MKGN9@ 9R,]&.Q->#87_2(Q+J?&^IN7MW=Z"34O$U%Q)'[=W>N@8;-;Y8FR"C
MIR' ._)CI7T%BH/D5/[()K01\"_Z<]"34N2?";CGJY]W>J%^I"<BHN&1Q]_=
MWKH;Q%09_,J?V03Q#0=%%3[^/O036@V%_P!.>6R:FWDU-Q'^^[O572ZFQYM3
M<?;N[UT-XAM_#P2G]D$%AM^\>!T_L@KK01\"_+GGG=3XQX3<O3S[N]4$FI1N
M\(N.>OGW=ZZ(\0T&!_0Z?V00V&W]%'3Y_A!36A=A?ESN)-3-)_I-QS_'=WJH
MEU-@YJ;D#_'=WKH;Q!;^/@=/[()XAM_R2G]D%=:$V%^7//.ZGV1BJN6?X[N]
M!-J@G?4W(?[[N]=#>(*#Y'3^R"Q][@L]FHS45=/2-9G +V ;\$]78IKPNPO^
MD%%^I>=<'5%QV<?KW=Z%VI"S=4W G/Z]W>IFTI56;4=**BDI*-['!QRQH=P.
M.I9X6*@Z**G]D$UH9V%_TYYV]2DX=5W)I_CN[T?)J8[A/<?3S[N]=#FP6_B:
M.G)_A!5%BM^/S.G]D$UH6/@7Y<[L?J?/YS<O;N[U5C]39_.;B/\ ?=WJ7KW=
MM/VJN;2R04/..8'[P <9(ZNQ96MI[?3V\U4=NII1NW; ''Z$C&@GX-X_Z0:]
MVI<;JJX^W=WKUM:E<W#JBX[/3F=W>IXMEOH*VG=*;?3,P<8YL'H]"UG4=^L]
MI+A#04=06\1N;@YQC@FO!L+_ *16QVI<Y\*N.[=M<^[=_->FOU*'8-1<0#^W
M=O[>*E_2]QL5^B(AIZ)DV=GFVM#CG&3T+)WJFHK=3&46VGFPT'>P#IQU*ZT)
ML+_I!7.ZE\X^$7'=T<^[O5.<U*-YJ;CZ.?=WKH"BM%!54L4W@-.W;8UQ;S8.
M,C*^YL%O^1T_L@IK0NPORYY,FI=V*BXG/[=W>ADU+@YJ;B#_ !W=ZZ&%AM^=
MU)3^R"KX@M_R.G/^T%=>"/@7Y<[\[J7=BHN)_P!]W>AEU*,#PFX[_P!N[O70
M_B"W_(Z?V03Q!;S_ -%3G_:"FM!L+\N=Q)J89_I-Q(_CN[T$FI<;JJXD_P =
MW>NB/$-O'_24Y_V@@T_;OD=.#_"":T';[\N>V/U, ,SW'V[N]>G.U)DD5-Q.
M>CGW;OYJ=[G16NW4LDTU-2X8US@'1@<!E:3'JZSNK^8=;*)K"X-#\C?G_2FO
M!L+_ *1Z7:E(QX1<1C]N[O7@NU-@?TFX^W=WJ5+Q?[+00-DBH:*<N."-PQ_)
M7NE:ZT7Y@V**C8_9VBT .QYV.I-:$V-_TA\2:F!R9[COZ.?=N_FCGZESYM1<
M3_ON[UT'-:+9$,R4M,T'<"8PL+?ZBQ6:F;+40T3=IX9YS0-^">KL36A=A>/^
MD+-DU+SA!J+CP_7N[T:_4V/SBX^W=WJ<-/16N\T#:N"CI2QQ(RU@/ XZEE19
M*#HHJ?V036C@CX-Y_P"G/+I-29SX3<?1S[N]4:_4HXU-Q]N[O70QL5O^1T_L
M@AL=!\BI_9!76@V%_P!.>0_4V?SBXG_?=WKUMZE+,BIN/MW=ZZ%%BM^<>!4_
ML@GB&@Z*2G]'-!36@V%^7/;7ZE$@_I-Q(Q^O=WKR'ZF&<3W%PZ^?=WJ:]45%
MCT]3&:KIZ)N-G<]H;Q..I?>P0VN\TCJB"DI=@/V?-8". /5VI&/!V^_*#1)J
M8?\ 47$_[[N]4V]3?*;B?]]W>NAQ8: ;C1TY_P!H+"V5E%<IIHW6NFBYN1T8
M.R#G'3P36@[?;E"C7:E .:FXXZ^?=WH9-2D8%3<?;N[UT,;%08QX'3X_A!>7
MV.WM;M"BI]W[()K0=OO^G/(DU,,YJ+CN_;N[U0OU.>%3<O;N[U-^W9Q6BFDI
M*-KB2!E@SNSV++,LEO<T.;24Y:1D>]!76@V%_P!.>@_4I:1X3<<C]N[O3G-3
M8QX3<?;N[UT0+!;_ )'3[_V0518+?O\ Z'3^R"FM!L+\N==O4WRFY>W=WIMZ
MG^4W+V[N]=$^(*#Y)3^R">(*#Y'3^R":T';[\N=N<U/\IN/MW=Z<YJ?Y1<O;
MN[UT3X@H/D=/[(*OB"W_ ".G]D$UX.WWY<Z\YJ?Y3<O;N[U4/U-\IN7MW=ZZ
M)\06_P"1T_L@GB"@^1T_L@FO!L+\N=MO4WRFX^W=WH'ZF^57+V[N]=$^(+?\
MCI_9!4\04'R.G]D$UH-A?ESOMZF^4W+V[N]-O4WRFY>W=WKHCQ!0?)*?V05?
M$%!\DI_9!76@V%^7.VWJ;Y3<O;N[TYS4WRFX^W=WKHGQ!;_D=/[(*GB"W_(Z
M?V04UH-A?ESOMZF^4W+V[N]-O4WRFY>W=WKHCQ!0?(Z?V05?$%O^1T_L@FM!
ML+\N=MO4WRFY>W=WJA?J?Y3<O;N[UT5X@H/D=/[()X@H/D=/[()K0;"_+G8O
MU-\IN/MW=ZH'ZF^4W+V[N]=%>(+?\CI_9!!8+?\ (Z?V036@[??].==O4WRJ
MY>W=WKT'ZFQ^<W+V[N]=$>(+?\CI_9!!8*#Y'3^R":T&PORYUV]3?*;E[=W>
MO39-39 -5<L?QW=ZZ(\06_Y'3^R"H;!;\'^AT^?X036A8^!;ESRY^IL$>$W'
MV[N]5TH:OROH/#'2NDYQV3([)S@Y70$ECH0T_P!#@'^V%$51"R#E#HV1,:QO
M/RC &/C+5<2+0XW^+;#F)S3=:_S2']QOW*\5G:_S2']QOW*\7EM[?:P_XP(B
M++8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("\.:UX\YH/I7M,;E)]$-2UC01^!N>US8SYHR&]JCFZ:QK&Q&CC,
MN#@[8F/0>K'8MVY39I11.C94.@:0P[8Z/.*BUUD89 9;LT@C.V6<.SBLU:GT
ME#DSC#J229]1SC^=.XC?O:%OXX*/.2\,C@?&R9LPYUV\?NA2&."ZV<J"(BRV
M(B("(AX% Z%$=BS[I5Z_SS?O<I;_ $5$E@_M)O/^=;][D$M]"\R?DG>@KWT+
MYS? /H5A)0+<,>ZW)D_]?!N^EJGF'\FW"@2Y?VN2?Y^#[VJ>:<^]M7;$]0\/
MQ/Y7_P#7V.[)6I:VI=NF,S9N;.2=PZFK;>.0M;UD&^+7[6!N=C/[I7&OMZ\3
M^*RT!,Y]MBVY#(=EW$_XRMO>06E:/R=[K;$<_HN_\RMT.YF[@M6AC#G_ %0M
MRG!IU(P9 ]]B_P#%2_1T\-12ALS&O;DG#AE0]RHM/E,S!V??8O\ Q4JRULU%
M;62T],^I>7[.PTX(&_?P/5_-;O\ QAY_C_\ UL\U5AI\F5DC(APW1_\ NM;;
M?YJ"IS%4/KAC'-\YCZ>E7C:6[W.7G35U-)$1CF2TN&[IXA9BBTW1P2<Z^&)Y
MQC!CPN$/?/AGAU\%C:VST=<_:JH8IAC'GL!63*\C &_<DD(ZUM;+3&\4\-!2
MM>6M=YK!GB5FJVR3OTZ^EM]0^F>YS7 Q,W]';V+$/S=]0LVFY:(BW/PN!*D&
M)@:QH' !7+P1*"* ^3=>3?;<*F'+G&:H\T#.X#>#TC^:WO7I\.T!5/LIP\\U
MLM@_?:?N3E:HZ.73-2'1Q"HS'LY'G8V__P":O=%T#IK"8*@'8<6[G-W8#0BY
MH3NLE'-99H;88C><-#1%^5V@1M?RVL_2IABN4L>G[;1&1WA$U+&TNVO.:X-&
M=RLKKI2R:?,MS;!225##M",1ACG;1V3OR>L]"M[E35%+I^KN+P\.:P209&-@
M'H!^E,_!,MCT_<K#1RBG-RI'7&0@/82 _;'$'MSE;<QS7M#F$%I&01TKF6!K
MPVONO/GPJ-W.M/Z0))SO4[Z!K9JW3=#+4%Y>:>,Y<<DDA/IEB>4_4DUDMV:>
M)SRYDGP9-GACL[5B.335\M?25,U? Z*-K(W%\DN0 =K)X=BO>6"&-]I87,&>
M;EWG_2M.L\D5'H^HYEK274OG[)QC /%9K/E9RR;K=.404M0]E);Q50-)!E;/
M@ =?P2M@TQJ:COE.#&^)DX +XA)M%I).,[@M0T)36JX:?E,[*=TI@&UM8)!.
M>*PVC(7TFO[M#2Y\%$T( 8,-QE=(KG*)F<X-:7..&C>2L#6ZAC;524M'&V>1
MI =L/WMR./!9U[=J,M(W$8*TZXZ=GBND];1S/9MD$L9'Q  W9SV+'VL+V.EN
M%9,7R33QQ.QYIR1U=:SM%2-I8PUI#NC.,=*P%'>ZFE#8*JCD#6[C*]^!O/H6
MP4=7#51AT$K'@]+3GI53-I_*K52TMFA,;W-!FP2#C=LN6MZ1MUHN6F.?G\&E
MJ V1VTY@+MQ.-ZD/55FCO5N-/)L@@EP<6;6#@CA]*A.X6"XZ7VXJ>]3.B>.:
M$38]@#:&<_"/4I#IXR9'1UZ?0P31BH<1S3\#;QQ(65Y,;537FC-5<VQU+W->
MW,K-H[B,;RL1I72]5'972S"2679>"3%OQGTK.<C-3&RU\S,YK'M;(XM<=_P@
MM3#&?AC+'4FS<H<]JAG(@;1&4,:=D9)&_"P5/)2TNKR=1NC']'_ZGT[N/TK+
M6YANG*S/5T\)? :#9VV^<,@MW94B7_15GN=3X360TS7X#=M\63NZ.*SEE.:Y
M_32^1RMFMFDWNKWO'])?^4=CB&X6SVZNM5/(:J^5]/#*,M#)SOV>@Y^M8^V4
M<-=[W0PM;1;SLL&6[0_Y4?7=KKGJ5E-45!;%S.<.WC<3T+4SG.1,>'0])54U
M3%SE-*R2,'&TTY"^XZQO46\D-RJ:B%\$SGO8)G[W.R-S6J4"]K6Y<0T=92T9
M,Q+6-;5&W0244;]F60-<,'?N=U?0H=M,;]):XHC-*1%*V29P=Y@.6N':MJU7
M'<=0W4-M%=-"YK3'M0C;P0XD\".A:-KK26H*"-MTK;A658IXVMR^$C +L8SD
MXXK-/$YRW:,XRATC05#*BCBE80YKF-.0<\0M>U-J^DM7O,(BJZIPRV$2[+B0
M<$<#VJWY-[HRNTZP->'R1M8P@.R<AHRHZTO40W#E"GCNY:7,K)V1-F.?-&WP
M[$GS.3,>&O7^L;<=?6F66$4CGF5VP3G.<GL65UK3P4%RL=1SS-\1?C&,\%\^
M4E]JI-?V-\<M-$U@EV@"!UJ[UF:2NJ=.\V8I6&GZ-XX!*08DYMPM'*'3TM-;
M*.>DC9&8FLYUT^,@-&_&RMKN.J:*CMC*ILD4ADCYQC.<QGAN!QVJ+=<6REI+
M38I(FQQO=2[6YN"3AJUO54E;/066".JEIV.A+0\;QC#=ZOLCPEBV<H\-37LI
MJJC92L>\-9(Z?.T.L#9]'UK+W_6EIL\$<DM93'G X@&79X8[.U0Y9>3^[59M
M]<Z]U#X8\28\')&#V[78LSRC6"&.RVX33,D>V.3+BSCN;VHDM^H->0UC8I*>
MF8^F=@OF;-D,;\;@K2[<HS*6IYNCH&UD378?(V? :WK/FGM^I8*T6^*BY*ZR
M:E@;)*+<]S7,&#D-=C"C;25ANVHA6"*Z5%.]S!M1",O+<Y&#O"GVU'IT)I[5
M5!>*1\K)H8Y(V;<L8DVBP;^.[L6MZPUK 8JNBHZ6.L\QS'.;+\$%O'&.U:E8
M=+U^E+9>YIKC+5/?2NRTQ;!& X]95WH!EMK;9<:BM-.ZI=3.+FOP7-._BEH\
M)5@>2^5DNM:\[FG9C\SJWM70G03G"YXT35VZDY1[E&R>!H/,M&' ?%70,KP^
MGD<P[MDX(Z59])]HZUO>75=]-I@D(YN2,DM?G(<T='TK:J*.DTW:6ND,8<-H
M D;&T=YQ_)1J6!_*16F:49V8CAWH8I'UE11UUK;&:EM. _+7$9R=D[N(5RRA
M?<Y,90Z]Y]X$UO$,1W"0SY!.>'P5G+OJ2CME&)7RQ/>7;.P7XZ">KL45LYVP
M4\#*^D=6PF0-;+)Y@VCOZCPP5YU+<(9]820U;F0VT1L+"]WF%^[<.WBLQ[68
MR;;2\I@$^S<[8V@BQNDDJ-V>@?!]*V6^ZNM5GH_":BLIQ'M!F72;(R<]RU7E
M+LUJ?96/:*:$\^W#MD=3MW%:Q=+6;EH%KKG'LR^%_P!ZW)P <*Q[R1MLO*;3
MF@\*IZ6.5FWL9;4;L^G97W'*/1S4)J*.&*=X=L[#)]_U[*T72MKI)M!.D<V,
MN\+(WM[ O/)C;:66W/=(R.3WYXP6]@2%RA*&F=9T5ZB+G&*!P<6[/.[7  ]0
MZUCKSRA,HI]BAH6US,;WLGQ@Y(Q\$]GUJ,M,/?2ME\'87NYUWFMW= 6%T[9[
MG?:J1D-UGIW&1PV PNX#.>(__ I'DF(AT#IG5%%?82Z*2)L@<6EC9-HY !/1
MVK8"0!G(PHDY,M%UFFJP^&W62J<Z1\G-OAV,@MQ\8]2E.;:93N(RX[E;>(S9
MKYG)JNH]<PVR7FZ"!E?(!O8R;9(.<$<#Z5]-,:WHKR\Q5 BI:DNPV$R[1.[)
MZ!VJ![?176^ZNK(&W&HHG>%3-:W9+L@;1R-X6VZ?T-<K+>X:ZIN<\^PYSMET
M!;G((X[1ZU*_QS6<L\DD:EUG2T!\'I8HZR5P/F-EP<@\.!40458VKY0*2:2,
M4[GSR.+,YX[16QZ,?2UVIJJ.Z<V9&U3VL,IR<>=P6"O4ELI>4.C#)Z=@;/,-
MQ Z2I'+5>$M735]+9Z&G9$R.IG,8Q&)=DDC QP*UN+E:+JYE*^RB-SG;(S5?
M\;"PFJ=B":@JZ&$70[!?S4?;C=G?_P#@5A9;167V_P!%526.:W,ADRX.87"3
M:[<#&,?S5S82U5ZKIZ2TPU<[(VS2Q<XR%TF"X]0..U8.W\I$<U?'!74+**.1
MX:R1\^0X=)'FCAN^M:#RO15<=98Z2&IDI&9E9M ;A\#H5E2\G]WKZ:BK'7ZH
M=%&-L'P<D8/;M=B-91EFF;4.K:2UTM/+ (JI]2'<VT2;.T1C<-QZUXLFJVW
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M[7."HW =!^"M+U_9Z:?15LJ2(]IE!$<[.>.STJ]CM-$WD\9*61;8HX3M;/\
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M&[>HXON@:^.M=+8+H^W,(#2R& G=T_I=.Y;:-86/INUO^U,[T=J^R'_N]O\
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M&0G;+QCS^&1V*RN]]TY=*4PU5SMCP,ENU4LW'!&>*L=.W2S6B(1^/K<]@!
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ML*D@:PLF/ZWM_P!J9WH-7V3.^[V\_P#\2SO5BDP3CUG[:8S26JV43H6ZEK,
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M3*7PDO;S0 W[0QO[5$=ST92PZ5FN$$;&UP<S9DVG' )&=V<=)Z%\ZK4-=4:
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M?7345%;IVPSRQA[G!@!D:-Y]*R='4-J:=DK""UV>G/3A0CRJ4<TM^HJQD[!
M^K86MZ=P'<MYMNJJ:SV:F9/&^1V7##2.LE6/0WB:011/>>#02?H5E:KG'<6[
M432!@GB#TX6+@U/0UMK-1*PQ0O:[(D>!D#((X]B\:>N=H%O$]O:R&'#L$RAP
M.#OWDGJ1<O&;9U\YI!&S:)W+5FZ[MCYGQQ8D+&[1V)&G=]:N;#J2WZC8YD&
M[9+MASP2,''0>U/:,M07.GK';,<C-K&<!X)5\%%-X=4:5NYGB=[PYK8PUC<[
MSOXGT*3J"H;4P<XT@C)&04R,UPB(@(B("(B F$1!\I_R;@H.N)_^(])@_P#4
M3?>Y3C/\!R@VX_VCTG^8F^]R[8;P_+]0FNV?FD'[C?N5XK.V?FD'\-OW*\7.
MWMZ\/^,"(BRV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B 5@-7T;*RW.CD+1YS3EQP%GUKNL/S$MX#+>/I*S9JK
M2:'DYMT\3G#P?X1W\\_O5V.3"@<-PISZ)9.]9)PBH[+(Z"H@:[G!^F#U+(Z1
MK6STKY:BJA.S(6[W ;L#O6H].;Z:4T_XD!CCV PN+L-)/1CI]"V96]+50SY$
M3@[?C<05<*RL"(BBJ'@54<$1 1$0%$EB_M*O?^>;][E+?0HDL/\ :5>O\\W[
MW();'!>)?@'T+WT+YR?DSZ%824!W+/NNR?Y^#[VJ>8/R;5 US<1RN2?Y^#[V
MJ>J?\DWM7;%]0\/Q/Y7_ /7U)P"5I.MM1SVUI930U!?M8RR,._1STK=ATA65
M7;Z>I>3*S)_>(7&LY3Y>S$K,QE".M(:GN-?5<U415(&,Y="&CX0'4I+8?>\$
M;^M6U-;:>G=F)F/]1*O7$!I 6[3$N6%2:QYE"/*@#Y4-W[N=B_\ %2P^O%NM
MS9I(WR!S]@!@WYW]RBCE0?C4[=K?[[%P_=4E7:YT]NLD<]935%2PR[(9",NS
M@G/$;MRU?^,.'Q\M6S'ON5VK92*5[XX<<'1 _P#"O(=+PROYRN8V5O# <X'/
MT86MP<JUL@9L1V2] ?PF_B5[0<I]#63<TRT7:,XSE\30/_)<8>^R06-V6X"#
ML7EC]L9X#M6H:TJ=01?U%51P[F_"B#^DY_1/8I)#7^4NRT@J!41Q@3"-K<[;
MLXVCT96M:V$_-QU,@=L,B8SX..D]ZW"SVB[WB3G=03Q3N&6^:TLW#>. '22M
MAU-IRGNEK=3!@QYO%SAP/8F7VK$WFMBBT+*]Q! ,? C_  K7.2NTBX6JOCK&
M;5/)5N):<MSYK2-X6/ET[J6K#K945E.ZW/.T8^;(X<-^SGH'2I8TU:8K30-A
MA:&YPYV'$[\ =/H6J^/+$PCZMT%;[1-)<:F.)\#'$F-LK]H[1P.)[56I$\%I
MJ:^0.V:5H-/YOP6]'8=V..5N-\MM1=+C##*YIH7,(D8<@DC)&\#KQTJ^NUIB
MK+%);]D;#HQ'@N/ 8^GH4EN)A!-/<KGSM7=?"0&T[^<:"QN<$GANPIPT9<G7
M.PT4\FT7O@C<XD 9)'8HD&B[V+M4T@J*?Q;),YICV79V 3@9V<_S4R:;MS;9
M9Z2F: #'$QFXD\!CI5^DEI?+-105%JC,L>UB.;I(^*M0TW!3VS2=5+2LV)'T
MP.<DX(!QQ]*E'7MHDNUHDCA+1*(WAI=GB<=7H6G:8TC7>+*ZEN$D+XW1!C0-
MH8&_/0%SK&4K,9P:5TW:[Y9I*FOB9-4NA#MKG7-PXYWX![%8Z&,UNUM=+="<
M4L4L3&M R ">L[^E?%EFU19:R:"SUE/%2/<&;)BV_-'1DM/65N^BM.NI))+A
M<-B2MJ USWM)&7 GHW ="ZU\>69AN+V[<+F@XR"%HMRLM337F:K80Z-SFG#0
M2< #L6^@!",@@\"L+#7K;?H@&TTD$S7-XN< !O*ST,K)6!T;@0>HY5G4VJFG
M+B6;S_B*^MOHF4<08P#<#P)/3E5%WTGJ6FZ^J'F&&&-V_GFY;C?C9*W$G<<<
M5J5TM-367ATI>S8\T[P>C'8IDU#+:8IFT]N8-@M=EW'/6KB[T%-74[F53 YO
M'X1&_!ZE]:@2-I3X,0Q^_B,]:CB2HUC-7NA=7P^#[.<<P./IV$2%KR<026_4
M#Z.#\T$#G -&1M$MZ2LUJ/D]I+E<O"VMA:=@,\Z1_0L_I*Q1VN#:>&F?S@7!
MQX$]OH5]J%M2ZW_T)X9+MC>1G=O5F"&A4%MB:WP"V,V("><SDN&>G?O6E7BM
MKJZ_-HZ2811F+:(>P<03V94V:=LT-LI"QK0'[1.YQ/'TJ,M7Z-NL5Y;5V>:"
M+$0;YP<[?DYZ#V)&<SY7Z;!R57VHKZ=\,[G.Q*\9V0!N:WJ4CD@!:1R<Z>=9
MJ1PJ-DRF5SMII.-[0.GT+8M2&M;;9#:Y&QU.6[+G-VAC._=@]"MV:HUUQ<;I
M6W-HM,CFEK-G'-A^\..>@]"CO6D&H8JJGN=PE<\01!F>8V< DCXH'2I)T+;=
M1TU^$MSJH9(R^0^;'C<6G'Z(Z5GN5.V5]XL$])0R,:][(_A-)&0\'H!ZEFO^
MOEO^3(: N;KAIZ)X=YS&,:<XX[(ZE'-F<S5&N)Z>[$/BAJIH0QYV"6C:.[9P
M>A7O)E;-46>L;3UE9 ZA<\E[&1;SYA WEHZ0.E5U-HVXT5^BNUBEAAF!?(XN
M#GDN<3DX((X$J6\SF1XAK6OK=06C7]A91!D3=F7/OA=C&1TE7FO&-JZG3S-I
MKVFG.<'CN'4O-TT#>K[>*"MN%13/?$TY)#F\=YX-7SOFD=2.KK>*6KIFQTS2
MP983N&X?HJU\,W\OMJVS4UOH+'4P1ALAI]LG:<=^&]?I6-U5=KA+:K3302EH
M? 6[V ]#>Q9#4%CU?<J:AA?74Y;3Q<V/>2.KJ9V++^1=RJ+%3&>6%U73P@-=
MAP =@9W8[%J%R:79],W^:KH*F"9K&[0>XF([_P#Y5LG*+9ZOQ+;O"9HWO$<F
MU@8R<-[%GM+#5]+,RCJZZ%]$PM8UC8 ,-&=V=G/4G*19;[=*:F90U,+-D2 [
M;">.SC@T]2C*TLMIIJ+DVJ:YL)-7%0.E8\.)PX-<0<<%&UII;Q?S5/9)M.<T
M'?%PSD;\#L4VZ%L]?Y*SVR^21S-=3"$!@+1OV@=^ >I:K-I_4>F[M,[3=5!3
MTTSP"TQF0[(X;W-/65,O+4>EGHV@O>GK5>Y*ZI:Z,TCN;:V/!:0''I:%>:/M
M-!?:&X5]R:V6=U.7C,A:01D9(! Z MVM-NN-TLM3'?)8YI98'-R&[&\@CH [
M%HC]+:@M%?5Q6FJIXJ68"/9+"[S<;]Y:>LI;R58S0#*:CY0KC$QS&M B &UV
MMZU/\YQ!(0>#3CZE"FD.3VNIM2RW*NE@>]Y826EX/FD=& .A36R/W@M._((5
MGTB%9SX1RD59EWX$)'1OPQ23KDD6&7)S\+_Q<M"U32NMFN)JT-(BE?$P$9/Z
M+>OT+:-:.KKQ8&QV:>-CW/.2]NT,;+AT ].%9]+$>6D<F%9)2:,,D0<'EDPW
M#/Z1[E'FF*>\7ZG,IDYQQ#N$74<= 4G\ENFKW04DE%=JB"2#F9  QI;O+AT[
M(Z,JT9IO4>E:]S=,U=/34VSLAIC,AW[SO<T](4'TY+['>[8QT-?4QF+8?AG-
M[)R2-^]H[5C+;0^)Q_3XG3G?Y\8(&_HZ%)VGXKM/1\_>)V351RW::S9W=&X
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M   U1YJ&BHY*:[/H*=PE$QR\.+AG;W])6VZ#T]J"FME915]3 Z*>;;< PC.
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MR;0D83L[/5N*D^S1W:@T^8+I50D\\7;F[/HZ M)M5FU%ATE+50#SB,\V3_\
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M\%J1@3"3\_#S3^7M<.Q&O;GCYJ@)W*5>#O;,/IA:O/NEWC]</8M30D[AAN@
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MQ(T(7M._/%<_GE*O.?RS<?P6KTWE+O&_,PS_  6IH2G<,-/P>P#<G.-"Y_\
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M#  QQ&#C_$M7TWK74VI;74>+J:WOJ!.6-!#FC #3TN[5?:<U':V:6F;.[/\
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M3QG3_K6_6N=@=4DD^$7+VKN]-K5/RBY>U=WJ:,<F_M^71/C.G_6M^M/&=/\
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M *UJ>,Z?]:U<Z[>J?E%R]J[O0.U3O_I%R]J[O31CDW]ORZ)\9T_ZUJ>,Z?\
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M:9Q[&!7'B>A.XTT'J!872M,;92F>Z5>\O)S*-G<0,=*RT^I++!^6N5(P]3I
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M^NP  7*:K?>;;7^925M/*YN 0QX."KU3D3A5S]/(LU" <4L'J!4\34/R6'U
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M@R3MG_A;_3U=/40":GE9)$03M-.1@<5>J4TZ\++Q-1?(X?4""ST)XTD _P!
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M^XW[E>*SMGYI!^XW[E>+G;V]>'_&!$19;$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(^$,^E:[J^PLN](3%LMGRT!^"[<,[EH1Y7J<-R;;49_B-[E7W7Z<#'BZH/\
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M,:<\=ZJV"!IRUK0?2HD'*]3[_P#TZH]HWN3W7J?YNJ/:-[E-&3?87*8 YH&
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M887"%AR1S]-73^HY5]R2?Y73^JY31LA-D)KV-AA<(6/)'/T5=/ZCD')'./\
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M"WN1SXW5=./]+D]R2?'YW3^HY33LA-D)K6-AA<(6'))4 '^F4_J.0<DM0/\
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M5,_.2Y?:3$6KZ*U"Z\TN)R[GXPP/V@UOG$;]P[0MGSQRM9,YJJ([#_:7>O\
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M9A!%/C#77SA2^P'X%3QAKKYPI?8#\"E=$$4^,-=?.%+[ ?@0W#771<*7V _
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MLM6)Z-U:9 "//E!&_P"A6OB4_IN\7GMST+WE&MPW!Z$\_L22'I$1%$1$!$1
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M540$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%\Y(VO.\9]*^B\O\
M@E2?2PAKEXVN9ML9 $;;C"01QSL.4G1P"IH//X[?0HJY7K7JB\W6."WV^EDH
MX)XIV/,H:XD-(.<NX9)Z%(VE)KO-9O\ U:EIX:GG#YL3LC'1TE:K_!/M'M@K
M:ZGULV@G(V33&3X1)^_L6.JY[J-2LHF;)8Z'G-[SGB>WL1EOU9#J]MTCMU(Z
M,4_-9,HQG)Z-K*^%73:O@U#'706RB>QL.QET@XY/^)9ANV3[VV>ZFX-MYV=I
MX,@\\YQZ<]BOM+ZEK+4Z2.JYO:YQQ&=IV[ '7V+$4%/K(7J.NDM=""UA9NE&
M.G_'VJEMT_J>:Z 5-!3MA=M$N;*W(.__ !),$^F-OFL!--)5\^YLD9V UH<&
M\>K/:IHY.;Z+U:0_()80S<TC]$'I43MTM?;5.X4UOIIVN)>>>>T[SNZPI@T3
M%4PT&*NGA@?D>;'C'P1VK?\ RX_;5N62K>*0TC3@2Q GCT/'<MBHH61:*@#/
MTJ:$NSUX:L?RM6J2LT_4U-.W:GC8QK02 /R@[U8^.JNMT5S%CBAJ*RF@BA>R
M0%H#QLY&21U%<ZQE$PW_ -9H[TII6LO-[OCZ1\P:VM>#LRAO$N/2KEM@JK)J
MZA\(=(X\Z_&W('<,CH6Q<F<&I[77UKJ^WTD<=34&5Q$@)&X\,.[5:ZIH]45F
MIH9Z:WTKX62R$$R ;B=WZ2W;VU;RRVI+Q57#P&VTFP'.88CC+3G=TY[%A8JF
MXZ>JF4]81BJ=AI+BX^;Z#NXJ^N>GKZ6T-PAI8S64[-O8YQH87'&0=_\ RJ45
MEOM^N-))>*2& 4SMW,R#?GCG)/4%(]LV],=8Z^OFO=?$UP+)90!EQR!D\-ZM
MXJZY25VHZ3(V82& [1S^EV]BR%WTU?+=>63VJFCE9SI<_G)6C&#NZ1VK7O%6
ML*:XW6IBMM([PQVT=J8=&>'G=J6\MQXAF=%ON=QGJZ9YW4NP&D/.3G/')[%>
MOI[@Z\R,J'.:RGD:6[$G'T[U[Y*Z+45#<;C-<Z&FC$QCQLO#N!=G@XK,:PEU
M#)--!1VZB=%/M1[9=AV",9^%QWK4S&63C6/+-W&(2:/+G[WBGE.3Z"K/DMK#
M+ ^F)'O,>>GXQ6-#YK5I*.DK_-JY87Q;&=H;1SC>/2%L')O;GTUHBGE;LNE8
M0<$'@XK-?34MR!SP14S]2JBB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@\NC8XY<QI/:%4-:!@  =@540>.9C_5
ML]4(88CQB8?](7M$'SYB(?W3/5"J(HP<B-@/H"]H@\&*,\8V'_2%Z:UK?@M
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I("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g942297g15t02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15t02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[2%L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (4\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%"$Q%4%1(C(%83,C<8$D0L'P-*&Q_]H # ,!  (1 Q$ /P#ZI
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MO9!$?1D@
M                    "F223;*BG&(/.XA'-.V#/L=!K^BK_P!D3C_9ZY+B
M*G)+_P!7/^PZ_P!L2;L[?#QBE7_LB<<[/<OB.GAO^;G_ &'II_5\[6G&H^I-
M.>;6CGY(_P!A=M(LM,;=M1V_=C_87KZO8X3/E[Z^G/>%OBU.&?"H;;K.N6.C
MT8U+ZMW<7+ESR2EOC/@C4N%H-:E!J6?VAE^.J-.II:[RE"?Q-_%%/]UFL9<L
MS6N8>.G]H7#=[7C;VM_*=2><+N*BZ+/C'Z$:CV@\/6<^2K?.+C)Q?["H^GY'
M > Z<[CB>RH*;BY.?Q>7P2?^!WO4.']/EPU5=2RM)UU:2?>.A%R<N3\6<9SG
M<UMB'.NK:T2R/#_%VD:U6C#3;IU9/.$Z4X].O5&P5*T5%MO9;]#Y1L-0NN']
M3C*G6KQ48OX83=/J=JXAXCE;\!6]92G&O<Z:YQFJN)*7=IYSU;RQL*:^8G+/
M:SQSH>D74Z%]>.G6CC,>YG+JLKHC#<3<6:1JO"^HPLKIU)2I82[J<=_S1R/@
M&G6XCXGJ0OJL[ANA*3[_ #5Z.*\3L7&.D6=MP3J/LUI;4:BM_P 5.E&+SMOL
M-N)2-2;UEP6A+.KW.?P\JQ^A]6T*G+0BWTPCY(M(36HUX\TI24=_T/J+6X5J
MG#US"UG4A6=-<KIYYD]NF"ZB=/,XE%?BO2K>ZJV]6Y:K4WRRCW<GA^A:7G&N
MDV*D[VZ[M))O%*;Z_9'*-)T[4X<0W\M1C>.FYKEJ5X2Q+??#9N/:E+2WP7J4
MK5V3N4J?*Z?)S_SL<XQOTR9BKI.I/MO.BZY8ZO2E4T^MWL4HR;<)1VEG'5?0
MQO&'$U#0["K.52*J0<5B4)26_P!CB_97JUU1U"M2=>XY)5:,5'O&EC,EC!UC
MM,H4:G#=><Z-.4N>'Q.*;ZC;B4C4FU)F'';'B&=WQCIMU?=W"C2O8U%*$7^'
MG3;QE^1]!Z/K^G:E4Y+.NZDN5RQR26R?U1\U<(PC4XQT^G4IJ=-WU.+C)96.
M?I@^EZ=M9V%%5*5M;T7^'FC!0_4U>(^F-"\SF9-9X@L-(2EJ-?NLQYEB$I;?
MDC&RXSTF%&%S4NL6U7:G+NI[_E@X0]?N-8XILHW5Q6="-1PE"K6<XR67U3VP
M=A5+3)\/6\%3LIN,-HXB\;/P,[,-\TS/AMVCZO9ZK3=6QJNI3C+D;Y7'?&?%
M?5'M?7]&SHSJW$^6G%-MX;V77H<%[)[_ %6VXELK.XIW_L]6I.4Y3<U!?LWU
M3V\$7W;#Q-7G6C96M6M0=&K.,W3K-<ZQT:0BGE9U\5RZ!_Z2.'9U52A?MMK/
M\Q4_R.>]M.K66KTM'G9U7448UF_A<>O)CJOH9+L9T.VU#0O;[RA0K2C7G#%6
MDIO&%XO[F.[=K&E:>YO9J<*49=_E4X**PN[PMC58B)<KVM-,RK[#L+48X_H:
MG]Y'<Z>Z.%=AN?>$<_T-3^\CN=)\RZ8P8U/;KTT_Q>R6$45'C[^!6F87BG4(
MZ?HMY7S^TA3YHQ4N63W\#G#TS.(<R[5[FZUJM[!90A4G9U92FOPM+'FWA_D<
M_P"SC6_=?$=C.LX1MXRFY2<6VLP:\/R.SZ#1M+RREJ%=V_>W=/+C-)R3^K?4
MX+Q-I<]%U*-*%;F?=J?-"/+U;1Z*Q&,/G:DS6<OJS3+J%[8V]Q"685*<:D6D
MUE-9/2ZK1ITG.3QC'@:!V4\1PU'3*%D]IVMM2C)NKS<SQCIX=#:.+*DUI-7N
MN:+YH[Q^YSVXEZJZF:9< [1N*:^M:E[/-4>6UJUJ<>2$D\.26^7_  G4>QK1
MJ-/AG3]23J=_4A5BUE<O\[)=,?0X1=KGUJ[[QX?M$OQ>/Q,^DNR>*CP)I:36
M,5>G_:S.EXQ#S:$[KS$MP@EAM^!9:MIU/4:')5<TLY7*TM\-%ZUY/8JBMNIY
M\^7OQF,.?=G?"]?A^G*E6IS@Y574^*<9?NI>'V+[M(PM(Q/;:>/^DW!Q2J+9
M9-/[2O\ [(>=]I_W3I6<RY7C;27SUPPU[ZH^?++^QGTUH$FM!L,]';4_[J/E
MS0*DJ>JTY1C*<L/9=>C.FZAQ]=Z;H]I;5-*O*2='NX575<%+$4N9?#^9VM&7
MATM3;G+7^V/NUQE<M-\W=T_[IMO84KB5M?XA'D56EE_3#-,X9TY<5Z\Z]]J,
M(RE2>5</O'\.%XL[YPQHUOI-HJ=M&@E)0YI4J:CS875X,WQAUT8FULLW2:RU
MXX/1^9$4E)X7YB?X'AG![_4+>YKQA%NJ\17BD:C5[2>'%7C2C?OGDLI=Q4_R
M-3[9>):UO9QM;.K6H5J=TE*=*LXMKDEL\?D8OL?T:CJ=O"^NZ5*MR7$X8JTE
M-M<B\7]SI%/&7FG5_EB&1[4M?T[5=*M/9J[FU*4OP276/U1KG8SE<46:\>6K
M_=9LW;%IE"WTRQ=M1HT?VD\]W34=N7Z&K=CF?Y5V;73EJ_W6;C^KAF>3R['Q
M5JNDVUC*AJMS.C3KTYP;A"3>,8ET3\S4^#I<(T]7SI&HW=:Y[N7PU(22Y=L_
MN+Z&1[4:%.6AU9\D7.-O7:?+NGRG(NRN4_Y2YE4E_,3V;^J,Q7,-WU)BV'TI
M<75*VMI5ZLN6$(\V<-[&(I<6:97KRHT;CFK17-)=W);>GU1@^T.C?5M"JQL)
MW+F[>2Q1YFV_R-3[*K:M;7U26MQJ0;MY)RNXN.9<\<?B\<&=KK-Y;[5X\T.A
M<PH75[R5YK,(JC-Y7I]&;%INHV]];0KV\^:E-9B^5K*_,X=VQ.TIZA;SL'0@
MU;KXJ.%A\[\C,]B&I7-U.YM[BK7G3I4$X\\W)?B\$S4T\99KK3NVNJZIJMOI
MEM.O>U.[I1QE\K?5X70PEOQKI%Y*JK2ZY^Y_G,TIK'JOHSEO;?J5]3UN-O2K
M75.A*VIR<(U)*+?/+?'3P1L_959V]72)5*M*E.=2A2<W*";;:?4S%?M9U9FV
M(;0^T#0(/E=\\_\ 85/\C)Z;Q1IFI4:U2TN>>%)?&^[DL>J^AP'M5BK+C"M"
MUQ3HJE3Q"E\,<X\D=@X IT:FB4W[)"FY4:7,^1?M/AZO;<LUA*ZUIG"YO^/^
M'K.ZG;7%\XUH8YH]Q4>,K/5+ZEQ_+717:5+I7;[JDLREW4]ORP<4[78PH\6:
MBJ,(T\.E^%8_]7$W+LFTV%UHUV[Q0N(=\DXU8<R:Y5MN79&&.>TVFL-EI]I_
M#;JR3U#X?#_=ZG^1N=I=PN*3G2ES13QG#1\X=IUA2L-7NYVM.G2@ZZBH4X**
MBN7Z?8Z;V-:A6N.$KJM=UJE24;R2YJLW)I<D/%_<33QEK3UIFVV6^:CJEMI]
M+O+JIR0WWY6^GV,+:\::3>476M+KG@GRY=*:W_-?4XSQ]Q-=7G$5Q84J]Q3I
MTKN4-J[<9+.,8\CJ/9_I-O3T2<:M"C-]])YE37DB;<>VHU9M.(9O3.+='U&X
MG1M+ISK4Y*,X]U-8DWCQ7FF; JJ<<^!\T<75Z^B<2=]:5:E*#O)RE"E)T^91
MGG#P=(TW7KK4^ X7=O[3[0Z[CRPJ.4\)OQ6^!L*ZWF8;54XRT97'<QNWW[ER
MJ/=3Z^A3>\;:-9TDKR[Y)IX:5&;_ +%Y'$.#^(Z6F:S4AJ=M[5WMPFJE>:_9
M8;S^),Z?J#T+B73*4:5QIEK6Y^\;YJ<I868XZKS0V,UULY;7J>OVMII=6][U
M=W3BI9<)/JUX=?$^?^T#BNMKFJ5()47:4ZW/3E&$HM[8WR_\#N=]IU.EP]<T
MZO=UX.*ZQRFMCYQXNA&EQ)=TZ4%&"JI*,5A+9>!K3K#&M>T/HOA;B;3;UJUM
M[CFKSFW&/=R6<+/5KZ&%XZU'A>ZKTJ&M7]Q1G0G-)4J<NNV?W7Y&S:!IUE1I
M=]1L[>G4C-I2C2BFMO/!R?MVI0HU;"=.$82J5:KDXK#?X>OF2*Q,MVO,4B71
M^!*NAJVIT]$NJU>GS2<74BTV_'K%&TW5W2MZ,ZM26(4XN4GAO"74Y!V+3E[-
M;)R<OCJ;Y^A8=L/%-?VNUM;&O7H)=[3J=U7:4MTMTOS)-/*UU<4RZC2XQT>O
M<NA;W3E<)9Y72FMO0HT_CC1+ZZC;4KSFKRGW:CW,UO\ =HUWLDTZC<\(6%Y<
M4Z56YGWJE5G!2F\5)+>3WZ(US5N#+ZGQ+9U;*K6HPY^9NE1DDOBZY3),1#47
MM/EVZE-3@G!Y16^AC.':%6VTBVHW%6=6K"+4ISSE[OS,BI93,.\3X>=:M&G!
MN;PDM]C77QAH\+N-O&Z?M$ES1BZ4]UOXX^C-2[8>)*EA94:5K4J4ZG?2A)TJ
MW*_POK@Q/8M:+4;+VN^Q<5(7$X*5://+'(MLOPW9N*^'"VK_ "VPWVGQUHDK
MM6SO/VTI]VH]S/\ %G&,X\S-W6K6MK:.O7J<M/.,\K>YS'CW@VXK7]C5TR4J
M3E7E*4J%!_#EIIMQ\C<N%]*JVF@QM=3JRO9JI*3E7BVWOM^+(Q"Q:SSI]HG#
MU6Z]FA?MUN?N^7N*G7..N#UU3C?0]/HJ=W>.$>91SW,WOOY(^=M1<WQG>TJ,
MY4L7]2,>5XY?VCQC!UW2^#GKW!]G&K=05;O)3=2I2YV\2DL=34TB(<HU;6G$
M-OTCC'1]5ISG973J1B^5ONIQW_-&I<5W?!M]J%:&J:E=TKB,\RC3IRPGC^H_
M O.#. :O#\YNM?JX@ZG/RNBXK&,8ZLY5VJ0='BS452?*N]2^';]U"M8DO>U8
MS,.\<+7>F>Z:U32J\ZMK&J^:4XM-2Q';HO#!SSM)XXG"J[.P="HX3G3J*=.6
M4NGFC/=C6:G"]TJGQ)WDNN_[D#1.UVA2M]1YJ5*$7.O4RXQ2STZEB(REKSLB
M6P]D_$6G:=H-.G?5W3J*M-X5.3V?V1UJC>49VBN8RS1E!5%+#_#C.<?8Y=V.
MZ?:7'#5.5Q:T*TN^J+FG34GX>9?=JVOO0["VMK>,J:KT:L(]W4Y.7"26R^Y)
MKF<0UIWVUS+::G&FC^W2M(W7^\)9<>ZGTQGKC!7#C#1U=T+9W3[^O+EIQ[J>
M[^^#D?935I7.HT:VH5:=6I*G43=>2DWOMELONUF&+K3*VC0Q.E&I)NT6Z>8X
MWCXC81K3/EVOVJFH*;EL_H:G7[1N&H/XM0:2Z_L*G_RGCV<W=S=<+:?"^A7=
M=0DY3K-N3?.^N=^AQ/M#Y:>I6RH05&+IO,8+E3W?D2M<RM]::QEW^XXQT>VT
MZA?5+IJVN%^SGW4WG;/3&46NC<>Z%JUY3M;6]<[BIGECW,XYPLO=KR3-1X*X
M6J:IPU93N+OGI5+9.%.I3<U!ORRSTX3[,JV@\06M_4U2->%+FS#N''.8N/7F
M?F68B$KJ7GSA>\:ZCPI>7%.EJ^H7-*I1J2PJ5.77;/[K,]P+5T>6G1AH=S6K
MT>>6'4BT\^/5(Y1VTT8V]U;.G%1E*M4RXK#?3J;1V(.7N6GEM_M*F_H6:?QR
MS34S?$ND:KKEEI48>W5N[YDW'$)2SCKT1CX<6Z;4I*I2N,T7T?=R_P CFW:K
M8ZO5U2PE:^W5://5<U3C-QBN:/7&V#:N!X6-+ABUI:DK:%PI3<E<**E^)XRG
MOT,15UY)F<,[I?'.B:E75"TO.>KSJGCN9KXO+=&SPGSQ3CN?*NJ74[/B&$["
MM*G%5G+%&?*G\7T/H;@"ZJ7?"FGUJTYRJ3A)MSDY-_$_$6K@TM;=.);,]U]#
M"<1:I;:;:3=W4Y%.,E#X6\O'T,V8K6[6C7M*W?TJ=7$).*G%2QMX9,5=K^GR
MQK5Y&YU95,KDY$LI/ZG:M/IZ%Q/PYHUE<W5=5+:VIPQ23CNX13W<6O XAJT%
M'4DE%)<B\/N?1W"]I:6O"6FW4;:@IJQI5)24$FVJ:>6ST6]/!I9FTKC3;73.
M#M(A3=>M&UI2:4JGQO,GG]U$VW&FF74*U2UN5.E0WJMTIKE6_FOHSBG:5Q'=
M7FN7,*%U<0MFH-4XUVX9Y5X+8[%PQH]K3TBE_N]!]_1IN?[)?%\/CY]3G-7H
MC4F?$,CIO%6DZE<.A;7+G54>9KNY+;\U]496\O:5G:U+BO+EI4UF3PWA?D?.
M/:#<W&D<;ZG&PKU;:$7"*C0FZ:2<(O;!V;AK6*>OZ7<.5).$&H2C*7.I;9&P
MKK9S"JMVC<-4:[HU-0:JYPUW%3K_ -)=:EQEHVGTY5+J[<%%)M]U-]7CP1\^
M\?XI<>:G2HQY(*I!*,5A1^&/@=,X?X2J:UPS>4+B]4ZTZW*JM6FYN*7*\;O[
M^IK9$0Q&M:TXANN@\::+K5:I3L+MU9QQE=U./5[=4;1!M]3F/!O9S7T/4[BN
M]352$W%J*HN.,//S'381QXY.4X>BF<>7AJ-U3M+>=6K+EC&$I-X;V2/F7M,U
M&GJ7%]W=6\E.E.%-*7*UTBET9].7U.%2A-5(QG'E::DLYV/F+M3HTZ'&]["A
M3C3IJ%/$(1PE\"\$==&,O/U5IB'1^%K[2-0T:>GW5S4BZ\(T6H1:>\<=<8+*
M]TC@K3*TK>YU+4(3@\-8;^OA V7LYT^TGI4IRMJ#J)0:DZ:RGR^9I/;-1A1J
M.=*,82=Q%.45AOX&6/,X<Y_C3+HG -?0EI]6.A7=:O2=9Y=6+3YN5;;Q7A@U
MCM^GR\/Z>X^-W_X)%CV'3?NRLFV_][?5_P $2Y_V@,KA[3O_ +[_ /!(F/+>
M[=1K79/JE'3J]O.[FH48U*CD^5O&88\/J=.J]HW#U"LH5+]I\W+_ #%1^/V.
M9=D5C"YU2S=:,*E+O*B<)1YD_@9N?:9PY:5--A5M+:WMYTE4G*5.@DY;9ZK[
M%M6,X9TIFM9ET'2=9M-5MXW%A5[VC)M*3@X].NS/#6N(M.T6FIZC7[J,E*2Q
M3E+9=>B?F<*[*-=N;;7K>A5KUYVZA4?=NL^3./+H=1[1HTJ_"]W5E2A*2LZT
MHMI-Q^#P9C9YP[1K9K,LEI7'>@ZG<.C8WKJ5%%RPZ,X[+[H\+SM&X>M:D8UK
M]Q;_ /<5'_@?/_!E.YN-4E"A<5:$NZ;YHM^:VV.N<1]G'OJ%*="[I6KA3Y7B
MWSS/SV:+-(ABFM>WJ'0=&URRU>SA=V%;O:52+DI.$HY2>.C7F8^XXOTBWNH6
M]2Z:NIQYH1[J;36_CCZ,T36:=7@3A&QHJZE<5%-T6Z<G2>_-+/5FK]DL*FIZ
MY:UKZK*YY:LX?MLSV[MO&_W)L\9:YIS$.OW'&VD6W+[7=<BF\0Q2F\O\D9ZP
MOJ%[2[ZWGST\N.<-;_F:#VF:9;O3[5T:-&E*,IO,::6=OH:1V.<2W-36J%A<
M7%><)=Y)NI7;7X?)_8FS,>&IUL6Q+KVL\9:+I-3NKZ[=.;<HX[J<MUL^B^IX
MZ=QMHEVE[->.:WZT9K^U'/NW.$(T])J481BYJO)RBL<WX-VS7NQJA*]UI1JS
M<H=S-\LOB6<HU%(QEBVM;=B'4;GM,X<I5G3=_NFXR_W>IMO]C-:9Q+IM_:T[
MFUN'.C43Y9=W)9P\=&OH<U[7-&M+6E3J6MM;T9*WJ2DZ=)1<FO%X\35>Q^I=
M:AQ%*Q=W65"%M.:@YMQ7Q1Z+./%C;&,I.M:+;77+KM+X<HUE3]OV\?\ =ZG^
M1G=#XAT_68J6GU^]S#G_  2CMG'BCG7:GHMG;Z7<UK>TMJ4H6^>:G1C%YYGO
ME(U7L6U"X6N75.5:LZ<;;"BYO"^./1#9$QX6=:8MB7<->XETO1E*.HW+I8BI
M/%.4MF\+HC"VW:)PY<UHTJ5^Y2;44NXJ+=O'D77&^C0U?0KNDH05Q.,5&IW?
M-)8FG]_,^>*5"II/%#IUG)PHW:BVURIJ,R5K$M:FK:LOJ.>J6U.TE<U*F**>
M'+E?7[&-TKBW2=4N:M"RNG4J4IJ$EW4XX;;2ZKZ&-N=:M*O#56[I4J52BJBB
MX1FFLY7B4<%:%3LI7EVX4W[4X58KNDN7\3Z^/4S-<-Q>9QAG]8URPTJDZFH5
MW2CE1RH2EN^G1%A6XMTV%&5:5Q^Q@LREW<MEZ',>UG3M9NN(+AVGM]2U:I\L
M*49RAGEW:QL;K9K35I-2%S[&I."3C4Y<O;R9J*PS;4G.&4T_CC0[ZK*E;7CG
M4C'F:[F:V_-&Q2FI4WCQ/E7C>\J6G%^HK3*LZ%%."C[/-QCCDCG'+]3Z3X?N
M97.GYGS96%EO/@A:N/*:>KN\2^=.T227'FK8Z^TO/Z'>NSAQ6A3P]N_E_8C@
M':(\\?ZPEX7/^1W/@.I*EPQ4E&$I-5Y;+KTB;M'B''2G^<RS^K\3:9H\H+4+
MATG-M0Q3E+..O1?5%F^,])5O[:[K_=<\O/W4^O3IC)P3B._O+KCFO2N*]Q*B
MM1G&-.I4DXP3J8PD^B.W4]+LUH7=RH6SAS>-...IG;#KRS/I[+M"X=E_^GO_
M /$5/\B^J<1:74TNG?JY?LE26(S[N6[RUTQGP9\[:;4<.-Z-"475HRU&,.3]
MUQ[S&,>1] RM+>>C4J?LE*%)2RJ?=K"W?A@;82-6TQ+2])J<%QUFA5M-3O)W
M*J9C&4)8<O\ H.I6=>G.VC.G+-)K,7@^6^'92_E5;?&^57'3/U9]!RC7J<.V
MWL\ZD98_<SGQ\A:N#2U,KF7&&D*M&BKI]_-9C'NI[_I]#PO..-'L>3VV[[M3
M?+'%&;R_R1R7L\L-0H\16=;6J=U&C&<N:5W"2BER/&7+PR;1VK/3GIEL[1VC
MFI3?[/EROA^A-K7+.W+I6CZS9ZM1[RRJ]Y3YG'/(X[K[F470^=>Q35;N?$]K
M:U+BXE2EWLG"55N+^!^!]$0EE(Q:,.FEJ;XRJ !EV
M                                                #64  Z(A]&2
M.>=J]G4N=.4X)8IT:[>7]%_D</X&K4[?7H3GG:$E^A]47]K"[MZM*HEB<91R
MXYZK!R;B;LN=2XJ7=G>55)\J5.G;_3'@SO2WC#QZVG,SEU/3)IV=NX]'"+_0
MOI2Q'<YIHE;6])I1H^ZKNX2PE*7,NFWD96O;:EKL.2O2N=/R^?*3?3;'AYY.
M<PZUM.%IV?3]OE<5H;JE6P\[>!G.,HMZ:TO!O^ZS+Z3IE/3J,X4\/F:;Q!1,
M3QHE[M>9<N[_ +K+6?*7KBCYZ[-,KBZPG/HG4Z?]G(^C;R<?Y.UI;X5K)_\
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MUWHUK2MI4JU2-.DJ:<HN/CUP;E6SW;2CEF+3Y=M.,5\N"]MZC[3;9S_/5?\
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M2WA.<73K\[Y:?-X-?XC=Y6*3MPYYV,)QO+1/KWM3^XSH_'LU#1:ZEXTJJ_\
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M0
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M"*Z(=W'+:74J ,0IY$NA4@ H
M                                           "G.^$3]R0!3AM;=24
MO/J2   \P "Z;@
M           0T_!D@ 1)-XPR4L ",>9(
M
M                 !]"%@D            P@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MI/M-7^DEZCY*#C9_O%YH=Y'S1K_M-7^DD/::O])+U'R4'$V#O%YH=XO-&O\
MM%7^DEZCVFK_ $DO4?)0<;8.\7FAWB\T:_[15_I)>H]IJ_TDA\E!QM@[Q>#0
MYUYFO^TU<;5)>H]IK?TDO41_D83C; IKS*D\F A>3C^*4W^9=TM0BWAJ1WIU
MU939+*@MZ5=32W_4]T\GMIJ5OZ8F,) \@=$
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M,1;WN%B3DS(TJJDDU]#Z.EU-=3TY37#V!2GN5'JCRR  H
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MZ'2]3-)Q+E:C98O*)+.SKJ<4LY:2\2\1^CTM2+QEYYC  #J@
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M6K:D^$F/#8;>LIQRG^A<IY1@;&LX3PY/&/,S5*7-%'Z3I-?DJ\MJX>@ /<P
M
M  0 \J\^2E)GJ6&HU,4)I>2_M//U%]E)E:QF6-O*CJ3?W+=;+!+;;?4I\3\M
MKZFZSUUC$) !P;20 4202 ()  @  202%XA$$H * $ 202O$@ O$="2 ) 1
M$HD@((D@ !X$$@*#H02$ " )7B @ 0 \ '0$ *D !$>!(("@    "2"2&!*?
M*AX$$]5L(\3EG#WL:KIU,?,T9RE/FCDUU/=-?NF8T^?-23^Y]OH-;Z<-2%^
MN@/MPX@ *
M             !1)XR5^!;W$\0?V9RU;;:Y6(RP]_4[RHTNC2+==%]"E-R>7
MDJQL?E=?4FUY>ND8@ "/.VC )R ( ) @ D!$D@!$D>  $ (D*@D !D  &&
M)()$H@E $$>8 *()\ 0%2""0@020% B2 )()1 #P     "< (" 2 (P"0!
M %/B5%*W>"2*HMKXD9O3ZO/#'EA&%QB./$O],GRRP_%H^CT&K,7PXZD,RN@(
MC^$D_35G,/,  H
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MG%4Y)? WOE9-CI[3;QE8//:)K*Q*F6,[=""9)I[H@D-(!(P   0&0 H/$=0
MP@MEL!X$!;9^IDM,D^5)=-S&^#,AI?A^9]#HI_FY:GIEX]"2(]"3]-7T\H #
M0
M     >!8WKPG^9?%C??A]3R=7_1JGM@ETV*UT*2I=#\K?V]D!**<$F0   @E
M@*A$C(    (Q<GA=02OH$137,GCJ>G(DEGJ<_P"+>,M5T!NJM,I2LX4^\J5I
MR:4=VO#\O4L.$NT.^XGO)T+&QH5>2"J2[N4MHY2SO]SO&A,UW,S9TN?PSQX$
MI/;R,%Q'J>H:?;5:FG6,;M146FWU;>&CG$.V"Z]Z^[IV%I&NJW<2ASRRI<W+
MC[Y%-"UO1-G9HTW*7A@J2A)2PGF/4QFC5[NYHQJW=#N<Y3P^AY\37USIUG*X
MLZ"K\E.<Y)O"V64<IIYPN?#*I*7PQ_%]2A)^)SK2..]8U.^E9T=)HNI&#GB,
MGG&W^9FN*^(=4T.QE>0TZ%2%*GSR<VTD=.*?$)EMF!-.#Y9?B>ZP<@TGM5U+
M6;F=O8Z9;5KB$>>=.$Y9BLXS^J,Y6XMXEMESW.@TX4UUE*3V_4U;IYK[-SH2
M:6TNI6H>?4TC0^T?2[NI.WU&YM;:Y@DI4\O*EGH9O6[Z_M8N6GVGM*27CXYW
M,<%L^5W,QNW+'@3ANBI+\63C5QVPW=#5ZNFRL+17$:[M^1SEGF4N7'WR='X9
MU74[Z,7J.GQMH-/=/.Z>QK4T+4B,I%FQN*Q''YE$XI;^!5",</X]WX$J&'U;
M?D<(:R\YQ<6HOJ^A3AK.35^(>*HV>:6D=U?5Y0S&#;3<LO8TO4.T/BNQ2E=<
M-T:5#FQ&I*;W_7[G?3T9O#,RZW3;>[Z$]&\]/ U?@OC:SXHM4^\MZ=>524(T
MZ;;SA)YW-I6SQX+Q.=Z36<2L2A9Y&5KE:Z/)'XI;"/*V^:7+)?A7F<XE5>(Q
MCF2>"B2Y&D^KZ$;QFYQ7-4Z<GACS-9USC;3-.BZ5O=6]:^FGW5&3>9R7@=*:
M<W3+:)1Y8*3\3S3ST-+T[B7B"^;J+1(=S)9C)2>'OCS-OL:M:=)NO15.6>A)
MKA8E[N+PL!KEE@A[MY>"<+KG)@  53P(\"2 B4/$  020%"/%$D>)F14WG=]
M3WL9/OX?='@^A[67\_#[H]G2?WASOZ9^FW@K/.ET/0_4Z7IY9  =$
M                                                     !!$NAA=
M2_G%_5_Q,S+=&&U/^=7]5?VL^=UW])=-/VL@N@!^;GV]4"\0 0 @1@*D@D=
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M()0"B"  !]  (,EI?A^9CL&0TSJOLSW=%_=RU/3+QZ$D06Q)^HKZ>4 !0
M
M +&__#ZE\6-_T]3R=7_QRU3VP?@5+HBE$H_*6]O9"0 1<A")( $@!    AD
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M67_$0_K'KZ3^[%_3/4NAZ'G2Z'H?J=+^KR2  Z(
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MG4V_2^ M'MDI5[*SK7";:J]UNECI_;ZFO+C^^>T9T.1=/V3*%V@2>TJU+_\
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M/=T7]V-3TS$>A)$>A)^HKZ>0 !0
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M>20 '1
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MA)$>A)^HKZ>0 !0
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M+H>AYTNAZ'ZK2_J\D@ .B
M                      "EF&U/^=7]7_$S+,-J?\ZOZJ_M9\WKOZ2Z:?M9
M(> !^;M[>N!>("\2""0$ "&!RX6Y&4$2$1-\DN5]>I7"#GTP!2$52@XO#P0E
MN%0"IP:\B(QYI)+JPB$#T[J2;6QYR^%X8 $+?.!3^-X0$@G&&TR7'$<LBJ0^
MA+BTXI_O=!./*W%]4,H@+J5=V_H0XM=2Y52$5RIN/7!$8N3:7@,HI))Y'S\N
MV28TVW)+&Q,B@GS$XN,L,JC!M-K!<JH1+*G!I9>",#*(\ 5]V\>!"BW-1\6,
MJH))E'E;R4Q^*6$!(\!+8IYEEIE1403X9(C\3PNI% 5.#2\"5!X\-R0*? $N
M#4N5XR2H/?H:3*D$+=X)2( &/,   %2""? (@R&F=5]F8][%_IG5?9GNZ+^[
M&IZ9B/0DB/0D_45]/(  H
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MJ70]#SI=#T/U6E_5Y)  =$
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MG;T$VU""PDWU+J"ZN+POWEYGS[XSB&X5./+!8WCX,I*F\PV>(^"*48A<()\
M HNH80"#Z%_I?5?9EA_@9#2^J^S/=T7]V-3TR\>A)$>A)^HKZ>0 !0
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MGJ70]#SI=#T/U6E_5Y)  =$
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M^J^S/=T7]V-3TS$>A)$>A)^HKZ>0 !0
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MT/0\Z70]#]5I?U>20 '1
M                    !X 0S#:G_.K^K_BS,&'U/^=7]7_%GS>N_I+II^UC
MD#/T!^;M[>J$KQ( (!!* 5.R?-#JO,A1BY.<OQ,EX\-BA9;>^$2/]HYEVL6-
M_.\CJ.F1IN\HV\(4^=_#^.6<K[29[\,<82L+"VAQ).,)PHPC#N:;?QI;]#H%
M:UHUX-5Z-.KX?'!/^TH]SZ74@E5T^RGA;<U"+Q^AZHUJ[-N&<-/U[M&LJEE.
MGIM64KQM-*=%XQG<TC@7L^O[[BFXXBU:E%1]MA?4)4ZJ64YN;;7IL=C>@:0G
MS+3+!R\_9X9_L+RA2A;15.A",(22CB"PHK[&Z]3LK,033+7NT"QEJ?#L*&,I
M5XRZXZ*7^9H?!FNZSHU2O'7U;PM(U?A=*/,^[6W@^IUZK2A*/+-1J1\FLHM?
M=5A4356RM9*7S48O_ Q75C$Q)AK-;M'X?A'XZ];K_0R.7:MP_JG:)Q9I^H3I
MTYV-&*MJDHS5.2PY2V3_ *R.YU.'=%G'#TS3OSMH?Y'O;V%I9K_<[:A16<XI
M4U'+\]C=.HBGFJ;<K;AK38Z1HEGIU--*WIJGAO/3ZF3BG!]W^Z]RFG+#;<=V
M54WS+FEL_)GEM:;3F6XC"UUM0>E7:W[SN9]W]^5]?T- X,U^XT^C2M-0<(N/
M,VHQSUW1TN2A.+C.,9)K&&LEE+2=/_&K2UY_/NHY-5OXPD^6@]H56RXCL8V=
MG*<[JK2J4J::Y4YR22W^YE.SWAAZ3P?I]EJ47&O24^=0GE;SDUO]F;3+3[*,
MZ<HV5MS1>5)4HY3\^A<RBN3X=OHCOW,XVPFQ\WZIP9KW!NM6^I:?1HKNY.MF
MI44_'R_,VW3.T?6:]&%&L[;VF*^)*EMGU.O7=I;WTHJZMZ52*6,5(*2Q^9;T
M-#T>G6FXZ3IZ>/Q*W@L_H;MU,7K_ "]IMPU[AVSUN_U"CJ?$=.A&]H-TZ?<M
M<O)ROJO/,F8[M0X&EQ+:T:M"#E7H2G67[116<;?V&_J/(L1_0KI/X9J>Z:QN
M<JZTTONA9KX<D[-=<N>%+6.E\1N%*+J3JM4H\[PTL;KZHSW%7$"UW3;C3M&D
MIN\HU+?%2/+GG7+'=].IM[TC3JT>>O8VDZG3FG1BWC\T51TJPI2IRHVEK"46
MFG&E%--=!;6W3N,>&E]EW!4N&;*E=WT'#4<3IR4:BE'E<MNGT2-,[;W+6]0L
M?=^)NC3J0GS?#\63N:2:PWA%G7TC3:M2+J6-G4?BY48O_ U7J?YY3;X:;V0W
M]O9<':=I]U*2O:,*CJ12REFI)K?[-&T<5Z13UW0;VPQ*4;BGR84N7Q\R^I:;
M84'BA:VU+PS"E%?V(N88<T\\J7@<YUOY[UV^'S53T[B'LZUV^GI=.WC;UI=T
MG5DJCY5O]#=;3M$UO4<4K1VTJTWB*E2PMM_/R.KW.EV%[5F[NUM:N^4ZM*,M
M_P RVHZ%I-'XJ.FV-*:Z.%O!->B.]^IB\9LD5:QPSI.IWM>=YKL*<>;EK4W2
MDOQ-Y>4;OB4MYXY?H1&*A",()**6%A8"6'C.4>.]HEO&'G<\BM:W/G\#QZ'.
M+_B6&DZY<*C+]K%)/FAE8<4SICC'#C+$U+;=="QK:-IM6;G5L+.I4?6<J,6W
M^>#>G?:DQEH/\O[Q27)*EC_LG_F>=3M!N7)\\Z7Y4G_F;_'A_2TFO8;+?Q[B
M.WZ%<-"TB"^+3;";\W;P_P CIRUGVF&CZ7QW=7-[3H*5)TYMY_9X?3[GEQIQ
M9KFD4;6XLE;=S5J--SAE\J7W-[]RZ;":G1L+.G)='&A%?X'I7TRQN:4:=S9V
MU:$>BJ4HR2^R:)%ZQ.3RT;ACM+L;NCW6HUI*X<GA0HO&,?\ \2GB-7W%5:VA
MI$:=2TC*2KN?P-0GC&,^.$S<Z?#NC49KN]*T^+^:-M!?X%[:VEO:N7<4*5-/
M'X(*.<?83J5B<U,2Q_"VAT>']+AIUDIJC"4I+GES/+>>IEX?$I)?AZ2*DN>I
M^+E6.HI8:GG$<?\ Q'"]IM.96(PEN*IJ$,X3\2@EXQML02%@     'NB_P!+
MV:^S,?GK@R.E[M/Z,]W1?W8U/3+QZ$D1Z$GZBOIY  %
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M^624,;!;'Z2'G  4
M                    "UNH9B_S+H\ZL<IG#7IOIA:^VL*.(E:Z(]+FFZ=;
MEWQ@\S\IK4FML/76<P !'*&X    00# )R1DJ !!%2$0,@20!X 2@0 )"\1D
M / $ "2 2@&   "  @E   0 B4$0 J?$$ "< 9""  "H)()\ !'B !(0  >
M\ N@0\0  *7U*BE+=D%4=T7>G0S53^J+/I'",MID,1;:\CZ'0TW7RYZEF1@L
M1*A'H#]-6,0\H #0
M                 !XUXJ4&F>Q$NC,7KNK,+#7;J"C5ECS/+J9F\H=XO'QZ
M&&E!TY;KU/S76:$UG,/3IVS"%U9)0\M[%7B?/S+JE>(1&'X(B.W78J*D"$A@
M  \^0P\$R920,#? R)!&!@9$CQ(P,#(D$88P,B40A@8&3*0,,AHN3*6$1AC!
M,B0B$O,-^!1)"\0OJ3C'Y@$&0D\D[C(#!&'Y$X9,@",$X8 CP&&,#(D@88P,
MB<@C P4$21@8)D"2.4)8&1(&&0EU&1(P1]^A"SX#(J(;P0D_$8\@))ZQ*4EC
MKN54Z<JDL)/\C>G2;V29P][.ES5%TV:,[1@HK"+6RH=W'QRTNI?(_2]%H[(S
M+S7MD !]!S
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MUI][4P_(SEO34(I)>1;V=OW<5U+Z'0_1=%T^R,R\M[92 #Z;F
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M"PL[+![1374^MTW113S+C:^2,<%0!].*Q#F  H
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M1Z<P %
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M4UY+T*E'!(-12(3)@ &P
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M  U@
M                                                   *9+J5%,C-
MO0P=_P#\>OZO^9EK3^9A_51B=0_XY?U5_B9>T_F8?U4?-Z?_ )I=;>GN #ZC
MD
M
M                 %M<_@9<EO<_@9PUOZK5B=(_XN]_KK^UF<A^$P>D?\7>
M_P!=?VR,Y'H>?I?MJRI ('NA@ !0
M
M                                       ID5%,C-O0PFH8]N7]4RMI
M_,P_JHQ6H_\ 'K^JO\3*V?\ ,P_JH^;T_P#S2ZV]+@ 'U'(
M
M
M   +>X_ RX+>X_ SCK?U6&)TC_B[[^NO[9&<CT,'I'_%WW]=?VR,Y#\)YND^
MVK*D #W0P  H
M
M                       4R*BF1FWH834/^/7]5?XF5M/YF']5&*U#_CE_
M57^)E;/^9A_51\WI_P#FEUGTN  ?4<@
M
M                                               M[C\#+@M[G\#.
M.M_588G2-[N^_P"T7]LC.0_"8/2/^+O?ZZ_MD9R'X3S=)]M65  ]T,  *
M
M
M        $2Z$E,O$S;T,)J'_ !R_JK_$RMI_,P_JHQ6H?\>OZJ_Q,K:?S,/Z
MJ/F]/_RRZV]+@ 'U'(
M
M                                  +>Y_ RX+>Y_ SCK?U6&)TC_B[W
M^NO[69R'0P>C_P#%WW]=?VR,Y'\)YND^VK*D #W0P  H
M
M                                                       4R\2H
MI?B9MZ&$U#_CE_57^)E;3^9A_51BM0_XY?U3*VG\S#^JCYO3_P#-+K;TN  ?
M4<@
M
M                   M[G\#+@MKG\#.&M_588K2/^+OOZZ_M9FX_@,'I#_W
MN]_KK^V1G(_@//TGVU96@$#W0P  H
M
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M8+1,RKW<OFDG^K,Y!;&^D])9Z($1Z$GT&
M
M                                               *6RHC&P'A5MJ5
M;><(R?U/+W?;_P!% O$L(-=#C;0I/F87=*S]WT/Z* ]WT/Z*!>X!GMZ?B[I6
M7N^W_HH#V"W_ **!>C!>WI^)NE9>P6_]% >P6_\ 10+W P.WI^&967L%O_0P
M'L%O_10+W P.WI^&967L-O\ T4![!;_T,"]P,#MZ?ANE9>P6_P#10'L%O_10
M+W P.WI^&Z5E[!;_ -%#T'L%O_10+W P.WI^&Z5E[!0_HH#V"A_10+W P.WI
M^&Z5E[#;_P!% >P6_P#10+W P.WI^&962L+?^B@/8+?^B@7N!@=O3\-TK+V&
MW_HH#V"A_10]"]P,#MZ?ANE9>PV_]% >P6_]% O<# [>GX;I67L%O_10'L%O
M_10+W P.WI^&Z5E[!;_T4/0>P6_]% O<# [>GX;I67L%O_0P'L%O_10+W P.
MWI^&967L%O\ T4![!;_T4"]P,#MZ?ANE9>P6_P#0P'L%O_10+W P.WI^&967
ML%#^BAZ#V"W_ *&!>X&!V]/PW2LO8+?^A@/8+?\ HH%[@#MZ?AF5E[!;_P!%
M#T'L%O\ T4"]P,#MZ?ANE9>P6_\ 10'L%O\ T4"]P,#MZ?ANE9>P6_\ 10'L
M%O\ T4"]P,#MZ?ANE9>P6_\ 0P'L%O\ T4"]P,#MZ?ANE9>P6_\ 10]![!;_
M -%#T+W P.WI^&Z5E[#;_P!% >P6_P#10+W P.WI^&Z5G[OM_P"B@4RL:"3Q
M2@7Q1-;/!B^A3'I8M+7;BC!7-2*BE@RL+&W?_JH&-NF_;*N#.TTCP]-I5F]H
MPW:9PM_=]O\ T4"?=]O_ $4"\!]'MZ?CGNE9>P6_]% >PV_]% O<# [>GX9E
M9>P6_P#10'L%#^B@7N!@=O3\-TK+V"W_ ** ]@M_Z*!>X&!V]/PS*R]@M_Z*
M ]AM_P"A@7N!@=O3\-TK+V"W_HH>@]@M_P"B@7N!@=O3\-TK+V"W_HH#V"A_
M10]"]P,#MZ?ANE9>P6_]# >PV_\ 10+W P.WI^&Z5E[!;_T4![!;_P!# O<#
M [>GX;I67L%O_10] K"W_HH%[@8';T_#=*R]@M_Z*'H/8+?^B@7N!@=O3\-T
MK+V&W_HH#V"W_HH%[@8';T_#=*R]@M_Z* ]@M_Z*!>X&!V]/PW2LO8+?^B@/
M8+?^B@7N!@=O3\,RLO8+?^BAZ#V"W_HH%[@8';T_#=*R]@M_Z* ]@M_Z*!>X
M&!V]/PW2LO8+?^B@/8+?^B@7N!@=O3\-TK+V"W_HH#V"W_HH%[@8';T_#=*R
M]@M_Z* ]@H?T4"]P,#MZ?ANE9>P4/Z*'H/8+?^B@7N!@=O3\-TK+V"W_ **
M]@M_Z&!>X&!V]/PW2LO8+?\ HH#V"W_HH%[@8';T_#=*R]@M_P"B@/8+?^B@
M7N!@=O3\,RLO8+?^B@/8+?\ HH>A>X [>GX;I67L%O\ T4![OH?T4"]P$.WI
M^&Z5G[OM_P"B@0]/M_Z*!>C [>GXNZ5O0M:5'F[N$8YZX+A8P1N2=*4BL>&1
M  V
M
M
M                             4S_  LJ(G^%_8S?U)#7KK_C*IGJ1@;K
M_C*IGJ1\WI/[V=;>GH #ZCD
M
M
M
M
M!3/\+*BF?X68OZDAK]U_QM4SU(P-U_QE4SU(^?TG][.M_3T !]-R
M
M
M
M
M                              IE^%E13+\+,7]2L-?NO^-JF>I&!NMK
MVJ9ZD?/Z3^]G2_J'H #Z;D
M
M
M
M                                                           "
MV*9_A9+914ELSG>T8E88*Z>+RJ9VF8"YWO:KR9V$CYW2S&^SI:/$/8="$T,G
MU(F)<D@+H"@
M
M
M
M                                           >=634)8ZX9Z$22<7E
M(Q>)F/!#!U]2G2J.$N58^AXO5HM/,E_TLO=0L8UHO"C&65\7+N:Y4@Z4FI1?
MYK!^8Z_6UM)Z]*M97%:[4ZLI96_T+Z.JI/=K_I9A6LMXV*X1YY))9?T/D:'6
MZN[$.TZ=<>6:CJO-)*#77Y69FUDYP;EY^!B-,L(Q2G-*64GAQZ&;I145LDC]
M9T'):,W>.^/I6 #ZKD
M                                                     0
M
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M9?B<8_\ ,7=.O&?X91?V9Z:=32_IB:S#W!">23TQ.60 %
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ML"F#V*C[%9S#B  H
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M262=:E!M3G%/ZM$1K4IOE52#D^F)(YC4X*N^)(^T:];5:-6?QM4*D4N;I]?
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M8
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M5I)8ECQ-JB^6IRR^-_.<;[!>(+J_]OTF][I+3Z-."4(X?5K=YWZ'8H)*W?\
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M:JUEU?>4OB_Y6=CX.4?Y,:3RY_X.CG_H1Q__ &@LQ=:*_!WE+^ZSGH>-:/\
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M-0^R/O\ ^,M,P\VM'E<  ^Z\X
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M+K^9S[4.S*>H:W<ZG=TZ4KFO+FG)5FDWMX8^ANVH:5=ZQPU>:?JKIU*M9I?
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M5(Q>&UUZI>>#+<+<*6>ASJ5K>FXW%6"C4?>.2>^?$X4U8TO/VUC+%=L$80X
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MWJ1Y8)UFWX?3Z&ZZ](K,)MEN&M:_9VNNVNF74+>=&XIJ4JE2JE&*S+JFL/\
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M.,:CYW)-K[FK=1NI-;+%<2STL+RD_,B4LX(73?J&XM;9/G?;< ("(IX$H H
M, "$2O$$!>)!*\0  (P!)!/@042BA]2LI\2"J.[Q@V2T7[*'V1@;*"J5L?0V
M&@N6*7T1]_\ Q=?&7EU9R]0 ?=<
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M+I'ZKH]+91X[3F0 'M8
M                         !$EDM+NW56$D\[XZ%XO$IDMCCJZ4:D8E:SA
MK-:WE0G+*>&WU/+.>AL5>VC5B\I>)B[BR[O/+C\D?G^IZ"8\P]--3/M8^#R0
MEY%3BT]R,I>!\V=*U?;M%H  S.P,$X(3P3D; 2& F"; P,$$Y&P,# &1L# P
M -@# 3 V!@#(R-@8"00&P1@G S@#8&!@#(V",$I! ; P,#)(V",$$@; P,#P
M V@,#(&P",$Y V!@C!.1D;1&"< 9&P!@9&1L# 1&2<C8 P!D;)# P$^HR-@8
M& !L$$C(&P,$8)R!L 8">PR-@8() V A@#(VA@8&0AL$8) \!L$8&"4,C:()
MP$,C8 P,C(V!@)#(&V1&"< 9&V1'+A;$CPZD1W3+MDS!X$D)9;W))C((> 0&
MP1@E(9"8V / #(V!@@G(R-@# ZA#8 P1DD; & !L# P!D; & ,[#8& B,DC8
M& !X#8&!@9"8V",$X R-@ #(V!@#(&P",$D9&P,$X &P, 9 V!@#(0V D!YC
M(V!@8" V D,#(R-@# R,[,; 0'@!L# P/ #8&",$C(V!@C!(\!L# P F-@8V
M(P2F!L# P$!L 8 R-@8V &1L# 2&1D; & !L!(8V R79((9R/ A$V!RA;,+(
M+%,B)++V)PDMR<-O"1<V]G*I^*2Q]CMI=/:R6O$/"A1E4?PK)FK2VY(I[YPL
ME=K:0I+HLY+Q121][I.BBOF7EO?*(K"*D, ^I6,>'( !H
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M)%8/331K7TQF1+  .N$  4
M
M
M                ID_A944S_"S%_4K#7[K_ (VJ9ZD8&Z7^^53/TO$^?TG]
M[9=+>E8 /I.0 "@
M
M
M
M                                                 !3/\+^Q44S_
M  O[&+^I6&OW7_&53/4C!77_ !E4SM(^=TG]Y=+>GH #ZCD
M
M
M
M
M                        !3/\+^Q44S_"_L8MZE8:_=?\95,]2,%=?\95
M,[2/G=)_>SI;T]  ?4<@
M
M
M
M                                                         *9_
MA?V*BF?X7]C%_4D,!=?\95,[2,%=?\95,[2/G=)_>SK;T]  ?4<@
M
M
M
M
M                           "B<U&+D^B623.!+(G^%EE/4J66OB]"B6H
MT\/>7H>/4ZS2K$QEN*3*QN-[ZJ9RF\/!K=>Y@[B<EG?Z&4CJ--/&9>A\WINK
MTXO:<NEJ3AE$/'.?R,<M3I-X?-Z%Y0J1K1YEG&<'V-/J*:G]7&:S#V 0.Z
M
M
M                                                     %GQ
M!D9)D ,C(R &1D9 #(R,@!D9&0 R,C( 9&1D ,C(R &1D9 #(R,@!D9&0 R,
MC( 9&1D ,C(R &1D9 #(R,@!D9&0 R,C( 9&1D ,C(R &1D9 #(R,@!D9&0
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MD9 #(R,@!D9&0 R,C( 9&1D ,C(R &1D9 #(R,@!D9&0 R,C( 9&1D ,C(R
M&1D9 #(R,@!D9&0 R!D ,@9  %
M                                         "$O,D/H00O$AS2\3SJ5
M5",OL8JXO\9Y5)'DUNJKIM5K,LG.YA#\32/!W]%/^<7HS"SKU:G6;Q]3Q<L-
MYW/E:G^3F)\.]='/MG?>%+YU^H]X4OG7ZF#!P^2NUPPSGO"G\R_4>\*7SQ_4
MP8W'R5SBAG/>%+YX_J3[PI?/']3!+(W'R=SBAG/>%/YX_J/>%+YX_J8/<C<?
M)7.*&=]X4OGC^H]X4OGC^I@T$/D[G%#.^\*7SQ_4CV^E\Z_4P8W'R=SBAG/>
M%+YX_J3[PI?/']3! ?)7.*&=]X4OGC^H]X4OGC^I@M_,;CY.YQ0SOO"E\\?U
M'O"E\\?U,%N"?)7.*&=]X4OGC^I'O"E\\?U,'N-R_)W.*&<]X4OG7ZA:A2^>
M/ZF#W ^3N<4,Y[PI8_'']1[PI?/']3!@?)W.*&=]X4OGC^I'O"E\\?U,'N/
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MR2VM[A5(]'U+A/8^KIZL7C,.4QA( .J
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M
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MYHIGZ?\ QVKNKAX]2N)>H /JN0
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MV5"C&C1M+IT'6HS<LQE-KF?Y1R9OC_0Z6F\*4J,KR5:,;B/[2:ZY4F6:SO\
M/@SX6O8-J=>_T[5(W=3G5*O"%/X4L1QTV+KMGTBSGI=O<JC_ +Q4N5SRYWNN
M27AG'@C$?[.;Q8Z_RKF4;N/]C-F[8L3T*T<GROVE?W)#4IMUO!GPU?\ V<YM
M<-WT<];^7_=P-B[5=,M[G2H2E3S/O7)OF:_=9KW^SC4<>&[Y<J?_ -(2W_\
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MV1]__&/-J^UR @?>AYP
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M]]SBVHWMM_Z4=8NU53MZE-*,\/?X8?Y,^F-/O;6[H?[O64\)+9,]O53BM?\
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M2<RJ !]AQ
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M2WISO:(A=:?1[NDMEG<O5L1".$5'ZC1T]E</',Y $#N@
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MY1]1V=S?"SP,%XK"MY1]1[!5\H^H[.YR0L\#!>>P5?*/J/8*WE'U':7-\+/
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M?\-\++'U&"\]@J^4?4>P5O*/J.SO^&^%F27?L%7RCZCV"KY1]1V=_P -\+/
MP7GL%;RCZCV"KY1]1V=S?"SP,%Y[!5\H^H]@K>4?4=G?\.2%G@8+WV"KY1]2
M/8*OE'U'9W-\+,%Y[!6\H^H]@K>4?4=G==\+/ P7GL%;RCZCW?5\H^H[2YOA
M9X&"\]@JYZ1]1[!5W_#ZCM+IR0L\#!>>P5O*/J/8*WE'U'9W_#DA:8&"[]@J
M_P /J%85?*/J.SO^')"SP,%Y[!5\H^H]@J^4?4=G<Y(6> 7GL%7RCZCV"M_#
MZCL[KOA9C!>>P5OX?4>P5O*/J.SN;X6>!@O/8*OE'U'L%7RCZCL[IR0L\ O/
M8*N>D?4GV"KY1]1VE_PY(6)*+SV"KY1]2585O*/J.TO^')"RP,%[[!5\H^H]
M@J^4?4=G?\-\++ P7OL%7RCZD>P5O*/J.SN;X6>!@O/8*WE'U'L%;RCZCL[G
M)"SP,%Y[!6\H^I/L%7RCZCL[IOA98&"]]@J^4?4>P5?*/J.SO^+OA98&"]]@
MJ^4?4>P5?*/J.SO^&^%E@8+WV"KY1]1[!5\H^H[2_P"&^%D$7JL*N.D?4CV"
MKY1]1VE_PY(6>"2[]@J_P^H5A5WVCZCL[_AR0L\#!>^P5?*/J/8*OE'U':7_
M  WPLL#!>^P5?X?4CV"KY1]1VE_PY(6>"<%W[!6\H^I/L%;RCZCM+_AOA98(
MP7WL%7^'U"L*OE'U':7_  Y(66!C<O?8*OE'U)6GU7X1]34=%?\ #DA8XP_F
M/2G2G4Z0DOR,E1TU9_:+T9?4;:%+HOU/7H?XVWVQ.JLK*R269I/?QB9.$.5)
M+^PJ@DD5'V]#IJZ<>'GFV1  ]+( "@
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M"(6<D@H
M
M
M   %,_PO[%13/\+^QB_J5A@+K_C*IG:1@;K_ (RJ9ZD?.Z3^]G2WIZ  ^HY
M
M
M
M
M                                     4S_  O[%13/\+^QB_J5A@+K
M_C*IG:1@;K_C*IGJ1\[I/[V=+>GH #ZCD
M
M
M
M
M          !3/\+^Q44S_"S%_4D-?NO^,JF>I&"N?^,JF>IGS^D_O9TMZ5@
M^FY@
M
M
M
M                                         4R_"RK)1)_"SG>8PL,!
M=/\ WRJ9^F8"Z_XRJ9VE(^?TEHWV=+>GJ",DGT\PY  *
M
M
M
M
M                !14ER0E)]$LE93-9BU]#%O1"P]X0YN5*?HBGVV+37Q>B
M++5=/E-RJ0YG)M;;&%E%K*DL-;'Y[K>MU-'Z>C3TXLR-Q<P=S4VEDR<+Z,?"
M?HC6?##)CE/IOX(^3H?Y.T7G'V[VT8PVJ.H0VVGZ(O*%55H\T<XSC<UO3K"<
MY=Y-22:31L=&/*C]/T6M?5\VAY+Q$/8!= ?2<P %
M
M
M                                ".8DS$"2,GC5KQAGF?Z%L[^BOW_T
M9Y[]16OVU%99#(RC&^\*7S+T8]X4?F_1G+O:?J[)9+*&3&>\*7S+T9/O"E\R
M]&.]I^FR62RAE&-]X4?F_1D>\*7S+T8[VGZ;)9/(RC&>\*7S+T8]X4?F_1CO
M:?ILED\H9,;[PI?-^C'O"E\R]&.]I^FR62RADQGO"E\R]&3[PI?,O1CO:?IL
MEDLC*,;[PI?,O1CWA2^;]&.]I^FR62R,F-]X4OF7HQ[PI?,O1CO:?ILEDLC)
MC?>%+YOT8]X4OF7HQWM/TV2R61DQOO"E\R]&/>%+YEZ,=[3]-DLED91C?>%+
MYEZ,CWA2^9>C+WM/TV2R>1DQOO"E\R]&/>%+YOT8[VGZ;)9+(R8WWC1^;_X6
M/>%+YEZ,G>T_39+)9&48WWA2^9>C(]X4OF7HR][3]-DLGD9,;[PI?,O1CWA2
M^9>C)WM/TV2R61DQOO"E\R]&/>%+YEZ,=[3]-DLEE#)C/>%+YEZ,GWA2^9>C
M'>T_39+)9&48WWA2^9>C(]X4OF7HQWM/TV2R>1DQOO"E\R]&/>%+YEZ,=[3]
M-DLED91C?>%+YEZ,CWA2^9>C'>T_39+)Y&3&^\*7S+T8]X4OF_1E[VGZ;)9+
M*&3&>\*7S+T9/O&E\R_Z6.]I^FR62R,HQGO"E\R_Z6/>%+YEZ,G>T_39+)Y0
MRC&+4*7S+_I9/O"E\WZ,O>T_39+)9&3&^\*7S?HQ[PI?,O1D[VGZ;)9+*&3&
MK4*7S+T8]X4OF7HR][3]-DLEE#*,8M0I?,O1D^\*7S+T8[VGZ;)9+(R8WWA2
M^9>C'O"E\R]&.]I^FR62R,F-]X4OF7HQ[PI?,O1D[VGZ;)9+(R8WWA2^9>C'
MO"E\R]&.]I^FR62R,F-]X4OF7HQ[PI?,O1CO:?ILEDLH9,9[PI?-^C)]X4OF
M7HR][3]-DLED9,;[PI?,O1D>\*7S+T8[VGZ;)9/(RC&>\*6/Q+T8]X4OG7_2
MQWM#9+)Y0RC&^\*7S+T9'O"E\R]&3O:&R63R0VL&-]X4OF7HQ[PI?,O^ECO:
M&R5[4BI(P.HV/6=+"PF_N9'WA1^?_P"%GG.\HR3^/]&?/ZR=+7K_ +=*9K+6
MVL-J2^)=69#3+-U9J=3&$\8:*KBE;5:DI2G/+?A__ R$+NBOWOT9\;INEI%\
MV=K6G'AD+>G&$$DDDD>WVZ&.5_2^;]&5+4*7S+T9^ETNITZ1B'FFLRR*:P3E
M&,]OI?,O1CV^E\R]&=>]T_U-DLGE#)C/;Z7S+T9/O"E\R]&.]T_TV2R64,F,
M6H4OF7HR?>%+YEZ,G>T_39+)90RC&^\*/S?HQ[PH_-^C+WM/TV2R61DQOO"E
M\R]&/>%+YOT8[VGZ;)9+(R8WWA2^9>C'O"C\W_PL=[3]-DLED9,;[PI?-^C'
MO"C\WZ,=[3]-DLED9,;[PH_-^C'O"E\R]&.]I^FR62R,HQOO"E\R]&1[PI?,
MO^ED[ZGZ;)9/*&3&>\*7S+T9*U"E\R]&.]I^FR62RAE&,]X4OF7HPM0I?,O1
MCO:?ILED\C)C/>%+YEZ,GWA2^9>C+WM/TV2R61E&,]XTOF7_ $LGWA2^;]&.
M]I^FR62RADQGO"E\WZ,GWA2^9>C)WM/TV2R61DQGO"DE^)>C"U"G\R]&.]I^
MFR63RAE&,]X4OF7HR?>%+YEZ,O>T_39+)9&48WWA2^9>C'O"E\R]&.]I^FR6
M2R,F-]X4OF7HR/>%+YEZ,G>T_39+)Y&3&^\*7S+T9'O"E\R]&.]I^FR63RAE
M&,]X4OF7HQ[PI?,O1CO:?ILED\H91C/>%+YEZ,+4*7S+T9>]I^FR63R,F-]X
M4OF7HQ[PI?,O1D[VGZ;)9+(R8WWA2^9>C'O"E\WZ,=[3]-DLEE#)C?>%+YOT
M8]X4OF7HQWM/TV2R64,HQOO"C\WZ,>\*7S?HR][3]-DLED91C/>%+YEZ,>\*
M7S+T8[VGZ;)9/(R8SWC2^9?]+)]X4OF7HR=[3]-DLED91C?>%+YEZ,>\*/S?
MHQWM/TV2R61DQOO"E\R]&/>%+YEZ,=[3]-DLED9,;[PI?,O1CWA2^9>C'>T_
M39+)90RC&>\*7S+T8]X4OF_1CO:?ILED\H9,9[PI?-^C)]X4OF_1CO:?ILED
MLC*,;[PI?,O^ECWA2^;]&.]I^FR62R,HQOO"E\WZ,>\*7S?HQWM/TV2R641D
MQRU"E\W_ ,+)]Y4OG7_2R][3]-DLCDC)C_>-+YE_TLE:C1?[_P#\++'64G[-
MDL@"WI74*G26?R9[*:9WKJUMZEG$J@$#IE  %
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M !0
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M;1F&S6U;O::>%ZGNMC#Z57;:AE]'X&8B\H_5]+K<E(F7BM7$I !ZV0
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M86LY5> 1"_"@>-L!*\0 (!* $!$E#(  > "  +J     $$@&!@@"2 200"2
M)QN4+JRLH\2"ZT^?=U_R\38:+S%/Z&K1ERRYC9+66:</LC]%_C+Y\/+JQA<@
M ^VX
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MP /N/.
M          $2642&LHDQF!A]6IY4<>#9BLFRUZ2G%II-_8UZYI.E4P\]/+!^
M<_R&A,3NAZ=*WT\?$KQE912ECZY*LX1\:,NZ$3DA JIR02 ( \"4!") * !
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M17BD\'2E)M.$F<0OM*IMU>;&V&9V'0LK"CW=-+&^_@7RZ'ZGH=+91X]2<R
M^@Y@
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MH
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M++7_ &"KYP]1[!5\X>IL'(.0?&5.66O^P5/.'J/8:GG#U9L'(.0?&5.66O\
ML-3SAZL>PU/.'JS8.0<@^,J<LM?]AJ?-#U'L%3SAZLV#D"@/C*G++7_8*OG#
MU8]@J?-#U-@Y">0?&5.66O>P5/FAZCV"IYP]6;!R#D'QE3EEK_L%3SAZCV"K
MYP]38.0<@^,J<LM?]@J^</4>P5/FAZFP<@4!\94Y9:][#4\X>I/L-3SAZFP<
M@4!\94Y9:_[!5\X>H]@J></4V#D'(/C*G++7_8*OG#U'L-3SAZFP<@Y!\94Y
M9:_[#4\X>K'L%3YH>IL'(.0?&5.66O\ L-3SAZCV"KYP]38.0<@^,J<LM?\
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M?_6*+^S9>T+6%/\ "L?FRY7U*ECP/7I]'2CG-YE3&."H ]<1$>F0 %
M
M       8
M
M
M                                !CS"6.@
M
M
M
M
M
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MLN?]BLEW-.7_ +RI_8C:]=XR=._M;&P5"X5:HZ-:49MNENEG;QW?H:?V*_\
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M**E'"EE/'3IE'I?\(U=4TM4[NG<0K<^7&$HKIGSR=+4=MB5!9SA9&XX8EH'
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MMD  2P1RK+?F2 (44NA..H !+!&$2 &  !"21( $81.   2P  "6X  C"P2
M P !"22)    !@     :R1C?)(   ",+& HI+8D &LD81(   !@)8  !;  1
MA$XW    !CJ/  !@     2P,  ,        CE1*6%L  (44GDD "$DB0 #60
M          QOD  UD+8          UE8"V0  8  #  #!#29( 8V"6   :R
M P  & M@    )8&     AI,.*;R2    A166R0    )8  $)8)  #
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ME)O+><]4NF/U-AY]_IYC#43$J@4J6>I5DB@!2YI RJ!2IY9/,@F4@9W&?,*
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MA%/]WPS_ !&B]D<8_P K;]-)Q]EEU_KP.P5[>G&VG3>(P>[>"6B(:T[3:,L
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M^+RMCB]E9\) !&@
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MI4CBG)/*:37@OHS8+6VK_P E+ZTJ5(RG4I\L7X+9'1'!>/0<GGT+N2-'#D'
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MJX*6TO K1)ENM<  (V
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MA*W06P\ (^B#\R5T"6 (3SX#\47X$CQ A?V$@=4!"6"6\#[ "(HE=6'T"QX
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M+R*L9ZD@1A>")7D$,;Y +H\;#HM]P1G" E        -9'B  ">1C<
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MXN*E9/.-J>2XRQ-XAMH**=13CE%9&HG(1G?H2 J,_0E_8  @    #/T \
M(;WPP)_4A=>OY&/U75K72X.5S*:7*Y?#'.R/32=0H:G:4[FV<G3J)M<RP]GC
M_ 83*\6<!-^1("G@   &0!&=\8)R$, 0GEX)&-R,@2"$WEC+P 2QD9PLA?4M
M[ZZIVU+FJMI92V60F<0]_P ^OZ%4=EUR:U9<6Z;=7:MJ4ZKJ2J*FLT\+.<&2
MU?6+;2;55[R4E3<E#X8Y>7G_ "+A(M#)I>>Y"6[\BTL;^C>T)5*#DTGC=8+E
M/*W)A<JNB\V3X%IJ-[2L+2I<W#:IPQG"SU>/\2VTC6K35)3C;2FW!)OFCCJ#
M+*!$*2;P210 %#QZ $)Y D /9 "'MN8K4]<M-,K6]*ZE-3N).%/ECG?*7^*/
M;4=1HV%I*XN7)0BTGRK/4L0SNAD"'OLGCZFISXZT=5Z5'O*_/4:BOV3ZYP7U
MAQ/87>H3LJ$ZCK1CS-.&%C;Q_,;4WPST7E/*$GA=,F!U/BBPTZI&G<SJ*4H\
MRY89VR933+RE?VE.YH-NG4CS)M8>!A8M$RN_ !] B-"W #SL  >? 9 ,   ,
M  G]    9&,]0)\",[9(;]/$P6K<3Z=IE24+F=12C+E?+#.^,EB&9G#/XWSD
M/;P+#3=2HWU*4Z+DU&7*\K!?1DF,+$Q*2&LDLL-3U2WTZFIW#DHM-[1ST)$$
MRODB2QTC4[?5+-7-JY.FVTG*.'L7R>1@B3  "@                  &+X@
MG5AI%S.WC*=51^&,>KW,H>5:$94Y1:V?4L,V].%\/ZQ&SXWUF>N584:<H)1A
M<SQ%2^'IGQP=)UBTT_7M'N+>PN*47-QCSVV&TU)/;'T,7Q?P%9:M5=Q;VM!7
M,Y\U2<ZDUS+&/#\CG56YXCX*O84;W4*;IN/?.-!*6>;,5UBO%'7&7ES-9\NQ
M\+64M+MG1JRJ.%.G&*G4VSCQ+VOKUA%.-*[MIU/E519-3H<6T[GAFE5YJ[KS
MMFY2<([OEZ]35NSBI#4=-C7U).M=\\X]YTV71;8)%&IU<>(=<T[6M/ON>-O>
M6U6I3PIQA43<6_!^C%]K%A9RE&XO+>E)8RIS2P<LL]+U'3]8KW&FUJ5&VG<=
MY6CG+E%2;QNGOC)B]2U1ZCVC7-M=RG4L.ZC)4FDMU!;[;]<^(BF5G6G#KU'B
M/3>^A1J7UK&I4:5.+JK,OL9B$HU(J4)*47T:9R/B+1'7O;"XTJ-.C4I03C*<
MGM+.S\3HO"L;J&A6D+VI&I=*+YYKH_B?T^QF8PWIWW,O4J0IQ<ZDE&*ZMLQ5
M37].E5J4:%]:U*U-_'"-1-Q^Z+O4J;K6M2G#&9+"S]SF]*WL-$UN_N-0H.;K
MMPS3;;SG.^6A%<K>^UO5GQ!IUQ<1MU>VOM,\N-)5%S226<I?D_0U3M:49:51
ME&7[M5[?U4:+J-W3H]H>FU=,4J-*-L\IK?FQ4W\?#!M_:+.57AK3IR>93H2;
M?GF"-17$N%M3-9>_8I5QP7"527_Z14W;^QM_\H+"4W&A>6U10>*C51/D^_ZF
MC]DU&M5X%C"WE&,_:)[O\C4-$URRT?5=1HZQ3K5E7KX7=)-84I)YW7FA-?+4
M:F(=NM-9L;NYE;V]Y;U*RCS.$*B;2\\?F4W>N:?;S5&5[;*O+\--U$F_LC3N
M'EI_MDM:T^A*E0K0=.*?X]FD\K+76/F:GP14]^:_5J:EFO*C=2A3;VY8[[;"
M:K&KEUE<0Z=36+F]M:3_ (JB1?7E];6-K.YN[BE1H0QS5*DE&*R\++^[.4=L
M=E3T_2+2M805&K.YY92RWE<K\_L;!I,Y<9<&W]&J^\<JRI_M?A7P\DOW28:B
M\^FYZ?JEAJ:?L%[0N.5)ONIJ6$_L73FN5I--&N<'\.1T.G-0A2@Y0C%\DF\X
M^YL:@N[;2,ND3,PXSVQR[K6^'Y0ER)UZCDT\?O4^INN@<0:=9Z)356^MHR4G
MM*JEXLTKMGASZSP[%XPZU1/Z_%3-@M>'-,K</0G4M(RFYO+YI>;^ITQX>7=,
M3+==-UJPU&G.=C>6]=4VE)TJBEA_7!I7:;Q=3TZQ=*VKT97$*\5*"JXDDXM[
MX_(UOLGJ2H76J6Z>*<KQ1Y5Y;HQ':Y;48ZG=R4,3=:&7G^ 16,K.K.,NWT-8
MLZMMWD;J@XQ2RU-;&CZOQC2N=7K6,*]",*%7:<*N\OOZFVTM%T^AI[C"VBH2
MBG)<SW_4XY9:?0EVB:W3K4U*W4WR0R]OB1(B&K6M#NBU>R5I4N97="-O!XE4
MYURI[=7^:+&CQ7HU:=:-+5;*;I_B4:T7C[[F-XETRUH<*WUO;T5"G-PDUE]>
M>/\ D<T[*]+M;SB+B&C>T55IPDE%9:Q\<EX$BJSJ3'AUJAQ;HTZZI>]+'G:S
MRJLL_P!IE:NI6M*W5:I<4HTI1YXR<TDUUR<8[3^'[?0Z52_TFC"WG!0BI*3;
MW>'L\F6N[B[O.#;"O"K\%O8*5=223DN[3>-OH_(NV$Y9AT1<0Z?%=Y*\ME0>
MRJ.HL-^62Z][V"M*MS*\MU0IK,ZG.N6*^K.0\+<1</7EA3TR_L[JM6AS5&\8
MCUVW4OJ;U2T#VGA^_M%&ERW45W:<GA+P3)-8AJNI,MCT[6=.U':QOK>X:7-B
ME44MLXSL:1VCWSJ:Q;Z5">]U06T9?%^*71>/0S'!W#$-!CGNZ4:G=N#<)2>?
MBSXFJ5T]:X_TB^CO2H+NY*>SV<GMC[DB%M,S#>='2T_A>UI5)<DJ=#'Q[-M(
MTK@*:O)4M;N:G=PHSG3;;^'\.-V_ZQGNT#45IUE9PBYQ524H8BD_#ZC@;1J5
M+A>K9U:<'2E6<G%2>'^'_(K,YF?#/VW$>DW$YTK?4K2K4IOEG&%5-Q?D_1D7
MG$NDV55T[O4K.C46,QG62:R<4A%:!QM>TZFU*\U!QIQI[X2J/9Y_K(N.UJA0
M6I7,J4.6>*>_Y(L58G6F'<):E:QMG<2N*2H*'.ZCFN7EQG.?+!X2U[359PN7
M?6WL\WB-3O%RM[^/Y,TC3-3M+W1[;39PJ2E<4(4-UB.7%+=YZ;F;7"UL^'[>
MPG0I.-.7-CGECJWUZ^)-N&ZZDVC,,W8:_IE_"I.RO[6XC!XDZ=52P_K@\*G%
M&C4[B5"IJEE&M%X<'62:?VR<=[-:\=/U&I8U4W&XN.D=UC?J8OCR-&TXEN:M
M&'(Y7*3QOL6*L3KS#Z$N=4M+2E*=S<T:45NW.:2ZEK7XBTNWHTZU?4;2G2J?
M@G*JDI?8U>_K6FL:O;Z=.G*5.M#>,MD\9?5//@>7&W"U"KP_2A;T:45:4YRP
MYRVQ'P]";8=.2<9;C0UW3Z]H[JC>VU2V4N5U8U$XI^63RM>)=)NKCN+?4K.I
M54U!PA53?,WC&/,Y7V::A:/A65IJ%.I5@[B4G%+;HL>*-?TFI#3./ULU1N]3
MCW,8[\L>]V3S])+S-;(8C7=]NM7L+:O*E<7EO3J))N,ZB3+Z%6,J<9Q:<6LI
MI]4:+4L+;4N,ZZNJ2J4G13Y6VMTEY&X5IPL["<L/NZ5-M);X21SF'>MLIN=3
ML[9M7%U1I-/&)S2,92XFTR-Q&WN+^TI5YOX(2JI2DO-(T/1;S^4/:-K%I=N5
M73Z=NJM*E-<O++%-9RM_%^/B9_6>";>]U.WO;2A0A4HP48RE.64\O[^9<,1:
M9]+3M6JPJZ995*-1.$JDFI1?78L.R'6;.TX4J1N;RA"K[3-J,ZB3QB)Z]H]M
M.WX?TRA-Q<Z<I)XZ="Q[(]"T[4.&YUKFUC4DKF<<N4EMRQ\F;Q&'',\GAT*P
MXFTN]K3HV^H6E2K!I2C"JFT\XW1?:AJEGI]*56]NJ-"G'"<JDU%+/3J<*H4O
M=G'5]3LDJ4)7SAA;_"JCVW.F<=Z8]0TJM&HH2IN4-FVNC^AG:Z5U)Q+-RXBL
MH1525U;JCCF[QU%CE\\^6"_LM4M+VA"M:7-&M2GGEG3FFGAX>_W1S#6;_1H\
M,7EM3M:RN*=G.G&7@I<C6?Q=,E/9#=5JEA:6LIMTXTZC4<+'XW_F-J1JSET"
M?%>B0KQI2U:Q523PHNM'+_4BYXKTFAO4U*SC!O"<JR6?U.+W.GV\^/=$I.DG
M1J5FJD<OXMS<NT+0-+M]%MZE"TC!NNE^*7RR^I=B<LS&72;+4;:]IRJ6EQ2K
M4XOE<J<DTGY%I<\0:?1KRH.\MN^B^64'464_L<\[(KB\N>#-4<:R]H]JQ"32
MV^&'T^YCN&(QN..M=I:RO:'"4>3&V)9Z[8&WRU.K.(=0J\3:7;3[N^U"TMZF
M,\M2JD\>>Y>T=5LZ]!UJ-U1J45'G<XS37+USGR.-]J%K;RXBA0I4\57;Q:;;
MQUD7O$=]+0.&N'Z5K*5)WEMR5N1)\^(07CT_$^GF2*IRS#I$^)M-4.]C?6CH
M=%4[U8SY9+ZUU2TNJ,ZM"YHU*<%F<H334?'<Y=P_::?<<+TX5[=S_:2?5^;^
MIDN!=*U*PCJ5*_KT:EK<5%W4(/I3WV>R\&AM(U9;E5XIT:G7E1EJEDJL=Y0=
M:.5^63RK\7:-1N*<*FJ6,>99WK)?XG'-;LJ/_I)UBA"FE3A2@U'+V^"G_F;M
MQCPAI*X:O+NVLJ<+RE;YIU'.7POSZX+-8(U)ET2UO[>ZH1K6U:E5I265.$LI
MKSR6%7B+3>=4J-]:U*S7PP559?Y'.^R;4[JM*6F5JSDK>U;QA<J?,NCZ^)ZV
MUOIVAZA2][6[JW<?CC.DVTHM-);M?4D57EG#?;;B/3*M:5%W]HJ\7RRI]ZLI
M],8+/C2&GWNC5[34=2IV-.3BW4<TL8::Z^9QC6KVE1XHHU].4Z,;B^6<K=IS
MZ/J=$[7+:$^#[RLHKON>FN;/\:&TY,PS?!]'3=.M[F5EJ=.\I1A!SGSIJ"2>
M&\?GZ&2?%>BJNZ+U6Q[U+/)WT<X^V30^R^E&>DZI3FLJ=O3C)>?PS-9GIUI'
MM*KTJE%.W5LGRIOKA%BK/+,0[!7XJTFE4IJ>I6<8OQ=9+_$R]A?6]];0N+.M
M3KT9YY9TY<R>'CK]T<J[0M#TVST*M5HVL85U;RE3DI2>'ZF<[&J]2?!^GTYR
MRU"H_P#][(DUQ#=-29G$M_YERO='/^-K30[^XA#4->I652%7FY74BGG'3=F^
MRBE"6%L<+[8[>C&_I5*<,5)7/Q//78E(RUJ6Q#M-O5H6U!RE7CW:>\I/"+6M
MQ%I\)N-.]M9<KQ/]HOA^YI/:'JM>QX2O/8ZDJ=92IN,DD\?&L]3'\,4;2]T-
M5J])SNJUO&52;;7-)Q>7U\S6URKK.I66IV=]24K*ZHUX-[.G-27Z&E]I&I.E
M?:9I\9+_ 'WFH_BWW:CLO'J67 .F:EI^I1DZ]+W6H22HQ>9<S\>G^)9ZG&6N
M\6Z=5;4E87B7Q[-?M$]L=?P^),8:F^8;OPYW.@\-VM*\KQHPIN2YJSY=W*3/
M>7$FFQDN>^M8Q\6ZJ.<=J^LW$7<6%"K*/=U*<DN58_#GK^9?ZCIEA?:+.G8V
MZIWDZ*4)S;PI8Z]7_87:D:GTZ3#4K2=K"XA<T94)_AFIKE?V9C(<7:'4J*-'
M5K">?EKQ?^)K?!VEZA1TZE::M6I5K>E2?+"#Z2SUZ+P;.;]F&EV]]J-LKJE&
MI!UI)IMK*Y/H3:O)/T[5_*S2(5^2IJ5E'FERQS66[]3/TJT*JS"49+S3.)]J
MNC66E1TJK84(T9RNL-J3>?'Q9O.D\04]-X7KZEJ'>U*=*MRODBG+?E2VRO,D
MUPM-2?4MU;6']#6N-H:=>:5*VU+4:=A3YXR[R4TM]\+<P=OVIZ)7N84(4=0Y
MZDU!9IPQEO'S%AVKU+>^X/E=TH24G7A',MGMGZB(;M?PV7@JVL+*A<K3]2C?
M0DXN4E)/EV>.AE;C7+"C<3MO;+;VJ&'.DZBYHK'5K\UZG->!+J=CPKKUS"3C
M*E3C--++6(LQ?"%[3U7BN\OK]3K*K;]6L/*<%X?8UM<9U<>'7M/UW3KRIW=&
M]MIU6\*$*B;8US4Z6G6\:E2=.*FW%<\L>!SBGHMU1XKTZXT>=*WLXY=6#;;E
M+?=93^GB>_:S?5:.CZ;#G?>]^U)I+#V9-N&^3PNNRE>Q<-U[K4JCH\EU)<U9
MXPG&*6[^K-NH\4:-.=6%/5+*<J?XDJR;C]]RPO\ 2J5MP[<VSIQ[J4U)Q3?7
M,?\ (YAP7I]K/BC7Z=S14Z??)067LN:18C+&^:SAUN/%VC=^J;U2Q4L9QWRS
M_:9IWE!6KN75AW"AWCJ<WP\N,YSY8./]IW#-EI6BW6I:9;TZ%6GW<8S4I-K,
MDGL\KQ-FX3O*NJ\&W-O5FYR5E&FN9)+>FUX$VM5U9SB6SQXAL*SS:W=M6B^C
MC43R>NG:]INH<RM;ZUK3C+D:IU%+#\C0-&GI&BVM.UO;6I.ZIYYI4]T\MM=6
MO!HT[@BYJ6_%%&G:S<+>M>)RCCJLC:D:V73^/*.D:E9QM]3UBE81C74\N<5\
M7+)8W?DV_P C+:14L=/L:]3V^G.C&693E-8CX=3GG;E:TJ>@4;F$$JL[V"<L
MO?\ 9S_R,Y9TJ=;A/5(RCF+DDT_R+%4WSF6T4>*M%JUJE.GJMC*<.J5:+:_4
M?RKTB-U&A/4K*,I+.'66?'Z_0Y%V;:5:77&.N4[NC&I1C'X(Y:Q\9[]JVF6F
MEW#K:=15&O&C!QDFWC,VGU^@VD:LXR[E0JPK4H5*<U*G**E&2>4T^C/1R26=
ML&IZ9K5+2^#M(N+Q59_[C3G+D2;>*:;\48:':GHE5\L:.H8^M*'_ ,QC#OOC
M#.<:PTVXLY4=2U.G8QG3G%2E-1V?5[^1'!-"PT[0[>G8:C"\MH\ZC6YDU+,V
MWNO)[&K=J/<:AP["[C!_%:3J4^;9I-)HN>R"G"? NG*HN99J_P#>R-[?#CR?
MRPVO^5>BNNJ:U6Q[S..7OHYSZE-;BW1Z$GWVI64(]$Y5DLG&-%TVA5X\LJ->
MG&=&I7GS1R]UN;+VM:!IUGI%E4LK6-*<J^)/FD\KE?FQM2-69B9=7HW]O5H2
MK4Z].5*+PY*6R995-<LW4E&E=4)N#^-*HOA^YI/!4KV_X%U*,*T?:7<.,)RV
M2V@_+[FJZ7Q)I^E:SJ5GK%*O6K<_=2=**:<DVGXK8FUJ=6<.QTM;T^XCFC>V
M\XOQC43-,L=/T-:_7KV^OTJM>I=<\J*J1?++G;Y>OGL7W#VG:?<TXW%A;]W9
MY:Y)-YSZO^TYIP_"-/CG4HXV6IXBEX?M9%VIOF7=[O4K2QI.=[<T:%)/'/4F
MHK+^Y8RXBLDG*I=6T:*W<W46$O,YQVOU;ZG;7#5=>Q\]/$,+.<?;_$SNLV%A
M'@:[JPM\5?87+FR^O)]Q%5Y?IMEIQ!I-[5=*TU*TKS2YN6%52>//]3BM"M&W
M[0]"G5K<E)-N3E+"_>,UV2Z93E>^T3A%J=M)=7G\<?\ (PD;:G=]H.APJP4J
M+RIQ;QG\18JYVO-O+LDN*=)M80574;.";Y5S5DC)T]3LZUM*O0NJ-2C%\KG&
M::3\L_FCF?:-H6FV^EV]2A:QA/O'OS2^5_4N>Q]RO^#[R-Z^]S>27ELH4WX$
MFKI74GTJUKC&E<<04;2%Q0A"WN>5RC5ZKF2W]#?UJMFK1W,KJBK?/+WCFN7/
MEDX3:V-M/M#U6E5I*4%>J,5E[?&SH_'^F58<'U;31G3MZG>PDG)O'7?KDFTK
M>?;9OY06<5.<KFW5&.[FZBQCS+VSU"UU"VC7L[BE6HRSB=.2DGAX>YQK0.(]
M'JT*FD:E;W%:[:C;2DHKD<\.+>>9/&?H=&X<IVVF:+1A;TW"W3DHP6^&Y-^/
MYC:1J2T[B*O/6..=#J4&Y4:%50GW;S'\?B:SVP1=O=S<&TG72VV_<-J[,K65
M[<:I<UW&;HWCY&WAI=? UCML:]H<5U5PO[AJD>7+4]9=KJW]M86LJUW7I4:4
M%F4JDN5)="O3M9L-03=G>6]=))YIU%+8Y??<0V_$>KVVF159VMQ!0G3J145)
MK+ZIY\$;SH^C:?HVFR=I;*E-4L-QDWG"?FS,U=::F66OM9L;2KW-:[MX5L)J
M$JB3Q]CPH<1:=.JJ;OK53DU&*[U9;\CC^GZJ]:X]L_;93JTI4Y1E&22SB$FN
MGU,]K^BNYOM/JZ"J=L[>OSUW4D_B65C'7R?D-O@Y)F?#I.H:YI^GJ3O;VVH)
M8SWE11QGIU*K#6+&_A4E9W="O&&.9TYJ6,]#1^--$>K<*RG)4Y7LJD<U)2:6
M$_I]/H:UV5ZK3M+77J=QWDG2<(_"EX<XVQ@G5F)Q+K]'5[&K>3M*=Y;RNH+F
ME24TY16V[7YKU,AE>9I7#.E6]?4IZY"E%>TTW'F;?-LTMUT_=/"^[2=(LI\E
M:E?-_P -.+_\1G#K%_#>*M>G1BY59QA'SD\&$?%FBRN84J.JV,Y264E6BWX_
M7Z&.TWB33^);6LK:G<)*DZG[6*7T\&SD/!UE1N>.],HU*:E1E&?-%M[_  3?
M^"+%6+:GX[6^+M&C<=U/5+&,W+E47666_+J9>-_0E2=6-:FZ><<REMDY5VC<
M+6%K;4;S3;:G1N(.=24W.3RTLKKDR'9C=76L<&/VBKWE=W$ES226RQY(NUF-
M28\-U?$-A4E5C;7EM5=%M55&HGW;^OET?H>FG:[IU_6="A>VU2X2YG3A43DE
MYX- L7I6B7.KQO;:<IW,WET\O+3EG.6O,U?1KV-/M"NJFD\U"W=MB,9+=;1S
MY^)8H<N'4.,J>EW5%PU+5:5EFE**YII97GN>_"4;'3M#M86FH0NK91:A6YEB
M7Q-]5]<FF]J=O3K:9&M.*=2-I-YSXX,IV84(5N!M*5:*E'EFTOKWDA%4WSEL
MD.+M$J5%"GJUA-O;"KQ>_J1+BS2*55JMJ=E!-XBY5DLOU.)<#:;;U^(;6E<T
ME.$J[367TP;'VP:+8:=I>G5=/MXT:LKM)R4F\KE?FR;2-2?;LUM7A7CS4IQG
M'.,Q>3W-(X6U?V+A2M?7LISC2JM/D2SNXI>7F6:[5-%E<RM^YU#G4^3/=0QG
M./F,X=HO&/+?*]S1MX.I7J0IP6W-)X1B[GB/3Z&)3O+94UERDZB227B:!Q[Q
M-.\TFM#3:E6E)RACGC'SW\S9H<-6.H<-QC.VA*YK6J7-*4DN:4.NWU+AF+YG
MPV/3]7LM1I*=E=T*\'G#IS4D\;>!;U>(--4U3IWUK*J]E%55ELU&STZ?!^DT
MW+DC!2<,46Y?B;?B:UV36\=8=[<:K%7%:C<)4I-XY4T_+!8JS.I/IU2AK^GR
MJ.E.\MHU4MX=XLK\CWU#5K#3:<IWUY0MXI)MU9J.V<>/U.3]J]+W-"WN]*Q;
MW%6ZC"I-;\T>5O&^?)&1[0ZE+5.!=5N>5NXAR0C.6V%WD?+[LNQ.5O4.*-'J
M0YZ6IV4XM9359/\ Q&F<2Z5>UE;T=1M)UY9:IPJIR:7T.;]F>C6-YI,/:[>-
M24:$6WS-;_DS&5[:CI?:7;+3(*A05JWRIM[M2R]\C8S.K.,NX5[NWHTN\K5J
M=."3ES2EA87B8EZWI]WO2N[:K1\)J::;- [2M9NK:EPY;V]:4(WBE3JKE6)I
M]VM_^I]/,V7A70;.GHE*-2A!R4I;J3\QMPUOFWIS#@RLZG&55QJ.45J2QOE8
MYV=4XWIZ7J.G*TU/5J5A&-6,^=S2></"W^YRC@VBJ7&<XTDHQ]Y+;_\ "&X=
MMUG27#BN*4%&O*Z@G/+W7++_ "1<,1:8AN7#\K'3M,KRHW].O1C+FE4<UA;+
MQ-5LN,:5UQ;J5I*XH0MZ6\)JKM+=?YGKPG2IU>$K^%6/-%RPU_RQ-+X0TVTN
M./M9I5:*E3A!N,6WM\4214Y)=>XBK:=?:+<T+K4:5O;SY>:MSKX<23\?KA?F
M8O@6STRSN;MZ;JT+YRC%-*:?*LO#V/#M%T^UI<&:EW-)1EB&-W_21-3[**JH
M1UB<,J5.V4L_;),-S?$X=5O=:L;*7=W%W;TZ^,]W.HD\>>#SAQ%81J4X7%Y;
M4I56E24JB3J/Z>?5>IR;0[FIQ)VA6ZOY.O:RH23A-<K;2;70V+M*TRWL[&UN
M[6E&G4LZ=6K"2;;BXJ+36?MXC;Y7EG&8="N=4L[:AWUQ=4:=%OEYYS26?+)C
MZ'%>C5E+N=5LJF'A\M:+_P 3GV@Z@M=X"MI:@Y5ZCKR;<DETE)+H8?L?TBUO
MJ>J._HQJN%>*C\36%A^1=D,\LNK0XLTB5S.E+4K).*SCOEG^TRMU?6]I;RK5
MZ].G2BDW*<L)?F<#[4+.CH]_6J:=!4)2JQAE-O;DSC?['1>/8W-3A:XJTJD5
M0C2@IQ?5OF7T^PVK&I+:%Q#8)<\KRV5*7X9]XL/[%]:ZC;7E!UK2O2K4D^7F
MA)-9\CCG#W$?#\[&C8ZE9W5:O1@HMJ*Y>;S_ !(WA4UPYPO7=-<B552_9_%U
M:7B3:L:GAKM5RX@XHO(QG)QTV[>>[?-A<[Z^7X3&]K.M*3N;6A77+^S:<:AL
MG9M88OM?O*BBXWTX5.KR\N;W\NII?;!84+>\N70IJ+2I^+-1#E:9V[F]V=CI
MFK:)8UI7-&F[:VAWDX<NSY4VV_R+;0-+T2CQ%6N;37J=Q=2IM.@JD6TMM]GG
MP7J9?2=+LZ'!T>ZH*+K6,7/=_$^[_P#,YIPS1C0[2[ZG37+"-OLO^6 PN<8R
MRW;#+DUBR:FX15MX/&?B9LW"/%&E6/"VFPN-2M(5(T^649UDFMW]36.V*FZF
MJ6<5C+M<;_UF93A[@S2+_A&PJW%C3G<.GS2FYS67OY,8\,1:V^<.A6&M:??T
M95K*]MZ]*,N64Z=122?E^J+2OQ5HM.M.E+5;)5*;:G%UHYBUY[G&^R.\N:5]
M2TZK5S;UZTI3@DL/X//KX(LKNUI5>.]3I."=.5[*+67NG/!-D.D:TS#NEEQ-
MI5]=QM[/4;2O6DFU"G54I/'T+B[UO3[9QA5O+>%6>8PA*HDY2\E^AKUKPMHV
MB7D;^SL8TJM--*49R;6=NC>/$Y]PK5K:]Q;J,=2GW].TO5W"EMR)U)>7]5=?
M(FUKDF'6X<1:?"?)<WMM2GY2J),N[C5+*VH=_<7="E2Y>=3G-)8\\^1S?M=T
MZA8\.N]L:<:5VZT(=YEOX</;#V\"UM[]:UP!JLKERJ5;:U4(N22Q\/AC[#:L
MZDQX=$H\5:-7FU1U2RFL9^&LG_B>=#BO1YU52]YV7>2>T>^67^IRSLJTJSN[
MF2NZ"J+N)/JUOSKR9;\8:9:Z;QWI%.RHJE1G1<IQ3;R\S\RQ2&)U9]NN7O%&
MEVZ7-J%HLO&]5(R-AJUG?VTKBRNJ%Q14N5SIS4DGY97W1S^_T+3*VA6MQ4M%
M*I--N7-+=X?U,?V(UJDN')T:LN:$KN>5_P L1MC"QJ3G#HE7BC1Z5S[/4U2R
MC7Y^3D=9*7-G&,9ZF0N=1MK6@ZUS6I4J2V<YRPE^9Q'M/T>.DZYIU]",(JXN
MIU'RMMO$HO?/W-SNK^EKO"TZ<5-RG-;U%CI+Z$VPL:LYQ+>*6J6=6WJUXW-%
MT:<>:4U-8BL9RW]BR?$-A46;6\MJZ?3DJ)Y+#W72I\-UZ%"$8NM:.,MWAMP:
M_P 35]&>D:11A:7=K4E=TT^>5/+B\O*QEKP:\!%<K.I,-\LM=TV_;C:7UM6F
MGRN-.HI-/R.=]NL52X>M*M-\LY7L4VMG^"?^1JW!5U.EQ7;4[23IT*MTN>..
MN[-J[>&OY+V.?_;H_P!R98KB6)U-U9;3P-45+3+B562455ZR?T1DWQ'I\JU2
MC;7EK5K4GBI"-1-P^Z\#4T[E<%ZK[!45*YYUR3?1/,?H_ U[LSIVU?6-75Y3
M=2[C2S7GX2ES;M#;F2MYB(ATQ<4Z.I<E;4[*%1[J+K)/'J8OBRII&H65)W6K
MT+:E.$^2?>1Q)-+=99SC6-/M+OM%LK>THJ%K*URX2;WDE/?^PS/:/I]O;\/:
M=35)*2H5(QPWLU&(VP3J3,9;SP)0LK/0:=/3K^-];J<FJRDFF\[K*+RKQ#IR
MJRITKVVG5BW&4%464_(U+L:BX<#4(OKWU3^\65.TL-&U6YJ:I0=6=Q7E4I.D
MV\++Z[KS1-K6^8AOEKQ'IE6XE;2O[6-S"/-*EWJYHK;JOS7J9B,D\-;I^)\Y
M\3ZA3I<7W]UI2G0YXPCEI9QR1RO'Q1]!Z=/FM*+>[<(_V$F,-Z=]R[ !AV
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MBBB+G3[:ZWN*$*C2PG)="S8KHX<S[3XU^(-.M[71*?ME6E7[R48=5'E:SO\
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M:GHL+<J(:\B3#L
M
M
M
M
(       /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g942297g15y04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15y04.jpg
M_]C_X  02D9)1@ ! 0$ 7P!?  #_[1B84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &'L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" -Q!QX# 2(
M A$! Q$!_\0 '0 !   ' 0$               $" P0%!@<("?_$ %D0  (!
M P$$ PL&"@D#!  ""P ! @,$$04&$B$Q!Q1!$R(R45-487&1H;$5,S1R<X$(
M%C9"DJ*RP='A(S528F-TD\+2)(*S%R9#@R5$\2=EH\/P&$559.+_Q  ; 0$!
M  ,! 0$              0,$!0(&!__$ "P1 0 " @$#! ,!  (" P$    !
M @,1!!(A,1,R05$%%#,B0O T4@8C87'_V@ , P$  A$#$0 _ /5(
M                     "6H\1,51A=5Y3W+B44I8XMA-LN#'*UNU_\ FO>Q
MU2\\Z][ R(,=U2[\Z?M9'JMWYU[V%9 &/ZI=^=/VLAU2[\Z?M81D08_JEWYT
M_:R'5+OSI^U@9$&.ZK=X^E/VL=5N_.G[6%9$&/ZI=^=/VLAU2[\Z?M81D08[
MJEWYT_:QU6[\Z?M8&1!C^JW?G7O9#JEWYT_:P,B#']4N_.O>QU2[\Z?M85D
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MW5;O'TI^UDDZ%W!.3N6TN/-@90%M82E4M]Z;;>7S+D*
M                                         "2J\1^\MM-Y5?K%S5\#
M[RVT[E5^L$7F..0 %
M
M
M
M            *-U\U+U,K%*Z^:EZF!2TY_\ 2KULNBUTWZ-][+H
M                                                  )*O@_>6^G<
MJOUBXJ^#]Y;Z=RJ_6"+L !0
M
M
M
M                 "C=?-2]3*Q1NOFI>I@4]-^BKULNBUTWZ,O6RZ!
M                                                      )*O@_>
M6VG<JOUBYJ^#]Y;:=RJ_6"+P !0
M
M           #L'K  )I@       !  !@       )I@
M
M                             !1NOFI>IE8HW7S4O4P*>F_1EZV71:Z;
M]%7K9= @
M      $E7P?O+?3N57ZQ<5?!^\M].Y5?K!/E=@ *
M
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M64CQJ8\O>X1 3R H
M                                                         %&Z
M^:EZF5BC=?-2]3 IZ;]&7K9=%KIOT9>MET"
M                                  25?!^\M].Y5?K%Q5\'[RVT[E5^
ML$7@ "@
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ML%L\RRU;:36JRQ6U2[G]:HV6%6[N*WSU:I/ZSR4$0,\8:P\3>47QYD$EXD,
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MFIT9[R?H:-:V.U?,,T7B?"[7$,E4T^TCS1X>X1
M
M           "C=?-2]3*Q1N_FI>I@4]-^C+ULNBUTWZ*O6RZ!
M                                                )*O@_>6^G<JO
MUBXJ^#]Y;:=RJ_6"+P !0
M                                            !Q  +EQ(-M>H")!L
MEE+M[#3MH]N=.TI.%2=:-7=4EBGE8;P>Z4FTZAXM:*^6W5KB%&.:DXQ7CE+!
MK>M[7Z?I]*4J=U9UIIKO%<Q3XG)MHND'5+VM.-I=_P#3N4E%2HP3W7]QI-Q5
MG7J.=5YEC'B-[%PIGO9KWY'TZ+M'TH7%PYT;:T=-)3AOT[E^I/@C0[O7-3NZ
MDISU"\W7CO'7DTO>6*27(AN+.<<3HX^-2C4MEM*6I5G-YG*4WXV\DL9OMX(J
M[J)73B^:,\5B&*;3*12[]-2]Y5[HL>"F2*C!<E[R;=1Z!SRN' A%MOF1W5X@
MHI#4"8    -*  (  B@ P6  !0 !     !#."1/CS)R&ZB"'=,=A&4^#X^\;
MJ\1*Z<7V 2;V7PEC[R#DWPYE14H+L]Y'N<?$742;E"E6JTGFG5J0?CC)HRNF
M[2ZI9U$U?WLXI/O>L32^)C-U>(@H1788K8:V\O5;VAU;9SI2J.I"C<V22;A!
MU*ET^'8WQ1TC2=I].OJ,9==LXS>>\5Q%M<3S%NK'K+BRNJME/?MY;LL8Y9X?
M>:.7A1/M;-,\QY>L:=:-1=[)/U,J1?%G!-G>D>_MZ\%J5VY4=Y94:$>6/0CJ
M.SFV&G:Q%=PG6E4W=Y[U/'#.#GY./:C:IEBS:PB7?CC(SE=Z:[-M,"&<K@17
MI
M                           !1NOFI>IE8HW7S4O4P*>F_15ZV71:Z;]%
M7K9=
M   !)5\'[RWT[E5^L7%7P?O+?3N57ZP3Y78 "@
M
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MA A%\.)$PLP
M                                 !1NOFI>IE8HW7S4O4P*>F_15ZV7
M1:Z;]&7K9= @
M          $E7P?O+?3N57ZQ<5?!^\M].Y5?K!%V  H
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M-9B=2VXM$^$^0O206"*9'H 3Y@
M                                         !1N_FI>IE8HW?S4O4P*
M>F_15ZV71:Z9]&7K9= @
M                  $E7P?O+;3N57ZQ<U?!^\M].Y5?K!%V  H
M
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M19QO1DFCBY<4XYU+H8\D6A< (=IC9
M                                            "C=?-2]3*Q1NOFI>
MI@4]-^BKULNBUTWZ*O6RZ!
M                     )*O@_>6^G<JOUBXJ^#]Y;Z=RJ_6"+L !0
M
M   [ GE $!9XY!"3+:YNJ5M'>K5806<9E+!ZB-I,Z37%>-&E.I-]Y%9? Y5M
M_M^Z-5VFE5%W:E4Q452EPQ@QVW^W<JSG:Z?);LZ;@YT;A]Z\OQ',IUYU9RG6
MJ2G4?-REELZ7%X>^]FGFS_$)9U9U'QQ@)\"G*6.!/'P4=:M8K&H:?5M$ %0
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M5J>7'>IS4EE'%S<>V.=2Z&/+%F3!+%\^)-VFM#,  H
M                                                   !1NOFI>IE
M8HW7S4O4P*>F?15ZV71:Z;]&7K9=
M                           !)5\'[RWT[E5^L7%7P?O+?3N57ZP3Y78
M"@
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MN7,R<8XX]H3\1'M-";3+:B(@  4"R 30  H
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MRGVD%XNPP,J(
M                     4;KYJ7J96*-W\U+U,"GIOT5>MET6NF_15ZV70
M                                                         25?
M!^\M].Y5?K%Q5\'[RVT[E5^L$7@ "@
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M+BAQXY(F+;(@ESP17+B D4
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MI6]-UJL8Q6[++6/6=BH5(U(J=-Y3[3A9<4X[:ETL=^J%9<61">4###* !/(
M
M    HW7S4O4RL4;KYJ7J8%/3?HJ];+HM=-^BKULN@0
M                                        "2KX/WEOIW*K]8N*O@_>
M6^G<JOU@B[  4
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MA<7DR2()+F16>TYDS-N\MV(T  B@
M                     0QS(C/$"SO;6C>4'2N*4*E-X;C-91R3;[8%[T[O
M3^KT8+NM64(0>9+@TN'WG9L=]Z"C4I*:DNSDS-ARSCG;%DQQ:'DFK2G!;LX2
M@_%)8)6L<<'==OMA8ZEOW6G4:E2\E**:=516ZECM^XXO?VE:SN)4ZD-UPDU+
MBGR9V<')C)V:&3%-5BXN:[UX]!-%IK@L$)I1DZD?"? C%Y7$W.S#KLB  @
M0$&LHB2SQN]]R"JUE<U+2YIUJ,Y0G"65*+PTSN?1EM5#4+&E9W,JCN*5*4YU
M*DUWW?\ \T<%BL/ON?87MAJ%;3INK:[O=)+=>\LK'_\ *-/D\?KKMFQ9.F7K
M&!,:UL9M!2UJQE4A54W">YP@X_FI]OK-D33.%:LUG4NE68F$7R(+T$>TAQR>
M7I$
M       HW7S4O4RL4;KYJ7J8%/3?HJ];+HM=-^BKULN@0
M                                           "2KX/WEMIW*K]8N:O
M@_>6VG<JOU@B\  4
M                  'G'  "6<DHMMI?>1;7(U;;G6UI&B74X3<+A04H/=RO
M"2/5:]4ZAYM;4-0Z5MIMV$;*TJRA4IU)1FZ=;#:W>U(XS4R^/%E_J][5U'4;
MBZKRWI59;V<8S]Q:0?>ML[O&PQCHYF:_5*SW9.HGAK#+I!<6\ W8\,.@   0
MBTT][FN0W>T\]D1)$U&3;:>?<3I-Q?\ :["C*G)R2X9;P)G2Q&US3C*K+<II
MRF^2BLLZKT<[%2=17=Y&+7]%5BJMOSYMX;++HSV+ZW4H7][1C.@I3C)JJT^6
M%P1VJUH*A1ITJ2Q3A%12SG@N!Q^5R=STU;V##\RC;T*=&&Y2A"$.>(QPBL17
M '.VW(@7+D "*
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MQR6_
M         4;KYJ7J96*-U\U+U,"GIOT9>MET6NF_1EZV70
M                                             25?!^\M].Y5?K%Q
M5\'[RWT[E5^L$78 "@
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MAP[[KNSH0HT]RG"--9SNQC@ND0W5G/:1./N9\M^(U&@!>D!0
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MD(S65QXK)\_R<719T\-^J%R #69P
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M\K7_ $/Y#KVL^5K_ .G_ " [*]1LW_\ /'WD%J-FG\_'WG&^O:SY6O\ Z?\
M(A&]UK/SM?\ T_Y =E6I6?'^GC[Q\HV>/GX^\XTKW6<_.U_]/^12KZGJ])9G
M7JQ7C<,?N [A;W-&X3=&HI8>.!6.?=&NH7-W3N'7K2GBI%<<>(Z"N*(H
M                         %GJUW"PT^XN:C2A3@Y-RY<"\R<UZ6]?=C9J
MRA.>+JC-/=QCFN9DQTZ[1#Q>W3&W*MMM3AJ>T%]6A*+ISJ*2<<XY8-<CG>7
MJU&I3<I<WVE*.=Y<3Z'!2*5TY5[=4JH ,SR  @  L"UBFY;W:F7^FV5Q?U90
MMJ<JDDLM1[$6L*;<U&/%M\D=FZ*ME:<+57]U3IS5Q1X+BFGO=OL-7D98QU9,
M5)M+=]BM!CH>FSME*<MZLZF9I9XI+L]1LJ6%@ITXM=I4.!:W5.W4K&HT  \O
M0
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MA)=O=X?!F\FC=*J7R'R_^>'P81B^BGO87*\=6/P.FHYCT6>#<?:Q^!TZ/($
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M-OBL+T' Y.7U+.GAITP9>,OF3+D, U6<                         ?(
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M+$9;O-'I?1[A76GV]7.7.G"7//-9.%R\71?LZ."^XTOUQ0(8P1--L@
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M?=)^V?P9M8IW67'Y4:SUU]O4-KX"]16*5LOZ./J*IJ3Y=JO@[#A6U'Y87O\
MFW^T=U[#A6T[_P#=][P__-O]HBNQZ!]"E]=_!&2,;L_]"G]=_!&2"@
M                 )*O@_>6^G<JOUBXJ^#]Y;Z=RJ_6"+L !0
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MYM\>WQ'.YN?IKJ&SQ\6Y[MBI4U",$N44D54T^ 2P1Y<D<7RZ,1H 7#M 4
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MSAM=1JU(6U.ANTX5.\K=TSO9]"\0&W@
M  @UDU;;S0WK.C5:"CFI*4/SL<GDVHDJ14UAI-'JENF=O-Z[C3R3J-OU:[N*
M./FYR@^.>3P6U)=]E<CH_2UL[\FW%M6MH.<;B5:=1PHX4.,7Q:];.=0CN\,Y
M/H>/EB]7+R4Z93@ SL8  @0?)D2$O!?J I+CR.^=$>M._P!-KTZDDW0[G3CB
M..Q_P. 4Y-<,9-TZ-]8J6&L6M!2E&G7NJ2E_2;JQO8XKMYFGS,<6IMGP7U+T
MBGF.2)1MJD:M-3A)2B^33RBL<'6G3B=P  *                     !2K^
M"RJ4J_@,L);PX=TY^'IOVE;_ &FQ]"WY+T?M*GQ-<Z<_#T[[2M_M-CZ%OR7H
M_:5/B;4^QQ\?]Y=0I^"O43DE/P5]Q.:CL0  *
M %&Z^:EZF5BC=?-2]3 IZ;]%7K9=%KIOT5>MET
M"$_!9$A/P6!@-H_F(?7_ ',\\]'GY>Z3]L_@ST+M'\Q#Z_[F>>NCS\O-*^V?
MP9N8O;+B<O\ O5ZAMOFH^HJE*V^:CZBJ:D^79KX.PX5M/^6%]_FW^T=U[#A.
MT_Y87W^;?[05V39_Z%+Z[^",D8W9_P"A2^N_@C)$4
M    !)5\'[RWT[E5^L7%7P?O+;3N57ZP3Y7@ "@
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MEZF5BWN?FY>I@0TWZ,O6RY+73E_TZ];+K!  !1"3P%GM(X @2Y9,N0
M         (2\%D2$O!8& VD^CP^O^YGGCH\_+W2?MG\&>A]H_H\/K_N9YYZ/
M/R\TK[9_!FYA]LN+R_[U>H;;YJ/J*I2MOFH^HJFI/EV:^#L.%;3_ )7WO^:?
M[1W7L.%;3_EA>_YI_M"!V/9_Z%+Z[^",D8W9_P"A2^N_@C)$4
M            !)5\'[RWT[E5^L7%7P?O+?3N57ZP1=@ *
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MEQ:G9XI@F+=W0]-H*VL;:BDDH4XQX>A8+LE7B1-R1R);\1J  !0
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M2RJO--]R<8]XFNSTG'YU-:F&]QK?#;D"#>$1.8W0
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MOO\ -O\ : ['H'T*7UW\$9(QNS_T*?UW\$9(B@
M )*O@_>6^G<JOUBXJ^#]Y;Z=RJ_6"+L !0
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M<^!CM%VAEH>VFKU[R<*4JK<)=XY+.\GV>HL8X)Y>HC;LMKM31K34';UH2?\
M:PC8[*JJU&-192DDTF:-;W6D;0W$;JSKSJW,/Z**4917#B^:\39NFF0[E:TH
M=L8I&*T:;6*_7WVO  >&P$)>"R)"7@L# ;1_1X?7_<SSQT>?E[I/VS^#/0^T
MGT>'U_W,\\]'F?Q]TG[9_!FYA]LN+R_[U>H;;YJ/J*I2MOFH^HJFI/EV:^#L
M.%;3_EA??YM_M'=>PX5M/^5]]_FW^T('8] ^A2^N_@C)&-V?^A3^N_@C)$4
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M*+5*.,24\/CV@=Q [0  SQQV@ "5[W9@BWV=H$0..   "X@ "#:2RP(AC(
M@LXX\R/8!+4JTZ4'*I.,(KFY/"**OK1M)75!M\OZ1<?>8C;>E<3V;NU8J/=\
MPW=[EX:S[CRO4Z2=I+7;*.G3G:*G2U#J^%23>%4W>>0/8T9*2S%IKT$3 ;%7
MM;4-"C7KN+J.I)<%A<#/8]H$0%Z0 !!XQQ(K..(    ^0;P'G'  ""P_N(@
M&\%"[N86UO.M4;48Q<GA9Y+(%:<HPBY3DHQ7-MX195-7TZE)QJZA:0><8E6B
MOWG -LNF>\U:[CINQM:G*5:E%I7-OCOU)N7%OENQ-NV2V-N]>TJUO]IX0=:O
M2C53H5-U;SY\/8!U:VO[2Y>+>ZH57_AU%+X,JU:]*E*,:E2$9SX0C*23D_1X
MSF6M[.:_L_;RJ[&PM^ZQ:W>LS4EQ\+F<XL.D?:'4^D'0=*U2=KW2AJ,+6NJ=
M+''ND8RP\^A@>EXO>CG&"(B\H  'GL  !O      'G'  %Q">0  ?O"](
M $\^H  ,K..T  %G+SR(96]CM B    ?'@!1NZ*KV]2G))J2QQ64><.DRUZI
MM?J*C!*"E!+$<+P(GI27@LXITUZ;W%N^2XUKB,<Y_P -]GW&YPK]-VMR*[JY
M11>7DK%&GPE@K'?CPYP     %WL]7ZMK%K7RUW.HGSQ[RT*<9M24H\T8LL;K
M+U2>[U/LK<=:T*SKY;WX9XO/;XS-=AIW1E=*KLIID&^_5#+X?WC<3YS+&K:=
M7'.X  >'L                   HUO 96*-;P&6J6\.'=.?AZ;]I6_VFR="
MWY+T?M*GQ-;Z<_G--^TK?[39.A;\EZ/VE3XFU/L<?'_>74*7@KU(G)*?@K[B
M<U'8CP  *A)9-5_%.UGJEY=7E*VNHUI.485:"ENMOTFUC!8G3Q:D6\M(UC8>
MSN[><;*E:659XQ5IVR3CQX\L<S$:/T>7-G?0KWNJ*\C3J1G"%2DWN8><++>.
MPZ;NH@X(]]<L7Z]-[8FZNJ.GT,UJD*--/G*2@N)S>KM/::WJ$:E:O2HT;2;C
M.E5KJ4:RS[,</3S-FV_T;5M8ISMK2-%VK<9+>DD\HYPNB_4._<J5///YY&2F
MOEK<CU/%6]O;32]-M81M86W<T\*G2K1BEG+SA?\ \\3:]"N:E6VJNJJF=[AO
M-^(XW3Z+M1DN%*GC[9';[6BJ=-J)+Z^'KC^I_P FI](>O?(]G0FMYNI5<,1J
M;N.#+?HHTF6FZ%6IUE_2.YE)-PW7C=BOW$FWNRNH:_*$:,*<J<*N^LSW7RP;
MW:VD*$=V">,YXL\[U&F6M)F^Y6]_?T+&EO7%2G!8>-^:CG'K,;I>T>G:E23I
MUK95&WWBK1D^':1VLT.GK-LH5$W*"GN8ECBU_(Y;IFP.T.E7RKV%*W346EOU
M4^8KK27M:+:AOFVEA8W>E7,JM*UG7[A5[CO0C*6\X\-WMSG'(DZ+K2K:['V-
M.O&=.HG4RIQ<6N_EV,N-+T6^NU0EKT8=TH;O<NY2PO3GV(V&ZMZU&TW;)+?3
M_.?86;?"5Q]^K36[6K%ZC&.4LU,8SSXF)Z4]#>IZ+2C;TTJO68R<HTMYM;LE
MV?<34-%VE6I4[B4+7<A4WO"7+)NUO;5*MI3ZXEW7G+=?#/$E;=,O-L?768EP
M?HIHW5QJ=*"J5G:.MBI#BX2[W\Y<O%S.Q:[2C1TJI".(QC"222PO!99;#;)0
MV?MZT=QQE*IOKO\ >[,%UM/9:K=T'3LHT7%MI[SQP:9[Z]RPTP33',.'=&\L
M[9V'YJQ4_P#'(]&T)8M88_L+X'(M%Z/M5TS4J5W;TZ2JT\XWJJ:XIK]YU33:
M=W3LXQOE#>C3BN]\>.),EHEZXE+4WN&3L9;U#/I9J'27)?BWJ2:P^K5<>PVZ
MPW>K9CGFS4-N-+U?5;>=O:1HNC4A4A+>DD\/D>,<ZEL\B)M28AQOHK_**MGC
M_P!-+]J)Z1M)J%O'/]E? XUH&P.M:1=RN+6E059P<'O54UAM/]R-\J1VG5JX
M4E:;^ZDLXYF7)/5#5XE+8M[A)M[M/3TBVI.C+NE5U=V4*=91E%8;XF,Z3<K9
M/4LMO^BCQ?UD8ROL7J^J:A7N-7IT<SX_T=1+CR^!L&VVBZEJ]K5L[6-)V]6D
MHRWI8>=[//V'FDQ#WEBUXEHO0-'%[JSSG-.G\9'4MJ-.6I:1<6K4<3W><=Y<
M))\ON-0V V/U/9RYN9[E*,:RC%_TBER;_B=+G2;IOQBUO];AZQ8I]/IEYHTV
M=QINTUW8456A&K>=Q;AF*PIN/+Q<3ON@6DK/2*5";<I1;[[&.UFN5-B%+75?
M*#XW/=F^Z?WL\C?H45&&[V"]]O''X_1MYTVWM:ECK5K4KQDX2JSEB46DUO+Q
MG3=B:>F7VSUFZE"SE)QDW&48R:[YE[MSLA1UZVWE&4KFE":H_P!)NK>>.?L1
MINC;+[8:1+<M*=DJ$8N,=Z:;XO)[Z]PPUPVQWF=;;]U?2;*VJU+:WL8J/%]S
MA"/'[C5]H=C;7:"@KBSG:6]:<NZRE"BI2?!\&U@S\=G:DM)NJ+BNLSQN=_P+
M;3=+UZP3A"-NHJ.ZLR3/%;:9KXHO'^H<IM;?4MEMI;2V=S=5(R@ZK47*">5*
M/+/H.^[+UYW&CVE:IO;TZ49/>>6::ME=2U3:.TO=9A2[E3ING)TYI/&)8X>N
M1T#3[2%I;4Z%+.Y3BHK+SP)>VWOBX9Q__P 7BY (&%O!"7@LB0EX+ P&TGT>
M'U_W,\\]'GY>:5]L_@ST-M']'A]?]S//'1Y^7FE?;/X,W,/MEQ>7_>O_ 'Z>
MHK;YJ/J*I2MOFH^HJFI/EV:^#L.%;4/_ -X7O^;?[1W7L.$[3_EA??YM_M$'
M9-G_ *%+Z[^",D8W0/H4OKOX(R04      0R4KNXA:T)5JBDXQQG'/G@"L0:
MRL9,=::S;7,YQIQJIQYY2_B7]2K&%-S><("VU)U';3HTH2DZD)0<H_FY6,^\
MUJGL>J]!=8NY.;YN=++][-OIS4UF.>/'B)Y2RN8'#M8L)Z+JE*%.4YN4G)/&
M[R9UO8^I*MLY93J-[[C+.7E^$SGFKIZWM+90H^!"KW.:GPSWW9@Z=I5JM/TV
MC;X24$UP>>UOM"-)URUL]H;RC*OJ5.UW([F&U+/'.>:*=OL#95G_ $&LQJ<,
M][23_P!QJ]]::E;R=3NU'AQX?_H*6G[3:KI]SA7"2X1>*<7PSZ4!UO9O0X:)
M85+=5%7WJCJ;SAN\TECM\1JVV.FQNXU902@Z;J2X0SDVW9S5H:O93KT]_$:C
MAWR2?)/L]9BKZ#KW=:D\-3J2C[7@#GVQ&H/2]=IRK\(*$N$Y;JXH[/;5%7MJ
M=6.,5(*2P\\UDXOMGITM+UQQH[L8*G%X3;YY\9T79?5^[[/SEF>;2WAG,5V1
M?+V A)M34=].6FQ[V4)1J;R>7R\7WG*](BH;16U*7?9N$N/UCJE"*NW\IKPJ
MG>9?!\.'+EV'*],DI;66^>?6E^T4=STJG&G8TE&*7!\ECM9=-X10T[Z%2]3^
M)7DEC)%8O7J<)V;<HQ;W9/BO0<=V52J:[;1DDT][G]5G8];^AR^K+X''=E>&
MN6SC_>_981V[3X0IV=#=45_1QY+'85\O>QCAXRWL_H=MGR<?@7&5G':%8S7Z
M=O6T^O0N;F%!5:<H*4L=JQDUO9+9ZRT_495Z&J4[F;IN.XHI<,KCS]!F=M*$
M9:+=UVN_H4*DHO/)XS^XT'HWOKBOKLXU:BE3[A)I;J7',0CJ5;4;.CB-:ZHP
MROSII$:-_:5EBC<TIXX][-,TWI LJE*AUFT<80ITFY9>7G/86/1I=QO+NM1K
M[TI0HN3X87A+Q = J7UK":ISN:49M92<EDK=TI]R[HJD=S&=[/#!K%_:4ZNT
MMG'=_H72>\LO.>^+#;36ZFFV]M::?*5/>E*E/,4TUCTE&V_*EAX3O;?'VB+B
ME6IUHJ5&<:D<9S%Y-'T33J5SL]*I<14KGNK2DI-+' M]F=?K6][J=K7G)PHU
M%2I*,%P2<E^Y$&^U[RVMY/N]>G3?BE)(IQU*RF^]NZ#]4T<[OM:5?:NO1OG.
MI9JDFH1BD]["XY]IL]?1J+H4ZVGP5..YO/?D\Y]X&S1J1G!3IM3B^33)RRT:
M$Z>FT8S:<DGG'K9>A0     -'Z5?ZC7V\/@S>#1^E7^HE]O#X,#%=%7@W/VL
M?@=,1S/HK\"Y^UC\#ID0D(@ *                   0[61R2OQDD257B+.
M=[25^Z7E2/\ 8J27/TG0+N2A3DWR2_><RU6>]J5V^SNLL>T^9_-Y-5TW^%7=
MMK7F&."]87I/AY=N/ @" 5$A+DR)"7@L(@N1=V%'NUQ&FN;SV9["TCR63,;-
M0WM8HI\L2^#-[\?CZ\L,'(MTT;WI-+<L:$7^;"*Y>@ORA:K=@DN22*Y^D\:N
ML<0^>M.Y"G5\#CXRIC'(IUO ^\V(>7SLUII:Q>\OGY_M,]K]!<XOHHV=Y+%N
M_P!N1X?UR;^6KWCWO=YY_29Z&V(VAVFTWHXT-:7?4:5OW)QA&5*,FEF7CBQ"
MNUZ3M70UC5*%"A"C4I5&XN4*N\DTF_%ZBALILPM(VPU_5,N,;V3:7<MU+OL\
M^TY3^#A?7&H4Z56\GOU5>5(II)<.YQ\7K.Y[5ZG'2M'N*\M_>5*;@XI/#46^
MT0BTVCVQT;1(5*=QJ5E&[BHON$Z\8R:;YXYF _\ 4.<'"K=Z=&WLWWT;B=;$
M)0_MYQC&.)YETG7;S;[I%MHZE5[O&M2E%J4%3SNPDUX)Z<VJV:T^71A=[]#-
M2UT>HZ;[I+@U1?IX\D!L^SVTVEZ]1C/3KZTN&\X5&LI\N?(H;5[34-G80G==
MRC2E&4Y3J5-Q12[3R5T/;;WFS.TT+6K6GU&-&H]RG2C)[SQVOC[ST5TT6MMJ
M'1QJ=[7@Y5H:=4J4I9:QF.>2X 7>D=*&AZG<RH4+_3W.,-]J%W&3QE+]Y:ZY
MTNZ%IUY1I4+W3;B,X[SFKR*W>/(\A["==EK-:.FU84[A4&Y2FN&[O1]#]!W+
MI"Z"KBO<T*FSD;&WIQI8DJUQ4;<MY\>3[ .RTMN+*OHMIJ%K.VK=867"%=-1
M7'M^XQ-ATK:#>W<*,-0TW?EG"5Y%O@FS']'O1_6TK9:UM==ZO6E2H.*[C4EC
M>RWXEV'D/99UI;0VT:,DJN)8;Y>"P/:FN=)NC:=1HSHWEA<2EG>BKJ*W<8)-
MD>DW1]H;J-&-W84[B2D^Y1NE*6%VX-<TSHSV=O\ 8&CJ-_8NI?ST_N\JBN*B
M3GN9SA/',\N:!>W^B;2QJ:76C1NE2:4G%26&N/-,#V=M)TCZ-I'"G>V%>24G
M./68K=<>QEMLOTH:)KE>-)WNGTJDHRDX*ZC)K#->GT;Z%J'1_6U;4K+NNHU=
M+=UW6->HEW25+>;PFEX7'&,'EJM>5MF=I*RL)=RE""BL)3X.*;Y@>\M:UBGI
M=G.YJ*#H1INI*I*>[%+QY\1IDNEK9]3<:FHZ9"2YIWD3+;44J=[T97=2NMZ4
MM-RWG'.'H/$6T484M>O*4%B,9+"^Y >]M;UQ:7"52K2CW&,%*524]U1XXXO!
MJ<^EC0H74:#O=.[I*:I[KNXY3SCD;!MW:4+C974.ZP;CW-)\6OSD>(MH'"AM
MW4ITDU&%^DES_.0'NS5Z\*NE5MUJ2RN3SVH\/:JT^E*[3>,:S/\ \[/9M-RJ
M;/7$L]^JB2?WQ/%>J9_]5+S//Y:G_P"=@A[4Z.N&SD)9_P#EGP)-6V[TNVK1
MH:==6=_=2;CW&G<+>WT\*.%GBV8[9ZXN;;8-5+.:A6ZPUEI/AGTGFOHZU"[O
M.E2TIW-13B]6A&2W4LIU'GD!Z-ONDMZ9'?U?3J=A2RHJ=>ON)R?%+C'GA/V&
MV[/[2Z3KU'?TS4;.ZPU&2H5E/#QG' YK^$9HUB]C+>JZ+[H[ZFF]]^3J>DY+
M^#OKMY:[6VNFT:N[:W%YW\-R+SB+[>?8!Z<VHVFHZ!3A.YC24)3W$ZE3<3>,
MFNZ/TIZ#?ZC0LZ6HZ;*55X3C=Q;Y-\ON(],5C;76CV76*;E_U&?":_-9XZZ-
M:-Q=[8:92LYPA7E5:@Y\D]U^L#V!M%TKZ%I-VJ$+[3JTU4<)KK<4X8\:,M;[
M=Z?7T.IJEO6M:UI">XZL*Z<,Y2QO?>CC&V70C>ZM8V%[I?4*>H5W*I=5*M>H
ME-M+DMUI<<\DC>>C?HWNM.Z.ZFA:_P!5KRG<2J2[C5GNM9BUQPGS0&4I]+FA
M.X=%WFG=U<]Q1ZY'+><8P;=I^O*_T^%W0I1E&3:6Y/*X/'/!X?VPTZ6S^W-T
MI[O<*6HU>YQ@W)J,*O+CZ,'KGH6OK75NC[3[B,*F)SJ^$L/A4DNQ@9"VV\LJ
M^HT[.,K;NLZG<E%5TWG.,8P;C1FZE-2:PWV'%.BW0K'6=H=8O*M'>JZ?>QE3
MDYRCNO>D^2?'P>T[;3CNP2\0$N]QX\'XCA/X2.USM=(M;2SJ;M:%VX5%3K.,
ML;DN:1W6:_IH'C_\(*O.>TFHTV^]C?2PL>A@A;_@^Z;&_P"D?1Z]7OJ<95XM
M2CO+YB?\3V-:TX4::I0W=V"PDEA(\G_@TK_W+8S_ #E7K_\ @9ZOM^,I@5VD
MUAI->DY)MGL-.6WVRVJ6%&<J=*_=Q<2HV_"/])"7?-??Q?I.MDG'=GD"2O6I
M4:6_5J1A'.,MX1I>I](NFT[N%MI-:SU*LWN.%&Y3:GG&[A9XFJ=/NVUSL_H"
MH:55G1O875-2FZ491W7"3QQSZ.PY]^#AIE+7J]]J=]%5*]"_A-2WG'#?'DN'
M,#M-OTB:?1KSCKM2UTJ27&-Q<*+4O%Q2[.)N#OJ3LJE>WJ0K1CVQEE'G;\*K
M2+;3='M-2MZ>Y6N+Z,)2WF\KN4NQ\.Q&<Z -N:^N:34L-=JU+BYK7DH0<:48
MQ4.YP:3QCMR!NVI=*6C:;>5K:[NK"E5IR<)1J748M->@RVR>V=KM#.FM/E0N
M*$Y2CW6C64TFEG' \Z?A([(QTC4X:E1C3C&^NJCX5)-\D^*?!?<;#^##JU"W
ME9:1.-3K-6XKS326[CN>>><]C[ .T[0;:V^BW$:5[&C1WZDJ=/NM;<[HT^S*
MX]AG-&U6GJ6EPO);E*,FUC>RN#QS.6]*MG9Z]K^@T*5*6];:@^[[\FE+OXIX
MP_0_$9+I<UZEL/L-76C]TMZE*M346HJIC>EQ\)L#.ZOTAZ7;7$+;3+BSU"YE
M)P=*E<+>4T\*.%GBV4;/I#LU=2H:YU;29QCEJXN%%I]BPTN:XG!_P?K:.TFT
ME]?7Z[K4H7E"K%M[N'*4V^"X=B,[^$]8T=-H5-0MH;E>=S1IN66^'<Y=CX=B
M ]%7E]&WL*MU!1J1A'>Y\']YH]YTIZ+:W4K6ZO-/H7$&E*G.[BI+/C18="&T
M]3;C9S5%J,YUH4:D*.)0C3X;N?S3S9TXVM*QZ5]=HVT=RG"M345EO']'!]H'
MJ_5ND70['3*]W4U'3U5IXQ2E=13DFTL^_P!Q2V-Z2M'VAKW%)7EA2=.,6MVZ
MC+.7@XWL=T=W6VFPVIUKUVU74(W/<:52524(J*4)8:BL=LNSM+S8#HAUS0M5
MU2I4K:=W)1CW-0JS;6&WVQ [AM)M;I6B*5*K?VCOL*2MIUU&;BWSQSQS-?K=
M(5S1IQK5M(<+5K?C6E5:C*'/>SN\L<3SUTF:KJ5;I)I=;KQG4ZI'BH)<.^]!
MZ'GI-G>=$EO6NJ3G5CH:FFI-<703?(#,[*[;Z'M#&*M-3L)734I.WIW$9R23
MQG'_ //,V:K4A"E*K.<8TXK><F^"7C/"FP>M7>S^U=2II]7N4E0E'P%+@\/M
M/6>W.N5M/Z-KRZI3E&ZGI,ZT9[J:4^Y9SA^D"KKW2)HFF5ZEO2O["O=PDE*B
MKF*DDUG+7L]I93Z2.J581UFQIZ;3DMYU+BONI1_M<4N!Y@Z.)5-JMN[NKJ\E
M7J5+:4Y/P,M.$5X..P[]T^:!;5=D-0O537=*%BE%N;X=]XOO VVATF;+7#C"
M&O:3O/L5Y!OXFVWNHVME:U+N[KT:-K3QOUJDU&,<O"R_6U[3QGT%:'HNL;17
M-'7+6I<0I6ZJ04*DHXGOQ6>#1TK\)#;FYT:=ULY95:E.A<6M*LX=RC)9[HWX
M3X_F(#IU;I'H5KBXI:-0H:FJ$GW25"OO;L4WB3PGA<"^V:VYTW5[B-M6N;2V
MOI9:MG<)S<4LYQP>.9S;\'W1;>IIMY=UJ>].]L:4YM2?%R3;X=G/L.<]*E]+
M8CI8I5M(;H*%E%K"53C+>3\(#U_%J23B\KGE$3$[*7WRAL_IUP]YU*EK2G-M
M)9<H)]AE,O>:0$7R9H'2W82OM$MH0BVU<J7".?S)&_LQ6N62O:$:;2>[/>XM
MKL9DQ3J88\D;AY5:Q4QXB<58[MQ-/GO,'TF.=PY4^0 'M  ! H-_TB7C*Y;O
MYQ/M),=C>G:^AF^[K/JN?FK5OPL_GKL^\ZT^1P?H/N'#:*\4VW'JCQA?WXG=
M\YY'SW+KK)+J<>=T17( &LS@                  %"OX#*Y0K^ RU2WAP_
MIR\/3?M*W^TV3H6_)>C]I4^)K?3EX>F_:5O]ILG0M^2]'[2I\3:GV./C_O+J
M%/P5]Q.24_!1.:CL1X  %     $LH*135%/.>'W%5I]A'L+M-1*DJ*SC]Q.H
MKDL$RS@AA(FY-0E22;)GXB&Z\MDR7C!"24$TB"I+.>'L*F"'' V:A+&*6>!'
M=WE@F]82P-FDFXAA8Y$_,ACQ\ALT@UQQ@E=-9;_<5 -FDBII>+V%.M#%.6%G
M@RN^"*==_P!%)_W6-FH4K#YA96.+*LX;W84K!MVV9<7EERALTI*DL>GU#N79
M^XJ@NSIA3[GA8Y_<.YJ2X\/N*@6>TFS4*2ANO@L_<56LH ;(A*HKCR8:R3)8
MR.T+I32SE-8(=R6?Y%7!!+M[1N4TD5-)-9]PW%CQLJ# V:20@HOL]A.,<0LY
MX@T  *$)>"R)"7@L# ;1_1X?7_<SSST=_EYI7V[^#/0VT?T>'U_W,\\]'GY>
MZ3]L_@S<P^V7%Y?]J_\ ?IZAMOFH^HJE*V^:CZBJ:D^79KX.PX5M/^6%[_FW
M^T=U[#A6T_Y87O\ FW^T0=CT#Z%+Z[^",D8W9_Z%+Z[^",D%   #Y  2O*7!
M99KNT>C3U6\A#NU:G2=-)N#\3;_@;(0W>.7S$(T2XV&4:<71OKMSCQPFEDL%
MH^M3INWG0N53?%SWN/Q.EI8 5C]%M)65C3C4E-R[G%2WNQI&*VDU:G!5+6E4
MBZZ<7NIM/',R.OWLK2TFJ;DJDZ<]V2['C@SE5=ZC<WLJTKM.LTLR:]'J"2Z+
MHE/2]+HSG*YA.=1JHW./&+]' R=MJ=*XN)1A*#H8S&:[3DG==3J9@[Q>+DOX
M&_:/IUS/9FS=&M"%UQWJC[5F7\@-BHSLKE_T:HS[/!,'M5L[;WUJY07<Y1DY
M]Y!+L9I%CJ.K:?>0W[URIMY<8I<?<;C:7UWJU&%.C6<));TW-+OERQP M>BR
M%2.C5LI[O69<7]2)D:T$]4;WGGNW+_N,K8VEOHEA4C0I*-/?WW&+?%O"[?4:
MI<ZO#Y4S"$TE6;?+CWP%YTB:7UG2JE>FFZN]".$ERR:5LA<W-&\J6"IN4+BI
M"C-M\8K+7[SJ\72U>P>8/N;EREZ/4:OLQL\J.L:A7J=SDH7"G32SF*WI/^ 5
ML"M.IZ53HQR]V7-^G+.-Z7%/:JA_FO\ <=BVCOU:6V6I/OTN'J9R>TM)4M8I
MW6]'=C6[HTN?/(1VG3EBSI>I_$N'R9B] O8W5E32C)-1;R_690*QNMK_ *.6
M>'>R^!QO9*+^7K;/+OOV6=3VFU&-.GW)1EGOHYX>(YQHUG4L]1I7$IQ<89X+
MGQ37[PCL5G%=3M^/YD?@4M6OH:?9RN*CBDFEWWI,/0VEMZ=G3BZ-5RA32SPY
MI>LUS5[^ZUJO.E3K.%K+#5.:7->H*VG:6HZ^S&H2DMU3M9M->F+.==&-/=V@
MJ)-M=7E^U$W[:.JJ>SRM7G>JVLJ:?9X.#2MBZ,M,U>=6HU*/<G'$?6OX!'2=
M=M.O:7<6^[F52&ZL+B<GC4J:#KMU12PTE#OGA\</L.T<'%/T'/MK- 5?5IW2
M=-.I4CG.<\E_ &FQ[,49U+>=:NFJD:C2SQX87\31.D2$XZ@G)-1=:6&=7H4*
M="#C2BHIO.#5=N=GWJ=O"I1=.$J;E.3EGCP$#'[%Z-3O]%=1W=:/]+)8B^'8
M9>WV5L[*M*J[JHW*6^]Y+CAY-,V;UBYT24;6I5G*EES<8)8X^OU&Z6E6[U"U
MK5^[]XH;\5)<4FFP0U_;#96=_<U+W3G5J5)N,=V"26$L/X&N:7>:AH5[2A=P
MGAU$\59/DGZS=]-U>K9UVKB4ZE)1?>Q2YF*UM6FM:I9QMJ#I2<MQN;YMOGP
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M/>CP_7 MN@'HVU+2=2N-1UBVNK6->SW5OJ.-[?B\+V&A_A-PJQZ1J/=HN/\
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M&&Y3ZO5X+U'I6+;38$Q#>R^ SP(0PT\((BUDCGAP"Y$N&HM9X@3 1Y<>8"@
M            0EX+(D)>"P,!M']'A]?]S//'1W^7ND_;/X,]#[2?1X?7_<SS
MST>?EYI/VS^#-S#[9<7E_P!JO4-M\U'U%4I6WS4?4534GR[%?!V'"MI_RPOO
M\V_VCNO8<*VG_+"^_P V_P!H0KL>S_T*7UW\$9(QNS_T*7UW\$9(B@     0
M:[>TB (8SS(@ &LC     ,!<  &..0'P0[,@"#?\PGE9P1 I5H1G#BWC);Z:
M^]JJ7]K"+FLN\X<.);:?Q53ZP1>KQ @N;1$*AC/,B    $)1RT^U$-WM[28
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MZDWE<_6>L+>2G%N/'B>3;/YZ/K7Q/5>E5-^E+ZW[CB\ZO?;?XLK]<@$#G-T
M                  HU_ 96*-?YMEJEO#AW3GX>F_:5O]ILG0M^2]'[2I\3
M6^G+P]-^TK?[39.A?\EZ/VE3XFW/L<?'_>74*?@K[B<DI^"ON)S3=B/   H
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M/!+QL(S,<XX\R)8:!J-/5M)M[ZBX.G63:<)[ZX-KGV\B_04
M              T;I6_J)?;P^#-Y-&Z5?ZB7V\/@P,7T5^!<_:Q^!TR/,YGT
M5^#<?:Q^!TU!(  %                   )9\B8DF>,GM(:;M?+C./CIQ^)
MJ<4;/M@\7+6?_CC\6:Q%\S\\_,?T=WA>Q$ (XS=   #Y!!\@%M](I^F2^)T[
M2H[M)K^\SF5O](H_77Q.I62Q'[SZS\#7OMRN?/PO5R 7('V<.4
M                               !\@))QC)K>[.1.EA$%QYKD1
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M-"T[ON1HQ23[S#WDO[QC.FV\UNEI]:-C5IQL9VE3K"<8Y:X\LK/(Q&A17_\
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M C:?2:?UU\3J=F^]^\Y;;?2:7UU\3J5EX/WGU_X%R.=Y7<.TB0B1/L',
M
M                           (2Y$2$N1!S;I<_J:Y7^%']LX8=QZ7G_\
MA-PO\&/[9PX[G"]CF\CW"!%$#H-;X  %"A#POO*Y0I\WZPBZMOG$>D]AGFQK
M/_%?[*/-EM\Y$]*;"QW;"MGRK_91RN?X;G&\MF !R6^
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M@9[Z<KG1\LA'M(B/('V,.4  H
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MK?U$OMX?!F\FC=*W]1+[>'P8&+Z*O N?M8_ Z9$YGT5>!<?:Q^!TQ!(1  4
M                  EGR)B#/-O U/:VG_059\.$(_M&EQYLWW:R'_X9<2\4
M8_M(T*/:? ?G*ZR.WP9_RB #@M\[ NT  B#\%CGS'872HT'_ $L/1)'2-!GW
M2U;_ +[^!S2+W9_>=!V.GOZ=)_XC^"/IOP,ZR:<SG]ZMB7) AV(B?;QX<< !
M0
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M/3NE39J_U*K96]>X=6G#?:="26.';]X&^ YJ^E_9V.IV]I*XK[U7DNKR]/\
M W^POZ-[I]*]H-NWJP[I%M8>/4!=16%Q>0W@U:MMC8U+V%I:5)NO4CF*E3>.
MW/'U(J:5MGI=_=5K.G4J.YH25.JNYM)2RT\/UI@8KI9N=4M]G*TM&Z]UC?IX
MZHY*>,\?!XF;V(N+JXT*T=_&XC75O2WG7;WG+=XYSQSGF6FU&W6B;+[TM5JU
MH**CG<I.7/ER,ILYKUGM!:NXL)SE1<833E%Q>)+*]P&4JK>CP>.)K&T-W6T[
M0M3N:+JR=*C.I_1R:>4GVEUM/M1IFS]#>U&I4C%34>\@Y<6FT:AM!M?9?BMJ
M\:E26:MO-T\4WR<7S"+7HCVKN]=VCOZ%S*[W*=MOJ-:LYI/>BN3]9UA<#@OX
M/]PKK:[5*M-YA*SRLK'Y\#LVM:_8Z,F[Z<XXAO\ >P;X9Q^X*RH- U'I/T/3
M72J75:LJ->6*3C1;;]9M.GZ_8ZCI,]0M9S=M&6XVX-/.5V?>@,L0QQSDT.[Z
M4=GZ%W.V5>OW2C4=.HNX/@T\/'L91LNE?9Z\VD>E4:]=U-S?PZ#79GF!T,@G
MWS6#6-6VTTFPK6=O4J55<WC<;=*FVG+@N/BYHQ]YT@Z;I-62U6K.,8M1>Y2;
MXOBO<!NS?!O#X%*E<T:E65*-:FZT5F5-23E'UKL,=M/JZTK0;J^@\2ITNZ1;
MCGW'%=@.D17'2;KT]4J)6TK>/<W3I/.]F'\P.Q;=U+NCLO?5=/=QUF*AN*@V
MI^''.,<>637^C"\U6YK7JU6-^E&G%PZTYO+R\XWC/ZKM=I6EV-6\NZE6-&EC
M><:;;XO'+ULM]D-M-+VKN[NEI=2I/JZ4I;]-PX-X7/U ;1%[RSC!$QVO:Q::
M%IT[[4)3C;P:BW&.\\MX7 U^6W6GU*#N;>K-V\(]TFW2>=W&?AD#<6\#L-:V
M9VSTK:2:AI=2K.;BY=_3<>">'S)=J-M='V9IMZG5JP;A*HMRFY<%S V=#D:+
M;]*&SM31[?4W7N.JUVXP?<'EM-KE]S*6RG2CL_M'=0M+2O7E7JU>Y03H.*SC
M/,#?P07"*W>1$   !HW2K_42^WA\&;R:/TJ_U$OMX?!@8KHK\"Y^UC\#ID>9
MS/HJ\&Y^UC\#IBYA$0 %                   (2(XX@#!;30W](N5CCB/[
M2.=M;DY+GQ.H:Q1=:QJP7-I?$T2IHMW4N*O<HQ:WGSD?'_FN'?-?=8=3A98I
M$Q+%)Y)MY+Q&8I;-7[??0ACZZ+^ALKO?/1?9RF<7'^(S3/>&Y;ETCQ+6J>ZW
MQ:*O<I2\&FY>J)MM+96S2_I%4QZ)F0MM(MJ/S:G]\C?Q_@K6\M>W/B/#1(VM
M=KA;5'ZH,NZ&DUJBXTYQX]M-F_TK>E37#/BYDTMV,6^)T</_ ,>^98+?D):7
M1V8J3[YU4L]CIFT:!8O3[9T924\S<LI8[/Y$MSJMK:9=>4EZHY*6F;1Z??W<
M+:WG-U9Y:3@UR63K\7\5^M/5#3R<KU?+.I A%YRO$1.E#$  H
M
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MMI_RPOO\V_VCNO8<*VG_ "POO\V_V@KL>S_T*7UW\$9(QN@?0I?7?P1DB*
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M%.I'E.*EP>2X,1LK6=?9_3JK>93MZ<GP\<49<X%NTS#IT\  /+T
M
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MSO(ITWEU,-MU1 !@9@
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M'1](U:RU:C*KI]Q3KP@TI.'8R^..?@SW]:_V?UF5>;FX7<8K*7!;B\1V,
M   $)>"R)"7@L# ;1_1X?7_<SSQT=_E[I/VS^#/0^T?T>'U_W,\\]'GY>Z3]
ML_@S<P^V7%Y?]ZO4-M\U'U%4I6WS4?4534GR[%?!V'"MI_RPOO\ -O\ :.Z]
MAPK:?\K[W_-/]H*['L_]"E]=_!&2,;L_]"E]=_!&2(H        ,<<@    "
MX     2P     EJ/$>!:Z=RJ_6+FKX/WEMIW*K]8(O  %           QQR
M               :/TJ_U$OMX?!F\&C=*O\ 42^WA\&!B^BKP;G[6/P.FHYE
MT5>#<_:Q^#.F($(@                       &,U^@JNEW2XY[C/&/JLR9
M2N::J49P>,2BT6LZEYM&X>4+VWE:W;I3BTDD^);3\%OQ&W=)M@K':BM2II*"
MIP?>K"Y&H5%A8SS/HN/;JIMRLL:E3I3<I\<%4HTUBHUZ"L;#&  ""BLD7QED
MB@#;-;'7LK/7['&[NU+FEO.6>"WU_$],V5Q3N*7=*4E*/+*/)]O5="XI58Y4
MH24DUZ'D]!=%NI._V<I2JR<JCJ3\*67P9Q^=3OMO<:WPW;CV$0N0.8W0
M
M                      (-X$#2.D_4XVV@7=K*4%*O0EA-/+X]AY[E!-MY
M>3HG2WK$KV_LH4W*,%3G&2WLI\3G;??M+D=OA8]5VYN>VY4%%1JKB5BFEF:9
M4.@UH  11^@1XY"X/ :W6O2$'P-^Z(]/=SJ<;E*35&O'BL8Y=IH*69,[AT0:
M8K*QO7-)RE4A)/=QC@:/,OTUF&Q@KN72(+=CE<RIG*)8\((G2.'+I0+D  H
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MXX<#YZ]=3IU*SN  $>@
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MO#X,#&=%7@7/VL?@=+1S/HJ\&Y^UC\&=,7,)"( "@
M  ,  4J\%*#3Y'FGI!TB6FZK4JSBHJXKUI1Q+.>^S^\]-264<NZ9=&G>6EI<
M482Q;0KU)[M//9%\7V<C;XF3HNU\].J'#Z26]GM*I)'C-OEZ"<[]9W&W-  4
M  !!\F4EB?>OPBK+P7ZBA3:SGM\0UORF]2[+T-Z_'N-S:W-1N;G2ITTH>M?P
M.OPSN\3RMLU?/3]9L*N\U"-Q3G+OMU84D^)Z5V=U*GJFFT;NG*+512X1EO+A
M)KG]QP>9BZ;;=+!?<:94 &DV0
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MO)H_2K_4:^WA\) 8OHJ\&X^UC\#I:YLYIT5^#<?:Q^!TM!$0 %
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MG)4]V$MW/!X1G^#1P+5FLZETZVZH[(KB "/0
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MPK:;\L+['9=/]H0.QZ!]"E]=_!&2,9L]).QFUY1_!&3RB* 90R@ &4   R
MR  &1D !D9  90  #(  9 DJ^#]Y;Z=RJ_6+BL\0^\MM.DL5%GG()\KP#*SC
MM&4% ,C( #(R  R,@ ,C*  90R  R,H !E#( #*   9  9(90$31NE7^HE]O
M#X,WG*P:+TJ23T)<?_GA\&$8SHJ\"Y^UC\#IB.9]%2[RY^UC\#ID00B  H
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MQ\GPZ:LX>>)%<B2#7(FRD<QO0B
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M>T?G.H_K'7OD6T_Q/TA\BVG^)^D#3D7RWM'YSJ/ZQ!:WM'YSJ/ZQU[Y%M/\
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M?(UJN*[IGZQ#32.B^C5I0N%5I5(YJQ\*+78=)7(M;.QI6BEW+>XO/%Y+H$
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MH4KZRH7%%MQJP4TVL<&<#/@G'+I8LD6AD$^&<!OD0;>?[I%<GXC79T0(\@
M
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MCDM[#E4^L5ZO@_>6^G<JOU@B[  4                             $
M                              WA$'ZB([ ,7K6FT=2M^Y7%.G.$9;R4
MX*:SAKD_6>9=:TBKH]S3HU>Z=_'?[^FX=K1ZJFN!SGI5V;A>Z?5U",8]TH45
M&+<VL=_XOO-SB9NBVI:V;'N-N&</&,DU:C.E5G"6,IX>"GC"P=VEMQMSY[(Y
M7C(E/'%8*AZ>  !5..7E89/'O5RR1 $M-M/>6<HZ)T=[95K&X5O<N52EN0I1
M52X:4>.."9STC3<H34X/$HO*-;-AC)'=DI>:R]9T*T*M/>ISC./CB\HN%Q2.
M/=&FVTIU*&GWTZDZDI3D]VG%+&,\_N.NT:JJ4XR6<22:.%DQ3CG4NGCO%H55
MR !B9 !<P(
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M       #[B'W$0 ^X  ,^@(    #Y#  $,>@+BN1$
M              25?!^\MM.Y5?K%S5\'[RWT[E5^L$78 "@
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M8WSN*U=*<W/=BE@ZU1GOQBUE929P\N*<<Z=''DZH5D^(7I(+@1,3*
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M[M9U>G!1BHQ6$CB\KD=<],.A@Q:C9!87/CXB=,ACQ<QCQ?><]MH@ H
M                                                       !1NOF
MI>IE8HW7S4O4P*>F_15ZV71:Z;]%7K9= @
M                                $E7P?O+;3N57ZQ<U?!^\MM.Y5?K!
M%X  H
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MYY<B6,E@G2QR,#+   H
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M XSH1&@ !0
M              HW7S4O4RL4;KYJ7J8%/3?HJ];+HM=-^BKULN@0
M                                                  "2KX/WEOIW
M*K]8N*O@_>6^G<JOU@GRNP %
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M2 !Y>@
M            "C=?-2]3*Q1NOFI>I@4]-^BKULNBUTWZ*O6RZ
M                                                "2KX/WEOIW*K
M]8N*O@_>6^G<JOU@B[  4
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MD4T4*%>G6AO4:D:D?'%Y*T>*])KSV9HG:(">0%
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MP17/]QP[WF\[ET:4BL(@ \O8
M                                 %&Z^:EZF5BC=?-2]3 IZ;]&7K9=
M%KIOT9>MET"
M          25?!^\M].Y5?K%Q5\'[RWT[E5^L$78 "@
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MDW*,4A%81$X][S>=RWZUBL PLY[0#P]@
M                                           !1NOFI>IE8HW7S4O4
MP*>F_1EZV71:Z;]%7K9=
M                   !)5\'[RWT[E5^L7%7P?O+?3N57ZP1=@ *
M
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MF>U6[BP?,L9H>B6NDV].G;480<8;C<6WP^\S"6.02P,'-M,S.VY6-0  B@
M
M            %&[^:EZF5BC=?-2]3 IZ;]%7K9=%KIGT9>MET"
M                                                 25?!^\MM.Y5
M?K%S5\'[RWT[E5^L$^5V  H
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MBHQX)(J+ES!"*P:FY9XC2( *H
M                                          %&Z^:EZF5BC=?-2]3
MIZ;]%7K9=%KIOT9>MET"
M                   25?!^\M].Y5?K%Q5\'[RWT[E5^L$78 "@
M
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M  I=@*:  %  -(     B& ECM(@BH8(;O'F3 0B7'I(X])$%5#!$ @>\ "
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M'H0
M                         %&Z^:EZF5BC=?-2]3 IZ;]%7K9=%KIOT5>M
MET"
M  25?!^\MM.Y5?K%S5\'[RVT[E5^L$7@ "@
M
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M:,U2HPIQQ%1BO$E@J)8(X-6;3/EL12(2Q6"9=H!Y>D,=]G)$)8
M
M                 *-U\U+U,K%&Z^:EZF!3TWZ,O6RZ+73?HR];+H$
M                                                      DJ^#]Y
M;:=RJ_6+FKX/WEOIW*K]8)\KL !0
M
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M.<M(OUCL)NS@:ULMK>99:XXA2ITU'DL%3!%)]H,;WH  4
M
M                  "C=?-2]3*Q1NOFI>I@4]-^C+ULNBUTWZ*O6RZ!
M                                                       )*O@_
M>6^G<JOUBXJ^#]Y;:=RJ_6"+P !0
M
M        30//8%Z0"@  (8)>YKQLG -).Y+QLAW*/C94 VFH6=;3Z=5MRE/[
MFBSGH-O/G.M[5_ S /<7M"=$->J;+6L\YJ7'Z4?X%..R-FO_ );G]*/\#90/
M4M]IZ=6N+9.S\K<_I1_@5*>S%K#E4N/OE'^!GP/4M]G1#%TM&HTWPE5]J_@7
ME*UC36$Y?>7 )-YE8I"7N:])#<2Y9)P>5TANC!$!="6!@ !VAK/   EA#
M
M                                      "C=_-2]3*Q1NOFI>I@4]-^
MBKULNBUTWZ*O6RZ!
M               )*O@_>6^G<JOUBXJ^#]Y;:=RJ_6"+P !0
M
M
M
M                                          "C=?-2]3*Q1NOFI>I@
M4]-^BKULNBUTWZ,O6RZ!
M                   )*O@_>6^G<JOUBXJ^#]Y;Z=RJ_6"+L !0
M
M
M
M                                              "C=?-2]3*Q1NOF
MI>I@4]-^C+ULNBUTWZ*O6RZ!
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M]S N 6_7;?RGN8Z[;^4]S N 6_7K?RGN8Z[;^4]S N 6_7;?RGN8Z];^4]S
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M:Z:UU98\;+H
M          #2?,H*TM\MNE#/J*X H]4H>2C[""M*'DH^PK@"CU6AY*/L'5:'
MDH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^
MPK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK
M"CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5:'DH^PK "CU
M6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY
M*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L
M'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5*
M'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH
M^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK
M "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "C
MU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6A
MY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/
ML'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5
M:'DH^PK "CU6AY*/L'5*'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'D
MH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^P
MK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "
MCU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6
MAY*/L'5*'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*
M/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'
M5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5:'
MDH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^
MPK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK
M"CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU
M6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5:'DH^PK "CU6AY
M*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L
M'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:
M'DH^PK "CU6AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5*'DH
M^PK "CU6AY*/L'5:'DH^PK "CU2AY*/L'5:'DH^PK "CU6AY*/L'5:'DH^PK
M "CU6AY*/L'5:'DH^PK "CU2AY*/L(=4H>2A["N */5*'DH^PAU2AY*'L*X
MEA"-..(145Z"8
M
M
M
M
F                                                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g942297g15y06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g15y06.jpg
M_]C_X  02D9)1@ ! 0$ ;@!N  #_[1?>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %\$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_K6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M0L$6)&*"LM(E0Y/P%S24PO$F-D2$9'2CL__$ !H! 0$! 0$! 0
M   ! @,$!0;_Q  I$0$  @(" @$%  (# 0$      0(#$2$Q!$$2!1,B,E$4
M814C,U)Q_]H # ,!  (1 Q$ /P#ZI*.3*%<[\$&IGJ&UB10(Q45N?: G8!!U
MKAV81K7#LP@3@0=:X=F$:UP[,($X$'6N'9A&M<.S"!.!!UKAV81K7#LP@3@0
M=:X=F$:UP[,($X$'6N'9A&M<.S"!.!!UKAV81K7#LP@3@0=:X=F$:UP[,($X
M$'6N'9A&M<.S"!.!!UKAV81K7#LP@3@0=:X=F$:UP[,($X$%'7#LPC6N'9A
MG @ZUP[,(UKAV80)P(.M<.S"-:X=F$"<"#K7#LPC6K^S"!.!!UKAV81K7#LP
M@3@0=:X=F$:UP[,($X$'6N'9A&M<.S"!.!!UKAV81K5_9A G @ZUP[,(UJ_L
MP@3@0=:X=F$:UP[,($X$'6N'9A&M<.S"!.!!UKAV82FM<.S"!/!!UKAV81K5
M_9A G @ZUP[,(UKAV80)P(.M<.S"-:X=F$"<"#K7#LPC6N'9A G @ZU?V81K
M5_9A G @ZU?V81K7#LP@3@0=:X=F$:UP[,($X$'6N'9A".N'9A G @ZUP[,(
MUKAV80)P(.M<.S"-:X=F$"<"#K5_9A&M7]F$"<"#K7#LPC6N'9A G @ZUP[,
M(1UPZ6P@3@0=:O[,(UKAV80)P(.M<.S"-:X=F$"<"#K7#LPC6N'9A G @HZX
M=F$:UP[,($X$'6N'9A&M<.S"!.!!UKAV81K7#LP@3@0=:X=F$:UP[,($X$#6
MN'9A*ZUP[,($X$'6N'9A&M<.S"!.!!UKAV81K5_9A G @ZU?V81K7#LP@3@0
M=:X=F$:UP[,($X$'6K^S"-:O[,($X$'6N'9A&M<.S"!.!!UKAV81K7#LP@3@
M0=:X=F$:U?V80)P(.M<.S"-:X=F$"<"#K7#LPC6N'9A G @ZUP[,(UKAV80)
MP(.M<.S"$=<.S"!.!!UKAV81K7#LP@3@0-:X=F$KK7#LP@3@0=:X=F$:UP[,
M($X$'6N'9A&M<.S"!.!!UJ_LPC6N'9A G @ZUP[,(UKAV80)P(.M<.S"-:X=
MF$"<"#K7#LPC6N'9A G @ZUP[,(UJ_LP@3@0=:O[,(UKAV80)P(.M<.S"-:X
M=F$"<"#K7#LPC6N'9A G @ZUP[,(UKAV80)P(*.N'9A&M<.S"!.!!UKAV81K
M7#LP@3@0=:X=F$(ZX=F$"<"#K7#LPC6N'9A G @ZUP[,(UKAV80)P(.M<.S"
M4UKAV80)X(*.N'9A&M<.S"!.! UKAV82NM<.S"!.!!UKAV81K7#LP@3@0=:X
M=F$:UP[,($X$'6N'9A&M7]F$"<"#K7#LPC6K^S"!.!!UKAV81K5_9A G @ZU
MP[,(UKAV80)P(*.N'9A&M<.S"!.!!UKAV81K7#LP@3@0=:X=F$:U?V80)P(.
MM7]F$:U?V80)P(.M<.S"-:X=F$"<"#K5_9A&M<.S"!.!!UKAV81K7#LP@3@0
M4=<.S"-:O[,($X$'6K^S"-:X=F$"<"#K7#LPA77#LP@3BF.*IQ,:^HKHI8DF
M;$C7N1NXR8%F7? %X $!R?\ C+>K9^I/(+OO=OR_4"<
M
M
M
M                                                  #'W5,OI/FH
M9 @73WZ7YB$\"F_X J !!=][M^7ZDX@N^^&_+]0)P
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M\  $        0  41<@5
M
M                                      $"Z>_2_,0GD"Z>_2_,0G@
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MZF[U/!3TY-!W,7E0<F@[F/RH!Y\NIN]3P4<NIN]3P4].30=S%Y$')H.YB\B
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MY1?R+T3=\>GXG2.>47(N5^!4-X<, H
M
M                                   (%T]^E^8A/(%T]^E^8A/    0
M7??#?E^I.(+OO=OR_4"<                             %%*@"B;^)4
M %3/$  4W\"H (     &&KOO^A_E=^RF9,-7??U#_*[]E+!#,IP0!." @
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M<"B+_0J
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MWX4R"+D]W;C$J@( H"BN1!K(!4#I"+D
M
M       "!=/?I?F(3R!=/?I?F(3P   $%WWPWY?J3B"[[X;\OU G
M    /S INX=1:^:)BX?(QJ_%R(>=9*L--,].+6*J>!R"YVV[Z1325S)J5(%3
M61'*K79:F.A%,[6(===60-8KUE8J)T(Y,D>UW:GN*?P-;@J^UCH_)3CUFT2N
MMRHUJHI:1$5';G.5%PB]6#;_ +,+:M)%KR*U9-5Z+A>C60W$,;Y=#3X ("-
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M41N]RKNSGI,[&U$3*=)5$PW'653=N/+-MOL4I%8U!JH5P@!&]
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M'/4O9,J5*(N4W%3:@
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M"H =# P !3"%40  J9*(B(5
M       !C?D    &-^0  P%3( %-5!JI@J":@4PA7  T! N5MIZ]J-J$<J(B
MHF%QQ_\ P3P9O2+QJ5K,UG<-=_V5MZ9PV3"_\8316@PB:LF$_P",V('F_P +
M%_'7[^3^L106*EHI%? CT5<<79,LC2H.],5:1JKG:TVYE3!A=)J6FJZ!(ZM'
MK&CT<FJN%SA3-F*O]%)6TB1Q)EVLCN..A3GY%9FDZ:QS'RC;F$3-5/9X%S\=
M!FET6KTW-8SSH7?[-7%/_+9YT/RU_%S3>9T^Y7R,<5UMAH'-AEVL>=IC&_J-
MUM.DL,S&Q2H_7X)AJ8W)^9C+9HS5LJ=:H:B,PONO0]+CH@YB+);M=\N.$CTQ
MG._H/K>)7-6NI?.SVQVGAN<4J/:BHNY4/5'93<<MIZVILE1LY6QI+E51,*J=
M70IM5KTFAG5K9E1'KV6+U'OIGF.+/+-/XVD;R/3U+)F9:N[\CV3!ZJWK;J7/
M4PN!3?T%4^)I  %
M                                        !!N?OTOS$)Q NGOTOS$)
MX   ""[[X;\OU)Q!=][M^7Z@3@          '0 !X5,>O321IGVFJGBAS^UR
MVVP7JH@N7O-BQ[3-?>N%3@G4;_6HYU',C?>U%QX*<IM^AL=_O$ZW6IJX9=GK
M*D,C>C")Q1>@S[7TW1-)M'E;G#?_ *=?0]K'4T-9=Y)J%5U5B5,:NJG%/@:^
MGV56I&XYPN>/F,_[3*Z*6%EBN3X::2:6)(EPZ5R*N55%Z$0Z1TYSVV\ &6P
M                       PU=]_T/\ *[]E,R8:N^_J'^5W[*(6&93@@"<$
M 0        +7+T=)=TEDBX,VG4$-5TSJE2+DZ8S[+OW-&T!@YXTD;=<9C9&^
M#=N3*;^"[^DDZ>7ET;.6,U51-5F]%QTFT_9M9UM5F?&]N'.F<_*JBKO1O5^1
MY\$;M,RF7G4-OBW-SU;CUZ2W'M)^1<>H@  4
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M3U2?PGY5<?Y50R+79X'HIEK9)K,+@4UO$)O3>=&50
M
M  !!N?OTOS$)Q!N?OTOS$)P   ""[[W;\OU)Q!=][M^7Z@3@          "J
MF  /&H:Y\$K&\5:N/SP<=N-FTG=?ZA+73:ZHQJX6H:W=A/\ B3I.Q5+]2GD>
MNY6M5?[&GVJZ7*KK9IFT4*4J1Y25'85<8RF,YZS"QTU%MFTXUE<^BP['#E;<
M?]9M6@45R@K'1W=FSG2-RJW7U]V4QORI@KQI%=KQ=WTME@9*QC6R:S9%8JHF
MY>*ITJ;;HG75$DJTESIXX*YK%>Y&KK+JY3&_>G3UG6.G.>VU( #+8
M                 8:N^_J'^5W[*9DPU=]_4/\ *[]E$+#,IP0!." (
M    HJX0QM[K$HZ3:+CWD3?DR#EPJFFZ8UFLUU.J[T<U>GJ/-GMQJ&J_USVI
M@DO%[2T-3*+%MMRX7=^>X[?21HR-K41$3!RS[+*"6LGYVG9[2:\.<HJ=']>D
MZQ&BM;PWG7#7XUTY1^5IE>GQ 7@#HV
M                                                        _(#
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M+E/R.U,U;>UFLO8%-9,9R5.VV0
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M^--?UTS1"U-M=L6!K43,BNW-1../0V \H6ZF[&#U/=TY4C4  #0
M
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MGBA<AWB8E@ !0
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M)XS\"H!ZE
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M[Q:)Z<U0 :
M              $"Z>_2_,0GD&Y^_2_,0G    (+OOAOR_4G$%WWPWY?J!.
M          AW2D;644T3D15<QR)E,[U14)@ YK1?9S$Z!-JL&OO]Z->L]%^S
MNE8JZ_)D_P")6+O.@U$FQB?(J91K57"? Y/?M)+Y=KO)2V1]1#$U&NW1(]$3
M"(O0O2IGH9:/[/Z)<[)](J=EK<_ZF=T6T=YEK'-C5FRV:HFHU43*JBFH04&E
M]*FV2Z.<G!6I3IE4\OP-VT3O3[E%LZF.2*H1%<K9$1'8SU?U.GIEL: HF2IE
MH    =  %.."N>( !   &=Z@ 8N^WNFL].DM2YN_*(BO1JKNSTF.T=TLI[[4
M.BIX7LPQ7ZRN147"HG1^9(G9/#904UD1JJJX_,U2\::0T-4L-)15%P5$1<TJ
MH_\ 8HVP&!T>TD@O+,M8M/)O_A2.36PG3CJ,ZGQ J  !AJ[[_H?Y7?LIF3#U
MJ9OU%UZKOV400S"<$ 3@     !5P@V*.7"&LZ8U:0T34:["Z^_"]&%,E=KK'
M0(W736UG:NY43&XT/3"YI-)(U%PU^&M7*8SJGAS98M/QAUK68C<H6A-)SAI;
M53O9KTO)\L54RW61S."\,\3K;/AN0T_[,K8M%H[3K,F:A5>CG85,IKKT&YX0
M]>./C73AK<S(BY 3<#;0
M
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M7=3W(BFZ>1ZLML4QTS8/.*9DC<L<UR=:+DOSU'IK:+=.6E0$!H
M                                                !!N?OTOS$)Q
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MO93]Q3R)B=6:G%[AMR318_Q&>9"NVB[QGF0Q\,%!)[FH[\I,_P"I[)04J_\
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M7GW<&/[=?B^;>WRG:B;D*@'=@
M
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M1X7@J]?P-K9IG9MGQGW)W9YI?[=<+O0MIUEU]Z-RW'0;AEMD>]B+UIO+D3'
MMC7+$QU%Q"  !08W@ 4QAV4XJ5  *F0G  "C6ZJ83@5     8>O^_J'^5W[*
M9@PU;]_T/\KOV400S*<$ 3@@ #'  "F_)1_NJ7%'>ZI)Z&@7U[7:3*U^=TD>
M,?DAO;&X1,<#0;TBOTL>J<->/]FG06<#Q^//Y6=\OZPN 3AN![7
M
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MU]R>[@S+9$5,]!ZZ9JV<;4FLZE>"B+G@513K#( %^
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M'04SJ[CGVA2NFKI783W,_P!T.@,W)OXGC\:/RL[99XA> #W.(
M
M                                                        !T@
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M:9XLY6QS7M(!1'9_(KD[Q.^F  %  (
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M(5 0!0             ,-7??U#_*[]E,R8:N^_Z'^5W[*(6&93@@"<$ 0
MQU^F2&VSY_S1N;^E3(FK:?U*04%.BN5NTD5O3U*<\DZJL,1H!&Y*F153<L?_
M -QOS33-!H%8U7Y7"L7_ *C=&G'!&IENZH"< >IS
M
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M0&6@             ,-7??U#_*[]E,R8:N^_J'^5W[*(6&93@@"<$ 0 *+T
M5-%^U1VK16U%7&:G']C>7+A#G'VC/9/400[556*9KM7J]DXYYU5:<SIGM#(\
M4;%RN]J_]2FTM3<8#0YB<S0/SQ1W_4IL' S@CC;5@ 'H8
M
M
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M7X&ZL2W6DH:>GUI(H6->]=951,*JDM.&\I%[B+T*F?R&=Z_#^Y%A< @"@
M          8:N^_Z'^5W[*9DPU=]_4/\KOV400S*<$ 3@@ !> *.X 6.7"9S
ME#E6E<R5.E=7 WV=FYB\<_Y6G4IE1L6<[L*<=K)%E^T>[MUM9F(L>5AP\C_S
MDI/YQ#I^BK-G9:=O'&M_U*9HQE@;J6V)OY_]2F27@7!^L-7[E4!-P.S(
M
M
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M3$1_V1+L%L;JTS$ZL_N2UX'E3-U(T0]43<7#&JPZVYE4 '5D
M
M
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M%L? N.F..'60 &T
M
M                                                  +7-14WH7(
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M
M
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M4HJ='5Z'0]#6HE1,J=C_ %-#6G=5Z::2/BWI'(URY7'0OH=!T*;BF15[*_\
M4IY/(_\ 2K'B=7;6W@ W@#TQTZ  *
M
M
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M>9/0<VQ][-YD] )P(/-L?>S>9/0<VQ][-YD] )P(/-L?>S>9/0<VQ][-YD]
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MR-5%\3>;0U6443<=?[J>".<DO32-8X3T ![89
M
M
M                                 #SE9K-5#T"\ DN>Z=Z%17ABSP(]
M*AK6L1K%:U%]I55=Z?$YEHYH565UW2GJ(W-IT<]KG-D;E,(N/]#Z*<S73./A
M@\(J.*)RJR-C55<Y1J(IVKFF(T\.7PJ7O\D2S6R&AI8HHF(W4:B+A$3*HF-^
M#+-3"!J(B8P57@<K3M[*4BL:A1.*E2B;N)4C8  (-S]^E^8A.(-S]^E^8A.
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M9-Z=.]#=8N!\_#S>SV3&L=87@ ]KF
M
M
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M/1-EN2U*H]V$<S5X(J=:G2.6'4V+K-1?@5+8DQ&W\D+C+4
M  !AJ[[^H?Y7?LIF3#5WW_0_RN_91!#,IP0!." #QJ%]AWY''7YK/M&Q[_)Z
MUJ]>KO3PX'7K@](Z>1Z\&M5>)RC1=B5&G=[G1R894QNPF_.]>G^AN.*S+RY9
M_**MN=_&O<C5;OCE;O\ ZFX1>[O-1I462^U;FY3$C55$-OB]W)\[Q_WM+Z&3
M]87  ]SB
M
M
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M_ N(L  "@             8:N^_Z'^5W[*9DPU=]_P!#_*[]E$$,RG! $X(
M,3I-+L;+6R=F)R_V.=_9DQ)+GI%52-X[-[<_\YN^G<VRT5NSD7>E.]4\#4/L
MRC5MDKZIRY66!COR]XMIU27EGG-5LE@7:W>XNQTM7]S;(_=3K-5T6:JU=8]%
MWNU5_<VIG \GCQS,O=D_BX 'J<P
M
M
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MG:),]B23MHW]U-G;P-?T5CQ0L5>EJ?NIL"<#S^/'&WKOV  ]+
M
M
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MLTQVCS-2U4S>IADNDF#](>B_[2  [,@
M
M
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M3'T^/SF6Q6INI0Q)U-)B*>%$F*=GY'N,,:I#O?\ :0 '5D
M
M
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M[F(;\/BNVX4Z88B? ]#SA7+3T0Z8OUAJ>P '1
M
M
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M*)MMV/,;CHY?&U[F17&.**L3#4:B*[?C?OWG2.F);-'_ (;?R0N#>&X&6H
M              ##5WW]0_RN_93,F&KOOZA_E=^RB"&7W^S@T;[5)]GH]5Q+
MQEAD1/CP-XRG7O.:?:],B/MM,J[YTE;CK]WU.F/MY_)G5)9_[.*=(M$K>_&%
M=3QJO@IY4B:^DE4O%$F;^YD-%&)!HG1-SC4IVI_8B6-NUO5<_JD:O]U/!Y,[
MRZ>KQHUCVVV/W2Y"C>!7I/32.&0 &@
M
M
M                                       0+I[]+\Q">0+I[]+\Q">
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M:].0 "@
M
M
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M<H55T;57CA"\(B(F$!%@4IPPA4HO% (MUJ>26ZJF7=LXGO3?C@BJ<YT:I_\
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M0)P(/(ZC\:_R_4<CJ?QK_+]0)P(/(ZC\8_R_4<CJ/QC_ "_4"<"#R.H_&/\
M+]1R.H_&/\OU G @\CJ/QK_+]1R.H_&/\OU G @\CJ?QK_+]1R.H_&O\OU G
M @\CJ?QK_+]1R.H_&O\ +]0)P(/(ZC\:_P OU'(ZC\8_R_4"<"#R.H_&O\OU
M'(ZC\:_R_4"<"#R.H_&O\OU'(ZG\:_R_4"<"#R.H_&/\OU'(ZC\:_P OU G
M@\CJ?QK_ "_4<CJ/QK_+]0)P(/(ZC\8_R_4<CJ/QC_+]0)P(/(ZC\8_R_4<C
MJ/QC_+]0)P(/(ZC\8_R_4<CJ/QK_ "_4"<"#R.H_&O\ +]1R.I_&O\OU G @
M\CJ/QC_+]1R.H_&O\OU G @\CJ/QC_+]1R.H_&O\OU G @\CJ/QC_+]1R.H_
M&O\ +]0)P(/(ZC\8_P OU'(ZC\:_R_4"<"#R.H_&/\OU'(ZG\:_R_4"<"#R.
MH_&/\OU'(ZC\:_R_4"<"#R.H_&O\OU'(ZG\:_P OU G @\CJ?QK_ "_4<CJ/
MQC_+]0)P(/(ZC\:_R_4<CJ?QK_+]0)P(/(ZC\:_R_4<CJ/QC_+]0)P(/(ZC\
M8_R_4<CJ?QK_ "_4"<"#R.H_&O\ +]1R.H_&/\OU G @\DJ/QC_+]1R2H_&/
M\OU G @\DJ/QC_+]1R.H_&O\OU G @\CJ/QK_+]1R.H_&/\ +]0)P(/(ZC\8
M_P OU'(ZC\:_R_4"<"#R.H_&O\OU'(ZC\8_R_4"<"#R.H_&/\OU'(ZC\:_R_
M4"<"#R.H_&/\OU'(ZC\8_P OU G @\CJ/QK_ "_4<CJ?QK_+]0)P(/(ZG\:_
MR_4<CJ/QK_+]0)P(/(ZC\8_R_4<CJ/QC_+]0)P(/(ZC\:_R_4<CJ/QK_ "_4
M"<"#R.I_&O\ +]1R.I_&O\OU G @\CJ?QK_+]1R.H_&O\OU G @\CJ/QC_+]
M1R.H_&O\OU G @\CJ/QK_+]1R.H_&O\ +]0)P(/(ZG\:_P OU'(ZC\:_R_4"
M<"#R.H_&O\OU'(ZC\8_R_4"<"#R.H_&/\OU'(ZG\:_R_4"<"#R.I_&O\OU'(
MZG\:_P OU G @\CJ/QK_ "_4<CJ/QK_+]0)P(/(ZC\8_R_4<CJ/QC_+]0)P(
M/)*C\8_R_4<DJ/QC_+]0)P(/(ZG\:_R_4<CJ/QK_ "_4"<"#R.H_&/\ +]2;
M&U6QM:Y=941$5>L"H    "!=/?I?F(3R!=/?I?F(3P   $%WWPWY?J3B"[[X
M;\OU G           >-541TL3I)GM:Q$5<N7"'L1+G2MK:.:%Z)[3'(F4ZT5
M ,+_ +9V=%5$KJ/'7RAIA+_<=&;PS,]3;EE5R*KG3-5=R*G6>-%]G%*L")*L
M2NW[UC7K_,]/_AQ1-7>D+EZ]FOJ08"AM>C5-4+++76Z5N,8UD3I_,W_1NZ4%
M0]::V1Q)"UJO1T3T<G%,_N8-OV<T6_.Q5.K9KZF6T8T=;9*QR1N:Z/9JB:K5
M1-ZHO^AJ&.=MH !&P(       !C( $.[4O*[;50],D3V)NSQ14.<:-U;M%[U
M64]?F*E1&LC=(NS:O!5QG\SJ9C+G8[9<G(ZOHHYUSGVL\>!F(T2Y_>=?2;2*
M/D6LZFBFCE26/^(UR;D7>GQR=#V]-:J9B5<T<,>=5))'(U%5<KC?_7P%MM-!
M;FZM#2QPHB8PW/7D]:^WTMRA2.NA;-$UVNC7=#DRF?[J:WQI-<[>E+4Q5$.U
M@>Q[,XRUV4.8_:]7TL](V"*>)\B2L=AKT5<8=T'3:.EAI(=C!&UD>]<)PWF,
MK-%;)62K)56Z&5V$3?GU(L/#0ZNI*FBU::HAD=K.7#'HO4;$8ZUV6W6M?_#Z
M2.#C[F>DR)4@"\ 4Z0JN[&\U;2BY0VRM@JYGLQ$Q=SG(W.5QQ_J;,J[_ ('*
M/MFCJEV>P616;+>C6YS[9TQQ$SJ7G\B\TI,U:9IAIG5W>I?#3ODC@:Y[7,23
M621%7=T? CZ&:2S6*M5Z:SF2/:LC$?JYQG<N[XFJHY6N<B[I,\5Z%+FN7@B*
MKU_S=:GT)QUBDP_-1Y.3[NWT-57JFO-E@EIGQK(Z)5?&UZ.5BKT+X*;#HXU6
MVFG14WZB'%OL\;6M65)TE;$_9ZFLU41R>UPZ^@[A9DQ0PIU-0^!,?]K];AR3
M?%$RG-0J >N
M
M
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MQ$/5  >UQ
M
M
M                     0+I[]+\Q">0+I[]+\Q">    @N^]V_+]2<07??#
M?E^H$X          #RG@9/$L<J9:J8XX/4= $*CM]/1Q;*G8K685,:RKQ,34
MV.V)7R3S[-NLB-PLJHO[_ SE9(Z.ED>SWFM54W?!3DE307[2NYR[&JI(VHU'
MXF16KNPG0U>LR1#H"6FR*F<Q_P#KKZE]HI:&GN;^1HG^'T/UNE/B<_3[.](V
MMW5UL\S_ /L-FT&M%5:*Y\-:^)\J1.RZ/.-ZIUHATCIAO*)A $7* RV
M                   &'K_O^A_E=^RF8,/6_?U#_*[]E$#+IO0LD3=O_H7X
MX%K^#C%_U(:C5-672&G5JHFI-OS^:&WQ[FFG4_\ %TCE7L3I^YN+.!X_%[EZ
M,W4+@ >]YP
M
M
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M-H;M+]7/ZIFK_=3;V<#4]&&[2YW!SN*/:N[_ )C;&\#R^+';KFGG2H /:X@
M
M
M
M          (%T]^E^8A/(%T]^E^8A/    07?>[?E^I.(+OO=OR_4"<
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MIU5JG;$Z(LQ4USNTK%_ZC:DX&M:)-_@.?VD:O[FRIP,>/'#63L !Z7,
M
M
M
M      ! NGOTOS$)Y NGOTOS$)X   ""[[X;\OU)Q!=]\-^7Z@3@
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MJ.F&-V7Z*Q(E!&N5WL;_ *F>,5HXS5M5,O7&TRIK!'XLW_:0 '=@
M           !-R#H^( =):F5X[BY.  )\0J9"\ "?$!/B        4 J @
M   %X %ST M57(FY,EP       '$ ,@IG?NX$%<]/0$WA 4 "G4!4%N79X;B
M[/4!1%15P54;D*)PW 5SOP"G]"H #)3/2@%0GQ*;\\-Q7.$7( 9*=&4WCCQW
M 5R A3CPZ *@   %ST  BC*9QTA/B                      "F<)O*;UW
M+N+@&0-V2G!,(N5 KG?@ HWIWY J!D(    (OB!^0 !-Z;PG4    =/P   H
MJKT)DIE4Z +@$      B8R  ZQP3  #&XIO1-V\"H1<IN*)G.]-Q7HW !^8
M  HJKT)D"H!3@!4 IOS\ *YSG'0$7(*8X]8%043XE5  #H )O 3@       !
MD         0+I[]+\Q">0+I[]+\Q">    @N^^&_+]2<07??#?E^H$X
M     #'7MKW6ZH1B+A(W+N_)3(ELC$D8YCD16N3"HJ<22-'T3OMNH+$R.IEC
MCG8UZKEJY]Y53>B&B7>JFTPTF<RFD?)2M5DJ-:Y5:F,-7<OYF]Z0: QW&I=)
M35DE(QRI_#AC1$QC&.*&5T5T2H[%$FJV.6755JR.B:CE15SQ+",G;Z*"V4"Q
M1-8UC<KE&HGQZ#!:,ZM1?Y:N!J)3N@5J*U,)G*&0OM@J+FY4BNM71M547$2J
MB<,8XH-&-'^8:=&<LEJ>*9>F.*YZ_@79IGP$X;P10
M     PU?]_4/\KOV4S)AJ[[^H?Y7?LHA89A%W&LZ6NRL#.UK)^QLW^4U;2Q<
MUEO:G2K\_P!CR^5^CK@_=FK&FK;J=.IB&0(=J3%'$G_"A,.F#](8O^T@ .S
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MFI)EVY7*[@HA6Q      !Y;1,\3,VBO8]0>>U3K&U0S]VO\ 5U+T"J>>UX_
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M=]\-^7Z@3@            %%SQ09765,;NLJ@Z '1U#B,
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MB(FJB)Q3K0]=%87W"_\ +Y(7*R)[V(YR93&%Z?ZA(;^Q<L:J]14-X;@1H
M  0+I[]+\Q">0+I[]+\Q">    @N^^&_+]2<07??#?E^H$X
M                                ,/6_?]#_ "N_93,&'KOOZA_E=^RB
M!E'>XO0:BU-II#VM29>'1O-MD7#%SU&J6ANO?JY>*)/X;U/%FG\M.N/J9;;&
MFXO+6;DP7'KITY  -           !:K2X THU,%0
M                                   62Q,E;JO1%3J4O!!K=!HV^WW-
ML]%4MBI<+K0-9[SE_P V<_EX&QX^)4HB;N.\HJ@*)E5ST%0        !:J+C
MXEQ3.]4P!KE?HT^X766HK:ELU(Y$5D#F>ZY$1,YS^?B;!!"R"/4C1$3J0NWY
M7?\ T*L14W+O7K"*@ *        8+58BEP)-8D6HQ"Y$P 2*Q   T
M                                         !@[_8(;FFT9J152(C4E
M5%543/#^YG !%MT$M-3[.>7;.SE'8QA,</[$I                     PE
M]M$UT<C4J4C@U41T:MSE455R9"W4$-!3[.G8UB;E75Z5QC)*1-RYWE?ZB$4;
MTE0 H     @73WZ7YB$\@73WZ7YB$\   !!=]\-^7ZDX@N^^&_+]0)P
M                        JA%R6O>UB*Y[D:B;\JN#P;6TJN1&U$*N5<81
MZ9 DC/$MUNE%RB]15>G'$ B[L\"J+D\GRQQMS*]K43I<N"R*LII5]BHA=\$>
MB@2 BY+47X[RR6HAB7$LL;/YG(A!Z@M8]'IEKD5/@7%   ##UVZ_T/\ *[]E
M,P8>M^_J+^5W[*!/K%U8'.ZD-<T;]JZW%R-7?*BJO]7&>NCM6AE55_RF$T1W
MU-P7H5[<?J/!DM_W1#T4C_KF6T)OP5*(G65/=7IYP %
M                                                          $S
MT@          %  8WY
M
M ! NGOTOS$)Y!N?OTOS$)P   ""[[X;\OU)Q!=]\-^7Z@3@
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MN/>0^'T&I<>\A\/H!/! U+AWD/A]"NI<.\A\/H!.! U+CWD/A]!J7'O(?#Z
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M.L"X    !!N?OTOS$)Q!N?OTOS$)P   ""[[X;\OU)Q!=]\-^7Z@3@
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M-PGYFYIP,7;K/343G.A1^5PN]V>!E$/N>+CMCI\;/EYKQ>VX  >MR
M
M
M
M R    @73WZ7YB$\@73WZ7YB$\   !!=]\-^7ZDX@N^^&_+]0)P
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MY55FPSN75W)C/$VG[.+A'4VUL6&H]%>[<U4Z4+4LW+H]CB7%$7?A2H(
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MG;2%CT_S-14.444DUKT@M456UN9&:Z:WM;L*=5IG(^")_0YJ*G@;F.&(>R<
M$7(,M   @73WZ7YB$\@73WZ7YB$\   !!=]\-^7ZDX@N^^&_+]0)P
M                                        ->TBT5I;[J[>6:G<S6PZ
M%41=^-_!>H\M'=#Z2QO>^&>HJ'N5JYG5KE3&>&[XFS 1P3RHU,(5
M  %$3";MY4 1)+?2RNS)30.^*QHIC;#HS1V57\F5[U>]9-9Z-RF4QA,)PW&=
M C@$W(          !:]J/:YJ\%3!< -*N7V>T-=6.J.75].JHB:L+VM3=_0S
MVC]BI[)3)#3.>]$5?:?C.]?@AEP(X%$3&[H*@         45N47XFJW[0FEO
M50DU175T>'.=JQO3&_'6GP-K!-#5*+0JFI:2>F;6UKHY8UB76>GLHO2F[XD"
MC^S>CHYFOAN=S]E47&T:B+A<]1O0*FGC14Z4M*R%'N>C<^TY<JN_)[ !0
M     T^]:"4EUJUGGKZ]JY5=1KTU=ZYZ4-P T-9I-$*6GMD]$M352QR(B9D<
MBJU$ZMQ#H- *&CKV53:RLE5KE<D<CFJS\L8X&Y ?['E!$V*-L;41&M3"8/5
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M[.:"KK)*E;C<(Y'O<_V'M35RN=VXS^C]C;9H7QQU-3.BXPLSD<NY,&8 30
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M)Y!N?OTOS$)P   ""[[X;\OU)Q!=]\-^7Z@3@
M
M                                R4UD3"+N5> %0,H.@
M *(J+P*HJ+P     BYX        !%R     9  HBYSN*]             ,A
M%R@ !51$WE,IG'2!4 IK;\(@%041R*A5%SD
M                                               "#<_?I?F(3B#<
M_?I?F(3@   $%WWNWY?J3B"[[W;\OU G
M
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M@W@NXNDA4 $4
M                     0+I[]+\Q">0+I[]+\Q">    @N^]V_+]2<07?>[
M?E^H$X
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M.^X__9MP3_G7_L-[QNW[QC=A5,-M$;IE?57"Z'W!OQ5Z_P#8;A;JF6IIMI/
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M:*ZW*].A2*EK;>C'(]^V8J:R9QJ\#<8][$7&%+*0Y_\ :PCN1TFJJI_O3/\
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MPN2!8Z1M+01LU41<(J[L;\(9$I  "*
M                                       (%T]^E^8A/(%T]^E^8A/
M   07?>[?E^I.(+OOAOR_4"<
M
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M997HJ)B-N5-;T:T?GFK4N=W<DU2U71L56JU48J;DPF$XJINP (F$3X
M
M        "!=/?I?F(3R!=/?I?F(3P   $%WWPWY?J3B"[[X;\OU G
M
M
M
M
M @73WZ7YB$\@73WZ7YB$\   !!=]\-^7ZDX@N^^&_+]0)P
M
M
M
M                                                     (%T]^E^
M8A/(%T]^E^8A/    07??#?E^I.(+OO=OR_4"<
M
M
M
M                                             "!=/?I?F(3R!=/?
MI?F(3P   $%WWNWY?J3B"[[X;\OU G
M
M
M
M                                      @73WZ7YB$\@73WZ7YB$\
M !!=]\-^7ZDX@N^^&_+]0)P
M
M
M
M                              (%T]^E^8A/(%T]^E^8A/    07?>[?
ME^I.(+OO=OR_4"<
M
M
M
M                      "!=/?I?F(3R!=/?I?F(3P   $%WWNWY?J3B"[[
MW;\OU G
M
M
M
M               @W-,OI?F(3B#<_?I?F(3@   $%WWNWY?J3C'O<C;PW65$
M39\5_J!D 6;6/ML\2NUC[;?$"X%NUC[;?$;6/MM\0+@6[6/MM\1M8^VWQ N!
M;M8^VWQ&UC[;?$"X%NUC[;?$;6/MM\0+@6[6/MM\1M8^VWQ N!;M8^VWQ&UC
M[;?$"X%NUC[;?$;6/MM\0+@6[6/MM\1M8^VWQ N!;M8^VWQ&UC[;?$"X%NUC
M[;?$;6/MM\0+@6[6/MM\2FUC[;?$"\%NUC[;?$;6/MM\0+@6[6/MM\1M8^VW
MQ N!;M&=MOB-HSMM\0+@6[1G;;XC:Q]MOB!<"W:1]MOB-K'VV^(%P+=K'VV^
M(VL?;;X@7 MVL?;;XC:Q]MOB!<"W:Q]MOB-K'VV^(%P+=K'VV^(VL?;;X@7
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DFRE[M?,I, $..WTS9,MC5'-5%1=92845> :OM*G0!4  ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g942297g16h05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g16h05.jpg
M_]C_X  02D9)1@ ! 0$ ;0!M  #_[12&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)$)B%J*R"$-5@A<E)D1C@Y.STO$V<\*4P]/_Q  8 0$! 0$!
M     0(#!/_$ "$1 0$  @,  @,! 0         ! A$2(3$#01,B43)A_]H
M# ,!  (1 Q$ /P#ZI      #7UMZK<;J;6)8X,#8 A]5EZ4O$1M9<<REX@3
M0^JR]*7B.JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3 0NJR]*7
MB.JR]*7B!-!#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3 0^JR]*7B.JR]*7
MB!,!#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK
M+TI>(ZK+TI>($P$+JLO2EXE>JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JLO2EXCJ
MLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3
M 0NJR]*7B.JR]*7B!-!#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3 0^JR]*
M7B.JR]*7B!,!#ZK+TI>(ZK+TI>($P$+JLO2EXE>JR]*7B!,!"ZK+TI>)7JLO
M2EX@3 0^JR]*7B.JR]*7B!,!"ZK+TI>)7JLO2EX@3 0^JR]*7B.JR]*7B!,!
M#ZK+TI>(ZK+TI>($P$/JLO2EXCJLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>
M(ZK+TI>($P$/JLO2EXCJLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>(ZK+TI>
M($P$+JLO2EXCJLO2EX@300^JR]*7B.JR]*7B!,!"ZK+TI>)7JLO2EX@3 0NJ
MR]*7B5ZK+TI>($P$+JLO2EXE>JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JLO2EXC
MJLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>)3JLO2EX@300U:R]*7B.JR]*7B
M!,!"ZK+TI>)56LO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JL
MO2EXCJLO2EX@3 0^JR]*7B.JR]*7B!,!#ZK+TI>(ZK+TI>($P$/JLO2EXE.J
MR]*7B!-!#ZHT^$I^)8E*G7BFWQDEQ8$\     !%N+B=.MT<%%\,\2QU[G&>C
MA_?S F@AJM=>KI^/ZCIKKU=/^_F!,!#Z:Z]73_OYCIKKU=/^_F!,!#Z:Z]73
M_OYCIKKU=/\ OY@3 0NFNO5T_P"_F55:Z]73_OY@3 0NFNO5T_[^97IKKU=/
M^_F!,!"Z:Z]73_OYCIKKU=/^_F!-!#5:Z]73_OYCIKKU=/\ OY@3 0NFNO5T
M_P"_F5Z:Z]73_OY@3 0U6NO5T_[^8Z:Z]73_ +^8$P$/IKKU=/\ OYE.FNO5
MT_[^8$T$/IKKU=/Q_4*M=/\ [NG_ '\P)@(?377JZ?\ ?S'377JZ?]_,"8"'
MTUUZNG_?S'377JZ?]_,"8"'TUUZNG_?S*=-=>KI_W\P)H(?377JZ?]_,=-=>
MKI^/Z@3 0^FNO5T_']1TUUZNG_?S F A=-=>KI_W\QTUUZNG_?S F@A]-=>K
MI_W\QTUUZNG_ '\P)@(?377JZ?\ ?S'377JZ?]_,"8"'TUUZNG_?S*=-=>KI
M_P!_,":"'TUUZNG_ '\RG377JZ?]_,":"%TUUZNG_?S*]-=>KI_W\P)@(?37
M7JZ?]_,=-=>KI_W\P)@(?377JZ?]_,=-=>KI_P!_,"8"'TUUZNG_ '\QTUUZ
MNGX_J!,!#Z:Z]73\?U'377JZ?]_,"8"'TUUZNG_?S'377JZ?]_,"8"%TUUZN
MG_?S*]-=>KI_W\P)@(?377JZ?]_,ITUUZNG_ '\P)H(7377JZ?\ ?S*]-=>K
MI_W\P)@(?377JZ?]_,=-=>KI_P!_,"8"'TUUZNG_ '\RG377JZ?]_,":"'TU
MUZNG_?S'377JZ?\ ?S F A]-=>KI_P!_,ITUUZNG_?S F@A]-=>KI_W\QTUU
MZNG_ '\P)@(?377JZ?\ ?S'377JZ?]_,"8"'TUUZNG_?S*=-=>KI_P!_,":"
M'TUUZNG_ '\QTUUZNG_?S F A=-=>KI_W\RO376?)T_']0)@(7377JZ?]_,K
MTUUZNG_?S F A]-=>KI_W\QTUUZNG_?S F A]-=>KI_W\QTUUZNG_?S F A]
M-=>KI_W\QTUUP_9P_OY@3 0I7%>'VH02)-O4Z6DI/&7W 9        "!3\[E
M\?\ 4GD&GYU/X_Z@3@
M
M                                    (=QYQ3^-$PA7'G-/XT!-
M 0:J_P#64>[=_,FI+')$.K^\8_#^9-7(!A#"[@ &%W#"[@ &%W#"[@ &%W#"
M[@ &%W#"[@ &%W#"[@ &$,+N  87<,+N  87<,+N  87<,+N  80PNX !A=P
MPNX !A=PPNX !A=PPNX !A=PP@ &%W#"[@ &%W#"[@ &%W#"[@ &%W#"[@ &
M%W#"[@ &%W#"[@ &%W#"[@ &%W#"[@ &%W#"  80P  PAA=P #"&%W  ,+N&
M%W  ,+N&%W  ,+N&%W  ,+N&%W  ,+N&%W  ,+N&%W  ,+N&%W  ,+N&%W
M,+N&%W  ,+N&%W  ,+N&%W  ,+N&$  PNX87<  PNX80 #"[AA=P #"[AA=P
M &&Y2Z&6>YENG^:Q^?XEUUY&7N9;I_FL?>_Q D        $*GYU+XR:0J?G4
MOC F@                %,K(%0,A-/EQ  =@  %$\L"H#?#AQ"    !GB.T
M !D9  IDJ     9  )Y   (  .T  ,]X #/
M                                                         "%<
M><T_C1-(5QYS3^- 30    $*K^\8_#^9-7(A5?WC'X?S)JY
M     ,\0  &0  3X  $\@  ,@    ">0 *9Y\ F!4              0
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M3;2I0RW)I=L?:>V?1UJ]36-GJ->M)RJ*$%)M)9;@F^19.MIOMU  (H
M
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M4FW3@^"ECL1NOHR^DBIM#J?4+WINFW)U,S4(\%CL7O+)VEZ>N  B@
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M2GRX_P"N9WFT7^;^B+48T$V\45W\=ZF=AJ7T9[/:A.,ZU"NY1BHK%:2X)O\
M,W6E[+Z;IFE5=.M*=2-O5GOR4IMO/#M_\J+?-$]>-?0;=PLJ=Y"K"6]TZ_Z3
MB;RNO_3#9UL-0_Q"K)O_ ,\CZ.L]A-%LZ]2K0I55*I-SEFJWQ9KZ_P!%VSE>
M[E<5*%=SE)S>*\N;>2RZNUGCSOZ2]J+VG4TBTH3FK>KTD)I0BTU]7MP<)M:M
MZYV:JQISRIR;>/@/I"ZV'T:XM+>VJ4JKI6\=RFNE?!</R*7.PVCW-K;4*U*J
MZ=O%QII56L)__HDZNTO<>-;?5X3^C'28RBV]RO\ A(Z7_LW5H_\ #%M3PTXT
M9</_ )LCN;[Z/-!O["C:W-&LZ-'.XE6:?$F;,[&Z5LWG_"Z=2#E'=>_4<N&<
M]I9?4TB?21=TZ&AS4^V6.?\ LD> _0CJ%*UVLK])"44[22R^"^W ^D-I-E=,
MVBIJGJ=.I.*DI_4FX\4FNSV,YNE]$FS%.HI1M[CAQ7[>1G'JK?'FW_:-NJ=3
M3JT:<6_KTN"X]YJ]IKR-3Z-:U%?;=S!]GL/;=7^CK0-4DYW=&M)O'*LUR(<_
MHJV8G1=.K;W#CG/"O(3J[:RNYIRGT#UHO82]CAI]>GP?P4SA-$X?2K;\./37
M'_34/5-:L-*V"T^J]-HW"A'%7&>D>9-1[7W)' [ :=4UC;FWU.E'=IPJU=[?
MRG]:$NSYE]8\:[Z8MGU3VGT:[O*?36G02E.,-Y/BWCC[VCKMB]C-DKNVT^\A
MI;ZW&$)J76:F5)KNWL'K.K:'::QIW4]0C*5.4(Q>[)QY-/G\C7[/;%:/H-:K
M5TVE5A4G)2;G4<N*SC\6/K2O"_I#TM[.[9Z-?TJ<G;]9J5%&";<4G'FW[SVG
M8O::WU'1K1QI5%/=XYQWON9OM:T2SUJTE;7\9RIN+B]V3CP?/\#6Z!L;I&@5
M7.PI58N6/M5'+D\HL_SI'D__ &CX5*]/1:D(2W5=2;6.S=1L]AM1I4OHUIT7
M"65"O_.4SUG6]%L]9MN@OHSE3PU]637-89J+3871;:Q5I3I5502:PZK;XYS^
M)GR:;WT\ ^AR47M5J":<=^QE%-_' E2TZ>@;?U[BX6]2ZNH_53YM+O\ <>TZ
M=]&>SNG7/3VM"O&IC'UJTGVI_P!#<:[LOI^M4G2OH3E3;4OJS<>**S'S_P#2
M!;5-K=M(*Q3A#JL5F:RLIR[L]Y=],$E3O(THK_W>GR^)GO>SFR6F;/1W=-IU
M(++?UZCESY\_<:[6?H[T'6+GK-Y1K2K**AF-9I83;_J3_A]O"?I&O*=38=TX
M)N?0T>7QQ/8_H2K*ILLDN#6XG_\ 3B2)_15LU4CBI;W#QP6*\CH-F]F--V>H
MSI:93J0A*6\]^;EQQCM-RZFF==MXO: #+0
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M%46<>TJ !3"SGM*@ 1;RQHWL'&LI--)<'CMR8].TVWL5)6RDDWE[SSQ)P$Z
M, !@-9  M?#D56'Q14 !CA@  4QE<2H (
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MWCLX@ $L+@  *1;?,/D5
M                 &&Z\C+W,MT_S6/S_$NNO(R]S+=/\UC[W^($@
M @P\ZE\9.(4$NLR^/^H$T  ")J/DZ?Q$LB:EY.G\8&:V\E\S*8[?R?S,@
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M/)MB-CYSUF%PJU>XMZ%6$H5*C3WH\>/'CV'M%"GT5*,(KA%81I/MD0"]H(H
M
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M]8-UF  (T
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M((
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M0
M                       8KKR,O<RS3_-8^]_B7W7DI>YEFG^:Q^?X@2
M      "%#SJ7Q_U)I"@D[F3_ -P$T%)248MMI)=YC5Q2QGI8?>0&7)$U'R</
MB,]*K"HLPE%OV/)@U!XIP^(#/;^3^9D,5H\T>6.)E                 #M
M
M                                                      $.X\YI
M_&B80Z_G%/XD!,     0JO[QC\/YDU<B#6_>,?A_,G+D
M!1K/:52P    #   )8"0  )8[<@
M                                                     &&Z\C+W
M,MT_S6/O?XEUUY&7N9;I_FL?G^($@        A0\YE\7]2:08/\ S4OC_J!E
MU'S.LT\8A)_R.*=U6Z>454^KG')'=U:<:M.4)K,9+#1 _P $L>.:"X_[I?F0
M:G9NO6EJES3<FZ,::<>'#L[3:ZDZF_'B]W>782;/3[:T;="GN-K#XM_B4U'A
M3A\166:V\EP[S*8K5+H_F94\H* -FBH:C7EK5.VG*6Y*+?)8[?R,W+34QVWH
M"!I !
M
M         !#N/.*?Q(F$.X\XI_&@)@    "#6_>$?A_,G+DB%5_>,?A_,FKD
M
M                                                       &*Z\E
M+W,LT_S6/S_$NNO(R]S+=/\ -8^]_B!(        ($.%W+X_ZD\@12ZV_C_J
M!/   B:CY.'Q$LB:CY.G\0&>V\E\R^*++?R?S,@!HT=6%*CJE.M)/>4&N?O-
MX:+6[652M&<'%8BEQ?M9SS;PK=P:<4UVEW')BM_JTH)\\(RKM-8UF@ -(
M
M
M0KCSBG\:)I"N/.:?QH":     A5?WC'X?S)JY$*K^\8_#^9-7(
M
M                                             ,-UY&7N9;I_FL?>
M_P 2ZZ\C+W,MT_S6/O?X@2        "%37^:E\?]2:0:;_S4_C_J!.   B:E
MY.G\1+(FH^3A\0&:V\E\S*8[;R7S,@ U6NP?5I27-8_$VI"U:3A9SE%)M8Y^
M\SEXUCZNT^2E1CW\/P)9KM)N)5J4LJ/"6."]AL4,/#+T !ID
M
M                                                   A7'G-/XT3
M2%<><T_C0$T    !"J_O&/P_F35R(57]XQ^'\R:N0
M
M                                    8;KR,O<RW3_-8^]_B7W7D9>Y
MEFG^:Q][_$"0   ##:0 %&UCF43SR N(4(XN9/OE_4FD.*EUEYY;P$P#D65*
MD::S-X0%Y%U#'1PSZ1GI5(5(YA+*[R/J+Q3A\0&>V\E\S(8K;R>3*"!CN([U
M)IF0MJ+,69RFXN/K3Z%<TJO2QI2RU4:Y-<3<IF@TBS5I<33DTYU'+!OX\43"
MM9J@ VP
M
M          0J_G-/XT32%6\YA\: F@    (57]XQ^'\R:N1"J_O&/P_F35R
M     +*M:%))U)87N*TJD*L%*F\Q?::_683J4DH9X)\F9-'4HV5.,\Y2?/WL
MSOMK76TX &F0
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M> Z.'HKP P=9EZ*'67Z*,_1P]%> Z.'HKP P=9?HH=8?HHS]'#T5X#HX>BO
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M+O(]]=T[.BZM5Q232XM(@SKV\RIK-&U>EJ<)2HK@I..5)/DL]GO-F4
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MA(  !/(           ##=P=2WG&/-_F76\7"A"+YI)&1\.833Y,
M    RLXR!&A1:KN7^[/(DC@AE=Z            S%=0<[><5S:,K>.8X,"RW
MCNT*<7V12+QR033Y,           !&=)]9C++PF^PD97>BOM  97>@
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MG+?>5+_:STR+S!-//#L/+]"T6M':&WE-+=COKM]%^P].HPZ.G&,>Q(T,B !
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MI7EC0KQ_UQ3.6UVI%;-4:>4YRM<1Q\*-QL?&4=G[)2YJDBHW:SEY94($4
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M(K^1*-;HE9UK=MXX*/+W&R)AXZ9>@ -,@
M
M                                !#K^<T_B1,(5QYS3^- 30    $&M
M^\(_#^9.7(@UOWA'X?S)RY(    ?)@,"/?<;"X]M.7X'$Z34<-=KQ6,_57X'
M<W'D)I\MUG!T*ZH[7W:;6X^C4>'LB9L)>WH$/L\>94MB\\RY<N!8 "Y< 4
M
M                                       &*Z\C+W,LT_S6/O?XE]UY
M&7N99I_FL?>_Q D  "C:+<-O/(O[#DOI U+4--TRI4TRW=>HE%I;S7.6'R]A
MFK'EGTRW<=/VGM*LK2A<)6^=VM'>7&<D<SI&TU"XU&WI0T?3:<I/&]"CAK@=
M/](NH:G.O9RCHM&ZJ2MHM[ZRT]YY1R^CWNJU=4MX5=F[:A!MISC%97!E^+I/
MD?2FSDE/0K"22CO6]-X7)?51);_;I87"1'V<36BV&]'=;MZ>5W?57 S-KK*P
M\_6XFKZSCXF  C01-1\G3^(ED34?)T_B SV_DOF9#';>2^9D !\@'R Y3:6F
MH:G0O'P5*GC/S?YF[@^ETF,FE*,J<7Q[>1I/I!;I[,7]:FOVD8QQ]]&VV>?3
M;.Z?O?:E;4L^_=1<O'/#_2ND7'2.K!0C%0DH\$;0T>EU(1O;F"DL]+C^;-XC
ME@[9>@ .D9
M
M          "%<><T_C1-(5QYS3^- 30    $*M^\8_#^9-7(@UOWA'X?S)RY
M     #Y 8:RS&2SS1YC-TZOTBW]"O5E2C2=*4-W_ %/$.#/3ZL>' \ON+*I/
MZ1]1JXDHYI/*^&!,O&)_J/4H<O87=G'@8Z&5329D)CXZ54!+ -(
M
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MZL
M
M  !#N/.:?QHF$.OYS3^) 3     $*M^\(_#^9-7(A5?WC'X?S)JY     # M
MEQ3X'GFI;\-L;R4&UQI\5V_5B>B/D<+KV[1V@G4PGF<,]G8B9>)/796$G.UA
M*7-YY^\DKD1--JJI9TYPBMUYY>]DLF/C5  :0
M
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MM94:B_U13,.J4XU+"MO8:W&-'E'J5&G3PE"*3PSC/]/1O>,3P44LMK'(J=&
M
M
MAU_.:?Q(F$*X\YI_&@)H    "%5_>,?A_,FKD0JO[QC\/YDU<@     "F.9P
M^U\8TM1I5)248SJQ3;X=B.Y?)GG_ -)+W'8[SQTEPHK/?@E\3QV>CJ"TZET4
MXRAQPXO*YLFHU6S%)T=$MZ<GF2WO^IFU[.9,5  :
M
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MEJ7:OF7'1@
M
M          (5QYS3^-$TA7'G-/XT!-     0JO[QC\/YDU<B%5_>,?A_,FKD
M      &>>?2[F-'0Y1Y]>C^!Z&<9])-*%2AI;J)M0NE)8]P9K>[/U7.PIYSP
MS_U,VR? TNSU:-2BE!-+#Y^\W2,[63H !I0
M
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M,FUCY'/Y)VZ?#>FVBEC@57 QT)QG2C*.<-=ID-2H  H
M
M                                        !"N/.:?QHFD*X\YI_&@)
MH    "%5_>,?A_,FKD0JO[PC\/YDU<@      <OMY252ULM[E&MO?R.H.>VT
MC*5C1W,<)O.?<$5V8E3E2S3SO;KY^\W\7]7B<AL33E&<Y\,.#7_,=@L]IG%J
M@ -(
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M/@_C/8O_ "E/'+=)*Y<#7:-O*UA&79%&Q,XW<;RFJ  T@
M
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M6]P !I
M                                               !ANO(R]S+=/\
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MNI2C=W-.,8Q<6EP7/F;A<CG\?CMGZ  Z,
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MI3DG'+:6.7_F.\7(QC=UO6H  V@
M
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MJ';T84=2N)NIQG-86#=Q>4:'5*52G?V\X2>[*IEI+VHWM)YIIXP<<'HR\7
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M"EG<CE]N#)V!%XPW5J@D5W2H0U$V8 !0
M            (5QYQ3^-$TAW'G%/XT!,     0:W[PC\/YDY<D0:W[PC\/YD
MY<@      1=32=E6SZ$OP)1&U%9LZWP2_!A*X3095EJ<H0W^B6,8?#FCT.)P
M.@W$:>JU*3AR2XY]J.^B\HQCZU?%0$#:
M
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MU-.,9)X3Y\VCA.LGHO\ EL  =7,
M     "G: SQ*M\#%4JP@_K2CQ]II]5UATZD:-"E6E*3W=^,4U[S-JS&UL[F\
MHT(MU*M.+[$Y)&LN;ZO=T8]44XMOFEO<"E+3I7E.$[S=GGCAY3R;6UM:5M34
M(02QW&>ZWUBUUEIU2<5UV?2KN<<&TM[:E06*4%%=R,J7$J:QQTS<K0 &F086
M0    8
M       "%<><T_C1-(5QYS3^- 30    $*K^\(_#^9-7(@UOWA'X?S)RY
M    P7SQ:5?@?X&<CWZS:U5_M?X")?'"Z).C+7[BG-14HQB\M\^1Z!3PX+#R
MCS72K>4]IKG#4<1@\OM^R>DT([E-+.3/V8W<7@ TH
M
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M&CTFA4I:U>;SCT>['"7R..766WHQ[Q= "G9PY%3;  "@
M              +B4>>SD!49+=['$A:CJ%*TI2E/>X8?!9[3-RD62U-E)13;
M:PC4U]8AT[HTX5'++CE)-$*SG>ZC5G)S@[5RRDUA[KY&VM--H4).<8M2?'[3
M,;M\;U,?6LJ6=W>UU-U(*DI9PUAX\#<6MK&C3C'"RN?$E)86 :QQ9N6U,)%4
M :TR  H
M                !"N/.:?QHFD.OYS3^) 3     $*K^\(_#^9-7(A5?WC'
MX?S)JY       Q7:S;U%_M?X&4LKK-&HO]K"/.;GI+?66Z'VG**EA9X<#T#3
MYRG;1E/[3SV>TXNO5=IK%1QX9<5W]B.TL*CJVT9M\7G\3%G:SQ) 0-@
M
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MQ]:M&+RCC\CT?%VWT<215<.!2F]Z.>UEWO-SQB^@ 3R4
M         ,C/8 &..2F4E["/<7=&@MZK)J/+EDEJR6I'M-?J&HPM8MO.\DNS
M/::S4*^HW=7<L:=*='"XRX//B3;/3(PI_M-[?SWG.Y7Z;F,Q[J)4KUM3HRC1
MW>+QQX>TF:9I-*S72?6Z1O+XY6<&RI0Z-82X&0LQ^ZESWXM248Y*QP^)48X>
MTW)KQ@ 7(%
M          !D    &>.!GC@  $\@ ,H    (=?SFG\2)A#N/.:?Q("8
M@U7_ .L8_#^9.7(@5EG48_#^9/7(      %M7R<L=S+BVI]E@<5=P4M:J[^>
M&Z^'N1UVGM.VBH\N//WG):Q1G5UBHJ2S+,>WV(Z?2:52C:PA424UG*S[3-]3
M#N)X -*
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MWZ7+^+:5*--<$9"BX%3<FF+0 %
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M0 :4
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M%O1QXY2?R+@1I2,5'[*2]Q%U'R=/XB61-2\G3^(#-;>2^9E,5MY+YF4
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M:?1M(8A&._C$I[J3E[R8H)+@7+@@N)N8Z8MM,#'  T@E[0
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M9^GQ^5T"X( &P
M                                    #W!   @"    $V *93Y,HN3X
MC8N!2)4H  ##=>1E[F6Z?YK'Y_B777D9>YENG^:Q][_$"0  &2C7MP5_$BW=
M[;VE)SNKBE1@L9E4FHK^9+=0D<+](&S-34;NG6H:I&P4::BTX9R]Y\>:[SBK
MC8NLM2LY6VOPQ%/?W:6<O[Q;]*FTMS>:Q0M='UF%.C*C]:I2G&<5)2D^/R2.
M6T=ZU#5+>53:7I89;=/=7UN#]H^*'R>/I30J+M]'L:,JG22IT*<'/&-YJ*63
M(GFY^SNXEXF#9QS>BV+J5.DDZ%-N7MW49_\ WE<<_6-5G'Q, !&@B:EY.G\1
M+(NH^3A\0&6V\E\S*8[?R?S,@      X&.O'>IR78T9"V7V6D(E<EI550UZ_
MIY7"I%<_:SKEQ7$XO=ZMM#7FXO\ :UH\>7:=G2>8(U6,.NE4E[BN #&G0*8X
M<RH*(.J4H2MY9I])+AP^9&T&]C=T9M)1<:CAC.>21M9Q4EQ1SMO.GIFJ0LU!
M15;-7?SA+G^1RRZKICW-.D3!;!Y2:>4UDN7:=(Y@ *    %&\/G\@*E&\(CW
M5Y1MH.5:M3AQ_P!4DC51U"XOJ;Z&C5I<<;W/^ABYM3';9U+V@G]6I"4O14ED
MTROKVXO5"-O7C2RUO<UV^PD:=I$J=55*]3?:;YQQV&XITH0^S%(S-UK>.+66
MVCT%5Z:O"$ZK>5)QXQR;2$(PCB*6$L(OP@;F,8N5JB\"HP#2
M  "G')4 "F<%DJB2;<DDN.6PFV0HY87$U-YKUE032NK>51?Z%5CDT536-2U%
M8MK6ZM_]VZWR^19&+G(ZNK?6]+RE:G'WR2,/^*V?\51_^HCG*6BWUW#-Q=23
MS_JILOH[+U(SS.YC)?!^IK2<LJWSU:U7_O%+[Z,4M9M5G]M2?_S$0Z>ST/\
M7*+_ /+^I(I:#:QSOTX2^3)T?LPU=H;6#?[2G_\ 411;04VLPBI=V)KB2O\
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ML\F*VW^BAOMYPLY,P!N33( "C#=>2E[F6Z?YK'Y_B7W7D9>YEFG^:Q^?X@2
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M5Z*CJLXW/'CG*]QMJ%"G1CNPBDN>$9XI<\!+OYFYBS<MBY<2J>0.PW(R (
M           # #/$ME)*.6TC7WNJ6UM%N52$I<?JJ2S^)9&;=)\I[KX\4S#6
MNJ=)-SG%+VR2.8N]H*UQ.5.QI5X27#><$T^XLHZ;J.HXE=UH.#YQ<=UX[>2+
M,=,7.WQLK_:&C0WHTHSJRY8IM,T_2:MJ[S:U:MK!\7&K#'#DUR-[8;.6-LU4
MC1_:KFU.7?[S<QBL92&Y"8V^N:L]F+7[=Y1IU:W;/CQ[CH*%K2HK%*"BB1A%
M%P?L)MJ82**."NZNXJ";:TIC@,<"H"J8*@
M                                     A7'G-/XT32%<><T_C0$T
M !"J_O"/P_F35R(57]XQ^'\R:N0      *27#@5#Y <AMPF[>S]E=?@S)H,:
M,=1G6:722IM-YX\U^1)VLIQE;T5)<JF5X,@:9;.-;I]Z*WEC';S_ $,YIA]N
MQ7(!<@:B@                                        !24DES2 J4[
M>+(]>]I4HYWU)YQB+3-3;:K6NZ^[3IU81QSE!8,7)J8VMS*YIQEARCGWHB5M
M4I4Y;O%^YHA6^EUY5=^XJ0DL8X97]":](M)X<J698Y[S_,S+E6M8Q26I1Z&5
M2,9M+N+:6IJ=*;Z*IP]A)AI]"%*5-0^J^S++Z=I2IK$8X3]K+K(WBU4-9ETV
MX[:X:SC[)AO-;J0J1C"UNL-M94#?JC!/,5A^\JX9YC53<:F=Y6G9TIPA54Y)
M_P"GBA;.\J4Y;U22;7#*Y,VZBDL8Y!K*X"0Y-%3M=359[UXI1]WZ%FH:;K-:
MIFTU*%*.5P:_0Z&.-W@N 26\WVEX)R:6>GWT[;<ZU%5=[.\UV>!?;Z;<0I_M
MZL9RSS1M\/\ U<2O,<(3.M+0T:"J;]50DUP[1<;/V%S)2K6T)22PFVS==@'"
M+SK62TBSG&,)4(N*6,99?2TNUIIJG1C%?,V&.>1[!,(G*H4+"WC+>C2BI9SG
MB9>JTMYMP39(P"\4Y,?0P:2W5A<D7*G%+DBX%U#:QTXKDBKBF7 :AM3 :X<"
MH&H@4*@:%/D5 &@0 *                ,-UY&7N9;I_FL?>_Q+KKR,O<RW
M3_-8_/\ $"0  &,KB<GM_HU76-&K*SW%<?4C%S;2X2R^\ZQK/!E.?%&=$NGR
MT_I.VPT&I5L[J^B]R;4.CM:;2BN"XN*[B7LOKVUFW&N6\;Z\HU+*$W"<9T8T
MVTTVL;L?8CZ(O=$M+R6:RJ9Y<)8,]CI]"QA*-#>W7C.7DUB531K=VNF6M"6,
MPHPAP?=%(N4?V[:](EKLQR(.,W$L\][@$C->W,;:VJ599Q"+D\>Q&@AM)2F^
M'28[/JK\S-?6-SOW-23I]%)-\'QP<^M&K1N.L4MW=E)2XR[B*Z_2M4IWLY4U
MO[\5EY27:9M12<(/_<:K0;*K3OZ]U4W<U()<'W8_(GZA"IF+>-UR1IE-MFG3
MS[3*8K9;E+'M,I&@     #Y,%) :/:6GOVDJG#]E"<OY?H9-DZW3Z':U%_J4
MO^IF77Z>_I-['M="HO\ E9KM@ET>SUI0?VH1EG[[-_3E/].E"Y!@PZ@  %'Q
M6"HXY(.>U%SM]2HRIO":;?;WF\MY;]&#?-Q62'K4&K2I5C]J*6/$@6VKQC95
M&\[U-)?9.6^-==<IMOI344_8:ZXU.G^TA3W^DCP3PL9-?:W%?4=Y/=Z)XSPP
M\,GV.DT+:I*K'>WFTW]8N[EXG&8^M91H:C>WDI5JE-VZ::6,/V]AO;:TI4L8
MCQ][)*2Q[QP2P:F"7/:N.( -L              ,@ME+ %SY#"(US<QHPWY>
M[@<S<[4PJ-QLU-3[-^'#V]I>+%SD=9*HHOGP-/J6T%K9*3JJK)KT(I]N.\TL
M+?4=6XU'0W.7#@^\VNF[-VMO-56I]*N/V^&<<2ZTSRM\:2MJVIZS.4-'JQI0
MRTU6@ESY=C)ECLI3J2IU]5A"K=+$MZ$Y);W;PX'54Z71Q48\DL+)>GC[78-Z
M)AOU%M+&E;04:<<17+BV2DBJPUE%2;=)-  (H
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M\"CS\C<QTS<K50 :9
M          &&Z\C+W,MT_P UC[W^)?=>1E[F6:?YK'Y_B!(   ICL["H 8
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M/J>.FQN_LI\,=G8=+9Z71M8XI[W//%D^*PRI+6L<)%D88X=A>N" ,MZ,  *
M
M                !"N/.:?QHFD*X\YI_&@)H    "%5_>,?A_,FKD0JO[QC
M\/YDU<@      494/V 0M7QU"MGT)?@SB%U3_AJTZ]TG1=-PW.><R_4[;6/W
M==>RE+_I9R>QMM3U#0+:E<.6$YRX=^\^_P!XRFXQO63LJ%6.[PR9E--9633S
MTN5.ANTYU&\]LD8K*UO:-RFXIPP^<OU..-L=[)>XW^1G@<_;N_Z9[].&,O\
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M*&IZ?*#?&ZAG'#AP-8N7R.SI/*P7K@8J#WDS(N"XF:Z3Q4!/@ H
M   3  IQQR&<<U@"H,=2M"$7*322[33W^T%K0C)0JQE47*/'O+)MFY2-Q.2Y
M$.^U.WT^DYW-3=@EEO=;_ YNOJ&IZB]VUMI1IO@YPJ8QVF:RV=K5I=)?7=Q-
M/#=*H]Z/M7%FM,<K?&*XVFK:A*5+0X4KB7)[Z<>?+FU[2RAHVH7\HU-2Z2A+
M*;C2J)K\6=-9:7:VJ_86]&$N&91II/\ D3XQ27(FR8;]:BPT:A;XYR:]))]O
MN-K&G"/",4O<B]+!3!+6YC(8X%>T C0
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MDT;:A9T*/&G1IP?^V"1(2'#?J<]>(]"UA"*6$\=Z1FBDN1<,&YCIFVT !I!
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M_.I_'_4G$&GYU/X_Z@3@  (NH^3A\1*(FH^3A\0&>V\E\S(8K;R7S,H(
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M[#>*"QPP7)87,;68?U@M[6E1BU3IPBO]L4C.DD,>TK@FVY-"]@& 10
M
M                        "%<><T_C1-(5=_YFG\: F@    (57]X1^'\R
M:N1"J_O"/P_F35R         PW/F]5?[7^!S&SO[UJ0Y8IMX^:.IK+-.2]AR
MFC_4VQNZ:^RJ'9R_TFL?'/+UUX"Y RZ   !\@'R TVJ6T(5Z5SA+HVYR>/<;
M"RKPN*490EG@GA%;VCT]K4IXPY1:Y9-7I.+6M4H3J<<J*3X'+_-=)^T;P"/(
M'5S      #)1R2YM$V*E&8JMS2I4Y3G.*2[V09ZI3DI="XU9+LC,S<Y&IC:V
M,IQ7.1K;C6;2E5Z'IH.KO;N[QYFOI]=NKU-QKTJ6_P!K;31L:.CVZN)5:L*5
M6;>4Y4UE/WF=V^-<<9ZAWL+V]<>@E6I4\_:A+FB7:Z;BWA"XFZTESZ19[39*
M"C%*&(I=B1=%>W)9BG._3%1MZ5)8A3A%=RBD9ERXH#'M-R:8MV ,%
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M)5+!4$70  H          ,-UY&7N9;I_FL?>_P 2ZZ\C+W,MT_S6/O?X@2
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MT$\W3C6EWRAC^INK6PM[;R%*,/<B5N\,%3.V\<)%%%+L*@$;,
M
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MMI4Z]1SWL<7$S6>ET;?BH1;>..#8+CDKQ-<&>54C%16$BN #4FF08 *
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M^$G3X?$R< ,-O;TZ*Q1CNKWMF+4/)P7^XED34?)P^(#-;+%+'M,ICMO)?,R
M        #'7I])3E%\FL&0 L<U'9>U>H3N)TXMO#^U+LQ[?8;^A;0HPW:<=U
M>]F8%VS,)  $:4?!<>)3&5[2X :W4]*H7U.4:U-2RL?::[?8:6VV62JOI'3E
M1WN$<R^SW'6 NV.$:^QTJVLU^PI;O+/UF^7O9.QA<N1<";:DD47%97 +.7E\
M"H"@
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M4UV[TG_4V@)MJ81CC345A%Z^JBH)MJ32BP^PK@ *-9YA+
M                !ANO(R]S+=/\UC[W^)==>1E[F6Z?YK'WO\0)
M!"I^=2^,FD*GYU+XP)H  $34O)T_B)9$U'R=/X@,UMY+YF4QVWD_F9
M
M
M      $.X\YI_$B80[CSFG\2 F     (57]XQ^'\R:N1"J_O&/P_F35R
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M?M-ZHA9XDVU,(C4;:%*,8I/Q)"@D7 FVYC(IRSW"..PJ@%$\@
M                              #%=>1E[F6:?YK'WO\ $NNO(R]S+=/\
MUC[W^($@        A0\ZE\?]2:0H>=2^,":  !$U'R=/XB61-1\G3^,#/;^3
M^9D,=OY/YF0
M
M                      !"N/.:?QHFD*X\YI_&@)H    "%5_>,?A_,FKD
M0JO[QC\/YDU<@        #Y,X+Z5I.CHMO4AS=W37'X9'>\<ON.3^D'2+C5]
M(I6]M'>E&O&I]I+DI=_O-8N?R3I/O=6HV-+>JRP\X^RV:.G2OM>EO7$80MWP
M;I2P\KWMDG1-GIREUG495(UVG%P4TXX['V\3K(48P6(Q27L1;8QC+E.T'2M,
MHV5+=I;SXYS+#><>XV2212*P5,[=<9H#Y $:0-5MNLV56ECC.+2.=V=NY6M_
M7L:F,4Y1IQ[7VG726>#^1RNU=G*A.CJ-%/=M7*M5>4EA8?'M?)FHY9S5VZJ+
MX%=YX>32:)K%*^TJE=;R^M%R>(M<F_R(.I[204G0T]QJ7+^KNSBTLM<./#V#
MBO.:;^[NZ=M2Z2HVHYQRR<M<Z]<:E6='3(TITL;V9IQ?M[?:66.S]YJ-P[K6
M'4H59K,J=&HMQ-/"PN/8CK+6SI4:>*<%[\(O49_;)SVF;-YJ*I=3J[^&L*::
M_ Z:A0ITH[L%CY&=+!3' S:WCA(JN  (V
M                                                       #%=>1
ME[F6:?YK'Y_B7W7D9>YEFG^:Q^?X@2        "#%I733YN?]2<0>/3U'&"D
MU+@!GN[B-M2<YM))-\?8:V&T%JWAU(I]V'^1AJW.HW%>YHW.G1A:QX1J[R>4
M^;P<Y=:?-7KG%R5-2337)HD'<VMY2N<]')-I9:299J.>CIX7^LT>S,*ZU6[F
MU+J[IK<>>&>'9XFWO.LSJJ,*.8)IYR5$VW\F9#';Q<:>)<\F0*
M
M
M 0KCSFG\:)I"N/.:?QH":     A5?WC'X?S)JY$*K^\8_#^9-7(
M6N"<FWQ+@!11297        (]Y0C7H5*4_LSBXOADD!K(B6;<-+9RX6IU^BG
M5C;RPENM))=O Z+2]&HV4%E])/&-Z45GF;512["Y(UR8GQR+(1QP+P#+I)H
M
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MJ_O&/P_F35R(5;]X1^'\R:N0                      "  ,
M
M                    8;KR,O<RW3_-8_/\2ZZ\C+W,MT_S6/S_ ! D
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M3^) 3     $&M^\(_#^9.7)$*M^\(_#^9-7(
M
M                               ,5UY&7N99I_FL?>_Q+KKR,O<RW3_-
M8^]_B!(        (--_YJ7Q_U)Q AYW+X_Z@3P
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M/YDU<B%5_>,?A_,FKD
M
M             &&Z\C+W,MT_S6/O?XEUUY&7N9;I_FL?>_Q D        $&G
MPNI>V?\ 4G$**S<O'9+^H$T
M                                        "X  4:R^/(JT !3#[.14
M "F/$J    #W@                  @
M A7'G-/XT32%66;F'LD@)H    "%6>-0C\/YDU<B#5_>,?A_,G+D
M
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M8 B=0I^LJ^/Z%'I]/'E*OC^A, $*.G4EG%2K]Y?D9*=E"$E)2FVGGBR2
M  "%5_>$?A_,FKD0JG[PCW[OYDU<@
M
M                        PW7D9>YENG^:Q][_ !+KKR,O<RS3GFTC[W^(
M$D
M
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M#[J BUKF%2#C%IY6#+8)QMHK'?\ B9>AI]D(+_RHO226$DE[
M
M
M
M
8                             /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g942297g16k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g16k01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1L*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &NT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4004%3$A,@4S(D%A(T)#4G'!L?_:  P# 0 "$0,1 #\ ^J0
M          "%>U.4AZV:I7&E&E4N"XM!$]TCXYIW-_694:B.3Q,J:<M5RY%O
MVLE%OL(NAY.$8M#B%,V2&1BHM]CT=L4]-KD5><DQ,,J:XJC,.0 $9@
M                 !UJRNIZ)B/J9,C57*BY577]7N.SR&I;H#G-PV-6.5J[
M\FO_ *7&5,9G#7<KT4ZFTQSQR>HZ_P!2G)<IG<]TY>^H;28B^1SY95M)+,B9
M4R]?N+;I*MD\37,5%:J(J.1UT4M5$TL+-^+D.W<&+=:6,C!O   1;BXV! "
MQS(G*@S)SIVCY,LK@PS-Y%3M)1R=).T?)ED#&Z=).T73I)VCY,L@8YDZ2=HN
MG23M'R,@8W3I)VC,G23M'R,@8W3I)VBZ=).T?)ED+F.9.DG:,S>DG:#+($(Y
MO.G:3>X     JV "Z$-V:U(<Y&HNP";H0V1KMBGG8CB4%'%GGFCB;FRW>]&I
M?ZS4-$=+'8]B,3HXY(8D<Z-6*_,BJC56_P!J&>CXRTS>B)TK"":R&K=J>XE-
M1@W
M
M
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MQ^FOU7;L3/*\:?U$7G1#D../]6U;VU)J.1%NAY_]OIH]  "@
M
M
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MC[B3P'G,PKVN/N)/ ;%1W]KE: *O\YF%>UQ]Q)X#SF85[7'W$G@-BH[^URM
M7*P\YF%>UQ]Q)X$><S"O:X^XD\!L5'?VN5H"Y5_G,PKVN/N)/ ><S"O:X^XD
M\!L5'?VN5H7%RKO.9A7M<?<2>!*;IF%>UQ]Q)X#8J._M<K0!5_G,PKVN/N)/
M ><S"O:X^XD\!L5'?VN5H"Y5_G,PK7_K<?<2>!'G,PKVN/N)/ ;%1W]KE:-Q
M<J[SF85[7'W$G@/.9A7M<?<2> V*CO[7*T$4FY5_G+PKVN/N)/ )NF85[7'W
M$G@-BH[^URM %7^<S"O:X^XD\!YS,*]KC[B3P&Q4=_:Y6@"K_.9A7M<?<2>
M\YF%>UQ]Q)X#8J._M<K0%RK_ #F85[7'W$G@/.9A7M<?<2> V*CO[7*T+@J_
MSF85[7'W$G@/.9A7M<?<2> V*CO[7*T!<J_SF85[7'W$G@/.;A7M<?<2> V*
MCOK7*T!<J_SF85[7'W$G@/.9A7M<?<2> V*COK7*T 5?YS,*]KC[B3P'G,PK
MVN/N)/ ;%1W]KE:%P5?YS,*]KC[B3P'G,PKVN/N)/ ;%1W]KE:%P5?YS,*]K
MC[B3P'G,PKVN/N)/ ;%1W]KE: *O\YF%>UQ]Q)X#SF85[7'W$G@-BH[^URM
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MY5$QJ)>ZM6QLFMSQT]37J:@J:J"2:"![V,6RJU-2'7?$^)RMD:K7[%1>0W[
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M/W6__P ?8M_=?XK#YQ]78F:^WJ/1Z3Z3_P"OE_S7[XC_ !'_ .RY*:%U0[+
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M&H(HOU -837M%^H)J0 B\XNHOU#Z@"ZU"=9!/U $VDI?E')J(OJ G4EQM0A
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M^H<?1=#\ZZF5'3-AB:QC$:U$U(C;(AW$2P:ED!QS.7N4TX  1D
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MD,8EO&WW(9)K/+?6QZ  %
M
M
M                              $.V'!5?JE_A4YW;#AJOU*_PJ6GVQJ]
M/FC=-U:=8HN;:L>K^[::ZC7(EWW21-C%VJ;-NEHUNG&*.D;F:JLLB<^]M-?A
MCDGE;$OIU#O4>B:D3_VYZMN8BE\?U-$U7IC_ "FF@EJ9610QN>][D;9J75%7
M46UN<Z%/I\E97->U_IMWJ6'[=9R;G.A+((V5N(-AF?*V*6.RN16KK77LZBU(
M(6L2R(<MZ]_4/7Z'H(IB*JBGB2.-$1$1$1.2QRMVK8714L2U+(<DSE[,1A(
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MIN152W..V]M3J0S1+(8M2S4]QDU+)K6YSO2@  4
M
M
M                                                0[8<53^I=[E.
M6W682MNQ4ZBPQGT^;]T2.273K%&PMS/O'=.K>VF];G.@[Z"9M96MGBJ(I5R,
MSL5JHK;76WO7E-CXG4\NE==BE2D,S9V(U(GP(N541J7NJ]7-RFWP1(SU41ON
M0WU7?C$/.M='&Y-<\D$*QIRG/;E4(EN6Y*&B9R]*(Q&$(EB56P!%$V
M
M          %V 8+?6G(9(U%;;D-?TDQZ+!ZBA9,^)C:B16W>ZVQ4V=IZE#61
M5<#989&/C=>SFK=%UET_VPBN,X=QO628M=K,B,PZN*_)=9]"_P#"IVCJXM\E
MUGT+_P *@57+^L4XTV*<DOZQ3C3U5+"(0DA#(R2)P(0201?;C4WS07]5+_ S
M^9H:F^:"_JI?X&?S(K:@ 0          !&I=1BC>1QE?6+:EUA!$)0Q2Z[=B
M;#(*
M
M
M                  "-6PBZ+J0E42][C8NP!LL2
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M=C#)=IOF@WZJ7^!G\S0S?-!OU4O\#?YFB7H0VH $4          "PL
M
M
M
M             %1%
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M_ S^9Y[Z:&U  C(
M
M
M
M                                 'G8Y\GU'\#ON4^6)=JJ?4^.?)]1
M_ [[E/EB;:IV]*\'\QZAUY-BB-%5B);5SB380U';VBHZQWOG6;&N<MK:SE;
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MFB&]Z#?JY?X&?S-;K;4 "*
M
M
M
M                                        #SL<^3ZC^!WW*?+$WK'U
M/CGR?4?P.^Y3Y9EVG;TKP?S'J'6DY3C151NHY)=AQ?L'>^<;7N9JKM-,,5>F
M[\#CZ3IM3&^X^:]S%/\ YGAG\;OP./I2G]1ON0\WJOL^J_$_J<XL <KURPL
M L+  +"P "PL  L+  +"P "PL  L+  +"R  +(0J:B0#"NMU+!ZC%IL)C@:C
MF)(]'W<B:ER_YGK:&Z,0X111HU'I,B.1;ONEE=<VF6%DCD5[6NLMTNE[&;6V
M6R)9.<V:YB,.?8IFO7(QB-M8S" UNB"QU<5U876?0O\ PJ=HZN*_)=9]"_\
M"H%5S+>1RJ876RF4OZQQAR*6$+JJ67D!#3+D*"+K)NJJJF/($ XUN;YH-^JE
M_@9_,T-3?-!OU4O\#/YD5M0 (
M
M
M                                                        &*R-
M1R)?6ID>%I3,ZGHY9&716M38MOV@/<1;["46^PUW1O&HZF%L4JL8]K6M]*2Z
MN4V).H                                           /-QSY/J/X'?
M<I\LS>L?4^.?)]1_ [[E/EB;U_J.WI7@_F/4.O)L.+]DY9-AQ_LG>^=;3N8_
MUSPS^-WX''TI3^HWW'S7N8_UTPS^-WX''TI3^HWW'F]5]GU/XG]3G !RO7
M                         MM(UVVZR0FH!8  #JXK\EUGT+_PJ=HZN*_)
M=9]"_P#"H%52_K'&'(IR2_K%.-/54L(( @*0($  XU-\T&_52_P,_F:+EUF]
M:#?JYOX&?S(K:@ 8@ "@
M
M
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MS^-WX''TI3^HWW'S7N8_UTPS^-WX''TI3^HWW'F]5]GU/XG]3G !RO7
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M>(V]:+X 96-F3G0FZ<Z%<<:L1Z4/P!-*\1Z4/P RL>Z<Z"Z<Z%<)I7B/2A^
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MNM+\I"%IVU[=0.IAM='70+)$JJF96ZTL=M%O<BG+M
M                  >=CGR?4?P.^Y3Y9FVGU+CGR?4?P.^Y3Y9E]:_(=O2O
M!_,>H=>38<:>J<DFQ3C3U3O?.MIW,?ZZ89_&[\#CZ4I_4;[CYKW,5_\ FF&?
MQN_ X^E*?]6WW'F]5]GU/XG]3G !RO7
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M$1-E_P#,@L=$UW).*EG;4PME9=$6^I=NTY0H
M          /.QSY/J/X'?<I\L2[3ZFQSY/J/X'?<I\LR^M8[>E>#^8]0Z\BW
M13B3U3FE2R*</[!WOG8;5N8Z]-,,_C=^!Q]*4_J-]Q\U[F*__-,,_C=^!Q]*
M4Z^@WW'F]5]GU/XG]3G !RO7                                #JXK
M\EUGT+_PJ=HZN*_)=9]"_P#"H%52_K%,.13DD_6../D4L(A"0@* 0! ,Y->M
MQPHMG.3D4Y9=;52]NLX52UK:^LB0H_=E2V-U"-YX_P !95;0I7:%)#)FNZC8
MU,JV_90K;=E3_;519;ZX]G\):C)&Q:)PR/5,K:5BJJK:WHH&2O=!,<GPG&\0
MPR1(FP4[$8Q5:JN77RJB]9O&D&&X93T,DM=-/'"W+F<W7RZMB%:8#135^F6,
M2PY][6SD5K5<EKIREOXG%1XO1OI6U%._/;8J/V+?9<(JC<WIDDT@Q=]/=T#:
MQBL<JZU;G=9>PNJ]E5W(4E!AM;@&EL#*2HF=!45R9VQ-5K4:DFQ;<EE4NVUV
MW74G,%9PW5%7F4EVU5(8JMU6U!=:JJ;"PB"18 "+$D $%P  3:"0( !%"454
MUM]9-A!*)Z*VV@&^EGS;5364ENHX?)1:0OQ.%JJR.)C;N5%37=-FWE+L1;)U
M\II>Z;A*5VB]:K&)ORK&B.1EUU/0)#CJ*V"NT WIK[U$F&HU&HBHF98]G::/
MN3US\-TNGI:O*Q(Z5R;+K=7-7D]YWMSZ2HQ"5])(V58J1T<+T==R*FM-:<FP
M\[32F?@&E5?B-,QS(WJV)&QMR(EV)R_])%6A2,9B6*P5\2JYD%V*J:DV+R+K
MY3KXMHM38G)4OK73M8JN>Q8WHEU6_4IZ&B-,^##I&R(N9[\R72W(AEI!B]-0
M4ZQOEB1\F:-+R(U6K8(JG1K#."MT?R6A1SVI3*Y-\5%76GU%X-5SHXULEVHE
MS0]&J:@HY$KZBLI*FNLK,RN;OF7WWO8WJ)]X[HNIR72Q8&2N<JJJVL03^RB<
MI!0 '(!)!) !   Y   0($ $M]9+$K='JJ>MRD)J5")554]'4M]J <;,JM5K
MEVE'Z843L'TVI:Q45&5&(9U5RHNI'HNI$]Y>>5,Z6LA7FZ[A2U%+254+;.I=
M]E<K675;(B[>3818=O3:9,8T15M.N='2M5+>CL5><UO<?Q=E+38E35#FM5U0
MB)Z*KL0[>YA+-BE%3^5MDDIG)(MI+N;='+]1K%92S8)I534L"2-2KE<]$8U6
MWUKR<I!:V&1*N/5E6W7#*Q$:[GV<GU'!I=6N="^AI\KGO1KD14Z^?9R'IX$Q
M> HE>U4F1CE553TEUJ5@W3&LCIG-JM':V6>^JH?FNB<VMO\ [<#DW,,R:38X
MV1$1S:F-'6Y/3>7#):UT]7D4HG<\QF2+2K$')0RO\NJX\R(J_H;O=MU?VNK8
M7LY+QHBKEU\I81*; $V H   +! !/(0A) $D  $ 0GG E-2&"6:BM;RF2KZ-
MB%VHJ:B#AJXDDI98UO=S%;JZT*/?#Q9W1Z)7W:U*97>GZ6U'IR%[<]]94V[#
MA;F/?BT2*CHHHXT<UFO6]4];ZP0[VZHOE>"451R^2O>VVI%NC5,-Q[%F\%4]
M%*YJ/8R1RHC5^<Y_K.?1F*32#1F6*MC<YT=,QD:RIGVMY+^Y#2Z9E5@>F=91
M4V_(V.%+)&BM36C5V?615B4U/.[1FO6-B+/OJ96JJ676W_,TG1W2*+!L<QR'
M%'MA?*W>FHC%==VO5JN6IB\D6$X//.D+71M1KE8GHHJJJ(5DNC\6DU5BE9#O
M=*YC5G3]'F5=NJ^KF ]_0?#IY,8AQ1K+T%GLWS,E[V5-FW:6,W7>VSD*?W,,
M3K(,3I\(G?.^.SWJKG*C=BKL+@8EFI[BPB1R <A1(('(   #:!R "2.0!  Y
M  (0DD@#KUM,VIIGQ/S976O9=>THQ9'X%IO5MF1&Q5%?EC5?25R)(O-LVH7Y
MM*=W7,+6DQ##:R%F=SIY)5R,UI96KM)*O6W7F)644D5)=]7GC7(NI+:^<RW-
M\7W[1C%7JK,\"Y;(U=J-.;16G?I)0MKJM'(KE<VTJ9UU+;::-HQ/589C,F$H
MR9(JZJRJJ7:U$5;:TY2"XM&J9)8UKDOGG99VO5MY$^HK+==HHJ>LED:K_1AC
MVK_:4MS!:9:3#X8LU\J*FRW*I5V[*U,U1=4OO,?XRHWO1.-K]"L/8JK>7#XD
M;UWC0\/&=":"MIEEJGU+9G.3,C'MMJU<W,;!H39NB6$*^UDHH=:\GH(>=I5B
MT#TDHH*R*"9CFN5R2I>UK[/K(-7W&6S1K5M8U%B95*BJNWU2UI%=G57(EE-9
MT6BPW#6K3T<E))).[.JQ*U%O;F3E-F?Z3&I>RH6 !)!1.P@  @Y  !) 0 "2
M )0@(2!DY$R(J[#C5<WI<AR7]'6ETYCB=T6[.=""E-T+#EPG2/!JRSD:^L?*
MJN5%34]B[$]YN.+U#,4T,HJA5]%\ZV5J6V9TY3EW4L(\NPA*AJ)FI(9I$7)=
M47*B[>38:WN82S8KAD&%U+9-ZA8^5'R7<U5S\W/Z1%>?N-XEY%5^0S*UKIZB
MZ)957U>=/<65@\>?'L77]E7?S4JO'J";1S2K"_)6OUM5_P"C8K->M"WM&F9\
M+@JW)EFGC1SU5/25>M2HU7==PZ)-$ZBJ57W1\;=J6]8;D3O]FU2_L(L=U^I3
MN[K2_P#PFI15NF^QZO\ J/,W+4=P'B21JJ.]"UMOJJ17G;I.E,KL5GPFBWI[
MZ>1CU1S%14167VWM^T;AHG481 B4N'5$LF=[G>FU;WRZ^1.1"M*JG27=)Q=M
M4W,J0L7](G]F/G.]B,D^%;HV&T](][874RO6.-5:BK:1+V3W)V!%RIF6]D]'
MD#5:WE.KAKWR8? ]^:[F(JW.TRUM=E7F*)S7"!;<UB$*" DCG ; @ !.4!"0
M(!) #420 ,F65=>PQ?JO;U>526K;D(EVMLNI=J!'5JJ9E7&C7J[*FM++8I3<
MQD?A.E5#AU2B,659);;5MO;N5-7[)>2-5;V7*A2^Z!2OP#3.BQ"D8[)#2I^J
M;EUJLC=OUF,LG-NJL2JK:*:@O)Y,^5\V;5EUM7EV[%-HT1QIG$"DJ,S<RS/3
MU5MZSCCH,(X0T8K:RI9G?44>_,SLNK5<Q5U+R[4-0T!6IDG3 )&RI'$QTUW(
MN6]T7U?K M*+",N'3TEG;U4I=RYDOKYC1]-]#Z&FH898GU"RYUNBO2VSW%H,
M5L,*.E>W*U-;G+9$-(TCJJ?&Z_R-M=#2QTTJ/5ZR(K9$YMJ AY6CF(5&%;F4
M]5EC163_ +2736YJ<B]9U=%7K-HWIC.EKSPK([FNK9%U=I[NG3*1="*VAP?>
M',<YCD6FLJ7SM5=2>X\+0M,FAVD[':G,I41U^?(\#N;E&++))'ACE9:*%[M3
M5OZZ<NSE+-2Z,5G(I46Y'2R-QYU2K7+&^F>B+EU>LWE^HMVUN6Y4<K/U:-3D
M0Q,FZFZC$H"P  D(0 %P "!-H" .<<@  E%RWR\NT@EVQ+ <%;31ST:Q2JY&
M*J+=%UE$8$^3!=-HHI$1K*JO:C57TE5$DZMFTOURYER\A3^ZEABX9BN#UU-&
MJJR2295C99=2M7:0=S=>C7$*&*.B_23LJ6O<U=2(W([G]Z':W-\<WW1'$IG*
MR[*BVIJ\S3LZ*4CL;PUE?6-5S9HW*C96YK*CK;?J-#T%\JHZZ+!')-O=9(KU
M545&ZF\K>7U2*N##L/;)1S3MS*M;'==:6UHNSFVFL:4Z%4/ [I:A]2V7.U+(
M]MK=AOE!&E-AL+'N1$BC1+KJM9#5=*L2AQ!'86RLB@5<LF_[XBIJY+7_ )E1
MX6XRD\$&)L>UJ1MJ41%Y;(A[&G%;+4MDIJ=&.6-V945+:LO^9C42TF":.5RX
M.Z&JJ%8CO]4<F97?5=;FF5VF-6_"HHYM'*UE3=<]2^]W[=OH^[EY"*]G<1<J
MX*JZOZ1)^%I:-T76FU-93NXUB3F(R@;2O5CY9'[^B^BGHIJV=7/REOLZ]7\R
MHV'1S&G4DC6OR)&C5UY55=I85/,R>-',6^I.0J*)KW.RQ-<KO[*7+)T8IYX*
M1Z5,CWJY45,Z*EDMUA7L  @           !=.<73G  7070 !=.<73G  73G
M%TYP %TYQ=.< !=.<73G  73G%TYP %TYQ=.<#SL<^3I_P"!WW*?+$OKGU-C
MCO\ 9]1;H.^Y3Y:F];4=O2O!_,>H=:38IQ_LG))RG'^R=SYR&T;F']=,,_C=
M^!Q]*P)^C;[CYKW,=6F>&?QN_ X^DZ9WH)[CSNI^SZK\3/\ I.PBW0!+(+IS
MG*]< NG.+IS@ +ISBZ<X "Z<XNG.  NG.+IS@ +ISBZ<X "Z<XN@ "X
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MO]/DRKU 8QMWJ-D;=36I9$,FM1'YA9<MB6V:VRJ <02JD%$\A  ! $) @
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MU*6/Q8H>E/\ $G@.+%#TI_B3P&17-^I0BV78I8W%BAZ4_P 2> XLT72G^)/
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MKXE71T$&^S(]6I?U4NNI+GF:.Z446/0MEHV5#6*Y6VE:B+=/<JC)A[3HT_\
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ML)/K8>"  H
M               7U7
M
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M_(-+[G?C4T[=1^4<#^D?][#<=#_D&E]SOQJ;9].6C]DM@;L)(;L)-3K@
M       Z.+_)U7]$_P"Y3O'1Q?Y.J_HG_<IHZCZ2SM_:%8R^NIBAE-ZZF*'Q
M5[[R^FM_6$)M46)3:H-,-J 2!A''RF[:&_JY/X&_S-)0W;0W]7)_ W^9ZGXS
M[PX.O_7+:V>J20SU23ZZ'@@
M                     ARV154\QV,435_I#/M._.MHW^XJNHE>C_678>=U
MG5;.'5TUC>RL1,:HO:(_M'#-%?\ I#/M*V21_24),^Z^DIYGE'9'X]9"8U0+
M_P 2S[3GI<3IIW.2*9CK<Q5V^NUZU0]_11[G3RHJJMD3[S=TWY#75AJN]%-$
M96#M0&+5NFHR/=IG+S@ %
M
M           5;)=3H5&)TL#U;+,QJHMK*=V1?14KK261RXE.UKE1$?\ R.+J
MNHVHRW6;4W)PW'AFB3_B(_M"XW0\M3']I7*R.1%])5,%E=SJ>1/Y28>A'X^9
M62F-T*KJJ(_M.6#%J25Z-CG8YR\B7*Q9*[G4]# I'\)P(KUM=?N4V6?R4UU8
M87.AT1E9S'(YJ*BW0DZU&[] SW'9/=MU:J<O-F,3@ !F@
M J&O:8Z\,G3DR)K_ .HV!R+;4MCRL>HW5M,^)JVS-1-E^6X17N%X;+7U+&Q,
M<YC'MS*WD15+*PF@;0TR1HJK9576<.!X7'04Z6:S.YK4<J):ZH>HFS6   4
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M\+?YGI_C/V0X.O\ URVMJ60D)L!];#P0 %
M                              '!5?JW>XJFI:N?ZBUZG]6[W%5U/K?4
M>!^6]0]3\=[EP67*0B+RG)R(0I\W,?T]F.7$MU-@T1OO\WN;]YX'(IL&B7ZZ
M;W-^\[>A_8Y^J^BP6;#(AFPD^TH]/F@ &0
M
M                       ,)-BE;Z2HO"E0J[,_\BR)-BE=:2_*=1_'_(\?
M\E]';T7W>.C51.LXW(Z_(<Q@O*?*U/H:6+454U[3TL"3_:D'O7[E/.:>E@7R
MI![U^Y3HZ3[PY^H^LK'H$_1-]QV3K4/ZEON.R?:V/I#YRO[2  VL
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M_1_Q>KQS<]IJW$IM^J73RM5^5K=2.U:D1$)W;UR:+5")RTE2G_8>=_HRI_\
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MKOURVQ-@"; ?6P\$ !0
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M1V^[L,JK<[EQ;23",6Q&LBGX.1K$;+$JJY$55U+?5M+':JM_1M];:<EE^KE
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M=^-33MU#Y0P3^-_WL-QT/^0:7W._&IMGTY:/O+8&["2&["34ZX
M .CB_P G57T3_N4[QT<7^3JOZ)_W*:.H^DL[?VA6,WKJ8H92^NIBA\5>^TOI
MK?UA";5)(3:I)ICTV" #D*./E-VT-]5_\+?YFDIMU&[:&^H_^%O\ST_QG[(<
M'7?KEMB; $V ^MAX( "@
M             !=BA;\AB];-40/.QG$&4-,KWMS76VVW(I2S](4D=G932.;L
MU.N6;IVJ+AT=^63_ ,5-5W-=&Z&NP-\U3&YSDG<W4]4U60U7NEHNQFII[BY1
M5BAK;<>5;VI)4^O_ ""8ZY-?DDJ_7_D6FFA6#N15WF2_TJF3="L)RVWF3O5.
M3QEIT1U74<JHX<=[)+V_Y'J8#I4E)-*KZ&9=2)ZUOY%AMT*PE%_4R=ZH70G"
M;JN\R=ZILM=!:MU9AA7?OUQC+Q5W0X^3#YN\3P(\X,?L$W>)X'MMT*PI/]S)
MWJD<2L*^9?WJGHQ-'IR:;W+Q?.%'[!-WB> \X,?L$W>)X'M<2L*^9?WJCB5A
M?S+^]4N:33>Y>+YP8_8)N\3P'G!CM_0)N\3P/:XEX7\R_O5'$O"_F7]ZHS2:
M;W+Q?.#'[!-WB> \X,?L$W>)X'M<2L+^9?WJCB5A7S+^]49I--[EXOG"C]@F
M[Q/ ><&/V";O$\#VN)6%?,O[U1Q*PKYE_>J,TFF]R\7S@Q^P3=XG@/.#'[!-
MWB>![7$K"_F7]ZHXE87\R_O5&:33>Y>+YP8_8)N\3P";H,?L$W>)X'M<2\+^
M9?WBCB5A?S+^]49I--[EXOG!C]@F[Q/ ><*/V";O$\#VN)6%?,O[U1Q*PKYE
M_>J,TFF]R\7S@Q^P3=XG@/.#'[!-WB>![7$K"OF7]ZHXEX7\R_O%&:4TWN7B
M^<&/V";O$\!YPH_8)N\3P/:XEX7\R_O5'$K"_F7]ZHS2NF]R\7SA1^P3=XG@
M/.%'[!-WB>![7$K"_F7]ZHXE85\R_O5&:33>Y>+YP8_8)N\3P'G!C]@F[Q/
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M9Z?XS]D.#KOURVQ-@"; ?6P\$ !0
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M/1K&/156UU5#U(79XT<%9V%@ %A8 !86  6%@ %A8 !86  6%@ %A8 !86
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M*QV5)<1F>B+K5-ON/,ZWJ:9CXEU]+9JU?,/0T=QIU.]L-0[T%57*][UU:O\
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M;MH;ZC_X6_S-)3:;MH;ZC_X6_P ST_QG[(<'7_KEMB; $V ^MAX( "@
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M@<]T;+V5ZW76JK_,["JK>NY+5NV]K 2   ":]@    !=.<;=@
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MY;8FP!-@/K8>"  H
M         !#O54DAWJJ(&HZ=_)S/I/\ Q4\O<C_JZ_\ ^P_\+3U-._DYGTG_
M (J>7N1_U<?_ /8?^%IMCTY)_8L*/U4]Q)$?JI[B34ZH  %
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M^:],:Z3")-!)*9U]_JF))=534CH^;WJ?1>&525U$V9%:J.54]'9J4#MILU@
M                         .0!=@!-A6VZ[\A5?T3?\1"R$*WW7?D*K^B;
M_B#_ &RT7O34]&?D:D^C0]<\?1GY&I/HT/8/B>L_;4^HZ+]4%@ AQP[2PL2"
MX1%@3M(& L18D(,"$3:$0R P,40FQ) P)! &%3;40"+# R"=9!*;!@  @$*
M @FPP=ZR&9"[;F5.?;&J(P]W1_&7P/WF9RK&UJ-:B-3G-[II4E3,V]MFLK7#
M,.?72V<U[6I9R*WEUEBX;3I3PY+JNM5UGTWXVJN8^7A]9%$3\.X #V7
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MG^,_9#@Z_P#7+;4V )L!];#P0 %
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M9Z?XS]D.#K_URVQ-@"; ?6P\$ !0
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M_"W^9Z?XS]D.#K_URVU-@"; ?6P\$ !0
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MF[:&^H_^%O\ ,]/\9^R'#UWZY;8FP!-@/K8>   H
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M;8FP!-@/K8>   H
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M/"625JTL3E>V17LS*JJJZ]5N5>0[<>Y+AE'H[B6%4]5B#V5J)F5SV9D]WHV
MK+2ZJ;4Z+Z,LI+QP0R78QW[*&W56 II3N55S52-U2ZJ:U'O541$1S%MJ.YYG
MJ/@ZEI'S5Z,@2S5WR.Z^_P!$]K!Z_!=SNE7 ZRN=%G<M3^F:KW>EJVL2UO1
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M2[8        !;6
M !9                  !T<7^3JKZ)_W*=XZ.+_ "=5_1/^Y31U'TEG;^T*
MQE]=3$RF]=3%#XJ]]I?36_K"$VJ20FU3(TQZ;$$@<A1Q)M-VT-]1_P#"W^9I
M/*;MH;ZC_P"%O\ST_P 9^R'#UWZY;8FP!-@/K8>   H
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M?[7<U:#)'^RMK9N;UFF6F6GV%Z,,1:UTZ7D2/T(LVM45>?J(-Q35M6Y*[%-
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M"0 "HB[4  6  !414LJ)8635J34     (B(ED34  %DO?E
M  78H"[% KO=E_JL_P"GC_F>UH+\F_#^%#Q=V3^JS_IX_P"9[.@R_P"SOA_"
M;O\ :XO^9M:; &[ :7;
M                                  !T<7^3JKZ)_P!RG>.CB_R=5_1/
M^Y31U'TEG;^T*QF]=3%#*;UU,4/BKWVE]-;^L(3:I)";5)Y#3#8;!R G84<7
M*;MH;ZC_ .%O\S24VF[:&^H_^%IZ?XS]D.'K_P!<ML38 FP'UL/   4
M                                                 AWJJ+Z[$+?*
MZZ@:EIW\G1_2?^*GF;D?]7'_ /V'_A:>GIW\G,^D_P#%3S-R)+Z./_\ L/\
MPM-L>G)/[%@L]5/<28L7T;&1J=4  "@
M1=K4NJI;G)(<QKFV5+H!0F[QAN+TND.!8WA-%55C</8^5R-:JLOF141RIL,-
M%-TFEQ]E-A^DL6'8=-3V<B2.])7JZUO2Y;*;YBF.L7&J+!\4@GJ8:YRQW1$1
MC6WMZ2ZE*ZW8M",)I*K"ZO1^@CIZJ6N;OKV.>Y7-M[UY0.U_I*9%P.KWI4?^
MAA]).3],=7'&S8IN<Z-T.%4OE<\F$MA=O+<SV.6)B)LY;W[!N_15$>$55*YK
MII'PQ.1S&W3];_D63N3X=0OT4P>3R3+4145,JN<JWS;VFO;SH!XFXU0\4]#Z
M-FD,\E#*U96NCJUR65SU5-2\Z%GTE=1XE ]U'/#4QHN558Y')?;8UW3O1BHT
M@I%BIIH8G;XU]Y+[$14Y$ZSDT)P*?1K":F*NFBF<^7?$6*]D2R);6B<P%'8N
MQ$W7L91NI$JV:D][3UO](#$)G5\U$MVPY8GZE7;KY#Q\7F5=US&'I3S9'5C+
M.RZMJ&X[OFCLE5ALV+4Z,5<T4=DNKMJ_40:ONHRNIF[ETL:KG93,<U$6V942
M$MS0:DIZW!J:OKV1R33,=FBE:CD:J.5+Z^I/M*RT[PR3%JO<KIXFZXX8XY%5
M%LU52%-=MFQ3T-.M-G:'4<6"T5-6^64DJ-DF@8CF/:K5=JO[TY.0+AU-S3 )
M':=8?B=$R5U%3R2-D?&W]&CE8[4JIR^DGV%_*MBB]SG=&PRLQJFPG <&Q+#X
MJE[G/WUJ95>C%555;JNQJ(;1@6Z7#6:3XOA,U)79Z.I2G1[FM1JKF<VZ:]FH
MJ-RTM?+'A:N@1SGYVZD^LHG<-JZZKDQM7)-+&W$%1RJY7(WJ/H'&H5GHU8Q4
M1V9%NI\^[AF(\$NTAI*BFG5\^(JK7(VR)R<H'FTU35TN[9I@^AIEG>D+;M:B
MZDM'KU&^:#;I=548I38=B5-3T[)7/5TCGNS(B-54V]:&KZ,YO/3IG.L,B,DI
MD1%5NW5&>5@%!-7;H&'4T;'1H]CO2>U<J68]?Y 6'!NB.Q:ITJ5R4\7 #I%I
MT9(O^L65]LWOWM-G.956Z)4LW.J/2-E/ M9/,L;J?.N5J(][;\_[*=IH.Y\Z
M@P?2[3>BTAPV>MBJJW>6;VBHED?*CN5-2W0V_=*I<*9N9T\6!89)21)5-R1Z
MU5J7??E7EU@=*LW2,;AP"LQ=<*9EI415NY^76J;5^LM3<VQ]^DNA^&8G,R..
M:IB5[HV*JHWTE3E]Q2F*9G;D>D<:PR+(K663+KVM+*W!&JS<\P5KVN:Y*=;H
MJ65/34&&C_Z3ZS)A-2GII!:'TKK:^93UL"Q>/1[071^>>"G2I?AL,E*V5++.
MYL353+RKK5-G.=;_ $F6NET?JHF1/?=85LU+_M'7TDPJ?$]!=!JF'T4PS#(W
MO8Y%S+^BB6R=?HKM ]+&MT.OP'1FCTGFHXDFKIO)W4\KW(QGK:TY;_H_M4\/
M=?KHL0TEPB>!['M6C3,YBWRKF<MCS=T^-^*[CN 0012>4-KU>Y%:JK:TR;$]
MZ&6G^&389C6$1O:LC'TC7+O:*J;7 P\?=/1%I= +:E2=-:<NN,N'3'3A^&XZ
M[!:1D$M7O;94BSKGLO+9.0I_=(8^6GT&WN"549.BZFJMM<9M>FV%3Q[K7#J^
ME3I1MBRHBYKV5/<%;(S3^IPO&L+PFK@AC=BDC6IOKU1R75&^BG+M.O5[H5;1
M:<8KA%32PQ4%,QJQ5+WN3?'*C5MS?M+V&L:2X=+CFZ+H75T[%:REFC1V=%^<
M:O(>IN[:,STM#28CAZL;55%:QDCVHJJK<CMJ6MR(##FPS=*JN/6'8!5P0105
M+%>Z5TCLS?1>NKD_9+-T3K:JLK\3;/"K:>-S=XDUVD;=VM/JMVE-Z7Z$54.G
M%'64KXFSQP(C9$1RV]=.;K+TT4IEIL P]);+/Y/&DCD_:=EUJ$:_NLX]4:,:
M+/Q.DB;-*DS(\CE5$LM]>KW&@85N@Z3XE74D\>CZK1QV265F=6LU<JFV?Z0-
MUW/9,K'/7RF+4U+KRG4W**?RS17$8$8L;WN8B*]%3]E /-PC=&EQ_2'%<)JV
M4])P>Q945DBYG*BHEEO[SBEW2ZN;<[J\=\EITK8JA(6TR/=96W;KY^5>PTG
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MX<S,B)>RY6!,(T@W3<:PK :7'7X7&D=7-O"(]ST9^UL7G]#[SVMTC2]V%X_
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M"+F38MD5=I47,BZKKJ#4M?7M)6RH1>P$@7
M     "[%!BZZ(!7N[+_55_T\?\SV=!_DY/\ I_"AXV[&E]%'+_SX_P"9[>A%
MN#D_Z?PF[_:XO^9M+=@"; :7:
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M 38#2[@
M                     #HXO\G5?T3_ +E.\='%_DZJ^B?]RFCJ/I+.W]H5
MC-ZZF*&4WKJ8H?%7OM+Z:W]80FU24";5!IAL  4<:)K-VT-]1_\ "W^9I7*;
MKH;ZC_X6GI_C/V0X.O\ URVQ-@"; ?6P\$ !0
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M:(=5*=O-]HWAO-]IV@-1HAU?)VVV?:3O#;;/M.R!J-$.KY.U.3[1O#>;[3M
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MUD@1.3[1Y.WF^T[(&9-$.NE.U%V?:<L;$;R&8&644Q  "*
M
M ='%_DZK^B?]RG>.CB_R=5?1/^Y31U'TEG;^T*QE]=3%#*;UU,3XJ]]Y?36_
MK FU23%-JDFF&Q) 0%''RF[:&^H_^%O\S2>4W;0WU'_PM_F>G^,_9#@Z[]<M
ML38 FP'UL/!  4
M          <=0EXW>XJZ>*17_JW[.92U52YPK"U5NMS@ZOIMZ'18O3:SA56\
MR77]&_L4+%(B?JW]BEJ;PWK'D[>OM//\6ZXZ^53[U(B+:-_PJ>_HG$]DTJN:
M[6B<G6;OY,WK[3ECB1FRYNL?C]%66NYUDUTX9-349!$L#V(C#@  4
M
M                                          &$GJJ5[I)#*N)3N:UR
MHK^1.HL54.-8D5576<G46-V,-MJYMSE52Q2;=[??W'&Z&7H/^%2U5IV]?:0L
M";-?:>7XMVQU\JJC@D3;&[X5/2P*&1,2A<YKK(J[47F4L-*9$Y^TY&Q(BWUZ
MC9:_&Z*LL:^MFJ,,*/\ 4,U<AV"$2UR3V**=,8<$SF<@ ,T
M
M                                  .CB_R=5_1/^Y3O'1Q?Y.JOHG_<
MIHZCZ2SM_:%8R^NIBAE+ZZF)\5>^TOIK?UA";5)(3:IDAIAL0"2"CCY3=M#?
M4?\ PM_F:3RF[:&^H_\ A;_,]/\ &?LAP]?^N6V)L 38#ZV'@  *
M
M
M
M
M                                                   '1Q?Y.J_H
MG_<IWCHXO\G5?T3_ +E-'4?26=O[0K&7UU,4,IO74Q0^*O?>7TUOZP)M4$)M
M4DTPV!) *./E-VT-]5_\+?YFD\INVAOJ/_A;_,]/\9^R'!UWZY;8FP!-@/K8
M>"  H
M
M
M
M
M    ='%_DZK^B?\ <IWCHXO\G57T3_N4T=1])9V_M"L9O74Q0RE]=3%#XJ]]
MI?36_K"$VJ20FU233#8 ("C!-INNAOJ/_A;_ #-*Y3==#/5?_"W^9Z?XS]CA
MZ_\ 7+;$V )L!];#P  %
M
M
M                                                    1?;J)1;H
M !BCEOK0RN
M                                  Z.+_)U7]$_[E.\='%_DZJ^B?\
M<IHZCZ2SM_:%8R^NIBAE-ZZF*'Q5[[2^FM_6$)M4FY";5,N4TPV('(.<%''R
MF[:&^H_^%O\ ,TGE-VT-]1_\+?YGI_C/V0X.O_7+;$V )L!];#P0 %
M
M
M
M                       +L!@Y=2JA)G$$//J<3;#.V-R/UNRZD0[\,B/;
M=NPTC3!V6:)S=N=R_<3H[C6\HD4RL:FM?555/,[V*;FF77V\S1JAO*=875MV
M'%!*V5B.:MSE36>C35%4?#EF)@;LUD@&:
M                                                     !T<7^3J
MOZ)_W*=XZ.+_ "=5?1/^Y31U'TEG;^T*QE]=3%#*;UU,4/BKWVE]-;^L(3:I
M*!-JCE-,-B0""C!=3K&ZZ&IZ$E^BW^9I5]5TVFZZ&W6-]^BW^9Z?XS]C@Z[Z
M2VN]DV$HI'[.H(J'UL/!2 BW%RB+BXL+ +DW(L+@2",R"Z 2 @  "X $7)N
M N+@ +D70"01=!= ) N+H  N1<"0+BXR "+<7    "+BX$@7     1<7 D"X
MN  N+@ 1=!F0"01F0FX "XN$ 1=!F0*D$9D)    !<BX$@7(N@$@C,@S(!((
M1;DW  "^L "+H+H!((S(,R 2"+H2BW     JV(N!((N2BW     HN !%R;@
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M4)RG&R1')<S1=I[U-45>GES&$A"/N)0R
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MZ[45-AR'OTU:HR\K& $7UD\ID
M                                        '1Q?Y.J_HG_<IWCHXO\
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M53Q^JZ7'\J6ZK94UA-3K<APQ2-D8BM<UR6O=%N<S%NA[U-451EYLQA( ,T
M
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M6JYVN_4?0_CNKFN8IEXW6=/%,ZH;2 #WWF
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M$3+PNHZB;DX9  ]-R@
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M/J.CZ2**<R\+J.HFY./Z2B6)L >E$0Y0 %
M                                               XJF+?HGQK?*]J
MM6W6<H,9IS&!KZZ-TZN5<\W:G@0NC=/?]9-VIX&PV%D.6>DIEMWJN6N\6J?I
MS=J> XM4_3F[4\#8K"P[2CA=ZOEKO%JGZ<W:WP'%JGZ<W:G@;%86':4<&]7R
MUWBU3?.3]J> XM4_3F^)/ V*PL.SHX-ZOEKW%JGZ<WQ)X$<6J?IS_$G@;%8B
MP[.C@WJ^6O<6J>WKS=J> XM4_3F[4\#8;"Q.SHX-ZKEKW%JF^<F[4\">+5-\
MY-VIX&PV%D+V='";U?+7>+5/TYNU/ <6J?IS=J>!L5A8=G1PN]7RUWBU3].;
MM3P'%JGZ<W:G@;%8BP[.C@WZ^6O<6J?IS=J>!/%NGZ<W:G@;#86'9T<&]7RU
MWBU3].;M3P":-4WSD_:G@;%86'9T<&]7RUWBU3].;M;X#BU36_63=J>!L5A8
M=G1PF]7RU[BU3].;M3P'%JGZ<WQ)X&PV%AV='"[]?+7>+=/TYNU/ GBU3].;
MXD\#8;"P[.C@WJ^6O<6J?IS?$G@1Q:I^G-VIX&Q6%AV='!O5\M=XMT_3F[4\
M">+5/\Y-VIX&PV06)V='!OU\M>XM4_3F[4\".+5-\Y-VIX&Q6%AV='!O5\M=
MXM4WSD_:G@3Q:IOG)NU/ V&PL7LZ.$WJ^6NIHU3].;M3P)31JF^<G[4\#8;(
M+#M*.%WJ^6O<6J;YR;M3P(XM4VS?)^U/ V*R"R#LZ#>KY:[Q:IOG)^U/ GBU
M3?.3=J>!L-A8=G1PF]7RUWBU3].;M3P'%JGZ<W:G@;%86':4<+O5\M=XM4_3
MF[4\ FC5/\Y-VIX&Q6060=G1P;U?+7>+5/\ .3=J> XM4W+)-VIX&Q6%AV='
M";U?+7N+5-\Y/VIX#BU3].;XD\#8;"P[.CA=ZOEKO%JGZ<W:G@.+5/TYNU/
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M1#O(ED/I^CZ2+<9EX74=1-R4)=$U(2B6#23T\.4
M
M
M
M
M                                           Y3%R^BIERF+]AC5Z(
M:-IG^LB_B?\ R-92W*;-IE^LB_C=_(\S!L+DK9$]%Z1JB^FC;I<^6ZFQ-R\]
MVQ=BBU\L\$PQ]9.U7(BQHZRZ[&]X;0LI86LC2UDMMORDX?1,I8D:UK>37E1#
MNIJY#V>CZ.+<9EYE_J)N3A+-2:@J$HE@>CARH;L)0(!   H
M
M
M
M
M                                                (1/24AZ:E,@2
M8S&"/AJ^+X:[$*R*SFHV.15>CKZT54\#V</HH:6+)%&C41574=\'/'34Q5J;
4)N3,88M,@#IPU@          _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g942297g78h35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297g78h35.jpg
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M*"@H*"@H_\  $0@"N@=D P$B  (1 0,1 ?_$ !P  0 !!0$!
M   & P0%!P@" ?_$ %L0  $# P("!0@&!@8(! 0!#0$  @,$!1$&$A,A!Q0Q
M05$7(E1589/1TA4R<8&1DA93E*&BL2,D-4)2<P@S-#9#8G2R<H*SP3<X@_ E
M8W7"X?$F)T3#TW:$M/_$ !L! 0 # 0$! 0             ! @,$!08'_\0
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MANCW2TLY'^JJ<YR/83S^WE_>5#I0N,%DME%H>S29IJ#$E=*WEQZ@\SGV#/\
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MZEM<ECKJ2GL388>L-G,>.T[^T;OJX["N65+^D[5%+JN^T]=0PSPQQTC("V8
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M=$]P^C+M262K;=".L5A#6-&UF6G<#S^Y82AUKHFS7F?4%FLUU%X>'ED$DC1
MQ[@<XP<XYGX!8[3FL[!^A]?9=44=QJ.MUSJUSJ0M:,D-[R1W@J_M%>]^IRK8
MZOLW%4^%X^"OPO?A>SMUX7*'2A5WN2EH(KQJJV7V(O<YC:)S'<(@ 9=M:.W/
M+["H[HVNLUMN$E5?+?)<3&T&FIP[;&Z3/(R?\OL[U<ZJJ-(S4,3=,45UIZL2
M O=5R-<TLP>0P3SSC]ZC#3AP/@5SRE^:_P#9[FS44]G]FTU\E'Z<C8W3]_\
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MHW7RLN!IX99&AW5V';V9]CL?<%XT3?:[I LFH[-JA[*W@4;JNFJ'QM:^%[?
M@#O(^[([%$-":PI;/;+C9+]0NK[%7D.DC8[:^-XQYS?P'AV#[\G4:RT[8]/W
M&W:(MU='47%G"GK*Y[2]K.>6M#3X$^';WJ(S5DV^'BBU39)*4X1IWDVL,N'!
M*WCS5K/AXDHZ*]9W^XV+577+@Z7Z.MCI*7^C8.&YK78/(<^P=N5 [$ZZ=(VN
M[7!>JEU7(XADDA8UNV%A+G#S0!WN^\JEH/5%)IVVZDIZN&>1]SH74L1B PUQ
M#AEV2.7/NRO?1YJNETE!>:IL,S[Q44_ HY6M:619YESLGQ#>X]BKCQ**D_B;
M/971E6G1II2=E'@O%6??BS8?2H8]8Z0N%QI*5T4VGZYT(&PCB4YP-P]F<'[&
ME1?6/_P7T3_FS_\ >Y?--=*]S%34P:OGGNEHJ:=\$D+(XPX;AVCD/:.WO7JF
MU;I"JT;:;%?J"\3_ $>Z1S'P%C,[GN(_O>!"NY1G=WYHYZ6SU]F4*;A=1E=6
MX\'%I\[>/U-8HLSJJ6Q35T;M,4];3T@C >VK<'.+\GF,$\L86&7*U9GOPECB
MI6M\3HCH]_\ E_NW_25W_:]<[KHCH]_^7^[?])7?]KUSNNBM^F'P/'_"O^VT
M?_=A$1<Y[01$0!;/Z&J8VNEOVKI(#-]&4YBI68)WSOY=WLP#['K6"V%2](DM
MCT7:[/I5U115D<CYJVH>QAXCCW-SGEW=@/FA:4FD\3\#A_$(5*M+V5-7Q.S^
M'CZ\OF9?I&MC&=(.G+]21N91WI]/4 $8VR;F[@?;S:?M)6T+@=70Z_?.ZX44
M.D06F2.=T8\S8-W=N!W9[_W+4$G2.V[Z;I:74S:FKNM'<(ZNGJ8V, V C+7<
MQSQN[!X*,=(=^I]3:OK[M1QRQ05&S:R7&X;6-:<X)':%M[6,;M>)Y2V"M7PT
MJJ2PQE&[6+Q5K<N-O'R-N:#=-/1=(3M$R1PR/K6&B>-H8!D\QNY 8SA6'2)-
M6,Z.*>FUK5T-3J4UH=3<$L+VQ\LYV@#LW>SFWO6OM-ZHI;7H?4=EFAG?47/A
M\)[ -C=IR=V3G\ HE&[:]KCW$%5=7\ME_N)T4OPV3KRJ2=DI)IVXNT4N?3JK
M'4>JX=:5&J6-TS?+=2T#(8WR4\Q:YXY^<XMV$X/VJ*4(T_?.EJ^7BBABJZ:V
M4!J<-;YDM0W +@._[?'FH)JKI -7T@4NI;"R>G,$<;-DV 7XSN:<$\B#A74W
M2!;[?K\ZCT];YHX:N(LKZ.?:&R$_6VD$]N >8[0?%:.K%OGX_P"L<-+\.KPI
MV4;-PMPLN/"ZEUOX/XF3T+TC7V_:RIK;?98:ZUW)Y@EI'PMV-!!QCEGER[<\
MOQ5_';HJ[2FN='0DODLM4^MH 3D[ XY:/N!'VO6'M^K=#6"N?>-/V.Y.NV'&
M&*JD;P('$$9&"3W_ /[%&M$ZREL>MW7ZX"2H;4&3K;68S('Y)QGE];!^Y44T
MK*3O]CJELLIN52A3P))-+@KR3OR7EPOXW);7N_1SH[TE9&^;5W>K9<*D=^S<
M-@/\'Y2IYKJHU#'J6I;;-<62T4H:S;254D8D9YHR2"TGF>?;WK2^M]6Q:BUI
M%=HH9(:"GX3((7 !S(V8., X[=Q^]2C4VJ^C_4EXFN=SM5_-5*&AQCDC:/-
M Y;O *RJ+BD^AE4V.HW"<X7;4F^"E9MIVL^BX?(R&@KM<:+3_23<F5[);G$Y
MC^MQ!I:]X=(-[>6"#V]G>J-JO-7K[H[U6S4ICJJNTQ-JJ:JX36/:<.);YH _
MN8^_[%AM*ZMTQ9X-3VZ>ANC[/=3&V)C',XC6-W9#B3VY/=E4+MK&R46EZZQZ
M-M=521W!PZU4U<@=(YH_N@ D8^)\55322N^''AZFDMFE*K)QIVDY1:E9*R2C
M?Z-61KY$1<Q] $1$ 1$0'1%-_P#+:[_HW_\ K%<[KHBF_P#EM=_T;_\ UBN=
MUT5__'X'B_@W.O\ _=A$1<Y[01$0!=#TO^_W1G_^9S_Z)7/"VC#TBVUFI=(W
M(TE9P;/0]5F;ANY[N&6Y;YW9D]^%M1DH\_+ZGE?B="I52P*_"?>-D;'HY-04
M=5?9.D"OM\FEG12AD,AC+B-WF@;0#G;D8//..]<SGM..Q7=WJFUMUK:J,.:R
M>=\K0[M <XGG^*M%6I4QFNP;%EKR;5Y6X)62MY<>/5A$19GH!$1 %T12?_+<
M[_HW_P#K%<[KHBD_^6YW_1O_ /6*WV?_ ,O@>+^-<J/_ -X_R<[HB+ ]H(B(
M B(@"(B V[_H_P!>VULU37R<V4U+'*[[ 7$_N4XT=96:8UMJBN<P;:VOAI:0
M]Q$O]*X#[ 1^5:6T9J6EL5FU-1U,,TDETH^K1&,##78=S=DCES[LJ7U?2M35
M4>D&2TU7_P#A4K)JTX;_ $KVLV MY\^UW;A==.I%15_ ^;V[8J]2M4<%PGP?
MR2:[IKYE_1?[!TP_YQ_[Y5@NE?\ W,Z/?_S<[_MC5E3ZWH8Z;749IZDF_P A
M?3D!O]&-SSY_/_F'9E9&HU?HV[Z>L-!J"VWF6>UTP@#J=S&M)PT$\W<_JA5<
MHRBU?_7-(4:M&LJC@VD_#_Z)?4N?]'XRMEU2:>HCI9A;R63R$!L3N>'.SW \
MS]B^:ZK=2?HQ5MN&N;)=J5^UKZ2EDC=(\;AV -!Y'![>Y8_2^K=+6"[7QM-0
M74V>XT8I>&7,,HSD.).['?R6,O-7H%]KJ6VBVWR*O+?Z%\\K"P.]H![$Q)0P
MI]?$NZ,I;6ZTH.SPV_*GX=7Q7R-FV*ZR7>QV"/0^IK?:IJ.!D<UIJ6-;Q9!]
M8DX).?8#X]J@.J-3:ETQK>[OIXHK'659C-1%3M;(R3 Y/!<#VY)Y=Y.5<2:K
MT9?:>WSZGL]PBN=)$V)QMY8V.<-["X$C'?V>/:HQTA:I=JW4LESX'5X0QL44
M><D,;G&3XY)/WI.?Y>#X_P"]"-CV1JLU.G^5IWNEUNN*_5UXJZZFP^GG5-YI
M+\ZRTU<8[;4T49EAV-(<7%V>9&>X=Z^=).I+CH&HM>F]*2MH*6"E9+)(R)I=
M,\D@DD@_X?WJ#=*.J*75NHX[C0PSPQ-IF0[9@ [(+CGD3RYK/2:STSJ6VT#-
M;VVX.N5%&(6U="]H,S!V!P<1_P#M)QC.$=2\I6?P*TMC=*E1QT[I)XE9<[<&
MUXV_DDE;P[X[HXU9-!%#<ZRO93U1C;MXI;)@.(\?-/X^P+,:LLE+=]=VC4=G
M;F>@N\-%<XP.8(D:&2?@0,^!'@5KF[](%+5W_39H:!]'I^QS,?#3-(=(X!P)
M)YXR0/'QY\U6L'22VS](MUO<4,[[3<9'.FISC?CM:>W&X'V]A*LJD.3\O_9B
M]BVE+'!6:4K+R;_3Z<O-(G6CS*W7W28::IBI)PQYCJ)2 R)V78>[/<#S/V**
M:\K=1_HS5,N.N+)=J60L:^DI'QND?YP((PT'D0#VJULFO;-3ZDU=67&CKI*"
M^-=&&1;0]K79SG+L X/=E8:]5>@GVNH;9[;?(K@6_P!"^>5A8#GO /@HE-.-
MD^II1V6<*ZE.&G_Q3Y)7XOBN/0VC9;K+>+186Z&U-;K8^D@9'+:*EC6<20?6
MR<%QSX@'Q[5J'I+96-UG<3<K;#;:M[@Y\$)RPD@><T]^[M^TE2>75FB[['05
M6I;-<(KI2QMC?]'EC8I]O/)&01W]G/GVJ*=(.IW:MU+/<S!U>(M;%%'G):QO
M9D^/,G[U6K)2CS_W\&WX?L\Z5=O!96=[VOSZK]7Q:NNIDYO_ ,,Z(Z=GU9;S
M<72?^**%NW'YW+/] %,^MJ]34L1:))[:Z)I=V9<<#/XJ%ZLO=-<Z&PT5 R5E
M-;:%L+A( -TI)=(X8)Y$D*_Z.=5TVE_ILU451(ZMHG4T1AQYCCV$Y(Y?8JQD
ME-=$;UZ%2>R5$E^:3OWX=DB<ZWADZ/\ 05)0:7+)(;BYT=?=HG N>]N08P1]
M4?6';W'OR5E-)RW.+H=L!L^H*"QS&HF#IJUS6M>W?)YHW \\X/W+76C-845!
MIJ[:=U'3U%7:JL;XN#M+X)?\0W$>P_:/:5D;5JW2LNA+;I[45#=9^IS23!],
M6-!+G.([7>#EI&<;W3MP.&KLE50]G*.)J=V[)XE9\;/IRMZ'W4NIM06+5=FN
M%7J.WWV:E#GL=1O:6!CCA\;MK1V@?R*F-R-ATK3UW2!:7,DFN\0;;:<M_P!3
M,_/$)^S'/P\X=X6I=6SZ8F;3?HM27*G(W<?KCVNW=FW;@GVJ\OFIZ6X='^G[
M#%#.VJMTDKY)' ;'!SG$8YY[^\*JJ6;O\OB=$MB]I&GA32?"2LE^7B^*7GTZ
MOJ1D.EKZ_=/*7S5$N7R..27./,G\5M_I(U;<]#WVCT_I61E!;J&"-Q8(FNXS
MCS)<2.?=]^5I@$@@@X(6T)]::4U(RBJ]:6FX27>EC;$Z6C>T,J6CLW@D8[^S
MQ[>Y4IRLFD[,Z=MI8JD)2AC@KW7#GPL[/YKRN9#0=70:SZ1J^^UEIIX!143J
MLTT9W-DE:0 \Y';S_$ JCHOI)OU[UG2T%YEAK+7<9>KR4;H6;&M=R&.6>7M)
MSWK#'I*GBZ03J*DH(8J;A]6-&, /A\"0/K9YY]@[EDJ'5NA+'<7WJQV*Y.NH
MRZ&&HD:((7D=HP2>_P#_ &+2,UX2\>/F<-39I<<5&]XI1Y/"^/"[Y>'$G/1M
M'3:4K-:4\8'4X+I3P-#CG:Q[]HS]@=^Y77199FZ1K[I3R,Q)<+M)2P9[3#%&
M][7+4%!K8-TUJJDKFSON=YGCJ&S, V-<U^XYYY'LQE2^NZ7:*LU5IRY24=8V
MFMT4O'C ;N?+(S;EOG8P/;CM*TA5@K>7\O[')M&P;5)U%:^+GYX8JWK*YG>A
MJKAI-/7L5+0Z"HO/57@]_$#6#]Y"R71+:?T5H*B@G;_6J^NJ6M)[3% "T'\W
M_<M0V[64%#H^[VR**<5U5<65T$H V,#7-< >><^;W!3"NZ7;=5:UMUUZE6MH
M*6CEAX6&[^)(>9'G8QR;WY40J025WR)VK8-HG*HHQX2Y_P#^5P]6^QD.CZ2X
M1=$(=:;W166H^DGCK-8YK6%N.;?.!&3R_!82X55YEUOHZ*\ZGMM]9U]CH^I.
M8X1'>S.[:T=O_L5B=.:MTVS0HT[J2AN<[15NJMU*6-&<8',G[5927C1]OO-E
MK]/4%WB=25C)YQ4O8[<QISAN#V\N]4<UA7'H=4-FFJM1N'%N5GA7BM7,VAJV
MR4MWUW:-16=N9Z"[PT5SB Y@B1H9)^! SX$>!4+KM4WFR=*UUHK76NIZ6KNS
M1,P1M=ORX#M()'+P5G8>DEMHZ1;K>XH9W6FXR.,U.<;\=K3VXW ^WL)49O-^
MIZ[7LU]CBE;3/K14B-P&_:' X[<9Y>*3J+G%\;C9=AJQ?LZT;Q4+*_'SM\GR
M\K$SZ<]47G]*KO8.NN^B/Z$]7V-Q]1C^W&?K<^U3'0]+36'35ATQ<*5SW:DB
MFEJW[3_1;V88">[(P/M6I]7ZBMFHND-]ZEIZEMKEDA,D)#>(6,:UKAVXY[3W
M]ZS6I.EW4%5>ZB:Q5LM#;<@0T[HHR6@ #GR/:<GM[U*J14I2;_\ 1$]AJSV>
MEL].*7"[\/S6LN2?&_'Y&6Z%+;4V?I&O]NE(954M%/%N/(9$C,.^SL*E=-57
MVUV"ZU?2+>[7<K%44KHH8X0UYEE/8&EK!X'O[>?+"B Z2;*-:55_;05K'UEL
M-)41M:SG-EOG#SOJX:!X\E&]!:RIK/:[I9-04TU;8ZZ,YBBQOBD_Q-R0/_U@
M%3&<8_E3Z_YE*VR5]H;K3AQM&ZLK\.>%^#^IG>CFH@UEIJHT/=9@RH;FHM=0
MX9,;ADN9]F,G["[P"QG2O?*9TU)I>R'%FLPX7+_C3#DYY\>>1]I<>]8/H_OU
M)IC6E%=JB.>:DIC+YK  ]P=&YHY$X_O#O6%NU2VMNM;51AS63S/E:'=H#G$\
M_P 5BY_DMX_P>C#9+;6Y_P#A:ZZ8G=/LN[+1$19'IA$1 $1$ 65TG_O39O\
MK8?^\+%+*Z3_ -Z;-_UL/_>%,>:,ZO\ SE\&=J(B+VC\I-5]/EJK;Y9;?2VJ
M U%1#4\1[&D#:W81GF1XK27Z :G]4R>\9\RZ;O?]HR?8/Y*P4RV&%7\[;/2V
M3\?K[%3]C"*:76_W.<_T U/ZID]XSYD_0#4_JF3WC/F71B*-V4^K.KWKVK1'
MO]SG/] -3^J9/>,^9/T U/ZID]XSYET8B;LI]6/>O:M$>_W.<_T U/ZID]XS
MYD_0#4_JF3WC/F71B)NRGU8]Z]JT1[_<YS_0#4_JF3WC/F3] -3^J9/>,^9=
M&(F[*?5CWKVK1'O]SG/] -3^J9/>,^9/T U/ZID]XSYET8B;LI]6/>O:M$>_
MW.<_T U/ZID]XSYD_0#4_JF3WC/F71B)NRGU8]Z]JT1[_<YS_0#4_JF3WC/F
M3] -3^J9/>,^9=&(F[*?5CWKVK1'O]SG/] -3^J9/>,^9/T U/ZID]XSYET8
MB;LI]6/>O:M$>_W.<_T U/ZID]XSYD_0#4_JF3WC/F71B)NRGU8]Z]JT1[_<
MYS_0#4_JF3WC/F3] -3^J9/>,^9=&(F[*?5CWKVK1'O]SG/] -3^J9/>,^9/
MT U/ZID]XSYET8B;LI]6/>O:M$>_W.<_T U/ZID]XSYD_0#4_JF3WC/F71B)
MNRGU8]Z]JT1[_<YS_0#4_JF3WC/F3] -3^J9/>,^9=&(F[*?5CWKVK1'O]SG
M/] -3^J9/>,^9/T U/ZID]XSYET8B;LI]6/>O:M$>_W.<_T U/ZID]XSYD_0
M#4_JF3WC/F71B)NRGU8]Z]JT1[_<YS_0#4_JF3WC/F3] -3^J9/>,^9=&(F[
M*?5CWKVK1'O]R!] MAN>G[W<I+Q2NIF3P-CC+G-=N=N[.1*B>N.C_5-PUA>J
MNCLU1+33U<DD;PYH#FEQ(/,K=]!_ML'^8W^:ERI5V2$8J"9C0_':ZKRVG"KR
M27C;A\SD;R9ZP]15/YF?%/)GK#U%4_F9\5URBY\G#J=WO-M.B/?[G(WDSUAZ
MBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/Y
MF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1
M[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^
M*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<H
MF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_ '.1
MO)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW^YR-Y,]8>HJG\S/BGDSU
MAZBJ?S,^*ZY1,G#J/>;:=$>_W.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1
M[S;3HCW^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_W-0] 6FKQ
MIQU\^FZ"6DX_!X>_!W;=^>PGQ'XK6FH.CG5E3?KE/!9*A\4M3(]C@YO-I>2#
MVKJE%=[/%Q4;\CDI_C=:G7GM"BKRM?GX?,Y&\F>L/453^9GQ3R9ZP]15/YF?
M%=<HJ9.'4Z_>;:=$>_W.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HC
MW^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_P!SD;R9ZP]15/YF
M?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN
M43)PZCWFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C
M>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O]SD;R9ZP]15/YF?%/)GK
M#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZC
MWFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J
M*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O\ <Y&\F>L/453^9GQ3R9ZP]15/
MYF?%=<HF3AU'O-M.B/?[FK^@>P733MEN<-ZHI*266H#V-=@Y&T#/+*TP_HTU
M@7N(L53@G_$SXKK=%>6SQE%1OR.2C^-UJ-6I6C%7G:_/P^9R-Y,]8>HJG\S/
MBGDSUAZBJ?S,^*ZY14R<.IU^\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BN
MN43)PZCWFVG1'O\ <Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[
MG(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R
M9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<
M.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSU
MAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15
M/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMI
MT1[_ '.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW^YR-Y,]8>HJG
M\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_W.6;;T<ZOCMESC-CC!D:P 3 .D.#
M_P ,@X!\<]RQGDSUAZBJ?S,^*ZY12]DCU*1__(]HBV\,>/Q^'4Y&\F>L/453
M^9GQ3R9ZP]15/YF?%=<HHR<.I?WFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9
M\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O
M]SD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXI
MY,]8>HJG\S/BNN43)PZCWFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9
M.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O\ <Y&\
MF>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'
MJ*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O
M-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/45
M3^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[FL=%V&Z4/0U<K/5T<D5REIJMC(
M#C)+VNVC/9SR%I3R9ZP]15/YF?%=<HKSV>,DDWR.39_QNML\ISC%?G=WS^YR
M-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY14R<.IU^\VTZ(]_N<C>3/6'J*I_,SXIY
M,]8>HJG\S/BNN43)PZCWFVG1'O\ <Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF
M3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F
M>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J
M*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-
MM.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453
M^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SX
MKKE$R<.H]YMIT1[_ '.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW
M^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_W-8T]ANC>@TV1U'(
M+KU9S.K\L[N*3C/9V>U:4\F>L/453^9GQ77**\]GC.UWR.39?QNMLV/#%/$V
M_'Q^9R-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY14R<.IU^\VTZ(]_N<C>3/6'J*I
M_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\
M5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O]
MSD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY
M,]8>HJG\S/BNN43)PZCWFVG1'O\ <Y&\F>L/453^9GQ6ZZ:PW1O0:;(ZCD%U
MZLYG5^6=QE)QGL[/:MG(KPV>,+V?,Y-J_&ZVTX<<4L+3\?#YG(WDSUAZBJ?S
M,^*>3/6'J*I_,SXKKE%3)PZG7[S;3HCW^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^
M*ZY1,G#J/>;:=$>_W.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW^
MYR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_W.1O)GK#U%4_F9\4\
MF>L/453^9GQ77*)DX=1[S;3HCW^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G
M#J/>;:=$>_W.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW^YR-Y,]
M8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_P!SD;R9ZP]15/YF?%/)GK#U
M%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWF
MVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I
M_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O]SD;R9ZP]15/YF?%/)GK#U%4_F9\
M5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY,]8>HJG\S/BNN43)PZCWFVG1'O]
MSD;R9ZP]15/YF?%/)GK#U%4_F9\5URB9.'4>\VTZ(]_N<C>3/6'J*I_,SXIY
M,]8>HJG\S/BNN43)PZCWFVG1'O\ <Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF
M3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F
M>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J
M*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453^9GQ3R9ZP]15/YF?%=<HF3AU'O-
MM.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SXKKE$R<.H]YMIT1[_<Y&\F>L/453
M^9GQ3R9ZP]15/YF?%=<HF3AU'O-M.B/?[G(WDSUAZBJ?S,^*>3/6'J*I_,SX
MKKE$R<.H]YMIT1[_ '.1O)GK#U%4_F9\4\F>L/453^9GQ77*)DX=1[S;3HCW
M^YR-Y,]8>HJG\S/BGDSUAZBJ?S,^*ZY1,G#J/>;:=$>_W.1O)GK#U%4_F9\4
M\F>L/453^9GQ77*)DX=1[S;3HCW^YR-Y,]8>HJG\S/BLCISHZU92Z@M=1/9*
MAD,55$][BYO)H>"3V^"ZH12MDBO$K+_\DVB2<7&/'X_<#F$1%U'SI&;W_:,G
MV#^2P\EPHXGN9)5T['MY%KI&@C]ZS%[_ +1D^P?R6K.D*W6&"5D-+IZV7#4U
MU>6T[98&N)/]Z60X^JT<R>_L7;%V@CE:O)DZ-PH@P/-93["2 [BMP2.[M]H7
MV.X4<CVLCJZ=[W' :V1I)_>HOI_H\L-MT[26NMH*6X&)SI7R3PM.Z5V-S@.Q
MH. ,#N 6%Z(M-V4V)EP-JHC715U2(Y^"W>W;,X-P>T8  5KN]A9&QF5$+^'L
MFC=Q,[,.!W8[<>*]RR,B87RO:Q@[7.. %J70=?%26/H\BEI:>3C==(GD!WP;
M0\DMY]XY'V*EK:\Z@OO1E<+L*6@CLM6UICAR_K#(N(-LA=]4DX!VX[#V\E&/
MA<8.-C<**)U]ZO%=J2LL^G(Z&,T$4<E54UH>X;I,EK&M:1W#).>_L4=GOU1J
M</ME?"*5]#'6/N%.QY+)Y(-@:P'D3&>('$=^ #RSF7)$*)L6FKZ.JD?'2U=/
M-(SZS8Y XM^T \E<K4NEZ9NH)6T[(*>FDBH&U+:N&W]2FHYW8V;.>7L(W]VT
M[<<\X6QM+7%]VTW:[A,T,EJJ:.9[1V N:"<>Q(RN&K&41$5BH1$0!$1 $1$
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MR,0BD>E=.,O8NF^I=#U*+B##,[^WEV\NQ1S!QG!PH4U)N*YH.+23?B$0 DX
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MBL0$6P[AH6S6UT++CJ+J\DK=S0^'M'XK$7W1K[5=;7 *MM117"1K(ZAC>S)
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M(+=;ZJMJWEE-31.FE< 3AK023@=O(*G;KE2W"T4USI)"^CJ(&U$;RTC+'-W
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M722ADKGAT<_59*@4\AIXYLXX;IMNP.SRP3VH"6(B( B(@"(B (B( B(@"(B
M(B( B(@(S>_[1D^P?R6O]'/-9JW6%;+SDCJHJ&,'^[''&'8'VN>XK8%[_M&3
M[!_)0JWT$]KUO<I8XGOH+M$R8O:,B*>,;2#X!S=I!\6E=L?TQ.5\V8"ILE#:
M>E+3LM'$X3U<==+/-(\O?(=K,9)[AG '8%,M45%-2:;NM17AYI(Z61THC^L6
M[3D#VX2LLU/5WVW7:1\HJ:%DK(FM(V$2 !V1C/\ =&.87V:SQ5%57254]3/3
MUD IY*21^80WF"6MQR)!YG*LE:Y%[V-7QT]ZM]CT7+J(4AL5'54YC93$]8C)
M\V R$C:X#< [:!GVJ1:ELDML^D:^:KB^A3717:6$1DSNF9LVQ,.<8<YC.[//
M"R5'H:FADH65-TNE;04,C9*6BJ)6F.-S?JYPT.=M[MQ.%G;M:H[G46]U1([@
MTDXJ." -LCP#LW>QI.['B!X*JCP+.7$A^G+[]#F:"OHYY)I:YD=RKV.;PXZN
M8-+8P,[BUH=&S('+E[5FNE#_ .'FHO\ HI/Y)5:0@J+O+5==J64D]5'6S430
MWAR3QAH:[.-P'F,) /,M"S%^M<%ZLU;;*MTC8*J)T3W1D!P!'<2",_<I2=FB
M+J]R W/4==9JZZ/AD<^&CTU%5Q0.YL$N]XW8^X9]@5O?[+6T<>CJRIOE=7OE
MN](ZHCJ'-=&YYR=S  -F.?(<L'V*<?HO;S<9ZN82S&>WMMLD4A!8Z($GLQG)
MW'//[EBH= TK9;::B[W>I@ML[)Z."69A9$6'D/JY<,<N9)QV%0XLE21C;7!<
M]51WNY&^U]O?!63TM'#3.:V.(1':"]I!WDD9.>[LPK2T7VY:PETS0OK)[='5
M6Q]PJY*0ACY7->V,-:[GM&27<N>.2DE;HFGFJJZ2CNESM]/7N+ZNFI9&B.5Q
M&'.YM):3WEI&5<7#2-#/#;!02U%KGMK#%2STC@',80 6$.!#FG Y$'L3"Q=&
M#O3ZNQV1]'6:HG+7US8XI(X>-6NB(SP1M!S(<'#L=GXK#VV[W"DNU^HH9[XV
MD%DDK81=L<5DK7%NYA^L&^P]X4I?H*@=1L:VMKVW%M7U[Z1XC3.9MNW)RW;C
M;RVXQA>X-$4C:^KKJFXW*KK:NB?0S2S2-\Z-Q!Y-#0&D8Y8 ',Y!3"PFB-T-
M1=;U7Z1HG7BMIH:NQ=:JG0. ?*X</F'$'!R[M'/&?%6=9J.[V:R7NW15E75U
M$%YBMM-5.:V2=L<C6N[.0<X N SWD*?6W3%%;ZRUU,,E0Z2W4/T?$'N!!C\W
MF[ES=Y@[,#MY*C4Z.ME5!>8J@U#VW2H;52'> 8I&AH:Z,@9:1M![^?X)A8Q(
MCNF*N[4^J**G@AU++:JB.053KQ&T\)X&6/8X<QGF".SF%7UW;S5ZZT816UD&
MZ6H;B&0-#<1.=D<NT]A]BS=ITI'1W:*Y5USN%TK((W14[ZM[,0M=];:&M:,G
M R3DJYU'IZ&]RV^9U75T=50RF6&>F<&N&6EK@<@@@@^"G"[6(NKD3M<-SU32
M7F[&_5]!+#5SP4<-,YK8H6Q.+07M(.\DC)SW'EA6EIN=TU=<M-M?<ZFWT]79
MW5=5'2N##(]LC6^:>9;S.<CGCDI+6Z(IIJBN=27.YT%+7O,E72TLK1'*X_6/
M-I+2[OVD96,NFE7RZTL[;:ZLMM#0VI\,-32$ 1.#V!K#N!!RW/(@^/:JV9*:
M,1=KU=;78]46X7&HFFM-?1QP5CB.*8IGQG8X@<R XC/>"LO20W#5=VU'(;U7
MVZ*W59H:6*D>&!KFL:XR/Y'?DN[#RP%ESHFW.L-3:Y9ZR3K50RJJ*IT@,TTC
M7M<"3C']P# &,=F%]N>CX:JXUE71W.Y6UU: *ME)(T-FP,9.YIVNQRRW!4X6
M+HC]]KYG5EMH:V^W*IF;1!\E-88#Q)GYQQ7/&=K.7(9'-8*2XUM?H=[+A+52
MOH]2PTL9JPWC!C9HR!)MY%PW8)4Y=HBC@JJ>HLU=76A\5,RC(I',(DB:<M!#
MVNYC)\[MYKS3:#M=/:YJ".HKC!+<&7)Q?*'.XK2T_6(R02P$YR>9YIA84D9+
M6GTK^C%?^CW]I[1PL$!V-PW;2[ENV[L9[\*'Z7K'5=RK+6R[ZAHJFHHGAM'>
M(OZ9LG9QHI>P@9[!D=_<IW?[12WRU3V^N#^#+@[HW;7L<""US3W$$ K%6_3+
M+=</I:MN%RN];3POC@-06$QM."X,:UK07' &3S4M.]R$U8C=KU%<+U1Z5M;)
MWPW5U0\71S#YS6TQQ(#X;W;!]CEBF7.YVVX-DU-<;_:ZX5G.I,0FMDD9DPU@
M#>306X&3@@\\J3:#M!=J'4&I9K?46\W&1K(*>I&V1K&M&]Y;GS2]PSC_ )0J
MPZ/Z+@]2^DKF;+Q>-]&<1G!SNW;<[=^W//;N5;-JY-TF8&$OLFJ^D6\,J:N=
M]%315#8'R98\F%S@",=C<8'@/%6%MN=_936NXTK=55=PE?$^J940,ZI+&XC>
M&@'S  26D>'/M6P7:7I#J"MNG'J<5T(@JJ0N:8)@&EH+@1G(!(Y%8VET'21=
M3@FNETJK91R-EIZ":5IB86G+02&AS@WN!)'(*<+&)$<J_I:X0ZXKOIZXTS;1
M43=3BIWM:UI9"U_G<CN;S'F]G;XJO2376BFT9=IKS6U,EYE9'5T\A;P,/A<\
M;& >;M(&#G)[U,6::HV4E]IA)4;+S)))4'<,M+XPP[.7+DT=N>:2:;HWTUB@
M,E1LL[V24Y#AEQ;&6#?RY\B>S'-,+&)&;1$6AF5Z#_;8/\QO\UK3I/\ ]^+E
M_P#2_P#3:MET'^VP?YC?YK6G2?\ [\7+_P"E_P"FU;[)_P!OE_*,=I_Y?,BR
M(B]4\\(B( B(@"(B (B( B(@"(O<+F,FC=*SB1AP+F9QN&>8SW* ;9LU@N4'
M1TRGM36MN%<]LTCG.V[6]HY_8&_B59]*MJE?!:KO+&UM1AL%2&G(![1]V=PS
M]BA^K=3SZ@K(91%U2*&/ALB8_('/F>P>S\%6M&J'T^GJJRU5-UJ&H?N8]TF#
M&>7L.>8!7GQH58M5'SOQ7Q\SM=6FTZ?A;G\";:^U-4:=U#31T%+3#B1-?,]T
M>72#<1MSW#D?Q5<VREHNE2C=31,C;4TKY7Q@8 =AP)Q[<#]ZI=(-_H[7J"EC
MN%H@N 9"V6)[G;7,=N=[#D<AR6%T9>ZB_P#2/%6U0:TF)[6,;V,:&G '[_Q7
M/"F_8XTK+"[^9M*:]IA;OQ7R,G8=0/N&KZO3]114OT6Y\L0A$0Y;<\SXDXY^
MTKQIAL-FLFKBV&.=M#5/$;9!D$M^KG[P%CJ[6L%MNUS?366F;=1))#UL.[0'
M$9+<=O(9Y\U';=J:2DL=VM\D'&?<'%SYB_!:3VG&.:V5"<D[1LG;^V9>VC%\
M7=\?_1+=+UYN[;UJ:Z4\$]90P!L,09YK< G..?/V_:O5BN3M;6:\TUZ@IS)3
M1<6&=C-IC.#\/PRH7I34=1IZIE?%&R>GG;LF@D^J\?'F?Q64N.LHOHJHH+%:
M8;9'4\IWL?N<X> Y#"O/9Y8GA72SZ%85HX5B?6ZZF4-,[5>@:#J[0ZXV^=M.
M[ YEKB&C]Q;^4K,55-15FM+/IW8Q]%;(-\C".4C]O('QY8/WE071FJ)M,U51
M(R 5$4[ UT9?MY@\CG!]OXJRI[]64^H3>8W#K9E=*<\P<YR/LP<*7L\\4DN7
M&WQ?V(5:%DWSX7^"-I/JH:NMN%%?[C8'6EP='%#'*!)"0<#M P<?@>Q8"PO;
MISH_JKO0QQ25\M08A,YN[:T.V\O9R)^]8ZHUO1XJYZ*P4T%QJFELD[G[QD]I
M#2,=O/\ GE8[3.JOHJW5-MKZ*.X6Z<[C$]VTAWB#@^ 6<=GFH\O%<.'&W/\
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MQ=S+76!M5H'25.\[6RU+8R? $N"OM4WV2S:BH[#1T5-]%AL;7P&('B!Q\?\
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M9Z%^C*."E+I*B%QB8&E[. XX<1V\P#S5QT6Q44+]3QTT=-'.R\U32V-K0YK
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MZ>9LK9JAQ;W/DR%?(@+:MHV5>S?)*S;G_5NVY7RBH64CGEDDS]PQ_2/W*Z1
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MUM(RK:T/DE9M.?Z-VU>**@92/<YDLSRX8Q(_<%=H@+.KMT=5+Q'RSL.,88_
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M9^/0Z-1<Y?I'>O6U?^T.^*?I'>O6U?\ M#OBF[)ZD,_'H=&HN<OTCO7K:O\
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MNJGJ7.+,<(RL#,#GSQC/<L:S15PH*&PLL.HIZ&IM= RWDR0":"HC:&C<Z(N
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MHJ=QIOZ01L#<NY=N.TK'='-E;>-0Q<=L4E+ >)*QY^L,'  [^>%G.F,.%5:
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M]>:5VUC?9GX*XNVC[K;)Z1E0V%T55(V*.>-^8]Q. "<<OP4EL\$UTZ*YZ*T
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MI^[T&O*VLK&.93.,O]*7#$VXY&/'Q]F%1T\UU99=8V^WN N;ZF1P .'.83C
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MM116W4]ALKX)'RW;C[) 1MCX3 XY'MRHO?7LI>G#3,M0YL<=3:JJGB<XX#Y
M]CMH]N.:^ZLD9/TQ:#IX7!\U-!7SS,:<F-CHVM:X^ +N00$MU7?Z33-CJ+I7
MME?%$6M;'"W<^1[G!K6-'>22 HU#KNOI+A00ZHTM6V6EKYVTU/5.J8IV"5WU
M6R!ARS/9WC*ONDR:Q.TL^GU,9A;*JIBIG30.P:>0O&R0NSYFUP!W=W)1._G4
M>@Z:BKWZD;J*SNJX(.I7&G9UAP>\-!BE;C>\9SS'8"@-LK"734$5OU/8[*^!
M[Y;JVH<R0$;8^$UKCD>W<LT'-+BT.!<.T9YA0'63@SI6T ]YPUL5R)/LX4:
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M7Q4M ^.0G'+!+W?AA7S-6V)]IH[G'<H7T59,*:G>T$F24N+0P-QG=D'ECN*
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M&-D>!&]PB:X9:9"&D,R.?G80$H1>8I&31,EB>U\;VAS7-.0X'L(/@O2 (B(
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M^>HUC<KU61.B9%"V@HVN[7,!WOD_\SL >QF>]2-$PH781$4E0B(@"(B (B(
MB(@"(B KT'^VP?YC?YJ7*(T'^VP?YC?YJ7+EK\T=%'DPB(L#4(B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MMD3#YC$7.:3PG_<F:3PG_<K9$P^8Q%SFD\)_W)FD\)_W*V1,/F,1<YI/"?\
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MWW':ZAVYY9W9PLDB INXW5CMX?'V\LYV[O@K*(77B,XKJ+AY&[;NSCOPLBB
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M-_6S2F+'_#W9S]Z]UHK=S>I&G#<>=Q<_NPKI$!;40K ']=,!/+;PL_?G*HU
MN?&=U8TG"_N[]V?OPK]$!2I>-P&]:,9F[^'G;^]6)%XSR=0X_P#,LFB ^-SM
M&[&['/"+ZB C-[_M&3[!_)6"O[W_ &C)]@_DK!=\/THY)<V$1%8J$1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 5Z#_;8/\ ,;_-
M:TZ3_P#?BY?_ $O_ $VK9=!_ML'^8W^:UITG_P"_%R_^E_Z;5OLG_;Y?RC':
M?^7S(LB(O5//"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MNQK@7-^T=R JHOCGM8 7N#03@9..:QK;G++>*>FI::.>@DA?(ZL94-(8]K@
MS9VG.3S'(80&314>MT_%?%UB'B1@%[-XRW/9D=RP=MU33U>HM0VN=C*46B6"
M(S22@"8RQ"08!QC&<=IR@)$BPU_U'1V2KM%-5[C)<JGJL6TC#3M<[<[)Y##3
M]Y"R;ZJGCG9!)/$V9_-L;G@.=]@[2@*R(B (B( B(@"(B (B(",WO^T9/L'\
ME8*_O?\ :,GV#^2L%WP_2CDES81$5BH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M^8W^:UITG_[\7+_Z7_IM6^R?]OE_*,=I_P"7S(LB(O5//"(B (B( B(@"(B
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M1=[]I(W'[ >P\NQ 2U%I[2^N;[9K]K.RZLK*:\?0%!]("NIX1"7 -#C&YHY
M\^7V'M6"L72!K.B=H^_ZBK*"HL>I:LTW4HJ<,=2;G88X/[7>///(?>@-_(M.
MZXN?2/3/U->*:KH+%8[.TOI89X8YC7M:#DEV26YQR'(\P,=ZOJN_ZRU)I73%
MQL$EOL-)6TO6KE<JD->VF\WD&L>>;2<\SGD1S[4!M1%K+HMU]5W+05VO6JWQ
M&*U5$T3J^GC(CJ8HP#Q6M'W]G@M@V6YTMYM-)<K?(9*.KB;-$\M+2YI&0<'F
M$!>(H?T<WNOO4NJFW&42"@O=114^&!NV)@9M'+M[3S/-?='WNNN6KM9T-7*'
MTUMJX(J9H8!L:Z%KB,CF>9/:@)>BUYTAZAKZ75-FL-->J;3M-6P2SON<\37[
MG-+0(6;_ #0X[B<G/(<EE=(MU/1W>IH[S6PWJS.@;-2W1K(XGA^[!B>QIP>6
M'!P " ER(H+:=7=6N>N9=05L<-KL]7%'$XL X;'0L=CD,N)<[EVGF $!.D49
ML>M[3=[LVV1LN%)7R1F:*&NHI:<S,&,N9O SC(]JJC65E.D#J<5+_H8 N,W"
M=G ?L/FXS]88[$!(448ONN+-9KK):ZAU7/<V1,FZK2TDD\CF.+@' -!Y#:<G
MNY>(7HZYT^-,P7X5VZW5#^%$6Q/,DDN2WAB,#<7Y!&W&>2 DJ+6NM.D.$:#U
M!7Z>GFI+M;.#Q8:RE=%+"'R- +HY!V%I.#V?@I#8]>6.\W>.VTLE7'4SL=+3
M=9I)(6U+&]KHW/: X#MY=W- 2E$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 1F]_VC)]@_DH_56.TU<[YZJUT,TS_K224['.
M=W<R1E2"]_VC)]@_DH50W":Y:TN43)G1V^T1,B>T' EGD&XEWL:S;R\7'P"[
MH?I1ROFS+QV6UQ4TM/%;:)E/+@R1-@:&OQV9&,'"\TUBM-+.R:EM=!#,PY;)
M'3L:YOV$!8&GU];YG03"AN3+5/,((KDZ$"G>XNVC^]N#2>0<6X56OUM2TU56
MQTUNNE?!0.+*NII86NCA<!DCFX%Q [0T'"F\2+,DLE/#)/%-)#&Z:+/#>YH+
MF9Y'![LKX^E@?4QU#X(G5$8+62E@+F@]H![0HHV^.J-?4#*>MW6B>ROK  ?,
M=_2-P_\ *5[IM>4$W5YW4%SAM51((H;E+"! \DX:?K;@TG #BT#FF)"S)144
MM/4\/K,$4W#>)&<1@=M<.QPSV'VK[)3PRRQ2RPQOEB),;W-!+"1@X/=R4=NF
MLJ:CN%924MNN=R=1-#JM]'$US8,C."7.&3CGAN2E3K2@!H8[73UEVJ*RG%7'
M#1L!<(3V/<7%H:,\N9SE3B0LS/5UOH[@QK*^DIZIC3EK9HVO /B,A>:&VT-O
MW=0HJ:FW?6X,369^W 6!.N+6+,+F^.L93,JA250=$ ZC?G!XH)\T D9(SVA6
MVI=5T#K7J!D,]PBCM@8V>MHVL.QY</,87'!< 1GE@ ]N5&)<Q9\B27"T6VXO
M8^X6^CJGL^JZ>%KRW[,CDKR-C8V-9&T-8T8#6C  4 BU7546NM2T!I+G=(X6
M4KX:>EC:[@M,9+SEQ &21RSD]P5]?]1MDTI1ZJLU1*ZCI9&S3Q8(XD.[9*QS
M>YS>9]A;[4Q(863-%3DGBCIW3OD:V%K"\O)Y!N,YSX844IM>T$II9I+?=*>V
M5<C8H+C-"&P2%QPT_6W-!Y8+F@<U+:1"39+T47&LZ1]_J;3!07*:6DE$53.R
M$<*#+0X.<[=]7!^WD>7C;1:_HWMI:E]KNT5JJI6Q0W"2%HA<7'#21NWAI.,$
MM[TQ(G"R8HHMI^OJJC76K*.:=[Z:E%)P8SV,W1N+L?:0KF]:GBMUT;;::WU]
MRKN#UA\5&QIX<9) <XN<T<R#@#GR2ZYBQ($4:GUE;H[/;ZZ.*LF?7O,=-21P
M_P!/(\9W-VDC&,'))P/%8G4.K^L:3U,*2.MM=YM]&Z4P5+0V1F0=KVD$M<.1
MY@E1B0463M%@[1?(9[A#:'B5U<VWQ5KWD#:6N);VYSG(/<HYJK7$D%%32V:E
MK)"+RVW3EL;#G;( ]HR[M=V-/V]BER25PHMD_11.#4=#27'4M17U=;%%0PTT
ML\-0UNRG#F$@,VY))[QXXPJMMUA3U-QI*.LMMSMDE8#U5U;$UK9B!G +7'#L
M<\.P4Q(862=%"9>D:WMIZBJ9;+O+04LSX:JJ9 TQP%KBTD^=DCEGS0< C//D
MIB^HB92NJ7/' :SB%_=MQG/X(FGR(::*J*,:0N4L^F)=0769[(ZL/K0QQ\V"
M#'F- _\   3XDE1[H_OUW?>XF7^9[H;[3.N% Q^!P</.8A_]-T;OQ48N1.$V
M0BC-UUA3T5QJZ*EMURN4M&T.JC1Q-<V $9 )<X9=CGAN3A75KU1;KI<J6CH7
M22NJ:$7".4-PPQ%VWQR'9[L*<2(LS.(H%K#6TE-:*B6S4U6^:FNL=NF<(V'!
MW,W8R[^\'8!\3W=JS%=JZ*GJXJ.GM=SK;@8&U$M+3QL+Z=CNSB$N#0>WD"2<
M*,2)PLDJ+'V*[TM[ML=;0N>8G$M+7M+7L<TX<US3V$$$$+(*Q!7H/]M@_P Q
MO\UK?I-BD=K:Y%L;R/Z/F&G]6U;(H/\ ;8/\QO\ -2Y1&O[">*U^ E1]M##>
MW$YAX$WZJ3\I3@3?JI/RE=/(MMZ/3W_HRW?^[L<P\";]5)^4IP)OU4GY2NGD
M3>CT]_Z&[_W=CF'@3?JI/RE.!-^JD_*5T\B;T>GO_0W?^[L<P\";]5)^4IP)
MOU4GY2NGD3>CT]_Z&[_W=CF'@3?JI/RE.!-^JD_*5T\B;T>GO_0W?^[L<P\"
M;]5)^4IP)OU4GY2NGD3>CT]_Z&[_ -W8YAX$WZJ3\I3@3?JI/RE=/(F]'I[_
M -#=_P"[L<P\";]5)^4IP)OU4GY2NGD3>CT]_P"AN_\ =V.8>!-^JD_*4X$W
MZJ3\I73R)O1Z>_\ 0W?^[L<P\";]5)^4IP)OU4GY2NGD3>CT]_Z&[_W=CF'@
M3?JI/RE.!-^JD_*5T\B;T>GO_0W?^[L<P\";]5)^4IP)OU4GY2NGD3>CT]_Z
M&[_W=CF'@3?JI/RE.!-^JD_*5T\B;T>GO_0W?^[L<P\";]5)^4IP)OU4GY2N
MGD3>CT]_Z&[_ -W8YAX$WZJ3\I3@3?JI/RE=/(F]'I[_ -#=_P"[L<P\";]5
M)^4IP)OU4GY2NGD3>CT]_P"AN_\ =V.8>!-^JD_*4X$WZJ3\I73R)O1Z>_\
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MF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB
M9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3X
MHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/B
MF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB
M9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3X
MHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/B
MF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB 9/BF3XHB
M9/BF3XHB 9/BF3XHB ^AQ!!!((6W.CK6XK1':[Q)BJ'FPSN/^L_Y3_S>WO\
MM[=1("000<$=ZPKT(UHX9&M&M*E*Z.HD6NNCK6XK1':[Q)BJ'FPSN/\ K?\
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M2M?6:LUUI>OI[%<K52V83R5,]?"(2XR1[!"P9\X9.21YOFCFME(@"(B (B(
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M(@X9?@'MY#/+*HR=(,551V Z?ME1<Z^]4YJX*4R-AX<0 W/D><AH!('?D]B
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MWX)(YX&W)^_"R-SO6HJ-T<52[3]NX<#72UE9,X132'.6Q-W!P P,EWCV+$:
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MS4#Z8?\ >MG_ $S/YN4\H/\ ;8/\QO\ -0/IA_WK9_TS/YN6NR_]U\#/:/\
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MR3ACBY>M-:;U%I>CTA=H[0ZLK*"UOM5?;XYXQ(&EX>U\;B[8<%O,;AR*V^B
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MGZ<31SF$\,OC.6DAN#@^&00L%T;6VW7/4)AN@:]HB+HXG.P)'Y'+V\LG"BJ
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MILEQ+)!NQ("'N!^KR4BT[8[S37>>YZ@OSJ^9\(@CIJ:(T]-$W.2[87.W//\
MB)Y#D%)D0&M^D2AN-;TBZ(^B*PT53'%7N$YAXL8\R+S7MR,@\QV@]X/)5JOH
MW-TL>HH+U=W5%WO?"X]9% &,B$1!B8R,D^8".8).<G)6PD0$#_0R]UU\L%TO
M>HH)9+/.9(J>EH.#$]KF%CL@O)W$$8.<#GYO/*^T/1Z*6CM,'TGNZA>I;QNX
M&-^\R'A_6Y8XGUN?9V<U.T0&!9IW;KJ74?6L\2W-H.K\/LQ(7[]V?;C&/O2Z
M:>Z]JZQWSK6SZ,BJ(N#P\\3BAHSNSRQM\#G/<L\B @4'1X(I:9_TGG@ZAFOV
M.K]O$W_T7UN[?];V=B^/T3>J!]TI]-:E;;;5<IGU#X7T?%EIWR<WF%^\;<G)
M&0<$\E/D0$+N&C:R&Y4%TT[>7TESIZ)MOFEKHC5-JH0<@R><TEX.3NSWE7N@
M]+S:7I[JVJN;[G47&N?723/B$9#G-:", D8RW([, X[N<G1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$9O?]HR?8/Y*P65NQIQ72
M<5LA=@=A]BL]U)_@E_$+MA+\JX'-)<7Q+9%<[J3_  2_B$W4G^"7\0K8O(KA
M\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV1
M7.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD
M_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $
MOXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-
MU)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@
ME_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)
MB\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA\RV17.ZD_P $OXA-U)_@E_$)B\AA
M\SS0?[;!_F-_FI<HM 83,P4[7MF+AL+CR!SRRLQ%'=!(WB34I9D;@&G..]<]
M9W9M25D9%%0K!4.B I'1MDSVO&1A4:1E>V;-7+ Z/'8QI!RL#4O45I6MK7/;
MU.2%K<<^(">:]43:MH?UQ\3S_=X8(0%RBL*AER,SC3RT[8O[H<TY5W3"80-%
M2YCI>\L') 5$6,X=W_7TGY2K^82F!PA<P38Y%PY90%1%CX&7,2L,TU,8\^<&
MM.<*XK6U3F-ZF^)KL\^("1A 7"*THF5S9'=<D@<S'(1@@Y7RL97.E!I)(&QX
MYAX).?\ [P@+Q%0HFU+8W=<?&Y^>1C&!A6TS+F97F&:F$>?-#FG.$!D$5.(2
MBG D<PS;>9 Y95@([MD9GI<?^$H#)HJ54)C"X4SF-EY8+QD*UIF7$3--1+3N
MB[PQIR@+]%;5K:MVSJ;XF=N[B G[%\HFUC7/ZY)"\8\WA@A 72*RJV7 S$TL
ML#8L<@]I)5>D%0V+%6Z-TF>U@P,("LBQTD=UXCN'-2AF3M!:<X5YB;JV-S./
MM[<>;NQ_) 546.CCNHD;Q)J4LR,@-.<*[JQ4.BQ2.C;)GM>,C" K(K*D9<&S
M U4L#HL=C&D%>ZUM:YS>IR0M;CSN("4!=(K:B;5M#^N/B>>6WA@A4:EEQ,SC
M3RT[8O[H>TY0%^BI4HF$+14N8Z7O+!@*Q,=VR<3TN/\ PE 9-%2E$QIR(W,$
MV.1(Y95I"RYB5AFFIC'GS@UISA 9!%0K&U+HQU-\;7YYF09&%2HV5S92:N2!
MT>.08"#E 7B*SK&5SI!U22!K,<P\$G*J43:EK'=<?&]^>7#! P@+A%CYV7,R
MO,,U,(\^:'-.<*\A$H@:)G,,V.9:.64!418SAW?]?2?E*OJD3&!PIG,;+RVE
MXR.U 545A3,N0F::B6G=%_>#6G*K5K:MP;U-\3#_ 'N("4!<HK2B;6M>[KDD
M+VXY<,$<UYJV5[ILTLL#8\=CVDG* O45&C%0V(BK=&Z3/:P8&%:21W0R/X<U
M*&9.T%ISCN0&114VB7JV'.9Q]O;CS=V/Y*Q9'==[=\U*6YYX:>Q 9)%1JQ.8
M<4KF-DSVO&1A6]*RX"8&JEIW1=X8T@H"^16M:VL<6=3DA8.>[B E*)M6W?UQ
M\3^S;PP1]J ND5C5,N)F<::6G;%W![22KFE$PA JG,=+WE@P$!518UT=VW';
M-2XSRRTJ^>)>KD,<P3;>1(Y90%1%CHH[H)6&6:F,>1N#6G.%=5C:ET8%(^-K
M\\R\9&$!716=&RO;*35R0.CQV,!!ROM8VM<]O4Y(6LQS$@).4!=HK>B;5-:[
MKCXGNSYO#!')4*AER,SS!+3"+/FAS3E 7Z*E3B80-$[F.FQS+1R5CP[O^OI/
MRE 9-%3J!*8'"G<QLO<7#DK2G9<A,TSRTSHL^<&M.4!?HK>M;5.:WJ;XFNSY
MW$!*\43:UKW=<DA>W'+A@@Y0%VBLJME>Z7-)) V/'8\$G*K4;:AL1%8^-TF>
M18,#" KHL=+'=#*\Q34PCR=H<TYQW*\8)NK /<PS[>T#EE 546-;'==PW34N
MW//#2KVJ$YA(I7,;+GD7C(0%5%8TK+B)VFIEIW1=X8T@JI6MK';.IR0L[=W$
M!/V("Z16M$VL:7]<DA>.6WA@C[53JF7 S.--+3MBY8#VDE 7R*C2"=L(%4YC
MI<]K!@85F^.Z[W;)J4-SRRT]B R2*DX3=6(:YG'V]I'F[L?R5G%'=!(WBS4Q
M9D;@&G.$!D45"L;4.B I'1MDSVO&1A4:1E>V7-7+ Z/'8QI!R@+U%:5K:USV
M]3DA:W'/B GFO=$VJ:UW7'Q/.?-X8(0%PBL*AER,SC3RT[8O[H<TY5U3"80-
M%0YCI>\L& @*J+&<.[?KZ3\I5].)C3N$+F";'(N'+* JHL? RYB9AGFIC'GS
M@UISA7%:VJ<QO4WQ-=GGQ 2,("X16=$RN;([KDD#F8Y",$'*5C*YTH-)) V/
M',/!)R@+Q%0HFU+8R*Q\;GYY&,8&%;31W,RO,4U,(\^:'-.<(#((J<0E%.!(
MYAFV\R!RRK 1W;(S/2X_\)0&314JH3&$BF<QLO+!>,A6U,RXB=IJ9:=T7/<&
M-(/8@+Y%;5K:MVSJ;XF=N[B G[,+Y1-K&N?UR2%XQYO#!" ND5E5LN!F)I98
M&Q8Y![22J]&*AL6*MT;I,]K!@80%9%C7QW7>[9-2AN>66G.%?8EZMC<SC[.W
M'F[L?RR@*B+'1QW42-XDU*69&X!ISA7=8*AT6*1T;9,]KQD80%9%94C+@V;-
M5+ Z/'8QI!RO=:VM<YO4Y(6MQYW$!* ND5M1-JVA_7'Q//+;PP0J-2RXF9QI
MY:=L7]T/:<H"_14J43"%HJ7,=+WE@P%8F.[9.)Z3'_A* R:*G*)33D1.8)L<
MB1RRK.%ES$K#--3&//G!K3G" R"*A6-J71CJ;XVOSS,@R,*E1LKFR$U<D#H\
M<@P$'* O$5G6,KG2 TDD#68YAX).54HFU+6.ZX^-[\\C&"!A 7"+'SLN9E>8
M9J81Y\T.:<X5W")A3@3.89L<RT<LH"JBQ@CNV><])^4J^J1,8'"F<QLO+!>,
MA 545A3,N0F::B6G=%_>#6G*K5K:MP9U-\3#_>X@)0%RBM*)M:USNN20O;CS
M>&"%YJV5YFS2RP-CQV/:2<H"]14:,5#8B*MT;I,]K!@85I)'=#([AS4H9D[0
M6G.$!D45(";JV"YG'V=N/-W8_EE63([KO;OFI2W//#3G" R2*C5B<PXI7,;)
MGM>,C"MZ5EP$P-5+3NB[PQI!0%\BM:UM8XLZG)"P<]W$!*^T3:MN_KCXG]FW
MA@C'CE 7**QJ67$S.--+3MB[@]I)5S2B80@53F.E[RP8" JHL:Z.[;CMFI<9
MY>:5>R";JQ#',$^WD2.64!518^&.YB5AEFIC'D;@UISA7-8VI=&!2/C:_/,O
M&1A 5T5G1LKVRDU<D#H\=C 0<K[6-K7/;U.2%K,<^("3E 7:*WHFU36NZX^)
M[L^;PP1R5O.RY&9Y@FIA'GS0YISA 9!%3IQ*(&B=S'38YEHY*PX=W_7TGY2@
M,FBI5 F,#A3N8V7N+AR5K3LN0F::B6F=%GS@UIR@+]%;UK:IS6]3?$UV?.X@
M)7BB;6M>[KDD+VXY<,$'* NT5G6,KW2YI)(&QX['@DY56C;4-B(JWQNDSR+!
M@80%=%CI8[H97F*:F$>3M!:<X5ZP2]6 >YAGV]H'+=\$!418UL=UW#=-2[<\
M\-*O:H3F$BE<QLN>1>,A 545C2LN(F::F6G=%WAC2"JE:VL<6=3?"SMW<0$_
M8@+I%:T3:QI?UR2%XY;>&"/M5.J9<#,XTTM.V+E@/:24!?(J-()VP@53F.ES
MVL&!A6;H[KN.V:EVYY9:>Q 9)%3<)>K$-<SC[>TCEN^"LHH[H)&&6:F+,C<
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MD^P?R5@K^]_VC)]@_DK!=\/THY)<V$1%8J$1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 5Z#_;8/\QO\U+E$:#_;8/\ ,;_-2Y<M
M?FCHH\F$1%@:A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MD$<CH7OB.0'C&6_:,A9!<SZ*U?6Z0Z(JV2SQ1272X:EEH:8S#+&/>UIW$=^
MW\2%.:6^ZOT9KW3MEU9>*6^T%^WQLECI6P/IY6@<@&]K<N Y^/=CF!LZS7NV
MWH51M5;#5"EF-/-PSGAR#M:?:LBN9]!0:N%JZ0;AI>^4UL@H+M55!B?2MF=4
MO:-Q:7.^HW:!C [25*KATAW2\:'TE=8=16S3/TDV3K;S3.JJA[V.+"((<'(W
M-.<]F1S\0-R76XTEIM\]=<JB.FHX&[I)9#AK1XE5**JAK:."JI)6RT\\;98I
M&]CVN&01[""N>FZON^INASI&IKY4]<EMC^!%5.INKOE87#&^/EM/+LQW^Q;J
MZ./_ (>Z7_\ S72_^DU 2%%SO9M4](M[T%>]4TVH:*"*SSS8IG4+'&I;'AS@
MYW]T!IP,#)YY/8LK>M?ZIO=SZ/Z73%73VUVHZ&2282P-E;$\#FX9Y^;AQ SS
MP,H#>:+2[KQK>\:T=HFU:AIJ.IM%"R>XW5U$Q[JB5V" V,^:&^<WP[#S6)N'
M2=J:EZ-]8BHFIX]3:<KXJ-]7#$TQS-=+MW;2, D!W=X=B W\BT35W[I"HM;:
M=LSM0V^5VI*1TK2;>T,H"&[G;!G+R&CEN.#WA5+/TE7VQ:9Z0CJ">&[5^FJI
MM/!4"$1<8O<6-W-;R !&3CGC(SWH#>2H];IS4R4XGB-1&P2/B#AN:TYPXCM
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M,C&'EN<-O+&!D\E&(G"3U%#-.UEPH];5U@J+G+=:6.B95B:9C!) \OV\-Q8
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J%PHX+A05-%61B6FJ(W0RL/
M8YC@01^!5=$!IKR*UT=LDL=+KJ[0Z8>XYMW!:2&$Y+!)GL]FW'L6?U!T64M0
M;#4Z9NE38+I9:?JE+511B;,6"-KVNP'=I/;_ 'CG*FNHKH;-9:NX-HJNN-.S
M=U:D9OEDYXPUO>5<6NK-?;:2K,$U.:B%DO!F;MDCW-!VN'<X9P1XH#7?DFAD
MT-?+%5WRLJJV\SMJ*NXRL!<7AX=YK,X Y'EGO/L"S'Z 4YUG:;_)6.?U"U_1
MG5C$-LK?.!<3GE];L4DU'=H;#8+C=JF.22"B@?4/9'C<X-!) SRSR7C2UZ@U
M'IVWWBDCDB@K81,QDF-S0>XX)&4!KVW=$E9;!';K=K2[TFF8ZGK++= T1R-Y
MY+!."'!N3V8_?S61U#T5V_4^I+C==2ULM?'-2&DI*8LVLHFG^^TY.7YYY/>3
M[,2N+4]LEU=+IJ*5[[K#2];E8&':QF6@9/B=PY!9I 8'0MAJ=,Z:I+157.2Y
M]5&R*>2/8[A_W6GF<X[,^&/!6&DM%1:=U3J>]1UKYWWR9DKHG1AHBV[N0.>?
MUOW*5RR-BB?)([:Q@+G$]P"Q.D]1V[5=F9=;-(^6A?(^-DCV%N[:XM) //&1
MWH#']).D(]<:5GLDU6^C9+(R3BL8'D;79Q@D*C?M%17?5.EKT^M?$^P\39$(
MP1-O:!S.>6-OM4N6+U/?:'35AK+Q=I#'14K-\A:,DY.  .\DD ?:@-:U'0Q(
MZCOUKI=5UM-8+M.ZJ?0LIHR1(2",R'F6@@<N6<=O:I';^CN.DU5IJ^.N4DDM
MEM8MC8^" )@&N;O)SR/G=BPUOZ9J)]PML5ZTY?;+17)[8Z2MK( V)Y=]7)SR
MSR\?PYJ_U5TJ4UAU;/IV#3]\NU?#"VH>+?"V7##CGC.>60.SO0DS-!HR*CZ1
M[GJX5CW2UU(RD-,8P&L#=GG;L\_J>'>HU'T0TS.BVIT7]+S&&:IZP:K@#<#O
M#L;<^SQ4BZ/ND"U:W;71T,-91UU"\,J:.MBX<L9.<$@$\N1'CRYA2*\W6ALE
MMGK[M514E'"W<^65V /B?9VE""!7#HQJ#JR:^634U7:9:NDCHZUD=.R0RL8U
MK<L<[_5G#1SP>:M8>ANACT)2Z<^EJH2T-:ZNH:^.,-DIWDY'+//G]G=V84FT
M?KZU:FT=4ZEC;-1VVG=+Q'5 &0V,9+N1/+"P^D>ERSZCOE';?HZ[6XW!CGV^
M>M@#(ZMK<YV$$^!__;R0'O3_ $:<"JN]9JJ^U>HJVYTAH97RQB!C82,%K6-)
M /M^)5IIWHON5HJ;7!)K6[SV*V2<2EM\;!"<9Y,DE:<O;[",8Y<EYO7319;;
M<;C#%:KW74%MFZO6W&EI@ZG@?G!!=GN/_P"K*V305<%?14]922"6FJ(VRQ2-
M['-<,@_@4!KRY]%\TNKKO>+3J:NM5->6-9<:2&%CC* ,>:\\V<L\P">9P593
M]#D+NCRTZ9I[Y/#-;*TUU/7" $A^YQP69P1YWCW!2N+7=L=6ZG:\/90:>:.M
MUIYL+]I<YC0.9+0.?M.%$(NF^WL%)5W+3>H+=8JMX9#<ZBG B.>QQP>P]O+/
M) 22ET&1K*UZCN-VDK:RDM?T;*'P-:*CMS(<'D3N/+&%%V]"KHH7VFEU;<X-
M)OJ>LFTLC;D'=NVB;.X#('+'M[>:SFKNE*ET]JIM@AL5YN]<ZF;5 6^)LOF$
MD9QG/=X=X5>T](O7+5>KA6Z8U!:H+72NJG=>IA%Q@T$EK,GF>2 Q]QZ+)7ZH
MN]TLVI*RU4MXA9!7TL5.R1TC6MVX9([FSE[">97FAZ)8:6PZ0M9O$KX].W U
MT3^  9<R%^PC/+F3S60T5TI6;5>E[S?*6&JIJ>U!SJB.<-W[0S?N&"1@@'\%
M9:9Z8+/J#2=_U!2V^X14UF:'31R!F]^03YN'8[N\A >=1]&-SNE3=V4>LKA3
MVFZN)J:&IIVU8;GM$;WG,8YG '9]P4ZTS9:73E@H+1;]_5:.(1,+SEQ [R?$
MGG]ZUM#TYVMM-35MRTUJ:@M4^W;<)J,& !W8=P=S'V94AUQTEV_2M19(66ZX
M7>2\,=)2"W-;(7@!IY D9R' C&4!:VGHN@M_1W>])MNDKXKG-),ZI,(!CW[>
M0;GGC;X]ZH7+HME=6Z:N-DU%/;+I9;>VVBHZJR82Q-:1]1QP#S=SY]OL62TM
MK^HO]T-$=(:DMO\ 1ND$U=2B*,D#ZN[/:>Y6MNZ7+!4Z:OMWJV55 ^S2&&KH
MJD-$[7YPUH )!W'('/M!SV("TMG1*+?8[];X=379DESJQ7"LB=PIHY>>2XM(
M#P<\P0!^[%WIGHWJ*+6,.I]1Z@DO=UIH#3T[A1QTS6-(()<&9W'!/,^/V*36
M'4L-STC'J&II:BW4;X'56RJP'MB )W$ D#(&?L*P_1CTCVGI"I:Z6TPU-.^C
M>ULD50&AV'#+7#!/(X(^Y 8[I[MT-PT-_3VNY5Y@J62L?;2./3. .)6C^\!V
M$>!SRQD:ZZ/K?5WOIAL=YIZK4%UIK?1RBKN-UIC  XM<UL;&]@^MG',DDE;L
MTOJBFO\ 77JA;#)35UIJC35$,A!.,99(,?W7#F/L*D" UC3]#UL_02MTS65]
M1,R>O=<8JIC1')!*0 "WM[,$?83V*XTYT:U%-J>COVJ=2UFHJZ@C,=$)H6PL
M@R,%VT$[G8[S]O<,;&1 :A/0W5T\-[AM&LKA007FHDEK8F4S',D8\_4&3EIY
MN&X'F#@CDLA<.B:&*;353I:]5%EK;'3NI89C VH#V.SNW-=@;B7..?\ F[.Q
M;.1 :PH.B6.EL&KK7)?:JI&HG-DEGFA:9&/R2YW(@.R3V8&%L#3UM;9K#;;8
MR0RMHJ:*F$A&"\,8&YQW9PK]$!S?T8]&UYONC+K337^ZV*BK+A,RLH#3 B>,
M;<.:78+,CD2,@@#ER6UW]'-"S4FDKG15+Z>#3M.^F@I@P.$C7,+>;L]O//9S
M4Y1 :_U=T=2735 U)IV_U6G[VZ'J\\T,+9F31]P<QV!GD.>>X>"L).A^@=H"
MZ:<%SJ755TJ&U5;<I6!\LT@>'9(SV<NS/>>U;/1 0ZMT-%5:OTO?C7/:^QP2
M0,AX8(FW,+,DYY=N58TO1A;0[6K+A4RU=+J>42S1; PPD%Q&TY.2"X$'': I
M^B U3;.B&;K5HCU#JJX7JSVB1LE%;Y86QM:YOU=[@27X'+GCP[,A9FEZ/IJ'
MI(N&J:"^S04]Q:!66[@-<V4B,L;Y^<@ G=C';WJ>H@-70=#MN;T?4VF)KE4F
M2DJW5M+7Q-$<D,I)((&3X_\ ["LAI7HYFM^J(]1:FU#5:AN\$)@I9)H6PL@8
M<@X8TGSB"1GVE;!1 :WMG173T/1?<M&-NLKX:V1TAJC" YN7-=C;GG]7Q[UY
MNG1A.^[6&[6/4=1:KG:[>RVF84K)A+$T8^JXX:>9Y\^[P6RD0&IQT-0#1E_T
MZ;[520W:N;7&HEA:Z1C@03GF [.T<^2VK3Q\&".('(8T-SXX"]H@"(B C-[_
M +1D^P?R6LKU<7PW&X4.K].376VNDWT-134/66<,@>8\#):X'//O6S;W_:,G
MV#^2QY< 0"0">P9[5W15XHY6[29INJL%>[HZU9#;[574UOK*F%]NMDC2Z6-@
M<S>=G,M!(<[;W!3^VZ"TM;:R.JHK'1QU$9W,>6EQ:?$9S@^U28$$9',(I4$@
MY-F!=IUYOOTE].7D-WA_4Q.WJ_\ X=NW./O5CJ2DJ)M=:.J(8)7T].ZKXTC6
M$MCW0X;N/=D\AE2Q%.$BY!ZR6736N;E<YJ&MJ;==*6%O$I('3.CFBW#:YK<D
M M<,'LRL)UJ_:>TI45%%::TW2^7.:J<V*F,[J&-YY.<UO:X-#<-)[3S["MIY
MYX11A&(A/1W+10<:BI+5?H*B0&HJ:ZYTCHW5#\@$N>>UW/D.X X576#3!K+1
ME?)_LS*F>E<?\+Y8B&?B6X^]3%65YME/=[?+1U8=PWX<',.',<T@M<T]Q! (
M/L3#PL+\;D4U%<9Z2\5E+J.P2W:P3-8^DDIJ/K/#.,/;(WF<YY@X["HQ#9*E
MVF=<NLUHKJ"T5M(&T-NE81(Z4-=O>V+F6AV6@#OQV+;N0T .=S\3WKZ"#V$'
M[%#C<E2L:LM55IZGM]&R?H]N9J8XF![_ * !)< ,G./'O62O=CEU#JVYMDIJ
MB*CKM/-@;-)&6ADIE<X GN<WD<+82)@\!B-/S6Z]W?1U==+G;:IEWJJJAAZO
MPR7MB@D9N=CMP7<5_P!A!6:BN<^G^D#5<]19+W54];U0PRT=$Z5CMD6'<QR[
M2MBY'B%]3 ,1K9U!<[Y4ZGU#4VVIHFRVA]MH*24#CR-PYQ<YHS@EQ  [5B]-
MR6&CT];::X]'UREK8::..>0V$/W/#0''<1D\\\UMU,I@&(@^HC7:GDH+'14E
M;0VJIA;/<*B6(Q%L7=3M_P"=W8['8,K'TYNNAA=K50V^MN-J,$E3:3!$Z7@R
M=]._ .!N(+2>[*V0BG#XD8O U?#T82RZ*^C9[]=Q42P\62#BQ\'K!\\G&S.-
M_/MS[5,M+2SWO2-$;]0OCJ981'54]3%C+QR=EI[B1D>PK/(.?8BBER#DV6M3
M;J*J>]]3203.>&!Q?&'%P8[<W.?!Q)'@5YJ74MIMU74ED<-/$V2HEV@ $\W.
M<?:>9*NC(P/#"]H>>QI/,JTO%L@N] ZCK-YIGN:9&-.-X!!VG_E.,$=XY*?@
M08/HMHIJ#H^L5/4@ME%,'EI[1N)<!^!4I7SD .P#L7U$K*P;N[A$0'/8I("(
MB (B( B(@*]!_ML'^8W^:TYJ/_>&Z?\ 52_]Y6XZ#_;8/\QO\UIS4?\ O#=/
M^JE_[RNK8_UOX'/M7Z$8Y$1>D<(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M=NZU;*>1S YI;S+26\1S6C.-PP5)='4UDMFNK7%2V&[Z5JJBFE$,4Q88KFP
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MAI*>2"=L7]Y["7N!('/![@L[KG4\UMTS1U-AX,]QNL\%+;A*"6/?*00X@8.
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MU4O_ 'E;CH/]M@_S&_S6G-1_[PW3_JI?^\KJV/\ 6_@<^U?H1CD1%Z1PA$1
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M=^";'?X7?@EP>47K8[_"[\$V._PN_!+@\HO6QW^%WX)L=_A=^"7!Y1>MCO\
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MY\3A&2,?G8]KL>!R@/2+RZ6-IPY[0? E?6N:\9:X.'B#E ?47@S1 X,C,_\
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MXIVS @;>>P-!SR6\;K%6MLE5%97PQW!L#FTSI@71AX'F[AVXSA7CI8VDATC
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MA]KB.'R-8XEIW!NTMQN!R1RQE6%/TA:=FJ8H7U513NE>&,=4TDL+"X]@W.:
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M1T:BQFGKW27ZW,JZ)^1V/8?K1N\"LFO E%Q=GS/834E=!$102$1$ 1$0!$1
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MJ*Y.HZ8.?M<^,,8=SLD][B,\@@)^BQEZU!:+)0QUEVN-+24TA CDDD $A(R
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M6-?24TA;0VJ%K96C']-/(-P&>X-:!][_ &*97O\ M&3[!_):]T>'TNI]:TA
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0$"Z5NC2AZ18[8ROKZFC%"9"W@-:=V_;G.?_"LMT<:.
MIM#::99J*JFJH6ROEXDH =EW=R^Q2=$ 5M<ZE]';JJIBIY*J2&)TC8(L;Y"
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M)#(&-WD8+L<R/M0&F+=-#=]:Z5=3:SH;U54W%EA9:[8QHBB,9:X2O;(>&PY
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M3./W*JB L:47+C-ZT:4Q<\\/=G]ZJ5HK/,ZD8!V[N+G[L85TB M:(5@+^NF
MCEMX6?OSE4ZH7'C.ZJ:41<L<3=G]ROD0%&DX_!_K9C,N?^'G&/O5F\7;<[8Z
MBVYY9#LX621 4W<;JQVEG'V]^=N[X*RB%UXC>*ZCX>1NVAV<>Q9%$!0K.L\(
M=3,0DSSXF<8^Y4:07#B_ULTQBQ_P\YS]ZO40%I6BNWMZF:<-QSXN<Y^Y>Z(5
M8:[KIA+L^;PL_ORKA$!85 N?&=U=U)PO[N\.S]ZNJ;C<!O63&9N_9G'[U51
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M(7SVT[-*A*SY'M4*ZK+S*J(BYC<(B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5\TI?(Z:6:=^^2:1W:YQ[SV?@%A9]45];<H[=IVW05-4*2.KJ)*J<Q10M?\
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MW0LDW;>'CZP./K% ;H1:\Z!M3735G1_%=+[.V>M=42QE[8VL&UI&.30 MAH
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M;X'])V8[<J(5,\E342SSO+Y9'%[W'M))R2J:*84H4_TJPE4E/]3"(BT*!$1
M$1 "2 !DE  "2 !DE;=Z.M$"B$=TO$>:H^=# X?ZO_F/_-[.[[>SYT=:(%$(
M[I>(\U1\Z&!P_P!7_P Q_P";V=WV]FQEX^V;;>].G\V>ELNRV_/,(B+RCT0B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M9(!@%[0TM'LPW]ZA19+:(-555_MFB:?6$M]GJ*DQQ5<]"Z.,4SHGEN8V@-W
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B(",WO^T9/L'\E8*72P1/>7/BC<[Q+02O/5:?]1%^
M0+KA.T4CGE'BR)HI9U6G_41?D"=5I_U$7Y K>T*X")HI9U6G_41?D"=5I_U$
M7Y GM!@(FBEG5:?]1%^0)U6G_41?D">T& B:*6=5I_U$7Y G5:?]1%^0)[08
M")HI9U6G_41?D"=5I_U$7Y GM!@(FBEG5:?]1%^0)U6G_41?D">T& B:*6=5
MI_U$7Y G5:?]1%^0)[08")HI9U6G_41?D"=5I_U$7Y GM!@(FBEG5:?]1%^0
M)U6G_41?D">T& B:*6=5I_U$7Y G5:?]1%^0)[08")HI9U6G_41?D"=5I_U$
M7Y GM!@(FBEG5:?]1%^0)U6G_41?D">T& B:*6=5I_U$7Y G5:?]1%^0)[08
M")HI9U6G_41?D"=5I_U$7Y GM!@(FBEG5:?]1%^0)U6G_41?D">T& B:*6=5
MI_U$7Y G5:?]1%^0)[08"-4'^VP?YC?YJ79'BK&JIX6TTI;#&"&G!#0L L*K
MQ,UIJR);D>*9'BHDBRL:$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN
M1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8
M$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ42
M1+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>
M*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%
M,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN
M1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8
M$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ42
M1+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>
M*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%
M,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN
M1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8
M$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ42
M1+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>
M*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%
M,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN
M1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8
M$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ42
M1+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>
M*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%
M,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EN1XID>*B2)8$MR/%,CQ421+ EJ
+*VMO^PP_8B@D_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g942297snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g942297snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M>]G:QSGP+^&4GP;^$W@KX92ZRGB"3PCIDVGMK,=BVF)?F74;V^$JV+7=R;8
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M<_/L5/#SQ->>$HRPV%E4FZ-*<_:2ITW)N$)5.6'/*,;)SY8\S5[*]C8JS *
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7,7\BWAA5F"%PWE1["_RL"5CU.D!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-1062542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 3,272<span></span>
</td>
<td class="nump">$ 3,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">10,619<span></span>
</td>
<td class="nump">26,442<span></span>
</td>
<td class="nump">34,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,268<span></span>
</td>
<td class="nump">9,397<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">28,704<span></span>
</td>
<td class="nump">41,547<span></span>
</td>
<td class="nump">46,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">31,451<span></span>
</td>
<td class="nump">32,453<span></span>
</td>
<td class="nump">36,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,481<span></span>
</td>
<td class="nump">13,481<span></span>
</td>
<td class="nump">13,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Other long-term assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">78,976<span></span>
</td>
<td class="nump">92,953<span></span>
</td>
<td class="nump">101,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">57,257<span></span>
</td>
<td class="nump">52,620<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued rebates and fees</a></td>
<td class="nump">168,429<span></span>
</td>
<td class="nump">162,517<span></span>
</td>
<td class="nump">89,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">3,482<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">7,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CurrentPortionOfDeferredConsideration', window );">Current portion of deferred consideration</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current</a></td>
<td class="nump">39,442<span></span>
</td>
<td class="nump">34,876<span></span>
</td>
<td class="nump">108,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiabilityCurrent', window );">Purchased revenue liability, current</a></td>
<td class="nump">4,303<span></span>
</td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">275,744<span></span>
</td>
<td class="nump">259,635<span></span>
</td>
<td class="nump">250,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongTermPortionOfDeferredConsideration', window );">Long-term portion of deferred consideration</a></td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="nump">17,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiabilityNoncurrent', window );">Purchased revenue liability, net of current portion</a></td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">7,894<span></span>
</td>
<td class="nump">18,303<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">290,460<span></span>
</td>
<td class="nump">285,594<span></span>
</td>
<td class="nump">274,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdditionalPaidsInCapitals', window );">Additional paid-in capital</a></td>
<td class="nump">448,244<span></span>
</td>
<td class="nump">454,614<span></span>
</td>
<td class="nump">407,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(589,132)<span></span>
</td>
<td class="num">(563,052)<span></span>
</td>
<td class="num">(490,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(76,915)<span></span>
</td>
<td class="num">(90,522)<span></span>
</td>
<td class="num">(90,522)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(211,484)<span></span>
</td>
<td class="num">(192,641)<span></span>
</td>
<td class="num">(172,938)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">78,976<span></span>
</td>
<td class="nump">92,953<span></span>
</td>
<td class="nump">101,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember', window );">Series One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdditionalPaidsInCapitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capitals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdditionalPaidsInCapitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CurrentPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CurrentPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">740,000,000<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStocksSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="nump">4,573,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,951,622<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStocksSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,493,359<span></span>
</td>
<td class="nump">2,857,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,493,359<span></span>
</td>
<td class="nump">5,235,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock share</a></td>
<td class="nump">1,458,263<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember', window );">Series 1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PreferredStockDividendShares', window );">Preferred stock dividend shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStocksSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stocks shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStocksSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStocksSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stocks shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStocksSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PreferredStockDividendShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Dividend Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PreferredStockDividendShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="nump">$ 5,004<span></span>
</td>
<td class="nump">$ 10,884<span></span>
</td>
<td class="nump">$ 56,590<span></span>
</td>
<td class="nump">$ 46,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Net operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">3,840<span></span>
</td>
<td class="nump">16,689<span></span>
</td>
<td class="nump">15,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,456<span></span>
</td>
<td class="nump">3,108<span></span>
</td>
<td class="nump">9,641<span></span>
</td>
<td class="nump">12,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">28,060<span></span>
</td>
<td class="nump">29,278<span></span>
</td>
<td class="nump">119,016<span></span>
</td>
<td class="nump">119,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">4,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Legal settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,891)<span></span>
</td>
<td class="num">(9,391)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total net operating costs and expenses</a></td>
<td class="nump">32,902<span></span>
</td>
<td class="nump">30,362<span></span>
</td>
<td class="nump">139,986<span></span>
</td>
<td class="nump">152,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,898)<span></span>
</td>
<td class="num">(19,478)<span></span>
</td>
<td class="num">(83,396)<span></span>
</td>
<td class="num">(105,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="num">(10,409)<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="num">(17,378)<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">6,114<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
<td class="nump">4,782<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, net</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">(Gain) loss on foreign currency exchange</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense, net</a></td>
<td class="num">(1,818)<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
<td class="num">(10,588)<span></span>
</td>
<td class="nump">8,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,808)<span></span>
</td>
<td class="num">(114,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="num">$ (24,377)<span></span>
</td>
<td class="num">$ (72,807)<span></span>
</td>
<td class="num">$ (114,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to common stockholders - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (2.26)<span></span>
</td>
<td class="num">$ (8.33)<span></span>
</td>
<td class="num">$ (7.24)<span></span>
</td>
<td class="num">$ (44.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (2.26)<span></span>
</td>
<td class="num">$ (8.33)<span></span>
</td>
<td class="num">$ (8.05)<span></span>
</td>
<td class="num">$ (44.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares during the period - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares during the period-basic</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="nump">10,061,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares during the period -diluted</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="nump">10,145,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="num">$ (24,377)<span></span>
</td>
<td class="num">$ (72,807)<span></span>
</td>
<td class="num">$ (114,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Changes in fair value attributable to instrument-specific credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,490)<span></span>
</td>
<td class="num">$ (114,331)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Debt And Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity / (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">4,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 36,239<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 412,149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (375,914)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements', window );">Shares issued under the Standby Equity Purchase Agreements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements', window );">Shares issued under the Standby Equity Purchase Agreements</a></td>
<td class="nump">34,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">34,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DisbursementOfFundsToSorrentoAmount', window );">Disbursement of funds to Sorrento Amount</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares', window );">Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue', window );">Repurchase of Treasury Stock, Preferred Stock, and warrants</a></td>
<td class="num">(143,721)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfPennyWarrants', window );">Issuance of penny warrants</a></td>
<td class="nump">10,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in connection with Settlement Agreement, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in connection with Settlement Agreement</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares', window );">Conversion of Convertible Debentures into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue', window );">Conversion of Convertible Debentures into common stock</a></td>
<td class="nump">7,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssued', window );">Retainer shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssuedValue', window );">Retainer shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares', window );">Issuance of common stock upon warrants exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue', window );">Issuance of common stock upon warrants exercise</a></td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(114,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants', window );">Placement Agent Shares and October 2024 Placement Agent Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfTrancheBNotesIntoCommonStock', window );">Conversion of Tranche B Notes into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering', window );">StockBlock Warrants issued in connection with the December 2024 RDO</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">$ (172,938)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 407,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(490,245)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">4,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Balance, ( In shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (24,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue', window );">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement', window );">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderBoughtDealOfferingShare', window );">Shares issued under Bought Deal Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderBoughtDealOfferingValue', window );">Shares issued under Bought Deal Offering</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="num">(189,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">415,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(514,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">4,748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Balance, ( In shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">4,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">(172,938)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">407,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(490,245)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssued', window );">Retainer shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssuedValue', window );">Retainer shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares', window );">Issuance of common stock upon warrants exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue', window );">Issuance of common stock upon warrants exercise</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(72,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue', window );">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</a></td>
<td class="nump">2,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement', window );">Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderBoughtDealOfferingShare', window );">Shares issued under Bought Deal Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderBoughtDealOfferingValue', window );">Shares issued under Bought Deal Offering</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering', window );">Shares issued under Registered Direct Offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering', window );">Shares issued under Registered Direct Offering</a></td>
<td class="nump">5,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering', window );">Placement Agent Warrants issued in connection with Registered Direct Offering and Representative Warrants issued in connection with Bought Deal Offering</a></td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter', window );">Fee Warrant issued in connection with the Commitment Letter</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="num">(298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement', window );">Common stock issuable under Sponsor Interest Purchase Agreement</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares', window );">Placement Agent Shares and October 2024 Placement Agent Warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants', window );">Placement Agent Shares and October 2024 Placement Agent Warrants</a></td>
<td class="nump">3,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfTrancheBNotesIntoCommonStockShares', window );">Conversion of Tranche B Notes into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfTrancheBNotesIntoCommonStock', window );">Conversion of Tranche B Notes into common stock</a></td>
<td class="nump">9,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares', window );">Shares issued under December 2024 RDO, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering', window );">Shares issued under December 2024 RDO, Value</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering', window );">StockBlock Warrants issued in connection with the December 2024 RDO</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockDividendDeclaredNotYetDistributedShares', window );">Stock dividend declared, not yet distributed, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockDividendDeclaredNotYetDistributed', window );">Stock dividend declared, not yet distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under ESPP</a></td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">6,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="num">(192,641)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">454,614<span></span>
</td>
<td class="nump">6,317<span></span>
</td>
<td class="num">(563,052)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,057,000<span></span>
</td>
<td class="nump">6,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Balance, ( In shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(26,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral', window );">Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares', window );">Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TreasuryStockPaidForGloperbaEx-USLicense', window );">Treasury Stock paid for Gloperba Ex-U.S. License</a></td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares', window );">Treasury Stock paid for Gloperba Ex-U.S. License, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension', window );">Treasury Stock transferred to Oramed for the Oramed Note maturity extension</a></td>
<td class="nump">1,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares', window );">Treasury Stock transferred to Oramed for the Oramed Note maturity extension, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="num">$ (211,484)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 448,244<span></span>
</td>
<td class="nump">$ 6,317<span></span>
</td>
<td class="num">$ (589,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,057,000<span></span>
</td>
<td class="nump">6,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Balance, ( In shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment of additional paid in capital of share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issuable under Sponsor Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures Into Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures Into Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfTrancheBNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Tranche B Notes into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfTrancheBNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfTrancheBNotesIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Tranche B Notes into Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfTrancheBNotesIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DisbursementOfFundsToSorrentoAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursement of funds to Sorrento Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DisbursementOfFundsToSorrentoAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee Warrant issued in connection with the Commitment Letter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Upon Warrants Exercise, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfCommonStockUponWarrantsExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Upon Warrants Exercise, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfCommonStockUponWarrantsExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfPennyWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Penny Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfPennyWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Treasury Stock Paid For Gloperba Ex-US License Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Treasury Stock transferred to Oramed for the Oramed Note maturity extension Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement Agent Shares and October Placement Agent Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement Agent Shares and October Placement Agent Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RetainerSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retainer shares issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RetainerSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RetainerSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retainer shares issued value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RetainerSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued During Period Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued During Period, Values, Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderBoughtDealOfferingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Bought Deal Offering, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderBoughtDealOfferingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderBoughtDealOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Bought Deal Offering, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderBoughtDealOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderDecemberRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under December Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderDecemberRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under December Registered Direct Offering, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Standby Equity Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockBlock Warrants issued in connection with December Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockDividendDeclaredNotYetDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock dividend declared, not yet distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockDividendDeclaredNotYetDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockDividendDeclaredNotYetDistributedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock dividend declared, not yet distributed, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockDividendDeclaredNotYetDistributedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TreasuryStockPaidForGloperbaEx-USLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock paid for Gloperba Ex-U.S. License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TreasuryStockPaidForGloperbaEx-USLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock transferred to Oramed for the Oramed Note maturity extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value Issued Under Placement Agent Warrants Issued In Connection With Registered Direct Offering And Representative Warrants Issued In Connection With Bought Deal Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>value issued under Standby Equity Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="num">$ (24,377)<span></span>
</td>
<td class="num">$ (72,807)<span></span>
</td>
<td class="num">$ (114,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash proceeds from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">4,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashOperatingLeaseCost', window );">Non-cash operating lease cost</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">3,558<span></span>
</td>
<td class="nump">15,689<span></span>
</td>
<td class="nump">14,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Issuance of shares under Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="num">(10,409)<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="num">(17,378)<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue', window );">Financing costs and allocated expense for financial instruments at fair value</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">In-process research and development expense</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Allocated expense for financial instruments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">6,114<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
<td class="nump">4,782<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AllowancesForCreditLosses', window );">Allowances for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="nump">15,823<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
<td class="num">(6,267)<span></span>
</td>
<td class="num">(13,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(584)<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(479)<span></span>
</td>
<td class="num">(441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">7,419<span></span>
</td>
<td class="nump">19,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedPayroll', window );">Accrued Payroll</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="num">(8,167)<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees', window );">Accrued rebates and fees</a></td>
<td class="nump">5,912<span></span>
</td>
<td class="nump">14,430<span></span>
</td>
<td class="nump">72,859<span></span>
</td>
<td class="nump">58,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLeaseLiability1', window );">Operating lease liability</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash proceeds from operating activities</a></td>
<td class="nump">6,007<span></span>
</td>
<td class="nump">9,391<span></span>
</td>
<td class="nump">19,349<span></span>
</td>
<td class="num">(20,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition', window );">Acquisition consideration paid in cash for Romeg intangible asset acquisition</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Cash paid for in-process research and development, net</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfEquitySecurities', window );">Purchase of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfConvertiblePromissoryNote', window );">Purchase of convertible promissory note from Denali</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(395)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(2,675)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement', window );">Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">2,671<span></span>
</td>
<td class="nump">35,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromIssuanceOfRevolvingFacility', window );">Proceeds from issuance of Revolving Facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,567<span></span>
</td>
<td class="nump">95,438<span></span>
</td>
<td class="nump">86,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromIssuanceOfFsfDeposit', window );">Proceeds from issuance of FSF Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of Tranche B Notes and purchased revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfRevolvingFacility', window );">Repayment of Revolving Facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,313)<span></span>
</td>
<td class="num">(112,791)<span></span>
</td>
<td class="num">(69,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of Oramed Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(64,200)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash consideration paid in connection with warrant repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction', window );">Transaction costs paid related to the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of Convertible Debentures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,375)<span></span>
</td>
<td class="num">(4,375)<span></span>
</td>
<td class="num">(15,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfDebt', window );">Repayment of Tranche B Notes principal and interest</a></td>
<td class="num">(1,596)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,283)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRefundPayments1', window );">Payments on purchased revenue liability</a></td>
<td class="num">(797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsPaidInConnectionWithShareRepurchase', window );">Transaction costs paid in connection with share repurchase</a></td>
<td class="num">(396)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of shares under direct offerings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">41,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,172)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of direct offering issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(4,370)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExciseTaxPaidInConnectionWithShareRepurchase', window );">Excise tax paid in connection with share repurchase</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger', window );">Payments of deferred transaction costs related to Semnur Business Combination</a></td>
<td class="num">(95)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,379)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DisbursementOfFunds', window );">Disbursement of funds to Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Cash consideration paid in connection with share repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used for financing activities</a></td>
<td class="num">(3,084)<span></span>
</td>
<td class="num">(11,196)<span></span>
</td>
<td class="num">(18,131)<span></span>
</td>
<td class="nump">23,582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,528<span></span>
</td>
<td class="num">(1,955)<span></span>
</td>
<td class="num">(1,457)<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperatingPaidInCash', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses', window );">Issuance costs related to direct offerings included in accrued expenses and account payables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter', window );">Fee Warrants issued and exercised in connection with the Commitment Letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SettlementOfFSFDeposit', window );">Settlement of FSF Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable', window );">Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfOramedNoteIntoTrancheBNotes', window );">Conversion of Oramed Note into Tranche B Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfTrancheBNotesIntoCommonStock', window );">Conversion of Tranche B Notes into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtIssuanceCostsIncludedInAccruedExpenses', window );">Debt issuance costs included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants', window );">Placement Agent Shares and October 2024 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,792<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering', window );">StockBlock Warrants issued in connection with the December 2024 RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock', window );">Conversion of Convertible Debentures into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification', window );">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OramedNoteIssuanceAtFairValue', window );">Oramed Note issuance at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase', window );">Other non-cash consideration in connection with share repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses', window );">Excise tax in connection with share repurchase included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AllowancesForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowances for Credit Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AllowancesForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Debt And Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfOramedNoteIntoTrancheBNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Oramed Note into Tranche B Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfOramedNoteIntoTrancheBNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfTrancheBNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Tranche B Notes into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfTrancheBNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtIssuanceCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs Included in Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtIssuanceCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Transaction Costs Related to Semnur Merger Included in Accrued Expenses And Account Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DisbursementOfFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursement Of Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DisbursementOfFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excise tax in connection with share repurchase included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExciseTaxPaidInConnectionWithShareRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excise Tax Paid In Connection With Share Repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExciseTaxPaidInConnectionWithShareRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee Warrants Issued and Exercised in Connection with the FSF Commitment Letter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Costs and Allocated Expense for Financial Instruments at Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accrued payroll</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Rebates and Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedRebatesAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs related to Bought Deal Offering included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLeaseLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLeaseLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OramedNoteIssuanceAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oramed Note issuance at fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OramedNoteIssuanceAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other long-term liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-cash consideration in connection with share repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of Deferred Transaction Costs Related to Semnur Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement Agent Shares and October Placement Agent Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromIssuanceOfFsfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of FSF Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromIssuanceOfFsfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromIssuanceOfRevolvingFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Revolving Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromIssuanceOfRevolvingFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of convertible promissory note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of equity securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfRevolvingFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Revolving Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfRevolvingFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SettlementOfFSFDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of FSF Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SettlementOfFSFDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockBlock Warrants issued in connection with December Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsPaidInConnectionWithShareRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs paid in connection with share repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsPaidInConnectionWithShareRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs paid related to the recapitalization transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRefundPayments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to customers for refund payments of revenue that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRefundPayments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperatingPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income from investment paid in cash, classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperatingPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. Nature of Operations and Basis of Presentation </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC (&#8220;SCLX JV&#8221;). The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12-hour</div> administration period. In June 2022, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. In January 2025, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the rights to commercialize GLOPERBA outside the U.S. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;) in the third quarter of 2023, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. The Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and the commercialization of ZTlido, ELYXYB and GLOPERBA. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, include all adjustments of a normal recurring nature necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2024 as filed with the SEC on March&#160;31, 2025 (the &#8220;Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K&#8221;).</div> The interim </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025 or for any future <div style="letter-spacing: 0px; top: 0px;display:inline;">periods.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">1-for-35</div></div> (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-Reverse</div> Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.&#160;Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single, reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the unaudited condensed consolidated statements of operations. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the unaudited condensed consolidated statements of operations and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the unaudited condensed consolidated balance sheets. Accordingly, the unaudited condensed consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the three months ended March&#160;31, 2025 and 2024, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 99% and 85% of the Company&#8217;s revenue for the three months ended March&#160;31, 2025 and 2024, respectively, and individually ranging from 14% to 47% and 24% to 31%, respectively. As of March&#160;31, 2025 and 2024, these customers represented 89% and 94% of the Company&#8217;s outstanding accounts receivable, individually ranging </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">between 18% and 37%, and 25% and 36% for respective periods. Additionally, during the three months ended March&#160;31, 2025 and 2024, the Company purchased ZTlido, ELYXYB and GLOPERBA inventories from its sole suppliers, Itochu, Contract Pharmaceuticals Ltd. Canada (&#8220;CPL&#8221;) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the three months ended March&#160;31, 2025 and <div style="display:inline;">2024.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2025, as compared to the significant accounting policies described in Note 1 of the Notes to Consolidated Financial Statements in the Company&#8217;s audited consolidated financial statements included in the Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the condensed consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 1 - </div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 2 - </div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 3 - </div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Cash equivalents were immaterial as of March&#160;31, 2025 and December&#160;31, 2024. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as selling, general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company reviews reserves and makes adjustments based on historical experience, current economic conditions and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for credit losses on accounts receivable were $1.1&#160;million and $1.2&#160;million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for prompt payment discounts were $0.4&#160;million and $0.6&#160;million,<div style="display:inline;"> respectively.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note and Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Tranche B Notes (as defined in Note 2 &#8220;<div style="font-style:italic;display:inline;">Liquidity and Going Concern</div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style:italic;display:inline;">Fair Value Measurements</div>&#8221; below) that were issued in October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of&#160;changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. As of March&#160;31, 2025 and December&#160;31, 2024, the weighted-average interest rates for the short-term loans, including these financial instruments, were 8.35% and 6.67%, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Treasury Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space:nowrap;display:inline;">2024-03,</div> <div style="font-style:italic;display:inline;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</div>, which will require additional expense disclosures for all public entities. The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space:nowrap;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space:nowrap;display:inline;">2024-04,</div> <div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options</div>, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space:nowrap;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space:nowrap;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">1. Nature of Operations and Basis of Presentation </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12-hour</div> administration period. In June 2022, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#8220;LBP&#8221;) in the third quarter of 2023, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. Since inception, the Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and the commercialization of ZTlido. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Chapter 11 Filing </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, and Sorrento&#8217;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#8220;Scintilla&#8221; and together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Debtors&#8217; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">23-90085</div> (DRJ) (the &#8220;Chapter 11 Cases&#8221;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. Pursuant to that certain Stock Purchase Agreement that the Company entered into with Sorrento on September&#160;21, 2023 (the &#8220;Sorrento SPA&#8221;), the Company repurchased shares of its Common Stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and Series A Preferred Stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221;), from Sorrento. As a result, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. As of December&#160;31, 2024, the Company had a $3.2&#160;million receivable from Sorrento, which was fully reserved. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the consolidated statements of operations and comprehensive loss. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the consolidated statements of operations and comprehensive loss and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the consolidated balance sheets. Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the years ended December&#160;31, 2024 and 2023, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 86% and 85% of the Company&#8217;s revenue for the years ended December&#160;31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December&#160;31, 2024 and 2023, three customers represented 95% and 91% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December&#160;31, 2024 and 2023, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). In November 2023 and February 2024, respectively, the Company started purchasing ELYXYB and GLOPERBA inventories from its sole suppliers, Contract Pharmaceuticals Ltd Canada (CPL) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers and limits its credit exposure by setting credit limits. During the years ended December&#160;31, 2024 and 2023, the Company had allowances for expected credit losses of $1.2&#160;million and nil, respectively. </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, FSF Deposit and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 1</div></div> - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 2</div></div> - Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 3</div></div> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consisted of deposits placed in a segregated bank account as required under the terms of the eCapital Credit Agreement (as defined below), which is discussed further in Note 7. Restricted cash was recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. There is no restricted cash as of December&#160;31, 2024, because Scilex Pharma paid off the outstanding amount of all obligations and indebtedness under the eCapital Credit Agreement in October 2024, which agreement was terminated thereafter. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents were immaterial as of December&#160;31, 2024 and 2023. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of December&#160;31, 2024, the Company recorded $1.2&#160;million of allowances for credit losses on its accounts receivable. As of December&#160;31, 2023, the Company did not deem any allowances for expected credit losses on its accounts receivable necessary. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2024 and 2023, the Company&#8217;s inventory was primarily comprised of finished goods. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations and comprehensive loss unless there is an alternative future use. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statements of operations and comprehensive loss. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging</div></div>, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contracts on an Entity&#8217;s Own Equity,</div></div> the Company determines how to account for warrants either assumed in connection with the Business Combination or issued under various financing arrangements. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. The Company records them in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. Warrants accounted for as liabilities are recorded at their estimated fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized in the consolidated statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Debentures, the Oramed Note, FSF Deposit and Tranche B Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures, the FSF Deposit, the Tranche B Notes (each as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below) that were issued in March and April 2023, June 2024, October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. The weighted-average interest rates for the short-term loans, including these financial instruments, were 6.67% and 13.55% for the years ended December&#160;31, 2024 and 2023, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Purchased Revenue Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchased revenue liability is associated with the Purchase and Sale Agreement (the &#8220;ZTlido Royalty Purchase Agreement&#8221;) that the Company entered into in October 2024 (Note 7). The Company elected the fair value option to account for the purchased revenue liability (as described in Note 4 &#8220;Fair Value Measurements&#8221; below). The Company recorded the ZTlido Royalty Purchase Agreement at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the purchased revenue liability were expensed as incurred. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Research and Development</div></div>. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;display: inline;"></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2024 and 2023, the Company maintained a full valuation allowance against its deferred tax assets. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido, ELYXYB and GLOPERBA. The Company&#8217;s performance obligation with respect to sales of ZTlido, ELYXYB and GLOPERBA is satisfied at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">point-in-time,</div></div> when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2024 and 2023 were not material. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns, special marketing programs and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Payment</div> Assistance </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-payment</div> assistance is presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, <div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#160;&#8211; Stock<div style="display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation</div></div><div style="font-size: 10pt;display:inline;">, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee&#8217;s</div><div style="font-size: 10pt;display:inline;"> vesting period. The Company accounts for forfeitures as incurred.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method required for participating securities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants, which consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share to the extent all vesting conditions or exercise contingencies are removed except for the passage of time. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Improvements to Reportable Segment Disclosures</div></div> (Topic 280), which requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted this ASU retrospectively on December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div>, which will require additional expense disclosures for all public entities. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8212;Debt with Conversion and Other Options</div></div>, which clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Liquidity and Going Concern </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying unaudited condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#8217;s and B.&#160;Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued 7,142 commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B.&#160;Riley (the &#8220;B. Riley Commitment Shares&#8221;). On, and effective as of, February&#160;16, 2024, the Company and B.&#160;Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of $25.0&#160;million (the &#8220;Convertible Debentures&#8221;)&#160;for net cash proceeds of $24.0&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender made available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $30.0&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B.&#160;Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;ATM Offering&#8221;) shares of Common Stock up to $170.0&#160;million (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the ATM Offering. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. During the three months ended March&#160;31, 2025, no sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold 2,637&#160;shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $0.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#8220;Commitment Letter&#8221;) with FSF 33433 LLC (&#8220;FSF Lender&#8221;), pursuant to which FSF Lender committed to provide the Company a loan (the &#8220;FSF Loan&#8221;) in the aggregate amount of $100.0&#160;million (the &#8220;Commitment Amount&#8221;). The Commitment Amount shall be payable as follows: (i) $85.0&#160;million no later than the date that is 70 days following the date on which the Company receives the FSF Deposit (as defined below) (the &#8220;Outside Date&#8221; and the funding of the initial $85.0&#160;million, the &#8220;Initial Closing&#8221;) and (ii)&#160;the remaining $15.0&#160;million within 60 days following the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial Closing (the funding of the second $15.0&#160;million, the &#8220;Second Closing&#8221;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a <div style="white-space:nowrap;display:inline;">non-refundable</div> deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million (the &#8220;FSF Deposit&#8221; and the date on which such funds are fully received, the &#8220;Deposit Date&#8221;), which amount was creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of 3,250,000 shares of the Common Stock (subject to adjustment for any stock dividend, stock split or similar transaction, provided that there shall not be any adjustment to the exercise price of the warrant in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares) (the &#8220;Deposit Warrant&#8221;), with an exercise price of $1.20 per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#8220;Satisfaction Agreement&#8221;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#8220;Endeavor&#8221;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#8220;Additional Product&#8221;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor would not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company was to fail to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#8220;Tranche B Securities Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;, and together with the Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $50.0&#160;million (the &#8220;Tranche B Notes&#8221;), which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $36.40 per share. In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $22,500,000. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the Company&#8217;s negative working capital was $247.0&#160;million, including cash and cash equivalents of approximately $5.8&#160;million. During the three months ended March&#160;31, 2025, the Company had operating losses of $27.9&#160;million and cash flows received from operating activities of $6.0&#160;million. The Company had an accumulated deficit of $589.1&#160;million as of March&#160;31, 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the FSF Deposit or otherwise) for at least twelve months from the issuance of these unaudited condensed consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA and ELYXYB are still in the early stages of commercialization.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are<div style="letter-spacing: 0px; top: 0px;display:inline;"> issued.</div> </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">2. Liquidity and Going Concern </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#8217;s and B. Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued 7,142 commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B. Riley (the &#8220;B. Riley Commitment Shares&#8221;). On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of up to $25.0&#160;million (the &#8220;Convertible Debentures&#8221;) for net cash proceeds of $24.0&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender made available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $30.0&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">ATM Offering</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#8221;) shares of Common Stock up to $</div>170.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the </div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">ATM Offering</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. As of December&#160;31, 2024, the Company sold </div>78,975<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $</div>2.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. As of December&#160;31, 2023, </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> sales of Common Stock had been made under the ATM Sales Agreement.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#8220;Commitment Letter&#8221;) with FSF 33433 LLC (&#8220;FSF Lender&#8221;), pursuant to which FSF Lender committed to provide the Company a loan (the &#8220;FSF Loan&#8221;) in the aggregate amount of $100.0&#160;million (the &#8220;Commitment Amount&#8221;). The Commitment Amount shall be payable as follows: (i) $85.0&#160;million no later than the date that is 70 days following the date on which the Company receives the FSF Deposit (as defined below) (the &#8220;Outside Date&#8221; and the funding of the initial $85.0&#160;million, the &#8220;Initial Closing&#8221;) and (ii)&#160;the remaining $15.0&#160;million within 60 days following the Initial Closing (the funding of the second $15.0&#160;million, the &#8220;Second Closing&#8221;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million (the &#8220;FSF Deposit&#8221; and the date on which such funds are fully received, the &#8220;Deposit Date&#8221;), which amount will be creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of 3,250,000 shares of the Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) (the &#8220;Deposit Warrant&#8221;), with an exercise price of $1.20 per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#8220;Satisfaction Agreement&#8221;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#8220;Endeavor&#8221;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#8220;Additional Product&#8221;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#8220;Tranche B Securities Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Tranche B Investors&#8221;) and Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) (together with the Tranche B Investors, the &#8220;Tranche B Noteholders&#8221;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $50.0&#160;million (the &#8220;Tranche B Notes&#8221;) which notes will mature on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $38.15 per share (which was </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes). The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $22,500,000, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $22,500,000. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company&#8217;s negative working capital was $218.1&#160;million, including cash and cash equivalents of approximately $3.3&#160;million. During the year ended December&#160;31, 2024, the Company had operating losses of $83.4&#160;million and cash flows from operations of $19.3&#160;million. The Company had an accumulated deficit of $563.1&#160;million as of December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the Tranche B Notes or otherwise) for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA is still in the early stages of commercialization. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and License Agreements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Acquisitions and License Agreements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space:nowrap;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of each of March 31, 2025 and December&#160;31, 2024, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022, the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;) for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensing</div> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#8220;Romeg License Agreement&#8221;). Under the Romeg License Agreement, among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> specified therein, to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; and (2)&#160;an exclusive license, with a right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory and (b)&#160;use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> license fee of $2.0&#160;million, (2)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (3)&#160;certain royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Royalty Term, with a quarterly minimum royalty of $150,000, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-single</div> digit </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory during the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory Royalty Term and (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> payment of $700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267 shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. For each of the three months ended March&#160;31, 2025 and 2024, the Company made royalty payments in the amount of $0.2&#160;million. No contingent consideration was recognized as a liability or included in the fair value of the assets as of March&#160;31, 2025 or December&#160;31, 2024.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ELYXYB Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and patents of DRL related to ELYXYB that is necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company had ending balances of accrued royalty payables of $0.1&#160;million. During the three months ended March&#160;31, 2025, the Company made royalty payments in the amount of $0.1&#160;million. The Company did not make any royalty payments during the three months ended March&#160;31, 2024. As of March&#160;31, 2025, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Rest of World License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025 (the &#8220;Lido Effective Date&#8221;), Scilex Pharma entered into a License Agreement (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Agreement</div></div>&#8221;) with RoyaltyVest Ltd. (the &#8220;Licensee&#8221;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, among Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">69557-111-30</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;SP-103</div> (collectively, the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Product</div></div>&#8221;). The Lido License Agreement supersedes and replaces that certain Rest of World License Term Sheet the parties entered into on October&#160;8, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Products outside of the United States and certain territories stated in the Lido License Agreement (the &#8220;<div style="font-style:italic;display:inline;">Lido Licensee Territory</div>&#8221;). The Licensee granted to Scilex Pharma a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable,</div> right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field. Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for <div style="white-space:nowrap;display:inline;">SP-103</div> and all existing Lido Products in each country or jurisdiction in the Licensor Territory. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Lido License Term&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Gloperba Rest of World License Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Gloperba Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Gloperba License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#8220;Gloperba Product&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit the Gloperba Product for commercialization of the Gloperba Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture the Gloperba Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#8217;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Gloperba Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#8217;s contract manufacturer of the Gloperba Product (the &#8220;Gloperba CMO&#8221;) as of the Gloperba Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Gloperba License Agreement commences on the Gloperba Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Gloperba License Term&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Elyxyb Rest of World License Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Elyxyb Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Elyxyb License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Elyxyb that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Elyxyb APA, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#8220;Elyxyb Product&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Elyxyb License Agreement, the Company granted to the Licensee during the Elyxyb License Term (as defined below) a worldwide, exclusive, <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Elyxyb License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Elyxyb Products, in all cases solely for commercialization of the Elyxyb Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space:nowrap;display:inline;">non-exclusive,</div> <div style="white-space:nowrap;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Elyxyb License Agreement), right and license under the Licensee <div style="white-space:nowrap;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Elyxyb Product for commercialization of Elyxyb Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture Elyxyb Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive 50% of the Canadian Net Revenue (as defined therein) generated based on the Licensee&#8217;s sale of the Elyxyb Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Canadian Net Revenue on a quarterly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Elyxyb License Agreement, the Licensee shall obtain and maintain regulatory approval for the Elyxyb Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Elyxyb Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and CPL as of the Elyxyb Effective Date, and (ii)&#160;use reasonable efforts to cause CPL to accept a direct engagement with the Licensee for the manufacturing or supply of the Elyxyb Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Elyxyb Product in the entire world other than the United States during the Elyxyb License Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Elyxyb License Agreement commences on the Elyxyb Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Elyxyb License Term&#8221;). </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">3. Acquisitions and License Agreements </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Acquisition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2024 and December&#160;31, 2023, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA License Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022 (the &#8220;Original Signing Date&#8221;), the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) (&#8220;Romeg&#8221;) for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensing</div> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#8220;Romeg License Agreement&#8221;). Under the Romeg License Agreement, </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> specified therein to (a)&#160;commercialize a pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg U.S. Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2)&#160;an exclusive license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof (collectively, the &#8220;Licensed Trademark&#8221;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#8220;Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory&#8221;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory and (b)&#160;to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> license fee of $2.0&#160;million, (2)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (3)&#160;certain royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $150,000, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-single</div> digit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory during the Romeg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Ex-U.S.</div> Territory Royalty Term and (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> payment of $700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267&#160;shares of our Common Stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $0.6&#160;million and $0.3&#160;million, respectively. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2024 or December&#160;31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ELYXYB Acquisition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $0.1&#160;million and $5.0&#160;thousand, respectively, which was recorded as accrued expenses under current liabilities on </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the consolidated balance sheets. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $0.3&#160;million and $26.0&#160;thousand, respectively. As of December&#160;31, 2024, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Fair Value Measurements </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657740;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657741;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of March&#160;31, 2025 and December&#160;31, 2024 was determined to be $15.0&#160;million and $12.2&#160;million, respectively, by applying a discount rate of 129.07% and 128.82%, respectively. For the three months ended March&#160;31, 2025 and 2024, the Company recorded a loss of $2.8&#160;million and $3.8&#160;million in change in fair value of the Oramed Note in the unaudited condensed consolidated statements of operations, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranche B Notes are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $24.5&#160;million and $23.6&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $2.5&#160;million in change in fair value of the Tranche B Notes in the unaudited condensed consolidated statement of operations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Purchased Revenue Liability </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2024, the Company entered into a Purchase and Sale Agreement (&#8220;ZTlido Royalty Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;ZTlido Royalty Investors&#8221;) and Oramed (see Note 7). In February 2025, the Company also entered into a Purchase and Sale Agreement (&#8220;Gloperba-Elyxyb Royalty Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability for both agreements with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The aggregate fair value of both agreements as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $7.3&#160;million and $6.8&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $0.8&#160;million in change in fair value of the purchased revenue liability in the unaudited condensed consolidated statement of operations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of $10.4&#160;million for the three months ended March&#160;31, 2025, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, Deposit Warrant, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each as defined below). The Company recorded a loss of $0.5&#160;million for the three months ended March&#160;31, 2024, attributed to warrant liability consisting of the Private Warrants and the February 2024 BDO Firm Warrants. The Company assumed the private placement warrants from Vickers in November 2022 in connection with the Business Combination (the &#8220;Private Warrants&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000&#160;Private Warrants, which are currently exercisable for an aggregate of up to 28,572&#160;shares of Common Stock, 3,803,447&#160;February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686&#160;shares of Common Stock, 15,000,000 April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, 3,250,000 Deposit Warrant, which are currently exercisable for an aggregate of up to 3,250,000 shares of Common Stock, 7,500,000&#160;October 2024 Noteholder Warrants, which are currently exercisable for an aggregate of up to 214,284&#160;shares of Common Stock, and 57,512,958&#160;December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock. As of March&#160;31, 2025, the fair value of derivative warrant liabilities related to these warrants was $7.9&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(10,409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be a Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#8217;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (as defined below), described in Note 9 of the Notes to Consolidated Financial Statements in the Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of March&#160;31, 2025 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">402.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">83.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">79.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">98.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.91</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">402.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">81.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">73.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">77.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">95.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.33</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Contingent Consideration Related to <div style="white-space:nowrap;display:inline;">SP-104</div> Acquisition </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space:nowrap;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space:nowrap;display:inline;">SP-104,</div> the Company will transfer $3.0&#160;million in cash or shares of Common Stock to Aardvark, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space:nowrap;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space:nowrap;display:inline;">SP-104,</div> and a discount rate of 9.6%. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">4. Fair Value Measurements </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased Revenue Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657738;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Unobservable<br/>Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657739;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The Oramed Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of such note recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2024 and 2023 was determined to be $12.2&#160;million and $104.1&#160;million, respectively, by applying a discount rate of 128.82% and 13.05%, respectively. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $3.6&#160;million and $2.8&#160;million in change in fair value of the Oramed Note, respectively. For the years ended December&#160;31, 2024 and 2023, the change in fair value due to instrument-specific credit risk recorded as a component of other comprehensive income was $6.3&#160;million and nil, respectively. During the year ended December&#160;31, 2024 the Company reclassified $5.0&#160;million from accumulated other comprehensive income to the consolidated statement of operations. This reclassification was related to the principal payments and partial conversion of the Oramed Note balance into the Tranche B Notes (see Note 7). </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">FSF Deposit </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In June 2024, the Company received the FSF Deposit in the aggregate principal amount of $10.0&#160;million from FSF Lender (see Note 2 and Note 7). The Company elected the fair value option to account for the FSF Deposit with any changes in the fair value of the deposit recorded in the consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recorded a loss of $4.7&#160;million in change in fair value of the FSF Deposit in the consolidated statement of operations. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. Upon the satisfaction of the FSF Deposit, the Deposit Warrant became a freestanding instrument under ASC 480 and was included in derivative liabilities on the Company&#8217;s consolidated balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Tranche B Notes are measured at fair value on a recurring basis using the Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of December&#160;31, 2024, was determined to be $23.6&#160;million. For the year ended December&#160;31, 2024, the Company recorded a gain of $6.6&#160;million in change in fair value of the Tranche B Notes in the consolidated statement of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Purchased Revenue Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In October 2024, the Company entered into the ZTlido Royalty Purchase Agreement with certain institutional investors (collectively, the &#8220;ZTlido Royalty Investors&#8221;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The fair value as of December&#160;31, 2024, was determined to be $6.8&#160;million. For the year ended December&#160;31, 2024, the Company recorded a loss of $0.9&#160;million in change in fair value of the purchased revenue liability in the consolidated statement of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Debentures </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $25.0&#160;million (see Note 7). The Convertible Debentures were measured at fair value on a recurring basis using Level&#160;3 inputs. The Company used the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations and comprehensive loss. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $35.0&#160;thousand and a loss of $4.4&#160;million in change in fair value of the Convertible Debentures, respectively. The Company fully repaid the Convertible Debentures in March 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company recorded a gain of $17.4&#160;million for the year ended December&#160;31, 2024, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">as defined below). The Company recorded a loss of $</div>0.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million for the year ended December&#160;31, 2023, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination (&#8220;Private Warrants&#8221;)</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">As </div>of December&#160;31, 2024, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000 Private Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>3,803,447 February 2024 BDO Firm Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>15,000,000&#160;April 2024 RDO Common Warrants,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, </div></div> 3,250,000 Deposit Warrant,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to </div></div> 3,250,000&#160;<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">shares of Common Stock, 7,500,000 </div></div>October 2024 Noteholder Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 214,284 shares of Common Stock,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>and 57,512,958&#160;December 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock</div></div>. As of December&#160;31, 2024, the fair value of derivative warrant liabilities related to these warrants was $18.3&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table includes a summary of the derivative liabilities measured at fair value during the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 89%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellation of Private Warrants as part of Oramed Letter Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant amendment and exercise as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(984</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(17,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#8217;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </div></div></div><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">February<br/>2024&#160;BDO<br/>Firm<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">April&#160;2024<br/>RDO<br/>Common<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Deposit<br/>Warrant</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">October<br/>2024<br/>Noteholder<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(2.5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 44%;"></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">402.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">59.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">38.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">1.20</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">36.40</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">22.72</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">22.72</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">2.86</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.18</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.32</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.47</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.77</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.95</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">2.45</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">109.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">81.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">80.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">73.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">77.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">76.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">95.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.22</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.29</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.30</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.30</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.32</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.33</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.21</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 19%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:19%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">402.50</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">3.86</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">76.0</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">3.90</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contingent Consideration Related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Acquisition </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> the Company will transfer $3.0&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-104,</div> and a discount rate of 10.0%. As of December&#160;31, 2024 and 2023, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&#160;31, 2024 and 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. Balance Sheet Components </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Investments </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Convertible Promissory Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#8220;Denali&#8221;) issued a convertible promissory note (the &#8220;Convertible Promissory Note&#8221;) in the total principal amount of up to $180,000 to the Company. The Convertible Promissory Note was issued with an initial principal balance of $<div style="display:inline;">15,063.74</div>, with the remaining $164,936.26 drawable at Denali&#8217;s request and upon the consent of the Company prior to the maturity of the </div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#8217;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $164,936.26 principal amount available under the Convertible Promissory Note are expected to fund future <div style="white-space:nowrap;display:inline;">one-month</div> extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $10.00 per ordinary share (the &#8220;Conversion Shares&#8221;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), in connection with Denali&#8217;s initial public offering (the &#8220;IPO&#8221;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. No interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of March&#160;31, 2025 and December&#160;31, 2024, the balance of the Convertible Promissory Note was $120.5&#160;thousand and $75.3&#160;thousand, respectively, as a result of additional draws after the initial amount. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (as may be amended or restated from time to time in accordance with its terms, including by Amendment No.&#160;1 and Amendment No.&#160;2 thereto, dated as of April&#160;16, 2025 (&#8220;Amendment No.1&#8221;) and July&#160;22, 2025, respectively, the &#8220;Semnur Business Combination Agreement&#8221;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#8220;Denali Merger Sub&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Semnur Business Combination&#8221;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and <div style="white-space:nowrap;display:inline;">de-register</div> in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Domestication&#8221;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#8220;New Semnur Common Shares&#8221;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares&#8221;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#8220;New Semnur Warrants&#8221;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#8220;Effective Time&#8221;): (i) each share of common stock, par value $0.00001 per share, of Semnur (the &#8220;Semnur Common Stock&#8221;), issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and <div style="white-space:nowrap;display:inline;">(b)&#160;one-tenth</div> of one New Semnur Common Share, and (iii)&#160;subject to Denali&#8217;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. Pursuant to Amendment No.&#160;1, among other things, the parties agreed to (i)&#160;modify certain covenants of the parties to address the potential delisting of the Denali ordinary shares and warrants from the Nasdaq Capital </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market, (ii)&#160;extend the Outside Date (as defined in Amendment No.&#160;1) to September&#160;30, 2025, and (iii)&#160;require Denali to amend its organizational documents to extend the period of time within which Denali can complete a business combination to December&#160;11, 2025, or such other date that is mutually agreed to by Semnur and Denali. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business Combination, these costs will be classified in stockholders&#8217; deficit as a reduction of additional <div style="white-space:nowrap;display:inline;">paid-in</div> capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations. As of March&#160;31, 2025 and December&#160;31, 2024, deferred offering costs related to the Semnur Business Combination totaled $6.8&#160;million and $6.0&#160;million, respectively, and were included in prepaid expenses and other current assets in the Company&#8217;s unaudited condensed consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution and delivery of the Semnur Business Combination Agreement, the Sponsor and the Company entered into a Sponsor Interest Purchase Agreement (the &#8220;SIPA&#8221;) dated August&#160;30, 2024 (the &#8220;Signing Date&#8221;). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class&#160;B ordinary shares, par value $0.0001 per share, of Denali (the &#8220;Purchased Interests&#8221;) that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000 (the &#8220;Cash Consideration&#8221;) and (ii) 8,571 shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#8217;s own stock and meets the conditions to be classified in equity under FASB ASC 815, <div style="font-style:italic;display:inline;">Derivatives and Hedging</div>. The Purchased Interests will convert automatically, on a <div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">one-for-one</div></div> basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price, which consists of the $2,000,000 paid by the Company to the Sponsor and the value of the 8,571 shares of the Common Stock at the closing price of $40 per share on the Signing Date for a total of $2.3&#160;million. The Company elected to subsequently measure the investment at cost less any impairment. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company&#8217;s investment in the Purchased Interests had a balance of $2.3&#160;million. No impairment loss was recognized during the three months ended March&#160;31, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Property and equipment, net </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $1.0&#160;thousand and $4.0&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">5. Balance Sheet Components </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Investments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Promissory Note </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#8220;Denali&#8221;) issued a convertible promissory note (the &#8220;Convertible Promissory Note&#8221;) in the total principal amount of up to $180,000 to the Company. The Convertible Promissory Note was issued with an initial principal balance of $15,063.74, with the remaining<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$</div>164,936.26<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> drawable at Denali&#8217;s request and upon the consent of the Company prior to the maturity of the Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#8217;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $164,936.26 principal amount available under the Convertible Promissory Note are expected to fund future </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-month</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $</div>10.00<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> per ordinary share (the &#8220;Conversion Shares&#8221;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC in connection with Denali&#8217;s initial public offering (the &#8220;IPO&#8221;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of December&#160;31, 2024, the balance of the Convertible Promissory Note was $</div>75.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;thousand as a result of additional draws after the initial amount.</div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (the &#8220;Semnur Business Combination Agreement&#8221;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#8220;Denali Merger Sub&#8221;).</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#8220;Semnur Business Combination&#8221;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-register</div> in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#8220;Domestication&#8221;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#8220;Semnur Pharmaceuticals, Inc.&#8221; (&#8220;New Semnur&#8221;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#8220;New Semnur Common Shares&#8221;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#8220;New Semnur Preferred Shares&#8221;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#8220;New Semnur Warrants&#8221;. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#8220;Effective Time&#8221;): (i) each share of common stock, par value $0.00001 per share (the &#8220;Semnur Common Stock&#8221;), of Semnur, issued and outstanding immediately prior to the Effective Time, will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;one-tenth</div> of one New Semnur Common Share, and (iii)&#160;subject to Denali&#8217;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business<div style="display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Combination, these costs will be classified in stockholders&#8217; deficit as a reduction of additional </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024 and 2023, deferred offering costs related to the Semnur Business Combination totaled $</div>6.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million and </div>nil<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">, respectively, and were included in prepaid expenses and other current assets in the Company&#8217;s consolidated balance sheet.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution and delivery of the Semnur Business Combination Agreement, Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), and the Company entered into a Sponsor Interest Purchase Agreement (the &#8220;SIPA&#8221;) dated August&#160;30, 2024 (the &#8220;Signing Date&#8221;). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class&#160;B ordinary shares, par value $0.0001 per share (the &#8220;Purchased Interests&#8221;), of Denali that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000 (the &#8220;Cash Consideration&#8221;) and (ii) 8,571 shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#8217;s own stock and meets the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div>. The Purchased Interests will convert automatically, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-for-one</div></div> basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price which consists of the $2,000,000 paid by the Company to the Sponsor and the value of the 8,571 shares of the Common Stock at the closing price of $40.25 per share on the Signing Date for a total of $2.3&#160;million. <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company </div></div> elected to subsequently measure the investment at cost less any impairment. As of December&#160;31, 2024, the Company&#8217;s investment in the Purchased Interests had a balance of $2.3&#160;million. No impairment loss was recognized during the year ended December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $14.0&#160;thousand and $40.0&#160;thousand for the years ended December&#160;31, 2024 and 2023, <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">respectively. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div></div></div> <div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,601</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued litigation expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Goodwill and Intangible Assets </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, with remaining useful lives ranging from 6.58 to 12.75 years. A summary of the Company&#8217;s identifiable intangible assets as of March&#160;31, 2025 and December&#160;31, 2024 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">31,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, the weighted average remaining life for identifiable intangible assets was 8.3 years. Aggregate amortization expense was $1.0&#160;million for each of the three months ended March&#160;31, 2025 and 2024. Patent rights, acquired technology and acquired licenses are amortized over a <div style="white-space:nowrap;display:inline;">15-year</div> period. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of March&#160;31, 2025 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">31,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">6. Goodwill and Intangible Assets </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the years ended December&#160;31, 2024 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, ranging from 6.8 to 13.0 years. A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2024 and 2023 is as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Intangibles,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">As of December&#160;31, 2024, the weighted average remaining life for identifiable intangible assets was 8.5 years. Aggregate amortization expense was $4.0&#160;million and $4.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Patent rights, acquired technology and acquired licenses are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">15-year</div> period. Assembled workforce is amortized over a five-year period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Estimated future amortization expense related to intangible assets as of December&#160;31, 2024 is as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">7. Debt </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable <div style="white-space:nowrap;display:inline;">in-kind</div> on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space:nowrap;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the ATM Sales Agreement, the Company made a mandatory prepayment of $9,578,835, $7,000,000 and $1,760,796, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from each of the April 2024 RDO, the FSF Deposit and the sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025, the fair value of the Oramed Note was $15.0&#160;million, which is classified as a current liability in the unaudited condensed consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Company and Oramed entered into a Letter Agreement (the &#8220;Oramed Letter Agreement&#8221;), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the &#8220;Specified September Payment&#8221;) on September&#160;23, 2024, which payment was applied as follows: (i) $1,700,000 was applied to the amortization payment due under the Oramed Note on the March 21, 2025 (the &#8220;Maturity Date&#8221;) and (y) $300,000 to purchase an aggregate of 4,000,000&#160;SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock) owned by Oramed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined in the Oramed Note) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined in the Oramed Note) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $0, and (ii)&#160;to extend the due date of the $20,000,000 amortization payment from September 23, 2024 to September 30, 2024. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed under which: (i)&#160;the Company made a payment of $12,500,000 to Oramed in lieu of the payment due on September 23, 2024, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $15,000,000 payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV, with a fair value of $1.4&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the Oramed Note was $15.0&#160;million and $12.2&#160;million, respectively, which is classified as debt, current in the consolidated balance sheets. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Oramed Note - recorded in the consolidated statements of operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $36.40 per share and (ii)&#160;warrants (the &#8220;October 2024 Noteholder Warrants&#8221;) to purchase up to 214,284 shares of Common Stock directly to the Tranche B Noteholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are immediately exercisable for cash at a current exercise price equal to $36.40 per share and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#8220;StockBlock&#8221;) and its affiliate, Rodman&#160;&amp; Renshaw LLC (together, the &#8220;October 2024 Placement Agents&#8221;) or their respective designees, (i) 62,794 shares of Common Stock (the &#8220;October 2024 Placement Agent Shares&#8221;) and (ii)&#160;warrants to purchase up to 104,848 shares of Common Stock (the &#8220;October 2024 Placement Agent Warrants&#8221;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the October 2024 Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement for $5.0&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables (as defined below) in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $50.0&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $2.6&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statements of operations during the year ended December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025, the Company was required to redeem in cash (the &#8220;First Amortization Payment&#8221;) such portion of the principal amount of the Tranche B Notes equal to each </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranche B Noteholder&#8217;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $6,250,000 per fiscal quarter at a redemption price equal to 100% of such Amortization Amount (as defined in the Tranche B Notes). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#8220;Nomis Bay Consent&#8221;), (ii) Oramed (the &#8220;Oramed Consent&#8221;) and (iii) 3i, LP (the &#8220;3i Consent&#8221; and, collectively with the Nomis Bay Consent and the Oramed Consent, the &#8220;Tranche B Consents&#8221;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#8217;s obligation to make the First Amortization Payment until January&#160;31, 2025 and then further to October&#160;8, 2026. In consideration of such deferral, (i)&#160;SCLX JV delivered to the Tranche B Noteholders an aggregate of 142,855 shares of Common Stock held by SCLX JV, with a fair value of $2.2&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#8217;s unaudited condensed consolidated statements of operations, (ii)&#160;the Company paid an aggregate of $1.1&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest, and (iii)&#160;the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement (as described below). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche&#160;B Notes (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Tranche B Notes principal and interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate principal repayments for the Company&#8217;s outstanding debt will be $46.3&#160;million and $19.3&#160;million in 2025 and 2026, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">ZTlido Royalty Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the &#8220;ZTlido Purchased Receivables&#8221;) with respect to ZTlido, <div style="white-space:nowrap;display:inline;">SP-103</div> and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $5.0&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $2.5&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $2.5&#160;million minus Oramed&#8217;s expenses (the amount so paid by the ZTlido Royalty Purchasers, collectively, the &#8220;ZTlido RPA Closing Payment&#8221;). Oramed&#8217;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $2.5&#160;million of the outstanding balance under the Oramed Note. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ZTlido Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $6.8&#160;million, recorded as a purchased revenue liability on the consolidated balance sheets. The Company incurred $0.2&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(797</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Gloperba-Elyxyb Royalty Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Closing Date&#8221;), the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement with certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#8220;Gloperba-Elyxyb RPA Purchasers&#8221;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma transferred to the Gloperba-Elyxyb RPA Purchasers the right to receive 4% of all aggregate net sales worldwide (the &#8220;Gloperba-Elyxyb Purchased Receivables&#8221;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#8220;Gloperba-Elyxyb Covered Products&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the Further Deferral and representing the &#8220;grant of the Royalty and Exclusive Rights&#8221; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#8220;Gloperba-Elyxyb Payment Term&#8221;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#8217;s account, such Gloperba-Elyxyb RPA Purchaser&#8217;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter no later than 60 calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Gloperba-Elyxyb Payment Term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the Gloperba-Elyxyb Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of February&#160;28, 2025 and&#160;March&#160;31, 2025, the fair value of the ZTlido Royalty Purchase Agreement was $0.5&#160;million, recorded as a purchased revenue liability on the unaudited condensed consolidated balance sheet.</div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">7. Debt </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Debentures </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $25.0&#160;million. The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bore interest at an annual rate of 7.00% and were initially set to mature on December 21, 2023. On October&#160;11, 2023, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $70.00 per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $17.50 per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to March 15, 2024. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest, may be converted into shares of Common Stock, at a conversion price of $280.00 per share at the option of the holder of the Convertible Debentures. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="background: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Price<div style="display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the Convertible Debentures and recorded the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Pursuant to the Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $15.0&#160;million in April 2023 for $14.4&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of 18,069 shares of Common Stock at a conversion price of $280.00 per share and reducing the outstanding Convertible Debentures fair value balance by $7.7&#160;million. The Company repaid $4.4&#160;million of the Convertible Debentures during the year ended December&#160;31, 2024. Interest expense related to the Convertible Debentures and included in the changes in fair value was $35.0&#160;thousand and $0.7&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,375</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revolving Facility </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $30.0&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $250,000&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds 95% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and 85% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the eCapital Credit Agreement, interest would accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.5%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provided for an early termination fee of 0.5% of the Facility Cap if Scilex Pharma voluntarily prepaid and terminated in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#8217;s collections and eCapital Credit Agreement funding accounts, which permitted the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement would be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement was earlier terminated. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eCapital Credit Agreement contained a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $1.0&#160;million at all times. Scilex Pharma&#8217;s obligations under the eCapital Credit Agreement <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">were </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">secured by a continuing security interest in Scilex Pharma&#8217;s accounts receivable, arising from customers in the ordinary course of business. The eCapital Credit Agreement contained customary events of default and also provided that an event of default included a change of control of Scilex Pharma and the failure by the Company to issue at least $75.0&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#8220;Subordination Agreement&#8221;) with the Lender and Acquiom Agency Services LLC (the &#8220;Agent&#8221;). Pursuant to the Subordination Agreement, the </div></div><div style="font-size: 10pt;display:inline;">rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consisted of all of the Company&#8217;s properties identified in the description of collateral in the </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">UCC-1</div><div style="font-size: 10pt;display:inline;"> Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#8217;s rights and interests under the Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by the Company and each of its subsidiaries with Oramed and the Agent (the &#8220;Subsidiary Guarantee&#8221;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also included other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $</div>30.0<div style="font-size: 10pt;display:inline;">&#160;million.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement were terminated, canceled and are of no further force and effect. As of December&#160;31, 2024 and 2023, the outstanding balance under the Revolving Facility for Scilex Pharma was nil and $17.0&#160;million, respectively, which was classified as a long-term liability in the consolidated balance sheet. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The Oramed Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, matures on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-kind</div> on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the sale of shares of Common Stock pursuant to the ATM Sales Agreement, the Company made a mandatory</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;display:inline;">prepayment of $</div>9,578,835<div style="font-size: 10pt;display:inline;">, $</div>7,000,000<div style="font-size: 10pt;display:inline;"> and $</div>1,760,796<div style="font-size: 10pt;display:inline;">, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from the April 2024 RDO, the FSF Deposit and sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note.</div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Company and Oramed entered into a letter agreement (the &#8220;Oramed Letter Agreement&#8221;), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the &#8220;Specified September Payment&#8221;) on September&#160;23, 2024, which payment was applied as follows: (i) $1,700,000 was applied to the amortization payment due under the Oramed Note on March 21, 2025 (the &#8220;Maturity Date&#8221;) and (y) $300,000 to purchase an aggregate of 4,000,000 SPAC Warrants (as defined below<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock</div></div>) owned by Oramed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined therein) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined therein) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $0, and (ii)&#160;to extend the due date of the $20,000,000 amortization payment from September 23, 2024 to September 30, 2024. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed (&#8220;Oramed Consent and Amendment&#8221;) under which: (i)&#160;the Company made a payment of $12,500,000 to Oramed in lieu of&#160;the payment due on September 23, 2024, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $15,000,000 payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March 21, 2025 to December 31, 2025. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the Oramed Note was $12.2&#160;million, which is classified as debt, current in the consolidated balance sheet.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64,200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion into Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; recorded in the consolidated statements of operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; due to instrument-specific credit risk recorded as a component of other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Commitment Letter</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2024, the Company entered into the Commitment Letter with FSF Lender, pursuant to which FSF Lender committed to provide the Company the FSF Loan in the aggregate amount of $100.0&#160;million. The Commitment Amount should be payable as follows: (i) $85.0&#160;million no later than the Outside Date, which is 70 days following the date on which the Company received the FSF Deposit and (ii)&#160;the remaining $15.0&#160;million within 60 days following the Initial Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Commitment Letter, FSF Lender provided the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> FSF Deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million on the Deposit Date, which amount would be creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender the Deposit Warrant to purchase up to an aggregate of 3,250,000 shares of Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction), with an exercise price of $1.20 per share. The Deposit Warrant was immediately exercisable and would expire five years from the date of issuance. If the Initial Closing did not occur on or prior to the Outside Date, the FSF Deposit should automatically convert into an unsecured loan on the first day after the Outside Date. Within five days after such automatic conversion occurs, the Company should issue a promissory note (the &#8220;Unsecured Promissory Note&#8221;) to FSF Lender to evidence such unsecured loan, which note should be unsecured, had a maturity date of five years after the date of the Unsecured Promissory Note and was prepayable without premium or penalty. The Unsecured Promissory Note should bear interest, payable quarterly in arrears, in an amount equal to the Unsecured Applicable Interest Amount (as defined<div style="display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px;display:inline;">in the Commitment Letter) for such period based on the actual number of days elapsed while principal is outstanding.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It was contemplated by the Commitment Letter that the Company and FSF Lender would enter into definitive documents with respect to the FSF Loan on terms to be mutually agreed in good faith. If such definitive documents were entered into on or before the Outside Date, the Company agreed to issue to FSF Lender (i)&#160;at the Initial Closing, a warrant to purchase up to an aggregate of 24,375,000 shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#8220;Initial Closing Warrant&#8221;), and (ii)&#160;at the Second Closing, a warrant to purchase up to an aggregate of 4,875,000 shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#8220;Second Closing Warrant&#8221;), each to have an exercise price of $1.20 per share (with such exercise price and underlying shares presented on a pre-Reverse Stock Split basis); however, neither the Initial Closing Warrant nor Second Closing Warrant were ever issued. The Initial Closing Warrant and the Second Closing Warrant would expire five years from the date of issuance. To evidence the FSF Loan, the Company agreed to issue to FSF Lender a Senior Secured Promissory Note (the &#8220;Secured Promissory Note&#8221;), which shall have a maturity date of </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">five years after the date of issuance. The Secured Promissory Note shall bear interest, payable quarterly in arrears, in an amount equal to the Secured Applicable Interest Amount (as defined in the Commitment Letter) for such period, based on the actual number of days elapsed, while principal is outstanding, subject to certain conditions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the FSF Deposit would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transactions contemplated by the Commitment Letter, the Company also entered into an agreement with FSF Lender and the FSF Lender&#8217;s strategic consultant, IVI 66766 LLC (&#8220;IVI&#8221;), dated July&#160;16, 2024, pursuant to which the Company agreed to reimburse the actual, reasonable and documented consulting fees incurred by FSF Lender in connection with the preparation, negotiation and execution of the Commitment Letter and the definitive documents with respect to the transactions contemplated thereby, which fees were satisfied in full by the Company issuing to IVI a warrant to purchase up to an aggregate of 7,142 shares of Common Stock (the &#8220;Fee Warrant&#8221;) on July&#160;16, 2024, with an exercise price of $42.00 per share. Subject to certain ownership limitations, the Fee Warrant is immediately exercisable and will expire five years from the date of issuance. The <div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;">Company accounted for the Fee Warrant as an equity classified instrument and recognized the Fee Warrant in additional </div><div style="font-size: 10pt; text-align: left; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div><div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;"> capital in the Company&#8217;s consolidated balance sheets. The fair value of the Fee Warrant as of the date of issuance was $</div>0.3<div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. In October 2024, the Fee Warrant was exercised by IVI.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, the Company entered into the Satisfaction Agreement with FSF Lender and Endeavor, pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#8217;s delivery of 28,000 cartons of ZTlido to Endeavor, which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of June&#160;11, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(13,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Tranche B Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the <div style="white-space:nowrap;display:inline;">two-year</div> anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $<div style="display:inline;">38.15</div> per share (which was automatically reduced to $<div style="display:inline;">36.40</div> per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and (ii)&#160;warrants (the &#8220;October 2024 Noteholder Warrants&#8221;) to purchase up to <div style="display:inline;">214,284</div> shares of Common Stock directly to the Tranche B Noteholders. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $22,500,000, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The October 2024 Noteholder Warrants are immediately exercisable for cash at an exercise price equal to $38.15 per share of Common Stock (which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such warrants) and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#8220;StockBlock&#8221;) and its affiliate, Rodman&#160;&amp; Renshaw LLC (collectively, the &#8220;Placement Agents&#8221;) or their respective designees, (i) </div>62,794<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;Placement Agent Shares&#8221;) and (ii)&#160;warrants to purchase up to </div>104,848<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;October 2024 Placement Agent Warrants&#8221;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement (as defined below) for $5.0&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $50.0&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $2.6&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statement of operations during the year ended December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">42,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Tranche B notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(9,255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,283</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate principal repayments for the Company&#8217;s outstanding debt will be $47.7&#160;million and $19.5&#160;million in 2025 and 2026, respectively.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Royalty Purchase Agreement</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the &#8220;ZTlido Purchased Receivables&#8221;) with respect to ZTlido, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $5.0&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $2.5&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $2.5&#160;million minus Oramed&#8217;s expenses (collectively, the amount so paid by the ZTlido Royalty Purchasers, the &#8220;ZTlido RPA Closing Payment&#8221;). Oramed&#8217;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $2.5&#160;million of the outstanding balance under the Oramed Note.&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;">The Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. </div><div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $6.8&#160;million, recorded as a purchased revenue liability on the consolidated balance sheet. The Company incurred $0.2&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity during the year ended December&#160;31, 2024 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sorrento Stock Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Sorrento Stock Purchase Agreement</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">8. Sorrento Stock Purchase Agreement </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into that certain Stock Purchase Agreement (the &#8220;Sorrento SPA&#8221;) with Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, pursuant to which the </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company purchased from Sorrento (i) 1,716,245 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221;), and (iii) 1,386,617 Public Warrants (as defined below), which are currently exercisable for an aggregate of up to 39,617 shares of Common Stock and 3,104,000 Private Warrants (collectively, the &#8220;Purchased Securities&#8221;), which are currently exercisable for an aggregate of up to 88,685 shares of Common Stock. As a result, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $0.01 per share and restrictions on exercisability, and warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $0.01 per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed 4,000,000 SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock), which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the agreement that the Company entered into in July 2023, to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $20.0&#160;million, a $10.0&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $12.3&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants (as defined below) based on their relative fair values as of September&#160;21, 2023. Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;SCLX JV, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary, which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 2). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares of Common Stock for the Company to settle the exercise of the warrants in shares of Common Stock. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 6,500,000 Penny Warrants outstanding that were fully vested and such warrants became exercisable on March 14, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the unaudited condensed consolidated balance sheets. During the three months ended March&#160;31, 2025, the Company made a total of $0.2&#160;million payments for the excise tax. As of March&#160;31, 2025, the remaining balance of the excise tax liability recorded as accrued expenses was $0.6&#160;million. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">8. Junior DIP Facility and Sorrento Stock Purchase Agreement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Junior DIP Facility </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, the Company entered into an agreement to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $20.0&#160;million (the &#8220;Junior DIP Loan Agreement&#8221;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of 12.0% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP<div style="display:inline;">&#160;</div>Facility.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#160;</div>The Junior DIP </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Sorrento&#8217;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into the Sorrento SPA, pursuant to which the Company purchased from Sorrento (i) 1,716,245 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock and (iii) 1,386,617 Public Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 39,617 shares of Common Stock</div></div> and 3,104,000 Private Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 88,685 shares of Common Stock</div></div> (collectively, the &#8220;Purchased Securities&#8221;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;display:inline;">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of </div>4,500,000<div style="font-size: 10pt;display:inline;"> shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $</div>0.01<div style="font-size: 10pt;display:inline;"> per share and restrictions on exercisability, and warrants to purchase up to an aggregate of </div>8,500,000<div style="font-size: 10pt;display:inline;"> shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $</div>0.01<div style="font-size: 10pt;display:inline;"> per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed </div>4,000,000<div style="font-size: 10pt;display:inline;"> SPAC Warrants, which </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">are currently exercisable for an aggregate of up to 114,286 shares of Common Stock, which </div></div><div style="font-size: 10pt;display:inline;">were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $</div>10.0<div style="font-size: 10pt;display:inline;">&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $</div>12.3<div style="font-size: 10pt;display:inline;">&#160;million.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Series A Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary (&#8220;SCLX JV&#8221;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;March 14, 2025, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company issued four Subsequent Penny Warrants, each for 2,125,000&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of March 19, 2024 (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-2</div> Warrant&#8221;), June 17, 2024 (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-3</div> Warrant&#8221;), September 15, 2024 (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-4</div> Warrant&#8221;) or December 14, 2024 (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;CS-5</div> Warrant&#8221;) (each, the &#8220;Subsequent Penny Warrant Vesting Date&#8221;) and (ii)&#160;the earliest of (A)&#160;March 14, 2025, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a letter agreement the Company entered into with Oramed, dated as of August 30, 2024, the parties agreed that: (i)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CS-4</div> Warrant shall fully vest on August&#160;30, 2024 and (ii)&#160;Oramed may immediately exercise the Oramed Warrants with respect to up to 5,437,500 shares of Common Stock. Pursuant to the Oramed Letter Agreement the Company entered into with Oramed, dated as of September&#160;20, 2024, the parties agreed that Oramed may immediately exercise the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CS-5</div> Warrant with respect to up to 1,062,500 shares of Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">During the year ended December&#160;31, 2024, there were 6,500,000 Penny Warrants exercised by Oramed for net proceeds of approximately $0.1&#160;million. As of December&#160;31, 2024, there were 6,500,000 Penny Warrants outstanding that were fully vested and such warrants became exercisable on March 14, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the consolidated balance sheet. During the year ended December&#160;31, 2024, the Company made a total of $0.5&#160;million payments for the excise tax. As of December&#160;31, 2024, the remaining balance of the excise tax liability recorded as accrued expenses was $0.8&#160;million. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS EQUITY</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">9. Stockholders&#8217; Deficit </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SPAC Warrants</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $402.50 per whole share (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220;SPAC Warrants&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $630.00 per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#8217; prior written notice.</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space:nowrap;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased 4,000,000 of the SPAC Warrants (which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock) held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, 5,467,692 Public Warrants, which are currently exercisable for an aggregate of up to 156,220 shares of Common Stock are outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, 1,000,000&#160;Private Warrants, which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock are outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 45,000,000 shares of preferred stock (the &#8220;Preferred Stock&#8221;) of which there are two series in total. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, there were 29,057,097 shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Series 1 Preferred Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;27, 2024, the Board declared a stock dividend (the &#8220;Dividend&#8221;) consisting of an aggregate of 5,000,000 shares (the &#8220;Dividend Stock&#8221;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share, of the Company (the &#8220;Series 1 Preferred Stock&#8221;) to record holders of certain of the Company&#8217;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to such later date to be determined in the sole discretion of the Board) (such later record date as so determined by the Board, the &#8220;Record Date&#8221;). Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Certificate of Designation&#8221;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $200,000,000 divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is 10 trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Certificate of Designation, (a) &#8220;Effective Time&#8221; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#8220;Determination Date&#8221; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is 15 trading days following the Registration Date, (c) &#8220;Registration Date&#8221; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and (ii)&#160;the time at which the Registration Statement is declared effective by the SEC and (d) &#8220;Registration Statement&#8221; means a registration statement, whether under the Exchange Act, or the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of March&#160;31, 2025 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Treasury Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025 and December&#160;31, 2024, there were 1,458,263 and 1,716,245 shares of Treasury Stock, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;"><div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">At-the-Market</div></div> Sales Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into the ATM Sales Agreement with the Sales Agents, which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell the ATM Shares through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM Shares offered and sold in the ATM Offering were issued pursuant to the Company&#8217;s shelf registration statement on Form <div style="white-space:nowrap;display:inline;">S-3</div> (which was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File <div style="white-space:nowrap;display:inline;">No.&#160;333-276245))</div> (the &#8220;Shelf <div style="white-space:nowrap;display:inline;">S-3</div> Registration Statement&#8221;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf <div style="white-space:nowrap;display:inline;">S-3</div> Registration Statement. The Sales Agents were entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2025, no sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold 2,637 shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $0.1&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">February 2024 Bought Deal Offering Underwriting Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;February 2024 BDO Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#8220;February 2024 BDO&#8221;), 168,068 shares of Common Stock (the &#8220;February 2024 BDO Firm Shares&#8221;) and accompanying common warrants to purchase up to an aggregate of 168,068 shares of Common Stock (the &#8220;February 2024 BDO Firm Warrants&#8221;). The securities in the February 2024 BDO were offered and sold by the Company pursuant to the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement, a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The February 2024 BDO closed on March&#160;5, 2024, and the combined price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $54.74, which amount reflects the combined public offering price of $59.50, less underwriting discounts and commissions. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $59.50 per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#8220;February 2024 BDO Representative Warrants&#8221;) to the underwriters, allowing them to purchase up to 13,446 shares of Common Stock, with these warrants being immediately exercisable at $74.38&#160;per share, representing 125% of the combined public offering price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note&#160;4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $0.3&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a warrant amendment (the &#8220;Warrant Amendment&#8221;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. During each of the three months ended March&#160;31, 2025 and 2024, there were no February 2024 BDO Firm Warrants exercised. As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 3,803,447 February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock outstanding and 470,588 February 2024 BDO Representative Warrants, which are currently exercisable for an aggregate of up to 13,446 shares of our Common Stock outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">April 2024 Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#8220;April 2024 RDO Purchase Agreement&#8221;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;April 2024 RDO&#8221;): (i) an aggregate of 428,572 shares of Common Stock (the &#8220;April 2024 RDO Shares&#8221;), and (ii)&#160;common warrants to purchase up to 428,572 shares of Common Stock (the &#8220;April 2024 RDO Common Warrants&#8221;). The offering price per April 2024 RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $35.00, for aggregate gross proceeds to the Company of $15,000,000, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $38.50 per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC, acted as exclusive placement agents (the &#8220;April 2024 RDO Placement Agents&#8221;) in connection with the April 2024 RDO. As compensation for such placement agent services, the Company paid the April 2024 RDO Placement Agents an aggregate cash fee equal to 8.0% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the April 2024 RDO Placement Agents $100,000 for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses and $15,950 for clearing expenses. The Company has also agreed to issue to the April 2024 RDO Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to 34,286&#160;shares of Common Stock (the &#8220;April 2024 RDO Placement Agent Warrants&#8221;), representing up to 8.0% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $43.75 per share (which represents 125% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note&#160;4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of the April 2024 RDO Placement Agent Warrants as the date of issuance was $0.6&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 15,000,000&#160;April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock outstanding and 1,200,000&#160;April 2024 RDO Placement Agent Warrants, which are currently exercisable for an aggregate of up to 34,286 shares of our Common Stock outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">December 2024 Registered Direct Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#8220;December 2024 RDO Purchase Agreement&#8221;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;December 2024 RDO&#8221;): (i) an aggregate of 753,009 shares of Common Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> warrants to purchase up to 68,604 shares of Common Stock (the &#8220;December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) and (iii)&#160;common warrants to purchase up to 1,642,871 shares of Common Stock (the &#8220;December 2024 RDO Common Warrants&#8221; and collectively with the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#8220;StockBlock Warrants&#8221;), the &#8220;December 2024 RDO Warrants&#8221;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $20.65 and (b)&#160;per December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant and accompanying December 2024 RDO Common Warrants was $20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $17.0&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">general and administrative expenses in the Company&#8217;s consolidated statements of operations. The fair value of StockBlock Warrants as of the date of issuance was $1.3&#160;million. On December&#160;26, 2024, the December 2024 RDO <div style="white-space:nowrap;display:inline;">Pre-Funded</div> Warrants were exercised by the holder for total net proceeds of approximately $0.2&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 57,512,958 December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock outstanding and 4,601,036 StockBlock Warrants, which are currently exercisable for an aggregate of up to 131,472 shares of Common Stock outstanding. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">9. Stockholders&#8217; Deficit </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">SPAC Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $402.50 per share (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220;SPAC Warrants&#8221;). <br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">If the reported last sale price of the Common Stock equals or exceeds $630.00 per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#8217; prior written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased 4,000,000 of the SPAC Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock,</div></div> held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were 5,467,692&#160;and 6,854,309&#160;Public Warrants outstanding, <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to 156,220 shares of Common Stock and 195,838 shares of Common Stock, </div></div>respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were 1,000,000&#160;and 3,613,383&#160;Private Warrants outstanding, <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock and 103,240 shares of Common Stock, respectively.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company is authorized to issue 45,000,000 shares of preferred stock (the &#8220;Preferred Stock&#8221;) of which there are two series in total. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024 and 2023, there were 29,057,097 shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series 1 Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On October&#160;27, 2024, the Board declared a stock dividend (the &#8220;Dividend&#8221;) consisting of an aggregate of 5,000,000 shares (the &#8220;Dividend Stock&#8221;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share (the &#8220;Series 1 Preferred Stock&#8221;), of the Company to record holders of certain of the Company&#8217;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;">such later date to be determined in the sole discretion of the Board). </div> Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#8220;Certificate of Designation&#8221;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into <div style="letter-spacing: 0px; top: 0px;display:inline;"></div>account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $200,000,000 divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is 10&#160;trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Certificate of Designation, (a) &#8220;Effective Time&#8221; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#8220;Determination Date&#8221; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is 15&#160;trading days following the Registration Date, (c) &#8220;Registration Date&#8221; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and (ii)&#160;the time at which the Registration Statement is declared effective by the Securities and Exchange Commission and (d) &#8220;Registration Statement&#8221; means a registration statement, whether under the Exchange Act, or the Securities Act, that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025).</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of December&#160;31, 2024 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, there were 1,716,245 shares of Treasury Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">A&amp;R Yorkville Purchase Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the Company had the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $500.0&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> anniversary of the date on which the Company&#8217;s registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-1</div> registering such shares was declared effective by the SEC. Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elected to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#8220;VWAP&#8221; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#8220;AQR&#8221; function. Pursuant to the terms of the Original Purchase<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-268607)</div> (as it may be amended or supplemented from time to time, the &#8220;Yorkville Registration Statement&#8221;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville </div>7,142<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock. During the year ended December&#160;31, 2024, the Company sold </div>2,770<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of $</div>0.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. During the year ended December&#160;31, 2023, the Company sold </div>330,059<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of $</div>32.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">B. Riley Purchase Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Pursuant to the B. Riley Purchase Agreement, the Company had the right, but not the obligation, to sell to B. Riley up to $500.0&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth therein, from time to time at the Company&#8217;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company&#8217;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-269205)</div> (as it may be amended or supplemented from time to time, the &#8220;B. Riley Registration Statement&#8221;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;display:inline;">The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to </div>98<div style="font-size: 10pt;display:inline;">% of the VWAP (as defined in such agreement) during the pricing period prescribed therein.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley 7,142 shares of Common Stock. During the year ended December&#160;31, 2024, the Company did not sell any shares of Common Stock pursuant to the B. Riley Purchase Agreement. During the year ended December&#160;31, 2023, the Company sold an aggregate of 40,415 shares of Common Stock for aggregate net proceeds of $3.2&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Issued under Settlement Agreement with Hudson Bay Parties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In August 2023, the Company, along with Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221;), Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), and HBC Investments LLC (&#8220;HBC&#8221; and collectively, the &#8220;Hudson Bay Parties&#8221;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $118.6&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $8.65&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $0.3&#160;million and $0.5&#160;million, respectively. This resulted in the issuance of an aggregate of 13,562 shares of Common Stock on September&#160;25, 2023.&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">At-the-Market</div></div> Sales Agreement</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#8220;<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ATM </div></div>Offering&#8221;) shares of Common Stock up to $170,000,000 (the &#8220;ATM Shares&#8221;), through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers at any time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The ATM Shares offered and sold in the <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ATM </div></div>Offering were issued pursuant to the Company&#8217;s shelf registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-3&#160;(which</div> was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-276245))</div> (the &#8220;Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement&#8221;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> Registration Statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Sales Agents were entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of December&#160;31, 2024, the Company sold 78,975 shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $2.7&#160;million. As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">February 2024 Bought Deal Offering Underwriting Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;February 2024 BDO Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#8220;February 2024 BDO&#8221;), 168,068&#160;shares of Common Stock (the &#8220;February 2024 BDO Firm Shares&#8221;) and accompanying common warrants to purchase up to an aggregate of</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">168,068<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock (the &#8220;February 2024 BDO Firm Warrants&#8221;). The securities in the February 2024 BDO were offered and sold by us pursuant to the Shelf </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> Registration Statement,&#160;a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The February 2024 BDO closed on March&#160;5, 2024, and the combined price per Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $54.74, which amount reflects the combined public offering price of $59.50, less underwriting discounts and commissions. Pursuant to the February 2024 BDO Underwriting Agreement, the Company also granted the underwriters a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> option to purchase up to 25,211 additional shares of Common Stock and/or common warrants to purchase up to 25,211 shares of Common Stock (the &#8220;February 2024 BDO Optional Warrants&#8221;, and together with the February 2024 BDO Firm Warrants, the &#8220;Common Warrants&#8221;). The underwriters did not exercise this option and it expired on March&#160;30, 2024. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $59.50 per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#8220;February 2024 BDO Representative Warrants&#8221;) to the underwriters, allowing them to purchase up to 13,446 shares of Common Stock, with these warrants being immediately exercisable at $74.38 per share, representing 125% of the combined public offering price per Firm Share and accompanying February 2024 BDO Firm Warrant. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note 4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in </div> capital in the Company&#8217;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling,</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $0.3&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a warrant amendment (the &#8220;Warrant Amendment&#8221;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. During the year ended December&#160;31, 2024, there were 59,398 February 2024 BDO Firm Warrants exercised for total net proceeds of approximately $1.6&#160;million, including the amended February 2024 BDO Firm Warrants. As of December&#160;31, 2024, there were 3,803,447 February 2024 BDO Firm Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock outstanding</div></div> and 470,588 February 2024 BDO Representative Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 13,446 shares of Common Stock</div></div> outstanding. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">April 2024 Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#8220;April 2024 RDO Purchase Agreement&#8221;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;April 2024 RDO&#8221;): (i) an aggregate of 428,572 shares of Common Stock (the &#8220;RDO Shares&#8221;), and (ii)&#160;common warrants to purchase up to 428,572 shares of Common Stock (the &#8220;April 2024 RDO Common Warrants&#8221;). The offering price per RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $35.00, for aggregate gross proceeds to the Company of $15,000,000, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $38.50 per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">StockBlock and its affiliate, Rodman&#160;&amp; Renshaw LLC, acted as exclusive placement agents (the &#8220;Placement Agents&#8221;) in connection with the April 2024 RDO. As compensation for such placement agent services, the</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">Company paid the Placement Agents an aggregate cash fee equal to 8.0% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the Placement Agents $100,000 for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses and $15,950 for clearing expenses. The Company has also agreed to issue to the Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to 34,286 shares of Common Stock (the &#8220;April 2024 RDO Placement Agent Warrants&#8221;), representing up to 8.0% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $43.75 per share (which represents 125% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note 4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of April 2024 RDO Placement Agent Warrants as of the date of issuance was $0.6&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, there were 15,000,000 April 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock outstanding,</div></div> and 1,200,000 April 2024 RDO Placement Agent Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 34,286 shares of Common Stock</div></div> outstanding. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">December 2024 Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#8220;December 2024 RDO Purchase Agreement&#8221;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#8220;December 2024 RDO&#8221;): (i) an aggregate of 753,009 shares of Common Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> warrants to purchase up to 68,604&#160;shares of Common Stock (the &#8220;December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) and (iii)&#160;common warrants to purchase up to 1,642,871 shares of Common Stock (the &#8220;December 2024 RDO Common Warrants&#8221; and together with the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#8220;StockBlock Warrants&#8221;), the &#8220;December 2024 RDO Warrants&#8221;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $20.65 and (b)&#160;per December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant and accompanying December 2024 RDO Common Warrants was $20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $17.0&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#8217;s consolidated statement of operations. The fair value of StockBlock Warrants as of the date of issuance was $1.3&#160;million. On December&#160;26, 2024, the December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants were exercised by the holder for total net proceeds of approximately $0.2&#160;million.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As of December&#160;31, 2024, there were 57,512,958 December 2024 RDO Common Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock outstanding,</div></div> and 4,601,036&#160;StockBlock Warrants<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"><div style=";text-indent: 0px;display:inline;">, which are currently exercisable for an aggregate of up to 131,472 shares of Common Stock</div></div> outstanding. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Incentive and Employee Benefit Plan</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">10. Stock Incentive and Employee Benefit Plan </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). As of March&#160;31, 2025, a total of 703,670 shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2025 pursuant to the Equity Incentive Plan. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2023 Inducement Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space:nowrap;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 40,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, options to purchase 1,022,353 shares of Common Stock were outstanding under all equity incentive plans. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the three months ended March&#160;31, 2025 (in thousands, except for per share amounts and contractual life): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">149.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. No stock options were granted during the three months ended March&#160;31, 2025. No options were exercised during the three months ended March&#160;31, 2025. The maximum term of options granted under each of the equity incentive plans is ten years. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $3.3&#160;million and $3.6&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space:nowrap;display:inline;">non-employee</div> stock option grants as of March&#160;31, 2025 were $24.5&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.1 years. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to 85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of March&#160;31, 2025, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed 170,573, which was increased from 127,902 shares as a result of automatic annual increase on January&#160;1, 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $50.2&#160;thousand and $58.0&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2025, there were no shares of Common Stock issued under the ESPP. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options granted to employees and nonemployees and shares issued under ESPP using the Black-Scholes option pricing method. The Black-Scholes option pricing method requires the use of subjective assumptions. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Semnur 2024 Stock Option Plan</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (the &#8220;Semnur 2024 Plan&#8221;). Under the Semnur 2024 Plan, 40,000,000 shares of Semnur Common Stock were reserved </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">for future issuance and Nonstatutory Stock Options (&#8220;NSOs&#8221;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of March&#160;31, 2025, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.2&#160;million for each of the three months ended March&#160;31, 2025 and 2024. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Retainer Shares</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;2023 SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued 114,286 shares of Common&#160;Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#8220;2024 SIA&#8221;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued 285,714 shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#8220;Retainer Shares&#8221;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of March&#160;31, 2025, it was not probable that any of the Retainer Shares would be applied against any outstanding legal fees. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">10. Stock Incentive and E<div style="display:inline;">mploye</div>e Benefit Plan </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). As of December&#160;31, 2024, a total of 575,220 shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2024 pursuant to the Equity Incentive Plan. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 10pt;font-weight:bolder;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2023 Inducement Plan</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 40,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the years ended December&#160;31, 2024 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, options to purchase 1,027,977 shares of Common Stock were outstanding under all equity incentive plans.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes stock option activity during the year ended December&#160;31, 2024 (shares in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 55%;">&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">946</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">153.15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7.5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7,459</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">129</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">33.21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">51.67</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited/Cancelled</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">160.56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1,028</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">138.23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">6.43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1,028</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">138.23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">6.43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">727</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">113.01</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">5.5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table>  <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024 and 2023 was $</div>23.49<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> and $</div>113.00<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> per share, respectively. The total intrinsic values of options exercised during the years ended December&#160;31, 2024 and 2023 were $</div>47.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;thousand and $</div>1.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;million, respectively. The maximum term of options granted under each of the equity incentive plans is ten years.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $15.7&#160;million and $14.6&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> stock option grants as of December&#160;31, 2024 were $27.8&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.3 years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to&#160;85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2024, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>127,902<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">, which was increased from </div>82,164<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> shares as a result of automatic annual increase on January&#160;1, 2024.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $242.8&#160;thousand and $21.0&#160;thousand for the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were 9,551 and nil shares of Common Stock issued under the ESPP during the years ended December&#160;31, 2024 and 2023, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP:</div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 71%;"></td>
<td style="vertical-align: bottom; width: 4%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.00%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">72.00%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div>119.08%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">3.79%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;-<div style="display:inline;">&#160;</div></div>4.71%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">3.0<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div>6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.00%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">129.30%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">5.39%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Semnur 2024 Stock Option Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (&#8220;Semnur 2024 Plan&#8221;). Under the Semnur 2024 Plan, 40,000,000 shares of Semnur Common Stock were reserved for future issuance and nonstatutory stock options (&#8220;NSOs&#8221;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of December&#160;31, 2024, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.6&#160;million and $0.5&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Retainer Shares </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;2023 SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued 114,286 shares of Common Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#8220;2024 SIA&#8221;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued 285,714 shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#8220;Retainer Shares&#8221;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of December&#160;31, 2024, it was not probable that any of the Retainer Shares would be applied against any <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">outstanding legal fees. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">11. Commitments and Contingencies </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi (together, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space:nowrap;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. Scilex Pharma made royalty payments in the amount of $0.9&#160;million and $2.4&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, Scilex Pharma had ending balances of accrued royalty payables of $3.8&#160;million and $4.0&#160;million, respectively. Total royalty expense recorded within cost of revenue was $0.7&#160;million and $2.3&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive <div style="white-space:nowrap;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon <div style="white-space:nowrap;display:inline;">six-months&#8217;</div> written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the Developers to provide commercial supply of ZTlido and <div style="white-space:nowrap;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following lawsuit, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the&#160;procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic <div style="white-space:nowrap;display:inline;">30-month</div> stay preventing them from selling a generic version of ZTlido during that time, which was extinguished by the U.S. District Court decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#8217;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#8217;s product does not infringe the Company&#8217;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. Briefing is underway in that appeal. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Operating Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space:nowrap;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of March&#160;31, 2025, the Company&#8217;s leases have remaining lease terms of approximately 2.5 years. The terms of the Company&#8217;s leases, ranging from 3 to 5 years, include extension options that are not reasonably certain to be </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets or lease liabilities, and are immaterial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of March&#160;31, 2025, the Company has no&#160;<div style="-sec-ix-hidden:hidden145659148;display:inline;">finance leases</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $0.3&#160;million for each of the three months ended March&#160;31, 2025 and 2024, and was primarily comprised of operating lease costs. The lease expense included variable lease costs and sublease income, which were immaterial for the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(227</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">11. Commitments and Contingencies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi Koseido Co., Ltd. (&#8220;Oishi,&#8221; and together with Itochu, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. For each of the years ended December&#160;31, 2024 and 2023, Scilex Pharma made royalty payments in the amount of $8.3&#160;million. As of December&#160;31, 2024 and 2023, Scilex Pharma had ending balances of accrued royalty payables of $4.0&#160;million and $2.4&#160;million, respectively. Total royalty expense recorded within cost of revenue was $9.9&#160;million and $8.5&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon six months&#8217; written notice. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div></div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, the Company filed an action (the &#8220;OTC Action&#8221;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">respective </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">OTC lidocaine</div></div> patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#8217;s claims, but which motions the court largely rejected. Discovery proceeded. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolved the OTC Action. The terms of those agreements are confidential. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Action </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, and together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">95-page</div> opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax would be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $3.5&#160;million (the &#8220;Initial Payment&#8221;) by two business days after the Effective Date (as defined therein), which payment has been made; (ii) $2.5&#160;million by July&#160;1, 2024, which payment has been made on July&#160;8, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provided mutual releases of all claims that existed as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. The court has requested additional oral argument on the topic of remedies against Mr.&#160;Mack, which argument occurred on November&#160;15, 2024. The parties are awaiting a final judgment from the court. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-month</div> stay preventing them from selling a generic version of ZTlido during that time which was extinguished by the U.S. District Court for the Southern District of Florida decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#8217;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#8217;s product does not infringe the Company&#8217;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA Patent Litigation </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#8220;GLOPERBA Patent Litigation&#8221;) alleging that the Company&#8217;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#8217;s colchicine product, Colcrys<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"> </div>(the &#8220;Colcrys Patents&#8221;). Takeda sought an order that the effective date of any FDA approval of the Company&#8217;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The Company had previously accrued $0.5&#160;million with respect to the GLOPERBA Patent Litigation. On March&#160;7, 2024, the Company entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Takeda to resolve the action and entered into a license agreement with Takeda pursuant to which Takeda granted a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to the Company and its affiliates of certain patents owned by Takeda. The terms of those agreements are confidential. The Settlement Agreement was subject to review by the Federal Trade Commission and the U.S. Department of Justice, neither of which objected during the review period. After the expiration of the review period, the U.S. District Court for the District of Delaware entered a final consent judgment on May&#160;3, 2024. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2024, the Company&#8217;s leases have remaining lease terms of approximately 2.8 years. The terms of the Company&#8217;s leases, ranging from 3 to 5 years, include extension options that were not reasonably certain to be exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2024, the Company has no <div style="-sec-ix-hidden:hidden145659460;display:inline;">finance leases</div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">In April 2023, the Company modified the lease term</div></div> for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $2.5&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $1.0&#160;million and $1.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">presented. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 69%;"></td>
<td style="vertical-align: bottom; width: 10%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 9%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(347</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">12. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total loss before income taxes for the years ended December&#160;31, 2024 and 2023 did not include a foreign component. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision (benefit) expense were as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax (benefit) expense:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current income tax (benefit) expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax benefit:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(16,279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(16,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(11,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax benefit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(19,082</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(27,761</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax (benefit) expense from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">tax purposes. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">71,434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased revenue liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(113,703</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(96,776</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,423</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,997</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(15,290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">true-up</div> and carryback</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,079</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,705</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $113.7&#160;million against its deferred tax assets as of December&#160;31, 2024. Realization of the deferred tax assets will be primarily dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had $336.5&#160;million and $248.2&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2033 for <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">both federal </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">and state. As </div></div> of December&#160;31, 2024, the Company had a total of $313.5&#160;million of federal net operating losses that have an indefinite life and will not expire, and had federal research and development income tax credits of $3.7&#160;million which will begin to expire in 2034. As of December&#160;31, 2024, the Company had California research and development income tax credits of $2.2&#160;million that have an indefinite life and will not expire. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2024 and 2023, there was no impact of such limitations on the Company&#8217;s income tax provision. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#8217;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2024. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the beginning of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to current year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the end of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024 and 2023, the Company had $1.2&#160;million and $1.1&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">million in total unrecognized tax benefits, respectively, which have been reflected as a reduction in deferred tax assets. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense</div></div>. No interest or penalties have been recognized as of and for the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that no material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>December<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>31,<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2024. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">12. Net Loss Per Share </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the three months ended March&#160;31, 2025 and 2023 (in thousands except per share data): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(26,080</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2.26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">March&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022,353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,027,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,114,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,158,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">428,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposit Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Noteholder Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">214,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,668,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,817,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">13. Net Loss Per Share </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2024 and 2023 (in thousands except per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(72,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(52,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(72,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reversal of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">mark-to-market</div></div> adjustment for liability classified warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8,895</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(81,702</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,061</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(7.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(44.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8.05</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(44.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Series A Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the Series A preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. Shares of the Dividend Stock, as declared by the Board of Directors of the Company on October&#160;27, 2024 and not yet distributed as of December&#160;31, 2024, are also excluded from the computation of net loss per share because the associated Series 1 Preferred Stock is not considered to be a participating security. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock were not vested as of the closing date of September&#160;21, 2023 and the vesting was based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). The Subsequent Penny Warrants became vested during the year ended December&#160;31, 2024, and therefore are included in the computation for basic and diluted net income per share as of December&#160;31, 2024, since all other exercise contingencies were removed except for the passage of <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">time. </div></div></div>    <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,027,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">946,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">195,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">114,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">103,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to the ESPP</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,158,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,817,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,376,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">13. Subsequent Events </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Scilex Bio JV </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2025, the Company and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">MAO-B</div> Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer&#8217;s disease. The Company contributed 5.0&#160;million shares of Semnur Common Stock owned by the Company to Scilex Bio, Inc. in exchange for a 60% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a 40% ownership interest in Scilex Bio, Inc. In connection with the formation of Scilex Bio, Inc. and the related transactions, on April&#160;16, 2025, the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed, and the Company entered into a Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note with each of the Tranche B Noteholders. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;">14. Subsequent Events </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferral and Consent under Tranche B Senior Secured Convertible Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025 (the &#8220;First Amortization Payment Date&#8221;), the Company is required to redeem in cash (the &#8220;First Amortization Payment&#8221;) such portion of the principal amount of the Tranche B Notes equal to each Tranche B Noteholder&#8217;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $6,250,000 per fiscal quarter at a redemption price equal to 100% of such Amortization Amount (as defined in the Tranche B Notes). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#8220;Nomis Bay Consent&#8221;), (ii) Oramed (the &#8220;Oramed Consent&#8221;) and (iii) 3i, LP (the &#8220;3i Consent&#8221; and, together with the Nomis Bay Consent and the Oramed Consent, the &#8220;Tranche B Consents&#8221;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#8217;s obligation to make the First Amortization Payment until January&#160;31, 2025. In consideration of such deferral, and to limit the Tranche B Noteholders&#8217; right to exercise certain secured creditor remedies (including recourse against the assets of SCLX JV as a grantor under the Security Agreement (as defined in the Tranche B Consents)), SCLX JV delivered to the Tranche B Noteholders (or their designee) by deposit/withdrawal at custodian with the Depository Trust Company an aggregate of 142,855 Scilex <div style="letter-spacing: 0px; top: 0px;display:inline;">s</div>hares held by SCLX JV, of which 71,428 shares were delivered to Oramed, 20,571 shares were delivered to BPY Limited, 36,571 shares were delivered to Nomis Bay Ltd, and 14,285 shares were delivered to 3i, LP. <br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">In addition, pursuant to the Tranche B Consents</div></div>, effective as of the latest of (i)&#160;the time of execution and delivery of the Tranche B Consents, (ii)&#160;the time of the delivery of the Scilex <div style="letter-spacing: 0px; top: 0px;display:inline;">s</div>hares and (iii)&#160;the time of grant of the Royalty and Exclusive Rights (each as defined in, and contemplated pursuant to, the Term Sheet that is an exhibit to the Tranche B Consents (the &#8220;Term Sheet&#8221;)), the Tranche B Noteholders agreed to further defer the Company&#8217;s obligation to make the First Amortization Payment until October&#160;8, 2026, provided that, as contemplated in the Term Sheet, the Company pays an aggregate of $1.1&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(which amount has been paid). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Sheet provides that the Company and the Tranche B Noteholders would enter into an agreement pursuant to which the Tranche B Noteholders shall collectively receive a 10 year, assignable, freely transferable, </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4% royalty on the worldwide Net Sales (as defined therein) of GLOPERBA and ELYXYB, excluding sales of ELYXYB in Canada. Please see section below titled &#8220;Gloperba and Elyxyb Royalty Purchase Agreement&#8221; for a description of such royalty agreement entered into by us. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Senior Secured Note </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;21, 2025, the Company entered into an amendment letter with Oramed (the &#8220;Oramed Amendment&#8221;), pursuant to which, among other things, Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Rest of World License Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025 (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Effective Date</div></div></div></div>&#8221;), Scilex Pharma entered into a License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Agreement</div></div></div></div>&#8221;) with RoyaltyVest Ltd. (the &#8220;Licensee&#8221;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, between Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">69557-111-30</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(b)&#160;SP-103</div> (collectively, the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Product</div></div></div></div>&#8221;). The Lido License Agreement supersedes and replaces the that certain Rest of World License Term Sheet parties entered into on October&#160;8, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido Products outside of the United States and certain territories stated in the Lido License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido Licensee Territory</div></div></div></div>&#8221;). The Licensee granted to Scilex Pharma a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable,</div> right and license under the Licensee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (each as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field (each as defined therein). Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, <div style="letter-spacing: 0px; top: 0px;display:inline;">or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">SP-103</div> and all existing Lido Products in each country or jurisdiction in the Licensor Territory (as defined therein). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Promptly after the Lido Effective Date, Scilex Pharma is required to (i)&#160;facilitate an introduction between Oishi, Itochu, and the Licensee, and (ii)&#160;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with the Licensee for the manufacturing or supply of the Lido Product in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lido License Term</div></div></div></div>&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Parent Guarantee for Lido License Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">On February&#160;22, 2025, in connection with Lido License Agreement, the Company entered into that certain Parent Guarantee for Lidocaine License Agreement (the &#8220;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Parent Guarantee</div></div></div></div>&#8221;) with the Licensee, pursuant to which the Company agreed to guarantee the due and proper performance of Scilex Pharma&#8217;s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee. Pursuant to the terms of the Parent Guarantee, the Company shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gloperba-Elyxyb Royalty Purchase Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">As contemplated by the Term Sheet in respect of the Royalty and Exclusive Rights described therein, on February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Closing Date&#8221;), the Company entered into a Purchase and Sale Agreement (the &#8220;Gloperba-Elyxyb Royalty Purchase Agreement&#8221;) with Scilex Pharma, certain institutional investors (collectively, the &#8220;Gloperba-Elyxyb Royalty Investors&#8221;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#8220;Gloperba-Elyxyb RPA Purchasers&#8221;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma sold to the Gloperba-Elyxyb RPA Purchasers the right to receive</div></div>&#160;4%<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#160;</div></div><div style="display:inline;">of all aggregate net sales worldwide (the &#8220;Gloperba-Elyxyb Purchased Receivables&#8221;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#8220;Gloperba-Elyxyb Covered Products&#8221;).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In consideration of the Further Deferral and representing the &#8220;grant of the Royalty and Exclusive Rights&#8221; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#8220;Gloperba-Elyxyb Payment Term&#8221;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#8217;s account such Gloperba-Elyxyb RPA Purchaser&#8217;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter (commencing with the calendar quarter beginning January&#160;1, 2025) promptly, but in any event no later than</div></div>&#160;60 calendar days after the end of each calendar quarter. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Payment Term. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Royalty Security Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the terms of the Gloperba-Elyxyb Royalty Purchase Agreement, the Company entered into a Security Agreement with Scilex Pharma and the collateral agent (as identified therein) for the benefit of the Gloperba-Elyxyb RPA Purchasers, dated as of February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Royalty Security Agreement&#8221;). </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma&#8217;s due performance and payment under the Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered Products. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div> <div style="line-height:normal;display: inline;"> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> </div> </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subordination Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, the Company entered into that certain Subordination Agreement, dated as of February&#160;28, 2025 (the &#8220;Gloperba-Elyxyb Subordination Agreement&#8221;), by and among the Company, Scilex Pharma the Gloperba-Elyxyb RPA Purchasers and the Note Agent (each as defined in the Subordination Agreement). Pursuant to the Gloperba-Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by first priority liens on the collateral under the Gloperba-Elyxyb Royalty Security Agreement (the &#8220;Gloperba-Elyxyb Royalty Collateral&#8221;) and the Note Agent&#8217;s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a second priority lien. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Amendment No.&#160;1 to ZTlido Royalty Purchase Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;28, 2025, the Company and Scilex Pharma entered into an Amendment No.&#160;1 to Purchase and Sale Agreement (the &#8220;ZTlido Royalty Amendment&#8221;) with the purchasers (the &#8220;ZTlido Royalty Purchasers&#8221;) under that certain Purchase and Sale Agreement, dated as of October&#160;8, 2024 (the &#8220;ZTlido Royalty Purchase Agreement&#8221;). Pursuant to the Royalty Amendment, the Company and Scilex Pharma may assign their respective rights or delegate their respective obligations under the ZTlido Royalty Purchase Agreement without the prior written consent of the Purchasers if the Company receives a commitment, contingent upon an asset purchase of Covered Products (as defined in the ZTlido Royalty Purchase Agreement), that would allow the Company to pay in full all obligations owed under the Debt Instruments (as defined therein), provided that such purchaser of Covered Products agrees to assume all of the obligations of the Company and Scilex Pharma under the ZTlido Royalty Purchase Agreement. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gloperba Rest of World License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;28, 2025 (the &#8220;Effective Date&#8221;), the Company entered into a License Agreement (the &#8220;Gloperba License Agreement&#8221;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#8220;Licensed Product&#8221; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;collectively, the &#8220;Gloperba Product&#8221;). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-transferable</div> (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Blocking</div> Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Gloperba Product for commercialization of Gloperba Products in the United States in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Gloperba Product for commercialization in the United States in the Field (as defined therein). Each of the Licensee and the Company will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#8217;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc"></a></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Promptly after the Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#8217;s contract manufacturer of the Gloperba Product (the &#8220;Gloperba CMO&#8221;) as of the Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The term of the Gloperba License Agreement commences on the Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;Gloperba License Term&#8221;). </div></div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Reverse Stock Split </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share. Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant, which were not affected by the Reverse Stock Split. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, include all adjustments of a normal recurring nature necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2024 as filed with the SEC on March&#160;31, 2025 (the &#8220;Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K&#8221;).</div> The interim </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025 or for any future <div style="letter-spacing: 0px; top: 0px;display:inline;">periods.</div> </div><span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single, reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the unaudited condensed consolidated statements of operations. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the unaudited condensed consolidated statements of operations and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the unaudited condensed consolidated balance sheets. Accordingly, the unaudited condensed consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#8220;CODM&#8221;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the consolidated statements of operations and comprehensive loss. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the consolidated statements of operations and comprehensive loss and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the consolidated balance sheets. Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Customer and Supplier Concentration Risk</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the three months ended March&#160;31, 2025 and 2024, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 99% and 85% of the Company&#8217;s revenue for the three months ended March&#160;31, 2025 and 2024, respectively, and individually ranging from 14% to 47% and 24% to 31%, respectively. As of March&#160;31, 2025 and 2024, these customers represented 89% and 94% of the Company&#8217;s outstanding accounts receivable, individually ranging </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">between 18% and 37%, and 25% and 36% for respective periods. Additionally, during the three months ended March&#160;31, 2025 and 2024, the Company purchased ZTlido, ELYXYB and GLOPERBA inventories from its sole suppliers, Itochu, Contract Pharmaceuticals Ltd. Canada (&#8220;CPL&#8221;) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the three months ended March&#160;31, 2025 and <div style="display:inline;">2024.</div> </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Customer and Supplier Concentration Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had three customers during the years ended December&#160;31, 2024 and 2023, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 86% and 85% of the Company&#8217;s revenue for the years ended December&#160;31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December&#160;31, 2024 and 2023, three customers represented 95% and 91% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December&#160;31, 2024 and 2023, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). In November 2023 and February 2024, respectively, the Company started purchasing ELYXYB and GLOPERBA inventories from its sole suppliers, Contract Pharmaceuticals Ltd Canada (CPL) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers and limits its credit exposure by setting credit limits. During the years ended December&#160;31, 2024 and 2023, the Company had allowances for expected credit losses of $1.2&#160;million and nil, respectively. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the condensed consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 1 - </div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 2 - </div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-weight:bold;display:inline;">Level 3 - </div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, FSF Deposit and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 1</div></div> - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 2</div></div> - Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level 3</div></div> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consisted of deposits placed in a segregated bank account as required under the terms of the eCapital Credit Agreement (as defined below), which is discussed further in Note 7. Restricted cash was recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. There is no restricted cash as of December&#160;31, 2024, because Scilex Pharma paid off the outstanding amount of all obligations and indebtedness under the eCapital Credit Agreement in October 2024, which agreement was terminated thereafter. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents were immaterial as of December&#160;31, 2024 and 2023. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as selling, general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company reviews reserves and makes adjustments based on historical experience, current economic conditions and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for credit losses on accounts receivable were $1.1&#160;million and $1.2&#160;million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for prompt payment discounts were $0.4&#160;million and $0.6&#160;million,<div style="display:inline;"> respectively.</div> </div><span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of December&#160;31, 2024, the Company recorded $1.2&#160;million of allowances for credit losses on its accounts receivable. As of December&#160;31, 2023, the Company did not deem any allowances for expected credit losses on its accounts receivable necessary. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2024 and 2023, the Company&#8217;s inventory was primarily comprised of finished goods. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations and comprehensive loss unless there is an alternative future use. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statements of operations and comprehensive loss. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging</div></div>, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Contracts on an Entity&#8217;s Own Equity,</div></div> the Company determines how to account for warrants either assumed in connection with the Business Combination or issued under various financing arrangements. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. The Company records them in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. Warrants accounted for as liabilities are recorded at their estimated fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized in the consolidated statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">The Oramed Note and Tranche B Notes</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">The Oramed Note and Tranche B Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Tranche B Notes (as defined in Note 2 &#8220;<div style="font-style:italic;display:inline;">Liquidity and Going Concern</div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style:italic;display:inline;">Fair Value Measurements</div>&#8221; below) that were issued in October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of&#160;changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. As of March&#160;31, 2025 and December&#160;31, 2024, the weighted-average interest rates for the short-term loans, including these financial instruments, were 8.35% and 6.67%, respectively. </div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock', window );">Convertible Debentures and the Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Debentures, the Oramed Note, FSF Deposit and Tranche B Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures, the FSF Deposit, the Tranche B Notes (each as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) and the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below) that were issued in March and April 2023, June 2024, October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. The weighted-average interest rates for the short-term loans, including these financial instruments, were 6.67% and 13.55% for the years ended December&#160;31, 2024 and 2023, respectively. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiabilityPolicyTextBlock', window );">Purchased Revenue Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Purchased Revenue Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchased revenue liability is associated with the Purchase and Sale Agreement (the &#8220;ZTlido Royalty Purchase Agreement&#8221;) that the Company entered into in October 2024 (Note 7). The Company elected the fair value option to account for the purchased revenue liability (as described in Note 4 &#8220;Fair Value Measurements&#8221; below). The Company recorded the ZTlido Royalty Purchase Agreement at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the purchased revenue liability were expensed as incurred. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Research and Development</div></div>. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2024 and 2023, the Company maintained a full valuation allowance against its deferred tax assets. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido, ELYXYB and GLOPERBA. The Company&#8217;s performance obligation with respect to sales of ZTlido, ELYXYB and GLOPERBA is satisfied at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">point-in-time,</div></div> when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2024 and 2023 were not material. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns, special marketing programs and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Payment</div> Assistance </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-payment</div> assistance is presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheets. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, <div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#160;&#8211; Stock<div style="display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation</div></div><div style="font-size: 10pt;display:inline;">, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or </div><div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee&#8217;s</div><div style="font-size: 10pt;display:inline;"> vesting period. The Company accounts for forfeitures as incurred.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TreasuryStockPolicyTextblock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Treasury Stock </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method required for participating securities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants, which consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share to the extent all vesting conditions or exercise contingencies are removed except for the passage of time. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space:nowrap;display:inline;">2024-03,</div> <div style="font-style:italic;display:inline;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</div>, which will require additional expense disclosures for all public entities. The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space:nowrap;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space:nowrap;display:inline;">2024-04,</div> <div style="font-style:italic;display:inline;">Debt-Debt with Conversion and Other Options</div>, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space:nowrap;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space:nowrap;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Improvements to Reportable Segment Disclosures</div></div> (Topic 280), which requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted this ASU retrospectively on December&#160;31, 2024. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</div></div>, which will require additional expense disclosures for all public entities. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#8217;s definition of selling expenses. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8212;Debt with Conversion and Other Options</div></div>, which clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-04</div> is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06.</div> The Company is currently evaluating the impact of this amendment on its consolidated financial statements. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reverse Stock Split </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">1-for-35</div></div> (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-Reverse</div> Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.&#160;Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#8217;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2025, as compared to the significant accounting policies described in Note 1 of the Notes to Consolidated Financial Statements in the Company&#8217;s audited consolidated financial statements included in the Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div> </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Cash equivalents were immaterial as of March&#160;31, 2025 and December&#160;31, 2024. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debentures and the Oramed Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Warrant And Private Placement Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TreasuryStockPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Policy TextBlock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TreasuryStockPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value assets measured on a recurring basis</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657740;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Balance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-hidden:hidden145657741;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased Revenue Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657738;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Significant<br/>Unobservable<br/>Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden145657739;display:inline;">Derivative liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(10,409</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table includes a summary of the derivative liabilities measured at fair value during the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 89%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellation of Private Warrants as part of Oramed Letter Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant amendment and exercise as part of December 2024 RDO</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of December 2024 RDO <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(984</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(17,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of March&#160;31, 2025 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">402.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">83.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">79.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">98.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.91</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the inputs used in valuing the derivative warrant liabilities as of December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Private<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">February&#160;2024<br/> BDO Firm<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">April&#160;2024<br/> RDO&#160;Common<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Deposit<br/> Warrant</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">October&#160;2024<br/> Noteholder<br/> Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants (5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;2024<br/> RDO Common<br/> Warrants&#160;(2.5yr)</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">402.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">81.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">80.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">73.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">77.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">95.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.33</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">February<br/>2024&#160;BDO<br/>Firm<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">April&#160;2024<br/>RDO<br/>Common<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Deposit<br/>Warrant</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">October<br/>2024<br/>Noteholder<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December<br/>2024&#160;RDO<br/>Common<br/>Warrants<br/>(2.5yr)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="26" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 44%;"></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 3%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">402.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">59.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">38.50</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">1.20</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">36.40</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">22.72</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">22.72</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">2.86</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.18</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.32</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.47</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.77</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.95</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">2.45</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">109.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">81.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">80.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">73.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">77.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">76.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">95.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.22</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.29</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.30</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.30</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.32</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.33</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">4.21</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 19%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Private<br/>Warrants</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:19%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">402.50</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">3.86</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">76.0</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);">3.90</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">0.0</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpensesTextblock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,601</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued litigation expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpensesTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses Textblock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpensesTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of identifiable intangible assets</a></td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of March&#160;31, 2025 and December&#160;31, 2024 is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">31,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2024 and 2023 is as follows (in thousands): <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Intangibles,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization expense related to intangible assets</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of March&#160;31, 2025 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">31,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Estimated future amortization expense related to intangible assets as of December&#160;31, 2024 is as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2029</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schdule of Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,375</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfTheOramedNoteTableTextBlock', window );">Schedule of the Oramed Note</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Oramed Note - recorded in the consolidated statements of operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit', window );">Schedule of FSF Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of June&#160;11, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of FSF Deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(13,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock', window );">Schedule of revenue liability activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement during the three months ended March&#160;31, 2025 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(797</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the purchased revenue liability activity during the year ended December&#160;31, 2024 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of purchased revenue liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfTheTrancheBNoteTableTextBlock', window );">Schedule of the Tranche B Note</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche&#160;B Notes (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2025</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of Tranche B Notes principal and interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfTheOramedNoteTableTextBlock', window );">Schedule of the Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(64,200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion into Tranche B Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; recorded in the consolidated statements of operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Change in fair value of Oramed Note &#8211; due to instrument-specific credit risk recorded as a component of other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember', window );">Tranche B Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfTrancheBNotesTableTextBlock', window );">Schedule of Tranche B Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of October&#160;8, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">42,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Tranche B notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(9,255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,283</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Revenue Liability Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfTheOramedNoteTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of The Oramed Note Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfTheOramedNoteTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfTheTrancheBNoteTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tavular disclosure of The Tranche B Note Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfTheTrancheBNoteTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfTrancheBNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Tranche B Notes [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfTrancheBNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of the Changes in the Balance and the Estimated Fair Value of the FSF Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Outstanding Activity</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the three months ended March&#160;31, 2025 (in thousands, except for per share amounts and contractual life): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">149.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of March&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes stock option activity during the year ended December&#160;31, 2024 (shares in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 55%;">&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 6%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life,<br/> in years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2023</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">946</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">153.15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7.5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7,459</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">129</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">33.21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">51.67</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited/Cancelled</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">(43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">160.56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1,028</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">138.23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">6.43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1,028</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">138.23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">6.43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable as of December&#160;31, 2024</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">727</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">113.01</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">5.5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumption Used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 71%;"></td>
<td style="vertical-align: bottom; width: 4%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.00%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">72.00%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div>119.08%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">3.79%<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;-<div style="display:inline;">&#160;</div></div>4.71%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">3.0<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">-<div style="display:inline;">&#160;</div></div>6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.00%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">129.30%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">5.39%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Leases Supplemental Quantitative Information</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(227</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(277</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate - operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 69%;"></td>
<td style="vertical-align: bottom; width: 10%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 9%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 69%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025 (Remainder of 2025)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(347</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Benefit for Income Taxes</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision (benefit) expense were as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax (benefit) expense:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current income tax (benefit) expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax benefit:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(16,279</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(16,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,803</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(11,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax benefit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(19,082</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(27,761</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax (benefit) expense from continuing operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">71,434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchased revenue liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(113,703</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(96,776</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,423</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,997</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2024&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(15,290</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">true-up</div> and carryback</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,079</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,705</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the beginning of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to current year tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross unrecognized tax benefits at the end of the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the reconciliation of basic and diluted loss per share</a></td>
<td class="text">The following table sets forth the reconciliation of basic and diluted loss per share for the three months ended March&#160;31, 2025 and 2023 (in thousands except per share data): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(26,080</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2.26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8.33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2024 and 2023 (in thousands except per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; text-align: center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(72,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(52,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(72,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reversal of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">mark-to-market</div></div> adjustment for liability classified warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8,895</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(81,702</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common stock warrants exercisable for nominal consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,061</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares, diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(7.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(44.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(8.05</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(44.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">March&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,022,353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,027,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,114,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,158,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">428,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposit Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Noteholder Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">214,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,668,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,817,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,027,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">946,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">195,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Firm Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">108,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 2024 RDO Placement Agent Warrants<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">399,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">114,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">103,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">February 2024 BDO Representative Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to the ESPP</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under the SIPA</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">October 2024 Placement Agent Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December 2024 RDO Common Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,642,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">StockBlock Warrants</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issuable under Tranche B Notes</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,158,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,817,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,376,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for expected credit losses accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AllowancesForPromptPaymentDiscounts', window );">Allowances for prompt payment discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">the Board of Directors of the Company (the &#8220;Board&#8221;) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the &#8220;Reverse Stock Split&#8221;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetRevenueSoleDistributors', window );">Percentage of net revenue, sole distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Expected Credit Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Minimum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Maximum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Maximum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.67%<span></span>
</td>
<td class="nump">13.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AllowancesForPromptPaymentDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowances for Prompt Payment Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AllowancesForPromptPaymentDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk threshold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Descriptionof Organizationand Business Operations Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfNetRevenueSoleDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue, sole distributors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfNetRevenueSoleDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sclx_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sclx_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 3,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 3,272<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
<td class="nump">$ 4,729<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Mar. 21, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 18, 2024</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Negative working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272,000<span></span>
</td>
<td class="nump">$ 3,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,898,000)<span></span>
</td>
<td class="num">$ (19,478,000)<span></span>
</td>
<td class="num">(83,396,000)<span></span>
</td>
<td class="num">(105,431,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (589,132,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (563,052,000)<span></span>
</td>
<td class="num">$ (490,245,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrincipalLaonAmount', window );">Principal loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long Term Commitment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentAmountPayable', window );">Commitment Amount Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long term Purchase Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheDepositAmount', window );">Company receives the Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheDepositPeriod', window );">Company Receives The Deposit Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonRefundableDepositAmount', window );">Non-Refundable Deposit Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfTheWarrants', window );">Deposit Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember', window );">Equity Purchase Agreement with Yorkville and B. Riley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Convertibledebentureprincipalamount', window );">Convertible Debenture principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfTheWarrants', window );">Deposit Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A&amp;R Yorkville Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember', window );">ATM Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember', window );">Satisfaction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProductLiabilityGross', window );">Liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member] | ATM Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockIssuableValue', window );">Common Stock Issuable Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Debt Instrument, Convertible, Conversion Price, Decrease</a></td>
<td class="nump">36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Tranche B Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="nump">$ 38.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Common Stock [Member] | Investor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument Repurchased Face Amount</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_OramedMember', window );">Oramed [Member] | Principal Balance [Member] | Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReductionOfThePrincipalBalance', window );">Reduction of the principal balance</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_InitialClosingMember', window );">Initial Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheDepositAmount', window );">Company receives the Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonRefundableDepositAmount', window );">Non-Refundable Deposit Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_SecondClosingMember', window );">Second Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheDepositAmount', window );">Company receives the Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment Amount Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockIssuableValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockIssuableValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompanyReceivesTheDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Receives The Deposit Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompanyReceivesTheDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompanyReceivesTheDepositPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Receives The Deposit Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompanyReceivesTheDepositPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Convertibledebentureprincipalamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ConvertibleDebentureprincipalAmount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Convertibledebentureprincipalamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExercisePriceOfTheWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Of The Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExercisePriceOfTheWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonRefundableDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Refundable Deposit Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonRefundableDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrincipalLaonAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal laon amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrincipalLaonAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReductionOfThePrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of the Principal Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReductionOfThePrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightToSellMaximumNumberOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Sell Maximum Number of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightToSellMaximumNumberOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProductLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount of the accrual for damages arising from third-party use of the entity's product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProductLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sclx_TrancheBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sclx_TrancheBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_InvestorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_InvestorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_OramedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_OramedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermDebtTransactionsAxis=sclx_PrincipalBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermDebtTransactionsAxis=sclx_PrincipalBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_InitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_InitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_SecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_SecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and License Agreements (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2025</div></th>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToAcquireLicense', window );">Payment to acquire license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedRoyaltyPayables', window );">Accrued Royalty Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember', window );">Tlido Rest Of World License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLidocaineTopicalSystem', window );">Percentage of Lidocaine Topical System</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePaymentOfCompany', window );">Aggregate Payment Of Company</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_GloperbaRestOfWorldLicenseAgreementMember', window );">Gloperba Rest of World License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, Remaining Performance Obligation, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ElyxybRestOfWorldLicenseAgreementMember', window );">Elyxyb Rest of World License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, Remaining Performance Obligation, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmountDueForNewDrugApplication', window );">Amount due for New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Tlido Rest Of World License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, Remaining Performance Obligation, Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Development milestones payment was recognized under other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember', window );">License Agreement | Romeg License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Upfrontlicensefee', window );">Up-front license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Non-RefundableNon-CreditablePayment', window );">Non-Refundable, Non-Creditable Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransferOfCommonStockShares', window );">Transfer of Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Deferredconsiderationliabilities', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedRoyaltyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedRoyaltyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePaymentOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Payment Of Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePaymentOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmountDueForNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due for New Drug Application</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmountDueForNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Deferredconsiderationliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredConsiderationLiabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Deferredconsiderationliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Non-RefundableNon-CreditablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Refundable, Non-Creditable Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Non-RefundableNon-CreditablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToAcquireLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to Acquire License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToAcquireLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentUponTheAchievementOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Upon The Achievement of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentUponTheAchievementOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfLidocaineTopicalSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Lidocaine Topical System</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfLidocaineTopicalSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransferOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransferOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Upfrontlicensefee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UpFrontLicenseFee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Upfrontlicensefee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_GloperbaRestOfWorldLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_GloperbaRestOfWorldLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ElyxybRestOfWorldLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ElyxybRestOfWorldLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SecuredNoteDiscountRate', window );">Note discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12907.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.82%<span></span>
</td>
<td class="nump">13.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeWarrantLiabilities', window );">Derivative warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,409,000<span></span>
</td>
<td class="num">$ (457,000)<span></span>
</td>
<td class="nump">17,378,000<span></span>
</td>
<td class="num">(512,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Common stock upon conversation of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate', window );">Discount rate of FDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfContingentConsideration', window );">Development Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">104,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueDueToCreditRisk', window );">Change in fair value due to credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember', window );">Tranche BNotes Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PurchasedRevenueLiabilityMember', window );">Purchased Revenue Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember', window );">FSF Deposit Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember', window );">Gloperba Elyxyb Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember', window );">February 2024 BDO Firm Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember', window );">February 2024 BDO Firm Warrants [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember', window );">April 2024 RDO Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember', window );">April 2024 RDO Common Warrants [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember', window );">October 2024 Noteholder Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember', window );">October 2024 Noteholder Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_December2024RDOCommonWarrantsMember', window );">December 2024 RDO Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,512,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,512,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_December2024RDOCommonWarrantsMember', window );">December 2024 RDO Common Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueDueToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Due To Credit Risk</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueDueToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Convertible Debentures Include Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DerivativeWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DerivativeWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SecuredNoteDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Note Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SecuredNoteDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_PurchasedRevenueLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_PurchasedRevenueLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_December2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_December2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">$ 14,962<span></span>
</td>
<td class="nump">$ 12,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Tranche B Notes</a></td>
<td class="nump">24,480<span></span>
</td>
<td class="nump">23,560<span></span>
</td>
<td class="nump">$ 42,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 7,894<span></span>
</td>
<td class="nump">$ 18,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">54,791<span></span>
</td>
<td class="nump">60,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Tranche B Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Tranche B Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">14,962<span></span>
</td>
<td class="nump">12,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Tranche B Notes</a></td>
<td class="nump">24,480<span></span>
</td>
<td class="nump">23,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">7,894<span></span>
</td>
<td class="nump">18,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 54,791<span></span>
</td>
<td class="nump">$ 60,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheBNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche B Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheBNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, beginning</a></td>
<td class="nump">$ 18,303<span></span>
</td>
<td class="nump">$ 1,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in fair value measurement</a></td>
<td class="num">(10,409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Settlement of December 2024 RDO Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, ending</a></td>
<td class="nump">7,894<span></span>
</td>
<td class="nump">18,303<span></span>
</td>
<td class="nump">$ 1,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, beginning</a></td>
<td class="nump">18,303<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,378)<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForfeitureOfPrivateWarrants', window );">Forfeiture of Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfFirmWarrants', window );">Issuance of February 2024 BDO Firm Warrants as part of the February 2024 BDO, April 2024 RDO Common Warrants as part of the April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of the December 2024 RDO, and December 2024 RDO Pre-Funded Warrants as part of the December 2024 RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit', window );">Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering', window );">Warrant amendment and exercise as part of the December 2024 RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Settlement of December 2024 RDO Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, ending</a></td>
<td class="nump">$ 7,894<span></span>
</td>
<td class="nump">$ 18,303<span></span>
</td>
<td class="nump">$ 1,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInValuationInputsOrOtherAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation inputs or other assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInValuationInputsOrOtherAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Firm warrant amendment and exercise as part of the December Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForfeitureOfPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeiture of Private Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForfeitureOfPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfFirmWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Firm Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfFirmWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclass of Deposit Warrant Liability Upon Satisfaction Of The FSF Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 402.5<span></span>
</td>
<td class="nump">$ 402.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402.5<span></span>
</td>
<td class="nump">$ 402.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">3 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember', window );">February 2024 BDO Firm Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">3 years 11 months 4 days<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember', window );">February 2024 BDO Firm Warrants [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember', window );">April 2024 RDO Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">4 years 25 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember', window );">April 2024 RDO Common Warrants [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrant [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember', window );">October 2024 Noteholder Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">4 years 6 months 7 days<span></span>
</td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember', window );">October 2024 Noteholder Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsFiveYearMember', window );">December Common Warrants Five Year [Member] | December RDO Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">4.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsFiveYearMember', window );">December Common Warrants Five Year [Member] | December RDO Common Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsTwoPointFiveYearMember', window );">December Common Warrants Two Point Five Year [Member] | December RDO Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsTwoPointFiveYearMember', window );">December Common Warrants Two Point Five Year [Member] | December RDO Common Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_February2024BDOFirmWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_April2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_DepositWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_October2024NoteholderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsFiveYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsFiveYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_DecemberRDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_DecemberRDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsTwoPointFiveYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_DecemberCommonWarrantsTwoPointFiveYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Acrcued expenses - Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional service fees</a></td>
<td class="nump">$ 2,153<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 2,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Accrued tax payable</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued litigation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued others</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">$ 3,482<span></span>
</td>
<td class="nump">$ 2,841<span></span>
</td>
<td class="nump">$ 7,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
<th class="th"><div>Jun. 18, 2024</div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Cash Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (10,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ImpairmentLoss', window );">Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember', window );">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Cash Consideration</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsNetAmount', window );">Net Amount of shares</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember', window );">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember', window );">Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member] | Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Cash Consideration</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 40.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_SemnurCommonStockMember', window );">Semnur Common Stock [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock at a conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Debt accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Principal Balance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,063.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Remaining Drawable Balance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,936.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock at a conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount applicable to investors of capital units or shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_SemnurCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_SemnurCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermDebtTransactionAxis=sclx_PrincipalBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermDebtTransactionAxis=sclx_PrincipalBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermDebtTransactionAxis=sclx_RemainingDrawableBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermDebtTransactionAxis=sclx_RemainingDrawableBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="nump">$ 13,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life for identifiable intangible assets</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="nump">$ 4,031<span></span>
</td>
<td class="nump">$ 4,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember', window );">Patent Rights Acquired Technology And Acquired Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property Plant And Equipment Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite Lived Intangible Asset Useful Life</a></td>
<td class="text">12 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite Lived Intangible Asset Useful Life</a></td>
<td class="text">6 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property Plant And Equipment Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 60,781<span></span>
</td>
<td class="nump">$ 60,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">29,330<span></span>
</td>
<td class="nump">28,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">31,451<span></span>
</td>
<td class="nump">32,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">18,314<span></span>
</td>
<td class="nump">17,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">14,316<span></span>
</td>
<td class="nump">14,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">9,509<span></span>
</td>
<td class="nump">9,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">12,431<span></span>
</td>
<td class="nump">12,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember', window );">Acquired licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">4,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract', window );"><strong>As of March 31,2023</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 4,006<span></span>
</td>
<td class="nump">$ 4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,423<span></span>
</td>
<td class="nump">12,423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">31,451<span></span>
</td>
<td class="nump">$ 32,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remainder of 2025)</a></td>
<td class="nump">$ 3,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization,after Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization,after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>Days</div>
</th>
<th class="th">
<div>Jan. 21, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 23, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 17, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 16, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 21, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LoanAmount', window );">Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonRefundableDepositAmount', window );">Non-Refundable Deposit Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DepositWarrantExercisePrice', window );">Warrant Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentAmount', window );">Commitment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheFsfDepositPeriod', window );">Company Receives The FSF Deposit Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Endeavor for Liquidated Damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,200,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value of the Fee Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,172,000<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiabilityCurrent', window );">Purchased Revenue Liability Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,115,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,876,000<span></span>
</td>
<td class="nump">108,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300,000<span></span>
</td>
<td class="nump">$ 46,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 23,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Maturity Date End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Payment to Oramed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,578,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,578,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">104,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 23,  2024<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 23,  2024<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember', window );">Deferral and Consent under Tranche B Senior Secured Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember', window );">Deferral and Consent under Tranche B Senior Secured Convertible Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPrincipalAmountPercentage', window );">Debt Instrument Principal Amount, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company had the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertibleDebenturesIssuedPercent', window );">Convertible Debentures Issued Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | First installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Second Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Third Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the sale of shares of Common Stock pursuant to the ATM Sales Agreement, the Company made a mandatory<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentExitFee', window );">Debt Repayment Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOwnedPercentage', window );">Debt instrument, owned, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentDefaultInterestRate', window );">Debt instrument, default interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount', window );">Debt instrument, percentage of interest accrued on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount', window );">Debt repayment, percentage of mandatory default rate of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest', window );">Debt repayment, percentage of mandatory default rate of accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing', window );">Percentage of usage of cash proceeds from cash sweep financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice', window );">Purchase price for the purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Monthly Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | First installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Second Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Third Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Fourth Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Five Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Oramed Note | Six Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember', window );">Satisfaction Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember', window );">Gloperba-Elyxyb Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetailLandSalesReceivablesStatedInterestRate', window );">Percentage of aggregate net sales</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoOfCalendarDays', window );">No of Calendar Days | Days</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesDelivered', window );">Shares Delivered | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesDelivered', window );">Shares Delivered | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=sclx_TrancheBNoteMember', window );">Tranche B Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=sclx_TrancheBNoteMember', window );">Tranche B Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A&amp;R Yorkville Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetCashProceeds', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Convertible Debentures Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common Stock at a conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOutstandingPrincipal', window );">Outstanding debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember', window );">ATM Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement | Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 23,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Maturity Date End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Payment to Oramed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement | Oramed Note | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Date of Maturity Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Maturity Date End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement | Oramed Note | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement | Oramed Note | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_OramedMember', window );">Oramed [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_OramedMember', window );">Oramed [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember', window );">Rodman &amp; Renshaw LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember', window );">Rodman &amp; Renshaw LLC [Member] | Tranche B Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_FederalFundsPurchasedAverageRatePaid', window );">Federal funds purchased, average rate paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Royalty Purchase Agreement [Member] | Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Amount paid for purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Amount extinguished and reduced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice', window );">Purchase price for the purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ZTlidoRoyaltyMember', window );">ZTlido Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiabilityCurrent', window );">Purchased Revenue Liability Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_InitialClosingMember', window );">Initial Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonRefundableDepositAmount', window );">Non-Refundable Deposit Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompanyReceivesTheFsfDepositAmount', window );">Company receives the FSF Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SecondClosingMember', window );">Second Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExistingFacilityCapMaximum', window );">Facility cap maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExistingFacilityCapMinimum', window );">Facility cap minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOutstandingPrincipal', window );">Outstanding debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan', window );">Accounts receivable revolving loan facility in an aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line Of Credit Facility Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Decrease in common stock at a conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsReceivedFromPurchaseAgreement', window );">Proceeds received from purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss in changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice', window );">Purchase price for the purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Investor Agreement [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Purchased Revenue Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Common Stock [Member] | Securities Purchase Agreement | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Common Stock [Member] | Investor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument Repurchased Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Tranche B Note [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Tranche B Note [Member] | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Tranche B Note [Member] | Investor Agreement [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Tranche B Note [Member] | Common Stock [Member] | Securities Purchase Agreement | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Oramed [Member] | Securities Purchase Agreement | Principal Balance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReductionOfThePrincipalBalance', window );">Reduction of the principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Oramed [Member] | Investor Agreement [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Oramed [Member] | Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Amount paid for purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Amount extinguished and reduced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Oramed [Member] | Tranche B Note [Member] | Investor Agreement [Member] | October Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember', window );">Senior Secured Convertible Notes [Member] | Scilex Pharma [Member] | Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaidToRoyaltyInvestors', window );">Paid to royalty investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice', window );">Purchase price for the purchased receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompanyReceivesTheFsfDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company receives the FSF Deposit Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompanyReceivesTheFsfDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompanyReceivesTheFsfDepositPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Receives The FSF Deposit Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompanyReceivesTheFsfDepositPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertibleDebenturesIssuedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debentures Issued Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertibleDebenturesIssuedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument outstanding principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentOwnedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Owned, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentOwnedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage of Interest Accrued on Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DepositWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DepositWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExistingFacilityCapMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Existing Facility Cap Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExistingFacilityCapMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExistingFacilityCapMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Existing facility cap minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExistingFacilityCapMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>net cash proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoOfCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No of Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoOfCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonRefundableDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Refundable Deposit Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonRefundableDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaidToRoyaltyInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid to Royalty Investors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaidToRoyaltyInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Usage of Cash Proceeds from Cash Sweep Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsReceivedFromPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received from Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsReceivedFromPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Common Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReductionOfThePrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of the Principal Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReductionOfThePrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Delivered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>termination fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TotalNumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Number of Shares Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TotalNumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_FederalFundsPurchasedAverageRatePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average rate paid on federal funds purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (3)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_FederalFundsPurchasedAverageRatePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepaidPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepaidPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount at purchase price of financing receivable purchased with credit deterioration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of revolving financing receivable converted to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 79<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRevolvingConvertedToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of all receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetailLandSalesReceivablesStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stated interest rate for receivables from retail land sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 976<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477332/976-310-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetailLandSalesReceivablesStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FristInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FristInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_SecondInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_SecondInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ThirdInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ThirdInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtPayableAxis=sclx_MonthlyBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtPayableAxis=sclx_MonthlyBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FourthInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FourthInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FiveInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FiveInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_SixInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_SixInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SatisfactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sclx_TrancheBNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sclx_TrancheBNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_OramedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_OramedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ZTlidoRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ZTlidoRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_InitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_InitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_SeniorSecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_OctoberCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_OctoberCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_InvestorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_InvestorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_PrincipalBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_PrincipalBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Summary of Outstanding Convertible Debenture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, beginning period</a></td>
<td class="nump">$ 12,161<span></span>
</td>
<td class="nump">$ 104,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfConvertibleDebenture', window );">Repayment of Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of Tranche B notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebentures', window );">Change in fair value of Convertible debentures</a></td>
<td class="num">(2,801)<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect', window );">Change in fair value due to instrument specific credit risk recorded as a component of other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, ending period</a></td>
<td class="nump">14,962<span></span>
</td>
<td class="nump">12,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, beginning period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfConvertibleDebenture', window );">Repayment of Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebentures', window );">Change in fair value of Convertible debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Convertible Debentures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Convertible Debenture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of FSF Deposit (Details) - FSF Loan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Beginning Balance as of January 1, 2024</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Change in fair value of FSF Deposit</a></td>
<td class="nump">4,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit', window );">Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit</a></td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfDeposit', window );">Repayment of FSF Deposit</a></td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Ending Balance as of September 30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclass of Deposit Warrant Liability Upon Satisfaction Of The FSF Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479024/942-230-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_FSFLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_FSFLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of the Tranche B Note (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Ending Balance as of December 31, 2024</a></td>
<td class="nump">$ 23,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Ending Balance as of March 31, 2025</a></td>
<td class="nump">24,480<span></span>
</td>
<td class="nump">$ 23,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember', window );">Tranche B Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Ending Balance as of December 31, 2024</a></td>
<td class="nump">23,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of Tranche B notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfTrancheBNotes', window );">Repayment of Tranche B Notes</a></td>
<td class="num">(1,596)<span></span>
</td>
<td class="num">(3,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfTrancheBNotes', window );">Change in fair value of Tranche B Notes</a></td>
<td class="nump">2,516<span></span>
</td>
<td class="num">(6,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TrancheBNote', window );">Ending Balance as of March 31, 2025</a></td>
<td class="nump">$ 24,480<span></span>
</td>
<td class="nump">$ 23,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfTrancheBNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Tranche B Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfTrancheBNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfTrancheBNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Tranche B Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfTrancheBNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheBNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche B Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheBNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TrancheBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of revenue liability activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Ending Balance as of December 31, 2024</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfPurchasedRevenueLiability', window );">Change in fair value of purchased revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Ending Balance as of March 31, 2025</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_ZTlidoRoyaltyMember', window );">ZTlido Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Ending Balance as of December 31, 2024</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfPurchasedRevenueLiability', window );">Change in fair value of purchased revenue liability</a></td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasedRevenueLiability', window );">Ending Balance as of March 31, 2025</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfPurchasedRevenueLiability', window );">Repayment of purchased revenue liability</a></td>
<td class="num">$ (797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfPurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Purchased Revenue Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfPurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased Revenue Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfPurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of purchased revenue liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfPurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_ZTlidoRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_ZTlidoRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of the Oramed Note (Details) - Senior Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, beginning period</a></td>
<td class="nump">$ 12,161<span></span>
</td>
<td class="nump">$ 104,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebentures', window );">Change in fair value of Oramed Note - recorded in the consolidated statements of operations</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="num">(3,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, ending period</a></td>
<td class="nump">$ 14,962<span></span>
</td>
<td class="nump">$ 12,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Convertible Debentures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Jul. 05, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember', window );">Oramed Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember', window );">Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfWarrants', window );">Fair Value Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PennyWarrantsExercised', window );">Penny Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member', window );">Subsequent Penny Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member', window );">Subsequent Penny Warrants 2 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member', window );">Subsequent Penny Warrants 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 17,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member', window );">Subsequent Penny Warrants 3 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member', window );">Subsequent Penny Warrants 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">Aug. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member', window );">Subsequent Penny Warrants 4 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="nump">5,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants5Member', window );">Subsequent Penny Warrants 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants5Member', window );">Subsequent Penny Warrants 5 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,617<span></span>
</td>
<td class="nump">39,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfSharesRepurchased', window );">Fair Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,386,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member] | Closing Penny Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member] | Closing Penny Warrant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member] | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransferOfWarrants', window );">Transfer of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member] | Subsequent Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note [Member] | Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfShareOutstanding', window );">Number Of Share Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Accured expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento | Junior DIP Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssueOfWarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of Warrants to Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssueOfWarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PennyWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penny Warrants exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PennyWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransferOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransferOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Vesting Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_OramedLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2024 </div>
<div>USD ($) </div>
<div>Days </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 21, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock Common Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of shares under direct offerings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 41,967,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment made to Investor | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CombinedPricePaidOfWarrant', window );">Combined Price Paid | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ClearingExpenses', window );">Clearing expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember', window );">Series One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Preferred Stock Dividends, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading Days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember', window );">Series One Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading Days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_HudsonBayMember', window );">Hudson Bay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of shares under direct offerings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember', window );">Rodman &amp; Renshaw LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPrice', window );">Public Offering Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember', window );">Rodman &amp; Renshaw LLC | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_CoveLaneMember', window );">Cove Lane [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A R Yorkville Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfStockPercentage', window );">Purchase of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">330,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A R Yorkville Purchase Agreement [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember', window );">B. Riley Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfStockPercentage', window );">Purchase of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember', window );">At-the-Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedSOfSaleOfCommonSharesPercentage', window );">Proceed's of sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember', window );">At-the-Market Sales Agreement | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RepresentativeWarrantsOutstandingMember', window );">Representative Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RepresentativeWarrantsOutstandingMember', window );">Representative Warrants Outstanding | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateGrossProceedsFromOffering', window );">Gross proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Securities Purchase Agreement | Common Stock | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share, warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CombinedPricePaidOfWarrant', window );">Combined Price Paid | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPriceCombined', window );">Public Offering Price Combined</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share, warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants | Rodman &amp; Renshaw LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPrice', window );">Public Offering Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants | Warrant Transfer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share, warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants | Warrant Transfer Agreement | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,613,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants | Registered Direct Offering | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_PublicWarrantsPurchaseCommonStockMember', window );">Public Warrants Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share, warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember', window );">Closing Penny Warrant [Member] | Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Securities Purchase Agreement | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Securities Purchase Agreement | Common Stock | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Representative Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Firm Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Firm Warrants | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfWarrantsExercised', window );">Number Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfWarrantsExercised1', window );">Number Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Firm Warrants | Securities Purchase Agreement | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Warrant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | December 2024 RDO Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,512,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,512,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | StockBlock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,601,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PreFundedWarrantsToPurchase', window );">Pre-funded warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | Securities Purchase Agreement | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PreFundedWarrantsToPurchase', window );">Pre-funded warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | Securities Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PreFundedWarrantPerShare', window );">Pre funded warrant per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.6499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember', window );">Common Warrants | Registered Direct Offering | Securities Purchase Agreement | Common Stock | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PreFundedWarrantPerShare', window );">Pre funded warrant per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.6499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents', window );">Cash fee percentage of gross proceeds paid to placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering', window );">Percent of total number of shares issued to agents in the Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentOfCombinedOfferingExercisePricePerShare', window );">Percent of combined offering exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Registered Direct Offering | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Registered Direct Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Registered Direct Offering | Common Stock | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember', window );">Placement Agent Warrants | Registered Direct Offering | StockBlock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,601,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants execiseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock Common Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock Common Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="nump">1,716,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_SpacWarrantsMember', window );">SPAC Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="nump">195,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="nump">103,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregateGrossProceedsFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds From Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregateGrossProceedsFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Fee Percentage of Gross Proceeds Paid to Placement Agents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ClearingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clearing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ClearingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CombinedPricePaidOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined Price Paid Of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CombinedPricePaidOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExercisePriceOfCommonWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Of Common Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExercisePriceOfCommonWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssueOfWarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of Warrants to Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssueOfWarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfWarrantsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfWarrantsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentOfCombinedOfferingExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of Combined Offering Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentOfCombinedOfferingExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of Total Number of Shares issued to Agents in the Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PreFundedWarrantPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre Funded Warrant Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PreFundedWarrantPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PreFundedWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre Funded Warrants to Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PreFundedWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedSOfSaleOfCommonSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceed s of sale of common shares percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedSOfSaleOfCommonSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPriceCombined">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price Combined</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPriceCombined</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Common Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of stock, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightToSellMaximumNumberOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Sell Maximum Number of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightToSellMaximumNumberOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SeriesOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_HudsonBayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_HudsonBayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_CoveLaneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_CoveLaneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RepresentativeWarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_RepresentativeWarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=sclx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=sclx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_PublicWarrantsPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_PublicWarrantsPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_FirmWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_FirmWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_SpacWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_SpacWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">1,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Outstanding, Forfeited/Cancelled</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="nump">1,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest as of March 31, 2025</a></td>
<td class="nump">1,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="nump">756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 138.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">149.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="nump">138.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price,Vested and expected to vest as of March 31, 2025</a></td>
<td class="nump">138.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 116.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, in year,Vested and expected to vest as of March 31, 2025</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value ,Vested and expected to vest as of March 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Outstanding, Forfeited/Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest as of March 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 138.23<span></span>
</td>
<td class="nump">$ 153.15<span></span>
</td>
<td class="nump">$ 153.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.23<span></span>
</td>
<td class="nump">$ 153.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price,Vested and expected to vest as of March 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, in year,Vested and expected to vest as of March 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value ,Vested and expected to vest as of March 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sclx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sclx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.49<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,558,000<span></span>
</td>
<td class="nump">15,689,000<span></span>
</td>
<td class="nump">14,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employee benefit plan contributions by employer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="nump">285,714<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAveragePeriodOverGrant', window );">Weighted average period over grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_Semnur2024StockOptionPlanMember', window );">Semnur 2024 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAveragePeriodOverGrant', window );">Weighted average period over grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 242,800<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WeightedAveragePeriodOverGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WeightedAveragePeriodOverGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_Semnur2024StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_Semnur2024StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases (in thousands)</a></td>
<td class="num">$ (227)<span></span>
</td>
<td class="num">$ (277)<span></span>
</td>
<td class="num">$ (1,042)<span></span>
</td>
<td class="num">$ (1,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years - operating leases</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (Remainder of 2025)</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,357<span></span>
</td>
<td class="nump">2,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,067<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LeaseLiabilityNetOfCurrentPortion', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">$ 1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LeaseLiabilityNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability, net of current portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LeaseLiabilityNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2013</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Additional ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="nump">2,943,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Corresponding lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,523,000<span></span>
</td>
<td class="nump">2,237,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember', window );">GLOPERBA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DueFromRelatedParty', window );">Due From Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember', window );">Former Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Agreement settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember', window );">Former Employee One[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Agreement settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember', window );">Epoladerm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember', window );">Probudur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember', window );">Envelta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Accrued royalty payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementMaturityDate', window );">Agreement maturity date</a></td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaturityRenewalDescription', window );">Agreement maturity renewal description</a></td>
<td class="text">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six months&#8217; written notice.<span></span>
</td>
<td class="text">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six-months&#8217; written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due From Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaturityRenewalDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity Renewal Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaturityRenewalDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RoyaltyPaymentPercentageOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RoyaltyPaymentPercentageOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage Related To Future Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RoyaltyPaymentPercentageRelatedToFutureYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(16,279)<span></span>
</td>
<td class="num">(16,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,803)<span></span>
</td>
<td class="num">(11,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(19,082)<span></span>
</td>
<td class="num">(27,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Changes in tax rate</a></td>
<td class="nump">2,155<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">16,927<span></span>
</td>
<td class="nump">29,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 85,226<span></span>
</td>
<td class="nump">$ 71,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsDebtRelatedInterest', window );">Debt related interest</a></td>
<td class="nump">16,228<span></span>
</td>
<td class="nump">16,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">5,228<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,415<span></span>
</td>
<td class="nump">3,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves', window );">Accrued expense and reserves</a></td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsPurchasedRevenueLiability', window );">Purchased revenue liability</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">116,700<span></span>
</td>
<td class="nump">100,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(113,703)<span></span>
</td>
<td class="num">(96,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">3,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,423)<span></span>
</td>
<td class="num">(2,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(574)<span></span>
</td>
<td class="num">(760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,997)<span></span>
</td>
<td class="num">(3,494)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, accrued expense and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsAccruedExpenseAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsDebtRelatedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, debt related interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsDebtRelatedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsPurchasedRevenueLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Purchased Revenue Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsPurchasedRevenueLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">$ (15,290)<span></span>
</td>
<td class="num">$ (24,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate', window );">Valuation allowance</a></td>
<td class="nump">18,559<span></span>
</td>
<td class="nump">29,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Compensation expense</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">3,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges', window );">Acquisition related charges</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true-up and carryback</a></td>
<td class="num">(1,182)<span></span>
</td>
<td class="num">(5,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal tax benefit</a></td>
<td class="num">(2,705)<span></span>
</td>
<td class="num">(5,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount', window );">Change in fair value of Convertible Debentures</a></td>
<td class="num">(4,449)<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount', window );">Change in tax rates</a></td>
<td class="nump">2,155<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(346)<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation acquisition related charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxReconciliationAcquisitionRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation valuation allowance at federal statutory income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 113,703<span></span>
</td>
<td class="nump">$ 96,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IndefiniteOperatingLossCarryforwards', window );">Indefinite net federal operating loss</a></td>
<td class="nump">313,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development income tax credits</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax expense, interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Income Tax Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount', window );">Tax credit, not subject to expire</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 336,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxCreditsExpirationYear', window );">Income tax credits, expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 248,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxCreditsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Credits Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxCreditsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IndefiniteOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IndefiniteOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Not Subject to Expire, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TaxCreditCarryforwardNotSubjectToExpireAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="num">$ (24,377)<span></span>
</td>
<td class="num">$ (72,807)<span></span>
</td>
<td class="num">$ (114,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPremium', window );">Premium on redemption of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss for basic and diluted loss per share available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,807)<span></span>
</td>
<td class="num">(166,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Reversal of mark-to-market adjustment for liability classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,895)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss for diluted loss per share available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (81,702)<span></span>
</td>
<td class="num">$ (166,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAverageNumberOfSharesOutstanding', window );">Weighted average number of shares outstanding</a></td>
<td class="nump">5,065,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,926,000<span></span>
</td>
<td class="nump">3,561<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration', window );">Weighted average common stock warrants exercisable for nominal consideration</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares - basic</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="nump">10,061,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfDilutiveSecurities', window );">Effect of dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares, diluted</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="nump">10,145,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share, Basic</a></td>
<td class="num">$ (2.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.33)<span></span>
</td>
<td class="num">$ (7.24)<span></span>
</td>
<td class="num">$ (44.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share, Diluted</a></td>
<td class="num">$ (2.26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.33)<span></span>
</td>
<td class="num">$ (8.05)<span></span>
</td>
<td class="num">$ (44.86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectOfDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of Dilutive Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectOfDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average common stock warrants exercisable for nominal consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480408/260-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">8,668,507<span></span>
</td>
<td class="nump">4,817,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,817,769<span></span>
</td>
<td class="nump">1,376,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,022,353<span></span>
</td>
<td class="nump">1,027,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember', window );">Stock Options | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,977<span></span>
</td>
<td class="nump">946,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember', window );">Retainer Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">399,999<span></span>
</td>
<td class="nump">399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember', window );">Retainer Shares | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,999<span></span>
</td>
<td class="nump">114,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderTrancheBNotesMember', window );">Shares issuable under Tranche B Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,114,770<span></span>
</td>
<td class="nump">1,158,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderTrancheBNotesMember', window );">Shares issuable under Tranche B Notes | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">156,220<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember', window );">Public Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="nump">195,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember', window );">Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">28,572<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember', window );">Private Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,572<span></span>
</td>
<td class="nump">103,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember', window );">Shares issuable pursuant to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">9,557<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember', window );">Shares issuable pursuant to ESPP | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember', window );">Shares issuable under the SIPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember', window );">Shares issuable under the SIPA | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,571<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDOFirmWarrantMember', window );">February 2024 BDO Firm Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">108,686<span></span>
</td>
<td class="nump">108,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDOFirmWarrantMember', window );">February 2024 BDO Firm Warrant | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDORepresentativeWarrantsMember', window );">February 2024 BDO Representative Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">13,446<span></span>
</td>
<td class="nump">13,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDORepresentativeWarrantsMember', window );">February 2024 BDO Representative Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,446<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_April2024RDOCommonWarrantsMember', window );">April 2024 RDO Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">428,572<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_April2024RDOPlacementAgentWarrantsMember', window );">April 2024 RDO Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">34,286<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_April2024RDOPlacementAgentWarrantsMember', window );">April 2024 RDO Placement Agent Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember', window );">Deposit Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_October2024NoteholderWarrantsMember', window );">October 2024 Noteholder Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">214,284<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_October2024PlacementAgentWarrantsMember', window );">October 2024 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">104,848<span></span>
</td>
<td class="nump">104,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_October2024PlacementAgentWarrantsMember', window );">October 2024 Placement Agent Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember', window );">December 2024 RDO Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,642,871<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember', window );">December 2024 RDO Common Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,871<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember', window );">StockBlock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">131,472<span></span>
</td>
<td class="nump">131,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember', window );">StockBlock Warrants | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,472<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_ConvertibleDebenturesMember', window );">Convertible Debentures | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderTrancheBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderTrancheBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDOFirmWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_February2024BDOFirmWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_February2024BDORepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_February2024BDORepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_April2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_April2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_April2024RDOPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_April2024RDOPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_DepositWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_October2024NoteholderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_October2024NoteholderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_October2024PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_October2024PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_December2024RDOCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_StockBlockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_ConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_ConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share (Additional Information) (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 18, 2024</div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,951,622<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sorrento Stock Purchase Agreement (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember', window );">Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfWarrants', window );">Fair Value Of Warrants</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">88,685<span></span>
</td>
<td class="nump">88,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">1,716,245<span></span>
</td>
<td class="nump">39,617<span></span>
</td>
<td class="nump">39,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement', window );">Shares Purchased At Par Value Under Stock Purchase Agreement</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfSharesRepurchased', window );">Fair Value of stock repurchased</a></td>
<td class="nump">$ 52.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement [Member] | Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">3,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement [Member] | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">1,386,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashPayment', window );">Cash payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Closing Penny Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Closing Penny Warrant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransferOfWarrants', window );">Transfer of warrants</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Subsequent Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="nump">114,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfShareOutstanding', window );">Number Of Share Outstanding</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Accrued Liabilities for Commissions, Expense and Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Junior DIP Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssueOfWarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of Warrants to Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssueOfWarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased At Par Value Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransferOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransferOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 17, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>Days</div>
</th>
<th class="th">
<div>Feb. 22, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 21, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 21, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Common Warrants Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CombinedPricePaidOfWarrant', window );">Combined Price Paid Of Warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,951,622<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember', window );">Rodman &amp; Renshaw LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Common Warrants Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPrice', window );">Public Offering Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember', window );">ZTlido Rest of World License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLidocaineTopicalSystem', window );">Percentage of Lidocaine Topical System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePaymentOfCompany', window );">Aggregate Payment Of Company | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember', window );">ZTlido Rest of World License Agreement [Member] | Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember', window );">ZTlido Rest of World License Agreement [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLidocaineTopicalSystem', window );">Percentage of Lidocaine Topical System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePaymentOfCompany', window );">Aggregate Payment Of Company | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember', window );">ZTlido Rest of World License Agreement [Member] | Forecast [Member] | Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember', window );">Gloperba-Elyxyb Royalty Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetailLandSalesReceivablesStatedInterestRate', window );">Percentage of aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoOfCalendarDays', window );">No of calendar days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember', window );">Gloperba-Elyxyb Royalty Purchase Agreement [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetailLandSalesReceivablesStatedInterestRate', window );">Percentage of aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoOfCalendarDays', window );">No of calendar days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember', window );">Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesDelivered', window );">Shares delivered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OwnershipInterestRate', window );">Ownership Interest Rate</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Three i LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Oramed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | BPY Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Nomis Bay Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TotalNumberOfSharesGranted', window );">Total Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Bio JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OwnershipInterestRate', window );">Ownership Interest Rate</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesDelivered', window );">Shares delivered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePaymentOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Payment Of Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePaymentOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CombinedPricePaidOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined Price Paid Of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CombinedPricePaidOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoOfCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No of Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoOfCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OwnershipInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OwnershipInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfLidocaineTopicalSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Lidocaine Topical System</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfLidocaineTopicalSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Common Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Delivered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TotalNumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Number of Shares Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TotalNumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetailLandSalesReceivablesStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stated interest rate for receivables from retail land sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 976<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477332/976-310-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetailLandSalesReceivablesStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ThreeILpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ThreeILpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_OramedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_OramedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_BpyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_BpyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_NomisBayLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_NomisBayLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexBioJVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexBioJVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Aug. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Scilex Holding Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Aug. 04, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">1,390,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">11.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 15,378,299.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 2,354.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"> Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), the shares being registered hereunder include such indeterminate number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. The amount registered includes 150,000 shares of common stock, par value $0.0001 per share (the "Common Stock") of Scilex Holding Company, a Delaware corporation (the "Company"), to be issued by the Company to the selling securityholder named herein (the "Selling Securityholder") and 1,240,443 shares of Common Stock that are available to be issued and sold by the Company to the Selling Securityholder from time to time at the Company's election pursuant to the common stock purchase agreement, dated as of July 22, 2025, between the Company and the Selling Securityholder, subject to satisfaction of the conditions set forth therein. The proposed maximum offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on July 25, 2025 (such date being within five business days of the date that this registration statement was filed with the U.S. Securities and Exchange Commission). <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Aug. 04, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 15,378,299.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">2,354.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 2,354.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>668</ContextCount>
  <ElementCount>610</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>172</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity / (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity / (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Acquisitions and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements</Role>
      <ShortName>Acquisitions and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Sorrento Stock Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement</Role>
      <ShortName>Sorrento Stock Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stock Incentive and Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan</Role>
      <ShortName>Stock Incentive and Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails</Role>
      <ShortName>Liquidity and Going Concern (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Acquisitions and License Agreements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions and License Agreements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses - Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Acrcued expenses - Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Balance Sheet Components (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtAdditionalInformationDetails</Role>
      <ShortName>Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/DebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Debt - Summary of Outstanding Convertible Debenture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails</Role>
      <ShortName>Debt - Summary of Outstanding Convertible Debenture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Debt - Schedule of FSF Deposit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails</Role>
      <ShortName>Debt - Schedule of FSF Deposit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Debt - Schedule of the Tranche B Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails</Role>
      <ShortName>Debt - Schedule of the Tranche B Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Debt - Schedule of revenue liability activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails</Role>
      <ShortName>Debt - Schedule of revenue liability activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Debt - Schedule of the Oramed Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails</Role>
      <ShortName>Debt - Schedule of the Oramed Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Shareholders' Equity (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Income Taxes (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Net Loss Per Share (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/NetLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Sorrento Stock Purchase Agreement (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Sorrento Stock Purchase Agreement (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d942297ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Subsequent Events (Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="d942297dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d942297dexfilingfees.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d942297dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="d942297ds1.htm">d942297ds1.htm</File>
    <File>sclx-20250801.xsd</File>
    <File doctype="EX-FILING FEES" original="d942297dexfilingfees.htm">d942297dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g942297g14k05.jpg</File>
    <File>g942297g14p06.jpg</File>
    <File>g942297g14t04.jpg</File>
    <File>g942297g15e08.jpg</File>
    <File>g942297g15h09.jpg</File>
    <File>g942297g15k07.jpg</File>
    <File>g942297g15r06.jpg</File>
    <File>g942297g15t02.jpg</File>
    <File>g942297g15y04.jpg</File>
    <File>g942297g15y06.jpg</File>
    <File>g942297g16h05.jpg</File>
    <File>g942297g16k01.jpg</File>
    <File>g942297g78h35.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1636">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d942297ds1.htm": {
   "nsprefix": "sclx",
   "nsuri": "http://www.scilexholding.com/20250801",
   "dts": {
    "inline": {
     "local": [
      "d942297ds1.htm"
     ]
    },
    "schema": {
     "local": [
      "sclx-20250801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 375,
   "keyCustom": 212,
   "axisStandard": 37,
   "axisCustom": 4,
   "memberStandard": 42,
   "memberCustom": 111,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 666,
   "entityCount": 1,
   "segmentCount": 171,
   "elementCount": 914,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1636,
    "http://xbrl.sec.gov/dei/2024": 23,
    "http://fasb.org/srt/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://www.scilexholding.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity / (Deficit)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity / (Deficit)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation",
     "longName": "1007 - Disclosure - Nature of Operations and Basis of Presentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.scilexholding.com/role/LiquidityAndGoingConcern",
     "longName": "1008 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements",
     "longName": "1009 - Disclosure - Acquisitions and License Agreements",
     "shortName": "Acquisitions and License Agreements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurements",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.scilexholding.com/role/BalanceSheetComponents",
     "longName": "1011 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.scilexholding.com/role/GoodwillAndIntangibleAssets",
     "longName": "1012 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.scilexholding.com/role/Debt",
     "longName": "1013 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement",
     "longName": "1014 - Disclosure - Sorrento Stock Purchase Agreement",
     "shortName": "Sorrento Stock Purchase Agreement",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.scilexholding.com/role/StockholdersEquity",
     "longName": "1015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan",
     "longName": "1016 - Disclosure - Stock Incentive and Employee Benefit Plan",
     "shortName": "Stock Incentive and Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.scilexholding.com/role/CommitmentsAndContingencies",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.scilexholding.com/role/IncomeTaxes",
     "longName": "1018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.scilexholding.com/role/NetLossPerShare",
     "longName": "1019 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.scilexholding.com/role/SubsequentEvents",
     "longName": "1020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies",
     "longName": "1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)",
     "shortName": "Nature of Operations and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables",
     "longName": "1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)",
     "shortName": "Nature of Operations and Basis of Presentation (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurementsTables",
     "longName": "1023 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.scilexholding.com/role/BalanceSheetComponentsTables",
     "longName": "1024 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables",
     "longName": "1025 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.scilexholding.com/role/DebtTables",
     "longName": "1026 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables",
     "longName": "1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)",
     "shortName": "Stock Incentive and Employee Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.scilexholding.com/role/CommitmentsAndContingenciesTables",
     "longName": "1028 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesTables",
     "longName": "1029 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.scilexholding.com/role/NetLossPerShareTables",
     "longName": "1030 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "shortName": "Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails",
     "longName": "1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
     "longName": "1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)",
     "shortName": "Liquidity and Going Concern (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "sclx:WorkingCapital",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
     "longName": "1034 - Disclosure - Acquisitions and License Agreements (Additional Information) (Details)",
     "shortName": "Acquisitions and License Agreements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "sclx:PaymentToAcquireLicense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)",
     "shortName": "Fair Value Measurements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "sclx:SecuredNoteDiscountRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "sclx:SecuredNoteDiscountRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
     "longName": "1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "shortName": "Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:SeniorNotes",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:SeniorNotes",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue",
     "longName": "1037 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value",
     "shortName": "Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "sclx:ChangeInValuationInputsOrOtherAssumptions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
     "longName": "1038 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities",
     "shortName": "Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
     "longName": "1039 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails",
     "longName": "1040 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses - Details (Details)",
     "shortName": "Balance Sheet Components - Schedule of Acrcued expenses - Details (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:AccruedExpensesTextblock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:AccruedExpensesTextblock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
     "longName": "1041 - Disclosure - Balance Sheet Components (Additional Information) (Details)",
     "shortName": "Balance Sheet Components (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "sclx:ImpairmentLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "1042 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)",
     "shortName": "Goodwill and Intangible Assets (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails",
     "longName": "1043 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
     "longName": "1044 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
     "longName": "1045 - Disclosure - Debt (Additional Information) (Details)",
     "shortName": "Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P04_30_2023To04_30_2023",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_11_2024",
      "name": "sclx:LoanAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
     "longName": "1046 - Disclosure - Debt - Summary of Outstanding Convertible Debenture (Details)",
     "shortName": "Debt - Summary of Outstanding Convertible Debenture (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfTheOramedNoteTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "sclx:RepaymentOfConvertibleDebenture",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfTheOramedNoteTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
     "longName": "1047 - Disclosure - Debt - Schedule of FSF Deposit (Details)",
     "shortName": "Debt - Schedule of FSF Deposit (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:Deposits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:Deposits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
     "longName": "1048 - Disclosure - Debt - Schedule of the Tranche B Note (Details)",
     "shortName": "Debt - Schedule of the Tranche B Note (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "sclx:TrancheBNote",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:DebtConversionOriginalDebtAmount1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfTrancheBNotesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
     "longName": "1049 - Disclosure - Debt - Schedule of revenue liability activity (Details)",
     "shortName": "Debt - Schedule of revenue liability activity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "sclx:PurchasedRevenueLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P10_08_2024To12_31_2024",
      "name": "sclx:ChangeInFairValueOfPurchasedRevenueLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
     "longName": "1050 - Disclosure - Debt - Schedule of the Oramed Note (Details)",
     "shortName": "Debt - Schedule of the Oramed Note (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfTheOramedNoteTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
     "longName": "1051 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)",
     "shortName": "Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "sclx:PennyWarrantsExercised",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
     "longName": "1052 - Disclosure - Shareholders' Equity (Additional Information) (Details)",
     "shortName": "Shareholders' Equity (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "PAsOn09_21_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails",
     "longName": "1053 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
     "longName": "1054 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "1055 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails",
     "longName": "1056 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "1057 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1058 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
     "longName": "1059 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails",
     "longName": "1060 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "1061 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "1062 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1063 - Disclosure - Income Taxes (Additional Information) (Details)",
     "shortName": "Income Taxes (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "sclx:IndefiniteOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
     "longName": "1064 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "shortName": "Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
     "longName": "1065 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "shortName": "Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To03_31_2025",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
     "longName": "1066 - Disclosure - Net Loss Per Share (Additional Information) (Details)",
     "shortName": "Net Loss Per Share (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2025",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
     "longName": "1067 - Disclosure - Sorrento Stock Purchase Agreement (Additional Information) (Details)",
     "shortName": "Sorrento Stock Purchase Agreement (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1068 - Disclosure - Subsequent Events (Additional Information (Details)",
     "shortName": "Subsequent Events (Additional Information (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "P01_02_2025To01_02_2025",
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P02_22_2025To02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "sclx:PercentageOfLidocaineTopicalSystem",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297ds1.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sclx_ARYorkvillePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ARYorkvillePurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A R Yorkville Purchase Agreement [Member]",
        "terseLabel": "A&amp;R Yorkville Purchase Agreement",
        "documentation": "A R Yorkville Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcceleratedShareRepurchasesAdjustmentToRecordedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 46.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Share Repurchases, Adjustment to Recorded Amount",
        "verboseLabel": "Cash consideration paid in connection with share repurchase",
        "terseLabel": "Cash Consideration",
        "documentation": "The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Accrued others",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r925"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "sclx_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      },
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "documentation": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AccruedExpensesTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AccruedExpensesTextblock",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses Textblock",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Accrued expenses Textblock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Fair Value Disclosure",
        "terseLabel": "Accrued litigation expenses",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1105",
      "r1106",
      "r1110"
     ]
    },
    "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities for Commissions, Expense and Taxes",
        "verboseLabel": "Accured expense",
        "terseLabel": "Accrued Liabilities for Commissions, Expense and Taxes",
        "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued sales and marketing costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional service fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued legal fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "sclx_AccruedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AccruedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development costs",
        "terseLabel": "Accrued research and development costs",
        "documentation": "Accrued research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AccruedRoyaltyPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AccruedRoyaltyPayables",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalty Payables",
        "terseLabel": "Accrued Royalty Payables",
        "documentation": "Accrued Royalty Payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r876"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r202",
      "r716"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r103",
      "r211",
      "r711",
      "r747",
      "r751"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r23",
      "r586",
      "r589",
      "r652",
      "r742",
      "r743",
      "r985",
      "r986",
      "r987",
      "r999",
      "r1000",
      "r1001",
      "r1004"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining life for identifiable intangible assets",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r871"
     ]
    },
    "sclx_AcquiredLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AcquiredLicensesMember",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired licenses [Member]",
        "terseLabel": "Acquired licenses",
        "documentation": "Acquired licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AcquiredTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AcquiredTechnologyMember",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired technology [Member]",
        "terseLabel": "Acquired technology",
        "documentation": "Acquired technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition",
        "negatedLabel": "Acquisition consideration paid in cash for Romeg intangible asset acquisition",
        "documentation": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r925",
      "r1170"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r999",
      "r1000",
      "r1001",
      "r1004",
      "r1102",
      "r1171"
     ]
    },
    "sclx_AdditionalPaidsInCapitals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AdditionalPaidsInCapitals",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paids In Capitals",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Additional paid in capitals."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment of Additional Paid in Capital of Share based Compensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Adjustment of additional paid in capital of share based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment of Warrants Granted for Services",
        "terseLabel": "Reversal of mark-to-market adjustment for liability classified warrants",
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash proceeds from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AggregateGrossProceedsFromOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AggregateGrossProceedsFromOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Gross Proceeds From Offering",
        "terseLabel": "Gross proceeds from offering",
        "documentation": "Aggregate Gross Proceeds From Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AggregatePaymentOfCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AggregatePaymentOfCompany",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Payment Of Company",
        "terseLabel": "Aggregate Payment Of Company",
        "documentation": "Aggregate Payment Of Company"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AgreementMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AgreementMaturityDate",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Maturity Date",
        "terseLabel": "Agreement maturity date",
        "documentation": "Agreement Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowances for expected credit losses accounts receivable",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r321",
      "r357",
      "r360",
      "r361",
      "r1135"
     ]
    },
    "sclx_AllowancesForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AllowancesForCreditLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowances for Credit Losses",
        "terseLabel": "Allowances for expected credit losses",
        "documentation": "Allowances for Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AllowancesForPromptPaymentDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AllowancesForPromptPaymentDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowances for Prompt Payment Discounts",
        "terseLabel": "Allowances for prompt payment discounts",
        "documentation": "Allowances for Prompt Payment Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r896",
      "r897",
      "r994",
      "r1114"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible amortization",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r385",
      "r392",
      "r892"
     ]
    },
    "sclx_AmountDueForNewDrugApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AmountDueForNewDrugApplication",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due for New Drug Application",
        "documentation": "Amount due for New Drug Application"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "sclx_April2024RDOCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "April2024RDOCommonWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 RDO Common Warrants",
        "terseLabel": "April 2024 RDO Common Warrants [Member]",
        "documentation": "April 2024 RDO Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_April2024RDOPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "April2024RDOPlacementAgentWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 RDO Placement Agent Warrants [Member]",
        "terseLabel": "April 2024 RDO Placement Agent Warrants",
        "documentation": "April 2024 RDO Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "sclx_AssembledWorkforceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AssembledWorkforceMember",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assembled workforce [Member]",
        "terseLabel": "Assembled workforce",
        "documentation": "Assembled workforce [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Common stock upon conversation of cash",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1099",
      "r1100"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r166",
      "r205",
      "r239",
      "r281",
      "r286",
      "r310",
      "r313",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r578",
      "r582",
      "r621",
      "r705",
      "r812",
      "r885",
      "r886",
      "r925",
      "r943",
      "r1053",
      "r1054",
      "r1124"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r215",
      "r239",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r578",
      "r582",
      "r621",
      "r925",
      "r1053",
      "r1054",
      "r1124"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "terseLabel": "Other long-term assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-Market Sales Agreement [Member]",
        "terseLabel": "At-the-Market Sales Agreement",
        "documentation": "At-the-Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AtmSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "AtmSalesAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Sales Agreement [Member]",
        "documentation": "ATM Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "sclx_BRileyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "BRileyPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "B Riley Purchase Agreement [Member]",
        "terseLabel": "B. Riley Purchase Agreement [Member]",
        "documentation": "B Riley Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r406",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "sclx_BlackScholesOptionPricingMethodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "BlackScholesOptionPricingMethodMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black-Scholes Option Pricing Method [Member]",
        "documentation": "Black-Scholes Option Pricing Method"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_BpyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "BpyLimitedMember",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BPY Limited [Member]",
        "terseLabel": "BPY Limited [Member]",
        "documentation": "BPY Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r572",
      "r904",
      "r905"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r572",
      "r904",
      "r905"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r145",
      "r573",
      "r600",
      "r601",
      "r602"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible asset",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Development milestones payment was recognized under other long-term liabilities",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946"
     ]
    },
    "us-gaap_CapitalUnitsNetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalUnitsNetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Units, Net Amount",
        "terseLabel": "Net Amount of shares",
        "documentation": "Net amount applicable to investors of capital units or shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash on hand",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r708",
      "r778",
      "r807",
      "r925",
      "r943",
      "r981"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r200",
      "r874"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r149"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r115",
      "r236"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r115"
     ]
    },
    "sclx_CashFeePercentageOfGrossProceedsPaidToPlacementAgents": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CashFeePercentageOfGrossProceedsPaidToPlacementAgents",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Fee Percentage of Gross Proceeds Paid to Placement Agents",
        "terseLabel": "Cash fee percentage of gross proceeds paid to placement agents",
        "documentation": "Cash Fee Percentage of Gross Proceeds Paid to Placement Agents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sclx_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment",
        "terseLabel": "Cash payment",
        "documentation": "Cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueDueToCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueDueToCreditRisk",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Due To Credit Risk",
        "terseLabel": "Change in fair value due to credit risk",
        "documentation": "Change In Fair Value Due To Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfConvertibleDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueOfConvertibleDebentures",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of Convertible Debentures",
        "negatedLabel": "Change in fair value of Convertible debentures",
        "verboseLabel": "Change in fair value of Oramed Note - recorded in the consolidated statements of operations",
        "documentation": "Change in fair value of Convertible Debentures"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Convertible Debentures Include Interest Expense",
        "terseLabel": "Change in fair value of debt and liability instruments",
        "documentation": "Change In Fair Value Of Convertible Debentures Include Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfDebtAndLiabilityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueOfDebtAndLiabilityInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Debt And Liability Instruments",
        "terseLabel": "Change in fair value of debt and liability instruments",
        "documentation": "Change In Fair Value Of Debt And Liability Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfPurchasedRevenueLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueOfPurchasedRevenueLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Purchased Revenue Liability",
        "terseLabel": "Change in fair value of purchased revenue liability",
        "documentation": "Change in Fair Value of Purchased Revenue Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfTrancheBNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInFairValueOfTrancheBNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Tranche B Notes",
        "terseLabel": "Change in fair value of Tranche B Notes",
        "documentation": "Change in Fair Value of Tranche B Notes"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInValuationInputsOrOtherAssumptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ChangeInValuationInputsOrOtherAssumptions",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangeInValuationInputsOrOtherAssumptions",
        "terseLabel": "Change in fair value measurement",
        "documentation": "Change in valuation inputs or other assumptions."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r208",
      "r209",
      "r210",
      "r239",
      "r264",
      "r265",
      "r272",
      "r274",
      "r283",
      "r284",
      "r352",
      "r419",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r456",
      "r457",
      "r459",
      "r462",
      "r469",
      "r621",
      "r759",
      "r760",
      "r761",
      "r762",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r799",
      "r821",
      "r840",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r960",
      "r995",
      "r1005"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercised price",
        "definitionGuidance": "Price per share",
        "verboseLabel": "Exercise price per share, warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants execiseable",
        "terseLabel": "Aggregate purchase of private placement warrants (in Shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ClearingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ClearingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearing Expenses",
        "terseLabel": "Clearing expenses",
        "documentation": "Clearing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ClosingPennyWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ClosingPennyWarrantMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing Penny Warrant [Member]",
        "terseLabel": "Closing Penny Warrant [Member]",
        "documentation": "Closing Penny Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CombinedPricePaidOfWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CombinedPricePaidOfWarrant",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Price Paid Of Warrant",
        "verboseLabel": "Combined Price Paid",
        "terseLabel": "Combined Price Paid Of Warrant",
        "documentation": "Combined Price Paid Of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Amount",
        "terseLabel": "Commitment Amount",
        "documentation": "Commitment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommitmentAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommitmentAmountPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Amount Payable",
        "terseLabel": "Commitment Amount Payable",
        "documentation": "Commitment Amount Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r156",
      "r707",
      "r798"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r410",
      "r411",
      "r868",
      "r1042",
      "r1047"
     ]
    },
    "sclx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "terseLabel": "Common Stock at a conversion price",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "sclx_CommonStockIssuableUnderSponsorInterestPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonStockIssuableUnderSponsorInterestPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuable under Sponsor Interest Purchase Agreement",
        "terseLabel": "Common stock issuable under Sponsor Interest Purchase Agreement",
        "documentation": "Common stock issuable under Sponsor Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommonStockIssuableValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonStockIssuableValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable Value",
        "terseLabel": "Common Stock Issuable Value",
        "documentation": "Common Stock Issuable Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r937",
      "r938",
      "r939",
      "r940",
      "r999",
      "r1000",
      "r1004",
      "r1102",
      "r1168",
      "r1171"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r799"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Ordinary shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96",
      "r799",
      "r818",
      "r1171",
      "r1172"
     ]
    },
    "sclx_CommonStockSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonStockSold",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock sold",
        "terseLabel": "Common stock sold",
        "documentation": "Common stock sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "verboseLabel": "Common Stock Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r710",
      "r925"
     ]
    },
    "sclx_CommonStocksSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonStocksSharesIssued",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Common stocks shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommonStocksSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonStocksSharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Common stocks shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "terseLabel": "Common Warrants",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CompanyReceivesTheDepositAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CompanyReceivesTheDepositAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Receives The Deposit Amount",
        "terseLabel": "Company receives the Deposit",
        "documentation": "Company Receives The Deposit Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CompanyReceivesTheDepositPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CompanyReceivesTheDepositPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Receives The Deposit Period",
        "terseLabel": "Company Receives The Deposit Period",
        "documentation": "Company Receives The Deposit Period"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CompanyReceivesTheFsfDepositAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CompanyReceivesTheFsfDepositAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company receives the FSF Deposit Amount",
        "terseLabel": "Company receives the FSF Deposit",
        "documentation": "Company receives the FSF Deposit Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CompanyReceivesTheFsfDepositPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CompanyReceivesTheFsfDepositPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Receives The FSF Deposit Period",
        "terseLabel": "Company Receives The FSF Deposit Period",
        "documentation": "Company Receives The FSF Deposit Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Incentive and Employee Benefit Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r220",
      "r222",
      "r229",
      "r699",
      "r723",
      "r724"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r70",
      "r71",
      "r319",
      "r867"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r70",
      "r71",
      "r319",
      "r753",
      "r867"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r70",
      "r71",
      "r319",
      "r867",
      "r965"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Customer and Supplier Concentration Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r175"
     ]
    },
    "sclx_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Threshold Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "Concentration risk threshold percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r70",
      "r71",
      "r319",
      "r867"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration",
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Purchased Revenue Liability",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures into Common Stock",
        "terseLabel": "Conversion of Convertible Debentures into common stock",
        "documentation": "Conversion of Convertible Debentures into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStockShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures Into Common Stock, Shares",
        "terseLabel": "Conversion of Convertible Debentures into common stock, shares",
        "documentation": "Conversion of Convertible Debentures Into Common Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures Into Common Stock, Value",
        "terseLabel": "Conversion of Convertible Debentures into common stock",
        "documentation": "Conversion of Convertible Debentures Into Common Stock, Value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfOramedNoteIntoTrancheBNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfOramedNoteIntoTrancheBNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Oramed Note into Tranche B Notes",
        "terseLabel": "Conversion of Oramed Note into Tranche B Notes",
        "documentation": "Conversion of Oramed Note into Tranche B Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "sclx_ConversionOfTrancheBNotesIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfTrancheBNotesIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Tranche B Notes into Common Stock",
        "terseLabel": "Conversion of Tranche B Notes into common stock",
        "documentation": "Conversion of Tranche B Notes into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfTrancheBNotesIntoCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConversionOfTrancheBNotesIntoCommonStockShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Tranche B Notes into Common Stock, Shares",
        "terseLabel": "Conversion of Tranche B Notes into common stock, Shares",
        "documentation": "Conversion of Tranche B Notes into Common Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConvertibleDebenturesAndTheOramedNotePolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures and the Oramed Note [Policy Text Block]",
        "terseLabel": "Convertible Debentures and the Oramed Note",
        "documentation": "Convertible Debentures and the Oramed Note"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesIssuedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConvertibleDebenturesIssuedPercent",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures Issued Percent",
        "terseLabel": "Convertible Debentures Issued Percent",
        "documentation": "Convertible Debentures Issued Percent"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConvertibleDebenturesMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures [Member]",
        "terseLabel": "Convertible Debentures",
        "documentation": "Convertible Debentures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "verboseLabel": "Convertible Debenture",
        "periodStartLabel": "Convertible debentures, beginning period",
        "periodEndLabel": "Convertible debentures, ending period",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r155",
      "r1134"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible debenture",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "verboseLabel": "Convertible Debentures",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r429",
      "r430",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debentures [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schdule of Convertible Debentures",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible Notes Payable",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sclx_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]",
        "terseLabel": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Convertibledebentureprincipalamount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Convertibledebentureprincipalamount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleDebentureprincipalAmount",
        "terseLabel": "Convertible Debenture principal Amount",
        "documentation": "ConvertibleDebentureprincipalAmount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost, Amortization",
        "terseLabel": "Amortization payment",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r239",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r621",
      "r885",
      "r1053"
     ]
    },
    "sclx_CoveLaneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CoveLaneMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cove Lane [Member]",
        "terseLabel": "Cove Lane [Member]",
        "documentation": "Cove Lane [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r1051"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r998",
      "r1097"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r998"
     ]
    },
    "sclx_CurrentPortionOfDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "CurrentPortionOfDeferredConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred consideration",
        "terseLabel": "Current portion of deferred consideration",
        "documentation": "Current portion of deferred consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r998",
      "r1097"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r319"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "negatedLabel": "Conversion of Tranche B notes",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current",
        "terseLabel": "Debt, current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r237",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r417",
      "r418",
      "r428",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r444",
      "r451",
      "r452",
      "r454",
      "r634"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r84",
      "r85",
      "r152",
      "r155",
      "r242",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r923",
      "r996",
      "r1043",
      "r1044",
      "r1045",
      "r1113",
      "r1115"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion Price",
        "definitionGuidance": "Common stock at a conversion price",
        "terseLabel": "Debt conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r431"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price, Decrease",
        "terseLabel": "Decrease in common stock at a conversion price",
        "documentation": "Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r470"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtInstrumentDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtInstrumentDefaultInterestRate",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Default Interest Rate",
        "terseLabel": "Debt instrument, default interest rate",
        "documentation": "Debt Instrument, Default Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description",
        "terseLabel": "Debt instrument, description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r45",
      "r76",
      "r84",
      "r152",
      "r155",
      "r634"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt principal amount",
        "terseLabel": "Initial principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r634",
      "r635",
      "r894",
      "r895",
      "r923"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r620",
      "r894",
      "r895",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt instrument, interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r447",
      "r1113"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Exit fee",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r430"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "terseLabel": "Principle amount of issued debt",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r923",
      "r996",
      "r1113",
      "r1115"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt maturity date",
        "terseLabel": "Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r893",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, End",
        "terseLabel": "Maturity Date End",
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, Start",
        "terseLabel": "Date of Maturity Start",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r242",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r923",
      "r996",
      "r1043",
      "r1044",
      "r1045",
      "r1113",
      "r1115"
     ]
    },
    "sclx_DebtInstrumentOutstandingPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtInstrumentOutstandingPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Outstanding Principal",
        "terseLabel": "Outstanding debt instrument",
        "documentation": "Debt instrument outstanding principal"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtInstrumentOwnedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtInstrumentOwnedPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Owned, Percentage",
        "terseLabel": "Debt instrument, owned, percentage",
        "documentation": "Debt Instrument, Owned, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Debt payment terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Percentage of Interest Accrued on Principal Amount",
        "terseLabel": "Debt instrument, percentage of interest accrued on principal amount",
        "documentation": "Debt Instrument, Percentage of Interest Accrued on Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r77"
     ]
    },
    "sclx_DebtInstrumentPrincipalAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtInstrumentPrincipalAmountPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Principal Amount, Percentage",
        "terseLabel": "Debt Instrument Principal Amount, Percentage",
        "documentation": "Debt Instrument Principal Amount, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Description",
        "terseLabel": "Debt Instrument Redemption",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption Premium",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DebtInstrumentRepaidPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepaidPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repaid, Principal",
        "terseLabel": "Convertible Debentures Repaid",
        "documentation": "Amount of principal of debt repaid."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchased Face Amount",
        "verboseLabel": "Debt Instrument Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r45",
      "r46",
      "r75",
      "r128",
      "r129",
      "r242",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r923",
      "r996",
      "r1113",
      "r1115"
     ]
    },
    "sclx_DebtIssuanceCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtIssuanceCostsIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Included in Accrued Expenses",
        "terseLabel": "Debt issuance costs included in accrued expenses",
        "documentation": "Debt Issuance Costs Included in Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtPayableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtPayableAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Payable [Axis]",
        "documentation": "Debt Payable [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtPayableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtPayableDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Payable [Domain]",
        "documentation": "Debt Payable [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "The Oramed Note and Tranche B Notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "sclx_DebtRepaymentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtRepaymentExitFee",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment Exit Fee",
        "terseLabel": "Debt Repayment Exit Fee",
        "documentation": "Debt Repayment Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest",
        "terseLabel": "Debt repayment, percentage of mandatory default rate of accrued and unpaid interest",
        "documentation": "Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount",
        "terseLabel": "Debt repayment, percentage of mandatory default rate of principal amount",
        "documentation": "Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_December2024RDOCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "December2024RDOCommonWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 RDO Common Warrants [Member]",
        "terseLabel": "December 2024 RDO Common Warrants",
        "definitionGuidance": "December 2024 RDO Common Warrants [Member]",
        "verboseLabel": "December 2024 RDO Common Warrants",
        "documentation": "December 2024 RDO Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DecemberCommonWarrantsFiveYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DecemberCommonWarrantsFiveYearMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Common Warrants Five Year [Member]",
        "terseLabel": "December Common Warrants Five Year [Member]",
        "documentation": "December Common Warrants Five Year"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DecemberCommonWarrantsTwoPointFiveYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DecemberCommonWarrantsTwoPointFiveYearMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Common Warrants Two Point Five Year [Member]",
        "terseLabel": "December Common Warrants Two Point Five Year [Member]",
        "documentation": "December Common Warrants Two Point Five Year"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DecemberRDOCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DecemberRDOCommonWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December RDO Common Warrants [Member]",
        "terseLabel": "December RDO Common Warrants",
        "documentation": "December RDO Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferral and Consent under Tranche B Senior Secured Convertible Note [Member]",
        "terseLabel": "Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]",
        "documentation": "Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred income tax benefit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r181",
      "r998"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueRefundPayments1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueRefundPayments1",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 53.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Refund Payments",
        "negatedLabel": "Payments on purchased revenue liability",
        "documentation": "Amount of cash outflow to customers for refund payments of revenue that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1096",
      "r1097"
     ]
    },
    "sclx_DeferredTaxAssetsAccruedExpenseAndReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferredTaxAssetsAccruedExpenseAndReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Accrued Expense and Reserves",
        "terseLabel": "Accrued expense and reserves",
        "documentation": "Deferred tax assets, accrued expense and reserves."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DeferredTaxAssetsDebtRelatedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferredTaxAssetsDebtRelatedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Debt Related Interest",
        "terseLabel": "Debt related interest",
        "documentation": "Deferred tax assets, debt related interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research and development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "sclx_DeferredTaxAssetsPurchasedRevenueLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferredTaxAssetsPurchasedRevenueLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Purchased Revenue Liability",
        "terseLabel": "Purchased revenue liability",
        "documentation": "Deferred Tax Assets Purchased Revenue Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development income tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "verboseLabel": "Deferred tax assets, valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "sclx_DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Transaction Costs Related to Semnur Merger Included in Accrued Expenses And Account Payable",
        "terseLabel": "Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable",
        "documentation": "Deferred Transaction Costs Related to Semnur Merger Included in Accrued Expenses And Account Payable"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Deferredconsiderationliabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Deferredconsiderationliabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredConsiderationLiabilities",
        "terseLabel": "Deferred consideration",
        "documentation": "DeferredConsiderationLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employee benefit plan contributions by employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r475",
      "r482",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DepositWarrantExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DepositWarrantExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Warrant Exercise Price",
        "terseLabel": "Warrant Exercise Price",
        "documentation": "Deposit Warrant Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DepositWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DepositWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Warrants [Member]",
        "terseLabel": "Deposit Warrants",
        "verboseLabel": "Deposit Warrant [Member]",
        "documentation": "Deposit Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "periodStartLabel": "Beginning Balance as of January 1, 2024",
        "periodEndLabel": "Ending Balance as of September 30, 2024",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r281",
      "r291",
      "r313",
      "r885",
      "r886"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "(Gain) loss on derivative liability",
        "terseLabel": "(Gain) loss on derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "periodStartLabel": "Fair value, beginning",
        "periodEndLabel": "Fair value, ending",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r598",
      "r599",
      "r612",
      "r620",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r813",
      "r815",
      "r816",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r877",
      "r1107",
      "r1108",
      "r1109",
      "r1169"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "sclx_DerivativeWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DerivativeWarrantLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Warrant Liabilities",
        "terseLabel": "Derivative warrant liabilities",
        "documentation": "Derivative Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r62",
      "r63",
      "r64",
      "r67",
      "r241",
      "r258"
     ]
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Line Items]",
        "documentation": "Descriptionof Organizationand Business Operations Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Table]",
        "documentation": "Descriptionof Organizationand Business Operations Details Table"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DevelopersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DevelopersMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developers [Member]",
        "terseLabel": "Developers [Member]",
        "documentation": "Developers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DisbursementOfFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DisbursementOfFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 45.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement Of Funds",
        "terseLabel": "Disbursement of funds to Sorrento",
        "documentation": "Disbursement Of Funds"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DisbursementOfFundsToSorrentoAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DisbursementOfFundsToSorrentoAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement of funds to Sorrento Amount",
        "terseLabel": "Disbursement of funds to Sorrento Amount",
        "documentation": "Disbursement of funds to Sorrento Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Sorrento Stock Purchase Agreement",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r488",
      "r518",
      "r519",
      "r520",
      "r907"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "sclx_DueFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "DueFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due From Related Party",
        "terseLabel": "Due From Related Party",
        "documentation": "Due From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic (Loss) income Per Share",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic",
        "terseLabel": "Loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r264",
      "r272",
      "r273",
      "r274",
      "r279",
      "r570",
      "r575",
      "r595",
      "r596",
      "r700",
      "r725",
      "r880"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted",
        "terseLabel": "Loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r255",
      "r264",
      "r272",
      "r273",
      "r274",
      "r279",
      "r570",
      "r575",
      "r595",
      "r596",
      "r700",
      "r725",
      "r880"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r276"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r275",
      "r277",
      "r278"
     ]
    },
    "sclx_EffectOfDilutiveSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EffectOfDilutiveSecurities",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Dilutive Securities",
        "terseLabel": "Effect of dilutive securities",
        "documentation": "Effect of Dilutive Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income taxes paid",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r535",
      "r561",
      "r909"
     ]
    },
    "sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount",
        "terseLabel": "Change in fair value of Convertible Debentures",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount",
        "terseLabel": "Change in tax rates",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ElyxybRestOfWorldLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ElyxybRestOfWorldLicenseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elyxyb Rest Of World License Agreement [Member]",
        "terseLabel": "Elyxyb Rest of World License Agreement [Member]",
        "documentation": "Elyxyb Rest Of World License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock option grants",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "sclx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "sclx_EnveltaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EnveltaMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Envelta [Member]",
        "documentation": "Envelta Member"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EpoladermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "EpoladermMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Epoladerm [Member]",
        "documentation": "Epoladerm Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r193",
      "r224",
      "r225",
      "r226",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r256",
      "r258",
      "r282",
      "r353",
      "r356",
      "r398",
      "r471",
      "r559",
      "r560",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r639",
      "r652",
      "r721",
      "r742",
      "r743",
      "r744",
      "r767",
      "r840"
     ]
    },
    "us-gaap_EquityUnitPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityUnitPurchaseAgreementsMember",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Unit Purchase Agreements [Member]",
        "terseLabel": "Equity Purchase Agreement with Yorkville and B. Riley [Member]",
        "documentation": "Contracts and securities that allow the holder to buy equity units from the entity."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise tax in connection with share repurchase included in accrued expenses",
        "terseLabel": "Excise tax in connection with share repurchase included in accrued expenses",
        "documentation": "Excise tax in connection with share repurchase included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExciseTaxPaidInConnectionWithShareRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExciseTaxPaidInConnectionWithShareRepurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 48.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise Tax Paid In Connection With Share Repurchase",
        "negatedLabel": "Excise tax paid in connection with share repurchase",
        "documentation": "Excise Tax Paid In Connection With Share Repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExercisePriceOfCommonWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExercisePriceOfCommonWarrant",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Of Common Warrant",
        "verboseLabel": "Exercise price of warrant",
        "documentation": "Exercise Price Of Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExercisePriceOfTheWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExercisePriceOfTheWarrants",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Of The Warrants",
        "terseLabel": "Deposit Warrant Exercise Price",
        "documentation": "Exercise Price Of The Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExistingFacilityCapMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExistingFacilityCapMaximum",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Facility Cap Maximum",
        "terseLabel": "Facility cap maximum",
        "documentation": "Existing Facility Cap Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExistingFacilityCapMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ExistingFacilityCapMinimum",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Facility Cap Minimum",
        "terseLabel": "Facility cap minimum",
        "documentation": "Existing facility cap minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Amount extinguished and reduced",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FSFLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FSFLoanMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FSF Loan [Member]",
        "documentation": "F S F Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Settlement of December 2024 RDO Pre-Funded Warrants",
        "terseLabel": "Fair Value of the Fee Warrant",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value assets measured on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r611",
      "r612",
      "r614",
      "r661",
      "r662",
      "r663",
      "r894",
      "r895",
      "r900",
      "r901",
      "r902",
      "r912",
      "r916"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r613"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Concentration of Risk [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements",
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r147",
      "r148"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r609",
      "r610",
      "r611",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r696",
      "r912",
      "r917"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r475",
      "r480",
      "r599",
      "r612",
      "r661",
      "r900",
      "r901",
      "r902",
      "r912"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r475",
      "r480",
      "r599",
      "r600",
      "r612",
      "r662",
      "r894",
      "r895",
      "r900",
      "r901",
      "r902",
      "r912"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r599",
      "r600",
      "r601",
      "r602",
      "r612",
      "r663",
      "r894",
      "r895",
      "r900",
      "r901",
      "r902",
      "r912",
      "r916"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect",
        "terseLabel": "Change in fair value due to instrument specific credit risk recorded as a component of other comprehensive income",
        "documentation": "Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r613"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r611",
      "r612",
      "r614",
      "r661",
      "r662",
      "r663",
      "r894",
      "r895",
      "r900",
      "r901",
      "r902",
      "r912",
      "r916"
     ]
    },
    "sclx_FairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FairValueOfContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contingent consideration",
        "terseLabel": "Development Milestone Payment",
        "documentation": "Fair value of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "sclx_FairValueOfSharesRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FairValueOfSharesRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Shares Repurchased",
        "terseLabel": "Fair Value of stock repurchased",
        "documentation": "Fair value of Shares Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrants",
        "terseLabel": "Fair Value Of Warrants",
        "documentation": "Fair Value Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Loss in changes in fair value",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sclx_February2024BDOFirmWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "February2024BDOFirmWarrantMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2024 BDO Firm Warrant",
        "documentation": "February 2024 BDO Firm Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_February2024BDOFirmWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "February2024BDOFirmWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February2024BDOFirmWarrants [Member]",
        "terseLabel": "February 2024 BDO Firm Warrants [Member]",
        "documentation": "February2024BDOFirmWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_February2024BDORepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "February2024BDORepresentativeWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2024 BDO Representative Warrants",
        "documentation": "February 2024 BDO Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_FederalFundsPurchasedAverageRatePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "FederalFundsPurchasedAverageRatePaid",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Funds Purchased, Average Rate Paid",
        "terseLabel": "Federal funds purchased, average rate paid",
        "documentation": "Average rate paid on federal funds purchased."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184"
     ]
    },
    "sclx_FeeWarrantIssuedInConnectionWithTheCommitmentLetter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FeeWarrantIssuedInConnectionWithTheCommitmentLetter",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Warrant issued in connection with the Commitment Letter",
        "terseLabel": "Fee Warrant issued in connection with the Commitment Letter",
        "documentation": "Fee Warrant issued in connection with the Commitment Letter"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Warrants Issued and Exercised in Connection with the FSF Commitment Letter",
        "terseLabel": "Fee Warrants issued and exercised in connection with the Commitment Letter",
        "documentation": "Fee Warrants Issued and Exercised in Connection with the FSF Commitment Letter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r648"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r358",
      "r359",
      "r362",
      "r363",
      "r365",
      "r367",
      "r368",
      "r369",
      "r453",
      "r467",
      "r591",
      "r619",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r722",
      "r890",
      "r912",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r926",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1104",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "sclx_FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Costs and Allocated Expense for Financial Instruments at Fair Value",
        "terseLabel": "Financing costs and allocated expense for financial instruments at fair value",
        "documentation": "Financing Costs and Allocated Expense for Financial Instruments at Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price",
        "terseLabel": "Purchase price for the purchased receivables",
        "documentation": "Amount at purchase price of financing receivable purchased with credit deterioration."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_FinancingReceivableRevolvingConvertedToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableRevolvingConvertedToTermLoan",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Revolving, Converted to Term Loan",
        "terseLabel": "Accounts receivable revolving loan facility in an aggregate amount",
        "documentation": "Amortized cost of revolving financing receivable converted to term loan."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r889"
     ]
    },
    "sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization,after Year Five",
        "terseLabel": "2029",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization,after Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization,after Year Four",
        "terseLabel": "Thereafter",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization,after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite Lived Intangible Asset Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r373",
      "r391",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r871",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2025 (remainder of 2025)",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1173"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r871",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r871",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r871",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r395",
      "r396",
      "r693",
      "r694",
      "r871"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r391",
      "r694",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r391",
      "r395",
      "r396",
      "r397",
      "r693",
      "r871",
      "r892"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r395",
      "r396",
      "r871"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r1037"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]",
        "terseLabel": "As of March 31,2023"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Firm warrant amendment and exercise as part of the December Registered Direct Offering",
        "terseLabel": "Warrant amendment and exercise as part of the December 2024 RDO",
        "documentation": "Firm warrant amendment and exercise as part of the December Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FirmWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FirmWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Firm Warrants[Member]",
        "terseLabel": "Firm Warrants",
        "documentation": "Firm Warrants[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FiveInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FiveInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Installment [Member]",
        "terseLabel": "Five Installment [Member]",
        "documentation": "Five Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "(Gain) loss on foreign currency exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r623",
      "r624",
      "r625",
      "r837"
     ]
    },
    "sclx_ForfeitureOfPrivateWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ForfeitureOfPrivateWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture of Private Warrants",
        "terseLabel": "Forfeiture of Private Warrants",
        "documentation": "Forfeiture of Private Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FormerEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FormerEmployeeMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Employee [Member]",
        "documentation": "Former Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FormerEmployeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FormerEmployeeOneMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Employee One[Member]",
        "documentation": "Former Employee One[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FourthInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FourthInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fourth Installment [Member]",
        "terseLabel": "Fourth Installment [Member]",
        "documentation": "Fourth Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FristInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "FristInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frist Installment [Member]",
        "terseLabel": "First installment [Member]",
        "documentation": "Frist Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Gloperba-ElyxybRoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gloperba-Elyxyb Royalty Purchase Agreement [Member]",
        "terseLabel": "Gloperba-Elyxyb Royalty Purchase Agreement [Member]",
        "documentation": "Gloperba-Elyxyb Royalty Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_GloperbaElyxybRoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "GloperbaElyxybRoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gloperba Elyxyb Royalty Purchase Agreement [Member]",
        "terseLabel": "Gloperba Elyxyb Royalty Purchase Agreement",
        "documentation": "Gloperba Elyxyb Royalty Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_GloperbaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "GloperbaMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GLOPERBA [Member]",
        "documentation": "GLOPERBA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_GloperbaRestOfWorldLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "GloperbaRestOfWorldLicenseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gloperba Rest of World License Agreement [Member]",
        "terseLabel": "Gloperba Rest of World License Agreement [Member]",
        "documentation": "Gloperba Rest of World License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r374",
      "r697",
      "r886",
      "r891",
      "r913",
      "r925",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill impairment charges",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1031"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1031"
     ]
    },
    "sclx_HudsonBayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "HudsonBayMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hudson Bay [Member]",
        "terseLabel": "Hudson Bay [Member]",
        "documentation": "Hudson Bay [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Loss",
        "terseLabel": "Impairment Loss",
        "documentation": "Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r159",
      "r165",
      "r701",
      "r718",
      "r882",
      "r885",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r406",
      "r407",
      "r604",
      "r608",
      "r613",
      "r739",
      "r741",
      "r824",
      "r871",
      "r915",
      "r1139"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r604",
      "r608",
      "r613",
      "r739",
      "r741",
      "r824",
      "r871",
      "r915",
      "r1139"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r535",
      "r536",
      "r544",
      "r555",
      "r909",
      "r1093"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r535",
      "r536",
      "r544",
      "r555",
      "r909",
      "r1093"
     ]
    },
    "sclx_IncomeTaxCreditsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncomeTaxCreditsExpirationYear",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Credits Expiration Year",
        "terseLabel": "Income tax credits, expiration year",
        "documentation": "Income Tax Credits Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r529",
      "r535",
      "r541",
      "r542",
      "r543",
      "r549",
      "r554",
      "r562",
      "r564",
      "r565",
      "r566",
      "r764",
      "r909"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax expense, interest and penalties",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense",
        "totalLabel": "Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r257",
      "r258",
      "r281",
      "r294",
      "r313",
      "r534",
      "r535",
      "r563",
      "r726",
      "r909"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r532",
      "r533",
      "r549",
      "r550",
      "r553",
      "r557",
      "r758"
     ]
    },
    "sclx_IncomeTaxReconciliationAcquisitionRelatedCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncomeTaxReconciliationAcquisitionRelatedCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Acquisition Related Charges",
        "terseLabel": "Acquisition related charges",
        "documentation": "Income tax reconciliation acquisition related charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r909",
      "r1088"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Changes in tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r535",
      "r539",
      "r909"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r909"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Compensation expense",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1088",
      "r1090"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Prior year true-up and carryback",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal tax benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r909",
      "r1088"
     ]
    },
    "sclx_IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Valuation Allowance At Federal Statutory Income Tax Rate",
        "terseLabel": "Valuation allowance",
        "documentation": "Income tax reconciliation valuation allowance at federal statutory income tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sclx_IncreaseDecreaseInAccruedPayroll": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncreaseDecreaseInAccruedPayroll",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accrued payroll",
        "terseLabel": "Accrued Payroll",
        "documentation": "Increase Decrease In Accrued payroll"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IncreaseDecreaseInAccruedRebatesAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IncreaseDecreaseInAccruedRebatesAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Rebates and Fees",
        "terseLabel": "Accrued rebates and fees",
        "documentation": "Increase (Decrease) in Accrued Rebates and Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deposits",
        "terseLabel": "Change in fair value of FSF Deposit",
        "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r161"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r993"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r389",
      "r394",
      "r892"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r389",
      "r394",
      "r892"
     ]
    },
    "sclx_IndefiniteOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IndefiniteOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Operating Loss Carryforwards",
        "terseLabel": "Indefinite net federal operating loss",
        "documentation": "Indefinite Operating Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_InitialClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "InitialClosingMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Closing [Member]",
        "terseLabel": "Initial Closing [Member]",
        "documentation": "Initial Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r1037",
      "r1039"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense, net",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r989"
     ]
    },
    "us-gaap_InterestIncomeOperatingPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperatingPaidInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Operating, Paid in Cash",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of interest income from investment paid in cash, classified as operating."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r858",
      "r859"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Debt accrued interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r1133"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r875",
      "r925"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r199",
      "r213",
      "r370",
      "r371",
      "r372",
      "r691",
      "r878"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "terseLabel": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r704",
      "r931",
      "r932"
     ]
    },
    "sclx_InvestorAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "InvestorAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Agreement [Member]",
        "terseLabel": "Investor Agreement [Member]",
        "documentation": "Investor Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs related to Bought Deal Offering included in accrued expenses",
        "terseLabel": "Issuance costs related to direct offerings included in accrued expenses and account payables",
        "documentation": "Issuance costs related to Bought Deal Offering included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfCommonStockUponWarrantsExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssuanceOfCommonStockUponWarrantsExerciseShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Warrants Exercise, Shares",
        "terseLabel": "Issuance of common stock upon warrants exercise, shares",
        "documentation": "Issuance of Common Stock Upon Warrants Exercise, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfCommonStockUponWarrantsExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssuanceOfCommonStockUponWarrantsExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Warrants Exercise, Value",
        "terseLabel": "Issuance of common stock upon warrants exercise",
        "documentation": "Issuance of Common Stock Upon Warrants Exercise, Value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfFirmWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssuanceOfFirmWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Firm Warrants",
        "terseLabel": "Issuance of February 2024 BDO Firm Warrants as part of the February 2024 BDO, April 2024 RDO Common Warrants as part of the April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of the December 2024 RDO, and December 2024 RDO Pre-Funded Warrants as part of the December 2024 RDO",
        "documentation": "Issuance Of Firm Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfPennyWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssuanceOfPennyWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Penny Warrants",
        "terseLabel": "Issuance of penny warrants",
        "documentation": "Issuance of Penny Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssueOfWarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "IssueOfWarrantsToPurchaseShares",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Warrants to Purchase Shares",
        "terseLabel": "Issue of warrants",
        "documentation": "Issue of Warrants to Purchase Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_JuniorDipFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "JuniorDipFacilityMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Junior DIP Facility [Member]",
        "verboseLabel": "Junior DIP Facility",
        "terseLabel": "Junior DIP Facility [Member]",
        "documentation": "Junior DIP Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LeaseLiabilityNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LeaseLiabilityNetOfCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability, net of current portion",
        "terseLabel": "Lease liability, net of current portion",
        "documentation": "Lease liability, net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal fees and expenses",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2025 (Remainder of 2025)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r1117"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r84",
      "r85",
      "r86",
      "r91",
      "r92",
      "r93",
      "r94",
      "r239",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r579",
      "r582",
      "r583",
      "r621",
      "r797",
      "r881",
      "r943",
      "r1053",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r157",
      "r713",
      "r925",
      "r997",
      "r1022",
      "r1112"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r198",
      "r239",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r579",
      "r582",
      "r583",
      "r621",
      "r925",
      "r1053",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r1105"
     ]
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liabilities for uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sclx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Line Of Credit Facility Interest Rate",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r90"
     ]
    },
    "sclx_LiquidityAndGoingConcernLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LiquidityAndGoingConcernLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Line Items]",
        "documentation": "Liquidity and Going Concern [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LiquidityAndGoingConcernTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LiquidityAndGoingConcernTable",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Table]",
        "documentation": "Liquidity and Going Concern [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Fee Expense",
        "terseLabel": "Agreement settlement payment",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "sclx_LoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LoanAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Amount",
        "terseLabel": "Loan",
        "documentation": "Loan Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.scilexholding.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LongTermDebtTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LongTermDebtTransactionAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Transaction [Axis]",
        "documentation": "Long-Term Debt, Transaction [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LongTermDebtTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LongTermDebtTransactionDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Transaction [Domain]",
        "documentation": "Long-Term Debt, Transaction [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LongTermDebtTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LongTermDebtTransactionsAxis",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Transactions [Axis]",
        "documentation": "Long Term Debt Transactions [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Payment to Oramed",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "sclx_LongTermPortionOfDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "LongTermPortionOfDeferredConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term portion of deferred consideration",
        "terseLabel": "Long-term portion of deferred consideration",
        "documentation": "Long-term portion of deferred consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Long Term Commitment Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
      "http://www.scilexholding.com/role/DebtTables",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
      "http://www.scilexholding.com/role/DebtTables",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r44",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Long term Purchase Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualProductLiabilityGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProductLiabilityGross",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual, Product Liability, Gross",
        "terseLabel": "Liquidated damages",
        "documentation": "Undiscounted amount of the accrual for damages arising from third-party use of the entity's product or process."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r1048"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Endeavor for Liquidated Damages",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r899",
      "r927",
      "r930",
      "r1057",
      "r1136",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "sclx_MaturityRenewalDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "MaturityRenewalDescription",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Renewal Description",
        "terseLabel": "Agreement maturity renewal description",
        "documentation": "Maturity Renewal Description"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r412",
      "r413",
      "r415",
      "r416",
      "r483",
      "r525",
      "r602",
      "r690",
      "r738",
      "r740",
      "r752",
      "r787",
      "r788",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r869",
      "r870",
      "r888",
      "r898",
      "r906",
      "r916",
      "r917",
      "r921",
      "r922",
      "r928",
      "r1055",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions and License Agreements",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r139"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r412",
      "r413",
      "r415",
      "r416",
      "r483",
      "r525",
      "r602",
      "r690",
      "r738",
      "r740",
      "r752",
      "r787",
      "r788",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r869",
      "r870",
      "r888",
      "r898",
      "r906",
      "r916",
      "r917",
      "r921",
      "r928",
      "r1055",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "sclx_MonthlyBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "MonthlyBasisMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Basis [Member]",
        "terseLabel": "Monthly Basis [Member]",
        "documentation": "Monthly Basis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r899",
      "r927",
      "r930",
      "r1057",
      "r1136",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "sclx_NetCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NetCashProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "net cash proceeds",
        "terseLabel": "Net cash proceeds",
        "documentation": "net cash proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used for financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash proceeds from operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117",
      "r160",
      "r196",
      "r218",
      "r221",
      "r226",
      "r239",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r257",
      "r258",
      "r270",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r570",
      "r575",
      "r596",
      "r621",
      "r720",
      "r820",
      "r838",
      "r839",
      "r941",
      "r1053"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss for basic and diluted loss per share available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r248",
      "r249",
      "r251",
      "r252",
      "r261",
      "r262",
      "r271",
      "r274",
      "r575"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss for diluted loss per share available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r274"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NoOfCalendarDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NoOfCalendarDays",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No of Calendar Days",
        "terseLabel": "No of Calendar Days",
        "verboseLabel": "No of calendar days",
        "documentation": "No of Calendar Days"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NomisBayLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NomisBayLtdMember",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nomis Bay Ltd [Member]",
        "terseLabel": "Nomis Bay Ltd [Member]",
        "documentation": "Nomis Bay Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Non-RefundableNon-CreditablePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Non-RefundableNon-CreditablePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Refundable, Non-Creditable Payment",
        "terseLabel": "Non-Refundable, Non-Creditable Payment",
        "documentation": "Non-Refundable, Non-Creditable Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonCancelableLeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NonCancelableLeaseAgreementsMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cancelable Lease Agreements [Member]",
        "terseLabel": "Non-cancelable Lease Agreements [Member]",
        "documentation": "Non-cancelable Lease Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonCashOperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NonCashOperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Cost",
        "terseLabel": "Non-cash operating lease cost",
        "documentation": "Non cash operating lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonRefundableDepositAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NonRefundableDepositAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Refundable Deposit Amount",
        "terseLabel": "Non-Refundable Deposit Amount",
        "documentation": "Non-Refundable Deposit Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense, net:"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfShareOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfShareOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Outstanding",
        "terseLabel": "Number Of Share Outstanding",
        "documentation": "Number Of Share Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Treasury Stock Paid For Gloperba Ex-US License Shares",
        "terseLabel": "Treasury Stock paid for Gloperba Ex-U.S. License, Shares",
        "documentation": "Number of Treasury Stock Paid For Gloperba Ex-US License Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Treasury Stock transferred to Oramed for the Oramed Note maturity extension Shares",
        "terseLabel": "Treasury Stock transferred to Oramed for the Oramed Note maturity extension, Shares",
        "documentation": "Number of Treasury Stock transferred to Oramed for the Oramed Note maturity extension Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral Shares",
        "terseLabel": "Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral, Shares",
        "documentation": "Number of Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Number Of Warrants Exercised",
        "documentation": "Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfWarrantsExercised1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "NumberOfWarrantsExercised1",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Warrants Exercised 1",
        "terseLabel": "Number Of Warrants Exercised",
        "documentation": "Number Of Warrants Exercised 1"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_October2024NoteholderWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "October2024NoteholderWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2024 Noteholder Warrants [Member]",
        "terseLabel": "October 2024 Noteholder Warrants",
        "documentation": "October 2024 Noteholder Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_October2024PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "October2024PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2024 Placement Agent Warrants [Member]",
        "terseLabel": "October 2024 Placement Agent Warrants",
        "documentation": "October 2024 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OctoberCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OctoberCommonWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Common Warrants [Member]",
        "documentation": "October Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total net operating costs and expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Net operating costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r882",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "sclx_OperatingLeaseLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OperatingLeaseLiability1",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability 1",
        "negatedLabel": "Operating lease liability",
        "documentation": "Operating Lease Liability 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Less current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Corresponding lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating cash flows from operating leases (in thousands)",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r645"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Additional ROU assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r924"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years - operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r924"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "sclx_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards, expiration year",
        "documentation": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "sclx_OramedLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OramedLetterAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oramed Letter Agreement [Member]",
        "terseLabel": "Oramed Letter Agreement",
        "documentation": "Oramed Letter Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OramedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OramedMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oramed [Member]",
        "terseLabel": "Oramed [Member]",
        "documentation": "Oramed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OramedNoteIssuanceAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OramedNoteIssuanceAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oramed Note issuance at fair value",
        "terseLabel": "Oramed Note issuance at fair value",
        "documentation": "Oramed Note issuance at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Operations and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r146",
      "r754",
      "r755"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued rebates and fees",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "negatedTotalLabel": "Total other comprehensive income",
        "negatedLabel": "Other comprehensive income",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r20",
      "r219",
      "r222",
      "r228",
      "r253",
      "r626",
      "r627",
      "r632",
      "r698",
      "r721",
      "r985",
      "r986"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "terseLabel": "Changes in fair value attributable to instrument-specific credit risk",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r102",
      "r103",
      "r721"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt, Noncurrent",
        "terseLabel": "Debt, net of issuance costs",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r796"
     ]
    },
    "sclx_OtherLongTermLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OtherLongTermLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Other long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OtherNonCashConsiderationInConnectionWithShareRepurchase",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-cash consideration in connection with share repurchase",
        "terseLabel": "Other non-cash consideration in connection with share repurchase",
        "documentation": "Other non-cash consideration in connection with share repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1026"
     ]
    },
    "sclx_OwnershipInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "OwnershipInterestRate",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Interest Rate",
        "terseLabel": "Ownership Interest Rate",
        "documentation": "Ownership Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PaidToRoyaltyInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PaidToRoyaltyInvestors",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid to Royalty Investors",
        "terseLabel": "Paid to royalty investors",
        "documentation": "Paid to Royalty Investors"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PatentRightsAcquiredTechnologyAndAcquiredLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PatentRightsAcquiredTechnologyAndAcquiredLicensesMember",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Rights, Acquired Technology and Acquired Licenses [Member]",
        "terseLabel": "Patent Rights Acquired Technology And Acquired Licenses [Member]",
        "documentation": "Patent Rights, Acquired Technology and Acquired Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PatentRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PatentRightsMember",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent rights [Member]",
        "terseLabel": "Patent rights",
        "documentation": "Patent rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1040",
      "r1041"
     ]
    },
    "sclx_PaymentToAcquireLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PaymentToAcquireLicense",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to Acquire License",
        "terseLabel": "Payment to acquire license",
        "documentation": "Payment to Acquire License"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PaymentUponTheAchievementOfNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PaymentUponTheAchievementOfNetSales",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment upon the achievement of net sales",
        "documentation": "Payment Upon The Achievement of Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Legal Settlements",
        "negatedLabel": "Legal settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Warrants",
        "negatedLabel": "Cash consideration paid in connection with warrant repurchase",
        "terseLabel": "Repurchase of warrants",
        "verboseLabel": "Repurchase of warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Royalties",
        "terseLabel": "Payments for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 44.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs",
        "terseLabel": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "sclx_PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 51.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Deferred Transaction Costs Related to Semnur Merger",
        "negatedLabel": "Payments of deferred transaction costs related to Semnur Business Combination",
        "documentation": "Payments of Deferred Transaction Costs Related to Semnur Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Dividends",
        "verboseLabel": "Payment made to Investor",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of direct offering issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Cash paid for in-process research and development, net",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant, and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_PaymentsToAcquireReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Receivables",
        "terseLabel": "Amount paid for purchased receivables",
        "documentation": "The cash outflow for the purchase of all receivables."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "sclx_PennyWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PennyWarrantsExercised",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penny Warrants exercised",
        "terseLabel": "Penny Warrants exercised",
        "documentation": "Penny Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PennyWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penny Warrants [Member]",
        "terseLabel": "Penny Warrants [Member]",
        "documentation": "Penny Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentOfCombinedOfferingExercisePricePerShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PercentOfCombinedOfferingExercisePricePerShare",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percent of Combined Offering Exercise Price Per Share",
        "terseLabel": "Percent of combined offering exercise price per share",
        "documentation": "Percent of Combined Offering Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percent of Total Number of Shares Issued to Agents in the Offering",
        "terseLabel": "Percent of total number of shares issued to agents in the Offering",
        "documentation": "Percent of Total Number of Shares issued to Agents in the Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentageOfLidocaineTopicalSystem": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PercentageOfLidocaineTopicalSystem",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Lidocaine Topical System",
        "terseLabel": "Percentage of Lidocaine Topical System",
        "documentation": "Percentage of Lidocaine Topical System"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentageOfNetRevenueSoleDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PercentageOfNetRevenueSoleDistributors",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of net revenue, sole distributors",
        "terseLabel": "Percentage of net revenue, sole distributor",
        "documentation": "Percentage of net revenue, sole distributors"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PercentageOfUsageOfCashProceedsFromCashSweepFinancing",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Usage of Cash Proceeds from Cash Sweep Financing",
        "terseLabel": "Percentage of usage of cash proceeds from cash sweep financing",
        "documentation": "Percentage of Usage of Cash Proceeds from Cash Sweep Financing"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PlacementAgentSharesAndOctoberPlacementAgentWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Shares and October Placement Agent Warrants",
        "terseLabel": "Placement Agent Shares and October 2024 Placement Agent Warrants",
        "documentation": "Placement Agent Shares and October Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Shares and October Placement Agent Warrants, Shares",
        "terseLabel": "Placement Agent Shares and October 2024 Placement Agent Warrants, Shares",
        "documentation": "Placement Agent Shares and October Placement Agent Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]",
        "terseLabel": "Placement Agent Warrants",
        "documentation": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "sclx_PreFundedWarrantPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PreFundedWarrantPerShare",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant Per Share",
        "terseLabel": "Pre funded warrant per share",
        "documentation": "Pre Funded Warrant Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PreFundedWarrantsToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PreFundedWarrantsToPurchase",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants to Purchase",
        "terseLabel": "Pre-funded warrants to purchase",
        "documentation": "Pre Funded Warrants to Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PreferredStockDividendShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PreferredStockDividendShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividend Shares",
        "terseLabel": "Preferred stock dividend shares",
        "documentation": "Preferred Stock Dividend Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "terseLabel": "Preferred Stock, Dividends Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsShares",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividends, Shares",
        "terseLabel": "Preferred Stock Dividends, Shares",
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940",
      "r1168",
      "r1171"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred Stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r456"
     ]
    },
    "us-gaap_PreferredStockRedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Redemption Premium",
        "negatedLabel": "Premium on redemption of Series A Preferred Stock",
        "documentation": "The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r799"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preference shares issue",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r456"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r799",
      "r818",
      "r1171",
      "r1172"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r709",
      "r925"
     ]
    },
    "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan, Held-in-Portfolio, Principal Outstanding",
        "terseLabel": "Outstanding principal amount",
        "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "sclx_PrincipalBalanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PrincipalBalanceMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Balance [Member]",
        "terseLabel": "Principal Balance [Member]",
        "documentation": "Principal Balance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PrincipalLaonAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PrincipalLaonAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal laon amount",
        "terseLabel": "Principal loan amount",
        "documentation": "Principal laon amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants [Member]",
        "terseLabel": "Private Warrants",
        "documentation": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProbudurMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProbudurMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probudur [Member]",
        "documentation": "Probudur Member"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProceedSOfSaleOfCommonSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedSOfSaleOfCommonSharesPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed's of sale of common shares percentage",
        "terseLabel": "Proceed's of sale of common shares",
        "documentation": "Proceed s of sale of common shares percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of Convertible Debentures",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Issuance of shares under Settlement Agreement",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r872"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of Tranche B Notes and purchased revenue liability",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "sclx_ProceedsFromIssuanceOfFsfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedsFromIssuanceOfFsfDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of FSF Deposit",
        "terseLabel": "Proceeds from issuance of FSF Deposit",
        "documentation": "Proceeds from issuance of FSF Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProceedsFromIssuanceOfRevolvingFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedsFromIssuanceOfRevolvingFacility",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Revolving Facility",
        "terseLabel": "Proceeds from issuance of Revolving Facility",
        "documentation": "Proceeds from Issuance of Revolving Facility"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement",
        "negatedLabel": "Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement",
        "documentation": "Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 49.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of shares under direct offerings",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sclx_ProceedsFromSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedsFromSaleOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock",
        "terseLabel": "Proceeds from sale of common stock",
        "documentation": "Proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 52.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "sclx_ProceedsReceivedFromPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProceedsReceivedFromPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds Received from Purchase Agreement",
        "terseLabel": "Proceeds received from purchase agreement",
        "documentation": "Proceeds Received from Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProductDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ProductDevelopmentAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Development Agreement [Member]",
        "terseLabel": "Product Development Agreement [Member]",
        "documentation": "Product Development Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductLiabilityContingencyAccrualDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyAccrualDiscountRate",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency, Accrual, Discount Rate",
        "terseLabel": "Discount rate of FDA",
        "documentation": "Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r218",
      "r221",
      "r232",
      "r239",
      "r246",
      "r253",
      "r257",
      "r258",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r570",
      "r575",
      "r577",
      "r580",
      "r581",
      "r596",
      "r621",
      "r701",
      "r719",
      "r766",
      "r820",
      "r838",
      "r839",
      "r910",
      "r911",
      "r942",
      "r987",
      "r1053"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r649"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r176",
      "r179",
      "r180"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r201",
      "r717"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 30.0
      },
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r649",
      "r702",
      "r717",
      "r925"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r176",
      "r179",
      "r715"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r649"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property Plant And Equipment Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Other Credit Losses",
        "terseLabel": "Expected Credit Losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r158"
     ]
    },
    "sclx_PublicOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PublicOfferingPrice",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Price",
        "terseLabel": "Public Offering Price",
        "documentation": "Public Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicOfferingPriceCombined": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PublicOfferingPriceCombined",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Price Combined",
        "terseLabel": "Public Offering Price Combined",
        "documentation": "Public Offering Price Combined"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant And Private Placement Warrants [Policy Text Block]",
        "verboseLabel": "Warrants",
        "documentation": "Public Warrant And Private Placement Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicWarrantsPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PublicWarrantsPurchaseCommonStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Purchase Common Stock[Member]",
        "terseLabel": "Public Warrants Purchase Common Stock",
        "documentation": "Public Warrants Purchase Common Stock[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseAgreementAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Axis]",
        "documentation": "Purchase Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseAgreementDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Domain]",
        "documentation": "Purchase Agreement Domain"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfCommonWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseOfCommonWarrants",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Common Warrants",
        "terseLabel": "Warrant Purchase",
        "verboseLabel": "Common Warrants Purchase",
        "documentation": "Purchase Of Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfConvertiblePromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseOfConvertiblePromissoryNote",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of convertible promissory note",
        "negatedLabel": "Purchase of convertible promissory note from Denali",
        "documentation": "Purchase of convertible promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseOfEquitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Equity Securities",
        "negatedLabel": "Purchase of equity securities",
        "documentation": "Purchase of equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchaseOfStockPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock, percentage",
        "terseLabel": "Purchase of stock, percentage",
        "documentation": "Purchase of stock, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchasedRevenueLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchasedRevenueLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Revenue Liability",
        "terseLabel": "Purchased revenue liability",
        "periodStartLabel": "Ending Balance as of December 31, 2024",
        "periodEndLabel": "Ending Balance as of March 31, 2025",
        "documentation": "Purchased Revenue Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchasedRevenueLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchasedRevenueLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Revenue Liability Current",
        "terseLabel": "Purchased revenue liability, current",
        "documentation": "Purchased Revenue Liability Current"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchasedRevenueLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchasedRevenueLiabilityMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Revenue Liability [Member]",
        "terseLabel": "Purchased Revenue Liability",
        "documentation": "Purchased Revenue Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchasedRevenueLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchasedRevenueLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Revenue Liability Noncurrent",
        "terseLabel": "Purchased revenue liability, net of current portion",
        "documentation": "Purchased Revenue Liability Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchasedRevenueLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "PurchasedRevenueLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Revenue Liability [Policy Text Block]",
        "terseLabel": "Purchased Revenue Liability",
        "documentation": "Purchased Revenue Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r412",
      "r413",
      "r415",
      "r416",
      "r474",
      "r483",
      "r514",
      "r515",
      "r516",
      "r525",
      "r602",
      "r664",
      "r673",
      "r690",
      "r738",
      "r740",
      "r752",
      "r787",
      "r788",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r869",
      "r870",
      "r888",
      "r898",
      "r906",
      "r916",
      "r917",
      "r921",
      "r922",
      "r928",
      "r935",
      "r1046",
      "r1055",
      "r1108",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r412",
      "r413",
      "r415",
      "r416",
      "r474",
      "r483",
      "r514",
      "r515",
      "r516",
      "r525",
      "r602",
      "r664",
      "r673",
      "r690",
      "r738",
      "r740",
      "r752",
      "r787",
      "r788",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r869",
      "r870",
      "r888",
      "r898",
      "r906",
      "r916",
      "r917",
      "r921",
      "r922",
      "r928",
      "r935",
      "r1046",
      "r1055",
      "r1108",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "sclx_ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclass of Deposit Warrant Liability upon satisfaction of the FSF Deposit",
        "verboseLabel": "Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit",
        "terseLabel": "Reclass of Deposit Warrant liability upon satisfaction of the FSF Deposit",
        "documentation": "Reclass of Deposit Warrant Liability Upon Satisfaction Of The FSF Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ReductionOfThePrincipalBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ReductionOfThePrincipalBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of the Principal Balance",
        "terseLabel": "Reduction of the principal balance",
        "documentation": "Reduction of the Principal Balance"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering",
        "documentation": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r481",
      "r653",
      "r654",
      "r706",
      "r714",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r817",
      "r819",
      "r845"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Agreement amount",
        "terseLabel": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r653"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r1123"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r481",
      "r653",
      "r654",
      "r706",
      "r714",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r817",
      "r819",
      "r845",
      "r1123"
     ]
    },
    "sclx_RemainingDrawableBalanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RemainingDrawableBalanceMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Drawable Balance [Member]",
        "terseLabel": "Remaining Drawable Balance [Member]",
        "documentation": "Remaining Drawable Balance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfConvertibleDebenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfConvertibleDebenture",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Convertible Debenture",
        "terseLabel": "Repayment of Convertible Debentures",
        "documentation": "Repayment of Convertible Debenture"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 43.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment Of Debt",
        "negatedLabel": "Repayment of Tranche B Notes principal and interest",
        "documentation": "Repayment Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfDeposit",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfFsfDepositDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Deposit",
        "terseLabel": "Repayment of FSF Deposit",
        "documentation": "Repayment of Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfPurchasedRevenueLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfPurchasedRevenueLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of purchased revenue liability",
        "terseLabel": "Repayment of purchased revenue liability",
        "documentation": "Repayment of purchased revenue liability"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfRevolvingFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfRevolvingFacility",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Revolving Facility",
        "negatedLabel": "Repayment of Revolving Facility",
        "documentation": "Repayment of Revolving Facility"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfTrancheBNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepaymentOfTrancheBNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Tranche B Notes",
        "documentation": "Repayment of Tranche B Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 42.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of Convertible Debentures",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of Oramed Note",
        "verboseLabel": "Repayment of debt prinnciple installment",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "sclx_RepresentativeWarrantsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepresentativeWarrantsOutstandingMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Warrants Outstanding[Member]",
        "terseLabel": "Representative Warrants Outstanding",
        "documentation": "Representative Warrants Outstanding[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Of Warrants",
        "terseLabel": "Repurchase of warrants",
        "documentation": "Repurchase of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r1087"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r1087"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r871",
      "r885",
      "r1132"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "In-process research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "sclx_ResearchAndDevelopmentFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ResearchAndDevelopmentFacilitiesMember",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Facilities [Member]",
        "terseLabel": "Research and Development Facilities [Member]",
        "documentation": "Research and Development Facilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Income Tax Credits [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r194",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r279",
      "r354",
      "r355",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r593",
      "r594",
      "r595",
      "r596",
      "r636",
      "r638",
      "r651",
      "r652",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r756",
      "r1012"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r194",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r279",
      "r354",
      "r355",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r593",
      "r594",
      "r595",
      "r596",
      "r636",
      "r638",
      "r651",
      "r652",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r756",
      "r1012"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r149",
      "r200",
      "r236",
      "r708"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_RetailLandSalesReceivablesStatedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetailLandSalesReceivablesStatedInterestRate",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retail Land Sales Receivables, Stated Interest Rate",
        "terseLabel": "Percentage of aggregate net sales",
        "documentation": "Percentage of stated interest rate for receivables from retail land sales."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r130",
      "r712",
      "r746",
      "r751",
      "r763",
      "r800",
      "r925"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r256",
      "r258",
      "r353",
      "r356",
      "r398",
      "r559",
      "r560",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r585",
      "r587",
      "r588",
      "r590",
      "r594",
      "r637",
      "r639",
      "r742",
      "r744",
      "r767",
      "r1171"
     ]
    },
    "sclx_RetainerSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RetainerSharesIssued",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer shares issued",
        "terseLabel": "Retainer shares issued (in shares)",
        "documentation": "Retainer shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RetainerSharesIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RetainerSharesIssuedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer Shares Issued Value",
        "terseLabel": "Retainer shares issued",
        "documentation": "Retainer shares issued value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RetainerSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RetainerSharesMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer Shares [Member]",
        "terseLabel": "Retainer Shares",
        "documentation": "Retainer Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r873",
      "r879"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Revenue, Remaining Performance Obligation, Percentage",
        "verboseLabel": "Percentage of net revenue",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Net revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r227",
      "r239",
      "r281",
      "r287",
      "r288",
      "r308",
      "r313",
      "r317",
      "r318",
      "r319",
      "r352",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r621",
      "r701",
      "r885",
      "r1053"
     ]
    },
    "sclx_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Policy Text Block]",
        "terseLabel": "Reverse Stock Split",
        "documentation": "Reverse Stock Split [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification",
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RightToSellMaximumNumberOfCommonStockShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RightToSellMaximumNumberOfCommonStockShares",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right to Sell Maximum Number of Common Stock Shares",
        "terseLabel": "Right to sell maximum number of common stock shares",
        "documentation": "Right to Sell Maximum Number of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RodmanRenshawLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RodmanRenshawLlcMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rodman &amp; Renshaw LLC [Member]",
        "terseLabel": "Rodman &amp; Renshaw LLC",
        "documentation": "Rodman &amp; Renshaw LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RomegLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RomegLicenseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Romeg License Agreement [Member]",
        "documentation": "Romeg License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expenses",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Accrued royalty payables",
        "documentation": "The amount the entity has committed to make for future royalty guarantees."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "sclx_RoyaltyPaymentPercentageOnNetSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RoyaltyPaymentPercentageOnNetSale",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payment Percentage On Net Sale",
        "terseLabel": "Percentage on net sale",
        "documentation": "Royalty Payment Percentage On Net Sale"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RoyaltyPaymentPercentageRelatedToFutureYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RoyaltyPaymentPercentageRelatedToFutureYears",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payment Percentage Related To Future Years",
        "terseLabel": "Royalty payment percentage related to future years",
        "documentation": "Royalty Payment Percentage Related To Future Years"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "RoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Purchase Agreement [Member]",
        "documentation": "Royalty Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number sale of common stock shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Excise tax liability",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r964"
     ]
    },
    "sclx_SatisfactionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SatisfactionAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Satisfaction Agreement [Member]",
        "terseLabel": "Satisfaction Agreement",
        "documentation": "Satisfaction Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r980",
      "r1003"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r258",
      "r279",
      "r568",
      "r570",
      "r571",
      "r574",
      "r575",
      "r593",
      "r594",
      "r595",
      "r636",
      "r638",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r756",
      "r966",
      "r968",
      "r969",
      "r970",
      "r1002",
      "r1012",
      "r1023",
      "r1024",
      "r1103",
      "r1120",
      "r1121"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r259",
      "r484",
      "r961",
      "r1003"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r572"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Quantitative Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Benefit for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Liabilities and Related Valuation Allowance",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]",
        "documentation": "Schedule Of Derivative Component Of The Obligation Is Initially Valued And Classified As A Derivative Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the reconciliation of basic and diluted loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r909",
      "r1088"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r394",
      "r397",
      "r892"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Summary of identifiable intangible assets",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1031"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r649"
     ]
    },
    "sclx_ScheduleOfRevenueLiabilityActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScheduleOfRevenueLiabilityActivityTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue Liability Activity [Table Text Block]",
        "terseLabel": "Schedule of revenue liability activity",
        "documentation": "Schedule of Revenue Liability Activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Outstanding Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r136"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Valuation Assumption Used",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ScheduleOfTheOramedNoteTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScheduleOfTheOramedNoteTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of The Oramed Note Table Text Block",
        "terseLabel": "Schedule of the Oramed Note",
        "documentation": "Schedule of The Oramed Note Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ScheduleOfTheTrancheBNoteTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScheduleOfTheTrancheBNoteTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of The Tranche B Note [Table Text Block]",
        "terseLabel": "Schedule of the Tranche B Note",
        "documentation": "Tavular disclosure of The Tranche B Note Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ScheduleOfTrancheBNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScheduleOfTrancheBNotesTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Tranche B Notes [Table Text Block]",
        "terseLabel": "Schedule of Tranche B Notes",
        "documentation": "Schedule Of Tranche B Notes [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r908"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization expense related to intangible assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1038"
     ]
    },
    "sclx_ScilexBioJVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScilexBioJVMember",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Bio JV [Member]",
        "terseLabel": "Scilex Bio JV",
        "documentation": "Scilex Bio JV [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ScilexPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ScilexPharmaMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Pharma [Member]",
        "verboseLabel": "Scilex Pharma [Member]",
        "terseLabel": "Scilex Pharma [Member]",
        "documentation": "Scilex Pharma"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecondClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SecondClosingMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Closing [Member]",
        "documentation": "Second Closing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecondInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SecondInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Installment [Member]",
        "terseLabel": "Second Installment [Member]",
        "documentation": "Second Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecuredNoteDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SecuredNoteDiscountRate",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Note Discount Rate",
        "terseLabel": "Note discount rate",
        "documentation": "Secured Note Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "verboseLabel": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r319",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r397",
      "r408",
      "r409",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r884",
      "r885",
      "r886",
      "r891",
      "r929",
      "r1136",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r316",
      "r318",
      "r883",
      "r884",
      "r887"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "sclx_Semnur2024StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Semnur2024StockOptionPlanMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semnur 2024 Stock Option Plan [Member]",
        "terseLabel": "Semnur 2024 Stock Option Plan",
        "documentation": "Semnur 2024 Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SemnurCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SemnurCommonStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semnur Common Stock [Member]",
        "terseLabel": "Semnur Common Stock [Member]",
        "documentation": "Semnur Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]",
        "terseLabel": "Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]",
        "documentation": "Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes",
        "terseLabel": "Oramed Note",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r1134"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfTheOramedNoteDetails",
      "http://www.scilexholding.com/role/DebtSummaryOfOutstandingConvertibleDebentureDetails",
      "http://www.scilexholding.com/role/DebtTables",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes [Member]",
        "terseLabel": "Oramed Note",
        "definitionGuidance": "Oramed Note [Member]",
        "verboseLabel": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SeniorSecuredConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SeniorSecuredConvertibleNotesMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Convertible Notes [Member]",
        "verboseLabel": "Senior Secured Convertible Notes [Member]",
        "documentation": "Senior Secured Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorSubordinatedNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorSubordinatedNotesMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Subordinated Notes [Member]",
        "terseLabel": "FSF Deposit Member",
        "documentation": "A senior subordinated note is a bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior subordinated debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors. However senior subordinated notes are junior to Senior Notes and Senior bond holders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series Preferred Stock [Member]",
        "verboseLabel": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r983",
      "r1056"
     ]
    },
    "sclx_SeriesOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SeriesOnePreferredStockMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series One Preferred Stock [Member]",
        "terseLabel": "Series One Preferred Stock [Member]",
        "verboseLabel": "Series 1 Preferred Stock [Member]",
        "documentation": "Series One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "sclx_SettlementOfFSFDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SettlementOfFSFDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of FSF Deposit",
        "terseLabel": "Settlement of FSF Deposit",
        "documentation": "Settlement of FSF Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the common stock percentage",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "verboseLabel": "Expected stock -price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of option exercise",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options Outstanding, Forfeited/Cancelled",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted weighted-average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Options Outstanding, Beginning Balance",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "terseLabel": "Number of option outstanding to purchase common stock",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value ,Vested and expected to vest as of March 31, 2025",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and expected to vest as of March 31, 2025",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price,Vested and expected to vest as of March 31, 2025",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r492",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r521",
      "r522",
      "r523",
      "r524"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term, in years",
        "verboseLabel": "Term of options",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted-average Remaining Contractual Life, (in Years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted-average Remaining Contractual Life, (in Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, in year,Vested and expected to vest as of March 31, 2025",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "sclx_ShareholdersEquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ShareholdersEquityDetailsLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]",
        "documentation": "Shareholders Equity Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]",
        "documentation": "Shareholders Equity Details Table"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesDelivered": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesDelivered",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Delivered",
        "terseLabel": "Shares Delivered",
        "verboseLabel": "Shares delivered",
        "documentation": "Shares Delivered"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuablePursuantToEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuablePursuantToEsppMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable pursuant to ESPP [Member]",
        "terseLabel": "Shares issuable pursuant to ESPP",
        "documentation": "Shares Issuable pursuant to ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuableUnderSponsorInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuableUnderSponsorInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Under Sponsor Interest Purchase Agreement [Member]",
        "terseLabel": "Shares issuable under the SIPA",
        "documentation": "Shares Issuable Under Sponsor Interest Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuableUnderTrancheBNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuableUnderTrancheBNotesMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable under Tranche B Notes [Member]",
        "terseLabel": "Shares issuable under Tranche B Notes",
        "documentation": "Shares issuable under Tranche B Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedDuringPeriodSharesRegisteredDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedDuringPeriodSharesRegisteredDirectOffering",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued During Period, Shares, Registered Direct Offering",
        "terseLabel": "Shares issued under Registered Direct Offering, shares",
        "documentation": "Shares Issued During Period Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedDuringPeriodValuesRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedDuringPeriodValuesRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued During Period, Values, Registered Direct Offering",
        "terseLabel": "Shares issued under Registered Direct Offering",
        "documentation": "Shares Issued During Period, Values, Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderBoughtDealOfferingShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderBoughtDealOfferingShare",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Bought Deal Offering, Share",
        "terseLabel": "Shares issued under Bought Deal Offering",
        "documentation": "Shares issued under Bought Deal Offering, Share"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderBoughtDealOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderBoughtDealOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Bought Deal Offering, value",
        "terseLabel": "Shares issued under Bought Deal Offering",
        "documentation": "Shares issued under Bought Deal Offering, value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderDecemberRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderDecemberRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under December Registered Direct Offering",
        "terseLabel": "Shares issued under December 2024 RDO, Value",
        "documentation": "Shares issued under December Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderDecemberRegisteredDirectOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderDecemberRegisteredDirectOfferingShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under December Registered Direct Offering, Shares",
        "terseLabel": "Shares issued under December 2024 RDO, Shares",
        "documentation": "Shares issued under December Registered Direct Offering, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderStandbyEquityPurchaseAgreements",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Standby Equity Purchase Agreements",
        "terseLabel": "Shares issued under the Standby Equity Purchase Agreements (in shares)",
        "documentation": "Shares issued under Standby Equity Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement",
        "terseLabel": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Share",
        "documentation": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value",
        "terseLabel": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value",
        "documentation": "Shares issued under Standby Equity Purchase Agreements and under ATM Sales Agreement, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesPurchasedAtParValueUnderStockPurchaseAgreement",
     "presentation": [
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Purchased At Par Value Under Stock Purchase Agreement",
        "terseLabel": "Shares Purchased At Par Value Under Stock Purchase Agreement",
        "documentation": "Shares Purchased At Par Value Under Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesPurchasedUnderStockPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SharesPurchasedUnderStockPurchaseAgreement",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Purchased Under Stock Purchase Agreement",
        "terseLabel": "Shares Purchased Under Stock Purchase Agreement",
        "documentation": "Shares Purchased Under Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "sclx_SixInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SixInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Installment [Member]",
        "terseLabel": "Six Installment [Member]",
        "documentation": "Six Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SorrentoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SorrentoMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sorrento [Member]",
        "verboseLabel": "Sorrento",
        "documentation": "Sorrento [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SpacWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SpacWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAC Warrants [Member]",
        "terseLabel": "SPAC Warrants [Member]",
        "documentation": "SPAC Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r195",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r319",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r397",
      "r400",
      "r408",
      "r409",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r884",
      "r885",
      "r886",
      "r891",
      "r929",
      "r1136",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r208",
      "r209",
      "r210",
      "r239",
      "r264",
      "r265",
      "r272",
      "r274",
      "r283",
      "r284",
      "r352",
      "r419",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r456",
      "r457",
      "r459",
      "r462",
      "r469",
      "r621",
      "r759",
      "r760",
      "r761",
      "r762",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r799",
      "r821",
      "r840",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r960",
      "r995",
      "r1005"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96",
      "r99",
      "r100",
      "r193",
      "r224",
      "r225",
      "r226",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r256",
      "r258",
      "r282",
      "r353",
      "r356",
      "r398",
      "r471",
      "r559",
      "r560",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r639",
      "r652",
      "r721",
      "r742",
      "r743",
      "r744",
      "r767",
      "r840"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r282",
      "r639",
      "r692",
      "r757",
      "r779",
      "r789",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810",
      "r811",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r840",
      "r936"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r259",
      "r484",
      "r961",
      "r962",
      "r1003"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r282",
      "r320",
      "r639",
      "r692",
      "r757",
      "r779",
      "r789",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810",
      "r811",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r840",
      "r936"
     ]
    },
    "sclx_StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockBlock Warrants issued in connection with December Registered Direct Offering",
        "terseLabel": "StockBlock Warrants issued in connection with the December 2024 RDO",
        "documentation": "StockBlock Warrants issued in connection with December Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockBlockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockBlockWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockBlock Warrants",
        "verboseLabel": "StockBlock Warrants [Member]",
        "documentation": "StockBlock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockDividendDeclaredNotYetDistributed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockDividendDeclaredNotYetDistributed",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock dividend declared, not yet distributed",
        "terseLabel": "Stock dividend declared, not yet distributed",
        "documentation": "Stock dividend declared, not yet distributed"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockDividendDeclaredNotYetDistributedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockDividendDeclaredNotYetDistributedShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock dividend declared, not yet distributed, Shares",
        "terseLabel": "Stock dividend declared, not yet distributed, Shares",
        "documentation": "Stock dividend declared, not yet distributed, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares",
        "terseLabel": "Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)",
        "documentation": "Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value",
        "terseLabel": "Repurchase of Treasury Stock, Preferred Stock, and warrants",
        "documentation": "Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r96",
      "r130"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Issuance of common stock in connection with Settlement Agreement, (in shares)",
        "terseLabel": "Stock issued for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r96",
      "r130",
      "r759",
      "r840",
      "r861"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Stock options exercised (in shares)",
        "negatedLabel": "Options Outstanding, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r96",
      "r130",
      "r498"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r96",
      "r130"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock in connection with Settlement Agreement",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96",
      "r99",
      "r100",
      "r130"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "sclx_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options",
        "documentation": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement [Member]",
        "verboseLabel": "Sorrento Stock Purchase Agreement",
        "terseLabel": "Sorrento Stock Purchase Agreement [Member]",
        "documentation": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r100",
      "r120",
      "r801",
      "r818",
      "r841",
      "r842",
      "r925",
      "r943",
      "r997",
      "r1022",
      "r1112",
      "r1171"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r193",
      "r194",
      "r225",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r256",
      "r353",
      "r356",
      "r398",
      "r471",
      "r559",
      "r560",
      "r567",
      "r568",
      "r569",
      "r571",
      "r574",
      "r575",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r626",
      "r628",
      "r632",
      "r638",
      "r652",
      "r743",
      "r744",
      "r765",
      "r801",
      "r818",
      "r841",
      "r842",
      "r865",
      "r942",
      "r997",
      "r1022",
      "r1112",
      "r1171"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r238",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r471",
      "r592",
      "r843",
      "r844",
      "r866"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Description of Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r656"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r656"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r656"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r656"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r656"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r657"
     ]
    },
    "sclx_SubsequentPennyWarrants2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SubsequentPennyWarrants2Member",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 2 [Member]",
        "terseLabel": "Subsequent Penny Warrants 2 [Member]",
        "documentation": "Subsequent Penny Warrants 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SubsequentPennyWarrants3Member",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 3 [Member]",
        "terseLabel": "Subsequent Penny Warrants 3 [Member]",
        "documentation": "Subsequent Penny Warrants 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SubsequentPennyWarrants4Member",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 4 [Member]",
        "terseLabel": "Subsequent Penny Warrants 4 [Member]",
        "documentation": "Subsequent Penny Warrants 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SubsequentPennyWarrants5Member",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 5 [Member]",
        "terseLabel": "Subsequent Penny Warrants 5 [Member]",
        "documentation": "Subsequent Penny Warrants 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SubsequentPennyWarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants [Member]",
        "terseLabel": "Subsequent Penny Warrants [Member]",
        "documentation": "Subsequent Penny Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "sclx_SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of The Changes In The Balance And The Estimated Fair Value Of The FSF Deposit",
        "terseLabel": "Schedule of FSF Deposit",
        "documentation": "Summary of the Changes in the Balance and the Estimated Fair Value of the FSF Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "sclx_TaxCreditCarryforwardNotSubjectToExpireAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TaxCreditCarryforwardNotSubjectToExpireAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Not Subject to Expire, Amount",
        "terseLabel": "Tax credit, not subject to expire",
        "documentation": "Tax Credit Carryforward, Not Subject to Expire, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable",
        "terseLabel": "Accrued tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r153",
      "r1133"
     ]
    },
    "sclx_TerminationFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TerminationFees",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "termination fees",
        "terseLabel": "Termination fees",
        "documentation": "termination fees"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ThirdInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ThirdInstallmentMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Installment [Member]",
        "terseLabel": "Third Installment [Member]",
        "documentation": "Third Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customers [Member]",
        "terseLabel": "Three Customers [Member]",
        "documentation": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ThreeILpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ThreeILpMember",
     "presentation": [
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three i LP [Member]",
        "terseLabel": "Three i LP [Member]",
        "documentation": "Three i LP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1122"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TotalNumberOfSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TotalNumberOfSharesGranted",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Number Of Shares Granted",
        "terseLabel": "Total number of shares granted",
        "verboseLabel": "Total Number of Shares Granted",
        "documentation": "Total Number of Shares Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "sclx_TrancheBNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TrancheBNote",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche B Note",
        "terseLabel": "Tranche B Notes",
        "periodStartLabel": "Ending Balance as of December 31, 2024",
        "periodEndLabel": "Ending Balance as of March 31, 2025",
        "documentation": "Tranche B Note"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TrancheBNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TrancheBNoteMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche B Note [Member]",
        "documentation": "Tranche B Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TrancheBNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TrancheBNotesMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtScheduleOfTheTrancheBNoteDetails",
      "http://www.scilexholding.com/role/DebtTables",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche B Notes [Member]",
        "terseLabel": "Tranche BNotes Member",
        "documentation": "Tranche B Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TransactionCostsPaidInConnectionWithShareRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TransactionCostsPaidInConnectionWithShareRepurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 47.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs paid in connection with share repurchase",
        "negatedLabel": "Transaction costs paid in connection with share repurchase",
        "documentation": "Transaction costs paid in connection with share repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TransactionCostsPaidRelatedToTheRecapitalizationTransaction",
     "crdr": "credit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 41.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs paid related to the recapitalization transaction",
        "negatedLabel": "Transaction costs paid related to the Business Combination",
        "documentation": "Transaction costs paid related to the recapitalization transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "sclx_TransferOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TransferOfCommonStockShares",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer of Common Stock Shares",
        "terseLabel": "Transfer of Common Stock Shares",
        "documentation": "Transfer of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TransferOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TransferOfWarrants",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer of Warrants",
        "terseLabel": "Transfer of warrants",
        "documentation": "Transfer of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r453",
      "r467",
      "r591",
      "r619",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r722",
      "r912",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r926",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1104",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "sclx_TreasuryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TreasuryShareMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Share [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "verboseLabel": "Treasury stock share",
        "terseLabel": "Treasury Stock Common Shares Outstanding",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "sclx_TreasuryStockPaidForGloperbaEx-USLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TreasuryStockPaidForGloperbaEx-USLicense",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock paid for Gloperba Ex-U.S. License",
        "terseLabel": "Treasury Stock paid for Gloperba Ex-U.S. License",
        "documentation": "Treasury Stock paid for Gloperba Ex-U.S. License"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TreasuryStockPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TreasuryStockPolicyTextblock",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Policy TextBlock",
        "terseLabel": "Treasury Stock",
        "documentation": "Treasury Stock Policy TextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockPreferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockPreferredMember",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Preferred [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockPreferredShares",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Preferred, Shares",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance, ( In shares)",
        "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "sclx_TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock transferred to Oramed for the Oramed Note maturity extension",
        "terseLabel": "Treasury Stock transferred to Oramed for the Oramed Note maturity extension",
        "documentation": "Treasury Stock transferred to Oramed for the Oramed Note maturity extension"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral",
        "terseLabel": "Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral",
        "documentation": "Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r96",
      "r99"
     ]
    },
    "sclx_TwoThousandTwentyThreeInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TwoThousandTwentyThreeInducementPlanMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Inducement Plan [Member]",
        "terseLabel": "2023 Inducement Plan",
        "documentation": "Two Thousand Twenty Three Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TwoThousandTwentyTwoEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]",
        "terseLabel": "2022 Employee Stock Purchase Plan",
        "documentation": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "terseLabel": "2022 Equity Incentive Plan",
        "documentation": "Two Thousand Twenty Two Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SorrentoStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r545",
      "r908"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r908"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r908"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r908"
     ]
    },
    "sclx_Upfrontlicensefee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "Upfrontlicensefee",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UpFrontLicenseFee",
        "terseLabel": "Up-front license fee",
        "documentation": "UpFrontLicenseFee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.scilexholding.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r173",
      "r174",
      "r177",
      "r178"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r916",
      "r1109"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r916",
      "r1109"
     ]
    },
    "sclx_ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Issued Under Placement Agent Warrants Issued In Connection With Registered Direct Offering And Representative Warrants Issued In Connection With Bought Deal Offering",
        "terseLabel": "Placement Agent Warrants issued in connection with Registered Direct Offering and Representative Warrants issued in connection with Bought Deal Offering",
        "documentation": "Value Issued Under Placement Agent Warrants Issued In Connection With Registered Direct Offering And Representative Warrants Issued In Connection With Bought Deal Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ValueIssuedUnderStandbyEquityPurchaseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "value issued under Standby Equity Purchase Agreements",
        "terseLabel": "Shares issued under the Standby Equity Purchase Agreements",
        "documentation": "value issued under Standby Equity Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant, exercise price, decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "sclx_WarrantTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WarrantTransferAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Transfer Agreement [Member]",
        "terseLabel": "Warrant Transfer Agreement",
        "documentation": "Warrant Transfer Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WarrantVestingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WarrantVestingDate",
     "presentation": [
      "http://www.scilexholding.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Vesting Date",
        "terseLabel": "Warrant vesting date",
        "documentation": "Warrant Vesting Date"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.scilexholding.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "terseLabel": "Warrants",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WeightedAverageCommonStockWarrantsExercisableNominalConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WeightedAverageCommonStockWarrantsExercisableNominalConsideration",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Stock Warrants Exercisable, Nominal Consideration",
        "terseLabel": "Weighted average common stock warrants exercisable for nominal consideration",
        "documentation": "Weighted average common stock warrants exercisable for nominal consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average number of shares during the period -diluted",
        "terseLabel": "Weighted average number of shares, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r274"
     ]
    },
    "sclx_WeightedAverageNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "presentation": [
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding",
        "terseLabel": "Weighted average number of shares outstanding",
        "documentation": "Weighted Average Number of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares during the period - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scilexholding.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average number of shares during the period-basic",
        "terseLabel": "Weighted average number of shares - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r274"
     ]
    },
    "sclx_WeightedAveragePeriodOverGrant": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WeightedAveragePeriodOverGrant",
     "presentation": [
      "http://www.scilexholding.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period over grant",
        "terseLabel": "Weighted average period over grant",
        "documentation": "Weighted average period over grant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.scilexholding.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital",
        "terseLabel": "Negative working capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.scilexholding.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "terseLabel": "Allocated expense for financial instruments at fair value",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "sclx_ZTlidoRestOfWorldLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ZTlidoRestOfWorldLicenseAgreementMember",
     "presentation": [
      "http://www.scilexholding.com/role/AcquisitionsAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.scilexholding.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZTlido Rest of World License Agreement [Member]",
        "terseLabel": "Tlido Rest Of World License Agreement [Member]",
        "verboseLabel": "ZTlido Rest of World License Agreement [Member]",
        "documentation": "ZTlido Rest of World License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ZTlidoRoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scilexholding.com/20250801",
     "localname": "ZTlidoRoyaltyMember",
     "presentation": [
      "http://www.scilexholding.com/role/DebtAdditionalInformationDetails",
      "http://www.scilexholding.com/role/DebtScheduleOfRevenueLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZTlido Royalty [Member]",
        "documentation": "ZTlido Royalty [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  },
  "d942297dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d942297dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ffd/2025": 6,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 22,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R69": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "69",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "70",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "71",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942297dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r954"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-22"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480408/260-10-S99-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-19"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-6A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477866/928-440-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001193125-25-172703-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-172703-xbrl.zip
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M=)9HCI4)P^A:(;G8%JRA&TJFX-7I]$J>]^ :CBY"\W'W)I1-,6OVI]-J"R)
M05.QVK>VO*#QZEKH; NQ]Y(.2^$-488;56WRM .[5DVCG;UQ_TU>$4<< \K
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MDSB? 3:K<;3&<S.-QX8S.BX9#L$G+\"?*QL/0ZQ;';Z <U?N.,;:V1N _YD
M?I7XK9X&K/216.=+OK8.R<HT'2S@[!O*F:[.^L5BYEY[;^OI8N;.QO[^P<Y^
MN9BYO04WMN:*F;3,YF7W(_#O2LWPB/Z"$ B<\\<08E)1#-XJH7<@(-T$]$93
M/M.HXLT$(_WW?7;7_2^0M]WP\U(U_.B[0_HS;QY>'A=7'^ZO^M]>#W^J(O[M
M166M>-+^4BUY>V^[?5@6_\[A_F%[_\NUY&>LL%C?RIQ;?;$RZDBP+<?@LUB2
MQ>.;S_[K?/:KB\-Y^6QM_MQ]26#<=.?#7XZT63G0MDO,J#2EJ>J([XE'J8W
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M,4HF_K9CL17-[O9(3%#'O;!M&\N^AYH[:EWU7=+*COI\D:5)G17_U)^WD5E
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MWG-M*'SN]6Z?"%XA(;VY_ 5NTG_%\#]02P,$%     @ XXD$6Y;!X)R.#
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MUO'G>HI(A@J^&,^^I\*F?Y(K&G"LU#_1\"LH'@:UL7O:V.2="DOH#'$,0XV
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M9>]8L[!#A7JG4:+8C\\ W&IP==7$B\E,L(\4KI/&\,]FVPNE!<*ZG8951#M
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M$7#>#,YI.54E](;JTPOPYAF\*1E5)>QFT-):X';?N#U"W>D\8W:A*U+\1HO
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MU$*HA25\!*$>  NM9[ZU6(Y]TU5[0"MF6R6FB]A^N31>^1#**X\.G)%)5<W
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M8)P!NVYXXT/F>!*\X8506QOI!%LAAG5!7/O$)S3)R%\./+/]LA X6+A4A%A
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M!K*OS_FP<+RRO7+0_,GX/,+#K#R4&AJ5QGQC\'X CH3#-8*S*\!9/,(6PIQ
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MEC/ZCPLO].RYV0N85MUM^$CIH%7/BF$F+[XLW?.8'09W.2O/,*6-R8U*7 ?
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M L>LU-=5<#UAD%/=UYPP#2^]7YY>/'VR;EV;G=F[Z#2XEB8:A&!/4.[R^@8
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M=)Z@QP^?L<041*YFJ(YE4Q'2$AC=JUWJGN1!-/K))P%>,26=FB^R'LH?9=D
MU%0=Q?;+I^$?F*NFLE-UPO,7H-WO]C^Q")[_/\'28XKY@CFM $0W&3)<$T)@
M4V#SL-@<4_/55:>8_,W^MB<(Q&<-L9&\HA?R4&)#'$ITGWR 0XE"NU1=N\29
M:WC$2M<)/T4!>@9C+G//)?8<7LQCUXQG+/+IUP)FZ.(%<5FY+[$T"O#N$[RQ
MN1MX+-$M22.R. 0,#P##&<MP8Y7.L90B/]?#-Q&Y+\%B-[*DS$>@%-TRYIBX
MP0[9"G0*=&8>-.2[@EZ094S,F0EH914$%--XUC6%'XPTX+%XP-%0@ <6*Y@
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MC87%U1)BVD)"2TFB-!@:G+I1;98S+X>7&P;)!'$D<H1F4<$<RT8==D+WT"N
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MLQ$D724I2)UVQ4$EVE@LO%#$4Z)GL=/96-I608]3CT871N"."]I4R9]31UU
MEDSC>*Y>QXA.I<3[SM-\2(PSI@<KK[%GZ,: L5,981;G&N/5:$4ZO(]D_U5D
M>1;)>5Y &,+MQMQ@?I)2L-1)>9_^2KZ^J>NHRAD/"2P1:TS81C#54I%%N8[)
MKL'+$7\71]=:;JN7&@;XYDQ=<,2$EHQWZ1,;W85XW"K+MA2L.M7P/"O'>@UL
M:)/EH(\5*[K&9SIY4<09 @>LI4&/.28Z& ]N^>/PEPB;WXA7I(:;_11A,(3%
M <=S&I$( 9CK/!([B*CEG%F0[J.GT]7SPN'K8\$P',I83(@XNT#WD]#!?&&
M1HQ46,LP=^,G7A<@ D>=&J%UK3-[5_ZD-7O$=V<0QB7O(@SNW)_ 5]8>#K*\
M=HYZ^DI8X&6,_Z]ZB=016M]T^-GX(A;)$8\NLCS-SQ<*#&_<.)'B4WC#*IHY
M?^"F.*@J6>7,D RCXRFA*M@'%$!))_Q1^C15=6)7(VXUD7%60;KXI#\7T0-+
M%(O9&6Q?X.2CN@,TBXLD']LS8)>D9"=D&\J8N&M,;A-]]VUYYZ4[5'L^<KKU
MRBN@\Y@;,*F=#1(-"&)CNP=D5[C=^R[1;)8F>J@!_6<D+8[9%>V<Q%H*,219
MA4;2X@DF8(Z[!$R7@/G+)&#HV?!"7#CPDKN')&1&XC==D-]*[X7@IK_,+L@P
MP.!(TA;I-#!> >(5A2^PG!8A$4FOJ2;1:,Y-TK 1*I:H[V$V!?^'O S<]"+O
M2>[7^B;\=QO]@6,>D99D*X54:$S*7VP!R:R0:-+73\C%4%N47AY_'J451!Z0
MA#-]*?[ZAKCAH@I>7)"5!M'YNH#,C@NNT,M-+$K7(A?;Q30AQU23!R^=\>CJ
M-VH!K;57VN?[]?GO(BWZV&$D</SO^A1YL3K)A2JFT8@G0\"'PF@(*3)<,1K1
M^8#^ YPKV#PI%\9_X4R$LXHTPV+%7M=<YU[C;_5U/"PJ6IKN]X#W>[ANO\O+
M9/I@J]5^^> J+](QHAL>L5CJXLP*8D9%$L]Q+GXD ,]UY,OFI[$U$'>F5\0D
M09A;U%?#LY50WV2FP9]S5.S56B!K^M.![%.;\:^S04A,U::?\Y ;\6JCT8BK
M\,X9&6\QG5WD9/'\').O?C&R,\+OTV%LVI:*7-!F7'YU !6'PG.@&2=?1RLB
M6<))#RE\\CZ\:2^F<Y7L%)E=\%^*3R7"J>?X]'EA8@O$2DRC4<B64D%TH DM
M&4BASR518Y('7[^?K1&RQ/GG9%B/Z#ZS'.AG;4P.F:@+U?\M!,*WO2 '<QR)
M</PQR5\:0Y'8*<XP'?@--+RT(:"5AT?+\(TD/>)S1"SK(D8OH1<:MO7/_Q:^
M:OF8 ^/,W;^09-!][W.PH(A'<<+.@!*/G+=PHGX"*W/JQ\FI$*1X!6.>OEL8
M_$@:,ZK85HN(O]G#"8,3^A[%N8C$7Y$!@3#"$^RGQ ;E VRRU]:M8J>RWH<7
M'O.+I&B7'28;$3;B]C[W&WYW$L#<Y>6EC::PAD6.,+@&,%4\&+5V"RD057]A
MS9"(@K?Z=F&[)HL[)<L?[,/G]]/XO#$0ZNW;%\%6]/=/?X]PF$M_!L>ZX"]?
MT:Z)<9:JA?<,HJ1X@Y%;152R.1'_66DT5J9]PLQ2SO 5^6 _V"HK_PD\(K3,
MS7V2%_+79@]DR6[HH0FX9H*MN,&@0)CQ0:0DZ1SDXG,4W-)ZR1S=VO'*S)E2
M.!SI#-<01#?-P962FZ;S@L>>#$WPK8Q3HLPZ3]NPM/KA4-&:Z?*L#(E$N)16
M,Y$U0O:RQKJ<RS*R*+BHIBBA7&$;((DPT-TQS*[2>BBP 1.B#SB$]TOY/<>$
MD/-90WC+&84BMZ>QB7RW)Q5JAT&"^2?^MX2@)?47%?,+U/>,\,VXEA@#J!":
M9+<'4=QDRM1_W!LTC+(X1ZB[[6SU31S?&=%3ABQ(BHI37:9VP$\GTV+2",V
M;%[HFA3T1,/._!5+Y CTQ62\BS7+Q1(IKF)R(6-T1#(N,29A4@3#-$?4Z UG
M/ (I""NK,<E@HDVX=<C@E?DXMFE1<?EDZ70RB&33NEFZS,&2!?H30_3@3><2
M'2^OB,KIHE[P:YYM:W80 %/(T=;VAQ 5M_Y9LA;_TD\K<MV"Y!LC8JL_\B*1
MX"T/B]$XNH0E1?&;;*-H,WQXA/.UJ #I7I)&Q:7887QJD9P;F=:DC*$<#<$0
M;5VIP9PFDYB)6>"Z(-0@I4JY-4I'.3E0:'&,/J%W91B7M$JM99OFG_@T?J_;
M9+0"1]^>9M(D4"VC<,5R(Y?A]K)TK7[A=(03,BH2(%"<DQ/I5!IW(:@VB^?D
M\WS"LXQ%IQ[QN?P#/F%<TI$H"([*+?@TC1@E'VV;K8.PA<B,)0O;/PEW$!C*
M Q_,JP+17(Y78T9R5D(*91S[]72-VKGKPNL_FN9:MK8&S\F+UGBG:ZNP?ZNK
MCFN4;Z]1OOZ8,PNPX#3U^7 Y!FN(F:((/_4\,,=(I% O?'!E/["@S^)IAGW5
M@QSJ@M@G\D5^Q.@=I_4&_9UCK]#+UK_I@AA55<KJ4-? VO!+ZR3:T@]F(#2G
M&I/R4PENE_QS/IELIQ$)!%=<89[D%5F8_;TZ>],L5^*"0,T><. .\;M@IZ'$
MYOQ9HHPXV!MMU5!F[MQ10<+)7<[J&BMI$I6,-#3ZY,9=T[-=%AU'7,NPF[2Z
ME_5><M0"VE2[6C<E([W@Q ]O1"3$4!2(%[^,1PFG7#[$)3D*<'UXGAB7/,,\
M=8J=E2P?SE[OJ*'B;9T@K[:L)L@E,]G9LI56MSKA^,Z A;'U_."P:+6*K?S(
M9^*X%EJ,BX!%=5[1><)CMFZ(5(A$I"]C/(D1"X9_2 :53$BB?3(%B9"X4%,R
MG0"/3&'!)2E4)XMRY)JFTI(93Y"G&K%.U479 I2W/YXNU<M-JW*$YJU95$Y!
M$G(+&_KT.GX\JRMY*==FO)%,/2M6%[1*<RGMKB?[A%A0/<44*<  D8LW&YHP
MQ3=<TW-)"Y&:0Q)EG(J68V1+*3D7ZUF>3R;1MY*%VNEW::@N#?572D/-\\_D
M)\#^+TSYCP324N/]D8G,32,CKX9\'"52!V:N*D7*HT"-'']X,D:I6'EF9364
MUFNHM8^LUM"!4+%T)MG(4OV*5(3)Y<<RX"9*%_\CNJPIY5EZ(U1,/D-N_"@V
M*[AQYAQ^D50VN@+#(,D:=>JFAB>+36V@*R9,:C# !B9%IL.J/8!B&JCN\@)C
M,Q&SD*B#U4%6)9BRJ?G"Z"5S0-<I<?'(:EI\=?WW-064$JMKL<OVX(%%KNRC
M5H78,,FNKX3<H!I1#M#5KW$C LP\+KF2($3*I5?!>8*R!RXGR:^T**I$5=(\
MUEB.E_V,+HE$6=AYE5:_NH62VTHV"U&8M2F=56@=7G^I[/(6<FI9[C9?BRBM
M6$*[Z0>70=(A<2TPA;7Y%BTXBZF@RO"S!(ZDR*L./10LEXN&SJU>H!$I/:<G
MT+&/%^7L@CX2_6>&D$4$S_IS$JLU0]\BGV;)PT2A<<)>%TV"!R63!?-3HVA3
M@N[-JD/F:%LC2$^9QNCN3\BZ$HN4??@QS[J-,W:_8=6H:>>LM\*VGL2?41V$
M2$:C7$^J=+C&$LU]^56)N"8ZW4P*!57VB ,!A4:[KYJY+KSF@JP#CV+PJ0M
M^6*79OKN_M;PV=;@F2FJ>AV/\46YK2/D1$:H;G0YY=:+$Q4$!I[ *\[SRG/O
M_QLC=N1P1&!ADUF9IA678L6E7\?-N.NTEV3&YC(]#^ *F69;O++D]OZ<;*RB
M;(-M>UL8W!1_H>TI_2]_R/6W_2^RGI(I^2/%Z+_^=BY-NN>'1Q>[^[T_9N=_
M(UJ<_]??WK[_Z?W?ZL;)06^WO[]_0$:;&IJ#WNY@[X!^@&'YZ!IZ-7S"DM+"
MZL>?8U)DR!OE8-58XIEI+OTHT5R.]/B@'YS1PT\RHI<DIS=&Q"6G9"0$)^F<
MW)P7:)G-"Y)R>L/>+I0P)YF1_B)9BHP^2=.*Y]H1JV\=[/<UIK^_<["]M[O3
MEWB::5?A5@/7N1D-$<]#OV9[>&V#=M5-0VZ-^)C7T7K=$^ZPXU4791I?KUO)
M!NVE#TF%9XW8Z%=_.[\5N?']EGM^6> A[FP_#1QPF 6J#B3(Y95$2(Z5>46N
M!EE;_$,1MN>+WBU\E;L)N=IH\@L'U7C?W;_OL^!74B#>J+^^3<QZ.),:C&]=
M<;-JC5SIJ>U9>1>3N5L;,UBKNK*XF7K=637DO[Z-SV&A2%'6_2OP9A9X>1>V
M)Z^&-/8BS4MNAS8X9&+%ZNFMPR&+YO4'2-_#2BBRT&)I<KV8_Q99JU::U,[1
MI+Z^F6#63A?,ZH)9?Z5@5ED5E\FEC\:@GK=A>LZ51!,@O)S+A2(;(*#84387
MU@7#,!ZAERQ:6=3KH!4E,ZX"$2%\O_%1K[%V%@,SZLBI  EV;L7#LB[BE)W?
MNO(Y#C7U\8;A6[+8H;>LU#].V K"G60XN#>.-ETO1FX@CO<VR+;>B7Y! SAG
MGWBXEMV>:$Z.H%6<H3%Z961,T35Z536(U#C,+=3)"J6M7]RUTOD5UG5(9Y<<
MM$I/'.YJCKXZ:5XRN,EUNJHA:_K7;XPF#0*K84*/<&2I8/>@,$90#2V(@ZFQ
MTF"L++??.SC<W3L^6CLPW.EBWMV*'9W:_MJOV]3-MA%L1;JV&DCU&6(V97"R
MM*JMJ.3P#[AX&),1(36^6T/WE&THE(LEY.SE<VFTB\NGEVIR'_#('>V&)'!#
M6'&<F0S",X#EK0<5:?)/-.>Z939W^C#MSTM(Y:?5D+P2@]LIKK_K3$\535ZD
M_J]1.8[^-',24): ^AX)K;$CMYB275%:(?CB[;];_&?\_'MH_N!ZP]/%_1_)
MAI[J1U<81%_2*)B6C\K[M&?9QA8%"KXN49-F6_=?H-APPO ?>.:;;.1:=\3P
M_G&11E>ES;"__.G%6]6]JH]'FKJ>.PA6G1=F %G;>UN6_MJLHZU5P$H![$[[
M5/87G%^B1Z"$F\_BHQ9FRLW_7S2=/:??4"_P(G?E+MY]KBP6H8';B^F\]#I2
M$$^I"F^HVY<'>EYH2?:'6-,5%\FLU."-! U.R6%:R#EHNN_V(SAW$RLXC45J
MJMYGX<^U2_<<+SAA/,%+5!V1.$*P)C551P@#YJ8$16ALMV^&YLEJI7/,E60V
MS,S&4&HT%ELNX1J4-&*"F<HA@)U-<3B]_P3_R=?^FFN[R([1)B>UYYSJ<XPQ
M+*S%S3Z-TG*.#BX_=W"3Y[;A*WLLK]^QU4I;;N%C6_%EG!$Y6KE_@E(X*?24
M.0 K<6ZYLDP<!\/N\BP/J@7P6?)\+R8C;7\1_84$'ZLDKYN1ZW=6.P[ZM/H+
MO8<[*?,0>9J-CE_;]&-)K[47_UOC6)7S)L8\@";(YA/S'RC:8<O9<[4 D[S)
M_2M_&)[B7W4?SD/D//<&G\4CQ=J[ZR3AK..:E3:2>)51=;4'V+W(!M 6--=J
MAW$PMM&L6%;:2EG)LI]42QGN'AW95QL=+'\9Q]L" VG4G2KF!EM<]X)!_\"\
M0.\4UY'-[M&\[?1J<3I'V[_9V3UKCFSUUS"10?=5!!C53QYRZM<_<_4JVOSA
M-86O1O,:A@7#U&M@>SK%P2.CD1A=9=L,A99S8;M+2%ZB%0ZV* <]++W:6G7\
M8KO&I758E\@!(=W=FCRWJ[XL:W'ZKL>JS=S)TLP*[)(@ZWB*-^(I-C;02F.8
MV"0EO?F(K#(&2%WS\@UUF7GX2UI$;57U-=C>2Q&NGJG&%5.DQ<244UM],_%]
MS?%MMH,G'"W:Z)3"C0@1J1N)-+G8$<><;BC/VF-,/S1B3#8N49,OSOKEUIJQ
MYK0WB,3H&KZ9#,B@RX!T&9"_4@:D57J(M8-NFWJH^/IXH9M4F+#G6<X9K%(*
M8HCL/(VJRCH&%+T-4IK [0=(QUI\2>W-C23OL^<KH\\K[9FOEH'W<)*UJ/5J
MN\E9[<L!:OVG1*E76%!+,6I/'SKWEA-2O-B9'4#Y7F)0;CB2*5C\XB]I)H N
M1YXC_Z/RHVHZS4QKH%=ES=2*?)*-PM]9^ZM;*;INA?*.85,D7BBT0> \@-3#
M4TSEJI*="VN.>/9') %LY#@D#]G$M.&DI"[YBR@V= 91_!GUD27:69.1U$4#
MNR0:_U&5\U5[>GQ1!PR&^#S3@HZ<_44RW14FZ(*+<HLQ)F(4<_FD$E*J&V\-
M0B]B[9:T);G<YU;CC5JR=JOM ]1,00<;4]*_RXD9\XJL<'(I*Q,C?D3'G_/(
M$N/[.@IY  S-#S$,!!\JJ_R"*.K==MM^0$4U?78)W)_-4O+V'Z;5]GWF!T9W
M30 3<=P?\Z@8N_P_2*%MW29^4DO+H!: @SSX\\XVF9S;N_NF6X)[+$U-4UY;
MP,Z^K* 7G)3<M,D]>_J*EK>3/&8\HMU]+_5'NG2[;:6U)4K&$6QI)&XM4<H@
M_M<]I#X(V81C,F^6I1U?">B#8%((%Z&U45;+Z%Y&PV^X8[IN^4'-J<C\X"*O
M.'H^1E>/\GH6X_JY]/*;M?$]1C8 /$*:6KG/@)G\"G+7X10M+6#I_<VJP=:=
MV >.HO("!Y<F<67VWGQ%#Q!&#3*;T@:U3IYM#@$RXF5S%W(1S]';(.E.IRFX
M%#4%.M1YA<-S(Y18UTY2UEXKZ+W*4JX_]>&6>0K-V!V5]">AJ\J^$X\SZV7$
MX_;OAI4P%@6N 6%P4,!.!K<ZD).ASHJXLDG(FFTAIN3,08GK6^U;7#)9:V:<
MNL"]V\.HU*1"G)5:#YI& &'VU#+0[+S)"_X*3N.,.,-ENTU&-6;H"ILMW6*K
M:BE]:P5&7 B<=&2DANKZEN_S"%&;M53B1Y*&O_SK4<AYP"-:2 Y&03Q]]\).
M*$(# '/Y'SD)QN"27LA81FX?H6:,B%VT V]I+%"\/#Z!QPX590*?_]W)^^T?
MZ2D\VBDOW R!Q/S$'7]DU3*!_'3RXXEI@M',@;1TPB@NB<E'B_FJB3Z*O2+=
M-$ ^&\=F39>,8(/6AM(;2762_L]%3 =86&;0BQ2Q)5-LE7&PW^O740$<5S>,
M<.'$J\SD4AESL7&>2[5"47#0_Y[OXI&5UO7"A4LW+WU&?Z$&SBPJRWB^Z<OW
M-G_YH^.Y]P5/KZW)'Q(7UF=Z&"Y<E5[GL"MW38[HB\7K9]1Q&OZ,9*Y763E@
ME%?NZ+7V1$/V^AYC-0M, IY<VW.MA#D(]_O]L-_OKU). $#E<WV 8JJL-=%.
MNVW6%*C3[[(#1BAX7Y\V9L^%%9F2BQ_/;C['I>9\VX855'O&6)]ID%"<[[[\
M%IO_9QPUL4+L8G%UXUN"**YR3I\PRFL-*W@%R=<F8M4^O7V3.-9T.-\-#D$'
M3 N;/#LX8<O&'5$C9=$:/'#9\6\F7K_;Q>N[>/U?*5X_-]/AI:*?1[]&OC,@
M\DWL3$A2=K%FT2+X;L=JFQ:I>QHM!.2\)E>< C(24,+U248.1YI*K(>3VAQ-
MDW"5#J+UZ]:.O/*OE^2#>NUQ!T:SU ME3Z5 2(LPS(0;GC_#CIT@B7A%R3/=
M0&T-' W5F5)7L0O]HM.>"RQ]'=TB]B-33.!/C:N]H6$6:(&>*,IIM/#5RFZX
MLROGWW@+],-W.[M6 =3K@VJOJQ_>[LZZM^T>KGG;GGD;>?FV%YG'Y$Y8QVN7
M2_-(?!7$%831P@_\UZE(:OC6:S#0%4;9AFVE0TO=CTT3(93P/OXTC8#\3E['
M6(TKOEYH]U<&A'5?__,\-M.1&'JN=IH'"B* @0B?XFT)VQCJ&E<:!Q<_GL,$
M9&":/]M7<,CV(:PVV;"L0\<@>FD-24=$BE*Y9+C)M[>$/L%$:\:Y_!1[>.P+
M87OO&(BB'+W:450F=#+V7Z9Q!(]_!?=PJ7+OX9M4KZ$\(Y.,E.5"QJ3]:DY$
MF;,?K^CP;2E>].)$DDD$6&P-,P;X2\2ZBO!"=[,QFP_Y6^E)2X)"J_E+/_((
M\8=EZ30W$_U"HWB[0R(^*\)QIA+&/<YE^UY$LUK&3_?S3/C%#ZEA8PWY5&"6
MN+KM2LXN%<,"W9PDZ[F;&;Z;$-?#^,]&0KK<J26>!PM@;>( KEYW*5%&1)H:
MW1C+U_K="2-,,E!#H%;9O>95]7IN(ZML\LU[B-X,8C+/^UDNL\]03HD_)R7W
M5GX4KR_XT49]5[1 U5BE_M*E1QEZ7PV5OF:[-HSHY5];=A0&.M-,N#IK%/MN
M1<^VCBTZD.L8025NZ!)&47"9IZ2JD7 LW44V=L5ADWHNN&4M]GJSZ)4G4@M"
MJ[!@ ;?D1R/5U3\,=_8&JSX"\F)9,Y$-?WOWH+?7=]DB8)@GM&P!7I5P3EU*
MTY,,67DG=6JM&:<8I$M!Y^3)41^:MHT:6$/EXO,"/H<YD!E+/*L!>/AJ&]4U
M#^*:2))/C6#R)OFM/JF]/GE>?EX-^7;_$9I3\XH-O(\FPR-AFS*F[##VS *4
M/THF:A@Q6@Q;NE)1RHF.J$@327Q;FV1NRFY-?<=QG_Z]:!;]^L6Q;<4GJWEK
MJ3Y?/D\R5]C V%N@;VJND=^\U"B0^GGUUCB!94R#^I!4!^IE FF^8N8"@?9O
MS,98NC!G4/M&*E.\UKZE2[;LX'8@CJ\Q M:\Y]EST]HQ#NEE5\@_A,NONH8>
M.-\G-"$&%>=L@:*WX@P9S?PR_IK3LFM;/H7*%)"5+<0O-B X9Y;HN@Q9U$2
MN,#'#V!YO$*O"[;Y4Y%?8;Z-&I0/@#'.M6E&#,5F7>>R+NVDLIVS=:ZMMY&0
MZEJEM^BV:3Y.)HG+6O[R_L<S_%&*'.A;K7BSP?HGC7G.23-P#9R?:'Q)'QN(
M?"B=5C4@+6 "*@@4ZLM(P<,9^!J/URHAXR]%4CCO^3XPU3F$/9,NY9%MAK%7
MLR?5NMZ$)V6;))H(6ES-LU/9NPWYWS+RVU8L"?(_QKQ9'SNB)R !&,WG0$'4
MU*&W=DZO>>>_U]^SQQ\5PRB+R^WWG]-XP4T\^<0T^_0'_#U,4Z&OA);O<\%L
M6F:%,<&:K\&4\)S.YUQ!,Z'T!&C<(;O5,N9))M"%/*"5CE6^B(Y0*/+/"R<Z
M=/1*\UMZ-5[V!"X4[ *)TVR8:-?]^!*S2A9D(TDOR(HE<2V YROY;AF8\1P_
M<R$+F<R"NJI^-CZAE\,RY4&];R>(O]<%\;L@_M,.XG^59GQ=%5 "85W&[O0'
M@&_=L8K.:#$55N5JM2 R;+W<S^C].3JW+MGVFEB81@1AJVPNY4PDMDC4E@%^
M "AJ<@G;QKUH2\UPV'AYJ5:YC0!>1/ >ZPIZE0DWCD<ISQAPQC M;YSK@P2*
M)(TD\N2YH:8KM59;Y;W2V>.LF8*=X]V]E4K)O]AY1D6\5GO>Z"3%@K2?LM8'
M;<!6,D;E">)4XUHYZHXK6Z/HPM=HYDN\6>2F)JBVO!8CA(>\8NA0GFVO)J*A
MEEFR_<N+T3IXLQZ8YP5M.V=CQ@T[<C\NY+Y8!D*@7 "^#91S&:>7L8.^L/I7
M2+=QI*TDR? @[!M U(>VTZ(1$.1:^HV>5WZ=+5:KH VU.)4K!XHJE:UBG)(P
MM]1#,>CW"-5\]44I="W?Q02=%%(--$-PU,&F1./<%@)BB^=5(MD3,TW20^6G
M2VQ RUX':G;KK,%]"IP\0,6YZ%(F!TI6R+\N].A]5 -X+1S :VX!7CEO:<!O
MK;VM3CDQ@PDM8PY8)?/9\)<A'=<DD8=A7+0F&^>VK]6SW^3=8D"N,,6-B]KT
M#]1Y )QXA6_CRH,<I/_M(+G>(8:NG9>UPN]K(+0\!& [LZI ^*]QQU3IU"-!
M/]1#02G&0HRCA:UAID.D8UK0#:Y;JAX:FB03!GW(T%11*G@#_M  $C Q'Q4'
M.<8-Z9]W=L,C#;<!HA^A$X0N5I7!<R3CF8?Y5\.!S9MC."4-N5-33&].WWNP
M<::K*\ELJ%23??F<1\AA@A1.LRRY!!13,>!GD&\8X\"^(R-G=U^>,91"RI"3
M>*.6!\O4AW@JR@^M;#)S@267SA?"F'G&2.6;IC'F7$I2EA&TI#1?P^K:I05^
MG"]L&(_Q"XD=H9)(S"1IPFE!+C=@*8BT4TQB^KO#?J,$-++A+*8&*\&4+!@A
M)R_G7/S.8LS!Q>N(#J4:;0%ZWA( K'?ZF^/60+$;%DX'VZ\=*P0'MJ2]9AQ4
M&,?#N6_!>*U(VB2$V4O;3,.BUWO$Z:[8GB/#'O;$"O8Q_&VSP/@L F12GR:5
MS(UX<W&2>P]2G8$=B!=]B.O'UT7$B-D?'&(V:.NMAEM4 M,!_YP@E+\(5\IM
M S3TP5=*[5D^MZ&#FXX'^%__D"%Y=6?OQ?NW;T].SU[]8/YC_2$U3W3(<UFW
M::DCVNH/?<]A_EL !,89M'MV_E]_Z\N_]4K\FY=D77#/6T^XCNF'Z#)/QG+5
MN.[>P2,S.YN/VZ[8_?[Y\DS;II/\-T%!.UCYE)VVIZQ^]29O]+YE4/]\P6H*
MWO!C++WL=Q_;4!D?<]Q:9EV$=GR;CB '89HAH,_9^%?A[STQCBX3MHMF,6M_
M8X1YSR=OP1AQY@4DH%O>X5M^1M>6B+$V9O/H:,]0Q]IQ[F"(@2<F@JJ]!3&/
M!.0)+7.K];@C=L:#",&KOB$*'N%/2O^KP/_"\SK6ZUCOBUE/HQ0F_IY;A7 A
M"H$I6 R'C)FJYE\%9'ZB+8:L%WAP%8]7DT8OZ6ZSR%2V)I+M:'Z6G7XV-H\Q
MN4,XQV4<2SZQ0E]11_H=Z=\JZ7]<*I9S99>VPL'5>>#G,DBF&*]KDVF.67A2
M@Q=3($$>V= 5^J&*9%23YDOW3-+X<^*-6N46NRA)D4=JQ.\XMN7>(4$/-[@4
MSNFE=K6-XTF$GZ44A"^,QNSLW5)DI./*CBMO5R%IG(6=#!]FQ!\_-:DR21^K
M[QXM-&GL3T3D)JD\TV"E_ :&YZ@!@J-IVM%O1[^W3;\^,:XQ]KF$#)9^7%PF
MUG9"F"4><R2(H9PX3IPFQ QC* 9,".V$;D>TMTNT@%XO8M,/94QQI+2<I@^)
M]LZE%YXI=\)30!5WTHKH427C79%*C:US4$0HSO2O&^?5<*Z# T'X9L8\&SHZ
M$9F!3LYS10HBDRO;@/ ?OB2^-=SVPH4:O)P'=QKIR$X/B*@+JG4\?1N*2/II
MV-H17UYA: 2O9R@-*Z%-;]A0&"?:O9+!O#935R=8C-(DXZ'5[OKVP;N2WG>/
MXNQ^=(76MQA3S4N92VVJWY;O9T'4SOC?1"'9?E=(UA62/;I"LF](91RO41EM
M,OX.Y32F]Z$S%\A>M"^<+TF]42Q2-#%3>^C."E"*5<&S]MXHJI<)ZD1L6 6*
MARHRM?2?D1?U1XC':\-)W,^C)5+FIN8]S9C3ZY<G9JB[F(-7K9[.).'0%29S
MD\$FEJ!N,<]6-H%V;GEG#=VU-80*+,G\ 3C5#,T5AX--#K:#C%4S%]-$IZS$
MF6+^7?,(]*^K(219B^8#B9<-M]8?HB6CFH>40JY15*#.IYIK,1TC=<E4AF!<
MS;F3PG2[^ZSJM6HHQR*-4V\,*'@&IX.8'<?1.$4$.&S-5FIKMO<XVPJ E$V[
MY=9Q<<?%M\K%;V 3)E-30D0OV@;-^FW8,S0.H\^^8$R-2,,8+:QMTI%1EN65
MEI]RU1R"&]Q-D\BP'/Z_X BMLC;5EC/2;EP#CM<,XQ&&U+OH,Z=PBEIA+S<L
M\1_H9&6T(%=!HX!TS BC7I;&I7.,H^07O4I)8";-G5'':!VCW2JCF1H85_5"
M1*O5,. $CB"@<:%,9,8JT? L5G781L-^Q8"+(Y(=24J)"P1#G5S0&@%@YHN
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MSRJ,?/,&,A@/MXPQ$LJBWGZLILFT922)"?>?T>4@7F]F4VBA0N55@AG(T0V
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M(_L[!]M[NSM].F.Z^"H>$OUBTM.X $72M5=75[V2CU$'4O;HX_<"%(,DGMP
M%4B=J YWD;Y>6OC0A&AYSG215^<7DL8R+].H=(TRAJ@!T1DD//@=LT5Y[:YL
MZBI:<$U[VW@DAC>\X(B3*@C "X#D9M(P1NO-M,*568V$O% PFS5):?_@U;!'
MF8IXJ2;/&C:1P*8WIK=A4HU.R G-Q)=4&4<&'9AQH>'2K% /2-0_:A>I?O6B
M%_Q'_3!3<Y;9 4/C?%3)<[ (/M.JK-V-0$>6<QK-S2&EW^V0*$L/\^ Z=7(Q
MG\]^^/O?F5SB4>\\OS23G[Z=R:&'79W-O=79W%_Y2,NG#I(Q[?'S\=Y@<'SX
MW_MT,C^_"MZ_?OWJPYM??_H2M?%UIMP'.QR\$4[XB\01&A[*Q_>GK?[5[M'W
MZSR5I7(F[R>FQL'W=?V^/;BI@C]KCZGQ,+>UN13G,/"^_OG;#,IC)]P][H=[
M>[M>L*[IB(1< Z+I'OJ[G5>WLR\CXW!Q(BI+EU>?-U;IJP9[S5?5]J!I5QZP
M&1KEYP*0(3M &% FNA>IXC6YJPT2LDM0/E D#QQC4(HUS]GU* AOVA[<U/?M
M>,3R2#7G&AY0BBC%>@W,/\JJY5,?HOZP+=BQM?.,[(^*/FZOR5L'X?'^?GAP
M?+B*U!^<S#H*^EH*BB9SE2]>#56-"H["W;V#<&>OWU'!TZ2"C[410"N^\L=U
MM1/C6-J!X^#J(I96(Z2ODKG^.2E-#(A!5]O)I&4@>-T5G? D:!APO>#G_"J^
M](J8,",4 0#1P=_MR)175MOPY<Y)&9XC&-*HD]I4>TH-QE*&3[N6K#J7'M-/
M\3J%/:L*5*G8XJY5+W9)PF4HOB6C@3UF24_(T)=X.6]I5FN/:H.]TXE?Y04[
M]".=?8F/JU.PO2I;#?/5>D^2;)16X]C>R5TGXP2@H&6X&F2F>9EKA)M,HJ0H
M&Q?400T;?_0"B:49MCV/1Q<9.8/G26S034TH@NYHBR&ZI&L1SZ*%?!WR]J1*
M&#-XB&C-''0F4A.ME/"@-]$$S6MZ'%Q15*=DSD@CS *(MW/IKF>.H0^+WAU\
M6(,DQ5?:T$=4+[^KQ5H6_C%PO'2.;W9.S^-)]-%(2.@LMK'AWV3IITH[7IRO
M$^6/693K=[,\WQ#B9K042,R( =!'O;;!+VQ;(:M7^U\U,KHNU-4@,XUS&6*+
MTS*^NHC-M-&:,G@$+DQ'BFM)\9VDO4W3\E*\Q2/+]\V_TZ=.M5%"$(Y^C<IQ
M]*>=OZS/=AJL7$R'>6J3%2_>_EN)J*.3QTXG/#A\X@T.]PCC!J+$GS_>D"-#
M4G49=ZX#:ABISL'ABHR FBSC%HFCW>ZPN:JRU-2?63=JN#1+,B*!J>#E.=<Q
M%,8+1SJ$?2J;X38XQEXYR#"6\),7Y[I6\/D!8]21;&MT^ZC7OXZJ!X[H["?^
MW.B*5!K<\8HN$*Y_[!QPDX*2O<W*13@6<F]5'S?/K[B:^*76D[4^?EE64X-;
M'/GN$MVU%.1!8JY^-R[[I4JU3F!7Z@3V)7,:?V:.*G_H:INZVJ;;K&W:.0H/
M]E=&'KD5A!N69FI"Q)\!:" &9RDL,%._T"-F:U)HS4M_YS#0VH=3(*)$H[CB
M<RB#-]FH%[PBQVJ^P'^CD(3,Z=.4&&@++ZQ73LC=WE-QH6JH9SJT(I!<%9P^
M.FXH*KMH6SWXW>"PU]]%F:)L_7G'5QU?W29?[9'\'AS= V,=ZQ/?2]R$&0=]
MS,POH;"7STCMMWP)"QWT>_O[&[#0TZRM..IJ*^ZOMJ(3D'\Y ;E_T ]W!CMW
M)B"#]EI++M/<P-YHO<)(R?!&ED9_M]<_[$R-CI/NB),D6;??/PS[!RO+91SV
M  (P.E/.=GH[KFFE^XYD.Y*] Y+=.3@(]_N#KR79M8)^.DOS11SK(VUR=EG>
MGYV>&O'>D7M'[K=/[K+:/:FFN!.2-S[A8)?D-_K-.).]1.J-OW54WU']'0IY
M!+Z/PD%_+S@[/7D1_!X5 "LN@ZVH#,8H_D!^)D[S*Z25 (,<;W^(>1R2\L39
M+$WFP3 JD_*9J8M!\%QK-M*%,;HMWS1C[ZIMCH_"H_Z^8;TM>5U>SM>\K\F@
MQO#/V@S]O?Z@M]]G0__J K.Y.W._8ZL[B-CWC\*#HX,O<YSQ[RO#@H!;,P91
M^]/6TOO^,9&['%OGW';4?D?4OAON[3T"8C_<Z^T>=<3>$?N=)HT&1^'^X4J'
M^/ZH???(6#(=H7>$?ON$OKL7#AZ#";.WVSO<[Z1Z1^QWFNGJKXWYW".U]WO]
M3JIWA'Y7A#[8V0F/C^^7T&WK3IL5<]#;Z^B]H_>[HO?CG;V0-K@9O8_R#%%&
MK7B7<O4L,8B'C&&5\0YE=AZ/HVN0N/>(CL@[(K^G $QXL#<(CPZ_L%+G-NV7
MP:!'SG%'ZAVIWU6L<2?<>PSAE\%^[VBG(_2.T.\J_!(.]A^)3[K3&]2L%S0[
M==3>4?LM4CN*S!X)M?=[?4^NKX1E?IH=$\==QX0^^2^%1GD@:)0??WOWYEWP
MZO__[<W'_P2OW_QZ\NN++\2F_#I(X\SKH04@L_307L4!KYU[TJ^!#!(&YK^&
M-9PAG8&N #,,9(-C MK-G,% \%,^I*.*+ 2A 1[4QT&]R7N3TEPJP+Q6K$BU
M$H-0 Z08W<<_!%N1HB,"DZG7#VCSJ882EF A_%J_CSF 'ASDHNM@8-#%H3Z5
M*[\5/1SP$+7J+.VN7W5<>)9,OBY1]#1."L4Q7@9<LD-A@'-E9.MJY"9O<K>!
MT\>-9>C/!K7#M\W8S_6KK9\.7Z0E[Z\-#I$YHU[P)@-4-"EW+K\4"'3,NK"?
M>!GZZ@/#;RFX^ >01^EOR1"/(" +%I)W@\5:QN$(N;7@)TP!8LY(TS7P9#HF
M _[EEXHZ4(03G:LHZ%] 19 UNQ*Y%GS/==B>M4(['7)(/Z]'^MP0WW,)%<R"
M?"J978/TJ0RW3(37 W;U[EUJ_6ZGI-1%BQTB#_IC""N#H-8VI$[VLP$@&7VG
M)!5,;BZ1S$Q9)1U=R_1=?;)%X7:P7)81@E) :H@<KV- F1>%D;PEW5I.@(*^
MQ2/ZL!@9]J+\^4*WSO>]I+\Z\240(PP# D+Y:DX:,K!(&D%#Z(2%R]@"- '8
M_#4H"10F6([>BLT\TDW5PC)-J@#UYF>Y3S1)BG).;[(XZO3-<<QT-&.,+TXQ
M)2)-\RL672K-5?_M;?/%\J\HRQ+$C^TH"H/+7J,!/J451TE?4K[<VJ-BAA0U
MH%3@J[?H>E -/K,<F!>Q"DEO/LJ_?C\Y=63U+OJ<3*MI<*(35J&UZ R3(<9/
MRX16K2YV;'$11TPX2F1,UH-KD7%./2PZE6:_7<MI#0B=!Q K=FIUD0LY$;V9
MT1A.8M=$2ZM8P=AO'I%K+UL- 7TC6:3(EX ;E KPRZA(XOG"QP6BYS%_*CRF
M&1VPQ$<ML(DA=@EMQ:1 Q)V=D_TP%>0K)^1$[!#%,V6L' 4:*LRB+$1- %E,
M9$?^$K$6.3T";%72$T9R2I-*.E0-E)<_LR3!]'([0>O^]<]I TUS[F.9KC;0
MO-''K';7P)+B^&,A!V<#T[4*HV=%IZ=2KO>U_:?JRND4V,J#[,TSDHVUWY\I
M. ]+\//D$M]#1!C;ZA#I3E#!F"!B%])P=LZUXHMMD;&_-AE=K_+L>B-+B'CI
M/227XS_!@MS,T#L^_MY\H38CK&U),H.EB3GD=,!UW[O*X)+\X##=KV(SY\,;
M["L,<"D+%<-LU4EE?"BE78;O@_#4%@<+S_O4+FO+GR ?3S?<CG7$ARQ3C3X+
MGN-W1[W^<; EWR4I?1/E79*Q CK%DHR<A_?$Q,1^3E)SI3Y4M-#]@]U]LV<%
MY7NK9C7^7CY[%NH#[/QBTP566L*\!=G+=#F,=9"2PZVL^8+.N])G>B?>MOA>
M\''=2^EL,>8]OTB&$'M&CJO?2 ]IL1EJ<F5IRSQC+;=2(E3X9,,48XW(P;AE
M+;!.<^'.89S1]QHE$>#G\BM5.+(L(ZVC";EP$/%X'1^C#(O')UYU):2<P,F;
MY_/3>3XG.]&\3[J"#G:6)S+31_0:K74J$/1DI.P9WF=GU./GE6& ']T;W430
MM_:[.H_WOA7/Q]:QL$S=#KGYYE8$V\T8>T3>@VA8F8J,0[91'%99&U@Q1,\U
MW=*X]?K5R50PVZXV0T.FPDO78&-98_ !=(C1=X\8+<'JIQAI'_2[2/LCC;1_
ME3 \*2W8J:A;B(%ZZ&7D0FH;F,<VK&!"LC;!)08^6Q(NR-J(^VP<TG$1$+'V
M5L?_K'&B(1MQWNX^=O,0:FVEKM+1A/0Q*Q)%]&K,79A!+&<:Q Y-PC&)EX/=
M6-,T XZ]3N[THM%J4N)4$F.(K7FVSLN\C#-.;KJ9B3#H871://Q2YJ%.HW$L
M;A5(T^@>]E$:EW-\0?YB4/?':BWA08CAIFZ\J5A$\\;ZK4_6>"YT''USCW+]
M! !?K(,5E08X_A&)=6G.9@U)W,W\VR\*(*VAW#L9?-L(<F)I2T'86PQX-D+Y
MWW#4D_WR=CMS$P/29$.$F6#B!0G9DY>YN&%713(G18G#9S/7RMFM.*+=,1/)
MW\@TLY.+:Y'47_G/QH,U=M=2$$*YV9,1YKF>NU%_,A.[1FC]Y[NEN:G$[8NS
MZ)3F&,9QFEQ*T&=C9S>78:0FQD>D)?)Q]6+K&A WMQV9#8'9>#6FF%X7).*K
M_(@.)WSS*\"9T[62$)&GK#G:>OC;'-,/?YU)C#>IESJ^MEYJ4_SRZ"G@E^,T
M;8!0 V?C*$D="USF:36-C757QS57BT^O?"?Q\IM4!01;>1&:J\C+S.;+;Y%0
M6N9-J2#/^!7M@9L@ON"E8?"UNV:^:RSAF;53)I#YL-'-I&Q]Z#84U2PNDIS$
MFL1BZ%E;8JYIHO)9+<6 &WQE-L,@&<UGKLEWO3(U95#$-_L>V /OKO;$KK;X
MWJ7'\"E(#S;#BWQ<D3FS5>30KURZ040TSJ\RH[&R&-IMKH!'HJ^>:4Y PJ;3
M*ITGLW0!TM[Z[ 7SOU86"=!3@U5#.!V.>YZ9FS=DJ'8>P3:V%KKT?F^OWY4I
M/PCCC)X*X_Q9D67(:<BOX9QQ<BF#;BS;?+=KQS'Z)#DW5NR-],%ML-6M:K,5
MS+>%+"%<A1'^):4 7HJ=WA:-_ZC8@!#P-X13\N(\RI+_4?^35B.Q7_M+EF?;
M]+P+.612V:&$A<F_21,.,@LDG/<C/J#FCQ(BA:CPQ_X%XZIHV:Z8!,]6%GK?
M9TBJM>HT&HUB8@,^WU;G9H;(>Z&Y8[CN=-[J?;FY8NN^JE1'),N5E+4Z@Y9(
MI%2'Z?$N5Z75@E7K*/TY]!@^LKAFX5+MP3!>48F[IIRAX1D*85QATY<1ACZU
MGN52NGN=,\>S2.%:&E\W:G\HU\RL^0!A??OUY+UQ7<T[7(XQSYK+T_=IR6CF
M)RL],1!Z*?N6%S27*L$#Y\<O.^D^9ZF%[:)$7AV.-?I7"9M_16DE5Y[*8VYL
M/0.=$AW;K>?BF$(HWI6@TH&8$XE<VM"C=ORZ^LD"E>D+7^+)RR2ORAHKUM\J
MH3G:%1A(HE<ZJ=+/99?!R]]/7IAHI"R!GL Y WGPPL9V6S?M4J1/.)NVTV73
MOL5L&F)[5I3;BB'6+-=7G*\,Y/K]()'CATU+%%!K8R)^QX<V4J&!/W&)QGD*
MZT(\HNVE$1.R%1.1J.W $Y4?B0+B[9=1,V;Y55*02[*.#^YPV>^S6U_TPV3_
MM%P!&R;C^1SYOCD,1_*&HRPFX>U+V-"6^&5VYC0=,5ME2_6(-Z$U,E/FJ;/3
M?,O4IH[Y$KZ+4R*M&98;:M9V2YZ=B(V3RFL_V]UDZ%[4>AYJ>2\<_DM/);8K
MZGM.UF'@;S1,4G0O(?FD-E;[VFZ2*DG*=<9X&$ IU5+X*DIKQ]7XNR5W,52T
MZ'RM5<%E;Z;SRZ_5UCX5AP6.624%*!;5<,F87]@LG. 2>*]QI+TRG*.\ANR[
M1$K7>/X5C><L-$>CJHA&G+$%V4Y)LG*]G,KYTJ=QS0XW*C:8F[RBC?ITY76.
M;Q>A[.CY-@<ZV IF<L11@14C;&:;^*28:$I&@M!F.[G;6FQ;=Q0VZWN\* ]J
M>!,[PGM=5;D6+&S0A:LQQ-8]Y(7; J^4M57'21TGW;IFL$5$F1<1K!'NF2U!
MDFH1D?MELQBRH\Z..F^=.@$HT&C/LTUD"Z1%D- :<Q]T.=.2AR6J#FV?#U=$
M+%U<.82=CO [PG\,A%_$3;+/1]RZ(X0OA4QJ;-2NC3\3_?(UUGQABI]K9R6<
M9Z]+YQ-77R_JM>Z1LY<X;L_EUFKE?PF#(%-25#'6(>]5<THZ&&D1%L<#250O
M]@$SB!L ;5.S7:>?>>,S0"EJIL( !=N\X>9.FG9<$Y6$+3*^U3V5%I'%2)>A
M0MY_!4ZON2BN(^/S,K?CHTR3,I5N_TY6=++B=F6%IB@5E*:>':Y+$ $[$=7G
ML0!I6")QZ:#MR+,CSULESRNCFY@"ZSYMHVM^$J/A+ V-Z :@5H[&SG/@=660
MK_2/-+I"5VB5>LVA-CI%I, ]F9+"( 61:<.9K?2(/W/)+*+'-A+,?;GBA7-9
MR#7X S?Q\3M^ZOCI]F.YPS)6.C6F6X4"&\<-H1@IH/$146+(C3G,->H )=D?
M52:L,5RHM5@57%M6X[:HFE_D12(P..#>F%O/_R"CJ1PGREMLTCDD!2V0*JOI
MU%;$<+HU,D@/QB9+%\$T'Z./*.=*CTB6HOSGE;6)L1>3\&#+[+H@7+XQ$E['
MGQU_WC5_FFQE64GQIN(L" ('ZG/DJH*8IP#00:#5H]=Q9!G'[#@QWB(H/,E"
MKLE2%E#HE/MB)2[*,&NR7M<XFD;G[>I8@&6\E77,V#'CK3*CAR-I&O^AA+1O
M6^.(LP;FV$I6\.Q8]J0$7DK+O5.#1EIPU;TJOLP $Z&</9FT=IYIH[+??28W
MA:8*]6LZT3J>ZGCJ5GDJRUU@,31!R0R-U_40(^.672K.!/$&F:@,]49$K*KA
M9"R]#:\$^.Y&9= >+WIQ4<80@WI+LFI=K.UIU@</NOK@^ZL/[B3;7U.R><6#
M:KZCD)@L[V(A?K/[)R.XC))99'(L<Z)F$FX08/6_<6JBS--+AH&C*X=1]JFH
M9O/1PO,&&,$5MK]6Z7:)Q8[$[\ [-0">K@#66*7M&%E=DW%'B'="B-P(1D_W
MYS\P8M,LR:2^>E@PI@6ZE<V/3(P9\%0!>Q$1+1<2[V=L)U-V/<JKK(Q30;<T
MUJ1@M4TKP(>C6U?PN9#R%>!L"P=M&] </M/ZC, -^VKOIFO@UYPX-R_FVV=$
MS.J*_AR/SSG.9([XGCL#3 ]@::LLZ<055G\4<=D->0G9.1IS%-J([LL 54V.
M>IFC^SGDG[41BE6P_G>)W3($JN[V0G?; F[U %T<IZ;D2 (!_XK(Z8&4^P""
M^N@'Y.[YH[Q<:F15LT?A8C:E>@'/^CQ+"N]&\@721!"GMGS(; .&%G@X:!9M
MV\*8O32)/]>\>]Q']VWI]0 MSU6BRWMQ+]QXY<_< !R5 F;4@[BB3)3 G>,9
M33Q=QJO9U8M E<NZM(X8TLC'8\+/991RH4@-F[OD[I&;0!IA'+,#J.71.9DF
M7XHXGSP32_527.Z5M+<6(?R:$VR9BH2N\ED3M%/K8!Z  S\N=V4_%GS#WQC!
MWG*+Z1^/&:S2-LI?BW=Z??.=?3)[MDC(C01.W&?7DK\B!U)XRE?7;=29=E]E
MVBVA9HX@]<91L0X^,[A.3S2A,F$SD'[EKHYVV%Y)I)&D*AF#?;[J0A9\:T U
M.T>\8Y);9Y(Z.?MH,&R9F,[H\2J<@ T:: 6(R)O+<E[D9=F$([!( # @FI,:
M-WA-QQT==]PQ=RPE3CU&F40RQ))KMTT25=*P?CK5: /ILV[D5#L2[DCXUDEX
MM_^/LFJAG\-]<A?:=C>_^,??Z8Y_!I,*IKL'/I71\QN64HU!Z@."T6>1 $E
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M=V<-U"K]UTEU3E)3)+0*Z+ &X<> P74TN%0G) I <OLTZ8D=1EJW>& '\(C
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MG/V?X/7)BX_O/YS=.^[9,A (__</R9P6/8+U>(G G,Q 8!PS!Z0JD]QXHC"
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M+@Y.7!;V#0G+(7U8CB1<9XGR:#S?) EYG.6A$^<(X(ZB$A\H1S!=\'!)2[W
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MRI,XN>4SVQ (0@9"G;KWV11&%<4;(;F:4^YZLAJ</NDI@U4@6^.7/%R#X<'
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MSF!7 C[>* PRP5#AB^TVMN$OMQRKO>U^!#IPRW:4N/VDHOX63CZ+W*QT9H>
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M\3ZBD;[CTCE][P4I%<5PS]'CBPV:G!_D=*$U#AZ=6*H>6.)$MJ /"25Z><$
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MC)MQPH[HP".FQ*YA3 E]>R;3F@Y-$@[,7L@ W+94Z%H%C)SBZFSV/]P/ROP
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M*%RU$9$^Y(&49^YCOG3"]4+_2![,081;6(/A,L*KV,E8N^SHDV]%=1#"KY?
MGM)RN-0N7OD6W*Y!Z#+K3N[ F2DV-=*87O (MW2(]Q'TW K(2V00Z91%@H,^
M@_/?4VDO7'MO2I*LTRC$I,B0*639;[#DD8BBF!''5)S0?@S!XNK^/%D\4UF
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MXKXF<'KPKJ2"/OO"@FN]H<G"T^>#TUF(Z4^VY./-8CIO65]3V&_4W$W947(
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M_ O,G0G3MY<$ZVCD;Y)MQP0/89"2BV6T,76K0DJ87*"PFA\R^2JC&:-WDVW
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M*HKTQ*;,5VXK%:J128!&9IM^54L"<B(*,Q<*.ZW0YK@[:_%H=E]_GH"IQT?
MU,<#3!VM]O]U5KM,B]#30"97,&^3G.K[*D&K3K 6*Y/#X.YE:M$>ODW)^N@&
M'3?4>]U09Q6+Z-X);[8% "N#RY6L#600Q$6N(@24!!/D,/"-&Q;*1D56!=?N
M  %IL\LUI1-0=P>Y>L2634D(YFBX*:R-Q^4E>U@0"S7:<8Y=8\>-]R%.LIC
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M2Q*I.#U33%3E\J*NKBJ?]J)?K.N=>'GWTZCMV+;(NXHY)5XW86\_Y*K11 Z
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MF43#H+M!(XP\;(YX?$;5O?PX0<KU!T&>$$:^56I([KT78:4EJWOA TTK8S.
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MR4D#KDR1I5@2!QO%C1?[WDJO<0W17RB;V=%;TN$09)N[@#E'+C:TD")Y*H2
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M#XVZ(3R:%)+H3C 2BI(FAA#0'^L]^29BW\O5;T._D[47XP3PVBW+2XY?%E"
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M;*!6A>IKM*CTC5,3'*=2\ZUUI\27((*T2I:)3 "T%8\<@!RKGHM%/R^:^;9
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M""04P4??@GF-Z/&D-4'0K>PXQ-R)DI'$M0EB:$$H&DNLVZ0$71%-/K(VPB:
M]E-@\GE9Z"?@["!H,O@ !F/"B8*]L_!"00(!>0!<F1F_ANY]\YF[+14F#Y*D
M1=&$0].\0ZCEX02L[+04"P%F2M[MO*QGX1D7>582O0>G75N[_WLO_8)S R>'
MW,"_16Y@Y%[B+LYL2\4CP!]NO.915[:--N^PU35ENKI^#S&7Q1LP^P8?Z@9*
M&I4-8F<=*E"$@?#V/4<*E-K-4/J9)6\C"8[<B]7'VM'WS!GZ<9AB1_06%Q-L
M,N7WI-D!=N^Z)3!/(A9/HX5.^_:QM!H5'BV (D*EXA)45D5*ML);8;47KD*C
MEV3"-LG*PVWG[:!OQ.S)W7@UO[(W -^[#A?X+%SRY&1T*<'D'IH*KY?0C(?-
MK6ZT)S#;>P@.L7/P!2[& 8PVW+S;C544:#.S33UE&XM'P$Z+Q@])4X<G$2Y3
M:=[P6!VOB) G'\&^SG?R,4RH1U]&*7;JF-*=GC<64TI*TQ%OGS%8%^.R_D$L
MC((Z!+@9;@PC8HMV7M;< 865A;XR?)TG<*0@UZYS#Y9=1\7WN?V,TU(BE*X4
MQ$G/7U^^/CV=*ODS_5UP/5FXQRZ!RWI!N2V*4#:3'Q1\<]JV-45.\\F#3  F
M#*6B1RSR9<%8;'[\PVE2+)*A@(M>#N*QEA"WR,I!7B*OO/'47%W4TED'E&(@
M[0*_'/):C$9MX4>T4?O/"O0!#,M1\:BV+88T'6HQQP$L5,;DE48J.>H,EGQA
MJMT&VQJTOYT.3B2AIN 5Z</<;Z:9T&BBXR-KG1=#/0=.@B0 *#>)!4@;=YFC
M3(G!8K/=Q#2U%8;(LSLM0",7>4>98+^\#/-1G/(W6H7D2]QD\ 0>!U^L0V6\
MS)(LWXJ(ON=P+O/8[\F-HJ_LI9:)LH+AN0R@SQG,KN%5,@R U5L6L,0&EE-+
MGS2"TY%PW^P8BU,(P;KT7N2OZ8FI%KI_'<96+!Q?7.)NC\Z'=T>T3-VHHDD;
M4OAA(0G* &II->&W*5[$-]RI5VE!%M6(C(U")JHZ7T+U[3Q<GDK/F;2HE'J,
M69>=4)?*2MH<!-,U6M<2,]C'# V%Q2%A_\:==)XP5V9^?OV:U/:X6W#0_L$E
MH0S;?#G'C;MVSP22BLY')571UN5E>%@GDH)P0;#:PM95!<FX/.BUO H-6I!J
M[2 "_4"3>IMGKZWSBL6#)+U2.XLW 0"?:,$/PU86"!RX7(A.7'C>R<-V@];9
M2]=,*KU8.(C$X*HY3CT:C2$R+L*GD)-)[1(P?^M;P,83I!^4/%+[$6;-6<J<
MZ(=7G&L5L7=#U65]PQ/I%2N]?M-;/+291J5A_6[_^CV1L82'" Y"5C/#>HK%
M=\Y<FAC8Z]=!-Q']8+Z0HA0%+@I IC3@1]!A% :)V&DWJ]-P.IHJWTW^PB5+
M4[70^8-A;1P+_:\9HC:;.D+U?PYZDO5O^-=S6F^NC^*J&9DS :7\;+^>VDV;
M9!>-H8[SG"S.HMYI+REZQC$\5@@M@Y!A;&A=+SD&<GP4\-\&54:^:<^@C-:G
M ),$"1%_S] 6W+1L12H4>D4)+8I&>!R,=9W*/=8F+ (QQO(K#%"3.HZJ%@=&
M$*O:RV%EX5Q>FKDO<77N]%3J#BVA*W7PVL]VVY@7058;USR1AS;/.RUM 48#
M;&;;) UVJ5L7_UEJT:5)H*P "A[4K3RV\S2H/T<T8*R%87IZ%VLT8#NCOH)T
MH:/P9D(1'[>VWLO@Y,P H!L4TU[-- DBK("*II0(E_&1 93 \.ZDO(;J;)$O
MH*)!;LWF.DR[CN\H:G65M6&8^1K"0 SD45M:\?V ?\/J.#=:7GFT(0%X;0&\
M4+W-56B$$-CD\ME5P0"Y!9>;V:WARE"<WE]*K&EP/ \,_%Y-XG7+58(/Y72*
M]4S8RC#FABO]K3!&3)4H]>%)ET6MQ1++CIOY('O8\32/)[^B^4+LG1@;Q$<,
M^(W>/;7G7D@*8EU?,1I3];,M'\UY$Y&8^/B*C[M0-1M--(/KE%(C6&!U&1,=
MSHO7?O7(*"ERD4;CPC?'P9J.L1Q%=(3/Q!HL61=D5>-SNJA-LFGZ4:'C+SD$
M_O@0 K^G(?"/1(VCOE3 5T-!MUY!RS\2JI-__&_[\2_/7[^9.N8*0 0)'? ^
M4:;81U ;[8I&ZO3:I?N!7AA;\8@=U9U#AS%?YI" I\!YB2O%E*->H3CF9"9Q
M]R/ZLC;D#.,*4W_RS==_?OR(3V58XE(BN5]_Q9YE10Z#9,J$*H3'[FK;= ;6
M1GFP5VHOLB=M.]AQCE$^(GX;6%>_C5H(+'"WY'7>S:/K19'6*"ASV\0%>=0
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MMW+V3%SEH%XNA0$W+&5C*$#-! K1<)(K$-O+\\6JF_519E>/S#9I+N9?QP$
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MN]LU(^,&!.U:<!V9%/W6<ST;1+20,D8,U]VE=5OKBUU+Z?;*R'62(VUFH [
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M4(!383RO,53';X]T;C,2UVVC,27A!:4[L;4:KN"W5(SA<2UZ[35: ?9"V(;
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MY._/CY\=ZY^G^O<P]G4N#!X/V:5LMA >% CQXITQ ZI@Y,,:#?EEE!7SBE6
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M\O7;5Y&Q>K-;DZ5:[I1WEE'[H+B T[9O\R-@,PA>3GVZS Z+*6U.-U=+;K7
MQ3D:-,(C\; X(H@&Z?XZUL ,O%[:W J#,JMS_GT%*0MB'1:9A:M$0%?8E#EG
MB=M!%YC?)"D<SXJ\9^ZQ>X57ZJ@30VZX%([ R]P/>EP:M*;MFB?@Q:S\4/=%
M4]# H(S;"MFB((B=$7%VPY3I4G?>FQ6W>TN831/TDS8#YEH%II9+;J,LO+!@
M-K:!G>2('>9$01CZ@J3K74&5S84;*5"@C%HN%Y6P',?R/5*) B-(*N\JCC_.
MB5M+B[1$ D Y(1./58*S;4&1$T>L+*/F>0F&F:.E<7R%RU$P\0X3+U!"KDS)
MD#EZV.6F]33.22NJ4<FYCU<-"B\CDL\B.3]*,ZMG==-LU]3%7%L-I18&>EG.
M^4.%]*0$8\X5X;$)"/&[-&5G)@?^^WS;ABFVVB+3*N',7G'F2ZS*27N4Z$D<
M*BO<N#Y#(P5[UL'#N-!=;9[U.@S*" SOCKBATVEH^@E[I-S19?FJWWC(+YS
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MX7";\6U&D8?PS4S6;9-G*]X,AG\W=;;PVDR;G&B7%.36D>/RV2:$RL1<>6^
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M0- <A/4_05A1 Q<NY*VR<+>NUD)[Q,V-0[#=CVUQ//T=*3X([D%P/R&BA$N
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MA@@.69+5SZ2$]6?(<\HW(\W81[+_6.S&0[4V^]M#:%_?T:QZ_XG2*L*^2FI
MB% 5H;7I=>M@OT[F-XB(L7/$;#+)&1T]-_<0'?DK#)\_"G@OK2.LZ7QH^5'*
M,A_;AD<W6#S@'K:G2:*76B_?Q%B^/@GO3)% 'DK30X)X,(R$31- ;M![V.?N
M[D)(5J#X; V9T*1]QZ>N,-V8@31KBZ)\FEKB5MV%C7;:)FVMBY:YI*929+A
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MYD.6$GD3W<"MX[OG8HV4)_H)!]P>=3+A]/)P$7!"C.Z2\%)^7"[E,://"G)
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M:LMEY)G\GV)I)-"(NN.F/U>/%)%1A W\3C=ANXIU">2BT'DZR"C(&]_E3I:
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M=04MS/2*(34W0LXI4,EH'Q"T+>@Y!"2:I-](E)(F1.>1N8&B [NGT!$\O'W
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MW<[!8<^L=2/Q@4_#6:+;T@](.G3)M)>D96*+_ S3^F,R"\3,>2B)VQ[2N+M
MDI-'71>[CR@5%E/)L0AHT:0>:_-12QET!PMU#-X[Z0ICGP%OT$+@A^KN,I>Z
M,3D;Z,K;.G\V*&%Z)9(KBW0U,M#-ZA]T6_9I.\XLL,$@RH(;]L!*7K;!%R3=
MRGB ,+:A/4"DS:NPD2UL31FIDJ86NCHZ08:H3#EG"@_&+4AC)O2=5+#W4NS)
MUJ'K=1=IJDI11?J/9-[H\>>9JOBAGKKZ#AS)U$<<$@*Z8T0V,C]H EBIQO4D
MRGFA1MS(C3X-AM0R10R"3O6=5D]9##0-]M'B@ <>>GWZH,:T%MUK=7M,<!Q!
M2[7RKQUJ]KTI'<056</\VM84@)[;[[;=P:&WZ%BIVTC_]6N$?WJX>N2YW86F
M5J%&%_A0L@X?6L)_[B;ALB4CNVFW#V 514'^JMT[&'BV]B+A!RG0>_:TAD2N
MZTQ%IPK.3);@1?N"_W:'_K_HH04:M%33%[50-490_,-RS:[RF452P5U)TE0\
MM7S .X^.N^C<:&B$>0[L[$DIH!2S6.9VV<RV]3-"!S!I)4N4.A529#92N&;5
M\1GC[EV@)<;WBA4M"1(=..>^8.[8=: \7J;AI&34JA%<!:1SZ0^E]1R]HJDK
M)?$6U9;D2&':O03P)8I%_&-!IM3796%=:X.)U.BX8313SL9)XN!685>I%$$*
M@:NNJ3%)#5R,6QQ.&@UAL/PF26?CB H!L(R$>#"([^P;D0-;A:Q86?*U_(&X
M:KXNA\BK)J#/=U6 2>\"M8(-1JJ4(HXQ04*"U91C)#<TO"ST:X5'_XU9D1I]
M;%;NREH,  D<H#X_N@.M:@!U9Z>!0G*X'TV2;$9M5N3[7&%Q4Z6KW6%=P:3W
MD\M]>'^?CP"G;@L2P-RVEC"KMSED<-B$#+8_9/# 7F#%Z_EX_&5^W!HPF1*D
M^ :YQT;S*I88.Y7^(Y6?LG(LO\JYPNF*CHX%4 :8('TN[HXH>;@,I>2<2%KM
M[ZP!8$+P*Z]ST/4T8GMAI 5V$^.=9B*3%ZS!*BBO]JC-$82L0AB3JN;Q5Q6"
M+S1$OT#7G95TC?E>>G#6-4JCLB8HJ4Y1.)LQUGHL+TOA@32J6JKZS.^A5D!7
M4GUT>1"K/O/#5>L_F\@;+RV324*V>AC;  A4>6!\J7-I-VRSSOVYU #D?MP/
M'5()YQ[J-BP)PRJ;3I]#KC^ZU94K5!XPQ*BAH/N#>2^EN5:WK^(C$UBF_PW.
M,J8Z%G!J-9ZSE#^OPVXUQ(8N1F"JE/5X_K+*>M:TLG;#FD7A$P?.,25,P;<C
M@TM.]+R+]IL3-<>1! Q+R#,K35L[+:T#<L^I44HG)9.C:26H:=G\3#,KU]/\
M#2/3_@1AXUDF(L;'E:E_#!9PQ0IWAB $5^Z-<$ 7>"[PBR NC2H8(E3QO\RH
MK9(<(K@Y6#)EI',>EO;9GLF&\;=\2CU7O7?([_VDPM)5!:GS^H_>FK(ZLX:
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MP4@<[4=)0E%(:Z(,!1%S.WDL2:'(LLHY5%F<5N'/@8,!=O&O*OI-B%<O*/S
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M6773!0PT;0J6I\$,]$:QUXI-&[&V^C*\0JQN!7>E1"_%ZQ>>=X$%4+C8E%Q
M%L'(D(HC%N@DU-\DIX;,5S>-K.I3B[Y#F:-J%FG!0EB%[7;QG@7Z8H,",AS3
MU"B+\E7]%8-[*)@^.A>.WMWG)D&Z&QAY;B/*@]6A!L;96M#:\',0P\THM"2D
M:F?&QM/%W7N$ S#77U0SC$#I4(IKZ%KWN?UY?J-H54Y5166;5G/LB95 Z;14
M-.G;W8[;\=KN8* 9'[IKBNG-[E'/<_OMMCSA%KO?5;7.*S:QF,-DLAEU5S-J
MU5J!K1$-!V-W#JHP:W6FT8([>O=-7(&E4B@XC@7NS4*)J1CL+(;O^B-!V9QC
M<-Q VG1+E1"S=>Y3&57:P1*SX(@G+-6T__-MULO[;+-I=NG$F*%+\P\$0T6
MZ!4$):X,F>:>DD *L)TU?O(;8D(O-;153%@MJ@CV"3\*IC2:1ID%$<U2P @
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MVVVHY\\_6Y!?5,MGRN:6=!BF!.=%O0@H6T%]H90 K3\,/!4+O8$D*!KP$1L
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M^RB SMY!MPCHW#D8+,)SKOJPX!DK).(1@@R_:A_TS!@&Y'DYX'$1DKD*^%A
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MXS,#_8P>*H1OCZ[#+$EO:1*78>S'"-VME^GRNU[ENU,515>/N_:G4YA\[%S
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MB0%NNHL )A;RLX6SP#+T@&U)R1KFXO/A,$64$VM^J-()S%,9<*IK9Q7;,RI
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M9SX6CWL?!'/\+8DK]WUEQK+2K,@I:8>F59N4P' ?X"_J8W0<@%C/[PQ#)KF
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MR=CW6\?OEO%8]](6P&;H>W%:U;3V,N/4?Z=68RFAP(7O1H[50Z$9M/S:OJ%
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MOTG+G8R6K!FQZO6DDWX9Z:JC!\W@*KN6-<J]*M_'Y_]1L>1=S'F]'Z@"Y83
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M3UT<1OW6]T1"CEMLU6Q9SDC"3%MN=7MA%?Q"0B:#U"<M"@L8C4+"0]>!<)F
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MB>!B.BN+WNF=\W?=SG[?="5/=Y'D[S^2_ GW)1_.O6=LU#P/6+KNT>V1<(?
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M]'=@A%P2K H*PQ!UTU 5&5[VN?1V3"-?/TR,JG EDT@!UL^:(. A)=A8)4_
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MD6W3OX2 5O3O@R+<V)@A)UAT!2),:\[-DO#0\M+8!IXDFCNH!GEGSJ8&8>N
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M3:&!&_&#Y2*W:+'<3MAX*3SE9L<(US/[I-A56AW+ZS9CRM)<.]SC>R1;UVH
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MR5W)Z4A?6K27OP8=(),!6#P3$*=<:6\%G;84>,9K)M=9*#'"_1,1*)T>G()
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M(!#+07E/GCHRR\R@$/4L""@Z?<I,7"<67V*=RS$O@"_8Z)B[8FNT'.=8&/?
M=L%6-@3^48&!A.\7^O8T=0:*4<>, .N8LNDJ.$Y7^.S1_TT$^)0:EW\MBBMQ
MCFD?;"4E(Z&:!NV0LEC=0F^IB6XL+&C,SD7@7*S.D*QBOM ]R,12$D/;(_'O
MTV1]KJ[0>V>CO48@EYQWB2*\CCVGEP96?>_C,?=CR+YG,Y(EF@LK[M#>U/@>
MARWDB+E#ER:7V8#6!K)/)Z)-'@2!8+9L^JI1/#R,;[H!"  "9)#+W60C"<GD
MB)^B(130?*.<8T&9L=]D$LC:F]8C6./:*!=M"3MCY4]WABNM5G(Z5XW>NR%"
MP -#1HZNIVBX,S2H^I!7FC.S'2,'T01,JWP I1IJ,.T56',_9E-N?T:RQW?"
M'FSAZ%T+(_.CX6"0M'/)@]<WX&-YZ(F.V!/AC!Z-=S%4([JHI,)[[+L)MPKC
M@K%C,'BW[14LY5JI1U/'I44GL_&:R@\#FICM;B"-2(^ZNO!!C70,P@Z.TP!3
M$'[C@+5 ZX&8=<*,E-9# N\AXG@&"_@JO]$J_;@8@):0-E [VVQU0,;P4<S5
MZC^#(:*>;5@S^=E2/'KZ8W0]0& \3=#1P:$F6@]/^#XKK<TSK$M-ANBNX]$,
MRI%4LU&J!H6 3E.%@?N*9%6XO=BEI?-$SF"93:?"D"7(6 .2O+DX^_7%1518
M)3=B:T5L\GD/Y+2#+/N=)KGV] -<A8X$KC[@<746GJY)28R2]3WZHB.F(U%>
MMHRUREY8,#9R-ZIJ'J27B]9^7%90QB07BJSWP] COFATF40WL0TQQ(J"KMO"
M3GS@HD570KG(-<7KG[.9)_+WHFBY&@]F8E.7!G!01J94&RR>.O> K-3T^."1
MU!OBCUSUQV^"&FO,DSX\4GXNB;,EFE4#<\FL*4IV7,%' 2\^V-X+NO_*K,'E
M/R?==#,L.>X1J67;/BWS\'D(BVC;&+8Y6^RB=MA +/GK"$'"G9'(8T8+6AM/
M2,K9&GHI-KZU53:I$R<Y]',G.5I!CV3E4[#?E?FL9;J1RS);T '/3-"C-T^E
MV4?WW@GJ+,FN8SI5K$;O#6T-@G#L,RM71(QC)FOX]57E>\];&+&_F$==Z,7M
MK6MLL\(U2/TC:LFU2FJK,MH"QBK3AO54;D5!:\VKN9UFL=:4SQ4*F =MW<ST
MMN:PLH!@/D"S-F0:#.N67S1%1IXVTT$K:B\PSJ[G$%.'1B;MV=%)$/^3IQB%
M&A//U./P*?O)LYS#7#+X\/E(->(AK)54+'TA+L>XNA$P7O;4+TBP "HTCL&!
M0PW\BNM4[ 5[B',I5AX@^D[N=$6L#I=L'-@5BJ2MU;EP#[;"7"'@#))8 0$B
M["GW!?+Y:DZAB5JNBJESZ;KCI.O!"5R'."^-R;!ZSJ0MCLIN87$7IPD&N;,*
M/'N29DQ#N855,U?"K=!;BRZ+D ;0:QZVQCV+L\9RPTSLF9,S$1'3$VG/0?0V
M-YL6J%BIX:QP@B:()X:##T-\F#T9C=/0.,0*>0.2;EJI<D+\+5IB_\R8RE47
MG@9 6L"Q;]42'(=BU\21C4*#T]F]X,Y_9\-JQ<(.\X:);LF4H14E]UUQZ3'-
M1%;"<E2Z6[I AHN6,P"#&ED<>T;TX# 7QSH0KK,6NIBEW3%Q9K4C<!-CW2D&
MS31Z+#SYWDHEUW\$P#M6!(11B!V<J;7V$D9&\HY/&7-62+K2K,!79R_?.2/0
M*SE/=L!@.E).M>2M] V.>$Z=T8!+-W5CFH([#<:MKKE-5<\7MW9Q?%5XJ'H:
M 2V<^&I,1<K#@1VD!TJLB=27K6KR#O4H[EV\DLQ<GC&6/E .@90JJ\"\:,>B
M#;DF=]1DX[FOYU#T$LWD;XN2B3 /?:0F=!AX_Q6HD ONR/9-B5[=U>E*O$4W
M>N/\_8L+WR?4F%W7<2>X&=,KN=2J&CJ\7<3SVRXN2>RQE4Q=I@RR4['!7]/=
M?LW(1)N88;:65J.3O25WL10O)AK-TCND)8T&C#!+=4?MP6E(IB98=P< G(&Z
M+2@"Y,\$#,!TGJLA8YG AM;:'-SW^;K+V[GS$.B TJFPI5JSA(%X6XM6CN\A
M]?,]Q^>?[.+S?XCXO*H3QR06G#?61M(2.-!)4"$DP5+(.LA*T8)]!\"(:J)7
M.+2*8CV%C(R.L],U??EV:5\%JUN#R:-\"O^ZL58^PCH0 E#"D1A Q,AJ!GD%
M[%4\=P5[?.DB4O&H?-Y]7%PNV.LA/0\T"M0>#:QP,'N^9[ED:IR\R(=<(2''
M_IBN$5 Z_M0=LA].H$:V(T/H>PA/^Q.?LNEK?=KE/^B %5.ZDIOA7W^X?'IR
M=/3T\>7AR?S@9/^?L\L?8&7]]8?7;W]^^T-\R![M'Q\\/3BF@Z;*X6C_Y/#)
MX>.B@C+XZO8D;+:I;YM@D"'@^[M&6"JXC&G-ML,U,(AV0!9M)MA<9K4"\7=(
M@\L$,+ @VXB-J8/5M:YMPR[U4:HGGME#.*G.V64VF"1E Y)7MEW461,S,Z+?
M16)*F\)E4^XG@]HU?81Y\%D$K+)X<F366A9+W6MQ]<$Q2X][?'"0D$3P[P @
MX:BI#J%-C@%*?_R7Y$C#8+"B[-O[T. MS9)YB5-O?R+L]($K5=C:''B:6XG+
M@K^#^TM)*;H?3C#?:!W""1HKF2V#!27$ ET>@KU:0 2V/=Y^\>1:GCQ%3& ?
M.>!"S[E/K<I6E34HR#PNK_4!DFEM73FN20(^E%R +T&4JF;5: 8OAZP*:&\H
M+[DW392<7)KQ_H!K4+ _XN-S ^MKSF4.Y3)]Z.@R0CRZ3H,,U++, 4CG>*'X
M $5@FM]/#,S2L5X.A&9?EM?'E(=#+FF1T@ .973$7"XC (N5(UOVE;Y[G'3D
M.(_DGE\*(SA*]S9<'BRUWJ?\81,[GQ[0WB@B$"H=.>-\-B,PN0)HF,T0Q!L)
M)1X,)L1$XLXK=G]KPYA?Q^+<SSC40;XP5@JO3#5WT7)G/!FJK&(<:^(598>E
M*$<-$)*S7*-3$DI?L=S2]$/ZSWA]%*0L,VLH<AWB$30J=NV* ,):H+@3BZ+'
M1O>*E!? _SJP4XA'\E"'\F;/<[._??]\7<!:77;!9PARK_+56*U\WWW:!Z"D
MH0IVN^DSY_:3-S4\[QM!R(&QU@P]" S+23;-?= 3(I%IT!Q%-XA079*NG?!Q
MP""@^QIAD,A*\E(M5.P;&X'5)6O0'9#UGQ!X2\Y-M)84YB'$-[1>125WCD'F
MF39?!J.GA_0[KF7(2,MI5B<=(>*";U"/!@UJ_4/&=9\@D>Z3-VX2F1Q6_ ])
M@OJ/8PZ^V8)))QWN0R.("^2=BE'>].V0#,BB%W.?D?<+RO4(-3])PE/Y953H
M)PMW_T - .XOZG+!HG]_F'\IU8E0[RXR$]AI6IG3;H3-.[)\VBJOY@.\()^C
ME]6H7BZ'8GR#QD>B0*0K3*"O_G9#'EOR9O^_/5D3_\KS 4A^V2/]Z:(*X$!N
M=E$RB%,Q5=@=F$-N<8Q**M+LFD!B F8$P,6D;ZO*F@K:4O%A0$=CW+IFB'1B
M.( :>$M(S+'0IW/PL<HUQ'$(!_LDPSA<R="SG#NW&E":-$;K8ZP(!X8!8,?-
M'^Q6M W+T=;N5G(-G&+(>"/VO^NPT--=6.B/$!;:I'W_3@?AK.\@7+7[\4DX
M\RG]G^50K$+(W4V\X4Y"'W<8M/AP<+HY:'%Z>NJ#%B?[AZ=/'C_Z]*#%K7::
M++'\I^3%KV?)7Y,70+$5*#-5__0.=^@/1+*Y9>.M__<K\F#>7F7+RR[([1O2
M_I]IPH26DLS'&G?3),]&@#3BOU'#/V>K2(.:!Q?/?]U[_>N+MWMG+W[9(V/^
MX3= 8JC:R.$F-Y=%1CG5-$BBLK6,*,02.DF)\UW+*V=FK?:H7/1[P5$#32>C
MB']2S_>F>3D/K$;#4?%GR7J9%A^-0,1]6G^'WJ6*],L_#HN9@LRK4>CW2LQ9
MS([AS[^=!X[ L&;.,\ **O[O<#%W;"5CE-9(.GG()/^<X^SVATS54^O:O*.-
M-B_'+NS2^ PV"G+AA'<#74\BU_CTQR7HAR/Y-RO8!A#!&IUIS%&X%58=G+3#
MHP0AE-8*WD+X#YSV^#BYUDXG)\#$_U- (BH:R$#FS*PV9^I_%MD0]N:]#0 .
MRCWXAHFTJ.SU'QQL(_7H?(FJ<;6"M70C:429T33/JL[>,$@'41WZ_-I8D?H.
MS@ 8YYQL@47-(94!&>X3'!,^0.3\'\NJN6,AU&NZ '&K.GK)-6@ZPAENM3V\
M ?SZY3WXA!7I5"]OM2[F5/6/USPBA!&RSMO:(:+RJ'5!P/L)C<;APP!=[ J;
MJ0S';,MLD-=U0UY.KIV572@ABG!Q3X9*U(;EIWV>K\U+J;L,(OH^[18DW22'
MYGTS(U/L<[8$XA4&>"TQ5S2-8F(^*ROWN:$V=)]H<[[X<J_F5B7[@RK\OE.8
M/.!+(SCQHF*V%6/]_E'P?0[-2N+0XVM(-H1UF,\=.;0UDXP*_H/AX3INN\8F
M7*%UDUS5)<H/$5B5ABT9=!!ZX(Z"-K?!3I-#5)=*<!8$,!"/TM*?O)K([?:@
MV,_W$45+FKRH.*<L,+:9\2]S1^9L/H=T59?2#46 GA'  JM+)Z258/2ZHY \
MP)8F!P^U;FF>'*?)HS01VL5U^CK82,ZIX>0M7>41ZPN.%31%K#97OT/WJG52
MA?[J_AQ$C^*L=YB8#\JLG,R\04VZ:R[]'0<03@]V 81O((#P.1[O[.#1)H_W
MX.#@,,S2/SX]/CZ^IRS]>TE=S9HBGW/S;W-^E9UE,2\$?!M4-V8PI"U"R7GS
M(/(9!$@=%M*ARUWZW">$&<3&W"UA?6H6&]B<*I&[W<9@)5=9-T*[U U7C ]3
MZE(Y-@IRB@^.'R%O&$P0677R)33[&.8<53/'\=T87Z#/0'^MO-+N5R 8:U;F
M1\]80:[6E\Y,0[H8H*).>?SA$\U[NJRBF[SX*BZ2JXQU[E+6''F>7>5Q$K7X
MC)3I)R4_UZ:0-^0TUZ9)@X3G=Y+EW%+ V$;-*RC4-BGFFMV* NS2<ENS"W9S
MA^4*4:S2NE:L]R9^SSOA!.MS-)(5E6V?AR.E\RQJ1$X@NSXB6<H"IIB JJZN
MN< 3 " ./I0U;Y1X>J9S-">RA "W(NKWD[S'S0[,U31<$S;8E4=(T=KZT"P9
ME_G' A>6#0@'3KI8ARK0V42"7R_TD/)I'09I1D:="-G<O)8- NK%$U^3GF,G
MCW::N3"D!(7<%R%;Q+KSZ6\$^LUJ5:$J_.6I(SU5SCN)X 3#X!6UR,8@Y_ @
M[>D:]ZRG:(0ESY:0_42?JROF(>Q=J'_*Z?("ZEI],-R#I<4JM^8\WGA:J0?,
M:!$3D%_<SP1 '\[8WR],9LD5#,]K:=CJP(BV'O;H!P@*GQ'37('7OAD6W+#0
MD>P\F O\G"9)7I 46K+P'!_LD1IF$!%*;\1UQ&4^0,69/0I1+=%U[!7K;?.P
MBV_!^.P*$RC+&Z- <%D\#FS4XW%840G82K/Q9H@4#@/>?53QTA(DG'F')I9U
M8N;3FV2V&*#:DA&BBKE9M ;&* )&!Y@/0:<55^$C2\R%JV&1D0?DLEQ;1&.N
M.^:_/]?8C"1J!ZCH4=OBFJSC3H5:/^U&%E=SG/]=K1L\UP 6%BWAK@FC_!*]
MY/FV&[/0 ^TT4!YJYT?EU168//60N&&8RQMP4+#'B<$ 8SD"GU7@>GH)&'+G
M3G%N0XDUBFD.(\M74I=B-I,-P> \@R^'YD##2:9HMO._JSE"9SAKY^EVTH!X
MC&V*4Z56! ?N70Y7.5-!"M<6%9-UW4-IO1D;QAJR]1R9S=,+G\806#E8H&*>
M/,CW+_=3_ED*WQED-"#%_2&?/W2X&-_:.CS*K!JLS1 ]N&FYV@J6YDV0RL^"
MBBXNZ!2#U.DF'HBMMZ\$ET\=GB:!+@K'R8>UXA#?J%A,28-QC%T] /+))K74
MI^NI]N>2P_OE@EDR^.5!>1[Y5*[=+V2W<6\LJD^5-BR][01N>$=.@9=_W_&%
MPUU\X1N(+WS)KF5![D\R=./LJA;RXW'.M>@K K32CJ5[(OI(Y/3 <R$8*GM;
M9S"+D<W?MS[*J/!O_)&CJTL#QD-PT8TY2,M!B)5?]:8V_;9 D7$^1:3/[&;Y
MF(AA7S8@P+DZ=!5I!7(T7/O"#FT,=_\"I)(1YP;(;M?ID]7+%9C#"7?!N2SS
MO7:"E@311,-BA-#FF!5T4ZL+3D^JK#E&/KH4U#B.H>NY#5NY9RU0!J#+;945
M 8>/+J0'YM>DQ)E*UH=NY'6=PD@QJ=0%\495FN0%RUX18Z/)3.$ZJH1KK=D\
MKKJA( #\D7QF-%L!QQ>85*&3Y.DY0TL?ZD=H3Z>5^#/S85YI^]E.T<?2J],.
M"8)TA&7O,;)B<1O>0V'VEA3 :FDJ$<)6?, 6%!M) ;NCUY6R-RGN+06VY_IT
M3./.)/P7IAR)2;XY4J#4=F9;:'7%JO<)<400V'ITJMRCJ:;:.%7"R86#%.U7
M9@U]M+F1M[N>NUQ)#;(48=E!:X!4V%; PV"- F9TK N)A'2^SEH@1,<W:G2L
M(>'1[M!AG$.(N6#^5GF,(5:>9,_Q1^+7Y*ZWH#S$Q2%D]<*&!B/-6O&XE3C3
MMT(S>E6+D ;MVI2 RMMZ7.$M,;"FT\S@^7]?),\S5%$T'_Y\EL^K#*T+5(S2
MY#E=AYGR@^)CR8- R!@\P'O<:.\0LDU??F3G([E@8$*[] 7N;K+T+:4I]42*
MT2C>DN,Z3=Y]3"XX11O][:RB+9LFSYX_NTCY?Y/7-=H)T1+R^_Z.OC<M]/B8
MR7+__/(C0%*+5K]"0_F5B0A27H=7*-6D693%1_(VG_=-MF ;]#F)'*UI!:K\
M5V3[%"/T8!AE$^40?$.'=)*\R#[4\ZS#"IE;'^P 5/BEZ+?3>^3?_E)Z$D+#
M?KJJ0M= A:Z&=EY<HMR=GE\HV;EK-A(0!-")+.O&^NAI#B+<%=&97A''Y$DD
MH3.$MQ9\Z(V'&NJ';G&A,.9J^B$).WT.6BDK+XO,1ZP1$&\Y A9T=K^'M@>;
M0+ 7YWN'!T?)@XN7O[UX^3]G#^^I#&%I& Q>MX[$YQ/85\>I5"I@[8$=8&OX
MJFB'0(RA=J_3^"B+W,HA"$"&M1+$B2$Z*]!1I-3G"7M)K1=%"PN:-HXC9R\O
M?A6GT@/E>DN"[KN@Y$('_8T0TY\EZ%<&VR_C%%+.9H7O3.J@!.@SD_'1FD\$
M>(>8FTXF",-EWCP-6->G.:YGU]!'V>O,8!0^]J:N2>TCRG+3#3U%)($"QD"[
MRB@^#V-'>T*)-FZ'2<1*SSD!?8XKHLFFJ*_21*D?AY%^^-]$X[9F4(OI( -Q
MWV5H_K8S>"4\=S#8U\,/>\Q(AIDMI)3Q];/SSF4CC2LRS(QQ3$R SSPC_$A9
M9QU.R$ V6) @##]H(H+#C!574Z4!-SW[+6;.CVDR.COA7V?=;<UK@NVGARCO
M)Y Z"PXW+A&\&Q%_R/%Z(_,%?;DSM?#$4J-0.1AQV/24)K,,+*3;#=E(L4Y-
MKJ1CE/:(.CS^$1MUXCG*_[%_L1\P'RL"9U!SX7:^-Y\4C6526Q=JQ=5K37K<
M\%&!YVS>C.F2.X2)F?* 03I?D+G+<O N;QG9W"8_TY;,."N#%+N?G_0VQU-/
M]I]T*.3=?<98)N%=EJFZ^:_A^S^Y?UWVW;(8G[5]\@-Z'HWJ]TNC!5>J7 .6
M;&$H1Z;</B@<,P1C:."9\=8ITNXTN#Q\DLI%1EOL#'2QB6@,C7CG9@5"K?H>
M<D>G/]YC$-Y7 #M693K6[ 9JLLS=%+J(RGB,N+ATQJ'K1?N6LO*7;]^D2QVJ
MXC5GXE2W/\QW*YHJ8&NFDSRM7=9HS=-X\:'NK+C5%=<J0QHCWQD8;XC_T'X!
MG;OW;;5WF"/S4R=YWO'^M*]+ZZ;+3S#22N.3;O))9JI9KRZ9B7YH/_FEOH8>
M#VKU*S:*7 R_C^\F6CVX(=E<J>:=53"/\+O:WWTQK-58 P7N:A9NNUHB@NWO
M.[!_M OL_Q$#^^>1<^G.A)*RX)3[[I7DY&:M-3Q$OT3WBR[!+IB,%PT#>")-
M8W\VRGNN.<D'9#[!$"$M !L2\#*FYQ[2%,&?3A:M_3PM2+N$OT!(GSY;R[_0
MP2+#GX'M0KRF88]WRG@0I6.O%B0S[H7X>#UNF+]F"#\ IJ9:53J8\<+5GD,Y
M\)54BIU-IE&9"=;:&(MMAG&C*BEE:.<<B6?3S*W8P!,[WG3(F&<(*%:7'$@8
MUE+TSKV8@_8/&GQ#(IP#V$I#RUI2&.$- LZ AHJI4=G+R5Q_#3PN>"L6#*4*
M GE!<U:&S#"/BMSC8ECB/N;;HY3HGPK#LG%@=U.!RQ^3SI6\?3]YO>:KS-2I
M@O*@>"BJC^0N(KUU6UL$F2-WF;A=;VG!Y^(,&%ZE=3M,TRUF7M,W /L!LHH
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MW*"P<07BABO#K%A?_.;0*M#633[?1)1TCZ5EQ\F#D.$M!,@\3$[W3W[\MF+
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M[SG1<;)+=/P1$QUZE";L\01 WIA0V2L"47E*$,_'+F",4.EW?7]]K^"-C]C
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MK8U&..\[*'<RO7WTT^JJXTF.B3XU6LBYQ SGV@I0K_7UW+F[5$K%M;6!2FO
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MVK+@JAR]Y=6P VLV!U:5%+X^MJ!K2I$7T;/%]OF0LE[!&4.23,)8 \[=;P(
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M_T51,JJ+2T@4#W8F>9>L.I90 K6LD35/[I?&N7*,0%Q)Q#A7#T0V'9,5QEH
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MMB:W>Q:E)VEE0M&VP=TXM68=G82T7UH3WIKP[E6JV@I-TX"R>SV-/7S]BPG
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M-)F!H</I,>,Y:UIL $ OW?# #,^Y\-]1,BME"HD<F/?<U=2OBW=9LU W0U<
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M8)L.V*HN^&$PYI'?DX*8]O:N<W_U=[;[^W[_B,%>_P;NKZ_4T51P5AO:H>2
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MPL:J&/S[(69VDVB ^>[[7U\?VJ]NO/]?T_JE; 9_YB81"&>]KQHJ=F;BO"S
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MO$PMUJ]^;,5'_&],%2Z0!1%)'U%"Z%UZB$7(/!U)L)[,^+2JO4&.7[MA5.T
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MT[T,>7;[JU2&+ ;;=O>+3=Q@K8Q!8E;2%)G7IOIM#!PK\Q+WO0=ZQ,-IL>\
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M%X/M^BPB?1_5Q*3X2K+ <\H5^,_A=K0QW(JC[39DRP?.(-HAF3.,HV%OK7Z
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MO$*ZJQP* YI2')E.@$<)C2HWF?Y_8+KGODE/;^T\,%K@K=.+[UR.\RRS!+X
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M=%C,R"PFZ]) #$%'F'O/P4,H,61N!,<L)"-6@O33!0GORZN^B<-3PD$2)-F
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MU_L-0L]%R=[ LJ%_^VX6>UV#$O@'],M%ZNV*6AQA]G=F]O00]!Z:C6J.]^P
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MY4^F%%_Q+"<M@S6;BO$10N\I."D\!X !'XO9HZ7K;[FPY;^VV/,&)KRY@E>
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M,@645<ZL?LGGOZWS$!:HDMR#WFC<JY,D_U0NT%ZDE( J0*).\R#'54-SG(;
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M,>8L/U6$L$SDB0! R+FGVP[DH_F^3ZTCX/F,PORFUM9W5]*4;NR56\C'9_)
MYHT8I/7QR(*X2OLJ1F,9A=MKC^'XIH!@B.; GU V9'N1N%(CP_R2*\AO^::^
M^MQ9=5FA.S097!R@!_@$O'PSEDDZV-NE+T=!UJ-'=,NG?^M3O^U<NE$3X[,M
M8Q,21>BTS<3)*N^:X;X2P<R+2M3[:[!9KIEO8^/&+JK4^OL/6E/UD>'($8*E
MN3&]7&0,<)-WO-(V5SEFUV3([NLM28(U?UM,C8+*^NFNW 8F1HY6Q)*IV/$:
MC./<?B6.LX"9TVC.H#XN(T6OW2QG$)J%2L;C]2^>I*=HUZ*5::WJO@"0,>10
MKFX&[49A<U+]:L:)/E/5:A1G+OIBSD<+5,^Y@N$LZ#\6M0J,FUV/QD*74ESQ
M\=9"C]9UW_1N;5UQM\R"-X0Q;H:4N70?EGG-;:Z$G/G5;#,8T C#D A<L9,O
M*\)8@4\.K;O*Q'AMHZ2OZRQ<%EXK]?2E*E!YTLL0C1;SSJ0L4-R<7!JE]L\#
M%];VLCJY+@?IF.JOL"T"EMP=SK\1>SD.^C/S)4OUR>DI\EQJ/[*^F&/*?^YO
M!3.Q:"4ZIG/FZ%"S;-R1GH#1F.Y";8HO$B AVNI5.N2%UG0$E1@M6F$M<#?&
MB77-X\4(Q5ZLM=^;_- .HZ[2UB2+F-)='%A_NQ?W>KTXA%&Y@<KDS*=56XI&
M0E]E2PW]WE1_N27;"?6=A.O4Z@P]+\%]R.RG^R2.5?Q;0MT\1_]B[/9XGY<S
MXEHXC%P_@&J:E"+-F9'9[N[NQUN[_:@BF>F0 >%=H^T\KHO1I\<)"J]V?*W.
M\I 2!J\S:TLYL\D$L0:(!; /\S=6?=\R+69#C60)LZNF]I21\Z,->&V][*E-
MKKZAR8S+Y.)J\\2BYFNM6 /Q$\W7$9A)QA 6*=?[*.(17M2$.-]0;;:O%45:
MO.0.%=.4';E&L+XHX_%TQ7[F1Z+U 4S-6!^<$J.$@5^NWJV;S*D_N.FD8M=Z
M6^ P@Y%1DNLXNR=B< 5,N"#S;L@XG:<:IT=1"<W?N_+]GE29:KE<^]R:V0'J
M._!G9;)M4LYX(3I5KI/- -A(XS"V03I*Q[ZR9'8>M9DG"(^9A7=U[K>@Z\2G
M:W="G,@9U.O@?*>7@N:07RX+U-ACS1X?1YV7BHPF[H/^NO$![6,MYG,JD9G4
M?S=%;NKM"-H!-[32C:L-YJ*9&?>HY=NCS)=.9;*8"NBF3,_4PC;G9=*L^)?R
M>262EX[]>Z=K=GD$(DS1T]M3LEQ84+0M[/N(^+2 H@GJ"3?Z$/(  +2 >S*4
MK>"Y%"A934UVE5_+XR<E25Y1T%K,P9Q)H9]Q9)U<MESH!4>>KI&]XT(JB6&8
M:'*3+3,WVV9]$*9N.ZC,]++)&A78FJ4G2[H#6P_2U^I&+I[)1:)3?LX1D_UU
MQ.2)1DQNAU\E:8UI%0H8R\;JL_8J?DD#M6(H+-X/TT+QD+G<ZJ]%=-'*UY6)
MG\V;8\4+<NT$)MWR,+ D9#ER?J3!OJ8GPIS0_Y^]MVMNV\JV1=_OKV"=ZJZR
MJR"U+,>.O?O>!UEV$O>.$Y7M[.QSWD 2E!"3!#= 2E;_^KOFF)\+ "6E.VW9
M??S0'5DB@?4Y/\<<,Z)%78!V9 -="JH5V(3U9;/<,<FZ/4S+%^NMOMF?%@4G
M%Y<3?';L*<J  $W;;=&UE-F75W77.;+V>;:$J/D NV*1B4_N.%FN(]@5^B@B
M=@46"# A06J<W3'@88%-<DSLYV2M6P?CV:XCWHZ6U..LIB7GA@XH-=5BVXB3
MH'GR4[FT8Z3N^Q^I:95'AG+6)5$B]1##=XVBT?<'-ON4T</I_%9)ER^DWI1^
M13&+!9T%[OKA=)/>5B6RSTR8W$0!<,2,S:I^:,4$6^'+P?#NU<6>=1P-%UBR
M\E^"WOV=6-U/ M#]!Q SMW=VOT>83 2A''^K!8/:483NR:K\C;ACTPFZ6E?,
M^%$G2YDZ)[]+5WG7CL%E @!Q_ZRI<$\ ,;ULXVT+%I ZI&SL"R_JAEOW+8O)
MCS^>&MQ0/["?$?OV=Q;^&90\9:S!_=XE=LURPN)^^X-.WT*/>/?JS<M7_WV"
MO%]T/F$3=%623"1B.L(#J(JZ:MH/DP?X0#E8O7?QD[\VGK.]7][<[*24D_W#
M'8"D_'S&."8[G?:805'E+5S=Z5-06:%%C=1:#KFVLSV+T>?QS>]ZT5?BZ>:"
M4Z%T0< +(0X;OAH5&=WVH.'5OO/E8^-5N4(?G,NF)@*?TDA1P3S->E,.%[[V
MZ<_%=PJG"6G,>%<!)/['EB)8,!!0BD/R@T)AW9!V]4P^L)D!2]M+L("$";)0
MO&4JMN0#O9\G-.-)CP:-MLO0*%T D.*K23+6VV7%=C?=G&ZK[;-&7W@_E_L.
M.HXSIC"<1LLMG[FWY&%CZK!5@P/XAO"QQHZ"WT7P97X82.>H>D,Z-?5#%J]N
MCE+<86)_4,D@Q=PZ)60;\P<# U4>[;G%[OYK[AN&,.:>4/!@$L-YF1/)#1 [
M\^*VD>.>6F1A2HO=FJ-CB)I+FID9N0KWPP E6*?EI9VG]$=ZVS)9B-WD?%<O
M.2Y64EBN/8>I?5DWUJF/&.JO,C;>&'XR63)-EWV=C@4[@'--\Z_/D^PW7SC=
M3)&?(<I4KY*@)OQ]T\P1U0S4ZCB/JK[!HC7XFIY6!$8U!F##<E@7VIA3L'.=
M+*->0,W.XO"8^E&*E%HA5(R*=L(NS'>5JH2.#X"<JW%6Q1ZA%E@\<=1"E%BZ
M%/#VP%RD3:+ *4>:_=^@Z.P8E6^S@;4X;RHA->1/RFK:"NFH@+'7/L748FH#
M3KGD===8\\]6_/US_K=K+2*<A=G]Y7B7=U@=:]?D=9KB8M[)PZSRUH"YC<Q)
MB=P+Y='3)?P,JDF_S-CULZ.OL>LO/W;]#\0S6/Q,3KQ$Z_[B%V^HT[$@%)_!
M.WR>]&1U3H2PPGID];LR[CX&9F0ZP>=_5Y^ORLD;-,R=O-M-B_B=5^DKV^N+
MM&J!J?]MUJV!7< %.F1R":3Z.NG9#7B@FV$TXO>-B?OY6N!=7&MY1H0<#Q_;
M"Z3(![I=$M"@H$B2-EM-U\=IULMA3.C3*Z7?MW2(8&\,X-=*-^Q@/[.+;#S
MHK8C KMWO C/DV/J2'FDG9%S01*$!V6+IYU<.P+UC.W0X& !:J] B6=' 2I!
M-JO!Y4)'AY%2S*Q9PQ[(7BA$?"#5; S! \#3NZQ,*S'$DRU7IDGX@=/8(3)
M:8FUMC?T(WY8:*4)&_KEY$_?Q#EICI^K.05"0(8K PZS5M_,9>X]..EI/U%3
M+/I!K[SG ^@KVAT\N-J&0!Q_Y0T+IE6>D=_?MSQT[RL5+]/]1R"]3=LY-O-]
M;_U34G'YYL]V7*MT6>7O[T^^"%;\[W[K\9-_YJWAM4]^UVN?_..31>"MOO0W
M/_I]K_[V'YWQW=HK!#9FMZCM$ +R@MSF-ID!YQ0NO1]K_R9AZMW*'=^5@Z[
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M.PZDKD&:6F>FYN9HM#C'1WWX"O,@=P)SJN9H28BZJ(X)K+BOB70F?>UI(3*
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M64'TEVDN3#RL*'6,:(EVX)YUH:W:M+L#DH)E!]3LB>9*I'Y0V#11-:>R)H2
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M6HOJ@"XV$1RBSP';PE1E+UP1%,PC4J]8W28HQ6U#.I12F.#10'02<CH9HRQ
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ML:O2:Q"*,DLHO*2KMEL_T? UV]XL\K8$\?WE]9UVG@8"=AT?:63NL16"'@D
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M%*![TR!4PM[FZ993X88KY)-#=Y92@$C.<I@2UM%HJW%LX\25CDM33+P9V%M
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MJB1(7"8HMOT9,2_2',<7 &VIH]]^.X[AC.04[]JE8TK>A5*91]XZ;4DHBH/
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M[=EN $EUFA!-;;S_G),!=J3=B.E+#=HMD24WRJ56SN^IYT*>M'FH\6@EGCZ
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M'>P(.E6BIVA"NM=5G<$14^9$,< N'F?)>4'Z/M1"#$L&J3=9XBO20)0-GK1
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M6O@MMMVRC/KKY9V_+$OBF D]Z3%:$U<Q/G;X9%0/KAF]D19"'%8_6M.04K)
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MD,\58QUS*F_!J-)ET;HS)F6_1-HAZ@:P_=M;&_\5:U9X97):@O:(*]RZQZ"
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MJ[/C=D_9'*D'Z]S9@W-'S="T$9ITJ7%:"7J8-,JZR=BD=+F1L<V7'9$BG\?
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M9&1(E[/)E5;VUC"OZ+N79?6)_E?E$B_;5#SRP@/C9V$Y=@7UA+T 2/4OYZ(
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M/=?4 BU!"5V1?J2VHI>Z3+8XBG8B"1B_HML%>T]TM]WMF.DOENJL "3@.F3
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M<R>;)<PJ[!1=+)C7QFP\6#)MURECG"O$.6W-M5OF:(EGX2;1P:_-!$2$]K(
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MQRC05A>T3'29 AW1@-<D!B&R_HG)2_!SY'&@#C85;6&=MLYQ))@Y@E/).'3
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MV>\\$U<5.T&(\F&=T5OP<%89)&19;,R:4V+SP3365%J\???AC;&F&0#^/"T
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M@3;]-"5&6&BV4J?'B,.4<ELYV8@+L$9Y@[^L=[RRNQ-+U!CE8XT$E!UCR,E
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M#%B/(4<3H.H5$H["UD55"[<[^*N#%&%B!%B,G@?EP4N' ^T#0+U1T=+'>0<
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MLZD&W%HCZ)B4J8_F:5NX2< ,2Z+ VC"&Y]S[QQFN!K%J!&!&)#OE15<4<G2
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M=6.-F!.$V1 E,&%2<M#)UH?&W,K;GAWX4$]A@D,4[F*?[<7&A_J' @.W\7G
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M+IM@.:K$0?<]SA/F(0[$G0^J7@$K?-7\G/9TSNZ9>JUE=<;QDF H5/NA53?
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MVA_X":GZ=K ,#-)9ZO_/<Z2+0]HCCYUFCN3,HOQ2MP7,*WFUO(T8!<+QD.&
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M<57++W9L+QB(N-1M]\3T&0X3%!RD'5Z'W=![*.WJ^0$.E(IY_G]S9:FX2.C
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M<T;!,?\1*D3RT'1N_:SZWOS.KY0,OO#KA'>V+=UFY'QB<VZQ[M%NPD\A7"R
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MQ%)C?).K>K&L.IB:6'#8(G.6X\G#W_')Y)LOI51JG^ER7!3=>3V3,+>SZIW
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MAC52;/'U>$A3.HB-O'$_AVR#D53TJL/5[SRT7G@[H2@R*8%S.JPHA5BZD1Z
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MN=O@6 U'9@?;?"6Z?&4I2RC[\MY?5+7.;B9\L=6\2IQ5:37EL^PCT-8BF F
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M<\GD;<\R^:4"6>+NPOO&37>J,SOQILX'<+8NR'U$ZV4NG5\/]J4VJZ1^\C+
MT-[9_(5ZS2T7PB:PFU.,IOR \,O"(A6>HC,GYU1W]#>;S$*(K^0-!S3 7(&J
M6FE6P ?!]^8#BXL7H[7(=:@LFI!@?.W,,/#.:)>?'F 3W6>]3323/O01B,&
M1!" ^--_,$E;L5BX/8 ^//_KS_M_QI\OP23EG_E5?WWWX?6;#T]>O?OUU^/W
M)V]^DG^,!R/B;2'W^L?#[U^>8L'V$W[S3_L\VI_VQ8W^$XRP^4_\SRQTSX\.
MOH=X0? 7B!I")20[[#1I?M\1?!P_'?_G]_2,__B+6RY<-'F.B=:46,W^4WY5
MNY.Y]IYAT&J=H9T[1P#WLOBIJJ^;_/+/]IA.PH,Y25YH/A#\JX.]??@DAJXG
M_]\^_M]+#$\L\IN?\.0^@9,:C?;6,BH(*KUU1IH(I':9N&7/CYRDB9; 3<H]
M^"_N\RD1"-\Z@E6\Y0-W#G97#%8E9_K- Y\58>L.RVR-G16)(7)#OS2M06A4
M_^O/ARHAUMC ].E)A>3&Y_,S]%]^@Q+W/TZ;O_PGZ$X0N66%/[X"KW'GNUV=
M[ZWF^K"7AGHPX#)0^0/^TRS&I@_VX=<\V'^@C8;0'Q:[T)$W1DF\XW^D5?F(
M)MJ731X5*=L?]Z9*T?R!N)USM)R;_(33(]-I4<SGXTH6[\UMU:E-5L"*0_;&
MVLQ/Y)>W,IQ?,>[JK3-FWX@Q*Y9]>Q^*9?1+?_FV'WH<X^]DC%_!-#[87V4;
M;]&U_4=^,WEUOJRRR3_W7N]ED_?G[C]?_;;^YW=K?M+*>8Q3_OD_GS_-#@Z/
M^M_O>QIIU7%?VNRK3?#98?;\^?[63/#+7[ON$Q)K@9'F0S>V%P<_/OLJ@]N2
M33\X.,I>_'A?Q_HK2;6';Z6\QG*)R<\8X8.<S%:+NH/G^]G1L]^SK#MX>I ]
MVW\4=G\L8?=T_R#[\=[.]1_=A/L_RV)RO"@^YYAB_=?R(1AQ!X?/LZ,MNO>/
M5MRC8+LGA7UX;[O^:,4-81NK:CEYFU_E54E^ZVTCS4]W.89\?S)R_1U.G*\O
MN%N3/\SE.GSZ8W:X19[_HTA]>+O^1[<5?W;^KS,2DT'ZQQC]XQBW<HR/=M!0
M-"N_<I/^M;A8MK>U@)[=OP7T-;S$_6Q_?__WK^1>O,A^>/KH+/[!+)O]^]QU
M@B:X_P4 W#TA06WYXZ*LBB=<J_EB;W_5D^!5$;CC\G.$[.!RSX/O_3NA^!36
M O&G_.;[P9?V4*6^V+2/;(V0KVLIGTAKT..??1]OG5NNN'R4,'VKSE'RB[?5
M0W<L%Z:7O6[V)O\HB4;68^%?G>=E0T0\1"_T3_>QD_/\/!N%SL,GWS=%BXU*
M,J4QX);,7)4 E1]$3X@X:H),=^?%!0*K+8A>*&0;K#T6'A,D1@Y0V<!C!H]5
MO8?W1J_- RWB/GPLXN8G?X,B[M^5>%I;2R;%SY^$J _I5Z5T86]"DL)35!JI
M8/HVVG(==U/S"Z(X9T'!W:ZE9MR*!6B80\4P78E]<[CFR4L9>&.ZK(3-B\D)
ML-@T-^$?\9QIB=1I?865HWTI\7LZ >LIJ,.'H*".L8I1*F0F4AR3!=4V0A W
M4'6#C&S2(QXJR(2QK0LJ@];IF/T3W@- 5_TT.<Q>'#U_B;? @P]^FAQE/[PX
M>HF?^]=2/X6GU_V*0MP_39YG!\\.]P9UUA_O-#Y]"*?1[R!:*_GE95U67 X)
M1^6O-;8?KB;_6"YN)H=!)=?C-G<<I-CZ;88KC2$88#0HD;L(*V+]%GNNPK=.
MHZ#<.'PNNSTHL^B9@^+H^<&(Y!D\1%^QRC,94XY+.K\M!]Y[PSD"2[3&$-\3
MI\><B_Q3Q<!IQ9%QO:94W\9J9T#=*.$B5PTW!911%_ \0\9RV3"]6D9$S&QU
MU94Y9: T@,QR*IP#+5A5I+':GQ[K0\GR?W&[^M ?'FLJ[UI3F?#JCNF,8Q%>
M4);TX,L.CR_J9=4]5A9]C2P'B;=_HG[\^H5$7Q3&/[Q'4-L?/56-<44E##]>
MSLK.LKH&6MO\_BUU699&Y[XSR-^0L!<IS,+&MO 3</ODTA$&?VL:B?C/;_7I
M>WJ?D,K'G.O L60Y]'@NU\_B'D$2=[O/Y8,Y?F_^>PFT8?=M/:UMI]SI!+S%
M8-EVGX"'+YE^J4J@16>B1&)[^ ;VTI<>#@QN;O?9>#!'@!VL!W8",.K]M6$0
M7SW8A(2[M/[(31KFM] _I!;6(]$@2'5)MXRRXJ8?[G\:YX,">V/5=OEB0?1X
MP.#:N(,-H:*P87H!_0SF%'WB+U.S-.""H^P9QX^(*76&+))/J'/5W/!L@C3A
MENRV]3IPI!6DAX))"K?9R 25'Y.>Z^:$C41,0_C)LQ?R3@RC:ALFZ2O7:Y2#
MI.PL^XC&G>*E]'%N[Q"_Y>#P#F_A[4V\!%MAX((#NWP0N_--[&39NW.G9L[.
MZ?/2>8M[S&LWZ@4Q+7(/F?+B= G-+"FBN.Q DNFRXIY14W0\.5V30X.PXC-L
M31'0,"*3IWS/YV>!Q)/8G?/.A!.GGB&V*&"4&^AC\F8P9@K8#M.]NP?S<#M6
M^EAIE*%^R)3]3Q_1'M\.[?'5MC9>AL1>3\J9F^/G'Y\='O[X_/\=_/#G_WSU
MYL/'XU_>3CZ\^?7XXR_OWI[\_9?W)Y/CMZ_I-V]>3]X??_CX?R8?/QR_/3E^
MA1_YYE<VY-"DMKZ,M@"OV79H;4L0.O_(G5QM;NA"40+LJ:=;IWP]M2<!RO.P
MB1#U$!?-)ER\" ]KD#D8VZ*%#:,"94BJF;LU(0+%F?U,08S2EWXQ^8[1R-(]
MU>F2*7=XQ<<X#9.?:<>95YYN%T4L$81RVZ$\R/F%3)Z:>EKD3DMVU[5V5'>Z
MN6R=\8-LH"UA[70F,.F!5YL450)= ^T16;W%7_SDK*Y%,3MS^NRTJ KW!5"Q
M]77%\8^+&CL!Y=7DZ/NAE_M^S=AO7L6R]OV9T"ER&H;B*LB1?9[[Y:=>7CP+
M:N/"_Q9>:VU&D06- &,Z8";U;QKH), 4P])0<%:TTZ8\#8BJ&6/$H9X2>UN@
M.;!L(]S12L;HU;@D3AWL"?CHZW+RIF3PBCF@3\&-18[#CL(G-=[0>D.4O>^J
MR4EQV9F[='"(=\G][W^5TT]PJE">2K<HV-QUIK,#'^0M3GZ>-VOWVUM%[Z-N
M&MHE97!N&1FZ*%6UE]$;129\1#)Y^"LFF.O)HH9(9>M7HZO/"KQ!N$B0:?:-
MH[.@=UKF6Q>3]4WM9J 7J[^> WW7=L-5EY?_S5G,E[+<1AJ! W$-?66@T8S"
M(4ZH[=PQ (RYM=0)R1\G[*&/+@\#+-K,=Z#3MX'X069PN!^9=K7 YA*G3D%+
MW_@:Y(:;&8@QM,S5(B>M4]5,6N\D[Z*82CN2-!!H!YY@FO/977Q-R!(/343C
M?+&@S0-78>"HRA=;6;N,B:L7W(SU^IPV%1V#U#>]#I4I!*,&^2G> 3J)_A$@
M_!<+=BFQ'<.RD19"^"QT>]2JAP[5IS?22@ TVZ(LEJAGZ/&[X>(!G[8.HX3^
M$#-B9)]C#V-W(*[RJ?-IW".=B=MY4O59 ;; LM%>1KIKJ%S@TZ9I,G5J^!]H
MJ*J0OPN? S! +M8:[K/A'\*>MN#3%5&'G"[_5" SO-@TZLS=^+8K=#OA' ;=
MX<_+TY(G%S:0P?.)W4_H;"8WEW;67?=;'57H60JZ'UI<WQC=R6N6E#_0&Z+?
MH0.\CC/WBK/,=R7%+E*^(8SIXNE'@):!;7T+6K2=W] J^G4@5UW;!P7]!<S'
MX"9[*\GW)(B# 'I20&YCIXH* B(J./)%&TF/4$A ,YS+1<[M+P+_G3I(I+8(
M9@Z-T+&=G1M\?=6'F''U@W\G[QR]T<W O2]GP\^*=';]<=G$Q_<-,Q5(Q+_!
M=WU[9?=Q4%_C>H<=4*ZQ]22U2^9VV_@CW818W9!<KP/%X$Z -#ZA)C+0E3+J
M=&*7\2?3PY1:N>2+#AIL7M2S<LX]F"X+()\5:7MZD^["F:%4NRP:!9Q!XRG;
MAVV7@G.^L8W8W1 9=3J18UB_5+8GYT[892/Z[&L^GO*X8>WI)&LQ\QW;3@IH
MF,QN'70_*;P%HL]>0#\8A*H)^)%MM'VRT4)]+Z\>&:)H,E0'> -NW#O8EE?Q
M[?XV*_C?@W+<*Q_8!6?3+TF-R;6R36!)1D-SX*EI[^ [)W?:E!J>S./ I^E(
M9/UO.8#[.USN90NPQ7!AO^BXL4S$MBOG&&%V"MSWEJ=X8]V<Y17GKMT 9_5T
MB9)W5Q1O4M $DY>NM7#R2*?7"^>MPYF[=-(*A\W=TZI  <Z="]_DU#(8#^-I
M7GUJEI?=](;4? O>/E@'..7*25<G)N;<$9CE,8\FZ@LL8]HYWH5]7J+=@.W<
MNJ%O@:2ECU+OQ%EQZA:H AN,&[&=G8%=UJ&XJ2!,L?"!"6GS[1[\W0'&(.#_
MG:6,-Y&O3OP],15!M[#AY3U9;/VC;;:YN 86LLFO*]T/,@&N\G)!7>LHAX'W
M;N>OO CH6*%;)4<RHX96=#(K)\5W5B_/ZJ?0002-W^1!CS[5!6%+N?M9XTTM
M,9PRN?;:<;L(;J99,UI6ZHIG%L@O#?2;(=&$B\BM%.?TZ7J13?Z-MH*[#V06
M-Z:C>5/8:VS::V.<;?RBJ.B:@>"A)U]"KSDTND%ITP[/2NC#Z]PL[ND8P]DE
MKO./906ZF+L?W3B)X[M8G1:+^AK/YOL<_SCR*6J)?>5%JZ#J041"%_EPI;DG
M(>XS[$8Y$XGI5F,)R&\4XXL;&YU:H,%^L]8\4H,NM#^S;[SH]]')'E8*/:$N
MPC5^R5P<'.V7'7X"'7>]U_F#SI \>\R0//P,B7OVT-F.;TO_;(>? !VC9FOK
M- M\&D(@J$%$+2Q*=\]GG,M&VQ?<.W<I7JV\;/& 2"S'=] ]ZK68D]B!T7>U
MI>[V[9KW-Z^2@L0]_\W:SQ];0WE^_)FA-;R$"-(Y==WU:TC:S WJYWL:5']1
M0([_S3R]+;IN04J/K'#W+S!2&:[ O2F-/Q29C3!!\#+1#Q:GNBHZ;?^)JHZ
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M-&E9D,1BA1/]B9UJ,67 \F-QRX@./^=(HLYY^W)B*L_Y#(,6^M[B@C'")#>
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MQ&HP8;U4% ".P'2TX(H!'QT;+^-&Z/@"63+A&@Z#ZS@S^9]H,$HR.5JW3@%
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MY(Z3C[KGG<#*-[&,)*[;#GEF>LQ'7+&+%VK$^'D_'&<8:E"%%%2U115>%&5
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M3Z)R$/TG*,!8*=?@5"<D(Y8]I[L$)!-<J/?J%5\NG1?QF]W7K:HM$HVP"FR
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MVMWAACM48W-G1G]%W-69FFU+KPLV =$F@%,UBM+:N/E&:1TE-^FCKX"D,I3
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MJ3L\>OB*_M2\ ZKYB37\KV'_*TG &%J*W,UP<$S%1Z<T=(<)MG09AQ[JP85
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MFX[CM#NZL!/RTTB.0)J2\A#]/U*DMU$?*?!CTWY=X&-%/,+C23>&_99W@L4
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MBN"&-M?A< W@9LK@]*?19/ZO[NLWO2 &X[NB+,-YE$3W(TX44K"0X8FA#[,
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M5()CL$CU6!D^!/R W<ZG;+0]I?O5\[S1V<O W[Z@6PW-N1F-E_G2R %CC@Z
M.97?@]%\WRWD/Y'LT2SA?PK\'Y2?I30NI?&1TMCG]BOY*"GY&D#-"Q?#=9Z#
M'1(1M9DT*J$NI+=<>)R)B31"XUWPA6C/_IDQ*.$VR5-S4\*-LQ3<I> ^J^!6
M&4@5&!NV2S:YDMH5E6Q^^03;MI93E/L-F?:;9*YZ\JIVRE)HET+[['>_2_5
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M*S@8P"2)TVYQN>$,D+B>4O>O]ER2!EC**F$1>!9\O.2Z-)RU&_1H>E]HU2W
M&CLW9&>]\1CN[%):P9XQ&NNE[;+/7A R]#F0W7AW S7N''LS$2M+C2"3T[(>
M4R9@*P^\?*X$G=>";BZ\W4V?8<0?S@U%U)D\&DQU#JD/\,10O=0\@Q2^SO9Q
M.@S3KIK"XXMB+F@ZDV- +LO;**UBZY!* 4DCN$DS4ONX43VZ%ORJ!+6-.9AV
M,K<1Z#RIT,'3S51%R%/3GT$[]'6DW"6MTL3.1^M8]R2_NF!A=S5DG:CD2FJ
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M:43D#+BL*WRTF/$I"L%0>CH< [Y:[U&>S9T0%TN%*5DB-8DKZV]\^>2",5W
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M(>RCM'OQ$'RBHA%OT[E2Z=IYS4S\,"."D5AH%R02+#8<5+H#)E5$0N6(=YT
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MSV12\X5%C]C39I_-&)*<PG9-S!1SA0[2.F_]Q(D<K&!JN"Y>U+ ]*5AA5*:
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MD.P4E#,IM*@LZ6EJNRFAUPS[''P@8TB?ORE39T%A5^V4(=PFS#3$HT:*0(K
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MR(6]$M'ZR#>"34\%VE'>N<XK):'I]_??Z''$G!U%S?!=JRMV61ZRWL384E5
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MV*7;]<,U->?FCF>B8[1X/G/MS<3FERC/VK5^HRZ+DHWRK!R<Y5J/T^S(Z#5
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M74;YA"3*[,FCK("T'U:XW=3:,J ,%=1\%=2L,]HYU=:Q/T>ILU1&O5)@LSI
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MF5VVE8JKX51JO6FY>5=.(T_LB?VMW(M7E(\$LWEXO T#;JEN/9+RU\K"V<K
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ME+,(PR%Y:(,I5OF>M(M&>Z'VG#\H=WFE*>:P0;LME5E>K-97*5.<A:*7@LM
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MI]Q2';,Z/%A'JY&MI.W5,@[N7O+!JL08N1.N+PW(>5D3XH?AH9W;D%I@45,
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MD%C-TD0OEGVLN#7+J*CE@1B!E;G/$RL1M58._U"!AII+&^\Q0?9XI>CG!PO
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MP>O]I[[/ X,KC'<:[_-R(IY [3N<-EC80=!W^D!H0>8D0?JSX00#'#@\>QC
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M@5]QC.=3Q8%-?(\?5!"KL'6>'\+V)X)@3SVP'N$VX ?72>SE_0PI]C,0@OL
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MIQ([T51>VIA1/&[>;%_9F%E2;MY;P'ILS%%I;MQ=NKBN6MTJ>3(HTA$DN6@
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M$P=6]&S:#GW'1#!/Q\'_XGKLV=RQM:]Z0]]5P/C#>4/CCTWC/-EBRB<$\:%
ML.FXOW+#5W0TVY2IX<VLP:=".,YI )N2:+&C4FBQXT*HSAI0YPQ,9P[I7!#
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M81-FW#TQMB#]"R(!+=!X@7G&:VAL\??F2EVYSR!'9ZD]*[)_6W%E]NY)4D0
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M">&*??HW@2@TZB-,C[$RK".?%5Z=^@]%6HSM [;DK:T,",(6[I.ZV]O!H\B
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M&9;QX0I/+?.56AA.$_T-O6$T@]*0"CE)T$T#W++KR<(+Z\7;6L<,MR\2W5*
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MG69G%8 G5YEV$N\7"VL:,@Q: .>W;H=XV^T0W=9NVB':G7(%V-WC;XAHEYN
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MGD!-2;0DC!V'LQ*TE"+E.#,AC8J.:94\/P2,\9^&896! "2S-/$.!51"C7W
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MVGTW6]TY.>LV!NUNHSO*JN5)131J/5BI'N3;?3!2O'MRUADU^L.T17RX>O#
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M<:132@T'=8JW7A4MN&!3BAY<YGO810HG-=3Q^.H\.H$7I?L[!%3&#2')K00
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MHJ;M+O!!6OM^LF9--&$P7SCZJ,>P_9DSHQ@M,!Y[Y%T]7$R[#,NV%P:ZV.Y
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ME7&/\/#\/NV-X3#@83Z]4,[IGC?I,.:$<4MOHG; !@.RS3.<T$1 ['=C/,/
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M$V*Y2NM@5JZZMN%H^3\@#(S/:$W^[<Z#54V8E/R7)'Y".13.*B)Z-2O1KDF
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M7C)\"'\]_JKY?O=0GSV9G)P-.JU.A_Z?K,D.:[$%P2(EV53-XPD*4+'-@FA
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M/)@>^XB4TR^X</=A/H\P%;[5'38%F(?  Q6)TQX8#[WJSLA&M=Q:RI[/9EX
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MOP<F(15\^$%HXG@J1#\Y]&:?Q[(L_5TM2[V"3TA2=:K0>78P+J4O2D<#99"
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MXK 9#NNKIL/6I#\YJ(/BK9D9E^S."TSOA6???/QT95Q:WF-SHNSB1)&TQS^
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M CJ#UF1054%>PX-E'SB'R(-9VD^_,69J>]I(%*"P6D>@$C<GS0Y.&DE]4:O
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MT]N-0IBLX)VG%F9 ('0.!!Y3#A0EU!B>0]DS"";'A:VCXKL: Z+SF5092.'
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M'?F)RV&#'\TE@&V0=!+2633>O[RYO?Z7]EOO]NKF[E?MLO?]OGOW;^6TH;X
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M(_1PPK2OVHW] H3@N!YB3OG\CFH61L0GTCDY1R>!*6I>_0+_5#KU')960**
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MA)LB-_R._:6/DT1D=:. *G".%V1BS$:/Q]1PPYP0QQU1-@E9(49(@7*F&D*
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M/2L#H0;U&7W?(^6S0B!0U2Z]A^:V'"CB:R'B?[?3B DW@P8YKS( BQDV[6/
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MI0??T)57A+Y[\L!P @<V2%]MEM7FB4,2$6PYI-?R&O3:*%VT]$H]G2JH0D]
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MVT02).%C%G';&+$RJ3"+6^88J>%EOS'#\B=#@^;*NM/SV,-NT7ATE_$[?A7
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M)92Z+]YKZR_$W[XZP/@EXEW<7D6)+RS3\RQ\#'T^QKQ+;*X=+TFZO5(I1>V
MA88GJ,G/[H2<2T++.IG"'AOI3#'$G>VG)LF,)-@\KCV-N$*#!;,;)#"UZ_0P
M2XVN,7_.;=<*Q+4<E9-8VM2^NZR#4UHZ8>=S*SX$5 SC9A1,6,9R:",T^Z3!
M+G "!L.W;&3B9\%V0%4@ A\3)35<"*IBE'EW68M R0(RD@1$#8H?1?WB14(
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MHO9D@)T)<FI/&I1$AQU=Y"@R/!>0040E6%Q& W1?=,_@DU#$\;/&D3A=AY#
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MU1KRWXZO2."T/[QSV-W!K=84'NP$## TR8=_?,"H(3F?Z>^O))IC\.O4\$O
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MI=LJ$W[I9X=?ZMO?ZO;]"GQ5-.3%$^9_>_!^/94"9.W U[Y#0Z1=LT52'(H
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MOEFVZ0>N8VJ<@C0OVAT.Y'C=#GW?#'QXY-PS?1-;-NN.YCX LC!(PCOFH#<
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MYL@ 8_#,L)\)E+047UC-C-_B-OP(;Q+7LC %G#6&;BG@R!1:UY?,;\X&.FM
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MRJH1ZLTL#$+2&R()"D*:*R21OW5G_D^1V&F@]NIKJ)=@Q18ZNEF=(P!RXOH
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MRS1 AWMDVAX#61;79"D=+/(2#Z U\,CUT@;P.M4G<'(G\*_J:0:UU;<H(0_
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M#6D GNF90%TAE<XD246?3+P0:]$#3=>F=C@),%B(A(;5Z XH[AC884_PL$F
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M;+!S=#ILM%HM_']J@X0TNSWPLV!&V)G0M._.K_X[I81O[=0Q;Z8QQ$ZJ&3-
M&H+S@I"U%PWD1HP)"%6-I*0O&">+/229ITIP1,G/)I> ^8RBD2)T0=.^SCJY
M@)((:V,]76:@,6MW@3OY*Y:-E<,"FMKOL 2'RUQ.[4(IUK7G#+VED1+0!L@P
MO#[PK,='SGW32D2F0MA<GM2WF?9RN4)1GTXM1 T  <'40<T3_YBX !0=A>Z#
MQ20,5V3$V9$N C_[X8-O&9;N@;$H\ !%.4@! !3L'&\E*1X\P6/\QLJG,&P
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M;RI(O+/Y,_%6E=3IC?>XO% [G,+V 8@F*QM0=D2E!.).05EXPQ=,I? 1_=D
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M<B$3;P$\M&)_8(V SW&R%X(@[A0+]^.41# #0!&<0CI@?<@ML-$\54R%3<E
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M5B%6XT+;$6-\,F7'Q&N#)/):!CL@0R28=@V#@)$D"9CH/Z?<#[HJL")&_*D
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M.EP88,$1_L]$EZ_>X*^@Q]3/'\ CP& Z7RXC ']03UR<_=^#_?G?WC'"R%-
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M6#D*+RV"^S">-)4RYQF5[HO,A\@LFMP#]^8L[WCK)2O0BX*XF@5&!ED,2'.
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M3A]K/T:U1I?7%@^T!L&!+*\U"+8R")0JRU>BYZIDT)[1./AL18954&:GWYH
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M-:S/<W%..)MXC",JSV;_ <TRQT%I?$HSOXB/ ^?$1R&/_%L:3EG;K.SN-VO
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M\S#PEHBB/''GH$1BGM1 7<("R5-_LAK[=,4*4X?X#F(=!N4F:16FB%0\WGM
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M!]@!,/%>V8,4_GWZF-D+NS@H$@3(?4DL<'?GZ/[Z[IDJ;.A@X[4@=OL)Z"I
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M:_=T4:H+$A<>1)MJ@?1%I>^/6RS'J6)+W2D[ 7-]AO/2TQ83,.TG @^["F7
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M@!=".'-&45N7956FVO/E720C*'P0*MB<6=%'R/L4B[Z8UUD+\JD8OY^(T'9
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M6LC>=0@.B@K CYI;3>LI9&/U>=154\O'=?M\)]NF(G>-[%DB>[)XQQ.+GN)
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M*A>Y>OVCF?LN[<\A+G;B=Z5_=- :J&K0RL 14%HP%R\GA(>'CU88S&7)+R@
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M?EV$*X30%!-_TQ4S9EKWAK2SN<J=5 J^+^4I K/)^.<" RBB:)-=M(2Q!I&
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M\"M&;C9L)_PQA5"47#/K9_'B)YTAQ%G9Z7F,Y".0H[O:MP#B&R(@)I:-)O7
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MO*1WBNF%<^\+>]GNR.'9F=\1BBEA(J/ZWY"P,;33N]+/*;2&LCY4D]3G/N5
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M$;N.L+4K=M/H?K_SM9-L.^VZ/[)&:<C3I*_#!Y,+*-@FX\X>_!,U]W-5)"H
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M=W<@+$0\7'\?%LD$$['FLA(H<*0_8+M1WY(Q_E1IQ6I8+W*2XN,PQ!7BX5!
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M/ 4+OUH5R<H$G]$;BW#(*H3_Q^[(U>^_X_2F"/\/65\9%4?7==D\:"!8<(<
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M%^>=7**;\GU[!_VJ73]O]AQ_+[N%QMIM?;D5R4G$-DQR"JYR&D/0)=@&1?=
M]>HC.V1P1JL4,$1J)U@F_5Z]1CR!DDA+WVX-K72*#(8CQKU*RKQO)H3"B '
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M6:1=M63HMA49GT>? ?F-:Q_=JE3BT&/Q9] (92@OY"N=:P?H<#NB#M%-&OB
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M_W=[U2YDZD[*E0\6%5ZK#.J72]D/-5UYP-XTRKO9-:Q*,P<SL*+(LNR2'?X
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MCKC*5T52ZC QWVYZCP,)@;Z+CRH# 2[EFNGF2AE3,]K#G?G?[PF='-=7VOX
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M#SAKY3(AR8)KC.^O4-2.QR8J0J:L2$O(NN&#9PROHI,!&\OT8!]V<[0DT+6
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MU5[!ZVVLB$X"E8467+(APNAK8ZH/UKK[7>!I!_LC(XH$T@*WS:![7WU1Y<:
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M5"*8(]KWNNYQ#PS:<_[,$KNM/JB![D-Q5<V[C9\AU6'IX,OC]X=4;Q(3D$[
MO&"DZ*R-IX]RWTMO.\G#&RLMF5[GYP;\EH^Z#ACZX#]_"J3Z!6W)P;#F1*I
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M7*6";ZC#=$J1XOA\96L56@2$TW*!;WZS\<1ZJGM$4"8I6;SR>H^B!9R7?8]
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MH@;9;Q"B!%#/077PKA#:1]:^N-T)!!'S-'4"8)K!*J8D>LQ]T"BN.I=2L=:
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M,HRY/G)S3KVO]AN41^1NZM);G>?$?LR9K>+=T\#8I6D<0>Z1Q\;.\:$H3"J
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M;\*DZ9CUZ= 5#_'UC19FZ B\1&.9_""$/\U@\K@@)UEJ/Q;LK3GPG4G1!P,
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M=RL2<RK(*0R-QBY MOURJ*.$!"_Z"$SY1+A3D*J!NGJCQ1N?]O^2/JNCR&"
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M?7VKTC):TX8M!;&U5V>=06-_ /S?5ESH7>?7,L;6KBBH\MNL6:V'I:V2EL:
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M1CX1KQ'T88GR</=?VJZ@$<*8,-,)W4;61OVJ:Q"+H8I+O4BJN[H'-W?A/W\
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MD$K\NJOS XRW\FI#!-'E9_=@/:_9HM=P4@]; +AW[E5_)G=1D^<EO9.)C?+
MO[VE%B"0:#?SH.,AIG%!!P/YW1=;'3,6)4MMIZ.B,F4A;_N7T(R; K$Z&,Y/
M2;7T[ ?*#_E!/<'RW!,><1R.\X<?7CG&@"G05DD7.#(MJ'+$>JP0KBUQNXX1
MRNW2&MY-X)U%(]792SN_">X/QG[BPE;X"4)V@4[3/1Y9^*_-:!RJ9RV4]!NQ
MPZ?*ZH9]SW4K.*HNFGEI$H(Z?[CW$AC1G^@7-9R6*S%G^ D"U3="2-UG;BH#
M]9[.8[\1ZA!2XJU<,"^.US"J<KU\@4-12J;$LLKNV!4D-O*@2.1:;9U8;@,M
MKE$ T7\9&_",J/#4A[33W+_P94=S5D;IBD%G /JH6NE_>P8W@$V^G]2$]^*8
M, #6O"GO!VL:=S,OK_(5.!$#=FO<2WT=TFL!>^=L32;R6&+73[DGEA;P#ZT0
M1-;>-BE4$-_%23'2-=*!-2H)FXG@''W?6A6^.=,:0>7I-T>T>W&@T;K6WN?K
M9FW%7WY)_+(VT)!?',@Q]>0 &[ZYDRO,2U^)S%'KO1;-Q:?X75[I>-@H21S]
M3=?JB"MA)Y\'(V%:R)FIK"?[P*7-SZZJ;>QIA>MQA<N63:!)7QFYM.AM!3 5
MI*3FF0?S2SFX\&N@IU;>K]8%Q3>JRQ.Y8('?7/K=ZDH0!7/7O-/26\F +%>4
MXX*@\$H?,BY'1\<%7RUMM5G.:WW;R]XI>GL\/##+G!Q0*/S^_ND-QW!0C(F4
ML=ZTGH7A8;_U!6QBW;CQT\YF7'$J1I/<@CU2,G,*.4&"VC#8YN>XB8H+]XWK
M2O=;T8>: U_6"O:?KO#@)=A<[V&9[66MU;0L)<.A$\BQ5ZAS8'G /9,V:YZ6
MW\E#_;A[%&_T[$<_T>?>)1OGRV)_\=B.#8TXJ\!0:F)RS S/5:*W_(?Z3BUC
M\]F,94'U+DYUCL]BD6&G/&%8I#%M:"CM752<G]E.6)W;E&8O?6K(VDK9V3^R
MZDC1DQ&08E.I$6]K7YA^]BOW]%FW\I*-Z*%_-GV=N)I/K9J #WH96Z#K<(R3
M4- //06Q/K6P#Q:_(-?^GXZ;Y_(+\9(#3_YQ[W49MM&:OZF<F'2=,G^MU==\
M[%MH^FND;^;5S]V[.O=6]!\?*5._B4[1BS]I6EHX=#7F3O)*<=#5)&;G2,U;
MC;7G4?F.$Z=ET_('H.2SYA?@U(T%. R3^XI(,JCK,;U0*8T/K8:,C7C.KQXK
MND[#J]6TX8CM\4V;&T=EXKWUQ7B#<E9#X=(DB^#^ZIYC-A_$]7(BB+,4[\M)
M<\'6[9%6>S+5/(?+@(ZVH>4N$ QQYUZ)"4D98=>KK*ETIN37HMHZB:#2U1.T
M3+N+\894DFAHK.9%  X/T+/KJZ#CZQ0.P[S#CH.@ $.\N:BDXK?;9'&SHB9F
M>=/)OC Q3GY?D-!"C(N680:\?*K]32ED)[UW-8: <IHOXL,'BI(R2S;0\Q-X
M36$7[C=Y3J#GJ"0N:[U_HZMF;U3T1&A\;*5- 4V<A:3SV$J+BKH[C[(YI^V"
M5X#8Z<NZD?7Z <?6^Y*/=LW%R1'B1][K2[7C23MS;[J^\HA-L]79""^7S3ND
M3\FVS;H_!4J,:.PMC5$HL#NIB^0+DC3],XWO^TWCEF\O2^IPNO-C/;^=)CJD
MTAO;?5*CC\S5*3EP?:6.DKHJ7?,]7:GKF9C<FF*6X/)2=>-O*S5-8'N4=1>J
MHC)6K\M&?;&_4H[TOFC847MEU.YK=(:Z\0B2KTDN6<9'C5='+UX<9%AH+!\E
M*W:;^BHQM.;4M;X6!JE3U.73#;WZC\^9H&:5JOT\*")Y@6/K-B8>YY+>#1B2
M.AWL[('BY6I,JDKHI4-PFBAC3$V#+F 5GK'!P4XQ;@I$ QR:+8@K)6+[].<7
MVP3'I(=G(CZ*-G6[:I3!#1D6;V=9=V^HN'@F]*11UQI!-:7T?LF[!B+%0V6V
MF@ZYM;H,L-Q(_"./IB<'1]X7#/%YKG84T$6+@L2C8]'MIC<Z![9.3?K6<=3H
M%H6UA\7M YI.WZ<&M)\GP(.I*7K%P0U#9'/NZ>7-KQF5&LBL6?6?D?9GQHA.
M"]\]-23U9*87:Z[8-0BIA8'<H14IUWHL5J_?F37W54@+[[4H%Q;XF<%.Y( &
M!O"]\ZV:7*JR?)0MDBH80X;OI6)QO::XDB.)@B$P7@R?@^+Q4J7B9XO OO/7
MURKZ\OQBP<H\B'5ZB,3EW!5+5\,^N=[M7N44S-JRN#!96;PBP?$4$W=]K6T/
M)-*NB([7-$/=I10C&FEZX'6\U7J%LA-*@-ZDG"/6O@@KA&LV;%M!47F[VO*R
MHU7B+S4O&]]9B[2ZJDWK,09=5//UHE"U!FYXG!FNAUHDA?P$F^J[K[=80_7T
MH69B&;K!64Y4IR/+3->IWN>.4TIYJ:SB$@.Q,O:VD,;J1'@ [XDA!44)?2<9
M/&Z.7;!79B@4L4NF3P/R)2.U'!'S!=Q4<*3#19+>E-E=L\G434ZI$]XZ\R @
M!6[+0O)26?2=M%!<DEA-J(T%M'9F U9$+3!@M,*SY#53GGY1M <2U^BW.VLO
M:2*1>W/92.5_.??URS*;($D1/$AWM[ZG)J.!]*+3$R)QS.%X0G_Y#3$\2\Q1
M5"]+28SX:65"N1X31R\L%M[C%O-24#]-_=U^6_VBV6M&MXP2[M!^EB*4@E+0
M1KW$:'FZHGWX@-Y6E[KR=/\6M:79+=GN0*?K "G5Q#1 FI0&9MZJR*,84_\Y
M&,L\ 2-M92,&K[VC^O2@4M\)/O=E0(SORHLQV.+9DJDM;Z/FEXFKWTH6\39L
M\:5=^T3K.<33>3$U O7=_P!PX$]/=6V"+'V4J_)*3#4S_$Y?&6T+;W8Y:*-6
M1>JV*((><.I=PF!;K-,G_6OR)1/*;Y:'W8$TEI3_*->EVA]V<_S2NC9N_>47
M/ \:&#:VM/T"V 9/.NMBM[19Z5N4!2MQ]"_=* )L&AF"Q;2-5F\\60"!'M=L
M+]/F$Z],'"9=B9>W?41+Z8X@0I^ -^&8DM[[8!J67CG*EB22AB1+U#(^8QJL
M_+_K)^'\.X\>U&9-GG;^!]"N:H)=XHR=5$;5+T.$R2!-.DNNL8D_^'2G=$3@
M/>'Y&ZS($C09+*Q<8F;:MW12K$1O9@$LYZH%^4\9N;*)_F'"*F"YR/\B5<#J
M$HHFB_X/XQ,FAJB0X3?OS B?E665H*,(['FHIX#ZQ,Q(I( AD.B)A/LK%79.
MW)@$ 1U*74/&AJ7=?-_ B#KO>) HS"1L\&)U:( [L[(>->.CO8I46WK\^*+O
M&?^A!0&!E]YB=8Z"\]P=_Q2_H,W!!5SI_59#^NCMP%#XZPQA/[8& Q+YM.B1
M+M&297Z[,WU9L1JX !.)'%"T-XDWRY76Q4^I@CU-U/5=*6REBB&MMQ\"\$(#
M,U#6;K4^VV6Q+G"Q+LW+HHQ,#)JE?MLW5,3^CY X0E2;Q"59@<I_<ZO7NCWN
M&EBE,L_Q86.IM 9>#_V^<_50ZXOX.JP@K4CLQWZ)4LM%&NW3"!0R)4K@'O8C
MGV.5D[):+PKZ^BR9 HQ2>-?,;G,!R?;9\#D@21/O;A[A<TI:\TK>.T*"UIY%
MYP/CU[;@[D++@WO,KJ[2V_.NU7S^-3)YAZY4G6+'KTEX#;)P_;V@'V-!NM7
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M<$^Z&>XE*^NRD/&RV%[-Z'*M^H"+P*][[P@Q[D=[O/"8H)G"*0T4BJ:]0CU
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M@N1#U^?MC2]^JM>(W[L#$;H%J .N%6 ^E-C/L9]1OO/3N*B5T+G)J!$PO!Y
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MH)%("^G+1BX-:>#PL737') WI'W_L[M-0%']D [C4<=%DD>"("JI.A7BXJA
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MODI5H-OSFKK'%C$8H:! OQ@3+(Q&QA[_' G ^^:%HJ@RJ25\SP4VE10HYN>
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M=D"/+"7-2VV,]NC6NWHZ(49O'H,5>;@)0[?LJ@ZB]07MG$%XUH9\8Z)T&Q(
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MY+>^\YY@+2].R"3 LR]Y(;SEHO-[?,I>0^E5JY@#QV%;//*,JN0/X/ [[1_
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MLTQ%A$X'H0PWM1)W.([8/:MH;3S.X9K(/W+B3<(MR8'WO1A506%<&H%[494
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MO%U;A&/E]X#K.UMX>$I=6*N((]NPYMT5W(/676F^@4@]4.ON-/2;5;S$7*K
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M<V7!:4WAU%3=+O=$?;GWGNT53EH9:GI?<K(\1^&,MFW56,[8T"?PY]\D>P;
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MRZBOE/,\=FD0B8ZG':.&8R/8@Y.7+,EGF8O)5/X7 (A =[]-)/('%K!DXYK
MT6L;=5UTU)%'4B6/VBY@QSQX^:7[55HMT)965T,3GMRT.SN,KF-#<J2Y:HK9
M*&=DH<[B]7PR%B7M;Z=R9G&ZG W5#"JLE:I%,CPUI)RM0JNT*U4MRBH9(JPR
MR2=T"(VXSG'ZRGM+O45LT].Y[V M>SVL]2N6:/BLE^;7R5EU[AS9!@-&>>?$
M+.^U=]HJEM92LGBR&OSCB&^QPO8YR/!<_LVI]-:=H8K8Z]0N$ (XI,Y/$2[H
M/-;!/JZSP4DE1-7PL8P<63G&/@M3M-M@)QS4DX6M4>MK'51M?'<J=P<,@C._
MV+8XWA[<M.0KI94Y\>J8XAOR4./"">G58&Y:NLMMJ#%67""*0 $M=GK]"S:1
MGQMLF=\+63K:PMGIXOE.G[RH.(V[^M[MO-7%RU7:*"G;)4UT,8+N'UL\]_P5
MJ1G6D;XYJ=_I6'H-26NNB=)3UD3XVG#G-SLK"XZZL%#.89;G3MD#N$M.=OL1
M8VC SGJFPR5C[3>*&Z0.FH:EDT8<6%S<\\ X^T*_!SOT1 '(V4JF1[8V\3C@
M+6JW7%BHIA%4W*GC>XEH!SN1]"FU;-G.P6JW?75KM=5#3U,569)1EI8QI'/]
MI>]3JNV?)K*N"KADC>_A#M\=?P7 ='U]MNL-=#<*YM.YTO"W&22/%3'NCZ3M
M-RAN5-'44X>&2-XAQ@ X^*O6GU2N!:9O=JM-ZJ*:.XLD9&. %V=]PNMUVL[)
M0G%5<8(SC/K9Y9QX+6V8V3F%'WK6Z76UAGCDDCN5.YK&\9(SL/@O*GUYI^H
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M\&I>'G,L9',\L-\U%?V44LU4Y['UQ! _VL?^%;9CDULNUPI77>DCGG%,Z9S
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M>N<0=DM&R6L<9*_%2\N=\['U)Y>KYKEJ[:FM-3[09K15\4M'0MCE=*W+L#)
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M'5A:TD[R,SS]RL=*=DM+8JL2Q/KS\YQ_.2QGIY-6\>HRUBELMK&K+MQ4D'
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MEM+!G/=1%PY'@&R]AY\UX5<PIX)''.0TD8456Z"(^VQA'@6A4>ATPY4\/NX
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M'&3+&-]]N['B%5I"QW=UZH:ZOF@D$,@W!WQCP "SCO2UO=3VLSTE=/3U=@=
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M)('+JN6WNYVZMT%)1P1RBI,H<"X8& [/BL;>+764TVFZJH?&:>)S9"&G?A'
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M04N <"UPV6L5^BZ&LE#G33,PW'J!OX+:,Y)"D'*FAAFZ>I6T+:8.=PB/N^+
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MS&3.#1PY(P=SE7-SOM5<(S ^IFB8'!PXI20M4QN_:SU2ZU3Z^LTE#4OE>&C
M((&>)WB%V[3Q_P T4N>?!_-<(O-F9;M;V/\ I;)2YH?L,=7>:[MIX9M5/O\
MH?S5DZ:S]LF-T1$0)P,E:3KZZ6:>RUU)5UA8]\,D>&M=GP/1976MRDMEG=/$
M'\7>-;ZKN$[Y7)12.OE!=JB>NX3&"1Q^MPYR?%<LZWC&5[,JZ@M$O#W_  T
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M^HKC-2354E.R"4@&1_$'9..6W@K:W6N.U:X;&V>.;AB)]48SEOO6)[6^G=*
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MZE_/?OE!@U4 J54$1.%"JSLJ4$=5+5'-3R05*G?"G*@H RAR@3*""%(R$SE
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M%(#(SA.'@]0?#R76(PX \7-58\T&ZNUT(B**(B("U#4OY_\ ?*V]:AJ8?/\
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MT3<1N .=U8FWM*[A8['@N&=J>I*^WWZ.&GG+&&G:['=M._$[Q'DNXS'YIX\
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MY[M1I#4MU911@8628Y:P0,F(!6<ZU>YYAQK*JSJ]MQ= XUY_JPQV]-5K6Y_
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M'XB,\).AG)>Y\_P&;9I?%2+XDB]Z0JFM><O+QL/#BE]JN<_E6J_@$3X_DH#
MUOU>'V&-\9S 9!A.B?.K*=2V5]L1]RE)S*:RXN&7:BUV8=9<9\D'J3W .K<X
M L1G&:+W@YY#XKSZ'?#I1G7^U&W_97USLR%K]H6-LPE]"-B,)]MQF?BI_LS,
MB(&Z^7PTU1G0"C488!PHTC'MR',_]1:T_A%W[<'1YKE)2/<4VKRB<EP %\9<
MQFUKO0XT7'0LN=ZBDE(*?29NQ3[DA_E.$"T:WB-3;UUSU5+A[0U+:Q%O;K9]
M8#(@NW-2\&9BP0M:TP+=&U1D<5)VFWC@OVV"$0RIKYK57XXO*N9#(QX$]HJG
MCNUKE0I1IM^HX M!W"X1>C*2 %'R']O@RH.:B6E*<)T9)TM:@U!A-/"7?$W0
MW&!5M7C1IEV+O!OTR\S;#1LR/]P,A1J,8 T"AD8O=\">WC(R$OH1LI#)?%7;
M][@>U$:OL;7H@'..E=<3&UJ?GIJ\]]]V>7%KHOMU,RM-M\%*6K1U1'3$, ;1
MW6[3] 4>%TD^P"HCND;,9;=<>YTHO,05_VJ9RV;C.13/55-$E_Z/46-S)T.E
MD^O9(/XH=DY:_>DJ/X'JZ4K!NSEMAR7%^5D5;5$R4L@WO+LM:(BA*71%J]HE
M\<>?Q\]5&-DYF/.9?-N\[TD\*]H77CDZQJO7DO&LT]!+?M[JT%)W:QY)'B"@
ME--YZ+-95.%:AR$GI_AO\_<_9B^2LH*0 5]>0<UA)+8_(=?*U2G<\2"^%-9N
M5%D+T:+/G2/=WV6<" K*<)L3OAM+JX%Q!1K:>)%9^4$)R0F)$F>O0ZLYHNII
M['\:>TI[\4 "G>"\0D*^FY5P1'77["=U O<;JZS]M(+@X&7-F6[C^#P-71O)
MYYT*K4-_'(>D'M5:!!?5\)K\=#@36&U!E4\WB 33U[AZ;MC;$[OX*++9<]:G
M7#5ED&A[6CG4>$X)C:^OO^;!6.]FZEV;J8%>5,QHZ^G113>4)KZ64@Z\"$G3
MH$J<36\O&Y>C?&%,*KI%F#]HYN "@KNTM,-&/GPEKLIK4'X;=CR@TKO_O6;A
MQY#$<E/7:HV2#'[4;)-K<=W<1)]\<=0$C:AD^@<>R=\GHIWI+;4]O_D@9S]\
M[\?20ZIF-\=W@36SU9SE[=]'V'/KE)*(.^QL,'ML_#JXK6PD?Z(N\3]WW.J_
MA^2?WC8%BSE_*[*+?O@K@Q3845M^RR/VB6;?[_L9]A3:S5FV24C/B1M-^B ]
MB>#!CS'T!NRY[(AORJ>N-M$=,5AD _\3;;;)ND_=ADM:S*8$[YZLUY,RJC%X
MM"AI2SX5!0ZI[-1E9^CT?R@A3AQ07<0E-1K@E>-4=6M>]=$1>_W2QOG[ABW8
MU*I6<.D?<4V,"\_OHGA$2&-Y'9=TMH$5@SH6E1*FE#,+2%%$$^)B2_1:?(X;
MTN3-(I042 /E^[40_IQ2Y(KN(GK2BDT?>XYTCP*".3,>^ -?6>*'0=_:*-'(
M NNO89^^F<SI\6=G&VVQ\0MG (F/FL:H8#8HG=GES9 /<8QGI,1,4X>_1GCN
M8O>;7NT5DD=IT7O*[14X5@.C+#U:3 YI-(*E)*MI.;KL65'92$>3'SY^YAO_
MF>&UB!+XV#+/?^4BQA;[88_O&%\*/:-!D(>&^^5'++N18@@'A@H0W!AG:W7)
MYW![QB-NET\+R\X/7CR@>R21>VEP(94B-'5ZZ-P4H'R9LBV+S-R"ESHAA=OU
M(Z03JM*3(\-:[>S=5>0JN.SL<4J/[4=0>V3??$;MH 2$@6^)7[UJ&M[.5Y:<
MY4"E5/C#*L3V&\@H7T;PBJTK[WYY2Y%P"?[O9462[-]U3&HO-K)50GGAP:E(
M"=A&,DY_ZJI!/:ZH/I[U#WB+LR$@&&3GOOH\]0<G1HGT<;^:8^*\*&R)K&("
M>![X%T!)F8M'7D^C/9\QW21^K,' T$<G++HUMB)*95<!G$,3]2\FY2>;R*VQ
M:PG)N0-^>BM*B@; )F9U X[*;>39G+ZMZW7K\ZX/[*:0:3<D^)=I/4()*?M-
M['%=/*2P]K""B6*?!KS:4WW-Q^J?L T>>!!(R;Q5L4DKNE-]*O+PN'D?MLW&
MS_N(V2X+][:R/D1JKVE<*,1E535EWB9A'73E48_"-C/F7!BK@%D^M3[QF'(T
M+@<WH-_]-/RM.B\(;&3%;],V"H1GCQDKC7IYZ>1:[6:CFX/F$PFRZW4D.EN6
M7WY [2O0T#*]N:HL@>X#=7*3>P4BH8%5!^)^^PY9SR"?$EP]J_?J3TSG(G:?
MS$%+UOT"@NE7K5S,Q)* [K'T2<&+8'U%SN=>'*(^TE?(%Z=[325';@\3Y@A^
MYGH42<B3TA][^,-F2[FK(>*7!O(R;]J9=6O9I8*2E0MI_D%:'PO!$V>1M[+;
M(_+-]*X%GLDC&C&^+(6N(GJQ\LUV0I*&C.T5%4%/DB95F$E+W\T+81J*;!^Q
M!)*Q3%.Y3$\,H2B@(*B^6'^04&^:KG^UE!#0YRYC)@'ZX@R"BL;6S^5I,P1_
M0QSYR/E;7O$V2?Q'L46HA^OJF!3\[DT2MNQ/MBJGZ)(*XV-C^9;')7IZI#8Z
MUO;,?N5/'$:VDG4PJ>-ZE4YARX-T<AY(P6=C[WDC:U2AH,LI'7-,I01C'%_K
M-R77664_/-P3.7W?/H9;RHB9ECWX$[$)#SQ)D4447UJH YRRCI8.TBUF5?36
M I_CWSD^\H^2+WN?T#9P]G&I"H1?\N0A*^'X^T/$=7[%E^[V%;? ,P(;*\AU
MM7-V?=DA._L_RBORV@=KM!N5U;9,;R+F@;=%VOHN8-F%:NE%JKR2%I'FPY,%
MP')*=[KA.E!G>$CP.$,44%'F9%E.LC<4%A)6GQU!9;"\,+3U&^L;_09>2?LX
M8$DU-RX@D]U=](J-=&W/@&-QI_745D>#<LFP='U=2"GCT^,CH 9K$)RM0X]@
M.;<H.;^B6%EL^[JRC^5!"9F17LS#_^D=4Q57ADK]VOZ/&JDG__XB$H_24D?L
MU5O5EV_Q.2E@CZ;XOARVQ[Q\K!JESY&=ZUSX7.+E)W(*THI*G,?X[,PEKS3C
M 'V/= J9'\8<:.L1'(A75"+9MN(>Z3T)_/)JE/D=R\>GY!2PBK<*.,K:7T9Q
MP()0X-/*'9B329\*_5?R_M0>YJ9["[?T[JASW:&;I]>Y?)VFZ7U:<O,V<A4N
M7(TOE.F=J<[::X _O]?/0N2*3FR@?V+U(7\!VZ/+OUZCP>D=1^@9-(J>07W'
MYBP]X5SP\HY:[M,F3F()X04#Y3:EM<"P$8V?.RV&9W'7&8WLW_183]_4/09G
M(<!#\U2IN,$>Z'G3_70U.&71FHE610W(.HQQ_W.@+/"\L2V8J,XI1[[&)[M,
MOI?=2P[.XX&[-+I]W') G7E\4EDJ>/9DKJ77<[<_;0L9&&RAW1"[-4.GX_X+
MTUS)>+;Z4U4M*QH7Q5KPNM3^"[B%RV;V1V+/O"DMVP;/V<1QF(_ ,:/_Z+*0
M?F[KI,-H!;Q!%]FAO.$A<4Y\2618.#TO)X5W?RQ"#F%ZOB&1&^'1TL71E."]
M,VYD45N>F!%7L?K!8</!0X(WU,CT<,QT<A5QS]NJ?LO^WCXGY 4C,[^(T5A>
MW#Y51?JF%DC"LW=29>1:=CO*L@HD,GK8!*L1CW/;*WPV6+]#N@J;HVYV\SYV
MIG;"0P5E!-Q5J/G1(8>O$<!=5@BVA@=B]K)#KA']N\GT??J#&X%N=P?14+[!
MR&%N[V">PHH87+"Z2>X%T[JY"$Q*3CNTN"T +.RP@1VA_Y.A"0Q)F3!?SE-*
M;TFY4O/DUST@RK2^?,)J?8H3.49J0I ;/(VL?!\'.S4S8\+--1*L 6R1#Z<T
MF32U:)M:QY[ 2I_7;M N_P5,&37K6!PT$>NVEV6&T[HQD['>@ZO=-,4";7[I
MMYG:V*1] 5]Y@2I.Z6[Z!7+ZR AV\>QHN;3K%KV)YS\L--GL%)$>):US0QTD
M0LULA<ZK<[9>$B?P6$+8EJV.<!.[#M%:8"W["B0-^:?D3V'^O^;<K]O,\\J^
MJ8% >-SY1:K1F8L9*KF[])?LUI<][)\;9N+:15<%\@EV68%]PVGM5GMO%>C^
M5X3Q_QGY-L:X=YN$DDE^6OE[FQP?NGV/H_\"!I+M+/?^U4P94VZTB;V>?3MT
M:^J3F)H' 9E^&!8G@551E]3U4_-0%C?JN=]:W)O;RQI'#FVMX%MQIJZQ'MFY
M39^((/>V[D3T3'H61THZ#Z%,V&Y"OA%2)J"MS;%]+*34F[Y,JC=&(JH><:(4
MA\+[V7_A_^?[]9ZA4V3T0Z8WT/U.4< #\75M-8Y 8K>#G<AS YP Q"WY#LW<
M"=_9FR&&,3JM-CWW27WA=8\G@Z]]!QA[?7O/C-H<O(:A1JRA>,SO R)# GF<
MBINZP!-_ 6IN56FG09UVEQJX.!\O&;>G8]G+,4W'PE#R!)?/E.]HZ:%JM, T
MQ2VCH37%]6N/;O>&K"&*""C5+GOBSU<G"YI^QM)1!CTIR3NPXO >F/1CZ'%D
M"$'JB7G4DW>LMG^*%8/2JZI^N,^0BU77>C]G+^?^')\Q3;5XJM6F06KB>%33
M' =OT((=PBK[^Q,EDSO"Q^]UB(:1D^T,L#7*=JBX?;R\4:X[0B2+(V.Z@8&2
M_2M2=,7)H3!7,&GMJQJI\2.:"[FM4H7_C1D%:="7KQ/"<GC$5H/O6%TUL06>
M/Y!Q89- +9V(9'HZ4IJU" (16I ]*@7^$"4X63B$FG'[QHNQ O@Y5Q%RYA(^
MVXHI+2;$VQUW$O\EDVK 3?Q9*22$R&$=_X,0I0 G7,A=TB9%<:?5CM9P;-8'
MVP/<W/G%>.-_KW5M>KXS^P/.P^!\58"!4FVOTN-_WT.D45"ZI8C*LK?^WNSL
MP9\^9/%H4B&F(8/(TFY/N6\@];L+MORE_3:!M:;&G"3!&AH\357E0)O5SQ0U
M.*W YM +_3OQ2^_6?=6DT>R1<B$\83F!7"S H??P+^!0_\8$M.1T/]+T3+<]
M]X]+(38R'&436'0L0L_>="9LB)M0^J=R@SY,_#/['K+UYZT7K%_%O;23W_A8
MWB36SN'$-KF7S,3GY%22I_\16?1,B$F!/>60[=>.N=5*4X[(J+3G$Q/+'F3L
M\\?)*B0 Z]+2WV^/FNS4-[9$KDWWO87:$KL,?'7U@"U=[@ /DOK!G:;NJ>JK
M--WOF_XP*W4XJR_YT9_I!2$P_H&9DFM6&L7]C&[; */?!J.JMTWZKI$#U'X[
M,O8B,@/HY7YFE%KTRVL%9%/1-#6\>"(P2_T$:SVQ[(E)^RZA#3U4,;<MZC*H
M4P/WKRAP+='P!@';9^,<*RNV?I0WH?  LDB%T0Z-H@Z]N9ZI%^%P&ZTG&V??
M+G1^691U>=]Z3GFZR-=FB'UT)FSW0N$L#M];;5YS3;^F<&LV& ]L/0-WI=SP
MI&'?KV.DYWZ?CWQP]5J"[IFQ'E2J,(NX$[)NS0:ZE\Q0>C7[,>FJ*[Q^2(^3
M ) Q&-%+U8P.C+VIHL]]?;%4&CCT/6F[508A5@.QRM]5\K/I=#2^.]=]MS#P
MR3>?S(2>E'6C440M^"]@:]Y]!NWA0=9SK2^-+G/"S@AG9Q8 2/+%V*]BV<X?
M>#182?!W20GA@T[Z@V!5*7\!7NGYFC3+S[8##=%]I$IP:/1&XU) _F9 ES98
M(0!^PN)GM; (W,GON%MU>KT$0A@L,?>ZA:Y%[#Z598WJ/S-B''>1X9C46"4X
M]\7(1PW\B3%9G?.F-YU!N3Q,F.F)393NT;VN>6!_.CN_9[\Y0ZU??[X;VS"L
MN"C9VIDQ*4)XUNOQ/>+!>DAD184WGL @6'5R :5^B1<"VWWM$OQ:D&%IW1D^
M0W%UP]F.4GR>>+KC@V''8I]ZY.)OZEXTU[6)3JWQ4"U@,.%XM>Y Z5U2)P8G
MQ&JW09N*MI1 E'6;C_A6[H_E[!&48]>"*WXS+,[>RLF'<&X7E:.Z^BY>E,=7
M>!(#]Q9YC&R-!.2KY.4UB-9IH<?]?3S*N3AF9S.[9Q%WKR3EXT.-"N9,&")5
MYL#3\S,8,[R4%,;I^>2V$0D ;%J_(['6<%YYQ))B*"<<3L@&K+MB5+"+<ZP?
M/FBR58;7GO07L!H#6+-,\\_E?+-O="4SJA*)R?Q =O3]2J#H:FJSB@V79S&L
MDL\][VTNTC24?/&F"&YR"''63W1^.6IFE]O[[,-<A$BCM6>4_0RE#%+O0A$5
M7]$9XE)\:@:,%:TB@BN[1*;K(VU#?G/FFZ6N')HSS0;HK+'E"*!'PN?7 7%Q
M$KWH^FEA/RE5",W9M0>VI*O&/)\J6,M"KBAPOXK3T?99\JK*NQ/N9V,2M8'>
MG_X"0&^%SBQX9HE)G]$8[R9']I U_4X7[B\]$3)VUIX=T;RPX5D<( W9SJDW
M<#316TUP>C6@!3'$-437+5<9J!D.AL]?4?*].56%ZHH$3*X_ES0?V4W+F1;A
M[#+Q+,]6*U6HZ_USI!N;>W+CO)OY*Z[WL,K[^M1(C))BH%VQ8VXYU6,*MC'V
MOG/);>;9.Y0&@X39X$N.F-3(,9#NHZ75O!THAX(:!4_:=%LD@1+$-[M-7]]7
MC1V/+._;--6##4GPP2SS?T=P/HP)BXDC4BN6KU068D!62P6MN\-=E(R<:GZT
MN]B92/@5/(]J;"7 [D;;_06P+PF]!3\S'GL%G!L;0F=X]JV+F$GX5=^^U=-0
MWQPX&S]/2-UJE*I%VY6UF1T&2C>/*X"\T.V^'FH4GR&YN"7TR=UB7'!:+2,%
MC]BTC(-VZ(4FRV*)S[+GRJ#_OG%@6LY;D_V$>D*^4\::3=_.*Z()I%O[>&AI
MVJ6L)9FD?"WK5KNB$USET*2@[T+%LA_9>M(:U75C[.(@+\]^T&V_%8MZ/MW#
M.';GX<\S-]<M862K1&-)NY\W3T;5@9T3!'\JRB$?,-D=^0N8O33*G]^'=AE6
M<0DYLUEP;HS;+U #;3;OQCH67!J6CR.RC1<=\QG-5GO$ULKYVS3ZIB#4)L%Z
MGKV,CG@I3_WO>G_RM#CG:\NMSK2*8=[:?#7MXEB./ECWMRTL+B_OQF2/QJY.
MTW+UNE43,I\*V;";G4P%9N?-QZ<IX1),9&UF$HJ.&#&XN'837>%K,"@(T -1
M?AN[QP]D%-X?OO0FT=AP;'.L5,N??#0D!A!SO^5>7S:V>^Z]K'X0;\:@<;%N
MPF!T"MRW#917W*3A$3-:L7#-;DY,XSU8RA81^QU$/NJS<-S8-WN:?BSGU6/"
M:::K&OCI[+3^$#L+D2J[UT927%'4Q 2RILM<E[QN-F@<C4^\&+5G\H>?VF;U
MZF7EWH@ )("_.P.JK>M6!8]W.M!-^*.&-EG?8\:YEE9R@W-;;[G7;-)5#Q6"
MN3B"7I"S0=TMV4[ZQ*,RCJ6_CY[*\35UFEWF^N4J28("K)S,:!4\:[L5C ]G
M(?MJIJL/;L2R<)G@4:U.[0$9#DMH-2/)ITI*/$RTS+L?L4?^M22XKH+"K59^
M;D\@MT_]T[QKHG2/P%/:70DIJD;&1&W6B,VBB9!L9 L98LKB\(.UG;;98KUD
M\%&TQ)_IM6-C:%F.JNENMHI-"O$Z*G/WO?@/8S L54=G8&K?JPV0&"85:F,K
M.%ZT;?*A56=.#7=9,*H$-R&!#) YD3GJ"'_E,I^G><M5.-,B3K,J,46A(S7.
MP-<8@:CI,##UBH*\J*VTAKH#Q.U$L6+E@^:#:J%U8^Q2#!J"7CTY5NY V9OT
MZA7AF.2E#[7=3[*A,N ^)2M:MXPN#7$M]5"K )_ZAKF9]AL#+O/GH3Y^=2L8
MCV.>TBHSW0NU*-J,KDVWG=@)Z:A2'QL%SV9]3%&^H3KST!R!6QA19_I?0#!D
M6=$,9SWT"0:^'8"FF<"DK+FV(P-CY@[4$HA3@F*VDK%6DBV^[/##0W:]NQH$
M,@069"&2\%2I;NT05%23<FY1\<KT%LNGQ+=PY#%XHG<P+N'Q5#S @=D)<QVA
M]IF'R3=E,(_G1M\ 1M3UJ6&M/[1-'?F6T6A5JO '$J&O]<ZQ?51*P,&*B2_?
M0:)<F</=?<)7FA.E/VU1\U1'*DUP,>X)RM"J]JC6& ZR\$#K3]Z@LRN UI#X
M&%K:[; :$NN;%H<\!<=6!0&WEOA<;KPD]5RV)$6R:G]G_<8JGD:3FN1VQ2XT
M+8KIV3!$F34;PRW2I<[*-VZ"X^#/0=[2?ZV?4UEMH#:XJL*6GC>(%D-R %%)
MQDN*NXL_*[HPBQ 1V">!J/,[:C_3E>@FU"U/(PW(WD%LF=941FZI-EU#'OBA
M*%/[(<:/OFV#=;RJ13>#)MO<\P@?-M#5%?'2C9UUW%;X?SHV.#>@4/#_X>NO
MP]H*NG9Q.%BA4*Q <0A6W*% \>)NP:T4=Y?@7J"X%G<+5J!H<5J"%+?B;L&M
M6(%?:)_WO9[S7>=\_TQ@9_;,FK76?=^3S,Z,QJT2CSVAC'Z_LY"2!W<3FXD=
MAMPA5NJ&FA)VG@(>MI<K="W.66? -*'O]HZMI"@RHZYU@Q*;^%G^+P$L(BCQ
MR> ">R?+TIX5N8JA4X$I@FM1Y'%O=]\.LI=?A4K!Q"S?[ ]--3KN(HNNCQ0Z
M3]NW(1^VR%B4A!,7V&9B/^]?2&NQA=$=IH\AC,GV[[0-Z!WPK\L]IU^7']ZW
M*DE3,<A5T&85G)/CM%VGQ?'"PA+?_=HQ;)]&=*28TZ%C3(C41^0YVL4ZJ_O&
M\A=S7I&KWHVU^?OUK<0>Q*PD:3;3N;GF&0T9)4W/RNQ#TV5CVEAGD<[T<QT_
MA))]P_(%[IJ4H,IRSS*O+QZB,[IL(X=-$/2KYSNE_&&]TRL702>ZF.P.K0N7
M^*]U\XYR.7U"/.E--YOBU 8? 39[TVZ)C2/7809!!S$K;[F3:L^-1>88+Y%3
M7A1Z%'[K;*-;.LUXIQ^4Y6-D;'/[<H,VETXPJ$OXI].(4-3-67BFNIHFEX:V
M FPG'O4S%%8M>B_H_2.A,/Q.4[@G;>M;H1_^JZOL_0%/X?NJ%I8KBUGT:W;G
MN?UJ37==TZWCDO3O9UO!*LL-"W9ZL<1'>"2MQGLT>10!T^?:).H+?G$:4'TZ
M)4Y$>CX'WS9^;86]$>7?_?N9?E*"2]IR54SGA&"J8($L[I <\MP+%[72W:/;
M-*5)*.;#QHLV!W"J ,45#IFT</[&;Q;AF6Z?LHP\%6'F3)KL:#([E8.J_;HA
M3?,ZHK7L4Z)YZ"K'CLO!]6ONDJK#8FO]AL&<%6,9YS:M6\6:[\HYGLY!]P99
MU;GY5>[#D2GN?&];YECTGV-$C( W4PI6W'8]&NJB+&J_CM"WV^:X> JEF=5W
MS>O;"V$2F=EU$0].2"<L2+I_V=.[O<6(46)>B^4@15I<3&(@[J?)-^B95?+W
MZTBMO8V"^=O7I::;K=AM""E /+XIZ3M--%QXW-"8%IEY'0N8R6('[1)RE^9/
MJ>I9EP]KLE?@Q)ELQ4T;U+:WZDYR:E?N$Q<;+)\YBQ)=WE,MZJQ?5\@/L9[-
MJBB!'4I:I_NVO?57N81X\P!'B%XC4/ZM<?U):X44P\R65'E35<.L4QS.7)?V
M8H>"RO>-"MJ*L/<HW)D]SW3\U+E[<PRU]=^:?.P<UBVKM"MW[RO);(\G>TYV
M8,JZD[#:"K7X_3;3'.G[E7S4""/2@ZL@%F[C9I7Z8:$-X]>O.!.?B6G,MHW6
M.=,H4=JM'!7M,19T:2A63U#1]H(V:S_J*QQ*M_CYK$8F4Y=P4;A<RR%'@UG1
M?SA4132^;5?1,V.CE6&)'2 Z83-DUQP2 IV2>(8GGF%)>[.9*ME^ ]DP:;=:
M82#)TB1L'M.E'W:69"R)ZCI/-[WZ409;/8*UU(X(#(U>?@R>=W";57A5S.)?
MV SZ3HV*E7)(+-JFG:V<T[+@. D29Q7TN;G.;A'HK9\"0QKL,=<;_]Q(GGA*
MOXDFC_5'7RX7%JXX)L04I^,E8/4SQ/OXDY@J_7O;-Z2(0&G8(T!)GQ<EZH97
MV.Q*(8:4BJI^%-JU\W*R48Z8-"PJ3<6PJB"Q.LK&:GGLM3-M=A_:K[!:-2-W
M J47%M[]!BXJV_-O<V%5?EP[.,L[Q:URBCW7@GL&BH?Q7Z$MCX!CWE]W;TO3
MI]:K];].%^@TFBX;D.Z[+N:B_%@J=M3$&V;>+F9GIRN-B+7\K:UR ,DY?[?'
MN%\:='':&\X;DK!^VJ6?\WDF6Z[CDHET:T!^*._?)/%?@:$ZE9LKVJBUW$ N
M=_,(6&'@L$Q0?];]KKPL8K,8%PF= T*6@&R"2CL8?11<C")?"L'11$%_AP""
M1!4C7XA%(3X?P:<'B0--5*2()0%JB, P5C&<@T 04#WCI:: NM!4/([88CFH
M' 6'PL871(W6DSS(4#Y8E=,-0MD=?9]/X2!8I6W45C=VAGTG756^I%4XCWK[
M]P>7'FN9 ^OG;%^JO6R6$1"@ZUKGO[8D5LIM^"-IQLE_/@(,/^4(F3AFQU#^
M45![!!0%7/UJ__/9EK#GY(9U:W*70=85RU=3/&:G1P1C),N[=+D]^,9SX5+G
M5MR*Q@G=B>]2IEN>NC"L$R+RO&MEVK%;'ECZS1+6M)J](*K6B:+^]S^^U7([
M>\J"E> +515%QOP1WDX+_-:":L;-9DTQ7=JX[_;6%+6H-2T:Q7=LQ;6*%(.W
MY5\F1)RK8*WB"T3J9.AR!6WE!3C?^_B<QE"[?:B9XB4EU?YO7W_AXN"<20K%
M@Y77?RTU29VOV%ZR.11%\,0+$V0'5&Y=D,ML9Q\Q[QC]>@3\D2-\2,E==CD'
M\^ETS*Z9M54\0&%DM["N=65%@]',5.VO\Y'E-2YO4W%YLEY<^G[YXA<;4,D$
MIW3*]B&K0Z+&C#TZQ02!PS53/[76C>X'[;/K@9R""DHKPA*0NH81R]BXY-D,
MYQ9TQI':?RMYRANJ/L$S9#IYT"QF1 (]Q2'C;-E9YVCPB;'3OOUD51 LJX@4
MFA9;2D&QM6%<QEQU]G9QS@;5"=PTMY7=P;SBXTOF;<XH*-5B9$>0*&<7_#;O
MZ#"!=V=FT_5W2KGUH4299>?B+Y:N6+Q<G0/N8[7"M9PH>HUI/)8Z>8-9A"]$
ME$&Z[0(Z@X*'4P,O0C_W]U/8YK@Z?/8D8F).Z9FKW'O=-!8%:>3\$9\4R]+0
M=9_.G*_+>SE8E3)<V=B+(L4!D";S]+A!W<.0_&*X5SC[E7M8B;E9YS0+>\HS
MHRW\7HY\^>18*O.E\OHB0E/EL2CO)"5L+:#>K<[V6[;[+W45VW#Z5VED_#OO
MO[ ?JJC*&/)R'_"L*U] T38\C#L0H=9#FYC3/3+B;P3K!+"QO:%O]Q4/99#K
M-.17YV.IOBS,&!0O*S\4%EICNAJ[-2LI>#;U2EZOLP/YD[*BL8,&O\.,)FMX
M-,+U6*8NAU='O!:%[;([B'0R[;=3#?6=W-PFOA"%;V+#;BI1!O.G&RK=FUO3
M YU2L^M</._25!J=#YNM*29YZ<X:O:W=+G [<#!Z*=:EE86TWSLH;[DL#R_(
MR>]M)KZYU2@DWPS)'-$6RVO]H<806>6O[,FO7\NWP!"%NEQLGO__R$-W*:1T
M,:&9VIK<WA(V+\%;P8>M^A3([V#1DQ^CCP#E1T"+J:CR@]"#<U=E"ON-GLEW
ME>'KOPO)E^4TH["X%M]O'RAWP(^ N@=[8]7YSK'T.YK_;%C$R!M.>?>'+=H>
MAMJMH+/H0[-:2HPNUG,I0L)/>ENX6HQ+@!(C-"_RO&?1--1TL1@'@!2OJC,Y
MG'>/KH8B_(1)Y*.YVZIKI@04-E/9WS+=8%#/0/EFZ%J;/6L_:72-"]8;M:"+
MO#'S@^T<_6$EUPI8/;/8:E=7%](-*RR'"@])1@I6CD7<ATO L.H(AWDQ+NB$
M^U+_1!W>![QW'#$KLD#E5SM"-");#(%YM:69<'H QN*N_F4'2A2&8"02 1[L
M?!FD ,V_[!"4"UD)SGGV4';-*(EED/#?;OQ7AR&8GS3:*=HGGK<PZ:FMIV[C
M@I/%R5COU4XT@E8C@C%(P VENVI+]9>D)YK4Z#Z-_A7^SY>:X,0$^BS"A*$0
M@\=LM1F8."+D/4P:_;33<?&<CV#P KBRYN(V_<79518V$M(,/8(C[#EZ02H/
MG\F EAB-<S)9HZ3./^OB^V*5D';5(X#PT>C#NXQ^;X*+_"RH'^&"L>M$4IP,
M$V[(NYD<>\J_ML)CD$73Y8M?@"Y!),#;B;SZ1(802=RNQ9U0^%7@?^U]!S@'
M%, ]T/GD@5=_/8!#@@I$3$38QL41,Y5Y'71!C^%Z !^L6-<)Z,KN7OH/@6QP
MSF%NV3^;GKBVJ/;I[FY8E2CY;:AZAS4049P>_[WE>VF1Z1PFU*@0S0F2=^1"
M<Q),%EGM:S?QF(T]\YEK8T"BG=9X"/ KQ7L"LA?W6O!FHV*?Q2I1HB#$H%H\
M68LC1N.$'PBWA1H!;F39FH-?PLD_!\ATPX=8!3<5MP<>3^15J\UQ^#N,?T=9
MQ(,EAITO#_P_'O>B!K+*J,?EW*\_G<=N_'0>>\A@I0O(U%V'E!JM6 P6+#[W
MSM0<+;*G%%+F(@EBE!SI1X(P#/HQ,*$5/A] 9D3 !^9(2:NZJN0C$:-7VN41
M +=0&/!3R'% ^?C ,@8Z:?1X'.%^A-T8--]X]* Z<]DKH+DTJ "M3Q5%J ?@
MJPHPJGVPNYM-)2PRG1(L$UKDT\NU,H99!CV<?K(;40B>NA.;_WD:<]?']D=T
M;NV\],[])QI-QLHWDD? *:O,0\+*RH>QW*:,%1]BRNO4PH _F9T=/XZW'FI&
MO43/.H)*1?*O:J2V5+YAMWN'G=4T[9]>_#V"'@U,#41*_OO<S0KI7S=0;?[7
M3.&_"S#PI RY[\"+X+S)#NQ0],GQ3X5HV^6%P4=6YF2/D&+3UJ4Y5=B\52V&
M;L_OS3OEE=R,\QNB(Y&:]992RM?S-:; UC7MS:<GVG:,;:-V9-]G3_"&=6V%
M6CIZ&9S7+W$-28&."9+/K\*%"XGZGI^?&RH+IZ]G$<'H-V\"+'S>'^I9)"Y>
MO26V]#!XOD%3.E;>8JWW]B:7)7$*52A8PF!,P+3;CE]JU[>* V?/AK_4K, F
M]O49<K3?8"1/,6EIJAJK#'X6%,])Y$<MYKC"*[<ITS&/F68AD)99@&[G&JA)
M?*&Y2"1!=Y_\WN(1$.: EFC-,Y4_UKB[E#JEF>N3^4 @LXG9+)0K6[FX,^]X
MK;4:63U=/)2_:P+VY=84@'[ R+QFT]0OY97D-1G3^[7*1YR20W\[M!N-]!-E
MVSK/8YMHX-Q*3G"NH]7%GK6(&::[O&2]@K0X)ALKC9MU-[CWZHY.&+] -I<Y
M8O2KS&I=M"EQ/=%,T"J!@E8]\ V WJ" 82P"R^4_@0AQ^C]C$P)A$ 3&FMO<
MY\7]87=]!#S]UEB%+GR:IZJJ?GJRY2!: 2_S^Y&$L'R??[876WU<1J6/X<[#
M$)S$I6SF8T7G*%TVOKYE8O*^H25$E]GZW&5U=FZ8$1F4?. @WH5$L]CBM%%A
M+'%&-BGD_"G88XYT0.!PM8A=8O._=L=$")7$C4[*D5?#P<6Q^[_*S+_B;9[8
M_S[D!2^P:27%:*C@&D3]_PO$_VM!]0M(C90L)ODN*%GRO]N1&$# ^;_?-.5.
M_W=;V1:;MTGGCX .U??3$HEY!,92.*IOU$.9D1@"J1'=),6)I!A#\2&!/45,
M@6*#8>JA )S00:1DA&&9J&0$9!2JMPRH_G*U#/B,* C/^L.0!)0CING=)!&C
MY-"37PH4A%$1(.>IOT-^4:)18.GV K*0<Y B+31;&/!&6LUT=&[@5*^ZG7+;
M,NGAM'/87B:WQ6;^EI&^04@:FIOE6,?5>K)D=G*3N,B6U?(]6%Q_QY34QCL1
M[$T*-_9'(9$9U5S,:ARL:J>.3&.EQ'?DQ;.4WIF%"_BLMT7AT^JUEWD<V_XN
MR0=^+"'M,M(*?F9K?BRF]SNW:UJV>ZAORT0C"(<Z5BJ@$UL$]<SE1B<SH'?K
MOA3H$/E6K]-E%3S7H<A5X)64C0./Z2. 5^6/6"[#^,8]6^YU$(';ISZ2,@MG
M7 72$VY8,P$WJ/?Y][J^X?I]?F2*LBI_U<)'0%3(=9#*(+[7:+'X'['@+8(V
MS>2S1&(AF<43=;UYJQQ]VE..N!DO-#9<O3_YTJ+GJ@$XP&;XG/T'O'9$J]0.
M_KA"FPMGESV\=8E]Q@V?3#I)19K"'$3F%5]PB7-TA?3LA.4]&_8Z]@]X)P&G
MH$? =[1/14:<H-[7!ZE\2%/\!-ML^.G J2ZTTWA@J\!NU)0!P^B##=QXE)[H
M.UY5O"V@E"%U?F+MX;IMAG[T)L&J WYAMB+20YZD(7!)S[=0YA% @'J*F)O,
M<(,.]Q2.(?79182B@U<JUQB7"DZ7T;L-:>E+M]5K3[@WHF:WT(4L)_8> 1'X
MC1T)BY#W(GN(&,D@$2W.XA$?"1EU#Z/7:])<F"!B<L&NX"V$43H;-KC1\#'3
MV.[)]=J\=Q9&#L)UG\8""&RVT4+"^4/C4M]\S4(T (!\\V4F(%F/@"FT&EWG
M)4$*%"?E&;8&GHS@-Y+;$</<SX=<._'27#(:4\:S0-U#ESVK]Q4+D'WW%^KC
MDRI"[])CV**XUG+H[1,NV$5%+FX[HX:(!]K2*?J/7*:UIJ,^(H408I'&%GL2
M<7>WKBXEC(,6]O?)C55X!0T^K'%S?"'#RS+W1*O&#VJ^^"P:@1?BXI&;W+RL
MLMXN97L61OE'4_04D:LUY9BJ@2.[51;]0D1O=PN5;HT7A,/_QKK A$:DOFM.
MXZDBB/([&IN:7F8,_2MA)NP +\(B38ZAFY;"@(-F?(K^-@M(\$O)>NF?_O6!
M1A9KLO^2H94>K4I$M9#FG@D>,VT"LY=9,BP.>[ V?*D>9D]M]=HC6QB5[4<.
M(\32+1+1:WB$<+5EGS)O7Q.>J>WK&0+Z/\BBG4ZM!]'']3L:TV.IY=:LS[W0
M<Y.M1=?S'H#B;KAZF6% _HLG%%1J_ "^%M Y>::"$=1#,RNX]LRUM>'F71+Q
M11GW?9XZ&[[7(T"A] $H99 _V$B(SN6\![>0*4:1E4PY@V,9S(86YT8,J_)7
M*Q*"/#7M7"AZ\R]EX(W$%8.0'P%6A(6P?%.,;);W6,5=P-_BVU52?7$/3-CK
MR#?OH@_WW%;A543Q-6=VJ^;T%<](R279Z>UST-.9]C:<7ZK@<=Z.(J"V,ALG
M,YP_I*G\$;\N'<1/?P3(PR&&Z_8QL<G<G2<.,[: D)(^&)):0"3&K4**=)]#
MCY#KPCR&\TQ^YO+GR">EQ:(1LE\4^DV)P[[Y<C]Z;-Y#X[Q>M5?MA%<H&WPH
M316@<\.VU8&B$I*Y %BV]F9#[J X=<NP;/?T:A\O2?!OWY[;=[_6Z)C)1$%^
M0]O?6 O6R&<LY21 ,T0G9"9.9-#$6Z[@Z@P2JU^W$7I'N+5>Y(04Q!7&,F>$
MI.%OS:#<R0Z<=0WV?J^5F?+H[\1*M]#%^""! 5,88S>X;J[CJ!D% H4);6K]
MT!>65'-&*E7%,;\2"U[EH@HA:_;XI-0,\N2><@3@T#^]PEU/S9;@!=7$^+73
MJ#.D__,C(F%ZLSJB>'D@Y2$B1I%6)X-ZP/=N..FLR2NC*"+?R,(#4=AF8DE(
MZN7K6G?"AR[F!"M#.(^GKHX_FX.SCUSN4W;C^Q;*392\@,<!E] T]<^8)6D-
MKI !H@0SDF'_Z0N"K;.8UP$3[^$Y8'C@'ZI5L/'$#_!,@YB[,R_U#'XV\"U"
M0>EAYQLBLU_WC;%USDH*;/-7*QP19GIJ$F[!UYMW\7$79:CW8D7:$W:D&DAQ
M@7!B4LYD)[8QB5C7-7W?YV<):'M0*URY?<(51GZ6 YRSK+'?/MU2$5N=H1$!
MH09OA;?A4^RVF4."J263)&>Q3$81P)]B_B'L4Q'<+.F \R<N1&_>9RR.YV**
M,-KHYUU-C+J2R+*#XRR<S+.N[^?A/C^*S!-KNL%K4D9A9)]NA_"O9'R]D4YZ
M2DF4?0))#7\;+<$:R*JJ#W6CNSNSA[LD\*8-3M!_^3_D5-*@X"FU2:<G'P$X
M_LP3<#%8/RJ.66L;,D!GGA,;U5R%P;0$L> 100*BH_3$/?R]2]PE:F$+7?2Z
M-0!.VSY<.LL3V[)0'G=4!F8IFUN8U:+>S1JR5QLR'XGX(R =GMLH$\PJR5:/
M@">\&E4]G>=29S4$-N/'"9E[6V&<S/C,51- \_ >CK<^OR>6@-<W,98U0+)Y
M3WLM2^!8'A:-Q=6' #/ \0$^>4;F%NZEYV=AQ(^ X2Y1&/8/7+>HY;?SUL:]
M<+B)8'HQ3^@61EC($8U';T'1:B3A>33^3X^"UV3B+OX"&J@U7%T,[F6B\FQ9
MA6Q"2B/6Y=:M=SX*(5/T5TGUQ._\IP>*@(F_%/-7)46Y61RA(H2()7J?J?E3
MK7X%5*[B>/]UG^C>OP# -08^R"?U$,4G9&BCJ2Q-7A=8]SQH(WBI-2DMZWO2
MM'R"8T#=0$@B%/"DIKD,:G%_ED1/4=>#]PBSN*'<KOC17@\5048NVAK23G#\
M^6)TB3OAZCTEQE,NP?'^'_NI3Z,@Q @LJ7P [OA5#R.'9O6OJU-P7R 3/G%G
MT3_5%E$KA-[^I>P$=5IK:T^<-7*7JB5C^=G4UI)G"1M ^'4X:F2RO/_3]@0$
MZ1&@2LV6Q/P=U+MT>E5[LD.\CO'3@.%J&$1,>8Z(476^&36V:,WYD 07U 1C
M^742.%Y40H,(W%MC#=*28'DQ>0-"2J@5.8AY<)%F^IL>*/WG_T3&\&F<D*BZ
MY\6K458YSKF:JWG-4CNTIU(W<T2C6/2 -LR^>#)OQ2=SQ_7^_(]L0][.@Y5I
M<N@3.DA.5 VHFQ(;<[@_CN)<M:'(-:NM!CPQ)\HLZ#\A?DIB=EFF#V7K1V:F
MU^"39C+@;UB@:>))*B2'6I].4LEIF^R$@/)O70UX76#K7]/T_AJJ36#P\D6=
M5?]6?9#X4;;FMXIR'5D_15::/C$"Q#5IE5L#2GB$J0\):@;Q346?TL+H5'[
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M;_$Z++<MH$ 6E;7C,N.&C6PG<@70OEUD5L7J#,0GNW;O*3ILV6[JM@GU3^I
M$&]X%R"W @C1K$_:4S--\UK\H]E70#LE2M;\<;%1QWY<<G55&2H$AWZXP*)"
M)/&)^&@0_9Q&%N;,^1D(2":P BC2R^_;@C< JCLVIA!X?S_$#&F6$GXEO2I(
M^>%GMT,L,5*&'$T_NQY$"_0,=0=S,R27CZY-)J- HXL+S'JAM[:[<8)!"2XN
M+2[(L!SHF>%H3C-%L+AUV[@B"1,Z<.U?26RO!*0VNZ%/1)W:)N8/$\2?/ML!
MW*5>$N!S<197T^+P$>GV#!YOFJ9RV1?SG 3JU\=QY=]E$;1AF.D*Y@9JG!G0
MP_V"43CPRD/,#TLQH)726>]RP[LP%]#D]=Y.D=7!29J@;6:W.  O<G0L1+(W
MG&].(]'@W?)P'6O37VHCNU.^1B;R4;DMJ/_DFA 67#;J_PCP7J$J-',6X5 F
M:S.T#8/2C5PCDW#0[VIJ)-(['F*W.ZS/_D4ZA@%5]Z+RKYUX\2UB2KKHAZ9S
M/3_9FYVD6^BQ(5*KHV?WN&[K'%Z6'-M*/W"\^4N)4!HV09MO"O:^X"K>9G-0
M/QS[6FP:#U9%Y$X-!83B/)5N+-$[F%J/ #J)7'CN1HS+;M;8F_(*4*#8=]))
MW(Y<HQAX[!8*6 M<(;_RS+UT#:A[4% !G":VTGYY(WM-/D2DU4G7>_MD++ ?
MQ5L]D=Z$[#K<G]GCA@GW%C[*5V4205@>T"[@=QO7%B@;PE5*-<H8S%I7M%%V
M@939,3'_WA(.!"(7727A!*V5!9NY#OF/EW#G3N2$\QNF)GJ.2FHUE8U>M#B/
M1O@-/0\;8V(PS?XQ0HNWVM:A\%01+>;%)F:JBC+E^3#_?<U1RE??%"SA4E_$
MB]*F'\C#"46;/O'OW<6!]?0.?*R^CD.)N[P@NS(H,0VJ(#MV8C[2/%QCQC-<
MZ^;<^B0R<PQ0CW7%_^6PSZ1Z(Q)L)Q7'6AOO'$IYOZ3WHNKP]Z^<@S3*0%#F
M7[(7+TA\6Q4BG[0TLY.&Y/R[<G9 -<?!LXO=6T]: S7\I5<XGWB10>>$2BQB
M RGKF;Z=.G]S&M(1>OC\OS%3+C9AR#T"^)1R<?^DS XX77];)9AR>L,_A$H=
M(O-M<WH@UD#^9_;,'5T'?5MS4M(F8>[ /W&)$*<%LT8M.IN?;S!S_],=;5QU
M+G[!_"Q+!H$_+5R"Y'*@(X&J@_E\ME&\#@3,:KRG2) H"0B?H^UJ.;1#-W]Q
M'EH&!.DVSJ_;!F'!3;8<[[ON?<[_'%5T:X"S<1]L#WDB%,8;MK\B/.UV_0C@
MK^]%/=(]% LHC#M8NF+>93WMY2.5NR-LNSA,;W86^A*2?53DH@_]IYV:9P9_
M/52F7T?K(?1*0G45!#[!;JL*%K13I/TH& !LM[&:$QB*'.$(R>4YVD2%$]7L
MJ[O<0'76)S?@O+_(%U*_=N:[@5P*_(REN<R\G_ZB/L&5^RDP^P]H2ITKP"H'
M/(<JO*GJRNS]C_OH_^.;;^^)4EJVOOMOK7D+E'D(.*<T24CV9V'(@88=HK1?
M[@CF> /'^@!SZIY7%_J_&I[2&_F&B?PI'ABL[ VTX)V/?OM(X&4+G[CE)CT]
MCVXB6]>FJ+.,8$99-OI5'"M,Y/(1:?1EE&J6[*43="D()2%<>EGC<]9]L[_5
M_IEY6;9M&JNCO\EC%\'/D]U'F%05WS)'^P<1$R=K@TF H/U/VA,,\4E!< 5&
M07ZG,G#F[ H]TW/_;E&G<6_>V<A!P[JK693Z*V=]75DE'F3UT0D2)["0L?3P
M%Q-H"P9_^9CC\!&@OGGGZSO3=G 5=U4=LAM]Y-.69<FTLEGFF@.G"$SB.:2,
MYL: TG=",YOV3@GPN04^U#Y*@&15629>O,;H$<#1/?GIAN6US&YU""^9RU?4
MEVTH)7_A2L).+31CJIAEJ//6Z=N1/N$_MWI/JLJHL)/*T8^B52H7T0?E[ 30
M560EI8Q!&-/Y>R,7A%*^-/Q5OHAQ%=89Y1ZQ[.M[E>W&@,1\*'P>9A2OOQ[V
M_6M20FP$K^VRX"KI4*#?UH??^A=3G(.K!BHL+AA#FV6>3P/DT3@$LV;*'@S^
MO.9^!$SHOIDW&?&":^)V8DKR'U_D'!97<0@,[Y[-V,=_ZZ/#C2$B7$&R%"('
MC*BG_W(C)JGIL"6++D\U_>7HXBO/S;*G&5)[^6[Z"_,J^AQ/\6(X',U&V6C"
MK*;A>ARYF:BL_"?XW!Y"YNK914O"K>RZ->!P:^G#@WQ^V=FF&?"/_L!*:,&O
M^N 3G<P T0G].*2K2F.ISBE5*'?=NC\"&,/@28_1Q8N^!Q3Q.O#(_)DZ/O"X
M)CA@=?IH"=?(ZG0T,ZF05(ZR,287NI5NKYB@'K@,T+O2K^+_AZ@P"4I9H9JM
M^K\+,X4:C88;>E#Y?!';S)1,,62H0]ZU.!KR[WUOXX,UI2U\\*T&LPV</3\S
M,X+GHDVCQ#T]A?W=S%EE7A,4;RA(%%"C&OP:%U\OMNC/S7T3:XO-VS3RO\>\
M 2O0XPDD$H&?Q>O,D7?L&"CDZI#%\="BO/+0TL7IS1&>#[J);7\>1,3/"R4'
MI<@_?SZ,F",;T1-(H*OVDSI*3!4G+SM!#%WU'85L/G*9^'8$^CL3CL! H#K.
M.V18$'*YK<L;50*3O&#/=T)93EI5-<6N+*-N9@U+&Y[Z:D0C;ZLTOB+Z2\,_
M5WV>G@UWI/_TL[6G97:05X>FPWM9D+2B+!,TS:5KL!W%1T:Y\&%G<X-??]:4
M-D9-_:@DYA&P\N'*9>,U>\B:BSG8W7:7Q#4UZ[I&M<VZ3\]O?\YWX?"VTN__
M/"[H_T]!M:GV%GB6>:X\&F0LZ-'+$Z(AV;^LA\F,)0K>WXU\!/ <.QN__=V%
MNL6C[#^,7[ERE=/6H33#WG!MX&_06C'25Y(RR]1-,_01G_]VQ%BL^X ]5Y 8
M:&#+X;'^\=CE]EG6;::+=M]#^4TD/;L*Z)W3IXGK'FJ\T'\K*%+$P*-@M6>[
M8+O $+>_"RHCUT)CEG3_NVJ#)YA'#5Q)1 0*# *I7ZOB(V7%H0"ORT8_2@(\
M>Z;OQ, D1CL]3G[D=_<8%NLT&3,^8L"]3ZE@[_^<?'1_)C,ZP[AUH_5^)^D\
MX"=[J;TEC_-#_UW:3RW1RZ_??81GSVUN77ZM,]*,LN'F!J]UVS=<!M#'?NDU
MOILX;1M,/5/E/.2#E('9-=:Z<9_W/*U9%@H>#L@C L^?K(5%3I72/BV$"8WC
MX"(^N?/?]:>UH<W "'R\F%':EQ%\JBKBP\@%;N?B0VY/;V[FG:/1X>.-N6HD
M9+F+2:KE(K^$-Q$YC< 1$1@1>"XFJ>+R+S8, QJYR,B2L,#([)/0-01\2U]&
M,4D*J_]>&DTG[D%D&(U*1E;TQ<'M> NDMEP-_:.*R[W^_UA'_=\B-/#?'S0,
MQ3BO\LL#1.^V[/?_?DC? 7;'RN</J(*9/@(+Z/!?JRKC  6I)^@+HAF9W@)1
MT-\QE*'GX>.CT:"_,\=Y!D-GW(Y'I1W$1D&CI48A5Y5W561 )1N3FWN7PC^'
M3.VF%OHR7QZ(C!8$4J%%>0<TD9'2\@#EQ6L7BK[QVQ_PKO\E<LFL)I%:_#^/
M8=E7/^U['S#U= 9B$^IO+Z&5/8/^,V:? \='P/<&REN9 +]/$@&)RW<D3RO-
MCP!9.)1K?6X"*LZ7"?_4Y)6W)QT;50QFPIN%=6C^OO<7"964^G\O"OYW@=6-
M+TA&+Q0/5MCGO#YAWAGYQ6!3W-FWFY<A?<N-"NF1^;IU01.)FR@ : EOG>&<
M=X@);/OX6>_T'+PM^Z PNBEGZ5AZ_?.L-\EKN($-:@4#5D.X-0:[%/G73<CE
MCYU>U)O&T0U_9:NPWRZP0$TT9;E_X4I_HNMGXMXN2:Y4F@VHOC00W(ZEH"CO
MK;14N"$[VQP%*_%]6#M6GX3M)&[IL8-@J(L_WA3Z<;HE\29<L9#5B8_^:EPR
MK&"H!.6?MXKYC!/W\K<$!R1>V)]EBOUR<,F'.N@:E"JL\#:LKR'_N'CV:P[C
M]:68)\OA*4:YF!G/ 9=I&[0J5C[3F\>DF9[^!TB B03!00^":L=03H^ [W+%
MN!L(LA3J>8'3<*CIE;J"L5;B1* 2%R7R>M-2V!_=S@YSVW,.5)OA[1V5*<72
MD/7:DX/0*?I%Y2=/"IL[*;$M N UQ#REEB_F9FVKSEOG0BJB::6<N325P>!L
M=Z7+9=&AKFO'G6\L*.CG9CG6  U9VMM#]+LRENO$&9@)T:?(17M4?Q;6C^^6
M;-E2F>0_19J4)8K0G_ A"3#&.;^9XVZB$\8!%^1%1!10 ^DSHA'E'?#;G_F"
M^+Z3MQ&*'B(>EA\F3K9.P=20HL.6-L2%:(CNGNLJ(7E7?=-;2US?)EXTSGFV
M:J>,1S&Q]&9QE3R9=XX"HZ_ ](6*3PO/RQ:CZIFW@4OT^9,J)<<?7 TDQZ.=
MG**/?/MU6SRJZW/S945LXZR5//V<CRY?)-^?)F$>?2!:@VZD1+1Y1)9O3A$D
M-Y9;^U$0OWDIR=W3T#&YMTRZD6P]X#&DW@1K-JM5T.5>@@UTQX]ZJA0;[=F&
MN??H#3 I6B2?M.:&OC_).K_E@$AW.:\V9(,Q5DH<Q(-&7F=?6Q'3F]>?"^S6
MDJ16JNHQP;*<J"-'MW(4!&X]5QLM>6XF!NRK;K0LB6R()BEU1B.,%?0;"][3
M),DLMBAU&DY,:PW@Y9R'._O;4E!&P5RF/#UV5' 7>7#CFT_W_40^YN;H;D0/
M^(Y:WKQV(F1L6Q24*FL&/2BWSNW&""D=!XYBB1)8E_!*?^6[M1$\W_4R(ENG
M?K_5X]S9QO9KJ4-S[U?0 FT9Z:5!KH8MZ>8T[N3>;/>*!$VZVHHTYR@2I2PS
M51%OF'.U?:>:<$YVST[""_\:;*7I!IIBQ+PLE'['VYE'@)KZLTP_461EI\R.
M:*_#Z+NHT5T_?5UCAN)VX?"J!($S3^=5RPA32G'TC3F'S$> ,3+9#82T>2A%
MR6J !H*KSC RMYMY& K:,4=R,)?;:CU/Z$YH.=H<3T&Q=!Y]OOEU\.[0I_H2
M_\(AKO4]LC.?O\2I?C0;6S2A:X^X7O3M+XUQ]65=1BGYI+7?%?HQ?>AHO3ML
MF,#L<# 3JS:33S:PK(B-\Z78.I' <T&E&H1?AT.'FCR;3&2&<=K$NRUL'=/S
M)=UE3/?D%S&-B'U2GWNSO^L\'YW\'J.\Y"FX)E_[=4I.0Q8Z*.Z:\;SK%/T"
M<[#5TOI_GLO$I@4UAQ^IDG=P'%!!V[S8-"LN[4_3"-6MK[J7&_-/*6XY8[TH
M;?H7JEOKEBSMC8K=*498P6%YY_P87"GC"+<<(9=IS_(.";7D?.W<N<9O48O"
M<X@^$GK^N%IS%^ EU3<)KJT6\+EV[=[V]D/_OF"Q/<$=7%P(0'31HNC6T-?
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M<GJL,XV$YE,MPJAM_;W0.%HLX%*X+^A7)UGLKM"K^H(C/N90 O86HDBS0.Y
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MCWY"RUF54%T[3('C8"23AF&TMW?[HKBG3X0Y7>U*._]@&HN-0U9GUL+)4[&
M'N3XXPF&4-.<ME4\I)(:M-O=75QL&'J3A]N_S\59X82=_OR<S(3GPOUBXT[X
M57=B8EO;0F8VHTW9AYQ"PIJQ;E):#C.+36-^X')ZV+VLI483_7]CVJII5)-T
MR>/0"B>]^=JB&=,Q3C'+]M/R2P$74^M]\[';\F$WY*QCAVUS+:BX?*BTS//&
M81)_7#/\>>XPEZL7_1\ KWDQSR'1$Z:$BWT8(W?PPLM5X+".5SDA"M@O_Z?\
M1++6%45NP1?O';NH[R-W\@_$3LJ>EN83M?%3H[(:L[ELK.P_(QR7"*Y8-]SH
M*)B2,X@=8LO@"&.I.X.@=>P9$! (I$.W)@KX;B/X?7 DK.8WZ5S6$W:A)6;L
M3$YM#&>.@X%'%;;;.R<:+&%7%S\!Q%+5RZHVQ]<ZE17'T-&)?8>8Q@!L#I_W
M%+'HZF&3Q"^$-BF3:F/BNNF 5!U'!-&;GVJV0JIW;Q=Y41GM%H91_Z*,V9$S
M0T\":AM!EKD$+N%4/B2?0>.+2F>XE(A-!L^P7WL;9A2MOZXB!273NS"!'X8\
M]O%Y(#SK-U;OJPN'R6''JD7EXUQU*N^7D-O!^<TA.W?<U0%"TFB\2?:P8ZK%
MP;5=>4J]$1;6Y;/ X0!S&WBX]QTW]S7+-S4$CC]G99DUZ:IUFRY946I=<1$/
M4<HCO@.(T<UHY5C'A*JMXU>=IZD9G',PC"EN6BABR[[LL@F>\HP_?H0G<OO7
ME6*A><.D+H)(-T  O6L$WNYT^HO'S%4[\9<V\V7NTQQQT4%_9]&^M/*P8,)5
M[RZ*Q8)0_<;C0/=BPFX:[5$&E2F&V^WY#5L(<G68?EM$^-4!%X96O,.\3/65
M<6&9MLOD.$*+_OOJX=I/.KI4:9V\@_'V0%A"0:M@(DMHWHER!Y\CY@S<,Y:7
MWL+<5.G>SO>+W/R!5H*$5)^4DQ?^>F+$64>7+=X@S^%3]L1"+HS=K?Y1/LJK
M1YCX2G9BXT?OB<95=:%H;%69$'JK@=PGV(I??03W<4;C>M^GC3&^%MK9[5JN
MSU-3(11+\CW8/YL"YI.GY&9]E)5Q'J@>U/LZZ]>M@3<EF(*C.A31TSHF3ARU
MM2CE$2G"(-)Y,UUY,X!? A\7WTD/LK85E_1%GKC;^Z\6_[.:#1TUFLDJM)H[
M]/:.)%>&NU6K^ C/S? OI"MKD#45U@ZX<%A!4Q'O>>3<@K]@IB)BJ$SBP!**
M6'L59)S8@2%06H1UA'618#-",\L'\5A8P-$VOK7"\'NL/.I8LGX_*ZU(^>H9
M:0_O5T8AE*!RQ0 CEP F\<V-Q/*4ZWGUJ?07?3"C=4]+28C)-/3(A*K36W:F
M-LR3(N^'*@YOO?!?P/?7AVBN?Q.N[./<]9K0&3?@FL^''">D<4M8>9TGN#A
MRO+6O\N1OGC)ZV3?5X"J9F,8<&9KP_SS X><A17JC=?\B3X3LS]/S5(LP,L-
MRCJLHKU#NI=+7??,5X?ZIZJZYI37@7WP@[_?[W+7YEJ^%+@MD^/:QJR2D?E3
M[HV*.&W IM5W-;R;-\JX=HK6\SH_[4/F9M.I3\X1C,0W'3-,GP@^;KGU,OT2
MGM*;)U/D)R"A+BFH&/,B+;2C(,J..6;TB_#["C;@P/@#@-4T%)?>-3YRPS)9
MHCTDXDXL?PK,7YC*3HYIZDCM[.VN9H1_FM6C?&DB;2!M7M-V])XUB5.H.^G
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M4=B%N*UFAU--43F>GRCIUT_>I[\57 UJO\Z=1@MRS&=X@>$S&5]G_C=OU6$
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MH4]HDOIX5:H? /=HS+^1X::,;3Y72>.2K:V,Q<9D3 *_I%=:Y76)5R)/O;=
ME%I4XV)Q:4V%%KF;?X$K?FFL:#AQM(!G+L99ZG'.5_MZR/&:$#(K>K&I-+TH
MHT*2UO#KHR_A6QKX%<M0SWQ=76F5S.<&'ER\>T2+2NPA7QZ=$Q[,HS2HS[+
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M #2;C=19//CC/ DDJM"8E@A2+X'VC2-FI[W)$86Y#1))88.HY>3KK BBS@>
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MM/AZQ3^V#;YQP>;MILEUMM/DIJMB^,:DZ,M88F,,?RY*[&4IE9U5?:K>Q9C
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M ,OV(O9R,40V\JRU%QC$78-XY70,=T,]-SICZ I;32""A*D!QG^7"ZS?UX1
M!]SYL2B_#YK+(1HRX*SGFG&3?;)R" >WH"0P&/^&A6[F=1Y4$I=C.<_)_0-P
MSJR3;6CFY"];<QI1/%W19BQWSW39?H-^\0JN,4MDJ1#]FIUG'TKH1W1[6:FT
M8%G"?R^R\O_4C+LP(AX /@./Q[#0/"ZHPJ2:*I1\5^0H\908R^,-78X9$5:
MB3/EJV>__>V_/I==D"+>>$>;+><?'B_YA!OR)JLDI ,53P8C]?5S]FPE E0F
MJR!,^F L#1<QR9?O  L:V25.@ZBT.X%QKV- GB28G*D:M:!IX7=%4AGAA$&V
M=8K>L+;A8TK@VB+?YXBR9G)8G%1/'P?>$'O31U\^6VII&C@5OVK.3X'[,)$'
MP E\N:$-9@EZ->Z";F%FXD/0R?811<C&,$-0I[G>1*!]IW4E.$* ?(C4&]I
MC4?SU&'C9'8G[?G8H=' 'YEVAP15+[$^YO[KL:)BDJ=:1/Z^W6]C2V$$F^&/
MVV YTN["%FM@>^+\5%)RQG]SC::\&( 7#>;$$@'Y'F'DJ^FW?F47M&>2\O36
M=]\3\!(BW9Z!;V(ULXQ\3H5\NPYU/.^^"G,T@?2.#LU=T*4"Q,%!)/'8\+:/
MNQ>T"1FBG_ EL&(V&VTTW$HIS??$]=YR,>/-W!#7:SF+?@JH%1,GWRHZU(WR
M^Y13B[SC6'6)"SF0K7#^T&>NKEA1YVFGCSTC_KG*XC'D<45[)D'_Y'N?*G+
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MB11OR Z?LW3N8R%PC?RN.LCZ:756Y::'+]3HS,7IV(XEZNZD!J$\=A;AXUC
M3*_:S&),TZ)BJ"T\V"#< 1.@1 Q:<6EIN(T^X<YRH!EC=LM(CQ/;ZIU..]6!
M31</A'%$(IE)H#:)"\WAQO6&E^K$$"@775>&#;BHU<["W75O]P#PT.2$ 6++
MK3%*_'2R&EJ4Z5B?MT:[$7RG!/N-ZMU8@]B5?=XV1Y0-%2P QTN#:I]/F:><
MWFIF]G)?]2+'%*A/DH!'DQ%/,!:Q5^1R7NL8=>_ZRV;EU.10GSM13F?-@^"Z
M"WB]8;\XMIX:?@7D'L+]6&A=%7'8=4B#)#"9OVW;0@/7%KV.HU)W;T!'3 AC
M80DG\TPHFB'2C]J@!J?5E=:[5OJJN_;)+=#OR\W<KH)N#1:P2:;NI'Z;4WY1
MR;^3C<P@T26D]IL;-)7,A=3Z]LX=="MBC.&5(E"CRIE/D5TA>#H7X7M7>[8%
M18F@WCG*Q2<1-)I=+LSXVX]:H6G36OI@'56>'2><==00.DO7K7_[14'V#](?
M<G5YOM=-'^8A+>JF#&=I15!F-N!QRAX;/0!HU0EBD9[X065N1@$?6VQC/$,.
M1R0W0\?L>[-7#[]/TO/*3_59#X &9!#KI_LT">:L7JRGN;S4Y5(>LTM&AB_/
M+[DB.JLP7ZBN/JY$=:-#_^GNFAO1B*ED2+(MW0-@4;N5J@1D_G32Q/M&(FO*
MMLZINLVUWA* -X</&AM%)A1?DW83:L=UC3/<6O^@-B)FF7NGF<1OE^Y/ O7,
MS,3<$/G@>ZB^9H!T'XK!9>/IIF-+V[O"N1".\_Z^$37.1/9)'!-AQT#ME@F%
MV0A>60K. R6ZDLJSOO;;6Z1;EI>,X+X?R#-F]!M]Z8Z-)J(\&.$[(U[F:28F
MFH[LMGYV$:&7>BF41-8W?S/UI;)C]%&L^J@T[INOR)2"VJ(,.#E.:MZ:1%.O
M@80%?#C2-C.^XH4H5-/7&R+(SU,3O]UXJ>K^_JC/ELJ'"0DDA-? PA9W(=%2
M[Q=B.I8]OY'RFJY >'LU@<FP6A4KZA^J VU)N_$0 R0 (KW89HE6??WV49A8
MX3;2".C-)#:;8N!MA]AKLP^+.PQ1TO8*#P!31X=C7?&/A9:H4EPW9EX3>K09
M"HGF-EZ2Z+G;":CX&4B!2 QL?@0KT5X-Q%WRW/6&&@OW_$W5>;]J>8>N0$)N
M6WR ]'9";$510CP! =V)X35LT#2W2FS*P<W$Y'K#0-$J1(>2!KT=,?N&AT!7
M-1,^<-[O:2;.B'B$U4Q:=9H+D]T$4=KVI6$:@ZRNF9W//DX45Z8=&#^B WJM
M=//#*90.I!M>SK ZD*]76)8>=8*-)I]$[Y(<?A"G,J&S_A%++38??7\BGI_:
M=QK+TG;/F:,WHT^4=IU" 9A/P=3GKU0_X8@NU\+6F[,L=M[_K:.C=R%V@D\
M7C%A+MKOC#J)1;PORK9A#6P+.["5]?/F='L -)4T53O0R9M]1S4W3^AFF:C#
M@\H!CSL7]BN/L;?TO"1XGDL@V(E^B\I$?0-ZV!56]!\CB3;G4CTZ: ;ID_VB
MWL4^9F+NPF>%=E/,)I"0-"<D )3P@LR!7R_OJINEAVZTS6,/\[W2+HD6 J%P
MR8#FB:'9:G+Z+&-'!WU-'CK:KU6!@(;0U)JB6DGN8+@QV+?J<>;X9\90V>GW
MYWH,XYG!@,P\I.)H:,<RM9O):*;>"$'&9&X@\NG,U9@]!I4))-\O3_ N5)[<
M.=9?>SFKJO<]MX7?5VDYZA3/KQJ2"=Q#Q4MAN@(/@#](8>58_5%72#M&O;PV
M[[91'#O+O<N\/_EI%IX>A2HE@)A[(]FE[-:7/2\!/(6GCN\P,]K G^KZY")O
MMLU)#\ALHIL8<DB(C(.AS!OH"#S:^8NNZOWUAW*-ZG)?=J\KGWDSFZC*L:-'
MD _H5 )R(+T1(ZVZ16\[C[ YK--/U[HM1?3)U97T80*T+8!.$2@$YHKITWK=
MH9SF9D)3KV(MDJ3Z "! SILG"YI<)?P*<02!UY*??Q@7]EU5-9SW7Q36B&/_
M36W'$]7)(W*-W6O8B+)W<TF/$F15T=(@=!+*O>Q?L&+2%S*<(7_2(C0INDYA
M3J/'KKP?3]%;6C0$1JI5LT-;Q=Q:872-#CDE3M^+%72\0D97HL[VK-YR1]I]
ME?A*D5G<B^;FA,5>,)A*JX69\0'@]^;NI$%NSEF3<=+6%5;[KHH7ZY,?+Y(:
ME%T;+)MJ(-7:-VWU.BX_^T1FI6?1EL'T%^-VU14R;* Y=9**M$X4Z,LW$B?B
MYD4,L9%NJ%'4C=- 9SU$@<9S:9^W4\S.95E1A4**?8Q"O5JXE6)<B?CECWI0
MP4 @0]NT5).PS_E+5,*!Y>KFJI]$:6XI\=(!;(IY-GP$EU7^=:2_/>(L;#L8
MG?I4E=NIA5<7L&8_ ^LV$69S=%A"^F=94_48[OO&;YRRC+/"FM#*L5/DPZ!(
MFPGER!*&ZXW/>TYR%WQ1VID:IP["FKV5ZLN/,&*DII]38(%KR\[Q)SY0O;@T
MO7I9EO9NM<6'+8OHD2O5>]@X"-]*!NX2OZ#PK4)R&6OT^ES4,.1PS;GG1^6I
M5..TT[@)NE:]'R4&1NV97/2W9-5WRC'@V/+[8TPR=I/\G)KX Y+7YXXDHPQ-
ML-M6?P!TR?EYE^58 PF%H'\P+L.SFWS3@)=(%B95RPQZ<KM7>-D_Q^HH,*Y&
M*H2@<]0.J^P8"=Q-B"W,,U5I8N<5L>"1+]/8^QG/J\N1$07ZHS7NDOJA7&M"
MW2)$%XA@!V9.,@^L4WP:.T7.88&Z9\C874)"$UR_(/;"]WCTU[>(R(6FRZNG
M\2:;#X#+!"^TIC?;X)B%QII]$JEL!C.QV.E4%4X_A1)<0RFN;4+D^ZM_\O^>
MB O?)7GZKV3.^JQ./66:2JC0MX*9YP-W1%;P8.P,8V[KS@Z8!&P$I*/T,_A9
M7%8EBVVR,O-KD@F7>TD^+1,N)^I=Q//X[H]1?B]6.'2,%#7-Y/_/M$7RL3A1
M/I!BVT@*GX]HY+-===L;SM^'@]^K?I>$P-&X5[6X4)\*YVANF-&!R'^OI']%
M!-')G/4'<"W)+;%Q9FEI/+G:1LXEU3]PR!>0FGK5B8Y'AT3=CF'-H2L@%4M:
M4^//F[-1&"\Y<_LRACG!>&G$"YU/#D(HNR3[^I"0_'FE?SP=5TA+P^YT],XQ
MH#KW[@PY%?Y8Q_)[- LOEK?O8XQ/*8S+T^6M.2WM\LTZ\&\6JBFS*+NYT<WR
MAU:O"K*4M2U0T9"Z#G.*@^.2L)U=/-8LP('[!"/H/[9=@(\@)ZZM>G^OBJ3S
M/9W*T4AVK,'9J?S]D0ZPL#@-T.^OI2"<!KO.C$@]BU/4EF=,42).''2OP0K<
ML+#2'CR?'$T2+7=S/P)C 8&+<%SM403\,62$0;GWKY'61W+.-=\]\XM^[T %
MI9&(^QD)3\L^ZFLMTM8A_L=#VED72USEAF?H;:795P7+<@)BXV/1V4W(=S-*
M1DM&B _PO,1AY^',ZF:&4DKF2+(MKJ\B.MN/=-*D=2Q?'V24R%:.K3WF"2_J
M+=?CR ?6724\%@:(-+7!IK2*C%/,UOGUG2A %(ZN>2])O3Z3+X>,_CZ? G7.
MFJ(OD?HL'+/ZAZ/-2 ;@7_X#[N)=OC;(0,'>%.X)D#9=Q_/0RW<Q6"T0HX\'
M^.F4#5;6528?5YWJS)16]M%EZ/")EJI8Y93GWMTB(2]Y9X<_Q#PI<Q=I;C0.
M@<<(EPSX(4 0^:M<Q;U>^YLTC?L!F^BD#H:6\J(H(I\2R822^HX]W[ITUCO]
M^4EG7$C_G6P)21NJK4KP[S]]*-<<;"MQF^B94GY)OG-2$U4I1EF#,05J9+'O
MYC(BXT5BI(EKAL[R1YL*D09IDF"2.M1#;N0HYD%EL7_:%PG\G?9)+'91@7\Q
MD*RN0KZX[PK)6W45^32Y&WBKI7M7?OL4$E:_ZU82Z.&[AVH3\Q85@R2J:I\^
MH1YYPUJ'"C>%+#O]J($"6>W&0!@WED@VD@\A K4?4J:AC$=9=:Y3>/^30>A!
M3&\9$7E(QCD#^NPC\66T5QI?FVC"S%<L4*0=MI]P*&T1GB$M$ &(C;:()[.>
M4/CCCA,GOA.E),),NIT P,^,-[_>@)QK%950 S<#ZX5S6G #DB/7D"$RB6LF
M-C?*@.2XG?GFWH,_#ZG7HH .P+\5XL;Y%T%(!&EK&):4H$=BV7%ZWT9F-SK6
M T"=F3&VU.L(<WUMN0KW9Y'H%9+(ZOL8EE.$&5QR"<"VGY?-&!=T7+4^ &RR
M)A4?TS<D;_Q1H\@2/\26<K4F-._]M.GJ:=H^$DLT%UBKW[QBQ>VY0OKTIS5-
ML!4U)4LRGE":9G%I$>S1P2%.NA]CN[L#G3(M*@B,"X=PD$Y(,5-:;#'[R!X;
MMF>H&')(>V4=V(:4E&LU&ZO48[^0(;F<Z9;EG+S"M!X[909T)\B*CZ(X16 E
M5<&N#]&M1P&%WR S+'V)"YW7'@[&U]T>MU^4,#8?>7F-KFJ/B"\RGEQ3+7$Q
M"!*N#D[W:= <3G#Y1/9\'"M>-4CTRJ.XKB!YJ>6)E@8Y.T,\!,D;F4'HOI[(
MA^ G) )"4L@9-M X'YQ\Y8=4;[#-VEUI(3RB+.22>=7_A=S>D;GY1\]ON"*\
M$4C_;RUMZ%9IG^*C(]M\A\LRJ>'TF).+_RR"7TL@X2=9QS*,MH?W'OK>N #Q
M"+R?6";4V_)"!UZ2 ^>]M3:KN.O=+9>Z)@&N=Z^J>\4)""3_^:?[)G&QCDI&
MQ/M^1CP Q44O%U35*/$N)EE)YMF(S'HV][.@?M11S*_A@8,:>/W$Q"2OHL(Q
M4I^)$>4$24K89+W6H(W')':45"+^R)F/@ID+DMH*X<S%\J"5)""F1Q/!(CX3
MZS<#*+P$Y($T$*:$/\TKM5//C,_Q6S%/W43D-?8!#X"4I;M<K6F/,OE:_'/P
M Z#6:K_S+H.&[UYPLY0N>'WMI9UAY /@;VK>&7?4_<V+\,7G4PXX98@J&(:5
MGO_(ERWD1=+F']>_A)<? /T[%#MW#M4JRJQ-2]L&!!CGB.X(&^@^H\5LM3?_
M=A(FK-0 -1FEVWG0(62[Z4I4B^-N&4K5;* ZG)HJ5^*9PD4>UO*R$2/1HR+A
MXL[[;%>048-+18U3S=AZ_I(O.!K^,J&>.S &O]7^#N_2LE70]JV00HBV6=7I
M>>5BV_G6XK#UH*6S"U$]RFMW?O(]1%*'B#Y/(832JT4[V&"PL"#1/(:24CX,
MC)M$W701JH\:G2&P0ZE8B;/RV3'GJJA"4TLNQ:3"Z1/W 9NEM:,X]0;GF1QT
MPC!O?NN 2WV.-5:S"X8C7.[0NS+D>FI(J6"P#AUNT\VUL<-?6<'HI=ELE#8_
M\.G?5=T^./PQGP1P7?J*]\W\YT1--RTD3M;R%:QT=#*M&>9]]GO^+--V?(G[
MU" #5H$HL3D;;<N>(-X[7]2;Y[]BIGSQJ]$  >&R8B0$TPL,?N8EW\K;MU,:
MB).+PPC?O X_=R_(R4_,:*R\M'6Z4]TUQG_KV3-SWNKR'I5(F:MPH?N6M>>%
MZ_@/YVDVC5&%3Z;'I,?VRV#OGQNGP4EJAB;C:@,,)@M$(%E67%N'[^OUUM$6
M?!@3LFBL$L?09/K$&C+8W422I:>KO2\V2JEM77TJ.MPN]ZR!\.#EKQ+ D*O>
M?J@^9P%,5Y?9"OC2#P_3UM.76:?-:C?8OH1X@A.FH+=*MMGP,4INJV>_X0+R
M$\1#\LQ'4\C^.U?*3F-ZH/CNH?ZP071E4KVUN#V&R'?:I0N*>I'A<RK)*) E
MTWILY-7OHV'\Y[9"OO$-[]W )VI2;D<&Y9VEUN7QJI/20F5A5T_*K9VJ8"<Z
M<]$6)(??HZ)RW',#A;=8S<L._I+P2HM/\>GM2I8(?H.0_TP90R>[G&EA$YB;
M%P&-U0RJ\A;4*ZJKHMH+?$]NU%EUQ;4<NC\/SQ[/.3;.=P[05E"F3%M&MY?9
MJKO_P_9J*J^<B)\?FJ#DJA\]8;R3YF>9X*H:6._!=%G.J#V+VU%W>%#":&.X
MB>*N.R"4N*9?!-K9(QH?5OA+CX=K:4_IV2DB_#R]H2T\@P6?![9/L;G:/]6I
MK\[=PLGS@Z>-GB2FQ>IZRI ^(-SCH^T30%TSI(FT4+4_)%.GH<,)896:JB]I
M<#K O![UZDAO<M^_3I!M9#=2?B/.,_3=YG79\F?Q!\"!Y@W?Y$(K27I]I5;G
M(KM %O#YH6,+IMRK5V^^?L5TQ?PJ9(7WR:VQ(AW\D7^\ROD^''XHX$/)[/@;
M(V!UH6#K>J#L1&"YJ-!$$JP;B@ +P#H'/6XC?'7.KI?"-F#?OGNP+T0 YZW9
MG7;?7T)]T# J&P_-FM1*X/H:UV'+[EXY%US#F<^;Z4UPE6DHHP2+KXP4/ 3X
MPO,DC$+[_XL5P?^A$7\IEU>[ ?!W[9]H%I]3,(@.!M]OU$&Z-RL%?P>?3V('
M$4#+G&.@6<V)N^2#,%MLCB&]J]^]#X#34AC*J=^?MT6LNF?\%X]_GA-9#$]4
M&>1[E5A^4W '.+A',RR6'3>!/O.L P&\EVQ"_/,0'YK>4Y.^*"Z2 65).C-Y
MJ?62T-2S-K'_O#;O_X]-'97L/YN%;/]MLQ"IDV:47,+6HD'L\W!7:3[*P-CE
MK$)RM:>)&6S)[_B5A4KHS$ "V9O^621@%]4)7'H72?[YES")Z6"R_B)C9S'I
MG:Q"S)(>9>$6=4#&5Q3CK,CP.'L/4_<B#/)>";'U?%ZI9:<%8K7<%.'G!9TY
MN#'$]+0F3!&T_7'^7[%H@[%4(F,H[ M!,7E905C2])CTH+F]"AX5^+,%S/R9
M_O$;,8QUMP> Q40]U9<EE^(+?^7>:,:[-;_4_<[]U<?B!#:C[S]\J5X$ SOK
M>&3@95M1<Y?3M6)*>'_UITSH?34T]G]E-_L]EBBX_':ZB/, <!D#2[4,JTS_
M?%F:)F6(Z5:]UD :<Z(7;:ZFRZ:IS*$E<WDI/HU#5W1LM:-YP6PVR\>+>(\F
M+[/\2@I!ER$"^O8YJ6IVWM"V;G2L,0K8\P>RW&;4[%OO:>53H5MB72O<G[A$
MD"A]:4 7ELN?D'<*$VN,S(#GS3"_;#/\R62=XZ3SR;B7$#>-D\R#(,IZYVHY
M/(<+^,=ZVJ/V7&^OB51>464[OTJER9R_I04&=1" =W]2U%8\6[Z.JU$>5F]+
MC5JACZVM#;@ @P^OLUT\!\[+4MD^[<0 LN^D?0NA-EQ;K*PB7KLD*'V;"E;W
MBER?XQ+&X?5C@D^']BIK/LV;8.OM*GD>VC)G57"37%J%2/([Z>,_?QE%DR?T
M[GCLTN(LTCCD=E.M[I#+;/"M$+TQC;;PN_T7^Y2%D&I!.4IA(+Z3NWP*]3/R
M(1)M5CIC:(M(VYBLRM'B<]//]EQIS.<%N5][<!?/G1O%^(M>7_6:V<Y#CCN6
M]K0-XPTM/K>-'0UAWSO9$EVW;<Q:U@XF)C[!Y:E/?1/H_E[O#X[[6TK;F+')
MF:#:%^&"'OII A$=Y-/%T;+Q<RFN/TK2J2092&1"!#T^L+"X6S=^<QS)\#[R
M?@'-,U3$RWZ=H2TBLK7<Z-62Y-2XK4_2=RS2-B&OLA7FA#V30>BQMDRLM@TF
MX4Y??U&BLQ1A5JIN-)ND1"K-8G8IR/9VF\0Q$9F82#-6O#PK,RH8M,[Y->&K
MKCFNTOT;X"1L]P&7UF;*N>^#4HW<] ^5F3FK?"*>>?%;RL#5E@-!+B6#O+<5
M-:KC0C&RWAY]*"A[LMQ)#63YE7I*:144G\L+ZHU>A@R$7,]!FO5'#'3/S7A2
MIX3K5^A5)F H.4[8P%6JMAER*FWSK+%$SS?S_6"($(M#G[5N1"8)1#VG=D'A
M,-6+E3BN96/(V2LAK\?RSPUVBUI]O)K\&\A[1&Q'&J-#N^#)EE;G[/YL5-P<
MAA^[.>5KW'/9H<YVUIZY?!O7/GV&MBEY93K'][F?,7L[C!H,12V;JR*@<]L[
M>G^.PBC3S#/G:^(7$^!@D:*0[9D['&[E0\:W,4?^4K^EW<NYKL#6N=#Q&O6)
M"96P30=SU_?5G(ZNUBWOKJLG/M7-TIKRSI(QY7QVUZ>T1U>2JVZT6 #;QU9K
MZVXAO!S%O;@B3N7!!IZICM8XUQ^4])AVWK!]'R! ?]WTF7^=4%D*'RUP=$+5
MX$QX,I'Q6$->P)IL6,KUXZ:KX?#6(/_.9_4?/.3!H:SF;I6(OPG;[_-LB'%8
M<FI'WXT>O"+[8[=VP6HR.5-CEUR\=^TJ."5=Q*;I',<SW67R;0K.FJHM];.E
MHZ"V3AX2Q^OY0HA_ "SK1F!/-D=M2*I2/#S[J42=53(J1!:[\5LZ]=6QT>FV
M-?$9/#=C3)X!?&3P&ZYQF-F"QC,9-N&]K<A*/.4IN*FTMC0T4S"] K4'0P:<
M5IL8KK?SY^2N0+9QE>LH7Q?N289-1O1LV4>H4L.R&U$(3GZ7Y$IMSR8F*IOG
MQA;F)J?JK20,S[N@)2+HF&8M7X;M64\OC^J(=P@(':_7?</-E+O$+6Q&(L,N
MV:AI9* 0(]BN7?J58$5Q<>UY06JBG 7KV7$'[8H7Q4(:1P1)E&O Z%#*Z _<
M)['S"PL'FAD7J;ORZ:QHW,1X$&!%0O#,0(N]4,!@8$/J:4%!2$H:\3$O[VGG
MNW.MA3@+"<G'$PW!0>_[T-CLK95C]/!*)^.U/%>45;D5'")$\2(1GV2V#_0G
MI$; \X^+5DBIY%\\0QG1O4.4 V>\/R\I'V>(",UG4NQ<JVN/&FUZ.U=WG9*;
MD^+8V7(J1T/M. XF3J<^E3O9\@32;SR6&G_WSL> $<^-:=97/L#>T?M3K6KZ
MD?]UUT<W[_&<_VYIU#]-J+-:,>7WN #QG:JD_DV5N1U0QC(Y$?:\##V.5Z+T
M6=6(M7!6FJ57,I7ETB6+V;C+"FPC+=(QJ98"*SQ48F:9S=K]*X'HP+'ABSAQ
MEB>=L8"*1!;<U\<B#X"]7S^TQWEK[G #17-$-N#?P)!HO_2U(1:'*M>Q..F
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MU6MS(MR.QVC^8XBS:6[7\I.;&X,&CINHGAC^8GF",^82EB:!+#"00SB:FE5
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M=?QNP8/9> ^N.3'_W9:^(D3T#:>H#4JT0_6^?&89[VRL\,6-JR($S6-Y:5:
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M(=G> >($FH37Q3"#7G6R*2RJ?>L^MDWO\[NSX6WV9BKZ%,Z9 1AB7:.A.S:
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MBOQ.0@JIAU8>B^'Y\:W7ZR*C^-LX<O,3GW^,@(&B750*='C+\&C$E%MH@;A
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M"7/]7S4KXG<;\G7C-] : 73SG8MVL7H1T,ZYEZ6"+)+BH^KXKAYGY$)-GG\
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M%'SZ +A]8;;O]F;+<IZ(^C?5$($Q>NK!+7M."8R[?@;<#A7-DA$D2<RSK'P
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M8-/MX:1(B<N.YOG]%MV#O.HG=(N1HXEY%N:M\QK-I0F'$R1FFWW][+*9RI6
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M >14Z1O;B*,U1,1()6/]R870Y:=5]6FEMU6Y6G1EP03,[CT7L:MV5%+S&FO
MN5T_ZF&.!9OZ<R:"XXXZ7"X9YWPW;;'W46_"P)N(J0.NPV!;?A)">P2<1_(:
M>#.U4 ;KB15GIRZ2L!PXJG@V7%PMX(TT\L,JKN:33H'MB[D!BY'B4*C)3&0P
MZ)V&OFA%?Z@'783KJ]CQU,MALF(1+$E3>"F[GXC[//51H1?84FPQM(P*!-LS
MI["H7G YQ?\<-,"*\S*FI</1K4!W!$Z#O37"&%X>K#SFR#F<G5UQ1S,D^?+3
M(_J1M,)9>^!S>I)3Z8$)N0,*WD4J4>]/'*=:$&7;]Z74,HY?NF;N!\3XGZ>_
M0<POT.%SV25IV60QX%.)B,X[*O,:A#D(EA(5!3W;4??46W?<'NMQ^^E-:.\1
M3LE0BS/HQA!Z77QXO_3"^X.0_ER?+T)G9[D%W?#$K*1FN7>#7IP:]L[OJ^._
M+NT#+%LJ;NO %;&75K_V$XP8"%K+J&3+W\(6./:_5OG<X;IY<M[R#7CY-NKV
MY>S\9+BJ9[+>.,_;S_\'C%UD)D3T.C<QH'<M19S!'>^=O'90\IP]%Y\R_YI^
M719VS(=E:%]<0G=U(TOTF FKLGYBD2D=>UNB&(5CC0 +5]?:SIC^W?$@T9>^
M:KV9S[;FY)!ICY2P,E/>JNN ?_N#6'YXZN) RW14IKF%;LSU9,D*K/F.O)CO
M'X)]L4TM:9V#7H 2?V3P,/A%Q"GJB:=3WO&O-<*@6?;T/&LF@ZJW8 M?"JAR
M_PP;[G41?^K0C']:2G*9B'? '9#P7)4"\VT\+K M_!V#NR1O'))0BVVHK*-A
M7]@_+\2L!K("C6*]HZZ S<M.3)*-CY;H%;PA;@Q/%+^V=R3= '*]6&MILWZ)
M?0Y57?GQ>^;!EB;2N;$Z&"USNEL/0=&.,#YTC<)_Y3290E9KB;(CO-"^,+(P
MW2E(K]-K-8/JG!#HH"D#01AP7]%*5)Z/O+Q<E<%#EH)7*2&*;EN-OUNHI/68
M%RPE$@/L$&]-@-[9/?%)+X-:9NM1:L?.GN/&/,[IBS-_Y5SPQM6)DL=\;NLU
M^TSR*.=:DP @W/Z/)*V1X "]%N@]%+;(6Y=_(+VVOE>-/F96]/K5Q+-3XR0-
M">%L%Z2-K%D=^*$553[%(Y4,&\6ZYSZ1W9D,D)U,BC.XU/0D#)IC:MLKZ":%
M]0R['.T2]N2NP+[Y(F11ER8+J<A1RJOE3Y83<MEF_JHS>Y^[LMVCS^F +[#+
M7@O>8OSK3UKN[]4:)M?WGJ594=T(5;6L9#&B6M]+:R)H3M4-'F#G0C4;T&?#
MO-+;J(X?_3&Z',GTBY9WL] PV'4S%<45FYX;Y##+2T\BZ)-5BQ#C?Q-Z5L8]
M(7T&]VWC L"&$HE_]O"GM6A/T+YA.&A=Y8%B)PQPP*"B;.+!^"RMG7S.-Z%D
MJ'PBNB6MW^()3W7> V/1$E86)PCA\$-GPPP+;/N&F[F [_;L?C)BU9TDE_HJ
M.FLG^X#3I^N/KM<_2K=("J+:4#%[]!;D2/-ZD3EE_(@1V@0\RQ5J:WO4H047
MZ"T:)[DO5#ZM]FAES^C^:X.N \[.12@PH81F=E#9+:C6/?#]>39/4\2F$.R?
M>'UJ?X O+'4IRO4V5)=Y.R2P(O)L/< Y_\WP1GZ"6^_CX@DX)=)-HTHK^,UT
MZ\@L/R\L+HIM'?DV*09_[=LB?[6A )6])H$2'^7;%U%UU=-]?FD+;_M6RPL%
M+93;,4?-4S\\&C9'J)?.TPH3BV@7*+=;#A:^JKRVTQKK7Q[2M@D*8F56B$NA
MPH%.+A=\@7E5:64)![ 5)YS"YS(RS>@^BF,X<QZAP%0XT<JR( /7_]05F>_'
M>AZ<A#E57*C,7@@FN?H,S39#U"47?V(+X\X3W\G3*\T\HB!9N?/UZ;=H2B]R
M,'KPD9C$[ W+<5^GW>T"RD5743KRNH6+DPL/G/*2,L%YX(<$H&5MZ[.ZSNZM
MG>^<#X37S0^#W[<Q=+RH]R*K:BL(S%[:X #DKCTIP279V0MZGGC"W6-_AKD+
M*&Z(X_IR?;&O-K11-$]^UZZ3N<F.%4CM2AP#6YT'QD5!59=?^2VH&+HU%@)=
M+X<\C"P#6#+"%,+""FL6\QQ;0#:]#N.F/);]5:Y?J$BB2HM^FZ/#:GKH54N*
M207UA+2PF(9Y>A4SO1I4TB[0(O!Y994E$U;%M:4;Q%,'X@=2Z[0%M47PPAQX
MP$T[O;.;"M (K>S>RX6W+:.N-,@EC?/$M;O?%%57I0\W7!9P$ZUCX*\2L6LR
MHOD=P]=\M4I (B"DO\)^ U",P<U PCW15;'&?:4GY=R<TT13D&'6CWDUO<A!
M9^NT''% 9D)<4\SNAQ4Z:^3.A!SGY]B).X4+)?4F)11,Y+Y3\FH<>EHF(O#"
MLGF?$H]0Y-]LWMFB6RQ!+J(.=0)I%T *BIP.RU1M(@R0:VLBQ]O_D1Y@$JYE
MJ.(U9UM'<UL056)QJQ4X<J[E R*4B.=S@Q>*"PW[[N>URF:W*.G\Y(Y94O5\
M]";#$"U.S@O*&^+V"'IBE+47UZV*_39;1P;F;$L4S,ICYEIN8...^@G8-)-B
MF>$FRA%<P(5=PZG5%83)J1."]4Y4SAM81\20>&S0KN04#[H4?B_55)KQP'D6
M$ZDV_UPK-H[N7?2A<]X/W);3YC"3 &*R06I._-M1!5,6%FYFKI%SU=)-]L*J
MW\.FX;6A3<B\-R4/G/IAL1(4?/1(0M.3[Q?6(-/]\(B.1!7+HWBDN^KDK, P
M3427RC7X9"Q=\ST#I3RBF/1<7KBJF,IA]+'8'@*7$9M:AJVK8U5SBS! V.,-
MV #.>9(O2-8RF+HI/F?A7.S7O$9%RMLE!7>8F,CU=DFFVK7,]FN+1<6&PJ-B
ME)[J$<>^YX.UV-\XH'[P^F3V?53G"-&]3NQAOM.;C>:(6BJ4EVZS])@_D;%[
MJ=_=+SOE?C(T?VA-'))5X&K*F1=T4T^Y8RU5& .S/N\BT^B\(!M)Z\;5%'IS
M4IK&JF@<I#;O_K.#MICRH%"B((FIW'L[7B?B>73.F_#YN#+(5'?)Q"D][<6(
MQ$ZVHL*S??(5^8FG]Y,UKEP\UE+<.72O42,-^;(%^VR4M+&K1CLU+"2K)Y8)
MKKB=BFQ>'T@=A#VJZULX3AOVOR JK]C\M-:SP\\H 9\WNYB#=^PS#UMTFE%-
MO]%0U'[RUI2VM]?L+!F?(S6+L<$_SZYH57_2B!J4M14<KJF(=839)MEEDR82
MN[MGGUXJNAVB%](YTL IH8QT.@U;,ZVV;B-0D^60";)O&++\/;\^KZ<Q CT2
M!US"QAU(OP TO\,1&D\=O]R O@&<R*\NIQ!1^_98%,M18HZ.K,K:#J(?U?:5
M3( )1;HM193AI[T>Q]DB50HO#=C\SUO]'U;4['+P>5'.OCN>.%2;FSKM[EV>
M3";1+'CI(;T%0ZFOGA!//E7@6C5[/[PQ\#F4>>!;;[M,C%W.*+&P4:T%&H R
M/F;-'XZOZP.),,<@]7(3TQ.2LG?H!7(?QA(3Q8 _FDQ^4*$#*;OJS(Y+_C^\
MNG=8T]NV-LHJ-A0;O;J4'IH"H82V1 %)3 *A=Q$!0RA20@?74M E$!!(B%*"
M$D)((""$WEPB1;I $B 4I=?0"<UR67M_^SO[//OL[][[W'/N_"?/''/.,=XQ
M?W.\<XSY!&5";AQ:,;4322IKQ2:%V2&#KFE4^]BU:?97#8+?,O*)ICB_#TPK
MV+G<GZ[1&:I(>["P9K9\T\0E[Y_<D>K=R@_LU?"W]\*J%=@8W%O&FH>EDPU8
MU[Q=LB#,HR*Q2TSC=2 L_PZE4%Z^[UGCJESNCPG9=_>E76.071O34<&TX'O+
M9M8X3A(*YL\K7M9L?^V@MV/B$S,^ E%"/NE?6!PX?=A;6D/O$*J15[TQ(Y]B
M^WC38.W#@PIK@/>KA4_*^S77HG3IV@>>#EVO:&U9*;CDL1SSZX)C*<IJ][>P
M7WQJC\>75;,B*\5?(DK_4%35:1<88OOIF91_YU%@.W5LIQ:!LYH3G)T@G_W+
M"M*G$CH5\]\X=,B&,_\8O#'2HVU);VUTBDS Z9!$.[:FO(%\6C1(25I6(6O)
M65?\S)VTF2=K/VG$U-F=L=7\>']!VTZXOPAM&G*@NZ_VN)-S+<JJO#HSWL<G
M!] K,,<.?,?(MM456/BXE>&=XH#4,WIE0R8.TNOBIHCR:HIR^R_@M9 NUS0,
M+WK6E#B1_OE-+TE$IJ88B^5?4NM0W-OQ 9WM:S1D5^QZ#S#BG*"J2*-G%([6
M!S<?L<K6[OM#/OZ&_M>:%6.>.EO:0XZ5%^1>GJ\D&*#)"FQH)@-H3M&+[+I@
MV1+(&#V$OO707$X\[0VKD)=04%-B8+*(\.0+(5<R'KR1.XPC2RGJQ?=$Z !5
MBD=\'-]_\G] N$(_63QY;S0!F'[!3\\U]3ZC-H>06H3<'",&N!9K9'>Z-0QO
MYZA.%>,@)$1V#21,UV%%*X;9_KM]J[257YFSY1E8=?X-JPH,X*4Y%/((3BFM
MZ%?T9>XT*HXB2([6!;M9X?/?>?*3R4-+^KM"X3+@49/UULS87'I)'[RT5K2.
M27$OP.L;/2/W>>P<*[*KLU::"W=Q+?U]&'LM>V-%)61(7SPI;5[?IQO9OL-Y
M_I91*3(&$MR[;O9$SZUEIW'$SWBN36@U/MJ45^+:=YX2(HT**3N;H!-^ZZWR
M8FY+<2VW%RD,\L([8B*#D]ROM^IZL(*_ OB/:CW-]#[C_:BST\6CUC0D*,2S
M5M&DF,1.]B3[VK[V+@IG-VYB)8(H#9FDW;.Z#Y8MS^0T]3I_\A':69VT/4_"
M,5A7>YXZC.R$Y;=-9%-5.A$)XY!D6[Y';>D8$5-GQP0H=UVVL,1<I'(B\PY&
M-Q13MK-@@6FT9UE/9V2UZ^-&^+!U P"XYK([ TM71A=+Z@Y.OT\->M0N<^OH
M,#"#((VI3:4ES8O])438) /J<:ZS8T 3%8GU15I1A/+3>V.*.P!([7?",NG-
MQD.CX>LF!IH&Y2.7L"CPW%/(P&J;XG756ZET$)I3$:F7:2,M,$679Z36>>CW
M0UOJGLVS4A[5CUJP<[(<,2*@J%6PT\31+55KYPT4QZAK!1.= B$/HY0,'O)3
MW('O[N05E'5<:>UXQZ\7W/ADY+!1CFB#M+%$AS44A]Y9"!FT=#"Y#/56E'W<
MKWS%<10EI9,?4G@ZX;BDM<,R0/TNF@,&H7$^@X'@JT%36;,K%\ZPHSV".IIB
M\V8&=;YFC"AA(F=-K9U=KS(\ET"R+J[QX@YVI8BK">&]RR"HA.('6H'#1XP6
M89@-2C8 JK1LY'1D">44#C0010<RL8Y0S<RO<EZ9(26.HX,3WS:%K"4=J3!=
M2(>#U^]VS6W/3JV&@)X\G+W!37XJBWL9I&,6I]"F9^)3%O]1;>L6"]1*ANEG
M5[6+/[4<Z2DK'Y)A9JMZU-<3TBZXAJE"N>*FWWE^LAJ.=-LQ(;:??93^I8VQ
M9\*]'/Y'SHUP%91=T#N4GHUG_@1 ^&H-=DS@RQ\%;[;87TV].I>$0Q19^?FO
M=2@JL^U\]^:S3(J0P,I;S:N<P<+%D@MQM9X'F'I88S6IP+@8(&\J0%29RU4.
MYH<ES'YC0YD[CB";>MH#JHYJH<PGN<,8TUIB^*\#.XFS 2CPID9@ %"Q556J
M0[WG!DJ9NM=S<JB _7BR5O5]KF_K+>M104" D?IWGNO4Z3%=SYGP@S!'M,!4
M9M_%[3L!0$<A(6J8H,"U,QN)#U^UC/K1L"6"AH0,65G!&?BSE%/XAYEEG#J1
M'I0M,7^$65-C(WM2AOT(NM7NI/J$:&QM$YL:$A0./\-4XY8/-,B#<WP0 4^T
M9=E*\/R.3"7Q6_W<[SP09H!+9:-2JZ4U1K\W&]$5OHUIXK=*MM-(O*\M*<=@
M8@4"]6J:W :\;6B%']]4)ZU2 8$!:*VLZ=8=L2:M:UZ;W.[YY!\*V'XXG ^5
MMU%;F #@E_6IA_BY^Q8QBTX./O@$;8,_97@WNQCZ5#W";+0[D.W]XC&<8R!M
M@=D_UO2-44]9D1"4BNN+U4G'K(2,U3#9WR?E>VQ'NW[KU<U4*1A'[H)=)'L4
M-3>:LS\ZH<E4.EDI$XR<EI38WQ6>SC"2PRPVB2KU/- TJ;8%TTF@;2N(D9E&
MR&N$QA3!\F7^>Y(Z:X+PY3E<5KWS)9KGOVRG/<\TX'D4B(]>_=?C_T7CN_>O
M\R7O%-C^&J2"'> HUU+$-,=F-AYG+->C,*XX7EA<&D5!O\W!^8%/Y6C&[=1;
M8W45KK:686<RVQ*+C0NR>)FR M42Y>F<>V*'2&_>U:LT\_7EN*Y)]6[ODJS,
M+ZV5XG&R:JT)'7\,H(O\P-DYO&59\',74"DLK\NSUZ/.=",'JA(CD>S=.#Z-
MF[44\"INAB24OK#8NN6PG*9$'XTBHRJ)X(&<,>?\Z:WG"5,9D?D=>NCK$%AB
MNU2FT:SW93I9Y82/,O%!G7Z;U28A'"C+7 %-YSM*W1XI37ZX\2FG.;YAJ4LO
M-7FK>?HQA*4OBQ1SX3CY;)=F?QZ(PDX-"1)J14%#"24]:ZT%9#_<NP/Y<T.R
MP%)6=EZUITYI=Z)S5$9PD%>J6)A?)GN9+Z)4@!PLT=$^_PM>EE#0DZ++%6ML
M9"AK[K,(*QZBP:CJTX6_>U=5A6E3V;A(1!9A3D"NYD6EWF"E1ENUUYJB@A4V
M5Z8<Z5@=9Z!V^VUH)<55MY 2(3 U=(ES<95+P/"FDG0'H5UA/:F]^G+6BVC'
MY$RH_PV.BN+A[=H=\2(ZLIJQ5FA*DP6*RGS)3Y]-0U+O:UO0/[ZVK<!ZB)A4
M#<9 WCP+KM;2!&P'U>1G<)=[=-.0HZ1@L^39^B!%@N[254>O>E2A$S5CAZC3
MT%#8$11+YZG:?-_F$:"7  AR@!!SO]4]FU3:8C:EHD]_<'#JK#21%YGO<8@N
M]ZFHZFVS642$"6PAP$H?<J7DO"V3T"J2VRH=YA"12<:0?>;M*&EE1R.J5@\'
M2FB$6E?$A\]6;J5"\&5TCX3)]-P]_7Y2_F(9#JUC#G.6&9Q?40\;=4'Y63;;
M()4]]9M=C%$'7B^!ET:J2GR#YMRWH7>325"055)#]GJB2RQ=22NO?%\T<Y%=
M]0SSOFUU26O;V[9@R]+A,T;/8CTU?]BY%^-C5Q*8GI(.4_%\>)]1-7]?DDL$
M-Z<7,.UUUJ&&%V.:W@</-P*TV-!3/9!(DHZ1TKGJ*72"C[::6H]6-<9*T^5-
M.9/2%OJQUKRUJRO.3CZYP&M[]""L(@<,]@$XE49X)!M%)+!"P([Q)YL1% DH
MY ,2#1Q9-M *;9\9Y7U>U"BTI!L!-<RO:WPB=YE%]^/VE2@\,*50."XD$M(*
M39GC:YV[N!0NCP3-GEY&@X"7Y>L;FU70!QV3ANPDYLM!G?US5LN:65^KWU0V
MV.ZL*AK[ZPTOS.U)I8WJ ="+5NC%Z*G.33FW4]Z;2HW:$JHFKA>OL>IP !:U
MP5L8VAZE$YW$QQT>Z:\)\7!,;X8GR<%/C5IEE(G[K<CC5JX*[(SZ5*&5!HI$
MC<_QK7;EGGOVE%3%!:H!G-JFTK/E:V7[^Q[WGM[HC-[Q+P%?"(H 5E;9GK,C
MDT/"# QN!9!K)<<"E_L*-YX,LJT;BP(&;UQ[LN64MA,-=8,S0J(:@S">X5^.
M,IWKUZ=%8O-:)=8^K&HN:7H.6%DY9T+O;;LV>36&%3LA6<\IB.*[V=K$%]58
M?&'KQ]%$WDHBO$W1LR)#L:^8<'%QRQ;DGV)@>ND^\-#E[(2-OX<#2?([3U;"
M0Q)1/@ !E&X4QAH/72&3AR:<M6^WA(Z3#U;%(.O5>53JV>37&1O;%E^)@1^!
MRWY>+&&A,IH(1&?Q2OKG#<9("^G2H5]<QE(]^=N],,A)DF#\S,91VGE^8V.+
MS7V1F\].&X?!,X&[E546#&EO'6=0>5&_W*NR[.F*[D^]FC0?&+$9DLL*SHQ\
MDAA8VAJ^TG!76,?2 I_3V(5']N)&FYR/L%<L ; ,(L&@H+%BU,6=WM/&S>DF
M+.7V7#?DFZ:5O)^8MZMX4X4![V!_F5CR5YG=6.&*>3&6N6S"[T&O$=GY8W8G
M.X+28CP39+=NWO ?&2\L'[+"Y:M>R1O8_T#J&QYY0_$>#BH]MJ/M'C)Q;:!]
M6\.?J94YT R[2#NFN3X8E[N@4E:@?(CIN@\UE(TXY(.;L[.<1N--@93:B@D!
MF:0>+MFT=\(&96UIZ3"5]?6X7/K9LHSR#^8G*S+X5$M&[=NFKN):94@&S*W@
M*:]O#I7Q^?XN]MOJ&4L9R_/MGQV*6V3N%=.1DY-;*D&623/[LNEF&6,C)KJP
M1MEC/=O!&J'LQL:)W*.TSP/@@[_%3G06^Y!@OF7K;;%1R^X2 ]&<1(VG"\CU
M&7G5X?F',5X=H@$2;9$%*6ZNI482L5=WPUZ]5E8]+>GZWGTHE#IH3F6V^CP
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MYM@OQ*SY#@]#AS>^$V6!%%88FFE+Z6F_F  7V8F"(D@KA"%3?YS?\$3UW$Y
M6N;C5&352[]&!HK:^+,WXBK&?E*Q(:(QUX' AFI-?+JW)FN*4>B!Z6#OI+M:
MW_8?1@H"E0!V54M7%P'D9]XZYJ5O-AK8HDNCVL$!8%R+O&ZQ[CN/QXG FKM7
MPO0B?8'F X,[IUH[=#KU":"78KWTMVPE=M@%M+10IE545R%W/<;%)IY9O,"
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M%:B!;)GTI'0H$'NK_8PZ3K;VQ I_@%2?Y/8TX;R6,5;5,PR6?X=D$W$M#Z_
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M"X?_:&-$WA'&C7;JND1> 0 R ,XQFYS<*<#9GMEZS#1 _8D3]ISA^0VEB\>
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MRU3OX'_RL]3FMNVBW]$'G5';GM+0.A/W)%L[RCT?8EYO$MYL1L?U6];8XG:
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MSZQP2[+J4">:#0LD]G@+P<JHI-X\_6N51AM,I;4H@WSC/6HU%K]CU^^\P&N
M-9DJIZE.5TXSE+=9M26\ILN-*%>*94]\2$Z[/'E&I*Y!H2PEE2YUSFB=.Z6
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M&'9]6@'Q#!9Y$<1PS,\%7V<M'@/.W*C&1V:<^/E(P5:AFA:LQ5:=+VH9'#9
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MQ0G0=B4\7N(R7-J3HJY31YAM_AA(;A0B3"DK>LI:-^6.5BP*5&(*ER%+-$'
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M]R=_\>@RFWF!S6-?S<OEFMUJ1GF#I?J@7BGJQRTU0%>K1/B7YF5S7>FBN?L
MO(;VRC(N^LC0J>@R0X-9^[?3[S7L=#MG![7*N^/+[2*#'187W7C #GMJ9?L
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M^K'TD!)6DIW0"9^)I3;]W4^UR.(^YE)1ES4,(XQM28':&C.$VU'@.=)G6%9
M"2\.,114R[9OGIKLGBQT7KO0-M8N8J=4 GF.>CW$E'S&=R),G;K$(*WSX%M>
M[@/TZ/>Y0WJM- 6\!UT4'7J'3.OR%67&SBA67O4A!8)?OW=W4JUA,53JB]6*
MFO]4QD2E!>77@5CD!&IZ#21U11]F#KN)*\!6N5UN8F:^3I0T!6&\2XLX5YUU
MSFF#12C**QK%TX1I/72CBZ9G_,%/;T?>_39M[&:W,D-U\1S^_Z:-0:Z)4H>%
MUN 7=9\4'1F;"+JU58939/(*8S-N!KULC5L0;+)2+LB,TS$-P&I5^)CJ/9I
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MT_&<Q=T&,@77</+E[S:@/:H !+"VG]":+B@_9Q?,^U+<\1=L\$F5J8VX9?C
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M#IR([7+^0HMGM>^94R'!M 6Y>H!-D;A48AZ</B_TN:>Q&BJ<[^(5ZK6YK=W
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M 6,MKWB)8/<!1'?%&NU=PZ+_ ^S_H*/"_U*^9S&"?\MBO(%@/[&QTE:8'@
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MY7U/9M>B,M^;LQ"BZKK4-C5XX*X#!^ER)][)XVU3##\E)68I!.ZQ!>JT7*F
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M]X&K5I?>T3WN_B]HEGR'Y/V0N3>$ W_7S^I=PN/;I -7^9&,S.J/.-1]O&(
MXCH*B*O,BKPX-M]6[0=VI_)E;V1;:N9!O<+*>QOE0LN#,TQ:C\1_=DEBC"6)
MP E%^#ZFNRGG)%W"RY]=6+C;7U)^6MYI7)O"RZ8J, (VLVMLX':\X?2VQ[4O
M&E(?L7GS9FRK!5%D^J/8=(;[\_T]I^I5CB=H466T&!8IYJ9? 40.6]A@]H,%
M(&B86*".P!ACF,L-;KBY7Z5BA"D-7B%E)R8IC+;(F.?46^.K:SR$\GHACHUG
M83<<LL202?Y9#\!#CO;C-7J\*6NW\3V]W@RD^"TUWS^4N^O!=;J38@V7)1N5
M0^Y6="_83NABLBC <:>%YYGC*^LQQNMAQI3Z4_4&**[$:QF;*48JXHE@9W,=
ML]L?^*W<1M?BUPSF.ZESI=&S?1C[C$R,T ']XT)>>5(<82^=I9>K+?!A6[+@
MFO#SZQO',%!)00BR^8)?)5> [/)J4A,WY^!G46697/GC+A^*JW;F*\L?\]7W
M1",_0G+$_3I=N>TA['&6V5_U+0JRW\[C5\!W9]-CE?^_[-HKC$".@Q8R-]ZI
M_X==^UW3AM<];#,D1UM*-HY;0T7#, 8>ESSQ8Y X8FZ'R<BT:=\JW&>UWZ0O
M.X0Z_N1F>+C.$U^?YH#[2Z7495VR%)\>ZDH_V)3W*4.1G)H+Z=7;3D%'4[UG
MBQR?2YP36_S3=1TIXZ\DZ,7,N]!B_.U=DSH)V1+P]FKG5BX$5:K"^S5:7?)L
MDD;1\9M[/^\M"]AUPE.B.>%=^>:$YPD-D/S;8NO$KI?V'TX[8]&9*B##GU/
M,4.IQ=27UN8QV6(2O8&FGJ.Y"O</9';6RW@<CX98SE6$^A+LAJLH<EP%\4NO
M*D&(+5$2/=J!4TBPR#)^S2'WI%:LX@7KU[=L2\64@(EY\1Y&3SO=$CSTVU#Q
M7D;CC.6SP+7K48L5(:P4)8@TE%MMR-"_XSB><<.J7\^6,8&$Z[=(2"E:S5O7
M'-61'O\8HCX/LZ[@_$+B+"(FOLW/HA1G?7D@QFK:7)OF=^G2I>DH=*91FR?:
M PJ<_T#E73>R=V.7?=TL5^$E^HD0L@$\I-'.6Q2#--$%96L%W?K24#LW_K&I
MWSY,SMND_#8/T/K9ELH6MKF@GV&]FJ1?Q*_3M%#MQN4Z,T'0\O!YGGD=L9>=
M8",@O69D#N\>I,+<WE@7ON#Z_%)_.TPFL]%'A/1$2(@*"HX:?+^T1XC#3S4N
M%#2DK0<I4SP]:"3/G*K*X5'Q(EIDBL^#KFA8,49#H'CM<2ST:%&ZN;[3$P4[
MJJYUF<C4.,?)R>M9V4R\#8'@$6I0D6FN4 >"J?YR0@1%/M/679(<S%+<Q1N=
M3Y</7;C,@B%:%:<B3%UGG7VR%%TLPJ) GQ1.X6%;!%1GI&O6>RX=*O3SK6FK
M3A8N&;Q\N3==00:UDV*,#Y]O40BB.*H>;;XDX9 C1-7]DGID<2XDU 0:RVW0
M_0Y/R*:#X-&W.H-'^I-/6K'WV7;8AM6R8B::+[,7'2,BPHP-Z(#J],+N;,6-
M((26;EE8N:V@$*N?D: L"^^'<R(^1%WG+*@U(<*8:=CXF'8+RS$>]:7]ZG&+
M=Z6.0*WDG45C!J3K??"D]Z].^:DF97<$1EOI'RD)E3FOBL@$9_.>GK%:3A.I
M%1)<^DR][FAKU.(]?Y95EQ![K],LTSI<28;>K*W8[!08%"'68::R'CI>1C]5
M26 2/CEIUI&.Q<V@6+3+@JS>6$_N^_3?&<@'F@"<6(#9_6,V+_U&VZ+JK2F\
M\_*3.F&W2AM<+GNOW="#:?9K0'+Y3$!H5J@D'>94X](;6$_3E(<)-\)4/\8X
M^ORX@(S:8J2IR8B7WX>)M6&HTIS5G**H%BG/QV$Y/X!7W4 3A.Q"01]FZ3B'
MJ.5R',LK)"9]X5$1'R0SU9FG3=B;1[%::<>M%HB[&RL@$C6CV>J46 L[:T>&
M6$KB8O#UB01Q)W)2C "'Y6'4XH9OUT\_SZIO*SO^;V'^Q/Z6LS3-M]G'E&"+
M*I?@.:+A57LAY<.G_*874Q#9#I3T=2!V[LGG:RU+0ELF*IF3_7W:00=>S"@)
MA2S?&HC-UQA=CSN19/)4H]F3NOHFXO B1>-&M.Y=09BP?-*%N0_O;5TG#>VG
M!V3P&8M)]Q.;+"1GN=66*\=U"&*3_2W=8:PUH4F)Y*!ZS'IH)=XN1E30$X9'
MT+UZ&@4*F9YND:W[J)VQ&%P8(XW7X[]63*J=]6UV''0<<A0[>ZB,2451W=/T
M3UL%'M3#EALMD_7BKT9-G/1A;$R"^B@VW6%FLHP\?V[W^HNWE3+]\Z6*A:^@
MTE\!'9=]MIXW5'J8>V@&B>3U9LD@#6R*@J07P+B,E+5P:R3UBG?*UIFNED07
MJ(_MXCB3(!/3K2OP^F!\ Q/1N=1I_"-JG'D^=J;GD_?W8(K[1@%__%E>8TKG
M?%67N7;,/&W$'G#U3SKK9P^]NDOAUX_I974B&0OZTU]QP5-XV#D]U*/7I:GZ
M8%228]9<J_OM0%[6]Q<AN80:48%Z><7"%@\)2(.*&Z2VLO>\614+_1)O6>B,
M];/]@K/7O1&!@N7@2HS>N8(1:KU"[P51T_D#-UI!-_OP=?LB@YL2-#"/@)8"
MLX(OW(FPH ]=LBRQF MKUYGN]:U'73CS?_X5]E]LV_^(=&2N."P- !Q>0@^#
MTZWY>/GGJR.(P$\3/8SS*P@5IPCTET(AXW0!9;RC@&CQK%U<EU66F2MCX@2E
M-31M)4JKA'#MY2<-V=C9,"/EC&'^!:VY*J>GGV[F+N%9.!\FD=X_6;#X,%$<
MC4;SJPQ*VBR^;83<E9=*MC!J+=;91A&/VMGF#U!X!>/C7J^BG=<#??@ZA4I>
M:6,+$EOT-S8G>MW!2#6XB4_>9E/7,GZ$Q3@H6J"T>49=.F1P4J6W4'==Y,*@
M^+-)D&^W$FO",R.U9IVG,:J!8<Z5_5-+..]H.UMVS%D^5M%G\/=:Q^> P:Z$
MSR11@64XL/S34;N0K"ZRDX;DA?'G]LGB"T25!*6@YJP.2:U7%,J*GS#),]&,
MD13T'L.38]_8$L>R=<5IB$Z.6^-6[$MCF*>6_[2P()UT'3?DTS)T]KZGY4]?
MOIL$'BGE3&$L/,3"QC@P+]>*W1<)UFJ-L%N"-==*UK\\I<\\73P!;OP*>!9Q
MP9>;I_.ITH>1X]<(EU)82#/U(Z )MB=&<_Z*F_Y\#\-3'")P$U6;$EPP!]Y%
M1H-M-OF QY>7E^KGN4L?XHF26Z?+NE,KF'JJ6);?4/B.X$6<H'],$[]$'$V4
M?0L_7*<IK2DQOY:@#'R90\5K(C3%E'RJ7HXVOV_@2I[BF'+A[LT (06NI!5T
MB-M=)=Q+TJLZM"6]"8SMM+3300N4$2 Y?OM68<S)L&L/72%*%BIAGX?-+4L4
M515?*W5]V+Y&B(Y;K]KVW-08?(R2C''X"B!$?)@.X#/Y"CBINBFA?X69XD<O
M-MM."?_C_0ZOHTISS>['U;&8;HANGJH;KU*=5C:A^7G- 5;U%IWZPQVD^FZ'
MHJF)CN0E6=>1#<O](6)3J($^783^B83(.JL#/'TA+/5LGL[D-9'B[+<]BUD0
M_.!ES70!?M+Q%(9#Q0;$C'@/Q6>#3X-!1BE<=ET\(FX%)1+9+>XL;NA.W\P.
MI^&ERRW)#0,# U)^ 4[Z(BYH8(._%U?<83L352\/MM<E94C-DRB@&J8U<6D]
M@OY"Q[B_ I,$I<NIT<%9EKE]ZH,DO\QU$%+R &,7YWBK0L:%Q@>B#B1^P:[2
M\U$3"76R/:>N8VR-;PHY6 T<D0UQ#XX[6(A7.N4/XXZ4-';EG],4-;=@J55L
MO?O*A-N/4Q\S"OVBBSS Q8A(SL7-@/R*ZP>R)TSU*DL3@^U.I6_Y^=1E>-^"
M+)EI;#021DIBU/@S9UM,IL5U.JDXKD&62P^UP7:GS OOY.7'0/3U^'M0\0H4
MQS:[JI>3'@4K'LRNE.SRQ147?.)J?%"T7UCO.DNYA&U7S/W^46R\V./G)6E%
M&VNR,K'3*IN5"AF3A=XB+8D((6L7(XR4<*GTPM+]&M"G#:0_51>7.S)&?@GR
MW.*-M3L<FZ GXHWKS*$*OGX?G-'1Z$_8H*^W<HV'Z+>ED<ZG(<;5I&K',ZLU
MK&;X3:'$(5,=32-;V)7"",LK,&;B2-#IU5I;#._SY"B9\4FKH9NJ#]I(H_CM
MVG50]M3YJNXE7C&29?@:ZQ;R;9Z?@ZRK4!<"QX@-'#+WCL^D;/"AC%J**%2/
MUVYL<5&:H.GMN)QF;UN3I6;C4V"$OH.ZO+%:4G%=M+![1D]M7UQSPYI_ X]=
MIX3"=2E)7J< #Y"TI22/J*^<43 \?P5$H)BI+U?TAX1SLGQ:7Y@\.<W7R7*]
M.[P$_,4C,HE7Q?&2;BE?[0+^_L#>R/PR7- ?^(O(H,K;I;U'WVA<Z<%04'-Q
MJFHY5>:LE'1[Q "F%M*%RP/IAD\.IO<0C99O'$TWZB *K68W:-+7YB5XDJ<;
MN/!?<N,>3F>JB >.]KF,;,CBGC5X%7A(B*YK',43?)-$GT5%E$1=H"3RL>F2
M29)ZMN%&.BC5X!FKP$ZS_+:)2;<O@BUZWH9KGH&11OX$JW&D"61=09 MF@H"
MH9+IU<CC^>(QQ0^6!Y?UA&=R(34ZC6&"SL%U7@_OPZRM<Y=$9&%\/N:23,"Q
M?HZ4"Q5^#ZSN9G1@X)"\/B$O3>U^AS+W$?,T_U2()EMXXA7R0I>.;P""^V4D
M,G_E6%IB&;JR5$!63&@A!/T*BS8F.FX/NXKCUS+6>Q9+G9DFWMQUSP8BY3(=
MRW#4UZ8]=R>]$#?4NN&RQ^ )R&H@LE7AF<I7P'UHKN"%F2_)YU/:U;;?5O0J
M7*>.(Y)3/9(LPV24NAF(]1F8W $"MKP8(<FX6NN8XY9X\'W-?/>7@@EX>X/R
M!2*4=3E*=%G419>7;9YREEM&FY2\(%1(%+%CK8Q$JR>QP Z6;V60.F4=0'5^
M5K4LCA?Q\8: _]'-&F:#'S[ 0S]=@/=_"Z-,.\"YM'N HXHM1SJH@Q--&3P;
M9OK"'R"*UJ_ ,_5"BI%'^)L;'JB= (?QYEG(]HB'%$3[!YMK#)IY69PL)IPU
M42N=($*=!>Z.S[T.A\.GZ?E=M>'0\M*YA-7X+;&;T?:VG94AH0CY-7'34J;3
MZ%>53SI%(4J\;?#36%(X [G_3@ZJ8J"X L4T*BN0LQY],@[;Z_.QOVM.'=*.
MXL.2)6']\3A8&PFIK&FK[I,KAF\UO]IZ=:&R&.%C94X<8U^TK:YQ:C322L"/
M^.0HGIW?+\$>L7^#Q\4<84N\;26PX'_9R#\?,=7]]&YA,A?3L]?73/I4JIMO
M^.N,D.I#$ZV=(WA>$;[M"S+UZ)NS:G__K7T_'=MM2_Q"T.[X8JF9,Y>TS>.;
M?,Q(7%FAY+:+%^%*3FJTC9CC5*>#WOA7P)%8-!;C7*^QLX"S3EG@7_3GTNH,
M<#Y#-6C'I((=YD-3#, 2,Q45JML]7P'I3<SMTY)"Z^HG$OR=%]C&PHV\,"\H
M/2P'%Q3>N_1NI8>GNK2MJ7TI<ZHN4O&29G[NNSC98R:1/!G!%.4?WF]<^T#/
M\RL ;RW/,?%FNE-I;[M25YO4*[S$\8J*!]MQSS<S3(NI7>/C >NW%[>ME*!2
MPZ-;4DU8TGD1_8ZP9IA-U[/E.SU7PE3"^XDM)EEYW&NW^[JL3(!NEK6:"7'>
M<I;-K K2H^_M_?O'M=JGNCO,E-NUG!_:X>..F1<BVP(A.@//#R^ST3\)<"V)
M*-;>H/^"LW5?W'8J*OSD$:$I.WVLR-ZVOT:2T71-3(P;(E@TH5W<[RB8/&DX
M2)4I+K-3B6TWTD/BDL5'MNP7";E,2R8:ZJUC_>5*O'>'B^)Y"H#.S-E&><8#
MYT?32C44-'JHL@H:";IWDL:9JET@' DKMTHZW63S2X9JU+S K1+QE_4#A!SH
M8>B>=EW$\[+JV<& N]9IG()!2VSS'_BXCG,YL\0Q\@#KTDF]X^>=B<MS;5"(
M9[*'M3QN)5GK.44!#='IP;"_&+0^&;[>/^\YJQS>H-Z.:B_IDS/6?Q/&IZ[U
MM)5# PT[AEABD]9)<HE0XZA0PR"1TT"<K%P?C -!EI][?Y$("^"LBK;S:H\*
M]="7;9K!B<*RZS,=!:#UQ]=O+7C'8"$SKJ_LI!=>XZ>%J9IU.;9YB4%29<\_
MK'S")1=W2;RIFTGO'XJ:YPT72%#5#$?:=^O=\@<+S<=4(;GQJER=1;*7L;II
MR-+1KX#3\9;I(%CMUJ&J8'_U>5QZ> -,=@#7+-OX,=HB/\-'S*BE^%R2_9+M
MLE/+%'^9T\AJ@U+11':WT3EWP.$__]?+ZA\.:URI+1'8_5E_W3T6W[U[_(L[
MS!\J[89#0\8ML3 WS4'G<(8DEWK%.MONQ,L8]\CHS$GWU]'8F00MA3E9P#Z3
MMD6'ZV%-V=05U]PL]6,B-7)E7H:C<6">Z8--NA5E0=V)X!A<LS1_C4MC/4LR
MA\&%YK?[.X'MRYICL ]VU!Y&1VM6 >7WE^JAY\/*8Z0[GP3JGROC>L0F_1G
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M2UFRREAJ5^QDJ"ZV>WWV2H!A>+9RBSCPGL@]Z;%;O&](#4QQPB^V73C1U*/
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M2)8ZA\Q\=;2:]2N-^(G:)Y?6O>;'BK4<G41B<,9!=B\,RN>)ON?6*POL=Q:
M.?GZ.*(YMJIHL ?@S6'Z%0#NM4LH6>ZR!(^HGWP_'^!U;L&*J@MW),GFH_[
M9CJU[O/<OR@#<WB%19GK69E3@;,DCJT, YU>XQA!%0P;1N]6[7G2,?D-8/^1
M*0B;>R/!!5R.TC>TXSQ_>7K,*',*K>XA*4C4RTDB&B+_>%B?.?C:T1/S!)YL
M9!_3S*D.Z\_JUP2%A/-RZRRMM]IMO8[.[D1I^55"&7LN^QM-6MU"GYQ:J@]9
M=-*+O3<RQ]#WX(IS90Q]2VQ1+/<A#A>; >\G_&,G>X\2W=9O=9<#KZRJKB07
M7=&<3YH$ZI4/HFK7E+ 4,\M7C]-LV"5=K%%ZI2@PZ3*R@JS:C?.'^US;SW#U
M_^2<YP;!EW;"\SS3Y3>!7+\G$-V9]/X"V!?G^>WF][L?-\$]?]P$_V<,UY_E
MXH;&80VU<I? ^RNR/3E-IX%9:#IO(#YI)/&Y2;T1[UT$Q:#<BG^@$RUD2)A8
MT;T?Z_(AJN 46G-.#Z$)1E3P!GV<[87Q :O*\V1GX6 '/M@7[ :P?!E6_!0)
M;2MNX0V]5EDPHX;.?T7<>*/E3JV1\'-.)/=;7H%#[+X",LLE/'6=2:Q5H$>5
M:/UM\3*#2Z%G1V6A])5*V"B4#KBXO6\D4E-K_B9]GBI1]+D:0@YS^LIHH<R"
MEZ>RB'NYFUU=3#-"%N1K$OT5X(2>S!]H=QA7.98NZU;#X<=C4PQ/,^]T.X=.
ME5@!NWEN1][JEDSL@N88]Z1J7G;.&@]ZC[YLTSN-F"M?2#6.%L ?\5>T8+9=
M3PE6-2QZZMK/I!\U^#D6Y ?3\#:Y9I&& BKCCTCR/O_8[VT]W4G5<&>5,([A
M0N:T9XRN,/:SM1A<<>R2+S>_75B?V;88-$*<8E+!9C7/#1-=-NPHY&(BD!]<
MHGN6*Y)]TW)_\L.WFK->?KPJS$RC)/V32<3HTK6!%"/_C@%MV!*6T]C3[6+W
M_!+;<J%^<4@F@2#L@3C""Q2TD^_ADO>A>_6ZQ$.<(%2K0U+6 46%X+6\XG'G
MEHW-7QYIQX0!B2>C?,MN5E,74QW^'% O(I'H!53%CK.:F8TU%&HC_%(7P4GG
MR=##E?*%IZJ%%G&HF%'/OAKQ 0>$_-)K1 [.6B,KRZ3FA#,(*M>?\" _6W!=
M)=])A<@DQ?,"_7%V).H*OMN=:/[8*>8P1F(5ZP)QB[2T?5Q0HB>"7CH"0G1(
M-]_E"UW@?6^7>]:98OJI+MHY,CIC==MR']R.,6=:;/#+1G1!_OF[2^I=7W+Y
M^^LH@FZ"%U /'2^\KK1+-%RLZRM!"JJ)B>K4- JG8G+=*#5HG+2*K_/X1IBU
M(^)ZQDNPH+:;%!QOZA5'/548)BN.D#7!)Y EFR(+*863W:_*BQ ^ZFIW9?/<
MO N;8O)7\#.:SZ.3L,AQZYRGI(L;"4@FZ1(Y]U+)B=A5A6(8^VF\UE.P:56Z
MOF7Q</<AP[^%K__OEJ-"6XPOEA7]KBO_)H#V(HZ69O1;.?3QT,>]H\Y'Q+9(
M ;1@%9.O/_)^OP9367:&Y<S_ O=_6=X!E'%5Q?D9XV[&$B,)1O<_19\D0\UC
M/DA--*LK9!:/X 1/NJ E#R\T,K2M[#<YNN%#54=@# DA+6Q+\J>"O_7QW]C$
M_$_AVG]_M"RN^)M+,99N9FRM>DA!C[?1:=TS41=*6<\^NBAKWD QME*54]?C
MX0MW8Q^UFG$0, =-9&<,1Z_*<WVFOY?\P880%<K?!8**C1N)9S11,/PUH2A"
M?Z"'0>P::PYN-/]]4::*8/CCNRHM5]X&=ITF(RH7ZI486*%OUT4PRK*NMCGN
M7?;$0YE"ANB=&HB 9IA^SZ:^"?VS=E17Z+!*[KU."]GUL/3]1BK1 CH#3WPR
MD$6RRK?ZKU.?!$]T1C7A'@R:\,:%$3K'(X6T\WO#I'1#1<4@A)B:#WVA1"/:
MUKE+F[U9ND,27[OR#&_E6OS-:$\5 3&0Z4/!B]ZYC11OV"VY<K?S),ZNEYCW
M,O+#2$/[+9R:48W3O/,"GYC4Z[>B N./54\W2/)GX&R$M M#,8G4&$_ITAGA
M67*@/5O&:[NLOI:@12M^+590E&DR2)8Q]= ;E4O+PBR55^TDBGE4D4>N@;(K
MQ%9SX)]@9Z6_M*.JOP+8FN.M<N4/,7WD,:WXU'R.JI6!T-L0E/!LO.LJ40)C
MZU<:*;3U+64<?:,?Y);!ZZ39W7 O1N ++U]7E%.'\*9ZAT3"?)1OLG>#>A*#
M,RC<(K/,I?$(W=*CO8_^J=/_1OD6.'"3DKRT3?/AA%WD!0!.[)ZQ=/QSZ.R&
MO>"6&!7?/EFU&WE^7N:/G^?13W<S ?ZO2/AMX;P&$)"I.^F<!#^=6SP;_,8O
M$^%EH5J*1.HA-<?4Y2)3>,G"2XHYD=8:)TLP#CZWX (JQ=EW-4$.DD(O+N0O
MA9@%J%9D48BV1#_OEU!IG;+ !+/2VVOX3M7N//?B[6?Y+@[F$>&.CO4-\Z;$
MR&$FPGV!7K\6AZ4M(484*.QPW25@(ZLV-"5'W_?/9%BWB4GAJ]BIXJ>W0J8\
MBGHFF?T^V7>V7 E1A:Y/BQ$5 ZH(FZR@3+);JFT!*EST<MQ70"T/N$N>"6^N
M\C@;R=<#MO@*8(13?( F6EAXA]&0<?\->A08S9KC3K[\=-6"6('OD;2AS)?J
MO\GHJF5K[FSER.6XO!0?)F;1-N5J!RVK,,DV=FDZE5F"C1TT8%4LW#?, $1F
M3$53,A&\QL<;HGR'<L:Y*8JPN#N">&,.:V-XW&M@"=\6(Z22J3@9@Q%H*]BQ
M<(':<KW\H(I/H<]:)UWME_6=U',WX <3@@."<0]0:'"J!]3-P^608N2I:,_A
M\>-ONS8B%:Z([9'R8/&1@8#'T$8-6664\WWK6D:$%J7/@M2CRL49T:4JV>2M
MRWDW)VT>\#X\?7#79_MGX 2Q?\2E$M\4XW[X+2/??W20E/P/#I(G_A59;<<>
MJW_Y<$ V^$^ Y/OG.\NRI.!'_'%<5E<!%P&,1E!YG/+5_XW][<7OT,!3U]H2
M/VTQ<=_3R*OSEQR9M'MD>^_\:/HC)</.TFXE?/=JBK]\^#5%[D6:@S/XV_?*
M_\5[WY=\E W2.AS/SU6++?#PF^@G"5;7Y/!(5]IJ",2_(=9K)8E,#AA/FTTW
MH:JO#;J^@J(%2H@F:"H;QB$'2[ A:L?(O@W5+7P?>*\,:IVYSD1ALXN*ZLSI
M+R.WAP=<4X.P^99],@YXROTX*\"PX_94 4JPVV>+26&3=.3A>?X'TC!IX84:
M!5G)T]+5_'G@:N>64W?9*KOL]5.*7.%'\2L2:1D9Y2Q,]?1NM<M)/C523^3H
MY8 P!\%Q4&DN8G^J/EK^[L*FKA]#.!_,QY:)%$R $,RB@@/2FU1MR7W<GSOJ
M9.7":GTFU)V>VOES191;%E=5<R6RJ_44EQ.L]5!2+.!D&1_D@T">PR,G068O
M[R#4G5 <FI<BI^QX(SD,WK54Z[R%JZ^/>6CG";H)E,I4UWKY(ZAR0.E,U9.-
MY@5$1@%0.']'D.1$G0!7)J&EXPS@Y%6:KG?3>+U,W_V>W2/ZWUWA*QQ:G_FY
MHM^-? G_)?S3F[/_O>O=_Y-B!3@HNS,L.A:_ JHP1^W\I=?PP?(:KLT!:ET7
MX$A;_1*P5PU"3R-.\>K]ZMNYA!O).S-BR0TY_,EL7$7I6&'RNPM/7D=&-AG;
M$72_=4A;-WU+/$(+&VL]?IOFP<^WTK$C#+[OZ=EI90]!_-7>^#'=W01!K:NJ
M<S]])R]_]YW\_R[ZZO>R]S^F0?X*^+>2#GI^KK'SWLI]DX#281@ JU578MWV
M)'(X;]"[W"*&V%$K@M,<&GA?2#9]@O/RC\D_4B8_%/PV$4TH]?C_\+]KPTIM
M,?]RR;+ZAT/>_Z6RAVR,D17R3H<S-8944VT4&7.**G"*D5V"W8%ZKCVJ?>5;
MMYN1&B>+!^C-V^=13%N(.0'P,JQ6YOH@3KIY%MC +:-PU,K89\4@N_<K8#[>
M+*[=W3@6[2!H()5K:^>A]!4@D#D=3R&X <.]<>J%!#ZH$["$/V/T[38\OBNH
M[OUT'](*=!W/O#9A@Q['\;;BY:R*T#E%MW3A K+J40/.1I\+7)K9-6+;')YT
M7QQ(SRPWF8N,8*S@9N#"258F=J.SLSE3/)R'!EU3%4^W<OAJLB*G.;^@2IAT
MLP@3<#_.+GY$=2O!50'=G4,=(E*6LC"'#AUZ(3_K5P5JN9MI:.*@)]V>+<7D
MQ;B2MB:P06]09DU9M I,":DM20Y(C[64T,@RN*(-8WUP7-JSWBA*4L#B*B",
M)K6_;IUL[WJ)_'GJ'>"PUDSFQA!$(DB,ME^TZS^WD*?/**#N$@DR[5.@ASKD
M\3H@>K2CM)S%GFZ_YDOC8NG311E$\ZO$W*H#JI%G50QN=@O82G1/I7;<+3E=
M6?]4O]?O"HP<,VWR0L49QLM?)@I$G=YB&_'V[S8E7@?J!#$%ECD-!$ L.V2]
M1]D_-]Y;C?%4>VPXIWHFLV>[?75R36I)LX2Y4!CH3$Y6/?<T8KO=I]!69TVJ
M=?NCP9T0(%/#@WL)'^"#!MZ*D3-[IT+3!B;6-;!058S'8W?M!L=%!?Z5L EO
MT,S>SR8X;G4%L@>)(CHK2 =5[3 C^=- _LS8].,=E-JM%@^FU9.EX'U<LZ+X
M:5:1)CG+G9X5LK%T3Q+G%N,\!R/2*]YE"N"XU3S":'CH0J-I57@:V&=3!JW7
M0%IM\3$!2V^%SQ:OHW5HL!DT(G:H$1E\CN":KVC?Z8?I  WA'*V?Q]HZ-#K8
M:=TSL0I4[53M]OFN@H=WM^VW#T)%5NZQ8YSY,^QMTQ&>3/AIH6B3-^[U6.B-
MC@A/%JL_=OC>X9*];1$^>* 9T<1<=BU7=(=;^ Y;0M%'/5(IJE@9FE > IEG
M:""#P5K!W^6UG#N'.ZY&DQ=^AT1[G[K%':X/]-X0*BKQ_H&0Y;X5\PQ-9C2&
MCA;H"!5E+.Z([?*Q3SN<&=C\#= ,SE]R<0>&QNZLZ$>1P8C?LTW3V*XH'S_\
M=YNJ7T33_DTTWZ2^7(^E&V6D":6.1L&!:\#5787O*$"7<>B?U?5_56_^OIK6
M>I\7;]*L8(+G4JQ:K8ZO>,5)O5KEW*,<CTH938<X8GYL6_WJF#S[\L=5E6'I
MIV(U<RM'WNV,%/YWZ8/4!OSB,PP:CD&!@9WABVQCI0**51!"MM/S;N>A0Q1P
M%THG$XO2330:7@UM]HNB*-F*D)"VS*=2:^2:L<+.=F_[E[TK\A!M4:.=7JWH
MA-Q!A% V?VVNW.0"_%XO?^E$=[L?*&#LP7"LLWRPE1/IXT)9Z+B*>G0)'Z$%
ME#G!#I6;+#.9!AJ[6NEKGM#VO^T\6_&BP^#Y$5Z-JPZS'K1=^\3(-7'Y -84
M!<_;[<59@\^BYI/;=,O!I;42(]VC%4"X2IO[H+Y:!S$A/WQAN'0;X,&1VQY#
M=!HJVZK8=M?;?#[+[=+GL3F5O7;\\R%+_+3 SKOZPHWO-09? AP7=E;M,0%G
M-P%3)HT[5IOD\<7'\2L 1JNB\VMU&%HHR!M5>L0903/I))<=@.\O#_5O#WP%
MR ENWUC=\VF^0L4 4L_<.OV]^49R7]6XE<7' ( <UXZ]34N/]$[_EAY6,R3'
M1LKWQGM6E$H"6O!5K[8![O*[;+3^EHU!,[A0$2G$>GEFK==@GON=WT^\-#*A
MHIWA?Q'^*R7S=2[OK"QE=H@9J(@XA(DQ7N%^UVWI5PPU0B']VOMGZJJNX<)9
M!^N\]BQJ[K9U3W*:6AXH"<+$@%=H:!P&E59_%8>3_?; SIH 0Y/'WMX?I.[+
M)[N'YM*(^+TX!LV0G#]YWIOR3WG\U^^2?\I*X:>LA'/;L16:,C]K]OVE0L"4
MUS^$E?>KWDKB:,H9[U_^4<7T"ZG,!A#3W,XP]$]RJEPVW*NVC&B]'*N/UO&B
M&<M/>SB\4JXX8&*"SRG.+8J$W+VV"9C>,2BH,%^R=6NBD([#E6?>@?P.(K5B
M#*AV#2\I[.I\S1+[\?XO Z5Y&R:[7=:M,NX0,U7\K4N+9>YWR(_L'IN3ORH]
MQ>6'[>X8VU_:\/HN\)]:3_G)Q04#")#\=TO:^$\"_]4 A7,[RLR0[#OOL %S
MN^QG_Y3AL=H8HOC?)1[@./=S(,6;(7;>ROWL[(#B^$_(AEW(*\5_C2,:C]_(
MN:\E_Q3"X2Q[<-":VRW&\RO@VB:=0DI?$V;%R.#Y(DU""7Z6.U(W)]WL*V=<
M&>SJMI,>/C1[T83%J3A1R\[+> @B:I/MW1("!I)),I]Q=_R.QA"EXB#U?^'_
M=:AX_=-*4_XQ:'^U"Y._F=O.T*S]VRSRT]R^32(N?UG@/^8)+3:"3<^\G0X2
M)*JHJR/#\M=;IAW\F*\ :CD-B9M>QB<2OK#88A6TRMQ=5)0*;(F!52[JZPL@
MECGRI[8'JKX"]+IVM"D@ NM#J1ZWI>[T<$HUHW?Z6*'ZNJZ#*T;P1'8@(0%H
M^38W"N-=\"<:94-(K6V\Y'"9Q>*>>S$V*=N!(:DP=D#&24#CKGO6J4%$$7L>
M1N<U3VKYT!1G93:=@214J -= ?M4^Q :(N/0\W2RU$%'VP ,9\<LO#&UQ#7U
M\116N$:"B.4H42[+52Z&7F"1F]1@9W.K#!0>=QG41C6YG($6 R*NZ281/$H;
M4UBB)&.2W)(@]E\&2">)>)1/Q&>S'0,*5MOJIC'"('<K3.Y4I-=[<I/,^8*A
M?6&JUNYS#20[VYQ*Q1NKIQ4*\HI]^"RA'AY%<2RZU!Y=W3,)[R'8.?.\%F6_
M ]&'E]V\;7V:Y4=?:?\2 .J7.,F[O]TOG/CI10P L$$#I64^Z=N=GB!MNSA?
M2MB*"*<LH=(7SL?]X3X:>>-H_H(%3XN03!B683/6=LYDP\TS;@ZT=>(\>.W&
M;5@7G3NE+A=2VS!7@Z?Z%PH5>$M:!P@UEJJ?@DEQ07+M/AL&.N8;RF.8'DZ)
M,B4^*>OW8T])0(2SG@?<>#/PR5,EIMFHUVPB. DGL1#1(),7[! U6]NN0KJ]
M9O>AL+)SHN32U/@2MP:)U<]:)#;1:SMY6WN".W@SI:PJ)O3+LO7Y#NP@;%A!
M#6IN(T.M"2@PFP\(G/);^W-%J5=V1^6/G50%U^1JW!4WVWQ2IB*B-OD"A&E/
M,-T]^$K-6=AFX;4O 06*FK-)7P%#$ESC&WQZ .>\*"R?V$KST;+M!F7DJB9I
MNVRWN[?[HC=3AF4"*FT4.K9>%7T%'!EJW 71!SBG[(!\!0A_0X+]@<1P!XG6
M; H-2=QN_?<FW[&G_,3^_<E-^Y# #K4>\\V'=G!;[%#[=X#OY((@@PQ5L38*
MK<N:.8=EM!I^?+I5CA [DN ?[^$%7KCQL 0NV_'!Q#,8^CR**K?G1=^!KX#[
M2UB7.;:O@*VR/1^OW-";C2B*=9TD#DS@+X,C*6=&5C4XU1+_<)TYTM\U]C2(
M&E#@X\D$-E&R$QD490K8"*5L%X0;B"C5/%W(D^!P>Q@W%;L)&Y9;>_!T0.R;
M<+Y]ZM_!D]>PS3"W,K;[3/WSF&[1S'=9G=TAO6-CX0>SW@&!,^2$XZY5]W?Z
M=;;P_\83@"RTPVN7UY\K&LNJ.]RE;'SOZ=TQO7F/70B7K<@4/D_-;:-4C[]K
MIG59?>?Q!QT[N+]#L+ALO=YY&M_^9AJ9N^1^AU#])D$S&NXCZ<Z8C%4M.[H%
MFLYB/9\'KBE5[6K9P/<DE'/I_3.9&%,?H^>!L,NWR[#9'FF2UQ,S5^[U#6]%
M<1>RI02&.0?#A'!,RN^]H-=RL=Y\NGU#V\>Z61QVS.5:UBI7N'!J;YO2PN,C
MD$H&@XVQ(!J1%:,S1RBSV%T] X5S>:^2M7;83]G%RC/Z0W(_#--ZAF8<'_\R
MDZZK'-D_6_V]/0+I^<-ZN?E6=Z3UG?<8W[]4]<OC7](Z_DU:WYZBLA[M&MGZ
MS \,G[YK\,XA >. 0#)-IAH[<H<-*RE]4V$6@&S!YZE%0[BCPA>>6A8S/WK2
MM??E:\3/-1]R^;2#\MVT"F*8^UH:V<D#+EE6-7JM<D=FSA'"E7^,<[$LC%RN
M(;4)^QN>!I[B8I $BA/G8\:>I1HG9):D=;[?;I"!;#-\!>R:/G#H#CPLO+UO
M;#IU_8]9#N0.D:U;"]]'%^S; *0-1W^M65AC/8T/7O_?#;MRBP*#?XD\X)_C
M6O?$[H#_7G_BFZW2[)"?K/13SD([,]'*W\SMK]$Q^(-NFJ1H(.^_ DQ_S%"6
M,]_T^H@#\7V@=VQ%5OT4YS<0S^]83G7Z\DN.#MJP+J'\&[J>CKXC50@455@X
M#',#>Z?A>4@"PD7%#3%"6(^^T,,A6LKY#,A?O,;AB)/B7K]NOT&*B!K?-AZ_
M[T7=2_3)"W59B@O<C:W]_*_8VIM_N]^_^Z.)=O7M,VV#@;_#E[7%#2>;^S)'
MNRJ=U Y&QM6+B30XK[>$&_&C'D;KF!=IY;>@>2QL\C+U'#DY!7+&&SRA*^S+
M*5!VXY-P[@]F99/G59+N)4^!UX-K+>-!H'K^,ZNS=&/;K/9D%]4; _51'G%Q
M5)7IPEGMSFB#]*9G([Z\C!WD:--8F=]N)\D Y5C1):59*P]G5LJ^ C[(Y@,_
MCLME*Y3N_=VVU7YZYV/>KB-E9/](3SOY=V.#AX7''=R*PDTJS8B^W+FJMS1"
MEJ(#&4T^Z/J%Q#_<GU_]FR[>[578Y 4_XPDEN\BT/@I1CTW0+&'+%<%O@TWR
MUODI_737+]'2;'UZ>^#JWP"ER<L  .^C\G> BP#FN]9$%^BQ[AA1=]L:B20=
M@S9?B\4+KDTNPM'G!A]$XX#WGRC&L;";*OHTQ>ZY"C@0LWM.E7)YL*3]UBPM
M8A0_ +"[[<-PR]EB\D?0D:=&IE?W*F@(V4:"873.D5Z-P0JHSB#)%RJ7S---
M 6< C"T*UG'!;7-YK!.0U3HI;^"0$&>\@L4Q9?$2W/W'SEY4 .._^3W.3CQ1
M7I@'!2G7H&5T(B/QD(QDT!37Q8^7O)DC'-*-:X(P@MJA#!KP)\$C\U:7Z@E@
M$<O'X$>_V?A;+WO,M=W!4JPWG<V/9[KWF1"KSYWY,FUB>5U7RF%8_8BJQXEG
M,^:W4R@",=WO,H_\+I[\)>_BU]"LCFA'2&>R_DP<_1?6ANBE<V%S=;?D)39L
MC(Q Q>EIJ>IT)T&&:F*@,^F>4G%-OTLZL>?5Q<C>22,'SLJWE/:Y+(D!Z5:X
M"462M\:"^,!.?NO&TQ$0*7AZ+_D#8W!-/4A[_V[@BS<WOJ7C^257:>,LUJ_&
MZ7O NG<_>[^]9D@]1S6PQ>-Q7E993BTLXD<T<JR?:?KHF/6XL2TEQWBHAPGZ
MF^A!ZN5P22D,0@4^-XRW<QQF[H^;H32\E'F#IH3/+_8]NOH;]QW%0@:T>4^J
MBG9Q[+0U(XF/L6,$TK->V0[!H/3*<*ERW@6#H"#)&*9F+^QL U>]ZD$^:S<^
M%*4HEVMY<:4P.DY DF 5DO:O;O=Z?00,GC O8$;Y'3UJI)\0I99K.'G_4WQ7
MDRC'H*:/"+S+3:XE1*TT;'_&YW5;I^EA0G.]2M!\201>$M6575[P^6UA?\B1
MXEN,IK-K,?\*F<-L5;N,7 M)7Z_0X).D<X[:U.W;U[FX[V:WY);FI#X*:1-#
MNIYS#XG3/U)_FD38T.*4LG&S4] ,RRUTHON2<1\FZ*1Q1 D\>?VXYJ/5>2LM
M(=M@#)T;3Y*FH*F?S=+^?R [9G2'SOJ%*8AKFU2+)DLDZ\OXW#KOOG3'7TP^
M">\#]=(Q#4/(:$I@+=,B74FU4,OX-N%<DX(@"!EE_4QZX9[".9>#80:@'HQT
M^;K" +NWHN.TK9V,Z7H\N=!$Q\MXBTAEXE1;S$JV/(SH2:ZI*?ELQ(I2UD#-
MBYGZ/3Y+RV9%.U"@Y2B1%\92@M1_!F7@J%R/P.[_:2/[%HS.W[D"-WD6=UTZ
MVEL]:J(CVF2DLYY'/SMS\DILLI0+%$HG,S!HZKG!&*&0C1)"I\YY6=7 /-6L
MR,YF%D88AP-HZ8F.IZ&F'IWO7V3"4JD/"0Z$U//]8*V3=N$*#[3;?#FZ8Z%G
M+\QUIA=LJ6S:WCUW=<^_!C?ULQV17$M*0$(TDP9-C>/&)J\P<.?HSYG8QD",
MLY88><]'DJ)+W4[8Z"WA=-0(MM?7PW"R:N>3I9*-M5 ;FE'7'1'R6([P<=":
MADD>ITIP4?A(K)"&/%A-5(#3/>K92+^3'4'7//GJOPV93I%#2PB/HS^D6%<^
M>RVXQZU<_\1 **E#78P.! V6S)*2;8%;I!<7I\J";=7&.13+V+:SOF!@]RZF
M33K6Y/RYPAXYTG"E/*R[U:Q<DM+M.H^JTXEZXF>%$DV%= @:9D7&>O$,[;<3
MQ(^$;QJ/AQ\_G^S[)OK1OV:W/<?!V*"P*C69\R61(XE;!X-$M(PJ*$(F)GTM
MT5SLY/7[UO*\ZD6NW&_TI,IMYIZY-"2;L.IW5T8X)V6.^_'5*J;?DLAMFMX_
MV0W#C*O21:]8OJA=:*&O=9)Q/8^:EG2[=@%6H^4R*.O&\25GM/,B%J#RZ&_H
M#\J^\WU4ZW!@6D-.,"H];7 T);KB9(9]2_O@D,.!+HRAMG:0"+F".45Z?>O!
M%DHG<,H.57-YGG=<>(FC[UH@9+H.<5KEDOJ3T?R)PY*=:;8KYF+6H!S7I(L)
M2PGZ* ^TBNA8&*8B54O<&1I)'<9"X]S;\PXBPZ7'"JYUHT (N$$X6:)<V%GC
MC*6[AG%LJA8<79I5PQH9:ES/8&,T*<$96ICDII&5[ZQ+/A 8=\Q/93/X\5\A
M.[577J!<?PT$M.N,<RUNV',C\/-/!N$E2XPBO,?5H[8N]$4(R:R'63@Z((QK
MTDD'5P0J!64FSX3E$^X582X,Q=SLIHP,U3"?F<=:Y'VR-V%W.PSI0.JXN;IZ
M#Q7UY)R9*=Y I">AY-Q+TDIBG8C&/@\&8=>3*N^)Y1U>BC@-QT=[W#U=^<$[
M#?_N1V::OPI/=W9;>W2LM'L2";*4A5F2E1 4M(VV4Z?/Q)($W&&7W<6!ZD*<
M86SA?9#E9 '95[J0;FT4_\@1M4;N]%?B?9?:-A/5M*/3L;G^"Y<?Q'PF97A;
M'3 B+%C7&2TV$SJN_D#(NL?GAUDU7.0^(Y!,7ZEZ:3;,2PZM3"'H6@ETALZ%
M*M)7^I:')_5$MC=>R4A"+P_&-!M*J5RA2/&^&,=/7E+LH9"A"@;74U7@)6F9
MI:B&!M1=7JKUM=YF-5MWQJP'HHYT8!!0K.5N<7Q?5QM/*45&O>_9Q:'S!G=L
M"$B;DN@2,VF2T//+<'J<L!@(')(B'\/SKR/X$TM6?$@SQUP%QJ^ &Q>8]8)1
MF@]C+YTG?0B4B7W?7Y?<H<XT.*VL8J3F<Z3/B]^S5D#'H17^.05K8-[['!H@
M1V2)+,%KSPM\67)'4B\N%_>PQ18ZL(#1MA!U\:BFCL^]MI$3)I*X>6#&O*F-
MSE> 0*QIZ<D<FU5<#$X"2W0*&0Z_%5W&? NP_^^$'=@WJJMXDZ/'ELUXZZF9
MP:FO '&I,%'!C!0U[/#X8N$MHD-K7 X6@YUL/+G=\1DJ*]N2HJ;$EW(<'5L9
M:;X<NSC-[WBMT4-FQ 5?/'BYJ'L!$7=:WZ=5NI[!N=N-:?^$R8B;I^1IC7"%
MY[%AR';,8+83OVM49,)0,-#C!>^;HB=(Z.%EGCY64XV[_"V*FFS4:E=]%ODG
MS#WKK%S,YJZMWD.[3A%O=%\!]K)O[)XO_'7D1BOIL??P3VZ-;5BHZ"<0'/-C
MP%B6 U2+??>)1]<MSN*SY^-NQ3(8\=D1;TH*63$G)IDO.@D[O:_.:NL- Q=Y
M'R6Z;IJD1$DF!2_MZZN>SB&1]'BK9?%JEMD'%V]T3MVU5K^8D<*;A%UBH+\]
M?0[P[VE<GIJI+J)U>O+VHM%[29CWLPIPR9;)40\M,;EI9^K&+<F4(]Y^12+8
M>QTG@KST TU"&NLF5WD\V\RT3L7=[D?@>GH#[6+[)'U\I!3NG0#;B<$33 T.
MK(413X+"3]YE,GWT[785G973TAYM'2%6(9J#^?[YG3][$QNE]Z8#-1-1$'YD
M=Y6:<'KLXD.ULTWNWK:=YBBZJFE13T4S^Z79L,/Z<_XO:QOK&!SDEUAA 0\$
M]?/8ED\T&\YHX%/^& W)F,)-&V\0T\^EE>:&VR5K6-S<L*^0T70M6L["4:!5
M;QO/QYW#@_K#6<XM);_=4<$_!_@Y6WW7&?2Z8)9X^+SGZU;18A]0.PFL[PUC
MTTT<<AWN7GCZ)[6](B9#F)'3@3P^7YW39[^U-6 V;7Y"0WJM+/?FE3I[]R@G
MXVU<;;-A"[#.IUE1C$]%X_!+2^NCLB<0&G+YZO+F7J>:SP/V7O\'ZH,%;_?[
M71NI&R[9;K'X<\Q8(FZ@,GTECDUHZ5@(&E2&M@+')(0DI?*O:6$>2M#)\>:"
M"-1!'<0-_S205V9^./=>U4)*IQ7O8:DK;^UD<>-XEA,8N,BG&76&1KQO@-/K
MKND91]?UHHFZ8]EUXK-E<.V2MN+([I&<"7#Q!W(<3G)R]7$9A9D@G*ERTG5=
MF>-*2D[#$EMR2#K5=LS-35I'4\TKTG3>X;6AH<JKL>L$[AC5P0NOEFAIE)35
MD;\&-IE;.?+A6TC7GYRU'FWT'# FP"62'KR=]WDD83+]JLOL SF#JHO.;)A[
MQGUZV?FRB5SAVXY(F&:X6[?^IDM#_":3QMX#IZ9_EZW[M(+C>[VRP$I- A.V
M!*S%2DIY'%32"[N',\3IZ"#=-$44>E@:\[)S!L UGPTR7YV#=$O8.Y#4PZ1K
M516AZ-'8G[Y$!U.RIL.."DB,APIOL?MY\GR:;L8U$2Q!Q42+FSV7.,,^G\9)
MZ89-)3QM!+4FAA>>SU*N;7"^:DHG(\KU=C3RJNX?<Y<2ZM :F@@^,%##P\M+
M9O)\Z!M_N JR1'^^;*)<-8Z7.\TO'69I;P,I(F01(#+\LQE#.@%W[S@"ZFT2
MHB79O71#6BZ0&CG5MC)4A2(R]SPBFJ48XUA=-9.$)!F1PK-J\63>T"4FP_H]
MJ7\2I_P+V=H,$M!LW7,009^\YJE1QP2W)&%TJOK)8*?@<-",@$BO1ONE )&V
MH/X)0A0^EOKANGCC4T'P*9UPRX^9_YR\]\S+3]824B4/54BQE&]P0R8 G8ZN
M].Y?QLP4T4?Z[MY+#!GO^]@R052@5Q2I.S'4XL*Q? >_06?Y:']9C.D)P*EW
M_^QOV(VMX.D$LKSUX2%90K&8(9;@:T=6%V*R B??6_@#N^Q#GZWZEB B+-!6
MCM6S4Y88BY,O;OID5*WX7 Y5('=S1M8-W4&1<L*5;^_?$$DF'N[7@8T5TA'^
M7*UWFS-+"B/P/JF1=Q"0E3A[1&(TEETUCX\JN#>'YGMIOTE)[J+%STR![<;/
ME%HA^(W<I=/8LE6<9;CZ&P/Z7=DW"F"K).!7Y(JCJ0W2HA<=[HX2T%^69/HU
MZ9A64!K!0[Z>2S#QKP G$]WH),M +++K0X=K18B77=Q#"L0Z0Z/%W""Z8:]Y
M2J:ZD^X7JBP3O+:Z@>QT12J',AL[]64"V1HB@<Y!J3S+T]=&:2;Z9 =&;NHP
M9.G"11 EH8XHE:=PLL)218I0S\ZOM7+K1F-'\!Q1QA>;MD8MOHADQ5,CGX[V
MC3GCG>%,[@-=K*7C3C.B'&M.%PV,I^V\%Y"@KCQE+Y3&D^4#'AH:DW88G(,Y
MDV7CI?OT/J Y=4V)R&@R<T<+%Y"[N@5E/ -"'N[(/NJ.?"\3_M!Z"4:Q=1_@
M\2GSY>U]?;%)XV3V()51A-*OSG27K<S?YU;!D$5HD:"CAV%>Y0+G2I)5O%D>
MZL;H))VC:\=\U'S<L</UAA19^R)9-X1^JZB#%0FS_K'?V\?^03YX3"?;1P8<
M*"A)!F)"7:0$C2M3= +@%7"15KGC<=MOG8',RR>#O#75+[EQRSP4+Q@(?E*8
MD)B]"&-H42A=+BB@G"1,98F=HR8N7VXEXR3SJFRV0:D0S+#ZO*NH8%UBZ&5R
M(R>LLM/H;;F>A'>+'JG3M=0H+B;T+&>BNV0N)$S>O-USG'P:[0("IVJB@S3C
M9:R^:&0?I#/6JVH Y>9.?U[G%1!EA7)U:#9WI0KJV4C293$F\T9WCDAH6/4.
M &W=';,&%I(\Y>?%,Q+?=KP?0-1$Q%0[M^YSGA1^]3^[][?GUW7N/T+3D[XP
M_-LS[O^EK#'7"EO)Q^V/-+QJQZZ68:+3.=GE]#12(XD%$MPA0964F"3F(P[P
MZX -GTP]"+"5J A3QZ.%?)"JW@(/@4NCM1,5,IG&QJ:=*!3>[SS87,-,JUM]
M,:J/%6FJAS1'2-<B3[O)GPX1N;=-NHTROYA)L*ZH@7):,$CIW,<PN8$Q"F"0
MCN& MJ^24F;0C3M+LLP=<"U#VT2?%L'$.I^M&[;SL64^*DEVLBY.3QJ;!@_K
M+1>C(<IECO)D!"C>.Y$^DY JJ*7O&?E^K63NTDQU6%^T!?[5Y_EMJ[E-<K;(
M^'U)I6A7LM2S_M'"I/F+>A#\AD5Q()GOV"6[A,DKP(0.YH@[Z,[0]'0R[C0I
M_E&7I9S" R)"6OV$6LGYM^7K#3:V.1?:*6_#MJ1!3\!ZQO/WHGQOJW13>IB)
M?C(]09J2X/F>+)5.$^L9##O>PW6)[S0^+1->/BB]H64&[U6XH9>>B=-44['U
MO4,<[8'FY$]$V!##MM0]7N47A<^HT7\%G!T>CP OGR:6=Y%A5NIIJ/A&-RAP
M[OW6F+D)N^^V#_G*%YX:22DN\,Q2@5GE1]T8NMQYJN2DXQI#C-0;C>/!I*DO
MAVLL)J5<<QRR)"6KY+UFNCV[NMR.3,X6(>CRO).7&8?R,E-\WJZLT%U:TV$<
M63A=[I"^T5BT%4S@MWV(S<Z6(82:.E.P),ZRO?@2-MC18 41MO:,P?O]R1>!
M7?R"L=T>C&,K227D)P^R"^-6S(X:)X("G7C+!P-DPJK"3#R)O77.V8+._8D1
M%H2# W_JZ4WQ*$S-^?D7GK_:GIG%_/K)LQ'@;-V1S__^<?M?&OCOLL1<ATII
M=(D5)5PO3972\3Y2*?)8XO1JW7! H1^Y+P;',KC_\[5^]$3E7)E)F]]GS?W'
MPDO2-O!?]!<M/!D>'W+>^5"O:J)H-[/WX9F=2FY/W4FQ6EH[3OS@TQE.3JCR
MRF/I$QY"WL>QCC]A_MRH(_]\(89U=8M<H+TYH(..D%P)TMSI\UW28;D8W*%!
M)MG&N5T@^#<2VK]W'3+#'I,_5CG+M_<8V=XK#XM4I;W2VL]%H^YOG0NZQ8U\
M:[=3&4:#_$$IC:L?+YYK%LOW_)/573P"[=WU"1OO7GO9:7X)I.@;!<:RM<@V
M<=*'MD\,J(_!Z((+(Q/]A,N044(T*!)-('7/I,"]]#S@'.J@=E*6O%56I&GL
M83=?[@E)WPW;B*\ -@L&!1HKPYTT?E],W(&L*K6=9>7OTR/17IZJ>BC+\"2D
M&!6TVU2.UO3_V6-0H!U2?K';/G'QY8"-RS5<S7Z</3U_2_>6;<:K6:.FO?MJ
ML<?LS*36DL\[?I_*"RN<EOE9:>MM6Z'CD=M#OFH5S5EY_&/*XZ.?G_@OW[C+
M12<Y8X7_PI[MDUZFGK^5DNBU)IRK0C]@_77V>X'-;0=?3/07^VKQG^'H1&/?
MF['&?E.>9KL5%F>>-I5^.J=NLB+4X<"@FY6LO\W><^^NN4>/2IY:\G':*L^B
MB-\<AA^J%QQ\[W1KV?<_+VM\FQ>#O#@5&*IV'V6E'%9ONI7K7>H6LOSBNW=;
M+]FY*0=>UMWB)=@VE=VOJ%9F^Y*G!S^^-@L%)8!35J;JSR]S-6ZR"K[\Y;O?
MHNC;;S],J^;YR1B\:NE4-E&M/7&OSZ<YS .FDK_L]\Q!$<UYH!GDMJ>R5N=!
M2>8@J].F/^XPJ::5UX")[\5KB+J+UUYW ],F*.$ I19"PA>6Z,1!>OAAQJ%+
MZ),B@>JRQXN1$AQ22HP'I40[H 0_."-)@_1!4J(=4DIL?L\WE[C,!,^S=A\O
M7CL/3+MS(%>E^?5M_A-^+U*[:O,4\T4?Q2>H SL"78Y)%EK0FQU NZOR,OS"
MN]8(5_2Q/:UW!)E9907.:YCE -A)2!)V:+D3AP1*B: %S?@HOJBRNK,]'BES
M.H+"JAF6:RO]^K;5 '/J!Y@'$>70,9!:6##D@7*X<",S)/V]>)U\%INC]WUX
M"<[=V&(+Y":81/#BM?--OS?:%J#X;F\*V#R-E=?BNWX?F'\E\+F,Y83MB-B9
MKJ>2?5M*?$/ACNY)V3)R_+J( 'B;F>EU:58KRY6@0Z?/,]^%:M2':'1Y>D
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MI7))5+B&#L>%#(L*$2\Y!F@DLT+$E/6 EQ?RLJ\PCD^3!%W&7,D+54L*WTH
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M[+E0@FU0W3I:1<-8WXH)7-C+,SJ<Z):2):Y7SU<85!^D]<( 2JJ:',,'#3V
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MGBE9%8@84"15LUPJV@V;19ATZ6Y-P;!> J=)L\'*D)ASVX6\-7R8%J>+'7:
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MK!IO^->]5%>6J8,/J0"'Q0DF))$!"P5D-#HV8ZQVSN0?)9:.Q\FC\]1D"9@
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M =MWAX=KQ20.3=4P#C6XYVE9CF<-W*TQ!6P/RH++.*A\FG>NB"K5U38@+M
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M^??> T7%?!>3>M5Q@V72(0I(#E5HA_+JB(.S*G#)2SV?+MM%50QS"\JQNL2
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MS QH]MCOY!#96]3<4H>PN*P_A]T+[BJ%Z\0J[:=SAMBW>1D'+YA-V71ZOA2
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MH2*E34KN5V'0>'RV<;J+B.C(7O*#TKZQESX0=(LU<5NU/,(MW &0S'N2?CX
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M ^%ED8K6Q^<V%2K%,:MJJY-XUQ6@F[WB&6'V^M]#X'_^VI-5Q+5)?GO ZG)
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MY#F1E@'+T;28UP.8X+ 3ZA@,C1*0(^C0*4.5%T!,TSC-,K*#I6OR!GYI*@-
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M$:K?H)Y<RI?>=RIW]"%5?[/0TP,Y1#C.E\.Q_%F#,=#9P8+MF^N!>WW.7=/
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M*,T1W=QUE3]8\GDA;UFR8!NS8*D8R/*C/%MY#]C"*SL2;O"Y 4Y$1],J!K
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M#9   R^ "JLFA2D"" !'/'^K_E5^L!1%2#->HK[Y(MF6%^C"/^\D,H%)GT_
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M  .U^F@VEYOGL7&B4P,VVYYDO4\.>V:RZ?J QNFF.G5"ILFPQ:^D^$XRDD
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M"NKR"3]GN1B2I%T1!>1>=Y2 ,EN_"]3YHX'W:7B#;I%N&7?^.CU HPC[-(*
MD#U)LU+T,-)=&6%BU;+L/:>TMW>C:C)&PRR?[1PYLW'\;E-IUMA$X.P/:=>H
M4SP^WA_Y%@!X]'JG<2[Q6W;M\P,W_C*S+?+V%,QOCEQ=6]KI_/[XH-;UO^EM
M_T71'G>Y(!%,Y*U__D@XM-*&N$T-.<M>LTS1M<RU'.':^N>P&%]YG68>_?*L
M7[S1=&Z>5[V#AP?DGFHK<<+<!C48_REI>:?8T*IUHR%T.B-&#C6?;IW,*7F/
MH2FDO7"-S'1.I>PS;E[#_6.45T7'TG0&]EU.PL*DE7VQ7=L6:S<I=$7KO.:4
MQ**3]4L:3V"N,UY5.I!^MR]>4H-B!PW/P\)PMZQ:'4M0&9B7RF<;[K@4RA4!
MS9J[8-QKE(_6B9-9\#V4!?E,8;^;GE)>I2%H^)KUE>F,."ZYVT;IY?++!-,%
MI>MA=>'7JE5Q#:\-0\O,S)\[M,Z>8CF_:D2IA16\XT!Y$]K)?Y2]O%:R+4M(
M:V23BW\PGAWWGJKAT6IZOD_R[N0-B:B6R4Z4C(*24OCLS*7<4+!54G1<9&5K
MTKM75M<+G>.Y@ Z8CY(7"S/P:()_+DNW*JN'V5#\XBB:RJCZ DM>2SS5(W2B
M](XEA/MEU.-$#RM-PNB;X0$YA>4G7=T=IW,:T*+!XDGO+7*$[F&T2.X:[B[.
M@4GST*VNHYP!ZTC)!!V8]_FGPV;K7]V'!7/TCJMI!)@D358.B"Z(8S2*'RR5
MZ[$5]NK<\7LRGP.W1ED[_9#GN5 <WB,626GLD=\-8EW.E=%SWCOU[B2TC67@
M,9YC5NW2'H.=DW22WX>YD#HO5JY0ERZ2H3]DR/*L6+Q-M*8<N_M*&OJH)_C%
MC)UU!HY43=,7I4H/RAGB!9Q'L;BLI7O;.H<!==?&N26T'"-FQ+YH!'8S$H_Q
MEY*"N",FU?E*<N92;+,P'VW#O'(J[R4L4XODC$$?]P$Y4XKR0NWA435R?Z1K
MA//!/DL(0=,\2UP5RL6_$MH=NNBXB<D^_Z4)H-6#U N?H^2"XOI;!YTB!WU1
M[S4$N48+@/REQ"+^TJO%24&'T''78$,EUO(7"S6C@U3<-F1A)+@K+"HO52E-
M<L1+3,$_JOH5[AJM>&*MNX_GI(U7XK$YJ[%^FI4HK+&&WBE'&9@Z^.@_[!<<
MX2'&F6O--U@RWOU5??LWZ\4O,TG\;]/)S;_==/F!+'3O:<;JU?H?N'[5_H:*
MY?6O:+W:<7]5'_\SV._W!()'RP/M\]:N!RL"$GZ.D?+[10'GGRF+F&]SJ/S.
M3\3O^ON1 >[FKR'C'\V)T\0,Y-)&!6\3X/RYKPG@J4X^[9QHF%Q.>$0AB^+I
M3_\UW3C2^$-9R -5/(Q$:,$5GELI@_UZ5%N#'A]\_K7!@#D-*Z_#6JH8"U/D
MZ(X,;N"Z'!%7V]C$Q0K&PVS"WS2_N/1?H6?2?FU%\R59P. SPP(MH)Q(I"*9
MY>6DI>+:UI$7WZ-W/7:TS7\'">J6'N$W<'RD(L^E-QE7,P#Y!:+5K')CPF4N
ME6YV0$U>;T9+^UF1VJ>\[\_J]C3W2+OI$Q=YEQ76.A<D +X#RADSU[RUZ.PA
MKWQ#FD?[;I0$_@F5^?8TE[!GBM"IYIW;!<NG3V]Q;4^MQ_Z"*CGPQ68Q/N/C
M *\#>._6^#Z /P2ZU_4+#/U8Q2FEV_.U,O_"\9I?<U'[!=;]Z4AT?(5>_!&;
MH'?_8LJ ;T4^VMT/YV-+1/<!E[[N ^)J""$.O^!T;E[\L2(E79ZX]5"AE:?S
MGE0G)">$2%$1!X]#R3S\9I65K=D!OU8HZ/8[P,E?W2Q_M?+^PN[H<+"Q95CX
M_Z/;]'N]2E)C9,Y141$TZCNS2'H<:ZA/!T25(S$IQR*\^<_#I?5[2/;_S1?S
M?^?'VS%\2.81-)([8UA55+\:P!'J/I%#RA:Q.O0#-E.J=CS6)"/H[3^[%BZ4
M>;Z?^G1N]"=1N1E;EWK3/.BG:?9O)YCOV^E9:C7IR&?9A'^H_@WL5UP,I(UM
MS0RY;,ORZ-_N^?W ];7FDQ$V=#,AX:_:/\/\RT )_^)FX:\@9\_?<?QYL_#2
MV<<_&F3P?X8Y.Z@3HM8WG;AUR^'V5)B*1:E_2<CQL^K.OR.?L=_]KXC7/Y<#
MP'I_C:+QG<I2^O2<!8A3KF,L34OH7E*VJ,<3]\,AA]%?VY!$9$5I"KM['_ID
MQ"+8<.4.1-]2FQW(UM6ISP>7UI1TF#BX^"<RYC IB5/\,?CUU:2S:'"8'GO.
M*',[T?N [,_6HU!(!&+3:@B5J' #W$&-N3Z8OT%..A,*Y#=+>HA>,-5QS8@H
M%C@1Z1 G@&I-VA3!SI,@ER0?/ZOUC>'6UI;34.5!\%L%IY7B9*W(=GY9]\C'
M/OS .J[2U5,GT-/<_#D:-U4UAY1C]<<M7^[2:6>=-QP>0]F]L]%/MHA8P5"A
MRQJK5\Y>BJW;\(<OI&$9MY&"*M.X^CAI[P8C.C;A5_[)OZ*ZM=7NO!2;-WDZ
MHZW-+O/%M%QW H[R,)939%>,20U,KHG_M*L5,N39%]KB$/$B->2SB13=$;%X
M8P#_3& IWF?9GS=G:>?%;SA]+92EW/B>_7SO1Z1/"WE+]3359[>N&CC:,AV<
M7K/(<Q'4[AN2M"/WWB9EV7E/_\[:#VW4]2\\6@DK#W@G@]N=+@C_1JD\,?P=
M^V)6>6^\BZ'2]V(KM=C\L/:HT-+$Z@V#T8U36PHAPN^V8_8!Y9Y^^O_M0]_]
MARAW36*>3SSS0@M;F#CE!&RPS#Q5!"WA==*G^;]&3V_U*SB]<L.N]/@IYD8(
M\_#"E=GQ+!L=KI0W"'=)QQGPU49%J4'NY8&!9ZHR?5CL!T#[^U]?[.E&$G<2
MT0#4QCU)E'%/$U;*X7W[[TNY_^N^JG])%OX'18;SD$9/>^>-2_IA,GHR8B%K
M:S]4V.SLNO.<@EY,@D'B"6LEW_0/]@A++6AHW%'H<JZ*/?]95QRIN/I*N4*D
MBX+%B6:/Q+B44Z$YO3B2 8L\KN R>IK1XM>M*5(#VC0R%91U%YI:<*:N2W'0
M'[M'W87,90*#3O&^;P*;:]]?OTL(-BB5)P#!8*.O*(-!F0F&<$J4V%C]:_<N
M\UML(&ANK^FR/ZYV IX(5MQ@X>2"&V:?4V610T],@%?X"F"IY84&%8]J1<DL
MC^+4FI[ FA0&KHU<R*NXPRP<*%I_=P077M&IN;2>HK-X[2DE] J!=C\?Q>[6
M^+Y'DVS)GXS%797V2#DI6X7O&F[@SHG<J(]>*3A*VXF[UR%B%).GR6KDE.YR
M. :\E3.?1KFQYWZ%U?!SO@4\XXO8)$\VHI#53#TK4?&1BW*\7*>DQ4AMT^."
M92LG!:8.APL')P+H^5:X-!@)E("L/QVFS-ZP=H_ZI&19'#-(]()(9[^[.KL=
MM3,0+/?'NIW9R5W(F7T E6>#TS')06$->F<?<-]GZ(_.V*7R,,6Q]_WO,*47
MN)$MXA7O&X>6G8<C"=#$1U>?NX5Z>5_*?6\EYG%%LE"KMNQ9<+& <_O@ULI(
M966]W5-,Q*-*Q1\[Q> 3W>;LZ%DG2??@R9+FL'W ];.OX\^#ZX)U3G&6"3;.
M]\ZU%03GWU?8LUW/EE]E]'O-N$6/]/EFE'T1@[(YY7MGL"<4P=4+=A/ML9;?
M)^A&[W=YMO/N7O^(-B\YMYV0TSXC>XRO6M4>QL XJ>M63?L48KEJ>LW'HEBM
MYFP\AY24!)&'&W;Y^!C(-&&AAX&K9 ,?J-;#: >17K32I 17KT5QS8>OT-0!
MW74>50%C*[/(-RJ) 1H\2J6DO(/6.7W:O!A?R4E]1:ON6E$+5T-%CP?2=O#.
M\6N,S'U W_L7N\#4 &U6'Q6(&F_=,=?Z!-VPJF5QMVY02T&M\LZ5J&EZ9;U*
M?R*701>^H^RDH<1!T/- J8Y*Y0L=9#_6-JV9=ZC3U8\./?4&I=$4N62C>VW<
MX5HX7'("&DV)*1?^6HY[]HQF@8 )V29*!AP]=T\7B,BM_1X\@"I=C;!UQ_D"
M*59$4*HLA2];(_);Z"S*65Y7]2Z:UFYU+PDEB,IM339@W0<DMPX'94>62'AE
MIU6 AL;-LIJ+>B01<*^DY*"9U!+:5W*:-Q=10@UZO+LA-U$^[8!FE57K2ZWT
MJ$P-PA-\TDLDMOI81@MU@6IA+[S@;KLP></3SZVB>WI6.T^".F2I<TN@9&E<
M#AUD86ODX<?ZZ&HXP3AR7C JK42-0P=XJ UW]XNQK5!><;N[;I^L!5D/S;.7
MD;(/T,G9?'#D6&$5\%SL@F\8MD_OE8YDQM="\%FA.1*IC(Y=NXHT[FER]O+(
MT&,XZ2C5Q(/$5S;8H,?@,6OO9N&>)!CUEA@+9$=RG =7W= 2%*KA=A*H^5+D
M_1</G394X/U\BVFJT8ZTD0/'X&&YQ9<<!A%791?2,^##'Z4B"1[T*%SR%GC@
M'0\PHA!?&RWI>=XY6F(1Z#N.]AK/L%="J-.Q5C=TO2>(T]V#M[0PH!ZC.UPH
MU@"#6-V^[OG$[GL] ]\H8]&?K"J80LTB&Q"LTL:,8HG')E^]!3+KU['S6=;C
M<3$FDT_V 4K"6:L/NEW?3E=WE+9^OR.V9 11G+6'9R.D^5P-^6K,98$#N(+R
MFO_T(O?0WN](\ 'E(7HUQ5]\:_IJEFXL TYRC_T3[63VCE*!N6Q<W0=8VTA5
MG?.ECBY:[C4V^ZFXS(9H]80<W3T]"SBEE=-6\BQF41Q/J'LM/ZH*G#R_DHLS
M9K#_O&\[0%AK\7;WASQ:VP>\:+&4CW840"T&#*NT$MPG\\8+1'PK&QM-";!&
M.=RF@ >*5<*6:M0>U&P0,CZZ79BVM^<2??-%MYT:J1<T*MZO%)9)N<6=ZT92
MK,A_@M?HA7.LEXK:+T[I!(>](72AGG2 P280.? ^(*7)YVYAD2JOE5%TM)4$
MTYU$L'0[. 9LJ=WUJ6;MT8L?$H9/XYADF&D4?F/^40;[>R5S5 %S-RBCV.AF
MGR;*!5K)%FQZM4.=XM+NW8'0G1L2<\130>"^GUXMB5ZD*4^\&=;KX+FFUU;
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MQKN/KCZR!G+Y1N7J25GF&\M+ZZG \_2KWI3VO8!,O$2)5Z=V>FBQM"9QB^"
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M6:%98B1I$@^<[I6CE,5!WS36X\(C<20^]Z32HQH-_;U349E N-=%8G5W%,F
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M>A:O&UR!>2&+^O>F BP*FT?G)]\DR[ALWJTZ;GAG^#JFX!F,*N&1UF=$C]8
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M?[9=ZO;&#_DK*WOYB5O#^;"HD^9?\DFNE2>0&2(?RTR]4.R@Q+;,JSHK#<#
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MF7^,!]=[K0],PZX=(F1CY*+;%B=MD5GFQ.,I(\KM\;<);ROJ)&3SS%[Q0R?
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M[\X3:!]&,+""G= )M7)*/"RJ!?ZCZGQ\TQ38"#BH2FFV?,P6D!+#@/SHOY"
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M_Z.][XYJ,NOVQEX0E1)0BHXT);01"$A7(?2 0$)H@9%.*"(E2!/+B!($!$R
MT!1(2"%1P!!"E2:]$TIHXM";2$=4KO.]CC-W_.Y:]X_OKOM^:\WY:Z_U/'L_
M.R=Y<GZ_??;>9U/G>+RVRV>,8M?R[7O:XV8E#>IC8U4W3]A&-?'""BY2*KA/
MCO\F;S>/16U$_CK>A+[181-_8\>?0Y6[D4C"R=7K/%@HWXS^@#FH66_)I@D,
M+&Q=C=XV''>5"$@(T9X<+$I50&R[YEUOO7YW9CR[:(!6O#68/_#+/0D$#=;$
MBV+!$//E"=O[?MWEV/'MV>5X5_3RH\7;](O&E@"P\MEBL(:I?H.8%"[.*R$
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M=VE!@9;=TFG'.NMK%-R 9(+QHH2TYOV#M+/$B@^(^DYS.-U*,#!>B7#;414
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M.^D_PW8FM02>E4NH! 1;PH:/5U;23*W>-RF.M%Z[N!&?0\JIVT+O<MPD,B$
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MII[E)##%<1JJ2Q7S#WE%-:NS4"@_C8]0Q%P+2:EF<XDAV,:GJD;3CK0/](!
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MQ"[KIR,[8L[5V6N23HT%IOH3;9J]5D;-%X^GP#F+%;!%ER@C_ _2NPE%0F%
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M>B[F^.F T!. _\;4_7>'U,<K6+$_GK7/:;U#**MUDYV;Y)_:CU='G;8*J1,
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MLHV$)6+E8M"Q3LF^W[DR\-YSINQ4-FZ:Z>)7V5']),($#W%EP%.7>RXJ).6
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M_N3S,I)\OHB*IN<@JH3*&T<R,R:%&/0+KC8]^)BU1"LYG]$MR50E9@)'4[=
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M+JMY4R3&7+7_)D"X:Q2JFEE2T0_2-36_WK*>VWFI+E<RTEAMS<I!:-?+E:%
M !;#\$X8_MGP[4;*P%,NU"%./0&"5EG;[5[/EFTN*HFV>F7K *Q\/V?NN_D"
MZ",N4G"\]+49KK@JP#^.+4J8L.CT5]8,-IR+)8<7FCN\H'=-=*\G?HG#2N'C
M^(6,K.IFRQ\JGLV]7VW(E?8V<\S_R;?R]@3D1<WW44(=4==V3X&Q,]B1,FX-
MQ. ZWX/IWUE/BB 32,_=O_7%N-:#B-5VA57Q>3;7F]&GHYB^KBG(Z) <A3H7
M\EHL56,V%.BX8#IM/]?6<7BKOBKZ<>V^9Q5ZZ>Z96("2_:><$?.*6O0I3/L.
M;2T"9B?Q91I1 A#14$_4CC66,V5,A?#E[:.EL6X>PL[@L^[P1_E:.WJ+LL&/
M.+PJ!36P9!9B.UZ,F94/?GMN""I\_4,%5>$";:)6NCX1E4\XDJF0GB7X7TA8
M@,NO^Q[T2U;CZ_ANZNN//[M_&9ETRKVP*HXY\F7\9R)1Z%.C0O-#YXPGG>,+
MSY0_>=AN4QV&]V]%DWIY4&C@7$/!Y?N&#R?1\I@9-#2"&T^\Y$+5K&B^^@$/
M>.V-67M<OR-;[]4O[<JZ']C\DW,Q_AGO/41Y2@G"U^7N+T_'VKPWKE<)-=!*
MK24)!/%,UD%7=.5 U-A 6!$<I 2Q>  ^OQFN34\N>#/Y]B-F5&=M:DLJ&I-<
M@D>1(O4[LE1_]>;/=''\'^CBVK^@B^G#/S>5^#..O68$YUE';$$@1@D]""W.
M%)HE[Y[AV!GI);N6KN86]I+J,NH.]&O0&B=+#$[H%U<%V\D;Y,N^<,B=JF!5
MR0<+HYH!<XOF \KYI!OB,^"!P=JF3R+K8W65(<T1(T1\!"]"?>J:8@(4I%#5
M[K"2#^6G#[Y:<@YJ"&^?,\J[C%M,E-V'C-9:@Z:K8%N,!*?VJ=6-L-5Z*WLG
MB78.A?3P8G(1>^G\H%-,,)',G^]^6NOTG5\.2G\*3;>O]=_8-MA6J:9RPT)S
M:3#G!.%3O?7#\_QA'#F9K,D@=09V>&,% 6T#\O:)V9;QD)=L2U=,NO75J>_6
M'HRFR:KA(SFC)4AU%_*L;L<E8)L7T9BU21:V-N:=R@^T=ER7/I\H"&]&X .E
M6W7\R=K]&F0!,(4!-5\+MH]N2MO1VOO=)G!B(X<%[0Z0X/+*"7"GTX&AP]IU
M':Z,MZOG;&P93NIIZ#^9B)LGUP<D:+/V"BB4RG7>_<O2.978=XT\.L]@)Y '
MS&TXV0_,V6HK8>A@+O)<,[P^UW3X^I_BN_\5$;?P)T3</Z\4^DLH??3#/Z ^
MI]GYVJ84FU).C&E;!.*MUJM!%_4;Q47?(K2*G !GNXOGH>7Y83N/GO/ T)CX
ML6()+T!]Q04VQ.'$Z+M#;QO"'.+V'.EAD-=7BYQ4#W6R)Z%]]A/+]T-$T/S9
M45AJ;=0<(=SS2$:XXB8_7#*#\CS'C9]2VG>Z^9##,ZLTIYJ)+>QB!T>;T7HI
M$DKPZ,4Y=[HBNEH..\CW'LU?>?DJQ'@.H+"?\XH<'6V??3MSF*L[C*^R&C"Q
M1^!]E\.'V7CNJHGP<QH >&FEI)BMME/!O;[TLFNWN[<^"D]O=VL>8#N(^L(+
MJ50[-3Q17<0")SVANYQAE2"U.'P,=M*C0>A\T94\>CO<6^?$A7LAIK:?M<,N
MIJY5;CLXWN_M54!1$N"5)EKXAG!W%0K7HE2I,U4WZXK,N9^WV#^_7_B/D/]!
MH QZLWEIQ572QO-?W_NCF**FY_S>OZ?/G(,F;G[D:YM2U>[&X=S;/05L^6W,
M[]AY(RR O(@T>>:$;_6PF5=M#\OJ2,8Y6V5?Y0X_4+XV*-RKZ1:5:Z ICZAX
MY8S&QVV09ZRDN[^GEBP'/;$[M ZWX(=;)C%"N+\S'[O,RMJH> Q^4Q!;R=2B
M%.F^)]454>H@L$QZ &YE!N:XM19Y(8K_LCI;#H.>F+;JC!=8^JW&%#GV@M'+
M%+ME6?]KP_B=<"^E"%[B7M'R&>_E4O_=ZTFW3W3HI;*+U^]/-3J"[X2G4>>U
MQT1X5/&%HK+]$T)$"/]U3+<_S9X2O-4 @P.GN+IE$[U^]S@</.-*"_I9'CD%
MB<9N\4C1"A]_R;WB7>JFDWYH8H(J>ONFSU"X&IE//(C4@QB+PKB"D@$S, 0"
M^@#X0;_; ZM[__"Z_O->$)7F?_:"Z(<?_MGEXM]O!0'LPCZZD7[F<1_%D0L!
M-R[FG4G%IC[AM^SRSE27>E8[<:6Q--F3UX?1\M9P'Z06-?H@8"Y^VWC,RQH_
M&P["L."V'F$H\OWQTTG9JF?![MCE<&];U\D!J%^)08[M%Z-IO%.@/A%9ZW"!
MYU<0_ICMZ!#%EP2LX8CJM%12^ZPBQ#'1HO_J/NS2K%XX<+A0I1L9LGFOY/Z&
ML_F8&RLV=%5T(63FX/<#/J! W>U9AZAT?U:.*NJ-)[%JS1$2"H])?]+Y,F#V
MY?S-PRIY^&'(:W_]T?>955??X)=XDPCU0WXZE++WNP0WT9N<6@ MX3IUU3T(
M@K+3+G@"5R:B9P87P@Z>?CM5@DNS+B>H4V<M+GJ>&QKL5>!YM8@2U4<Z7%F7
M/IV5CY\JSQO53/)Z-J& G2Q! WN^ USYZEV)S/&62IFA!W]W@?]!G8[G7Y/!
M_TE'7?3'SJK_UO[I\S?5,/\<U#/*7G5*[JKJE&B+2S34==LFB(C91D(,D6N?
M"AQJ#16,U:1R0V;6]I0?<,+(J?KML.7\O;'#J[Y 12]XC.F&3383'\A=:$GA
MYN63/",?F]?5%ZF<XX\WD>]Q_!E^, @,2\7'[[#-Q\\4G<7HN1;9Z0UQCF3<
M9FS'5J@O%\>QJ;GEA 1?I])+-2.)&F.=-FT\Y_I>J[J^]Y\<^#6 IEI6SBJ>
MH3Q'H':%E:+B4ZPSXK2@U"$K$<LZU/P-G]S<L0B6.G2W3FGG;Z+H<D<RX7"O
ML_>N]ZZ%R[\@,74&S1(^!<V04C\>[LS>(.3.. /XUS8 2I%DKNJP;T@"'A@3
MGTWRA'L=].7IBBZ>4%,O9%DSWZ2/510SF'AFOZ[3X+C1NI0>@\<0?G4MOTA9
M3LZ "G-BNP7D*ZBW#US0L?#I#W!K:AL_B-L"R<9;CBH;^[%?R\,K,;.0R$-B
MFR:W:NZ\<0],"0TLLZOT!2/%U[I#W73XUX:_@-@[4,)=3GSSTV_G[^00Y)B_
MZ<#R=_M7__T +)_0P.5U;ZJ*7^"H*0&9"5;-;1?*;G&X(8/3UR]J:&@+^(T"
M3;)8+_K:<&ID&+EMC(JG;R)PT7%* 0-!X"MB3VM)Q7+@8?#G[,/^J U''C7+
ML,1\_&K$DJQ_7C\XI5YI"S*6OQ53I;WTMNKC <PNGA=/K4:\Q(1'\/JL..@7
MA[6I%EIMKK@\Y/L#N0/NGSSJJS5EY&KF>'!M-0RM^M.8*@_[3<"22D]R;#.$
M"Y&:SOET. .:XXEQP_2P(+X\# 18CAD:&LTWS&-EWW:?'ME5%7<'9,!!@ETT
M*P[W;9"L[\-DAM6 )TW:"YMH'Y@UC0;L) Q ,+PL#$WU:M+YAJNJWJ9YGP38
M?5?M.V:7KN%>9V26D*C&)%%VLL]4L=X(E5NZA![\VMSA*B^?S4<NV$?N:@BW
M;W\JK_C/]9'_!R+@>WQ_R9D36V_\3H^ *D3XYH&33/SMFD]_$%>$3"YJ)A8.
M^UX)%#_6GVI8+0L8"4SHV*T\'-HQX]4T#O/<*A=H]1:WF4&=KN>L;)AF*VLY
MV(GHI!WWI88^=[\:DT"_J J6I?NMDHABJ3UCBVL .Y5"K!#,P(&6?5LA$5ER
MRG5C&V/+Z6 UEA$)]G50LX0%'$[-)094>YK6\W(\=L!U!SK9W'43<\>WNQA!
ME">;95J7$.Q3-89-*?'?J!/=I.-O!T4FTMZ;N"HJR+6@ZHWM[9P_DHDO[]ZD
MG$XEU89I3KRMH??F3,%?=," </:1C BW$G[A4:N]=L#SUXY) 4S2,EJD9[E4
MHREKEV J4A1%^TJZK9QIGY;1KO2%=6]D0$,/;FG06&/%GXV.19V?P_5$?\^4
M8)-7@JA$W\U'+%3T@69DL?)D^K+]\0:<SBC,V]@:9G(_$1*]AEG=:?A@_S[$
MFDR,+V%&9N[0A>:Z',;2HXTY9;VE^?!YS**S4GL$-S1>V.I>@H@)&'5]\-DG
MB=_\]=?T[_- ^L>%4O\2CJLN7<B@?O,+PV_?QE@:2NGZ\7DX$ZF/XU,Z9HRN
MW+6W],\!'024[C]M5%K*:)B[(+Q,X31>Y/E<V](F5^K#@ELU HJ6]>(V^Y#Y
M\/#P4YZPEIT&9%QCZP2./\6*X"M!T++H!77\=@3,^=Y!$SE-;\#?Z#V&$3E8
M:&W:DI62./]Q;A";PGO!Q@3V._(]'3O#B>TSVQY6]L;(E/JU1X^!PV.Z$F20
M.QVR5Y&_,L43]61BQ2S68\TE94.<V<JIY&2>'!*9-/[IL'L+IKDWHO^4DTM5
M-C<DH:+5FYJ@EIK$EBU,O)]W)*-CH^W[J'A?XB8)]AY5[,/G'EP.MN+44,/$
MC!3_K)22\F*I1Z:J;/&QNN'WH7*@Y'JK_@CA2@0,?EO?&QH7%]S9T:?&'U4+
M$D)#S=>N5D)NE^A^, "\]J*C>@IS-^U19>(W=]4I,?]S=?]]1@D&__W>[A_6
M$?P+@0%0VGKUXBS &B3\57J2;IMWNMY("?4:[M[WR4MK.]$H;"?CA=]PBH;N
M<#VR*MY1E!Y7*+!\F[^XS-Y94T#C)N2@<I?B>O"1*\9RQ(.E\X."F-4)*%3:
MGV/;'W3>N:S_%EELSG/ZJO@S4:$GN:)4X<L9#@9/9EG<5MW\H'<8QPA(*=T=
MXM0KBO'/IV)AO6Y$_U:^+N#S-P=^S:#IEB5E]5F1ZP-..Q"^Y\@'\KOSEU^.
M3;X^K5#J'LESM'^(Y1IHE./)K6/4?.%.$SY^NTYXO>GU%6I /7SO"4]L.&4^
MKG5A'=;^^WA%VNZM42+3O[:,;24A/XMW3WO.Y:706VCWN_)NYBY190^E]>V
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M\I$+>NXH=1X1WV.K7=.15'!'.YDSRN':>G"MXO>5Q^A!B\Y Z^T9/G^#DJD
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MV[^G9C&SG9R<'#>:$)YAD)=5?#G,/>;NR=L?_72EI_=W*CW3_[^YW1Y7 K5
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M+):D*=CW[,A!>)9.U(JW\=I)CO_DC=F=N,3C6>?"U"7\PQQ[J,4@0@]6,^0
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MB"WI_NA7H$!S\O4K)PT!  5B9-'U@KH"G4)D5-7DL^&FR^=UQU*KY=O=I')
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MT -59>T6\2&2F'9;Y' ^_\DQ?P[UN@R)?RP=K-M>M[GT(U"&QL_6T,<E8Y:
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MOR(Q5)T%2)2-.39->4'J$/4_\0[MQW!8N84^Z81@7KHSVW6*]A!NTYKRE\1
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M6)::6,Q/#W<4AZ(HCI7S_[JUWT_^GCLZBKJ9[/F0?H.,[Z_5V098LPP?N 2
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M8&*P)F:W-*Z?C\S?3!FS4C@EBHP6,W,H?3Q U5D;#1LTMVE_#!#YNQ3T+9T
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M,7.]._"86NK; :6Q@N'&B9@"8M7&0S0-\-(^NN\Z+?R/2:EL1\O7Y:ZM?$[
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M78=5%XQD\LZB>K0B:S#A8SO_7?B>+<DCV+)6<R88H36C*<Z1GL7S7Q73:?_
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M@%^.#IM^?>(RI-?%TM@"8BJ2I-HVL,6O"DUS>=YX;CSFMT7A?3,\RSG%-F"
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MA3>]PL3I&2.) >P<>^_"Y<D@O!/5\?E9O<A9:*Y3+L[Q_./2+?F\6(OQ7+Q
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MD14]QM3>@*7#D3X:[)6.]PR&O((*-D)/4O)L*C\++8Y4S=28?Q:1"DD(5+$
M#X^!UN.22&W&=L4);N=*"G:T$3-ER,--I\<5O%%7^=[CEMH25CJQ0;]7+<BH
MK69LQ*D-I*P;^TE:F1L[!IP'74E#!UY/G0MFU1<@#)Z*NJ72K@E:MF )-]=
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MD2&^LWO*_D*'T1W"TU$[Z:3Y3@\_$6)W>-"$**/^<O#H'7_55I&RE:!#[!$
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MVIE]AH0M^.V-&61J%5BDI,VM0U3'H/'/8;Y"O#/61'5<WJGV/V5*U'B-2,K
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M,?!+H#YS=U_?[G]*M-*TW3\W*2N7K=&E4G*31J"US:SSG;7YP?M3J9%BQO>
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M85M!Z1H=E?B8T/$!M3)O=I4.1^9D6BSBW##2IA5B0G8^&<_:U3J^8BM<1]!
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M?2LK1>;5ZLSS$]%"H&>L9U4F-!PH)GV!,':5&&@YW/\II,F4?CKU&M9O:YX
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MZ;,<6KCF$?J&WG?3/4U(AA8*4\DV?F@\TSA.:;Y'7)$>8S[A62'NI"2WP=4
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M%2&=RRZ[GKFJMGH]3PWH?-OY-L.H=>8#J3/"IQ4[1$AG1&)IDN5 6S[9]"^
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M$=R7+X VHI3A,S=@>IZRWBZ?%@/,61CC;U$%ITNT2]-$,:*+8$]\=[\1N @
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M%M]*7DL2T8US9QH\5BNB;+UG5@<6[ZT(3(DK^2O>W2!HX_!8<^>GE\:Z.XO
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MU@0_=3967KF+](D_,@/AE@R6M<I%!!K7QXK-KDD'?V(+Y*=">F@%1@T)V"^
M41/:73'G.Q@(U0428KZ6M/:Q'@I?G9H=G9WVDST7?!=5M^3;P&F5P\NWJ9S0
M.BJW)>T=-.*EAB[P.D_ Y4+S%8KT6;O"\:)[7AEPV%I2F8H22?+MI,^T'[U[
MR8(.*20D0U?>09QCILV'?]*D$K4[T(Z%<>G!W35W"XL2[@E.:0>_L\T8$ZC#
MM[Z>A)4HQ*YFFW8'V8JA6(]VOV_KFXF#E"0-22P[U.'%NJGSU589A@XP'?R'
MF1LC)^X(CMEL@:(BEGTS.LDX;X9&3%-&BMPRPNOM$;!!LWX%I*S4E? $[EG=
MJ*%B\0O.00&%WT8BS*V8VQD#/D2\M(ZW<-".VWMK.X(-.9-_C.'-0&#8+YC-
M4#'A"LEHI'4TPJ;DC<HP3FP*F*OQX.S$;^0%Z69ES8U6S>)@883&EMC$::Z4
M97O#^XX*C")88I/>B*$;Z.%S''&[V6_ 3V$A=2 7;**323>-;HGSL?%^4PYO
M%M-$SHK:E3$'5[SMNMH0,W_%VY\-0JX9U_,$OHH0D&4&I1Y;.'>S/<:7C#)8
MOI+D,L8INC3:]N24G?BR-XHZ19 ,'Z6%I>]4?%+U[700Z^']A*_EOQ>TM\BP
MYA80K$E"R2 -.4O\1<T^3#$)@/P]-:R4?J.LA2;XK?E2]#'U;4^&^Z/I6H5Y
M 3K!RSZ8A6D]I3EIKNE"X_B:,%)7O1X!ESTYC7]00&(&#=)AB<RH?@7:4XQ9
MJV92MBA?.T>%;S0I ^61L"V?W4\)EC=$&3=(HKA6"XB#I^UI)<)MH9Y.(Y!S
MR<9-3E?CH,ZG&3W9/[_T=L32:XUK$_L'W#2-/JXT3_,[RB;'Y7N.\V_Q[ZHS
M-[H;#?7;6.#B;YL"D:"$:CVU_5?]XX3?4V>?S?\=>FC_<*V$@=D[?W'/2LF_
M?[CV3\3>]!O *MN^2U]XLQ&R6K9H/7TE7,ZI6K#.[>YZW/=[N&$WI2^.B-^K
M^P)X/BN;J#<6WTZ6_.VX@9]-;E)BVM%4TFA"Z:/O6PWL8,LH1(Z@";@IC,EZ
ML\CH>Q7JY<5IGHQ-'R"W'QWF  N3N_P['8;--Z)_!-O=)E'F%KS];IL6-I\^
MTN</,U@:0!V.\@%\3Z]MDJ_&C"G5,PZ]VKDJPNY)&-+ K+3=R_J-FT_S7.9'
MLNOLQ5JUHG [?=W55&[;VP=N(WUX#7/VV>%'OJ68LFD?%8<R/LT6:HIQ,W6/
M^1F(%"+K_4IB*C %/)B>-&"&$XLS^@?-[P4S7$D'WTQX!ZG^RM:!>Q=FDL\U
MC>=D&V2.R:PDO;EXV,CH0WAY.G&#VT#RMM^1IT4[_:5+:V%9!_GBDIUM4J_^
M)$M;!GW=A#EP<$4#5^Z;?TR ;E94D&9WC.&L:Z2OX('PE)<VPHG+3Y,J+R%(
M)$4?)W+(7>+7+IY96-WVGT2YLO*2]AQYWNW?#G.I@O %B+X;=96G(W>]SC\Z
MR,6E0(NU,SCS;EMC?[@Y'QVL&T.)$/UC*:YM/I)BF>$V#KI!P;)LWF_.[+U]
M^ND/E1D(ZUSJ<V#QHGI/059)"_S7#]QI?JZSO])F<4)@^JMKLELL#BX>XG!^
M:]1'74%B2IL)O,V),,-K_2*W_"2R*@#UE Y1AW:_:RF!L^\SHFN,[GSMW5GG
M',2"5;DK2W?9Q^=;!VNS$QO>V10<%^WKHZ3?@: Y=4- /[T48V_2#QC%;)DJ
MM+P07-$\B[Y0?T(0]=1O[_F#H@,F$&+&5)=Q:-.X.>#!PUJ:GY'>V-K=&"Y)
MVK4 \A/MV<9K!U[ZJZ(KO@#B);)O]XFPL[BX$D)# G.BOX[6$A0I3'')*F9M
MJ7_X?'6];\6M>38J[N2CLZ(>,W ! 6>6I+*QB<]ET79<GX"2M6#+E$=G$:)9
M?4V:2%D3OH"ORGHP0JC!<^DV''[2WTY6[8([HBH'"6@PG5PW/#^(U2)O*)U#
MB$Y";WD]9=*Y_%U+_V)PI#\;W(]39Y?N_4<&]\_3 =@XSA[BR==XP(/=>GT:
MJ3>:JXMFCI>0^P)811+ZB(9GW%'VJ,.+@TEPGMWT0N(A1CA&C^JQ!JT7TYAX
M'%_%Y2,I(USTEJCFO5B&^^T5X#U 5[F"X=$AI6T@$'C6+?[PHRQI!P0S<..\
M%Y(P6:/8NC"B7,'^<X/3Y&IE2&Y,3E'"8$#WYS.RVO<]<]-V69VP>@3(<Q;Z
M%P!OG/])147\E:[LK ^_QLKN]"T4*R5<=WPD\&I_F-],W]>[U-J/YH!%1+<@
MS>5&LJHG:0O)Q%A4IZPPFD@2FQU26C8?.O3@R/DYX?_N&!TV^?U8X(NO)PJ
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MW2!MG-[AV?;%=ML7!$)>444)(25GJP*24@ IV$HAD&B0E(J\LHVB+ J%E%-
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MNG_25<]UHN93Y.OYGCQ/$5$:V"=*?K0WJ3/<TPL&_2U4(<U[I+3(1V'!=Z!
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M![Q'0%[K56#<YF!NR4VFW4K2Z&S091G6WCCU3#)3? T?.1(4QPP2G?]#\34
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MXQN"'-F R[G> ==6P^$ERX\O=XI8^J:3F#SQI&#J*,0AZLALI1:Q*[/P</G
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MP_M="J9_T*' ^GF^,TG/=]XA)@ >UNMP4C[$Y"!%PWU^A^NK7P&1HO&^]#$
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M E%GJ2?UN')O;I<>K!M'0Y<%>$ Y^* <7#[G2IT/0V_3/=,V!26?&(:7J!7
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M!^'1=<.^>HY?/R1Z*K1"_$(B1+B8JWW5OB\<#\]&6?&$#M%U*FM.;D*N5_+
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MEWR(?#.S"<<4FX9-_*,.&@BRL9<K4"M9&R6]:GLZ-.*9\^"<N!L<'1?JA8M
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MI.%F_HM)$$%Y-3-F[7D'PW&A\N7!N?#+@_/#=]X<1B2O;1Q&9$D%_FL4ZC4
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M?>D59L_]F#3OX+EG0L9SMZ4<<)4F#2BOGO&F)3$W83NO:4 7IV0&/01J"5
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M0"PY.@]0Z42*T63QO"P),V%UT25W41W(GP<6^QK=4LX\9J 4G%(83LE]:5]
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M:]RMUPP!M5 _72&AK<_:_P]02P,$%     @ Y(D$6VTORG*MJP$ *CD" !$
M  !G.30R,CDW9S$U<C V+FIP9^R\!U23W=8N&@0!J2+2JQ1I4D,-3:3W7@-2
M0H  @4#HQ0**J!3I'97> M*;*" 2Z;UWZ1VDB*AP@G[?WNZO[/'O\__WGG/'
M93)X1[+FFO.9;<VUWI"7T]'36<!E-255)0 6%A; %?,#.-VD7=%Q</5P13JX
M(IB!? ( \5NJFC@X  S1=@#.Z9S.Z9S.Z9S.Z9S.Z9S.Z9S.Z9S.Z9S.Z9S.
MZ9S.Z9S.Z9S.Z9S^+Z73.=E\!P\/!(B?WP7)9VWK:@/E@[C"^7VL$?R"? +\
M "E9'X0UQ GJP6P#M8>Y2+-LU[]E88;92K,8BV@*:"+DH0XP%3]WJ+Z?E@'$
MSPDB8<LB*T,@Y0/R@2/@4 ]K9A^XLPL2Y"/-\D,Y"//Z;)B?A?G'% \G:1:Y
M,P:SB:8.L[RK.Y19@D^0%R(@(,0L)L%G!Q01AMI!;C +"0@!^04%^04D> 6%
M0,("("$QYM^(188 <Y5RM[4#Z2DH_8:'>2?-\IMCWM[>?-Y /E=W>WY!"0D)
M?@$A?B$A7LP,7J2OBX>U#Z\+DO6GDM_U*$"1$'<8P@/FZL)\]M[:QM730YJ%
MA8#Y%_K-,3CB'T!_&<&_$D+\8MV_"&$8&"'@7PK90OXA@_!T=_[ACRV$'^H,
MA4-=/) 8.<&_!OO]#YE_ _D[^V^MQ;BHJ?GOG83#_U(2Z:'HY?'O)9$&O@@H
MOQX4Z>KI#H$J>F%<8?UK57K0OPG:7ZO"3/]+11XPN[_1<\;YVR! ?6!_(W;&
M^2DF\T\Y*4S00/+N4&L/J +F5P93OR*\ N*\ H(&@H(@H#A(0()'0 0$%)#B
M_\/,O]+AZF[@ZNHLHZ/_HRI%^&R=G9F-H.[(L_H4X1/B$_I%RV]S_Z!&T]46
M9N?[)U.$0$+"($'@KZ;\,O./.C#KUM;:P_J_I.77N;_HP10X2,?=U=83 G67
MD8.XN]I8>S KP) >,&=GJ#NSH  ?YH>9TQCF8NOJC>22XO\7@5\4V4(PF?1P
M_E4Y\V^K5\[9XU]'?V<XP\Z2"7*V=K&79O'AM87:67LZ>[#(:,(PAB!=[3R8
MC5W=;9EYF?4A,&>H#^:%HH:V/+,>IO$A/=RM?[0#?0^,1V<+CAGS1LG5'<ZL
MSRO(;"G&!Q3D$Q*Q%!0'BHF(B4M@LB)A*<7_$_4/-O+_V4@I_K_PY\Q'R,^4
M_H67^E"WO_-2QMT=*"(A( '\=P;\J_P/ _X,=F:"'<9):P\9&-S:'LH/12#M
M?LS];?37U/[>2$#RKLZN[I@Z@LH(2_'_U?"_%I:F)DC5!>EA[0*!JBK(8 ;X
M8#!;D* MU-K&SD:4%R@F)L8+%1<6YQ4'B@KQV@I:BXO:V%C;2=B)_:BU?Q7_
MDVH%5XCG6;XPO)\[D*TK!*/^GV8)B8D*0@2$17DEA.T@O! [80BON(B=+:^
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MW>P153TL'V#>LI2X(48)G+[/(9O-K,_I5-RU_MSU%'#?;YDV\Z73X(TC@>9
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MA!F1T40+?.R"L9\=PWKOB]?W$X3D,*<L\%(C4X9,UAALA4DO#:Y$:0DG$0S
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M!"_+^$@HA_N'MMR5](UDG\ 4_X3(ZRLGFJ3EKNZE_3VG@-S^86E/B)33O5.
MG79S [&G]<QWV5- )L?<[87^"M<Y<KP,T1(\-3VR"'AFM75^G,:N3^#L,*7O
M6PXCTJ_:3#O%)%E5(0N#1'>)ISKH%N+$9:R1@<0.VFP9'^T3^FHU7N95<1 5
MF07-<.YQ8V&.X/4)(^BK:5<B#:<Z+GQG&;&WR_$ZV;JPNW!GNZ?@NU62W)!7
M&T/W)1GLIE. JJ4V\=-YTCR43*ZBRC=G\_6DKR58 5*/4I:=(BLT7H*VW_G
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M,_:J0 /.GOG12_M/NT<-KEP\.^@8D%PTN.S#61OZGQU*[J^:,.@K$@>2V0Z
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MEKINC^[YR,J9M1RS][C0>!:&+C\5N]M>)O7<$*M>=PKX%;W+0W8)^/B >,%
M;)[_12P6FEN:5FB9IL.U6E5:B*GE37.'KU/ >-VR5Y*V7]*M]YN?B8^D/ LV
MO?*.52J)6*?G\I\==IT"ZJJHX!9D)YG^CTPQ37E*2$3H6!6"O1\GQ^ H]BG%
ML.+NL3/Y4$_$02!C7OV&_T%VD;<Q*(V'^M6TMI%WB?FM_K'"",$;SD['54]\
M76]./N9FM5X]LFCW:!.O#%F.&'3-Y=&--#?=71YIE7GDS5,CXIFCE"!:)03:
MV5I8C0LSZ[!5?/!4%VQ[1!$NB_'9ZW8^?<#8^)U*(:=B&@4CP4FK.V[,Z/XW
M&<5B"!^-A&(JSC>\Z6(NI-,%[-3,]',:"05,!I;7.-&84PC"6ZV6YMVHA.*"
ME4?! E=4<E[2I=JK/Q:@7 -6>P["&X="\>;-50W[;#+S!P8.: H#?<+N[5O[
MXF[MY34]G0,)PM QNOM->O9-A&!4]X3FI9TV:^*IVLV>;[SNTHK983,7)I<#
M7&SM3P$4CVMAA!$9SQH^PU9,P],2!&I<)'J:&>ZV!:#9-T??N>IN!EAKO\7<
M<U_38R^KBLB17=$."]NQ0M]Z2_=(+P).Z[68NTP";<^HNY9P>;@VTZ=5A@S\
MG;XX^?+MYF8! 6V*6CLFS[UDA[GP?K6=81*V$GGFV6T"X470KNX\MSKOC?X!
M4)F0[["*4G='>:/;W'!YBBY-EIKCFF/J'KG(D;BX87)=,M%>667-NLY0_@@#
MTYUJ90MD?HV\&=&T_V1C7YFW*P>7!2_:9)([P-(MOQJMR9.)"-_R\5)MFE02
MYRZGN>7T1$FM]8T8GDCC966]_0I&+9<X.D^C\3;VI/T2N'BT<DQU&3Y?TURJ
M)VIWVXG6_".V\A4_BL2VT#CMBU=,\*6R;]=]DWCN'YO"_G&\?ZFN+E&B/E2(
MN)U[X&#099%E8VGPW?)PN3T)H]=GA*X^"S^NTA[T"QW 7F*R:,(K<_G!;3(R
MWVLU$S3MA/OME47%05%A'OVEX;Z3YAOL[($B1F-!)C-E0E[F) M4*D66GEFV
MK:Q28*O[X:5QGZ.+*178/,*(USG<2>MXN)W2>.5:]!7FT5T^W#%37%8Q=JH?
MG6JL7N-0?1 K1)KB/U"OZ@IR2T-U+&HBL_*>E7%]1-[KIMW1N?UBNJA@*[:B
MG#HG^;H4T5P/H*1!6D/_77?K8;P]#=XUO#%*D&37U8AWCM<X2N?,#4?DU+_X
MFO1,>UTVSZC**0YZ6:^KAB::OS9F2>:5M>PE<5155]5,N&\T1%&QOSD>;S(N
MF%H[:I!5'%3X2:CTZ^Y2/2=?E(FF5^;#]R5YH>(>5/>*&0S)89W=_@I6V-'>
MUGA3%.$B_=$9NO3Z+9_)PT1FX]9RYC4U=L9RPA\L6'=C7?S(8S?<N%+;Q$HH
MF+KITOQ%WB,[7I_N>F@-O944\QM%)UU+;2V@<&GYY[2')CPODCE4Z<.0-\<_
M>"EA[$4_K:2)*]W;A4<#Z" 2EGX%HUPF#%)%#I+WD:6Q5%QQ,%5$4)[X.U8F
M3,@M4B_N!0Z'QU!W[L+#7"9HY.X\G6,WT A56:6F&]9:W,VI'3"X<BU9+-6^
MRX>37]>T"YG]<$*HAYQ4/_W"<7*-;SHRU:[5+75+[K,B1-LS.R_&AN:C?VFJ
MR&S!L/DJC&UI.?FZ+,V[="PYOZ?SVH97=_>BI(OMW"I(E PS^86UO3H<K_&M
MD>(+<:(<"U_DT,0K"4-DD*^>&<M)JF?&1="T+D,O]O.0TNDAFV7N\!:C7KT9
MHGAULQ<:%PZCZ4A[0,6)REO/7VL24$//SG=Y&;<ZH>CUG-]D7*]Q:?+!Y^\+
M8"M\'-OJ?KAGA5V9-BI=.*^)S,[WL=576&88=6J2\WO2G;&HJ<UL6ZXTPC#*
MAQ5(9TSX4N@231DNLB)HCB+6&&1ZVY2^3Z)Q]MZ.VH$N(C<7.SU>U'Y>$I^O
M#RP')NH#J2Q $ONBY<L EEA>6<"J:U**BTTOX&&+N'(4* N/J^%.N5%A)',5
M9T4NK>,68C))>Q9Q'$R1,WAFD2?6'E6UXHJV&D^;U60^4/E<B9)F_\!'9CI@
MGN\HQ)(N-FN/O&^0OJI.>&B;?+U>_,PE?9[9M1HP_K,//XM\7A697?"LC";C
MK,AG=6YGE!;4]@^HV:3[9/J<1=WX\B!:V'Q!RRDIU9;^ 9.MR5')5?=4H8PK
M6R]VW@QY]NJ%=;'2?>UN)LPRZC66 XIF1$6XN#W;*'E<UP_?( BM.JYJU;',
MJ,I'!25B"X=9,=/7CJJ!QOVJ8K1ON#:ADS=>U"I:\XY'<Q$R2<E-*<[S;(O8
M"NKO=?M+O,)J\]I<P?BB-YE?D$Y#5%J+?EE\D:-V0.YZ2XS2B&T8U;V@ XJW
M(?*=2;ZMSEB8$K?DY/,H?VO#E8$L#\.[@&&F:;:FI]#OEY;+THS>GBL*,;'@
M88,DXGH%EPD$+0(?6G6@6)?(1'V>MK5BM[J_J8P;W+\?X@NQ\B;.M<;4C*/C
M"C?ULCPK_7#88G'[%Y_A9YI=-!])/U!C2CS@Z9RT@<#[;ADEW'2<U(N?<FH&
M#+"[U.E> 6O'Y'R>M(*SV?2<91R2O\U?G*4XC"ZCO,GN$4;$ 4APD4,\:8]?
MU-3Y],$^0AD+4^5;:O5IO&RO)_<4T!!Q9".FRN>(#?3E,5VE-JE5[H-1YVO=
MA@G>O ?U>5+,'U@J"TIRLVF23<;J,45>J W&V1R/4!*WIR%I)XPUNK"I EUJ
MV85[PL-**A6=KVZ2Q!L)0R20KX(6*2H9/"BL$MD@C>)[%G&[\9NJ5W/$NLC-
M201N7[;,.%(U)N3ZLJS2Q(@USN%%U9J\J*JSF9C[N&<6X,/VHD$1)M(:@1?2
M8TCD*DWB<S%0T4+B:2JY<M>\)!C\*GCCR3!=.'T_I:(AX30)OE.3A&%^<58.
M^H&!(J,/7!P'LS<+#LG=N&Z2#9G'=H(5?V@^$EJ_N8IC4TR">";JU8H<Q&2J
M0=.3EQ.6E_>$>?,=O!'*M0YS-)O7UKUZ/Y.MLG&6N4;1?EZ-T>/]' (9O._5
M:CSN6.<#(8UW&'W7U.UU@;2,/()[//U-=.8G"D'5@:4:BH].:41"SIK&V$R[
MYCL$A,V(IQ_7\A0"YK.LGM[SE2Q[8S "XLXG\AA"M.\ R]!!B*!-(8ILS>Z0
MY-LN&<7X6:U>MW<(CM_IXY0B2S^@@>+C>*R<,A^*(/4365Z=GA5;TG)S@05.
M^3 M;D>6I[D]"'P^LH!KA4%V5.^!](V8XG_X"=Y_OQ\)+[SW]N-FV(O7BJZZ
M8$TMH-1NJ^!SB49V7JB(OGI^3H11<)#)QNP+C'.\_2$<&ZK&V):#M[$L39VX
MYAZEQ9N,46)-(%\)^.D$]IGI33H46)9K&Q(5<P0S$JB[9X1HN9CEF7R;A_8
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M@&D""O:DQ QD.UA&,KM>^8&&BG#,-A6*&/F,BZ+&_MI&7,%_HGK/M'>:=8"
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M/BQET;"_1UWUQZKY&M1'^5T,UT)-E3@@#S\.=681OR'$[%W;D,J6QP?TG>?
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MY]RWO1G\P%XD=:8$A<P4V,1DJ7X-A3Q5J3M$'(60OQ9[(2@'";9[V;3'O(?
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MWSO59V8CL@G\TV;_ $,Q-LCE"\S,=KT>RG=FSG\P,Y'?B$? S[88N24WIIK
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MSV]/UJ.ZAY11F'$5^&[QJYOH(?"[3%%9&E'WE+U'3>,$ QK(PVACQ&*4Z>F
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M-JS(O3/P88'A</U^\#;39U2CU[KA.XK>!O;']A0WW6>O012MNZLL>TO#1].
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M:0J>.YV=&IF-G"KJ,+Z00='W3ZPEZR*G#*+EVI..RY9\N5TJ=4%C^QH=2T:
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M-1V(7"ML\EAUL?P*4Q<[G>K+X'?XU;SX6UFM>'@ 6?547(D4]'[R4_R=8OZ
M#[,^+&9[6<+$+/9NSCFA3-=W(VO/(=EF'-S6.URR!GP;O0/8IF&6B^2NTQM!
MCEX\<=,%E=[55VR,9M[%B2DVB6)X_(!GS3+3\MV)P@0)JK;=*?#+ J<PRI%L
M1]JGM1<B>Y8S=OH2MK$QW!$CWYV:B!9>]'>NM0]/@9\-JIZ;@:1UE=0&O#U6
M]1;*'0']2Q.9^A0CN-L8%]2;*2#$9Q(86/ T(U:K.#YQR]K-)Q7OH",A72/7
MMVR&R03A<N]$R:5(\ G>EP=9Z<(3*,.S+*>BQN55W[,P6H$38"TM$XD526@&
M89E(Z3[SI[5>QN"W0T=')'*U&H91,G$2%&-B6GV%-<MHVM22XNA$]?[5$3W@
M8V4QP@'PPIV.._7ASZ*>HJUK>)C5RBU=X>R-/Z-;]=R[4V@'+*@M2>+EM0:F
MI9N4K.Y;S'&34"'Z[>[2,!*X7MIUK5%>!WX=XM/:9E/6*58[T3:U*78R#.U[
M*9_J!G\V^BHQ2WB3PA>!;J^<'!! $8:N#[$4Z"G%'L_DD[\R>3.E;Q_F0;7J
M5,$U;PO%8O"OJ[2XMSQRU%OT6!RB-B;P*RC98@](>4IX7]2V/Q&,IMB>N?A>
MYI0#_AEZ;<D-+]=H+_1)NU"MUK*<FLRS/?ZZL39#WQDY>J?&VA$7=UQ*,]10
M-!]*X9>8@Y &BD5$G)XMK-8LN1ZL*TN&K.\E5847X8S%^[G/7,>LQV JW7_-
MEF(5]@OR;H9WG_DE4<VIJ",*ZYIM-&%YHR,_-P6",S;R2N"QD^U#3NX)+&L&
MP'$@T'TLD8Y'+:7HO:ZE;B5VT8'[GD)"YVBA3WJ=(# 76%>^HBXMR;F^86;Y
M$$V!^J!P+5B DW>X6E$TBN2.F&*(2XXJJ\!SVFH%5![6ERGH<65WK&A?CK0[
MH^FD9F>92&*0A5=I,Y"L(Z"/?-4"=;$TVF11_<<ZA:B]I+0@KS[#NKP\Q".U
M)&J$[E7L@\B]*HG?I?_P>ST96)+QF?7RPCT$R?B-@:J#&SF)81OCK!7BJ*PI
M;O&Q9!B_3[9TE6G79&R&*[],>U5?H79F7E%Z!P.8%%R? G7[3A,ZE2WBG(WR
M&(OP80[:E!NGZD8=V4&RY;7VP\X8$1N4JBS/&[1I9"@Z'M1)U-,U\Z(4WYWN
M)^7@_#CM6C?UHN<4KYIH>68!Y;V2=4.2?B\/YR) FW:AQA^YDQ1.&.46YN[V
M]$:)T'Y>3MXJO4M+TTFG9LCPM*%:5U!LBM+I!=9'0;)%M7?V"_C''&B#>1;&
M;>>V^<8:$9< BX^TBF-QA5UDE>&51.H&X\\T>SS-4F(7#A>IR*?#PO?,TSR:
M)Q S_;^M!."1H1,$!U;D0]=9 I1%G)K1+ X8:IA*%(ZU.U!F8N%%I%2:YU;&
M+N:Z_PB*DMJLEBPCAHU@B,&Q0;NHKOSTVNK*!A9&<.TF1+?0YJJ2RH9LK45K
M5XPWJK?'M"S![0ZTNB'*#8W3%@FBBGV2->8,6)1[-X#R,;!<=KWZY*N<"J6Z
M;$D;*NZ%^K;J/=HT&Z-UQ9^=<ZL%2UI*S7"#\S&S"A:RV/!*]DS;J=D>F[QO
M7=6"._!.K!SH[EL:RC+UJ,2G):5SRS[M770J3DA9_F7GOA=9O<\?8(T'<B0V
M,LX-@&AD*!%,-#%0H5BC"MPBCW>>JZ-%.Q1Q]SL+E:N2<?G>'*N L$TGA/$K
M@; ET^:Y0U7Q5S^FSCVS.7C3#2*+7P,JH^'')"]/A^,K VAU'HITXQ<)@:1N
MRY,D6JT! 54$JEO==U^L%6%]\(4[%&?^,P!E[J#]-*.R?,LV-T?(.OG-74 R
M6-_!)9O\9#6EQ+$ &C-_K51_Q<2-X;QN6M-$C8F-#:8MUW-8/MA$R".7@,""
MP1S+.L^V#J*H-MBJJJNJL*3/T]LPTBGD>QF"1D"?<67/[81>6P^$6L+>HK6C
MVX*=NPKTWA<7E6]J;<DK:LL:1 Y!^D]*OT[=P0[Q_6XTY?(P=E1+Z#Z%USWO
M P@?^ ,<B_RYZ\ZZ,FEH7I@#BYNGJH"=+-RI[QH#72&A6N@M$D=5N]%COO67
MM9,FP3!UL7&ILRG[006%.X)6AKG?D@/[IECIB&HU*8O8^;/L#O02G7-:3]I3
MBN@KF,@0 U/ )DO*9<_ZMJ+*@S[B?+(37L$B%'MS>):12W+*&$DUGZ8EZX$*
M#U-;%WJZQ;AH)MB"5,;[3T=8KWPHU7NX!TEW['*Q3O9(O3C*T=6Q6%N?SJ$C
M\)=O" [:.3SKH>/2W5_(61=@0YUKK>%G3EK#I.T9L,"'3.ZZEE^?R\Q)'"DY
MY]!=+/G!:J4QX.D;'ZT]5%O)[2JM+=/WPUS%WZV>P75<0B:FR$&(V:Q*O:;9
MUS7,4SV<'$*T.^&EZFTJA]=F5:L@G:>GT6@MKJ]I][5JUBW)IA6=Z-OUG&N;
M_]3\/D^3)D)\(Z?5BFO).'ORX6XD+7ZYL&2XU7>"J7B"_>JS?/?9Q&R)\"+S
M=*VQ$D8&'4L"38>2!_Y]0'$0SQQO=Z\)\:!.N4H5M;YM N+IA5C:%G2 JPO6
MXO1SVS'!VU).<05# 2(N692U8^%%6F-&Y'"M@2F.T;)-_E\)AWVE#5*RO@2B
M3C7H(NM*M5 7ZC!/AO5U"53:V6X0.N-2-]@>I.7T0P*]+N*:S;!?U#&<(X8@
M&SV"$8Z,)3E9I^8%UOF^,_EN1Y^6D>KWK4QO7]]H=,Q6@JY6TR0X2C,S=I_/
M+ E>NF0OZ XAKQLQWR_"6M>G#)PBDJ3-B+!]8$Q.S:(IR_Y53^LA*W$BXN$7
MRZ\NXB;R+XKX]\>WGO$WBQ4=2"O!\'&J2!_34'/)VPL:?@ J#%A\[BBL51_E
MLXQ'QR\EU&M:?YQ7O-,(5=)9MQ?5:QG;YEV3*OQ)7V3F4YY;UL23?67M!W.?
M2CPJNK9R[M%"K$2)A^XA0)NW6(^<*[KMJ#"=(MTWRB4KN['JLYS0O&:MN=4D
M#JOQ..FGH';D#0 CHT@)\44T]_&9C):PAEUG=FUH[/R](V K?SYV ^!:C[D=
M450V.6*U^ZL! S=_],G!$"N171MO%94[,(2%\<+R7T.W _]/7W2U]CN7C^@Q
MTOA_!D;_TP(&&\HU!64*R/_.OP746VTC]$4>)I'&WK:*?\3^57=+%UUVBFG_
M[;[P?]SO7,Y6X_]K3V6OZ+_$3=77- ;^+DN]'3EQ6> 'N\4!33J-N?]ML;>N
M2/W/V%J.,&%$']LGZOY7)"W_,Y*RUF4J]AH#%"/_*O_/M7:];/^[#JMDGIQ;
M;7\LLB;_GT/L]C?$_WT*U?_KE%M'P8+2T<C_<+;DOVVOK.=_[%7RWT'G[@W,
MIH.._O?;_R,(ZNV5IT+G?U7$KKP](#RZ?8)A)7\#."+VV89@C_,Y_L#..,N%
MYDOT=+]Z83AU<N9W\5V'-][]6G71L0ND+<SU^83RA.67N?7E\(-+B:ON/<?J
MZNJ'IRU?O@&__%^_,I"<O$-F_,A6U9;[GL\#1R&Y:B>:\JH'#]!9UE,_^!(8
M[V8^)EVIC_>2^=7(K6_AN*2:#^US@,VHEQ/VR_U"W6_,J=NHR9CDZ6X9&AF(
M_5( S<LBQ&LG(!]8N7L#B/4"5JO?A[R^SJFH/QSP1$A+>Z<@516)DS0IEZ+A
MM(2N?F+ "<:+:/(<KAU3LSG^_OH%>(K_$W]2678EHJ=:?]_=\4LL[N]KZIMO
M?^"1+DOZ]]L8MQ_7LTLM@3='"07NI)9P^$K/!AJD*%B.MQN60'T?Z-&CI\LU
M[$5:VDE;A"& N752&D6A[:.D>K%)L$92%!>XI#BPAE80"!'C8?ZG?34*?@.H
M)"UW>%GV,%#_FXV.K)SB=$HB?3;@!B!3LWOE53\>Y@9Q'M4)\H-N'PT]>UF]
M1;/F?-W)PMS-(L@^"4N.S!%D#PRU<$T)L A?_LB# (FK]DS7-ZK#D<N^3H['
MVSN0(^[R<7[7A:PL+\5_:/%_VSB3,;2L=UR(<*?Q\,1?*Y@7@Q[>_>4<G> (
MZMQ7\.13DPY'?DP^4K+O>)\TLVFZ\C+J+C>Q]A-V1+9&$,6@L+@T1$E)27OR
M]8?6%Z\G6PVH?9*^%>T9,WJ4-E%G'Y"G41?)#7V$.#ALH&=F0UUS!M"DU,E-
M/C,;#AE/-8/T%24IK]E:A'?+?W38.7E/R3@*?R(%6GC6^YPYM<]F43$7,UR=
MN.7< %!HOT"=C]?\]>.BWP@:'MSG<YKNPRG9\"RPC4PLBBFO=VB]T^ T.0';
MK<>_CNCTS9V>4W+$*DEQ\\3;L'=8<..<'*AOM'.TUF)LY=1@(N/KZ5C0;LQF
M,76Y5\#%56CA.M"";8]7@,!$ '3U?'%+!G<C,3P',_N0#CF)]0-*YW*PO:.,
MXUJ8FE/X1M0X,ZE^?WX>M'P#^%QFN\LQ9AM4GAT<A_O G)6,O$.!'Z)%$'@#
MD +!D0N3+O*==X8&ZOT.1-AR@&Z'B7'C:V$^TS< 6&0>PB7*JS33IRFP;*4M
MJ5. <ZABHCJW2&U\I-Q!6KYT]3.>D_%'>0L>TJOGN,V0.RGW:J+<,5.;8?>X
M>12LH$(S,QN.:<'CZJH"1$K#T93']QY0-R9]8YPFN8/'A<D'^DJBW=?"A^B/
M]-EX/JH_S\W=/$DW=$]S:]"GVSNZ]R](:D/87%Z]P?);]M\C@4VRN3+EA?&E
MWR/;M7G=D^*Q)1]"D?CE!H#9IR!YQ=7?2%28,";=!J]?I I8K%]%*#[2;G>0
M5OSM;RU2VLSFCN;F<62&:JZ?G+CE?]XP-X$5A&=@HK=F]VB0X!H/(^8>/#<D
MJ2 \=:\$]\<-((?_ )9( T=I7U_4CY?19T^V64'I_*AG-E.7*[2-+3F4(0 ^
M.4-W_U'KA-0V69F%2;(_<0"?"D,^HE5U/F#28%0.!@_OW];81,\TG^5=ET]:
M9WWH$@1R:@EQ&5H<U14/X!@&\>L2+W4>[./1'&8:8]Q<I^:3ER^]EU>SMX!)
M!C5U*S>!WRJH@+I/F)((3*84'/Z>%)0<$8J^\V%7*+!H@T#2LDHU?GWKT(5P
M!OYHIF--7>L%#ZCGC)9>.L_5CZ^F'I.8)52K.:L\#<PKU7!?W<D+Y&2.286>
M96TG$V-KUX%6B[L//EXN@CIJ5'\^)#4M:?K%%5:8YYOL2D_=4$Q^#.T@DXF:
MTN<IP\?K&[WUKA1_JJ J1C&N*7CZ5'T;?9&7DY7IA?6-8PRKC3HI/S92*Q4N
MQF2I^X)28P*PM*&N]GQB[C# %2'$XTV_[ 4^<<N>S3Z3[\"4NC,_J]K!9_=7
MP@]'<?0?3;?O8.<(;^%PIQG/ZW\7^,K-([);\/UV>YQ@267UW.ILPB5NGBD;
M6W'=,F[RW-0L&JA_Y(R+K#T]]XR:5+OD"8"$TR;.[A9X_+2"TF1[0@2!2]>1
MSZ,A'\_Z.F\ 3=M'REM2SU!(E-L>%68W1<I[1/;Y_,Q(Y,/F?B'_Y.$[F]L\
MC.O*"S#Y)=^Y,[.SO2-"G]-R'>U(?E5?CT0X-:UOX%>JG4 &G<I)">:Q(I-#
M7)E59P\O29X,'G"].OCG;<NV5,=7AODIP4GBKPAV;'?5#N$.-\][W,+RXATT
MF*L42Z#:1K &VI2$IS?D(;8$GX0Z2F.-/04K1Q ^J*YU]_3I%7@S"5G["@&B
M@6X?/L94#Y$#^=+.]MSEN"@^03/Y+I_#]: *#\6#[<R<8Y';9%L9D-"5<PI.
M#-O!!!1[*K;!JIA6N!J3TH:&U8=*(Q?/@UKM,)5PXMM)WT")OX_&8++)#4"Z
MUM7KHG[4HT].^VRT1U#H&E,RZ6UVPH<JUYVO0VWSQR7EZ4:4AQ%%EJZG+?,<
ML#W<'P?''SSZY,M1*JB:Z\:9-?2&LJ,5%(S)<&2U9=U$L3H3$]/Z&GS5YO+1
M0RI7UZ)<#8M[X R,DYKM_D(X9TZ=OED.SY$HR8OM'4GIO+( )8>!O9G9G(T+
MV^Q@+#HDL@@KLQW7S513,P,Q(^*LHE+3"GZ ][%#.3(4^Q*#E![1$.H?V8O#
MH.VDF0U_7?E*J;R:"S>WXB#;L(#L(+A?Y:,)X%(@M7#YO2)LO_#F]0&<\YCM
MW8*OU#J89?(<\?CQU@1<8N2_\."[+XAC"KWD"Z/0'UQX]_MU3]+/J=BV9T0.
M6 68;,O[#J&^)G&\=:^.;,+V=.96W#UH+J47@R?R%O*!9T[C_'E2+?FW#F *
M*YLR">+088,!JT?3!,TT"2/AQ_Z4.,W98;?\2(R!V#.GIMFL#C2(&(,BHV*P
M^!!W\3_9#_H"7+H.2YF\S?UKR?_P)1D;%D_#E[V(A[&?3Y-749>]*'GKRI,)
M1M -0!13(=A[)  :& 1CQEHL^\=E[>]ZY9UGQ YS&'?R23=LDT;57TIN8680
MC5E[28SDKE=)$O<%%G2YE_+L G_GI#D7>R5\P'7D' K[.1Y@Z#=,^WC#VRZO
MULO-+35:>8^;]/&?R;B4W$T:B<\S<EZT\.\;9_G@! <LJ_R+UN=.@]'*RQB@
M1]_&*\TWD^%E^D)DQQQF&N5/%?++[I1)[#T"/'$2H6NA0^(_)*/@80-+]. &
M$=W&0)<MNR,1XH"A>%V"14J_A]B8-,$)FFMPQ^S?_4T1FG\N:]%)R-..3ZA&
M 8PX-BP&NOLMS//L!+-_>P2X>(=\?B:/)FROGCB?73^":)$:^NILTR'[&,[E
M_]1;[G>(P6KV\L.]/_X\O1;"^[N!^S)^)B1CGR8PX')0EV)BE+^2LG1;,ZE)
M1Z 7MP@OZNX?L(R! E:?;7Q!6 A2=628.Z'EM0'EKJ*ZT5_&5O+-0NM0*SE,
M=FS.S 9.152XR+? ,?6P838<JV8K*</,Q,0XVX%'59:&(N2+<]?(Y6/,N\T:
M<T._D637(R9>%]VN' RQ27;EA2T(=HQ@4-097*I]"N-S]/M$(AX\%_XWRS1.
M25?Z?_MBNA#0:PR?J0E#S _^Y3F]QIG*J_S:RG(1T7[PQXL6/'+:@C)3:\NM
MP^,#5>HZF%*]:PN5[Z<0"X;Y6>%UW,:I[Y3YQ1@6WAP;RW*RW_@6-J" X=AD
M8-SY_2DW&=O#WM9V<*FG(+XFTFU3,+-&5$3RO?9/*)30(>PO"6:J=5CIH'\4
M\U?;.FW/7(YG-RM_-D#JO!6N=KV>9=8?/J$D.7_Y(B?=9')R=6IP"6YRR)JT
M 0N>D3-].N51.NA62@AW82FZA^$U'*>Z[_T81)O!-!J-$#@RPR.OYAQ#",4?
MTBO?JRK_ GT8J;8-=;#C(>3@:%IMM3N[S8>_12$'^^[*S,9PBVSDW&R$5M#G
M-P ,#Z<%!LTE(6.N.YE/_>?V^9RN!]7U[MZ&[G([:R;XV]?;@*V9(C,PK1'_
M#>!/8_"\^C+L-C]Q&FX 0Y"48W_8H,TM L#BS<_E?X;?9@3L-F)T?PRD"XC:
MT1S&H*]2 Q2GFR05'NYB.HGIG9[DB2LY0.\)!J6/UON1"70J* 5/\ GTVLJM
M=DAK"UDNS\W-1C;.BR>!=R<VLZ.@<+MDE=HFW1H_0'0?A+YB^AM83]T\J8Y/
M.A*W'<M\/<3 3_H64O*4]_S*!]].ODQ+A]?,A[;1=.FM:VV*GP48!8>&3TX!
M ?S/7/FBM8B-_89I'EL9.)K7[*RA9^K/,E+RG%:1.HH8A-7%XTZ??-0;4]F'
M9T__IK3Z_!L)+*$<*2HVDQ/DT8?E>V_CM[R%+H8?(RI,D T+N.E+;4?;.Q+-
M$..#;^&8$,.Y#M7J^["LYC.R6!UH@08"F%Q6T63\-Y?GPP,\,+V10)V\-/Q4
MON-V,Y5*D!FA?SF=O4S[#YA14N-U8L35_RW_A\C)R\5%OSDWSZ/J/%D.YMN^
M<#,-D_!P=Q(,:B]2$ ;+^$ER/1D+P%3S\?B&TO/K: =:&@SC[]/D!3D(_FJ[
M;9)A1^+BX8H0\OSUM<30I $+.^*PK)-24>N&8;[T^S*Z'ZY2N#^$ 8Y<,XU;
MIW>Z"1Y;&=X E!R$=S#I9@?QSOYC?\W!,)4RE!I\ [!@!<;&J#-EAX[56=36
M4I/Q/T=3"Q!K$<Y!WV?HYKT%Y]4LW1HEYV8B([DEY*/!]E\B(>[40IC>__O$
MUA9T,#UGYN(Y;-#UXAJ^3X=L ^?6;&-:A5'\(_ "Y,\1QG<&KA9LR<0XM2A%
M;M#_^YBU@C7NA M<&;.2:>(U^&]P/!\BLS+=Y3MH,3,4G"#&&#"_Q<9'K$]O
M )$C.U<1JD_Q?6\ MZ<GIB)<#.*/WRYF!0/3B9XI*W\ 8DCH>>K9J]M WG\8
M.?+7IWTTU ERF;V$D8.OYIR)WYZNG!4QO"?YA_^ -P!:#/!RSV^=K/0W8 3D
M;P54A/]57<?P\X_YB^?)&-6WS%IR:WKZUO2MRH_GB2OJ_YK^4U(XBH_>>]^6
MUI\MW*G.:_H3 OE&^?W$[[<=23AF/.H/W?W]ZY**@6)^VPV[&%1C??T('#G'
M](?3O^[A--_",+/[;4W[F3SY/RG\RY]_4^Y/C^\ZC=%SRV88+O3[HWE<_%]<
M9_AW[7_E7O]K+Q_O7P]NY?X8?*3Q'[%)W3JY M]&._\V)(UX&S9_CZ:Z1(OX
M?IT8I!8Q^!N;_[DMC3SR\A$$JCVW/1_&R[_>I95J[_JEC:!/16X[7.WO K7G
MB=CN?XI&78:BF65-@'VX3L%ADH.?@1>L>^=5V"<N#-]_\*MZ(JZ$_WR%,#22
MO=!.F+&%[+1']><WT=!K8.DJ ]>,]>4P#<H.54*25'(@Y>?0[-B@I^WE4RB\
M],]+UJK_']_K([36$U@-6-<;H8Q)$>,&&HO0?*S=<C(6LNBTLPJ#PMK+RBAX
M>VMX^8V,!SW+)JJA$+,8)3X>%3[<B+8J/H'%]'%-,A-<[0HI6GY3.#]OX6C>
M80R8,X0O2CI%J5\XB?_+7&.:W9)_./CU@S"\]J[$-VC=!M\U9;+YNLEN_W\]
M?H:#E2;FRGJ1I=?\YT,A-P#Q/V^L.+AV:?:*D/7![TV)<DLM\<%'@UIN_U_#
M/RCV[6IZQ2MORJ:XO%6:KNK[V+5^UE%^?W[=8CG0B'#]>?3PX<]K]1O ^,1V
MEU9<5=9T-B</U&8YJ2VOP'8I M%H0KDXOF4 =>6\R'(HJ2XA/BVLQ.[WJ0+6
M/OALBE(\[9Z>%;'4$F;P*BJCNO[6?,#BS)]0[S^:%H)!$15@M[TE,H0<:\[H
M!O!+]M!Y%ZD<U-O>6,M 2/[^A!DH!.'$,_\S)E,^UB=N:U)Y.)#GX=O?IG"7
M\F174+\/>@-H?^87?@,8&^!6H_!.T*1]2062O '4C4W[P?QSV%6$:HRIYL#A
M.5EZ/'$[3M^3N%VX(HG"3"IKH.N+3XV^R0^U,O"=&GFTOS'^L?#0^]3\LSY.
M:%'%T+BP53Y9-EE'<HN:7 DMP X5]8YO;*Q'SN[)[J R8J7(#=::_,JLP":Z
M6:$I;N[]N7EMGST[IY^DG=%/89#/N[[LE?27J$LV[#Q<>MRR5/L[.@U$C"\_
MG('TY(]1S(8]<+/<@[?]\Z" 86'8[-'Z[M8=E0NFM@'N\@EAGYQM!;7<M941
M[A=#/YDYG_5+)H4VWP!@C4/.A+ ?!KEXAK_JX3,3!'=KT_@+8YPTS8(FC$!P
M+B[Q,]U4B?']J8'A;+)BY8Z<K4H)27<Q9%EEO76_=8"$&PM+<4RYY0&PKU19
M^GU;)2U1$'A:TF2G:U/P_NR*O))LSL;VZX>$UM@1)L8&SS[XQ@RT<DP<7G6W
M23+F@)@E=4R>"W[Z<%7V\QEJQ;;726]P]9&6A @U2X*!=9OU=L/9;NY,?^5U
M!!U\!]+TL0A6+3_8\UY/SW()[-!%]^G<].N*L+*\2;59,H- ;90W.8^[<07"
M",PUNC\^K-*GCY4>6ACZ:U\VXLY4U\)$B8=!$&A*0Z<U&:J+OF)1J.@B>1:>
MNZHUK"N+_@TW!NQI%IYI]M!O.J\\4D8*QL3MJ6))XZH-?,#3;V4Q&*& A9TI
M/+#[&OT!?_&Q[=,H!<X:H.@[B%8QA2^$GVF&Z8.MK4&$@GLA3TC@(>QZBX#-
M^XG\W3L!!.WJ4L6.7Q/Z"2R=PBA 4:7<=4$\H]*RDI3FD9EX-L)>CKR[FN/5
M5AS#("+_RLVPI&26S*-*)\%$D\?MDC\!('/!;S36^!/K4))HTBZNO9^_/7+H
M7%P*MTAH+8T)+ G7^MF'2Y^XU<'>3S#G+A- EUCF/C:</VV55"=0,1R4Z0@8
M'DF.A?"D=!>I5%99R-DYB21B!X1.LVG-1E9KL6D9IZ2T9N421$XK&+"A%$!Y
M#U4U,QJU0P42G_OK4&DB OQY?9B):S38^/2AS%[(_J]+,"(>P0\\04Z[X<H1
MZTOTDI)Z*:+80\&?B?J$L>RHI#3UY&Q5QF&<JDXV+J^=]%#=?1DU(78L1%G.
MC2JNZK)OHC1=]>ZQV[7[L( [^^1L$ ><X$(O;=IO.FZ7SQ%OVGW)>JBE*QP_
M"^:3=WZLE'C?GA09)7')2B(04UG7D"2QUG'H=YZBL"TLTZ,=#X47#J@KWO/&
M#3"W;;+O!,[$OM0_5$U&0Q:X(T:X3PFFO37YZW@+5V)6:Z^XFB19S*HL076-
M.S3#^F>2QE^@3P>@Q0A(IU5)[.%N-\=@5_]5<D!*D?%6C/VXU\P#H.W3@_+6
MN*V'9TI',\6U&VH0%96GOWK1A+,@XD$$)WQ9SMU9\)4JMYS."E=AU!N'RI&(
MIJ5".R4[.A S[(L^=K_7!+WO"3^MDU;6/\>(6@<":E,@.>?C,6Z$Q QVC%*S
MF2:6SANW;3?UP;1I.;MAK<4O?4Q$,I/T]F[QA%H+4U5%ZM0=[V=$;4E&WJU6
M=B#N3K<2TNW2IEE,;4I;W;\[[5Q4HZ8:[#Z%:GK\!K\L9'DIN$] P7$F@[>;
MFE;D?7<P;Y8AH77\2(333Z 7Q.I<5KWAQ\N"?/L>P\>_:R+L);&FBLY =1SU
M"J7<"_L28V\^_(8'A>1NRB)%[5?NNV^O9/46)D7R&*=PV>[^ECX <SZC.+HN
MJZ;VL8S3$*=--G5M!?<[>CU5UQII%7$L0SKUSA'YLH?LZ@LIZUMECA^#.H!<
M\@;?+?[!TZH?,XNJRU$X,&/2L#P'A=UAPJ5;10&ITD:&1[09T9FAD?&P?I>1
MI>=<=NW=4]M\V<%A$]W974^"I,[:.>'M[E \ZGS@^--N+5GY8*E$*CL7MK'5
M^>B@(CM5:6U!G+B[&UDYQFG AY3M;V8V+FA_:%0YAA/(>S'EYT[*=#1P1_%Y
M;Q&6\OC0:/7,'65E#V [RFK*>;0LWOEN'L3/KP(V7;[>4K,]ZF]$"I'MT0M0
M109,(R8J!#(T7H3U0(GENIY-+/=\X]VVLZ*KWB#P(# VBDI.",]VQ5^UF7Q@
MUSY?Q(;*X(C+2<Q(M361=Z6A-6^Q]AR >?EF^5=J+Z8O%Y=;:5#2I:-.N'O)
MP 2N;S)L7QG66[W0>%FG FGLI52ZV]/C%!G0P'2,]'2F3QY5(0V6[.Y*"Y.:
MK&8UDD]O;0[;_E6T26!])[@X."R.;X"]URGQ=2M.@T/8:)Z&<Z-O3)7>*FP)
M")F3^5WYJU0"*UQ3W?-.W-2T:7MZY4A=%K*?S7I79Z0Y6$O@E<8SV163NK&&
M;<O)\-Z-V='!)&PT?C*7O&Y==(Q7C$TR;D!OI6&+M^H@1X-0LN2;[4E>VBS-
MPQ2+3>U9774?GG@ZVL0H#EE]^&<N9Q\6J_2P:/DIK?4'AFT6_TBT#\TZ7,98
M:=!TBUO"E)+BPZC7C"*/8I^XC%6U6VDK8.V/$\&3HNN_J+.F^?3+F1(VHF>Q
MQ_8>2-I'#&"@TIL$7K\APV]*%KO_\^2[S6_2I=3DXE\D%4FED);N<TFU'R8$
M-N4> 18[&P)OU)-D[8-\#.FXH28\0Y3X^#.KI-LH?O?"#D1\5]7P?CSV!8C?
MV.)E^SI=[DSRQUT?%M.FC4W5Y/ ?5BQ,/[U$$IP3:1D$>U17V/JL?&+#+;(_
M'6RU54E"JAVT?@V/0;5PBFL[*EYCVGY/%!Q@7^C516G3D#T">W@_)RM,S?:W
M*8*R8GU2WZ%;D I)GQY&EN/NVM_&,'?TNXA49FJ=?E ALB^D_D?G[&Q+P[ZQ
M;58<ZD2J<_D$'?+T&#NP^W%0PIBS>NXWN-''UE_U MOC@(?O-S4V!QCETE.,
M@@(1O>TGY=X&RR'>Q)-'N3UR@H=%WULG]+9=9JW=G'$"1ZJ\DH[S)41=DI/:
M)0D^_-C& B\*7]Z7C#)Z,<AGKJ*D;\B&J8WG#I;&)E-@ /'05-4_;\D[?WP%
M<PRYP*Q*3VW'9'+X)+OZFJA#_%'>QL@L<%6"PB+'4JVV>\AD24)7_H:@$T&Y
M'M0?5[T3]YC#-HH0@P_K^O+L16LEK]E5[N99R99.R-6+;7>M4>?C50_IVM75
ME>.BK!B3%B#<19-LG922M.[:T)3!<1;@-L5&(OS@-[A_TAFGMI,V;&A3N;F#
M&U[116>E:R[[UOM9'./F*WLA8]/63@%>DD=*:CPE,?>E,T,@M0>=B[WHL"'M
M9R$^0-?L_+#UO@1*E>/2;D<'M+T&"S*N6^_]6AM#CH'- <%/PJA,QU%W675Y
M?5GSM!P3N;!L)[*?1KI14BT=_R!J:K78BDU9?J>#P-.TW/I[I:6P'*-[N<QK
MAJ2BI?I]DM.ADW,W@'FUI]KBIL>8%E;U59BUTXMH-D)#^VCK:BRRC@-UGL>C
M>@4YF95MZORT-L._^CE(I?V7D(3\:H1SW6).ZATX+OB,&9$+A9$'R[S.D:MA
ME$V(U/U&$AV7.#XI*Y-,,U.S0<K/+6MJ*@TI,YOKN074OKG.2J&EWG\!)M24
MW"P!05B4B1@>Z0$$YQV]0$V+)?*+&=NC/,>_T1?8MK1TK0>REC^M?-,3'>40
M=L=2*T!1R%H"'J*#;YY!>%#;>$ #JG8CG&693:KI$'?/SJQ5#NHT,WX)4S>H
MG=9YVV&QKOWEJRF0NBWL:7WND3QW0E:JI,!%!ZC?!K[TW%Y S?&=/#]JI-)5
M&LJG(NJ:&Z9KUXNBF$FY%X+;Z7FLSAW49[5"00%+P_&A9"P7%?$^ZV(X>=>$
MY+L>L/"VX>8:%AQX .BK: @Y(BG8_V:1^JTE.\V&O7.]AKW^!"?=FE*4+GA$
MB;\=%2N/#:X_\1'\]KYLA4%E/T41N_3S4/N+V(70"*3!8[_A\KK:F*D F2X6
M4X,0[AUL@K2(<1RJ319=5C[E#DZC$/!H_-3D4F./5QK!B9 ] <#)R6[SU/*-
MJ,*R0NE498AR!\TGP_)M///#@VEDU0QG-V6)V^M_>,H4MOPO#RXD7?EX)+7&
MSG#\^4)!5([<Q78@MD7.JT4$$OA-<F. C" ^]Y)*,J6KVB)Z9+Q6\V0Y9;UA
M;//SR&Q@8]RL2SN;DX5\6%-H\J^:]MU5/,8+:8B(1QU^FC'58(=HF_5GN^%,
M>NXB*"X[,BXDBH&+IAM1QXMXH'R05KQK=AU^.C=5G1B46SG%.A2\SI2R^N:W
MU*6)_0#AK]S]YHJE+P&= P$5X3N-WK62E9 NXS"W.L'L7X\F@4MH3R\UR_6"
MY4@KN[(1#7U-:*9-$26#$6@)W*' %QQ0.9865[6N-54/^LP]R@&-DON]QR^,
M(T\A<==DY%44=XF9%BAT#J?@[7+^G"3P>'ZX,]F;QP!7^(?JE_TR]F$D(X)
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MI/4<CK)]%AI;EN@K/)^1<?HZV<N=S-=.240Y_XNSKPR+LHVZ'40!I50$:4%
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MJ.5 !RYJX\K)H< EMF#.8PDA9@_FMEF"7*FJ[57>-$-$'/]8ETE[OMJY2)F
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M\*<-B2.]JS7,]9VV69"OM*AB5^&+7\2(KDK8LI77O&IMGX6=,+SS<MTQT;S
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M@TX#CE;*JC)]\,\L"C#FK6 0EZR(ZYZ>\S^./.0OA8<<'0(&-&#A,CZ5D46
M %QTP2_OBW=>:/AW*C)D'>&_QI-8TRZ2$-D7=)2@4E-G#2:Y(=Y*QP:S>Q[3
M34@%XM).HN/L1=9ZF; 3(@;*P9)';0;0$X5OXA3!@>,U?=86F<\'6;66!SD?
M"]#RS<(?R@B1VE4I12RY1CT;OFT(CFZPPLAO$\TU&?F-ZM,AZI_;AC.J1[7-
MK7;!I'8G@HVFNI@:K^U(Q:A M3ZABV<CLUQ7CIMC-EL&GPAF \JN ;:?(L'8
M[_HC;*.J#.;RK+!M-F>A57-,_F3*'_RYV$ E%;G&V "E(H\S!3JZ?/5S<T!0
MB5902>[I7S/*1DQ#K4>W%[8I*JQ9G1_;-J00"P*U_QV2_O69?!E-+E$- UN8
MT?]U97PK(G@*8FP8*^2%4\'  G]GHE7.V\OPF.F$QV!X9'?(< P96!TQM1S<
M*$?VGT%F-4PGOM0LJ+AM0V,DXOCOD1G('V'_[^G_-%2^_']/-_U_3E];<@V[
M01KA<KS4PQE,<50P-M[AHJ6_07G_LQ)Y<6LV1F82,ER2]-=E#O_$B1S).-<Z
M#6^A^<_\>/Q?"_X?@D,,B6<W\LYXBY#T3QF1!CG7IG.1U&L *W!ZZ46=BKH6
M_&L)RLW@GIFMD4E?(?0C-%9M62]6L;@5'?M<6S*/S)!<-NR+>@<ECZ8@A_?M
M/Q6:70S@(O\&[RF)L_/_]ZT[K[@S@1)]^YQ0_V_M6(]E-CT+"-M5IV*4H!HB
M%XSM.*Y5&U.2]C .FR=E#(J?>R86VB9E-9V4.8[]<JNUHCDYVZ/0RD%=H6Q3
MHVTDP4+M"D,;LN/Q4B$"L9$9@/OD5P''$1EO.B:8'#+Q!=C 0@<F$XD\A%-#
MS1JY9Q:QNM(*:A3+J^JD9LSCE-_WZLEH"XS.>"/KTBW8M**E!@_>"'^UHFB8
MB_B)/;MDJN[#.E(#/JL\4C7\'JH!4O[8^+I/F&Y<7,"2<!(WS>R94\OZ@_9,
M)GQ\%B$FJ5Q40VY?+>M9(&[:!Q7BO,\CUKI&L;&U0\KF"85FG!&B'WLFQ2D>
MXKXYR+$]@'&:^4Y!,BL(MKA$!JJ,2^H7T &S, :)F1F!C&BM3%.Z]2FYJ_<]
M7!CD=I881*J5][<RJTV-AH#FW?EN#:"?7/$YZ@[B&HIR[UQ^F'W'2!_3"WW*
M]_37/)O&7)_(GO=@40=S7_#HX(A(_4"+0.[6X9:%=<@V5"#1U_&#_J(SR;<6
MK"@G@G1"GV&'%<L'-(@RF@!32'' FDT#2P<5X"DA?(.^YO2=X,!\)EQS'HJ@
M@N5<VA=/>>,2RZLEU445Q6E]WDH:0=K;7[7-\H8K[=="7="=GO:[+/]&[U/^
ME"1C-M(G*9^W7?"&=*76L 1FW$Y=C.*1JYZZ0Y/!@5]Q#6"\O :TFXVP\ _K
MEM1Q[EZ2C&>H40:T3*5[U:C\6OOLHB7X!>;<XPXQ)%8Y*!0\'-\I$JR06V/H
MOP:4C;C&7'9FG/K: .*[7(6,=,^<0#;62]< ZGQ=(/*]CEIQ'3<A+<$K(L2R
M3ZQ'N##Y7=%"^WN<UX#4I+W^,^L([>P\?P@D/=&P38S0Y6.&.W:S 5%:OLST
M./VD>Z2[]>2I-(23"E4,->'K-0"?13-9/YG<N.5H^/<TY5+#;_7I_K@XM-#J
M1(+U6<%.P0J^T!J7*>UCU1/FQ&4U(-JVC$D=/G3D*C%OXED&RRF-TVEEU6;O
MMM*^Q,&!J_U8TF2E>ZQ%L_(RU?H#\#5 U#P8'G6!V&%&^]CHA/Z?Y=H"%$;-
M][M8+$T1BR0G] ^7<:EWW(&JEQ&7[8L1.\OKUX#"N@J;$XX9_WBXU:ZB[IG,
M/\?5;>9O"Z?FWZY& !5YH;0<-XBX[.A'[H.2BH3I9I^$C>4S)*XVUP".Z=1E
MHKTW$,&TK8(SZVM J&I=W$9MQ]7BOL1)\/K9#N(P6US69\U*RT2#>%:79)6"
M,N^))8Z0;Q7=0G"3 ',2\OUH(SGIUD.[\?V;HJA=Y>>=,YQ_,V$8Z1Z:^>AN
MO8ZCER!T%VO]?OE56.E(%(LCU4W2^=NR?RN(K.[1W642Y%&OS(.T&A8C_H2*
M..EB1A<)=A+R[6@+Y$D)I3Q0P(!JKKNJJFO$99L-8O'ZSK_PN-'? CU8\<F$
MH0]!H#\H(K:\1?$:P#;C[_7B0MG^&0*B(^;W^R)'![;N8[J3B6+3M1;(Z*-D
M#Z1_9W45'[ZH.[0;O>3Q;B<9Z3Y"9O-/]-J"7>R9M&S3:<!G \>C2UWDXCJU
M$.1G(_[ @PCZ^[_P))165WBW_S>>G7_C8>GY'M_IY'53CLYHOK :_;.;L@HA
MRSIR6U8$0BQE68C#[!"'"?Q[6 B"CK<(/0+.9[!-ITZZ(UD6C19:@WONBLPJ
MYQ;.&X00[_^+<]V_0=S$K(LLZ?<;H!$QNZ\B@HEJ053@9G_Z! 39:O_-'!%S
M7/#-$@2?]<]J_[#^4'#K!J=U9KVD)[0LO?Y_Z*.[+W%T*PAO1.P(D-F1(&/]
M3N;QM;V+"!F""!GG+Z]H0U7SXW(0?%R"7S3Q>F4@ZHK@\X#=ZB6/'[(2-[PB
MHW%J/4+LJ'LK,2%,68)T1+40:]S;07^JA4W[-V;A+M$]91Y?%[FXX#5G&[?X
M>HZ$/Z#\SVS^6]'\&Y##$#3\IZ+X?&0U0DAW019+Y&^Q:6\T=(6,>1X-P>9;
MX2"HBAZ*I.H(@JH=-ZDC=XR2@R($@8#QQ<(9R,P:H78+I!00;.8(W'"_2M*^
MI;P&+QXBLYM*G$$Q!H!_0$$(1UWPS/9OZ@K0&W$%(1W!\;9(O4AQ_5$B$N:_
M9^E,D%9X()5Y-&/H;IV,$-$U0/5&@ID\OOJSGVY-X4>9Z%H7ZM\RA;7_5?+:
MU4U-D85?NXUZQ_V/MT1LI/]A(1(@'H0'(6D8I-6T^%>=__7-N#UEQ_0+I9&K
MS]< ,F345'_*)/L7!R3A;>\N:P[BZ?X-NN^F%T0@_7[ZZH]*H=B(S( W*)H[
M(I&^+<$BL<3)P0WW*]T1]51B*;9!+)%![.-WD\PU )']#51(E6GS=R.4<\NQ
M_HD?A\O/$%%0W*9.,M+&4-MUPT.!ES*(])$@3I$BI$PRC/R>\UO6BYP<W!+1
M&W$:LB'<L /1>GXC:[:!V& 1X3%UUP#9O-OB_VLNJY>2-PWA!AKZ0!KG/WP5
MH+"0DT$8)Q#I45$LIW\14D+JZ$_I8RP0!AVWA^@&(#.W^*;%P(UG0S>%PJ;Y
MQZ00J65C_&?-OXH/^>M22<@]8DQ6I=UOE''CONO_NH+VW[+^XV0\-QTC_[9C
M$,L<_3?YOR$?_M.A;TE]2P);= 1[LA QI=_ZZB>3OVK.'+B1/!+J282%?_?)
M.%1$ZD=01N\?Y_"[I>0-I;'_*Q^4U!V'6[(CR#IS*_VU!4RAWW1_CEJ]L?!I
M]QQDR$NZ_S:>BO0+91U$S(B"_2AM74-J_I9;WVY5<LOZ!"$>A/U.NDLB2Y%
MZ_3L&($/<D(Q84#N>75K5$Y>4*9;(2+Y ;KA&;)CT-XTZ5ZD;P(S_R_Y(,)
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M]!D#0(?0@3*] ?P([=K$M,6.KJ1I2JO<)0&=+HFN%KF@8M^,\I$AJ/(C)<^
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MQ@ 0L%-XD!B*"6G\VHIZ%BD]EU2Z*L@D=<'Y-<(OORH0#T\8<%60D,EH%JX
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M*Q=AL*G,*W[A$FE50K[GJ(2M#^TS4YK27Q'DY//<W>6,ME\-:QT8^GSU]AI
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M#R/E>W[S93]-^Y=O3)%WH?_YLA_!\ID*'6:[XZ.Y:P#AHT<?"_Z7SUA_] @
M@ZK#I57-H'1MN.,6C8<1!=D\5<+H7ETMEC\]-5-*J/NJ'90?ZMG?(?O]=!@;
M.ROK.Y1$4ZA0NR28^QIP3#>X\MVCNK@LUVB@!&.@0N![]G>?;A@3]+31NMYJ
M]_4ZIH,.\?(*-D6^\;?GSU\B;[U[]J5(8EP#YI4W+@YN_T[M[U/&0A[/O-E#
MWFMV7M6AOH@Y9+C[G22&*J+=J5H MR;;/B,"%G"G8D1S6%RX [\G'=6O&62
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M/L%BU0P]1_!M,_0%9&>TQ.EK>$Z#?0*[U05!ND\AR)?8'==":+KZP)O6;0F
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M&7/S.[J+:$/SFJ1DGN?G8'/:F8-182EA!_?".:M:^%;!5T$OC@T-.\@&YAX
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MED=9-H1S3A^/=*I[24,_LZW10?8!3HQ!51;>Z24XQ'P4QZ\> ..O/]TF-#T
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MZ*;0.[&'D:6A\ "@_UE !!OG>/'\:=J*Z'S^ ^ ZL^'.6O^R,&3N"@4ZV?P
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MBT]O?P:@LONE8D,@C#&4TP9C7)<&4,*F3[,.J4'[I[9J<B-<=>#%FR]BP=3
M5+Q[U?HL;)IZ^=$O2H-/Q0^,,SB"_4:A0Y/?8V/GC.,1Y>E%1OWGYUI:I.FJ
MMI\#-)NWKDES"008#^(DL61$;(<^\ZQ%SU1&'5M9!&'\Z=TY)U^(;4T54&W)
MHAA7J]Q*<4[KFJB2OUWC\Q# J$!#[&7:U/,./T_07(LUYUL\%[YI)ISZS@KY
MR\2)1A? TKH[R]1_*#4\"J\D@!/.:JIL+U'O.E!&#49Q8WNJUF9A$U3+:.\=
MS 7F-)/I3)UM%IH><LDHH&V_Z"7\VT]V?K,4:;/+[#D<\6:/!STH:'U_WD>,
M*<22%\=*_."X9\K&!\+:^JL%3PN^0QF1)?!#:YJ[QD1[SF;T2[4IXYH/LI+?
MOK-;AJTO3O1 J* %W,A6H+@K7J"C4VM2>XE]I@/N2@^T+0B0JW?TLLPJV%Q)
MSFDQBX I7*M)G^2^9VY_/A#V-K/1P)POPOW3S$OT)UVYYB5#<+_COMT8[&:Z
M[S!AC;E@NJFFG6Q%CMJW-_>XW;NIMWJ3#5E8]*2>*G&E^:;&X1G<PQU#Z(2M
MZAFE\9Q!.?V*I*&AWTU[B.DNU.:_,^XE7):>KK[7V>0 L.V:V?]N* BL_GVY
M=*C#79[U=KL,YZT=OLQ[I\PQ/O,UL\B)REA'L"6T<+S-,J&EH7EP9AL)\85H
MV3"X\#I\?+A*S[N@,9^*)CU03RZS-(9(RK-CE,R?R^7:<[&K-BM;F80<3D_U
M4]"FCH?OU/5.&EX>6ZRJ:K5CG)R?R@Q?J&RX+G86IS0_=K2R\(!?#*MM<JP;
M5ZP] .)M"#V,N9IXMI<]YKO#GMR:1;@_Z7F7K3W!*^A_]3ZF3 J^O%?";A;!
M.H;9]2M66S8:G=>]!1>5\9;!58RDJUEB;LM<G-$V?A<0*62<M@XMFSP,%=&F
MBC1**V#:X1,*M.D)T"3A]=4F%A^2?V<5&L0%3KM+*QJ:S&""S.KL6!2),#%1
M#:)BC$PVOL,A9)8M?2DS5.=>=6M$77U8VA>2%%<)MF9F&G(I_B;6:V&?&53'
M;&NZ;DR.>J]6+YEA$U?+?T);Z-!!RLR$9  [\7=LJ9.A3;.%^QRT\1NC%5%@
M<I2%4R;WT-@45:!&09![QB'N;C72"X_5JZBXAC>_#,+U!?3]7N(8)$!(]"KI
M3=<V4U9P4YHAE6.'.GJE2/>4J6ZK)T61>N]EA007Q,5O.J&8M;<V/YGU4EP/
MAFV"[*VM *V:K3GG.CH85JZ'C@@2,GU]>@I[D66<.F<RNC7Z00E^O^X8',4(
M$W:X%)7KWA]K3 7YNT:A$S;W.5N_;A)$S"Y4;;;O^?F#6YBJ?48JZXOYWUB"
M<:3L#='R >2"\4E#:OR4]S+6Y^&?K9($Y,0<)8R(OJ.TSND:G'VH&OV:4SN2
M_)D-08C^A@<G"]UU&5(L@QZ3625]]8'LMJ4F-2B"&(8"KZ-DC<\RX\KE"JB3
MTF523,@LCYZ3QYF%W=,?S^:^MQD;I %%)3G4UI".;F$9BGTST,PMT'3@].T=
M2@R.#EJCVE)MVPXA[>>RA,R&I7:3IJT!D>FAG-SC9?:?PY_%GOR(:SL,U?)9
MT5 ]=K L+N)\I: RRX:7K#EZ#^UJSL(AE)=C8ANB]3PS:?=G0RZ,KX/O'<T5
M$BO@0Q'</,S=+JG%$PHEL;2-A1SAN!GVSM:QW$.XG5RNOI*?!:S(W03K7%E\
MAU4' Z);6[Q4&[.BB9EMY.<R2Z?.B;81A=WW-*V"OB6M@S;H\O8*ZK5A9@.W
M#&[B$JVZN>\9*!$(IX8>/E$S(<<KM2TX9@.HD":5FW)_=E^;C3K\G:#<GN(G
M(^,SDYS-I]6'1:*]M7E$NJ^="6RLTFH^,V((%BV^1/_.P50WF-RG:0GJ=@*F
MDNUOH4A">CG.=&U$VM0FE&5[=;J_&U$3GJ5S' RIW%"14F'IL&%.,M305)6!
M&=*I;85>E@)!.\I[II[&D[OG(50._AY .;%=<Z$X/KX>@8!,Z=>9OZ$L!]](
M4*[CP_/Z%:P-K&F&8#*^.S"EWE+9RI>Q:T+M]'@-/N:GZ0C:F_G\Y_<H7[Q@
M-Y+_&5XZ_7SMRCN3\_\<2KI2OZ\>FM;:ZNK3_51,TUI,[*F8\/_H95M,C$3_
M/:0Y?"AP=*YQY*2Z#82*NPINB:J >,L%?(_94%:E"MJ51K0842C(JST ("W:
MI8J)\V;6<@LM%<T_VI<QNW2=2V,6,/B8K$@&4&-)KQ4,E-H(?M9JOZT;/_F"
M,SL,X&4=W5+O)S5M45Q8WC1'O.+FZ;$ $F\#BZEK!IY]S_K^W3?M61H::N9_
M^UM1_4B6#-YYK/L#@/<__RN*/38;:3W]^,I;]IK _PO!\'^?B.-7YGKQGW.'
M$X4KKK(9:.;*97H?TK#?"/'APLALM6@S8JX4'#T*ML4J&P?)G3*P#<P@:I=M
M2K^G#Q@M!#(=?O3IS4WS6$**529C+TVLWWU(\]<:>S9O+Q2EK=:+P[!-9A@
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M?YB,HA@WK[JT!#"VF7@'-N6O18Q1J<*$'JLK9U\M(U ')?[[\[ #76=$?O>
M9R6FDD0[+C1WX^QEOW5>1-Z'-'PCJZ%#=*DAK_>%GU&A71:*]OE!1;QNQK-0
M81GB*OD1BEY)7H\XJS38EU 3U;KD5]OD4[LM,:(BH+6(0'+]6KV\V'AM[:_U
M-;VD^<8LX$OK4E*/X;0(TC$J4$^D9I-J"IP,#[CS^\0Q8E:2\3C!MR-M&0KM
MD@&*RY[/4)=^$^7+-O1 Z;'ZOBA82^(X#6Y3&MW]HCW+B&M4!S69A:6R-C-P
M/P#TL30&3XLVZ#>!,),XCKQ(F\XTFMG9H;6P!\#O&$87POF]B3.F;N/P<GN
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M)$B@HQ6,0]\=C^P$7;/L'L3*'"]N2=O#0A4%MK[R!S@T"E(]*W8IE#\G'.:
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MIJPGV):9#T.DFO1GS-,?;@ZTU)YC66G[+(F:;OO8-YH;_C.PN>"F<^;*'3*
MY'ZVHHDHVPUTE\H)H'[>)HU/(?BSBL G-,&"_;[C\SLY[R*N *GW-3H_MN78
M$A\57P'FL[3A>[:E7][/Q. F1P;XSCFUEG_3-X@*T6JML*\H^*30)YZ8[TR@
M.+5<A?5-7\*FXDUWC1LS;)H2?"/4*1F>K]-W/%!:^%IBW(+87+ ^A\J13%5B
M70@*3$3P!LLLWA6RR>D(;'4RLM_X'#[S4A8QGS?N$7]&2I3^X;B'JH]TD:S+
M>G,B&,^58 %R(\!J'?Q40Z1#C0W7V%]85ZP0^=A1+=<$/K@#1?0XD-0W>'U9
MM7L[;&;&+=-21-@FBP^R&_/BZ1;H.;QY0&9%Y5Y>_-&WB8QHE%"RI_*KB>?$
M/S<3<6RP)U*R;._ZC?@EJT"=Y\+V>,F)<4*&\+L0/'?+JW\7\V9\8,/G\"$G
MS=\X>Q?G(N0ON_(@ZAFRP(7*:R_^2^MGJV?YXHKU5'RRH]5QB,R/R&^%8Q8"
M=&GZ^.S_7 &R0H;P_EG,7K&OW-!$',DL0\ ,4*.>6B!=H@,VM?#7U7L0&IU&
MND?Z>1W)0BMKD616_]SAZ0.(-Y%FI)7R&>$',0DH]/1\[U'K7MZ0E'RUIZ9%
M*-SE:E.+ZQAH63CL3)5:4J)+#X7)MEL;C5G8*CS+U#?-_5IT)UL6+*((IC=E
ME>NYI<V?_WZ+[*C2,JZ/#(;SS$Z9*+NP2L7* XL=U)W#7>L@0/%=)2OX IP0
MG$!GG^-T]I#,)GPESXI=T*Q5I4S0I'Z/E[@C]>"&&S1DL<_#7[];38Z 4<LL
M(AJ@5ZZP211O+N=3KO;C;7:52M>3AV3(V208GG.7MMJ<A%G:"1M-JB))WWD"
ML1(K/'1=]BW.8.O7!3^J39.B< T=KT$*XP*_SDE3_Z:/R2J6HR&]K;_%&0*'
M\& ,:4S[FJ*?U0H:QU:SEZVV>8J[/O+1/L1E"FC(S,O)>R<GSTH?,=8"=20Z
M9P*A$#,\$ZV/8/B]RT,4TX1XFUTFQQS)J"(X:XZ5YL4;M!Z<$&!AX!@,2\6N
MJL..&0PB_V7D!(</04JM\ECH_C$A%Z83MGE=_F-1@?HM=\>S8U2:Q1[^(O(O
M?VF*/B_]#+#O+,15<9;)T:<H(E$Z3\"^],N;]Z"-;EZ_&8\:]?;HHUNYZ: C
M!W$;L0IUG--,Z2=48JGHW.EI?CSELM)A4][J@&2"N2,R'GZM2ZM2'FTSS<@-
MM6@>&S<NY4*G'53Y(=='!K?LSKP5;0QJU^5\Y3%+D^5U6Z=H<<HQ)S\JWV/2
M'QI"E(^X2N'DK43X+94W,&]K1+U-FCB7I'5(G"YP"%\U?>G6C+*7#8F5H>#X
M3&]@BRC%IDZ$VO2,#+9)?D$ &5F(C>@LP7UTE&(ONE^F=#^BKL72?N!)9Y7X
M1I))['RSS,3<E=13T;5R,LV^4D-">#^\=7?KW&?IYL#D]OVD(B5IAX+/JI3P
M9V/4P9MSQU> =V%O>J3B'7OI%]G*Q1E":*M(1>0D&T_IQ5)E62\*\S8#8 U0
MF4NB%A.<E3Q3;0EL*KQZC+K(K.BN #+$N>1?LT.'Y4_<\KZ<_< RA5L997T8
M ,E^S[#H@$3>"#I1'GIT8!^F-RF"S3CX.+;<T'M#%+*&IK8Z;,(FU]!)2;4Z
MT^2?IH8&IK2YV;Y3?Z,3L3R.P?MEPS(QS N0I/V?ZFK0R!_K,.,VGKK#D9YV
M 6Y8ED=6LM#N :K.L1+K.&166%< .=PRO!9-*RM60JA''E.(1>M1&T&BL&2&
M<&A%'[0F3&E<2]@\),G:Z!=_,C%;AX@K46;8C\)X-S.O:WKD6@^)2-(S710W
M.%IYWG<6(SI# ,W'"9=_! J*W")39YY+(/)@?K#ZON>G\'N%/)[\%BJV(6GW
M3)2W_$BH=7K#D0!+CMA@PRM;%^8AO07SC*=CQ"$,>8W5H6GCR5.V=B1OG>?2
M0^.2/O/Q@>^2T)(Q7MGOCL'^<1;?1]2L[;2\:=[GBB^;!II\^^Z;=X@>%*OP
M3+/><J\D^'%N-[&M@B#\&EHC6B.;:V9[IXL:EL0$6NQ)AORN)+,BHL''S46A
M]7)0!G6U8OU4K?),DB"1]!.>IL''9R< X6/63H]<EGGB[/B8]CVH(PE<0Z&.
MS4OQQ2T].0!U =Z  %O,&\-P%2%=&^O@\#EO7L+#";N(?C5=YME/KM C/]>
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MB+ING(6)$O$/M*S?3/TE[6Q-AK<>5F\(IOML(\-=#$SP;Q^H/&4]R*Z:CVR
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M=3>P]F\*?^*+LJ5E#&G1_+KV!C05GPIPHF8D8*U&B#3).#;T-C6<'N-)8E<
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M/M"**NUVGH!IS44P]^J)F#4H6"'9ZT&]184U:&($W&K_$A!*@P@'F&T:\/)
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M<_3>'P51L>G<( QELOZ#VN^Z' JRR$X]Y*C[1VAP$:+L/5=?RU!:&]5\N\B
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M\QEF=HN:3/989FC8_TLH-_O_!U!+ P04    " #DB01;63\"QBLQ @ <RP(
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M4,49+ N4E7=645&0L7=045#^-=;^G?X'T[>1CMBO\\6J^\<.Y(1T9)G_5[?
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MQ(\%GDB;V?(A&4?3*B@@<RF4KGMRUV6P%^Z:,0ZSA16G=/K21T9%XB(?O=3
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M!O8.G>X9WD*1+ F?QTWI&^1+CYBVEQVV"W' :QS]B-&]&"]OO=1>I\YMO7W
MES#B6O(Z-([0$C?J(;+<<P8\GZ7Q\.U>0R#XM2[U>)VZ0)'F7-IXZ^%T"K-P
M_&(SJJX7.T5+RO1>'4Q*Z[,RZ<@3%]6I"#$W?:=_7C_AH69"7SL^3-_8$]6S
M[3C7<\FZ<$C)UW [H_\3K#2N:.^JH)99O%WGF4YE%ZBU>1YDO0]W31SF;WZN
M,N@L3[CJY)G[W5L&J60/WE.ZMQ)-*)G+]E@_^8?V/=K7NUN4='.*1I^T;[[@
MC'W%,R&Z(7CIW?SJZ8#$Q6"KK$6ND1>97;.B85Q^'1';D]'--O6&2V"-7K_X
MHBJ"ASNS.\62V $C2M" N;KNBYL7JQM77"'$2NG<:1BUR5O9@2JBV".T&(1.
M-VZP173MW0O5*0(&0;LPV8;.N1-TDO0[D6Y-$S<B;MQ;*W%Q/'NWVYV1CX@%
MKK3P>&A'7.XS5&> !<H>A5(_303%^7A@OK;PU,P.=8EIR5\TRT[OO]<<FHV&
M*,QT$OB"A0=EGV$,/] W(-;7#,UI+S(9W65SXPOTX.CQ?LW2:I8T+^=X2E>R
ML/4HTH;<4OZ0+/0EUW@/-F$JLO-^#<G$U:/9AV .GP+%O;%Z?7VFS);X[Z(4
MO08;A/#<B+B9Y@B^2-=VZPZ;@?C!9),?MF^E!5K=S.8[-5!6X2]E-.%1\PM]
M6Z*8ZA$(LQQPO5'A+RI96CIAO=@XLOB.F%O@CRSR6[Z5@F;C,:^,FR@XF27O
M;YNL[6[IF88,]&!;6YX@@5]6F[VMD0_S>3\KSN1>?H.YTE6^D3ELOUQS3?Y3
M* F-54T*>%XT"8T[.MJF)+)1R0%66(QWHZH6E^=2LOJGXSOS HPK2/SPI9*N
M88Q,_(Y;NJU>5F'YY%P0H54\YT%>F@K28RMN5=U3<27;QCA%TA7E%:$K5M(&
M7.Q\QZ<)-_-9Q3PSR=:+G82%B"J)7>]'K,IS;5MT)11?+=3XJ'!2P_SA,NL8
M8;R#>Y54S^M,TB[2UW_E![/CFQO+9U:''9HUDVC!2=[LX9S*,EEDLSN#CA+V
M.0L@:V<\,]@6%B\S(GW8Y)G5$,SS: $'YQ9E>)75C.X)%I03B^J7(^X[)JK7
MZ^!R5O69UD% C#D"-FU3S8S^0&(8(EM.<,[ZR*35)SY/.]E91]HPTUSU5@(U
M%7ZRN=_CN7AS1& )"K;_D#ANY6GS(E1E5C&Q#D[N"V(O?VMX=^.A)H,9]**L
MSZ9V)(8HCM92<V&_K.Q#M->K,Z\@4B&8US.9F:S4^GQ\*S RZ1,KED>#<[-M
MNBDPH\KHB6REZWAA-;L! S4X51V1Y!&_F<F,[PL$+3')PDI#<=7)CJ?=&A(-
MQGDL.V9>G5H:[T@<6K8SQBVN<]C8>G/5ATBL<TYW5,0JY@XX%> <?V&J)T\K
MKJSH-E#9Y -77L$-_(4\&HO3S#R40Y%W1AB7C4J)?/ID"'TL37G=^%Z,WZ(M
M(NEP%@']^6%[?=?,%$%WR-*4HG=V"14KKMLY8?3*:P$3H61;3M\XR^.SUSE[
MMB)*2D+%\%0-5_7QVO)!9SY3J%Q[7".:KV2H#)6Y;CPS91S0T <F"N>!-J^_
MXC5QW@?D^_/?>K(1&9^00P\E>\S:S-:ZDOSS>NTK]X1IR9GJIY]AFHU(WAF6
MW9/S?!-D<7MG96;EQT^MV(+X'LK,6G&BC=7@JB]FA(0_I4'UPRYJ!,T>>3[C
MEDCZ7D2KSYC:!C4*3AW\-"2]<W8RD&Q,JNM18*YC/X^4-XI3HPA^Y>=)[_&8
MZ1O:;%EZLO?TX9_=H&\:BF;/I6Y8/2OL[Z9ZS*EDTSP:U ?BO0JZ\E)"1JDZ
M(7/9'2E4NP$CXJE6$3U"^6PRXY%VZVM$MPG"E^X^.TW']<$BQ#**E]\U;?N0
MV,#NHM#SP5FF66,C;X:&9R:^S[E3XO8!)M*^<2$WE$KI; =EFY-;17E@0,6=
M!_5\!ET,R0?RV;![(<IENL.5(O0Q@7"H;:L[@5 -29J<NN=35P_>S>WN;JAZ
M<,JWD.EKV@=C #MVFA26BKKJY9@*I8TZ>:@I*X:*M<@K<STWY,T(S4@%_9G,
M?ECE1)[XNJOZA^Y]@$^$[UL#2$3;R7NVUL8DLXE 9IS%.STDEW!)S% JN-7J
MB31E$4BTDBC*K$M.*#=QBMXH'Y>[<QO,4[CIPS0V?NSEKX5,P0WW<7D4AKLJ
M<;F8Y0C1R6KC<SL?GL<;R\QS#$]:%B+>E54*EWSJL;MX?Z$BHM(SN5 7K0V*
M7;?:&)UJU2\6%*;8P[7CJ'JQ3-^.8*+$0-Y"=:FL>K@E4+NE;S[?&\;#\3CN
M_G(+?[A[#7MO:5[8:==] /#-$&*Q^YEDD?N\IL>OSNP#N+UQHQ]:&:[=Q<61
M50\(A<NXI9*R#W[K3SPE[3YU=8I(0$W'Q?5"3BR,9R1Y+RF!>#JR^N[+%M&9
MS6NNZ>GCML"2ZJ'P:]_ENZE-KSVKZ_*L2N29[9Z<VPQX3D1'EJICH4H?5[8D
M?'TCST\8M:&5JO>^W^PW0C]T"=##C>OSK%X3-(^TZU-S/&'3L:$R,W#9A;?D
MKFE%DP&=HD^LU-,7,# 0NMH,]D"\5]R]AL,$FA$FX1BFMG1<]=?3O3:IWO<A
M7V"F62B%8M-1BEL6ZR1+B48Q-0\O/U$^GG>.YEFT5?J$TM8\59KC>)%),^U+
M%Q"4HIN*-E?0JP5JL&S=PE6S]S[457H5#2;,)78I9"UGN_'F)1J'&^B?[T]=
M>->FJCOZK#:[X U&0AF*88IWQL.F)W#KCA:4VG4]\GOB6/G\]D\*T)[[L!*Z
M/P46;#U#;\'!VJ"DISA2GJJ0U3FG'2TRHH\=XMO%@#PO'.1244_N%7"-&+_4
M)_FR10%^S$C_W,*H2N.G<4;D]!J>'PPUYRZ4U*_.+",;Z&[XXQG9;O.WWA07
ME^ H62NNM>H,*-1:.+YE3C?7Y;MNXEJ/7)^K=T;4;$=A1,]VK87W'+GST@R.
MJPZG@/6]V<O0V*LL0S26OYJ??_)BS=@LCI:F79QB1K2,)ALIV>H9S!=;25=8
MA((*F_L49"%&E.NSW-,3RH,:U^QY.S5L\OHHF>)E[GNA9+M"3]XG&T7'HV>V
MV9)WR%$N2KY*UD!R[187 WM*!5K@:;!<73:4\G[[UCB98B7QG8G#=&7#Z3CU
MH1>2ULU#EFZ7?+<C9=MG"YD\7:#$XE*[@F2L$K&@\Y)6;D1C.3?5']K=O4H;
MR?!W'*"IU+8P\H1;=1Z76F90ZLR,2RLF2;!>96,*Z[A>(U70&;PM1WV]>(RZ
M:P ##^LGR<SQHU^6KDX\@K]\JL>T?3@<T% >Q?9U368S>12RC"A2$B;C/>Y[
M,_(#I\UUXHD7[_N"L]LGXP6^+UP>[;H6Z].IK;AN1B.8P"6ZY%CI!9K1_ND)
MO@PQ7K*ME[3%C=A!M8+E'^JGNY:/Q\==#,!ZSB<H\=^$T2 KVAK\5AGT]"Q8
M:2M/^SIJ'W MR2?;,;NK2TK$;;;K_G(7VF14Z6+N_=6&3XJY)T(B0!>+2!3)
M^];B!DW68I1'HCARS:WSYK:Z"76JI$7:,XJY"5!:A;F<Y3?G7"T-;"^H?;@(
M54V68.*-"T8N0FL+*?5FJ/I+2^3%P',II8>9I"$VQ&HV%$51UBU145%:U#SO
M^KFCFZ$<_V'=[M:I]Y:DXB2$DJ_Q"ZC<W0VKEL:/K2^IGMT1 7J,70FL]REE
M2KT^GY]3O4W>]%)#D3\?T<*D>6Q,7UR3TE>X]8"'8V$B H[&VI@4%Y//P*"J
MI5KJ Y8+RJ'48P*Z(IQXH87M9!VO*A(I[Q2BQ*CX=48.PB0V]H)'%F*\H!UI
M>#S>N:.TTP-#.]MQU:"'RF<)0^B1&Y9%DQFW^[TS$K!L74!/D^F[@]F8C#*S
M/;<IFGB?^7F&K1M>)@7K?=KY=9=RC^>E<=O3COE>#5%NAM^3]N9OK*\@RO::
M'MJ=BTHV)G1-1>@F?_?+=*5I.M/\;$A1"]%4T+FB#%@#7M4V6UJ+(U+UGR^-
MDPR<#=F''^G0U%\/#"#XD92&VBJK^UJU$@K7I],)0FOO>DO=[I'SIGW/FL0$
M\P:GB:,I'B_>Y!:CV;)](NI,W,K!X.-9D^R^7)!]0(>-JS4\#;$R#F/.OM.Z
M/H15ZAI]=UEC<4_<>X*LA_._DG5#K-Y>9SCJQT[EH. L-VMY_YLCJ]#"&516
M$:*LE-2\6+&]E=A[_HQV$54Y=.;U8D8XU8P"K9WM(GC',:#JM@RCPALE] DU
MOM[6P'/&I;FK8!B'MZM$>*3,\K* XOG&2*AQ6&I"(SXT#0OM&,2ZML3+!J</
M\O5>F[#M!/,^P/,P&%9-T-AA W%448<XQJ433Q^&!7=]W^ ]CJ!(33I.@.A3
MG2D-ZV]2H K3F<;OK_*++$@?Q;;C*G=-,ZZV;UAN?T]70$ROFX.%9FH5+(,M
M QH%O!\WKW__F2I72)W# F]R/*F[AYP9/@+_,FE8^"I.O+GO268L;TS&VV3I
MA/2U5FU.5Y4.G+VH-^<X5^C>\7O+RNCDT3OEHH">C_')9A NANL*T05O!M3P
M-"U>M+T(CAPBM]1M!41%#.V=XE8/,]A^^]:C9KVD:Q]P5#]Y[>_-P[.J^X#J
M?<#"]R^7!F?I;C8QS%@,<VVY(C'D(CUS;-.JP3[J'*4S:RVBCBXI9E*#6&8M
M05FCC=U(>"\7#H355[*4H>A79A)$!)WVCGL&9GBQ D*1RP-(G9W4-2&0H(^A
M5BY9V]Q=N&&B>&(W_".&Z-QI6A)1'V*[ADO2@YY5AWQI8W=[6CC+G?@JS:X<
M%YN>#X6Q;G;)";458CV>'D4S#[C<>HCE(3J,\K88Y:4IK&![FE[-:497G)B>
M'JTPM<^@\?."LZ)_7:&;<X%4?%SC@[-DKZE/@^5QG-9OIFBJTN5JTJK:PS.6
M+R+<UKGW >M<ES<N:R[ 59,B8'=3O,V"*S(V4X<2^QUSO2^["&Z%B'^L(+D.
M&\:-#*FUM3F'*SQU2.PIR<0(\%F_[?HR[&MO546"@?2@%R)A?E,]"5&E([M"
M@TSN55!B.<$_19#I :Z)U,"U@Q.Q?AS![O>S*=8FQA@KLJCN?*O4JG->KY2$
MZX-QJAOS;=EXMO*C?OG^"B3?;E-!@^4$X3UDMY$/P3U0W8/])6/Q#"RI9>?%
MJS?5*0'ZU27)ZFJED^S(S<1SB$1X1>>L#:\"0D\NZ0."1*P.??%I\L( O3OS
MGK6U.4%D4+<\KM\NK&GW68'L,*6[/A]4E;,8'YY.G\O+9:B4B(V6$TJL-,*9
M?M,#'JDVI"\]D6Z/"IUKBOBW2Y1O*JPDQMI?+,M:0CUO5/K,*+#]XAJ<AR7Q
M%J#"T$HMTL]<Q.@PV7@@U>-3F%'9K'R8N!F&L3==VK([F-&_B^M.>%_NL4M5
M3;(*@X YQO&^(@0UC-L4VK9'P4W?TH1IV6_5'EU"$8=@8JT3%_T6P;:-3!M7
M?BU)'E^+NR&%$Z\G!LSK!<.5%QW='<4AW>$>V);<C@U4!-RP?VUQ'^!+V=/V
MO34BH&GQ/#[9KNJ#"BN*TXJ]1R*Q?:_"79"D@>Z2PF*2F-5D(O%B_63"?&R$
M>;['S6$WO,FX90&9SUVLK%(Z4OV[7@Y!;FP&\)DO>\ S3-4E/4A$"^DI1<TX
MMAAY.E6FF)'J-=YZOX/T:/PZ'38G >QO?(%MV%( ![+-10=SO1_EXB4.*<1?
M3Q[ZL#D2QY9HR G!$@ABC,SB'@E7>1&W"]T9U&SIS,DL*^/"N%:]EZFO^,OL
M[/(C.DI+=+M KA_?EF,E8(G!>*SR<'$'LSI4D74$S:XS]9R&D6#/,U.'+V44
MQ(T8O;/D4A6WM2DU?D0?-I,LU\<O:E2KWVGU&K!UN>BR&H&JTTMGNG(QQ,9U
M)"[$SY-OWS,;82ARPBW-+^<_9ET#6^!3:,%NS*SSS%.0 +F$7N2:+"6NC0KU
M]W7CXZ,F=IK%P'@T&M(_QT1 K:LJ$S)SY#UT:9<,6"=P5>9;DH??)$QVPJTL
ML7]9NUZ<8NRWJ&$Z&M <3[#+I,KE3!E!V33:E"Z.1JLT2M.W#,/FX&CRQ,/>
M>Q9(C9.6I4N)#RHJ]2>A[<)X0==/,[/2FBF#%<K>EIP+:_/CNT\_"Z2J+>Z]
MP8>T;0JT_9VIAS]C$FLO#K:U E4)>;:/\&/(FQ\*MFHX$(EJKXM.A^FV%ITQ
MCBV(K.+IXD;B5N*0L[DSNSUJE;OTK95I'('CZ?P\J'2B2O+Y^H74HDL-"DR3
M&!P'!2>\=:W$N.-+=PBC.:0@3"E">91"?#/3(C_]I>+F<&_05L ^8)%+\Y=J
MRGM+&P,0<:OL41/L'FZ[S'.IYX[+NV151!&_\F#$*:VN-*"VS-ANC^#RQ<87
M*V>HP,DT&/E+;(JNOD2RSYN21Q?Y[*^9=5[H6$DD\ @XAU@90)=\)3(<+]V\
MQTJ3KYEFV&E:GSQ9JL--UD_#:KA7?]/48[':U+M3TRSPA%@/I:YXL WR(EX3
MK;*XQ)W+#KR3"V_@O4GEE9A>7[; !5#FMP+/G:8IMW_Q5R^>KS!^F%]_J;*F
MB1]?T,)^,^J\17<WA:&-<P$A;&KUQ%%J\):ZZ^U]!9VO$MQG!=(28X>^;**J
M+Z<H%K6HHJ8M-0I<LHWFI;+68S<)Z%]&R[<3M#YN]N0;F,T]-'1S@XV,F) &
MFVI-K<(W+O^X<ELD%F<I,TVB5,ME N"?_OM_D6&' XZD7EUQ^KO*I.L:%H09
M5Q9YCG$KP:_8C7GM':="AVR#)XDI(EN73>SZ:N<&J1+/'+QC4:.OLD]<'_%L
M(>H_Q_OXQIDD2YA,]^_*?J:ME.#4'O2AY?'&G=>)Q(HHG9,U'ZMC\P5HB%2S
M[I5$H[2Y[(K@-[&D#^4>8W"W?E?++RJ2'66=2YM+,8&*C6&OH.BS187#B-Z5
MW6ISKI1RDM4Y5;]+-+GP!V[Z[VKF"J33IV-7F/(A:AK.2>\Y[QCRBLSU)*#F
M]@'E+19+^%RQS9F".[F@-X0M46/R+B$J#2EZ>6P6@0QQ$]T'_/RP[9W9V_(1
M*U6_KCB-1T'/U<VNBNZ=<*9_ 4OTP4]#.'/))PS+L4))S0TJD?'^A>1+WD1G
MC84NNAC2Z)VC*O M9E"^D]GVHT(89XU]1G4@:X?R9IUR)7]F$ .REGCPX$DS
MHXDH$<N+S,I^I>U=$'$MP99FG8^;UHM^^&PI(_]CC$]VFOR%S?5\W88H;CJZ
M;4>J>ZC[6=_&\.235<7R<C[^;;,O<_-0NJMY9]9 =[/1;MQ9F_P:G15%OJH3
M=[L5GK7GS9K1%+K44"6MJQPJ2T4YW=?Y]7H\+$?QFS339.DCTU56=\FD^W'S
M;HHIVHDQ")<5%9L:N*EK=TS<>+U29'5;SRK$9N^)Y!Y_9:>HK??\:,N@\G@C
M.?31X\X+Y::)XTUSI9/&W:NNA<!)W=X&\I=EPPOC 9[N-JD+77%11YGFG-?
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M85P[-5T#D KB/N!6U<+1"Q_'\- MNT\1IRV_+$VR4AJ2:5)*DNB<])J3C\I
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M^E'^Z=+S3R\N4P#( 9<X:1A"GM.\HP0\I7G&U_+N>@N"\QTGV5.:4';V4'8
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M#(GN:M?;A-'69L>&&=;[*Z0X-L+U*]]K$6SI*OC"'..!K?RF/$31LL@:EMK
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M*\VH"6E^?+L.U#+,TXOR8C:QUQ_D@]#698 =7=-=N>[5S:;ZQ_QRM0/O,5>
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MS!B')][)9Z8[]$2KH+FZN 1*DS>,K_7XJ(PTU#8GHPW&'S:Y%LX:NW)([9)
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MGU3]E?+F HBQ5*&* :E*"YM-!,<OW-OQ4"M B2@-K^S:@V!#RTH3Y5A9Z_[
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MBTC300XA@-/Q$'\48L5L+I'*]:C ,=ZQV;;]E88BBMWJQ7'<0ED6(LZ.!LO
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M3_^5$W-E&4 P?[-EQ6&_Y)CE2*'MCD^F,H_9J#['FHB! ;><7=3"AY4@CQ?
ML=+VP -OV98Z5>2E&T-1CT8<GP%>N]V3O7R+& "XA -X!'C[&' %( *@! "6
M 5>) F\R2VP! ,0TW=1>ERDO ;:NM)C=I'UPI?'M8Q7 O0>1ES, 5UYV (!7
M&MVN7I< 7.<'W(S:Q-6[-NIHV((;8DE)KRP?WI@RV2[I&BX:TI:D'!.I+,:
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M=Q#>O8OV:.# ^ UC_ 0X]NT"(ON"J>*0/X:-UD^S/7F-HG8ESU?[?CKN4[:
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MRX9LPAGOY..&MMVZAOOFO2P)KA_F59+ZT:,WC#<;FVCO?&C\&GW]J?$=LV@
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M>>CL&:,#Y508I'[=)5'2#MI*Z"*H&>H''BZU,L\9\+VK?L@S:I@"?9OR/'+
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MST>H3Y_%;3:BQ?,-0+,PV3TB#5VP\CC]M _]*[AU9-+-+FN=:+69QD7?'V>
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MLMH73],WK_@VI].=[R?-<5ZB+S7!15?5QA!+ME!T8U>I"R6BU_Z#K.3E>I#
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M"$+,K+GOVKZ]K1<-Y>]$L.2GW!Z"H5I9?LN6MPAR) 1#-MK1C*7V279&,:)
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MPU7@2(3&L* MO@GB5ENXNHNLMC-Z*_% #H82L=KV.F>JDB#<S38J),*BH<!
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MD65NM\0AF+/*,UGOYOPH39Q&NP8I1"=Z.^%A]>4[B2)S84Q3U1[VZ[OA4>N
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MXQZS*?:Q-569/26OB^,B7789'\Z*==:;3GL.Q:9WONNSGS$',=Z7<TC\VB
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M_OUO.@&?*".*XT/Q+_PC?Y QG2![M-#$\TK8G_/EE^WAE6.)+OUAVF\_>,3
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M>K^C:#"T(U_GEL4_R.$:/,//72-JQ+167Q ) ^"ODO:E+Y@+F8U&LG$GZ(.
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M:HN9[NEHDVP1VT]FT!B9\,)K5@&/?7>F51R+WLV$)SI_J'5?N@S3*$OB%<:
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M8GF4]1C1KZFEFC[KV2UU9'# K/B,DK<$QCXPE<SC1-L;TN>KK<%961D6;P7
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M:5_V&39%Y&13[S!P_%#%QO!*WRG1*)CP (M(=N(+?:[XX"D=^G$"JM.$KFL
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MS:5 'JB*U+<WX+]B'V3**KD<O;G#QE\]\M5/C#(.]^"QJK\>B.%%47)UBW2
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M7(I=G^YH9NXQ>+S3TNK3-T,J$T7=+3,7/8OB'=+!OIT*I/55\C:C2E;4U&&
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M^KC1<> PK'+-VNE5=GSPBPV6Z=ZI,=R&C"EH4!HO)B'V$MTQSQ=587BBHT[
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M$[R:!K(<#*K<<[*TNV==(UH;TVG</WJBO^P,"E'=7!?JQ_,*C_D#ET*W[9.
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M0?.&7J0)\.67+=:;,Y<X?%[S7M@#Z(S=D*2).4][_/EZ%9O [X#(/P#\-ZF
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M5PSV7A7LNHRX=?K8IDC[YR]QD,\_2AOK"MQ / X&C13H*/E.O'<&V 1.7MS
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M65>FQ"'$=IN230/?[1#+RJH0LAX:Q 257TC?:LHQ='IZMAJ)(IG VONHVI1
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M6*[=G:Z75L-E0# AE<7%$=L&C1CWGFK3\R:M*R['[<+-R>;??/4UH;8HS.B
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MJ*I<"Y:;!&(A#KPHS&Z% 9FK?%Q'NC3>"8/>CHA:=N=A!UK<Z@MF:XE2T:>
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M=ZO1K3<.&]X+RN6NZ"C++G+D>M3\4/Y5K:F27G*(QYD761\DEER 6ZY(*=?
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M5W8/RGHT7![X<U(&V:@\=TF%F9LM;U]:T?8^JD\%FI[24HDB/L[<3?S4$(O
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M'$DL,,:/5>RO=]B0^A!G2^[^%M]TU!/.LL\TB7T/Y+]NO)I]QO];8=F=<J>
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MCG?(SFR6(QWRUG&8"A%(M>N>BG@[HA4N'295?*^N%5D!A1)5UF8KB'T%_WW
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MB<7I[-Q4$\!>'0W)ARF2U5X4U0L]BW<OLQ9(@SP;59<0J#QK'K[U0[""1X[
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M$AHKS*J;SD($4^NW:KQ@+Y._9Y3#D=^XA2 I;=".[(K35I_A@F6&:0W/=4R
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M*%F#@*GR>)ZA>R?;@&K=O^9.EK6":LV.=0?_)9HT_;X9=T$QN@I#1Q4E&D>
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M4"9MN#&SK98I,RL3"S. 3]#65$O;$&I)_@"J!S/AIY@K**$@A^GP4RAR@EG
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MMW-Q=*8(O+60L>"JC$J8%2_F1.U9S.W1<[G1"TC[N$WHY#;3:OA,"JBYV2^
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M)EP*J>[V0V#Y\/PX I!_U:DN=?=XP@:F4^G9H;Q"RDVIL#60DZZ9I[:,<G^
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M2&0P8@\^HM&NHFK3Y>/O-!Z\C+G]%MH'S5'(C[91D%FRUVYHA#]ZZ87/\B[
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MN@'),5>86VJ9TKS:>E:4-JK=HUL+GS/GW/'K-\A;MO[:7/<, [/Z&+QKT5\
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M"Y^K3'<]\) G.YB1D&2T:XW"K^ +S 2C<Q]8@O,VZN_2P4\%/7,;.B2'6(<
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MQ-;BLF;-D/YJ+O\7/)IW\FY_P=I\VNUZ%_QBD99FW;(DEY7%ODO?/]XMEXM
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MOMAVMS/M./O@/:$,AZ$A!##Z&#%>D;=5:X_.N<#$'NXH?FA$LB.#1<24-_[
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MG(,="B;4X84WT'&N"]<[23]9N.'QP4]-Z Z98:!G9 9A7<+X7YI,!VG^R$=
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M<U2I<QV8,VIQ,Q)*3-+)B8T;G0SNQ2R[.:[+5^Z@P!KVZ*H9P<1C VIG4 ]
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MW6!V:63E:M-53ZUO2B]/7&^Z1RSOGQNB("$F;V J"IDR#5?0C7.APA!K#XP
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M313AQAE;T% +N15 [SA$7<#,8V2&^ZGM_T3ZX/X/TH>OU82O_:HQEYYS?B>
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M';B>C#A3/C 28ZU_'#]4TJL*F\8CY7*AQ9&(Q7EH"@NUT55CY6I9/G 4D3O
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MY*W1D6L_13^.R >[+N,#5+;%B#(0L?*E]*-)9SX*0^)_0&9R AT)H&Q:IH_
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M/0<__I6W-_\X:?^8=V+C.EJ'I.<R7J>',8W_MI3R++!X='D70+7_]]JMO]N
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M7=AM-A>0(2)V;&1H^G F>P)I< +0V C@Y 2<\?<X1HNC<0='H0F =Q_WT .
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M$"/#EE.K**@4(!&['>=QK!-GJHATCR:;+F990]9@(;KGCZ4+9$@UZ/>2DVW
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M^#PY$F93UYKH030.-%K[M!P]6C!*WV[K.= )2ACG_H1K: L<J13SJ$\NM!:
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M62? 2]N.;>1VUE!@#VC3B(5*<;-I8HKN<^8O.>2A"J*,GQF?=PIS\Y>RQ%/
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M):Y4/9>/B9@^YXOW#,P]WP1T1M<%\[TH -=1,<B5,P'(C@C_2,9W'RF"TP2
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M^H\5B'9$KSG:=Y0DC)P7-UJ)PFFE977UQ<V>K#.74UUB++;(C+%3RIC2]7U
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MW=%U9P*OO*=;"_5;[LFC)_@%5A_4$1<0PUVX<_+ KP;Z[0;[]^.+/M]2>V\
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M46.ZM[<<AP_"%+7!!)EX_=E*QWIXW,-;ICH"//!A5]HB.DSRAK J"6<!=*4
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M9:5VK)';0^D% 2.0FHF2\E80,IV/)*"FW2JA',5LT3!%H-WV,ZE6V9Q/BOS
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MB4 ]'!8#F]P[=/(+!TZ3\X 9-@8 H.I]7(N8_=YD9KY"C(54FX-!T)N?Q@$
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M<Z]Z LQM/%7*IJ0$G8V"+12M"GP$3SOLCY:)"E09MV@87BE;,%?T 7I%G,U
MBZ_='K?L#RNW![-KJ(FD6V$9:]]<#5PDL?I-&FV1+"5Z7^3I2J2;33\L[R[Z
MQK!X"6)@K#YG\A&=-3KF$[<+$,A23_U*6B#1+EJ_60:KMF9*3I]L?S@D65 _
MY<:$8P(#T_#]O85JV'VG';_/\<981XMF3&4-+^2#K%?-$-/$GPH:4!!F6I@L
MZ]K/>YY+.E@UHE0D1S@^S<<YW2@V:T6\G5,Q%GA?B'YLC6]@SX-[R0,2A--2
M==)L^/E4AS,'T"JT[NMKWMX!-ZK;(6!ZYI+#D?KQYZ9T=G=W:WQ?!T\#;BT
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MZ4GRJG]FZ5GRWNNCR>4L#E^@C;O$>/3.,10H1"1U(BI4!B" .5KZG_ 0^-<
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MN_B$-3<0JL7%"#2A112/*OG8J"[R].SBG5\$G7!%+ 'AOKJ;Z]?V_#;CG4,
M(8C>/%TL;4;M7AA!)>3;F_/B\2XQ<P'HE!()^"Z@=*Q6!1PS<BR745Y)1!&3
M$!;V)!":K*G\H.W8H^Z!^>-N"(1%M7)$ILVBJR)>E)\"5,F!'\:3GO_A5D:G
MTG; +R_AL&0\+A1!*[#?[CWX#+J!UH."#($]LZD6]A;QE&=%-7L$LO%YI>:_
M&+UU/")CT5DN)]!AOR/W 'P2#S,?SK1IE.Y^,S"/*D>*E*].5;0#3IV/C@#]
M\2I?>P)C1*:5=& JW6#A]^^E=!$=FKWC-[W'W$L#E!LDD5K$7!\]?4U=KET
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M4 /#I&M6\D<7)NZ.>?[9AW'V@MVV>=[[IDD]UIY3@Z +7K&R&=*[@)#XG(!
M(3DY>4+R8&K@F1)TNV"\9E$]_B,XAO:)M'[$](L(SD4N[>I#01:&4UES,&JN
MV*/F@9D+6Y5I7-P1A6\+TF2W.N.+T]O@B"I,M1O+G5IA1Q>YL48AY^M:7CC.
M@B%N9^P" E957>MMZZ_NM8K,WLB*V@'24<NM32^_!8##A+NVJ_K, L\DM$,%
MUQ'=9:*DY9%OSK(;A-OTY$CC,&UR9;8+VKXT!HR1/EN/N7N5+7'-AXOJ(U-*
M^^'3-B.>SI;D]U]O$/ GS4M#KSN5]6G2RMPL^Q;0N?A8Q, 88;(*@Q;643O?
M:QL //9:L5U"N$EAVF3U6Y.U"<C]?J?*)XA, E,D<V_X\0-WB45%B Z$Q<1]
M,>)$D:.'+$W%25]3%:5Z5$V6+7@[VT-/I??*EI[(<#RI6%5<&GZF?[],V4X@
MHRR/P:-GF&NJ1+O?-:9G]1\[B*UU(G:[TS/%&,C+WA@Y&\H[C/OVRH6GW).A
MS"?(/CJ#@+"(JP.1Y(09T(4N#HX.4=@88HBN/#AU?CX9;"T!R<G(@ D$G^.;
M\&=$1G=;#LG1>9;L:+HPDS85LWPY0*G^XOD"1H "V>4#^5Q\#-Y':-;,QLP+
MD1CT;#A>T/;K171KX*-QC$VE'.ZE,>U]?AXM02-3!/;A]:(:QK?C6*;;D'R-
M@@73.GC:+M4!Y-NG+- &S!7:QI5!5/$-"+L^C+BF&LA=-F.;OG4JH%=K^>I.
MNI_95O^W^M#&I>U&M5L6]=X"E:YAB+K9L-J70.PNX*W/R?DTE&=9XJLOP6@0
MJCHX(97;5,J6:U#+AD7TY+8SD%=G/,EA"6J'K7&[@!7?74#>T=%,>]3/]SVI
MC$"6!C>H] )2!CC"YM?240C<$"O)*[)[!WDS=^FM709<3#=?1/[82^4A4=2,
MA@"U"73;/I#M.7S8I &K^)%EUXD^\ECDP/SVG>I\Z>?EP[/@;NWRUQ5Z>IW(
M^H/.OY3^PGLLC_"*;S?_O"0P2,.;E!]I^@1C!G'6>*5,I''N2:)1&OB6548_
M^*O0Z=EOCW\)Y+\\J/X6\>0NVI1'7GI;)_QY\!BNS0;'()E87'^CAHB9<;7O
MCGO3")N3XLFA&9TE]I86N!=E88DL&$R147\_N,Q)I=Z*,ATXOZYCRL2KF<23
M:3ZZ;96'+W%'2AW*& DVM'F/T7<0P^HG_K:97X6"/KF\L$)YS-+1[S"5-"J#
M0*50-K3"S^(_:M<MV/)?*.5N$+<C!VB-=&>$?N!:P/3EPP)DLFIU.3W, 6^7
M_]Q%A6ML,F/4:!"S..$7@R*>=:MPR*<G)VQ+B7"%9U@%O.^Z_V)IIGX]B:BP
MY<0VEK3+TFQ4LY0]12GX7'XQ.MI5K%_/-_%*0A:3E/9133X_^JUE^3WUN\9B
MN6MMOVP$6J5(\_H<1U0H&^S6^;#E1LW FA]T\YUS<*=FT%.Y?1[,<KG>; ,J
MVGNV26*LS(E<["Y<Q=^HO:C7>*+XZ<PN 'UH&6)(HSU;,?G^SAO;L^=V ??U
M\,(=.WVQ^4&C]FB<S7"EK&HL&XD!F\GOJ5 EUS62Y%Q\.(28&AZX,EK,,VR)
M$I9_?4#A.&L)(O/B3UX7O7N((5/=+(-Q@UZ/,=>K_H:]T0IJ(AEQ^2P[512N
M\1R&_&[S7%;/$:ZW:[RS:]94(7/L*PLQLG-88+-@(WW#)K6XK2<C>Q>P5EJ^
M9"^TDYX.4UKR^"SS2>#*FWG47$Z@&+2L^$1 7**# 9=:J]D[CMW)?4-@O!]T
M%^^4$!&70,H]PJQ)?WLPE)1_]/TCM%3^,80C>A? XL>EU;V[[YSK+;_?BZMK
M)\Y<]*T[??PIX-#SOV/E^VO1X/_FKXS_:<#@KRE[HS*PC6J^(, M/N<8 @!^
MZ)U)-N(&0'R:3^;X<SX_\XI5 )_$[5?B@1] @)O.(=_S:.B-YX@4=5GP'[G'
M%]%2#P"8\Z;D.'?\]F8(/3[^'-#Q,14$$'?^%<"G,)FZ47/@U36R@" &^)OG
MX2.UU_;B#L7$L.U'#EP[86'ZG)(INP4$"%R*$%(' 3ZE15_P=4X\_\X"?IU6
MCO38:4=Y4];S[A48GC!!@MSYZ 2]$<YVYO[C$A#&96J>M1,$I?'L!^E/W<-J
MP .GAM:]2E44B(=<";.45!P;;MO-.)N%ZF./#"=:L.Q%@#8,"R?RN[I;ZK3T
M%X#H1V:__IV=]E_R0?@?$W][/,+_>?AKYNR1O]6<_8^)OSU:Z?\X_']MLOU?
MM[K]]^!O#B7^/P\_#_=>_,O&4L45C.KJB*LN]!GPVW.7/6Z\*T.7C9:<E\I?
M'[GO\YVXJ_^GR[6*D[\]\_YO9AC]3M3^^ZFZ,\LV<3E:WA_VCMN6NGO72*#/
M>M?\;'<D*'YC:%*UZ/OEP*OR/SW[9T;1/Q3#H^/W-IT>\HT:5"X;^TGA $<_
MZ!])PO^?\=_-^-.8^'\Z[?X!&(_]?U/&3P);]2N-+)SC;XN[\[E<VU,%F-L4
MR"<]R![L442\;0)>UP\K .X5MI6%J>G7N(H.&;]U5$H$_+15G/+BKY!EOY$#
M_VNH7(KT^F*7W827NPV;R5"NH.6NV2#N79#)DPY N9IGM]QM_:QIP,@_.W,W
M][/ LUOV0KF:U?BXF9C<@&FW0OXS*/V<,H.A'6)J7.ZR-_HS/1,X:L!NZ,M=
M"N(VP+G+H%RP^UNV75K^4_S,D@,L?F )=[/+94#N!A8[*#?H&UC6#FR*N]DE
M*#=G*:HL2+'7YU+SQ)I3W@PNSU[E'?HYI1B5NQQB-!;-J$:C69R#)HN7BUTQ
MS%[L%A%IU#(B].*R"(M_O3[G0D+'^=DM<&"!N3X@;AR8JX^=>PK,34653<6A
MF!BC<G$8A546EV*L>A&R>22X"LHU1]5KCM55WKE&]1-K3H6#<U%0!).Z>3 P
M!I9:@C.H&H/B9[ 3$%RP/LMMJ%PTQ;AD\2N&<F?CLP@_EX#)*(H1'@8GN<4P
MKCPXR2T&%PQ!"41R-:NW@HH3/NM:XY33R2'%H:+BD9ZMHA5LZ[>LO,#JP%#_
M_R8 4$L#!!0    ( .2)!%O$;+(-]J(  -P< 0 1    9SDT,C(Y-V<Q-F@P
M-2YJ<&?LO =4DUGS/QX4+%A1L  "HO1>0B\VP 1IH4D7(4 20B@)5<1"4:I2
ME2J$$$((2.^H(" H(%WIO8-25>HO@+KNZNZ[[[O[_9_S/X=1DLM]9N8S,W?N
MO7.?)V']W7HOX#!8$:0(H*"@ "#)_P#K4[3>ZE8H-,K!"F7+(L(O")"X %*A
MI 20B18&V*9MVJ9MVJ9MVJ9MVJ9MVJ9MVJ9MVJ9MVJ9MVJ9M^L>TWB=/LD*C
M;:4$!&P<^$W-4=>A_&8HI("SJ:V $+^@ $!&WMG6U P!1;-<AUK";&19/Q0]
M8V6!F<NRZ@)5!%5L+T*M8)==[:&:KJI:9JX(,TES5GDY:AEG*6>D+1**-F5Q
M1EK;.$@YR[)N*I<BMS>Z!5A9-EG0"%G6\QL76*ZJJ+-<1-E#623YA?C,! 6%
M6<0E^2U$@*)0"S->%F%!81$!(2$!04D^(6$I44$I87&6K\0J1TU^E;$WMY""
M7%+\BD?^39;UJV-.3D[\3B+\*'M+ 2%)24D!06$!86$^,@>?@XL-VM29S\;A
MS):2;WHN01W,[&&V:!C*AF7C=]/K* Q:EI65FN4'^NH8TO8[T"\C^"LAVQ^L
M^YT0^0)92.270N9FWV5L,?;6F_Z8FPE K:%(J W:@2PG]&NP;[>9_P3RV^4_
MM9;LHHK*7SN)1/Y2T@&MX(C^:TD'+1=;J  $ZH#"V)M!%1S)KISYM2H(]$^"
M]FM59/9?*D+#+/Y$S\:5/PT"U!GV)V(;5[;$Y'Z3DR$'3>JB/=04#;U$_I$C
MYR^03U""3U!(2TA(2D1"2E"21Q H)2(H(_ 'SE_I0-EKH5#6<NJ:FUD)Y#>W
MMF;1@=H[;.0GD%^87_@'+5]Y_Z!&!64.LW#YR11A*6%)\O\?3?F!\X\ZR//6
MW!1M^K>T_,C[@QYR@DNIVZ/,,690>[GS9O:HZZ9HEDLP!S3,VAIJSR(DR$_^
MQ\*I"[,Q1SDY<,D(_$[@!T7F9N211%O_J)SEZ^P];XW^?>^W"]:PC<&4LC:U
ML91E=>8SAUJ88JS1K'(J,+(A#B@+-(LNRMZ<A8]%TPQF#74F-Q2NJ%UD@9 7
M/@>TO>GF<J"))GNT,>%8R+\HHNR1+)I\0BPFXOPB0OS"0!,A"1%QH+B$)'E4
M)$UD!+90_V"CP,]&R@C\PI\-'\VVAO077FI"[?[,2SE[>Q&@I*"DR%\9\'OY
M30-^!MLPP8+LI"E:#H8TM80*0&T=+#9YO_;^.+3?%A*IBRAKE#TYCZ!RHC("
MO^K^?6*IJ$B!;!S0IC9F4- E.7('/PQF+@44%A(Q%9($\ED KP/Y1,1%)?@D
MS20L^,Q$)<TM) 1%345$H)NY]GOQGU1?0IEA-L:+?&UK!S)'F9'5_V:6J:F(
MD*20H#B?B*2H.)^HF*@HGZF0!90/*@$4-Y40-1,7-05^ _I!V4] :O8P\@9I
M:OT#SX8OYAN^F I!KPN*BO!=E[@NP2<L2(:0@ +%^*X+B0E:F(E;B$H"+;Y!
M_$+-3U"7R?F(LG?Y[[)B<R>S-;5W@&ZLD[*LWQ9*UI\$-F0VEVXI4[.-I)=S
M,'6$FLL(_*[OSX5@OQC,OQ6 G\3_',/)"FKS5VO0#UQ_KF1CRCN9VD//6Y+C
M++=5AOSV4%88R"_ZXTKT*YD_UVUF15YEH.9R M\$OW7\-#J_G*/_RK"9H6P<
MH?;H_V+HR#BFY/*,O+7(6=BCD"RFMK;6,+/-E4_ T<;\ZZ[W?>ZPH%$L/ZX+
M/RGY_]!9<Z@][+_)TA^L_!XGEO^_.?W/)^;?6F6W)^8?>O^X>?[9LOQM#]K*
M3<6-[/I[@RVS6>_^DZ7T#^*_TF[^O^Y4/XG_2COJG^Z'?ZKFY\C_$. ?KVY4
M]!L;*EEL<SK+"<D(_-3W1_ZK&T-BC=GB%Y04%MDX>0J2Z:OLC]?_**OW'V3U
M_D+VMTO:-C"TG/!7D3]T_R"U<?#8*JHTR4=TJ)P8$"A"KE3^V/U'"768,]3Z
MZB48.9@;!P@Y,4'AKT)_O/)+2;W?K@M+"/THJ?>3Y-9D^>$TO754%_AZ5I>C
M)H_?MQL%OYJR_SYM@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#
M;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L@VR#;(-L
M@VR#;(-L@VR#;(-L@_S+(-2_??4>:F,NR^K$*B^WW@&X"-A%2;6+BG+7+JI=
MNW?OVD-]F)IZ[UYJVH.']A\^3GOBQ'':8\?H3[$QTS.<83QVC(67Y0P[!Q<W
MUTEF/D$^3D$V3B[.#244NW?OIMY#?92:^B@G_3%ZSO^:UI\#:/;LI-R%V4G!
M"MA!0[&3AF+])8 10 &@H**@^.$O#%!2[-A)MG0/^:KF8< .BIT4E%1[=N^B
MW$E)34$%(%^DI*':=>2TT%':\QH/140AFJ9V]K=WLPH'9S3TG0%JQ;_X2'?V
MPO5C"9E[+FK?.<[&?LGL;DA6XXR80UEH>1-9Z0F*3?KQCQIL*"5?.4U#[MZQ
MD_S_^V6*'31DJ)WGC[)J")NNMP/V[R1ST.RD <@#EA(W&'::&+B2*L>1UZ_V
M/G^W@UD[ B= PZ!G]P;73_G\XGCF/*Y?*K6$R_FVX.&EC?= H@#8F.4*I=S&
M^YF4UXT1]XY2[-M\WV2F?/MWA0[](/3?(=TW_G?U_2/++VR^Z_YG^_YMT_^N
M$/\/0N?_MNF;4FRN_XL5FE^Q#NC_A*6M_^\ZK/G=+='/X)ML]\$QSDD])]DJ
M;LMLI#:-#3^':IX2U?%R&>53;M&66)]/<SNL3J>T&:?%!8U+(=)UU9:_;$!N
MM0(C)UJ:UM:ND6&W6F9)A0OH=<"S1^3@?&T^UM;_QL2_Q01U_:ZG\/=Z5"B!
M^G^JQ_@[V,],A[XQJ7[7M&G1S.H%$KE_>FP=X"'(OH-9!3.^T11J,G(M].AY
ML_>6S]<6>L-#LJ_73L]OM;B^L3SY'4O0.#F08VDE1O+,S;_)?&V= K81\:LK
MSR/WN&^UJK[B_24T_CO3G6],PC'?-1EMM6KF_VC@-[!'_PGLIGSRUP"M>&C\
MA>-?6SQ_9>#Q;P:6_ WT'[SXATQ_*VB_,7E];:6K8.(XU*H6_LJYGP;^5W$M
M7[3=3#PN0UV?=L\C9SN:QV!<,M!/% ^VMHS;:G5#,^L B,NNN!BU@;4GJO_W
M?Y1GBTYWNE3(!QS=H\ODH#9P3F5C]]J5L@YHU9CN6JDF\-I?DGI6;/9QS;SE
MU:[#9=. 7<=M_^KU3UC^7/(_*?P3H<// 8+>QVV_OA3]"Z^'?]DDOYH6*,>'
MNSVVB1O.^++&UF:L:#QL@/^2ZOYA9L>YK=V>.BY&>8#] >%+<ZD@^ZT?@ZO)
MPZ*UW[-IZ"7@U"T U='7.YZ(E_L<)K-0Q)[)!IP\": V3R:S[3H'B#T'V $
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M:M'*3+F"O7-77.,N(E0G=,$+/=H<[.E$4-PK\ZG/T7Q,K!Z>1EJT",0FUMV
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ML_R.R=PW5R>',N--Z7WWR=NX=7:K?#SZQ/ <0/HY0%.VXAQ%M[3$+0I>?@"
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MLELD\H/3C)221#(*K.STC.TD!2ZSG<'M]:NW":%12'<]?+6834C?]Q/(@8.
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M3K%UG"05.CC1K*WO]]H/$;(8<UTB")M"UZ<ZB[2!Q"!'%94/**3MMBFP T(
ME I?<Y*+P_,=(U-3ZI1QR(L^51=I)J)B?V,PD8KWO)E?KRV#6LHT$ABE\^F(
M%EQ+I?+DE!0QQO%8(9#'ZT)? 403=%Z\VM&<QR G5W0<7!:V!R>A@O,OEML-
MBF\,.\#?'=UM>:*OV$V5U;O%P+"[4GLRO;.YR6^T$332[52(@3I8JF:;<58B
MN$"F3VJ4KR74N7M=V)J,5,51_%S\-*C\4%N#R^N Q<"*LVU?PJJ&[QL@""T9
M#:,0K'B)4:&*TB')*TU3_/AU0';NS/BG(P$\7N'QY9%B40J6:VQ)>ET0SXB+
M<E%'ZIPM,QR#<($>%C;Q6,70M%0><AT=G-KDZV' $Y?U45:NLE]<9X:T*P\:
MV[G8.Q?9'MR*))'H<MY8JKK5UITP7 UJ=RJD(N8T<6F$BYR:-FY]7S1 DWG5
M\);1\]=;6RJ%=TD._6>,:4GA;'ZIA9D1":[11()J-!'%?0)>X=\':]0A6TC<
MV7QFX%@+(GOC:\3MI-;3.G1F*&.]EUA^GEVN#&HH!X.;XS5+FLZ57+BJER'9
MHI88L/A;S[SH9MLVQK/+<A=IF&VX>!B ^G<JG"!"]D;O/![VZ+U.S/-S?_U1
M9GQX.*U)I2F ^VE2:2YWN9-OW_O8N4;."Z)6E4*&@G#_6[P#]UBVQIMFVGIJ
M6J(M"><3BSQR@+\!L0^< PGC;CD[C%V6P->*K^X1E3: IZ4'8YFD_28<ILRG
M##2TQHC<3H>]=.ED1]A>+RN&J+6[P1?$B>]-).WT1AO7DKHG+.*3=71!"B E
M.Q0HC;EC=T?<>PP*F7ULQO-)=%ZWUK/V^BM^;XZJR4@?$GB;K=_0SN"BPO?N
M0UJ/PO(A5>S!P&@SII<!^^\!OA8HYO#P4 X-[3!@(YOG;#6';';[;"-!1B-=
M<CHI1H++<:#XKEKJ>YZ8Y,RPE"X['.<'.YA\*D(L,D!%;JU]6" )W1=!C^ K
MSE9I6 QLQ=5T9Y:.#7;X%P*]RO."BH/2#>MZU+'Z_6'ZX=/\JJ(#"T\[>O45
M50("&":^&&F!8ZRT(!I1+S/GWKGNUQMV$WKFD'ZA)(8[U I=U*AMYMU4)UU_
MY4[9XF*87-OO/@.0P&T%V#AJ/G-6ZENI)C[\?E=W1T#VS$J=)ASC%NDD:IV]
ME!8#3P&IL/&*+@=FI&)OM9PNRCW&;\@ZKC70#QI]C1V7PL7B42A"5^%X<;Z[
M B/;K'2DO:9O\&#=48-0.')7*,'.SEYE3MK@[ !"36;F92,+DM\XPKYM":8R
M,@@3VS6,4X+X1Z'[U'A\#F6C%A_BGHP?F-59D!^SY)BW=*+.F>:L $E 7M>_
MM"_-$U#]#$!OW.ZFL,851D>!>6)5SR!RO6=;BV'O6D*/MZHD1O:N5EW,SEM5
M4B/*UH2 V)O/1-0R6:8C6L.>9,!<J!^-<)[-BG.1J\<3K%==\Z1D<?!9>Z*4
M1FBL9-:UJ'HF^;<CBQP:>)>$C@LQW$_18^?%@9YSL8;N/A<[RF\33_K>NDV_
M679Q1(?MO19JQV!*'*?-87#CV7=??[XA8HJ-MC_2O<"X3.YN\@0MAEH+A2KL
MY%;A+:,!"01/"2-339V2#3K>+N5!_$/9.!9TF237 ?.(14>2D;Q&P('S*<&A
MS=?&TO:=K'-QVW<[JA%6,LJ^[!=2#3V& Q^4B>0WRM]+!R 7?CN=S\D,W#I6
M/%TL(W*[J*35>C&SL3OI"1YI<-/ EZ8W@Y=WX%W@%SN7:8E3\6Y%T*1E4_EU
M0+Z?#"8BI)!@NJ=#I3+G,J]65XV:S]&0HORV;+=EE^YQ65GJ8)2]:&-OD:2;
M:G\=3*_1'D&][Z-DET7<YUPL"LQG PG%\DTSSG1-\_#[J.9/Z&@A3$F?N>S.
M/ISD)+K!T6;^FKY!NX//L0"HR1'2E*@[UXA$F7@_UD^*02>K<LLX:0X4%[79
M'3(32$=Q&6(F L.UADXD]4>8U9]%.OHQ]W[:]\QI+=&AB%FVAMZS(+_6C%E8
MH;%(.7LV'M.<.C[=&A(JWM__2=\].2Z+=D&/2Z>DV=1.-<$?2T49K<LXLJ??
M&ET UU\D&MO?"9,F2*#$,AY?'EW47YH.QSG =.S"),@SIXCN!30-&GLF_QS_
MYL2EH%_#G$'Q^[BH>=/K39T-#3\R\.K@;IUUP+U4SI:26'S)A;A6=!A;>%29
M84E266Z#ECYP;T6U;MB)O-=\?9:WQ6'PA9J#97>7%K">/6P^L7*[9<FS'.RH
M]1F5<C5$S5N'<D\W(CP$Z^)P8UQ?>S5=D8 K.NB,.O5F6K0(YV)VH=BCC;;.
MP(A EZ4%&Y*L::.I*@NHK*K4>+_,Q@\/YA9'2+I +U!N?DW^+>)M"S\;O13R
M=6XH=K%+=C#6O:MRI<(XVPH2.MRVPSU0Y%+S@K011"PRYB4Q3YQQFA/ON>K]
MR:3E5$PH#NR1'<J(]8ZZTE(9I.P&62OL#CA9TES0-S(GV:5DA<3K#(OK.&6B
M<9Q-=G= O,L59W#O:G7F-(A.K1-@C;O>XW;*)[OKV2:ERFL7=^O%&ZB3SW;'
M:<8X5/A&TY@1<4<;!CHZX8DIM_9LG!7VM#42&5P*)2%7*X^YJ3)?)61+:>$\
M=#4<LGW(H3P;RU"F5Y7#=+?:3I*4Y-&O-62JDA:8\#*K.]8EW4[N)9^9<8%W
M@"(I>X0ZC%/1[;/: =R;AJOCA4,,1=QA.?PYX#X"&CU6)6A4OZ]C)6"X0+&N
MXS+>NH]O[;82MZ&$J5-T91Q#@-A:(^YE'P\\&.)I6JO@--+M)RL0I)E)X,[-
MQLL0P%S%CU^U K418.#IL),*P.#+EW__'&]YZX%&\<8##:_+ (!SU1%VK)F2
M>F[8OD<%FN'"(54<P;K%Z;W*O3-&V/=3.8UIT+6][KBFG(C6KF0<EP/,(W[Q
M6ANLW:D1.&4<F(9+1"/[A@]XK&6]$_.QFA0](7YC'%>(6SA=\J*8-J>=@7N5
M^=+XS08N):%%\_S%L*/F8@XKPNU E#B'FT29-E15I:*>62\55\X7E4SJB A\
M?V2L6C7:O #$KJ0,[,D\!Z9BINP8]#-LU+M1M"-]ZC1<:T#*MGO^_H/@R)I!
MA>8;,?+W(A46M5JD)()<6*I0@4&W'Z30 .G=^;+[E^T^![_!A-@Z\XY%XU4=
MS(E<BL7'V?25OQQ-Y[X0GFZ5& LM\0XX^ K56%#@F;&0QKX.>%C<8J8J'M["
M4;*@.6@V^ GQL3N[2V&8*ZTQB0?&I7$WB*_E38U>ISJ G+0WRQ[U/4_>\=#7
MMXS[MQ,%@&I*J,8?&C-H#C"@*WQ:</RW*XZW=NU&@2$A=B[U3&S3T89:^KWA
M- \HO P@*MFQ)MFO:1.>%M !!#._"^RD33Y?_?J00-R1SQ6<-HO7\BF\:4^?
M1"G8W?C\V/FWSUWNLU056;Z<3W'; ((LEGD&"SO/.5WUT';G*2EUSSG:N;LL
M@./9WW@ST?' ^_Q4O?ME=<*%?()<PNRY 0F^AKK"3[ZK$VK%TA./F+QY!7@!
M]H05OS!U'(I0#86GDZ:%;PF519LR*ARO>JA^^-MS4R<F![7^\YH;DN>W/F>G
M:GB/O.E6;6RZ#W8Y+"O'JT'N$&#<=@5WW#()[,'(Y:-2 )6#:N??%Q491&(6
MZ$.Y5:-4^:/CG)A>8A[UW:)F0=A"&C[$"V1Q'S69S0I<DLL(2$IWTSE@HQH,
MLA2(E#;2EUZ"#KJ-@3S8[3I.*Y3K%:IETJQH^(W7G^KOOW6N^1Q _0 40)7E
M:7G\I+WD%/8M6\IY;M7(+A5W%V#'I)(BX&Y"N_0!,:_BIT.JU *'>&Z+/U;G
M!CT!T&Y5CC53['6=QMV0HB:\8DS+V4]L.FI[\ZJ\F2TN%^K4PN&+,>[&.23C
M0+#&:)0Q>7M+-VVGD!) P"HND&LFD.G7\;:K?PK@JMJ]-\6ZLL@EM6PQIM97
MJS-4/#HSI'[9'>\,&$GG!<)&9W*P^N\-T>"#:M)%G;+1 7R!7CEB<[!N6!<#
MPH5W9"VD"*#T%*<31N+LE*C)]-6T&^QY^NWF CTR,:/T60;A0B7NA"K(M+E.
M B0W\@Z>:W*N);L]1VK*#=08'1*<U&U75<HY<5M4HE;-0D![2CF "5?" ;&/
M40U7&<HK9V3.;K=>\X%4:I*<N!W29=^#FD(J9^O<:)Y1474?WL39HT_B*6P-
M\0H=*R-6,GYQ^'3T'.,!OMAVW^,'20RUDK+#GT?6 2^[ZR^E.R0UX]VY-0M"
M=?X?;=\=UN2R[1U[1;?2FZCT+KV#HJ D% FAAJ(B):&&W@0+X*9+%PA!" %"
M*%)"+TH5$)"$(@%"[[U+_T#/KN>>?<X]W[[KGSSDF3?,.[-FM5GKM\Q.=[J6
M>\JT^1ZK@UH7I2Y,RY1UYQ=AV+ -PC$KKUU[)X.90[*I[12I1C>>O#<':")^
M'*#3H5"8: A\.Y4F"0$[#RV)P"&+D_P2'W"\9D^%0>\H9TO.2.AH<]WWYYZ4
M/%0E\Q.H''Y.D/\:NKQUZ.NQY';K#3\YX9%#>TNM 1<4.I?0(-+.2W*2!+PK
M^;%D?IG@LFP8.!$YW8!KF$T2\%X8#4M_9Z/-L)IX84!*J:GJT%Q9DOERAM^G
MH)BV6S)76F!9"^2NDK'HLN'0A"WJE3-WGE+>'VEVB4*QT@&!T&K7KZ&[QUXV
MD,6["Z<^VOM"=)GB/OPAZ=#DUT#"/Y(.J497>30?IP%E%:91I)"J=.69#6U6
M=2H:UVON;7K#JY(XBIR2+CPCB$(*'+'B8RP@^'*X4;ZV1SYB8U3ERUBVG14X
M1(6H!73BE&><=P1]M2\[0] )X%>/YC7H)F#!&BSCF0*2WA^7(:T+C"+GWWQ9
M6S=AOEF<B@G5'] 7:1JIP @TV7.G&O)62A-&).N!#^-K:D:I6F*8:[]58V&R
M5@)B\=0S1B1SZ#(4R4JVE-97'($0M[&IJ^UG''5\.<\'U)M;46#J_)@Y@K4:
M=AR&5GK&E. NM@4>^"ZV56518I#7#D51LD,Q^M*T0*T<)HK?L<-.GF[TY8"R
MI.\UA4X=_7FWCF&RN5#?ECSSQ.TO8,,GS:\_71(F ?M@-E,>C=P^W-[*LT9X
M5RH(>O_M:%+A%RM-I/<;T0 E[_9D=Q^OZ745)P\;@Z"(0*]G8UN<JKL2NJK;
MUH;64_6KP3>KP[FZIZ(3CVK&N58V&6\^'DTS?GY"]3G@_XI.2N\?2KY[-=\#
M;U\H;_]! (K]\#I:(@Z_9>$X<5QND_%"F(V4]QG*U$/WT:K>5$';^XPC8HPC
MB;_;WHDW4\;$)0$:AM8<G@M(..?I<5*^_9H9Z,GJYU*'(3V @.&QVW_CQ/^8
MTO"]*-S\U_ 6%XF_UDXV:.<2:/H$N%-T0!BC)CS0DQ%E &UUC&$1?!R?-YZD
M6HP@;J (6=E<ANQVB:0.LJ$%FZ.T,O%A2:?-]-W[1%BS!N,7M'\)LP)!(!G;
M5HE$IW2487DMBZORB63W^X)H\@S>&>2FW5L._\DF7;+>S-[L6YE&^%I:FXJ&
MXOL(H$SW&IF6?5V3O;H/XU=S[QE2S;*(L6/ EHS2=>TRO-B:D_]^=;TDOJH@
M+.#Y<=$_)^U&'"7MDD$33P$LUUFN2ZEATI*Q7RJ\J'G<VEOWS1<N8PBF'%%H
M'H27ISN#1BK-]%S]'MQJ(SP8L=E1U#M)M%Y(JMS V(#D]SH-*QQK]WA3#9U"
MLZA8J<]Q+2E_Z9AVOL'8]Y:;;ZUDWYK,&G.IUP-P*?SO33GY _V(YZK]T+;'
M?H1U?ZD9_373[FB@_.W'607T?*OWW[82<6M!/HJ5^N 03N##@0. 5IVD"'&F
M\?6)E@6^3(UI%DU< -=$9/.W1ZH53WPRUKD<-FA=$$.FR=%J'$\YY*6U;X,
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MN3I#RS2KQ4(N?W9682(X(;8+VBP8\2VNZQG/5"$.7FC+#M1FLAR]94?TB?L
MG<*I]?!9* 9O3O1'ZKL-;84%."ZO5;7K^#V[6I,MV2R46"G%U1*OSCT<9[Q2
M\AG#/+!X7+[5;"I&I@GK[.'>[CTCW'PKT95)5NJ),5&WVR(03HV<AH1DUW-U
M!7HQ:H19G(A!E?HHCN*T<16;48YT?-ZG1U8MYH=E@A+H;(TTA!VB$M1R#,]2
MK3%NO\499)_AK!]5"*?.ZW ^C\^U,NB*6<50\Z7F-1X >O.J(A"!Y+!SKN&B
MS]A[^[5S->L[L<S=(X.;7\T[;2R+&4(%!4"%66E]R^D?FI\4@9*W*R? 8@
M3:N]E)S!E?1"<>J\#=>D$>=\_2 I-5P$!J'LYJ[I$Y!EN!KJ;S]+HR:X7NO_
MK$[N)C)#NR1M1BN&02]HO#U.4"UF/]9V9UKI , &$Y46\"_-; /Y <,1^Q9,
MVSD' !8$D3TJ, 9#JC)K5/X[F>"/])^7V!Q#N:^5O^WX,G[MF8?"BRD+^K5(
M(#47S#;%1G%:Q;2?/GNAO<OQ?3IRJ7U/M8_S V%NW;(S)8H2=#FI8H!51E\:
M<#KJW\SE?T/'_'^OS]DWCS ^]7_%^#S1)LE419X=7-H(,YA6:71UC(*4MIQY
M:,\") 6+5LJ[BA5T-/RD<4$P>,E"D);%^+[&M.W^U6SU[2I(6K\KU_VYC2L;
M"G;KC"'8HI NRS(1'!^["F>PL'KI6I)%AN)/[I^OO\M3RM$@6\/VN$@S;3T:
M821[2,^<P5CYZIS$<D'D8&%F\ZAZ45;U(K>B-R^[ 7#8ZYX-,DDE>7K5$&.G
M=@!H#IZ5,YLDT!+<W@)N^JJ!FHC? IY^_WC>:C-69:[%7'QH3AZ^)EHJ.QM3
M#9+KV$]7W6(PRO 7+2/.!_MD\IDJ7'72MU M#G/F$AQ3+"F=P@.I\O<KU<C&
MG4][XQ/9H\!SP;HK@IVFBA(03LUV#V$;TS''+4[;)(KIHD"](6U[H2]("Z!P
MJ'T/[$UGQO?0\O\)_3M4N]_*F(^US(^S@[M;/*.L['Q8,Z3F"X,QIO<=F3A6
MD^R57)Y QD&BJY5E6SNMNR9=(PZ,E.J:R,G:2Q0^GUTNR*4AX,]///@[Y_V7
M-0BGA&J9_=,-.[C@LPZ3J?T#H)G"4MD-M-WBR8*GT\W9?@0((B&LDN7PP5YK
M@5BZ8HUT\MQVQ^[/?19K+S!S7=K*"Q.W<%S<J=.06(J)<MKWDWS>L6M!Y64N
M:P)8H/.UJU/PW'I:JKP9&IJ.PD*T(OU ^MF/9LM#[TV#;,=WV$S2#'$M#+17
M:D,,$/%6I'R#OMD++W=N!SP")%-JKM@?<=+]N;N'+LD1#UW4.71)S Y7]]"=
MA^;<327:LI*KL?FLY+O>P2,[H" I-\(<&B@VW$?/_BW2.9#'B(GLG6,R!-MP
M*#L 7*G&T&[82O@D2)35L<OHEK<[1X[)7QZ5"SH <&LP%:OPQIXP0MOQZBD;
MA2O7M4D@*M(R *+/_]LE/W$=8"-@N@0XL4$U7G?^>0$) !"^?4I8\I&U[HTE
MKGCNZFO+!: 7@9AZ:;O9%A96IERNALC,\77*!ONF)F?PG?,HM V8GXA#^N!C
M? +ZQNLAHTMY36[='QC*2)7GP<%FHLB2W,P6 ;% T<?T4KE9^54X3LD*7EL*
M,0K=M%<1FN-OE[R ]Q_FS&:LV=?"+EF,9G??:2<;P3-'$'@\1I*SM9VE4STG
M%TR2PJ=E6@1JF1SJ>2=Z_8]J8S ^=$;E BHPJ'9<]-#0!SV3'NYLU8<$-C[]
M,JXN5.Y\$R4,E?[R\C-*7CETTWS4U03C6NRTGR-T;O@J)E41DBB?9S19+*M2
M$7*O_MF= T#V-V%5MK0"V@\OK#!$M%JCMT-+F]E+9TFN^V>[97;,9Z?M 83#
M8R7Y'QXK#*FPNI9M)RIIQ7RJTT;6M3!S98V[S60ECY(WXXLUM8J,6Q4=PF>=
M.:]V[QH96!1[7W0HAKU><+.@Q#!X=!;:#SC]=[J9?Y+;?\)F/NW9\N2;K*.
M6:  ]S+GER7!M,3[JD1Q?U+VP /US.+F='!"!*P-5#*ZQES0(; .A8MFZ"NC
MW=3%5S0B-YC#B&+U>!21I%-&R,X=9;3+,^!.CVMR25^4>L9BTC$SH[,VOR'Q
M *VCX0=T&DI%L>R<J:L6U,"XV"*PR5_541)F=FI9?/8#RI!8_>U\NUG$!D+(
M>A3<P<=.QP/K(WH&17EG#EEHUM?"',-QLY+?8D[ '+E2JXR" [&4#W=^^A8
M2_\4D+'D*W\]N/OHT E!W14>1W$! %MT,WPI&SOG5<S.1M=9+KN4[2UL^%@Y
M<U2M2O=M[BL71K0\M!['G\YVB6@3?*VF7[6XSFQ-2*R(H816*'N++!N3LI'9
MTI$Y:>_1Y:'RJQZPM;(HM*NCNE"PH8$AK;SYL(/4KK>,Q11 ^M:_7?Y#&Q#
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M[9$6RJ)]:N)YY2Q/Y'^N[. 79(]O3G.WC[FX(?WL AU05*+86"0V4B]:C6&
M-!U3R!Y<$WSCXZ;2S7&6OJ+*FP9SC3<OB2#X5LE#5T6,^QM()(R^Q4]!D8UY
M#&=MV+FKF#EDY#-W/_=T2\ALBK%-KX'5EKSL'6>5LQE#\T"N+F#PJ, (;RX!
M#W0MB!:KKJ:.C8J%)6BJU%S>:\#=R<>I[U=VJ?5WOC1D<5&XZ9U\/B[(;<!!
M.4ZM"$9L+VQ^4@2-RIL7#O^^</*J5&\8Y##IU3 >I(+9N98M;W^UR&SBE N>
M=CNJ>L;<R!NU'^EYK4?QT(:-CI]_:72MW>"A#_Q*C/>.Q-JX A%SX<VCV@P
M0'-9CT=R[!6JTW!^G4<X;2G>9F,SH<7=KN.55[_. X].AD*LC@*<V[3NA0VN
M05R;L6U=-+97RB[$N8>[:%M+4^.K58Z8M$^AG]Q^A"QE38/:L^SZ9_?=Y<@!
MH[*WEIHVI-4NP"-PS/,31!^]\E(WI+D\/LH2+E$<$0V/&BB#88(5[!Y7%A5B
M0'1A+)YLJ7F+3%<_8E\:;N1(/J=X_QM_7'S9"P(8;EV\*=;ZV;+6VWCAC(@C
M_E9&OW5GYX[$<&T?R9C/<,PY(B-E:TET.^:+02^W=&96_-K-)%N95C[^=69H
MR/V[CK&7+E>0ILLEK.S$M+%KN+"^821"H+"=UPO&"R>A"J3NWL<Q/&Q1TWEI
MN.4B;!;:K(7E<5[74\PFU!4G2[%7]M6^Z-+"=-0KRT;4-'FX[1B]\N!@7*<A
M-$074L$:KQB6% $?9-;J*ZD4JX@"SOZ>N_]S.O8CAS?^]Y5%OY;Q_MKRZ_;1
MT#./F)_#Q&/BL38:[F8-GH--\2"#B&8DZM$WUI2>=^/F_0B_F-4%"W[&MFQT
M7^<! (0M;R$= &X^?;N]>".1+-L<0]QAKVNL!YS^5Q+UV)(^5[P9R(R_*_93
M AMISI7*1L \9U0?#<S'!"Q*V>Y%4,,&!OJ;11/E@WB3SKRB54B;8''&5W7"
M](F#V(I1Y#/M2"U7=^=,/2(J7 P(3NJ>3HDQK9??)SA3\%P2<G:L*%DR;TX4
M.\M6?@[WS*AI%)0VM7>UE12<64A$1#:*(-2#84LOZYY-&"YQK:Y("!$E>+7_
M<R#^?U44\B,!Y[QIP?N,8\\!)]\K!1?8$^?"N8X:DC2<)#=H"IRZ305BDCE;
M%M@JZ74O7R#Y*,4EID^.Y7VSZ9$O?_W'[U]9U-G+MLQ=5P1M,4VT=/5W"<R;
MD#"GDI)89IRI:1ZSD^/J+=\[N4SJ1]HY/$R+]56[SU>6TUMUMM03Q%K/1QOG
M=-2][W@3<3 HN*IEXEYR.AA-6%A\YAH;HWXR7SNFOG (6Z_D0@N _)K(>]HM
M^#G]B %9Y!4U]&<PAKO3+5C+9C2/@J,W/U^S$R3[C6E^@@#=LS104T]W>M=3
MT@U!X;"C#M%BIU??MEPNQ\>'!R4M5W<ZMT"YBDU2&Q#KIJC:)%3UL\RFQMM3
M[[_EH"2'2C<BK<4-HN!KF]1692&FSJV2JYN>E_RC\=(^YE?"2MF,T<)FSQQB
M//EYX_?DTT,3&*OSDRZZN##SHV*5NR73*]ME]>5Y+V+YK9C8].E,7S_V&'HN
M3 X^ LS[;^G?U8S\+L2E#%%X]!/>R_E\[QK[-Y&?C;3V&0IG!SB5B/;]D\B6
M=1D;TTWGGORHZFD+SKRBSG6*XZ3HVAA*9(GKHOP!P*W95JCRZ5R&=NCBQ;@H
MHKZ^Z"IA7-U_7JK33BY?F9<72I+@+DF_*.^PIR[9QSP76S(X9O&BO:]\/VZ1
MZ"]\J%BWXP2<&7$PVS6G+8M0'Q$OHI^=S+$L_Q3TW=1LWZ6DDY^+/$)X VP;
M3*"2AG1QS;&,E,\UKO<_/8'_P]H<JS@>4/6%%R5)/_HRU*C_L]@"]Y=0N$IN
MN 2MZM;H*V9X!^8,M\6%$N(@/-J5 1_,=N@YQ<]OQO#R]'030HC1$GRFZ-AV
MTI/)7;CIGDINYEUT9O8J(0?:XO^ QDD,A M07\2MN_)E-S8Z)Z@IJ*?#U.JE
M5(:?58@\IHH"/XADWH9RAM@412I'PR#0OM;TSU\SV"*4/C%S"(O89/*-;U(#
M,J@:F:+_>LLHGI^B5+I-1;[S"1UQ5P7?$J":PMRU?L$LO@#FF2"F[1+3'HC6
M\GC6=I4ON'_,29]_4,\N[$0$"N]J-$).Y+:HYMU^:X3*<Q8C@'UA55\[&]<%
M(I.6>[5P#'$#[6=>KFHGPU;RT6+<ZN $M460Y)"-[G&QD"+ <='_H%7(T1E7
MNT[TF4A?/@ \Y#P\Q<Z7.2__''6OTPLI?UVDSUTP[DWC4='5[1\/\$<,M<EO
M[N9TM.'TIBW.3E:_E*')#^6U9N6">WB]&V3,L&"2M!<+BOTT-RV;19MSFN>R
MN\C-H9*XG,CZVQK/?\N-H02<1S3>0#KJ'7_7""Z\0<LM&C$ONKESQTI1^"&.
M'F*(;JS(MTF("JD;*_UI$2_S3#XRL57M*WO,)G3WDFU5,G9&T*6;I)GV3:HF
M38ADGM]+ZL(03(SZU60E@&AR&!YA7MC(Z_6DA 0G^6) =_UX QP\IQN3!&P\
M05R6)+]=M!9XF@O$74+(B-_5)^K#7(IP&S1KCP7HHV"I!X!P>2$5!XXF_STX
MGRB<YMLD1R5;DET)J0')6B,$Z@\B?%2]VCTA3#>D6WA<],][_;^E_Z%#WJ]%
MVK_6&O[8K=,GU=09NVFO&!6.54=*90>^2K92#S(Q%_9995;:,,)8>US=O63W
M='!>2/YJOY>\^?)R"_?.?;W8Q\HE0SC]V[69";A2&B=$+,G7Y-.G<QDV_BY+
M$;6@:Z,J.5J)?MQ&FH']:?FKBXV/O[P5F%*LK)CN!&I&C,0WBR#LF#+E0YQR
MYKBZ-&:!YPHU]&ND=F1*>@=EC#XU7()?:;QTX:O=R&K+FYH]#BWMA\>*;O_V
M=IHMYXH_O7;U4?>3FU9Q_)@0$P/R MGAZ:R,M%(+./U:(L6N5N6Z6B>>?5S<
M)OS1V3]26T(F(9#0W#"'TJUHY%T;I)=[? "@RW6&.FKX2><U2D2MKIH;>(A$
MFTGCK2R8BB.527Z)YV5A'>EG]K^R/7A@/XAM-V;]@O>]&4/9Z*%LF5I*>Y'Q
M[72"#>#TF]O_O/B_D1*6+T>)<G'BU!W5S2C'!Q=>!#H/GXH3C1#;-!B/IBWG
M60;/Z?F$.[4VBY?RDQ>E$A+1V\WB2R&J2Q,=IR=6]4JCC"JS-MF^E70UT 8X
MM6ZQYN*,?VHS61%C""7 NC5HQ?K9D:8.&@5?0XSDSF]O</>;&$-;$H(MDF:L
ML\4=R%'@THARJSWM=ZF# 1X6[CIE:<3N\K#]M'3@Z*BZK(P[ON]EVVNCZO2@
M<DO-T:1>;9,$:<]GXH27>R'XLUZB! XN3)/@<1LWZ&Q$?F],S_QLOP2J-\UF
MW@GD(;=(CAVS>5\N>=%3I2CMJI B*8KV[/T%-$_@@\R3?08O-XY4T6\9+O^<
MF'M$9T5W9WQ8UCE_@FW]TD_H>Y[KU9_CCP(D_XB,9%?$?FX^^^,)IK8N37 B
M7KFJ7IMOM&0ZY!KQ8W-'85)7R[Y2L(4$96%F)3]&.F#24R&(DT$M,@$58#V.
MW+/UH91XDG.-1>"$+(B=[SZ*0FF_U J^:6: LD]B>'N5EIOQ;<4RS]WW56A7
MYAD1WUA!'%\D99,8)O;1H>%P+.)03;18B-$5<Z3$6H:+5\N"'"(FX(MB"0;G
M, 91F/ZT2%%7Z?GQ.H29A7&:B;2CW84//30"MBDSVV32)>W,ABOC,8X]"5KG
ML=D</U4FH>G%%N=NW#5?7#0C],.=1VEKDY'0K3TT)J]C+MO R89_6! H&L%\
M;P^7$!*:G0'1RM:9Z99%LFKB!U'F(^VWT1K./9K9@OMLE',2@1>8;AG&T KA
MW_KH\<_#-(,@TS6\>WD/VB+N7B.4</1%*FX<>Z[TKWGS/Z>SW_LEW2-0N^Z;
M_ZZ'PY5?>CC\H>%FK>/$NNZ.R9 CH\Q.=ZK4DP2W+30VJT =]-4A7J&SC[',
M:BZ3&5E-L&)A6EGO>5YZ0N#P0:_G7L^)\)@O?AZZDB"TK8/;)N,%GJ42#+VB
M_A#J"I0D)Y<-=*N-,AB/U$T=Z<8#*;&-/-SR9P17C3CG&3^P?F(V_'#TOX4U
MFP1L*)]@Z .S6WD@XU)MW (;=U!8=:#1A1!]@4^?6]N4T\2+A)&Z4@Q](>:$
M:./7::]PE>7EC7&YZ3VVN5J(7&#, <#*1M3:<FIC9D0;7A.M7QPUKF:FX)[8
M-VJ(0"63:S;6&]]%PR&K&\D"EK%6:2/DGTH2LMG;4_7GQ8'GA8!T@48!M$J>
M#OJ!CM6J$)MIL)Z?I)(K5ZJY8<D[H7D)CK?%CRY2_<5:TP.T9(W=J1PU)^Z5
M=/)G-&5&3]=O2CV"B<<+AU"0OT ))@51/(BYC-O9N?W=K[>@/ 6C;90^X3E\
MW@]F6$5CG]P8@!>Y6.VVUCWNBXU\ZQ)?E7Q9LB+?9RMI_5Z(@AGN[J9_,F]7
MTLZ,S3Y_B+*[26I9GQ9,5^@][D)@Y1NUK,V-GS!8JU@-!VG#Z8\'@!PQ=\8^
M(X8:WRBL7I\R:$\S-5+\H2\$015;>IG&U"Y''/4::Z@]F)UA3%0;KWU66(EL
MC:YJTPH*QFD[I^9M#,5UL)4'<E4NC*EE?3P=&FMUT9P4JLO9D6+(I?6RSI0.
MTW+A]$/QS@:E3#DR._CC0Z4OOZ6Y_GLCXQ7+]\Z&=9=WMM].5GXX%\VC&&68
MJ:+,;<$_])I?G<2/-XB*7(@7E5X?'[#L*<:H5TA T-7E'\<=I3*%RS#2MW ,
M!= F<?3'Y>MK.*M,W0NB,W>J;'GT+1LS)M'I80\ZK,?@_#HST'R(M%A97JVL
M@I:-CXYGAU[,PHI8JGK1BH\(=V#71-CGYG^<,0I;O(9W6RX3.[W"F/7/'NF,
M/+-,V)8EOG5D!;Q()T6':CH-->-5Q6$K('!#468=KGPAMMM-,I%1-]V4YTV4
M606ZACMKM2DF2XS"NPBFC;6[ZUL,OU_^>EW"PE9O<JTUTRI6-W+*J=G9O$0^
M/I)LW/7Q*I^X@W"01W#TY]4V^\;+E(YITSH;HIN6A&#WE29Y(9%*L5N#.>*;
M&M6$=**>>M8T9@Q[9]G.W^>$'=IJ32 B'0&FLA7Q4W>F6:V9#&,YX2I9OZ?+
MA)PH*'":&/ \2TQVB-",5\,WAJU8E_<VC(YB?#MCM#1D W/=&Z?+ZCT9 OL>
MANC+#FM'# 2J>*J-K7M:@K6T'WVS.&\9KX^TD<C[7&N\$'(J'G_CU"#WHXE%
M<7]'6YI.WM:*K(\6)X'2YEBL3@@T*"T[H04-YI?K:75@4/=I: &3#$0-T4]'
MW;5BQGD"\ ,M'-D@W:ZQ5(SC8[6*$B#_TGAHK:=IP88XP9G51DW;:ZR@CD3
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M#O/&WGTD:&.F!30&#M6CUK3#2:UVCL7&P+QTMR%U5)"K!+'3/;#,*@@^Z4:
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MA3$13=^H[*<S=4=>G"Z$MYN:5DZ']Y6>T'(V[NTV*L^?])LJ>F9HT*<=?YA
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MZUO_MQ:W2Y+L<E_779^]5Y1/W9]^ ^PT-3(Q JQ9 U@[OG8< /@T*[GEY*E
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M9!5D%6059!5D%6059!5D%6059!5D%6059!5D%6059!5D%>2_#++EG_^9'A.
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ME-7J+ S11G:VI5Z,&GC=-0*-CAF'2\30(D^$<7=ONSL70#,N]R*/S@G9CC_
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MR?+J.I8?:Z*O #U9(C%7^C&EA^FT4%)."U8?*>$@S%N:- 25:X>+$S<4.7>
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MEU+542>?/[_W0-+\G6\Y-F^=EV1!\FU[-HUK7KP>UW"75]6(?728#G?GR$.
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M'3)(/1:A9L,3'5YD!^HS57EN@#&)[82:*&+-QKVQL^7NA!MO5'(:I\S[[Y2
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M\2HI.=$5*MX?AR12XXM$615-A5H(E#9KP^O#@^LZ#U1-.R_VF0"UM YV4)%
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M_1/E70/B^<-S%;>([>9$WAU $2KD9]_H__,#TE\][8BA;PQ&AX//Z?R=N?W
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MFLL% ") S_5/T0BT*0N9/ST@HI6>7EJ'@>ND7P%4 F@831VN0:\##I4670$
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M(_:PN\+:75[*G@!MH:=3*TJ%,O-*WWD/2>[)S._:8LU$W8M2[*P('J^*0KR
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MEAOCI0*O&*]?*N4Z!/CW0_5^NTXL0#1.4],5MHB4S6?O,G< ];IB;I<I'W<
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MO$B\H[V5!R7AD#&E(?YZ?U8LSJDD,E9C0Y!CU=0U4UMDQ4Q6M+&%(1 A1PF
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M=-X>T#IH_//*4=U%N<JV?\G6LFDUC&RM'*AK\W/ 6%T$_C + ^3S0I+S"N7
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M]I@E/LHM,^Z;GI.G-[LD&U%?,YCUR,6<QH8(*:>HZ%)#A2C//@?,0P&YF^2
MP(H/^>V9_?&P@M,39O%]5-P)6)3QZ,# RLN'A/>:L)N=H4/J'ZL"NRR48LX/
MI91<%!1 '^41%?M]"D38$)M08,LUW'B\^8[N96F0\NJ1E$])IF!A7^Z5U.U
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MO0V4-0<;?9&_;T[YX%M>-[,F/NN$M$8%H'ABOJTI/;'GC+M:>2W8#=1N\2Q
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M+=)DS1!X,]%8C"&+6:Z7WCM_C,"YO_'Q)8Z3L;=N@5Z%GS)7D?35FYM$I*6
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M^Y9Y?^D*]&FQ2SP[/-+2VZ=+#:DA./%"/"9\?)_=N*)3\D>&*K4@096YU5U
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M3$KA]LGQ2C$Q1]ZY"#81[I C>DO))))3C*SW%=J:KTV\HLG*2DU[WIQ<ND0
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MCRI+([BUP#9:M*Y N. 92_[HYT..PU-XP?YIK*VN]D7_1]O1<Q*64,&93(:
M7L+P>LQ*L;"Y/,<KY*G4ZX*]65^<)/0KX:7=4TTDK=J\ MA5V?YO(/58 O(4
M+BA2?LW(H$MSNV>@5PMR4_>B!TOV*>73G1(R=>'*G0WI04XIMX(7#O2V5"D6
M/?6P>Z0^E1'$5YC4-J8K-!IZM:! UG5#H4+W-\^-Z1(JWN?\=^=]#<(D94-N
MYB5T6'>-G9=Y6Q/^^\F+=*F7AU=\(TUPE>5M)?+3MCE?; ;MH ]45O-#_;C-
M:H8AV0,'?COEL:R<]>HX"IX"S1&M[@C0\GCSQ45NGB$R0M.PKA(>(O>^=&E(
M]MAM#__S)GX4KW_'Z$6GSZ(**EJ<?9P?ZG+,F<G58^3T*H5S0Q)7X6N'G$+[
M-I+%6)Y_3*SF"AO,#$.Y%L'12+WZ8/2"W(KO$X,>AQ:A!_#>1OI#DBPE\+I%
M[4_M8:;NMWI765JBWO2^2TJ?1B+/TN=G)4IY>5@DHY8XLA>')>5%J/BX _)8
M$7HF+6JKZ;@\]%F4R6@@I6QQ5R^N>B7@"OVUBW3TPH8$0[7YKF5S E[!ILQ#
MIQ)7VD#K]#'/X9V[=Q!T6&5LN&^VRD%[YM8#A&(.G6=,45#9B_W<-DKHD0$=
ME]+E'@W;[*>GEV,[%*);HF05'(8\<U4:"-WR>ADLPE]UHOBZ(%JM2[((F@X_
MG[J6NP]=[F=^P7CR?)K>*&#S4K>U\W2$HK&5MS.I!MR')$I>6@B&P/3GVCUE
M!'*6NNB;KJ@(N_K&!Q8IZPY=.#?*[>'@ML75?"VQ$M9[S9<!;J"&3\[-C37=
M[!;TULQ+<B?4>K<Y]%9"'CPL;UTS-O6:>S]IWJC^]$V JK=)+];-1Q8U,]E%
MJ\^#Q"=6$48BZ4:6M^,.AKAK+.Y[SINIO7U6QJ3@<^5<Q0W07!OAO*SI@_-U
MU9HLPTP,WK;N2SC;KAE/'Y[UCA:4!\M]5CM&EBRM[D<][J6SAME9WT"92\69
MOE*'U>)+U!.U1%J#XK9A7W4*#[/V72LX==<JDF,83Z]G4K5E\YK3:%G.V]3X
M274]M[8J75D?A)O;.AE?>3WUQ%D"E<L!]0R$<TZP^J<;B>WQF;Z1G/TC(U4Q
MI-.A!DXR[L[<:D]RG7#+[HC\H=G/J>?C2>=K5*4X;'-2[,99UMD*1F8?/G\Q
M9JB-?/BFS.#9176SE@_.Y:G1!G/6-=ERSH897[S".Y35Z>J1*D.CS0@EJTG7
M]-B)?L.D;%D2"Y5^Y$51YY7$TC$_&_F%/I-:VB<)8-_2-YV=@7&EDU>TN-5D
MM%N*\RGBV&\QLJ@:2G\,7)-GWC1E3'NU^=+1(TS,B_'1T\%<!U1?6^)\K^/P
M>]XP5D^&\W[-'FZ1C> Z<:$\/1PNR*%[<?9840O80!$,G-96B(8U+%0S.1-L
M<U:&Y>],>R)$#HIZ"=D8D<P"N[2(([>IIZR2LJR9$-:?CB5+GWFKI#*L*LM<
M('S#%%NQ9-\RF3N8B2Y9Z P<&5DQU8F=M5\O][)/H Q>6((22>:7A<=$^O#V
MXNQLSV?>W=-AN<OQ_JI9)Z(J[V5Y_^R:6O/I4"L4Q9M/:JVID1FOWR.]'.5\
MG_1;$J^'W\^;GC!3+M=ZS:],HAFJ\?P& E\[I@'YZN*3;,F==M/%IG.^'M-G
MGJ5S0:RS*QCJ$:Z2CL;"LE-([[Z$RVL&P)HE/][@(*IQ%!I"A"(EW2VX4(:7
M9H.]55Z (2.NM>ME%_/8GVP^=C",[7LI=3V5,U][AI ?5;]61S"[XT2P#GE[
M/?:>?J%@0(%D/Y;>9 )IT!U4E?NYW(+Z%C6^,L9*Y"[FN$[NUJPN8B-:/\E\
MUC.&Y,-Z.**GBZ4 9M >1[JZDFC @=MZ4=XMY:\4V:6$$O(L?"IM)J2-8G]"
MQQ1*1_>Q;GD._(*]!VN#J*I>$EC3>@%9WI^GQOW<:&'V"5>9V8I=_]+G#57%
M0XX9HR]/6#7SW>9&0VP'2G3J@ROFOX%4G1!)G8';-,KM!:8+(1%45:?ZVE#E
M>A5SRII2$7H?'H4AS +Q>@BZ#[_[9J@&N&C>?_<9]JJ7D/WDH[!L:4E]<HW<
MUO$ME*&N8]Q%-W\>B:N>[)$2A:/!UP:N(*[G;)R=GI12CU)Y^YM/19=I^M44
M:=-\)A-J!XZ(BR%]+SBH><H74?A>B%QK)=+"RBL6<7")^(9:6QC5-L9@&R;+
M,')L[8)4_2/&)^B7%PWK*Q%60CVT^E#&2!]B:>[HBSZ5+XGYCDD>J(4+@E]U
M=4O8SGHP%\NU"[Q)MY73P-#(MN(QU,Y=[4[0,Y/:=D=-3=G/VMA*W<@/Q@WP
M%N7WW^[]374R_)Z9SWTAU+CPY2D4I$8$(^TT(>U#*>%TUIUEH'.J7B.80BV7
M:#K.+V;/LOK>QV:V\S;UPV6ZF#DV 7P"UM $I>]AK9ORR%*?U"=,\U888Q4>
M)4C?OJR$PHVX-",VPC3=60(=/,H8_9S9>L5?@7F3G+TON8G0Y_;,1-/U&*I>
MU#Z@_[%*,O4]'H&;((B!<ZYPQ&)F"I0IHNP[:=](/8JJ+&":Q#!*::8$5LXM
MUS=F$+K\7)-9AKV$L?N56=*Y8P=:D_T;LAUAL$S"/J@B;^Q51,E2@]B"T!L$
M8FK W6;L!D^(SAR?C;YL")O#="4P&W]@)MW%V>=]A6GJMWO$?/$^PTL#;>=*
MA9 L$!Q25I8JXY);PJ=S^I44):<"FIH\Z+41\"2+\XT:O1MFIS3FBJ?9_=5&
MU8D+_L<2$'HE!2272F32#<HUUOM,C5(O.9[-S:[-LIPQ&33IWSB"C[8:HO?"
M,$J(YA4^)E:L+/ ZY2K/'[Q[[1].+42;*40)G/2+\PTDPYU+AAZGOE\R?.?2
M$M>C*O;U"W"&M3"M7"VK,/.5[\-J=<.4LPAP!D,19_\_/[/:_?R7YU<220,P
MNI_OBM315]/&Z0IFL])<X#UV!J\]H"B_NXA3UI[KB?]7YU?'9T][XZHDD0\@
M9I<T]?N*HA-<D\DG4_SHJ[<_#>Q>2?0E.&L+?_$U/:@OK[>VS)*W*=0)/T,A
M&WR%J)-M>P@]-KNE,>5<Q4L(D7'(/F_;)44J$C^^%05EK8IHX]6<TX]T27C'
M\@U$%#^Q\@T4$SN3?9I0K4#]P6)=FY:HU^&!>N.5&::CEP*=$^20?<=<-''&
MOVB]Z&N.R/EXZVA\&P=C$&&,F:/A2X*>3W =+4)OD5'%:\1^'):<4]V<&9C&
M;7WJ&\A]*5S<X=3B38M*W78/95G4ZQ?+U=[$]ZRS[C%K3!Z/ULZ+C?!/LEGV
M*HQ^:7!*B[&7B3NQD?S.3P>=^HXA<OM]\Z;-UXQ0.=7--,:%Z*4PBJ4W@'A7
M;#=LU.I'%[<0-4#-._;26WJ/7YN=G74/6Y%]E5/=F'D;_^G6D(+ NQ,_Y%RL
MK:XBON?>$7[B'X2G4&PD3\JWL'-OO0Q9;5M7_6DC"]5D8WW.F1WO_I#-L$?V
M?W:+8=>ME/_@5MO+5;H]O:W^# K*$2&XW+MCVNQ<]-+#7A&PTLNG@X0EFUKR
M0;$8;2IY+0E5</U+39&81JI&AVN3Z#Z"LB$?HK.*-&A V2O"78K[_4L#8>F6
M_IG&3-3D-Y#UNZ,K;>LJ@3*Q^<L>GT6OXC=%L#H:9RRS5'ETO+,<QW.Q?6I2
M8>Q+*J+8#]%+"7P1,_2IM;^%S X5ZK9+)75XVN@@3B<)?Y(39.SQ&J'G\5',
MU)>>>V"UL):?%N/O<"(R#\%XI+GGQH<=_-*>$0'\R>N0<5>Q6@>++.#PKGZV
M:@3%3!0>1M'<)[9@KGU[-;J%':PN>>V\*+;GNUOT]%"VZ+;CJ84)0RD)KD46
M0:'E4BNT=4M"GT5'!(T:3O726V5<"S6FAZ&$$QL63GN=S41?&DQZ:/6I+L\S
M>CG.VQ G=;&V?,9^9B;UT<.7".7ZBG-,Y7X51LT(A+N-M;[S$KUC=.\RQG-A
M5JH"P-2K_)F;UPBBB*]A4RM:S<-_G/OM%D"N=*K)RAF]C@*_$^Z9,70+"+C[
M8IY?ECGA8J9:Y]??0HKX--O6U9&<O7P0_@-O%QM$)DC?0/8]%$NO3%@<D6:;
M1<;B;Y9[9-D&%"3<B];I[SDP1+3@)I^5.% /1S9DD@9F(QLWE%D19_@9?3Z_
M!L %+(;D"LYFYD0IW[)GE'2J)52NLD7U/8-^QH_K(0HC'&AA!M0A-0IFJ8^V
M,J]M1\HF7.=G1"T7[2#]>)C%J\(H_):A<[^[?B.]1.$R#H>UQ<.S(QUH7Q-_
M=T(&E:Y%+P4  ;IJD V$<ZNHU_$;J-S^_@T4 J8(XW.@'ZBH8+Y(>;FDTZH@
M.=:S'2L5H(;QKC_2W!<G/_$U4U0A4R-<Z;F;%PY5-P'4(OM7KB+'S,XGQE$G
M%LHH^$7BD9XD9_,C5XTU#\$8;[E'(RKH+9BD@L J'W5$"[4+:^,L-M6U.7MY
M$@K-N!G=88ZNO'';/>E4*RD3=.O<**'YKL3NIN6/VON;5KPTQPUZ<781,\?.
M&XK^%@(Y:V6NJ[K=Q_1IBUO#M^9H,VEM,(_W&^@( #3I<?:]NU$\QR8=8Q>[
M\M_'^6*"$@P&ZM/3O2)F6/"X^/.B0>UQT19;F=D1#@RVYD>:%[IN0&\/ TA7
M(3H-S3<ZD[AA5A@:AQ,1'QRW7S27N0-AN *0T\'V]U"D:Y490,;[-YSA+^@5
MZ:,@DW4K3+W/J.37*KQ&YB Q &U4[0!<88E+MV ,,R<BAP:>[50(P"YB4<8]
M/$M47AVCW;)!4WWLX:822 UX;@[R L ?&HA]8#6;1Y8>.T,1:3YW_^WVW&Y&
MNML+#@<'%TUIVZP?DF@)-3S?5N1@6*8F%;S8]<!JKLL3""#0PY9@R;1;)&+=
M3V\8]&AKO)"WCNLGS&T2 EV8-6N;:0A:)3Z$;Z#6 KM>=DZ-P.'.4PP&.$>X
ML7#::GP51R^_NLC'?&-J:4< F@PEU@YY>T&,:\+:VC=0Y/& /@ADZE9APQ)D
M%5 %L06BI5,#T/P=1:1HX9'FWC'T=]I<K?1/4'#8Z72BT8$>2M#<!#3FQZE)
M/6R+/'W3&)?XF9S;_C,G(O#]9J=VI)!]]'D%RS,)=Y\?-S3F4-2NA^2EW;Z]
M3A_J<S%38X;Z6JAY6PEBIU)>*K'Y_:8Q>Q^Y(MSW&QJC59P3'^-ZSNN?L*1W
M:4#Z:J5*A4EPG>.M)NA7;W0L2?EPU$4$=Q)$'G;;"C70[3.7Z7-AD,1XL#DE
M+U6W7<EH*J).[-F9\IN56T"Z<,EDN53"79J)GHXS@G,IQSK?F_/6H&<'\I[F
M&6>:*.6E7#-#4D-M =6BD0XG:JX,UM>;MN5M]SSQCDWONY3_FH2TZ;]6=B(+
M!8'V&OL ;N<-J$D]$C4_VKR85G$#^@TT;"L:,4/5!]!W2Q/0QSENW!'0BS.5
MW+S=>N.0]&J^H8)Y799U"SM7Z>V23[Y%9D 18U/(%.1#/'>[RJ^QM%-ZXN?E
MHB7ID;PC91;K[+CK[X+:\Q$5!?DXYDR32Z,+9JR,MYS#D9][@&@$6&\H]0^=
M#D7Z] #0*;&.O['7>[-,C,J,E%T#2M\&/GRCG3C@EW6Q102L3/C]"R%'9D9!
M4#!33BG$\]DG;_"2N;;%*C DC:3YQIX+1U1\R V8O"G$4O3$4:P:^Z4Q4P%?
MXNHW\37[Z",'=M(9(<;2%3(8CU^;4#W.0N$J7A* N40D9>-,1KXMS&QK)<B&
M,#LY.R?$Z$ 1";;5.L5HBMX&F/8$2"S-&:#*IQ@" ^!)5Q%&/5@]\I/9U_4R
MYTEZN@@X"H-,<DDO?'2JET?=]<';]KPRLT1@TFKC_VY#:1:8FIRIL;AM;*"Y
M39U^I+;<[DEV*K]*X2T$,/"]S[@'.</*AIHOT.1=P2@NWU>+(SW[Y$%JJ[\%
MRY..LXXX*UQMQQ>N7)J1Z7/[K:59\RF)]J1HA=X9IS"E94,]YAZQ(@<-T<1W
M1Z%])YJ<70W];D^>Z#MG&7*;J^G4+>V5[4=;.0KNJB)I'0\''[WGE[-P4 ,.
MAJ2]$N<@3Z(F'FF58'D<F0.L=! 3ZN3)$>Q6<#U8WRYW.\ZD/7F"/'=IRS11
M+8!1M- S J/HF1^3"<$>NBF6JH;G/V8X7W_.'L)/SWR?02'W3(!^-KL%D"=
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M^"JF8MS5Z,5-OX4$U3BRP YRD7GT0R#N?<["07<2O;O@+A:_TDU5_K;]U=M
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MFB5QK&J@M==7_MV4[\]_XO[UT2@_3_%+MO#N;(&)'S<*'(9$62= 0UL=G-3
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MI(7Y,3[<AE$Q362^=<<E&W4^LC.A@>*=]R5.VE%*<@E,%+<F'?>,3-@O2X&
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MI#R!3\#_/K"">CO@11XEY:,>D(15,-R<\Y,'IA>;G7CYXT65AQOS544OO75
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M)T&/8\&1C,@$YH)@I\S1F4NTNB8K@*?$?FW?1WE]<G;G"#"TJ!_0X0+![;U
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M^T&/!NWL*7I\%3WO>!C;Y>DV'18FXKC$8";Z\=S?S<:YI )Q)O;H+B@7@[4
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MQ/%$71U(VJYU9'#K7KWX93&#6*-"J3<>\;QNA"9#MI5#@K*DT64N<NENEFR
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MMBX=')FW=H62@Z"ND]/)UI&,)TM5#LN=N#67VWL(R"++<G2 LMC-;D&&66,
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M4AQ.NG-#W9'@1UA-MDTM%2<$DV"?*W^5.A+\0PX)%7^@Q86SJV/\%]10).F
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MS$B%P:R0\O(<W>8CK"UZ9']D ^T"S4AF\YK"B6X8*C4?]0TWH9G%Q+C/NIF
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ME"J1)G+6FL"QZUG0ZC9WEW[$9Z>C:0[<88$4%+UW0G<H-AF[<]*SE/BXS3_
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M2*1IKDS4@@OZ++%LEK0WG1L!:VZLN?38Z/MNPC "O;3G<-_#[J<2N:0=:?Y
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M<TUK-7?'CB2R.?E\HS,](2/KH2A]]^R\C*;59;4IX,N>HD%-XDTXAW*<T=@
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MT%2CFMF^3V;>:+&!<:C&H%")6O D!BJE?KZ,9'$N*JNB>;=\W)6TT*>GQ(X
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MUCOSD*\ _]3O:2L^@=:D^,>5D-S.>/(%]@L7,18#^3AQL ]6S"BNIU\N^W'
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M$7AA2N6$_#UR$!)ZM\D)_456*5-)JE(T)_Q$D1WJCRJ?4#4V'9$8FVR&)G$
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MEE6D8FCU='% 1D+?L#:M_JB-Z9L,LS5;6'GK%]OE&4=,PJ-UT(X>[.CD3<
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M/7K\I\@,O+L[C>,@%7%AX%Z[#""P+"?TL]$\&D8[T>K4.F,J8$_3 -B(;&R
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M=L2BQ2?2.YJ:]UD$(J,!+[X%9!D:US0X9A3QNVN3ABU3IL@$X^UIF698HH:
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M'M&C%P! C1_?,\2X]HXS@%_@Y0_:[8+WBI>W8(P(&ZE&G\U#[0;FSZ.& =(
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M<.9L@E*>4?W0>O<_P0C*O&[ME9%SB#**@99?HHLG)4]?4@JZ/Q!IK5KQOP:
M!B8" %%.>GH:A#50)^WI6I<UY9BOZ$^,AS5=UU"+=_E(X4GH0OK?;6K9^J;
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MVYK?.]X? F^?LCT/G@P;8BNJ]_K#(2*[5T#)_O="7/N/J:BW?>/Y5R$^OL#
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M=$[56^V9=K9%6V0B9<?O%Z.]+!S"(,.)!XS;O>>2NOSDW(O#+4R/P:M D.:
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M<=V6WM=^T-?WU4(=N$L0O,US7=8:3.3./">MPZ#?9TT71/BVS,KJ64-D0@Q
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M507M7ZYNF=2HP%>D2NV?/PW_-![3/K>GE20?B4A&BN]%O],?=%A<$E&[G_8
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M+M4NI0*__?\@Q'G.%V UQP[FA(]C31W)(R1$6(+R[E%1^,4'>#3<QQ@,@&M
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M1&G*/UFV+>!??O]E]?WBY07$<O?+V:_WO%W.UX"4_B@.CE,]N?]VZ@1Y#FP
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M*?#-?B+LX3!]6IG^\TJ_BOF)U@S<*Z$FC=\!PFD/#]*ZVN]K\"O99B?O/?>
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M92]$^6.)-1Z8;Z0('1-(>FB%YDI=FI!EV)>NGC-"M"=4M9WX\2IOG?NZ8^&
MITI='+)XB9"<GHWL*JMMS 1$,&R'ZZFZQ:\5[K@4HKIHV'0#\L=W8"NQ'4>X
M]2F$P+P3+0$1-(/FXX[069HSNI,-;LL<5$SOB/961?OXHC/8.TS47\F\FS:
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M-T?7BIH5@:Q%9=,0&!HU-NDZ^0 R Y'WUZ#^[I(:L[G>V[)\N!5;X\4]TZ0
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M&KJACB31!:5\NHB,7+Y6LFS59_QON_483;LEV>>@"O/C$.CA4"7%U9'Y!W>
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MT[OU"A7DL,V\+V6@EIN1FI:]D+C-CL[K1B/(51Y(5_M#->5MS$43SD+NQ2^
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M4LC,-WHGRY[K+3/^G*Q$!N+TXI+8WDH&2CZR8"8I4N] V[<BB[^9K0*SM!8
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MQ*AYG&5\G,7%I5]D?QON\%ZP,([%N4D+HG,IMZ<K[WSKV.6#M]//2\MG,[\
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M!<_()<F>*ZW0U5V2$)/<%[J9/>6K='?J9WIC+QX"1^PV[KDBQ0QA'778>IP
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MK\; T#6RC'VB'N&Z:')ED;S")O UC+L.S;;>0Z'CGJ$2+N\G%0Z-LO6W5T@
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MO)LV%>D[2FU*FF,AE,H['[YKMZ8Q;+[HY5;)XR9 "/Y]'+-F?CN7I EDI=.
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M"DC)&ID( X]]0$D#:G*P!T[7]K5/2T#N;Z>E)J5H4OUYQ18DD4E)ZW:I2Y8
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M*$"+S+Q9:N_QP(R\ [Z_@!%E0\&"*:2I_NHVQPL2[Y.$2V#DZ4]"7-W)H3/
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MS83>1WC3( A/J_&@A[]>*578MJK)B$BIO1TTJR=,0F9>I8]&+RNPE%K;/BM
M()(@1&1.ABV]YE<O0B;<VYV!C*9R81PL*:LEUN@W/V_3__= "RS)0X:#OA,?
M[U\#+UT+FG:SU-2?5/>K6488T>7S$(Q?VY6+)1Y:S=$"#IU"[G8U+$SWV$9-
M(*E3KNEZY7R\+V>S+QK%3)-\G-E)Q,0&9<2V6G>QM%:5>JW5RRHL99Z!Y""Y
MUY]:JK8EZ'895(P/:&0<]I=@M?W?ADNUQ$O\7'6A>0A$F9=L?W'BR8M&$>*5
M$*4N]T'S[Z;XN>.G=@6;&0K]CH- =AK9Z2</>I]BY^=HO*<9+E"D-X"'\&<D
MP84W@)_]Y=([V-L@UI<G_F5*SGO2G^Y^<6[*;>(/1Q0DB!Y9/[JS.QB(J_HP
M*+-S_G3:G\[XJ\OX?;>!RVD%X.LFF$]M.C'-"#Y_P)TB;7.T[MN=(\@XWX6R
MZ#(%)1ZL"GK91=N!!>4W?Q$TE2]N7#@=FG$4*[0Q2Y_HX8"->PSL,G4&1!WQ
M6+_QJ?%(=B0B:5+H*.3%./I'+#CR>GZN5G9\RU*OP-'U,R2)07&P9A&J8F5T
M.I4]/9CYS)XE+E4L1]-@(O5>]G'D0U(_)M*1)16@[3=QCU&WL.J(T$['P#-W
MGM=)U3F@9F'0U[(;P,"=.\MPIC]4>SDW )'!&X"#)GH7"T&<?A;.C%OK4+ O
M*[#6:H5"M34L>0 HZF;40S$[(NM%+"HUQD:W<9TP PH7H*A*I3ITP-+BD5]P
MGG[O55>G>%#GK(GBBQMQ [03DEBH67Z9!+(L<?M4<4\W 5NA$D%$A1 #60QV
M/(%P814E AH0Q 1\&._7M,ZOB&C-GD-LP^%?RI&>\NMO^B[<1/-'W"W<L7TG
M?N<\M0A47*:&KJRN!_P3LG."GI-C.^F>+!G_XH';D]9.M^))>R0(%)$QM&^M
M6C<AJ8+[&)+OJ;Z]78MEZ5@8S8+!8%^$*)?*Z1BA9]CJ[+!]RWIMX0P_G@G=
M>ZM%9 $RGF0.E^48)5KLX7T%4,:'+*Z]DNE..1UOFCV:8]8&Q4,!DP,[8,A=
MX?!7#K,NU$1V&OP3)D1JAAE^;$D>XT0^BJ;-ZPP-/_3U23AL*UKE?$L*>.M[
M<8O?(Y,/%FE)[Y8#0E:W)5 ,-CAEGE@GU'5F?IRZOM:Q:S&Z>L8=LJ!(/]?*
M088"%=Z6"EF6Y8_,.+DSP$HLV:[C5ZBI*<&>L@G7R C3N]*/LJ=3A I",2^!
M^^Y3#A)/S)+!F8@OUBEZ/7V9JF8'^*BPL2:)A@=BVYQK9T58GU(5ESKQ9UMY
M#@[6@?-=/)>%!>8HZ!KA,T)JA<\^1/(-9;F74AG#3ADAJBXNC?>+A#6?XI79
MXE@ILC%XL)&>[1=:0+SK=WX;Y"@ >\OTW+(,>J58K@E '06,0^>,"QQPV#@Z
M3N*)*KK1+CH:YE[R-/U$A1D8TK+1A-LEJI]\ZQ?[R8VMY3 E?5?(HMK3;5+:
M .^F!%$QAH9-'/+<<4S$=C%6/\X"@E:>UTP\1:5@['JZ6.=1+8<!L#<XHCB.
MER Q.;)7U"#5WBGA"Q4>G=-:'D2 FIB-2@@Q8 4W3+%7,GFLE%"P\+-#\>G/
M7*;7JHQL16O2I$MKVWYSB\/=V9/XK9.)$XX@*WWE^2?O"DOR"T+4U'FL'! [
M@QUNK-DF%Z36*RLXL=PDV5QQ)WE7/ Q"GVL&*=?R^, E]6)AK33+3SGF1::]
M\0G[.DAH-]#(&5D#WE36M[I*7(Y9]!:)WW0&R6CC#IQ#H3@KP</)QQ@RM4P6
ME/ ,@_>QAN,<A6N J-:GK.,$CZ[;K2V$/V1*MZ[8<RMZ>C(E,VA"?<G<1C#^
M2P:R1E:YWXR5?Z)/($1^#3(KPTQ,^0EEQ"O,HPG?^E(],6LHI'"G</SM786W
ML94;5 ]$^@A)21E^,:ZAU?(59K$Z7J>HR<>*^SV8.IV^W64-OEC0*%N]>6*8
M&[]N2\S+W?TGG9R8^QSB0R3<H1.3*B]"BQ+)(^LCB#TVH28)-%*PMD5CNQM
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MP7L?&[)\[/'=C(<..NR#5G%'+^QR/LOM2[%5%.X-_=3T6Y3AUQ?^OOP'3D[
M\65(4H=7;D5)?E'@[Z=*GT+N$0 +&X#YJ;6"Z)*B>H<6 7TO1"&\?LDA/T7<
M&^;.:,"PTI.DA"NUX/.%;0?)Z\/)I?L"T: KJX(38+6F_'WZT+U+7OWC1IDS
M';P7P98A\60Z":TH\]Q:Z\Y6^*S[2F#  ]K/FG5.+;SSE6CZLV9]=U%)J1<W
M $.8\ZCMP8\>CY(@R0%CY&^30ZIZY/3.ZJ?A@/>5!(*IM#5]N/$BP+F!.S(Q
M!,Y3E^]VO5-FP,UC.@NL(SNLGZD]L+U0B>/9FO_'0408XRRY7H.9<6U%8UG'
M#\CD?*8)=>8%_(!P(X+;,9;I9O\QT.A"(7)\+\A)46:?MPR*S&P@X%?,H+^P
M@3)Y8.-W%;BVAM2"1C7G<IP1]68<6XUZNKWT9>Y?:5U)CCIF%7)2ZK+7W/M^
M&+K(OBL=;X2*-]6^_*2J)RAOS<TT"0>LLQ&G2,_#*.DFSUPG4VRU!=2GQO?-
M6&GZZ96WHNV$;@#[=^7YNGK4'T-@%G9"=QOSC=\^J9F6U<;/R.TH=G?*%ZHA
MWZHM:HG#LGFP,][G_7VO^ICSFXZC!#J[T8Q6 +$!NX?\_":NU=IY:XF=>TL5
M0KM!QNNH7G28L'3P640<K*G[:DX&A.S;(D,QOO6 [@S,?RC/:!U%9 ID.8!W
MRLDL5B<G0K?JFVI\<4F!+;]_E2P^FE!1&<,F?T+5'GV<P,_^-M,R:O^;@3*O
MSV:*9"!OLPQ,\4W1T+6V>W830+9KEP#&?G=ROVB;S=>]1*^3HCV'DMOR*:82
MC>SH"<26QE4SFV2<8ETDCX=*SHWZN9--F2WO.7*NENZ/==$397%9?V@"X*9O
M=4JM5:%,Z:>G[(LTII</-4<-:1&(HGEJLC*)4;$3$8_@.LG/PLN/M532)=KV
MZ+A8X- "=2%=)9ZPC Q6[NH5Z]7\>M)Q/RYE%RM[!!R>7JW:!7)R6>!@@5A#
M/>X1!Z@+_[C/Y%QOPE*_NZ@26*<?$>.,QK1C[%I.3^[1^7X( 6.PD6D$*$X,
MM*1ZW[6@J<.J.#HZ^N*N!LG[L^@HFO$99:N>PQD/@FQ\OZ=/7WPB6LJ#HX?U
ME>D%:[^-B:/D&.1^F7LO'2X%+1&1F4^?_K ?U)T^'(C0U8V0GS54Q9X,&-U;
M%:@=_LZ:RCL%+4)D7)>7.B%VN-)E]A_MYF7G98W=LUX+#V'  ;;\'"'SB.M5
MTM8L0LDYY;9J==G&G>IV9A#PYU'38$1J"PL:OL0^Q-EX-^GQ#D>.7KD#\:S"
M%BYN(2DDV'UOM\223X71+\PH(-Z=(0772-=TN=1S,V_".P@M/KN7PQW[(>E3
M%S'/QDJ@^AK"GE.Q<%*?*TNT59U,WT; "0S%V';%5/8-TAV(2!O\A#UMK)1[
M-T.GQWG)X>@R%%T3NW5$8H$9;H"XQR8.YDAR-+FSL*6?0]%G5M/GF4(]/^:_
M"@W09OM,5'-P#)D_.!)(=#C8DM"] 7PF$C9DM@D>._K\:CY2)UB/EQ<C7=!K
MZV=7@ZEP$=<;+4K7!D7/X.G&Q]8%?(3D+-&9K"G2XCAF=C28"EJM9V&2X&=I
MBZ!&3M:[0E)S.*PX(:( ,;\1]L0KECH*967YD4Q-K7FP>(;C?FRUMK$A[D9X
M" !.ZB )$VOS<:W20>]SF09-WR><-R9.YH$46R/@@>Z3$;&?Z*.V!W-F<S'E
MB\;2GVM(*%7#2C)B7Z+9&3F(Q4@VMZW:[BN5<+!_TK0OZE+G6@\KD>5*ZWQM
M%;)"%.\VRNO@\^=GS.,KY842MHIF#.]#6D?L1%QU D[2/?R=!?<E,=0-8'74
M/Q'A%0=_]TF(1S5XS[RPL- =&*$.V@C*+7==@W,>;^B^?ZWU7TNO*,)XQ1O
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M(]X]W\9R*I^;/#MO:19V\1N,$)/ 'LN\;GQ:D ($W@VR4G$"_^CW1!"@Q.W
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MJOK@&45DQ&) =+D; C7V-;PZ27Z#,/$=V8-_EAMD4)N['OCU@,)!]#?3OJT
M;_#JK;]-97Z=AZ#%8\!^UA*BAFPRVC[TI<!"6%#+K_FFE;(\:C-6W_+\U0TP
M!@@+H))[0,$E/DKH)?#@D^3/]!ZI3?D$$]&VZ6&^&*;OM_COG3V@2OX?-LV
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MK,H@_4G\0DG>G<XTDY_#^Z0%J\$!?WGB_]7>=P=%]6UK@J"H!$4R-$$:1:*
MY"1(SCF#@L2FH<D9%% R--!(:G)NLH0F@^0<)$-WDS/2C4A2$!V\]W??O)JY
MKU[-U)N9FJK[3_>IO4_M.GN=M;[O6WOO6L>TWB!AN="*Z/(/ZG!]D#&=O/MY
MQVM:TRQ>)"Q[!6(47>.Z\59?L)O[;>]2YM7PZ7U*AXN!VZ<]Y$G/OUX'XOZ4
MK->Z1/B^5+K$M8!A7#2AE-$#0"I'ZRJ<_OX";+J\EY=P^>AL7[+Q/[[O>#%
M=)$7J_9W^[_X8.[;4TFO1_/V3Q2VR]^L=*@<$4\,)@MH:KY:>.409KDRKTY4
MYT+\_(W'^?73&<_$I-(M&4]%7A/'M?7-IXZ^ RMI1]M_2FZ<ER&"^YLLSAFK
M\OO];,1>#EW#8/@U&(R(H7-"RZ[!@G6OSY[N&BSBT')U\:^;*[Y(\L^,OE _
M7K^V9[*GC,ED]"^.+^%I U!SR9WG_I?&7(V-I7#748_U';'+9!0+SVZ8-KAE
M[WVKM,L?:D1H\@;:?V6\UHX9;=?:L?Q$1J]DPY5A@'O#.OL:!VG_#0>3_X:#
MUAL^+N,KF$I0WT3L\L=]3>I ;,CB9?(%"\\7A9=SI\#;WH%_*(TF^J$Y$Z[E
M'\+R&GWKRFG(GI[*76O+G^H[S]W+E>9\_T9"6SW7\K%L-WA E;?-Z&N64L]?
M--1NSU >MW6-/8O7V%/&2D _Z8,1^0--JV(O9]V^LY>E]39O]8X_=R^+)*;7
M<=L@JP>I6_R46KS:+W*H^&-Z;]SZ#JZ?:HJ%Y]KZ3Z\UC]BUYCD<-Q#/<]N0
M*(/KT'"[B=B?<VW*Z!1N?'U;F3;:_!<?0FB<!\#7:)LBUTJM<I]RJ7]_ /1W
M&CH,K8VT\(U=OX:*Q%8';[>5L,1K]Q^OZ[YV?[8)Z<?7\*-;\&>:=>K6 S__
M6+]-_F;17SSD]C<>>KD;9@R^V'N?^9^#H/>O4X/[M*,OG_?)?1=[-=&_*A'\
M!P-__(6!)?\9!KK],PS\C1?UAPTC@_.N7X!]%6W,\<C?)CU-?!V$--<*[6]!
M6,X2>5?GJ*5IW6D#NQ.+G>@R$;3X=FU]QN]DU[2@6[;Q5<N /\K/.BKSS9:S
M.J^YW6FJ[M?6,\C$H=%@<$,E582]+A_9$L;\:J'[ASR77,Z\.J'UV!_%>0U#
MP]<<-/#'_CX4WF_=JU7F1)_/C=I=I\%_<X3!X %)B\96:T2#?8I<79B_[Y)9
MHKWQXM]T-.<U%4[&5).W*>D<#"X%_\G^<-45KI_*:-^G_YG7M0I(Q+=5Y@6X
M?+%+ZXO_'E"7TQY02=6:,1,G"I'\XY9_O 'QWQ7PM3?0A[AO2)2W)(5=+5W6
MG:^]RO\#@\%_@\&#ZQRMAO4P6_,/]B?)$_7O."S%+>R\?Z6#3]?^&\]AZ.S>
M)M*@_]#,?<Y'31V>#O<7EZ8M?J_$_*#<PX=.1)E,T<^J S W^V_W.O_:4.7U
M.A'?T*(??OAX_VZ3 Z-V#SG!&!N$QU?LZ_#!JSS R@]^1!4</C2YM)W?DO\8
ML_<8S%%>8'T[&PC$2ZA+ _5$ A=*'1OW+1[:IIQ<Z9PD<62/S7A1ZB@^OME5
ME#?61;8SI/2%^[1J%VTHZ]*(>5T_H]_M_($".9Z>&%'G1[J]7=_T@,A5[X(L
M_J2/U-Q V]3ZF?SJ[A)W_ >AGH_!ZXI!B*H?%%T/PC/K =; &EG'4ZJ]I8<F
M/$LJ,\*@S=+8%MWI1SI0 1_\"?"S4(F)A;JJC[,9AU/,6DN$##T7"?Q?W7XQ
ME[<R^W^<F9D>J19T.I+C6@N;S32A[S8=[0EI.K?YMEV%TS$N<:MH61;RLH!/
MNPL/!P0)>FA)NM:J,+.%H4U%0@ED(%K<F=7^/OJ)1554C><U2.JR*,1^#H4K
M6R"DD\<EIA9SCR+,WDCO@K\*Y\.)\F]$0SY\#)&2DMA>Y#8+'[AU0U$NA(@6
M:YSQ,K'-XLGK)N%Z4]N4+SK>^TA!S$L7%H7VUG# 7.Q&W_)#0]Q/8A.SJ*S=
M]5.?-I6W-',-'*5?Y-VFZ^_MTEJ#W]UA+(1L!WI@BL$6)T&R 0TK7A8:*,2$
MUIQ:C)F\M= ]\KH+14"V\<TFNIWE$FIPK C80BB(R\9)B.2>0V*K.5&]#Y6#
M-$!UR&WUQ9/GRM6H&%TEC=*BQFEMP[N^>;8  1)7%&Z>Y"PY8=H_N@I6]@,\
M:R"XG3_5KPF&+S,\#NE,^+:"2PR]S>S>LW@8-]V28RC0LNB;8& 4914D10BK
MP:[5VXB2>(=6/*4F[D @P<2(O&PH.)9/5D%%F(XK/PP-7;N:.D[ /SC4_Z1I
MBYW)0'G%U6Y9:*G.&4ZKZ$[MVQM,=5#/X EXTY %-F\T$E.5"+E&:$R\>H,(
MA#%D*0!(HWDF$J+,Y_@K'(9$F5OA76:Y):VON)U#+<PL'DG).=HZ=]*^+N A
M^I*J*,(4X%U_/+1=F2<"?IE9#'Y87E ".S?<+T,@OD_K];[\-E\35I*X*6*Y
M2MD[V!W5)KX\LP_^D*1DH<;3\E!'1TM'?5MU8>*\1\MATR_^9G)%N_;4%4.'
M[F&AK9,^FMZB+275_J"3+?G&E*!=^4OS5\"G0BG#&<KO#2R 'KXK4WZ=-^:P
MM#YVM_RRQ\$#2IY"2/J0F532?D8>RI0+OWL_E=H'[EWFD<?_[%--(GOR8:+J
MX/.,^CQ]HV[/TQNFVWJ2TXH_5R-48MTEHPZ8.'''995G+6>34LG)!G;2S_(+
M2CS'H9(; 0U0N?/D,@0/I''/KX*&?7^(UWE=[XI1E5]+%["Q(ZQ)YV!%Q):4
M.*:VRWS!7 9QQX"X<I1>J:FB_%9#3D4]=5)H,XTQFV?O@LE4.80!.AF[J%.I
MWWB:0Q9ZHH@E$^W!35+24>>$<'<\'VM4$2?SI+E>7[']%WT/'95'0?JA=TR0
MHV3)O21!$:VP-*X!&!>O%3EE\O^TY@B<>G[F]?1'R0\J/+U?_ZYNZ*GPJQ_9
M;R8O%N05/K_^WS^FH#MVIWQ[>E:2;J2H8?!06GJJY]?CWW@XB1D-*DZ]..6U
M5-;/&>_Z*$H<]JTJBJ'Y*8HC)'&8^?K-^V65%'E"@2C_DG=BG@V+C#L#*..W
MO2L1_LN"7GQS>DHZ:D#;<-GK1'7P8>#9=)WJ^XH?3+-W]VN/.?-9MT7^WR_I
M\BC]2I "+OM+A_=? @1UX?/J;%]TFK\OUM'V1'R/3CCA**^B1\L-^+8.:##J
ME<!84=[4=:1 0!3[>2Z[0W26>GPTW(0U=@1(:[[0U?^-Z.%Y+B?K9(OB4?F^
MOT]XCJ&DCG" W#X0.3W^BI)T)3S".BEG$(8+^N1:Y+1'_4[]I*\*=&K[+?\N
M23=*U'9]N)\QMQ5L>MO%I0:_?1*4'>8E=RJBC+KP!Q=I>.5*$^DT*'VRIO?9
M 5N<!DC>2/6,*GF*@K;,WR3]I2:<$Q. >UJ8UJ?'_E10:($%'^HGM=.(CR^J
M,)9RY150ZPFNWLEOG;5X@N!*5[!OGLGZ)BK55R41/X=:*F2F6!M2%JQ(C:.;
M\DZKG5G!^?@SRD(\ZX0[K)^2Y55ZQ*1I66[%^C+Y;08O.S2O%):_*9YJ$%]2
M\YV;/9BIG1=J0 >1[)2UA_5<2),[8&26LG%R8H\TO-YD?UK>SV_>)_US2'.)
MI[E6@[$EMXO+D8\X\SB6&FI-)_6N-U<8SB,VF8+LF#Z18L1A9=T_C0\WRFIU
MQK;X1_I8*BN](5O+>8U&>G$7Y<.+M;T5Z!([O5=)<C:#*V(,=K$2TDW3]:@D
MW>6GI.5-[W0(*0VF]/J4Z-BMC>?NW^F_PSNN.EZ+?97O623I#\\[+X_9O\BZ
M9^AR,AL0M2:TV'D/1;:Q.)CY@7")4B#>7"IYUOOR%%X\[1X==SHI_\.$BY/5
M?F[A+!,"J"63D-VF9I).9IRII*&K;Y]-*:]QTM=#'C5_&]V&S;F>VQ#=EW'K
M/!0%?&;@H7P@G:!.V9+PTBG9\$L8+,%(174OG9WZ 4 6C'++X0N5B#YWF9]2
M,7 04;OIU8#V"7B=5P%7%!7#$=946XI9N0+J<B#W*=Z;MJKM;]C7.-[-B*IH
MFOFD9ZBMHR>$WDSLUZ6C$ '@X4FMXMT=S0)9Q"1WU/;HN7Q2D+\8=K37 L0A
M+$4?P0@:>=AL -[0&<(UZKHIT_U:,JC@EO-V:%75L3MYEQH!6]R4D62=#X58
M#T-<+ZX?[Y(:DF31@]_24^I\O CFJ<]Z8UR86(O\ZL&PX:').&H)56+SS7W\
M!,E4.$<3O;]$R6S;O @JKQ;$08WT^:+R>-Y8)_ O@L1 *'<QIJ]U5V(&$W*3
M[=W^ID.[A133@A,DQ>PUQ=Y$5IV;[H_PI13RD39SE5)R&F;YIWW]6V^_: ]H
MR+@P>B'-"O%'/?TD&V >([0F%QI:_@5[#!:39E@:X@W05F$ J[,:$)H5GEX8
MGIH)<1M"34ZD/R&MB*8=\V/T"A]P_8CBPNF])(BEQ)+&1]3[_31JPMK=!M9O
MGMF:D26N%B$=Z0Z]RUJ#G!.Z.4$BM;JXIT]BF,BF )H";M 3PB-*TY$R+D>N
MXJ*.!<Z#2XXX/4=&+O:042)".KJA*L8FJ44@%SF1\M;,AWG_N.>OM(HY;<"L
MS1W*/X1PJ"%&:A^A]XD3G:$O""Q9^QVCF,G@K2,4F"$ZE6?P[4SJA)[0>]%]
MGB9Z4O9*]([%52!V1$HH^Q WE-<#8RJ@(CDDHTKN&/!4F48BB*FEQ9'+624/
M::Y&%U7@<Z<I*O\^O=^&]\\SP-F6[=I,G=&^,^](9?ZA?7:9?_%4[WZQ4W+<
M>XG "I#8II_@,3B4P#)__EPZD1/AX(A;R9]GW]M7 0R!+;C=VI!5J#T&8N@Z
M9J>1$.JKGX5@A.P1&\[,S(Q>6I!"L^OEV@YH!5+O+W<J.^R<L0AS\GB 9PS$
MWZHLE%279.\@A"@Q=GK"VEV]B<4:&=FN_?S!@O?LK1[96ABYSOK[G\I<$(>%
M'FF$]^\T44?)W(L[&EP1P@[2,3L\Q.=7"/W<N%9:'U=V]%'Q D%0:/EK\UT2
M^EST?AWBGX/RO^VJ6E8?OD4)!+W[P4.J*XAIV3'\!?ML#F:SU7]-H<$HU\/0
M#5$Z"8QX3H6F,WVR[?C-;E^AW#.ET"M'QIQ7.YW+8;WY*P=+MM,(R=/D6#";
MY"#0353R*$RL:3F.J:@.)8^_OCJT;+L4E\DWO0CUPU04PCG71X=YO.2F;@Y;
M<.F4<E;H]#C8B$5&5PS^$ U) T+H1Y-V?&[M$(O8M:]PJ8^F+$(^B&>.:1@H
MF=J6>!R',"Q]I,[V&R3TSH=9$\N74HKD<Z+CWKQOF+%0>P5$J3T62&=^,G2<
MD\#GD6U^2224/E?8J/0J1H506U.6<66R6=7'B'K#FN\L0K!^A]!R=4VOL"0<
M!N?T=T!3D@ORQSIT.C"&6)W0\4X*$XG"- @)DU:N:(U]]EO[P%4&PL3<5-[H
MP.JP0SABX)%<^NEW#5)@XN 0D,-KU!B>'VF&[.,QGY;LM<Z[X&AT>,R[_?U'
M1#UT?8K(#VLX%^?])2YTPICGIT184 ]"/''*(ZJSU8\=\+4?=W"(K\C&5^L:
M33%-0 @755S'P@RG:CH?"$P_DZ5CZHN9$U==*18\M3U7=\/.,WCX]YBCH@!#
MIM.I_%B/2);8@B19KHP'M01Z*H(W0%8"?!_5R'L6$V/KS^]7>&)A\!Z9?5.C
M,8Y *-RDY,V/QXE+56Z'4CG!QB:G"D'.PQ+>68VR>OH<P'($K,R#4AOY&\^@
MF=2-5U1JP9!*BB6MXB!QAGQZ23I!>,BJ%$$2?N>=6J.X>9"ZY3NHWYTH#VJ;
M4TJUDZHRM%4+QHNJ.4'XO= H# 81-)!=,0I?QQ]7!@SXZC\1<@XT4O,2.@L/
MS^:*^:XM#6N$ODX"N=J\<]B6D>Q7?/%:COAQ9.Z2P(O]+*9AWVT8D9:%!LV#
M9Q$BGKDV;[CP$=7)7E*T^V:V2^BG<\4"]+!I*)=/H\W8F:C'I3O4T/N1XO:"
M GV;136_(=Q,H39]4H'8!E;;D=MSAUW:VG6>ALG\$F\S_]SBA1=IDK)1 U#C
MX0Q?%[=&DB^956(5?L\7P0TQ);9(G>8Z'<=+7D0;Z@ U]<6K.-QWEVL3U3\K
MUDO^T16=\LV!B.7[3H))=.4K[_QP*#U:2E!$(K:O7A]7T2-OU9KYXU7C&(KL
M-MW0@;J#E<T:I7", <:>QI$"4@2[E"-PM Z]6_EUIE^%SOIL$U ?2XZ.I_HV
M6<U134''<X(31IG*&;B6)J2<VEMF4_./;1 !4_#.BJ]]PBZ:Z +D%3JO$=1D
MPOI.:X::$5O*BP@726  +C9"Q&*O,TZ#/D5$N_ZRB_<E8PH\%[7<Q8:D4A0>
M9*3U!<N CINSE^52I4%1)-QPUG>M+^^6VX:=P4577OE&30U0J:\_606_:<W^
MR22324(&YBKRHL#-^A '>4D*GG,RABMVB=!ST'[U;H=VBFXJWB:T4KT..3:'
MR$+$_]I'CNZ,W4JK-SWX,"]EH"=!JCTJ^#GHM83[FP.F UOM&;CW%#=W.VA_
MOB/#>Z"'GZ'K8&O!SWT+.SSL636@_]D87-KE19'+ XZP5B$%'C$/R=_*KKYB
M$H'U"T=*0,P/1(\)6)@FDZ O;[I.053T/QR@M]:^BI<]HEXM".!].V2K!*FL
M)!/4]Z+"_V3<QY 3WXBOXRPYCE@5YB#Y@>XAE:A;@\[6GE9.U:FCG3R].<21
M7'G+-M:RZQ*I(" Z!V)PBA+6>#OIPV'M9' J0]=)N[1=?\S4K?4;STH5563[
MN$D"O34CE>5FM%[Y-KT\K&K5.GD]'%$+C&+L]J8[^[;9%L1L,BL^KX_8_U2U
MEI6306OFN!10E5ITMQ5<+*50Z2'/0MH&)WN#V3G2%\Q"5>T%S'R@@A%-*@'B
MH(RY0G%D/'CW:@RP>JHX+EC@!:S!5\3FI^F)D+ZG@6[O(FMQUE$[FGZ[7YGW
M*U$?UY-]AT+R.;TQS6\"#%S$*LS^"W/1%^4N\A-EN1+V-IMW^&&=%J%*&_'M
MNBWZ(_Z[%4866@^J[@8O%+GV9(K@_XSZ234WR6W>]+)/*K116KB9>=[PKAIE
MRO9DB]'=2-'X=5&F-Z-X'W7-N J*J 1T]&LS8Z,L*-Z]!5@Y<UUQ4\$G5.3T
MYUJ M]0L%I0)0[X'5[.UR=XJJ[!U_CZF3E 05*\CU54Y$$ET=&@BYP@+-6Q%
M7L)'[&.2?&K;6^EQ?47LS0N\-.J## 1:=Q\KJA7YU"V>V5J6(ASWBST%9^K&
MN-[4 6.;>[#X3DMB[BFIBHYR$(1K>+1]M)+S=K\],)%I^71_#,@A+AY=TZA5
MX,CE"-C;[WVL1 /QX28;[YI8KTS/-*]J<XJ^O%U?.74PF]3#(UD5G2_2!PPP
M/DM)/*>"U9LX.H(KK^Q@I1\,* ;(,\+E7'?PAQ8&_#.7BY#+CO6MC\N^(%_G
M)6H\*UVZ#Q<(*B#*?OZ@?.GTYAQ9$@>V1GGMQ:/HAW@.J.VF&UJ'DI<?B[#/
M8+6&WBZ?PUYP+'70R-.8FN;6[HN7W94#YD7RU0^Z^]53+&%-LAA+G&E(Q5YY
MMJGH]^L.FOJR!9D3++Z;@"/WE*[.JG_C]3#_RM"/+]B94LI]ZM(L_P.!YA>H
MB2!S12W+I?T"Z1;6'B5_;Z6XK816,0MM?BU8&7KL4%4Z;3"K65H(.5<0!?3?
M&;#$=FW7>+5 J'=;#<83D0_F9T>M^1O'"?VN@DE^XWERQ\([QISJYW1!,>8S
M4[,BUEOIBRR6L6>99YE<%QE%%N7YY8+U#]+L8-;,]\DL[5ZXK2U0\1O&-1\%
M/OUZ5.,DN/7V4?\*A?GLU(S.2'=YJ#%;O[=J]_1W*HN4F*2][P>-LRTD]I$/
MW2"2'F'2LU>OL<4GR;)@^R;-LX\T^#M-(8.7=_"5>9*]M/>'_=6*?M0:IC@+
M7YBZLS)926*",F>7YQ\1H^.9.FX:CF=6O@%(P.U2X/ZE\OH?AP1+:A+KFW[A
M!U3DE>>[.MMRG^"D0HU'[OPT[*_!.%2F8@VT=#DY@/ \+-6'HZ0N_/&M!++E
MSVU@>M7A./8YCFK7I4K78>+L,P*N.Z(72[_QC-TW_<KM7@I15V2U?C@C)@ =
M*784-<P;=.^!'/;MHMJKH>RB]]IN.BJ2W7-<$@_/YY)LB#8U6T7*4CISA]17
M?="8:(MGO@<Q;-NC-J6/4^,^PWS=LK9@X6].>\OG=_^>ZW-_.(-<V0_7M^2&
MH<7-1YQ[6"DEURF1C$Q<FKZN?3C]*GT@YIA6!^U0Y!5X8W6/0?FE:/'S"H:5
M,/')G)^B,RL_/AT0O^2:@NC"70:^<^D\Z>=Y>F]ST1LK5,A+7382)Z0Q.JUK
M'ZV"!S79%#[6(5YBK/5O*I@:JRJ#=.\1QF)6/3!X![I!%-<NU:YU)O&K#_QY
MYW)6Y(KK-Q[.<4<W6=+=N>VYM3V5)'FM$; AQL2K/V;/T71AUYY] LH.\>V2
M=@'F-&LWZXCLE46;V1@(*++Q1,5;K9-C:<??;/%\7,'19/DYVSJA<\/SY2BM
M\O*"ZV/=F?"\*\)(C!Y6>"D8=/B;*K_V>'^J5^<6US8!E_2SQQEY%=%)6HA_
MW=;1C4W=^G*\"1X>\7*^#:HL1)20':SW;]L?$4N55U"FQ&A$%R=/I7/EKJLR
MK<I(&/NY_\9+*PV:RQ?'Q595TW! VCC2;LK7.+'@[%GN27I(7A69[/\PN\D4
M!E<FE0-&57O*V+3ATP'OUJ >B2FMSP^$C8CSQ[[J"E(FKJ2AGCZ-,-OOI9VX
MWXUM.AKGJT@YH*IHM7CU*%5G1,/T;&/WHJGML_?9+0"S"W>EE'<)'+9GI*5/
MRPXU$EI[1SJN95\#?M&*0,'JGE6JR%I(I$1&ML3^761SV+V?/0;M9Y-L3:%M
M?'*805:_\2C>GC/N/PY^($/ 5J9?0I_H]D\6?-YYO)Q.>%&6%T1KC*..45MR
M3<<Z;4I]*/G%7/^=8NTWWB>;R< QXR<:_;R[YZ5#PQQ(R\@8@;7_TQ_@^[=+
MZM3?>"H\/F\G^?;.0<,->O2-FH^7B-F6&B/B*\BD:V0@[TV/<YTU/&>SF/L\
M.\87OUCH<-MBXRH83!7%!/$:Z/&BP[HY=G)+HZ%N&KK?,Q>*N5=Z_ B)G+<R
M 0"?2KF@Z0^F=I]4)Q<<'4OFZJZCKTS^F]CI_7=7KU6ZW  "S]#+,K=)AV/T
M40>4+;B-"O"A%B+P))7.N>';T/)X\4+:BC3?%-_Z.0W%F0]G Z.U1\N)7S''
M;N$#QYC16X\'%>5EW]>:IL;?VA ]](!+?&90H&[8=49B=_-B\[*2S$VDP ]3
MD.,>YD<Z+#<W/8 #Q ,*?.8@K_#6XC;S'/<*:'Y"A_M8W*//N!ZSJ[G8U7MX
MP8N1?Z53))JYTX86\@LWS^957._;]'*RWEO,M*<[&"=:K>)N"/""OM=9W,W-
M+R3C)9?IG-L\R[P9^"<;$QI3S&QI+8$[OT"]<#JHA2OINS$,OP1"EYJ7%I0D
MK<P<EAZY%NY9FRWS-FP'T;FN>JED;S^/0C9Y,\"4EF\L[@;/23'L@8M2"]O]
M/"KR*,_0L8GT8@0+\B&M=>'O$E$2,H864I^_F&WQ4&6HH+9*ZT=%,&S194\L
MGDQ<Y)JORG2R93)-8HF=\PE4AXJJ+TKRR\>32Z<\4<9ZM13.<<C8K#JQ*E[O
M=<SJC]P' 6K'&*/*1U:S1K\2*L3?Z2\RV)=\-!M[1NM(QU5FQ\/#RQ# $$$Q
MT>DAA<Z[#]BZV5CHYW6E6-KA(.N#L$*[A((S2:!1Z:*HI0'>@YV-)/1B\I[[
M8C728']>BRD55JTQK41Y*JC>I'"[-*V1%YS5*F&JN3SNR^8=*M+-(G3%B#;1
MVY43XHTI*FR3E; ,G4$-C@;B,>P0A=+SCUHOE,!Z4='V?1*R-K$\ 8&RM _U
MY6]53PLX9MUS@&1=T99VZ$ZF*LF:J>A1$";:I AKG]_HQN]B(1_B.L%59O?8
MMQ@-D?9H:UO$32.$91;0%._@H T_/-M*'W:)3]?9;#TY?D5Y96.["4(Z!5&G
M!2K*;3"8UI,UX+9SC"IV($H";"-S!3W8TZ6)#UKL#CSM%6=X"GXA016Y*0W2
MP.?Y3F[4;3NBHNRM8C@S_OOT!849&DZZGB'>@;2-$\4*DNXX)L^X9S0D]I+O
M(B2MX8C!ZHN.5%7M.>.B!MW/^GI&LW-#@A"H)H7[7#>]&G0#:B-"(/7%UGR7
MHRIE'T[__?U,,G\+AS5;\%EBJ)C'@4%N5((L@*_1R:V>O_(KGB7AK?1F!^)*
MV_#*:3,S'2GITK)6I1?[(<QFQ0&9?$S3VTW(13I@'7P$),73<FE@HE38$5+D
M3/+A:,1"U[849O3M85ZM5*4=D8!?4BQ/<20IJZ?7]EI>?0"ON+_2'*B4A,+L
ME7X__6"L+#30G7^!2)3EP;-W.<XS](3+I4( ?3BHQ3V["N6P5U2!\)Q]FM D
MP7M#"5FS5;EU&N]2 Y&7<1Q)G_6/#GJD)9T*#VL8R:02.A[2(T[S)KKQNB?*
MPV^'C6"!SV]=;@J;TJCM8-KJ59MFH#\D]>R]PAADN\%;#(.1N<A-%I"_)1S:
M9=^HU=^(<CZILV98+;9F_![\T=1PTD*N2@@9I \05XN=J2Y*\M"Z+Y!5X</B
MSK>J),GASR(81YTZTW#UJ,"!"SLO'F,+=%087X)4.CT3PR6D99HS+6'Q,H-Q
MIVY64SYE^%7,*D5/K(J;^Y1!/*=(TO0DH8S>V,2N@0?W/6#*A%#[FQ ;&="8
M2$$YLT]9Z#2H%90EH>."*"HOK*AP&H69W)I+*[CW9JF9W5LQ@*]&>(E(@H>2
M6N4$^,HC<H#DG#[Z7#QLLCYVF'Y1;HC%YIE#ES2^RP<9ZU-20:2I_XZ&^MBQ
MAAJW6R.+;=][_"2L\3B49]8P[J9EH_GKU3G=207*21P9:O7S[4$VYF;E2?P2
MEQ87[3'0'MG(3;B*PAP2>>+UPJ'G$6$W,9_Y;=>%C5'KU,7T:U^>G_L21^-:
M^"[H4?NI7;'&&$#J*]:%U=W=SWTXC94@QX5>1'OI)'DN=*>$5X3'B"55A+,U
M2>/A<10H+%.=H!&_<H$O0%F/N"JI!8.C;QXOXI?SF$[XW/WM+&>O,XFG4VS3
M?#DH!L1*8&2(O"@H<'[*)7@J]&O9.KY:NRU<BPY,K!+6-X9_X,L2*@MDL3+:
M/8,VJNLYJH4-<U[:P:WI>!A)NROTU33G^/N-;,30IGY6K?'VWOJ_EB"%#='A
MG[L?.AV+YRO69](QGD82U;&G#_BQUW]H09?RUFL5-KUX7!P WU%4P4>; _ '
M' ;IB!(/)!/(LR.P2.H.*/>'TPK^F0X1?:D(9+A1BT;)P5(8_W]$>HHN?RV0
M6=\D*ZUSM) S B/17T 0 Y)T*/QC[S8V5H1V(9!Z_!\;U1^GYJ<5W$+#IMZ:
MI4,3$X-54!C;@4Z;D(FVJH7R/D#E8BV!<'3KW!Y6<;\94="V5)973BYO;AG;
M:VJ,24S*RAR7F%/,?J>-.0U+.?3*+\@MRHOV'26?.<I60]TZP!( PHE0Y62P
MD_1Q=*DK86P#_+78M2*Z,?9,US03H/#J\21QU"B$MD3L^%(J(M6E1E7GZ^MO
MNY8'W@SM=06F 5(2NVBO: &,NFA"ZP0;$M-*K/D,:F)(;Z9FH+N_@)M<1)Q<
M/6,)])B>TC^ZJ;<4^^ S@2E#J =Z3.M)F55E06A9\D]5OPVGFD^$$'"X[,X!
M9VTF5PAM.O4N:M&]%N0?H(&Z37O!W0=(&&E3'X4QQI*VM\?PES[9:@*A*ZFD
MEX4TN#_6N75BMN\_.T].5. P,8XY:B:<UIP3;K6M1?- YW8Y7D.SIHE#AL R
M(.]E9L@MM^3ME/E2)W(+YP9'5?IAU98H^^*RE-Q^T/?W,*:Q$N\[;);'9QS[
M3WJV-8&F*_[29=XYTREH SEB1/I,V:8?NK<X"6 >X/Y9YJPBN5'%0,\SQL@[
M8/T"0*2E0:R5B8JB'5P^\'6V^MFG297E-0P+SX?2-[]WGU/K"BFD:/_.#F@5
M(T"E/5C7?&PEKE!O]+)^L0A9RS[;D$^'6GQ54V(3TFM/Q!A#[MOH.&8@_\5@
M*@4-:M!<Y2P,+YH>_MXU9'WK\RVWV&1IPQSEJ2MNY\Q77[K)ZKI1;V=QZ%;1
M 1=N^R?KZ7<68F=150W.6GH^'W7UYO4,]10(3V :71Z,3'* ><M0OO7;QF>@
M# PUO+DP?/Z5F6N3>$-+J%6:36R]H/Q\2B9U>#T.F#Z\P#D7OJ9A?E&LI]*B
M"E)_)AA*S(0GRG)YF^4\-$V[=\Q%8_)4PZ) 5X_>$<PCU)?HY7B[^-D 96*K
M][D['D244-#[YEN;:8.WZNCB)+6]+Y*>5>M:4A(F7-NN@/=O++GI=F >F ;Z
M)YU1_8.XEGK]Y4K!F1DST<2YZ7&?5@(P&YG/2O!'"RZ'LDHU>4YN6"UQKKU1
MDA]J<967L&9@0<;U\J?^%653R6C8XSB_H&FJ6?J6LC4=N]Q/NFHDZD6VMHK]
MD\VY$7YA582BQX-T^CS^PE@-JSH=S2>],W\^&/322L+8"G.\'>M^L6+@5*A^
M^[5=8]-> &8NRQX$O:MW<RIOUA,)"'RP0VT+A8A9@W:24^;AK]7Z%++7M)04
M7@DU3Y#E5_S&,Y)T<2"C8UGK#);M3F>UE*-@$<[@65\A76Z8MZY!E3\.^S@Y
MU<FPG7D<6"M4(#7@L#6":C,3E#+(FJ441&J6(BWVV**W;=^>A.:-L8Q/_#1A
MB;<TNTEQ@S:]BKW&$9R27CR%/#GAU^%3(#FGW>$5Z*&C13-A(A(^DVD2"3VJ
M,=EWJ&[)KG+.9'@_.72+,2F\=P[PW>.F<B*E+FV<$75(94D=*.IQ(QKBE=)D
M6X+(*V,9X&+"=M;T%1+=('(XY-3+YTY"ES09Z)MB#8MGJ(4Y56G1*4*YFQTR
MDTTP#VAGD4/T':+'W:Q<5-<)2.1_5&=6(_67?<Z_KS.+_V@:-;YC6R#H=-]
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M*9N^Q4K14:S&_QKJ7T/]:ZC_ZJ$<N< NER3/7S]A^[WXWP!02P,$%     @
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MQ'=AS;_V@PR6VFJ]S< 7=MM4*$;-$"N(DE._B(XWEP'X+7^?ZN9;":_HRT'
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M6>J#9MA&L]WX[K$9)+JWFH);]:WW12Y)"V\3M.0S[XNWD@#=)KY*LU;QZ"<
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M9'Q(P,Z^EL,66U":M0;2ZNPAN UB4E$$+.F'=(/:J#&0%=';=_O:40%L*_C
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MZ)*Y]W($>DU5EXJHF)9>TTL:&QT?TKK3L?R:7@D=T292D25S3\+$YWWDL2X
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M+QJU!X+MLY&]A4P09>MLWCA]P5KQGX>)N,^*92H(1)LZ&D"!0^?_XS[;KT[
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MX8P8<9&X4W;)?\9SPNM5!WG0NCAIKSE&R,6:<+8?=VL-3=B P#'Q%34*\Y.
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M"#G4&,^#FOB(I(PQXQ0/NZFL!**BL4?1Y$>?U"H^*CEA,'_,V ]=?^X$ET[
M/7/D<ZFX-!R>:,RJNIP(F)0ALY77A<:M )=/JI\I6E1\='I$XV*HG0D'A]:;
MM"W;$)4V''$%D"(-;WLU=7I45V%13\G"0C^*X3B<04<J*8Z_1RE3!$_6J I[
M2AK66!VFA&8"38B=2.-BY%.ZBTBIIT>4MF1-)W8-C+0SOYB\AK 2"O7DG(:A
MR8!!,?42>+1SR#2+.:).Z[Q=%K:TM"YC)(PA3A=B2+0SSAAY= 4\8L6#$Z>+
MZDGT<E']BV*:UV\$1A,-)^)V<[XI8-KY;AJJBW+VKQ<&F=*:#TR)5*M#%6BG
MT][HI_$[/:)DD3$VF-:Q4$EITYPW_4Q]5)YRU5E :*IVW%8.F[T0U2#QVP4-
MPXB0BSI=@L[W)JF,G:CAI\=],&U*L/4F5\S^PH*?7-"XCM1@6ZP>C0!3R1Z#
MV4E!ZLFXZ/=@$K,<B\(^BE<9G1[2F-A;428RF*HPVTH7LTL'@]S>ZZ<^2QZR
MV)TZ"=-E7%41]CFTCD/6>-=#;BM'C"4S.>K6^LH2**S).E(<$-.Z^[#%M12O
MK2PQ.XT2M:VB,L\A86%8_6C,WRU<AB3 J.1VT>5/[B:$% ?!$-J+2]C0X:X*
MB4IV%2S4T>-_1O$?KWX0,,/E55US=').R-HL94G JBX^6YE2=AK0*IWQ_**)
M+K7BXB"J+O,I ]6?E"?+R]2KP$D2S43,6!V8\6ALFBRY"(CQV4I^LG?NJ_"4
MMT/UPG DI#&\-7E#;HP17%2RD*#9;>91XJ>_YX> 5.'K)2P\.CJ^H.'0HZ)"
M,#G+$-E* K+W\3D(4YB_@HR'T5P?T6_>W"#SF'<+\N.>$=GR:?J-$X<PRR7+
M3!:7"W$#BME]AU^%<4ACQFBW/NQ<0K:RCQ#58*T'XZJJHQ,B05'?32M,E'%;
M3K;RENQ=HPJ/L!^AG];V\^J[''5E.*+1N& WHU>L&KIP;24HH?&&Y>\L26%@
M*5:Y2JG1\>$)C:FDW;)4AV0KU\C>1WT)3;EH;)3C0J UF.L,29G<@&$K$\B.
MSB/\!L*=LDN-ER>"HAPC#:<T&06"<PB.Q5;"C5T]V45FF7M5 E1E1=BLT*"R
MS8-L/9"V<F?L?7[-C]QW29(Q[QJV&.$$=J5^Y.4;T^0[^YG_26X2U&D -BLT
M+ XF)&,V0GW ME)8[/;>_/<H_H,+P9G[*>^F>/AOEH(!U(&Q+B441=6O-!/O
M$S3Z]+ #]G^M\6V =]?9)-XYT&F1-B*<%+EX>#(ZB5H(2H-0:+P7;*\$*#J$
M\OWXP;6FG">Y!3W/TQ%ZS+M<_$B8=Q>NT ]X(J?<[@#"@U]D\+MU=A&)=K1K
M>'1ZU $W'2U%LB$(1.<ZFGKXD4=T#IFW-(,.7#>;9?F[K&LV]EUIUB-U91 9
M#3?L]KJC"Q;1CXY:\39C0MXZ+AO,>!(PB59@54 \-,Q [75!#A'1 &-SWV[/
M&95 '!Y[ 1A9S.;+"$L.1K)N59!$UW<?9E 1TO>3(5@52.S> =E+*184!1G1
M<+MO22D*#8E:NQ^/0 L1*%::RZ<KV9ERLR0(HR_6(2$RA&9C:R&5*$/+8'K+
MRT4>>\-/<^]GU5*MJ@H"Z\OV30\JHANDLMQN]_S!6<@R@"#% 6_7=V-J> B=
M';4=+L.NU56X,'HK!KJL*HBKZ]LU,ZB(9NS'6(@/]+D3+AZ9R_Q7ECQ/6>EN
M*=^Z*:J-3K\0>K'3:N"K82(TDWHHBP)!1[5.-<#?B]VZ%DR$YOW8Y!":OT?A
M(QMGH>?DNU&-@8S7 -1=-\EJ(41X[:@M#8F:50!.AN/*[Z1&5^U60(A].<D9
MHT949U]&. N;OZ2\E)BPT%T,7#?.G. ACKS,3>]]Y\4/0+1?8_D]H4$K(,:^
M7"(;HT:49S_&/,LV_$<V+W?&7@-SOK V"*TO9@)MM$A^)&-C(97YI1*QM7">
M*IRJI&9#80T03P>\N#7-AQ*$B +L)^,$LN>\>6.QZR?L(?9=!HODE"U?ZF%[
M3KP&H.Z%P4B%$.&5E D0EBZ7,2_AKYGXX_CAN**J^)6.I!)@[X4'H09(A.#]
M& 4E-MZRTWS.X<<CS#-06AX0=]VNIX$/8924,>^1\<UF_N00IISM5$88K_):
MH].37ICR=% B''?4U6]SFUFYIBS^F0#*?'TZU-Z82]H  7;=6M00,Z(TQ"+E
M/?J3:?H</;$@*&/_?L_X"Z:-M:O8@*+SA'X3()FN&X6:04:4H:/&Q K(!R<>
MQGG0%2]?%)=/V?7.;EAM$%I?[#_::!$5V4_BUG=;9*Z9&S,GD>F+:5.CP[,N
M9#>PNN9L84=TR<9#X;]]JDD2D/Q1+2$LL"%K]I:RT%M;>&K23EP_8&_3*/!
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ME\"?Y-RM92/UF39JB4NS'R: 9L 1-2)EG1Q,)C&#_B_MJKE%CJ<)0I<#K *
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MHS^9IL,L35(GY+$-9#M"1=41M0Q1S=5"#VH70LM=L_QQD__*2C#W.A%'\3J
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M+V5T2.L69:>*L0&:4LQ6$L'!CKX<$?/<M;4_E<"U%,EU[WL)6^&_#L\_T[*
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M:.(DXC.$G=;92YP!<*X#E]?#JG5+?C6MK CH:1EW= D3G9[UP'; %6@PC_V
MPWB\'A;I+/7H5M4# =!R$&K!MAY62O&CT.Q-56.C@F%AX='Y:6\&L02@)<>A
MW1I6AVX:08^Y8O)GT/R$R6(];C6J@B!H' DL,*T-UY*7T6['<&&.W9R(;N%\
M\Y_,B55#6ET7!$'+ -5JA.OBI>3D8T3\\\_H(?+#M(T"B-L P="ZO[>N"#+<
MEGQ[:%QG"/-/*L[S:!T0,C&]L'>>5X"VY<2S]P.]$*?R)"^I!?*AY?FA8-*
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M_S801BMX5X>& "Y/Q&>OJRD==C%O7/NOOL=";Q^K0/7;0!@Q'Z/N# !<GL@
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MUY\[P:43.*$J_YNX-)<-K?V; 8=J7$ATCG>WQR$,7N=]<'ARARO8@8!T?O"
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MW*GV+E3>T1NUPR79?6-A$\ABY3G\3,IV")-?PFTCMX[K!WZZN'+F9=![;$G
M:P#N\X[;#Y7@,%))^?N)4!1A\4U(+6IPW-VU NJ!PT@E]7IY$_8P2Y/4"3V
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M\JG2JJ&5@:,[NRZ?4-P+/_*R,C- .?1EY9[U0Y_?WI+X 0C+GJM(\>GSXZN
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M"?HOH3AYN*;<K1K&J _J><GFJ??T^7</,Q=C,0;XKPC @GX0Z7OH*Y/%F'T
M1<?#;]5*8:S 'E0HI/E46=IY3A:;Y;=0H#R<8#TM-]NX.050$J[/WT7X\@HC
MGKR+U'L1MP6& 4V?2]EDTR+/<B_&(P3E!#7M#Q+YSL.[U4@3FF =07JI'40U
M?5XMDI<?(O7##/7]-D%W7G2>Q%D8B,H-;*@6]A]&&?)P:SG3E\9"X)0HJO5^
M9#J)=(:OU7=0D#P<6ZWVH2:81Q#+63GBIL_EYAF^BP?A%ZFR""/= U'S>J!A
MOVYHT1U44B="J9>6E(DATO!+*$P>T5U=+ H:U,XR0['0H5W!Z38/:7N4S %X
M5%786 5U.F==?X E>J!T#L"5JD;7=7 GIWNMNP0^DX=>%"U6FVAM"=SLI[^+
M5%Q^^%$!OQ(3U#R^HI7^5N3+*["E!'>^?FBW7]\)!U\_6,JWJ.B9TV7DV&XX
M._KZ:30F_7?R_944U*$DVUB#.X^\+(.#"IY]-6]NR3XH&UX> 2EW&IH)5(>2
M9*,.3_NJ=K\Q2H/7]92..#G=)#(F636(@W@YWFDYNHQ\%4NT1("\'+PD"9(C
M-XF'TUT0P=H]FB/Q<M/1\"9K"TB/QLN< M$(KE^J45]G68%;R&]@^J:/J1?[
MK^+L%FQ8W2PTZ@W2..;EY[":F3881W#E<E<\1:&_N@!0\RMKBY+BY>"T85.!
MB-,M!\5=&KZ#.6!(GJPQKDPC9D\!:03W#-M+R5V1PA]B?+64O;W9++2RGB@%
M7BZDYHNL A^GFP?S+?7A#<RZ)%V]/ %\_JN7B<E+*DK;WGJ7-?L@RHS7::;E
MQFL%F]4- Z$K5^(I+;QT@>?8LXOI59C.EXN;6B5T_5"JXUT-#-&YNDSHZ#"[
M@^)>;"3_;KB%6WP"E7Z\1K8]4%>W"1V1/WE+PPC1W%],J[@;,\9U_6;'WYB\
MMFM"LR$Z5VD@>N#V+O+\<NN9O,!_[#E6]4<Y\@I>;<JU <HQ9&VX$&_X&-2,
M96GCV?'WX_$>OU20QI!F8>KG"8P8E1)=-U7(M!F;!EU!$%_&RZTY0%;I%O1,
M-UFA#;NCTV^\CFL[D*SR(Y#KLU\.N8'=9= 5!<'KPM]N[38%Z"JS@:,$C*JK
MPK.H%LMN<&$H:8^@Q[MJ:U"Y2B70D2$M+5&MIE'1!0^&O%X*VC"I!T:$:'"*
MF,W2O!:D 7_;!&C 7S#7\RJ:@0C"D;1"D?%R;!B$W= X"!:9Q%:9$T@&UTC;
M(7@>H<TT,TH&MV 0'#*)EM)P^."+V$O#Y"X5[V%29-'B'HYU:2X">N4UZ#;[
M?/29Q^JK8FZ?8T-<!.7C*T>T7KQN%-GJZ<8H1QXTMPF"W(5#L&OM?!J<W4F<
MA\'>JZUZA/E6>/E>Q#"5;]3I]S$>F9=?DU0,N1ZYE *A>L[\9IQ>13"M.NKT
M,</78^+&O>?EW?HQPV=>O@V-A#4+?!W4P3UFN/RS"/,%+C%)#'_-3!\TR/JA
MC'C=)THYU-"M0'8H#QMV(&K?-DC;X^1ANO,J*)23KP+(Y)5#^Z?IFE@@:3N4
M&J];"155<G)E@!R]A!B<U/8GL,^\'-9-5NQ=.(Z>2@Q.;BW'SB9^4?DDG.B!
MTX/I07N7.SG5:EP=/Y08]-3SD)2)PI,2^UZ,*M-#T";%]?095VH19^7([D6$
M&4O/DRS/2AZ? $QPYRWFY2ZM/RJU^_#LZ)2J<]_3:KW.4+U*9H%CWL"8X$;U
M4C*;G2TV;99 )EBA1'L6<_4[4%J\ KZ=L$_L)8ZE=BCGQ+,B@P4ZRR8^F%U5
M[0+-"9'H 7)A5FO<->5RQ5*+XU .E#*4^$?8IK2'2VU?E!4O?Y*:5'-%D,%D
M<MRD(F66YH@F/F:K%0!C4HC#E@M9D(P,&NO3I.X:'A<Y503%ZN> E5D2TVY7
M<!EXUB=+$Z*5U_*U%C@!> 3*R&@@B-H:NJ-#X>!;ZTT2O\#)='XAGO)'^#T:
M\TO6?';TC=G;CWYL+X4L'+W/9Z<=6FM+W@'G#(^0*@/NS,C> N;H/7]'1M5_
M%7&8I!?AVY7GEU7CU-85T1QM$5[[LY(2B6VE!L;IM7Y[3Y! J.JL.&1;% BO
M]=R":1TJ5B_M6_.,PI@^U[8SS?8M;0_KWA&O U0_^[=*&%S>Z[>/LJN):A('
MMX!G\R^8'"KS?'4.NX9?PMG)*ZV#BF^YAC2#S/RYO_RJQ^!%$IG"Y/24UQU^
M,]IDWA@];%?O_WGL)\M70,N0AFEZC^GR-7L*V0>FUC$OB[&??44G$%?I P;?
M6Z1 33/9RGKAG.)U)ZCCTD(#MB"Z2D'0U6O'*,G"^.5.Q/'"*,D3V0%G"J_8
M$#TYDIU AV\,B08>BJ=,_%F B.HP=&^159W07\K+K].(7!.,8\@I8$&K%.@W
M9OG$&Y%)(W.5+("'J58:(Q=>KO/8;[7#78O'O4N_)IE,"%P2#KC3!*WIM=,2
M)Q&OO5G&DX;1+2BN\@X,SFE'#VB^42^^#GKVFPB%=ZZ#_A_?G)[RN@(PX5#.
MO@H@[^P(S6+YM8[<O;8X>7BQK>*,.'(3H XF&<+=:KAF),N:XU&&UT6//<\*
M7*XR(W"OBO"-658+<Q*UJ+K.,,"C*,DW9MFO;0FD01'\#>,&&_[UXS=FCUM[
M-K=W)4%HQ_C"XC .Y3K.\K1 F%>>K\]&0W7!L!1F2D+1)V=; XS@G&&MF]4]
M;U"5[Y!>_9)><N,OH"QYV6"&?#?#2= _TK ZJ4.Z5BS9]M9SJ]3\-ZY/Y<W6
M 4. Q/LC5I5N=K1\DM]YZ3^\J!#M5P:C;Z&H>%F(+=8(&\2$<E@[X;I4CC(U
MP%K/L\=D!:;"3>F!IAL*@-=-J@WE9N (=JV=;8SW@LL/D?IA)N",Z]<$LOQI
M=F2[0>B^AY+E%63I8M<P1$WHTS"A=\1J<5O@Z7AYWE);"LKV")G9U8W%^J!!
M11#)RG%WY875+K;11XI#25,$RLMI9T,?#8A@CDL86QGK^XR:I^-LOR4BY'4I
M8D,9B8=@;*0>NAOQXD570FIV[;4!"7P9M:ME%PG!):N8M',O>UVZ#\G8T4T3
M!,8L9-QBTNT#(1ABY?VJK>Z5N7XOWE:'-X,M;J\/0A^OA\L &4'J ?FTLAPC
MJS Y^.^OH?^Z:X O[7--IK!V'T99'YP_S!H^D?EEI*]5'[Q(X(.LRP\\W3UZ
M'[!8(MCSHDQZH[I<4_=$:8WZ&&R&C]"&8=QC[<-6?3\M8,2A]X2O\4.1724I
MAO&$68:/\RX_\%Y2@%1 'DH+S_)+(,V341H9[? 2VN/,_39L'M/U$X[+]S(J
MD&?FTKUAZG.24ETPH2WA,1X$BS9QJ*0Y8#AA=M&AEC:Q>M/0#B51YRY$?:8H
MH@?*A=GI@&;/C.YM9(>2<U."4AM+3O8!V7 [$RI)-"9^"QZ3W)JNJ==G$)*U
M1YDPN['0T&=$^A8XUHDYAW]M]/4K[SFO7^D-\+'.V=G_NZ&O7/VW"@KEY*L
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M0-TXA;>WG$9U3!UD9S6>0FK+4-\)-6]\M!CCXIA>=4^7S*Q[53?0P_&MB.;
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M+JC4[::MDB,Z.,6O4P4:G.!WV@*^?B)B#'=@U7RB3N]R2!Q3):)[X3K.\K1
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MC1Z8"^"O$*>--)C>Y@R@%Z,+<6H9*$'E>QE!H$0YBQL$2GPF_2T=O$K9JQE
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M4E-$\&H(E&%,0 \$,[LXZ8'I+F_YJ?.D>$H+P(($GUU,ZWX0]9V*MB, XN1
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M$[Z+O1'?&.2B,^D^^W[")!O==;SD7#YB\YQT)A^:??_2R[%?F9G.G!_"X&@
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MW6:]]M+M<M4(:Q4])#DO3DK\".)T1=\7]8*8VYSS73[T/(FBY!OX6BZ3M+0
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MC!A';K/N[@,KRA-PY2W6BT%I=0&8<_?8:&)$J,0.#&-.-PE!TO8P\J-PV"@
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M>.L,VM<?])2FM4 Y#NUHM68,V!-O."%/7L:"6_;"X@VK#?4MKK&:_1SMA!J
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MFW/W+^OOD2Y\T82)/Z-A)*I<3T,T$<E"F<W(JA\Y241S\CLG^]_8P&D^N4/
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MG(-_A;24MQ8LZPBV PKFWV<81RO,=7 '53L/PC5D?8=KB)<8M?$[SXO6&/+
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MN<H1$C:CX2RV^X.GKSR/+*_>U?(GY0>0&&0'0Q6U0T6[0S5\)<R':M8P.3/
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MRTK8URZSSCXP1[JR+#8BTD \1EM^NM=F#$-S5KR,0@RU?E%M<&(0FAB"3L<
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MJ(I_M 38:F3.FDAUK5CS6713%V"T6X^:Q_%@2H]5 2:%@H(R1_F W7#RI*(
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M]O9: U88N3^P L4;@K4F$^9F"%;2DOI?G)<2-&IC%;;[('O'%]5D@M2A%EK
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M=IA:N>Z-KN*R.>.^R=(/HDY^<>!H00@-'O2T;L3T"LKPX>QJ$K,Y<5WL8/:
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MXILT+P:[-9D=89:6C%KD%"F97(3JLUX\O6$V2>#46Z=V*V>OG#K ]A^FO$%
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MU+=?E&*UK4&_:"4I0\QA3^VIXY>F_:RIN2]*GS6XXR=(+AFQ G^#6? *6Y'
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M  +WWD6T+@6ZO5IR@XS2+A9GC4ODJL$M0/(9DG9Y.-ZC/2I@)):U?CM'TC8
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M:E]OJ\PA=@O2"@%8($OH>ML\N=I-_=F=VVC80!@'.<W#VHP;K;<O<C_5? W
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M_P]02P$"% ,4    " #CB01;PF6ULZ\"   *#   $0              @ $
M    9#DT,C(Y-V1E>#(Q,2YH=&U02P$"% ,4    " #CB01;C)ONCN("  #&
M!@  $0              @ '> @  9#DT,C(Y-V1E>#(S,2YH=&U02P$"% ,4
M    " #CB01;U_$X+5X.  "100  $               @ 'O!0  9#DT,C(Y
M-V1E>#4Q+FAT;5!+ 0(4 Q0    ( ..)!%N6P>"<C@P  ,Y*   8
M      "  7L4  !D.30R,CDW9&5X9FEL:6YG9F5E<RYH=&U02P$"% ,4
M" #CB01;8SAUVM+H" "%M4\ #@              @ $_(0  9#DT,C(Y-V1S
M,2YH=&U02P$"% ,4    " #DB01;+8@O(2G1 P C200 $0
M@ $]"@D 9SDT,C(Y-V<Q-&LP-2YJ<&=02P$"% ,4    " #DB01;W4HV/35-
M 0 SQ@$ $0              @ &5VPP 9SDT,C(Y-V<Q-' P-BYJ<&=02P$"
M% ,4    " #DB01;YEZG0_9M 0 ([P$ $0              @ 'Y* X 9SDT
M,C(Y-V<Q-'0P-"YJ<&=02P$"% ,4    " #DB01;T*A7(<R9   1+P$ $0
M            @ $>EP\ 9SDT,C(Y-V<Q-64P."YJ<&=02P$"% ,4    " #D
MB01;;62PZQ3&  !?3@$ $0              @ $9,1  9SDT,C(Y-V<Q-6@P
M.2YJ<&=02P$"% ,4    " #DB01;,.:3$;J&  "W"@$ $0
M@ %<]Q  9SDT,C(Y-V<Q-6LP-RYJ<&=02P$"% ,4    " #DB01;;2_*<JVK
M 0 J.0( $0              @ %%?A$ 9SDT,C(Y-V<Q-7(P-BYJ<&=02P$"
M% ,4    " #DB01;63\"QBLQ @ <RP( $0              @ $A*A, 9SDT
M,C(Y-V<Q-70P,BYJ<&=02P$"% ,4    " #DB01;YTGO8%[V  #0@0$ $0
M            @ %[6Q4 9SDT,C(Y-V<Q-7DP-"YJ<&=02P$"% ,4    " #D
MB01;!AL_FVO*   <80$ $0              @ $(4A8 9SDT,C(Y-V<Q-7DP
M-BYJ<&=02P$"% ,4    " #DB01;Q&RR#?:B  #<' $ $0
M@ &B'!< 9SDT,C(Y-V<Q-F@P-2YJ<&=02P$"% ,4    " #DB01;NY&#\NE4
M 0 #\0$ $0              @ ''OQ< 9SDT,C(Y-V<Q-FLP,2YJ<&=02P$"
M% ,4    " #DB01;61]/V2]Y @#X'@, $0              @ '?%!D 9SDT
M,C(Y-V<W.&@S-2YJ<&=02P$"% ,4    " #DB01;H< 9450[ @!/WR0 $0
M            @ $]CAL <V-L>"TR,#(U,#@P,2YX<V102P4&     !, $P"P
)!   P,D=

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>d942297ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclx="http://www.scilexholding.com/20250801"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sclx-20250801.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_25_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_21_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="P10_08_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_11_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <context id="P04_30_2023To04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="P06_11_2024To06_11_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="P07_16_2024To07_16_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="P06_27_2023To06_27_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="P07_01_2023To07_01_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="P02_13_2023To02_13_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn06_18_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-06-18</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="PAsOn10_08_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:PublicWarrantsPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:Semnur2024StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PatentRightsAcquiredTechnologyAndAcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SemnurCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:GloperbaElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:GloperbaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CoveLaneMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:CoveLaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_HudsonBayMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sclx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EpoladermMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EpoladermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ProbudurMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ProbudurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EnveltaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EnveltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SeniorSubordinatedNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PurchasedRevenueLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="P06_11_2024To06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:InitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:InitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="PAsOn06_18_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-18</instant>
        </period>
    </context>
    <context id="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SatisfactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionsAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis_TrancheBNotesMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:InvestorAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2024_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P06_30_2024To06_30_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionAxis">sclx:RemainingDrawableBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:LongTermDebtTransactionAxis">sclx:PrincipalBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="P08_30_2024To08_30_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="PAsOn08_30_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="PAsOn10_11_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-11</instant>
        </period>
    </context>
    <context id="PAsOn10_11_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-11</instant>
        </period>
    </context>
    <context id="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FourthInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FiveInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SixInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:DebtPayableAxis">sclx:MonthlyBasisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="PAsOn09_20_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-20</instant>
        </period>
    </context>
    <context id="PAsOn09_20_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-20</instant>
        </period>
    </context>
    <context id="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-23</startDate>
            <endDate>2024-09-23</endDate>
        </period>
    </context>
    <context id="PAsOn09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-23</instant>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:OctoberCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-21</startDate>
            <endDate>2024-12-21</endDate>
        </period>
    </context>
    <context id="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:InitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <context id="PAsOn06_11_2024_SecondClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SecondClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <context id="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2024_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To12_31_2026_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To12_31_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-20</startDate>
            <endDate>2024-09-20</endDate>
        </period>
    </context>
    <context id="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-27</startDate>
            <endDate>2024-10-27</endDate>
        </period>
    </context>
    <context id="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-27</startDate>
            <endDate>2024-10-27</endDate>
        </period>
    </context>
    <context id="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-26</startDate>
            <endDate>2024-12-26</endDate>
        </period>
    </context>
    <context id="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-26</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-17</instant>
        </period>
    </context>
    <context id="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="P02_13_2023To02_13_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis_ThreeILpMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ThreeILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_OramedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_BpyLimitedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:BpyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_NomisBayLtdMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:NomisBayLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-02</instant>
        </period>
    </context>
    <context id="PAsOn01_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-21</instant>
        </period>
    </context>
    <context id="P02_22_2025To02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="P02_22_2025To02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2025_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ZTlidoRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-22</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_GloperbaRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:GloperbaRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2025_ElyxybRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ElyxybRestOfWorldLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:Gloperba-ElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-21</startDate>
            <endDate>2025-01-21</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SeriesOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:PublicWarrantsPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:Semnur2024StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PatentRightsAcquiredTechnologyAndAcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SemnurCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:GloperbaElyxybRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:OramedLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:RepresentativeWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ZTlidoRoyaltyMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDOFirmWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:February2024BDORepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PrivateWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RetainerSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuableUnderTrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PublicWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockBlockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:October2024PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:December2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:April2024RDOPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:October2024NoteholderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:DecemberRDOCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DecemberCommonWarrantsTwoPointFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:February2024BDOFirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:April2024RDOCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:DepositWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TrancheBNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PurchasedRevenueLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SpacWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:SpacWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_MinimumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_MaximumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_OramedMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:OramedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TrancheBNoteMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sclx:TrancheBNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="P09_01_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_17_2022To10_17_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:FirmWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P04_17_2025To04_17_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="P04_17_2025To04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexBioJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="PAsOn04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexBioJVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-17</instant>
        </period>
    </context>
    <context id="P04_03_2025To04_03_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-03</startDate>
            <endDate>2025-04-03</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:TreasuryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:FSFLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-10</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:ZTlidoRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Days">
        <measure>sclx:Days</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2025To03_31_2025" id="ixv-38807">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2025To03_31_2025" id="ixv-38808">0001820190</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden145656811">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2025To03_31_2025" id="hidden145656812">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2025To03_31_2025" id="ixv-44187">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2025To03_31_2025" id="ixv-44188">Scilex Holding Company</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2025To03_31_2025" id="ixv-44189">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2025To03_31_2025" id="ixv-44190">2836</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2025To03_31_2025" id="ixv-44191">92-1062542</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2025To03_31_2025" id="ixv-44192">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2025To03_31_2025" id="ixv-44193">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2025To03_31_2025" id="ixv-44194">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2025To03_31_2025" id="ixv-44195">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2025To03_31_2025" id="ixv-44196">516-4310</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-44197">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-44198">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-44199">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-44200">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2025To03_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-44201">516-4310</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2025To03_31_2025" id="ixv-44202">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2025To03_31_2025" id="ixv-44203">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2025To03_31_2025" id="ixv-44204">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2025To03_31_2025" id="ixv-44205">true</dei:EntityExTransitionPeriod>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2024" id="hidden145657738">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2023" id="hidden145657739">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn03_31_2025" id="hidden145657740">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2024" id="hidden145657741">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="PAsOn03_31_2025" id="hidden145659148">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2024" id="hidden145659460">http://fasb.org/us-gaap/2024#DerivativeLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44216"
      unitRef="Unit_USD">3272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44217"
      unitRef="Unit_USD">3921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44218"
      unitRef="Unit_USD">26442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44219"
      unitRef="Unit_USD">34597000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44220"
      unitRef="Unit_USD">2436000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44221"
      unitRef="Unit_USD">4214000</us-gaap:InventoryNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44222"
      unitRef="Unit_USD">9397000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44223"
      unitRef="Unit_USD">4049000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44224"
      unitRef="Unit_USD">41547000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44225"
      unitRef="Unit_USD">46781000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44226"
      unitRef="Unit_USD">708000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44227"
      unitRef="Unit_USD">722000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44228"
      unitRef="Unit_USD">2225000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44229"
      unitRef="Unit_USD">2943000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44230"
      unitRef="Unit_USD">32453000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44231"
      unitRef="Unit_USD">36485000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Investments
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44232"
      unitRef="Unit_USD">2420000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44233"
      unitRef="Unit_USD">0</us-gaap:Investments>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44234"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44235"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44236"
      unitRef="Unit_USD">119000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44237"
      unitRef="Unit_USD">897000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44238"
      unitRef="Unit_USD">92953000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44239"
      unitRef="Unit_USD">101309000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44240"
      unitRef="Unit_USD">52620000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44241"
      unitRef="Unit_USD">40954000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44242"
      unitRef="Unit_USD">1505000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44243"
      unitRef="Unit_USD">2681000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44244"
      unitRef="Unit_USD">162517000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44245"
      unitRef="Unit_USD">89658000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44246"
      unitRef="Unit_USD">2841000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44247"
      unitRef="Unit_USD">7408000</sclx:AccruedExpenses>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44248"
      unitRef="Unit_USD">447000</sclx:CurrentPortionOfDeferredConsideration>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44249"
      unitRef="Unit_USD">491000</sclx:CurrentPortionOfDeferredConsideration>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44250"
      unitRef="Unit_USD">34876000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44251"
      unitRef="Unit_USD">108429000</us-gaap:DebtCurrent>
    <sclx:PurchasedRevenueLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44252"
      unitRef="Unit_USD">4115000</sclx:PurchasedRevenueLiabilityCurrent>
    <sclx:PurchasedRevenueLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44253"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44254"
      unitRef="Unit_USD">714000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44255"
      unitRef="Unit_USD">759000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44256"
      unitRef="Unit_USD">259635000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44257"
      unitRef="Unit_USD">250380000</us-gaap:LiabilitiesCurrent>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44258"
      unitRef="Unit_USD">2448000</sclx:LongTermPortionOfDeferredConsideration>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44259"
      unitRef="Unit_USD">2895000</sclx:LongTermPortionOfDeferredConsideration>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44260"
      unitRef="Unit_USD">845000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44261"
      unitRef="Unit_USD">17038000</us-gaap:OtherLongTermDebtNoncurrent>
    <sclx:PurchasedRevenueLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44262"
      unitRef="Unit_USD">2685000</sclx:PurchasedRevenueLiabilityNoncurrent>
    <sclx:PurchasedRevenueLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44263"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44264"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44265"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44266"
      unitRef="Unit_USD">1523000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44267"
      unitRef="Unit_USD">2237000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44268"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44269"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44270"
      unitRef="Unit_USD">285594000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44271"
      unitRef="Unit_USD">274247000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2024"
      id="ixv-44272"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-44273"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44274"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44275"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44276"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44277"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44278"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44279"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44280"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44281"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-44282"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-44283"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <sclx:PreferredStockDividendShares
      contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44284"
      unitRef="Unit_shares">5000000</sclx:PreferredStockDividendShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44285"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44286"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-44287"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-44288"
      unitRef="Unit_USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-44289"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44290"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44291"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44292"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44293"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <sclx:CommonStocksSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44294"
      unitRef="Unit_shares">6951622</sclx:CommonStocksSharesIssued>
    <sclx:CommonStocksSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44295"
      unitRef="Unit_shares">5493359</sclx:CommonStocksSharesOutstanding>
    <sclx:CommonStocksSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44296"
      unitRef="Unit_shares">4573693</sclx:CommonStocksSharesIssued>
    <sclx:CommonStocksSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44297"
      unitRef="Unit_shares">2857448</sclx:CommonStocksSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44298"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44299"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <sclx:AdditionalPaidsInCapitals
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44300"
      unitRef="Unit_USD">454614000</sclx:AdditionalPaidsInCapitals>
    <sclx:AdditionalPaidsInCapitals
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44301"
      unitRef="Unit_USD">407828000</sclx:AdditionalPaidsInCapitals>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44302"
      unitRef="Unit_USD">6317000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44303"
      unitRef="Unit_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44304"
      unitRef="Unit_USD">-563052000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44305"
      unitRef="Unit_USD">-490245000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-44306"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44307"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44308"
      unitRef="Unit_USD">90522000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44309"
      unitRef="Unit_USD">90522000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44310"
      unitRef="Unit_USD">-192641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44311"
      unitRef="Unit_USD">-172938000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44312"
      unitRef="Unit_USD">92953000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44313"
      unitRef="Unit_USD">101309000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44314"
      unitRef="Unit_USD">56590000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44315"
      unitRef="Unit_USD">46743000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44316"
      unitRef="Unit_USD">16689000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44317"
      unitRef="Unit_USD">15681000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44318"
      unitRef="Unit_USD">9641000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44319"
      unitRef="Unit_USD">12746000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44320"
      unitRef="Unit_USD">119016000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44321"
      unitRef="Unit_USD">119641000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44322"
      unitRef="Unit_USD">4031000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44323"
      unitRef="Unit_USD">4106000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44324"
      unitRef="Unit_USD">9391000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44325"
      unitRef="Unit_USD">0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44326"
      unitRef="Unit_USD">139986000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44327"
      unitRef="Unit_USD">152174000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44328"
      unitRef="Unit_USD">-83396000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44329"
      unitRef="Unit_USD">-105431000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44330"
      unitRef="Unit_USD">17378000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44331"
      unitRef="Unit_USD">-512000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44332"
      unitRef="Unit_USD">4782000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44333"
      unitRef="Unit_USD">7189000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44334"
      unitRef="Unit_USD">1963000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44335"
      unitRef="Unit_USD">1068000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44336"
      unitRef="Unit_USD">-45000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44337"
      unitRef="Unit_USD">-118000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44338"
      unitRef="Unit_USD">10588000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44339"
      unitRef="Unit_USD">-8887000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44340"
      unitRef="Unit_USD">-72808000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44341"
      unitRef="Unit_USD">-114318000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44342"
      unitRef="Unit_USD">-1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44343"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44344"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44345"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44346"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44347"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44348"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44349"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-44350"
      unitRef="Unit_USD_per_Share">-7.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-44351"
      unitRef="Unit_USD_per_Share">-44.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-44352"
      unitRef="Unit_USD_per_Share">-8.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-44353"
      unitRef="Unit_USD_per_Share">-44.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44354"
      unitRef="Unit_shares">10061000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44355"
      unitRef="Unit_shares">3722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44356"
      unitRef="Unit_shares">10145000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44357"
      unitRef="Unit_shares">3722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44358"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44359"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44360"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44361"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44362"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44363"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44364"
      unitRef="Unit_USD">6317000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44365"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44366"
      unitRef="Unit_USD">-6317000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44367"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44368"
      unitRef="Unit_USD">-66490000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44369"
      unitRef="Unit_USD">-114331000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44370"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44371"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44372"
      unitRef="Unit_shares">4038000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44373"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44374"
      unitRef="Unit_USD">412149000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44375"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44376"
      unitRef="Unit_USD">-375914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44377"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44378"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-44379"
      unitRef="Unit_USD">36239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44380"
      unitRef="Unit_shares">379000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44381"
      unitRef="Unit_USD">0</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44382"
      unitRef="Unit_USD">34258000</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44383"
      unitRef="Unit_USD">34258000</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:DisbursementOfFundsToSorrentoAmount
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44384"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFundsToSorrentoAmount>
    <sclx:DisbursementOfFundsToSorrentoAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44385"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFundsToSorrentoAmount>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44386"
      unitRef="Unit_USD">-3000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44387"
      unitRef="Unit_USD">-53196000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares
      contextRef="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44388"
      unitRef="Unit_shares">-1716000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44389"
      unitRef="Unit_USD">-90522000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44390"
      unitRef="Unit_USD">-143721000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:IssuanceOfPennyWarrants
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44391"
      unitRef="Unit_USD">10401000</sclx:IssuanceOfPennyWarrants>
    <sclx:IssuanceOfPennyWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44392"
      unitRef="Unit_USD">10401000</sclx:IssuanceOfPennyWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44393"
      unitRef="Unit_shares">14000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44394"
      unitRef="Unit_USD">750000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44395"
      unitRef="Unit_USD">750000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44396"
      unitRef="Unit_shares">18000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44397"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44398"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue>
    <sclx:RetainerSharesIssued
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44399"
      unitRef="Unit_shares">114000</sclx:RetainerSharesIssued>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44400"
      unitRef="Unit_USD">0</sclx:RetainerSharesIssuedValue>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44401"
      unitRef="Unit_USD">0</sclx:RetainerSharesIssuedValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44402"
      unitRef="Unit_shares">1000</sclx:IssuanceOfCommonStockUponWarrantsExerciseShares>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44403"
      unitRef="Unit_USD">521000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44404"
      unitRef="Unit_USD">521000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44405"
      unitRef="Unit_shares">10000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44406"
      unitRef="Unit_USD">614000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44407"
      unitRef="Unit_USD">614000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44408"
      unitRef="Unit_USD">14596000</sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation>
    <sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44409"
      unitRef="Unit_USD">14596000</sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44410"
      unitRef="Unit_USD">-114331000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44411"
      unitRef="Unit_USD">-114331000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44412"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44413"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44414"
      unitRef="Unit_shares">4574000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44415"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44416"
      unitRef="Unit_USD">407828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44417"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44418"
      unitRef="Unit_USD">-490245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44419"
      unitRef="Unit_shares">-1716000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44420"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44421"
      unitRef="Unit_USD">-172938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44422"
      unitRef="Unit_shares">81000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44423"
      unitRef="Unit_USD">2671000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44424"
      unitRef="Unit_USD">2671000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue>
    <sclx:SharesIssuedUnderBoughtDealOfferingShare
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44425"
      unitRef="Unit_shares">168000</sclx:SharesIssuedUnderBoughtDealOfferingShare>
    <sclx:SharesIssuedUnderBoughtDealOfferingValue
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44426"
      unitRef="Unit_USD">0</sclx:SharesIssuedUnderBoughtDealOfferingValue>
    <sclx:SharesIssuedUnderBoughtDealOfferingValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44427"
      unitRef="Unit_USD">3769000</sclx:SharesIssuedUnderBoughtDealOfferingValue>
    <sclx:SharesIssuedUnderBoughtDealOfferingValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44428"
      unitRef="Unit_USD">3769000</sclx:SharesIssuedUnderBoughtDealOfferingValue>
    <sclx:SharesIssuedDuringPeriodSharesRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44429"
      unitRef="Unit_shares">429000</sclx:SharesIssuedDuringPeriodSharesRegisteredDirectOffering>
    <sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44430"
      unitRef="Unit_USD">0</sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering>
    <sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44431"
      unitRef="Unit_USD">5919000</sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering>
    <sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44432"
      unitRef="Unit_USD">5919000</sclx:SharesIssuedDuringPeriodValuesRegisteredDirectOffering>
    <sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44433"
      unitRef="Unit_USD">956000</sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering>
    <sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44434"
      unitRef="Unit_USD">956000</sclx:ValueIssuedUnderPlacementAgentWarrantsIssuedInConnectionWithRegisteredDirectOfferingAndRepresentativeWarrantsIssuedInConnectionWithBoughtDealOffering>
    <sclx:RetainerSharesIssued
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44435"
      unitRef="Unit_shares">286000</sclx:RetainerSharesIssued>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44436"
      unitRef="Unit_USD">0</sclx:RetainerSharesIssuedValue>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44437"
      unitRef="Unit_USD">0</sclx:RetainerSharesIssuedValue>
    <sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44438"
      unitRef="Unit_USD">310000</sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter>
    <sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44439"
      unitRef="Unit_USD">310000</sclx:FeeWarrantIssuedInConnectionWithTheCommitmentLetter>
    <sclx:RepurchaseOfWarrants
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44440"
      unitRef="Unit_USD">-298000</sclx:RepurchaseOfWarrants>
    <sclx:RepurchaseOfWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44441"
      unitRef="Unit_USD">-298000</sclx:RepurchaseOfWarrants>
    <sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44442"
      unitRef="Unit_USD">345000</sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement>
    <sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44443"
      unitRef="Unit_USD">345000</sclx:CommonStockIssuableUnderSponsorInterestPurchaseAgreement>
    <sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44444"
      unitRef="Unit_shares">63000</sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrantsShares>
    <sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44445"
      unitRef="Unit_USD">3792000</sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants>
    <sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44446"
      unitRef="Unit_USD">3792000</sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants>
    <sclx:ConversionOfTrancheBNotesIntoCommonStockShares
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44447"
      unitRef="Unit_shares">263000</sclx:ConversionOfTrancheBNotesIntoCommonStockShares>
    <sclx:ConversionOfTrancheBNotesIntoCommonStock
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44448"
      unitRef="Unit_USD">0</sclx:ConversionOfTrancheBNotesIntoCommonStock>
    <sclx:ConversionOfTrancheBNotesIntoCommonStock
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44449"
      unitRef="Unit_USD">9256000</sclx:ConversionOfTrancheBNotesIntoCommonStock>
    <sclx:ConversionOfTrancheBNotesIntoCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44450"
      unitRef="Unit_USD">9256000</sclx:ConversionOfTrancheBNotesIntoCommonStock>
    <sclx:SharesIssuedUnderDecemberRegisteredDirectOfferingShares
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44451"
      unitRef="Unit_shares">753000</sclx:SharesIssuedUnderDecemberRegisteredDirectOfferingShares>
    <sclx:SharesIssuedUnderDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44452"
      unitRef="Unit_USD">0</sclx:SharesIssuedUnderDecemberRegisteredDirectOffering>
    <sclx:SharesIssuedUnderDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44453"
      unitRef="Unit_USD">328000</sclx:SharesIssuedUnderDecemberRegisteredDirectOffering>
    <sclx:SharesIssuedUnderDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44454"
      unitRef="Unit_USD">328000</sclx:SharesIssuedUnderDecemberRegisteredDirectOffering>
    <sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44455"
      unitRef="Unit_USD">1265000</sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering>
    <sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44456"
      unitRef="Unit_USD">1265000</sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering>
    <sclx:StockDividendDeclaredNotYetDistributedShares
      contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44457"
      unitRef="Unit_shares">5000000</sclx:StockDividendDeclaredNotYetDistributedShares>
    <sclx:StockDividendDeclaredNotYetDistributed
      contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44458"
      unitRef="Unit_USD">1000</sclx:StockDividendDeclaredNotYetDistributed>
    <sclx:StockDividendDeclaredNotYetDistributed
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44459"
      unitRef="Unit_USD">-1000</sclx:StockDividendDeclaredNotYetDistributed>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseShares
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44460"
      unitRef="Unit_shares">321000</sclx:IssuanceOfCommonStockUponWarrantsExerciseShares>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44461"
      unitRef="Unit_USD">0</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44462"
      unitRef="Unit_USD">2311000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44463"
      unitRef="Unit_USD">2311000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44464"
      unitRef="Unit_shares">10000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44465"
      unitRef="Unit_USD">246000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44466"
      unitRef="Unit_USD">246000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44467"
      unitRef="Unit_shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44468"
      unitRef="Unit_USD">227000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44469"
      unitRef="Unit_USD">227000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44470"
      unitRef="Unit_USD">15690000</sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation>
    <sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44471"
      unitRef="Unit_USD">15690000</sclx:AdjustmentOfAdditionalPaidInCapitalOfShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2024To12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44472"
      unitRef="Unit_USD">-6317000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44473"
      unitRef="Unit_USD">-6317000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44474"
      unitRef="Unit_USD">-72807000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44475"
      unitRef="Unit_USD">-72807000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44476"
      unitRef="Unit_shares">34057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44477"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44478"
      unitRef="Unit_shares">6952000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44479"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44480"
      unitRef="Unit_USD">454614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44481"
      unitRef="Unit_USD">6317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44482"
      unitRef="Unit_USD">-563052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-44483"
      unitRef="Unit_shares">-1716000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_TreasuryShareMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-44484"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44485"
      unitRef="Unit_USD">-192641000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44486"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44487"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44488"
      unitRef="Unit_USD">4046000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44489"
      unitRef="Unit_USD">4146000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44490"
      unitRef="Unit_USD">316000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44491"
      unitRef="Unit_USD">65000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44492"
      unitRef="Unit_USD">718000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44493"
      unitRef="Unit_USD">507000</sclx:NonCashOperatingLeaseCost>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44494"
      unitRef="Unit_USD">15689000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44495"
      unitRef="Unit_USD">14596000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44496"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44497"
      unitRef="Unit_USD">750000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44498"
      unitRef="Unit_USD">17378000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44499"
      unitRef="Unit_USD">-512000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44500"
      unitRef="Unit_USD">17297000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44501"
      unitRef="Unit_USD">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44502"
      unitRef="Unit_USD">4782000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44503"
      unitRef="Unit_USD">7189000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:AllowancesForCreditLosses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44504"
      unitRef="Unit_USD">1186000</sclx:AllowancesForCreditLosses>
    <sclx:AllowancesForCreditLosses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44505"
      unitRef="Unit_USD">0</sclx:AllowancesForCreditLosses>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44506"
      unitRef="Unit_USD">661000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44507"
      unitRef="Unit_USD">57000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44508"
      unitRef="Unit_USD">6267000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44509"
      unitRef="Unit_USD">13361000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44510"
      unitRef="Unit_USD">-1462000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44511"
      unitRef="Unit_USD">2838000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44512"
      unitRef="Unit_USD">479000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44513"
      unitRef="Unit_USD">441000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44514"
      unitRef="Unit_USD">30000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44515"
      unitRef="Unit_USD">-855000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44516"
      unitRef="Unit_USD">7419000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44517"
      unitRef="Unit_USD">19880000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44518"
      unitRef="Unit_USD">-1176000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44519"
      unitRef="Unit_USD">1327000</sclx:IncreaseDecreaseInAccruedPayroll>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44520"
      unitRef="Unit_USD">-8167000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44521"
      unitRef="Unit_USD">2310000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44522"
      unitRef="Unit_USD">72859000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44523"
      unitRef="Unit_USD">58765000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44524"
      unitRef="Unit_USD">-758000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44525"
      unitRef="Unit_USD">-711000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44526"
      unitRef="Unit_USD">-24000</sclx:OtherLongTermLiabilities>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44527"
      unitRef="Unit_USD">16000</sclx:OtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44528"
      unitRef="Unit_USD">19349000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44529"
      unitRef="Unit_USD">-20707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44530"
      unitRef="Unit_USD">600000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44531"
      unitRef="Unit_USD">300000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:PurchaseOfEquitySecurities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44532"
      unitRef="Unit_USD">2000000</sclx:PurchaseOfEquitySecurities>
    <sclx:PurchaseOfEquitySecurities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44533"
      unitRef="Unit_USD">0</sclx:PurchaseOfEquitySecurities>
    <sclx:PurchaseOfConvertiblePromissoryNote
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44534"
      unitRef="Unit_USD">75000</sclx:PurchaseOfConvertiblePromissoryNote>
    <sclx:PurchaseOfConvertiblePromissoryNote
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44535"
      unitRef="Unit_USD">0</sclx:PurchaseOfConvertiblePromissoryNote>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44536"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44537"
      unitRef="Unit_USD">30000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44538"
      unitRef="Unit_USD">-2675000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44539"
      unitRef="Unit_USD">-330000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44540"
      unitRef="Unit_USD">-2671000</sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement>
    <sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44541"
      unitRef="Unit_USD">-35458000</sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44542"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44543"
      unitRef="Unit_USD">24000000</us-gaap:ProceedsFromConvertibleDebt>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44544"
      unitRef="Unit_USD">95438000</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44545"
      unitRef="Unit_USD">86354000</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:ProceedsFromIssuanceOfFsfDeposit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44546"
      unitRef="Unit_USD">10000000</sclx:ProceedsFromIssuanceOfFsfDeposit>
    <sclx:ProceedsFromIssuanceOfFsfDeposit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44547"
      unitRef="Unit_USD">0</sclx:ProceedsFromIssuanceOfFsfDeposit>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44548"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44549"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44550"
      unitRef="Unit_USD">112791000</sclx:RepaymentOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44551"
      unitRef="Unit_USD">69001000</sclx:RepaymentOfRevolvingFacility>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44552"
      unitRef="Unit_USD">64200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44553"
      unitRef="Unit_USD">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44554"
      unitRef="Unit_USD">300000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44555"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44556"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44557"
      unitRef="Unit_USD">1372000</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44558"
      unitRef="Unit_USD">4375000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44559"
      unitRef="Unit_USD">15625000</us-gaap:RepaymentsOfConvertibleDebt>
    <sclx:RepaymentOfDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44560"
      unitRef="Unit_USD">3283000</sclx:RepaymentOfDebt>
    <sclx:RepaymentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44561"
      unitRef="Unit_USD">0</sclx:RepaymentOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44562"
      unitRef="Unit_USD">4172000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44563"
      unitRef="Unit_USD">380000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <sclx:DisbursementOfFunds
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44564"
      unitRef="Unit_USD">0</sclx:DisbursementOfFunds>
    <sclx:DisbursementOfFunds
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44565"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFunds>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44566"
      unitRef="Unit_USD">0</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44567"
      unitRef="Unit_USD">-10000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44568"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44569"
      unitRef="Unit_USD">1987000</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:ExciseTaxPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44570"
      unitRef="Unit_USD">450000</sclx:ExciseTaxPaidInConnectionWithShareRepurchase>
    <sclx:ExciseTaxPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44571"
      unitRef="Unit_USD">0</sclx:ExciseTaxPaidInConnectionWithShareRepurchase>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44572"
      unitRef="Unit_USD">41967000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44573"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44574"
      unitRef="Unit_USD">4370000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44575"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44576"
      unitRef="Unit_USD">1379000</sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger>
    <sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44577"
      unitRef="Unit_USD">0</sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44578"
      unitRef="Unit_USD">2113000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44579"
      unitRef="Unit_USD">1135000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44580"
      unitRef="Unit_USD">-18131000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44581"
      unitRef="Unit_USD">23582000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44582"
      unitRef="Unit_USD">-1457000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44583"
      unitRef="Unit_USD">2545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44584"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-44585"
      unitRef="Unit_USD">2184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44586"
      unitRef="Unit_USD">3272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44587"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestIncomeOperatingPaidInCash
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44588"
      unitRef="Unit_USD">1561000</us-gaap:InterestIncomeOperatingPaidInCash>
    <us-gaap:InterestIncomeOperatingPaidInCash
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44589"
      unitRef="Unit_USD">1426000</us-gaap:InterestIncomeOperatingPaidInCash>
    <us-gaap:StockIssued1
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44590"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44591"
      unitRef="Unit_USD">1869000</us-gaap:StockIssued1>
    <sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44592"
      unitRef="Unit_USD">1845000</sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses>
    <sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44593"
      unitRef="Unit_USD">0</sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses>
    <sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44594"
      unitRef="Unit_USD">610000</sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter>
    <sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44595"
      unitRef="Unit_USD">0</sclx:FeeWarrantsIssuedAndExercisedInConnectionWithTheFSFCommitmentLetter>
    <sclx:SettlementOfFSFDeposit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44596"
      unitRef="Unit_USD">13000000</sclx:SettlementOfFSFDeposit>
    <sclx:SettlementOfFSFDeposit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44597"
      unitRef="Unit_USD">0</sclx:SettlementOfFSFDeposit>
    <sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44598"
      unitRef="Unit_USD">4602000</sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable>
    <sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44599"
      unitRef="Unit_USD">0</sclx:DeferredTransactionCostsRelatedToSemnurMergerIncludedInAccruedExpensesAndAccountPayable>
    <sclx:ConversionOfOramedNoteIntoTrancheBNotes
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44600"
      unitRef="Unit_USD">25000000</sclx:ConversionOfOramedNoteIntoTrancheBNotes>
    <sclx:ConversionOfOramedNoteIntoTrancheBNotes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44601"
      unitRef="Unit_USD">0</sclx:ConversionOfOramedNoteIntoTrancheBNotes>
    <sclx:ConversionOfTrancheBNotesIntoCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44602"
      unitRef="Unit_USD">9256000</sclx:ConversionOfTrancheBNotesIntoCommonStock>
    <sclx:ConversionOfTrancheBNotesIntoCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44603"
      unitRef="Unit_USD">0</sclx:ConversionOfTrancheBNotesIntoCommonStock>
    <sclx:DebtIssuanceCostsIncludedInAccruedExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44604"
      unitRef="Unit_USD">3063000</sclx:DebtIssuanceCostsIncludedInAccruedExpenses>
    <sclx:DebtIssuanceCostsIncludedInAccruedExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44605"
      unitRef="Unit_USD">0</sclx:DebtIssuanceCostsIncludedInAccruedExpenses>
    <sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44606"
      unitRef="Unit_USD">3792000</sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants>
    <sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44607"
      unitRef="Unit_USD">0</sclx:PlacementAgentSharesAndOctoberPlacementAgentWarrants>
    <sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44608"
      unitRef="Unit_USD">1265000</sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering>
    <sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44609"
      unitRef="Unit_USD">0</sclx:StockBlockWarrantsIssuedInConnectionWithDecemberRegisteredDirectOffering>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44610"
      unitRef="Unit_USD">0</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44611"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44612"
      unitRef="Unit_USD">0</sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification>
    <sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44613"
      unitRef="Unit_USD">2523000</sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification>
    <sclx:OramedNoteIssuanceAtFairValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44614"
      unitRef="Unit_USD">0</sclx:OramedNoteIssuanceAtFairValue>
    <sclx:OramedNoteIssuanceAtFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44615"
      unitRef="Unit_USD">106252000</sclx:OramedNoteIssuanceAtFairValue>
    <sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44616"
      unitRef="Unit_USD">0</sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase>
    <sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44617"
      unitRef="Unit_USD">26154000</sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase>
    <sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44618"
      unitRef="Unit_USD">860000</sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses>
    <sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44619"
      unitRef="Unit_USD">1310000</sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24090"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;1. Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Scilex Holding Company (&#x201c;Scilex&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is an innovative revenue-generating company focused on acquiring, developing and commercializing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#x201c;Legacy Scilex&#x201d;), Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;), Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#x201c;Business Combination&#x201d;) was closed in November 2022. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;12-hour&lt;/div&gt; administration period. In June 2022, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-licensed&lt;/div&gt; the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#x201c;GLOPERBA&#x201d;), a U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#x201c;U.S.&#x201d;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#x201c;ELYXYB&#x201d;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;FDA-approved,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;ready-to-use&lt;/div&gt;&lt;/div&gt; oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is currently developing three product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-102&lt;/div&gt; (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-102&#x201d;&lt;/div&gt; or &#x201c;SEMDEXA&#x201d;), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#x201c;LBP&#x201d;) in the third quarter of 2023, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; (4.5 mg, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-dose&lt;/div&gt; naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-104&#x201d;),&lt;/div&gt; a novel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-dose&lt;/div&gt; delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. Since inception, the Company has devoted substantially all of its efforts to the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-102,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104,&lt;/div&gt; and the commercialization of ZTlido. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sorrento Chapter 11 Filing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;), the Company&#x2019;s then-controlling stockholder, and Sorrento&#x2019;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#x201c;Scintilla&#x201d; and together with Sorrento, the &#x201c;Debtors&#x201d;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#x201c;Bankruptcy Code&#x201d;) in the United States Bankruptcy Court for the Southern District of Texas (the &#x201c;Bankruptcy Court&#x201d;). The Debtors&#x2019; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;23-90085&lt;/div&gt; (DRJ) (the &#x201c;Chapter 11 Cases&#x201d;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. Pursuant to that certain Stock Purchase Agreement that the Company entered into with Sorrento on September&#160;21, 2023 (the &#x201c;Sorrento SPA&#x201d;), the Company repurchased shares of its Common Stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), and Series A Preferred Stock, par value $0.0001 per share (the &#x201c;Series A Preferred Stock&#x201d;), from Sorrento. As a result, Sorrento no longer holds a majority of the voting power of the Company&#x2019;s outstanding capital stock entitled to vote. As of December&#160;31, 2024, the Company had a $3.2&#160;million receivable from Sorrento, which was fully reserved. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#x201c;CODM&#x201d;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the consolidated statements of operations and comprehensive loss. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the consolidated statements of operations and comprehensive loss and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the consolidated balance sheets. Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer and Supplier Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had three customers during the years ended December&#160;31, 2024 and 2023, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 86% and 85% of the Company&#x2019;s revenue for the years ended December&#160;31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December&#160;31, 2024 and 2023, three customers represented 95% and 91% of the Company&#x2019;s outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December&#160;31, 2024 and 2023, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#x201c;Itochu&#x201d;). In November 2023 and February 2024, respectively, the Company started purchasing ELYXYB and GLOPERBA inventories from its sole suppliers, Contract Pharmaceuticals Ltd Canada (CPL) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers and limits its credit exposure by setting credit limits. During the years ended December&#160;31, 2024 and 2023, the Company had allowances for expected credit losses of $1.2&#160;million and nil, respectively. &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, FSF Deposit and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/div&gt; - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt; - Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt; - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash as of December&#160;31, 2023 consisted of deposits placed in a segregated bank account as required under the terms of the eCapital Credit Agreement (as defined below), which is discussed further in Note 7. Restricted cash was recorded as other long-term assets within the Company&#x2019;s consolidated balance sheet. There is no restricted cash as of December&#160;31, 2024, because Scilex Pharma paid off the outstanding amount of all obligations and indebtedness under the eCapital Credit Agreement in October 2024, which agreement was terminated thereafter. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash equivalents were immaterial as of December&#160;31, 2024 and 2023. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of December&#160;31, 2024, the Company recorded $1.2&#160;million of allowances for credit losses on its accounts receivable. As of December&#160;31, 2023, the Company did not deem any allowances for expected credit losses on its accounts receivable necessary. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;on-hand&lt;/div&gt; inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-launch&lt;/div&gt; inventory costs prior to regulatory approval. As of December&#160;31, 2024 and 2023, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations and comprehensive loss unless there is an alternative future use. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Contingent Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statements of operations and comprehensive loss. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging&lt;/div&gt;&lt;/div&gt;, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;815-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contracts on an Entity&#x2019;s Own Equity,&lt;/div&gt;&lt;/div&gt; the Company determines how to account for warrants either assumed in connection with the Business Combination or issued under various financing arrangements. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. The Company records them in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. Warrants accounted for as liabilities are recorded at their estimated fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recognized in the consolidated statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Debentures, the Oramed Note, FSF Deposit and Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Convertible Debentures, the FSF Deposit, the Tranche B Notes (each as defined in Note 2 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&lt;/div&gt;&#x201d; below) and the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x201d; below) that were issued in March and April 2023, June 2024, October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. The weighted-average interest rates for the short-term loans, including these financial instruments, were 6.67% and 13.55% for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Purchased Revenue Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The purchased revenue liability is associated with the Purchase and Sale Agreement (the &#x201c;ZTlido Royalty Purchase Agreement&#x201d;) that the Company entered into in October 2024 (Note 7). The Company elected the fair value option to account for the purchased revenue liability (as described in Note 4 &#x201c;Fair Value Measurements&#x201d; below). The Company recorded the ZTlido Royalty Purchase Agreement at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the purchased revenue liability were expensed as incurred. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2024 and 2023, the Company maintained a full valuation allowance against its deferred tax assets. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from product sales is comprised of sales of ZTlido, ELYXYB and GLOPERBA. The Company&#x2019;s performance obligation with respect to sales of ZTlido, ELYXYB and GLOPERBA is satisfied at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;point-in-time,&lt;/div&gt;&lt;/div&gt; when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2024 and 2023 were not material. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns, special marketing programs and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates and Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prompt Payment Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-&lt;/div&gt; payment assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Co-payment&lt;/div&gt; assistance is presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#160;&#x2013; Stock&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt; vesting period. The Company accounts for forfeitures as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants, which consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with FASB ASC 260, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnings Per Share, &lt;/div&gt;&lt;/div&gt;Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share to the extent all vesting conditions or exercise contingencies are removed except for the passage of time. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt; (Topic 280), which requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted this ASU retrospectively on December&#160;31, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/div&gt;&lt;/div&gt;, which will require additional expense disclosures for all public entities. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#x2019;s definition of selling expenses. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&lt;/div&gt; is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-04,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/div&gt;&lt;/div&gt;, which clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-04&lt;/div&gt; is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06.&lt;/div&gt; The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      id="ixv-44620"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_21_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      id="ixv-44621"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ReceivablesNetCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44622"
      unitRef="Unit_USD">3200000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24139"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24146"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#x201c;CODM&#x201d;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the consolidated statements of operations and comprehensive loss. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the consolidated statements of operations and comprehensive loss and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the consolidated balance sheets. Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. &lt;/div&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2024To12_31_2024" id="ixv-24153"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2024To12_31_2024" id="ixv-24159"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer and Supplier Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had three customers during the years ended December&#160;31, 2024 and 2023, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 86% and 85% of the Company&#x2019;s revenue for the years ended December&#160;31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December&#160;31, 2024 and 2023, three customers represented 95% and 91% of the Company&#x2019;s outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December&#160;31, 2024 and 2023, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#x201c;Itochu&#x201d;). In November 2023 and February 2024, respectively, the Company started purchasing ELYXYB and GLOPERBA inventories from its sole suppliers, Contract Pharmaceuticals Ltd Canada (CPL) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers and limits its credit exposure by setting credit limits. During the years ended December&#160;31, 2024 and 2023, the Company had allowances for expected credit losses of $1.2&#160;million and nil, respectively. &lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="INF"
      id="ixv-44624"
      unitRef="Unit_pure">0.10</sclx:PercentageOfNetRevenueSoleDistributors>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="INF"
      id="ixv-44625"
      unitRef="Unit_pure">0.10</sclx:PercentageOfNetRevenueSoleDistributors>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44626"
      unitRef="Unit_pure">0.86</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44627"
      unitRef="Unit_pure">0.85</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44628"
      unitRef="Unit_pure">0.23</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44629"
      unitRef="Unit_pure">0.34</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44630"
      unitRef="Unit_pure">0.22</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44631"
      unitRef="Unit_pure">0.32</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44632"
      unitRef="Unit_pure">0.95</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44633"
      unitRef="Unit_pure">0.91</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44634"
      unitRef="Unit_pure">0.30</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To12_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44635"
      unitRef="Unit_pure">0.33</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44636"
      unitRef="Unit_pure">0.24</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-44637"
      unitRef="Unit_pure">0.36</sclx:ConcentrationRiskThresholdPercentage>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="P01_01_2024To12_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="-5"
      id="ixv-44638"
      unitRef="Unit_USD">1200000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="-6"
      id="ixv-44639"
      unitRef="Unit_USD">0</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24184"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, FSF Deposit and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/div&gt; - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt; - Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt; - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24204"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash as of December&#160;31, 2023 consisted of deposits placed in a segregated bank account as required under the terms of the eCapital Credit Agreement (as defined below), which is discussed further in Note 7. Restricted cash was recorded as other long-term assets within the Company&#x2019;s consolidated balance sheet. There is no restricted cash as of December&#160;31, 2024, because Scilex Pharma paid off the outstanding amount of all obligations and indebtedness under the eCapital Credit Agreement in October 2024, which agreement was terminated thereafter. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash equivalents were immaterial as of December&#160;31, 2024 and 2023. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24212"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44641"
      unitRef="Unit_USD">3272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44642"
      unitRef="Unit_USD">3921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44643"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44644"
      unitRef="Unit_USD">808000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44645"
      unitRef="Unit_USD">3272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44646"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24317"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of December&#160;31, 2024, the Company recorded $1.2&#160;million of allowances for credit losses on its accounts receivable. As of December&#160;31, 2023, the Company did not deem any allowances for expected credit losses on its accounts receivable necessary. &lt;/div&gt; </us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44648"
      unitRef="Unit_USD">1200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2023"
      decimals="-6"
      id="ixv-44649"
      unitRef="Unit_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24323"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;on-hand&lt;/div&gt; inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-launch&lt;/div&gt; inventory costs prior to regulatory approval. As of December&#160;31, 2024 and 2023, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt; </us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24333"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24339"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations and comprehensive loss unless there is an alternative future use. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24370">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24377">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Contingent Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statements of operations and comprehensive loss. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging&lt;/div&gt;&lt;/div&gt;, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. &lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24384">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;815-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contracts on an Entity&#x2019;s Own Equity,&lt;/div&gt;&lt;/div&gt; the Company determines how to account for warrants either assumed in connection with the Business Combination or issued under various financing arrangements. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. The Company records them in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. Warrants accounted for as liabilities are recorded at their estimated fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recognized in the consolidated statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. &lt;/div&gt;</sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24412">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24417">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Debentures, the Oramed Note, FSF Deposit and Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Convertible Debentures, the FSF Deposit, the Tranche B Notes (each as defined in Note 2 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&lt;/div&gt;&#x201d; below) and the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x201d; below) that were issued in March and April 2023, June 2024, October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. The weighted-average interest rates for the short-term loans, including these financial instruments, were 6.67% and 13.55% for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;</sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-44652"
      unitRef="Unit_pure">0.0667</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-44653"
      unitRef="Unit_pure">0.1355</us-gaap:DebtWeightedAverageInterestRate>
    <sclx:PurchasedRevenueLiabilityPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24426">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Purchased Revenue Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The purchased revenue liability is associated with the Purchase and Sale Agreement (the &#x201c;ZTlido Royalty Purchase Agreement&#x201d;) that the Company entered into in October 2024 (Note 7). The Company elected the fair value option to account for the purchased revenue liability (as described in Note 4 &#x201c;Fair Value Measurements&#x201d; below). The Company recorded the ZTlido Royalty Purchase Agreement at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the purchased revenue liability were expensed as incurred. &lt;/div&gt;</sclx:PurchasedRevenueLiabilityPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24431">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24436">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24463"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2024 and 2023, the Company maintained a full valuation allowance against its deferred tax assets. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24474"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24482"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from product sales is comprised of sales of ZTlido, ELYXYB and GLOPERBA. The Company&#x2019;s performance obligation with respect to sales of ZTlido, ELYXYB and GLOPERBA is satisfied at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;point-in-time,&lt;/div&gt;&lt;/div&gt; when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2024 and 2023 were not material. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns, special marketing programs and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates and Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prompt Payment Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. Service fees are presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Product returns are presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-&lt;/div&gt; payment assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Co-payment&lt;/div&gt; assistance is presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheets. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-24535"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#160;&#x2013; Stock&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt; vesting period. The Company accounts for forfeitures as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statements of operations and comprehensive loss. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <sclx:TreasuryStockPolicyTextblock contextRef="P01_01_2024To12_31_2024" id="ixv-24574"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt; </sclx:TreasuryStockPolicyTextblock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24580"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants, which consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with FASB ASC 260, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnings Per Share, &lt;/div&gt;&lt;/div&gt;Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share to the extent all vesting conditions or exercise contingencies are removed except for the passage of time. &lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24592"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt; (Topic 280), which requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted this ASU retrospectively on December&#160;31, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; (Topic 740): Improvements to Income Tax Disclosures. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/div&gt;&lt;/div&gt;, which will require additional expense disclosures for all public entities. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#x2019;s definition of selling expenses. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03&lt;/div&gt; is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-04,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/div&gt;&lt;/div&gt;, which clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-04&lt;/div&gt; is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06.&lt;/div&gt; The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-44657"
      unitRef="Unit_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24635"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2. Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#x201c;Original Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#x201c;A&amp;amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;amp;R Yorkville Purchase Agreement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#x201c;B. Riley Purchase Agreement&#x201d; and together with A&amp;amp;R Yorkville Purchase Agreement, the &#x201c;Standby Equity Purchase Agreements&#x201d;) with B. Riley Principal Capital II, LLC (&#x201c;B. Riley&#x201d;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#x2019;s and B. Riley&#x2019;s respective commitment to purchase shares of Common Stock at the Company&#x2019;s direction, the Company issued 7,142 commitment shares to each of Yorkville (the &#x201c;Yorkville Commitment Shares&#x201d;) and B. Riley (the &#x201c;B. Riley Commitment Shares&#x201d;). On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#x201c;Yorkville SPA&#x201d;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of up to $25.0&#160;million (the &#x201c;Convertible Debentures&#x201d;) for net cash proceeds of $24.0&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#x201c;eCapital Credit Agreement&#x201d;) with eCapital Healthcare Corp. (the &#x201c;Lender&#x201d;), pursuant to which the Lender made available loans (the &#x201c;Revolving Facility&#x201d;) in an aggregate principal amount of up to $30.0&#160;million (the &#x201c;Facility Cap&#x201d;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp;amp; Co. and H.C. Wainwright&#160;&amp;amp; Co., LLC (the &#x201c;Sales Agents&#x201d;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;ATM Offering&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201d;) shares of Common Stock up to $&lt;/div&gt;170.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million (the &#x201c;ATM Shares&#x201d;), through or to the Sales Agents as part of the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;ATM Offering&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. As of December&#160;31, 2024, the Company sold &lt;/div&gt;78,975&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $&lt;/div&gt;2.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million. As of December&#160;31, 2023, &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; sales of Common Stock had been made under the ATM Sales Agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#x201c;Commitment Letter&#x201d;) with FSF 33433 LLC (&#x201c;FSF Lender&#x201d;), pursuant to which FSF Lender committed to provide the Company a loan (the &#x201c;FSF Loan&#x201d;) in the aggregate amount of $100.0&#160;million (the &#x201c;Commitment Amount&#x201d;). The Commitment Amount shall be payable as follows: (i) $85.0&#160;million no later than the date that is 70 days following the date on which the Company receives the FSF Deposit (as defined below) (the &#x201c;Outside Date&#x201d; and the funding of the initial $85.0&#160;million, the &#x201c;Initial Closing&#x201d;) and (ii)&#160;the remaining $15.0&#160;million within 60 days following the Initial Closing (the funding of the second $15.0&#160;million, the &#x201c;Second Closing&#x201d;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable&lt;/div&gt; deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million (the &#x201c;FSF Deposit&#x201d; and the date on which such funds are fully received, the &#x201c;Deposit Date&#x201d;), which amount will be creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of 3,250,000 shares of the Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) (the &#x201c;Deposit Warrant&#x201d;), with an exercise price of $1.20 per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#x201c;Satisfaction Agreement&#x201d;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#x201c;Endeavor&#x201d;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#x2019;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#x201c;Additional Product&#x201d;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#x201c;Tranche B Securities Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;Tranche B Investors&#x201d;) and Oramed Pharmaceuticals Inc. (&#x201c;Oramed&#x201d;) (together with the Tranche B Investors, the &#x201c;Tranche B Noteholders&#x201d;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $50.0&#160;million (the &#x201c;Tranche B Notes&#x201d;) which notes will mature on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-year&lt;/div&gt; anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $38.15 per share (which was &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes). The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $22,500,000, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $22,500,000. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company&#x2019;s negative working capital was $218.1&#160;million, including cash and cash equivalents of approximately $3.3&#160;million. During the year ended December&#160;31, 2024, the Company had operating losses of $83.4&#160;million and cash flows from operations of $19.3&#160;million. The Company had an accumulated deficit of $563.1&#160;million as of December&#160;31, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the Tranche B Notes or otherwise) for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA is still in the early stages of commercialization. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. &lt;/div&gt; </us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44659"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="4"
      id="ixv-44660"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-44661"
      unitRef="Unit_shares">7142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:Convertibledebentureprincipalamount
      contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-44662"
      unitRef="Unit_USD">25000000</sclx:Convertibledebentureprincipalamount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2024_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-44663"
      unitRef="Unit_USD">24000000</us-gaap:ConvertibleDebt>
    <sclx:PrincipalLaonAmount
      contextRef="P06_27_2023To06_27_2023"
      decimals="-5"
      id="ixv-44664"
      unitRef="Unit_USD">30000000</sclx:PrincipalLaonAmount>
    <sclx:CommonStockIssuableValue
      contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-44666"
      unitRef="Unit_USD">170000000</sclx:CommonStockIssuableValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-44667"
      unitRef="Unit_shares">78975</us-gaap:CommonStockSharesIssued>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44668"
      unitRef="Unit_USD">2700000</sclx:ProceedsFromSaleOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-44669"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-44670"
      unitRef="Unit_USD">100000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <sclx:CommitmentAmountPayable
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-44671"
      unitRef="Unit_USD">85000000</sclx:CommitmentAmountPayable>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="P06_11_2024To06_11_2024" id="ixv-44672">P70D</us-gaap:LongtermPurchaseCommitmentPeriod>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-44673"
      unitRef="Unit_USD">85000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-44674"
      unitRef="Unit_USD">15000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:CompanyReceivesTheDepositPeriod contextRef="P06_11_2024To06_11_2024" id="ixv-44675">P60D</sclx:CompanyReceivesTheDepositPeriod>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-44676"
      unitRef="Unit_USD">15000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-44677"
      unitRef="Unit_USD">10000000</sclx:NonRefundableDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-44678"
      unitRef="Unit_USD">85000000</sclx:NonRefundableDepositAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_18_2024"
      decimals="0"
      id="ixv-44679"
      unitRef="Unit_shares">3250000</us-gaap:CommonStockSharesIssued>
    <sclx:ExercisePriceOfTheWarrants
      contextRef="PAsOn06_18_2024"
      decimals="2"
      id="ixv-44680"
      unitRef="Unit_USD_per_Share">1.2</sclx:ExercisePriceOfTheWarrants>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-44681"
      unitRef="Unit_USD">13200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LossContingencyAccrualProductLiabilityGross
      contextRef="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-44682"
      unitRef="Unit_USD">20000000</us-gaap:LossContingencyAccrualProductLiabilityGross>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44683"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis_TrancheBNotesMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-44684"
      unitRef="Unit_USD_per_Share">38.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44686"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-44687"
      unitRef="Unit_USD">22500000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:ReductionOfThePrincipalBalance
      contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-44688"
      unitRef="Unit_USD">22500000</sclx:ReductionOfThePrincipalBalance>
    <sclx:WorkingCapital
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44689"
      unitRef="Unit_USD">218100000</sclx:WorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44690"
      unitRef="Unit_USD">3300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44691"
      unitRef="Unit_USD">-83400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44692"
      unitRef="Unit_USD">19300000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44693"
      unitRef="Unit_USD">-563100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24698"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;3. Acquisitions and License Agreements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; Assets&#x201d;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets (the &#x201c;Sales Milestone Payment&#x201d;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2024 and December&#160;31, 2023, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;GLOPERBA License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;14, 2022 (the &#x201c;Original Signing Date&#x201d;), the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) (&#x201c;Romeg&#x201d;) for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-licensing&lt;/div&gt; of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#x201c;Romeg License Agreement&#x201d;). Under the Romeg License Agreement, &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; specified therein to (a)&#160;commercialize a pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d;) in the United States (including its territories) (the &#x201c;Romeg U.S. Territory&#x201d;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#x201c;Licensed Products&#x201d;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2)&#160;an exclusive license, with right to sublicense, to use the trademark &#x201c;GLOPERBA&#x201d; and logos, designs, translations, and modifications thereof (collectively, the &#x201c;Licensed Trademark&#x201d;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#x201c;Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory&#x201d;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory and (b)&#160;to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;up-front&lt;/div&gt; license fee of $2.0&#160;million, (2)&#160;upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (3)&#160;certain royalties in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single&lt;/div&gt; digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $150,000, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-single&lt;/div&gt; digit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory during the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory Royalty Term and (b)&#160;a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-creditable&lt;/div&gt; payment of $700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267&#160;shares of our Common Stock. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $0.6&#160;million and $0.3&#160;million, respectively. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2024 or December&#160;31, 2023. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ELYXYB Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In February 2023, the Company entered into an asset purchase agreement (the &#x201c;ELYXYB APA&#x201d;) with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Sellers&#x201d;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#x201c;ELYXYB Territory&#x201d;). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), dated August&#160;3, 2021 (the &#x201c;DRL APA&#x201d;), including an irrevocable, royalty-free, exclusive license to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $0.1&#160;million and $5.0&#160;thousand, respectively, which was recorded as accrued expenses under current liabilities on &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the consolidated balance sheets. During the years ended December&#160;31, 2024 and 2023, the Company made royalty payments in the amount of $0.3&#160;million and $26.0&#160;thousand, respectively. As of December&#160;31, 2024, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. &lt;/div&gt; </us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <sclx:AmountDueForNewDrugApplication
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-44694"
      unitRef="Unit_USD">3000000</sclx:AmountDueForNewDrugApplication>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-44695"
      unitRef="Unit_USD">20000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-44696"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-44697"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44699"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44700"
      unitRef="Unit_USD">13000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-44701"
      unitRef="Unit_USD">150000</us-gaap:PaymentsForRoyalties>
    <sclx:Non-RefundableNon-CreditablePayment
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-44702"
      unitRef="Unit_USD">700000</sclx:Non-RefundableNon-CreditablePayment>
    <sclx:TransferOfCommonStockShares
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-44703"
      unitRef="Unit_shares">22267</sclx:TransferOfCommonStockShares>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44704"
      unitRef="Unit_USD">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44705"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:Deferredconsiderationliabilities
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44706"
      unitRef="Unit_USD">3700000</sclx:Deferredconsiderationliabilities>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44707"
      unitRef="Unit_USD">600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-44708"
      unitRef="Unit_USD">300000</us-gaap:RoyaltyExpense>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-3"
      id="ixv-44709"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-3"
      id="ixv-44710"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sclx:AccruedRoyaltyPayables
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44711"
      unitRef="Unit_USD">100000</sclx:AccruedRoyaltyPayables>
    <sclx:AccruedRoyaltyPayables
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-44712"
      unitRef="Unit_USD">5000</sclx:AccruedRoyaltyPayables>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44714"
      unitRef="Unit_USD">300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-44715"
      unitRef="Unit_USD">26000</us-gaap:RoyaltyExpense>
    <sclx:PaymentToAcquireLicense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44716"
      unitRef="Unit_USD">0</sclx:PaymentToAcquireLicense>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24778"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;4. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tranche B Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Purchased Revenue Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden145657738;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden145657739;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9&#160;million (the &#x201c;Oramed Note&#x201d;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of such note recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2024 and 2023 was determined to be $12.2&#160;million and $104.1&#160;million, respectively, by applying a discount rate of 128.82% and 13.05%, respectively. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $3.6&#160;million and $2.8&#160;million in change in fair value of the Oramed Note, respectively. For the years ended December&#160;31, 2024 and 2023, the change in fair value due to instrument-specific credit risk recorded as a component of other comprehensive income was $6.3&#160;million and nil, respectively. During the year ended December&#160;31, 2024 the Company reclassified $5.0&#160;million from accumulated other comprehensive income to the consolidated statement of operations. This reclassification was related to the principal payments and partial conversion of the Oramed Note balance into the Tranche B Notes (see Note 7). &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;FSF Deposit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In June 2024, the Company received the FSF Deposit in the aggregate principal amount of $10.0&#160;million from FSF Lender (see Note 2 and Note 7). The Company elected the fair value option to account for the FSF Deposit with any changes in the fair value of the deposit recorded in the consolidated statements of operations and comprehensive loss. For the year ended December&#160;31, 2024, the Company recorded a loss of $4.7&#160;million in change in fair value of the FSF Deposit in the consolidated statement of operations. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. Upon the satisfaction of the FSF Deposit, the Deposit Warrant became a freestanding instrument under ASC 480 and was included in derivative liabilities on the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Tranche B Notes are measured at fair value on a recurring basis using the Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of December&#160;31, 2024, was determined to be $23.6&#160;million. For the year ended December&#160;31, 2024, the Company recorded a gain of $6.6&#160;million in change in fair value of the Tranche B Notes in the consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Purchased Revenue Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In October 2024, the Company entered into the ZTlido Royalty Purchase Agreement with certain institutional investors (collectively, the &#x201c;ZTlido Royalty Investors&#x201d;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The fair value as of December&#160;31, 2024, was determined to be $6.8&#160;million. For the year ended December&#160;31, 2024, the Company recorded a loss of $0.9&#160;million in change in fair value of the purchased revenue liability in the consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $25.0&#160;million (see Note 7). The Convertible Debentures were measured at fair value on a recurring basis using Level&#160;3 inputs. The Company used the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations and comprehensive loss. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the years ended December&#160;31, 2024 and 2023, the Company recorded a loss of $35.0&#160;thousand and a loss of $4.4&#160;million in change in fair value of the Convertible Debentures, respectively. The Company fully repaid the Convertible Debentures in March 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company recorded a gain of $17.4&#160;million for the year ended December&#160;31, 2024, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;as defined below). The Company recorded a loss of $&lt;/div&gt;0.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million for the year ended December&#160;31, 2023, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination (&#x201c;Private Warrants&#x201d;)&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;As &lt;/div&gt;of December&#160;31, 2024, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000 Private Warrants,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;3,803,447 February 2024 BDO Firm Warrants,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;15,000,000&#160;April 2024 RDO Common Warrants,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, &lt;/div&gt;&lt;/div&gt; 3,250,000 Deposit Warrant,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to &lt;/div&gt;&lt;/div&gt; 3,250,000&#160;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;shares of Common Stock, 7,500,000 &lt;/div&gt;&lt;/div&gt;October 2024 Noteholder Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 214,284 shares of Common Stock,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;and 57,512,958&#160;December 2024 RDO Common Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock&lt;/div&gt;&lt;/div&gt;. As of December&#160;31, 2024, the fair value of derivative warrant liabilities related to these warrants was $18.3&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 89%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;512&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants as part of December 2024 RDO&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancellation of Private Warrants as part of Oramed Letter Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrant amendment and exercise as part of December 2024 RDO&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Settlement of December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(17,378&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#x2019;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Private&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;February&lt;br/&gt;2024&#160;BDO&lt;br/&gt;Firm&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;April&#160;2024&lt;br/&gt;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Deposit&lt;br/&gt;Warrant&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;October&lt;br/&gt;2024&lt;br/&gt;Noteholder&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&lt;br/&gt;2024&#160;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;br/&gt;(5yr)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&lt;br/&gt;2024&#160;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;br/&gt;(2.5yr)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="26" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;402.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;59.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;38.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;1.20&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;36.40&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;22.72&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;22.72&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2.86&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.18&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.32&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.47&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.77&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.95&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2.45&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;109.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;81.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;80.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;73.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;77.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;76.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;95.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.22&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.29&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.30&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.30&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.32&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.33&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.21&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Private&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:19%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;402.50&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3.86&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;76.0&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3.90&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Consideration Related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Development Milestone Payment related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the achievement of FDA approval for a new drug application for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104,&lt;/div&gt; the Company will transfer $3.0&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104,&lt;/div&gt; expected timing for receipt of FDA approval for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104,&lt;/div&gt; and a discount rate of 10.0%. As of December&#160;31, 2024 and 2023, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There were no transfers between fair value measurement levels during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-24781"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tranche B Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Purchased Revenue Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden145657738;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden145657739;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44717"
      unitRef="Unit_USD">12161000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44718"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44719"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44720"
      unitRef="Unit_USD">12161000</us-gaap:SeniorNotes>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44721"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44722"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44723"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44724"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44725"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44726"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44727"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44728"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44729"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44730"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44731"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44732"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44733"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44734"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44735"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44736"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44737"
      unitRef="Unit_USD">60979000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44738"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44739"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44740"
      unitRef="Unit_USD">60979000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44741"
      unitRef="Unit_USD">104089000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44742"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44743"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44744"
      unitRef="Unit_USD">104089000</us-gaap:SeniorNotes>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44745"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44746"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44747"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44748"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44749"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44750"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44751"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44752"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44753"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44754"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44755"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44756"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44757"
      unitRef="Unit_USD">110126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44758"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44759"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44760"
      unitRef="Unit_USD">110126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44761"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44762"
      unitRef="Unit_USD">12200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44763"
      unitRef="Unit_USD">104100000</us-gaap:DebtInstrumentFairValue>
    <sclx:SecuredNoteDiscountRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-44764"
      unitRef="Unit_pure">1.2882</sclx:SecuredNoteDiscountRate>
    <sclx:SecuredNoteDiscountRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-44765"
      unitRef="Unit_pure">0.1305</sclx:SecuredNoteDiscountRate>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44766"
      unitRef="Unit_USD">3600000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44767"
      unitRef="Unit_USD">2800000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <sclx:ChangeInFairValueDueToCreditRisk
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44768"
      unitRef="Unit_USD">6300000</sclx:ChangeInFairValueDueToCreditRisk>
    <sclx:ChangeInFairValueDueToCreditRisk
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      id="ixv-44769"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueDueToCreditRisk>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44770"
      unitRef="Unit_USD">5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P06_30_2024To06_30_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44772"
      unitRef="Unit_USD">10000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2024To12_31_2024_SeniorSubordinatedNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44773"
      unitRef="Unit_USD">4700000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44774"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44775"
      unitRef="Unit_USD">23600000</us-gaap:DebtInstrumentFairValue>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44776"
      unitRef="Unit_USD">6600000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44777"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2024To12_31_2024_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44778"
      unitRef="Unit_USD">900000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P04_30_2023To04_30_2023"
      decimals="-5"
      id="ixv-44779"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-2"
      id="ixv-44780"
      unitRef="Unit_USD">35000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      id="ixv-44781"
      unitRef="Unit_USD">4400000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To12_31_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-44782"
      unitRef="Unit_USD">17400000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-44783"
      unitRef="Unit_USD">-500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44785"
      unitRef="Unit_shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44786"
      unitRef="Unit_shares">28572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44787"
      unitRef="Unit_shares">3803447</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44788"
      unitRef="Unit_shares">108686</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44789"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-44790"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44791"
      unitRef="Unit_shares">3250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44792"
      unitRef="Unit_shares">3250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44793"
      unitRef="Unit_shares">7500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44794"
      unitRef="Unit_shares">214284</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44795"
      unitRef="Unit_shares">57512958</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-44796"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sclx:DerivativeWarrantLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44797"
      unitRef="Unit_USD">18300000</sclx:DerivativeWarrantLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-25346"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 89%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;512&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Issuance of February 2024 BDO Firm Warrants as part of February 2024 BDO, April 2024 RDO Common Warrants as part of April 2024 RDO, October 2024 Noteholder Warrants as part of Tranche B Notes, December 2024 RDO Common Warrants as part of December 2024 RDO, and December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants as part of December 2024 RDO&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancellation of Private Warrants as part of Oramed Letter Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrant amendment and exercise as part of December 2024 RDO&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(428&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Settlement of December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(17,378&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt; </us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44798"
      unitRef="Unit_USD">1231000</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44799"
      unitRef="Unit_USD">512000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <sclx:ForfeitureOfPrivateWarrants
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44800"
      unitRef="Unit_USD">-225000</sclx:ForfeitureOfPrivateWarrants>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44801"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <sclx:IssuanceOfFirmWarrants
      contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44802"
      unitRef="Unit_USD">34330000</sclx:IssuanceOfFirmWarrants>
    <sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit
      contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44803"
      unitRef="Unit_USD">1690000</sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-3"
      id="ixv-44804"
      unitRef="Unit_USD">-445000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <sclx:FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering
      contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44805"
      unitRef="Unit_USD">-428000</sclx:FirmWarrantAmendmentAndExerciseAsPartOfTheDecemberRegisteredDirectOffering>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44806"
      unitRef="Unit_USD">-984000</us-gaap:FairValueAdjustmentOfWarrants>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2024To12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44807"
      unitRef="Unit_USD">-17378000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-44808"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-25504">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Private&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;February&lt;br/&gt;2024&#160;BDO&lt;br/&gt;Firm&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;April&#160;2024&lt;br/&gt;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Deposit&lt;br/&gt;Warrant&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;October&lt;br/&gt;2024&lt;br/&gt;Noteholder&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&lt;br/&gt;2024&#160;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;br/&gt;(5yr)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&lt;br/&gt;2024&#160;RDO&lt;br/&gt;Common&lt;br/&gt;Warrants&lt;br/&gt;(2.5yr)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="26" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;402.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;59.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;38.50&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;1.20&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;36.40&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;22.72&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;22.72&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2.86&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.18&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.32&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.47&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.77&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.95&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2.45&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;109.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;81.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;80.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;73.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;77.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;76.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;95.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.22&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.29&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.30&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.30&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.32&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.33&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4.21&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 44%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="text-wrap-mode: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Private&lt;br/&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:19%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;402.50&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3.86&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;76.0&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3.90&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"&gt;0.0&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44809"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44810"
      unitRef="Unit_USD_per_Share">59.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44811"
      unitRef="Unit_USD_per_Share">38.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44812"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44813"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44814"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44815"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44816">P2Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44817">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44818">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44819">P4Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44820">P4Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44821">P4Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44822">P2Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44823"
      unitRef="Unit_pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44824"
      unitRef="Unit_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44825"
      unitRef="Unit_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44826"
      unitRef="Unit_pure">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44827"
      unitRef="Unit_pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44828"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44829"
      unitRef="Unit_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44830"
      unitRef="Unit_pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44831"
      unitRef="Unit_pure">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44832"
      unitRef="Unit_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44833"
      unitRef="Unit_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44834"
      unitRef="Unit_pure">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44835"
      unitRef="Unit_pure">0.0433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44836"
      unitRef="Unit_pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44837"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44838"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44839"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44840"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44841"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44842"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44843"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-44845"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-44846">P3Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44847"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="4"
      id="ixv-44848"
      unitRef="Unit_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="3"
      id="ixv-44849"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44850"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ProductLiabilityContingencyAccrualDiscountRate
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-44851"
      unitRef="Unit_pure">0.10</us-gaap:ProductLiabilityContingencyAccrualDiscountRate>
    <sclx:FairValueOfContingentConsideration
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-44852"
      unitRef="Unit_USD">200000</sclx:FairValueOfContingentConsideration>
    <sclx:FairValueOfContingentConsideration
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44853"
      unitRef="Unit_USD">200000</sclx:FairValueOfContingentConsideration>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-25950"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;5. Balance Sheet Components &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Promissory Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#x201c;Denali&#x201d;) issued a convertible promissory note (the &#x201c;Convertible Promissory Note&#x201d;) in the total principal amount of up to $180,000 to the Company. The Convertible Promissory Note was issued with an initial principal balance of $15,063.74, with the remaining&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;164,936.26&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; drawable at Denali&#x2019;s request and upon the consent of the Company prior to the maturity of the Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#x2019;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $164,936.26 principal amount available under the Convertible Promissory Note are expected to fund future &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-month&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $&lt;/div&gt;10.00&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; per ordinary share (the &#x201c;Conversion Shares&#x201d;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC in connection with Denali&#x2019;s initial public offering (the &#x201c;IPO&#x201d;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of December&#160;31, 2024, the balance of the Convertible Promissory Note was $&lt;/div&gt;75.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;thousand as a result of additional draws after the initial amount.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (the &#x201c;Semnur Business Combination Agreement&#x201d;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#x201c;Denali Merger Sub&#x201d;).&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#x201c;Semnur Business Combination&#x201d;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#x201c;DGCL&#x201d;), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;de-register&lt;/div&gt; in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#x201c;Domestication&#x201d;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#x201c;Semnur Pharmaceuticals, Inc.&#x201d; (&#x201c;New Semnur&#x201d;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#x201c;New Semnur Common Shares&#x201d;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#x201c;New Semnur Preferred Shares&#x201d;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#x201c;New Semnur Warrants&#x201d;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#x201c;Effective Time&#x201d;): (i) each share of common stock, par value $0.00001 per share (the &#x201c;Semnur Common Stock&#x201d;), of Semnur, issued and outstanding immediately prior to the Effective Time, will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(b)&#160;one-tenth&lt;/div&gt; of one New Semnur Common Share, and (iii)&#160;subject to Denali&#x2019;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Combination, these costs will be classified in stockholders&#x2019; deficit as a reduction of additional &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2024 and 2023, deferred offering costs related to the Semnur Business Combination totaled $&lt;/div&gt;6.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million and &lt;/div&gt;nil&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;, respectively, and were included in prepaid expenses and other current assets in the Company&#x2019;s consolidated balance sheet.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution and delivery of the Semnur Business Combination Agreement, Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the &#x201c;Sponsor&#x201d;), and the Company entered into a Sponsor Interest Purchase Agreement (the &#x201c;SIPA&#x201d;) dated August&#160;30, 2024 (the &#x201c;Signing Date&#x201d;). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class&#160;B ordinary shares, par value $0.0001 per share (the &#x201c;Purchased Interests&#x201d;), of Denali that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000 (the &#x201c;Cash Consideration&#x201d;) and (ii) 8,571 shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#x2019;s own stock and meets the conditions to be classified in equity under FASB ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt;. The Purchased Interests will convert automatically, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price which consists of the $2,000,000 paid by the Company to the Sponsor and the value of the 8,571 shares of the Common Stock at the closing price of $40.25 per share on the Signing Date for a total of $2.3&#160;million. &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Company &lt;/div&gt;&lt;/div&gt; elected to subsequently measure the investment at cost less any impairment. As of December&#160;31, 2024, the Company&#x2019;s investment in the Purchased Interests had a balance of $2.3&#160;million. No impairment loss was recognized during the year ended December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized depreciation expense of $14.0&#160;thousand and $40.0&#160;thousand for the years ended December&#160;31, 2024 and 2023, &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued litigation expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,841&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-44854"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-44855"
      unitRef="Unit_USD">15063.74</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-44856"
      unitRef="Unit_USD">164936.26</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-44857"
      unitRef="Unit_USD">164936.26</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44858"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-44859"
      unitRef="Unit_USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-2"
      id="ixv-44860"
      unitRef="Unit_USD">75300</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="5"
      id="ixv-44862"
      unitRef="Unit_USD_per_Share">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44863"
      unitRef="Unit_USD">6000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2023_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-3"
      id="ixv-44864"
      unitRef="Unit_USD">0</us-gaap:DeferredOfferingCosts>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-44865"
      unitRef="Unit_shares">500000</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="4"
      id="ixv-44866"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-44867"
      unitRef="Unit_USD">2000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-44868"
      unitRef="Unit_shares">8571</us-gaap:CommonStockSharesIssued>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-44869"
      unitRef="Unit_USD">2000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn08_30_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-44870"
      unitRef="Unit_shares">8571</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-44871"
      unitRef="Unit_USD_per_Share">40.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CapitalUnitsNetAmount
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44872"
      unitRef="Unit_USD">2300000</us-gaap:CapitalUnitsNetAmount>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2024To12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44874"
      unitRef="Unit_USD">2300000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <sclx:ImpairmentLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44875"
      unitRef="Unit_USD">0</sclx:ImpairmentLoss>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-26051"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44876"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44877"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44878"
      unitRef="Unit_USD">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44879"
      unitRef="Unit_USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44880"
      unitRef="Unit_USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44881"
      unitRef="Unit_USD">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44882"
      unitRef="Unit_USD">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-44883"
      unitRef="Unit_USD">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44884"
      unitRef="Unit_USD">772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44885"
      unitRef="Unit_USD">780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44886"
      unitRef="Unit_USD">64000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44887"
      unitRef="Unit_USD">58000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44888"
      unitRef="Unit_USD">708000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44889"
      unitRef="Unit_USD">722000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-2"
      id="ixv-44890"
      unitRef="Unit_USD">14000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-44891"
      unitRef="Unit_USD">40000</us-gaap:Depreciation>
    <sclx:AccruedExpensesTextblock contextRef="P01_01_2024To12_31_2024" id="ixv-26208"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued litigation expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,841&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </sclx:AccruedExpensesTextblock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44892"
      unitRef="Unit_USD">667000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44893"
      unitRef="Unit_USD">2029000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44894"
      unitRef="Unit_USD">876000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44895"
      unitRef="Unit_USD">1601000</us-gaap:AccruedMarketingCostsCurrent>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44896"
      unitRef="Unit_USD">315000</sclx:AccruedResearchAndDevelopmentCosts>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44897"
      unitRef="Unit_USD">1546000</sclx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44898"
      unitRef="Unit_USD">876000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44899"
      unitRef="Unit_USD">1452000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44900"
      unitRef="Unit_USD">0</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44901"
      unitRef="Unit_USD">500000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44902"
      unitRef="Unit_USD">107000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44903"
      unitRef="Unit_USD">280000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44904"
      unitRef="Unit_USD">2841000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-44905"
      unitRef="Unit_USD">7408000</sclx:AccruedExpenses>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-26341"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;6. Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024 and 2023, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the years ended December&#160;31, 2024 and 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, ranging from 6.8 to 13.0 years. A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2024 and 2023 is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Intangibles,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,796&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;As of December&#160;31, 2024, the weighted average remaining life for identifiable intangible assets was 8.5 years. Aggregate amortization expense was $4.0&#160;million and $4.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Patent rights, acquired technology and acquired licenses are amortized over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;15-year&lt;/div&gt; period. Assembled workforce is amortized over a five-year period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Estimated future amortization expense related to intangible assets as of December&#160;31, 2024 is as follows (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2029&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-44906"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-44907"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-44908"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-44909"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis"
      id="ixv-44910">P6Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis"
      id="ixv-44911">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-44912">A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2024 and 2023 is as follows (in thousands): &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Intangibles,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,796&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44913"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44914"
      unitRef="Unit_USD">-17770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44915"
      unitRef="Unit_USD">14860000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44916"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44917"
      unitRef="Unit_USD">-9143000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44918"
      unitRef="Unit_USD">12797000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44919"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44920"
      unitRef="Unit_USD">-915000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44921"
      unitRef="Unit_USD">4796000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44922"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44923"
      unitRef="Unit_USD">-500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-44924"
      unitRef="Unit_USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44925"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44926"
      unitRef="Unit_USD">-28328000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44927"
      unitRef="Unit_USD">32453000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P01_01_2024To12_31_2024" id="ixv-44929">P8Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-44930"
      unitRef="Unit_USD">4000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-44931"
      unitRef="Unit_USD">4100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-44932">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      id="ixv-44933">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-26532"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Estimated future amortization expense related to intangible assets as of December&#160;31, 2024 is as follows (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2029&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44934"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44935"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44936"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44937"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44938"
      unitRef="Unit_USD">4006000</sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive>
    <sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44939"
      unitRef="Unit_USD">12423000</sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-44940"
      unitRef="Unit_USD">32453000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-26615"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;7. Debt &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $25.0&#160;million. The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-1&lt;/div&gt; with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Convertible Debentures bore interest at an annual rate of 7.00% and were initially set to mature on December 21, 2023. On October&#160;11, 2023, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $70.00 per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $17.50 per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to March 15, 2024. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest, may be converted into shares of Common Stock, at a conversion price of $280.00 per share at the option of the holder of the Convertible Debentures. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#x2019; prior written notice to Yorkville (the &#x201c;Redemption Notice&#x201d;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;Price&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company elected the fair value option for the Convertible Debentures and recorded the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Pursuant to the Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $15.0&#160;million in April 2023 for $14.4&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of 18,069 shares of Common Stock at a conversion price of $280.00 per share and reducing the outstanding Convertible Debentures fair value balance by $7.7&#160;million. The Company repaid $4.4&#160;million of the Convertible Debentures during the year ended December&#160;31, 2024. Interest expense related to the Convertible Debentures and included in the changes in fair value was $35.0&#160;thousand and $0.7&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(4,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revolving Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $30.0&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $250,000&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds 95% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and 85% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of the eCapital Credit Agreement, interest would accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.5%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provided for an early termination fee of 0.5% of the Facility Cap if Scilex Pharma voluntarily prepaid and terminated in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#x2019;s collections and eCapital Credit Agreement funding accounts, which permitted the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement would be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement was earlier terminated. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The eCapital Credit Agreement contained a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $1.0&#160;million at all times. Scilex Pharma&#x2019;s obligations under the eCapital Credit Agreement &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;were &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;secured by a continuing security interest in Scilex Pharma&#x2019;s accounts receivable, arising from customers in the ordinary course of business. The eCapital Credit Agreement contained customary events of default and also provided that an event of default included a change of control of Scilex Pharma and the failure by the Company to issue at least $75.0&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#x201c;Subordination Agreement&#x201d;) with the Lender and Acquiom Agency Services LLC (the &#x201c;Agent&#x201d;). Pursuant to the Subordination Agreement, the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consisted of all of the Company&#x2019;s properties identified in the description of collateral in the &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;UCC-1&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt; Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#x2019;s rights and interests under the Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by the Company and each of its subsidiaries with Oramed and the Agent (the &#x201c;Subsidiary Guarantee&#x201d;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also included other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $&lt;/div&gt;30.0&lt;div style="font-size: 10pt;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement were terminated, canceled and are of no further force and effect. As of December&#160;31, 2024 and 2023, the outstanding balance under the Revolving Facility for Scilex Pharma was nil and $17.0&#160;million, respectively, which was classified as a long-term liability in the consolidated balance sheet. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#x201c;Scilex-Oramed SPA&#x201d;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, matures on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-kind&lt;/div&gt; on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the sale of shares of Common Stock pursuant to the ATM Sales Agreement, the Company made a mandatory&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;prepayment of $&lt;/div&gt;9,578,835&lt;div style="font-size: 10pt;display:inline;"&gt;, $&lt;/div&gt;7,000,000&lt;div style="font-size: 10pt;display:inline;"&gt; and $&lt;/div&gt;1,760,796&lt;div style="font-size: 10pt;display:inline;"&gt;, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from the April 2024 RDO, the FSF Deposit and sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#x201c;Guarantors&#x201d;) entered into a security agreement (the &#x201c;Security Agreement&#x201d;) with Oramed (together with its successors and permitted assigns, the &#x201c;Holder&#x201d;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;20, 2024, the Company and Oramed entered into a letter agreement (the &#x201c;Oramed Letter Agreement&#x201d;), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the &#x201c;Specified September Payment&#x201d;) on September&#160;23, 2024, which payment was applied as follows: (i) $1,700,000 was applied to the amortization payment due under the Oramed Note on March 21, 2025 (the &#x201c;Maturity Date&#x201d;) and (y) $300,000 to purchase an aggregate of 4,000,000 SPAC Warrants (as defined below&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock&lt;/div&gt;&lt;/div&gt;) owned by Oramed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined therein) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined therein) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $0, and (ii)&#160;to extend the due date of the $20,000,000 amortization payment from September 23, 2024 to September 30, 2024. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed (&#x201c;Oramed Consent and Amendment&#x201d;) under which: (i)&#160;the Company made a payment of $12,500,000 to Oramed in lieu of&#160;the payment due on September 23, 2024, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $15,000,000 payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March 21, 2025 to December 31, 2025. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the Oramed Note was $12.2&#160;million, which is classified as debt, current in the consolidated balance sheet.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion into Tranche B Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(25,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Change in fair value of Oramed Note &#x2013; recorded in the consolidated statements of operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Change in fair value of Oramed Note &#x2013; due to instrument-specific credit risk recorded as a component of other comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;font-weight:bolder;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commitment Letter&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;11, 2024, the Company entered into the Commitment Letter with FSF Lender, pursuant to which FSF Lender committed to provide the Company the FSF Loan in the aggregate amount of $100.0&#160;million. The Commitment Amount should be payable as follows: (i) $85.0&#160;million no later than the Outside Date, which is 70 days following the date on which the Company received the FSF Deposit and (ii)&#160;the remaining $15.0&#160;million within 60 days following the Initial Closing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Commitment Letter, FSF Lender provided the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable&lt;/div&gt; FSF Deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million on the Deposit Date, which amount would be creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender the Deposit Warrant to purchase up to an aggregate of 3,250,000 shares of Common Stock (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction), with an exercise price of $1.20 per share. The Deposit Warrant was immediately exercisable and would expire five years from the date of issuance. If the Initial Closing did not occur on or prior to the Outside Date, the FSF Deposit should automatically convert into an unsecured loan on the first day after the Outside Date. Within five days after such automatic conversion occurs, the Company should issue a promissory note (the &#x201c;Unsecured Promissory Note&#x201d;) to FSF Lender to evidence such unsecured loan, which note should be unsecured, had a maturity date of five years after the date of the Unsecured Promissory Note and was prepayable without premium or penalty. The Unsecured Promissory Note should bear interest, payable quarterly in arrears, in an amount equal to the Unsecured Applicable Interest Amount (as defined&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;display:inline;"&gt;in the Commitment Letter) for such period based on the actual number of days elapsed while principal is outstanding.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;It was contemplated by the Commitment Letter that the Company and FSF Lender would enter into definitive documents with respect to the FSF Loan on terms to be mutually agreed in good faith. If such definitive documents were entered into on or before the Outside Date, the Company agreed to issue to FSF Lender (i)&#160;at the Initial Closing, a warrant to purchase up to an aggregate of 24,375,000 shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#x201c;Initial Closing Warrant&#x201d;), and (ii)&#160;at the Second Closing, a warrant to purchase up to an aggregate of 4,875,000 shares (subject to adjustment for any stock dividend, stock split, reverse stock split or similar transaction) of Common Stock (the &#x201c;Second Closing Warrant&#x201d;), each to have an exercise price of $1.20 per share (with such exercise price and underlying shares presented on a pre-Reverse Stock Split basis); however, neither the Initial Closing Warrant nor Second Closing Warrant were ever issued. The Initial Closing Warrant and the Second Closing Warrant would expire five years from the date of issuance. To evidence the FSF Loan, the Company agreed to issue to FSF Lender a Senior Secured Promissory Note (the &#x201c;Secured Promissory Note&#x201d;), which shall have a maturity date of &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;five years after the date of issuance. The Secured Promissory Note shall bear interest, payable quarterly in arrears, in an amount equal to the Secured Applicable Interest Amount (as defined in the Commitment Letter) for such period, based on the actual number of days elapsed, while principal is outstanding, subject to certain conditions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At issuance, the Company concluded that certain features of the FSF Deposit would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the transactions contemplated by the Commitment Letter, the Company also entered into an agreement with FSF Lender and the FSF Lender&#x2019;s strategic consultant, IVI 66766 LLC (&#x201c;IVI&#x201d;), dated July&#160;16, 2024, pursuant to which the Company agreed to reimburse the actual, reasonable and documented consulting fees incurred by FSF Lender in connection with the preparation, negotiation and execution of the Commitment Letter and the definitive documents with respect to the transactions contemplated thereby, which fees were satisfied in full by the Company issuing to IVI a warrant to purchase up to an aggregate of 7,142 shares of Common Stock (the &#x201c;Fee Warrant&#x201d;) on July&#160;16, 2024, with an exercise price of $42.00 per share. Subject to certain ownership limitations, the Fee Warrant is immediately exercisable and will expire five years from the date of issuance. The &lt;div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;"&gt;Company accounted for the Fee Warrant as an equity classified instrument and recognized the Fee Warrant in additional &lt;/div&gt;&lt;div style="font-size: 10pt; text-align: left; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;"&gt; capital in the Company&#x2019;s consolidated balance sheets. The fair value of the Fee Warrant as of the date of issuance was $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; text-align: left; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million. In October 2024, the Fee Warrant was exercised by IVI.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;17, 2024, the Company entered into the Satisfaction Agreement with FSF Lender and Endeavor, pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#x2019;s delivery of 28,000 cartons of ZTlido to Endeavor, which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor will not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company fails to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of June&#160;11, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(13,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the &lt;div style="white-space:nowrap;display:inline;"&gt;two-year&lt;/div&gt; anniversary of the issuance date and will be convertible into shares of Common Stock at a conversion price equal to $&lt;div style="display:inline;"&gt;38.15&lt;/div&gt; per share (which was automatically reduced to $&lt;div style="display:inline;"&gt;36.40&lt;/div&gt; per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such notes) and (ii)&#160;warrants (the &#x201c;October 2024 Noteholder Warrants&#x201d;) to purchase up to &lt;div style="display:inline;"&gt;214,284&lt;/div&gt; shares of Common Stock directly to the Tranche B Noteholders. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has received in exchange for the issuance of the Tranche B Notes to the Tranche B Investors an aggregate amount in cash of $22,500,000, excluding fees and expenses payable by the Company. The Company has received from Oramed in consideration for the Tranche B Notes issued to Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The October 2024 Noteholder Warrants are immediately exercisable for cash at an exercise price equal to $38.15 per share of Common Stock (which was automatically reduced to $36.40 per share of Common Stock subsequent to the December 2024 RDO (as defined below) in accordance with the terms of such warrants) and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#x201c;StockBlock&#x201d;) and its affiliate, Rodman&#160;&amp;amp; Renshaw LLC (collectively, the &#x201c;Placement Agents&#x201d;) or their respective designees, (i) &lt;/div&gt;62,794&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock (the &#x201c;Placement Agent Shares&#x201d;) and (ii)&#160;warrants to purchase up to &lt;/div&gt;104,848&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock (the &#x201c;October 2024 Placement Agent Warrants&#x201d;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement (as defined below) for $5.0&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $50.0&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $2.6&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statement of operations during the year ended December&#160;31, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of October&#160;8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;42,740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion of Tranche B notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(9,255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(3,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Aggregate principal repayments for the Company&#x2019;s outstanding debt will be $47.7&#160;million and $19.5&#160;million in 2025 and 2026, respectively.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;font-weight:bolder;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Royalty Purchase Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the &#x201c;ZTlido Purchased Receivables&#x201d;) with respect to ZTlido, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $5.0&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $2.5&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $2.5&#160;million minus Oramed&#x2019;s expenses (collectively, the amount so paid by the ZTlido Royalty Purchasers, the &#x201c;ZTlido RPA Closing Payment&#x201d;). Oramed&#x2019;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $2.5&#160;million of the outstanding balance under the Oramed Note.&#160;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;The Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. As of December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $6.8&#160;million, recorded as a purchased revenue liability on the consolidated balance sheet. The Company incurred $0.2&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the purchased revenue liability activity during the year ended December&#160;31, 2024 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of October&#160;8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-44941"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentDescription
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-26623">The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.</us-gaap:DebtInstrumentDescription>
    <sclx:ConvertibleDebenturesIssuedPercent
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-44942"
      unitRef="Unit_pure">0.96</sclx:ConvertibleDebenturesIssuedPercent>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-44943"
      unitRef="Unit_USD">10000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-44944"
      unitRef="Unit_USD">7500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-44945"
      unitRef="Unit_USD">7500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      id="ixv-44946"
      unitRef="Unit_pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-44947">2023-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-44948"
      unitRef="Unit_USD_per_Share">70</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-44949"
      unitRef="Unit_USD_per_Share">70</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-44950"
      unitRef="Unit_USD_per_Share">17.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-44951"
      unitRef="Unit_USD_per_Share">17.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-44952">2024-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-44953"
      unitRef="Unit_USD_per_Share">280</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-44954">The Company had the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.</us-gaap:DebtInstrumentPaymentTerms>
    <sclx:DebtInstrumentPrincipalAmountPercentage
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-44955"
      unitRef="Unit_pure">0.05</sclx:DebtInstrumentPrincipalAmountPercentage>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="P01_01_2024To12_31_2024" id="ixv-44956">The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#x2019; prior written notice to Yorkville (the &#x201c;Redemption Notice&#x201d;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44958"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <sclx:NetCashProceeds
      contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44959"
      unitRef="Unit_USD">14400000</sclx:NetCashProceeds>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44960"
      unitRef="Unit_USD">5000000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-44961"
      unitRef="Unit_shares">18069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-44962"
      unitRef="Unit_USD_per_Share">280</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <sclx:DebtInstrumentOutstandingPrincipal
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44963"
      unitRef="Unit_USD">7700000</sclx:DebtInstrumentOutstandingPrincipal>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44964"
      unitRef="Unit_USD">4400000</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-2"
      id="ixv-44965"
      unitRef="Unit_USD">35000</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-44966"
      unitRef="Unit_USD">700000</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-26660"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(4,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-44967"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebt>
    <sclx:RepaymentOfConvertibleDebenture
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-44968"
      unitRef="Unit_USD">-4375000</sclx:RepaymentOfConvertibleDebenture>
    <sclx:ChangeInFairValueOfConvertibleDebentures
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-44969"
      unitRef="Unit_USD">-35000</sclx:ChangeInFairValueOfConvertibleDebentures>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2024_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-44970"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebt>
    <us-gaap:FinancingReceivableRevolvingConvertedToTermLoan
      contextRef="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-44971"
      unitRef="Unit_USD">30000000</us-gaap:FinancingReceivableRevolvingConvertedToTermLoan>
    <sclx:DebtInstrumentOutstandingPrincipal
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-44972"
      unitRef="Unit_USD">250000</sclx:DebtInstrumentOutstandingPrincipal>
    <sclx:ExistingFacilityCapMaximum
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-44973"
      unitRef="Unit_pure">0.95</sclx:ExistingFacilityCapMaximum>
    <sclx:ExistingFacilityCapMinimum
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-44974"
      unitRef="Unit_pure">0.85</sclx:ExistingFacilityCapMinimum>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-44975"
      unitRef="Unit_pure">0.015</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <sclx:TerminationFees
      contextRef="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-44976"
      unitRef="Unit_pure">0.005</sclx:TerminationFees>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-44977"
      unitRef="Unit_USD">1000000</us-gaap:Cash>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P01_01_2024To12_31_2024_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-44979"
      unitRef="Unit_USD">75000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:FinancingReceivableRevolvingConvertedToTermLoan
      contextRef="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-44980"
      unitRef="Unit_USD">30000000</us-gaap:FinancingReceivableRevolvingConvertedToTermLoan>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-44981"
      unitRef="Unit_USD">17000000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44982"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-44983">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-44984"
      unitRef="Unit_USD">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-44985">2023-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-44986"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-44987">2024-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-44988"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-44989">2024-06-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-44990">2024-09-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-44991">2024-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-44992">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26772">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the sale of shares of Common Stock pursuant to the ATM Sales Agreement, the Company made a mandatory</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44993"
      unitRef="Unit_pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      id="ixv-44994"
      unitRef="Unit_pure">0.085</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <sclx:DebtRepaymentExitFee
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-44995"
      unitRef="Unit_USD">3100000</sclx:DebtRepaymentExitFee>
    <sclx:DebtInstrumentOwnedPercentage
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44996"
      unitRef="Unit_pure">0.50</sclx:DebtInstrumentOwnedPercentage>
    <sclx:DebtInstrumentDefaultInterestRate
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44997"
      unitRef="Unit_pure">0.15</sclx:DebtInstrumentDefaultInterestRate>
    <sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44998"
      unitRef="Unit_pure">0.50</sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount>
    <sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-44999"
      unitRef="Unit_pure">1.25</sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount>
    <sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-45000"
      unitRef="Unit_pure">1</sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest>
    <sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-45001"
      unitRef="Unit_pure">0.70</sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45003"
      unitRef="Unit_USD">9578835</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-45004"
      unitRef="Unit_USD">7000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2024To12_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45005"
      unitRef="Unit_USD">1760796</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_20_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45006"
      unitRef="Unit_USD">2000000</us-gaap:LongTermNotesPayable>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45007"
      unitRef="Unit_USD">1700000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-45008">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P09_23_2024To09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45009"
      unitRef="Unit_USD">300000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn09_23_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45010"
      unitRef="Unit_shares">4000000</sclx:PurchaseOfCommonWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45011"
      unitRef="Unit_shares">114286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45012"
      unitRef="Unit_USD">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45013"
      unitRef="Unit_USD">20000000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-45014">2024-09-23</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P01_01_2024To12_31_2024_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-45015">2024-09-30</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-45016"
      unitRef="Unit_USD">12500000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-45017">2024-09-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45018"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-45019">2025-03-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P01_21_2025To01_21_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-45020">2025-12-31</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45021"
      unitRef="Unit_USD">12200000</us-gaap:DebtInstrumentFairValue>
    <sclx:ScheduleOfTheOramedNoteTableTextBlock
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26829"> &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Oramed Note&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion into Tranche B Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(25,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Change in fair value of Oramed Note &#x2013; recorded in the consolidated statements of operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Change in fair value of Oramed Note &#x2013; due to instrument-specific credit risk recorded as a component of other comprehensive income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </sclx:ScheduleOfTheOramedNoteTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45023"
      unitRef="Unit_USD">104089000</us-gaap:ConvertibleDebt>
    <sclx:RepaymentOfConvertibleDebenture
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45024"
      unitRef="Unit_USD">-64200000</sclx:RepaymentOfConvertibleDebenture>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45025"
      unitRef="Unit_USD">25000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <sclx:ChangeInFairValueOfConvertibleDebentures
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45026"
      unitRef="Unit_USD">-3589000</sclx:ChangeInFairValueOfConvertibleDebentures>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="P01_01_2024To12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45027"
      unitRef="Unit_USD">-6317000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45028"
      unitRef="Unit_USD">12161000</us-gaap:ConvertibleDebt>
    <sclx:LoanAmount
      contextRef="PAsOn06_11_2024"
      decimals="-5"
      id="ixv-45029"
      unitRef="Unit_USD">100000000</sclx:LoanAmount>
    <sclx:CommitmentAmount
      contextRef="PAsOn06_11_2024"
      decimals="-5"
      id="ixv-45030"
      unitRef="Unit_USD">85000000</sclx:CommitmentAmount>
    <sclx:CompanyReceivesTheFsfDepositPeriod contextRef="P06_11_2024To06_11_2024" id="ixv-45031">P70D</sclx:CompanyReceivesTheFsfDepositPeriod>
    <sclx:CompanyReceivesTheFsfDepositAmount
      contextRef="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-45032"
      unitRef="Unit_USD">15000000</sclx:CompanyReceivesTheFsfDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-45033"
      unitRef="Unit_USD">10000000</sclx:NonRefundableDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-45034"
      unitRef="Unit_USD">85000000</sclx:NonRefundableDepositAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_11_2024"
      decimals="0"
      id="ixv-45035"
      unitRef="Unit_shares">3250000</us-gaap:CommonStockSharesIssued>
    <sclx:DepositWarrantExercisePrice
      contextRef="P06_11_2024To06_11_2024"
      decimals="2"
      id="ixv-45036"
      unitRef="Unit_USD_per_Share">1.2</sclx:DepositWarrantExercisePrice>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn06_11_2024_InitialClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-45037"
      unitRef="Unit_shares">24375000</sclx:PurchaseOfCommonWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn06_11_2024_SecondClosingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-45038"
      unitRef="Unit_shares">4875000</sclx:PurchaseOfCommonWarrants>
    <sclx:DepositWarrantExercisePrice
      contextRef="P06_11_2024To06_11_2024"
      decimals="2"
      id="ixv-45039"
      unitRef="Unit_USD_per_Share">1.2</sclx:DepositWarrantExercisePrice>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-45041"
      unitRef="Unit_shares">7142</sclx:PurchaseOfCommonWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-45042"
      unitRef="Unit_shares">7142</sclx:PurchaseOfCommonWarrants>
    <sclx:DepositWarrantExercisePrice
      contextRef="P07_16_2024To07_16_2024"
      decimals="2"
      id="ixv-45043"
      unitRef="Unit_USD_per_Share">42</sclx:DepositWarrantExercisePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-45044"
      unitRef="Unit_USD">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2024To12_31_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45045"
      unitRef="Unit_USD">13200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-45046"
      unitRef="Unit_USD">20000000</us-gaap:LossContingencyDamagesAwardedValue>
    <sclx:SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit contextRef="P01_01_2024To12_31_2024" id="ixv-26947"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the FSF Deposit (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of June&#160;11, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reclass of Deposit Warrant liability upon satisfaction of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of FSF Deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(13,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </sclx:SummaryOfTheChangesInTheBalanceAndTheEstimatedFairValueOfTheFsfDeposit>
    <us-gaap:Deposits
      contextRef="PAsOn06_10_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45047"
      unitRef="Unit_USD">10000000</us-gaap:Deposits>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45048"
      unitRef="Unit_USD">4690000</us-gaap:IncreaseDecreaseInDeposits>
    <sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit
      contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45049"
      unitRef="Unit_USD">-1690000</sclx:ReclassOfDepositWarrantLiabilityUponSatisfactionOfTheFSFDeposit>
    <sclx:RepaymentOfDeposit
      contextRef="P06_11_2024To12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45050"
      unitRef="Unit_USD">-13000000</sclx:RepaymentOfDeposit>
    <us-gaap:Deposits
      contextRef="PAsOn12_31_2024_FSFLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45051"
      unitRef="Unit_USD">0</us-gaap:Deposits>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-45053"
      unitRef="Unit_USD_per_Share">38.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-45054"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-45055"
      unitRef="Unit_shares">214284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-45056"
      unitRef="Unit_USD">22500000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:ReductionOfThePrincipalBalance
      contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-45057"
      unitRef="Unit_USD">22500000</sclx:ReductionOfThePrincipalBalance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-45058"
      unitRef="Unit_USD_per_Share">38.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="P10_08_2024To10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-45059"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-45060"
      unitRef="Unit_shares">107142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-45061"
      unitRef="Unit_shares">107142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-45062"
      unitRef="Unit_shares">62794</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_31_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-45063"
      unitRef="Unit_shares">104848</us-gaap:CommonStockSharesIssued>
    <us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-2"
      id="ixv-45064"
      unitRef="Unit_USD">5000</us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice>
    <sclx:ProceedsReceivedFromPurchaseAgreement
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45065"
      unitRef="Unit_USD">50000000</sclx:ProceedsReceivedFromPurchaseAgreement>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45066"
      unitRef="Unit_USD">2600000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <sclx:ScheduleOfTrancheBNotesTableTextBlock
      contextRef="P01_01_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-27059"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of October&#160;8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;42,740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion of Tranche B notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(9,255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(3,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </sclx:ScheduleOfTrancheBNotesTableTextBlock>
    <sclx:TrancheBNote
      contextRef="PAsOn10_08_2024"
      decimals="-3"
      id="ixv-45067"
      unitRef="Unit_USD">42740000</sclx:TrancheBNote>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45068"
      unitRef="Unit_USD">9255000</us-gaap:DebtConversionOriginalDebtAmount1>
    <sclx:RepaymentOfTrancheBNotes
      contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45069"
      unitRef="Unit_USD">-3283000</sclx:RepaymentOfTrancheBNotes>
    <sclx:ChangeInFairValueOfTrancheBNotes
      contextRef="P10_08_2024To12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45070"
      unitRef="Unit_USD">-6641000</sclx:ChangeInFairValueOfTrancheBNotes>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-45071"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2025To12_31_2025_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-45072"
      unitRef="Unit_USD">47700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2026To12_31_2026_ScenarioPreviouslyReportedMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-45073"
      unitRef="Unit_USD">19500000</us-gaap:RepaymentsOfDebt>
    <srt:FederalFundsPurchasedAverageRatePaid
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-45075"
      unitRef="Unit_pure">0.08</srt:FederalFundsPurchasedAverageRatePaid>
    <us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-2"
      id="ixv-45076"
      unitRef="Unit_USD">5000</us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice>
    <sclx:PaidToRoyaltyInvestors
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45077"
      unitRef="Unit_USD">2500000</sclx:PaidToRoyaltyInvestors>
    <us-gaap:PaymentsToAcquireReceivables
      contextRef="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45078"
      unitRef="Unit_USD">2500000</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P10_08_2024To10_08_2024_OramedMemberdeiLegalEntityAxis_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45079"
      unitRef="Unit_USD">2500000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45080"
      unitRef="Unit_USD">6800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-45081"
      unitRef="Unit_USD">200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-27168"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the purchased revenue liability activity during the year ended December&#160;31, 2024 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of October&#160;8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn10_08_2024"
      decimals="-3"
      id="ixv-45082"
      unitRef="Unit_USD">5900000</sclx:PurchasedRevenueLiability>
    <sclx:ChangeInFairValueOfPurchasedRevenueLiability
      contextRef="P10_08_2024To12_31_2024"
      decimals="-3"
      id="ixv-45083"
      unitRef="Unit_USD">900000</sclx:ChangeInFairValueOfPurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45084"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-27223"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;8. Junior DIP Facility and Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Junior DIP Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In July 2023, the Company entered into an agreement to provide Sorrento with a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-amortizing&lt;/div&gt; super-priority junior secured term loan facility (&#x201c;Junior DIP Facility&#x201d;) in an aggregate principal amount of $20.0&#160;million (the &#x201c;Junior DIP Loan Agreement&#x201d;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of 12.0% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;Facility.&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;The Junior DIP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, Sorrento&#x2019;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into the Sorrento SPA, pursuant to which the Company purchased from Sorrento (i) 1,716,245 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock and (iii) 1,386,617 Public Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 39,617 shares of Common Stock&lt;/div&gt;&lt;/div&gt; and 3,104,000 Private Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 88,685 shares of Common Stock&lt;/div&gt;&lt;/div&gt; (collectively, the &#x201c;Purchased Securities&#x201d;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#x2019;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of &lt;/div&gt;4,500,000&lt;div style="font-size: 10pt;display:inline;"&gt; shares of Common Stock (the &#x201c;Closing Penny Warrant&#x201d;) with an exercise price of $&lt;/div&gt;0.01&lt;div style="font-size: 10pt;display:inline;"&gt; per share and restrictions on exercisability, and warrants to purchase up to an aggregate of &lt;/div&gt;8,500,000&lt;div style="font-size: 10pt;display:inline;"&gt; shares of Common Stock (the &#x201c;Subsequent Penny Warrants&#x201d; and together with the Closing Penny Warrant, the &#x201c;Penny Warrants&#x201d;), each with an exercise price of $&lt;/div&gt;0.01&lt;div style="font-size: 10pt;display:inline;"&gt; per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed &lt;/div&gt;4,000,000&lt;div style="font-size: 10pt;display:inline;"&gt; SPAC Warrants, which &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;are currently exercisable for an aggregate of up to 114,286 shares of Common Stock, which &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $&lt;/div&gt;10.0&lt;div style="font-size: 10pt;display:inline;"&gt;&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $&lt;/div&gt;12.3&lt;div style="font-size: 10pt;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Series A Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#x201c;Holdco&#x201d;), a single purpose entity that is the Company&#x2019;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#x2019;s indirect wholly owned subsidiary (&#x201c;SCLX JV&#x201d;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Penny Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;March 14, 2025, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company issued four Subsequent Penny Warrants, each for 2,125,000&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of March 19, 2024 (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;CS-2&lt;/div&gt; Warrant&#x201d;), June 17, 2024 (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;CS-3&lt;/div&gt; Warrant&#x201d;), September 15, 2024 (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;CS-4&lt;/div&gt; Warrant&#x201d;) or December 14, 2024 (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;CS-5&lt;/div&gt; Warrant&#x201d;) (each, the &#x201c;Subsequent Penny Warrant Vesting Date&#x201d;) and (ii)&#160;the earliest of (A)&#160;March 14, 2025, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to a letter agreement the Company entered into with Oramed, dated as of August 30, 2024, the parties agreed that: (i)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CS-4&lt;/div&gt; Warrant shall fully vest on August&#160;30, 2024 and (ii)&#160;Oramed may immediately exercise the Oramed Warrants with respect to up to 5,437,500 shares of Common Stock. Pursuant to the Oramed Letter Agreement the Company entered into with Oramed, dated as of September&#160;20, 2024, the parties agreed that Oramed may immediately exercise the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CS-5&lt;/div&gt; Warrant with respect to up to 1,062,500 shares of Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#x201c;cashless exercise.&#x201d; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#x201c;Oramed Beneficial Ownership Limitation&#x201d;); provided, however, that upon 61 days&#x2019; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#x2019;s own stock and meet the conditions to be classified in equity under FASB ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging,&lt;/div&gt;&lt;/div&gt; including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million.&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;During the year ended December&#160;31, 2024, there were 6,500,000 Penny Warrants exercised by Oramed for net proceeds of approximately $0.1&#160;million. As of December&#160;31, 2024, there were 6,500,000 Penny Warrants outstanding that were fully vested and such warrants became exercisable on March 14, 2025. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Excise Tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#x201c;IRS&#x201d;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the consolidated balance sheet. During the year ended December&#160;31, 2024, the Company made a total of $0.5&#160;million payments for the excise tax. As of December&#160;31, 2024, the remaining balance of the excise tax liability recorded as accrued expenses was $0.8&#160;million. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-45085"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="3"
      id="ixv-45086"
      unitRef="Unit_pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      id="ixv-45087"
      unitRef="Unit_pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      id="ixv-45089">Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.</us-gaap:DebtInstrumentDescription>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45090"
      unitRef="Unit_shares">1716245</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45091"
      unitRef="Unit_shares">29057097</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45092"
      unitRef="Unit_shares">1386617</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-45093"
      unitRef="Unit_shares">39617</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45094"
      unitRef="Unit_shares">3104000</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-45095"
      unitRef="Unit_shares">88685</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45096"
      unitRef="Unit_shares">4500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-45097"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45098"
      unitRef="Unit_shares">8500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45099"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:TransferOfWarrants
      contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45100"
      unitRef="Unit_shares">4000000</sclx:TransferOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_21_2023_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45101"
      unitRef="Unit_shares">114286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sclx:CashPayment
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45102"
      unitRef="Unit_USD">10000000</sclx:CashPayment>
    <us-gaap:LegalFees
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45103"
      unitRef="Unit_USD">12300000</us-gaap:LegalFees>
    <sclx:FairValueOfSharesRepurchased
      contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45105"
      unitRef="Unit_USD">52600000</sclx:FairValueOfSharesRepurchased>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45106">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-45107"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-45108"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-45109"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-45110"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45111">2024-03-19</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45112">2024-06-17</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45113">2024-09-15</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2024To12_31_2024_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45114">2024-12-14</sclx:WarrantVestingDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45115">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <sclx:WarrantVestingDate
      contextRef="P08_30_2024To08_30_2024_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45116">2024-08-30</sclx:WarrantVestingDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45117"
      unitRef="Unit_shares">5437500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants5MemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45118"
      unitRef="Unit_shares">1062500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45119"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:NumberOfShareOutstanding
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      id="ixv-45120"
      unitRef="Unit_pure">0.099</sclx:NumberOfShareOutstanding>
    <sclx:FairValueOfWarrants
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-45121"
      unitRef="Unit_USD">10400000</sclx:FairValueOfWarrants>
    <sclx:PennyWarrantsExercised
      contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45123"
      unitRef="Unit_shares">6500000</sclx:PennyWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2024To12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-45124"
      unitRef="Unit_USD">100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45125"
      unitRef="Unit_shares">6500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2024To12_31_2024_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45126">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-45127"
      unitRef="Unit_USD">1300000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-45128"
      unitRef="Unit_USD">500000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="PAsOn12_31_2024_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-45129"
      unitRef="Unit_USD">800000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-27357"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;9. Stockholders&#x2019; Deficit &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SPAC Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $402.50 per share (the &#x201c;Public Warrants&#x201d;, and together with the Private Warrants, the &#x201c;SPAC Warrants&#x201d;). &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;If the reported last sale price of the Common Stock equals or exceeds $630.00 per share for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-trading&lt;/div&gt; day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#x2019; prior written notice. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Public Warrants are equity-classified warrants and recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased 4,000,000 of the SPAC Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock,&lt;/div&gt;&lt;/div&gt; held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of December&#160;31, 2024 and 2023, there were 5,467,692&#160;and 6,854,309&#160;Public Warrants outstanding, &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to 156,220 shares of Common Stock and 195,838 shares of Common Stock, &lt;/div&gt;&lt;/div&gt;respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of December&#160;31, 2024 and 2023, there were 1,000,000&#160;and 3,613,383&#160;Private Warrants outstanding, &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock and 103,240 shares of Common Stock, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;font-weight:bolder;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company is authorized to issue 45,000,000 shares of preferred stock (the &#x201c;Preferred Stock&#x201d;) of which there are two series in total. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of December&#160;31, 2024 and 2023, there were 29,057,097 shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series 1 Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On October&#160;27, 2024, the Board declared a stock dividend (the &#x201c;Dividend&#x201d;) consisting of an aggregate of 5,000,000 shares (the &#x201c;Dividend Stock&#x201d;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share (the &#x201c;Series 1 Preferred Stock&#x201d;), of the Company to record holders of certain of the Company&#x2019;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;such later date to be determined in the sole discretion of the Board). &lt;/div&gt; Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#x201c;Certificate of Designation&#x201d;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $200,000,000 divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is 10&#160;trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of the Certificate of Designation, (a) &#x201c;Effective Time&#x201d; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#x201c;Determination Date&#x201d; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is 15&#160;trading days following the Registration Date, (c) &#x201c;Registration Date&#x201d; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) and (ii)&#160;the time at which the Registration Statement is declared effective by the Securities and Exchange Commission and (d) &#x201c;Registration Statement&#x201d; means a registration statement, whether under the Exchange Act, or the Securities Act, that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025).&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of December&#160;31, 2024 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024 and 2023, there were 1,716,245 shares of Treasury Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;A&amp;amp;R Yorkville Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the A&amp;amp;R Yorkville Purchase Agreement, the Company had the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $500.0&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which the Company&#x2019;s registration statement on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Form&#160;S-1&lt;/div&gt; registering such shares was declared effective by the SEC. Pursuant to the A&amp;amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elected to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;amp;R Yorkville Purchase Agreement, &#x201c;VWAP&#x201d; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#x201c;AQR&#x201d; function. Pursuant to the terms of the Original Purchase&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Agreement, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;333-268607)&lt;/div&gt; (as it may be amended or supplemented from time to time, the &#x201c;Yorkville Registration Statement&#x201d;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville &lt;/div&gt;7,142&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock. During the year ended December&#160;31, 2024, the Company sold &lt;/div&gt;2,770&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock pursuant to the A&amp;amp;R Yorkville Purchase Agreement for aggregate net proceeds of $&lt;/div&gt;0.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million. During the year ended December&#160;31, 2023, the Company sold &lt;/div&gt;330,059&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock pursuant to the A&amp;amp;R Yorkville Purchase Agreement for aggregate net proceeds of $&lt;/div&gt;32.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;amp;R Yorkville Purchase Agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;B. Riley Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Pursuant to the B. Riley Purchase Agreement, the Company had the right, but not the obligation, to sell to B. Riley up to $500.0&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth therein, from time to time at the Company&#x2019;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company&#x2019;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;333-269205)&lt;/div&gt; (as it may be amended or supplemented from time to time, the &#x201c;B. Riley Registration Statement&#x201d;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023.&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;display:inline;"&gt;The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to &lt;/div&gt;98&lt;div style="font-size: 10pt;display:inline;"&gt;% of the VWAP (as defined in such agreement) during the pricing period prescribed therein.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley 7,142 shares of Common Stock. During the year ended December&#160;31, 2024, the Company did not sell any shares of Common Stock pursuant to the B. Riley Purchase Agreement. During the year ended December&#160;31, 2023, the Company sold an aggregate of 40,415 shares of Common Stock for aggregate net proceeds of $3.2&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Issued under Settlement Agreement with Hudson Bay Parties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In August 2023, the Company, along with Hudson Bay Capital Management LP (&#x201c;Hudson Bay&#x201d;), Cove Lane Onshore Fund, LLC (&#x201c;Cove Lane&#x201d;), and HBC Investments LLC (&#x201c;HBC&#x201d; and collectively, the &#x201c;Hudson Bay Parties&#x201d;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $118.6&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $8.65&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $0.3&#160;million and $0.5&#160;million, respectively. This resulted in the issuance of an aggregate of 13,562 shares of Common Stock on September&#160;25, 2023.&#160;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;font-weight:bolder;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Sales Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp;amp; Co. and H.C. Wainwright&#160;&amp;amp; Co., LLC (the &#x201c;Sales Agents&#x201d;), which agreement was voluntarily terminated by us effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#x201c;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;ATM &lt;/div&gt;&lt;/div&gt;Offering&#x201d;) shares of Common Stock up to $170,000,000 (the &#x201c;ATM Shares&#x201d;), through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers at any time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The ATM Shares offered and sold in the &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;ATM &lt;/div&gt;&lt;/div&gt;Offering were issued pursuant to the Company&#x2019;s shelf registration statement on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Form&#160;S-3&#160;(which&lt;/div&gt; was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;333-276245))&lt;/div&gt; (the &#x201c;Shelf &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement&#x201d;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Sales Agents were entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of December&#160;31, 2024, the Company sold 78,975 shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $2.7&#160;million. As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;February 2024 Bought Deal Offering Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#x201c;February 2024 BDO Underwriting Agreement&#x201d;) with Rodman&#160;&amp;amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#x201c;February 2024 BDO&#x201d;), 168,068&#160;shares of Common Stock (the &#x201c;February 2024 BDO Firm Shares&#x201d;) and accompanying common warrants to purchase up to an aggregate of&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;168,068&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock (the &#x201c;February 2024 BDO Firm Warrants&#x201d;). The securities in the February 2024 BDO were offered and sold by us pursuant to the Shelf &lt;/div&gt;&lt;div style="font-size: 10pt; text-wrap-mode: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; Registration Statement,&#160;a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The February 2024 BDO closed on March&#160;5, 2024, and the combined price per Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $54.74, which amount reflects the combined public offering price of $59.50, less underwriting discounts and commissions. Pursuant to the February 2024 BDO Underwriting Agreement, the Company also granted the underwriters a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; option to purchase up to 25,211 additional shares of Common Stock and/or common warrants to purchase up to 25,211 shares of Common Stock (the &#x201c;February 2024 BDO Optional Warrants&#x201d;, and together with the February 2024 BDO Firm Warrants, the &#x201c;Common Warrants&#x201d;). The underwriters did not exercise this option and it expired on March&#160;30, 2024. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $59.50 per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#x201c;February 2024 BDO Representative Warrants&#x201d;) to the underwriters, allowing them to purchase up to 13,446 shares of Common Stock, with these warrants being immediately exercisable at $74.38 per share, representing 125% of the combined public offering price per Firm Share and accompanying February 2024 BDO Firm Warrant. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note 4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in &lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;general and administrative expenses in the Company&#x2019;s consolidated statement of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $0.3&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2024, the Company entered into a warrant amendment (the &#x201c;Warrant Amendment&#x201d;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. During the year ended December&#160;31, 2024, there were 59,398 February 2024 BDO Firm Warrants exercised for total net proceeds of approximately $1.6&#160;million, including the amended February 2024 BDO Firm Warrants. As of December&#160;31, 2024, there were 3,803,447 February 2024 BDO Firm Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock outstanding&lt;/div&gt;&lt;/div&gt; and 470,588 February 2024 BDO Representative Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 13,446 shares of Common Stock&lt;/div&gt;&lt;/div&gt; outstanding. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;April 2024 Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#x201c;April 2024 RDO Purchase Agreement&#x201d;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#x201c;April 2024 RDO&#x201d;): (i) an aggregate of 428,572 shares of Common Stock (the &#x201c;RDO Shares&#x201d;), and (ii)&#160;common warrants to purchase up to 428,572 shares of Common Stock (the &#x201c;April 2024 RDO Common Warrants&#x201d;). The offering price per RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $35.00, for aggregate gross proceeds to the Company of $15,000,000, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $38.50 per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;StockBlock and its affiliate, Rodman&#160;&amp;amp; Renshaw LLC, acted as exclusive placement agents (the &#x201c;Placement Agents&#x201d;) in connection with the April 2024 RDO. As compensation for such placement agent services, the&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;Company paid the Placement Agents an aggregate cash fee equal to 8.0% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the Placement Agents $100,000 for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; expenses and $15,950 for clearing expenses. The Company has also agreed to issue to the Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to 34,286 shares of Common Stock (the &#x201c;April 2024 RDO Placement Agent Warrants&#x201d;), representing up to 8.0% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $43.75 per share (which represents 125% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note 4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#x2019;s consolidated statement of operations. The fair value of April 2024 RDO Placement Agent Warrants as of the date of issuance was $0.6&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, there were 15,000,000 April 2024 RDO Common Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock outstanding,&lt;/div&gt;&lt;/div&gt; and 1,200,000 April 2024 RDO Placement Agent Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 34,286 shares of Common Stock&lt;/div&gt;&lt;/div&gt; outstanding. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December 2024 Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#x201c;December 2024 RDO Purchase Agreement&#x201d;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#x201c;December 2024 RDO&#x201d;): (i) an aggregate of 753,009 shares of Common Stock, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(ii)&#160;pre-funded&lt;/div&gt; warrants to purchase up to 68,604&#160;shares of Common Stock (the &#x201c;December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&#x201d;) and (iii)&#160;common warrants to purchase up to 1,642,871 shares of Common Stock (the &#x201c;December 2024 RDO Common Warrants&#x201d; and together with the December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#x201c;StockBlock Warrants&#x201d;), the &#x201c;December 2024 RDO Warrants&#x201d;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $20.65 and (b)&#160;per December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant and accompanying December 2024 RDO Common Warrants was $20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $17.0&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#x2019;s consolidated statement of operations. The fair value of StockBlock Warrants as of the date of issuance was $1.3&#160;million. On December&#160;26, 2024, the December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants were exercised by the holder for total net proceeds of approximately $0.2&#160;million.&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2024, there were 57,512,958 December 2024 RDO Common Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock outstanding,&lt;/div&gt;&lt;/div&gt; and 4,601,036&#160;StockBlock Warrants&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style=";text-indent: 0px;display:inline;"&gt;, which are currently exercisable for an aggregate of up to 131,472 shares of Common Stock&lt;/div&gt;&lt;/div&gt; outstanding. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2024_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-45130"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-45131"
      unitRef="Unit_USD_per_Share">630</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45132"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45133"
      unitRef="Unit_USD">4000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2024To03_31_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45134"
      unitRef="Unit_USD">114286000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-45135"
      unitRef="Unit_shares">5467692</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-45136"
      unitRef="Unit_shares">5467692</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-45137"
      unitRef="Unit_shares">6854309</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-45138"
      unitRef="Unit_shares">6854309</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2024_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45139"
      unitRef="Unit_shares">156220</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45140"
      unitRef="Unit_shares">195838</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45141"
      unitRef="Unit_shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-45142"
      unitRef="Unit_shares">3613383</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2024_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45143"
      unitRef="Unit_shares">28572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45144"
      unitRef="Unit_shares">103240</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-45146"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45147"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45148"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45149"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendsShares
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45150"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-45151"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45152"
      unitRef="Unit_USD">200000000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45153"
      unitRef="Unit_Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45154"
      unitRef="Unit_Days">15</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45156"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-45157"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45158"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <sclx:PurchaseOfStockPercentage
      contextRef="PAsOn12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-45159"
      unitRef="Unit_pure">0.98</sclx:PurchaseOfStockPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45160"
      unitRef="Unit_shares">7142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:CommonStockSold
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45161"
      unitRef="Unit_shares">2770</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2024To12_31_2024_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45162"
      unitRef="Unit_USD">200000</sclx:ProceedsFromSaleOfCommonStock>
    <sclx:CommonStockSold
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45163"
      unitRef="Unit_shares">330059</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45164"
      unitRef="Unit_USD">32300000</sclx:ProceedsFromSaleOfCommonStock>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45165"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <sclx:PurchaseOfStockPercentage
      contextRef="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-45166"
      unitRef="Unit_pure">0.98</sclx:PurchaseOfStockPercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-45167"
      unitRef="Unit_shares">7142</us-gaap:CommonStockSharesIssued>
    <sclx:CommonStockSold
      contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-45168"
      unitRef="Unit_shares">40415</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45169"
      unitRef="Unit_USD">3200000</sclx:ProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45170"
      unitRef="Unit_USD">118600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDividends
      contextRef="P01_01_2024To12_31_2024"
      decimals="-4"
      id="ixv-45171"
      unitRef="Unit_USD">8650000</us-gaap:PaymentsOfDividends>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024_CoveLaneMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45172"
      unitRef="Unit_USD">300000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024_HudsonBayMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45173"
      unitRef="Unit_USD">500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_25_2023"
      decimals="INF"
      id="ixv-45174"
      unitRef="Unit_shares">13562</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-45175"
      unitRef="Unit_shares">170000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sclx:ProceedSOfSaleOfCommonSharesPercentage
      contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="3"
      id="ixv-45176"
      unitRef="Unit_pure">0.03</sclx:ProceedSOfSaleOfCommonSharesPercentage>
    <sclx:CommonStockSold
      contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45177"
      unitRef="Unit_shares">78975</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2024To12_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45178"
      unitRef="Unit_USD">2700000</sclx:ProceedsFromSaleOfCommonStock>
    <sclx:CommonStockSold
      contextRef="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45179"
      unitRef="Unit_shares">0</sclx:CommonStockSold>
    <sclx:CommonStockSold
      contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45180"
      unitRef="Unit_shares">168068</sclx:CommonStockSold>
    <sclx:CommonStockSold
      contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-45181"
      unitRef="Unit_shares">168068</sclx:CommonStockSold>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45183"
      unitRef="Unit_shares">168068</sclx:PurchaseOfCommonWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45184"
      unitRef="Unit_shares">168068</sclx:PurchaseOfCommonWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45185"
      unitRef="Unit_shares">168068</sclx:PurchaseOfCommonWarrants>
    <sclx:CombinedPricePaidOfWarrant
      contextRef="PAsOn02_29_2024"
      decimals="2"
      id="ixv-45186"
      unitRef="Unit_USD_per_Share">54.74</sclx:CombinedPricePaidOfWarrant>
    <sclx:CombinedPricePaidOfWarrant
      contextRef="PAsOn02_29_2024"
      decimals="2"
      id="ixv-45187"
      unitRef="Unit_USD_per_Share">54.74</sclx:CombinedPricePaidOfWarrant>
    <sclx:PublicOfferingPrice
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-45188"
      unitRef="Unit_USD_per_Share">59.5</sclx:PublicOfferingPrice>
    <sclx:PublicOfferingPrice
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-45189"
      unitRef="Unit_USD_per_Share">59.5</sclx:PublicOfferingPrice>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn02_29_2024_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45190"
      unitRef="Unit_shares">25211</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-45191"
      unitRef="Unit_shares">25211</sclx:PurchaseOfCommonWarrants>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45192"
      unitRef="Unit_USD_per_Share">59.5</sclx:ExercisePriceOfCommonWarrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-45193"
      unitRef="Unit_shares">13446</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn02_29_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-45194"
      unitRef="Unit_USD_per_Share">74.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:PublicOfferingPriceCombined
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-45195"
      unitRef="Unit_pure">1.25</sclx:PublicOfferingPriceCombined>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-45196"
      unitRef="Unit_USD">300000</us-gaap:AdditionalPaidInCapital>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45197"
      unitRef="Unit_shares">50421</sclx:PurchaseOfCommonWarrants>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-45198"
      unitRef="Unit_USD_per_Share">20.65</sclx:ExercisePriceOfCommonWarrant>
    <sclx:NumberOfWarrantsExercised
      contextRef="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45199"
      unitRef="Unit_shares">59398</sclx:NumberOfWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2024To12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      id="ixv-45200"
      unitRef="Unit_USD">1600000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45201"
      unitRef="Unit_shares">3803447</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sclx:NumberOfWarrantsExercised1
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45202"
      unitRef="Unit_shares">108686</sclx:NumberOfWarrantsExercised1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45203"
      unitRef="Unit_shares">470588</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45204"
      unitRef="Unit_shares">13446</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45205"
      unitRef="Unit_shares">428572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45206"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-45207"
      unitRef="Unit_USD_per_Share">35</us-gaap:SaleOfStockPricePerShare>
    <sclx:AggregateGrossProceedsFromOffering
      contextRef="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45208"
      unitRef="Unit_USD">15000000</sclx:AggregateGrossProceedsFromOffering>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45209"
      unitRef="Unit_USD_per_Share">38.5</sclx:ExercisePriceOfCommonWarrant>
    <sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45210"
      unitRef="Unit_pure">0.08</sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents>
    <us-gaap:LegalFees
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45211"
      unitRef="Unit_USD">100000</us-gaap:LegalFees>
    <sclx:ClearingExpenses
      contextRef="P04_23_2024To04_23_2024"
      decimals="0"
      id="ixv-45212"
      unitRef="Unit_USD">15950</sclx:ClearingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45213"
      unitRef="Unit_shares">34286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering
      contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45214"
      unitRef="Unit_pure">0.08</sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45215"
      unitRef="Unit_USD_per_Share">43.75</sclx:ExercisePriceOfCommonWarrant>
    <sclx:PercentOfCombinedOfferingExercisePricePerShare
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45216"
      unitRef="Unit_pure">1.25</sclx:PercentOfCombinedOfferingExercisePricePerShare>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn04_23_2024_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-45217"
      unitRef="Unit_USD">600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45218"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45219"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45220"
      unitRef="Unit_shares">1200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-45221"
      unitRef="Unit_shares">34286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45222"
      unitRef="Unit_shares">753009</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:PreFundedWarrantsToPurchase
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-45223"
      unitRef="Unit_shares">68604</sclx:PreFundedWarrantsToPurchase>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45224"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-45225"
      unitRef="Unit_USD_per_Share">20.65</us-gaap:SaleOfStockPricePerShare>
    <sclx:PreFundedWarrantPerShare
      contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="4"
      id="ixv-45226"
      unitRef="Unit_USD_per_Share">20.6499</sclx:PreFundedWarrantPerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-45227"
      unitRef="Unit_USD">17000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-45228"
      unitRef="Unit_USD">1300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-45229"
      unitRef="Unit_USD">200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45231"
      unitRef="Unit_shares">57512958</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45232"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45233"
      unitRef="Unit_shares">4601036</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45234"
      unitRef="Unit_shares">131472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-27658">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;10. Stock Incentive and E&lt;div style="display:inline;"&gt;mploye&lt;/div&gt;e Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2022 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;). As of December&#160;31, 2024, a total of 575,220 shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2024 pursuant to the Equity Incentive Plan. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;font-weight:bolder;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2023 Inducement Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan provides for the grant of equity-based awards in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-statutory&lt;/div&gt; stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 40,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, options to purchase 1,027,977 shares of Common Stock were outstanding under all equity incentive plans.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2024 (shares in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;946&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;153.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7,459&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;129&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;33.21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;51.67&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;160.56&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;138.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;6.43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;138.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;6.43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;727&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;113.01&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;5.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024 and 2023 was $&lt;/div&gt;23.49&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; and $&lt;/div&gt;113.00&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; per share, respectively. The total intrinsic values of options exercised during the years ended December&#160;31, 2024 and 2023 were $&lt;/div&gt;47.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;thousand and $&lt;/div&gt;1.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;million, respectively. The maximum term of options granted under each of the equity incentive plans is ten years.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded within operating expenses was $15.7&#160;million and $14.6&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total unrecognized compensation costs related to unvested employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&lt;/div&gt; stock option grants as of December&#160;31, 2024 were $27.8&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.3 years. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2022 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The purchase price of the Common Stock is equal to&#160;85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2024, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;127,902&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;, which was increased from &lt;/div&gt;82,164&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares as a result of automatic annual increase on January&#160;1, 2024.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded as operating expense for the ESPP was $242.8&#160;thousand and $21.0&#160;thousand for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There were 9,551 and nil shares of Common Stock issued under the ESPP during the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Valuation Assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP:&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 71%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&#160;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.00%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;72.00%&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;119.08%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;3.79%&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;4.71%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term of options (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;3.0&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee stock purchase plan:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.00%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;129.30%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;5.39%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected life (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur 2024 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (&#x201c;Semnur 2024 Plan&#x201d;). Under the Semnur 2024 Plan, 40,000,000 shares of Semnur Common Stock were reserved for future issuance and nonstatutory stock options (&#x201c;NSOs&#x201d;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of December&#160;31, 2024, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.6&#160;million and $0.5&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Retainer Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#x201c;2023 SIA&#x201d;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued 114,286 shares of Common Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#x201c;2024 SIA&#x201d;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued 285,714 shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#x201c;Retainer Shares&#x201d;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of December&#160;31, 2024, it was not probable that any of the Retainer Shares would be applied against any &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;outstanding legal fees. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-45235"
      unitRef="Unit_shares">575220</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_17_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-45236"
      unitRef="Unit_shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45237"
      unitRef="Unit_shares">1027977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-27710"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2024 (shares in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;946&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;153.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7,459&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;129&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;33.21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;(4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;51.67&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;(43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;160.56&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;138.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;6.43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;138.23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;6.43&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;727&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;113.01&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;5.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45239"
      unitRef="Unit_shares">946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45240"
      unitRef="Unit_USD_per_Share">153.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-45241">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-45242"
      unitRef="Unit_USD">7459000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="INF"
      id="ixv-45243"
      unitRef="Unit_shares">129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45244"
      unitRef="Unit_USD_per_Share">33.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45245"
      unitRef="Unit_shares">4</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45246"
      unitRef="Unit_USD_per_Share">51.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="INF"
      id="ixv-45247"
      unitRef="Unit_shares">43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45248"
      unitRef="Unit_USD_per_Share">160.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="INF"
      id="ixv-45249"
      unitRef="Unit_shares">1028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45250"
      unitRef="Unit_USD_per_Share">138.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-45251">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-45252"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45253"
      unitRef="Unit_shares">1028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45254"
      unitRef="Unit_USD_per_Share">138.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-45255">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-45256"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="INF"
      id="ixv-45257"
      unitRef="Unit_shares">727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="2"
      id="ixv-45258"
      unitRef="Unit_USD_per_Share">113.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      id="ixv-45259">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-45260"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-45261"
      unitRef="Unit_USD_per_Share">23.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-45262"
      unitRef="Unit_USD_per_Share">113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-2"
      id="ixv-45263"
      unitRef="Unit_USD">47300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-45264"
      unitRef="Unit_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-45265"
      unitRef="Unit_USD">15700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-45266"
      unitRef="Unit_USD">14600000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45267"
      unitRef="Unit_USD">27800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <sclx:WeightedAveragePeriodOverGrant contextRef="P01_01_2024To12_31_2024" id="ixv-45268">P2Y3M18D</sclx:WeightedAveragePeriodOverGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-45269"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45270"
      unitRef="Unit_shares">127902</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45271"
      unitRef="Unit_shares">82164</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      id="ixv-45272"
      unitRef="Unit_USD">242800</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      id="ixv-45273"
      unitRef="Unit_USD">21000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45274"
      unitRef="Unit_shares">9551</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2024To12_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45275"
      unitRef="Unit_shares">9551</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28154"> &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 71%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&#160;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.00%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;72.00%&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;119.08%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;3.79%&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;4.71%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term of options (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;3.0&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee stock purchase plan:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.00%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;129.30%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;5.39%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected life (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45277"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45278"
      unitRef="Unit_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45279"
      unitRef="Unit_pure">1.1908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45280"
      unitRef="Unit_pure">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45281"
      unitRef="Unit_pure">0.0471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      id="ixv-45282">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      id="ixv-45283">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45284"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45285"
      unitRef="Unit_pure">1.293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-45286"
      unitRef="Unit_pure">0.0539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      id="ixv-45287">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-45288"
      unitRef="Unit_shares">40000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-45289"
      unitRef="Unit_USD">600000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-45290"
      unitRef="Unit_USD">500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_13_2023To02_13_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45291"
      unitRef="Unit_shares">114286</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P07_01_2023To07_01_2023"
      decimals="0"
      id="ixv-45292"
      unitRef="Unit_shares">285714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45293"
      unitRef="Unit_USD">0</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28285"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;11. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with Itochu and Oishi Koseido Co., Ltd. (&#x201c;Oishi,&#x201d; and together with Itochu, the &#x201c;Developers&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. For each of the years ended December&#160;31, 2024 and 2023, Scilex Pharma made royalty payments in the amount of $8.3&#160;million. As of December&#160;31, 2024 and 2023, Scilex Pharma had ending balances of accrued royalty payables of $4.0&#160;million and $2.4&#160;million, respectively. Total royalty expense recorded within cost of revenue was $9.9&#160;million and $8.5&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon six months&#x2019; written notice. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;23, 2021, the Company filed an action (the &#x201c;OTC Action&#x201d;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt; (&#x201c;OTC&#x201d;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;respective &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;OTC lidocaine&lt;/div&gt;&lt;/div&gt; patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#x2019;s claims, but which motions the court largely rejected. Discovery proceeded. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolved the OTC Action. The terms of those agreements are confidential. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Former Employee Action &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#x201c;Plaintiffs&#x201d;) filed an action (the &#x201c;Former Employee Action&#x201d;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;, and together with Mr.&#160;Mack, the &#x201c;Defendants&#x201d;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.&#160;Mack&#x2019;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#x2019;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;95-page&lt;/div&gt; opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax would be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $3.5&#160;million (the &#x201c;Initial Payment&#x201d;) by two business days after the Effective Date (as defined therein), which payment has been made; (ii) $2.5&#160;million by July&#160;1, 2024, which payment has been made on July&#160;8, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provided mutual releases of all claims that existed as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#x2019; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. The court has requested additional oral argument on the topic of remedies against Mr.&#160;Mack, which argument occurred on November&#160;15, 2024. The parties are awaiting a final judgment from the court. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#x201c;Aveva&#x201d;), Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#x201c;ANDA&#x201d;). Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-month&lt;/div&gt; stay preventing them from selling a generic version of ZTlido during that time which was extinguished by the U.S. District Court for the Southern District of Florida decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#x2019;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#x2019;s product does not infringe the Company&#x2019;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;GLOPERBA Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#x201c;GLOPERBA Patent Litigation&#x201d;) alleging that the Company&#x2019;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#x2019;s colchicine product, Colcrys&lt;div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"&gt; &lt;/div&gt;(the &#x201c;Colcrys Patents&#x201d;). Takeda sought an order that the effective date of any FDA approval of the Company&#x2019;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The Company had previously accrued $0.5&#160;million with respect to the GLOPERBA Patent Litigation. On March&#160;7, 2024, the Company entered into a Settlement Agreement (the &#x201c;Settlement Agreement&#x201d;) with Takeda to resolve the action and entered into a license agreement with Takeda pursuant to which Takeda granted a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive&lt;/div&gt; license to the Company and its affiliates of certain patents owned by Takeda. The terms of those agreements are confidential. The Settlement Agreement was subject to review by the Federal Trade Commission and the U.S. Department of Justice, neither of which objected during the review period. After the expiration of the review period, the U.S. District Court for the District of Delaware entered a final consent judgment on May&#160;3, 2024. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company leases administrative and research and development facilities under various &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2024, the Company&#x2019;s leases have remaining lease terms of approximately 2.8 years. The terms of the Company&#x2019;s leases, ranging from 3 to 5 years, include extension options that were not reasonably certain to be exercised. Many of the Company&#x2019;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2024, the Company has no &lt;div style="-sec-ix-hidden:hidden145659460;display:inline;"&gt;finance leases&lt;/div&gt;. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;In April 2023, the Company modified the lease term&lt;/div&gt;&lt;/div&gt; for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $2.5&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease expense was $1.0&#160;million and $1.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,523&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45294"
      unitRef="Unit_pure">0.25</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45295"
      unitRef="Unit_pure">0.35</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-45296"
      unitRef="Unit_USD">8300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To12_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-45297"
      unitRef="Unit_USD">8300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45298"
      unitRef="Unit_USD">4000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45299"
      unitRef="Unit_USD">2400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45300"
      unitRef="Unit_USD">9900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45301"
      unitRef="Unit_USD">8500000</us-gaap:RoyaltyExpense>
    <sclx:AgreementMaturityDate
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-45302">2028-10-02</sclx:AgreementMaturityDate>
    <sclx:MaturityRenewalDescription
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-28295">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six months&#x2019; written notice.</sclx:MaturityRenewalDescription>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2024To12_31_2024_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-45304"
      unitRef="Unit_USD">3500000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2024To12_31_2024_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-45305"
      unitRef="Unit_USD">2500000</us-gaap:LitigationSettlementExpense>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2024To12_31_2024_EpoladermMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-45306"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2024To12_31_2024_ProbudurMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-45307"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2024To12_31_2024_EnveltaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-45308"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:DueFromRelatedParty
      contextRef="PAsOn12_31_2024_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-45310"
      unitRef="Unit_USD">500000</sclx:DueFromRelatedParty>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-45311">P2Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-45312">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-45313">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45314"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      id="ixv-45315"
      unitRef="Unit_USD">2500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      id="ixv-45316"
      unitRef="Unit_USD">2500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-45317"
      unitRef="Unit_USD">1000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-45318"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28419"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45320"
      unitRef="Unit_USD">1042000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45321"
      unitRef="Unit_USD">1021000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2024" id="ixv-45322">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-45323">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2024"
      decimals="3"
      id="ixv-45324"
      unitRef="Unit_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-45325"
      unitRef="Unit_pure">0.111</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28498"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,523&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45326"
      unitRef="Unit_USD">916000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45327"
      unitRef="Unit_USD">944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45328"
      unitRef="Unit_USD">724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45329"
      unitRef="Unit_USD">2584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45330"
      unitRef="Unit_USD">347000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45331"
      unitRef="Unit_USD">2237000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45332"
      unitRef="Unit_USD">714000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sclx:LeaseLiabilityNetOfCurrentPortion
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45333"
      unitRef="Unit_USD">1523000</sclx:LeaseLiabilityNetOfCurrentPortion>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28605"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;12. Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total loss before income taxes for the years ended December&#160;31, 2024 and 2023 did not include a foreign component. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the provision (benefit) expense were as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax (benefit) expense:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current income tax (benefit) expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax benefit:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(16,279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(16,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,803&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(11,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred income tax benefit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(19,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(27,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in tax rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax (benefit) expense from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;tax purposes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;85,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;71,434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt related interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credit carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense and reserves&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Purchased revenue liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,754&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;577&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;116,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;100,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(113,703&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(96,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit at federal statutory rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(15,290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(24,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquisition related charges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior year &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;true-up&lt;/div&gt; and carryback&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(5,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State, net of federal tax benefit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(5,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(4,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in tax rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $113.7&#160;million against its deferred tax assets as of December&#160;31, 2024. Realization of the deferred tax assets will be primarily dependent upon the Company&#x2019;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had $336.5&#160;million and $248.2&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2033 for &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;both federal &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;and state. As &lt;/div&gt;&lt;/div&gt; of December&#160;31, 2024, the Company had a total of $313.5&#160;million of federal net operating losses that have an indefinite life and will not expire, and had federal research and development income tax credits of $3.7&#160;million which will begin to expire in 2034. As of December&#160;31, 2024, the Company had California research and development income tax credits of $2.2&#160;million that have an indefinite life and will not expire. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#x2019;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2024 and 2023, there was no impact of such limitations on the Company&#x2019;s income tax provision. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#x2019;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2024. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to prior year tax positions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to current year tax positions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross unrecognized tax benefits at the end of the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024 and 2023, the Company had $1.2&#160;million and $1.1&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;million in total unrecognized tax benefits, respectively, which have been reflected as a reduction in deferred tax assets. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense&lt;/div&gt;&lt;/div&gt;. No interest or penalties have been recognized as of and for the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company believes that no material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;December&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;31,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28614"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the provision (benefit) expense were as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax (benefit) expense:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current income tax (benefit) expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax benefit:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(16,279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(16,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,803&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(11,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred income tax benefit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(19,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(27,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in tax rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax (benefit) expense from continuing operations&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45334"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45335"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45336"
      unitRef="Unit_USD">-1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45337"
      unitRef="Unit_USD">13000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45338"
      unitRef="Unit_USD">-1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45339"
      unitRef="Unit_USD">13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45340"
      unitRef="Unit_USD">-16279000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45341"
      unitRef="Unit_USD">-16514000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45342"
      unitRef="Unit_USD">-2803000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45343"
      unitRef="Unit_USD">-11247000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45344"
      unitRef="Unit_USD">-19082000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45345"
      unitRef="Unit_USD">-27761000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45346"
      unitRef="Unit_USD">2155000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45347"
      unitRef="Unit_USD">-1471000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45348"
      unitRef="Unit_USD">16927000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45349"
      unitRef="Unit_USD">29232000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45350"
      unitRef="Unit_USD">-1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45351"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-28847"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;85,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;71,434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt related interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credit carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense and reserves&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Purchased revenue liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,754&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;577&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;116,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;100,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(113,703&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(96,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45353"
      unitRef="Unit_USD">85226000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45354"
      unitRef="Unit_USD">71434000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45355"
      unitRef="Unit_USD">16228000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45356"
      unitRef="Unit_USD">16898000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45357"
      unitRef="Unit_USD">5228000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45358"
      unitRef="Unit_USD">4936000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45359"
      unitRef="Unit_USD">4415000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45360"
      unitRef="Unit_USD">3960000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45361"
      unitRef="Unit_USD">1157000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45362"
      unitRef="Unit_USD">525000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45363"
      unitRef="Unit_USD">1812000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45364"
      unitRef="Unit_USD">1584000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsPurchasedRevenueLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45365"
      unitRef="Unit_USD">1754000</sclx:DeferredTaxAssetsPurchasedRevenueLiability>
    <sclx:DeferredTaxAssetsPurchasedRevenueLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45366"
      unitRef="Unit_USD">0</sclx:DeferredTaxAssetsPurchasedRevenueLiability>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45367"
      unitRef="Unit_USD">577000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45368"
      unitRef="Unit_USD">774000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45369"
      unitRef="Unit_USD">303000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45370"
      unitRef="Unit_USD">159000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45371"
      unitRef="Unit_USD">116700000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45372"
      unitRef="Unit_USD">100270000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45373"
      unitRef="Unit_USD">113703000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45374"
      unitRef="Unit_USD">96776000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45375"
      unitRef="Unit_USD">2997000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45376"
      unitRef="Unit_USD">3494000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45377"
      unitRef="Unit_USD">2423000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45378"
      unitRef="Unit_USD">2734000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45379"
      unitRef="Unit_USD">574000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45380"
      unitRef="Unit_USD">760000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45381"
      unitRef="Unit_USD">2997000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45382"
      unitRef="Unit_USD">3494000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45383"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45384"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-29164"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2024&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit at federal statutory rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(15,290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(24,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquisition related charges&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior year &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;true-up&lt;/div&gt; and carryback&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(5,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State, net of federal tax benefit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(5,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(4,449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in tax rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45385"
      unitRef="Unit_USD">-15290000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45386"
      unitRef="Unit_USD">-24007000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45387"
      unitRef="Unit_USD">18559000</sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate>
    <sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45388"
      unitRef="Unit_USD">29232000</sclx:IncomeTaxReconciliationValuationAllowanceAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45389"
      unitRef="Unit_USD">2772000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45390"
      unitRef="Unit_USD">3798000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45391"
      unitRef="Unit_USD">485000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45392"
      unitRef="Unit_USD">260000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45393"
      unitRef="Unit_USD">-1182000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45394"
      unitRef="Unit_USD">-5079000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45395"
      unitRef="Unit_USD">-2705000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45396"
      unitRef="Unit_USD">-5127000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45397"
      unitRef="Unit_USD">-4449000</sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45398"
      unitRef="Unit_USD">1752000</sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45399"
      unitRef="Unit_USD">2155000</sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45400"
      unitRef="Unit_USD">-1471000</sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45401"
      unitRef="Unit_USD">-346000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45402"
      unitRef="Unit_USD">655000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45403"
      unitRef="Unit_USD">-1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45404"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45405"
      unitRef="Unit_USD">113700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-45406"
      unitRef="Unit_USD">336500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-45407"
      unitRef="Unit_USD">248200000</us-gaap:OperatingLossCarryforwards>
    <sclx:OperatingLossCarryforwardsExpirationYear
      contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-45408">2033</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:IndefiniteOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45410"
      unitRef="Unit_USD">313500000</sclx:IndefiniteOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45411"
      unitRef="Unit_USD">3700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sclx:IncomeTaxCreditsExpirationYear
      contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-45412">2034</sclx:IncomeTaxCreditsExpirationYear>
    <sclx:TaxCreditCarryforwardNotSubjectToExpireAmount
      contextRef="PAsOn12_31_2024_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      id="ixv-45413"
      unitRef="Unit_USD">2200000</sclx:TaxCreditCarryforwardNotSubjectToExpireAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-29367"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows for the years ended December&#160;31, 2024 and 2023 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to prior year tax positions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to current year tax positions&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross unrecognized tax benefits at the end of the year&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45414"
      unitRef="Unit_USD">1071000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-45415"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45416"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45417"
      unitRef="Unit_USD">536000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45418"
      unitRef="Unit_USD">127000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45419"
      unitRef="Unit_USD">127000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45420"
      unitRef="Unit_USD">1198000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45421"
      unitRef="Unit_USD">1071000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45422"
      unitRef="Unit_USD">1200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-45423"
      unitRef="Unit_USD">1100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45424"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45425"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45426"
      unitRef="Unit_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-29539"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;13. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2024 and 2023 (in thousands except per share data): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(72,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(114,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Premium on redemption of Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(52,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for basic loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(72,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reversal of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;mark-to-market&lt;/div&gt;&lt;/div&gt; adjustment for liability classified warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for diluted loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(81,702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,561&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common stock warrants exercisable for nominal consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,061&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(7.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(44.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(44.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Series A Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the Series A preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. Shares of the Dividend Stock, as declared by the Board of Directors of the Company on October&#160;27, 2024 and not yet distributed as of December&#160;31, 2024, are also excluded from the computation of net loss per share because the associated Series 1 Preferred Stock is not considered to be a participating security. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with FASB ASC 260, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnings Per Share, &lt;/div&gt;&lt;/div&gt;Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock were not vested as of the closing date of September&#160;21, 2023 and the vesting was based on the passage of time, the Company&#x2019;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). The Subsequent Penny Warrants became vested during the year ended December&#160;31, 2024, and therefore are included in the computation for basic and diluted net income per share as of December&#160;31, 2024, since all other exercise contingencies were removed except for the passage of &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;time. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,027,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;946,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;195,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Firm Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Placement Agent Warrants&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;114,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;103,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Representative Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issuable pursuant to the ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under the SIPA&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;15,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;StockBlock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,158,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,817,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,376,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-29542"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2024 and 2023 (in thousands except per share data): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 1pt solid rgb(0, 0, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(72,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(114,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Premium on redemption of Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(52,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for basic loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(72,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reversal of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;mark-to-market&lt;/div&gt;&lt;/div&gt; adjustment for liability classified warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for diluted loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(81,702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,561&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common stock warrants exercisable for nominal consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,061&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;10,145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(7.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(44.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(44.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45427"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45428"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45429"
      unitRef="Unit_USD">0</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45430"
      unitRef="Unit_USD">52645000</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45431"
      unitRef="Unit_USD">-72807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45432"
      unitRef="Unit_USD">-166976000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45433"
      unitRef="Unit_USD">-8895000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45434"
      unitRef="Unit_USD">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45435"
      unitRef="Unit_USD">-81702000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45436"
      unitRef="Unit_USD">-166976000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <sclx:WeightedAverageNumberOfSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-45437"
      unitRef="Unit_shares">3561</sclx:WeightedAverageNumberOfSharesOutstanding>
    <sclx:WeightedAverageNumberOfSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-45438"
      unitRef="Unit_shares">3722</sclx:WeightedAverageNumberOfSharesOutstanding>
    <sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-45439"
      unitRef="Unit_shares">6500</sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration>
    <sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-45440"
      unitRef="Unit_shares">0</sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45441"
      unitRef="Unit_shares">10061000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45442"
      unitRef="Unit_shares">3722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-45443"
      unitRef="Unit_shares">84</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-45444"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-45445"
      unitRef="Unit_shares">10145000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-45446"
      unitRef="Unit_shares">3722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-45447"
      unitRef="Unit_USD_per_Share">-7.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-45448"
      unitRef="Unit_USD_per_Share">-44.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-45449"
      unitRef="Unit_USD_per_Share">-8.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-45450"
      unitRef="Unit_USD_per_Share">-44.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-45451"
      unitRef="Unit_shares">8500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-29834"> &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,027,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;946,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;195,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Firm Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Placement Agent Warrants&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;114,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;103,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Representative Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issuable pursuant to the ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under the SIPA&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;15,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;StockBlock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,158,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,817,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,376,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45452"
      unitRef="Unit_shares">1027977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45453"
      unitRef="Unit_shares">946275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45454"
      unitRef="Unit_shares">156220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45455"
      unitRef="Unit_shares">195838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45456"
      unitRef="Unit_shares">108686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45457"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45458"
      unitRef="Unit_shares">34286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45459"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45460"
      unitRef="Unit_shares">399999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45461"
      unitRef="Unit_shares">114285</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45462"
      unitRef="Unit_shares">28572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45463"
      unitRef="Unit_shares">103240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45464"
      unitRef="Unit_shares">13446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45465"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45466"
      unitRef="Unit_shares">2204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45467"
      unitRef="Unit_shares">851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45468"
      unitRef="Unit_shares">8571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45469"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45470"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45471"
      unitRef="Unit_shares">15626</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45472"
      unitRef="Unit_shares">104848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45473"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45474"
      unitRef="Unit_shares">1642871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45475"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45476"
      unitRef="Unit_shares">131472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45477"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45478"
      unitRef="Unit_shares">1158617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-45479"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45480"
      unitRef="Unit_shares">4817769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="0"
      id="ixv-45481"
      unitRef="Unit_shares">1376115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-30061"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;14. Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferral and Consent under Tranche B Senior Secured Convertible Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025 (the &#x201c;First Amortization Payment Date&#x201d;), the Company is required to redeem in cash (the &#x201c;First Amortization Payment&#x201d;) such portion of the principal amount of the Tranche B Notes equal to each Tranche B Noteholder&#x2019;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $6,250,000 per fiscal quarter at a redemption price equal to 100% of such Amortization Amount (as defined in the Tranche B Notes). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#x201c;Nomis Bay Consent&#x201d;), (ii) Oramed (the &#x201c;Oramed Consent&#x201d;) and (iii) 3i, LP (the &#x201c;3i Consent&#x201d; and, together with the Nomis Bay Consent and the Oramed Consent, the &#x201c;Tranche B Consents&#x201d;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#x2019;s obligation to make the First Amortization Payment until January&#160;31, 2025. In consideration of such deferral, and to limit the Tranche B Noteholders&#x2019; right to exercise certain secured creditor remedies (including recourse against the assets of SCLX JV as a grantor under the Security Agreement (as defined in the Tranche B Consents)), SCLX JV delivered to the Tranche B Noteholders (or their designee) by deposit/withdrawal at custodian with the Depository Trust Company an aggregate of 142,855 Scilex &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;s&lt;/div&gt;hares held by SCLX JV, of which 71,428 shares were delivered to Oramed, 20,571 shares were delivered to BPY Limited, 36,571 shares were delivered to Nomis Bay Ltd, and 14,285 shares were delivered to 3i, LP. &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;In addition, pursuant to the Tranche B Consents&lt;/div&gt;&lt;/div&gt;, effective as of the latest of (i)&#160;the time of execution and delivery of the Tranche B Consents, (ii)&#160;the time of the delivery of the Scilex &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;s&lt;/div&gt;hares and (iii)&#160;the time of grant of the Royalty and Exclusive Rights (each as defined in, and contemplated pursuant to, the Term Sheet that is an exhibit to the Tranche B Consents (the &#x201c;Term Sheet&#x201d;)), the Tranche B Noteholders agreed to further defer the Company&#x2019;s obligation to make the First Amortization Payment until October&#160;8, 2026, provided that, as contemplated in the Term Sheet, the Company pays an aggregate of $1.1&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;(which amount has been paid). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Term Sheet provides that the Company and the Tranche B Noteholders would enter into an agreement pursuant to which the Tranche B Noteholders shall collectively receive a 10 year, assignable, freely transferable, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4% royalty on the worldwide Net Sales (as defined therein) of GLOPERBA and ELYXYB, excluding sales of ELYXYB in Canada. Please see section below titled &#x201c;Gloperba and Elyxyb Royalty Purchase Agreement&#x201d; for a description of such royalty agreement entered into by us. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amendment to Senior Secured Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;21, 2025, the Company entered into an amendment letter with Oramed (the &#x201c;Oramed Amendment&#x201d;), pursuant to which, among other things, Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Rest of World License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;22, 2025 (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido Effective Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;), Scilex Pharma entered into a License Agreement (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;) with RoyaltyVest Ltd. (the &#x201c;Licensee&#x201d;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#x201c;Product&#x201d; under Scilex Pharma&#x2019;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, between Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;69557-111-30&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(b)&#160;SP-103&lt;/div&gt; (collectively, the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido Product&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;). The Lido License Agreement supersedes and replaces the that certain Rest of World License Term Sheet parties entered into on October&#160;8, 2024. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-transferable&lt;/div&gt; right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido Products outside of the United States and certain territories stated in the Lido License Agreement (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido Licensee Territory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;). The Licensee granted to Scilex Pharma a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-transferable,&lt;/div&gt; right and license under the Licensee &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Blocking&lt;/div&gt; Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (each as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field (each as defined therein). Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; and all existing Lido Products in each country or jurisdiction in the Licensor Territory (as defined therein). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Promptly after the Lido Effective Date, Scilex Pharma is required to (i)&#160;facilitate an introduction between Oishi, Itochu, and the Licensee, and (ii)&#160;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with the Licensee for the manufacturing or supply of the Lido Product in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido License Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parent Guarantee for Lido License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;22, 2025, in connection with Lido License Agreement, the Company entered into that certain Parent Guarantee for Lidocaine License Agreement (the &#x201c;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parent Guarantee&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x201d;) with the Licensee, pursuant to which the Company agreed to guarantee the due and proper performance of Scilex Pharma&#x2019;s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee. Pursuant to the terms of the Parent Guarantee, the Company shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gloperba-Elyxyb Royalty Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;As contemplated by the Term Sheet in respect of the Royalty and Exclusive Rights described therein, on February&#160;28, 2025 (the &#x201c;Gloperba-Elyxyb Closing Date&#x201d;), the Company entered into a Purchase and Sale Agreement (the &#x201c;Gloperba-Elyxyb Royalty Purchase Agreement&#x201d;) with Scilex Pharma, certain institutional investors (collectively, the &#x201c;Gloperba-Elyxyb Royalty Investors&#x201d;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#x201c;Gloperba-Elyxyb RPA Purchasers&#x201d;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma sold to the Gloperba-Elyxyb RPA Purchasers the right to receive&lt;/div&gt;&lt;/div&gt;&#160;4%&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;of all aggregate net sales worldwide (the &#x201c;Gloperba-Elyxyb Purchased Receivables&#x201d;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#x201c;Gloperba-Elyxyb Covered Products&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In consideration of the Further Deferral and representing the &#x201c;grant of the Royalty and Exclusive Rights&#x201d; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#x201c;Gloperba-Elyxyb Payment Term&#x201d;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#x2019;s account such Gloperba-Elyxyb RPA Purchaser&#x2019;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter (commencing with the calendar quarter beginning January&#160;1, 2025) promptly, but in any event no later than&lt;/div&gt;&lt;/div&gt;&#160;60 calendar days after the end of each calendar quarter. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Payment Term. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalty Security Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the terms of the Gloperba-Elyxyb Royalty Purchase Agreement, the Company entered into a Security Agreement with Scilex Pharma and the collateral agent (as identified therein) for the benefit of the Gloperba-Elyxyb RPA Purchasers, dated as of February&#160;28, 2025 (the &#x201c;Gloperba-Elyxyb Royalty Security Agreement&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma&#x2019;s due performance and payment under the Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered Products. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;div style="line-height:normal;display: inline;"&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subordination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, the Company entered into that certain Subordination Agreement, dated as of February&#160;28, 2025 (the &#x201c;Gloperba-Elyxyb Subordination Agreement&#x201d;), by and among the Company, Scilex Pharma the Gloperba-Elyxyb RPA Purchasers and the Note Agent (each as defined in the Subordination Agreement). Pursuant to the Gloperba-Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by first priority liens on the collateral under the Gloperba-Elyxyb Royalty Security Agreement (the &#x201c;Gloperba-Elyxyb Royalty Collateral&#x201d;) and the Note Agent&#x2019;s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a second priority lien. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amendment No.&#160;1 to ZTlido Royalty Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;28, 2025, the Company and Scilex Pharma entered into an Amendment No.&#160;1 to Purchase and Sale Agreement (the &#x201c;ZTlido Royalty Amendment&#x201d;) with the purchasers (the &#x201c;ZTlido Royalty Purchasers&#x201d;) under that certain Purchase and Sale Agreement, dated as of October&#160;8, 2024 (the &#x201c;ZTlido Royalty Purchase Agreement&#x201d;). Pursuant to the Royalty Amendment, the Company and Scilex Pharma may assign their respective rights or delegate their respective obligations under the ZTlido Royalty Purchase Agreement without the prior written consent of the Purchasers if the Company receives a commitment, contingent upon an asset purchase of Covered Products (as defined in the ZTlido Royalty Purchase Agreement), that would allow the Company to pay in full all obligations owed under the Debt Instruments (as defined therein), provided that such purchaser of Covered Products agrees to assume all of the obligations of the Company and Scilex Pharma under the ZTlido Royalty Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gloperba Rest of World License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;28, 2025 (the &#x201c;Effective Date&#x201d;), the Company entered into a License Agreement (the &#x201c;Gloperba License Agreement&#x201d;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#x201c;Licensed Product&#x201d; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;collectively, the &#x201c;Gloperba Product&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Blocking&lt;/div&gt; Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Gloperba Product for commercialization of Gloperba Products in the United States in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Gloperba Product for commercialization in the United States in the Field (as defined therein). Each of the Licensee and the Company will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#x2019;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc"&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Promptly after the Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#x2019;s contract manufacturer of the Gloperba Product (the &#x201c;Gloperba CMO&#x201d;) as of the Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The term of the Gloperba License Agreement commences on the Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#x201c;Gloperba License Term&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;3, 2025, the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the &#x201c;Reverse Stock Split&#x201d;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share. Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#x2019;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant, which were not affected by the Reverse Stock Split. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-45482"
      unitRef="Unit_USD">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-45483"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-45484"
      unitRef="Unit_shares">142855</sclx:TotalNumberOfSharesGranted>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_OramedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-45485"
      unitRef="Unit_shares">71428</sclx:TotalNumberOfSharesGranted>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_BpyLimitedMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-45486"
      unitRef="Unit_shares">20571</sclx:TotalNumberOfSharesGranted>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_NomisBayLtdMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-45487"
      unitRef="Unit_shares">36571</sclx:TotalNumberOfSharesGranted>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis_ThreeILpMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-45488"
      unitRef="Unit_shares">14285</sclx:TotalNumberOfSharesGranted>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_02_2025To01_02_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-45489"
      unitRef="Unit_USD">1100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <sclx:SharesDelivered
      contextRef="PAsOn01_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-45491"
      unitRef="Unit_shares">92857</sclx:SharesDelivered>
    <sclx:PercentageOfLidocaineTopicalSystem
      contextRef="P02_22_2025To02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-45492"
      unitRef="Unit_pure">0.018</sclx:PercentageOfLidocaineTopicalSystem>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45493"
      unitRef="Unit_pure">0.50</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <sclx:AggregatePaymentOfCompany
      contextRef="PAsOn02_22_2025_ScenarioForecastMembersrtStatementScenarioAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-45494"
      unitRef="Unit_USD">200000</sclx:AggregatePaymentOfCompany>
    <us-gaap:RetailLandSalesReceivablesStatedInterestRate
      contextRef="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-45496"
      unitRef="Unit_pure">0.04</us-gaap:RetailLandSalesReceivablesStatedInterestRate>
    <sclx:NoOfCalendarDays
      contextRef="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="0"
      id="ixv-45497"
      unitRef="Unit_Days">60</sclx:NoOfCalendarDays>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45500"
      unitRef="Unit_USD">5800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45501"
      unitRef="Unit_USD">3272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45502"
      unitRef="Unit_USD">10619000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45503"
      unitRef="Unit_USD">26442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45504"
      unitRef="Unit_USD">3017000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45505"
      unitRef="Unit_USD">2436000</us-gaap:InventoryNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45506"
      unitRef="Unit_USD">9268000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45507"
      unitRef="Unit_USD">9397000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45508"
      unitRef="Unit_USD">28704000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45509"
      unitRef="Unit_USD">41547000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45510"
      unitRef="Unit_USD">707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45511"
      unitRef="Unit_USD">708000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45512"
      unitRef="Unit_USD">2049000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45513"
      unitRef="Unit_USD">2225000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45514"
      unitRef="Unit_USD">31451000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45515"
      unitRef="Unit_USD">32453000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Investments
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45516"
      unitRef="Unit_USD">2465000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45517"
      unitRef="Unit_USD">2420000</us-gaap:Investments>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45518"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45519"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45520"
      unitRef="Unit_USD">119000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45521"
      unitRef="Unit_USD">119000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45522"
      unitRef="Unit_USD">78976000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45523"
      unitRef="Unit_USD">92953000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45524"
      unitRef="Unit_USD">57257000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45525"
      unitRef="Unit_USD">52620000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45526"
      unitRef="Unit_USD">1654000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45527"
      unitRef="Unit_USD">1505000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45528"
      unitRef="Unit_USD">168429000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45529"
      unitRef="Unit_USD">162517000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AccruedExpenses
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45530"
      unitRef="Unit_USD">3482000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45531"
      unitRef="Unit_USD">2841000</sclx:AccruedExpenses>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45532"
      unitRef="Unit_USD">437000</sclx:CurrentPortionOfDeferredConsideration>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45533"
      unitRef="Unit_USD">447000</sclx:CurrentPortionOfDeferredConsideration>
    <us-gaap:DebtCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45534"
      unitRef="Unit_USD">39442000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45535"
      unitRef="Unit_USD">34876000</us-gaap:DebtCurrent>
    <sclx:PurchasedRevenueLiabilityCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45536"
      unitRef="Unit_USD">4303000</sclx:PurchasedRevenueLiabilityCurrent>
    <sclx:PurchasedRevenueLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45537"
      unitRef="Unit_USD">4115000</sclx:PurchasedRevenueLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45538"
      unitRef="Unit_USD">740000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45539"
      unitRef="Unit_USD">714000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45540"
      unitRef="Unit_USD">275744000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45541"
      unitRef="Unit_USD">259635000</us-gaap:LiabilitiesCurrent>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45542"
      unitRef="Unit_USD">2343000</sclx:LongTermPortionOfDeferredConsideration>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45543"
      unitRef="Unit_USD">2448000</sclx:LongTermPortionOfDeferredConsideration>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45544"
      unitRef="Unit_USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45545"
      unitRef="Unit_USD">845000</us-gaap:OtherLongTermDebtNoncurrent>
    <sclx:PurchasedRevenueLiabilityNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45546"
      unitRef="Unit_USD">2997000</sclx:PurchasedRevenueLiabilityNoncurrent>
    <sclx:PurchasedRevenueLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45547"
      unitRef="Unit_USD">2685000</sclx:PurchasedRevenueLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45548"
      unitRef="Unit_USD">7894000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45549"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45550"
      unitRef="Unit_USD">1327000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45551"
      unitRef="Unit_USD">1523000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45552"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45553"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45554"
      unitRef="Unit_USD">290460000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45555"
      unitRef="Unit_USD">285594000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45556"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45557"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45558"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45559"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45560"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45561"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45562"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45563"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2025_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-45564"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-45565"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <sclx:PreferredStockDividendShares
      contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45566"
      unitRef="Unit_shares">5000000</sclx:PreferredStockDividendShares>
    <sclx:PreferredStockDividendShares
      contextRef="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-45567"
      unitRef="Unit_shares">5000000</sclx:PreferredStockDividendShares>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2025_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-45568"
      unitRef="Unit_USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-45569"
      unitRef="Unit_USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45570"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45571"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45572"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45573"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45574"
      unitRef="Unit_shares">6951622</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45575"
      unitRef="Unit_shares">5493359</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45576"
      unitRef="Unit_shares">6951622</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45577"
      unitRef="Unit_shares">5235377</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45578"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45579"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <sclx:AdditionalPaidsInCapitals
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45580"
      unitRef="Unit_USD">448244000</sclx:AdditionalPaidsInCapitals>
    <sclx:AdditionalPaidsInCapitals
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45581"
      unitRef="Unit_USD">454614000</sclx:AdditionalPaidsInCapitals>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45582"
      unitRef="Unit_USD">6317000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45583"
      unitRef="Unit_USD">6317000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45584"
      unitRef="Unit_USD">-589132000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45585"
      unitRef="Unit_USD">-563052000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-45586"
      unitRef="Unit_shares">1458263</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-45587"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45588"
      unitRef="Unit_USD">76915000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45589"
      unitRef="Unit_USD">90522000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45590"
      unitRef="Unit_USD">-211484000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45591"
      unitRef="Unit_USD">-192641000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45592"
      unitRef="Unit_USD">78976000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45593"
      unitRef="Unit_USD">92953000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45594"
      unitRef="Unit_USD">5004000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45595"
      unitRef="Unit_USD">10884000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45596"
      unitRef="Unit_USD">1384000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45597"
      unitRef="Unit_USD">3840000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45598"
      unitRef="Unit_USD">2456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45599"
      unitRef="Unit_USD">3108000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45600"
      unitRef="Unit_USD">28060000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45601"
      unitRef="Unit_USD">29278000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45602"
      unitRef="Unit_USD">1002000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45603"
      unitRef="Unit_USD">1027000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45604"
      unitRef="Unit_USD">0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45605"
      unitRef="Unit_USD">6891000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45606"
      unitRef="Unit_USD">32902000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45607"
      unitRef="Unit_USD">30362000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45608"
      unitRef="Unit_USD">-27898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45609"
      unitRef="Unit_USD">-19478000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45610"
      unitRef="Unit_USD">10409000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45611"
      unitRef="Unit_USD">-457000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45612"
      unitRef="Unit_USD">6114000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45613"
      unitRef="Unit_USD">3905000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45614"
      unitRef="Unit_USD">2481000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45615"
      unitRef="Unit_USD">531000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45616"
      unitRef="Unit_USD">4000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45617"
      unitRef="Unit_USD">-6000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45618"
      unitRef="Unit_USD">1818000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45619"
      unitRef="Unit_USD">-4899000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45620"
      unitRef="Unit_USD">-26080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45621"
      unitRef="Unit_USD">-24377000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-45622"
      unitRef="Unit_USD_per_Share">-2.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-45623"
      unitRef="Unit_USD_per_Share">-2.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-45624"
      unitRef="Unit_USD_per_Share">-8.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-45625"
      unitRef="Unit_USD_per_Share">-8.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-45626"
      unitRef="Unit_shares">11565</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-45627"
      unitRef="Unit_shares">11565</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-45628"
      unitRef="Unit_shares">2926</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-45629"
      unitRef="Unit_shares">2926</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45630"
      unitRef="Unit_shares">34057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45631"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45632"
      unitRef="Unit_shares">6952000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45633"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45634"
      unitRef="Unit_USD">454614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45635"
      unitRef="Unit_USD">6317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45636"
      unitRef="Unit_USD">-563052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45637"
      unitRef="Unit_shares">1716000</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45638"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45639"
      unitRef="Unit_USD">-192641000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45640"
      unitRef="Unit_USD">-5353000</sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral>
    <sclx:NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45641"
      unitRef="Unit_shares">-143000</sclx:NumberOfTreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferralShares>
    <sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45642"
      unitRef="Unit_USD">7535000</sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral>
    <sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45643"
      unitRef="Unit_USD">2182000</sclx:TreasuryStockTransferredToTrancheBInvestorsForTrancheBNoteDeferral>
    <sclx:TreasuryStockPaidForGloperbaEx-USLicense
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45644"
      unitRef="Unit_USD">-808000</sclx:TreasuryStockPaidForGloperbaEx-USLicense>
    <sclx:NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45645"
      unitRef="Unit_shares">-22000</sclx:NumberOfTreasuryStockPaidForGloperbaEx-USLicenseShares>
    <sclx:TreasuryStockPaidForGloperbaEx-USLicense
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45646"
      unitRef="Unit_USD">1174000</sclx:TreasuryStockPaidForGloperbaEx-USLicense>
    <sclx:TreasuryStockPaidForGloperbaEx-USLicense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45647"
      unitRef="Unit_USD">366000</sclx:TreasuryStockPaidForGloperbaEx-USLicense>
    <sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45648"
      unitRef="Unit_USD">-3523000</sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension>
    <sclx:NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45649"
      unitRef="Unit_shares">-93000</sclx:NumberOfTreasuryStockTransferredToOramedForTheOramedNoteMaturityExtensionShares>
    <sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension
      contextRef="P01_01_2025To03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45650"
      unitRef="Unit_USD">4898000</sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension>
    <sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45651"
      unitRef="Unit_USD">1375000</sclx:TreasuryStockTransferredToOramedForTheOramedNoteMaturityExtension>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45652"
      unitRef="Unit_USD">3314000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45653"
      unitRef="Unit_USD">3314000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45654"
      unitRef="Unit_USD">-26080000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45655"
      unitRef="Unit_USD">-26080000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45656"
      unitRef="Unit_shares">34057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45657"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45658"
      unitRef="Unit_shares">6952000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45659"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45660"
      unitRef="Unit_USD">448244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45661"
      unitRef="Unit_USD">6317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45662"
      unitRef="Unit_USD">-589132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45663"
      unitRef="Unit_shares">1458000</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45664"
      unitRef="Unit_USD">-76915000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45665"
      unitRef="Unit_USD">-211484000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45666"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45667"
      unitRef="Unit_shares">4574000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45668"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45669"
      unitRef="Unit_USD">407828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45670"
      unitRef="Unit_USD">-490245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45671"
      unitRef="Unit_shares">1716000</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45672"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45673"
      unitRef="Unit_USD">-172938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45674"
      unitRef="Unit_shares">5000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreement>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45675"
      unitRef="Unit_USD">156000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45676"
      unitRef="Unit_USD">156000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreementsAndUnderAtmSalesAgreementValue>
    <sclx:SharesIssuedUnderBoughtDealOfferingShare
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45677"
      unitRef="Unit_shares">168000</sclx:SharesIssuedUnderBoughtDealOfferingShare>
    <sclx:SharesIssuedUnderBoughtDealOfferingValue
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45678"
      unitRef="Unit_USD">3769000</sclx:SharesIssuedUnderBoughtDealOfferingValue>
    <sclx:SharesIssuedUnderBoughtDealOfferingValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45679"
      unitRef="Unit_USD">3769000</sclx:SharesIssuedUnderBoughtDealOfferingValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45680"
      unitRef="Unit_shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45681"
      unitRef="Unit_shares">46000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45682"
      unitRef="Unit_shares">46000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45683"
      unitRef="Unit_USD">3558000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45684"
      unitRef="Unit_USD">3558000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45685"
      unitRef="Unit_USD">-24377000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45686"
      unitRef="Unit_USD">-24377000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45687"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45688"
      unitRef="Unit_shares">4748000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45689"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45690"
      unitRef="Unit_USD">415357000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45691"
      unitRef="Unit_USD">-514622000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45692"
      unitRef="Unit_shares">1716000</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2024_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-45693"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-45694"
      unitRef="Unit_USD">-189786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45695"
      unitRef="Unit_USD">-26080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45696"
      unitRef="Unit_USD">-24377000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45697"
      unitRef="Unit_USD">1003000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45698"
      unitRef="Unit_USD">1031000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45699"
      unitRef="Unit_USD">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45700"
      unitRef="Unit_USD">31000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45701"
      unitRef="Unit_USD">176000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45702"
      unitRef="Unit_USD">180000</sclx:NonCashOperatingLeaseCost>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45703"
      unitRef="Unit_USD">3314000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45704"
      unitRef="Unit_USD">3558000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45705"
      unitRef="Unit_USD">10409000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45706"
      unitRef="Unit_USD">-457000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45707"
      unitRef="Unit_USD">4057000</sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue>
    <sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45708"
      unitRef="Unit_USD">1375000</sclx:FinancingCostsAndAllocatedExpenseForFinancialInstrumentsAtFairValue>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45709"
      unitRef="Unit_USD">566000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45710"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45711"
      unitRef="Unit_USD">6114000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45712"
      unitRef="Unit_USD">3905000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45713"
      unitRef="Unit_USD">38000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45714"
      unitRef="Unit_USD">26000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45715"
      unitRef="Unit_USD">-15823000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45716"
      unitRef="Unit_USD">-4881000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45717"
      unitRef="Unit_USD">584000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45718"
      unitRef="Unit_USD">-726000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45719"
      unitRef="Unit_USD">-129000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45720"
      unitRef="Unit_USD">39000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45721"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45722"
      unitRef="Unit_USD">30000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45723"
      unitRef="Unit_USD">5128000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45724"
      unitRef="Unit_USD">1265000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45725"
      unitRef="Unit_USD">149000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45726"
      unitRef="Unit_USD">1046000</sclx:IncreaseDecreaseInAccruedPayroll>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45727"
      unitRef="Unit_USD">841000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45728"
      unitRef="Unit_USD">1120000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45729"
      unitRef="Unit_USD">5912000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45730"
      unitRef="Unit_USD">14430000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:OperatingLeaseLiability1
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45731"
      unitRef="Unit_USD">170000</sclx:OperatingLeaseLiability1>
    <sclx:OperatingLeaseLiability1
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45732"
      unitRef="Unit_USD">197000</sclx:OperatingLeaseLiability1>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45733"
      unitRef="Unit_USD">0</sclx:OtherLongTermLiabilities>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45734"
      unitRef="Unit_USD">3000</sclx:OtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45735"
      unitRef="Unit_USD">6007000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45736"
      unitRef="Unit_USD">9391000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45737"
      unitRef="Unit_USD">150000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45738"
      unitRef="Unit_USD">150000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45739"
      unitRef="Unit_USD">200000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45740"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <sclx:PurchaseOfConvertiblePromissoryNote
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45741"
      unitRef="Unit_USD">45000</sclx:PurchaseOfConvertiblePromissoryNote>
    <sclx:PurchaseOfConvertiblePromissoryNote
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45742"
      unitRef="Unit_USD">0</sclx:PurchaseOfConvertiblePromissoryNote>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45743"
      unitRef="Unit_USD">-395000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45744"
      unitRef="Unit_USD">-150000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45745"
      unitRef="Unit_USD">0</sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement>
    <sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45746"
      unitRef="Unit_USD">-156000</sclx:ProceedsFromIssuanceOfSharesUnderStandbyEquityPurchaseAgreementsAndAtmSalesAgreement>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45747"
      unitRef="Unit_USD">0</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45748"
      unitRef="Unit_USD">32567000</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45749"
      unitRef="Unit_USD">0</sclx:RepaymentOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45750"
      unitRef="Unit_USD">33313000</sclx:RepaymentOfRevolvingFacility>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45751"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45752"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45753"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45754"
      unitRef="Unit_USD">4375000</us-gaap:RepaymentsOfConvertibleDebt>
    <sclx:RepaymentOfDebt
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45755"
      unitRef="Unit_USD">1596000</sclx:RepaymentOfDebt>
    <sclx:RepaymentOfDebt
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45756"
      unitRef="Unit_USD">0</sclx:RepaymentOfDebt>
    <us-gaap:DeferredRevenueRefundPayments1
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45757"
      unitRef="Unit_USD">797000</us-gaap:DeferredRevenueRefundPayments1>
    <us-gaap:DeferredRevenueRefundPayments1
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45758"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueRefundPayments1>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45759"
      unitRef="Unit_USD">396000</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45760"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45761"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45762"
      unitRef="Unit_USD">10000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45763"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45764"
      unitRef="Unit_USD">1277000</us-gaap:PaymentsOfStockIssuanceCosts>
    <sclx:ExciseTaxPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45765"
      unitRef="Unit_USD">200000</sclx:ExciseTaxPaidInConnectionWithShareRepurchase>
    <sclx:ExciseTaxPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45766"
      unitRef="Unit_USD">0</sclx:ExciseTaxPaidInConnectionWithShareRepurchase>
    <sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45767"
      unitRef="Unit_USD">95000</sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger>
    <sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45768"
      unitRef="Unit_USD">0</sclx:PaymentsOfDeferredTransactionCostsRelatedToSemnurMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45769"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45770"
      unitRef="Unit_USD">46000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45771"
      unitRef="Unit_USD">-3084000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45772"
      unitRef="Unit_USD">-11196000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45773"
      unitRef="Unit_USD">2528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45774"
      unitRef="Unit_USD">-1955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45775"
      unitRef="Unit_USD">3272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-45776"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45777"
      unitRef="Unit_USD">5800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-45778"
      unitRef="Unit_USD">2774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45779"
      unitRef="Unit_USD">0</sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses>
    <sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45780"
      unitRef="Unit_USD">1501000</sclx:IssuanceCostsRelatedToBoughtDealOfferingIncludedInAccruedExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33027">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;1. Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Scilex Holding Company (&#x201c;Scilex&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is an innovative revenue-generating company focused on acquiring, developing and commercializing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#x201c;Legacy Scilex&#x201d;), Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;), Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC (&#x201c;SCLX JV&#x201d;). The business combination with Vickers (the &#x201c;Business Combination&#x201d;) was closed in November 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;12-hour&lt;/div&gt; administration period. In June 2022, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-licensed&lt;/div&gt; the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#x201c;GLOPERBA&#x201d;), a U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#x201c;U.S.&#x201d;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#x201c;ELYXYB&#x201d;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;FDA-approved,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;ready-to-use&lt;/div&gt;&lt;/div&gt; oral solution for the acute treatment of migraine, with or without aura, in adults. The Company launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024. In January 2025, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-licensed&lt;/div&gt; the rights to commercialize GLOPERBA outside the U.S. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is currently developing three product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-102&lt;/div&gt; (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-102&#x201d;&lt;/div&gt; or &#x201c;SEMDEXA&#x201d;), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company completed a Phase 2 trial in acute low back pain (&#x201c;LBP&#x201d;) in the third quarter of 2023, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; (4.5 mg, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-dose&lt;/div&gt; naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;SP-104&#x201d;),&lt;/div&gt; a novel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-dose&lt;/div&gt; delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. The Company has devoted substantially all of its efforts to the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-102,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-103&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104,&lt;/div&gt; and the commercialization of ZTlido, ELYXYB and GLOPERBA. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, include all adjustments of a normal recurring nature necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2024 as filed with the SEC on March&#160;31, 2025 (the &#x201c;Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&#x201d;).&lt;/div&gt; The interim &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025 or for any future &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;periods.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;3, 2025, the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved a reverse stock split of the Common Stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;1-for-35&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Stock Split&#x201d;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-Reverse&lt;/div&gt; Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.&#160;Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#x2019;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#x201c;CODM&#x201d;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single, reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the unaudited condensed consolidated statements of operations. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the unaudited condensed consolidated statements of operations and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the unaudited condensed consolidated balance sheets. Accordingly, the unaudited condensed consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer and Supplier Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had three customers during the three months ended March&#160;31, 2025 and 2024, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 99% and 85% of the Company&#x2019;s revenue for the three months ended March&#160;31, 2025 and 2024, respectively, and individually ranging from 14% to 47% and 24% to 31%, respectively. As of March&#160;31, 2025 and 2024, these customers represented 89% and 94% of the Company&#x2019;s outstanding accounts receivable, individually ranging &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;between 18% and 37%, and 25% and 36% for respective periods. Additionally, during the three months ended March&#160;31, 2025 and 2024, the Company purchased ZTlido, ELYXYB and GLOPERBA inventories from its sole suppliers, Itochu, Contract Pharmaceuticals Ltd. Canada (&#x201c;CPL&#x201d;) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the three months ended March&#160;31, 2025 and &lt;div style="display:inline;"&gt;2024.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2025, as compared to the significant accounting policies described in Note 1 of the Notes to Consolidated Financial Statements in the Company&#x2019;s audited consolidated financial statements included in the Annual Report on Form &lt;div style="white-space:nowrap;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the condensed consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1 - &lt;/div&gt;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2 - &lt;/div&gt;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3 - &lt;/div&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Cash equivalents were immaterial as of March&#160;31, 2025 and December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as selling, general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company reviews reserves and makes adjustments based on historical experience, current economic conditions and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for credit losses on accounts receivable were $1.1&#160;million and $1.2&#160;million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for prompt payment discounts were $0.4&#160;million and $0.6&#160;million,&lt;div style="display:inline;"&gt; respectively.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note and Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Tranche B Notes (as defined in Note 2 &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&#x201d; below) and the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&#x201d; below) that were issued in October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of&#160;changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. As of March&#160;31, 2025 and December&#160;31, 2024, the weighted-average interest rates for the short-term loans, including these financial instruments, were 8.35% and 6.67%, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space:nowrap;display:inline;"&gt;2024-03,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/div&gt;, which will require additional expense disclosures for all public entities. The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#x2019;s definition of selling expenses. ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-03&lt;/div&gt; is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-04,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;"&gt;Debt-Debt with Conversion and Other Options&lt;/div&gt;, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-04&lt;/div&gt; is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2020-06.&lt;/div&gt; The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33053">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, include all adjustments of a normal recurring nature necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2024 as filed with the SEC on March&#160;31, 2025 (the &#x201c;Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&#x201d;).&lt;/div&gt; The interim &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025 or for any future &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;periods.&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <sclx:ReverseStockSplitPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33081">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;3, 2025, the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved a reverse stock split of the Common Stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;1-for-35&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Stock Split&#x201d;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-Reverse&lt;/div&gt; Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.&#160;Stockholders who would have otherwise received a fractional share of Common Stock pursuant to the Reverse Stock Split, received cash in lieu of the fractional share. All Common Stock amounts and references have been retroactively adjusted for all figures presented to reflect the Reverse Stock Split unless specifically stated otherwise. The Company also adjusted the amounts for shares of Common Stock reserved for issuance upon the exercise of outstanding warrants, outstanding stock options and shares reserved under the Company&#x2019;s stock-based compensation plans, with the exception of the outstanding Penny Warrants and the Deposit Warrant (each as defined below), which were not affected by the Reverse Stock Split. &lt;/div&gt;</sclx:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="P04_03_2025To04_03_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-33086">the Board of Directors of the Company (the &#x201c;Board&#x201d;) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the &#x201c;Reverse Stock Split&#x201d;), which was effected on April&#160;15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common Stock was combined into one share of post-Reverse Stock Split Common Stock, without any change in par value per share. No fractional shares were issued as a result of the Reverse Stock Split, as fractional shares of Common Stock were rounded down to the nearest whole share.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33090">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker (the &#x201c;CODM&#x201d;) in making decisions on how to allocate resources and assessing performance. The Company has determined that its CODM is its Chief Executive Officer. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single, reportable segment. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated results that are reported on the unaudited condensed consolidated statements of operations. The Company has also evaluated the significant segment expenses incurred by the single segment that are regularly provided to the CODM and concluded they are consistent with those reported on the unaudited condensed consolidated statements of operations and include cost of revenue, research and development, selling, general and administrative. The Company manages assets on a consolidated basis as reported on the unaudited condensed consolidated balance sheets. Accordingly, the unaudited condensed consolidated financial statements and accompanying notes contained herein include the measure of profit or loss, net revenue, categories of expenses, assets and other financial information that is evaluated by the CODM. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2025To03_31_2025" id="ixv-33096">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, fair value of financial instruments and certain assumptions used in estimating stock-based compensation. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2025To03_31_2025" id="ixv-33101">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer and Supplier Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company had three customers during the three months ended March&#160;31, 2025 and 2024, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 99% and 85% of the Company&#x2019;s revenue for the three months ended March&#160;31, 2025 and 2024, respectively, and individually ranging from 14% to 47% and 24% to 31%, respectively. As of March&#160;31, 2025 and 2024, these customers represented 89% and 94% of the Company&#x2019;s outstanding accounts receivable, individually ranging &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;between 18% and 37%, and 25% and 36% for respective periods. Additionally, during the three months ended March&#160;31, 2025 and 2024, the Company purchased ZTlido, ELYXYB and GLOPERBA inventories from its sole suppliers, Itochu, Contract Pharmaceuticals Ltd. Canada (&#x201c;CPL&#x201d;) and Ferndale Laboratories, Inc., respectively. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the three months ended March&#160;31, 2025 and &lt;div style="display:inline;"&gt;2024.&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="INF"
      id="ixv-45782"
      unitRef="Unit_pure">0.10</sclx:PercentageOfNetRevenueSoleDistributors>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45783"
      unitRef="Unit_pure">0.99</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45784"
      unitRef="Unit_pure">0.85</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45785"
      unitRef="Unit_pure">0.14</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45786"
      unitRef="Unit_pure">0.47</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45787"
      unitRef="Unit_pure">0.24</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45788"
      unitRef="Unit_pure">0.31</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45789"
      unitRef="Unit_pure">0.89</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45790"
      unitRef="Unit_pure">0.94</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45792"
      unitRef="Unit_pure">0.18</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2025To03_31_2025_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45793"
      unitRef="Unit_pure">0.37</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45794"
      unitRef="Unit_pure">0.25</sclx:ConcentrationRiskThresholdPercentage>
    <sclx:ConcentrationRiskThresholdPercentage
      contextRef="P01_01_2024To03_31_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-45795"
      unitRef="Unit_pure">0.36</sclx:ConcentrationRiskThresholdPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33128">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2025, as compared to the significant accounting policies described in Note 1 of the Notes to Consolidated Financial Statements in the Company&#x2019;s audited consolidated financial statements included in the Annual Report on Form &lt;div style="white-space:nowrap;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2025To03_31_2025" id="ixv-33133">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the condensed consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The valuation of the derivative warrant liability for the Private Warrants, the February 2024 BDO Firm Warrants, the Deposit Warrant, the April RDO Warrants, the October 2024 Noteholder Warrants and the December 2024 RDO Common Warrants (each as defined below) is outlined in Note 4, utilizing the Black-Scholes option pricing model. The Company has chosen the fair value option for the Convertible Debentures, Oramed Note, and Tranche B Notes (each as defined below), with the valuation methodologies detailed in Note 7. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1 - &lt;/div&gt;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2 - &lt;/div&gt;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3 - &lt;/div&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33143">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Cash equivalents were immaterial as of March&#160;31, 2025 and December&#160;31, 2024. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2025To03_31_2025" id="ixv-33147">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as selling, general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company reviews reserves and makes adjustments based on historical experience, current economic conditions and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for credit losses on accounts receivable were $1.1&#160;million and $1.2&#160;million, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, allowances for prompt payment discounts were $0.4&#160;million and $0.6&#160;million,&lt;div style="display:inline;"&gt; respectively.&lt;/div&gt; &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn03_31_2025"
      decimals="-5"
      id="ixv-45797"
      unitRef="Unit_USD">1100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-45798"
      unitRef="Unit_USD">1200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <sclx:AllowancesForPromptPaymentDiscounts
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45799"
      unitRef="Unit_USD">400000</sclx:AllowancesForPromptPaymentDiscounts>
    <sclx:AllowancesForPromptPaymentDiscounts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-45800"
      unitRef="Unit_USD">600000</sclx:AllowancesForPromptPaymentDiscounts>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33170">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note and Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Tranche B Notes (as defined in Note 2 &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&#x201d; below) and the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&#x201d; below) that were issued in October 2024 and September 2023, respectively, as discussed further in Note 7. The Company recorded these financial instruments at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of&#160;changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to these financial instruments were expensed as incurred. As of March&#160;31, 2025 and December&#160;31, 2024, the weighted-average interest rates for the short-term loans, including these financial instruments, were 8.35% and 6.67%, respectively. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn03_31_2025_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-45801"
      unitRef="Unit_pure">0.0835</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-45802"
      unitRef="Unit_pure">0.0667</us-gaap:DebtWeightedAverageInterestRate>
    <sclx:TreasuryStockPolicyTextblock contextRef="P01_01_2025To03_31_2025" id="ixv-33176">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;</sclx:TreasuryStockPolicyTextblock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33180">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space:nowrap;display:inline;"&gt;2024-03,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/div&gt;, which will require additional expense disclosures for all public entities. The amendments require that at each interim and annual reporting period, an entity will disclose certain disaggregated expenses included in each relevant expense caption, as well as the total amount of selling expenses and, in annual periods, an entity&#x2019;s definition of selling expenses. ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-03&lt;/div&gt; is effective for annual reporting periods beginning with the fiscal year ending December&#160;31, 2027, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-04,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;"&gt;Debt-Debt with Conversion and Other Options&lt;/div&gt;, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2024-04&lt;/div&gt; is effective for annual reporting periods beginning after December&#160;15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU &lt;div style="white-space:nowrap;display:inline;"&gt;2020-06.&lt;/div&gt; The Company is currently evaluating the impact of this amendment on its consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33192">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;2. Liquidity and Going Concern &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern for at least one year after the issuance date of the accompanying unaudited condensed consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#x201c;Original Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#x201c;A&amp;amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Original Purchase Agreement. On, and effective as of, March&#160;25, 2024, the Company and Yorkville mutually agreed to terminate the A&amp;amp;R Yorkville Purchase Agreement.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#x201c;B. Riley Purchase Agreement&#x201d; and together with A&amp;amp;R Yorkville Purchase Agreement, the &#x201c;Standby Equity Purchase Agreements&#x201d;) with B. Riley Principal Capital II, LLC (&#x201c;B. Riley&#x201d;). Pursuant to each of the Standby Equity Purchase Agreements, the Company had the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. As consideration for Yorkville&#x2019;s and B.&#160;Riley&#x2019;s respective commitment to purchase shares of Common Stock at the Company&#x2019;s direction, the Company issued 7,142 commitment shares to each of Yorkville (the &#x201c;Yorkville Commitment Shares&#x201d;) and B.&#160;Riley (the &#x201c;B. Riley Commitment Shares&#x201d;). On, and effective as of, February&#160;16, 2024, the Company and B.&#160;Riley mutually agreed to terminate the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#x201c;Yorkville SPA&#x201d;), pursuant to which the Company issued and sold to Yorkville convertible debentures in an aggregate principal amount of $25.0&#160;million (the &#x201c;Convertible Debentures&#x201d;)&#160;for net cash proceeds of $24.0&#160;million, as discussed further in Note 7. The Company fully repaid the Convertible Debentures in March 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#x201c;eCapital Credit Agreement&#x201d;) with eCapital Healthcare Corp. (the &#x201c;Lender&#x201d;), pursuant to which the Lender made available loans (the &#x201c;Revolving Facility&#x201d;) in an aggregate principal amount of up to $30.0&#160;million (the &#x201c;Facility Cap&#x201d;). The proceeds of the Revolving Facility were used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. On October&#160;8, 2024, Scilex Pharma paid off the outstanding amount of all obligations and indebtedness of Scilex Pharma owing to the Lender under the eCapital Credit Agreement. Accordingly, the eCapital Credit Agreement, the related Loan Documents (as defined in the eCapital Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B.&#160;Riley Securities, Inc., Cantor Fitzgerald&#160;&amp;amp; Co. and H.C. Wainwright&#160;&amp;amp; Co., LLC (the &#x201c;Sales Agents&#x201d;), which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell (the &#x201c;ATM Offering&#x201d;) shares of Common Stock up to $170.0&#160;million (the &#x201c;ATM Shares&#x201d;), through or to the Sales Agents as part of the ATM Offering. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and could suspend offers thereunder at any time. During the three months ended March&#160;31, 2025, no sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold 2,637&#160;shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $0.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;11, 2024, the Company entered into that certain Commitment Side Letter (the &#x201c;Commitment Letter&#x201d;) with FSF 33433 LLC (&#x201c;FSF Lender&#x201d;), pursuant to which FSF Lender committed to provide the Company a loan (the &#x201c;FSF Loan&#x201d;) in the aggregate amount of $100.0&#160;million (the &#x201c;Commitment Amount&#x201d;). The Commitment Amount shall be payable as follows: (i) $85.0&#160;million no later than the date that is 70 days following the date on which the Company receives the FSF Deposit (as defined below) (the &#x201c;Outside Date&#x201d; and the funding of the initial $85.0&#160;million, the &#x201c;Initial Closing&#x201d;) and (ii)&#160;the remaining $15.0&#160;million within 60 days following the &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Initial Closing (the funding of the second $15.0&#160;million, the &#x201c;Second Closing&#x201d;). Pursuant to the Commitment Letter, FSF Lender was required to provide the Company a &lt;div style="white-space:nowrap;display:inline;"&gt;non-refundable&lt;/div&gt; deposit in immediately available funds in the aggregate principal amount of $10.0&#160;million (the &#x201c;FSF Deposit&#x201d; and the date on which such funds are fully received, the &#x201c;Deposit Date&#x201d;), which amount was creditable towards the $85.0&#160;million required to be funded by FSF Lender at the Initial Closing. The Company received the FSF Deposit on June&#160;18, 2024 and issued to FSF Lender a warrant to purchase up to an aggregate of 3,250,000 shares of the Common Stock (subject to adjustment for any stock dividend, stock split or similar transaction, provided that there shall not be any adjustment to the exercise price of the warrant in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares) (the &#x201c;Deposit Warrant&#x201d;), with an exercise price of $1.20 per share. The Deposit Warrant is immediately exercisable and will expire five years from the date of issuance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;17, 2024, the Company entered into a Satisfaction Agreement (the &#x201c;Satisfaction Agreement&#x201d;) with FSF Lender and Endeavor Distribution LLC, a Delaware limited liability company and affiliate of FSF Lender (&#x201c;Endeavor&#x201d;), pursuant to which the remaining obligations in respect of the FSF Deposit shall be fully satisfied by the Company&#x2019;s delivery of 28,000 cartons of ZTlido to Endeavor (the &#x201c;Additional Product&#x201d;), which delivery shall occur no later than December&#160;31, 2024. Upon satisfaction of such remaining obligations, the Commitment Letter shall be terminated and of no further force or effect and neither FSF Lender nor the Company shall have any further liability or obligations thereunder. In consideration of Endeavor assuming the payment obligation of the Company in respect of the FSF Deposit, Endeavor would not be responsible for making any payment to the Company for (i)&#160;the product already delivered as of the date of such agreement in an amount of approximately $13.2&#160;million and (ii)&#160;the Additional Product. Pursuant to the terms of the Satisfaction Agreement, if the Company was to fail to fully deliver the Additional Product by December&#160;31, 2024, the Company shall be liable to Endeavor for liquidated damages in the amount of $20,000,000. In November 2024, the Company delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, the Company entered into a securities purchase agreement (the &#x201c;Tranche B Securities Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;Tranche B Investors&#x201d;) and Oramed Pharmaceuticals Inc. (&#x201c;Oramed&#x201d;, and together with the Tranche B Investors, the &#x201c;Tranche B Noteholders&#x201d;), to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders, a new tranche B of senior secured convertible notes of the Company in the aggregate principal amount of $50.0&#160;million (the &#x201c;Tranche B Notes&#x201d;), which notes will mature on the &lt;div style="white-space:nowrap;display:inline;"&gt;two-year&lt;/div&gt; anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $36.40 per share. In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note (as defined below) of $22,500,000. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025, the Company&#x2019;s negative working capital was $247.0&#160;million, including cash and cash equivalents of approximately $5.8&#160;million. During the three months ended March&#160;31, 2025, the Company had operating losses of $27.9&#160;million and cash flows received from operating activities of $6.0&#160;million. The Company had an accumulated deficit of $589.1&#160;million as of March&#160;31, 2025. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures and to service its debt obligations (whether under the Oramed Note, the FSF Deposit or otherwise) for at least twelve months from the issuance of these unaudited condensed consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, ELYXYB and GLOPERBA, among which GLOPERBA and ELYXYB are still in the early stages of commercialization.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As a result, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt; issued.&lt;/div&gt; &lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45804"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-45805"
      unitRef="Unit_shares">7142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:Convertibledebentureprincipalamount
      contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-45806"
      unitRef="Unit_USD">25000000</sclx:Convertibledebentureprincipalamount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn03_31_2025_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-45807"
      unitRef="Unit_USD">24000000</us-gaap:ConvertibleDebt>
    <sclx:PrincipalLaonAmount
      contextRef="P06_27_2023To06_27_2023"
      decimals="-5"
      id="ixv-45808"
      unitRef="Unit_USD">30000000</sclx:PrincipalLaonAmount>
    <sclx:CommonStockIssuableValue
      contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-45809"
      unitRef="Unit_USD">170000000</sclx:CommonStockIssuableValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-45810"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-45811"
      unitRef="Unit_shares">2637</us-gaap:CommonStockSharesIssued>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2024To03_31_2024_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-45812"
      unitRef="Unit_USD">100000</sclx:ProceedsFromSaleOfCommonStock>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-45813"
      unitRef="Unit_USD">100000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <sclx:CommitmentAmountPayable
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-45814"
      unitRef="Unit_USD">85000000</sclx:CommitmentAmountPayable>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="P06_11_2024To06_11_2024" id="ixv-45815">P70D</us-gaap:LongtermPurchaseCommitmentPeriod>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-45816"
      unitRef="Unit_USD">85000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-45817"
      unitRef="Unit_USD">15000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:CompanyReceivesTheDepositPeriod contextRef="P06_11_2024To06_11_2024" id="ixv-45818">P60D</sclx:CompanyReceivesTheDepositPeriod>
    <sclx:CompanyReceivesTheDepositAmount
      contextRef="P06_11_2024To06_11_2024_SecondClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-45820"
      unitRef="Unit_USD">15000000</sclx:CompanyReceivesTheDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024"
      decimals="-5"
      id="ixv-45821"
      unitRef="Unit_USD">10000000</sclx:NonRefundableDepositAmount>
    <sclx:NonRefundableDepositAmount
      contextRef="P06_11_2024To06_11_2024_InitialClosingMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-45822"
      unitRef="Unit_USD">85000000</sclx:NonRefundableDepositAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_18_2024"
      decimals="INF"
      id="ixv-45823"
      unitRef="Unit_shares">3250000</us-gaap:CommonStockSharesIssued>
    <sclx:ExercisePriceOfTheWarrants
      contextRef="PAsOn06_18_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-45824"
      unitRef="Unit_USD_per_Share">1.2</sclx:ExercisePriceOfTheWarrants>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P09_17_2024To09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-45825"
      unitRef="Unit_USD">13200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LossContingencyAccrualProductLiabilityGross
      contextRef="PAsOn09_17_2024_SatisfactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-45826"
      unitRef="Unit_USD">20000000</us-gaap:LossContingencyAccrualProductLiabilityGross>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45827"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-45828"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45829"
      unitRef="Unit_USD">22500000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:ReductionOfThePrincipalBalance
      contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionsAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-45830"
      unitRef="Unit_USD">22500000</sclx:ReductionOfThePrincipalBalance>
    <sclx:WorkingCapital
      contextRef="PAsOn03_31_2025"
      decimals="-5"
      id="ixv-45831"
      unitRef="Unit_USD">247000000</sclx:WorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2025"
      decimals="-5"
      id="ixv-45832"
      unitRef="Unit_USD">5800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45833"
      unitRef="Unit_USD">-27900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45834"
      unitRef="Unit_USD">6000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2025"
      decimals="-5"
      id="ixv-45835"
      unitRef="Unit_USD">-589100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33261">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;3. Acquisitions and License Agreements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; Assets&#x201d;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets (the &#x201c;Sales Milestone Payment&#x201d;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;SP-104&lt;/div&gt; Assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of each of March 31, 2025 and December&#160;31, 2024, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;GLOPERBA License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;14, 2022, the Company entered into a License and Commercialization Agreement with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;) for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-licensing&lt;/div&gt; of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, which was amended by that First Amendment to License and Commercialization Agreement, dated as of January&#160;16, 2025 (such agreement, as amended, the &#x201c;Romeg License Agreement&#x201d;). Under the Romeg License Agreement, among other things, Romeg granted the Company (1)&#160;a license, with the right to sublicense, under the patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; specified therein, to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d;) in the United States (including its territories) (the &#x201c;Romeg U.S. Territory&#x201d;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#x201c;Licensed Products&#x201d;) and commercialize any such products in the Romeg U.S. Territory and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; and (2)&#160;an exclusive license, with a right to sublicense, to use the trademark &#x201c;GLOPERBA&#x201d; and logos, designs, translations, and modifications thereof (collectively, the &#x201c;Licensed Trademark&#x201d;) in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3)&#160;pursuant to the amendment thereto, a license, with the right to (a)&#160;sublicense under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and, if any, patents existing worldwide other than the Romeg U.S. Territory (the &#x201c;Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory&#x201d;), as specified therein, to develop, manufacture and commercialize Licensed Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory and (b)&#160;use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1)&#160;an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;up-front&lt;/div&gt; license fee of $2.0&#160;million, (2)&#160;upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (3)&#160;certain royalties in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single&lt;/div&gt; digit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Royalty Term, with a quarterly minimum royalty of $150,000, and (4)&#160;pursuant to the amendment thereto, (a)&#160;certain royalties at rates in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-single&lt;/div&gt; digit &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory during the Romeg &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Ex-U.S.&lt;/div&gt; Territory Royalty Term and (b)&#160;a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-creditable&lt;/div&gt; payment of $700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267 shares of Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. For each of the three months ended March&#160;31, 2025 and 2024, the Company made royalty payments in the amount of $0.2&#160;million. No contingent consideration was recognized as a liability or included in the fair value of the assets as of March&#160;31, 2025 or December&#160;31, 2024.&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ELYXYB Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In February 2023, the Company entered into an asset purchase agreement (the &#x201c;ELYXYB APA&#x201d;) with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Sellers&#x201d;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#x201c;ELYXYB Territory&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), dated August&#160;3, 2021 (the &#x201c;DRL APA&#x201d;), including an irrevocable, royalty-free, exclusive license to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and patents of DRL related to ELYXYB that is necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company had ending balances of accrued royalty payables of $0.1&#160;million. During the three months ended March&#160;31, 2025, the Company made royalty payments in the amount of $0.1&#160;million. The Company did not make any royalty payments during the three months ended March&#160;31, 2024. As of March&#160;31, 2025, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Rest of World License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;22, 2025 (the &#x201c;Lido Effective Date&#x201d;), Scilex Pharma entered into a License Agreement (the &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido License Agreement&lt;/div&gt;&lt;/div&gt;&#x201d;) with RoyaltyVest Ltd. (the &#x201c;Licensee&#x201d;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#x201c;Product&#x201d; under Scilex Pharma&#x2019;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi Koseido Co., Ltd. (&#x201c;Oishi&#x201d;) and Itochu, as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, among Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;69557-111-30&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(b)&#160;SP-103&lt;/div&gt; (collectively, the &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lido Product&lt;/div&gt;&lt;/div&gt;&#x201d;). The Lido License Agreement supersedes and replaces that certain Rest of World License Term Sheet the parties entered into on October&#160;8, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-transferable&lt;/div&gt; right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Products outside of the United States and certain territories stated in the Lido License Agreement (the &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Lido Licensee Territory&lt;/div&gt;&#x201d;). The Licensee granted to Scilex Pharma a &lt;div style="white-space:nowrap;display:inline;"&gt;non-exclusive,&lt;/div&gt; &lt;div style="white-space:nowrap;display:inline;"&gt;non-transferable,&lt;/div&gt; right and license under the Licensee &lt;div style="white-space:nowrap;display:inline;"&gt;Non-Blocking&lt;/div&gt; Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field. Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for &lt;div style="white-space:nowrap;display:inline;"&gt;SP-103&lt;/div&gt; and all existing Lido Products in each country or jurisdiction in the Licensor Territory. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#x201c;Lido License Term&#x201d;). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gloperba Rest of World License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;28, 2025 (the &#x201c;Gloperba Effective Date&#x201d;), the Company entered into a License Agreement (the &#x201c;Gloperba License Agreement&#x201d;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#x201c;Licensed Product&#x201d; under the Romeg License Agreement, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#x201c;Gloperba Product&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the Gloperba License Agreement, the Company granted to the Licensee during the Gloperba License Term (as defined below) a worldwide, exclusive, &lt;div style="white-space:nowrap;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Gloperba License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Gloperba Products, in all cases solely for commercialization of the Gloperba Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a &lt;div style="white-space:nowrap;display:inline;"&gt;non-exclusive,&lt;/div&gt; &lt;div style="white-space:nowrap;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Gloperba License Agreement), right and license under the Licensee &lt;div style="white-space:nowrap;display:inline;"&gt;Non-Blocking&lt;/div&gt; Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit the Gloperba Product for commercialization of the Gloperba Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture the Gloperba Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive 50% of the Net Revenue (as defined therein) generated based on Licensee&#x2019;s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Net Revenue on a quarterly basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Promptly after the Gloperba Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and the Company&#x2019;s contract manufacturer of the Gloperba Product (the &#x201c;Gloperba CMO&#x201d;) as of the Gloperba Effective Date, and (ii)&#160;use reasonable efforts to cause such Gloperba CMO to accept a direct &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;engagement with the Licensee for the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The term of the Gloperba License Agreement commences on the Gloperba Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#x201c;Gloperba License Term&#x201d;). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Elyxyb Rest of World License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;28, 2025 (the &#x201c;Elyxyb Effective Date&#x201d;), the Company entered into a License Agreement (the &#x201c;Elyxyb License Agreement&#x201d;) with Scilex Pharma and the Licensee with respect to (i)&#160;services, compositions, products, dosages and formulations comprising Elyxyb that have been or are later developed by or on behalf of the Company, including the product and any future product defined as a &#x201c;Licensed Product&#x201d; under the Elyxyb APA, as amended and as may be further amended or restated from time to time, and (ii)&#160;any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by the Company ((i) and (ii)&#160;together, the &#x201c;Elyxyb Product&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the Elyxyb License Agreement, the Company granted to the Licensee during the Elyxyb License Term (as defined below) a worldwide, exclusive, &lt;div style="white-space:nowrap;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Elyxyb License Agreement) right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by the Company to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Elyxyb Products, in all cases solely for commercialization of the Elyxyb Products outside of the United States in the Field (as defined therein). The Licensee granted to the Company a &lt;div style="white-space:nowrap;display:inline;"&gt;non-exclusive,&lt;/div&gt; &lt;div style="white-space:nowrap;display:inline;"&gt;non-transferable&lt;/div&gt; (except in connection with a permitted assignment of the Elyxyb License Agreement), right and license under the Licensee &lt;div style="white-space:nowrap;display:inline;"&gt;Non-Blocking&lt;/div&gt; Patents (as defined therein)&#160;(i) in the United States, to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Elyxyb Product for commercialization of Elyxyb Products in the United States in the Field, and (ii)&#160;worldwide, to develop and manufacture Elyxyb Product for commercialization in the United States in the Field. Each of the Licensee and the Company will receive 50% of the Canadian Net Revenue (as defined therein) generated based on the Licensee&#x2019;s sale of the Elyxyb Products, and the Licensee shall effect the foregoing by paying to the Company an amount required for the Company to receive its share of the Canadian Net Revenue on a quarterly basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Elyxyb License Agreement, the Licensee shall obtain and maintain regulatory approval for the Elyxyb Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Promptly after the Elyxyb Effective Date, the Company is required to (i)&#160;facilitate an introduction between the Licensee and CPL as of the Elyxyb Effective Date, and (ii)&#160;use reasonable efforts to cause CPL to accept a direct engagement with the Licensee for the manufacturing or supply of the Elyxyb Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Elyxyb Product in the entire world other than the United States during the Elyxyb License Term. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The term of the Elyxyb License Agreement commences on the Elyxyb Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#x201c;Elyxyb License Term&#x201d;). &lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <sclx:AmountDueForNewDrugApplication
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-45837"
      unitRef="Unit_USD">3000000</sclx:AmountDueForNewDrugApplication>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-45838"
      unitRef="Unit_USD">20000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-45839"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45840"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45841"
      unitRef="Unit_USD">13000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45842"
      unitRef="Unit_USD">150000</us-gaap:PaymentsForRoyalties>
    <sclx:Non-RefundableNon-CreditablePayment
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45844"
      unitRef="Unit_USD">700000</sclx:Non-RefundableNon-CreditablePayment>
    <sclx:TransferOfCommonStockShares
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-45845"
      unitRef="Unit_shares">22267</sclx:TransferOfCommonStockShares>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45846"
      unitRef="Unit_USD">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45847"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:Deferredconsiderationliabilities
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45848"
      unitRef="Unit_USD">3700000</sclx:Deferredconsiderationliabilities>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To03_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45849"
      unitRef="Unit_USD">200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2025To03_31_2025_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-45850"
      unitRef="Unit_USD">200000</us-gaap:RoyaltyExpense>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2024_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-3"
      id="ixv-45851"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sclx:AccruedRoyaltyPayables
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-45852"
      unitRef="Unit_USD">100000</sclx:AccruedRoyaltyPayables>
    <sclx:AccruedRoyaltyPayables
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45853"
      unitRef="Unit_USD">100000</sclx:AccruedRoyaltyPayables>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45854"
      unitRef="Unit_USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-45855"
      unitRef="Unit_USD">0</us-gaap:RoyaltyExpense>
    <sclx:PaymentToAcquireLicense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45856"
      unitRef="Unit_USD">0</sclx:PaymentToAcquireLicense>
    <sclx:PercentageOfLidocaineTopicalSystem
      contextRef="P02_22_2025To02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-45857"
      unitRef="Unit_pure">0.018</sclx:PercentageOfLidocaineTopicalSystem>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="PAsOn02_22_2025_ScilexPharmaMemberdeiLegalEntityAxis_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45859"
      unitRef="Unit_pure">0.50</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <sclx:AggregatePaymentOfCompany
      contextRef="PAsOn02_22_2025_ZTlidoRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-45860"
      unitRef="Unit_USD">200000</sclx:AggregatePaymentOfCompany>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="PAsOn02_28_2025_GloperbaRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45861"
      unitRef="Unit_pure">0.50</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="PAsOn02_28_2025_ElyxybRestOfWorldLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-45863"
      unitRef="Unit_pure">0.50</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33401">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;4. Fair Value Measurements &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-hidden:hidden145657740;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-hidden:hidden145657741;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, the Company issued a senior secured promissory note to Oramed in the principal amount of $101.9&#160;million (the &#x201c;Oramed Note&#x201d;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of March&#160;31, 2025 and December&#160;31, 2024 was determined to be $15.0&#160;million and $12.2&#160;million, respectively, by applying a discount rate of 129.07% and 128.82%, respectively. For the three months ended March&#160;31, 2025 and 2024, the Company recorded a loss of $2.8&#160;million and $3.8&#160;million in change in fair value of the Oramed Note in the unaudited condensed consolidated statements of operations, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2024, the Company entered into the Tranche B Securities Purchase Agreement to issue and sell the Tranche B Notes in the principal amount of $50.0&#160;million (see Note 7). The Company elected the fair value option to account for the Tranche B Notes with any changes in the fair value of such notes recorded in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Notes are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Tranche B Notes. The fair value as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $24.5&#160;million and $23.6&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $2.5&#160;million in change in fair value of the Tranche B Notes in the unaudited condensed consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Purchased Revenue Liability &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2024, the Company entered into a Purchase and Sale Agreement (&#x201c;ZTlido Royalty Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;ZTlido Royalty Investors&#x201d;) and Oramed (see Note 7). In February 2025, the Company also entered into a Purchase and Sale Agreement (&#x201c;Gloperba-Elyxyb Royalty Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;Gloperba-Elyxyb Royalty Investors&#x201d;) and Oramed (see Note 7). The Company elected the fair value option for the purchased revenue liability for both agreements with changes in fair value recorded as change in fair value of debt and liability instruments in the unaudited condensed consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. The Company uses a Scenario-Based Method valuation technique to measure the fair value of the purchased revenue liability. The aggregate fair value of both agreements as of March&#160;31, 2025 and December&#160;31, 2024, was determined to be $7.3&#160;million and $6.8&#160;million, respectively. For the three months ended March&#160;31, 2025, the Company recorded a loss of $0.8&#160;million in change in fair value of the purchased revenue liability in the unaudited condensed consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded a gain of $10.4&#160;million for the three months ended March&#160;31, 2025, attributed to warrant liabilities consisting of the Private Warrants, the February 2024 BDO Firm Warrants, the April 2024 RDO Common Warrants, Deposit Warrant, the October 2024 Noteholder Warrants, and December 2024 RDO Common Warrants (each as defined below). The Company recorded a loss of $0.5&#160;million for the three months ended March&#160;31, 2024, attributed to warrant liability consisting of the Private Warrants and the February 2024 BDO Firm Warrants. The Company assumed the private placement warrants from Vickers in November 2022 in connection with the Business Combination (the &#x201c;Private Warrants&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025, the following warrants to purchase Common Stock that are included in derivative liabilities were outstanding: 1,000,000&#160;Private Warrants, which are currently exercisable for an aggregate of up to 28,572&#160;shares of Common Stock, 3,803,447&#160;February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686&#160;shares of Common Stock, 15,000,000 April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock, 3,250,000 Deposit Warrant, which are currently exercisable for an aggregate of up to 3,250,000 shares of Common Stock, 7,500,000&#160;October 2024 Noteholder Warrants, which are currently exercisable for an aggregate of up to 214,284&#160;shares of Common Stock, and 57,512,958&#160;December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock. As of March&#160;31, 2025, the fair value of derivative warrant liabilities related to these warrants was $7.9&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(10,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be a Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on the Company&#x2019;s historical volatility, historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (as defined below), described in Note 9 of the Notes to Consolidated Financial Statements in the Annual Report on Form &lt;div style="white-space:nowrap;display:inline;"&gt;10-K.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A summary of the inputs used in valuing the derivative warrant liabilities as of March&#160;31, 2025 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:30%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;2024&lt;br/&gt; BDO Firm&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;April&#160;2024&lt;br/&gt; RDO&#160;Common&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deposit&lt;br/&gt; Warrant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October&#160;2024&lt;br/&gt; Noteholder&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants (5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants&#160;(2.5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;402.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;59.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;38.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;109.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;85.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;83.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;79.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;98.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A summary of the inputs used in valuing the derivative warrant liabilities as of December&#160;31, 2024 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:30%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;2024&lt;br/&gt; BDO Firm&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;April&#160;2024&lt;br/&gt; RDO&#160;Common&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deposit&lt;br/&gt; Warrant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October&#160;2024&lt;br/&gt; Noteholder&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants (5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants&#160;(2.5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;402.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;59.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;38.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;109.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;81.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;73.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;77.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;95.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Consideration Related to &lt;div style="white-space:nowrap;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Development Milestone Payment related to the &lt;div style="white-space:nowrap;display:inline;"&gt;SP-104&lt;/div&gt; Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the achievement of FDA approval for a new drug application for &lt;div style="white-space:nowrap;display:inline;"&gt;SP-104,&lt;/div&gt; the Company will transfer $3.0&#160;million in cash or shares of Common Stock to Aardvark, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for &lt;div style="white-space:nowrap;display:inline;"&gt;SP-104,&lt;/div&gt; expected timing for receipt of FDA approval for &lt;div style="white-space:nowrap;display:inline;"&gt;SP-104,&lt;/div&gt; and a discount rate of 9.6%. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33403">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-hidden:hidden145657740;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level 2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-hidden:hidden145657741;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45864"
      unitRef="Unit_USD">14962000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45865"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45866"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45867"
      unitRef="Unit_USD">14962000</us-gaap:SeniorNotes>
    <sclx:TrancheBNote
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45868"
      unitRef="Unit_USD">24480000</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45869"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45870"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45871"
      unitRef="Unit_USD">24480000</sclx:TrancheBNote>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45872"
      unitRef="Unit_USD">7300000</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45873"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45874"
      unitRef="Unit_USD">0</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45875"
      unitRef="Unit_USD">7300000</sclx:PurchasedRevenueLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45876"
      unitRef="Unit_USD">7894000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45877"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45878"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45879"
      unitRef="Unit_USD">7894000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45880"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45881"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45882"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45883"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-45884"
      unitRef="Unit_USD">54791000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45885"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2025_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45886"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45887"
      unitRef="Unit_USD">54791000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45888"
      unitRef="Unit_USD">12161000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45889"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45890"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45891"
      unitRef="Unit_USD">12161000</us-gaap:SeniorNotes>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45892"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45893"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45894"
      unitRef="Unit_USD">0</sclx:TrancheBNote>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45895"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45896"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45897"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45898"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45899"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45900"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45901"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45902"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45903"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45904"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45905"
      unitRef="Unit_USD">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-45906"
      unitRef="Unit_USD">60979000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45907"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45908"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45909"
      unitRef="Unit_USD">60979000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_01_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45910"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45911"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45912"
      unitRef="Unit_USD">12200000</us-gaap:DebtInstrumentFairValue>
    <sclx:SecuredNoteDiscountRate
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-45913"
      unitRef="Unit_pure">129.07</sclx:SecuredNoteDiscountRate>
    <sclx:SecuredNoteDiscountRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-45914"
      unitRef="Unit_pure">1.2882</sclx:SecuredNoteDiscountRate>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45915"
      unitRef="Unit_USD">2800000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2024To03_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45916"
      unitRef="Unit_USD">3800000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P10_01_2024To10_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45917"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45919"
      unitRef="Unit_USD">24500000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45920"
      unitRef="Unit_USD">23600000</us-gaap:DebtInstrumentFairValue>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45921"
      unitRef="Unit_USD">2500000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45922"
      unitRef="Unit_USD">7300000</sclx:PurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_GloperbaElyxybRoyaltyPurchaseAgreementMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45923"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2025To03_31_2025_PurchasedRevenueLiabilityMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-45924"
      unitRef="Unit_USD">800000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2025To03_31_2025_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-2"
      id="ixv-45925"
      unitRef="Unit_USD">10400</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To03_31_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-45926"
      unitRef="Unit_USD">500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45927"
      unitRef="Unit_shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45928"
      unitRef="Unit_shares">28572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45929"
      unitRef="Unit_shares">3803447</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45930"
      unitRef="Unit_shares">108686</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45931"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-45932"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45933"
      unitRef="Unit_shares">3250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45934"
      unitRef="Unit_shares">3250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45935"
      unitRef="Unit_shares">7500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45936"
      unitRef="Unit_shares">214284</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45937"
      unitRef="Unit_shares">57512958</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_December2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-45938"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sclx:DerivativeWarrantLiabilities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-45939"
      unitRef="Unit_USD">7900000</sclx:DerivativeWarrantLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33916">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the three months ended March&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(10,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45940"
      unitRef="Unit_USD">18303000</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-45941"
      unitRef="Unit_USD">-10409000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-45942"
      unitRef="Unit_USD">7894000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-33988">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A summary of the inputs used in valuing the derivative warrant liabilities as of March&#160;31, 2025 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:30%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;2024&lt;br/&gt; BDO Firm&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;April&#160;2024&lt;br/&gt; RDO&#160;Common&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deposit&lt;br/&gt; Warrant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October&#160;2024&lt;br/&gt; Noteholder&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants (5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants&#160;(2.5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;402.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;59.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;38.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;109.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;85.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;83.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;79.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;98.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A summary of the inputs used in valuing the derivative warrant liabilities as of December&#160;31, 2024 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:30%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;2024&lt;br/&gt; BDO Firm&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;April&#160;2024&lt;br/&gt; RDO&#160;Common&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deposit&lt;br/&gt; Warrant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October&#160;2024&lt;br/&gt; Noteholder&lt;br/&gt; Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants (5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;2024&lt;br/&gt; RDO Common&lt;br/&gt; Warrants&#160;(2.5yr)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;402.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;59.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;38.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;36.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;22.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;109.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;81.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;80.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;73.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;77.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;95.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4.21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025"
      decimals="2"
      id="ixv-45944"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45945"
      unitRef="Unit_USD_per_Share">59.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45946"
      unitRef="Unit_USD_per_Share">38.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45947"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45948"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45949"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45950"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2025To03_31_2025" id="ixv-45951">P2Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45952">P3Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45953">P4Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45954">P4Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45955">P4Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45956">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45957">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025"
      decimals="3"
      id="ixv-45958"
      unitRef="Unit_pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45959"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45960"
      unitRef="Unit_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45961"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45962"
      unitRef="Unit_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45963"
      unitRef="Unit_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45964"
      unitRef="Unit_pure">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025"
      decimals="4"
      id="ixv-45965"
      unitRef="Unit_pure">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-45966"
      unitRef="Unit_pure">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-45967"
      unitRef="Unit_pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-45968"
      unitRef="Unit_pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-45969"
      unitRef="Unit_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      id="ixv-45970"
      unitRef="Unit_pure">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      id="ixv-45971"
      unitRef="Unit_pure">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025"
      decimals="3"
      id="ixv-45972"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45973"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45974"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45975"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45976"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45977"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To03_31_2025_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45978"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-45979"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45980"
      unitRef="Unit_USD_per_Share">59.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45981"
      unitRef="Unit_USD_per_Share">38.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45982"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-45983"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45984"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-45985"
      unitRef="Unit_USD_per_Share">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-45986">P2Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45987">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45988">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45989">P4Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-45990">P4Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45991">P4Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45992">P2Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-45993"
      unitRef="Unit_pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45994"
      unitRef="Unit_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45995"
      unitRef="Unit_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45996"
      unitRef="Unit_pure">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-45997"
      unitRef="Unit_pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45998"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-45999"
      unitRef="Unit_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-46000"
      unitRef="Unit_pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-46001"
      unitRef="Unit_pure">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-46002"
      unitRef="Unit_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-46003"
      unitRef="Unit_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-46004"
      unitRef="Unit_pure">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      id="ixv-46005"
      unitRef="Unit_pure">0.0433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      id="ixv-46006"
      unitRef="Unit_pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-46007"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-46008"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-46009"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-46010"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="3"
      id="ixv-46011"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-46012"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024_DecemberCommonWarrantsTwoPointFiveYearMemberusgaapSubsidiarySaleOfStockAxis_DecemberRDOCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-46013"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-46014"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ProductLiabilityContingencyAccrualDiscountRate
      contextRef="PAsOn03_31_2025"
      decimals="INF"
      id="ixv-46015"
      unitRef="Unit_pure">0.096</us-gaap:ProductLiabilityContingencyAccrualDiscountRate>
    <sclx:FairValueOfContingentConsideration
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-46016"
      unitRef="Unit_USD">200000</sclx:FairValueOfContingentConsideration>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-34458">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;5. Balance Sheet Components &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Promissory Note &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;9, 2024, Denali Capital Acquisition Corp. (&#x201c;Denali&#x201d;) issued a convertible promissory note (the &#x201c;Convertible Promissory Note&#x201d;) in the total principal amount of up to $180,000 to the Company. The Convertible Promissory Note was issued with an initial principal balance of $&lt;div style="display:inline;"&gt;15,063.74&lt;/div&gt;, with the remaining $164,936.26 drawable at Denali&#x2019;s request and upon the consent of the Company prior to the maturity of the &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Convertible Promissory Note. The Convertible Promissory Note matures upon the earlier of (i)&#160;the effective date of the consummation of Denali&#x2019;s initial business combination or (ii)&#160;the date of the liquidation of Denali. Any future drawdowns of the remaining $164,936.26 principal amount available under the Convertible Promissory Note are expected to fund future &lt;div style="white-space:nowrap;display:inline;"&gt;one-month&lt;/div&gt; extensions as necessary to provide additional time for Denali to complete a business combination. At the option of the Company, upon consummation of an initial business combination, the Convertible Promissory Note may be converted in whole or in part into additional Class&#160;A ordinary shares of Denali, at a conversion price of $10.00 per ordinary share (the &#x201c;Conversion Shares&#x201d;). The terms of the Conversion Shares will be identical to those of the private placement shares that were issued to Denali Capital Global Investments, LLC, a Cayman Islands limited liability company (the &#x201c;Sponsor&#x201d;), in connection with Denali&#x2019;s initial public offering (the &#x201c;IPO&#x201d;). In the event that Denali does not consummate an initial business combination, the Convertible Promissory Note will be repaid only from funds held outside of the trust account established in connection with the IPO or will be forfeited, eliminated or otherwise forgiven. No interest shall accrue on the unpaid principal balance of the Convertible Promissory Note. As of March&#160;31, 2025 and December&#160;31, 2024, the balance of the Convertible Promissory Note was $120.5&#160;thousand and $75.3&#160;thousand, respectively, as a result of additional draws after the initial amount. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur Business Combination Agreement and Sponsor Interest Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;30, 2024, Semnur entered into an agreement and plan of merger (as may be amended or restated from time to time in accordance with its terms, including by Amendment No.&#160;1 and Amendment No.&#160;2 thereto, dated as of April&#160;16, 2025 (&#x201c;Amendment No.1&#x201d;) and July&#160;22, 2025, respectively, the &#x201c;Semnur Business Combination Agreement&#x201d;) with Denali and Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (&#x201c;Denali Merger Sub&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Semnur Business Combination Agreement provides that, among other things, (i)&#160;on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the &#x201c;Semnur Business Combination&#x201d;), and (ii)&#160;prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the General Corporation Law of the State of Delaware, as amended (the &#x201c;DGCL&#x201d;), and &lt;div style="white-space:nowrap;display:inline;"&gt;de-register&lt;/div&gt; in the Cayman Islands in accordance with Section&#160;206 of the Cayman Companies Act (the &#x201c;Domestication&#x201d;). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to &#x201c;Semnur Pharmaceuticals, Inc.&#x201d; (&#x201c;New Semnur&#x201d;). Shares of Denali common stock following the Domestication are hereinafter referred to as &#x201c;New Semnur Common Shares&#x201d;. Shares of Denali Series A preferred stock following the Domestication are hereinafter referred to as &#x201c;New Semnur Preferred Shares&#x201d;. Warrants to purchase New Semnur Common Shares following the Domestication are hereinafter referred to as &#x201c;New Semnur Warrants&#x201d;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with the terms and subject to the conditions of the Semnur Business Combination Agreement, following the Domestication and at the effective time of the Semnur Business Combination (the &#x201c;Effective Time&#x201d;): (i) each share of common stock, par value $0.00001 per share, of Semnur (the &#x201c;Semnur Common Stock&#x201d;), issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, a number of New Semnur Common Shares equal to the Exchange Ratio (as defined in the Semnur Business Combination Agreement); (ii) each share of Series A preferred stock of Semnur issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive, without interest, (a)&#160;one New Semnur Preferred Share and &lt;div style="white-space:nowrap;display:inline;"&gt;(b)&#160;one-tenth&lt;/div&gt; of one New Semnur Common Share, and (iii)&#160;subject to Denali&#x2019;s receipt of the Option Exchange Approval (as defined in the Semnur Business Combination Agreement), each option to purchase a share of Semnur Common Stock that is then outstanding shall be converted into the right to receive an option to purchase a number of New Semnur Common Shares as determined by the Exchange Ratio upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time, with the exercise price thereof adjusted by the Exchange Ratio. Pursuant to Amendment No.&#160;1, among other things, the parties agreed to (i)&#160;modify certain covenants of the parties to address the potential delisting of the Denali ordinary shares and warrants from the Nasdaq Capital &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Market, (ii)&#160;extend the Outside Date (as defined in Amendment No.&#160;1) to September&#160;30, 2025, and (iii)&#160;require Denali to amend its organizational documents to extend the period of time within which Denali can complete a business combination to December&#160;11, 2025, or such other date that is mutually agreed to by Semnur and Denali. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company defers specific incremental costs directly attributable to the Semnur Business Combination, such as legal, accounting and other general and administrative costs. After the consummation of the Semnur Business Combination, these costs will be classified in stockholders&#x2019; deficit as a reduction of additional &lt;div style="white-space:nowrap;display:inline;"&gt;paid-in&lt;/div&gt; capital recorded as a result of the Semnur Business Combination. In the event the Semnur Business Combination Agreement is terminated, all deferred offering costs will be reclassified to general and administrative expenses in the Company&#x2019;s unaudited condensed consolidated statements of operations. As of March&#160;31, 2025 and December&#160;31, 2024, deferred offering costs related to the Semnur Business Combination totaled $6.8&#160;million and $6.0&#160;million, respectively, and were included in prepaid expenses and other current assets in the Company&#x2019;s unaudited condensed consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution and delivery of the Semnur Business Combination Agreement, the Sponsor and the Company entered into a Sponsor Interest Purchase Agreement (the &#x201c;SIPA&#x201d;) dated August&#160;30, 2024 (the &#x201c;Signing Date&#x201d;). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class&#160;B ordinary shares, par value $0.0001 per share, of Denali (the &#x201c;Purchased Interests&#x201d;) that are currently held by the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000 (the &#x201c;Cash Consideration&#x201d;) and (ii) 8,571 shares of Common Stock. Pursuant to the SIPA, the Company has paid the Cash Consideration on the Signing Date and has agreed to issue Common Stock to the Sponsor contingent upon and following the occurrence of the Effective Time. The Company accounted for this promise to issue shares at a future date as an equity classified instrument as it is indexed to the Company&#x2019;s own stock and meets the conditions to be classified in equity under FASB ASC 815, &lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;. The Purchased Interests will convert automatically, on a &lt;div style="white-space:nowrap;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, into one New Semnur Common Share at the effective time of the Domestication pursuant to the terms of the Semnur Business Combination Agreement. The Company determined it does not have significant influence over Denali and accounted for the Purchased Interests as equity securities at the transaction price, which consists of the $2,000,000 paid by the Company to the Sponsor and the value of the 8,571 shares of the Common Stock at the closing price of $40 per share on the Signing Date for a total of $2.3&#160;million. The Company elected to subsequently measure the investment at cost less any impairment. As of each of March&#160;31, 2025 and December&#160;31, 2024, the Company&#x2019;s investment in the Purchased Interests had a balance of $2.3&#160;million. No impairment loss was recognized during the three months ended March&#160;31, 2025. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized depreciation expense of $1.0&#160;thousand and $4.0&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,153&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,841&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-46017"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_PrincipalBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-46018"
      unitRef="Unit_USD">15063.74</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-46019"
      unitRef="Unit_USD">164936.26</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_RemainingDrawableBalanceMemberSCLXLongTermDebtTransactionAxis"
      decimals="2"
      id="ixv-46020"
      unitRef="Unit_USD">164936.26</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-46021"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="PAsOn08_09_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46022"
      unitRef="Unit_USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="PAsOn03_31_2025_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-2"
      id="ixv-46023"
      unitRef="Unit_USD">120500</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="PAsOn12_31_2024_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-2"
      id="ixv-46024"
      unitRef="Unit_USD">75300</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2025_SemnurCommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="5"
      id="ixv-46025"
      unitRef="Unit_USD_per_Share">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-46026"
      unitRef="Unit_USD">6800000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-46027"
      unitRef="Unit_USD">6000000</us-gaap:DeferredOfferingCosts>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-46028"
      unitRef="Unit_shares">500000</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="4"
      id="ixv-46029"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P08_30_2024To08_30_2024_CashMemberusgaapCashAndCashEquivalentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46030"
      unitRef="Unit_USD">2000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-46031"
      unitRef="Unit_shares">8571</us-gaap:CommonStockSharesIssued>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P08_30_2024To08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46032"
      unitRef="Unit_USD">2000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-46033"
      unitRef="Unit_shares">8571</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46034"
      unitRef="Unit_USD_per_Share">40</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CapitalUnitsNetAmount
      contextRef="PAsOn08_30_2024_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-46035"
      unitRef="Unit_USD">2300000</us-gaap:CapitalUnitsNetAmount>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2025To03_31_2025_SemnurMergerAgreementAndSponsorInterestPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-46036"
      unitRef="Unit_USD">2300000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <sclx:ImpairmentLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46037"
      unitRef="Unit_USD">0</sclx:ImpairmentLoss>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-34521">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2025_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46038"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46039"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2025_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46040"
      unitRef="Unit_USD">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46041"
      unitRef="Unit_USD">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2025_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46042"
      unitRef="Unit_USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46043"
      unitRef="Unit_USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2025_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46044"
      unitRef="Unit_USD">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-46045"
      unitRef="Unit_USD">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46046"
      unitRef="Unit_USD">772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46047"
      unitRef="Unit_USD">772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46048"
      unitRef="Unit_USD">65000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46049"
      unitRef="Unit_USD">64000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46050"
      unitRef="Unit_USD">707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46051"
      unitRef="Unit_USD">708000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2025To03_31_2025"
      decimals="-2"
      id="ixv-46052"
      unitRef="Unit_USD">1000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2024To03_31_2024"
      decimals="-2"
      id="ixv-46053"
      unitRef="Unit_USD">4000</us-gaap:Depreciation>
    <sclx:AccruedExpensesTextblock contextRef="P01_01_2025To03_31_2025" id="ixv-34688">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,153&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;667&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,841&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:AccruedExpensesTextblock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46054"
      unitRef="Unit_USD">2153000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46055"
      unitRef="Unit_USD">667000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46056"
      unitRef="Unit_USD">337000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46057"
      unitRef="Unit_USD">876000</us-gaap:AccruedMarketingCostsCurrent>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46058"
      unitRef="Unit_USD">182000</sclx:AccruedResearchAndDevelopmentCosts>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46059"
      unitRef="Unit_USD">315000</sclx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46060"
      unitRef="Unit_USD">663000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46061"
      unitRef="Unit_USD">876000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46062"
      unitRef="Unit_USD">147000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46063"
      unitRef="Unit_USD">107000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <sclx:AccruedExpenses
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46064"
      unitRef="Unit_USD">3482000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46065"
      unitRef="Unit_USD">2841000</sclx:AccruedExpenses>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-34808">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;6. Goodwill and Intangible Assets &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the three months ended March&#160;31, 2025 and 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives, with remaining useful lives ranging from 6.58 to 12.75 years. A summary of the Company&#x2019;s identifiable intangible assets as of March&#160;31, 2025 and December&#160;31, 2024 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,704&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;31,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,796&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025, the weighted average remaining life for identifiable intangible assets was 8.3 years. Aggregate amortization expense was $1.0&#160;million for each of the three months ended March&#160;31, 2025 and 2024. Patent rights, acquired technology and acquired licenses are amortized over a &lt;div style="white-space:nowrap;display:inline;"&gt;15-year&lt;/div&gt; period. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Estimated future amortization expense related to intangible assets as of March&#160;31, 2025 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2025 (Remainder of 2025)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;31,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2025"
      decimals="-5"
      id="ixv-46066"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-46067"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46068"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-46069"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis"
      id="ixv-46070">P6Y6M29D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis"
      id="ixv-46071">P12Y9M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-46072">A summary of the Company&#x2019;s identifiable intangible assets as of March&#160;31, 2025 and December&#160;31, 2024 is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;18,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,704&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;29,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;31,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;17,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,796&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46073"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46074"
      unitRef="Unit_USD">-18314000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46075"
      unitRef="Unit_USD">14316000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46076"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46077"
      unitRef="Unit_USD">-9509000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46078"
      unitRef="Unit_USD">12431000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46079"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46080"
      unitRef="Unit_USD">-1007000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46081"
      unitRef="Unit_USD">4704000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46082"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46083"
      unitRef="Unit_USD">-500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46084"
      unitRef="Unit_USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46085"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46086"
      unitRef="Unit_USD">-29330000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46087"
      unitRef="Unit_USD">31451000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46088"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46089"
      unitRef="Unit_USD">-17770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46090"
      unitRef="Unit_USD">14860000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46091"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46092"
      unitRef="Unit_USD">-9143000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46093"
      unitRef="Unit_USD">12797000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46094"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46095"
      unitRef="Unit_USD">-915000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46096"
      unitRef="Unit_USD">4796000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46097"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46098"
      unitRef="Unit_USD">-500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-46099"
      unitRef="Unit_USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46100"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46101"
      unitRef="Unit_USD">-28328000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46102"
      unitRef="Unit_USD">32453000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P01_01_2025To03_31_2025" id="ixv-46103">P8Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-46104"
      unitRef="Unit_USD">1000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn03_31_2025_PatentRightsAcquiredTechnologyAndAcquiredLicensesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-46105">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35141">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Estimated future amortization expense related to intangible assets as of March&#160;31, 2025 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2025 (Remainder of 2025)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;2029&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;31,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46106"
      unitRef="Unit_USD">3004000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46107"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46108"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46109"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46110"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46111"
      unitRef="Unit_USD">12423000</sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46112"
      unitRef="Unit_USD">31451000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35222">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;7. Debt &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#x201c;Scilex-Oramed SPA&#x201d;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable &lt;div style="white-space:nowrap;display:inline;"&gt;in-kind&lt;/div&gt; on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the &lt;div style="white-space:nowrap;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). Following each of the April 2024 RDO (as defined below and as described under Note 9), the receipt of the FSF Deposit (as described below) and the ATM Sales Agreement, the Company made a mandatory prepayment of $9,578,835, $7,000,000 and $1,760,796, respectively, to Oramed, which equals 70% of the net cash proceeds the Company received from each of the April 2024 RDO, the FSF Deposit and the sale of shares of Common Stock pursuant to the ATM Sales Agreement. Given such payment was not a voluntary prepayment, such prepayment did not trigger the make-whole amount under the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#x201c;Guarantors&#x201d;) entered into a security agreement (the &#x201c;Security Agreement&#x201d;) with Oramed (together with its successors and permitted assigns, the &#x201c;Holder&#x201d;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025, the fair value of the Oramed Note was $15.0&#160;million, which is classified as a current liability in the unaudited condensed consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;20, 2024, the Company and Oramed entered into a Letter Agreement (the &#x201c;Oramed Letter Agreement&#x201d;), pursuant to which the Company agreed to pay to Oramed $2,000,000 (the &#x201c;Specified September Payment&#x201d;) on September&#160;23, 2024, which payment was applied as follows: (i) $1,700,000 was applied to the amortization payment due under the Oramed Note on the March 21, 2025 (the &#x201c;Maturity Date&#x201d;) and (y) $300,000 to purchase an aggregate of 4,000,000&#160;SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock) owned by Oramed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The parties further agreed, upon receipt of the Specified September Payment by Oramed, (i)&#160;that notwithstanding the minimum Liquidity (as defined in the Oramed Note) requirements set forth in Section&#160;7(b)(x) of the Oramed Note, the Company and its Subsidiaries (as defined in the Oramed Note) shall be required to maintain the following minimum liquidity during the specified time periods instead: from and after September&#160;19, 2024 until the Maturity Date, $0, and (ii)&#160;to extend the due date of the $20,000,000 amortization payment from September 23, 2024 to September 30, 2024. Oramed further agreed to extend such due date to October&#160;8, 2024, on which date a consent and amendment letter was signed with Oramed under which: (i)&#160;the Company made a payment of $12,500,000 to Oramed in lieu of the payment due on September 23, 2024, using the proceeds from the issuance of the Tranche B Notes, and (ii)&#160;the remaining payments under the Oramed Note were amended as follows: installment payment of $15,000,000 payable on December&#160;21, 2024, which payment was made on December&#160;13, 2024, and the remaining principal balance, accrued interest and fees payable on the Maturity Date. On January&#160;21, 2025, the Company and Oramed agreed to extend the Maturity Date under and as set forth in the Oramed Note from March&#160;21, 2025 to December&#160;31, 2025. In consideration of such extension, SCLX JV agreed to deliver to Oramed an aggregate of 92,857 shares of Common Stock held by SCLX JV, with a fair value of $1.4&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#x2019;s unaudited condensed consolidated statements of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the Oramed Note was $15.0&#160;million and $12.2&#160;million, respectively, which is classified as debt, current in the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of Oramed Note - recorded in the consolidated statements of operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tranche B Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, the Company entered into the Tranche B Securities Purchase Agreement with the Tranche B Investors and Oramed to refinance a portion of the Oramed Note and pay off certain other indebtedness of the Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company agreed to issue and sell, in a registered offering by the Company directly to the Tranche B Noteholders: (i)&#160;the Tranche B Notes, which notes will mature on the &lt;div style="white-space:nowrap;display:inline;"&gt;two-year&lt;/div&gt; anniversary of the issuance date and will be convertible into shares of Common Stock at a current conversion price equal to $36.40 per share and (ii)&#160;warrants (the &#x201c;October 2024 Noteholder Warrants&#x201d;) to purchase up to 214,284 shares of Common Stock directly to the Tranche B Noteholders. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In exchange for the issuance of the Tranche B Notes to the Tranche B Investors, the Company has received an aggregate amount of $22,500,000 in cash, excluding fees and expenses payable by the Company. In consideration for the Tranche B Notes issued to Oramed, the Company has received from Oramed an exchange and reduction of the principal balance under the Oramed Note of $22,500,000. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The October 2024 Noteholder Warrants are immediately exercisable for cash at a current exercise price equal to $36.40 per share and will expire five years from the issuance date. The October 2024 Noteholder Warrants issued to the Tranche B Investors are initially exercisable for 107,142 shares of Common Stock in the aggregate. The October 2024 Noteholder Warrants issued to Oramed are initially exercisable for 107,142 shares of Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the offering of the Tranche B Notes, the Company issued to StockBlock Securities LLC (&#x201c;StockBlock&#x201d;) and its affiliate, Rodman&#160;&amp;amp; Renshaw LLC (together, the &#x201c;October 2024 Placement Agents&#x201d;) or their respective designees, (i) 62,794 shares of Common Stock (the &#x201c;October 2024 Placement Agent Shares&#x201d;) and (ii)&#160;warrants to purchase up to 104,848 shares of Common Stock (the &#x201c;October 2024 Placement Agent Warrants&#x201d;). The October 2024 Placement Agent Warrants will have the same terms as the October 2024 Noteholder Warrants, except that the October 2024 Placement Agents have agreed not to exercise the October 2024 Placement Agent Warrants for a period of 180 days following the date of issuance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In conjunction with the Tranche B Securities Purchase Agreement, the Company entered into the ZTlido Royalty Purchase Agreement for $5.0&#160;million of the aggregate purchase price for the ZTlido Purchased Receivables (as defined below) in full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement. The $50.0&#160;million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $2.6&#160;million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statements of operations during the year ended December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Tranche B Notes, commencing on January&#160;2, 2025, the Company was required to redeem in cash (the &#x201c;First Amortization Payment&#x201d;) such portion of the principal amount of the Tranche B Notes equal to each &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Tranche B Noteholder&#x2019;s Holder Pro Rata Amount (as defined in the Tranche B Notes) of $6,250,000 per fiscal quarter at a redemption price equal to 100% of such Amortization Amount (as defined in the Tranche B Notes). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;2, 2025, the Company entered into a deferral and consent letter with each of (i)&#160;Nomis Bay Ltd and BPY Limited (the &#x201c;Nomis Bay Consent&#x201d;), (ii) Oramed (the &#x201c;Oramed Consent&#x201d;) and (iii) 3i, LP (the &#x201c;3i Consent&#x201d; and, collectively with the Nomis Bay Consent and the Oramed Consent, the &#x201c;Tranche B Consents&#x201d;), respectively, pursuant to which the Tranche B Noteholders agreed to defer the Company&#x2019;s obligation to make the First Amortization Payment until January&#160;31, 2025 and then further to October&#160;8, 2026. In consideration of such deferral, (i)&#160;SCLX JV delivered to the Tranche B Noteholders an aggregate of 142,855 shares of Common Stock held by SCLX JV, with a fair value of $2.2&#160;million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company&#x2019;s unaudited condensed consolidated statements of operations, (ii)&#160;the Company paid an aggregate of $1.1&#160;million in respect of a portion of the First Amortization Payment and related make-whole interest, and (iii)&#160;the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement (as described below). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche&#160;B Notes (in thousands):&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Repayment of Tranche B Notes principal and interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Aggregate principal repayments for the Company&#x2019;s outstanding debt will be $46.3&#160;million and $19.3&#160;million in 2025 and 2026, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Royalty Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the &#x201c;ZTlido Purchased Receivables&#x201d;) with respect to ZTlido, &lt;div style="white-space:nowrap;display:inline;"&gt;SP-103&lt;/div&gt; and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $5.0&#160;million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $2.5&#160;million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $2.5&#160;million minus Oramed&#x2019;s expenses (the amount so paid by the ZTlido Royalty Purchasers, collectively, the &#x201c;ZTlido RPA Closing Payment&#x201d;). Oramed&#x2019;s portion of the purchase price was paid by exchanging a portion of the outstanding principal balance under the Oramed Note equivalent to its portion of the ZTlido RPA Closing Payment, which amount extinguished and reduced $2.5&#160;million of the outstanding balance under the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The ZTlido Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $6.8&#160;million, recorded as a purchased revenue liability on the consolidated balance sheets. The Company incurred $0.2&#160;million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement during the three months ended March&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Repayment of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gloperba-Elyxyb Royalty Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;28, 2025 (the &#x201c;Gloperba-Elyxyb Closing Date&#x201d;), the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement with certain institutional investors (collectively, the &#x201c;Gloperba-Elyxyb Royalty Investors&#x201d;) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the &#x201c;Gloperba-Elyxyb RPA Purchasers&#x201d;). Pursuant to the Gloperba-Elyxyb Royalty Purchase Agreement, Scilex Pharma transferred to the Gloperba-Elyxyb RPA Purchasers the right to receive 4% of all aggregate net sales worldwide (the &#x201c;Gloperba-Elyxyb Purchased Receivables&#x201d;) with respect to Gloperba, Elyxyb, and any related, improved, successor, replacement and/or varying dosage forms of the foregoing (the &#x201c;Gloperba-Elyxyb Covered Products&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In consideration of the Further Deferral and representing the &#x201c;grant of the Royalty and Exclusive Rights&#x201d; (as defined in the Term Sheet), during the period commencing on the Gloperba-Elyxyb Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the &#x201c;Gloperba-Elyxyb Payment Term&#x201d;), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser&#x2019;s account, such Gloperba-Elyxyb RPA Purchaser&#x2019;s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter no later than 60 calendar days after the end of each calendar quarter. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Gloperba-Elyxyb Payment Term. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company elected the fair value option for the Gloperba-Elyxyb Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of February&#160;28, 2025 and&#160;March&#160;31, 2025, the fair value of the ZTlido Royalty Purchase Agreement was $0.5&#160;million, recorded as a purchased revenue liability on the unaudited condensed consolidated balance sheet.&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46113"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46114">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46115">2025-03-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46116"
      unitRef="Unit_USD">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46117">2023-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46118">2023-12-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46119"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-46120">2024-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-46121">2024-03-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-46122"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46123">2024-06-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46124">2024-06-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46125">2024-09-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46126">2024-09-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-46127">2024-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-46128">2024-12-21</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46129">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46130">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription
      contextRef="P01_01_2025To03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-35227">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;the greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March&#160;21, 2024, an exit fee of approximately $3.1&#160;million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).</us-gaap:DebtInstrumentDescription>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46131"
      unitRef="Unit_USD">9578835</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-46132"
      unitRef="Unit_USD">7000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2025To03_31_2025_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46133"
      unitRef="Unit_USD">1760796</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2025_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46134"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_20_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46135"
      unitRef="Unit_USD">2000000</us-gaap:LongTermNotesPayable>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46136"
      unitRef="Unit_USD">1700000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46137">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46138"
      unitRef="Unit_USD">300000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn03_31_2025_OramedLetterAgreementMemberSCLXPurchaseAgreementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46139"
      unitRef="Unit_shares">4000000</sclx:PurchaseOfCommonWarrants>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_01_2025To03_31_2025_MinimumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46140"
      unitRef="Unit_USD">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_01_2025To03_31_2025_MaximumMembersrtRangeAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46141"
      unitRef="Unit_USD">20000000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46142">2024-09-23</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P09_23_2024To09_23_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46143">2024-09-30</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P10_08_2024To10_08_2024_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46144"
      unitRef="Unit_USD">12500000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P10_08_2024To10_08_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-46145">2024-09-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P12_21_2024To12_21_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46146"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <sclx:SharesDelivered
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46147"
      unitRef="Unit_shares">92857</sclx:SharesDelivered>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_OramedMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-46148"
      unitRef="Unit_USD">1400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:DebtCurrent
      contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46149"
      unitRef="Unit_USD">15000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46150"
      unitRef="Unit_USD">12200000</us-gaap:DebtCurrent>
    <sclx:ScheduleOfTheOramedNoteTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35270">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;12,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of Oramed Note - recorded in the consolidated statements of operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;14,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfTheOramedNoteTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46152"
      unitRef="Unit_USD">12161000</us-gaap:ConvertibleDebt>
    <sclx:ChangeInFairValueOfConvertibleDebentures
      contextRef="P01_01_2025To03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46153"
      unitRef="Unit_USD">2801000</sclx:ChangeInFairValueOfConvertibleDebentures>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn03_31_2025_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46154"
      unitRef="Unit_USD">14962000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-46155"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46156"
      unitRef="Unit_shares">214284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn10_08_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_InvestorAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46157"
      unitRef="Unit_USD">22500000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:ReductionOfThePrincipalBalance
      contextRef="PAsOn10_08_2024_OramedMemberdeiLegalEntityAxis_PrincipalBalanceMemberusgaapLongtermDebtTypeAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46158"
      unitRef="Unit_USD">22500000</sclx:ReductionOfThePrincipalBalance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn10_08_2024_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-46159"
      unitRef="Unit_USD_per_Share">36.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46160"
      unitRef="Unit_shares">107142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_InvestorAgreementMemberusgaapTypeOfArrangementAxis_OctoberCommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_OramedMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-46161"
      unitRef="Unit_shares">107142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_08_2024_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-46162"
      unitRef="Unit_shares">62794</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn10_31_2024_TrancheBNoteMemberusgaapVestingAxis"
      decimals="0"
      id="ixv-46163"
      unitRef="Unit_shares">104848</us-gaap:CommonStockSharesIssued>
    <us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46164"
      unitRef="Unit_USD">5000000</us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice>
    <sclx:ProceedsReceivedFromPurchaseAgreement
      contextRef="P10_08_2024To10_08_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-46165"
      unitRef="Unit_USD">50000000</sclx:ProceedsReceivedFromPurchaseAgreement>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2024To12_31_2024_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-46166"
      unitRef="Unit_USD">2600000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-46168"
      unitRef="Unit_USD">6250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_02_2025To01_02_2025_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-46169"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <sclx:TotalNumberOfSharesGranted
      contextRef="P01_02_2025To01_02_2025_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-46170"
      unitRef="Unit_shares">142855</sclx:TotalNumberOfSharesGranted>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TrancheBNoteMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-46171"
      unitRef="Unit_USD">2200000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="P01_02_2025To01_02_2025"
      decimals="-5"
      id="ixv-46172"
      unitRef="Unit_USD">1100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <sclx:ScheduleOfTheTrancheBNoteTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35352">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche&#160;B Notes (in thousands):&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;23,560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Repayment of Tranche B Notes principal and interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;24,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfTheTrancheBNoteTableTextBlock>
    <sclx:TrancheBNote
      contextRef="PAsOn12_31_2024_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46173"
      unitRef="Unit_USD">23560000</sclx:TrancheBNote>
    <sclx:RepaymentOfTrancheBNotes
      contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46174"
      unitRef="Unit_USD">-1596000</sclx:RepaymentOfTrancheBNotes>
    <sclx:ChangeInFairValueOfTrancheBNotes
      contextRef="P01_01_2025To03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46175"
      unitRef="Unit_USD">2516000</sclx:ChangeInFairValueOfTrancheBNotes>
    <sclx:TrancheBNote
      contextRef="PAsOn03_31_2025_TrancheBNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46176"
      unitRef="Unit_USD">24480000</sclx:TrancheBNote>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2025To12_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-46177"
      unitRef="Unit_USD">46300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2026To12_31_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-46178"
      unitRef="Unit_USD">19300000</us-gaap:RepaymentsOfDebt>
    <srt:FederalFundsPurchasedAverageRatePaid
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-46179"
      unitRef="Unit_pure">0.08</srt:FederalFundsPurchasedAverageRatePaid>
    <us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46180"
      unitRef="Unit_USD">5000000</us-gaap:FinancingReceivablePurchasedWithCreditDeteriorationAmountAtPurchasePrice>
    <sclx:PaidToRoyaltyInvestors
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-46181"
      unitRef="Unit_USD">2500000</sclx:PaidToRoyaltyInvestors>
    <us-gaap:PaymentsToAcquireReceivables
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46182"
      unitRef="Unit_USD">2500000</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P10_08_2024To10_08_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46183"
      unitRef="Unit_USD">2500000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2025To03_31_2025_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-46184"
      unitRef="Unit_USD">6800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2024To12_31_2024_RoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorSecuredConvertibleNotesMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-46185"
      unitRef="Unit_USD">200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35438">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement during the three months ended March&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Repayment of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Change in fair value of purchased revenue liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Ending Balance as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfRevenueLiabilityActivityTableTextBlock>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn12_31_2024_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46186"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <sclx:RepaymentOfPurchasedRevenueLiability
      contextRef="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46187"
      unitRef="Unit_USD">-797000</sclx:RepaymentOfPurchasedRevenueLiability>
    <sclx:ChangeInFairValueOfPurchasedRevenueLiability
      contextRef="P01_01_2025To03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46188"
      unitRef="Unit_USD">797000</sclx:ChangeInFairValueOfPurchasedRevenueLiability>
    <sclx:PurchasedRevenueLiability
      contextRef="PAsOn03_31_2025_ZTlidoRoyaltyMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-46189"
      unitRef="Unit_USD">6800000</sclx:PurchasedRevenueLiability>
    <us-gaap:RetailLandSalesReceivablesStatedInterestRate
      contextRef="PAsOn02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-46190"
      unitRef="Unit_pure">0.04</us-gaap:RetailLandSalesReceivablesStatedInterestRate>
    <sclx:NoOfCalendarDays
      contextRef="P02_28_2025To02_28_2025_Gloperba-ElyxybRoyaltyPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-46191"
      unitRef="Unit_Days">60</sclx:NoOfCalendarDays>
    <sclx:PurchasedRevenueLiabilityCurrent
      contextRef="PAsOn03_31_2025_ZTlidoRoyaltyMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-46192"
      unitRef="Unit_USD">500000</sclx:PurchasedRevenueLiabilityCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35505">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;8. Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into that certain Stock Purchase Agreement (the &#x201c;Sorrento SPA&#x201d;) with Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;), the Company&#x2019;s then-controlling stockholder, pursuant to which the &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company purchased from Sorrento (i) 1,716,245 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share (the &#x201c;Series A Preferred Stock&#x201d;), and (iii) 1,386,617 Public Warrants (as defined below), which are currently exercisable for an aggregate of up to 39,617 shares of Common Stock and 3,104,000 Private Warrants (collectively, the &#x201c;Purchased Securities&#x201d;), which are currently exercisable for an aggregate of up to 88,685 shares of Common Stock. As a result, Sorrento no longer holds a majority of the voting power of the Company&#x2019;s outstanding capital stock entitled to vote. On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#x2019;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#x201c;Closing Penny Warrant&#x201d;) with an exercise price of $0.01 per share and restrictions on exercisability, and warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#x201c;Subsequent Penny Warrants&#x201d; and together with the Closing Penny Warrant, the &#x201c;Penny Warrants&#x201d;), each with an exercise price of $0.01 per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed 4,000,000 SPAC Warrants (as defined below, which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock), which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the agreement that the Company entered into in July 2023, to provide Sorrento with a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-amortizing&lt;/div&gt; super-priority junior secured term loan facility (&#x201c;Junior DIP Facility&#x201d;) in an aggregate principal amount of $20.0&#160;million, a $10.0&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $12.3&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants (as defined below) based on their relative fair values as of September&#160;21, 2023. Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#x201c;Holdco&#x201d;), a single purpose entity that is the Company&#x2019;s direct wholly owned subsidiary and (b)&#160;SCLX JV, a single purpose bankruptcy-remote entity that is the Company&#x2019;s indirect wholly owned subsidiary, which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 2). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Series A Preferred Stock. The Series A Preferred Stock is classified in permanent equity and does not have any bifurcated features. Therefore, the repurchase of the Series A Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Series A Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Series A Preferred Stock, with any excess amount allocated as the reduction in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital. The Series A Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Penny Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#x201c;cashless exercise.&#x201d; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#x201c;Oramed Beneficial Ownership Limitation&#x201d;); provided, however, that upon 61 days&#x2019; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#x2019;s own stock and meet the conditions to be classified in equity under FASB ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging,&lt;/div&gt;&lt;/div&gt; including sufficient available shares of Common Stock for the Company to settle the exercise of the warrants in shares of Common Stock. The Penny Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 6,500,000 Penny Warrants outstanding that were fully vested and such warrants became exercisable on March 14, 2025. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Excise Tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#x201c;IRS&#x201d;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability during the year ended December&#160;31, 2023, which was recorded as accrued expenses under current liabilities on the unaudited condensed consolidated balance sheets. During the three months ended March&#160;31, 2025, the Company made a total of $0.2&#160;million payments for the excise tax. As of March&#160;31, 2025, the remaining balance of the excise tax liability recorded as accrued expenses was $0.6&#160;million. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-46193"
      unitRef="Unit_shares">1716245</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-46194"
      unitRef="Unit_shares">29057097</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      id="ixv-46195"
      unitRef="Unit_USD_per_Share">0.0001</sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-46196"
      unitRef="Unit_shares">1386617</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-46197"
      unitRef="Unit_shares">39617</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-46198"
      unitRef="Unit_shares">3104000</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn03_31_2025_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-46199"
      unitRef="Unit_shares">88685</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-46200"
      unitRef="Unit_shares">4500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-46201"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-46202"
      unitRef="Unit_shares">8500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-46203"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:TransferOfWarrants
      contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-46204"
      unitRef="Unit_shares">4000000</sclx:TransferOfWarrants>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-46205"
      unitRef="Unit_shares">114286</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_21_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-46206"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:CashPayment
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46207"
      unitRef="Unit_USD">10000000</sclx:CashPayment>
    <us-gaap:LegalFees
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-46208"
      unitRef="Unit_USD">12300000</us-gaap:LegalFees>
    <sclx:FairValueOfSharesRepurchased
      contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46209"
      unitRef="Unit_USD">52600000</sclx:FairValueOfSharesRepurchased>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-46210"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:NumberOfShareOutstanding
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      id="ixv-46211"
      unitRef="Unit_pure">0.099</sclx:NumberOfShareOutstanding>
    <sclx:FairValueOfWarrants
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-46212"
      unitRef="Unit_USD">10400000</sclx:FairValueOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-46213"
      unitRef="Unit_shares">6500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-46214"
      unitRef="Unit_shares">6500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2025To03_31_2025_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-46215">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-46216"
      unitRef="Unit_USD">1300000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-46217"
      unitRef="Unit_USD">200000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="PAsOn03_31_2025_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-46218"
      unitRef="Unit_USD">600000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35574">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;9. Stockholders&#x2019; Deficit &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SPAC Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the completion of the Business Combination, the Company assumed the Private Warrants and the public warrants to purchase Common Stock, each with an exercise price of $402.50 per whole share (the &#x201c;Public Warrants&#x201d;, and together with the Private Warrants, the &#x201c;SPAC Warrants&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the reported last sale price of the Common Stock equals or exceeds $630.00 per share for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-trading&lt;/div&gt; day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#x2019; prior written notice.&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Public Warrants are equity-classified warrants and recognized in additional &lt;div style="white-space:nowrap;display:inline;"&gt;paid-in&lt;/div&gt; capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). On September&#160;20, 2024, the Company repurchased 4,000,000 of the SPAC Warrants (which are currently exercisable for an aggregate of up to 114,286 shares of Common Stock) held by Oramed (refer to Note 7). Following the repurchase, these warrants were cancelled. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of each of March&#160;31, 2025 and December&#160;31, 2024, 5,467,692 Public Warrants, which are currently exercisable for an aggregate of up to 156,220 shares of Common Stock are outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of each of March&#160;31, 2025 and December&#160;31, 2024, 1,000,000&#160;Private Warrants, which are currently exercisable for an aggregate of up to 28,572 shares of Common Stock are outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 45,000,000 shares of preferred stock (the &#x201c;Preferred Stock&#x201d;) of which there are two series in total. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, there were 29,057,097 shares of Series A Preferred Stock outstanding. On September&#160;21, 2023, the Series A Preferred Stock was repurchased and derecognized for accounting purposes. The Series A Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series 1 Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;27, 2024, the Board declared a stock dividend (the &#x201c;Dividend&#x201d;) consisting of an aggregate of 5,000,000 shares (the &#x201c;Dividend Stock&#x201d;) of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share, of the Company (the &#x201c;Series 1 Preferred Stock&#x201d;) to record holders of certain of the Company&#x2019;s securities as of the close of business on November&#160;7, 2024 (which date was subsequently changed to such later date to be determined in the sole discretion of the Board) (such later record date as so determined by the Board, the &#x201c;Record Date&#x201d;). Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Mandatory Exchangeable Preferred Stock (the &#x201c;Certificate of Designation&#x201d;) filed with the Secretary of State of the State of Delaware on October&#160;28, 2024, the Series 1 Preferred Stock ranks senior to the Common Stock but junior to all other series of Preferred Stock with respect to distributions of assets upon voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company. The holders of Series 1 Preferred Stock may become entitled to a pro rata portion of the number of shares that represents the lesser of (a) 10% of the shares of the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted), held by the Company as of immediately prior to the Effective Time (as defined below) (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction) and (b)&#160;that number of shares of Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) equal to $200,000,000 divided by the closing price of such Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) on any national securities exchange on which such shares are listed on the date that is 10 trading days prior to the Determination Date (as defined below), which shares shall be paid from the shares of Semnur Common Stock (or &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;such other securities into which or for which such stock may be exchanged or converted) held by the Company as of immediately prior to the Effective Time (taking into account any adjustment for any stock dividend, stock split, reverse stock split or similar transaction). Furthermore, the holders of Series 1 Preferred Stock shall not be entitled to receive any dividends and shall not have any voting rights by virtue of their ownership of any shares of Series 1 Preferred Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of the Certificate of Designation, (a) &#x201c;Effective Time&#x201d; means the effective time of the Semnur Business Combination as determined under the terms of the Semnur Business Combination Agreement, (b) &#x201c;Determination Date&#x201d; means, if the Semnur Common Stock (or such other securities into which or for which such stock may be exchanged or converted) is listed for, and trading on, any national securities exchange, the date that is 15 trading days following the Registration Date, (c) &#x201c;Registration Date&#x201d; means the earlier of (i)&#160;the Effective Time, at which time the shares of Semnur Common Stock (or such other securities into which or for which such stock has been exchanged or converted) are registered under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) and (ii)&#160;the time at which the Registration Statement is declared effective by the SEC and (d) &#x201c;Registration Statement&#x201d; means a registration statement, whether under the Exchange Act, or the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), that is filed by Semnur or any successor thereto or affiliate thereof with respect to the registration of the Semnur Common Stock or any securities into which or for which such stock may be exchanged or converted. The Board has the right to change the Record Date and the right to revoke the Dividend at any time prior to the payment date therefor. There can be no assurance that the Board will not revoke the Dividend or that, even if such Dividend is paid, the conditions for the mandatory exchange set forth in the Certificate of Designations will ever occur (including that the Registration Date shall have occurred on or before 11:59 p.m. Eastern time on October&#160;28, 2025). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Series 1 Preferred Stock does not have any bifurcated features and is classified in equity at par value because the Company had an accumulated deficit position as of Dividend Stock declaration date. As of March&#160;31, 2025 and as of the date of this filing, none of the Dividend Stock or any shares of the Series 1 Preferred Stock were issued or distributed. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, there were 1,458,263 and 1,716,245 shares of Treasury Stock, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Sales Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2023, the Company entered into the ATM Sales Agreement with the Sales Agents, which agreement was voluntarily terminated by the Company effective as of March&#160;5, 2025. Pursuant to the ATM Sales Agreement, the Company was able to offer and sell the ATM Shares through or to the Sales Agents. The Company had no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The ATM Shares offered and sold in the ATM Offering were issued pursuant to the Company&#x2019;s shelf registration statement on Form &lt;div style="white-space:nowrap;display:inline;"&gt;S-3&lt;/div&gt; (which was initially filed with the SEC on December&#160;22, 2023, as amended, and declared effective on January&#160;11, 2024 (File &lt;div style="white-space:nowrap;display:inline;"&gt;No.&#160;333-276245))&lt;/div&gt; (the &#x201c;Shelf &lt;div style="white-space:nowrap;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement&#x201d;). The ATM Shares were offered only by means of a prospectus forming a part of the Shelf &lt;div style="white-space:nowrap;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement. The Sales Agents were entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company agreed to reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the Securities Act. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the three months ended March&#160;31, 2025, no sales of Common Stock had been made under the ATM Sales Agreement. During the three months ended March&#160;31, 2024, the Company sold 2,637 shares of Common Stock pursuant to the ATM Sales Agreement for net proceeds of approximately $0.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;February 2024 Bought Deal Offering Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#x201c;February 2024 BDO Underwriting Agreement&#x201d;) with Rodman&#160;&amp;amp; Renshaw LLC and StockBlock, acting as representatives of the underwriters, to sell, in an underwritten offering (the &#x201c;February 2024 BDO&#x201d;), 168,068 shares of Common Stock (the &#x201c;February 2024 BDO Firm Shares&#x201d;) and accompanying common warrants to purchase up to an aggregate of 168,068 shares of Common Stock (the &#x201c;February 2024 BDO Firm Warrants&#x201d;). The securities in the February 2024 BDO were offered and sold by the Company pursuant to the Shelf &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement, a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The February 2024 BDO closed on March&#160;5, 2024, and the combined price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant paid by the underwriters was $54.74, which amount reflects the combined public offering price of $59.50, less underwriting discounts and commissions. Subject to certain ownership limitations, the Common Warrants are immediately exercisable, set to expire five years later, with an exercise price of $59.50 per share, subject to adjustments. Additionally, the Company issued the representative warrants (the &#x201c;February 2024 BDO Representative Warrants&#x201d;) to the underwriters, allowing them to purchase up to 13,446 shares of Common Stock, with these warrants being immediately exercisable at $74.38&#160;per share, representing 125% of the combined public offering price per February 2024 BDO Firm Share and accompanying February 2024 BDO Firm Warrant.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the February 2024 BDO Firm Warrants as a liability classified instrument (see Note&#160;4) and the February 2024 BDO Representative Warrants as an equity classified instrument. The February 2024 BDO Representative Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheet. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations. The fair value of February 2024 BDO Representative Warrants as of the date of issuance was $0.3&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2024, the Company entered into a warrant amendment (the &#x201c;Warrant Amendment&#x201d;) with one of its investors to exercise the outstanding number of the February 2024 BDO Firm Warrants that the Company issued to such investor in the February 2024 BDO. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding February 2024 BDO Firm Warrants to purchase an aggregate of 50,421 shares of Common Stock in cash at an amended exercise price of $20.65 per share. During each of the three months ended March&#160;31, 2025 and 2024, there were no February 2024 BDO Firm Warrants exercised. As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 3,803,447 February 2024 BDO Firm Warrants, which are currently exercisable for an aggregate of up to 108,686 shares of Common Stock outstanding and 470,588 February 2024 BDO Representative Warrants, which are currently exercisable for an aggregate of up to 13,446 shares of our Common Stock outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;April 2024 Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;23, 2024, the Company entered into a securities purchase agreement (the &#x201c;April 2024 RDO Purchase Agreement&#x201d;) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#x201c;April 2024 RDO&#x201d;): (i) an aggregate of 428,572 shares of Common Stock (the &#x201c;April 2024 RDO Shares&#x201d;), and (ii)&#160;common warrants to purchase up to 428,572 shares of Common Stock (the &#x201c;April 2024 RDO Common Warrants&#x201d;). The offering price per April 2024 RDO Share and accompanying April 2024 RDO Common Warrant to purchase one share of Common Stock was $35.00, for aggregate gross proceeds to the Company of $15,000,000, before deducting the placement agent fees and other offering expenses. Subject to certain ownership limitations, the April 2024 RDO Common Warrants are exercisable on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; anniversary from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $38.50 per share. The exercise price of the April 2024 RDO Common Warrants is subject to certain adjustments, including stock dividends, stock splits, combinations and reclassifications of the Common Stock. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;StockBlock and its affiliate, Rodman&#160;&amp;amp; Renshaw LLC, acted as exclusive placement agents (the &#x201c;April 2024 RDO Placement Agents&#x201d;) in connection with the April 2024 RDO. As compensation for such placement agent services, the Company paid the April 2024 RDO Placement Agents an aggregate cash fee equal to 8.0% of the gross proceeds actually received by the Company from the April 2024 RDO. The Company also reimbursed the April 2024 RDO Placement Agents $100,000 for actual, reasonable and documented fees and expenses, inclusive of fees and expenses of legal counsel and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; expenses and $15,950 for clearing expenses. The Company has also agreed to issue to the April 2024 RDO Placement Agents or their respective designees common warrants, substantially in the form of the April 2024 RDO Common Warrants, to purchase up to 34,286&#160;shares of Common Stock (the &#x201c;April 2024 RDO Placement Agent Warrants&#x201d;), representing up to 8.0% of the total number of the April 2024 RDO Shares issued in the April 2024 RDO. The April 2024 RDO Placement Agent Warrants have an exercise price of $43.75 per share (which represents 125% of the combined offering price per share of Common Stock and the April 2024 RDO Common Warrant sold in the April 2024 RDO), will become exercisable on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; anniversary of the date of issuance and expire five years from the commencement of sales in the April 2024 RDO. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the April 2024 RDO Common Warrants as a liability classified instrument (see Note&#160;4) and the April 2024 RDO Placement Agent Warrants as an equity classified instrument. The April 2024 RDO Placement Agent Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations. The fair value of the April 2024 RDO Placement Agent Warrants as the date of issuance was $0.6&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 15,000,000&#160;April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572 shares of Common Stock outstanding and 1,200,000&#160;April 2024 RDO Placement Agent Warrants, which are currently exercisable for an aggregate of up to 34,286 shares of our Common Stock outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December 2024 Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2024, the Company entered into a securities purchase agreement (the &#x201c;December 2024 RDO Purchase Agreement&#x201d;) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the &#x201c;December 2024 RDO&#x201d;): (i) an aggregate of 753,009 shares of Common Stock, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(ii)&#160;pre-funded&lt;/div&gt; warrants to purchase up to 68,604 shares of Common Stock (the &#x201c;December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&#x201d;) and (iii)&#160;common warrants to purchase up to 1,642,871 shares of Common Stock (the &#x201c;December 2024 RDO Common Warrants&#x201d; and collectively with the December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the &#x201c;StockBlock Warrants&#x201d;), the &#x201c;December 2024 RDO Warrants&#x201d;). The combined offering price (a)&#160;per share of Common Stock and accompanying December 2024 RDO Common Warrants was $20.65 and (b)&#160;per December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant and accompanying December 2024 RDO Common Warrants was $20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $17.0&#160;million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants as liability classified instruments (see Note 4) and the StockBlock Warrants as an equity classified instrument. The StockBlock Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The issuance costs allocated to the equity component are recorded as the reduction of the offering proceeds and the amounts allocated to the liability component are expensed as incurred within the selling, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;general and administrative expenses in the Company&#x2019;s consolidated statements of operations. The fair value of StockBlock Warrants as of the date of issuance was $1.3&#160;million. On December&#160;26, 2024, the December 2024 RDO &lt;div style="white-space:nowrap;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants were exercised by the holder for total net proceeds of approximately $0.2&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of each of March&#160;31, 2025 and December&#160;31, 2024, there were 57,512,958 December 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 1,642,871 shares of Common Stock outstanding and 4,601,036 StockBlock Warrants, which are currently exercisable for an aggregate of up to 131,472 shares of Common Stock outstanding. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2025_PublicWarrantsPurchaseCommonStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46219"
      unitRef="Unit_USD_per_Share">402.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2025"
      decimals="2"
      id="ixv-46220"
      unitRef="Unit_USD_per_Share">630</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-46221"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P09_20_2024To09_20_2024_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46223"
      unitRef="Unit_USD">4000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2025To03_31_2025_SpacWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46224"
      unitRef="Unit_USD">114286</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46225"
      unitRef="Unit_shares">5467692</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46226"
      unitRef="Unit_shares">156220</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-46227"
      unitRef="Unit_shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-46228"
      unitRef="Unit_shares">28572</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46229"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-46230"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendsShares
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46231"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-46232"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46233"
      unitRef="Unit_USD">200000000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P10_27_2024To10_27_2024_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46234"
      unitRef="Unit_Days">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P10_27_2024To10_27_2024_MaximumMembersrtRangeAxis_SeriesOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46236"
      unitRef="Unit_Days">15</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn03_31_2025_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46237"
      unitRef="Unit_shares">1458263</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46238"
      unitRef="Unit_shares">1716245</us-gaap:TreasuryStockCommonShares>
    <sclx:ProceedSOfSaleOfCommonSharesPercentage
      contextRef="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="3"
      id="ixv-46239"
      unitRef="Unit_pure">0.03</sclx:ProceedSOfSaleOfCommonSharesPercentage>
    <sclx:CommonStockSold
      contextRef="P01_01_2025To03_31_2025_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46240"
      unitRef="Unit_shares">0</sclx:CommonStockSold>
    <sclx:CommonStockSold
      contextRef="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-46241"
      unitRef="Unit_shares">2637</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2024To03_31_2024_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-46242"
      unitRef="Unit_USD">100000</sclx:ProceedsFromSaleOfCommonStock>
    <sclx:CommonStockSold
      contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46244"
      unitRef="Unit_shares">168068</sclx:CommonStockSold>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46245"
      unitRef="Unit_shares">168068</sclx:PurchaseOfCommonWarrants>
    <sclx:CombinedPricePaidOfWarrant
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46246"
      unitRef="Unit_USD_per_Share">54.74</sclx:CombinedPricePaidOfWarrant>
    <sclx:PublicOfferingPrice
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46247"
      unitRef="Unit_USD_per_Share">59.5</sclx:PublicOfferingPrice>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46248"
      unitRef="Unit_USD_per_Share">59.5</sclx:ExercisePriceOfCommonWarrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46249"
      unitRef="Unit_shares">13446</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46250"
      unitRef="Unit_USD_per_Share">74.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:PublicOfferingPriceCombined
      contextRef="PAsOn02_29_2024_WarrantsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46251"
      unitRef="Unit_pure">1.25</sclx:PublicOfferingPriceCombined>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-46252"
      unitRef="Unit_USD">300000</us-gaap:AdditionalPaidInCapital>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46253"
      unitRef="Unit_shares">50421</sclx:PurchaseOfCommonWarrants>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-46254"
      unitRef="Unit_USD_per_Share">20.65</sclx:ExercisePriceOfCommonWarrant>
    <sclx:NumberOfWarrantsExercised
      contextRef="P07_01_2024To09_30_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46255"
      unitRef="Unit_shares">0</sclx:NumberOfWarrantsExercised>
    <sclx:NumberOfWarrantsExercised1
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46256"
      unitRef="Unit_shares">3803447</sclx:NumberOfWarrantsExercised1>
    <sclx:NumberOfWarrantsExercised1
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_FirmWarrantsMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46257"
      unitRef="Unit_shares">108686</sclx:NumberOfWarrantsExercised1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46258"
      unitRef="Unit_shares">470588</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RepresentativeWarrantsOutstandingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46259"
      unitRef="Unit_shares">13446</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46260"
      unitRef="Unit_shares">428572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_23_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46261"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-46262"
      unitRef="Unit_USD_per_Share">35</us-gaap:SaleOfStockPricePerShare>
    <sclx:AggregateGrossProceedsFromOffering
      contextRef="P04_23_2024To04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46263"
      unitRef="Unit_USD">15000000</sclx:AggregateGrossProceedsFromOffering>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn04_23_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-46264"
      unitRef="Unit_USD_per_Share">38.5</sclx:ExercisePriceOfCommonWarrant>
    <sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-46266"
      unitRef="Unit_pure">0.08</sclx:CashFeePercentageOfGrossProceedsPaidToPlacementAgents>
    <us-gaap:LegalFees
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-46267"
      unitRef="Unit_USD">100000</us-gaap:LegalFees>
    <sclx:ClearingExpenses
      contextRef="P04_23_2024To04_23_2024"
      decimals="0"
      id="ixv-46268"
      unitRef="Unit_USD">15950</sclx:ClearingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46269"
      unitRef="Unit_shares">34286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering
      contextRef="P04_23_2024To04_23_2024_CommonStockMemberusgaapStatementClassOfStockAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      id="ixv-46270"
      unitRef="Unit_pure">0.08</sclx:PercentOfTotalNumberOfSharesIssuedToAgentsInTheOffering>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-46271"
      unitRef="Unit_USD_per_Share">43.75</sclx:ExercisePriceOfCommonWarrant>
    <sclx:PercentOfCombinedOfferingExercisePricePerShare
      contextRef="P04_23_2024To04_23_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-46272"
      unitRef="Unit_pure">1.25</sclx:PercentOfCombinedOfferingExercisePricePerShare>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2025_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-46273"
      unitRef="Unit_USD">600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46274"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46275"
      unitRef="Unit_shares">428572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46276"
      unitRef="Unit_shares">1200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-46277"
      unitRef="Unit_shares">34286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P12_11_2024To12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46278"
      unitRef="Unit_shares">753009</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:PreFundedWarrantsToPurchase
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="0"
      id="ixv-46279"
      unitRef="Unit_shares">68604</sclx:PreFundedWarrantsToPurchase>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_11_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46280"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="2"
      id="ixv-46281"
      unitRef="Unit_USD_per_Share">20.65</us-gaap:SaleOfStockPricePerShare>
    <sclx:PreFundedWarrantPerShare
      contextRef="PAsOn12_11_2024_CommonStockMemberusgaapStatementClassOfStockAxis_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="4"
      id="ixv-46282"
      unitRef="Unit_USD_per_Share">20.6499</sclx:PreFundedWarrantPerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P12_11_2024To12_11_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_SecuritiesPurchaseAgreementMemberusgaapDeferredRevenueArrangementTypeAxis_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-46283"
      unitRef="Unit_USD">17000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_26_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-46285"
      unitRef="Unit_USD">1300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P12_26_2024To12_26_2024_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-46286"
      unitRef="Unit_USD">200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46287"
      unitRef="Unit_shares">57512958</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46288"
      unitRef="Unit_shares">57512958</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46289"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-46290"
      unitRef="Unit_shares">1642871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46291"
      unitRef="Unit_shares">4601036</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46292"
      unitRef="Unit_shares">4601036</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2025_CommonWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46293"
      unitRef="Unit_shares">131472</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2024_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis_RegisteredDirectOfferingMemberusgaapSubsidiarySaleOfStockAxis_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46294"
      unitRef="Unit_shares">131472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35739">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;10. Stock Incentive and Employee Benefit Plan &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2017, the Board adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan.&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder.&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2022 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;). As of March&#160;31, 2025, a total of 703,670 shares of Common Stock were available and have been reserved for future issuance under the Equity Incentive Plan, which number of shares accounts for the automatic annual increase on January&#160;1, 2025 pursuant to the Equity Incentive Plan. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2023 Inducement Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;17, 2023, the compensation committee of the Board adopted the Scilex Holding Company 2023 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan provides for the grant of equity-based awards in the form of &lt;div style="white-space:nowrap;display:inline;"&gt;non-statutory&lt;/div&gt; stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 40,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the three months ended March&#160;31, 2025 and 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025, options to purchase 1,022,353 shares of Common Stock were outstanding under all equity incentive plans. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2025 (in thousands, except for per share amounts and contractual life): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;149.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Outstanding as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Vested and expected to vest as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercisable as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;116.98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. No stock options were granted during the three months ended March&#160;31, 2025. No options were exercised during the three months ended March&#160;31, 2025. The maximum term of options granted under each of the equity incentive plans is ten years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded within operating expenses was $3.3&#160;million and $3.6&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total unrecognized compensation costs related to unvested employee and &lt;div style="white-space:nowrap;display:inline;"&gt;non-employee&lt;/div&gt; stock option grants as of March&#160;31, 2025 were $24.5&#160;million, which the Company expects to recognize over a weighted-average period of approximately 2.1 years. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2022 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The purchase price of the Common Stock is equal to 85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of March&#160;31, 2025, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed 170,573, which was increased from 127,902 shares as a result of automatic annual increase on January&#160;1, 2025. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded as operating expense for the ESPP was $50.2&#160;thousand and $58.0&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2025, there were no shares of Common Stock issued under the ESPP. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Valuation Assumptions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company calculates the fair value of stock options granted to employees and nonemployees and shares issued under ESPP using the Black-Scholes option pricing method. The Black-Scholes option pricing method requires the use of subjective assumptions. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur 2024 Stock Option Plan&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Concurrent with the signing of the Semnur Business Combination Agreement, the Board, the Company (as the sole stockholder of Semnur) and the board of directors of Semnur approved the 2024 Stock Option Plan (the &#x201c;Semnur 2024 Plan&#x201d;). Under the Semnur 2024 Plan, 40,000,000 shares of Semnur Common Stock were reserved &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;for future issuance and Nonstatutory Stock Options (&#x201c;NSOs&#x201d;) to purchase the same amount of Semnur Common Stock were granted to certain executive officers of Semnur. The NSOs were granted on August&#160;30, 2024 and expire on August&#160;30, 2034. No expense was recorded in connection with the NSOs as of March&#160;31, 2025, as until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, such options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions or have any voting rights in respect of the Company or any of its current or future subsidiaries of the Company, and following the closing of the transactions contemplated by the Semnur Business Combination Agreement, the Company, Denali or any of their respective current and future subsidiaries, successors and assigns. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.2&#160;million for each of the three months ended March&#160;31, 2025 and 2024. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Retainer Shares&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#x201c;2023 SIA&#x201d;) with a law firm for the provision of legal services to the Company. Under the 2023 SIA, the Company issued 114,286 shares of Common&#160;Stock to the law firm. On July&#160;1, 2024, the Company entered into another Stock Issuance Agreement (the &#x201c;2024 SIA&#x201d;) with the same law firm for the provision of legal services to the Company. Under the 2024 SIA, the Company issued 285,714 shares of Common Stock to the same law firm. All such shares are held by the law firm as collateral for current and future outstanding legal fees due from the Company (the &#x201c;Retainer Shares&#x201d;). At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. As of March&#160;31, 2025, it was not probable that any of the Retainer Shares would be applied against any outstanding legal fees. &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-46295"
      unitRef="Unit_shares">703670</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-46296"
      unitRef="Unit_shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-46297"
      unitRef="Unit_shares">1022353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-35770">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2025 (in thousands, except for per share amounts and contractual life): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2003;&#x2003;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;149.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Outstanding as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Vested and expected to vest as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;138.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Exercisable as of March&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;116.98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46299"
      unitRef="Unit_shares">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-46300"
      unitRef="Unit_USD_per_Share">138.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2024To12_31_2024" id="ixv-46301">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46302"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46303"
      unitRef="Unit_shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-46304"
      unitRef="Unit_USD_per_Share">149.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46305"
      unitRef="Unit_shares">1022000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2025"
      decimals="2"
      id="ixv-46306"
      unitRef="Unit_USD_per_Share">138.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2025To03_31_2025" id="ixv-46307">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46308"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46309"
      unitRef="Unit_shares">1022000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2025"
      decimals="2"
      id="ixv-46310"
      unitRef="Unit_USD_per_Share">138.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2025To03_31_2025" id="ixv-46311">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46312"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46313"
      unitRef="Unit_shares">756000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2025"
      decimals="2"
      id="ixv-46314"
      unitRef="Unit_USD_per_Share">116.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2025To03_31_2025" id="ixv-46315">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46316"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-46317"
      unitRef="Unit_USD">3300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-46318"
      unitRef="Unit_USD">3600000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-46319"
      unitRef="Unit_USD">24500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <sclx:WeightedAveragePeriodOverGrant
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      id="ixv-46320">P2Y1M6D</sclx:WeightedAveragePeriodOverGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="P10_17_2022To10_17_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-46321"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-46322"
      unitRef="Unit_shares">170573</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-46323"
      unitRef="Unit_shares">127902</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      id="ixv-46324"
      unitRef="Unit_USD">50200</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      id="ixv-46325"
      unitRef="Unit_USD">58000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2025_Semnur2024StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-46326"
      unitRef="Unit_shares">40000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-46328"
      unitRef="Unit_USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-46329"
      unitRef="Unit_USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_13_2023To02_13_2023"
      decimals="0"
      id="ixv-46330"
      unitRef="Unit_shares">114286</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P07_01_2024To07_01_2024"
      decimals="0"
      id="ixv-46331"
      unitRef="Unit_shares">285714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="PAsOn03_31_2025"
      id="ixv-46332"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36014">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;11. Commitments and Contingencies &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with Itochu and Oishi (together, the &#x201c;Developers&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;div style="white-space:nowrap;display:inline;"&gt;SP-103&lt;/div&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. Scilex Pharma made royalty payments in the amount of $0.9&#160;million and $2.4&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025 and December&#160;31, 2024, Scilex Pharma had ending balances of accrued royalty payables of $3.8&#160;million and $4.0&#160;million, respectively. Total royalty expense recorded within cost of revenue was $0.7&#160;million and $2.3&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;div style="white-space:nowrap;display:inline;"&gt;one-year&lt;/div&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon &lt;div style="white-space:nowrap;display:inline;"&gt;six-months&#x2019;&lt;/div&gt; written notice. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the Developers to provide commercial supply of ZTlido and &lt;div style="white-space:nowrap;display:inline;"&gt;SP-103&lt;/div&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following lawsuit, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#x201c;Aveva&#x201d;), Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the&#160;procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#x201c;ANDA&#x201d;). Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex and Aveva were subject to an automatic &lt;div style="white-space:nowrap;display:inline;"&gt;30-month&lt;/div&gt; stay preventing them from selling a generic version of ZTlido during that time, which was extinguished by the U.S. District Court decision described below. However, to our knowledge, Aveva has not received FDA approval for any generic version of ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and enforceability of the Company&#x2019;s patents. Trial in the ZTlido Patent Litigation was held from July&#160;8, 2024 to July&#160;11, 2024. Final post-trial briefing was submitted by the parties on July&#160;25, 2024, and the case was submitted to the U.S. District Court for the Southern District of Florida. On August&#160;26, 2024, that court issued a decision finding that Aveva&#x2019;s product does not infringe the Company&#x2019;s ZTlido Patents. The Company is appealing that decision to the U.S. Court of Appeals for the Federal Circuit, and it filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September&#160;25, 2024. Briefing is underway in that appeal. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company leases administrative and research and development facilities under various &lt;div style="white-space:nowrap;display:inline;"&gt;non-cancelable&lt;/div&gt; lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of March&#160;31, 2025, the Company&#x2019;s leases have remaining lease terms of approximately 2.5 years. The terms of the Company&#x2019;s leases, ranging from 3 to 5 years, include extension options that are not reasonably certain to be &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;exercised. Many of the Company&#x2019;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets or lease liabilities, and are immaterial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of March&#160;31, 2025, the Company has no&#160;&lt;div style="-sec-ix-hidden:hidden145659148;display:inline;"&gt;finance leases&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease expense was $0.3&#160;million for each of the three months ended March&#160;31, 2025 and 2024, and was primarily comprised of operating lease costs. The lease expense included variable lease costs and sublease income, which were immaterial for the periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Three Months&lt;br/&gt; Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(227&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years - operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate - operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025 (Remainder of 2025)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,067&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-46333"
      unitRef="Unit_pure">0.25</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-46334"
      unitRef="Unit_pure">0.35</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2025To03_31_2025_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-46335"
      unitRef="Unit_USD">900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To03_31_2024_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-46336"
      unitRef="Unit_USD">2400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46337"
      unitRef="Unit_USD">3800000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn12_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46338"
      unitRef="Unit_USD">4000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46339"
      unitRef="Unit_USD">700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2024To03_31_2024_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46340"
      unitRef="Unit_USD">2300000</us-gaap:RoyaltyExpense>
    <sclx:AgreementMaturityDate
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-46342">2028-10-02</sclx:AgreementMaturityDate>
    <sclx:MaturityRenewalDescription
      contextRef="P01_01_2025To03_31_2025_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-36037">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six-months&#x2019; written notice.</sclx:MaturityRenewalDescription>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-46343">P2Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn03_31_2025_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-46344">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn03_31_2025_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-46345">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn03_31_2025"
      id="ixv-46347"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-46348"
      unitRef="Unit_USD">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-5"
      id="ixv-46349"
      unitRef="Unit_USD">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36078">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Three Months&lt;br/&gt; Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(227&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years - operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate - operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46350"
      unitRef="Unit_USD">227000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-46351"
      unitRef="Unit_USD">277000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2025" id="ixv-46352">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2024" id="ixv-46353">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2025"
      decimals="3"
      id="ixv-46354"
      unitRef="Unit_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2024"
      decimals="3"
      id="ixv-46355"
      unitRef="Unit_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36156">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025 (Remainder of 2025)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(290&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,067&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46356"
      unitRef="Unit_USD">689000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46357"
      unitRef="Unit_USD">944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46358"
      unitRef="Unit_USD">724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46359"
      unitRef="Unit_USD">2357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46360"
      unitRef="Unit_USD">290000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46361"
      unitRef="Unit_USD">2067000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46362"
      unitRef="Unit_USD">740000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sclx:LeaseLiabilityNetOfCurrentPortion
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-46363"
      unitRef="Unit_USD">1327000</sclx:LeaseLiabilityNetOfCurrentPortion>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36270">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;12. Net Loss Per Share &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the three months ended March&#160;31, 2025 and 2023 (in thousands except per share data): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(26,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(24,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common stock warrants exercisable for nominal consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method or the reverse treasury stock method, as applicable). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with FASB ASC 260, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnings Per Share, &lt;/div&gt;&lt;/div&gt;Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#x2019;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022,353&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,027,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,114,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,158,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under the SIPA&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Firm Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Representative Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;428,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deposit Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Noteholder Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;214,284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;StockBlock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,668,507&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,817,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-46364">The following table sets forth the reconciliation of basic and diluted loss per share for the three months ended March&#160;31, 2025 and 2023 (in thousands except per share data): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(26,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(24,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average common stock warrants exercisable for nominal consideration&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares, diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(8.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-46365"
      unitRef="Unit_USD">-26080000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-46366"
      unitRef="Unit_USD">-24377000</us-gaap:NetIncomeLoss>
    <sclx:WeightedAverageNumberOfSharesOutstanding
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46367"
      unitRef="Unit_shares">5065000</sclx:WeightedAverageNumberOfSharesOutstanding>
    <sclx:WeightedAverageNumberOfSharesOutstanding
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-46368"
      unitRef="Unit_shares">2926000</sclx:WeightedAverageNumberOfSharesOutstanding>
    <sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46369"
      unitRef="Unit_shares">6500000</sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration>
    <sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-46370"
      unitRef="Unit_shares">0</sclx:WeightedAverageCommonStockWarrantsExercisableNominalConsideration>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-46371"
      unitRef="Unit_shares">11565</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-46372"
      unitRef="Unit_shares">2926</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46373"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-46374"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-46375"
      unitRef="Unit_shares">11565</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-46376"
      unitRef="Unit_shares">2926</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-46377"
      unitRef="Unit_USD_per_Share">-2.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-46378"
      unitRef="Unit_USD_per_Share">-2.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-46379"
      unitRef="Unit_USD_per_Share">-8.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-46380"
      unitRef="Unit_USD_per_Share">-8.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_21_2023"
      decimals="0"
      id="ixv-46381"
      unitRef="Unit_shares">8500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36457">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,022,353&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,027,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;399,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under Tranche B Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,114,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,158,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;156,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;28,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issuable under the SIPA&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Firm Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;108,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;February 2024 BDO Representative Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;13,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;428,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 2024 RDO Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;34,286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deposit Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;3,250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Noteholder Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;214,284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;October 2024 Placement Agent Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December 2024 RDO Common Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,642,871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;StockBlock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;131,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;8,668,507&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,817,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46383"
      unitRef="Unit_shares">1022353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46384"
      unitRef="Unit_shares">1027977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_RetainerSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46385"
      unitRef="Unit_shares">399999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_RetainerSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46386"
      unitRef="Unit_shares">399999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46387"
      unitRef="Unit_shares">1114770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_SharesIssuableUnderTrancheBNotesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46388"
      unitRef="Unit_shares">1158617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_PublicWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46389"
      unitRef="Unit_shares">156220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PublicWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46390"
      unitRef="Unit_shares">156220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46391"
      unitRef="Unit_shares">28572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46392"
      unitRef="Unit_shares">28572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46393"
      unitRef="Unit_shares">9557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46394"
      unitRef="Unit_shares">2204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46395"
      unitRef="Unit_shares">8571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_SharesIssuableUnderSponsorInterestPurchaseAgreementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46396"
      unitRef="Unit_shares">8571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46397"
      unitRef="Unit_shares">108686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_February2024BDOFirmWarrantMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46398"
      unitRef="Unit_shares">108686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46399"
      unitRef="Unit_shares">13446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_February2024BDORepresentativeWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46400"
      unitRef="Unit_shares">13446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46401"
      unitRef="Unit_shares">428572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_April2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46402"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46403"
      unitRef="Unit_shares">34286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_April2024RDOPlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46404"
      unitRef="Unit_shares">34286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_DepositWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46405"
      unitRef="Unit_shares">3250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_DepositWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46406"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46407"
      unitRef="Unit_shares">214284</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_October2024NoteholderWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46408"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46409"
      unitRef="Unit_shares">104848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_October2024PlacementAgentWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46410"
      unitRef="Unit_shares">104848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46411"
      unitRef="Unit_shares">1642871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_December2024RDOCommonWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46412"
      unitRef="Unit_shares">1642871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46413"
      unitRef="Unit_shares">131472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_StockBlockWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46414"
      unitRef="Unit_shares">131472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025"
      decimals="0"
      id="ixv-46415"
      unitRef="Unit_shares">8668507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-46416"
      unitRef="Unit_shares">4817769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2025To03_31_2025" id="ixv-36700">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;13. Subsequent Events &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Bio JV &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;17, 2025, the Company and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;MAO-B&lt;/div&gt; Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer&#x2019;s disease. The Company contributed 5.0&#160;million shares of Semnur Common Stock owned by the Company to Scilex Bio, Inc. in exchange for a 60% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a 40% ownership interest in Scilex Bio, Inc. In connection with the formation of Scilex Bio, Inc. and the related transactions, on April&#160;16, 2025, the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed, and the Company entered into a Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note with each of the Tranche B Noteholders. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-46417"
      unitRef="Unit_shares">5000000</us-gaap:CommonStockSharesIssued>
    <sclx:OwnershipInterestRate
      contextRef="P04_17_2025To04_17_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-46418"
      unitRef="Unit_pure">0.60</sclx:OwnershipInterestRate>
    <sclx:OwnershipInterestRate
      contextRef="P04_17_2025To04_17_2025_ScilexBioJVMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-46419"
      unitRef="Unit_pure">0.40</sclx:OwnershipInterestRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>d942297dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-331">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-332">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-333">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-334">0001820190</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-335">Scilex Holding Co</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-363">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-364">Scilex Holding Co</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-365">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-366">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-367">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_1" id="ixv-368">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-369"
      unitRef="Shares">1390443</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-370"
      unitRef="USD">11.06</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-371"
      unitRef="USD">15378299.58</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-372"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-373"
      unitRef="USD">2354.42</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-374" unitRef="USD">15378299.58</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-375" unitRef="USD">2354.42</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-376" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-377" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-378" unitRef="USD">2354.42</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-379"> Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), the shares being registered hereunder include such indeterminate number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. The amount registered includes 150,000 shares of common stock, par value $0.0001 per share (the "Common Stock") of Scilex Holding Company, a Delaware corporation (the "Company"), to be issued by the Company to the selling securityholder named herein (the "Selling Securityholder") and 1,240,443 shares of Common Stock that are available to be issued and sold by the Company to the Selling Securityholder from time to time at the Company's election pursuant to the common stock purchase agreement, dated as of July 22, 2025, between the Company and the Selling Securityholder, subject to satisfaction of the conditions set forth therein. The proposed maximum offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on July 25, 2025 (such date being within five business days of the date that this registration statement was filed with the U.S. Securities and Exchange Commission). </ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
